Sample.ID,Sentrix.ID,Batch Number,Date added to list,Expected Result,ScanDate,TAT,Added by,Study,Batch Integer,Scanned Slide #,NZConnect,Origin,Diagnostic query,Rationale,BLOCK,DOB,Age at OP,MC 12.6,MC 12.6 Score ,MC 11.6,MC 11.6 Score ,Purity,BRAF Fusion,Merged.1,Initial Diagnosis (CoPath),Revised Diagnosis,Outcome,,Folder generator,MDM4,MYCN,GLI2,FGFR3_TACC3,PDGFRA,TERT,MYB,EGFR,CDK6,MET,KIAA1549_BRAF,FGFR1_TACC1,MYBL1,MYC,CDKN2A_B,PTCH1,PTEN,MGMT,CCND1,CCND2,CDK4,MDM2,RB1,TP53,NF1,PPM1D,C19MC,SMARCB1,NF2,mgmt.Status
NH14-2217,9989536136_R01C01,#001,,,2/26/2015,42061,SB,Diagnostic,001,5,,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,4/18/1981,33.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.97,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-2217,"Anaplastic Oligoastrocytoma (WHO grade III).
IDH1 (R132H IHC): Mutation. 
ATRX (IHC): Loss of expression (indicates mutation). 
1p/19q: Test pending (previous specimen NH13-1919 showed 1p/19q LOH).
  
","Histology: Astrocytoma, IDH-mutant (WHO grade III)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #001\NH14-2217,-0.11,-0.036,0.072,-0.101,0.051,-0.346,-0.297,0.236,0.073,0.005,0.04,-0.015,0.114,0.047,-0.004,0.14,0.055,-0.136,-0.079,0.154,-0.022,0.009,0.051,0.022,0.046,0.038,-0.405,-0.022,0.083,methylated
NH14-911,9989536136_R01C02,#001,,,2/26/2015,42061,SB,Diagnostic,001,5,,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,8/27/1957,56.8,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.17,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-911,"
Glioblastoma (WHO grade IV) - see comment. 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #001\NH14-911,0.114,-0.507,-0.259,-0.551,-0.428,-0.407,-0.061,0.068,0.146,0.253,0.04,0.102,0.272,0.037,0.115,0.027,-0.028,-0.317,-0.358,-0.288,0.139,0.239,-0.151,-0.114,0.178,0.341,-0.725,0.044,0.209,methylated
NH14-2331,9989536136_R02C01,#001,,,2/26/2015,42061,SB,Diagnostic,001,5,,NHNN,,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,4/10/1964,50.7,"glioblastoma, IDH-wildtype, RTK1 type",0.96,GBM_RTKI,0.63,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-2331,"Glioblastoma with oligodendroglial component (WHO grade IV). Please see comments.
IDH1 (R132H IHC): No mutation; further tests pending 
ATRX (IHC): Retained. 
1p/19q: Test pending   
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #001\NH14-2331,1.103,-0.051,-0.026,-0.001,0.876,0.02,0.017,1.112,0.225,0.159,0.131,0.027,-0.005,-0.028,-0.561,-0.062,-0.396,-0.295,-0.015,-0.012,0.038,0.114,-0.013,0.033,0.027,0.02,-0.164,-0.023,0.079,unmethylated
NH13-581,9989536136_R02C02,#001,,,2/26/2015,42061,SB,Diagnostic,001,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,8/25/1964,48.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.89,AIDH,0.65,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH13-581,"Glioblastoma with oligodendroglial component (WHO Grade IV)
IDH-1 (G395A) mutation
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #001\NH13-581,-0.213,0.04,-0.004,-0.094,0.023,-0.128,0.053,0.207,0.065,0.28,0.208,0.009,0.047,0.059,-0.235,0.063,-0.048,-0.098,-0.035,0.118,0.114,-0.26,-0.015,0.021,0.069,-0.02,-0.11,-0.041,0.156,methylated
NH15-40,9989536136_R03C01,#001,,,2/26/2015,42061,SB,Diagnostic,001,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,2/25/1983,31.9,supratentorial pilocytic astrocytoma,0.99,LGG_PA_GGST,1,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH15-40,"Oligodendroglioma (WHO grade II)
IDH1 (R132H IHC): No mutation; further tests pending 
ATRX (IHC): Retained. 
1p/19q: Test pending  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #001\NH15-40,0.008,-0.051,-0.051,0.011,-0.017,-0.184,-0.024,0.028,0.063,0.081,0.013,0.042,-0.044,0.055,-0.028,-0.056,0.035,-0.089,0.006,0.029,0.069,0.065,-0.043,0.063,0.025,0.02,-0.135,0.024,0.098,methylated
NH13-1256,9989536136_R03C02,#001,,,2/26/2015,42061,SB,Diagnostic,001,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,6/22/1963,50.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.89,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH13-1256,"Glioblastoma with oligodendroglial component (WHO grade IV)  see comment
","Anaplastic oligodendroglioma, IDH-mutant and 1p/19q codeleted (WHO grade III)
IDH1/2Seq: IDH2 mutation
ATRX (IHC): Retained
1p/19q: Codeleted
TERT promoter: Mutation

  
",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #001\NH13-1256,0.099,-0.018,0.05,-0.349,-0.496,-0.064,0.189,0.025,-0.031,0.032,-0.062,-0.022,0.071,0.025,-0.544,-0.446,0.002,0.074,-0.09,0.072,0.006,-0.232,-0.463,-0.144,-0.024,-0.063,-0.555,-0.128,-0.018,methylated
NH15-5,9989536136_R04C01,#001,,,2/26/2015,42061,SB,Diagnostic,001,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,6/14/1946,68.6,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type C]",1,CN,0.09,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH15-5,"Anaplastic Oligodendroglioma (WHO grade III). Please see comments
IDH1 (R132H IHC): No mutation; further tests pending. 
ATRX (IHC): Retained. 
1p/19q: Test pending  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #001\NH15-5,0.243,-0.074,0.192,-0.059,0.007,-0.113,0.047,-0.022,0.016,0.056,0.022,-0.041,0.004,-0.452,0.022,-0.089,-0.255,-0.443,-0.007,-0.029,0.027,0.104,-0.457,-0.002,0.006,0.021,-0.203,-0.012,0.037,unmethylated
NH14-1589,9989536136_R05C01,#001,,,2/26/2015,42061,SB,Diagnostic,001,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,3/21/1991,23.5,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.94,OIDH,0.95,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-1589,"Glioblastoma with oligodendroglial component (WHO grade IV). 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #001\NH14-1589,-0.135,-0.145,-0.011,-0.102,-0.103,-0.038,0.017,-0.16,0.168,0.192,0.159,-0.025,0.124,0.032,-0.081,-0.225,0.061,-0.015,-0.084,-0.013,0.048,0.048,0.033,-0.043,0.011,0.051,-0.755,0.01,0.177,methylated
NH14-1206,9989536136_R05C02,#001,,,2/26/2015,42061,SB,Diagnostic,001,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,4/12/1948,66.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-1206,"Glioblastoma with oligodendroglial component (WHO grade IV)
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #001\NH14-1206,-0.17,-0.099,0.005,0.037,-0.036,0.011,0.021,-0.019,-0.057,-0.021,0.002,-0.028,-0.025,0.337,-0.108,0.016,0.064,-0.238,-0.026,0.13,0.017,-0.042,-0.384,-0.066,-0.058,0.027,-0.12,0.046,0.086,unmethylated
NH13-1730,9989536136_R06C02,#001,,,2/26/2015,42061,SB,Diagnostic,001,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,5/28/1979,34.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.91,AIDH_HG,0.81,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH13-1730,"Oligoastrocytoma (WHO grade II).
IDH1 mutation (R132H). 
","Oligodendroglioma, IDH-mutant and 1p/19q-codeleted (WHO grade II)
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained      
1p/19q: Codeleted      
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #001\NH13-1730,-0.146,0.066,0.038,0.059,0.096,-0.023,0.124,-0.035,0,0.162,-0.018,-0.1,0.045,0.308,-0.083,0.022,0.008,-0.268,0.062,0.145,0.005,-0.087,-0.332,-0.146,0.048,-0.037,-0.175,0.014,0.081,unmethylated
NH13-1444,9989536145_R01C01,#002,,,2/26/2015,42061,SB,Diagnostic,002,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,6/1/1955,58.4,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.7,GBM_RTKII,0.69,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH13-1444,"Oligoastrocytoma (WHO grade II)
IDH1 gene mutation (see comment)
",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #002\NH13-1444,0.17,-0.074,-0.028,0.055,0.088,-0.094,-0.008,0.303,0.243,0.241,0.164,0.11,0.051,0.124,0.033,-0.015,-0.021,-0.266,-0.076,-0.054,0.043,-0.021,-0.072,-0.023,0.042,0.007,-0.291,-0.101,-0.013,unmethylated
NH13-1014,9989536145_R02C01,#002,,,2/26/2015,42061,SB,Diagnostic,002,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,2/8/1970,43.4,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.56,PXA,0.09,0.95,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH13-1014,"Anaplastic oligoastrocytoma (WHO grade III)  see comment 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #002\NH13-1014,-0.088,0.002,0.024,-0.115,0.074,-0.264,-0.06,0.076,0.192,0.178,0.137,0.023,0.069,0.05,-0.027,0.187,-0.127,-0.104,-0.036,0.591,0.6,-0.051,0.031,-0.053,0.019,0.034,-0.383,-0.017,0.1,methylated
NH14-1226,9989536145_R02C02,#002,,,2/26/2015,42061,SB,Diagnostic,002,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,12/15/1979,34.6,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.15,DMG_K27,0.18,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-1226,"Glioblastoma multiforme (WHO grade IV)  see comment
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #002\NH14-1226,-0.278,0.016,-0.082,-0.058,0.163,0.088,-0.083,0.061,0.092,-0.065,-0.211,0.026,0.029,-0.165,-0.843,-0.038,-0.165,-0.354,-0.127,0.077,0.075,0.501,0.103,-0.371,-0.299,0.294,-0.214,-0.366,-0.029,unmethylated
NH11-1207,9989536145_R03C01,#002,,,2/26/2015,42061,SB,Diagnostic,002,6,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,4/30/1979,32.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH11-1207,"Malignant glioma with a primitive neuroectodermal tumour-like (PNET) component (WHO grade IV)  see comment 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #002\NH11-1207,-0.002,0.011,0.018,-0.053,0.073,-0.517,0.072,0.067,0.018,-0.021,0.091,0.017,0.061,0.044,-0.502,-0.048,-0.28,-0.414,-0.056,0.664,0.66,0.065,-0.071,-0.026,-0.027,0.006,-0.795,0.004,0.127,methylated
NH14-1514,9989536145_R03C02,#002,,,2/26/2015,42061,SB,Diagnostic,002,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,9/22/1966,47.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.32,GBM_MES,0.75,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-1514,"Glioblastoma (WHO grade IV)
",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #002\NH14-1514,-0.008,-0.343,-0.201,0.19,-0.003,-0.184,0.065,0.48,0.386,0.414,0.281,0.14,0.302,0.157,0.203,-0.231,-0.175,-0.547,-0.294,0.155,0.689,0.161,0.073,-0.101,0.036,-0.044,-0.429,0.01,0.082,methylated
NH13-1974,9989536145_R04C01,#002,,,2/26/2015,42061,SB,Diagnostic,002,6,NDP,NHNN,,"(2) unusual histology, location, demographics",,4/30/1979,34.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH13-1974,"Left temporal tumour: Glioblastoma with PNET component, WHO Grade IV. 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #002\NH13-1974,0.121,0.443,0.025,-0.11,0.104,-0.145,-0.178,1.047,0.464,0.149,0.138,0.209,0.175,0.022,-1.571,0.247,-0.101,-0.683,-0.044,0.186,0.017,0.099,-0.082,0.011,0.001,0.346,-0.984,-0.059,0.033,methylated
NH14-1533,9989536145_R04C02,#002,,,2/26/2015,42061,SB,Diagnostic,002,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,6/3/1955,59.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.4,OIDH,0.82,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-1533,"Glioblastoma (WHO grade IV)
",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #002\NH14-1533,-0.017,0.037,0.004,-0.082,0.054,-0.085,0.097,0.04,-0.043,0.057,0.005,0.009,-0.018,0.065,-0.017,-0.032,-0.024,-0.002,0.014,0.063,0,-0.057,-0.369,0.003,-0.109,-0.021,-0.474,0.029,0.073,methylated
NH14-4,9989536145_R05C01,#002,,,2/26/2015,42061,SB,Diagnostic,002,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,1/12/1966,48,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.97,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-4,"Glioblastoma with primitive neuroectodermal tumour (PNET) component (WHO grade IV); IDH1 (R132H) negative
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #002\NH14-4,-0.267,-0.281,-0.078,0.044,-0.076,-0.142,-0.05,2,0.437,0.371,0.256,-0.015,0.046,-0.061,-1.819,0.062,-0.571,-0.588,-0.264,0.226,0.136,-0.217,-0.012,0.031,-0.051,-0.09,-0.043,-0.094,0.142,unmethylated
NH96-415,9989536145_R05C02,#002,,,2/26/2015,42061,SB,Diagnostic,002,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.98,OIDH,0.97,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH96-415,#N/A,#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #002\NH96-415,0.058,-0.047,-0.013,-0.167,-0.013,-0.532,0.163,0.07,0.051,-0.044,-0.013,0.033,-0.051,0.045,0.102,-0.016,0.049,-0.243,-0.078,0.085,0.108,0.153,-0.007,0.081,0.007,-0.012,-1.002,0.039,0.117,methylated
NH07-1129,9989536145_R06C02,#002,,,2/26/2015,42061,SB,Diagnostic,002,3,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,1/7/1983,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH07-1129,"PNET (see comment)
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #002\NH07-1129,-0.156,0.004,-0.094,-0.166,0.173,-0.226,0.128,0.298,0.168,0.274,0.174,0.205,0.08,0.232,-0.017,-0.034,0.018,-0.204,0.188,0.168,0.04,-0.002,-0.032,0.049,-0.019,-0.019,-0.605,0.053,0.05,methylated
NH14-1,9989540022_R01C01,#003,,,2/26/2015,42061,SB,Diagnostic,003,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,7/3/1973,40.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-1,"Oligoastrocytoma (WHO Grade II)  see comment
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #003\NH14-1,-0.139,0.028,0.07,-0.038,0.04,-0.254,0.09,0.002,0.029,0.021,-0.022,-0.013,0.005,0.102,-0.159,0.025,0.03,-0.039,0.028,0.134,-0.231,-0.329,-0.05,-0.013,-0.027,-0.039,-0.071,0.019,0.063,methylated
NH14-495,9989540022_R01C02,#003,,,2/26/2015,42061,SB,Diagnostic,003,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,11/12/1979,34.4,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.73,OIDH,0.95,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-495,"Anaplastic oligoastrocytoma (WHO grade III)
IDH1 gene mutation  see comment
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #003\NH14-495,-0.004,-0.06,0.036,-0.081,0.052,-0.112,-0.019,0.079,0.289,0.333,0.219,0.173,0.075,0.208,-0.321,-0.076,0.046,-0.063,-0.022,0.006,0.014,0.067,-0.111,0.036,0.015,-0.012,-0.66,0.042,0.062,unmethylated
NH14-205,9989540022_R02C01,#003,,,2/26/2015,42061,SB,Epigenetics,003,4,NDP,NHNN,,"(6) Research sample, for stratification or subclassification",,4/17/1990,23.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.91,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-205,"Oligoastrocytoma (WHO grade II); positive for IDH1 mutation (R132H) 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #003\NH14-205,-0.038,-0.002,0.016,-0.051,0.048,-0.07,0.027,-0.006,-0.021,0.035,0.021,0.024,0,0.106,0,-0.042,0.036,0.017,0.027,0.086,0.076,0.052,-0.315,0,-0.033,0.004,-0.117,0.024,0.041,methylated
NH14-660,9989540022_R02C02,#003,,,2/26/2015,42061,SB,Epigenetics,003,4,NDP,NHNN,,"(6) Research sample, for stratification or subclassification",,6/4/1971,42.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.99,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-660,"Oligoastrocytoma (WHO Grade II); positive for IDH1 (R132H) and ATRX mutations  see comment
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #003\NH14-660,0.028,-0.149,0.011,-0.07,0.041,-0.271,0.066,0.127,0.088,0.043,0.027,0.025,0.067,0.079,-0.04,-0.029,0.072,-0.227,-0.022,0.046,-0.039,-0.058,-0.152,0.038,0.036,0.094,-0.211,0.083,0.051,unmethylated
NH14-261,9989540022_R03C01,#003,,,2/26/2015,42061,SB,Epigenetics,003,4,NDP,NHNN,,"(6) Research sample, for stratification or subclassification",,4/16/1988,25.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-261,"Oligoastrocytoma, WHO grade II. IDH1 mutation R132H
","Diffuse astrocytoma, IDH-mutant (WHO grade II)
 
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)

  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #003\NH14-261,-0.206,0.026,0.061,-0.036,0.024,-0.152,0.11,0.127,0.152,0.26,0.158,-0.021,0.102,0.384,-0.058,-0.014,0.036,-0.133,0.009,0.097,0.067,0.042,-0.128,-0.029,-0.08,-0.013,-0.14,0.026,0.079,unmethylated
NH14-855,9989540022_R03C02,#003,,,2/26/2015,42061,SB,Epigenetics,003,4,NDP,NHNN,,"(6) Research sample, for stratification or subclassification",,1/4/1973,41.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.97,AIDH,0.96,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-855,"Anaplastic oligoastrocytoma (WHO Grade III) 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #003\NH14-855,-0.151,0.032,0.068,-0.055,0.061,-0.098,-0.389,0.054,-0.036,0.073,0.02,-0.009,0.047,0.086,-0.37,-0.039,0.036,0.081,0.018,0.064,0.076,-0.024,-0.303,-0.047,-0.092,-0.017,-0.623,0.059,0.048,methylated
NH14-306,9989540022_R04C01,#003,,,2/26/2015,42061,SB,Epigenetics,003,4,NDP,NHNN,,"(6) Research sample, for stratification or subclassification",,6/20/1978,35.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.98,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-306,"Oligoastrocytoma (WHO Grade II)
","Astrocytoma, IDH-mutant (WHO grade II) 
IDH1/2Seq: Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Retained          
EGFR: No amplification          
Histone H3F3A (K27M IHC): No mutation     
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #003\NH14-306,0.014,-0.196,-0.088,-0.097,0.051,-0.119,-0.114,0.072,0.015,0.063,0.009,0.024,0.083,-0.049,0.022,-0.124,0.016,-0.079,-0.064,-0.035,-0.038,-0.044,0.002,0.091,0.019,0.037,-0.204,0.043,0.085,methylated
NH14-1319,9989540022_R04C02,#003,,,2/26/2015,42061,SB,Diagnostic,003,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,3/6/1959,55.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.39,AIDH,0.58,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-1319,"Anaplastic oligoastrocytoma (WHO grade III)  see comment
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #003\NH14-1319,-0.247,-0.045,0.079,0.001,0.157,-0.251,-0.089,0.19,0.05,0.17,0.06,0.009,0.016,0.025,-0.433,0.039,-0.037,0.054,-0.056,0.144,-0.052,-0.434,-0.172,-0.234,-0.002,0.002,-0.516,0.005,0.082,methylated
NH14-326,9989540022_R05C01,#003,,,2/26/2015,42061,SB,Diagnostic,003,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,5/3/1938,75.8,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.94,GBM_RTKII,0.61,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-326,"Anaplastic oligoastrocytoma (WHO Grade III); negative for mutant IDH-1 (R132H)  see comment
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #003\NH14-326,0.177,-0.058,-0.009,-0.045,0.035,-0.062,0.062,0.303,0.32,0.273,0.204,-0.019,-0.031,0.017,-0.043,0.02,-0.244,-0.505,-0.052,-0.002,0.034,0.081,-0.026,0.042,0.041,-0.017,-0.705,0.042,-0.22,methylated
NH14-1367,9989540022_R05C02,#003,,,2/26/2015,42061,SB,Diagnostic,003,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,11/15/1981,32.7,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.14,GBM_RTKII,0.22,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-1367,"Right medial frontal tumour : Anaplastic oligoastrocytoma (WHO grade III). No IDH1 or ATRX mutation.  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #003\NH14-1367,-0.07,0.061,0.086,0.021,-0.008,-0.149,0.083,0.44,0.25,0.269,0.22,-0.025,-0.034,-0.026,-0.016,0.233,-0.017,0.018,0.14,0.168,0.305,0.016,-0.016,-0.087,-0.043,-0.065,0.137,0.046,-0.017,methylated
NH14-411,9989540022_R06C01,#003,,,2/26/2015,42061,SB,Diagnostic,003,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,9/21/1967,46.5,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.59,AIDH,0.72,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-411,"Recurrent anaplastic oligoastrocytoma (WHO Grade III)  see comment
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #003\NH14-411,-0.244,0.072,0.03,-0.276,-0.007,-0.324,0.229,0.255,-0.005,0.207,0.021,-0.38,0.034,-0.419,0.139,-0.062,-0.039,0.045,-0.117,0.034,-0.011,-0.274,-0.023,-0.139,0.107,0.111,-0.698,0.038,0.094,methylated
NH14-2103,9989540022_R06C02,#003,,,2/26/2015,42061,SB,Diagnostic,003,5,NDP,NHNN,,"(4) IHC, sequencing, or copy number assay ambiguous",,6/27/1983,31.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-2103,"Oligoastrocytoma (WHO grade II)
IDH1 (R132H, IHC): No mutation
ATRX (IHC): Loss of expression
","Astrocytoma, IDH mutant (WHO grade II)
IDH1/2Seq: IDH1 mutation
ATRX (IHC): Loss of expression (indicates mutation)
MGMT Promoter: No/insignificant methylation*
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #003\NH14-2103,-0.126,0.059,0.051,-0.042,0.062,-0.278,0.09,0.001,0.001,0.08,0.001,0.005,0.052,0.081,0.004,-0.02,0.012,-0.022,0.063,0.04,-0.068,-0.112,-0.109,0.031,-0.043,-0.02,-0.124,0.085,0.038,unmethylated
NH08-210,9989540035_R05C02,#005,,,6/5/2015,42160,SB,Diagnostic,005,9,NDP,NHNN,GBM-PNET,"(2) unusual histology, location, demographics",DEF1A,9/5/1959,#N/A,"glioblastoma, IDH-wildtype, with primitive neuronal component",1,MB_SHHCHLAD,0.16,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH08-210,"Gliosarcoma with PNET-like features (WHO grade IV). Please read the diagnostic comment.
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #005\NH08-210,0.414,-0.16,-0.037,-0.069,-0.097,-0.166,0.042,0.322,0.29,0.251,0.227,-0.004,0.094,0.03,-0.076,-0.068,-2.12,-0.532,-0.096,-0.01,0.162,0.137,-0.264,-0.529,0.167,0.131,-0.175,-0.374,-0.123,methylated
NH15-1334,3999308207_R06C01,#007,20/07/2015,,8/6/2015,17,SB,Diagnostic,007,1,NDP,NHNN,Anaplastic astrocytoma,"(6) Research sample, for stratification or subclassification",SP1A,11/9/1981,33.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.94,AIDH,0.86,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH15-1334,"Anaplastic astrocytoma (WHO Grade III)

IDH1 (IHC and sequencing): repeat testing in progress
ATRX (IHC): Mutation present
Histone H3K27 (IHC): No mutation
1p/19q: No LOH (previously tested)
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3 [2021 WHO classification]
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: IDH glioma, subclass astrocytoma  
MGMT promoter (Illumina array): Methylated 
  
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #007\NH15-1334,0.065,-0.145,0.042,-0.102,-0.003,-0.125,-0.038,0.344,0.296,0.561,0.244,0.278,0.298,0.129,-0.073,-0.274,0.012,-0.053,-0.048,-0.069,0.122,-0.206,-0.185,0.111,0.162,0.006,-0.114,0.049,0.104,methylated
NH16-440,101070190045_R03C02,#013,2/3/2016,,3/16/2016,14,SB,Diagnostic,013,1,NDP,NHNN,Astrocytoma without high-grade features,"(4) IHC, sequencing, or copy number assay ambiguous",SP1A ,8/25/1962,53.5,"glioblastoma, IDH-wildtype, RTK1 type",0.39,GBM_RTKII,0.91,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-440,"Astrocytoma morphologically without high-grade features, please see comment.
 
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
1p/19q: Test pending
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #013\NH16-440,-0.079,-0.012,0.038,0.02,-0.017,0.019,-0.051,0.283,0.358,0.458,0.347,-0.022,-0.008,0.001,-0.329,0.231,-0.278,-0.271,-0.075,0.02,0.042,-0.032,0.018,0.089,0.092,-0.024,-0.005,-0.117,0.001,methylated
NH16-270,200512330080_R06C01,#014,4/5/2016,,6/10/2016,37,SB,Epigenetics,014,2,NDP,NHNN,Glioblastoma (Epigenetics study),"(6) Research sample, for stratification or subclassification",DEF1A,8/1/1951,64.6,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.97,0.56,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-270,"Glioblastoma (WHO Grade IV).

IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
1p/19q: Test pending
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #014\NH16-270,0.124,-0.117,0.003,-0.031,-0.144,0.008,0.016,1.613,0.238,0.266,0.25,-0.025,-0.003,-0.057,-0.481,-0.05,-0.024,-0.184,-0.122,-0.041,0.098,0.105,0.094,-0.106,0.013,0.057,0.244,0.039,0.057,methylated
NH16-580,200512330122_R04C01,#015,1/4/2016,,6/10/2016,70,SB,Diagnostic,015,3,NDP,"Charing Cross Hospital, London",Anaplastic oligodendroglioma ,"(4) IHC, sequencing, or copy number assay ambiguous",,7/4/1977,38.7,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.85,OIDH,0.98,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-580,"Anaplastic oligodendroglioma (WHO grade III) 
IDH1 (R132H IHC): IDH1 mutation; 
ATRX (IHC): Retained; 
1p/19q: See comment
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #015\NH16-580,0.009,-0.021,0.002,-0.132,-0.068,-0.123,-0.129,0.066,0.015,-0.029,0.013,0.04,0.048,-0.026,-0.113,0.017,0.032,-0.058,-0.062,0.006,-0.003,-0.11,0.042,-0.04,0.082,0.019,-0.342,0.214,0.221,methylated
NH16-623,200512330122_R05C01,#015,21/04/2016,,6/10/2016,50,SB,Diagnostic,015,4,NDP,Brighton and Sussex Hospital,Glioblastoma,"(4) IHC, sequencing, or copy number assay ambiguous",TBC,3/24/1973,43,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.95,AIDH_HG,0.92,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-623,"Glioblastoma (WHO Grade IV).

IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
1p/19q: Retained
",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #015\NH16-623,0.181,0.494,-0.005,-0.024,0.636,-0.163,-0.224,0.126,0.168,1.474,0.062,0.173,0.111,0.185,-1.518,0.092,-0.049,-0.235,0.05,-0.092,-0.077,-0.057,-0.316,0.011,-0.012,0.002,-0.296,0.057,0.131,unmethylated
NH16-862,200512330122_R06C01,#015,13/05/2016,,6/10/2016,28,SB,Diagnostic,015,4,NDP,"Cardiff, University Hospital","Clear cell tumour, possibly of glial lineage","(2) unusual histology, location, demographics",,4/5/1950,66.1,pleomorphic xanthoastrocytoma(-like),0.67,PXA,0.34,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-862,"Clear cell tumour, possibly of glial lineage (see comment).
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #015\NH16-862,-0.051,-0.055,-0.014,-0.154,-0.047,-0.122,-0.341,-0.008,0.055,0.057,-0.02,0.012,0.01,0.022,-0.053,-0.132,-0.172,-0.259,-0.409,-0.366,-0.331,-0.426,-0.324,-0.343,-0.498,-0.24,0.031,-0.05,-0.044,unmethylated
NH16-1084,200577430059_R08C01,#018,7/9/2016,,9/20/2016,13,SB,Epigenetics,018,11,NDP,NHNN,Glioblastoma (Epigenetics study),"(6) Research sample, for stratification or subclassification",DEF1A,10/16/1960,55.6,Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters,0.47,OIDH,0.09,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-1084,"Anaplastic oligodendroglioma, IDH mutant (WHO grade III)
","
Molecular and methylation profile: 

Anaplastic oligodendroglioma, IDH-mutant and 1p/19q codeleted (WHO grade III)

",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #018\NH16-1084,-0.001,-0.041,-0.02,-0.055,0.048,-0.008,-0.02,0.036,0.068,-0.034,-0.012,0.004,0.035,0.025,-0.281,-0.001,0.018,-0.02,-0.038,-0.055,-0.12,0.08,-0.015,-0.007,0.187,0.23,-0.262,0.006,0.019,unmethylated
NH16-2632,200577440025_R05C01,#019,15/11/2016,,1/13/2017,59,SB,Diagnostic,019,3,NDP,Royal London Hospital,"GBM, survived since 2012, check diagnosis","(2) unusual histology, location, demographics",B1,6/24/1943,68.9,pleomorphic xanthoastrocytoma(-like),0.98,PXA,0.76,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2632,"Anaplastic pleomorphic xanthoastrocytoma (WHO grade III)
BRAF V600E mutation (see comment)
",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #019\NH16-2632,-0.1,-0.148,0.142,-0.059,0.034,-0.065,-0.188,0.075,0.074,0.026,0.07,0.14,-0.074,-0.088,-0.818,0.259,-0.556,-0.547,0.021,-0.002,0.102,0.058,0.088,0.091,0.031,0.054,-0.022,-0.578,-0.287,methylated
NH16-2995,200362700166_R01C01,#020,16/01/2017,,1/26/2017,10,SB,Diagnostic,020,1,NDP,Royal London Hospital,IDH wtGBM?,"(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF1A,10/15/1978,38.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.53,GBM_RTKII,0.14,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2995,"Preliminary diagnosis:
Malignant tumour with features suggestive of glioblastoma (WHO grade IV)  see comment
","Glioblastoma (WHO grade IV) 
IDH1 (R132H IHC); IDH2 Seq: see comment 
ATRX (IHC): Retained 
1p/19q: Retained 
EGFR: Amplification (see comment)
MGMT Promoter: No methylation  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #020\NH16-2995,-0.086,0.069,0.075,0.038,-0.026,-0.201,0.193,-0.018,-0.045,-0.319,-0.19,-0.088,0.076,-0.491,-1.267,-0.068,-0.283,0.13,-0.093,0.038,0.09,-0.123,-0.275,-0.259,-0.011,0.074,-0.214,-0.039,0.086,methylated
NH17-100,200362700166_R01C02,#020,16/01/2017,,1/26/2017,10,SB,Diagnostic,020,4,NDP,Newcastle,Ependymoma molecular subtyping,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",5A,7/26/1981,35.3,"spinal ependymoma, MYCN-amplified",1,GBM_MYCN,0.6,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-100,"
Histological diagnosis: Anaplastic ependymoma (WHO grade III) 

Methylation class: Ependymoma, posterior fossa group A  see comment

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #020\NH17-100,-0.037,1.034,0.007,0.089,0,0.101,0.07,-0.048,0.096,0.066,0.007,-0.025,0.015,0.043,-0.123,-0.012,0.025,-0.012,0.002,-0.033,-0.361,-0.057,-0.018,-0.497,0.038,0.007,-0.082,0.003,0.015,unmethylated
NH16-2798,200362700166_R02C01,#020,16/01/2017,,1/26/2017,10,SB,Diagnostic,020,1,NDP,NHNN,"?Glioma, ?Inflammation",(1) small biopsy or nonrepresentative sample;,DEF2A,11/22/1947,69.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.47,GBM_MES,0.84,0.55,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2798,"
Probable glioma, molecular investigations pending, see comment

IDH1 (R132H IHC): No mutation, further tests pending 
ATRX (IHC): Retained      
1p/19q: Test pending
  
 
","
Molecular profile of Glioblastoma, IDH-wildtype (WHO grade IV)  see comment 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #020\NH16-2798,-0.023,-0.109,0.063,0.064,-0.026,0.021,-0.232,0.237,0.165,0.146,0.124,-0.013,0.042,-0.024,-0.119,0.026,-0.112,-0.082,0.001,0.01,-0.024,-0.042,0.029,-0.034,0.03,-0.001,0.033,-0.176,-0.067,unmethylated
NH16-2771,200362700166_R02C02,#020,16/01/2017,,1/26/2017,10,SB,Diagnostic,020,1,NDP,"Cambridge, Addenbrooke's Hospital",GBM vs Ganglioglioma,"(2) unusual histology, location, demographics",E1,3/10/1960,56.7,"glioblastoma, IDH-wildtype, mesenchymal type",0.21,GBM_MES,0.51,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2771,"Appearances compatible with anaplastic ganglioglioma (WHO grade III)  see comment
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #020\NH16-2771,1.024,-0.041,0.016,0.141,-0.015,0.089,0.086,0.065,0.172,0.163,0.11,-0.054,0.027,0.089,-0.113,-0.043,-0.213,-0.047,0.038,-0.058,0.621,-0.164,0.002,-0.14,0.33,0.005,0.119,-0.035,0.005,methylated
NH16-2435,200362700166_R03C01,#020,16/01/2017,,1/26/2017,10,SB,Diagnostic,020,1,NDP,Romford,IDH wt GBM??,"(4) IHC, sequencing, or copy number assay ambiguous",C1,1/21/1978,38.8,diffuse leptomeningeal glioneuronal tumour,1,DLGNT,0.74,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2435,"
High grade glioma, IDH-wild-type, corresponding to at least WHO grade III  see comment

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
1p/19q: Retained (LOH1p)
EGFR: No amplification
Chromosome 7p: Gain (4 copies)
TERT promoter: Test failed repeatedly
Chromosome 10q: LOH

Histone H3F3A: No mutation
BRAF (V600E): No mutation 
",#REF!,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #020\NH16-2435,0.238,-0.096,-0.025,0.04,0.001,0.017,-0.011,0.173,0.337,0.322,0.325,0.202,0.222,0.175,-0.034,0.025,0.075,0.023,0.074,0.024,0.029,-0.174,0.007,-0.014,0.02,-0.02,-0.069,0.028,-0.025,unmethylated
NH16-2875,200362700166_R03C02,#020,14/12/2016,,1/26/2017,43,SB,Diagnostic,020,9,NDP,NHNN,Medulloblastoma vs. Metastatic small cell lung ,"(2) unusual histology, location, demographics",SP1A,10/17/1958,58.2,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.16,ETMR,0.08,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2875,"Favour metastatic small cell (neuroendocrine) carcinoma, see comment
",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #020\NH16-2875,-0.125,-0.039,0.044,-0.029,-0.184,0.152,0.061,0.052,-0.166,-0.278,0.159,-0.44,0.361,0.436,-0.042,-0.273,-0.051,-0.02,-0.299,0.183,0.135,-0.058,-2.444,0.002,0.699,-0.04,0.001,-0.283,-0.099,unmethylated
NH17-3,200362700166_R04C01,#020,10/1/2017,,1/26/2017,16,SB,Diagnostic,020,4,NDP,NHNN,?Glioblastoma,"(2) unusual histology, location, demographics",DEF1A,7/25/1963,53.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.8,GBM_MES,0.95,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-3,"Recurrent glioblastoma, IDH wild-type (WHO grade IV)

","
Glioblastoma, IDH-wildtype (WHO grade IV)

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #020\NH17-3,-0.05,-0.077,-0.024,0.381,0.065,0.133,0.06,0.245,0.352,0.372,0.225,-0.02,0.025,-0.014,-0.091,-0.017,0.021,-0.01,0.004,0.114,0.265,0.068,0.02,-0.03,0.06,0.027,0.115,-0.109,-0.166,unmethylated
NH16-2566,200362700166_R04C02,#020,16/01/2017,,1/26/2017,10,SB,Diagnostic,020,1,NDP,London Clinic,"Spinal Glioma, inconclusive molpath","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1 (9125-..),10/25/1983,33,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.47,LGG_RGNT,0.61,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2566,"Preliminary diagnosis:     Glial tumour, no definite high grade features  see comment

","
Methylation profile most in keeping with pilocytic astrocytoma (WHO grade I)  see comment
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #020\NH16-2566,-0.018,-0.062,0.031,0.011,-0.066,0.021,0.12,-0.031,0.016,0.015,0.015,0.005,0.048,0.016,-0.042,-0.011,-0.002,0.033,0.035,0.005,-0.02,0.001,0.056,-0.038,0.021,0.041,-0.018,-0.075,0.046,methylated
NH16-2660,200362700166_R05C01,#020,16/01/2017,,1/26/2017,10,SB,Diagnostic,020,4,NDP,NHNN,Subependymoma (??),"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,7/11/1958,58.4,infratentorial pilocytic astrocytoma,0.23,LGG_MYB,0.49,0.59,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2660,"Subependymoma (WHO grade I)
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #020\NH16-2660,0.161,-0.491,0.045,0.008,-0.084,0.116,-0.207,-0.075,0.065,0.172,0.049,0.126,-0.182,0.054,-0.268,0.058,-0.194,0.041,-0.146,-0.161,-0.023,0.198,0.071,-0.187,0.022,-0.021,0.166,-0.146,-0.272,unmethylated
NH16-2561,200362700166_R05C02,#020,16/01/2017,,1/26/2017,10,SB,Diagnostic,020,3,NDP,Romford,"LGG, unclear type","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A5,2/25/1993,23.7,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.5,CONTR_HEMI,0.36,0.59,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2561,"
Preliminary diagnosis:

Low grade glioma  see comment

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
1p/19q: Retained
EGFR: No amplification
Chromosome 7p: Gain (3 copies)
TERT promoter: No mutation
Chromosome 10q: LOH

Histone H3F3A: No mutation
BRAF (V600E): No mutation 
","
INTEGRATED DIAGNOSIS:

Diffuse glioma, IDH-mutant (WHO grade II)  for typing see supplementary comment
 
IDH1 (R132H IHC); IDH1/2 Seq: Mutation
ATRX (IHC): Retained
1p/19q: Retained
TERT promoter: Test unsuccessful 

Histone H3F3A: No mutation
BRAF (V600E): No mutation 


",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #020\NH16-2561,-0.014,-0.039,0.036,-0.018,-0.069,0.015,0.088,0.025,0.052,0.057,0.019,0.011,0.067,-0.016,0.018,-0.02,0.036,0.05,-0.017,0.051,-0.007,-0.056,0.052,-0.101,0.002,0.012,-0.105,-0.076,0.008,methylated
NH16-2872,200362700166_R06C01,#020,16/01/2017,,1/26/2017,10,SB,Diagnostic,020,1,NDP,London Clinic,"Unclear glioma., CHECK REOPERATION FIRST ","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1B,4/17/1977,39.7,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.52,LGG_GG,0.23,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2872,"Infiltration zone of a glioma, see comment
","Infiltration zone of a glioma.
Molecular test results non-contributory

COMMENT:
The molecular test excludes any type of IDH mutant glioma. Also, the possibility of a BRAFV600E mutant low grade glioma can be excluded. All other tests are non-contributory, i.e. they do not allow for a further differential diagnosis.
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #020\NH16-2872,-0.135,-0.08,-0.004,0.029,-0.042,0.026,-0.067,0.288,0.243,0.265,0.2,-0.035,0.065,-0.048,-0.072,-0.039,-0.385,-0.093,-0.085,-0.022,-0.007,-0.083,0.086,-0.147,0.106,0.068,0.053,-0.23,-0.101,unmethylated
NH16-2851,200362700166_R06C02,#020,14/12/2016,,1/26/2017,43,SB,Diagnostic,020,4,NDP,NHNN,Ependymoma molecular subtyping,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2A,4/20/1973,43.7,spinal ependymoma,0.99,EPN_SPINE,0.91,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2851,"Ependymoma (WHO grade II).
","
Ependymoma (WHO grade II)

Methylation class: ependymoma, spinal
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #020\NH16-2851,0.013,-0.155,-0.03,-0.001,0.126,0.017,-0.016,0,0.032,-0.004,0,-0.197,-0.064,-0.129,-0.009,0.096,0.009,0.065,-0.052,0.092,0.072,0.001,-0.259,-0.078,0.093,-0.013,0.076,-0.342,-0.308,unmethylated
NH16-1240,200577440082_R01C01,#021,26/01/2017,,2/9/2017,14,SB,Epigenetics,021,3,NDP,NHNN,"GBM, Epigenetics","(6) Research sample, for stratification or subclassification",DEF2A,9/4/1965,50.8,"glioblastoma, IDH-wildtype, RTK2 type",0.99,GBM_RTKII,0.87,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-1240,"Glioblastoma (WHO grade IV)

IDH1 (R132H IHC): No mutation.  
ATRX (IHC): Technically not satisfactory.    
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #021\NH16-1240,-0.017,-0.082,0.24,-0.044,-0.122,0.056,-0.467,0.221,0.298,0.366,0.267,-0.02,-0.018,0.087,-2.053,0.015,-0.426,-0.42,-0.001,0.224,0.033,0.02,-0.486,-0.429,-0.532,-0.011,-0.062,-0.095,0.071,unmethylated
NH16-2214,200577440082_R02C01,#021,26/01/2017,,2/9/2017,14,SB,Epigenetics,021,1,NDP,NHNN,"GBM, Epigenetics","(6) Research sample, for stratification or subclassification",DEF1A,12/11/1942,73.8,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.96,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2214,"Glioblastoma, IDH wild-type (WHO grade IV)

IDH1 (R132H IHC): No mutation; further tests pending 
ATRX (IHC): Retained (no mutation)
1p/19q: Test pending
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #021\NH16-2214,0.001,0.002,0.033,-0.07,0.037,0.046,0.06,1.096,0.157,0.19,0.118,-0.024,-0.03,0.051,-0.582,0.039,-0.243,-0.127,-0.015,-0.019,0.483,0.685,-0.214,0.04,0.023,-0.061,0,-0.021,-0.006,methylated
NH16-1976,200577440082_R03C01,#021,26/01/2017,,2/9/2017,14,SB,Epigenetics,021,1,NDP,NHNN,"GBM, Epigenetics","(6) Research sample, for stratification or subclassification",DEF1A,4/26/1968,48.4,"glioblastoma, IDH-wildtype, RTK2 type",0.99,GBM_RTKII,0.96,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-1976,"Glioblastoma (WHO grade IV)
 
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
1p/19q: Test pending
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #021\NH16-1976,0.136,-0.046,0.027,0.023,0.269,0.013,-0.014,1.474,0.295,0.323,0.233,-0.014,0.061,0.035,-0.018,0.029,-0.324,-0.305,-0.09,-0.013,1.059,2.055,-0.064,0.045,0.164,0.082,0.182,0,0.082,unmethylated
NH16-2251,200577440082_R05C01,#021,26/01/2017,,2/9/2017,14,SB,Epigenetics,021,4,NDP,NHNN,"GBM, Epigenetics","(6) Research sample, for stratification or subclassification",DEF1C,10/2/1948,68,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.97,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2251,"
Glioblastoma (WHO grade IV) 

IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
1p/19q: Test pending
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #021\NH16-2251,0.305,-0.063,0.049,-0.022,-0.018,0.02,-0.009,1.358,0.38,0.217,0.156,-0.006,0.026,0.045,-1.359,0.002,-0.375,-0.321,-0.011,-0.02,-0.006,0.011,-0.014,0.011,0.079,0.078,-0.059,-0.022,0.02,unmethylated
NH16-2255,200577440082_R06C01,#021,26/01/2017,,2/9/2017,14,SB,Epigenetics,021,3,NDP,NHNN,"GBM, Epigenetics","(6) Research sample, for stratification or subclassification",DEF1D,12/24/1949,66.8,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.88,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2255,"
Glioblastoma (WHO Grade IV) 

IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
1p/19q: Test pending


",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #021\NH16-2255,-0.129,-0.083,0.036,-0.025,-0.007,0.017,-0.36,1.221,0.246,0.335,0.232,0.007,0.015,0.005,-1.606,0.014,-0.366,-0.312,-0.067,-0.07,0.004,-0.002,0.003,-0.011,0.044,0.031,0.203,-0.04,0.061,unmethylated
NH16-2342,200577440082_R07C01,#021,26/01/2017,,2/9/2017,14,SB,Epigenetics,021,4,NDP,NHNN,"GBM, Epigenetics","(6) Research sample, for stratification or subclassification",DEF1D,3/27/1972,44.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.96,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH16-2342,"Glioblastoma (WHO grade IV), IDH1 mutant

IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (mutated)
1p/19q: Test pending
",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #021\NH16-2342,0.031,-0.111,-0.003,-0.041,-0.062,0.014,0.039,-0.12,-0.433,-0.163,-0.101,-0.008,-0.012,0.03,-0.334,0.04,0.011,0.038,-0.052,0.179,-0.009,-0.361,-0.13,-0.008,-0.032,0.02,-0.012,-0.212,-0.247,methylated
NH16-2806,200577440082_R08C01,#021,26/01/2017,,2/9/2017,14,SB,Epigenetics,021,3,NDP,NHNN,"GBM, Epigenetics","(6) Research sample, for stratification or subclassification",DEF1B,6/10/1950,66.5,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.99,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2806,"Glioblastoma (WHO grade IV)

IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained
1p/19q: Test pending
","INTEGRATED DIAGNOSIS:

Glioblastoma, IDH-wildtype (WHO grade IV)

MGMT Promoter: Low level methylation (10%)

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
1p/19q: Retained
EGFR: Moderate amplification
TERT promoter: Test unsuccessful repeatedly 
Chromosome 10q: LOH

Histone H3F3A: No mutation
BRAF (V600E): No mutation 

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #021\NH16-2806,-0.13,-0.074,0.026,-0.11,-0.058,0.027,0.144,1.544,-0.021,0.025,-0.044,-0.025,0.131,0.028,-1.89,0.019,-0.449,-0.419,-0.038,-0.028,-0.002,-0.006,0.043,0.014,0.059,0.086,0.187,-0.093,0.064,methylated
NH11-44,200362700167_R01C01,#022,16/01/2017,,2/24/2017,39,SB,Diagnostic,022,4,NDP,NHNN,GBM IDHwt. Long survival,"(6) Research sample, for stratification or subclassification",SP1A,3/8/1947,63.9,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.97,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH11-44,"Glioblastoma multiforme, WHO grade IV
","INTEGRATED DIAGNOSIS:

Glioblastoma, IDH-wildtype (WHO grade IV) 

(Methylation profile of glioblastoma, IDH-wildtype, subclass mesenchymal)


",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #022\NH11-44,-0.019,-0.251,-0.089,0.109,-0.155,-0.07,-0.069,0.15,0.356,0.369,0.14,-0.086,0.027,-0.029,-0.014,-0.019,-0.17,-0.236,-0.143,-0.097,-0.02,-0.282,0.075,-0.08,0.204,0.032,-0.122,-0.08,-0.011,methylated
NH17-157,200362700167_R01C02,#022,13/02/2017,,2/24/2017,11,SB,Diagnostic,022,6,NDP,Brighton and Sussex Hospital,"GBM, ATRX loss, IDH-wildtype; H3-wildtype","(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF1A,5/17/1974,42.7,"Diffuse hemispheric glioma, H3 G34-mutant",1,GBM_G34,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-157,"Glioblastoma (WHO grade IV), please see comment.
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Test pending
","
Methylation profile: Glioblastoma, IDH-wildtype, H3.3 G34 mutant (WHO grade IV)

Molecular profile: Glioblastoma, IDH-wildtype (WHO grade IV)  see comment

MGMT Promoter: Intermediate level of methylation (15%)

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Loss of expression (indicates mutation)

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #022\NH17-157,0.147,-0.284,-0.043,0.01,0.156,0.066,0.052,-0.033,0.619,0.175,0.012,0.026,0.148,-0.052,-0.255,0.005,0.004,0.061,-0.112,0.032,0.026,-0.071,-0.414,-0.008,0.165,0.104,-0.099,-0.092,0.019,methylated
NH17-131,200362700167_R02C01,#022,19/01/2017,,2/24/2017,36,SB,Diagnostic,022,4,NDP,NHNN,"Recurrent ""1p/19q codel"", IDH wt glioma. ? PXA?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,4/28/1972,44.8,pleomorphic xanthoastrocytoma(-like),0.21,PXA,0.51,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-131,"
High grade glial tumour, await molecular profiling for final diagnosis, see comment. 

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
1p/19q: Test pending
  
","
Molecular profile compatible with glioblastoma, IDH-wildtype (WHO grade IV)  see comment

MGMT Promoter: No methylation

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
1p/19q: Partial 1p loss (detected on Illumina 450k copy number variation profile; qPCR  inconclusive results)
EGFR: No amplification
Chromosome 7p: Gain (detected with qPCR and Illumina 450k)
TERT promoter: No mutation
Chromosome 10q: LOH (detected with qPCR and Illumina 450k)

Histone H3F3A: No mutation
BRAF (V600E): No mutation 

Illumina 450k copy number variation profile: Multiple chromosomal losses

",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #022\NH17-131,0.045,-0.079,-0.048,-0.197,-0.174,-0.074,0.001,0.143,0.246,0.278,0.132,-0.026,0.056,0.015,-0.255,-0.023,-0.216,-0.285,-0.353,0.007,0.002,-0.168,-0.286,-0.284,-0.233,-0.305,-0.042,-0.284,-0.312,unmethylated
NH17-211,200362700167_R02C02,#022,1/2/2017,,2/24/2017,23,SB,Diagnostic,022,7,NDP,Royal London Hospital,?GBM; ?PA,"(2) unusual histology, location, demographics",DEF1A,7/27/1994,22.5,infratentorial pilocytic astrocytoma,0.66,LGG_PAPF,0.57,0.5,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-211,"The features are those of a glioma. The most likely differential lies between a pilocytic astrocytoma and an ependymoma, however the morphology is unusual. High grade features are not seen. 
","Pilocytic astrocytoma (WHO grade I)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #022\NH17-211,-0.121,-0.061,0.046,0.034,-0.071,0.031,0.008,0.164,0.246,0.217,0.191,-0.005,0.044,-0.02,0.011,-0.004,0.185,0.201,0.176,0.22,0.086,0.141,0.086,-0.086,-0.037,0.036,0.002,-0.043,0.072,unmethylated
NH17-168,200362700167_R03C02,#022,19/01/2017,,2/24/2017,36,SB,Diagnostic,022,1,NDP,NHNN,?GBM,"(2) unusual histology, location, demographics",DEF2B,12/11/1979,37.1,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,0.23,ANAPA,0.77,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-168,"Histology and immunohistochemistry favour glioblastoma (WHO grade IV). Please see comment.
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
1p/19q: Test pending
","INTEGRATED DIAGNOSIS:

Histological diagnosis: High grade astrocytoma, for grading  see comment
Methylation profile: Anaplastic pilocytic astrocytoma  see comment

MGMT Promoter: Intermediate level of methylation (15%)

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
1p/19q: Retained
EGFR: No amplification
Chromosome 7p: Gain (detected with qPCR and Illumina 450k array)
TERT promoter: Test unsuccessful repeatedly
Chromosome 10q: LOH (detected with qPCR)

Histone H3F3A: No mutation
BRAF (V600E): No mutation 
Illumina 450k array: Multiple chromosomal deletions (see below) 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #022\NH17-168,-0.052,-0.298,0.016,-0.033,0.094,0.187,0.149,0.186,0.102,0.157,0.073,-0.072,0.086,-0.04,-0.532,-0.026,-0.024,0.07,-0.145,0.022,-0.04,-0.076,-0.186,-0.378,0.09,0.118,-0.245,-0.236,-0.18,methylated
NH16-2577,200362700167_R04C01,#022,16/01/2017,,2/24/2017,39,SB,Diagnostic,022,3,NDP,"Charing Cross Hospital, London",Oligodendroglioma,(1) small biopsy or nonrepresentative sample;,F1,2/25/1975,41.7,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2577,"
Infiltration margin of diffuse glioma, IDH-mutant - see comment

MGMT Promoter: Low level methylation (10%)

IDH1 (R132H IHC); IDH1/2 Seq: IDH1 mutation
ATRX (IHC): Retained
1p/19q: Retained
EGFR: No amplification
Chromosome 7p: Gain (3 copies)
TERT promoter: Test unsuccessful repeatedly
Chromosome 10q: Retained

BRAF (V600E): No mutation 


","INTEGRATED DIAGNOSIS:

Anaplastic oligodendroglioma, IDH-mutant and 1p/19q codeleted (WHO grade III)

MGMT Promoter: Low level methylation (10%)

IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
1p/19q: Codeleted (detected via copy number assessment using Illumina 450k methylation profiling) 
Chromosome 7p and EGFR: No significant gain and no amplification
TERT promoter: Test unsuccessful repeatedly 
Chromosome 10q: Retained

Histone H3F3A: No mutation
BRAF (V600E): No mutation 


",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #022\NH16-2577,0,-0.098,-0.081,-0.086,-0.165,-0.015,0.044,0.03,0.071,0.082,0.012,0,0.087,-0.058,-0.049,0.031,0.063,-0.024,-0.016,0.074,-0.009,-0.056,0.058,0.04,0.107,0.072,-0.562,0.152,0.206,methylated
NH17-156,200362700167_R04C02,#022,19/01/2017,,2/24/2017,36,SB,Diagnostic,022,1,NDP,Royal London Hospital,"High grade glioma, nos ?ependymoma","(2) unusual histology, location, demographics",DEF1A,12/18/1988,28.1,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.09,GBM_RTKII,0.32,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-156,"High grade glial tumour. Please see comment.
","INTEGRATED DIAGNOSIS:

Methylation profile in favour of Glioblastoma, IDH-wildtype (WHO grade IV)

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #022\NH17-156,0.151,-0.186,-0.014,-0.052,-0.134,0.027,0.023,-0.005,0.025,0.049,0,-0.022,0.067,-0.043,-0.008,-0.032,-0.232,-0.305,-0.226,-0.085,-0.038,-0.041,-0.028,-0.314,0.056,0.052,-0.032,-0.175,-0.223,unmethylated
NH16-2903,200362700167_R05C02,#022,8/2/2017,,2/24/2017,16,SB,Diagnostic,022,1,NDP,Oxford John Radcliffe Hospital,"Glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,8/15/1955,61.3,posterior fossa subependymoma,0.86,SUBEPN_PF,0.95,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2903,"Referred diagnosis: 
Glioma, NOS  see comment
","Molecular profile of subependymoma (WHO grade I)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #022\NH16-2903,-0.036,-0.146,-0.016,0.105,-0.039,0.117,-0.077,0.011,0.012,0.04,0.009,-0.03,0.001,-0.441,-0.064,0.004,0.014,0.037,-0.064,-0.04,-0.007,-0.051,0.184,0.132,0.242,0.157,0.157,0.174,0.197,unmethylated
NH17-171,200362700167_R06C01,#022,19/01/2017,,2/24/2017,36,SB,Diagnostic,022,1,NDP,Royal London Hospital,?GBM; ?PXA,"(2) unusual histology, location, demographics",DEF1A,11/28/1960,56.2,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.99,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-171,"Glioblastoma (WHO grade IV)
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained
1p/19q: Test pending
","INTEGRATED DIAGNOSIS:

Glioblastoma, IDH-wildtype (WHO grade IV)

(Methylation profile of glioblastoma, IDH-wildtype, subclass mesenchymal)

MGMT Promoter: Low level methylation (10%)

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
1p/19q: Retained
EGFR: No amplification
Chromosome 7p: Gain (5 copies)
TERT promoter: Mutation

Histone H3F3A: No mutation
BRAF (V600E): No mutation 


",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #022\NH17-171,0.24,-0.058,-0.013,0.012,-0.049,-0.029,-0.185,0.556,0.028,0.019,0.021,0.016,0.016,-0.068,-0.566,-0.024,-0.113,-0.107,-0.082,-0.013,-0.031,-0.016,-0.158,-0.095,0.119,0.023,-0.01,-0.176,-0.156,methylated
NH17-386,200362700167_R06C02,#023,16/02/2017,,2/24/2017,8,SB,Diagnostic,023,1,NDP,NHNN,?pilocytic,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,10/24/1977,39.3,high-grade astrocytoma with piloid features,0.63,ANAPA,0.87,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-386,"Preliminary diagnosis: 
Glial (or glioneuronal) tumour; molecular studies in progress for typing and grading of the tumour  see comment 
","Methylation profile of anaplastic pilocytic astrocytoma (see previous comments grading)
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #023\NH17-386,-0.017,-0.111,0.045,0.066,-0.037,0.064,0.246,-0.016,0.003,-0.001,0.002,-0.031,0.02,-0.072,0.125,0.126,0.134,0.14,0.079,-0.034,-0.047,-0.067,0.012,-0.121,-0.027,0.063,0.044,-0.269,-0.222,unmethylated
NH17-414,200069280223_R01C02,#023,22/03/2017,,4/7/2017,16,SB,Diagnostic,023,3,NDP,"Belfast, Royal Victoria Hospital",,"(4) IHC, sequencing, or copy number assay ambiguous",417463,5/31/1974,42.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-414,"
Astrocytoma, IDH-mutant  for grading, see comment below and the original pathology report (41700463, Belfast)

MGMT Promoter: Low level methylation (10%)

IDH1 (R132H IHC): Mutation  
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Retained (confirmed with qPCR and Illumina 450k array)

EGFR: No amplification
Chromosome 7p: Gain (confirmed with qPCR and Illumina 450k array)

TERT promoter: Test unsuccessful repeatedly 
Chromosome 10q: Test unsuccessful repeatedly

",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #023\NH17-414,-0.035,-0.104,-0.026,-0.079,-0.029,-0.073,0.015,0.172,0.046,0.053,0.178,0.018,0.019,0.021,-0.053,-0.035,0.069,-0.032,-0.043,0.005,0.01,-0.131,-0.001,-0.035,0.005,0.035,-0.147,0.024,-0.047,methylated
NH16-378,200069280223_R02C01,#023,8/2/2017,,4/7/2017,58,SB,Diagnostic,023,1,NDP,NHNN,"Low grade glioneuronal tumour (to confirm)IDHwt, ATRX retained","(2) unusual histology, location, demographics",DEF1A,10/24/1977,38.3,supratentorial pilocytic astrocytoma,0.33,LGG_PAPF,0.45,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-378,"Low grade glioneuronal tumour, see comment
","
Methylation profile of anaplastic pilocytic astrocytoma  see supplementary comment

",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #023\NH16-378,-0.093,0.024,0.023,-0.003,-0.026,-0.033,0.269,-0.063,0.078,-0.018,-0.014,-0.074,0.013,0.069,0.182,0.079,0.136,0.137,0.153,0.053,0.032,-0.011,0.066,-0.045,-0.064,0.027,-0.034,-0.17,-0.122,unmethylated
NH17-314,200069280223_R03C01,#023,22/02/2017,,4/7/2017,44,SB,Diagnostic,023,1,NDP,NHNN,Low grade glioma: Diffuse astrocytoma vs. Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,6/7/1999,17.7,"diffuse glioma, MYB(L1)-altered, subtype D",1,LGG_MYB,1,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-314,"Low grade glioma (WHO Grade II)  see comment
 
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Technically suboptimal
1p/19q: Test pending
","Low grade glial tumour, NOS (see comment)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #023\NH17-314,-0.052,-0.028,0.02,0.033,-0.072,0.005,0.067,-0.039,0.047,0.038,-0.003,0.002,0.219,-0.009,-0.002,-0.04,0.065,0.022,0.029,-0.033,0.012,0.041,0.003,0.001,0.019,0.037,-0.118,-0.029,-0.006,unmethylated
NH17-380,200069280223_R05C01,#023,14/02/2017,,4/7/2017,52,SB,Diagnostic,023,1,NDP,Nottingham University Hospital,,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,5/5/2005,11.8,spinal subependymoma [subtype A],0.35,SUBEPN_SPINE,0.62,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-380,"Methylation profile suggestive of subependymoma (WHO grade I)  see comment
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #023\NH17-380,-0.042,-0.024,0.039,-0.037,-0.047,-0.019,0.065,-0.009,0.011,0.085,-0.007,-0.019,0.066,0.018,0.046,-0.043,0.012,0.016,-0.034,-0.035,-0.025,0.018,0.022,-0.032,0.035,-0.028,-0.09,0.03,-0.013,unmethylated
NH17-683,200069280223_R06C01,#023,17/03/2017,,4/7/2017,21,SB,Diagnostic,023,5,NDP,"Leeds, St James's University Hospital",,"(5) Confirmation of rare, unusual or interesting histo-molecular results",B1,9/5/1971,45.6,"Diffuse hemispheric glioma, H3 G34-mutant",1,GBM_G34,1,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-683,"
Glioblastoma, H3.3 G34R mutant (WHO grade IV)

IDH1 (R132H IHC): No mutation
ATRX (IHC): Loss of expression (indicates mutation)
Histone H3F3A (G34R IHC and Seq): Mutation
",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #023\NH17-683,-0.031,-0.05,-0.184,-0.01,0.15,0.099,0.106,-0.049,0.425,0.324,0.147,-0.032,0.137,-0.037,-0.482,0.279,-0.171,-0.532,-0.011,-0.065,0.001,-0.071,-0.509,-0.652,0.137,0.03,-0.851,-0.262,-0.287,methylated
NH17-419,200069280223_R06C02,#023,24/03/2017,,4/7/2017,14,SB,Diagnostic,023,1,NDP,"Birmingham, Queen Elizabeth Hospital",?anaplstic pilocytic astrocytoma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,8/31/1979,37.5,high-grade astrocytoma with piloid features,0.89,ANAPA,0.86,0.53,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-419,"Preliminary diagnosis:
Appearances raising the possibility of anaplastic pilocytic astrocytoma  for grading and typing see also comment
","Methylation profile of anaplastic pilocytic astrocytoma  for grading, see supplementary comment 
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #023\NH17-419,-0.057,-0.086,-0.027,-0.022,-0.029,0.005,0.012,0.002,0.084,0.15,0.059,-0.018,0.156,0.033,-0.344,0.009,-0.006,0.033,-0.019,0.008,0.081,0.126,-0.01,-0.031,0.043,0.003,-0.122,-0.053,0.068,methylated
NH17-916,200362700171_R01C01,#024,21/04/2017,,6/2/2017,42,SB,Diagnostic,024,6,NDP,NHNN,Subependymoma with associated ganglioglioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1B (subependymoma),7/9/1947,69.8,supratentorial subependymoma,0.94,SUBEPN_ST,0.94,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-916,"Composite subependymoma ganglioglioma (WHO Grade I)  see comment
","
Molecular profile of subependymoma (WHO grade I)  see supplementary comment
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #024\NH17-916,-0.119,-0.013,0.054,0.038,-0.051,-0.007,-0.021,0.004,0.028,0.103,-0.002,-0.252,-0.224,-0.259,0.005,-0.029,0.017,0.004,-0.029,-0.056,-0.006,0.045,0.039,-0.039,-0.068,0.068,-0.07,-0.021,0.045,unmethylated
NH17-1123,200362700171_R01C02,#024,19/05/2017,,6/2/2017,14,SB,Diagnostic,024,5,NDP,"Belfast, Royal Victoria Hospital",APA vs H3mt Diffuse midline glioma (ATRX loss),"(4) IHC, sequencing, or copy number assay ambiguous",,1/17/1944,73.3,high-grade astrocytoma with piloid features,1,ANAPA,0.97,0.53,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1123,"
Methylation profile of anaplastic pilocytic astrocytoma  see comment
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #024\NH17-1123,-0.117,-0.086,0.024,-0.015,-0.061,0.033,-0.133,-0.008,0.001,0.031,0.023,0.02,-0.049,0.009,-0.272,0.001,0.005,0.011,-0.006,-0.06,0.04,0.214,-0.049,-0.023,-0.106,0.114,-0.051,0.02,0.061,methylated
NH17-1036,200362700171_R02C02,#024,22/05/2017,,6/2/2017,11,SB,Diagnostic,024,4,NDP,"Belfast, Royal Victoria Hospital",AO vs GBM,"(4) IHC, sequencing, or copy number assay ambiguous",,10/11/1980,36.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1036,"
High grade glioma, IDH-mutant  see comment

MGMT Promoter: High level methylation (75%)

IDH1 (R132H IHC); IDH1/2 Seq: Mutation  
ATRX (IHC): Retained
1p/19q: Raising the possibility of codeletion, but qPCR test is inconclusive requirying further / repeated testing
EGFR: Weak amplification
TERT promoter: Test unsuccessful
Chromosome 10q: Test unsuccessful 

Histone H3F3A: No mutation
BRAF (V600E): No mutation 

","
Glioblastoma, IDH-mutant (WHO grade IV)

MGMT Promoter: High level methylation (75%)

IDH1 (R132H IHC): Mutation  
ATRX (IHC): Retained
1p/19q: Retained (as per Illumina 450k array CNV profile)

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #024\NH17-1036,-0.16,-0.027,-0.011,-0.024,0.047,-0.008,-0.513,0.051,0.023,0.124,0.029,-0.016,0.069,0.168,-0.022,-0.096,-0.755,-0.444,-0.064,0.2,0.85,-0.07,0.013,-0.184,0.001,0.031,-0.147,-0.083,0.005,methylated
NH17-1049,200362700171_R03C02,#024,22/05/2017,,6/2/2017,11,SB,Diagnostic,024,5,NDP,Royal London Hospital,"IDHwt diffuse glioma, low grade",(1) small biopsy or nonrepresentative sample;,DEF1A,6/27/1985,31.9,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.26,GBM_RTKII,0.36,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1049,"
Low grade glioma (WHO grade II) (see comment)
  
IDH1 (R132H IHC): No mutation ; Further tests pending 
ATRX (IHC): Retained      
1p/19q: Test pending
  
","Histological diagnosis:
Low grade glioma (WHO grade II)

Molecular and methylation profile: 
Raising the possibility of infiltration margin or early stage of IDH-wildtype glioblastoma (WHO grade IV)

MGMT Promoter: No methylation

IDH1 (R132H IHC); IDH1/2 Seq: No mutation
ATRX (IHC): Retained
1p/19q: Retained

Histone H3F3A: No mutation
BRAF (V600E): No mutation 

",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #024\NH17-1049,-0.092,0.012,0.043,0.044,-0.04,0.017,-0.37,0.178,-0.054,-0.133,-0.001,0.021,-0.057,0.007,-0.295,-0.03,-0.275,-0.229,-0.017,-0.045,-0.01,0.038,-0.323,0.015,-0.155,-0.006,0.018,-0.248,-0.157,unmethylated
NH17-1079,200362700171_R03C01,#024,9/5/2017,,6/2/2017,24,SB,Diagnostic,024,2,NDP,Romford,?glioneuronal tumour; await MB4 results before processing,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,10/15/1966,50.5,ganglioglioma,0.49,LGG_MYB,0.37,0.56,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1079,"Low grade glioma, methylation class ganglioglioma (WHO grade I)
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #024\NH17-1079,-0.083,0.021,0.048,0.103,0.05,0.01,-0.204,0.163,0.133,0.113,0.134,0.013,-0.047,-0.004,-0.027,-0.084,-0.145,-0.108,-0.017,-0.007,0.047,0.085,-0.162,0.008,-0.117,-0.066,0.084,-0.076,0.083,unmethylated
NH17-1017,200362700171_R04C01,#024,17/05/2017,,6/2/2017,16,SB,Diagnostic,024,6,NDP,"Birmingham, Queen Elizabeth Hospital","GBM, IDH wt and H3 wt","(2) unusual histology, location, demographics",B,4/1/1995,22.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.98,GBM_MES,0.67,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1017,"
Glioblastoma, IDH-wildtype (WHO grade IV)  see comment

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
TERT promoter: No mutation
Histone H3F3A (K27M and G34R IHC and Seq): No mutation
BRAF (V600E): No mutation 

","
Molecular and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
TERT promoter: No mutation
Histone H3F3A (K27M and G34R IHC and Seq): No mutation
BRAF (V600E): No mutation 


",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #024\NH17-1017,0.061,-0.044,0.017,0.066,-0.081,0.267,-0.099,0.239,0.371,0.38,0.264,-0.024,0.009,0.005,0.02,-0.01,0.037,0.041,0,0.164,0.102,0.203,-0.068,-0.029,-0.031,0.048,-0.173,-0.065,0.079,methylated
NH17-982,200362700171_R05C01,#024,17/05/2017,,6/2/2017,16,SB,Diagnostic,024,6,NDP,"Birmingham, Queen Elizabeth Hospital","GBM, IDH wt and H3 wt","(2) unusual histology, location, demographics",,1/30/2001,16.1,"Diffuse paediatric-type high grade glioma, MYCN subtype",1,GBM_MYCN,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-982,"
Glioblastoma, IDH-wildtype (WHO grade IV)  see comment

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
Histone H3F3A (K27M and G34R IHC and Seq): No mutation
BRAF (V600E): No mutation 

","
Molecular and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)


IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
Histone H3F3A (K27M and G34R IHC and Seq): No mutation
BRAF (V600E): No mutation 

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #024\NH17-982,0.266,0.289,0.34,-0.055,-0.174,0.061,-0.074,0.373,0.368,0.411,0.311,-0.118,0.027,-0.117,0.379,0.277,0.191,0.304,-0.149,0.258,0.129,0.203,0.351,-0.106,-0.068,0.047,0.271,-0.096,0.035,unmethylated
NH14-108,200362700171_R05C02,#024,11/4/2017,,6/2/2017,52,SB,Diagnostic,024,5,NDP,NHNN,"Ependymoma, other glioma?","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,12/27/1983,30.1,pleomorphic xanthoastrocytoma(-like),1,PXA,0.99,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-108,"Anaplastic ependymoma WHO grade III. 
","
Molecular and methylation profile in keeping with anaplastic pleomorphic xanthoastrocytoma, BRAFV600E-mutant (WHO grade III)  see supplementary comment

",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #024\NH14-108,-0.094,0.094,0.101,0.037,-0.073,0.066,-0.267,0.087,0.201,0.18,0.103,0.099,0.136,0.105,-1.597,-0.041,-0.202,-0.227,-0.246,0.218,0.241,0.338,-0.043,-0.035,0.037,-0.006,-0.011,-0.063,-0.014,unmethylated
NH17-1086,200362700171_R06C01,#024,17/05/2017,,6/2/2017,16,SB,Diagnostic,024,6,NDP,"Leeds, St James's University Hospital",RGNT vs DNET; 3rd ventricle tumour,"(2) unusual histology, location, demographics",,1/9/1987,30.2,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.76,LGG_DNT,0.86,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1086,"Histological and methylation analysis: Dysembryoplastic neuroepithelial tumour (DNT), midline/septal. WHO grade I.
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #024\NH17-1086,-0.12,-0.018,0.034,0.088,-0.106,0.019,-0.005,0.03,0.051,0.012,-0.022,0.017,-0.016,-0.034,-0.007,-0.006,-0.009,0.014,-0.008,0,-0.049,0.052,-0.007,-0.072,-0.043,-0.038,-0.173,-0.047,0.036,unmethylated
NH17-734,200362700171_R06C02,#024,1/4/2017,,6/2/2017,62,SB,Diagnostic,024,1,NDP,Royal London Hospital,"?Long survivor (5Y) of Giant cell GBM, ? Epitheliod GBM","(2) unusual histology, location, demographics",DEF1A,4/5/1982,35,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.82,GBM_RTKII,0.14,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-734,"High grade intrinsic tumour, see comment.
","
Molecular and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)

MGMT Promoter: No methylation

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
1p/19q: Retained
TERT promoter: No mutation
Chromosome 10q: Retained

Histone H3F3A: No mutation
BRAF (V600E): No mutation 



",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #024\NH17-734,0.089,0.121,0.151,-0.181,-0.142,0.316,-0.038,0.275,0.362,0.336,0.281,0.033,0.001,-0.025,0.296,0.234,0.068,-0.011,-0.099,-0.072,-0.06,0.135,0.017,-0.055,0.07,0.043,-0.222,-0.03,0.002,unmethylated
NH17-1131,200362700212_R01C01,#025,10/6/2017,,6/29/2017,19,SB,Diagnostic,025,11,NDP,Brighton and Sussex Hospital,,"(4) IHC, sequencing, or copy number assay ambiguous",,5/17/1974,38.7,"Diffuse hemispheric glioma, H3 G34-mutant",1,GBM_G34,1,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1131,#N/A,"
Methylation profile: Glioblastoma, IDH-wildtype, H3.3 G34 mutant (WHO grade IV)  see supplementary comment
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #025\NH17-1131,0.403,-0.407,0.022,0.183,0.751,-0.496,-0.102,0.438,1.496,0.146,0.026,0.199,0.204,0.288,-0.118,0.301,-0.404,-1.281,-0.09,0.245,0.278,0.12,-0.408,0.157,0.175,0.228,-0.616,-0.319,-0.034,methylated
NH17-1428,200362700212_R01C02,#025,19/06/2017,,6/29/2017,10,SB,Diagnostic,025,3,NDP,,,"(2) unusual histology, location, demographics",,4/21/1987,30.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,0.98,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1428,"
Methylation profile supportive of glioblastoma, IDH-mutant (WHO grade IV)


IDH1 (R132H IHC): Mutation  
ATRX (IHC): Loss of expression (indicates mutation)

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #025\NH17-1428,-0.198,-0.052,0.059,-0.027,-0.113,-0.014,-0.433,0.049,0.051,0.13,-0.032,0.004,0.083,0.189,0.039,-0.017,0.039,0.036,-0.114,-0.009,-0.011,-0.564,-0.329,-0.097,0.117,-0.076,-0.148,-0.178,0.018,methylated
NH17-555,200362700212_R02C01,#025,24/04/2017,,6/29/2017,66,SB,Diagnostic,025,7,NDP,NHNN,?Undersampled/early-stage TERTmt IDHwt GBM,(1) small biopsy or nonrepresentative sample;,DEF2A,12/25/1970,46.2,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.74,GBM_MES,0.18,0.55,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-555,"Diffuse low grade glioma (WHO Grade I/II) - see comment

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
1p/19q: Test pending
  
","Diffusely infiltrating astrocytoma, with molecular features of glioblastoma (see comment) 
IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained 
1p/19q: Retained 
EGFR: No amplification (7p gain)
TERT promoter: mutation
MGMT Promoter: No methylation  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #025\NH17-555,0.107,0.057,0.063,-0.007,-0.06,0.012,-0.032,0.208,0.155,0.222,0.124,0.001,0.126,-0.038,0.032,-0.047,-0.342,-0.078,-0.115,-0.04,-0.003,-0.046,-0.022,-0.113,-0.007,0.024,-0.316,-0.236,-0.125,unmethylated
NH17-1388,200362700212_R02C02,#025,14/06/2017,,6/29/2017,15,SB,Diagnostic,025,1,NDP,,,"(2) unusual histology, location, demographics",,9/1/1987,29.8,supratentorial subependymoma,0.74,SUBEPN_ST,0.84,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1388,"
Ependymal tumour  see comment for grading and typing
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #025\NH17-1388,-0.179,-0.075,0.063,0.168,0.28,0.209,0.035,0.015,0.013,0.142,-0.024,-0.56,-0.335,-0.58,0.38,0.268,0.063,0.043,-0.093,0.278,0.303,0.28,0.022,0.243,0.362,0.204,0.256,0.244,0.245,unmethylated
NH17-1256,200362700212_R03C01,#025,13/06/2017,,6/29/2017,16,SB,Diagnostic,025,6,NDP,NHNN,"Low grade glial tumour, more spcific? ","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,7/6/1988,28.9,supratentorial pilocytic astrocytoma,0.78,LGG_DNT,0.93,0.57,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1256,"Low grade glial tumour- See the comment
","
Methylation profile supportive of pilocytic astrocytoma (WHO grade I)  see supplementary comment
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #025\NH17-1256,-0.23,-0.113,0.01,0,-0.039,0.055,0.02,0.081,0.075,0.017,0.031,0.002,0.156,0.017,0.062,0.026,0.016,0.039,-0.008,-0.011,0.053,0.103,0.034,-0.125,0.09,0.019,-0.101,-0.037,0.116,unmethylated
NH17-1417,200362700212_R03C02,#025,22/06/2017,,6/29/2017,7,SB,Diagnostic,025,12,NDP,NHNN,H3 K27mt diffuse midline glioma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF1A,3/16/1976,41.3,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",1,DMG_K27,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1417,"Diffuse midline glioma, H3 K27M-mutant (WHO grade IV)
  
IDH1 (R132H IHC): Negative (no mutation)       
ATRX (IHC): Retained
H3 K27M (IHC): Positive (indicates mutation)     
  




","
Diffuse midline glioma, H3 K27M-mutant (WHO grade IV)

MGMT Promoter: No methylation

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
Histone H3F3A (Seq and K27M IHC): K27M mutation
BRAF (Seq and V600E IHC): No mutation 



",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #025\NH17-1417,-0.161,0.06,0.094,0.029,0.207,0.113,-0.054,-0.012,0.063,0.013,-0.033,-0.03,0.077,0.009,0.134,0.101,-0.024,0.007,-0.023,0.209,0.255,0.458,-0.274,-0.241,0.021,0.001,-0.318,0.108,0.158,unmethylated
NH17-1246,200362700212_R04C01,#025,13/06/2017,,6/29/2017,16,SB,Diagnostic,025,8,NDP,NHNN,"Low grade glial tumour, BRAF V600E mutation - more spcific? ","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF3A,9/19/1988,28.7,"control tissue, hemispheric cortex",0.69,LGG_GG,0.51,0.49,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1246,"Low grade glial tumour, see comment

  
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
1p/19q: Test pending
  
","Low grade glial tumour
BRAF V600E mutant
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #025\NH17-1246,-0.068,-0.068,-0.011,0.027,-0.059,0.032,-0.02,-0.006,0.113,0.135,0.034,-0.011,0.059,-0.009,-0.058,-0.052,0.038,0.003,-0.076,-0.008,0.024,0.069,0.014,-0.026,0.054,0.016,-0.077,0.029,0.051,unmethylated
NH16-155,200362700212_R04C02,#025,20/06/2017,,6/29/2017,9,SB,Diagnostic,025,6,NDP,NHNN,?Neurocitic tumour versus Oligo; previous Illumina in 2016 confusing,"(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF1A,8/20/1949,66.5,Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters,0.69,CNSNB_FOXR2,0.33,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-155,"Anaplastic oligodendroglioma (WHO grade III)  see comment
","
Neurocytic tumour Grade II/III  see comment below

MGMT Promoter: No methylation

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
1p/19q: Retained
Chromosome 7p and EGFR: No gain and no amplification
TERT promoter: No mutation
Chromosome 10q: Retained

Histone H3F3A: No mutation

",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #025\NH16-155,0.055,-0.086,0.071,-0.068,-0.092,-0.067,0.245,0.068,-0.065,0.12,-0.001,-0.05,0.165,-0.009,-0.211,0.019,0.057,0.04,-0.094,0.053,-0.018,-0.144,0.006,-0.174,0.328,0.195,-0.675,-0.102,-0.003,unmethylated
NH17-626,200362700212_R05C02,#025,20/06/2017,,6/29/2017,9,SB,Diagnostic,025,6,NDP,NHNN,Anaplstic ependymoma (Illumina on 2014 suggests PXA!),"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1C,12/27/1983,33.2,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-626,"Recurrent/residual anaplastic ependymoma (WHO grade III)
","
Molecular and methylation profile in keeping with anaplastic pleomorphic xanthoastrocytoma, BRAFV600E-mutant (WHO grade III)  see supplementary comment
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #025\NH17-626,-0.122,0.049,0.095,-0.038,-0.104,0.032,-0.341,0.165,0.266,0.271,0.137,0.144,0.158,0.123,-1.406,-0.069,-0.503,-0.204,-0.304,0.202,0.266,0.315,-0.289,-0.097,0.123,-0.066,-0.002,-0.049,0.029,unmethylated
NH17-1389,200362700212_R06C01,#025,15/06/2017,,6/29/2017,14,SB,Diagnostic,025,6,NDP,Romford,"Pineal lesion, morphology pilocytic astrocytoma",(1) small biopsy or nonrepresentative sample;,A2,4/8/1973,44.2,supratentorial pilocytic astrocytoma,0.68,LGG_PA_GGST,0.66,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1389,"
Appearances in favour of pilocytic astrocytoma (WHO grade I)  see comment

",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #025\NH17-1389,-0.34,-0.073,0.039,-0.005,-0.058,-0.029,0.034,0.032,0.071,0.1,-0.018,-0.03,0.058,-0.109,0.019,0.045,0.022,0.033,-0.053,-0.018,0.011,0.018,0.095,-0.204,0.165,-0.05,-0.051,-0.114,0.031,unmethylated
NH17-839,200362700212_R06C02,#025,5/4/2017,,6/29/2017,85,SB,Diagnostic,025,1,NDP,Royal London Hospital,"?Long survivor (5Y) of Giant cell GBM, ? Epitheliod GBM","(2) unusual histology, location, demographics",A2,4/5/1982,29.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.29,GBM_MES,0.61,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-839,"Giant cell glioblastoma, WHO grade IV, see comment. 
","
Methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #025\NH17-839,0.104,-0.264,-0.023,0.057,-0.101,0.121,-0.158,0.353,0.478,0.361,0.293,-0.092,0.122,-0.059,0.255,0.338,-0.046,-0.123,-0.088,-0.183,0.053,-0.112,0.002,-0.158,0.28,-0.047,-0.334,-0.352,0.05,unmethylated
NH17-1158,200362700151_R01C02,#026,18/08/2017,,9/7/2017,20,SB,Diagnostic,026,1,NDP,Romford,IDH wt glioma? Low grade Histolgoy,(1) small biopsy or nonrepresentative sample;,A,7/31/1955,61.8,ganglioglioma,0.47,GBM_MES,0.88,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1158,"
Diffuse glioma  see comment

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
1p/19q: Retained
Chromosome 7p and EGFR: No gain and no amplification
TERT promoter: Test unsuccessful
Chromosome 10q: Retained

Histone H3F3A: No mutation
BRAF (V600E): No mutation 

","Astrocytoma, IDH wild-type, with molecular features of glioblastoma (WHO grade IV)
Methylation class glioblastoma, IDH wild-type, subclass mesenchymal,
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #026\NH17-1158,-0.511,-0.186,0.017,0.51,-0.316,0.106,0.321,0.472,0.492,0.171,0.291,0.043,0.32,-0.25,-0.015,-0.09,-0.24,-0.13,-0.085,0.111,0.071,0.032,0.135,-0.639,0.312,-0.028,0.056,0.03,0.085,methylated
NH17-1746,200362700151_R02C02,#026,18/08/2017,,9/7/2017,20,SB,Diagnostic,026,1,NDP,NHNN,Low grade glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,#N/A,#N/A,ganglioglioma,0.23,LGG_GG,0.43,0.52,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1746,"Low grade glioneuronal tumour (WHO grade I)

IDH1 (R132H): No mutation
ATRX (IHC): technically unsatisfactory
1p/19q: test pending
","Low grade glial neuronal tumour (WHO grade I)
Methylation class low grade glioma, subclass hemispheric pilocytic astrocytoma and ganglioglioma (see comment)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #026\NH17-1746,-0.322,-0.178,0.042,0.085,-0.158,0.041,0.229,-0.058,0.096,-0.163,-0.053,-0.085,0.402,-0.072,-0.039,-0.037,-0.067,0.088,0.101,-0.038,0.128,0.077,0.02,-0.58,0.305,-0.071,-0.123,-0.018,0.118,unmethylated
NH17-1654,200362700151_R03C01,#026,1/8/2017,,9/7/2017,37,SB,Diagnostic,026,4,NDP,Royal London Hospital,"IDHwt, H3wt GBM with ATRX loss","(2) unusual histology, location, demographics",DEF1A,1/3/1944,73.6,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.99,GBM_MID,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1654,"Glioblastoma (WHO grade IV)  see comment. 

IDH (R132H IHC)  No mutation, further tests pending
ATRX  Test unsatisfactory, a repeat is in progress
1p/19q  Test pending

","
Glioblastoma, IDH-wildtype (WHO grade IV)

MGMT Promoter: No methylation

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Retained
Chromosome 7p and EGFR: No gain and no amplification
TERT promoter: Test unsuccessful repeatedly
Chromosome 10q: LOH

Histone H3F3A: No mutation
BRAF (V600E): No mutation 

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #026\NH17-1654,-0.113,-0.338,-0.06,-0.071,1.53,-0.079,0.3,0.061,0.11,1.499,-0.067,-0.057,0.287,-0.225,-1.955,0.158,-1.985,-0.326,0.066,-0.1,-0.071,-0.16,-0.381,-1.237,0.334,0.248,-0.218,-0.077,0.047,unmethylated
NH16-1309,200362700151_R04C01,#026,31/08/2017,,9/7/2017,7,SB,Epigenetics,026,2,NDP,NHNN,"GBM, Epigenetics","(6) Research sample, for stratification or subclassification",DEF1A,10/4/1944,71.7,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-1309,"Glioblastoma (WHO grade IV).  
IDH1 (R132H IHC): No mutation (wild type). 
ATRX (IHC): Retained. 
1p/19q LOH: No LOH
","Glioblastoma, IDH wild-type (WHO grade IV)
Methylation class glioblastoma, subclass RTK I
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #026\NH16-1309,-0.154,-0.131,0.075,0.01,-0.094,0.079,0.283,0.188,0.275,0.166,0.125,0.043,0.427,0.125,-0.739,0.038,-0.183,-0.156,0.102,0.001,0.045,-0.058,0.008,-0.352,0.108,-0.056,-0.358,-0.468,-0.502,unmethylated
NH17-1786,200362700151_R06C01,#026,8/8/2017,,9/7/2017,30,SB,Diagnostic,026,4,NDP,,Ependymoma vs subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,12/8/1966,50.7,posterior fossa subependymoma,1,SUBEPN_PF,0.99,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1786,"Ependymoma  (WHO Grade II).
","Subependymoma (WHO grade I)
Methylation class subependymoma, posterior fossa (see molecular report).
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #026\NH17-1786,-0.101,-0.131,-0.009,0.052,-0.102,0.037,-0.397,0.022,0.14,0.205,0.004,-0.035,0.196,0.124,-0.143,-0.053,-0.068,0.028,0.05,-0.072,-0.143,-0.012,0.038,-0.25,0.234,-0.156,-0.06,0.045,-0.122,unmethylated
NH17-1776,200362700151_R06C02,#026,31/07/2017,,9/7/2017,38,SB,Diagnostic,026,1,NDP,"Charing Cross Hospital, London",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",,12/19/1976,40.6,spinal ependymoma,0.22,EPN_SPINE,0.36,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1776,"Ependymoma, WHO grade II
Methylation Classifier: Ependymoma, spinal
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #026\NH17-1776,-0.358,-0.204,-0.019,0.077,-0.164,0.118,0.159,0.044,0.065,0.084,-0.037,-0.055,0.378,-0.103,-0.032,-0.082,-0.129,0.047,0.022,-0.041,0.048,-0.01,-0.112,-0.37,0.147,0.011,-0.029,-0.217,-0.153,unmethylated
NH17-1049,200362700107_R01C01,#027,20/07/2017,,7/27/2017,7,SB,Diagnostic,027,5,NDP,Royal London Hospital,"IDHwt diffuse glioma, low grade",(1) small biopsy or nonrepresentative sample;,DEF1A,6/27/1985,31.9,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.28,GBM_RTKII,0.4,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1049,"
Low grade glioma (WHO grade II) (see comment)
  
IDH1 (R132H IHC): No mutation ; Further tests pending 
ATRX (IHC): Retained      
1p/19q: Test pending
  
","Histological diagnosis:
Low grade glioma (WHO grade II)

Molecular and methylation profile: 
Raising the possibility of infiltration margin or early stage of IDH-wildtype glioblastoma (WHO grade IV)

MGMT Promoter: No methylation

IDH1 (R132H IHC); IDH1/2 Seq: No mutation
ATRX (IHC): Retained
1p/19q: Retained

Histone H3F3A: No mutation
BRAF (V600E): No mutation 

",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #027\NH17-1049,-0.009,0.03,0.046,0.018,-0.075,-0.001,-0.423,0.298,0.005,-0.033,0.001,0.002,-0.036,-0.002,-0.298,-0.019,-0.306,-0.236,-0.059,0.003,0.009,0.009,-0.285,-0.018,0.013,0.023,0.03,-0.309,-0.228,unmethylated
NH17-1482,200362700107_R02C01,#027,3/7/2017,,7/27/2017,24,SB,Diagnostic,027,2,NDP,Nottingham University Hospital,DMG vs PA (H3 K27M IHC neg),"(4) IHC, sequencing, or copy number assay ambiguous",D1,5/27/2014,3.1,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.99,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1482,"
Glial tumour, further studies in progress  see comment

MGMT Promoter: No methylation 
  
","
Methylation profile: Pilocytic astrocytoma (WHO grade I)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #027\NH17-1482,-0.053,-0.04,0.061,0.103,-0.037,0.046,0.018,-0.046,0.053,0.061,-0.029,-0.025,-0.021,-0.045,-0.134,-0.021,-0.005,0.014,0.1,-0.045,-0.016,0.022,-0.012,-0.109,-0.061,-0.036,-0.133,0.04,0.052,unmethylated
NH17-1535,200362700107_R04C01,#027,4/7/2017,,7/27/2017,23,SB,Diagnostic,027,5,NDP,NHNN,"LGG, BRafins599 T (1798insTAC)*","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,6/12/2000,17.1,supratentorial pilocytic astrocytoma,0.65,LGG_PA_GGST,0.99,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1535,"Low grade glial tumour- see comment

  
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
1p/19q: Test pending
  
","
Pilocytic astrocytoma with BRAF insertion mutation (WHO grade I)


",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #027\NH17-1535,-0.029,-0.055,0.026,0.042,-0.059,0.045,0.046,0.012,0.041,0.094,0.025,-0.004,-0.063,0.034,0,-0.061,0.024,0.007,0.025,-0.048,-0.057,0.04,-0.012,-0.029,-0.085,-0.021,-0.019,-0.068,0.022,unmethylated
NH16-872,200362700107_R04C02,#027,14/07/2017,,7/27/2017,13,SB,Diagnostic,027,6,NDP,NHNN,Medulloblastoma 1st tumour classification,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,5/16/1962,54,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.46,GBM_MID,0.93,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-872,"Medulloblastoma (WHO grade IV).

Histological subtype: Classic 
Molecular subtyping not done. 
","
High grade neuroepithelial tumour (WHO grade IV)  see supplementary comment 
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #027\NH16-872,-0.255,0.125,0.032,-0.015,0.083,-0.064,0.053,-0.015,-0.015,-0.051,-0.001,-0.034,-0.052,0.073,-2.931,0.005,0.041,-0.084,-0.025,0.023,0.052,-0.035,-0.019,-0.623,-0.029,0.282,-0.083,-0.528,-0.455,methylated
NH17-1619,200362700107_R05C02,#027,14/07/2017,,7/27/2017,13,SB,Diagnostic,027,5,NDP,NHNN,"Medulloblastoma recurrence post rad, classification","(4) IHC, sequencing, or copy number assay ambiguous",DEF2A,5/16/1962,55.2,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.76,GBM_MID,0.93,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1619,"Recurrent high grade neuroglial tumour  see comment. 
","
High grade neuroepithelial tumour (WHO grade IV)  see supplementary comment 
 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #027\NH17-1619,-0.108,0.037,0.035,0.019,-0.012,0.132,0.006,-0.017,-0.045,-0.003,-0.004,0.02,0.022,-0.002,-2.572,-0.11,-0.009,0.106,0.025,-0.054,-0.012,0.053,-0.396,-0.412,-0.062,0.146,-0.066,-0.377,-0.271,methylated
NH17-1293,200362700107_R06C01,#027,10/7/2017,,7/27/2017,17,SB,Diagnostic,027,1,NDP,NHNN,Glioma vs inflammation,(1) small biopsy or nonrepresentative sample;,DEF1A,9/20/1943,73.8,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",1,GBM_RTKII,0.2,0.53,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1293,"CNS tissue with infiltrative, proliferative lesion. Very mild inflammation - see the comment
","See supplementary comment and comment in the main report 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #027\NH17-1293,-0.056,-0.041,0.045,0.092,0.074,0.072,-0.187,0.171,-0.025,-0.184,0.139,-0.088,-0.096,-0.044,-0.277,-0.09,-0.196,-0.124,-0.007,0.006,0.007,0.03,-0.037,0.047,-0.19,-0.061,0.131,-0.199,0.055,unmethylated
NH17-1053,200362700107_R06C02,#027,17/05/2017,,7/27/2017,71,SB,Diagnostic,027,4,NDP,NHNN,"Spinal ependymoma, WHO grade II","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",,9/22/1979,37.6,spinal ependymoma,1,EPN_SPINE,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1053,"Ependymoma (WHO Grade II )
","Spinal ependymoma (WHO grade II)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #027\NH17-1053,-0.073,0.022,0.01,0.145,0.197,0.181,0.021,0.237,0.231,0.316,0.225,-0.015,0.031,-0.021,0.25,0.201,-0.011,0.065,-0.061,0.368,0.352,0.362,0.014,-0.103,-0.093,-0.013,-0.088,-0.497,-0.325,methylated
NH17-1923,200362700192_R01C02,#029,6/9/2017,,10/6/2017,30,SB,Diagnostic,029,5,NDP,NHNN,"IDH wt glioma, possibly GBM, no high grade features",(1) small biopsy or nonrepresentative sample;,SP1A,5/16/1954,63.3,"glioblastoma, IDH-wildtype, RTK2 type",0.56,GBM_RTKII,0.54,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1923,"Diffuse glioma  see comment
  
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Difficult to interpret due to technical issues
1p/19q: Test pending
  
","Diffuse glioma, IDH wild type (grading see comment)  
IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Technically unsatisfactory  
1p/19q: Retained 
EGFR: No amplification
MGMT Promoter: High level methylation (>25%)
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #029\NH17-1923,-0.277,-0.032,0.028,0.108,-0.199,0.208,0.126,0.459,0.459,0.387,0.355,0.192,0.384,0.184,0.098,0.273,-0.004,0.045,0.096,0.717,0.156,0.033,0.007,-0.731,-0.343,-0.025,-0.254,-0.109,0.232,methylated
NH17-2466,200362700242_R01C02,#030,26/09/2017,,10/26/2017,30,SB,Diagnostic,030,3,NDP,Royal London Hospital,?GBM metastasis in lymph node,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,6/27/1985,32.3,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.94,GBM_MID,0.95,0.95,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2466,"Mediastinal lymph node: Features in keeping with metastatic glial/glio-neuronal tumour. Please see comment. 
","
Methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #030\NH17-2466,-0.184,0.017,-0.002,-0.009,-0.203,-0.042,0.203,0.5,0.453,0.307,0.315,0.048,0.336,-0.12,-0.113,-0.127,-0.078,0.044,-0.069,-0.013,0.149,-0.133,-0.445,0.036,0.404,0.258,0.273,0.021,0.118,unmethylated
NH17-540,202013790083_R03C01,#034,18/08/2017,,11/10/2017,84,SB,CRUK Accelerator,034,1,NDP,NHNN,Recurrent anaplastic oligodendroglioma,"(6) Research sample, for stratification or subclassification",,1/1/1966,51.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.82,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-540,"Recurrent anaplastic oligodendroglioma (WHO Grade III)

IDH1 (R132H IHC): Mutation (tested on the previous resection specimen, NH09-1064)
ATRX (IHC): Retained      
1p/19q: Co-deleted (tested on the previous resection specimen, NH09-1064)
     
 
","Recurrent anaplastic oligodendroglioma (WHO grade III) 
IDH1/2 Seq: IDH1 mutation 
ATRX (IHC): Retained 
1p/19q: Codeleted 
EGFR: No amplification
MGMT Promoter: Intermediate level methylation (>10-25%)
",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #034\NH17-540,-0.059,-0.243,0.047,-0.758,-1.015,-0.347,-0.171,-0.047,0.042,-0.282,-0.016,0.309,0.212,-0.204,-3.319,0.39,-0.027,-0.401,-0.136,-0.087,0.216,0.294,-0.117,0.098,0.214,0.31,-0.486,-0.336,-0.521,methylated
NH17-676,202013790137_R04C01,#035,18/08/2017,,11/10/2017,84,SB,CRUK Accelerator,035,7,NDP,NHNN,Glioblastoma,"(6) Research sample, for stratification or subclassification",,1/13/1949,68.2,"glioblastoma, IDH-wildtype, with primitive neuronal component",1,GBM_RTKII,0.18,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-676,"
Glioblastoma (WHO grade IV)

IDH1 (R132H IHC): No mutation      
ATRX (IHC): Retained      
1p/19q: Test pending
  


","Glioblastoma (WHO grade IV) 
IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained 
1p/19q: Retained 
EGFR: No amplification
MGMT Promoter: No methylation
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #035\NH17-676,-0.217,0.032,-0.002,0.069,0.134,0.042,0.048,0.405,0.324,0.258,0.264,0.027,0.166,-0.24,-0.195,0.205,-0.697,-0.665,-0.032,0.022,-0.02,2.452,-0.358,-0.323,-0.02,0.065,0.221,-0.004,0.056,unmethylated
NH17-2453,200379120087_R02C01,#037,21/11/2017,,12/5/2017,14,SB,Diagnostic,037,1,NDP,Oxford John Radcliffe Hospital,"Giant cell GBM, ATRX loss","(2) unusual histology, location, demographics",2A,3/28/2005,12.5,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type C]",1,DMG_K27,0.09,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2453,"
Referred diagnosis: Glioblastoma, giant cell variant (WHO grade IV)  see comment

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Loss of expression (indicates mutation)

Histone H3F3A (Seq and K27M IHC): No mutation
BRAF (V600E Seq): No mutation 

","
MGMT Promoter: No methylation 
  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #037\NH17-2453,-0.295,-0.095,0.009,-0.014,-0.028,-0.037,0,-0.038,0.161,0.083,-0.012,-0.05,0.202,-0.002,0.039,-0.212,-0.019,-0.023,-0.062,-0.051,-0.019,0.137,-0.063,-0.138,0.592,0.293,-0.192,-0.042,0.019,unmethylated
NH17-2559,200379120087_R03C01,#037,1/11/2017,,12/5/2017,34,SB,Diagnostic,037,4,NDP,NHNN,Ependymoma vs Myxopapillary ependymoma vs Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,1/9/1972,45.8,myxopapillary ependymoma,1,EPN_MPE,1,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2559,"Glial tumour with composite histological features of ependymoma/myxopapillary ependymoma (WHO Grade I/II) - see comment
","Myxopapillary ependymoma (WHO grade I)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #037\NH17-2559,-0.167,0.094,0.021,-0.013,0.071,-0.006,0.267,-0.059,0.157,-0.071,-0.046,-0.116,-0.114,0.01,0.126,-0.131,-0.118,-0.009,-0.067,-0.043,-0.112,0.213,0.079,-0.117,0.037,-0.128,-0.191,-0.27,0.054,unmethylated
NH17-2598,200379120087_R03C02,#037,22/11/2017,,12/5/2017,13,SB,Diagnostic,037,3,NDP,NHNN,?IDHwt GBM,(1) small biopsy or nonrepresentative sample;,SP1A,11/27/1990,26.9,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",1,GBM_MYCN,0.73,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2598,"High grade glioma (at least WHO grade III)  see comment
  
IDH1 (R132H IHC): Technically unsatisfactory 
ATRX (IHC): Retained
1p/19q: Test pending
","
Molecular profile suggestive of glioblastoma, IDH-wildtype (WHO grade IV)  for grading and typing, see comment

MGMT Promoter: No methylation

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
1p/19q: Retained
Chromosome 7p and EGFR: No gain and no amplification
TERT promoter: Mutation
Chromosome 10q: Retained

Histone H3F3A: No mutation
BRAF (V600E): No mutation 

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #037\NH17-2598,0.215,-0.072,0.026,0.032,0.011,0.054,0.167,0.02,0.058,0.052,-0.023,-0.06,0.065,-0.001,-0.046,-0.023,0.057,0.058,-0.067,-0.035,0.033,0.124,-0.424,-0.21,-0.006,0.04,-0.056,-0.049,0.036,unmethylated
NH17-2506,200379120087_R04C01,#037,1/11/2017,,12/5/2017,34,SB,Diagnostic,037,11,NDP,NHNN,"LGG vs DLGNT, vs LG-N, BRAF (F and mt) neg","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/30/1970,47.2,rosette-forming glioneuronal tumour,0.91,LGG_RGNT,0.92,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2506,"Low grade glial/glioneuronal tumour corresponding to WHO grade I  see comment

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
BRAF V600E (IHC): Negative (no mutation)
H3K27M (IHC): Negative (no mutation)  
","Rosette-forming neuronal tumour (WHO grade I)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #037\NH17-2506,-0.48,-0.196,0.054,0.286,0.011,-0.043,-0.026,-0.006,0.046,0.057,-0.069,-0.066,0.075,-0.195,-0.099,-0.012,-0.004,0.152,-0.111,-0.08,-0.095,0.277,0.009,-0.388,0.179,-0.191,-0.034,-0.042,0.099,unmethylated
NH17-2689,200379120087_R04C02,#037,24/11/2017,,12/5/2017,11,SB,Diagnostic,037,1,NDP,Nottingham University Hospital,,(1) small biopsy or nonrepresentative sample;,A1,12/21/2013,3.9,infratentorial pilocytic astrocytoma,0.63,LGG_PAPF,0.63,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2689,"Pilocytic astrocytoma (WHO grade I)
","Pilocytic astrocytoma (WHO grade I)
BRAF V600E mutation 
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #037\NH17-2689,-0.425,-0.17,-0.055,-0.022,0.083,0.052,-0.113,0.147,0.269,0.14,0.115,0.03,0.005,-0.018,-0.07,-0.015,0.17,0.289,0.004,0.117,0.17,0.078,-0.086,-0.274,-0.002,-0.407,0.076,-0.156,-0.154,unmethylated
NH17-2163,200379120087_R05C02,#037,21/11/2017,,12/5/2017,14,SB,Diagnostic,037,4,NDP,NHNN,"HGG, IDH-mutant","(4) IHC, sequencing, or copy number assay ambiguous",DEF2A,9/26/1971,46,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2163,"Recurrent IDH mutant high grade glioma (WHO grade III at least)  see comment
  
IDH1 (R132H IHC): Mutation  
ATRX (IHC): Retained 
1p/19q: Co-deleted (NH12-1561)      
  
","Glioblastoma, IDH mutant (WHO grade IV)  
IDH1 (R132H IHC); IDH1/2 Seq: IDH1 mutation 
ATRX (IHC): Loss of expression (indicates mutation) 1p/19q: Retained 
MGMT Promoter: No methylation     
Methylation class: Glioma, IDH mutant; subclass high-grade astrocytoma  
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #037\NH17-2163,-0.408,0.308,0.168,-0.017,-0.001,-0.642,-0.066,0.147,0.442,0.838,0.401,-0.113,-0.185,-0.159,-0.475,-0.05,0.213,-0.253,-0.177,0.15,0.113,0.082,-0.477,0.017,0.253,0.1,-0.542,-0.108,-0.39,unmethylated
NH17-1972,200379120087_R06C02,#037,21/11/2017,,12/5/2017,14,SB,Diagnostic,037,4,NDP,"Birmingham, Queen Elizabeth Hospital",Diffuse leptomeningial glioneunonal tumour?,"(5) Confirmation of rare, unusual or interesting histo-molecular results",B2,9/14/1953,63.9,papillary glioneuronal tumour,0.11,DMG_K27,0.16,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1972,"Features supportive of a diffuse leptomeningeal glioneuronal tumour (see comment)
","High grade glioma (see comment)
No matching methylation class
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #037\NH17-1972,1.493,-0.535,-0.06,0.125,0.217,0.296,0.306,0.38,0.748,0.528,0.502,0.048,0.425,0.162,-0.133,-0.149,0.015,-0.19,-0.167,0.346,0.34,0.596,-0.041,-0.317,0.24,0.095,-0.073,-0.386,-0.254,methylated
NH17-2739,200379120100_R01C01,#038,25/11/2017,,12/15/2017,20,SB,Diagnostic,038,4,NDP,NHNN,Spinal tumour; ?ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1G,7/27/1998,19.3,spinal subependymoma [subtype B],0.37,SUBEPN_SPINE,0.51,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2739,"Ependymoma (WHO Grade II)

","Methylation profile of spinal subependymoma  see supplementary comment
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #038\NH17-2739,0.058,-0.002,-0.022,-0.02,-0.016,-0.029,-0.196,0.118,0.173,0.183,0.113,-0.202,-0.165,-0.18,0.156,0.087,-0.003,-0.016,0.086,-0.043,-0.016,0.045,0.009,0.12,0.177,0.119,-0.04,-0.128,-0.192,unmethylated
NH17-2862,200379120100_R03C02,#038,8/12/2017,,12/15/2017,7,SB,Diagnostic,038,1,NDP,NHNN,"IDH1 R132H mutant desmoplastic glioma, highly unusual morphology","(2) unusual histology, location, demographics",SP2A,11/23/1955,62.1,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.62,OIDH,0.87,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2862,"Glioma, IDH mutant, desmoplasia (grading and typing see comment)
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
","Oligodendroglioma, IDH-mutant and 1p/19q codeleted, with widespread stromal desmoplasia  for grading, see comment

MGMT Promoter: Intermediate level methylation (>10% - 25%)

IDH1 (R132H IHC); IDH1/2 Seq: IDH1 mutation
ATRX (IHC): Retained
1p/19q: Codeleted
EGFR: No amplification
TERT promoter: Test unsuccessful 
Chromosome 10q: Retained
Histone H3F3A: No mutation
BRAF (V600E): No mutation 


",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #038\NH17-2862,-0.21,0.115,-0.204,0.276,-0.078,0.287,0.38,-0.044,0.558,0.203,-0.036,-0.261,0.163,0.134,0.188,-0.169,0.224,-0.05,0.507,0.044,-0.296,0.132,0.227,-0.443,0.492,0.238,-0.91,-0.331,0.11,methylated
NH17-2912,200379120100_R04C02,#038,8/12/2017,,12/15/2017,7,SB,Diagnostic,038,2,NDP,NHNN,"Pontine glioma, high grade. Ordered before MB01 result available",(1) small biopsy or nonrepresentative sample;,DEF1A,4/12/1945,72.7,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.83,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2912,"High-grade glioma, (at least WHO grade III)  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Histone H3.3 K27M (IHC): No mutation.
BRAF V600E (IHC): No mutation
","
Molecular and methylation profile of Glioblastoma, IDH-wildtype (WHO grade IV)

MGMT Promoter (MGMT-STP27, Illumina 450k array data): Methylated

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
TERT promoter: Mutation
Histone H3F3A: No mutation
BRAF (V600E): No mutation 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #038\NH17-2912,-0.179,-0.038,-0.055,0.243,-0.029,0.106,-0.119,0.362,0.432,0.487,0.258,-0.371,-0.025,-0.368,-0.531,-0.425,-0.17,-0.257,0.027,-0.071,0.018,0.174,0.037,-0.11,0.058,0.044,-0.228,-0.23,-0.163,methylated
NH17-2797,200379120100_R06C01,#038,21/11/2017,,12/15/2017,24,SB,Diagnostic,038,1,NDP,"Cambridge, Addenbrooke's Hospital","Unusual papillary glioneuronal tumour, parietal, peripheral","(2) unusual histology, location, demographics",1A,9/12/1994,23.2,extraventricular neurocytoma,1,LGG_DNT,0.95,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2797,"Cystic, papillary glioneuronal tumour, probably corresponding to WHO grade I.
","Methylation profile of dysembryoplastic neuroepithelial tumour (WHO grade I)  see supplementary comment
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #038\NH17-2797,-0.129,-0.033,0.038,-0.062,-0.065,0.001,0.026,0.005,0.029,0.065,-0.011,0.186,0.036,-0.025,0.063,-0.015,0.026,0.029,-0.034,-0.056,-0.003,-0.072,0.035,-0.042,-0.023,-0.018,-0.048,-0.005,0.069,unmethylated
NH17-2915,200379120113_R01C01,#041,13/12/2017,,1/19/2018,37,SB,Diagnostic,041,4,NDP,NHNN,IDH-mutant glioma with MVP (reported as GBM),"(2) unusual histology, location, demographics",DEF2A,9/23/1994,23.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.94,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2915,"Glioblastoma, IDH mutant (WHO grade IV)
IDH1 (R132H IHC): Mutation  
ATRX (IHC): Loss of expression (indicates mutation)

","
Glioblastoma, IDH-mutant (WHO grade IV) 6 see supplementary comment

MGMT Promoter: No methylation

IDH1 (R132H IHC): Mutation  
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Retained
Chromosome 7p and EGFR: No gain and no amplification
TERT promoter: No mutation
Chromosome 10q: Retained
Histone H3F3A: No mutation
BRAF (V600E): No mutation 
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #041\NH17-2915,-0.243,-0.329,-0.009,0.056,-0.045,-0.06,0.084,-0.016,0.149,-0.07,-0.004,0.033,0.25,0.064,-0.33,-0.097,0.154,-0.093,0.02,0.012,0.127,0.006,0.14,-0.058,0.354,0.31,-0.605,0.058,0.085,methylated
NH17-2845,200379120113_R01C02,#041,20/12/2017,,1/19/2018,30,SB,Diagnostic,041,7,NDP,NHNN,"IDHwt, TERTmt LGG (gliomatosis radiologically)",(1) small biopsy or nonrepresentative sample;,DEF1C,7/23/1954,63.4,ganglioglioma,0.27,GBM_MES,0.36,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2845,"Glioma- see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained 
1p/19q: Test pending
","
Molecular profile suggestive (but not diagnostic) of glioblastoma, IDH-wildtype (WHO grade IV)  see supplementary comment

MGMT Promoter: No methylation

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
1p/19q: Retained
EGFR: No amplification
TERT promoter: Mutation
Chromosome 10q: Retained

Histone H3F3A: No mutation
BRAF (V600E): No mutation 

",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #041\NH17-2845,-0.155,-0.129,-0.016,0.049,-0.013,-0.023,0,0.265,0.265,0.218,0.204,0.022,0.131,0.113,-0.007,-0.051,-0.004,-0.123,0.037,0.022,0.068,0.015,0.081,-0.034,0.132,0.155,-0.045,0.063,0.058,methylated
NH17-2955,200379120113_R04C01,#041,20/12/2017,,1/19/2018,30,SB,Diagnostic,041,4,NDP,NHNN,GBM,"(2) unusual histology, location, demographics",DEF1A,4/4/2000,17.7,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.97,GBM_MYCN,0.68,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2955,"Glioblastoma (WHO grade IV)

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
1p/19q: Test pending  
","Glioblastoma, IDH-wildtype (WHO grade IV)  see supplementary comment

MGMT Promoter: No methylation     

IDH1 (R132H IHC); IDH1/2 Seq: No mutation     
ATRX (IHC): Retained     
1p/19q: Retained     
EGFR: Moderate amplification
TERT promoter: Test unsuccessful 
Chromosome 10q: LOH     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation      
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #041\NH17-2955,0.134,1.106,0.038,0,0.032,0.03,0.056,1.051,0.274,0.294,0.209,0.035,0.053,-0.008,0.002,-0.38,-0.247,-0.39,-0.01,-0.005,0.01,0.011,-0.411,0.006,0.01,0.075,-0.15,-0.05,0.037,unmethylated
NH17-2904,200379120113_R04C02,#041,21/12/2017,,1/19/2018,29,SB,Diagnostic,041,4,NDP,Latvia,?DIA; ?PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",5821-2,9/18/2005,12.2,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.98,0.56,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2904,"See comment
","2016 resection material: 
Astrocytoma (no paraffin block available for further characterisation)
2017 resection material: 
Methylation class: Pilocytic astrocytoma / ganglioglioma spectrum (WHO grade I)  see supplementary comment 
MGMT Promoter: No methylation 
BRAF (V600E and three fusions): No mutation
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #041\NH17-2904,-0.169,-0.061,-0.045,-0.008,-0.066,0.118,0.036,0.188,0.212,0.214,0.147,0.097,-0.004,0.088,-0.074,0.013,-0.001,-0.046,0.118,0.079,0.021,0.017,-0.093,-0.059,-0.105,-0.058,-0.101,0.022,-0.016,unmethylated
NH17-2967,200379120113_R05C01,#041,20/12/2017,,1/19/2018,30,SB,Diagnostic,041,6,NDP,NHNN,?PA in the lateral ventricle,(1) small biopsy or nonrepresentative sample;,DEF1A,2/19/1941,76.9,posterior fossa ependymoma group A1,0.08,SUBEPN_ST,0.15,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2967,"Glial neoplasm (definitive grading and typing deferred to molecular testing)

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained
","Glial neoplasm  see supplementary comment


MGMT Promoter: No methylation     

IDH1 (R132H IHC); IDH1/2 Seq: No mutation     
ATRX (IHC): Retained     
1p/19q: Retained     
EGFR: No amplification          
TERT promoter: No mutation
Chromosome 10q: Retained

Histone H3F3A: No mutation     
BRAF (V600E): No mutation      
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #041\NH17-2967,-0.477,0.096,0.153,0.36,0.166,0.142,-0.183,-0.254,0.326,-0.14,-0.123,-0.033,-0.044,0.034,-0.709,-1.119,0.174,-0.046,-0.061,-0.089,-0.07,-0.436,-0.425,-0.218,4.977,-0.019,-0.7,-0.157,-0.434,unmethylated
NH17-3065,200379120113_R05C02,#041,2/1/2018,,1/19/2018,17,SB,Diagnostic,041,12,NDP,Newcastle,?GlioSa; ?other sarcoma,"(2) unusual histology, location, demographics",1A,11/29/1973,44.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_RTKII,0.15,0.54,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-3065,"Preliminary diagnosis:
Poorly differentiated tumour with biphasic cytoarchitecture  see comment
","Histological diagnosis: Poorly differentiated tumour with biphasic cytoarchitecture,  in combination with copy number profile compatible with glioblastoma/gliosarcoma, IDH-wildtype (WHO grade IV)
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #041\NH17-3065,-0.102,-0.026,0.035,0.028,-0.088,0.111,0.11,0.316,0.313,0.363,0.204,0.023,0.076,0.073,-0.028,0.003,-0.128,-0.242,-0.006,0.01,0.714,1.156,-0.031,0.001,0.086,0.053,-0.09,0.069,0.011,unmethylated
NH17-2839,200069280193_R01C01,#046,20/12/2017,,2/23/2018,65,ZJ,Diagnostic,046,6,NDP,NHNN,LGG vs glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,1/26/1980,37.9,"control tissue, white matter (corpus callosum)",0.92,LGG_DNT,0.48,0.43,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2839,"Low grade glioneuronal tumour (WHO grade I)  see comment
Focal cortical dysplasia (Type IIIB)
IDH1 (R132H IHC): No mutation  
ATRX (IHC): Retained but staining is weak and patchy
",#REF!,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #046\NH17-2839,0.046,-0.139,-0.083,-0.258,-0.116,-0.134,0.039,-0.072,-0.119,0.01,0.048,-0.007,0.116,-0.079,0.004,-0.021,0.018,0.083,-0.292,-0.031,-0.029,0.325,0.045,-0.171,-0.072,0.118,-0.125,0.04,0.185,unmethylated
NH17-3068,200069280193_R01C02,#046,11/1/2018,,2/23/2018,43,SB,Diagnostic,046,1,NDP,"Cardiff, University Hospital","Pilocytic, or HGG?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/25/2002,15.4,supratentorial midline pilocytic astrocytoma,1,LGG_PAMID,0.92,0.43,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-3068,"Methylation profile: Pilocytic astrocytoma, subclass midline pilocytic astrocytoma  see comment
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #046\NH17-3068,0.03,-0.144,-0.021,0.042,0.013,0.015,-0.009,-0.02,0.073,0.047,0.013,-0.018,-0.044,0.107,0.036,-0.046,0.138,0.081,0.193,0.095,0.135,0.103,-0.054,-0.189,0.024,-0.01,-0.045,-0.119,0.071,unmethylated
NH17-2698,200069280193_R02C01,#046,20/12/2017,,2/23/2018,65,ZJ,Diagnostic,046,8,NDP,NHNN,MGMT status differs between us and Bristol,"(2) unusual histology, location, demographics",SP1A,9/2/1960,57.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.76,GBM_MES,0.65,0.57,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2698,"Giant cell glioblastoma (WHO grade IV)     
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained      
1p/19q:     Test pending
","
Giant cell glioblastoma, IDH-wildtype (WHO grade IV)

MGMT Promoter: No methylation

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained
1p/19q: Retained
Chromosome 7p and EGFR: No gain and no amplification
TERT promoter: No mutation
Chromosome 10q: Retained

Histone H3F3A: No mutation
BRAF (V600E): No mutation 

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #046\NH17-2698,0.001,-0.094,-0.007,0.069,-0.189,0.036,-0.062,0.036,0.114,0.352,0.262,-0.011,0.01,-0.119,0.014,-0.001,-0.002,0.011,-0.048,-0.051,0.014,0.102,0.008,-0.108,0.039,0.067,-0.179,-0.164,0.02,methylated
NH18-65,200069280193_R03C02,#046,16/01/2018,,2/23/2018,38,SB/AK,Diagnostic,046,4,NDP,NHNN,Low grade ependymal tumour,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,6/1/1962,55.6,spinal ependymoma,1,EPN_SPINE,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-65,"Low-grade ependymal tumour  see comment
","Methylation profile: Ependymoma, spinal  see supplementary comment
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #046\NH18-65,0.215,-0.305,-0.561,-0.056,-0.593,-0.042,-0.074,-0.286,0.102,0.2,0.105,-0.013,0.211,-0.218,0.147,0.244,-0.065,-0.176,-0.122,-0.097,-0.129,0.408,-0.577,-0.379,0.272,0.29,-0.206,-0.292,0.028,unmethylated
NH17-2956,200069280193_R04C01,#046,3/1/2018,,2/23/2018,51,ZJ,Diagnostic,046,7,NDP,NHNN,"?GBM, IDHwt, TERTmt","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,4/26/1968,49.7,ganglioglioma,0.13,GBM_RTKII,0.54,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2956,"Diffuse glioma (WHO grade II)

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
1p/19q: Test pending
","Molecular profile suggestive (but not diagnostic) of glioblastoma, IDH-wildtype (WHO grade IV)  see supplementary comment


MGMT Promoter: No methylation

IDH1 (R132H IHC); IDH1/2 Seq: No mutation     
ATRX (IHC): Retained     
1p/19q: Retained
EGFR: No amplification          
TERT promoter: Mutation     
Chromosome 10q: Retained

Histone H3F3A: No mutation     
BRAF (V600E): No mutation      
 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #046\NH17-2956,0.172,-0.059,-0.096,0.063,-0.144,-0.005,-0.251,0.154,0.084,0.178,0.092,-0.022,0.125,-0.106,0.136,0.07,-0.171,-0.241,0.039,-0.09,-0.012,0.294,-0.182,-0.156,0.01,-0.047,-0.121,-0.315,-0.13,unmethylated
NH18-99,200069280193_R04C02,#046,16/01/2018,,2/23/2018,38,SB/AK,Diagnostic,046,1,NDP,"Charing Cross Hospital, London","Ependymoma, type?","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",C2,11/5/1980,37.2,papillary glioneuronal tumour,0.45,LGG_DNT,0.22,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-99,"Methylation profile: No matching methylation class  see comment
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #046\NH18-99,-0.068,0.013,0.063,0.022,-0.021,-0.037,-0.168,-0.036,0.152,-0.242,-0.019,0.158,-0.074,-0.191,0.039,0.097,-0.037,0.01,-0.266,-0.135,-0.154,-0.058,0.049,-0.572,0.363,0.119,-0.244,-0.149,0.254,unmethylated
NH18-101,200069280193_R05C02,#046,16/01/2018,,2/23/2018,38,SB/AK,Diagnostic,046,10,NDP,NHNN,Low grade glioneuronal tumour ?DNT,"(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF1A,5/9/2000,17.7,supratentorial pilocytic astrocytoma,0.56,LGG_PA_GGST,0.91,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-101,"Dysembryoplastic neuroepithelial tumour (WHO grade I), see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
BRAF V600E IHC: No mutation
","Low grade glial / glioneuronal tumour, in favour of pilocytic astrocytoma (WHO grade I)  see supplementary comment
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #046\NH18-101,0.239,-0.657,-0.266,-0.031,-0.42,0.107,0.203,-0.258,0.013,0.057,0.036,-0.015,0.17,0.015,0.045,0.053,-0.061,-0.07,-0.261,-0.212,-0.264,0.298,0.169,-0.342,0.102,0.131,-0.253,-0.1,0.247,unmethylated
NH17-2982,200069280193_R06C01,#046,11/1/2018,,2/23/2018,43,SB,Diagnostic,046,2,NDP,Royal London Hospital,Metastasising Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/27/1985,32.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.11,PXA,0.08,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2982,"Histological diagnosis: Poorly differentiated tumour infiltration in host bone
Methylation profile: No matching methylation class
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #046\NH17-2982,-0.555,-0.301,-0.083,-0.049,-0.2,-0.308,-0.247,0.284,0.045,0.095,0.126,-0.07,-0.044,-0.474,-0.119,0.18,0.109,0.098,-0.084,-0.133,-0.108,-0.535,-0.244,-0.435,0.2,-0.013,-0.069,-0.204,0.208,unmethylated
NH18-151,200069280193_R06C02,#046,22/01/2018,,2/23/2018,32,SB,Diagnostic,046,4,NDP,Nottingham University Hospital,"Anaplastic PA, GBM, reported  to have H3 K27M mutation","(2) unusual histology, location, demographics",B1,12/12/1960,57.1,pleomorphic xanthoastrocytoma(-like),0.33,DMG_K27,0.71,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-151,"High grade glioma, H3 K27M-mutant  see comment
","Methylation profile: Diffuse midline glioma, H3 K27M-mutant (WHO grade IV)
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #046\NH18-151,0.111,-0.308,-0.182,0.068,-0.194,-0.007,0.136,-0.029,0.044,0.019,0.006,-0.059,0.101,-0.233,0.03,0.105,0.051,0.038,-0.047,-0.086,-0.121,0.233,0.098,-0.37,0.044,0.051,-0.386,-0.217,0.247,unmethylated
NH18-198,200069280195_R01C01,#047,25/01/2018,,3/9/2018,43,SB/AK,Diagnostic,047,4,NDP,Tehran (IR),Low grade glial / glioneuronal tumour,"(4) IHC, sequencing, or copy number assay ambiguous",S96.8919,8/28/1970,47.4,ganglioglioma,0.49,GBM_MES,0.82,0.57,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-198,"Methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)

MGMT Promoter (Illumina): No methylation      
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #047\NH18-198,-0.181,-0.081,0.013,0.336,0.009,0.013,0.105,0.32,0.381,0.407,0.3,0.015,0.041,0.038,0.076,0.011,0.053,0.041,-0.051,0.088,-0.023,-0.005,0.097,-0.101,0.011,-0.142,0.185,-0.019,0.082,unmethylated
NH18-51,200069280195_R02C01,#047,26/01/2018,,3/9/2018,42,SB/AK,Diagnostic,047,1,NDP,NHNN,? Central neurocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/14/2001,16.9,dysembryoplastic neuroepithelial tumour,0.94,LGG_DNT,0.8,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-51,"Low grade glial/glioneuronal tumour- see comment

IDH1 (R132H IHC): No mutation; further tests pending 
ATRX (IHC): Retained        
","Central neurocytoma, WHO grade II), see comment
IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #047\NH18-51,-0.077,-0.051,-0.009,-0.011,-0.08,-0.018,0.028,-0.052,0.013,0.009,0.002,0.01,0.04,0.033,-0.031,0.004,0.046,-0.005,0.025,0.008,0,-0.019,0,0.027,0.027,0.001,-0.088,0.053,0.071,methylated
NH18-289,200069280195_R02C02,#047,9/2/2018,,3/9/2018,28,ZJ,Diagnostic,047,1,NDP,Brighton and Sussex Hospital,"Poorly differentiated, biphasic tumour (gliosarcoma vs metastasis)","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,11/15/1969,48.3,"glioblastoma, IDH-wildtype, mesenchymal type",0.41,GBM_MES,0.48,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-289,"Preliminary diagnosis:
Malignant, poorly differentiated tumour  see comment
","Molecular and methylation profile in favour of Glioblastoma, IDH-wildtype (WHO grade IV)  see comment  
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: No amplification          
TERT promoter: Mutation     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: No methylation      
 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #047\NH18-289,-0.054,-0.176,0.007,-0.041,-0.075,0.012,0.074,0.171,0.241,0.283,0.173,-0.005,0.061,-0.041,0.009,-0.016,-0.334,-0.335,-0.085,-0.054,0.819,1.096,0.019,0.104,0.225,0.127,0.162,0.018,0.053,unmethylated
NH18-205,200069280195_R03C01,#047,26/01/2018,,3/9/2018,42,SB/AK,Diagnostic,047,3,NDP,Nottingham University Hospital,? Low grade glial / glionueronal tumour,"(2) unusual histology, location, demographics",A1,12/31/1998,19.1,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.24,OIDH,0.31,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-205,"Low grade glioma (see comment)
Methylation class: inconclusive result
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #047\NH18-205,-0.307,-0.035,0.1,0.33,0.464,0.204,0.406,0.167,0.44,-0.183,-0.032,0.104,-0.493,0.19,-0.085,-0.087,0.181,-0.155,-0.064,0.144,0.129,0.508,-0.054,0.413,-0.217,-0.513,-0.283,-0.175,-0.017,methylated
NH18-258,200069280195_R03C02,#047,19/02/2018,,3/9/2018,18,ZJ,Diagnostic,047,19,NDP,NHNN,Poorly differentiated tumour (recurrence from NH14-2205),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,1/16/1992,26.1,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.42,GBM_MYCN,0.96,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-258,"Glioblastoma (WHO grade IV)  see comment


IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
  
","Molecular and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)  
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation
MGMT promoter (Illumina array): No methylation          
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #047\NH18-258,0.178,0.359,0.451,0.093,0.138,-0.021,-0.827,0.485,0.482,0.55,0.419,-0.145,-0.195,-0.146,-2.079,-0.23,-0.433,-0.589,0.038,-0.185,-0.181,-0.177,-0.146,-0.224,-0.254,0.061,-0.39,-0.222,-0.082,unmethylated
NH18-199,200069280195_R04C01,#047,26/01/2018,,3/9/2018,42,SB/AK,Diagnostic,047,1,NDP,Nottingham University Hospital,High grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/17/2017,0.4,Infant-type hemispheric glioma,1,IHG,1,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-199,"Histology: Glioblastoma (WHO grade IV)
Methylation class: Infantile spheric glioma, see comment
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #047\NH18-199,-0.051,-0.034,0.033,-0.017,-0.001,-0.043,0.045,-0.002,0.052,0.022,-0.005,-0.002,0.105,-0.004,0.027,-0.036,0.01,0.017,-0.062,0.059,0.024,0.035,0.084,-0.016,0.027,-0.003,-0.062,-0.036,0.069,unmethylated
NH18-586,200069280225_R01C02,#048,13/03/2018,,4/16/2018,34,SB,Diagnostic,048,9,NDP,Oxford John Radcliffe Hospital,Spinal LGG DD gliosis,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",Block 1-4 pool,11/27/1964,53,spinal subependymoma [subtype A],0.18,LGG_MYB,0.95,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-586,"CNS tissue, low grade glial tumour
Methylation class: Low calibration score (see comment)
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #048\NH18-586,-0.056,-0.056,-0.027,0.011,-0.014,0.001,0.012,-0.014,0.091,0.075,0.039,0.03,0.133,-0.003,0.105,-0.065,0.005,0.013,-0.071,-0.072,-0.03,0.111,0.091,-0.072,0.063,0.076,-0.044,0.018,0.076,unmethylated
NH18-514,200069280225_R03C01,#048,7/3/2018,,4/16/2018,40,SB,Diagnostic,048,2,NDP,Manchester Children,"Myxopap Ep/ PA, PlomyxA. ","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,1/19/2012,6.1,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.32,GBM_MYCN,0.31,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-514,"Referred diagnosis: myxopapillary ependymoma versus pilocytic/pilomyxoid astrocytoma. 
Methylation class and interpretation see comment
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #048\NH18-514,-0.067,-0.109,0.038,-0.017,-0.112,0.069,-0.516,-0.045,0,0.025,0,0.023,0.024,-0.064,0.015,-0.022,-0.266,-0.326,-0.05,-0.071,-0.05,0.081,0.034,-0.015,0.013,0.02,-0.127,-0.026,0.026,unmethylated
NH18-145,200069280225_R04C01,#048,7/3/2018,,4/16/2018,40,ZJ,Diagnostic,048,8,NDP,Plymouth,"High grade NE tumour (IDH,H3, wt)","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",ABC,3/22/1989,28.8,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.97,GBM_MID,0.54,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-145,"Preliminary diagnosis:High grade tumour - see comment
","Histology: High-grade neuroepithelial tumour
Methylation class: Glioblastoma, IDH wild-type, subclass midline (see comment)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #048\NH18-145,-0.083,-0.604,-0.059,-0.03,0.325,-0.073,-0.505,-0.016,0.124,0.557,0.028,-0.025,0.22,0.408,-2.15,0.03,-0.023,-0.057,-0.007,0.028,-0.01,0.033,-0.421,0.002,-2.307,0.064,0.253,-0.372,-0.387,unmethylated
NH18-595,200069280225_R04C02,#048,21/03/2018,,4/16/2018,26,SB,Diagnostic,048,1,NDP,Nottingham University Hospital,"looks like Oligo. IDH 1/2 neg, ATRX retained BRAF wt","(5) Confirmation of rare, unusual or interesting histo-molecular results",C1,10/9/1988,29.4,rosette-forming glioneuronal tumour,1,LGG_RGNT,0.99,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-595,"Histology: Low grade glial neuronal tumour
Methylation profile: Rosette forming glioneuronal tumour
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #048\NH18-595,-0.149,-0.08,0.023,-0.029,-0.096,0.037,0.012,-0.06,-0.047,0.013,0.016,-0.007,0.047,-0.028,0.008,-0.054,0.014,0.073,-0.004,-0.084,-0.02,-0.017,0.051,-0.028,-0.011,-0.031,0.027,0.036,0.025,unmethylated
NH18-553,200069280225_R06C01,#048,13/03/2018,,4/16/2018,34,SB,Diagnostic,048,4,NDP,NHNN,low grade glioneuronal tumour. ?type,"(4) IHC, sequencing, or copy number assay ambiguous",DEF1A,8/29/1991,26.5,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.76,LGG_DNT,0.75,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-553,"Low-grade glioneuronal tumour (WHO grade I)

IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
1p/19q: Test pending
  
","Histology: Low-grade glioneuronal tumour (WHO grade I)
Methylation class: Low grade glioma, dysembryoplastic epithelial tumour
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #048\NH18-553,-0.121,-0.113,0.005,-0.025,-0.084,0.005,-0.071,-0.016,-0.014,0.023,0.015,0.033,0.026,-0.015,0.03,0.009,0.047,0.003,-0.024,-0.057,-0.105,0.086,0.033,0.033,0.004,0.047,-0.035,-0.024,0.043,unmethylated
NH18-663,200069280225_R06C02,#048,22/03/2018,,4/16/2018,25,SB,Diagnostic,048,19,NDP,"Birmingham, Queen Elizabeth Hospital","Ganglioglioma CD34+, BRAF-","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,5/2/1974,43.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.82,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-663,"Histology: Diffuse, low grade glioma
Methylation class: Glioblastoma, IDH wild-type, subclass mesenchyma
EGFR: amplification
Chromosome 10q loss
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #048\NH18-663,-0.045,-0.066,0.03,-0.036,-0.038,0.007,-0.053,1.323,0.225,0.233,0.178,0.034,0.014,-0.009,-0.604,-0.074,-0.164,-0.178,-0.051,-0.003,0.037,0.032,0.056,-0.012,0.067,-0.002,0.166,-0.051,0.092,unmethylated
NH18-582,200379120026_R01C01,#049,26/03/2018,,4/23/2018,28,ZJ,Diagnostic,049,2,NDP,"Belfast, Royal Victoria Hospital","Low grade glioma, IDHwt","(4) IHC, sequencing, or copy number assay ambiguous",A,8/5/1988,29.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-582,"Referred diagnosis: Low grade glioma, IDH-wildtype  
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained          
EGFR: No amplification          
TERT promoter: No mutation     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: Low level methylation (>0-10%)      
","Molecular and methylation profile: Diffuse astrocytoma, IDH-mutant (WHO grade II)  
IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained          
EGFR: No amplification          
TERT promoter: No mutation     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: Low level methylation (>5-10%)      
  
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #049\NH18-582,-0.132,-0.017,0.08,-0.001,0.061,-0.019,-0.103,0.001,0.005,0.111,0.013,0.045,-0.05,0.182,-0.047,-0.05,0.055,0.003,0.045,0.004,0.089,-0.078,-0.134,0.065,-0.042,-0.02,-0.029,-0.059,0.017,methylated
NH18-588,200379120026_R01C02,#049,5/4/2018,,4/23/2018,18,ZJ,Diagnostic,049,1,NDP,NHNN,Subependymoma (focally increased cellularity,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,8/3/1981,36.6,posterior fossa subependymoma,1,SUBEPN_PF,1,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-588,"Ependymal tumour  see comment for grading/typing
","Histology and methylation profile: Subependymoma (WHO grade I)   
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #049\NH18-588,-0.102,-0.05,0.032,-0.031,0.022,-0.029,-0.318,-0.04,0.012,0.031,0.006,0.022,-0.008,0.039,0.063,0.006,0.016,-0.018,0.016,-0.081,0,-0.051,-0.011,0.015,0.017,-0.02,-0.055,-0.012,0.052,unmethylated
NH18-646,200379120026_R02C01,#049,27/03/2018,,4/23/2018,27,SB,Diagnostic,049,12,NDP,"Cambridge, Addenbrooke's Hospital",Ventricualr LGG/Glioneuronal,"(2) unusual histology, location, demographics",A,9/28/1990,27.5,papillary glioneuronal tumour,0.77,LGG_DNT,0.72,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-646,"Methylation profile: Low grade glioma, dysembryoplastic neuroepithelial tumour  see comment
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #049\NH18-646,-0.168,-0.081,0.079,0.077,0,-0.026,-0.313,-0.086,0.103,-0.076,-0.025,0.056,-0.037,0.048,0.082,-0.195,0.078,0.006,0.146,-0.028,0.099,-0.078,-0.057,0.1,-0.068,-0.12,-0.172,0.023,-0.019,unmethylated
NH18-807,200379120026_R02C02,#049,12/4/2018,,4/23/2018,11,SB,Diagnostic,049,8,NDP,"Cambridge, Addenbrooke's Hospital","GBM, subtype?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,2/17/1988,30.1,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.95,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-807,"Histology and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)  
MGMT Promoter (derived from Illumina 450k array data): Unmethylated
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #049\NH18-807,-0.197,-0.011,0.04,0,-0.057,0.038,0.021,0.233,0.293,0.227,0.193,0.012,0.062,-0.088,-1.051,0.084,-0.334,-0.247,-0.026,-0.016,-0.027,-0.01,-0.283,-0.013,0.034,-0.213,-0.057,-0.034,-0.268,unmethylated
NH18-804,200379120026_R03C02,#049,12/4/2018,,4/23/2018,11,SB,Diagnostic,049,2,NDP,"Birmingham, Queen Elizabeth Hospital","LGG, could be infiltration zone? Non diganostic poss!",(1) small biopsy or nonrepresentative sample;,D1,11/20/2003,14.3,infratentorial pilocytic astrocytoma,0.16,LGG_PA_GGST,0.28,0.52,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-804,"Methylation profile: Control tissue, hemispheric cortex  see comment
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #049\NH18-804,-0.151,-0.034,0.029,0.025,-0.022,-0.055,-0.064,0.004,0.065,0.091,0.006,0.019,0.015,0.055,0.057,-0.077,0.048,-0.001,0.052,-0.001,-0.028,0.005,-0.007,0.028,0.025,-0.062,-0.058,-0.05,0.017,unmethylated
NH18-320,200379120026_R04C02,#049,12/4/2018,,4/23/2018,11,ZJ,Diagnostic,049,1,NDP,"Belfast, Royal Victoria Hospital",Possible infiltration zone of glioma,(1) small biopsy or nonrepresentative sample;,1,2/18/1966,52,"control tissue, hemispheric cortex",0.14,LGG_DNT,0.27,0.41,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-320,"Appearances raising possibility, but not diagnostic of glioma infiltration  see comment  
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: No amplification          
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: No methylation      
  
","Histology: CNS tissue fragments with single cell infiltration raising the possibility but not diagnostic for glioma infiltration
Methylation class: Control tissue, hypothalamus (see comment)
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #049\NH18-320,0.011,-0.117,-0.064,0.056,-0.022,-0.042,-0.098,0.048,0.089,0.237,0.086,0.011,0.024,0.002,-0.065,-0.082,-0.006,-0.134,-0.036,-0.019,0.064,-0.014,0.027,0.011,0.118,0.04,0,-0.023,-0.045,unmethylated
NH18-716,200379120026_R06C01,#049,5/4/2018,,4/23/2018,18,ZJ,Diagnostic,049,2,NDP,Royal London Hospital,"LGG, favouring pilocytic astrocytoms","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,10/9/1985,32.5,high-grade astrocytoma with piloid features,0.79,ANAPA,0.57,0.56,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-716,"Low grade glioma in favour of pilocytic astrocytoma  see comment
","Morphology: Low grade glioma favouring pilocytic astrocytoma
Methylation class: Anaplastic pilocytic astrocytoma
ATRX: Loss of expression, CDKN2A/B loss
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #049\NH18-716,-0.234,-0.025,0.025,0.068,-0.073,0.014,-0.028,-0.04,0.133,0.125,0.005,-0.171,0.343,0.023,-0.619,-0.038,-0.103,-0.127,0.253,0.063,0.166,0.178,0.055,-0.072,0.085,-0.04,-0.26,-0.119,-0.076,unmethylated
NH18-552,200379120026_R06C02,#049,12/4/2018,,4/23/2018,11,ZJ,Diagnostic,049,6,NDP,Preston,"LGG, BRAF neg","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1D,12/18/1994,22.1,"supratentorial ependymoma, ZFTA fusion-positive",1,EPN_RELA,0.63,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-552,"Referred diagnosis: Astroblastoma 
Methylation class: Not classifiable with certainty, see below 
","See main report
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #049\NH18-552,0.261,-0.062,0.044,-0.002,-0.057,0.136,-0.066,0.225,0.31,0.35,0.237,0.241,0.325,0.286,0.027,-0.115,0.047,0.003,0.248,0.023,0.061,-0.131,0.255,-0.031,0.063,0.083,0.159,-0.024,-0.063,unmethylated
NH18-800,202093120072_R01C01,#050,17/04/2018,,5/3/2018,16,SB,Diagnostic,050,5,NDP,NHNN,"Astro II with MVP, ?A-IDH vs GBM IDH","(2) unusual histology, location, demographics",SP1A,8/24/1995,22.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-800,"Diffuse astrocytoma  see comment

IDH1 (R132H IHC): Mutation  
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Test pending
  
","Diffuse astrocytoma, IDH-mutant (WHO grade II)  see supplementary comment 
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained          
EGFR: No amplification          
TERT promoter: No mutation     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: No/insignificant methylation* 
  
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #050\NH18-800,0.002,-0.061,0.039,-0.069,-0.001,0.011,-0.008,-0.027,0.093,0.108,0.107,0.021,-0.027,0.01,-0.009,-0.003,0.039,0.03,-0.001,0.006,-0.021,-0.054,-0.225,-0.006,-0.026,-0.012,-0.005,0.026,0.028,methylated
NH18-738,202093120072_R02C01,#050,17/04/2018,,5/3/2018,16,SB,Diagnostic,050,2,NDP,Manchester,"LGG, diffuse, non-spec. All Molecular non-informative","(5) Confirmation of rare, unusual or interesting histo-molecular results",A,#N/A,#N/A,dysembryoplastic neuroepithelial tumour,0.95,LGG_DNT,0.96,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-738,"Low grade glioma; compatible with a paediatric diffuse astrocytoma (see comment).
","Histological diagnosis: Low grade glioma, compatible with a paediatric diffuse astrocytoma 
Methylation profile: Low grade glioma, dysembryoplastic neuroepithelial tumour  see supplementary comment

BRAF (V600E and three fusions): No mutation
MGMT Promoter: No methylation



",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #050\NH18-738,0.026,-0.035,0.028,-0.012,-0.002,0.008,0.021,-0.049,-0.072,-0.086,-0.021,0.009,0.016,-0.015,0.025,-0.004,0.021,0.015,0.028,0.004,0.009,-0.033,0.009,0.017,0.017,-0.008,0.039,0.041,0.064,unmethylated
NH14-2173,202093120072_R03C01,#050,18/04/2018,,5/3/2018,15,SB,Diagnostic,050,1,NDP,NHNN,"LGG, 4Y survival, TERT250T, no EGFR; ?GBM",(1) small biopsy or nonrepresentative sample;,DEF2A,8/22/1970,44.3,ganglioglioma,0.4,GBM_MES,0.33,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-2173,"Low grade glioneuronal tumour, with features raising the possibility of central neurocytoma (WHO Grade II). Please see comments. 
",#REF!,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #050\NH14-2173,0.127,0.005,0.059,0.16,0.05,0.243,0.285,0.398,0.452,0.476,0.414,0.249,0.279,0.252,-0.025,0.01,0.03,0.014,-0.056,0.021,0.072,0.104,-0.032,-0.008,-0.052,-0.062,0.165,-0.051,0.055,unmethylated
NH18-692,202093120072_R04C01,#050,19/04/2018,,5/3/2018,14,SB,Diagnostic,050,3,NDP,"Liverpool, The Walton Centre","Anaplastic PA (ATRX loss, NF1 pat)","(2) unusual histology, location, demographics",A,7/27/1990,27.6,high-grade astrocytoma with piloid features,0.99,ANAPA,0.64,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-692,"Referred diagnosis: Diffuse astrocytoma, probably high grade 
Methylation profile: Anaplastic pilocytic astrocytoma (anaplastic astrocytoma with piloid features)  see comment

",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #050\NH18-692,-0.128,0.036,0.082,-0.043,0.067,0.058,-0.075,-0.105,-0.064,-0.147,-0.026,0.054,0.115,0.079,-0.488,-0.099,0.146,-0.025,0.049,0.172,0.071,0.151,-0.125,-0.003,-0.056,-0.033,-0.039,0.042,0.048,methylated
NH18-762,202093120072_R05C01,#050,20/04/2018,,5/3/2018,13,SB,Diagnostic,050,5,NDP,NHNN,"ATRX mutant High grade glioma, 38Y, no IDH, H3.3 mut","(2) unusual histology, location, demographics",DEF2A,8/10/1979,38.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.84,AIDH,0.56,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-762,"Provisional diagnosis: high grade glioma with astrocytic lineage

IDH1 (R132H IHC): No mutation; further tests pending 
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Test pending
  
","Anaplastic astrocytoma, IDH wild-type (WHO grade III)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)
EGFR: No amplification
Histone H3F3A: No mutation
BRAF (V600E): No mutation
MGMT Promoter: No/insignificant methylation*
 

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #050\NH18-762,-0.059,-0.019,0.067,-0.039,0.019,-0.354,0.087,0.035,-0.015,-0.034,-0.014,0.005,0.035,-0.023,0.055,0.027,-0.202,-0.863,0.178,0.047,0.813,-0.177,-0.019,0.006,0.02,0.015,-0.03,0.042,0.079,methylated
NH18-864,202093120072_R06C01,#050,20/04/2018,,5/3/2018,13,SB,Diagnostic,050,1,NDP,NHNN,"Intramedullary C3, ? Clear cell ependymoma, or else?","(2) unusual histology, location, demographics",DEF1A,7/3/1945,72.8,spinal ependymoma,1,EPN_SPINE,1,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-864,"Most in keeping with clear cell ependymoma (see comment)
","Methylation profile: Ependymoma, spinal  see supplementary comment
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #050\NH18-864,-0.03,0.19,0.177,0.126,0.136,0.028,-0.012,0.183,0.203,0.211,0.197,0.002,0.033,0.015,0.202,0.186,0.008,0.02,-0.001,0.195,0.155,0.183,-0.039,0.232,0.244,0.19,-0.019,-0.249,-0.252,methylated
NH16-1488,202073210004_R02C01,#051,26/04/2018,,5/11/2018,15,SB,Diagnostic,051,5,NDP,NHNN,rapid progression from AII to GBM-IDH. MC A_IDH or GBM_IDH,"(2) unusual histology, location, demographics",DEF1A,9/4/1981,34.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-1488,"Diffuse astrocytoma (WHO grade II), IDH1 mutant.

IDH1 (R132H IHC): Mutation.  
ATRX (IHC): Loss of expression (indicates mutation). 
","Diffuse astrocytoma, IDH-mutant (WHO grade II)  for grading, see also supplementary comment 

IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained          
EGFR: No amplification          
TERT promoter: No mutation     
Histone H3F3A: No mutation     
MGMT Promoter: Low level methylation (>5-10%)      
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #051\NH16-1488,0.05,-0.015,0.03,-0.004,-0.001,0.045,0.03,-0.048,-0.018,0.006,0.016,0.001,0.069,0.025,-0.428,0.267,0.034,0.03,0.031,-0.031,0.033,-0.003,-0.086,0.016,0.023,0.016,-0.391,0.027,0.028,methylated
NH18-825,202073210004_R03C01,#051,27/04/2018,,5/11/2018,14,SB,Diagnostic,051,1,NDP,St George's Hospital London,"LGG, BRAF no mut. ","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/4/1993,24.2,ganglioglioma,1,LGG_GG,1,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-825,"Methylation profile: Low grade glioma, ganglioglioma  see diagnosis comment 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #051\NH18-825,-0.006,-0.014,-0.021,0,-0.019,0.02,0.102,0.079,0.094,0.122,0.083,0.032,0.067,0.046,-0.014,-0.011,0.01,-0.028,0.001,0.078,0.038,0.125,0.01,-0.032,0.015,-0.04,0.027,-0.016,0.025,unmethylated
NH18-823,202073210004_R04C01,#051,27/04/2018,,5/11/2018,14,SB,Diagnostic,051,2,NDP,NHNN,"GBM ATRX loss, no H3 or IDH1/2 mut","(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF2A,4/24/1947,71,"glioblastoma, IDH-wildtype, RTK2 type",0.89,GBM_RTKII,0.92,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-823,"Glioblastoma (WHO grade IV)

IDH1 (R132H IHC): No mutation; further tests pending 
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Test pending
  
","Glioblastoma, IDH-wildtype (WHO grade IV)  
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Retained
EGFR: No amplification
Histone H3F3A: No mutation
BRAF (V600E): No mutation     
MGMT Promoter: Low level methylation (>5-10%) 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #051\NH18-823,0.032,-0.051,0.027,-0.099,-0.045,0.044,-0.004,0.351,0.389,0.471,0.304,0,0.077,0.048,-1.109,0.028,0.053,0.026,-0.022,0.185,0.104,0.29,0.033,0.064,0.041,0.185,-0.02,-0.035,0.132,methylated
NH18-941,202073210004_R05C01,#051,27/04/2018,,5/11/2018,14,SB,Diagnostic,051,6,NDP,Brighton and Sussex Hospital,SEGA,"(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF2B,9/17/1987,30.6,subependymal giant cell astrocytoma,1,LGG_SEGA,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-941,"Low grade glioma, in keeping with subependymal giant cell astrocytoma (SEGA)  see comment

IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained      

","Subependymal giant cell astrocytoma (WHO grade I)
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #051\NH18-941,-0.008,-0.029,-0.001,0.004,-0.031,0.048,0.041,-0.037,0.002,-0.023,-0.006,0.006,0.096,0.005,-0.025,-0.032,0.015,0,-0.006,-0.047,-0.028,0.009,0.018,-0.032,0.013,-0.009,-0.006,-0.018,0.038,unmethylated
NH18-930,202073210004_R06C01,#051,30/04/2018,,5/11/2018,11,SB,Diagnostic,051,4,NDP,"King's College Hospital, London","AII, IDH, ATRX mut. Prognostication","(4) IHC, sequencing, or copy number assay ambiguous",A,6/6/1988,29.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.62,AIDH,0.54,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-930,"Anaplastic astrocytoma, IDH mutant (WHO grade III)

IDH1 (R132H IHC): Mutation (tested in the referring laboratory)
ATRX (IHC): Retained (tested in the referring laboratory)
1p/19q: 19q loss only, tested in the referring laboratory

","Anaplastic astrocytoma, IDH-mutant (WHO grade III)  see supplementary comment
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #051\NH18-930,-0.009,-0.026,0.021,0.004,-0.037,0.036,-0.471,-0.024,0.006,-0.019,-0.012,0.227,0.217,0.212,-0.017,0.006,-0.006,-0.017,-0.013,-0.029,0.014,-0.509,0.008,-0.009,0.024,0.02,0.358,0.018,0.029,unmethylated
NH18-921,202073210004_R07C01,#051,24/04/2018,,5/11/2018,17,ZJ,Diagnostic,051,1,NDP,Nottingham University Hospital,"Glioma, NOS","(2) unusual histology, location, demographics",A1,7/16/1986,31.8,pleomorphic xanthoastrocytoma(-like),0.38,PXA,0.44,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-921,"Astrocytic tumour, raising the possibility of pilocytic astrocytoma (WHO grade I)  see comment
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #051\NH18-921,0.028,0.022,0.004,-0.194,-0.017,0.061,-0.037,-0.031,0.012,0.038,0.003,-0.044,-0.015,0.001,0.004,0.011,0.033,0.002,0.025,0.046,-0.006,0.008,-0.175,-0.204,0.01,0.014,-0.004,-0.034,0.031,methylated
NH18-951,202093120022_R03C01,#052,8/5/2018,,5/18/2018,10,ZJ,Diagnostic,052,2,NDP,NHNN,"LGG, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,4/29/1957,61,"glioblastoma, IDH-wildtype, RTK1 type",0.91,GBM_MID,0.59,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-951,"Astrocytoma (no high grade features confirmed on histology - see comment)

IDH1 (R132H IHC): No mutation; further tests pending 
ATRX (IHC): Retained      
1p/19q: Test pending 
","Histology: Astrocytoma (no high-grade features) 
PDGFRA amplification,
CDKN 2A/B deletion
Methylation class: Not classified (see comment)
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #052\NH18-951,-0.149,-0.087,-0.002,-0.004,0.929,-0.026,0.057,-0.152,-0.058,0.099,0.248,-0.027,-0.036,0.007,-0.979,0.327,-0.107,0.1,-0.004,-0.193,-0.033,0.08,-0.205,-0.072,-0.098,0.084,-0.081,0,0.168,methylated
NH18-976,202093120022_R04C01,#052,8/5/2018,,5/18/2018,10,ZJ,Diagnostic,052,4,NDP,"Birmingham, Queen Elizabeth Hospital",HGG,"(5) Confirmation of rare, unusual or interesting histo-molecular results",C1,6/5/2008,9.8,"glioblastoma, IDH-wildtype, RTK2 type",0.49,GBM_RTKII,0.28,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-976,"Histology: Glioblastoma , IDH wild-type (see comment)
Methylation class: Glioblastoma, IDH wild-type (see comment)
","Histology: Glioblastoma, IDH-wildtype (see comment)
Methylation class: Glioblastoma, IDH-wildtype (see comment)
BRAF V600: No mutation
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #052\NH18-976,-0.008,-0.02,0.064,0.008,0.048,-0.006,-0.371,0.226,0.187,0.22,0.155,-0.359,-0.258,-0.294,-0.723,0.128,0.006,0.014,0.009,0.688,0.692,1.1,-0.005,-0.276,-0.398,0.112,0.003,-0.269,-0.118,methylated
NH18-1022,202093120022_R05C01,#052,9/5/2018,,5/18/2018,9,ZJ,Diagnostic,052,3,NDP,"Cardiff, University Hospital",Cerebellar LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,1/10/2017,1.3,infratentorial pilocytic astrocytoma,0.96,LGG_PAPF,0.71,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH18-1022,"Morphology: Cerebellar low grade glioma
Methylation glass: Pilocytic astrocytoma, subclass posterior fossa pilocytic astrocytoma
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #052\NH18-1022,-0.047,0.034,0.053,0.026,-0.066,-0.01,0,-0.036,0.025,0.009,0.151,-0.04,0.103,0.08,-0.019,0.042,0.037,-0.032,0.088,0.054,0.032,0.067,-0.016,0.043,0.054,-0.002,-0.022,-0.033,0.062,unmethylated
NH18-995,202093120022_R06C01,#052,11/5/2018,,5/18/2018,7,ZJ,Diagnostic,052,1,NDP,NHNN,"HGG, BRAF mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,12/24/1994,23.4,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-995,"High grade glial tumour, BRAF mutant (see comment)
","Histology: Anaplastic pleomorphic xanthoastrocytoma (WHO grade III)  
BRAF (V600E): Mutation
ATRX: Retained
CDKN2A/B locus: Deleted
Methylation class: Anaplastic pleomorphic xanthoastrocytoma
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #052\NH18-995,-0.022,0.069,0.061,-0.082,0.04,0.186,-0.288,0.054,0.194,0.325,0.12,-0.161,-0.083,-0.084,-2.164,-0.325,-0.317,-0.225,-0.039,0.037,-0.038,0.064,-0.122,0.013,0.044,0.043,0.02,-0.048,0.075,unmethylated
NH17-2085,202093120022_R07C01,#052,11/5/2018,,5/18/2018,7,ZJ,Diagnostic,052,1,NDP,Oxford John Radcliffe Hospital,LG glioneuronal tumour,"(5) Confirmation of rare, unusual or interesting histo-molecular results",Block 3,10/2/2001,15.8,rosette-forming glioneuronal tumour,1,LGG_RGNT,0.95,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2085,"
Referred diagnosis:
Differential diagnosis between pilocytic astrocytoma and rosette forming glioneuronal tumour

BRAF (Seq and V600E IHC): No mutation
KIAA1549-BRAF fusions: No fusions between 16_9, 16_11, 15_9 exons 

","Referred diagnosis: Rosette forming glioneuronal tumour (see previous report), WHO grade I)
Methylation class: Rosette forming glioneuronal tumour
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #052\NH17-2085,-0.007,0.032,0.002,-0.024,-0.065,0.042,0.097,0.013,0.001,0.051,0.008,0.019,0.011,0.099,-0.03,0.008,-0.029,-0.018,0.056,-0.001,0.035,-0.005,-0.024,0.082,-0.054,-0.009,0.007,-0.14,-0.001,unmethylated
NH18-973,202073210050_R03C01,#053,16/05/2018,,6/1/2018,16,ZJ,Diagnostic,053,1,NDP,"Birmingham, Queen Elizabeth Hospital","?LGG, glioneuronal tumour","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",Block 1,7/13/2001,16.8,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.83,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-973,"Referred diagnosis: Glial tumour  see comment
BRAF (V600E and three fusions): No mutation  
","Histology: Low grade glioma, with features suggestive of a pilocytic astrocytoma
BRAF: No point mutation or fusion mutations
Methylation class: Pilocytic astrocytoma
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #053\NH18-973,0.039,-0.004,-0.04,-0.032,-0.019,-0.049,0.059,-0.055,-0.033,-0.025,-0.028,0.009,-0.022,0.067,0.088,-0.001,0.024,-0.028,0.004,0.036,-0.03,0,0.045,0.058,0.04,0,-0.042,0.014,0.014,methylated
NH18-1108,202073210050_R05C01,#053,18/05/2018,,6/1/2018,14,ZJ,Diagnostic,053,1,NDP,Nottingham University Hospital,"Glioma, NOS","(2) unusual histology, location, demographics",B1,12/15/1958,59.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.95,OIDH,0.79,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1108,"Histology: Astrocytic glioma with extensive gemistocytic morphology
Methylation class: Glioma, IDH-mutant, subclass high grade astrocytoma  see comment  

IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
1p/19q (Illumina copy number profile): Suggestive of codeletion
MGMT Promoter status prediction (Illumina array): Methylated 
",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #053\NH18-1108,0.093,-0.033,0.003,0.082,-0.004,-0.043,-0.278,0.099,-0.001,-0.06,0.041,0.03,0.015,0.003,-0.55,-0.154,-0.049,-0.113,0.008,0.015,0.043,0.065,0.046,-0.2,0.266,0.105,-0.502,0.069,0.113,methylated
NH18-828,202073210050_R06C01,#053,21/05/2018,,6/1/2018,11,ZJ,Diagnostic,053,3,NDP,NHNN,,"(2) unusual histology, location, demographics",DEF1A,9/4/1981,36.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,0.93,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-828,"Glioblastoma, IDH mutant (WHO grade IV)

IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
  
","Glioblastoma, IDH mutant (WHO grade IV)
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
MGMT Promoter:  Low level methylation (>5-10%)
Methylation class: Glioma, IDH mutant, subclass high-grade astrocytoma 

",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #053\NH18-828,-0.126,-0.042,-0.016,-0.01,-0.067,-0.195,-0.011,-0.015,-0.034,0.047,-0.02,0.002,0.015,0.006,-0.298,0.189,-0.268,-0.253,-0.091,-0.028,-0.045,-0.092,-0.831,-0.079,-0.082,-0.103,-0.466,-0.167,-0.239,methylated
NH18-1086,202073210050_R07C01,#053,22/05/2018,,6/1/2018,10,SB,Diagnostic,053,4,NDP,"Cambridge, Addenbrooke's Hospital",Anaplastic Meningioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,11/28/1958,59.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.65,GBM_MES,0.35,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1086,"Malignant poorly differentiated tumour in keeping with an anaplastic meningioma (WHO grade III) - see comment
","Histology: Poorly differentiated intrinsic tumour (see comment)
Methylation class: Glioblastoma, IDH-wildtype, subclass mesenchymal

",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #053\NH18-1086,-0.018,-0.044,-0.003,-0.003,-0.03,0.032,0.075,0.135,0.209,0.225,0.169,0.005,0.005,0.01,0.062,0.091,-0.278,-0.224,-0.028,-0.028,0.837,-0.016,-0.004,0.011,-0.007,0.011,-0.074,0.004,0.038,methylated
NH18-1196,202073210028_R02C01,#054,30/05/2018,,6/23/2018,24,SB,Diagnostic,054,3,NDP,"Belfast, Royal Victoria Hospital","Temporal HGG, HGG component","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,3/9/2008,10.2,"Diffuse paediatric-type high grade glioma, RTK2 subtype",1,GBM_RTKIII,1,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1196,"Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, RTK III subclass 
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, RTK III subclass 

EGFR: No amplification
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #054\NH18-1196,-0.065,-0.033,0.055,-0.008,-0.03,0.138,0.048,0.276,0.239,0.283,0.216,-0.023,0.077,0.034,0.053,-0.015,0.001,0.052,0.03,-0.051,-0.026,0.08,-0.001,0.006,0.007,0.046,-0.066,0.041,0.063,unmethylated
NH18-1196,202073210028_R03C01,#054,30/05/2018,,6/23/2018,24,SB,Diagnostic,054,3,NDP,"Belfast, Royal Victoria Hospital","Temporal HGG, LGG component","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,3/9/2008,10.2,"Diffuse paediatric-type high grade glioma, RTK2 subtype",1,GBM_RTKIII,1,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1196,"Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, RTK III subclass 
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, RTK III subclass 

EGFR: No amplification
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #054\NH18-1196,0.034,0.001,0.006,-0.007,-0.036,0.097,0.029,0.047,0.004,-0.001,0.009,-0.023,0.078,0.019,0.03,-0.002,0.025,0.022,0.026,0.026,-0.022,0.064,0.022,0,0.058,-0.007,-0.063,0.009,0.049,unmethylated
NH18-1228,202073210028_R04C01,#054,5/6/2018,,6/23/2018,18,SB,Diagnostic,054,1,NDP,"Charing Cross Hospital, London",Ependymoma C2-C3,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B2,1/2/1963,55.5,spinal ependymoma,1,EPN_SPINE,1,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1228,"Methylation profile: Ependymoma, spinal
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #054\NH18-1228,-0.037,-0.003,0.062,-0.017,0.029,0.177,0.063,0.192,0.216,0.226,0.207,-0.02,0.034,0.067,0.227,0.196,-0.01,0.032,0.019,-0.004,-0.019,0.034,-0.034,-0.014,-0.065,-0.007,0.035,-0.335,-0.346,unmethylated
NH18-1082,202073210028_R05C01,#054,7/6/2018,,6/23/2018,16,SB,Diagnostic,054,1,NDP,Preston,"Intrinsic tumour, IDH, BRAF wt, ?Neurocytoma?","(4) IHC, sequencing, or copy number assay ambiguous",B ,12/7/1966,51.4,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.96,OIDH,0.92,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1082,"Histological, molecular and methylation profile supportive of anaplastic oligodendroglioma, IDH-mutant and 1p/19q codeleted (WHO grade III)  see comment

",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #054\NH18-1082,0.098,-0.371,-0.266,-0.049,-0.181,0.109,-0.019,-0.046,-0.06,-0.036,0.004,-0.033,-0.016,0.064,-0.019,-0.008,-0.184,-0.547,0.041,-0.401,-0.218,-0.262,-0.395,-0.131,-0.108,-0.146,-0.353,-0.081,-0.074,methylated
NH18-1259,202073210028_R06C01,#054,11/6/2018,,6/23/2018,12,SB,Diagnostic,054,4,NDP,Malta,"Ependumoma, L4 after RT, Myxopap, malignant?","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1B,6/11/1977,41,myxopapillary ependymoma,0.93,EPN_MPE,0.84,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1259,"Ependymal tumour with histological high grade features  see comment
","Histology: Ependymoma with high grade features 6 see supplementary comment
Methylation profile: Ependymoma, myxopapillary
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #054\NH18-1259,0.01,-0.086,-0.007,-0.041,-0.038,0.023,0.061,0.314,0.392,0.418,0.338,0,0.075,0.017,0.461,0.379,0.052,-0.114,0.051,0.015,-0.062,0.017,0.075,-0.018,0.073,0.036,0,0.011,0.015,unmethylated
NH18-1234,202073210028_R07C01,#054,11/6/2018,,6/23/2018,12,SB,Diagnostic,054,1,NDP,"Birmingham, Queen Elizabeth Hospital",CNS with glioma (?) infiltration. ,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,8/29/2012,5.8,"diffuse glioma, MYB(L1)-altered, subtype D",1,LGG_MYB,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1234,"Methylation profile: Low grade glioma with MYB/MYBL1 alteration  see comment
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #054\NH18-1234,0.051,0.021,0.03,0.038,-0.042,0.007,0.322,0.049,0.005,-0.025,0.008,-0.005,0.055,0.009,-0.002,0.006,0.019,0.003,0.029,0.01,-0.015,0.021,0.025,0.014,0.028,0.007,-0.01,0.004,0.058,unmethylated
NH18-1233,202073210028_R08C01,#054,13/06/2018,,6/23/2018,10,SB,Diagnostic,054,4,NDP,"Birmingham, Queen Elizabeth Hospital",Midline tumour H3K27 non-mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,2/10/1940,78.4,"glioblastoma, IDH-wildtype, RTK2 type",0.41,GBM_RTKII,0.87,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1233,"Molecular and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)  see comment
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #054\NH18-1233,0.919,-0.059,0.007,-0.075,-0.014,0.106,-0.371,1.137,0.19,0.161,0.135,-0.104,0.084,0.045,-1.012,-0.375,-0.233,-0.215,0.011,-0.011,-0.036,0.118,0,0.019,0.073,0.055,-0.015,-0.249,-0.209,methylated
NH18-1271,202073210005_R05C01,#055,20/06/2018,,7/11/2018,21,ZJ,Diagnostic,055,2,NDP,NHNN,LGG (?GBM),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,8/12/1970,47.9,ganglioglioma,0.58,GBM_MES,0.88,0.52,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1271,"Glial tumour without high grade features on histology (see comment).
IDH1 (R132H IHC): No mutation, further tests pending.
ATRX (IHC): Retained.
1p/19q: Test pending.  
","Histology: Glioma with no high grade features 
Molecular profile of Glioblastoma, IDH-wildtype (WHO grade IV)  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: Amplification          
TERT promoter: Mutation
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #055\NH18-1271,0.014,-0.079,-0.015,-0.039,-0.038,0.077,-0.272,1.118,-0.024,-0.1,0.154,0.048,0.029,0.015,-0.094,-0.053,-0.149,-0.196,-0.005,0.024,-0.008,0.042,-0.002,-0.128,-0.042,-0.032,0.17,-0.065,0.069,unmethylated
NH18-1269,202073210005_R07C01,#055,20/06/2018,,7/11/2018,21,ZJ,Diagnostic,055,2,NDP,Royal London Hospital,?GBM (has EGBs),"(2) unusual histology, location, demographics",DEF1A,7/11/1952,65.9,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.86,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1269,"Glioblastoma (WHO grade IV)

IDH1 (R132H IHC): No mutation, further tests pending. 
ATRX (IHC): Retained.
1p/19q:     Test pending.  
","Molecular and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: No amplification          
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: Methylated 
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #055\NH18-1269,0.044,0.581,-0.018,0.021,-0.005,0.018,0.059,0.096,0.16,0.108,0.155,0.124,0.186,0.161,-0.208,-0.005,0.01,-0.033,0.031,0.165,0.085,0.333,0.025,0.031,0.207,0.02,0.145,-0.001,-0.005,methylated
NH18-1250,202073210005_R08C01,#055,22/06/2018,,7/11/2018,19,ZJ,Diagnostic,055,1,NDP,"Belfast, Royal Victoria Hospital",?GBM (radiology LGG),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",P18.14341,9/13/1958,59.7,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.49,GBM_RTKII,0.64,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1250,"Molecular profile raising the possibility, but not diagnostic of glioblastoma, IDH-wildtype (WHO grade IV)  see comment 

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: No amplification          
TERT promoter: Mutation
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: Unmethylated (0%)
","Molecular and methylation profile suggestive of glioblastoma, IDH-wildtype (WHO grade IV) 

MGMT Promoter: Unmethylated

  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #055\NH18-1250,0.488,0.053,0.049,-0.071,-0.065,0.064,0.039,0.244,0.196,0.244,0.184,-0.002,-0.001,0.051,0.101,0.023,-0.32,-0.332,-0.003,0.047,0.01,-0.035,-0.008,0.076,0.085,0.049,-0.445,0.027,0.04,unmethylated
NH18-1296,202073210006_R01C01,#056,26/06/2018,,7/13/2018,17,ZJ,Diagnostic,056,1,NDP,Oxford John Radcliffe Hospital,?clear cell ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",3A,5/7/1995,23.1,dysembryoplastic neuroepithelial tumour,0.99,LGG_DNT,0.98,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1296,"Glial or glioneuronal tumour  see comment 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: No amplification          
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
","Histology: Glial/glioneuronal tumour
Methylation class: Low grade glioma, dysembryoplastic neuroepithelial tumour
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #056\NH18-1296,-0.062,-0.005,-0.007,0.051,-0.051,0.075,0.125,0.032,0.043,0.115,0.068,-0.008,0.015,0.082,0.01,0.013,-0.043,0.043,0.024,-0.082,-0.06,0.022,-0.028,-0.111,-0.022,-0.142,0.061,-0.136,0.044,unmethylated
NH18-1423,202073210006_R02C01,#056,26/06/2018,,7/13/2018,17,ZJ,Diagnostic,056,1,NDP,Southend,Oligo-like morphology,"(2) unusual histology, location, demographics",A2,2/21/1977,34.4,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.67,GBM_MID,0.58,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1423,"Low grade glial/glioneuronal neoplasm (see comment)
No methylation class assigned (see methylation report) 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #056\NH18-1423,0.092,-0.293,-0.011,0.142,0.514,-0.392,-0.096,-0.141,0.145,0.236,0.416,-0.356,0.048,0.157,-1.713,0.665,-0.105,-0.166,0.078,-0.071,0.163,0.187,-0.005,-0.626,0.208,0.174,-0.39,-0.089,0.088,unmethylated
NH18-1486,202073210006_R05C01,#056,3/7/2018,,7/13/2018,10,ZJ,Diagnostic,056,3,NDP,St George's Hospital London,GBM vs PNET,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/23/1975,43.3,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.49,GBM_MID,0.99,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1486,"Histology: Poorly differentiated intrinsic neoplasm (corresponding to WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #056\NH18-1486,-0.001,0.135,0.011,0.037,-0.003,0.077,-0.034,-0.029,0.014,-0.196,-0.03,0.018,0.065,0.079,-0.439,0.038,-0.003,0.079,0.06,0.049,0.001,-0.034,-0.163,0.098,-0.024,-0.02,-0.133,-0.024,0.052,unmethylated
NH18-1475,202073210006_R06C01,#056,2/7/2018,,7/13/2018,11,ZJ,Diagnostic,056,2,NDP,"Leeds, St James's University Hospital",GBM year later metastasis to skin (face),"(2) unusual histology, location, demographics",A,3/19/1949,68.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.44,GBM_RTKII,0.62,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1475,"Primary tumour: Glioblastoma, IDH-wildtype (WHO grade IV)-see also referring pathologist's report
Metastasised tumour: Glioblastoma, IDH-wildtype (WHO grade IV)-see also referring pathologist report

Methylation class (primary tumour): Glioblastoma, IDH-wildtype, subclass RTK II
Methylation class (metastasised tumour): Glioblastoma, IDH-wildtype, subclass RTK II

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #056\NH18-1475,0.124,-0.013,0.036,0.115,0.033,0.124,0.018,0.366,0.383,0.458,0.381,0.203,0.159,0.248,0.201,0.19,-0.018,0.019,0.031,-0.027,0.056,0.027,-0.056,-0.02,-0.265,-0.005,-0.037,-0.032,0.033,unmethylated
NH18-1453,202073210006_R08C01,#056,2/7/2018,,7/13/2018,11,ZJ,Diagnostic,056,13,NDP,NHNN,"LGG, glioneuronal tu in pineal region","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,7/23/1973,45,rosette-forming glioneuronal tumour,1,LGG_PAPF,0.46,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1453,"Low grade glial/glioneuronal tumour  see comment
","Histology: Low grade glial/glioneuronal tumour
Methylation class: Low grade glioma, rosetted forming glial neuronal tumour 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #056\NH18-1453,0.017,-0.032,0,-0.016,-0.021,0.007,0.011,-0.019,-0.007,-0.01,0.002,0.007,0.002,0.009,-0.018,0.003,-0.04,0.018,0.069,-0.002,-0.027,0.017,-0.015,0.009,0.012,0.004,0.001,-0.033,0.044,unmethylated
NH18-1330,202066270125_R01C01,#057,28/06/2018,,8/4/2018,37,ZJ,Diagnostic,057,14,NDP,NHNN,?PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/6/1960,57.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,CONTR_REACT,0.6,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1330,"Glial neoplasm; further investigations pending (please see comment).
","Glial neoplasm, further investigations pending  see supplementary comment 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: No amplification          
TERT promoter: No mutation     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: Unmethylated (0%)
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #057\NH18-1330,-0.007,-0.016,0.01,-0.026,-0.045,0.002,-0.099,0.068,0.112,0.11,0.056,0.007,0.064,0.058,-0.183,-0.007,-0.063,-0.101,-0.006,-0.021,0.001,0.102,-0.034,0.011,-0.072,-0.055,-0.016,-0.025,0.04,unmethylated
NH18-1513,202066270125_R02C01,#057,10/7/2018,,8/4/2018,25,ZJ,Diagnostic,057,3,NDP,"Belfast, Royal Victoria Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2BN,6/4/1960,58.1,"glioblastoma, IDH-wildtype, with primitive neuronal component",0.98,GBM_RTKII,0.24,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1513,"Histology: High-grade glioma
Methylation class: Glioblastoma, IDH-wildtype, subclass RTK II
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #057\NH18-1513,0.196,1.325,0.028,0.116,0.026,0.083,0.026,0.14,0.178,0.148,0.114,-0.262,-0.134,-0.335,-0.022,-0.023,-0.436,-0.326,0.014,0.034,0.905,0.077,-0.133,0.02,0.318,0.063,-0.064,0.018,0.017,unmethylated
NH18-1361,202066270125_R04C01,#057,13/07/2018,,8/4/2018,22,ZJ,Diagnostic,057,7,NDP,"Belfast, Royal Victoria Hospital",AO vs GBM,"(2) unusual histology, location, demographics",,1/7/1976,42.5,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.65,GBM_MID,0.78,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1361,"Molecular profile raising the possibility of glioblastoma, IDH-wildtype (WHO grade IV)  see comment 

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained (isolated 19qLOH)
EGFR: No amplification          
TERT promoter: No mutation     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: Unmethylated (0%)

","High-grade glioma, with molecular profile raising the possibility of glioblastoma, IDH-wildtype (WHO grade IV)
See comment in previous report
",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #057\NH18-1361,0.299,-0.021,0.01,-0.363,0.452,-0.011,-0.005,-0.039,0.306,0.908,0.285,-0.005,0.047,0.015,-0.14,0.017,0.025,0.035,-0.008,-0.032,-0.008,0.019,0.021,0.061,0.048,0.033,-0.434,-0.458,-0.548,unmethylated
NH18-1224,202066270125_R06C01,#057,24/07/2018,,8/4/2018,11,ZJ,Diagnostic,057,5,NDP,Latvia,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2000/18,4/17/2002,16,"Diffuse hemispheric glioma, H3 G34-mutant",0.29,GBM_G34,0.97,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1224,"Glioblastoma (WHO grade IV) 
MGMT Promoter: Unmethylated (0%)
 
","Glioblastoma, H3 G34-mutant (WHO grade IV) 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained          
EGFR: No amplification          
TERT promoter: No mutation     
Histone H3F3A: Mutation (G34R)
BRAF (V600E): No mutation          
MGMT Promoter: Unmethylated (0%)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #057\NH18-1224,0.048,-0.033,0.027,0.009,0.165,-0.032,0.053,0.008,0.021,-0.067,-0.017,-0.018,0.031,-0.031,-0.381,0.014,-0.022,0.004,-0.009,-0.032,-0.058,0.105,-0.473,-0.022,0.082,0.046,-0.662,-0.063,0.034,unmethylated
NH18-1609,202066270125_R08C01,#057,19/07/2018,,8/4/2018,16,SB,Diagnostic,057,1,NDP,"Liverpool, The Walton Centre",Small C2 spinal intramedullary glial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",NB18-680-03A,5/12/1973,45.2,high-grade astrocytoma with piloid features,0.95,ANAPA,0.57,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1609,"Histology: Low grade glioma
Methylation class: Anaplastic pilocytic astrocytoma (see comment)
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #057\NH18-1609,0.089,-0.035,-0.02,-0.076,-0.205,0.02,0.003,-0.065,0.007,0.038,0.017,-0.184,-0.13,-0.145,-0.508,0.031,-0.034,0.018,0.092,0.029,0.067,0.121,0.019,0.024,0.058,-0.031,-0.22,-0.013,0.05,methylated
NH18-1659,202066270100_R03C01,#058,30/07/2018,,8/24/2018,25,ZJ,Diagnostic,058,1,NDP,"Cambridge, Addenbrooke's Hospital","GBM, IDHwt","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,2/28/1968,50.4,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.63,0.96,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1659,"Histology: Glioblastoma, WHO grade IV
Methylation class glioblastoma, IDH-wildtype (see comment)
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #058\NH18-1659,-0.005,0.002,-0.009,0.009,-0.046,0.029,0.069,0.271,0.175,0.153,0.134,-0.003,0.011,0.015,-0.42,-0.009,-0.435,-0.158,-0.007,0.002,-0.01,-0.018,-0.159,-0.021,0.029,-0.022,-0.151,-0.148,-0.161,unmethylated
NH18-1679,202066270100_R05C01,#058,30/07/2018,,8/24/2018,25,ZJ,Diagnostic,058,1,NDP,"Birmingham, Queen Elizabeth Hospital","Brainstem glioma, H3K27M negative","(2) unusual histology, location, demographics",B,5/6/1975,43.3,rosette-forming glioneuronal tumour,0.86,LGG_RGNT,0.49,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1679,"Histology: Glioneuronal tumour, most likely corresponding to WHO grade I
Methylation class: Low calibration score, see comment,
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #058\NH18-1679,0.121,-0.017,-0.029,0.229,0.081,-0.12,-0.092,0.001,0.018,-0.1,0.02,0.046,-0.056,0.076,-0.043,0.016,-0.001,-0.053,0.122,0.15,0.073,-0.065,-0.047,0.097,0.013,-0.076,0.016,-0.052,0.02,unmethylated
NH18-1680,202066270100_R06C01,#058,30/07/2018,,8/24/2018,25,ZJ,Diagnostic,058,1,NDP,"Birmingham, Queen Elizabeth Hospital",Temporal lobe GG/PA,"(2) unusual histology, location, demographics",1,12/11/2002,15.6,ganglioglioma,0.97,LGG_GG,0.63,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1680,"Referred diagnosis: Low grade glial neuronal tumour, (WHO grade I) 
BRAF: No fusion, no point mutation (V600)
","Histology: Low grade glioneuronal tumour
Methylation class: Ganglioglioma
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #058\NH18-1680,0,0.002,-0.002,0.033,-0.008,-0.016,0.037,-0.008,-0.018,-0.055,0.002,0.031,0.048,0.039,-0.001,-0.002,0.011,0.006,0.074,-0.011,-0.016,0.018,0.029,0.012,0.024,0.008,0.024,0.009,0.044,unmethylated
NH18-1660,202128330027_R02C01,#059,10/8/2018,,9/6/2018,27,SB,Diagnostic,059,1,NDP,"Cambridge, Addenbrooke's Hospital",HGG white matter frontal,(1) small biopsy or nonrepresentative sample;,A1,12/7/1999,18.6,"Diffuse hemispheric glioma, H3 G34-mutant",1,GBM_G34,0.99,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1660,"Histology: Diffuse glioma 
Methylation class: Glioblastoma, IDH-wildtype, H3.3 G34 mutant
Histone H3.3: G34R mutation detected 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #059\NH18-1660,-0.154,0.035,-0.01,0.041,0.11,0.142,0.028,0.003,0.041,0.041,-0.021,0.004,0.013,0.015,-0.783,0.006,-0.238,-0.167,0.008,0.032,-0.038,0.017,-0.268,-0.024,0.038,0.288,-0.253,-0.06,-0.02,methylated
NH18-1760,202128330027_R03C01,#059,10/8/2018,,9/6/2018,27,SB,Diagnostic,059,3,NDP,Lund (SE),"HGG, EGFR mut (?), Illumina request by sender","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,12/5/1943,74.7,"glioblastoma, IDH-wildtype, mesenchymal type",0.26,GBM_RTKII,0.66,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1760,"Histology: Glioma infiltration of the CNS
TERT promoter mutation 
Methylation class: Glioblastoma, IDH-wildtype, subclass mesenchymal
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #059\NH18-1760,1.284,0.03,0.005,0.009,1.127,0.035,-0.088,0.482,0.137,0.182,0.184,-0.007,0.06,0.234,0.027,0.046,-0.222,-0.267,0.012,0.034,0.039,-0.022,-0.063,0.067,0.025,-0.019,0.037,-0.061,-0.135,unmethylated
NH18-1829,202128330027_R07C01,#059,23/08/2018,,9/6/2018,14,SB,Diagnostic,059,2,NDP,"Cardiff, University Hospital",RGNT? Papillary Glioneuronal tumour? GBM?,"(2) unusual histology, location, demographics",A1,2/28/1974,44.5,dysembryoplastic neuroepithelial tumour,0.83,LGG_DNT,0.78,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1829,"Histology: Glioneuronal tumour (see comment) with features of ganglioglioma
Methylation class: Low calibration score, results supportive of ganglioglioma or pilocytic astrocytoma (see comment). 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #059\NH18-1829,-0.04,-0.073,-0.065,-0.019,-0.056,0.11,0.192,0.148,0.149,0.178,0.191,0.003,0.007,0.117,0.126,0.105,0.022,0.073,0.045,0.147,0.185,0.201,-0.096,0.06,0.041,0.005,0.039,-0.37,-0.222,unmethylated
NH18-1878,202066270106_R01C01,#060,28/08/2018,,9/21/2018,24,SB,Diagnostic,060,2,NDP,"Belfast, Royal Victoria Hospital",Blue cell tumour frontal. ,"(4) IHC, sequencing, or copy number assay ambiguous",C,10/24/1945,72.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.16,GBM_MES,0.56,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1878,"Molecular and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV) 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained (isolated 19qLOH)          
EGFR: No amplification          
TERT promoter: Mutation
Histone H3F3A: No mutation     
BRAF (V600E): No mutation     
MGMT Promoter (Illumina): Methylated   
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #060\NH18-1878,0.008,0.001,-0.033,-0.032,-0.076,-0.035,0.096,0.213,0.229,0.281,0.212,0.011,0.017,0.055,0.242,0.238,-0.323,-0.019,-0.037,0.04,-0.01,-0.008,-0.376,-0.317,0.057,-0.044,-0.025,-0.361,-0.358,methylated
NH18-1875,202066270106_R02C01,#060,29/08/2018,,9/21/2018,23,SB,Diagnostic,060,2,NDP,"Birmingham, Queen Elizabeth Hospital","Ganglioglioma, PA?. Test for BRAF by IHC also","(2) unusual histology, location, demographics",B2,1/20/1950,68.6,ganglioglioma,0.26,LGG_PAPF,0.2,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1875,"Morphology in favour of Pilocytic astrocytoma (WHO grade I)  see comment
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #060\NH18-1875,0.057,-0.005,-0.018,0.023,-0.032,-0.046,0.072,0.01,0.001,-0.032,0.007,0,-0.014,0.067,0.015,0.003,0.042,-0.002,0.067,0.066,-0.01,0.058,0.045,0.083,0.115,0.028,0.02,-0.023,-0.003,unmethylated
NH18-1780,202066270106_R03C01,#060,29/08/2018,,9/21/2018,23,SB,Diagnostic,060,4,NDP,St George's Hospital London,"HGG, ","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/18/1989,29,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type C]",0.91,GBM_RTKI,0.24,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1780,"Histology and molecular profile: 
High grade glioma, in favour of glioblastoma, IDH-wildtype (WHO grade IV)  see comment

Methylation profile: 
No matching methylation class 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: No amplification          
TERT promoter: No mutation     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter (Illumina): Methylated
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #060\NH18-1780,0.072,0.002,0.04,-0.057,0.015,0.018,0.137,0.024,0.082,-0.017,0.009,0.03,0.085,0.097,0.099,0.063,0.038,-0.007,0.117,0.024,0.059,0.05,-0.027,0.119,0.045,0.063,-0.02,0.037,0.026,methylated
NH18-1925,202066270106_R04C01,#060,4/9/2018,,9/21/2018,17,ZJ,Diagnostic,060,4,NDP,Latvia,Glioblastoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B3601-3602,2/2/2002,16.6,"Diffuse hemispheric glioma, H3 G34-mutant",1,GBM_G34,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1925,"Glioblastoma, H3.3 G34R mutant (WHO grade IV) 
ATRX (IHC): Loss of expression (indicates mutation)     
Histone H3F3A (Seq): Mutation (G34R)
MGMT Promoter (assessed with Illumina): Methylated
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #060\NH18-1925,-0.067,0.018,0.095,-0.001,0.037,0.007,0.184,0.064,0.744,-0.016,-0.052,0.003,0.042,-0.011,0.109,0.044,-0.265,-0.316,0.03,0.152,0.04,0.064,0.029,0.025,0.071,0.051,-0.062,-0.008,-0.005,methylated
NH18-1828,202066270106_R07C01,#060,7/9/2018,,9/21/2018,14,SB,Diagnostic,060,2,NDP,Lund (SE),RGNT? PA?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",.1-.1,1/18/1968,50.6,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",1,GBM_RTKI,0.37,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1828,"Low grade glioma with features raising the possibility of rosetted glioneuronal tumour (see comment) 

BRAF (V600E): No mutation     
BRAF fusions: No fusion mutations 
  
","See previous supplementary report and comment below
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #060\NH18-1828,0.504,0.029,0.045,0.08,0.005,0.005,-0.687,0.064,-0.094,-0.101,-0.052,-0.018,-0.048,0.089,-0.128,0.127,-0.017,0.057,0.163,0.144,0.133,-0.004,-0.616,0.114,0.11,0.038,0.023,-0.058,0.18,unmethylated
NH18-1963,202066270106_R08C01,#060,10/9/2018,,9/21/2018,11,SB,Diagnostic,060,2,NDP,"Cambridge, Addenbrooke's Hospital","HGG, Ependymoma?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,10/31/1980,37.9,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1963,"Methylation profile: (Anaplastic) pleomorphic xanthoastrocytoma  see comment
","Methylation profile: (Anaplastic) pleomorphic xanthoastrocytoma  see comment in the main report

BRAF (V600E): No mutation

",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #060\NH18-1963,-0.003,0.083,0.051,-0.086,-0.051,0.156,0.142,-0.02,-0.035,-0.048,-0.035,0.268,0.289,0.303,-1.255,0.072,-0.282,-0.302,0.033,0.081,-0.016,0.033,0.039,0.014,0.035,-0.005,0.226,0.022,0.015,unmethylated
NH18-1981,202066270129_R01C01,#061,11/9/2018,,10/4/2018,23,SB,Diagnostic,061,1,NDP,Lund (SE),PA?,"(2) unusual histology, location, demographics",.01-.01,7/4/2007,11.2,dysembryoplastic neuroepithelial tumour,0.46,LGG_PAPF,0.49,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1981,"Appearances in keeping with pilocytic astrocytoma (WHO grade I)  see comment
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #061\NH18-1981,-0.125,-0.089,-0.032,-0.012,-0.164,0.162,0.181,0.17,0.168,0.203,0.152,-0.075,-0.01,-0.046,0.109,0.168,-0.096,-0.014,0.141,0.062,0.129,0.219,-0.082,0.119,0.226,0.186,0.14,-0.074,0.034,methylated
NH18-1982,202066270129_R02C01,#061,11/9/2018,,10/4/2018,23,SB,Diagnostic,061,2,NDP,Lund (SE),?,"(2) unusual histology, location, demographics",.01-.01,9/3/2009,9,supratentorial pilocytic astrocytoma,0.52,LGG_PAPF,0.56,0.97,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1982,"Histology: Pathological tissue
Methylation profile: Inconclusive  see comment
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #061\NH18-1982,0.053,-0.013,0.019,0.071,-0.024,-0.033,-0.099,-0.006,0.013,-0.003,-0.003,0.012,0.005,0.086,-0.029,0.01,0.001,0.021,0.045,0.025,-0.015,-0.036,-0.002,-0.002,0.001,-0.019,0.008,-0.02,0.097,unmethylated
NH18-1912,202066270129_R05C01,#061,13/09/2018,,10/4/2018,21,SB,Diagnostic,061,3,NDP,St George's Hospital London,IDHwt glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,6/10/1978,40.3,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.78,DMG_K27,0.89,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1912,"Molecular and methylation profile: Diffuse midline glioma, H3 K27M-mutant (WHO grade IV)
 
ATRX (IHC): Loss of expression (indicates mutation)     
Histone H3F3A (K27M IHC): Mutation
MGMT Promoter (Illumina array): Unmethylated
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #061\NH18-1912,0.12,-0.062,0.01,0.022,-0.053,0.06,-0.042,-0.029,-0.023,-0.022,-0.004,-0.037,-0.046,0.022,0.013,0.012,0.003,0,0.041,0.025,-0.023,0.008,-0.012,0.035,-0.263,-0.011,-0.081,-0.177,-0.122,unmethylated
NH18-2002,202066270129_R06C01,#061,13/09/2018,,10/4/2018,21,SB,Diagnostic,061,5,NDP,Preston,PA? posteror fossa,"(2) unusual histology, location, demographics",A2,1/13/1989,29.7,high-grade astrocytoma with piloid features,0.84,ANAPA,0.97,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2002,"Histology: High grade glioma
Methylation profile: Suggestive of anaplastic astrocytoma with piloid features  see comment
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #061\NH18-2002,-0.075,0.029,0.06,-0.013,0.012,0.131,0.051,0.597,0.251,0.166,0.561,-0.262,0.032,0.111,-0.668,0.088,0.006,0.09,0.049,0.03,0.108,0.278,0.047,-0.187,0.046,0.127,-0.23,-0.145,-0.115,methylated
NH18-2060,202066270129_R08C01,#061,18/09/2018,,10/4/2018,16,SB,Diagnostic,061,2,NDP,"Cambridge, Addenbrooke's Hospital","R LV, ?Subependymoma?","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,8/7/1974,44.1,supratentorial pilocytic astrocytoma,0.39,LGG_PAPF,0.21,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2060,"Provisional diagnosis: Low grade glial / glioneuronal tumour  see comment 
BRAF (V600E): No mutation           
","Histology: Low grade glial / glioneuronal tumour, corresponding to WHO grade I
Methylation profile: Suggestive of low grade glioma, hemispheric pilocytic astrocytoma / ganglioglioma  see supplementary comment
 
MGMT Promoter (Illumina array): Unmethylated
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #061\NH18-2060,-0.014,-0.031,0.029,0.175,-0.083,0.02,0.001,-0.067,-0.044,0.043,-0.001,0.002,-0.043,0.012,-0.06,-0.009,-0.063,-0.006,-0.022,-0.171,-0.061,0.024,-0.041,-0.045,-0.004,-0.002,0.071,-0.033,0.062,unmethylated
NH18-2050,202135260056_R02C01,#062,18/09/2018,,10/12/2018,24,SB,Diagnostic,062,3,NDP,"Birmingham, Queen Elizabeth Hospital","Oligo-Astro 1p/19q del, ATRX loss","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A,5/19/1980,38.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.68,AIDH_HG,0.98,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2050,"Methylation profile: High grade astrocytoma 

Histology: Glioblastoma, IDH-mutant (WHO grade IV)  see comment
IDH1/IDH2 (as per referring pathology lab result): IDH1 mutation 
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q (derived from the Illumina array): Retained          
MGMT Promoter (derived from the Illumina array): Unmethylated 
","Methylation profile: IDH glioma, high grade astrocytoma 
Histology: Glioblastoma, IDH-mutant (WHO grade IV)  see comment
IDH1/2 Seq: IDH1 mutation 
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q (derived from the Illumina array): Retained
1p/19q (qPCR): Retained (isolated LOH19q)          
EGFR: No amplification
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter (derived from the Illumina array): Unmethylated

",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #062\NH18-2050,-0.419,0.477,0.05,0.012,0.015,0.087,0.045,-0.039,0.012,0.307,0.266,-0.002,0.043,-0.008,-0.46,0.023,-0.028,0.023,0.189,0.272,0.008,0.04,-0.003,-0.022,0.021,0.003,-0.566,-0.002,0.022,unmethylated
NH18-2063,202135260056_R03C01,#062,18/09/2018,,10/12/2018,24,SB,Diagnostic,062,2,NDP,"Belfast, Royal Victoria Hospital",intramedullary cervical spine,"(2) unusual histology, location, demographics",3,7/30/2011,7.1,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",1,DMG_K27,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH18-2063,"Molecular and methylation profile: Diffuse midline glioma H3 K27M-mutant (WHO grade IV) 
H3F3A (K27M IHC): Mutation
MGMT Promoter (derived from the Illumina array): Unmethylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #062\NH18-2063,-0.077,0.004,0.061,-0.346,-0.037,0.04,-0.496,0.006,-0.236,-0.246,-0.191,0.018,0.043,0.004,-0.345,0.018,-0.017,0.06,-0.308,0,-0.002,0.011,-1.001,-0.148,0.009,-0.009,-0.185,-0.071,-0.151,unmethylated
NH18-1828,202262730190_R01C01,#063,1/10/2018,,10/19/2018,18,ZJ,Diagnostic,063,2,NDP,Lund (SE),RGNT? PA?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,1/18/1968,50.6,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.99,GBM_RTKI,0.35,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1828,"Low grade glioma with features raising the possibility of rosetted glioneuronal tumour (see comment) 

BRAF (V600E): No mutation     
BRAF fusions: No fusion mutations 
  
","See previous supplementary report and comment below
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #063\NH18-1828,0.391,0.009,0.068,0.079,-0.031,0.032,-0.532,0.009,-0.095,-0.167,-0.034,0.014,-0.022,0.13,-0.058,0.035,-0.015,-0.065,0.119,0.1,0.133,0.035,-0.53,0.176,0.041,-0.072,-0.118,-0.019,0.085,unmethylated
NH18-2160,202262730190_R03C01,#063,9/10/2018,,10/19/2018,10,ZJ,Diagnostic,063,3,NDP,Royal London Hospital,"GBM, IDHmt versus Anaplastic oligo","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF3B,7/22/1989,29.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.98,AIDH_HG,0.95,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2160,"Recurrent/residual Glioblastoma (WHO grade IV)
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained in present sample (previously retained)
1p/19q: Retained (previously tested)
  
","Recurrent / residual Glioblastoma, IDH-mutant (WHO grade IV) 
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained     
1p/19q: Retained (tested in previous resection: NH18-1897)          
MGMT Promoter: Methylated
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #063\NH18-2160,-0.018,-0.367,0.045,-0.278,0.692,-0.001,0.055,-0.03,-0.044,0.003,-0.04,0.007,-0.02,0.003,-0.013,0.013,-0.041,0.022,0.015,0.667,0.595,-0.441,-0.02,-0.019,-0.013,0.158,-0.09,-0.017,-0.045,methylated
NH18-2236,202262730190_R06C01,#063,9/10/2018,,10/19/2018,10,ZJ,Diagnostic,063,1,NDP,"Birmingham, Queen Elizabeth Hospital","LGG in tectal plate, H3K27M neg","(2) unusual histology, location, demographics",B1,4/1/1999,19.5,infratentorial pilocytic astrocytoma,0.22,LGG_PAPF,0.3,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2236,"Provisional histological diagnosis:
Low grade glioma 
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained     
Histone H3F3A (K27M IHC): No mutation     
","Histology: Low grade glioma
Methylation from a: Suggestive of pilocytic astrocytoma-see comments
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #063\NH18-2236,0.049,-0.029,0.048,-0.063,-0.004,-0.001,-0.038,-0.008,0.175,0.205,0.155,0.007,0.003,0.051,0.007,-0.011,-0.007,0.019,0.051,-0.003,0.022,-0.035,-0.058,0.035,-0.045,0.005,-0.009,-0.006,0.076,unmethylated
NH18-2253,202128330159_R01C01,#064,9/10/2018,,10/26/2018,17,ZJ,Diagnostic,064,1,NDP,"Birmingham, Queen Elizabeth Hospital",Cerebellar glioblastoma,"(2) unusual histology, location, demographics",B1,7/5/1967,51.3,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.52,GBM_MID,0.69,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2253,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: No matching methylation class
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #064\NH18-2253,0.046,-0.119,0.049,0.095,-0.037,0.232,0.049,-0.133,1.287,-0.255,-0.179,-0.017,0.002,0.023,-0.074,-0.273,-0.198,-0.189,-0.011,-0.41,-0.381,-0.426,-0.464,0.001,-0.429,-0.155,-0.287,-0.001,0.054,unmethylated
NH18-2237,202128330159_R02C01,#064,10/10/2018,,10/26/2018,16,ZJ,Diagnostic,064,2,NDP,Oxford John Radcliffe Hospital,LGG,"(2) unusual histology, location, demographics",D,11/13/1990,27.9,supratentorial pilocytic astrocytoma,0.95,LGG_PA_GGST,0.95,1,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2237,"Referred provisional diagnosis: Low grade glial neoplasm  see comment
","Low grade glioma, see comment
BRAF: No point mutation, no fusion

",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #064\NH18-2237,0.058,-0.02,0,0.009,-0.004,0.015,0.039,-0.067,-0.003,-0.035,-0.006,-0.009,0.024,0.002,-0.012,-0.01,-0.014,-0.003,0.003,-0.045,-0.007,0.011,-0.023,0.032,0.041,0.005,0.013,0.011,0.046,unmethylated
NH18-2207,202128330159_R04C01,#064,10/10/2018,,10/26/2018,16,ZJ,Diagnostic,064,1,NDP,"Liverpool, The Walton Centre",Supratentorial ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",3B,12/2/1990,27.8,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,0.98,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2207,"Histology: Ependymal tumour
Methylation profile: Ependymoma, RELA fusion
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #064\NH18-2207,0.035,-0.065,0.049,0.001,-0.057,-0.021,0.056,-0.012,-0.048,-0.006,-0.021,0.006,0.025,-0.035,-0.326,-0.284,-0.018,0.005,0.123,-0.038,-0.015,-0.016,-0.05,-0.001,0.025,-0.067,0.01,-0.253,-0.316,unmethylated
NH18-2060,202128330159_R06C01,#064,10/10/2018,,10/26/2018,16,ZJ,Diagnostic,064,2,NDP,"Cambridge, Addenbrooke's Hospital","R LV, ?Subependymoma?","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,8/7/1974,44.1,supratentorial pilocytic astrocytoma,0.77,LGG_PA_GGST,0.22,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2060,"Provisional diagnosis: Low grade glial / glioneuronal tumour  see comment 
BRAF (V600E): No mutation           
","Histology: Low grade glial / glioneuronal tumour, corresponding to WHO grade I
Methylation profile: Suggestive of low grade glioma, hemispheric pilocytic astrocytoma / ganglioglioma  see supplementary comment
 
MGMT Promoter (Illumina array): Unmethylated
",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #064\NH18-2060,0.035,-0.008,0.029,0.154,-0.087,-0.004,0.034,-0.03,-0.015,-0.097,-0.014,0,0.047,0.035,-0.007,-0.005,-0.033,-0.033,-0.019,-0.108,-0.065,0.019,-0.02,-0.038,0.045,-0.014,0.055,-0.01,0.013,unmethylated
NH18-2070,202128330159_R08C01,#064,13/10/2018,,10/26/2018,13,ZJ,Diagnostic,064,4,NDP,Brighton and Sussex Hospital,"GBM, ATRX loss","(4) IHC, sequencing, or copy number assay ambiguous",DEF1A,6/19/1970,48.3,"glioblastoma, IDH-wildtype, mesenchymal type",0.84,GBM_MES,0.92,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2070,"Glioblastoma (WHO grade IV)

IDH1 (R132H IHC): No mutation; further molecular tests pending 
ATRX (IHC): Loss of expression (indicates mutation)
  
","Molecular and methylation profile:
Glioblastoma, IDH-wildtype (WHO grade IV) 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained          
EGFR: No amplification (chromosome 7 gain)          
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: Methylated (>10-25%)

 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #064\NH18-2070,0.077,-0.018,0.023,-0.045,-0.122,-0.039,0.054,0.287,0.291,0.335,0.281,0.019,0.068,-0.006,-0.005,0.035,-0.058,0.002,-0.036,-0.027,-0.038,-0.011,0.006,-0.002,0.012,-0.003,0.03,0.001,0.078,methylated
NH18-2284,202093120023_R01C01,#065,17/10/2018,,11/2/2018,16,ZJ,Diagnostic,065,5,NDP,Royal London Hospital,LGG; ?PA (thalamus),"(2) unusual histology, location, demographics",DEF1A,12/22/1981,36.8,infratentorial pilocytic astrocytoma,0.97,LGG_PAPF,0.88,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH18-2284,"Provisional diagnosis: Low grade glioma  for typing and grading, see comment

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained
H3F3A (K27M IHC): No mutation
BRAF (V600E IHC): No mutation

","Histology and methylation profile: Low grade glioma, in favour of a pilocytic astrocytoma (WHO grade I)
See comment
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #065\NH18-2284,0.075,0.039,0.021,-0.034,-0.046,-0.012,0.195,-0.111,-0.026,-0.016,0.176,-0.001,-0.001,0.031,0.008,-0.026,0.009,0.018,0.19,0.021,-0.031,-0.042,0.029,0.075,-0.009,-0.059,0,0.007,0.055,unmethylated
NH18-2314,202093120023_R02C01,#065,17/10/2018,,11/2/2018,16,ZJ,Diagnostic,065,3,NDP,"Cambridge, Addenbrooke's Hospital","HGG, BRAF mutant, ATRX loss","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,1/2/1988,30.8,high-grade astrocytoma with piloid features,0.69,ANAPA,0.49,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2314,"Histology: Glioblastoma (WHO grade IV)
Methylation class: See comment 
ATRX (IHC): Loss of expression (indicates mutation)
BRAF (V600E): Mutation
CDKN2A/B: Homozygous deletion
MGMT Promoter: Methylated 

",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #065\NH18-2314,-0.025,-0.155,-0.053,0.01,-0.024,-0.22,0.048,0.011,0.013,0.03,0.005,-0.053,-0.053,-0.073,-1.609,0.052,-0.177,-0.115,-0.057,0.026,-0.055,-0.043,-0.401,-0.209,-0.171,-0.153,-0.121,-0.004,0.01,methylated
NH18-2316,202093120023_R03C01,#065,19/10/2018,,11/2/2018,14,ZJ,Diagnostic,065,5,NDP,NHNN,LGG; ?undersampled HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,6/23/1954,64.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.82,GBM_MES,0.7,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2316,"Provisional diagnosis:
Pathological tissue, in favour of anaplastic astrocytoma (WHO grade III)  see comment

IDH1 (R132H IHC): No mutation, further tests pending 
ATRX (IHC): Retained
1p/19q: Test pending
  
","Histology: Anaplastic astrocytoma (WHO grade III)
Molecular and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)  see supplementary comment

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: Amplification          
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: Methylated (>10-25%) 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #065\NH18-2316,-0.028,-0.048,-0.01,-0.015,-0.039,0.057,0.042,0.967,0.28,0.311,0.232,0.016,-0.013,-0.015,-0.497,-0.026,-0.249,-0.123,-0.04,-0.034,-0.033,0.024,-0.143,-0.021,-0.035,-0.021,-0.195,0.044,0.048,methylated
NH18-2352,202093120023_R06C01,#065,23/10/2018,,11/2/2018,10,ZJ,Diagnostic,065,3,NDP,"Birmingham, Queen Elizabeth Hospital","Rec anaplstic ependymoma, supratentorial","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",C,5/10/1991,27.5,posterior fossa ependymoma group B,0.99,EPN_PFB,0.97,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2352,"Histology: Ependymoma (grading see comment)
Methylation profile: Suggestive of posterior fossa ependymoma  see comment
Copy number profile and Histone H3 trimethylation: Suggestive of posterior fossa ependymoma type B
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #065\NH18-2352,0.313,-0.071,0.012,0.045,0.092,0.017,-0.452,0.133,0.114,0.066,0.057,-0.075,-0.103,-0.006,0.05,0.14,-0.068,-0.081,0.032,0.097,0.061,0.093,-0.161,-0.264,-0.645,-0.474,-0.166,-0.049,-0.041,unmethylated
NH18-2346,202093120023_R07C01,#065,24/10/2018,,11/2/2018,9,SB,Diagnostic,065,4,NDP,NHNN,"A II, IDH mutant ? CDKN? for validation, CNV","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,6/29/1999,19.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.43,AIDH,0.81,0.96,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2346,"Gemistocytic astrocytoma, IDH-mutant (WHO grade II)  see comment

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
  
","Histology: Gemistocytic astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma  see comment 
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained          
EGFR: No amplification          
TERT promoter: No mutation     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: Unmethylated (0%)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #065\NH18-2346,-0.023,-0.017,0.028,-0.069,-0.032,-0.001,-0.011,-0.005,-0.069,-0.039,-0.037,0.015,-0.021,0.067,-0.01,-0.027,-0.063,-0.174,-0.008,0.071,-0.04,-0.03,0.006,-0.016,-0.057,-0.066,-0.047,-0.02,0.023,unmethylated
NH18-2298,202093120023_R08C01,#065,24/10/2018,,11/2/2018,9,SB,Diagnostic,065,4,NDP,NHNN,"A II, IDH mutant ? CDKN? for validation, CNV","(4) IHC, sequencing, or copy number assay ambiguous",DEF2A,3/1/1972,46.7,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.11,AIDH,0.28,0.99,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2298,"Diffuse astrocytoma, IDH-mutant (WHO grade II)

IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
  
","Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma  see comment
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained          
EGFR: No amplification          
MGMT Promoter: Methylated (>0-5%)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #065\NH18-2298,-0.028,-0.025,-0.018,-0.009,0.003,-0.087,0.009,-0.036,-0.04,-0.019,-0.007,-0.004,0.041,0.011,-0.003,-0.012,0.001,0.019,-0.018,-0.029,-0.035,0.009,-0.01,0.017,0.007,-0.024,0.009,0.016,0.014,methylated
NH18-2439,202135260087_R07C01,#066,5/11/2018,,11/17/2018,12,ZJ,Diagnostic,066,3,NDP,"Birmingham, Queen Elizabeth Hospital",IDH-mutant anaplastic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,8/13/1980,38.2,posterior fossa ependymoma group A1,0.07,GBM_RTKII,0.05,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2439,"Glioma, IDH-mutant, in favour of anaplastic astrocytoma (WHO grade III)  see comment
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Retained     
  
",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #066\NH18-2439,2.088,-0.274,-0.032,-0.068,-0.216,0.082,-0.408,2.743,0.035,0.237,0.161,0.071,0.062,-0.353,-0.031,0.264,-0.331,-0.166,-0.405,-0.37,1.677,-0.022,-0.492,-0.225,-0.025,-0.392,0.432,-0.248,-0.086,methylated
NH18-2352,202135260087_R08C01,#066,6/11/2018,,11/17/2018,11,ZJ,Diagnostic,066,3,NDP,"Birmingham, Queen Elizabeth Hospital","Rec anaplstic ependymoma, supratentorial","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",C,5/10/1991,27.5,posterior fossa ependymoma group B,1,EPN_PFB,0.99,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2352,"Histology: Ependymoma (grading see comment)
Methylation profile: Suggestive of posterior fossa ependymoma  see comment
Copy number profile and Histone H3 trimethylation: Suggestive of posterior fossa ependymoma type B
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #066\NH18-2352,0.422,-0.19,-0.082,0.238,0.204,0.172,-0.701,0.086,0.133,0.116,0.162,-0.167,-0.242,-0.031,0.135,0.23,-0.219,-0.112,-0.042,0.181,0.146,0.071,-0.186,-0.636,-0.609,-0.613,0.027,-0.209,-0.125,unmethylated
NH18-2423,202081130192_R01C01,#067,5/11/2018,,11/30/2018,25,ZJ,Diagnostic,067,1,NDP,"Birmingham, Queen Elizabeth Hospital",?anaplstic oligodendroglioma,"(4) IHC, sequencing, or copy number assay ambiguous",E,3/10/1960,58.7,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,OIDH,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2423,"Histology: Anaplastic oligodendroglioma 
Methylation class: Oligodendroglioma, IDH-mutant, 1p/19 q codeleted
Copy number assay: Codeletion of 1p and 19q
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #067\NH18-2423,-0.008,-0.019,0.021,-0.052,-0.074,0.05,0.017,0.053,-0.019,0.01,-0.011,-0.004,0.028,-0.007,0.135,0.027,0.01,0.137,-0.006,0.012,0.013,-0.009,-0.058,0.027,0.026,-0.004,-0.429,0.02,0.02,methylated
NH18-2503,202081130192_R02C01,#067,8/11/2018,,11/30/2018,22,SB,Diagnostic,067,2,NDP,"Charing Cross Hospital, London",Ependymoma?,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,2/9/1950,68.8,"supratentorial ependymoma, ZFTA:RELA fusion-positive",0.11,PXA,0.12,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2503,"Histology: Low grade glioma (see comment)
Methylation class: No matching methylation class (see comment)

",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #067\NH18-2503,0.212,-0.019,0.018,-0.017,-0.016,-0.021,-0.001,-0.031,-0.024,-0.032,-0.035,0.039,-0.014,0.054,0.013,0.04,-0.044,-0.006,-0.276,-0.227,-0.185,-0.367,-0.318,-0.272,-0.417,-0.344,-0.036,-0.254,-0.235,unmethylated
NH18-2420,202081130192_R03C01,#067,12/11/2018,,11/30/2018,18,ZJ,Diagnostic,067,5,NDP,NHNN,Spinal malignant tumour (DLGNT vs Neuroendocrine),"(2) unusual histology, location, demographics",DEF1A,10/26/1957,61,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.6,GBM_MID,0.37,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2420,"Poorly differentiated tumour - see comment
","Histology: Poorly differentiated tumour
Methylation profiling: No matching methylation class (see comment)
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #067\NH18-2420,-0.146,0.05,0.058,0.037,0.02,-0.054,-0.028,0.051,0.024,0.011,0.029,-0.359,-0.009,-0.003,-1.637,0.079,0.1,0.187,0.04,-0.036,0.323,0.432,-0.103,-0.41,-0.861,0.19,-0.271,-0.294,-0.3,methylated
NH18-2555,202081130192_R06C01,#067,13/11/2018,,11/30/2018,17,ZJ,Diagnostic,067,1,NDP,Southampton General Hospital,?ependymoma; ?PA,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1A,11/25/1990,28,spinal ependymoma,0.95,EPN_SPINE,0.98,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2555,"Histology: Ependymoma
Methylation class: Ependymoma, spinal
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #067\NH18-2555,-0.044,-0.013,0.028,-0.007,-0.022,-0.043,0.019,0.011,0.019,0.042,-0.005,-0.004,-0.031,0.038,-0.017,0.031,-0.056,0.031,-0.003,0.011,-0.007,-0.02,-0.373,0.004,-0.071,-0.034,-0.063,-0.22,-0.212,unmethylated
NH18-2552,202081130192_R07C01,#067,13/11/2018,,11/30/2018,17,ZJ,Diagnostic,067,1,NDP,Southampton General Hospital,Infiltrating astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,11/30/1952,66,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.23,GBM_MES,0.56,0.55,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2552,"Histology: Infiltration zone of a glioma
Methylation class: Glioblastoma, IDH-wildtype
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #067\NH18-2552,0.588,-0.036,0.031,-0.024,-0.029,0.035,0.044,0.139,0.116,0.158,0.095,-0.001,-0.048,0.043,-0.395,-0.006,-0.169,-0.105,-0.011,-0.041,-0.002,-0.011,-0.017,-0.011,0.037,-0.028,-0.042,0.019,0.031,methylated
NH18-2606,202081130192_R08C01,#067,19/11/2018,,11/30/2018,11,SB,Diagnostic,067,2,NDP,Royal London Hospital,"Brainstem  ? Ependymoma, PA, APA?","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,1/10/1981,37.9,spinal ependymoma,1,EPN_SPINE,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2606,"Ependymoma, WHO grade II, see comment.
","Histology: Ependymoma (WHO grade II)
Methylation class: Ependymoma, spinal subtype
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #067\NH18-2606,0.042,0.046,0.06,0.081,0.012,0.003,-0.004,0.224,0.246,0.231,0.22,0.231,0.181,0.265,0.245,0.247,-0.018,0.02,0.064,0.013,0.022,0.014,-0.049,0.04,0.028,-0.039,0.003,-0.401,-0.393,unmethylated
NH18-2624,201530480010_R01C01,#068,19/11/2018,,12/7/2018,18,SB,Diagnostic,068,1,NDP,"Cambridge, Addenbrooke's Hospital","Glio(neuronal?) tumour, Parieto-Occ","(2) unusual histology, location, demographics",B1,7/9/1984,34.3,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.6,0.59,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2624,"Histology: astrocytoma, no high grade features
Methylation class: Glioblastoma, IDH-wildtype,
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #068\NH18-2624,0.703,-0.017,0.023,-0.021,-0.047,0.012,-0.128,-0.015,-0.008,-0.008,-0.005,0.007,-0.001,0.021,-0.148,-0.003,-0.188,-0.117,-0.023,-0.082,-0.007,-0.036,-0.183,-0.087,-0.22,-0.049,-0.014,-0.012,-0.11,unmethylated
NH18-2314,201530480010_R06C01,#068,27/11/2018,,12/7/2018,10,SB,Diagnostic,068,3,NDP,"Cambridge, Addenbrooke's Hospital","HGG, BRAF Mutant, ATRX loss","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C,1/2/1988,30.8,high-grade astrocytoma with piloid features,0.47,GBM_MID,0.65,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2314,"Histology: Glioblastoma (WHO grade IV)
Methylation class: See comment 
ATRX (IHC): Loss of expression (indicates mutation)
BRAF (V600E): Mutation
CDKN2A/B: Homozygous deletion
MGMT Promoter: Methylated 

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #068\NH18-2314,0.007,-0.132,-0.056,0.01,0.025,-0.256,0.055,-0.015,0.039,-0.018,0.03,-0.033,0.012,0.072,-1.704,0.08,-0.166,-0.224,-0.035,0.016,0.022,0.025,-0.379,-0.162,-0.21,-0.171,-0.212,0.003,-0.026,methylated
NH18-2669,201533500048_R01C01,#070,27/11/2018,,12/14/2018,17,SB,Diagnostic,070,1,NDP,"Birmingham, Queen Elizabeth Hospital",GBM- PNET; type?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",D2,10/15/1944,74.1,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.86,GBM_RTKI,0.35,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2669,"Histology: Poorly differentiated intrinsic tumour, corresponding to WHO grade IV
Methylation class: Glioblastoma, IDH-wildtype 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #070\NH18-2669,0.014,1.072,0.031,0.022,-0.014,0.034,0.029,1.451,0.266,0.554,0.385,-0.033,-0.004,-0.03,-0.018,-0.021,-0.805,-0.443,-0.067,-0.069,-0.012,-0.026,-0.045,-0.459,-0.447,0.058,-0.029,-0.024,-0.018,unmethylated
NH18-2665,201533500048_R04C01,#070,27/11/2018,,12/14/2018,17,SB,Diagnostic,070,2,NDP,Nottingham University Hospital,Pilomyxoid Astroctyoma,"(2) unusual histology, location, demographics",A1,5/8/1978,40.6,pleomorphic xanthoastrocytoma(-like),1,PXA,0.98,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2665,"Histology: Glioma, features compatible with pleomorphic xanthoastrocytoma
Methylation class: (Anaplastic) pleomorphic xanthoastrocytoma (see description below)
BRAF (V600E): Mutation
CDKN2A/B: Homozygous deletion
MGMT Promoter: Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #070\NH18-2665,0.023,-0.015,0.204,0.051,0.218,0.216,-0.328,0.313,0.352,0.39,0.27,0.002,0.108,0.039,-1.049,0.034,0.028,0.005,-0.001,0.03,-0.003,0.022,-0.339,0.022,0.02,0.056,0.152,-0.019,0.053,unmethylated
NH18-2678,201533500048_R05C01,#070,28/11/2018,,12/14/2018,16,SB,Diagnostic,070,1,NDP,Oxford John Radcliffe Hospital,"GBM, Type?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3,1/21/2007,11.8,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.98,GBM_RTKIII,0.83,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2678,"Histology: Glioblastoma (WHO grade IV)
Methylation class: Inconclusive results, but suggestive of glioblastoma, IDH-wildtype (see comment). 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #070\NH18-2678,0.059,0.779,-0.017,0.018,-0.027,-0.003,0.05,0.301,0.248,0.373,0.322,0.015,0.042,0.013,-0.029,-0.158,-0.355,-0.167,-0.163,0.078,-0.013,0.019,-0.208,-0.073,-0.417,-0.406,-0.029,0.031,0.09,unmethylated
NH18-2738,201533500048_R06C01,#070,4/12/2018,,12/14/2018,10,SB,Diagnostic,070,2,NDP,"Belfast, Royal Victoria Hospital","Astrocytoma, Type?","(2) unusual histology, location, demographics",18-37766,1/11/2004,14.9,dysembryoplastic neuroepithelial tumour,0.99,LGG_DNT,0.97,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2738,"Histology: Low grade glioma
Methylation class: Dysembryoplastic neuroepithelial tumour (corresponding to WHO grade I)
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #070\NH18-2738,-0.034,-0.031,-0.025,0.007,-0.065,-0.013,0.084,-0.026,0.016,0.026,-0.004,0.001,0.037,0.02,0.012,-0.037,0.045,0.009,0.006,-0.033,-0.025,-0.012,-0.01,0.018,0.029,0.016,0.038,0.017,-0.005,unmethylated
NH18-2748,201533500048_R07C01,#070,4/12/2018,,12/14/2018,10,SB,Diagnostic,070,1,NDP,Lund (SE),"Test QC from Lund (GBM IDHwt), DO NOT BILL","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,12/21/1974,44,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.34,GBM_MID,0.59,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2748,"Histology: Glioblastoma (WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype, subclass midline
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #070\NH18-2748,0.114,0.006,0,-0.052,-0.031,0.06,-0.011,0.064,-0.002,0.005,-0.026,-0.011,0.068,0.083,-0.02,0.033,0.057,0.025,0.063,0.038,0.007,0.013,0.045,0.053,0.096,0.086,-0.11,-0.022,0.011,methylated
NH18-2749,201533500048_R08C01,#070,4/12/2018,,12/14/2018,10,SB,Diagnostic,070,1,NDP,Lund (SE),"Test QC from Lund (AII-IDHmut),  DO NOT BILL","(6) Research sample, for stratification or subclassification",1,4/9/1956,62.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.97,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2749,"Histology: Astrocytoma (WHO grade II)
Methylation class: IDH glioma, subclass astrocytoma
",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #070\NH18-2749,0.084,-0.094,0.005,-0.018,-0.043,-0.033,-0.09,0.071,0.019,0.052,0.006,-0.029,0.041,0,-0.022,0.06,-0.016,-0.044,-0.052,-0.013,0.067,-0.081,-0.032,0.031,0.067,0.033,-0.346,0.001,0.081,methylated
NH18-2750,202066270146_R01C01,#071,4/12/2018,,1/10/2019,37,SB,Diagnostic,071,1,NDP,Lund (SE),"Test QC from Lund (GBM-IDHwt), DO NOT BILL","(6) Research sample, for stratification or subclassification",1,1/11/1985,33.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.99,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2750,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: IDH-mutant glioma, subclass high grade astrocytoma 
MGMT Promoter (Illumina array): Methylated 
  
",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #071\NH18-2750,0.414,0.075,0.088,-0.069,0.131,-0.095,-0.038,-0.009,-0.115,-0.017,0.041,0.007,-0.128,0.188,-0.09,0.129,-0.084,-0.164,0.092,0.092,-0.268,-0.649,-0.676,0.115,0.095,-0.005,-0.146,-0.613,-0.368,methylated
NH18-2804,202066270146_R04C01,#071,13/12/2018,,1/10/2019,28,SB,Diagnostic,071,1,NDP,Bristol,Ventricular astrocytoma,"(2) unusual histology, location, demographics",A1,10/16/1961,57.2,supratentorial subependymoma,1,SUBEPN_ST,0.99,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2804,"Histology: Subependymoma (WHO grade I)
Methylation profile: Subependymoma, supratentorial  see comment
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #071\NH18-2804,-0.05,0.016,0.055,-0.014,0.026,0.015,0.022,-0.059,-0.02,-0.034,0.032,-0.415,-0.297,-0.307,-0.081,-0.024,-0.028,0.012,-0.048,-0.024,0.048,0.006,0.031,-0.138,-0.029,-0.052,-0.067,-0.013,0.04,unmethylated
NH18-2829,202066270146_R08C01,#071,13/12/2018,,1/10/2019,28,SB,Diagnostic,071,2,NDP,Salford,Anaplasic PA (NH18-2002 previously seen here),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,1/13/1989,29.9,high-grade astrocytoma with piloid features,0.41,ANAPA,0.76,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2829,"Anaplastic astrocytoma with piloid features  see comment
",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #071\NH18-2829,0.17,0.103,0.05,-0.055,0.074,-0.134,0.054,-0.278,0.33,0.154,0.788,-0.137,0.045,0.174,-2.158,0.127,0.135,-0.305,0.115,0.351,0.587,0.578,-0.003,0.007,0.088,0.363,-0.47,-0.238,-0.187,methylated
NH18-2768,202047860035_R01C01,#072,18/12/2018,,1/18/2019,31,SB,Diagnostic,072,1,NDP,NHNN,"Oligo; no IDH, no 1p19q, but ATRX loss","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,3/30/1951,67.7,papillary glioneuronal tumour,0.31,GBM_MID,0.48,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2768,"Glioma, possibly IDH mutant (see comment)

IDH1 (R132H IHC): No mutation, further tests pending 
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q:  Test pending
","Glioma, IDH-wildtype (corresponding to WHO grade II) 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Retained
EGFR: No amplification
MGMT Promoter: Methylated (>0-5%)

",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #072\NH18-2768,0.138,-0.055,0.036,0.035,-0.055,0.069,0.025,-0.078,-0.041,-0.03,-0.009,0.006,0.004,0.014,-0.011,0.033,-0.202,-0.145,0.002,-0.004,-0.033,0.021,-0.017,-0.001,0.02,0.152,-0.475,-0.011,0.041,methylated
NH18-2869,202047860035_R02C01,#072,18/12/2018,,1/18/2019,31,SB,Diagnostic,072,1,NDP,Newcastle,"HGG, probably GBM","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2D,10/20/1968,50.2,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.27,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2869,"Methylation profile: In favour of glioblastoma, IDH-wildtype (WHO grade IV)  see comment 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #072\NH18-2869,0.064,-0.01,0.044,-0.02,-0.053,0.05,0.032,0.081,0.149,0.157,0.168,0.006,0.028,0.039,-0.064,-0.051,-0.302,-0.288,-0.06,-0.09,0.806,-0.011,-0.158,-0.268,-0.005,-0.031,0.011,0.009,0.041,unmethylated
NH18-2910,202047860035_R07C01,#072,28/12/2018,,1/18/2019,21,ZJ,Diagnostic,072,3,NDP,Oxford John Radcliffe Hospital,"Periventricular glioma, H3F3A K27M neg","(2) unusual histology, location, demographics",1,8/25/1993,25.3,supratentorial pilocytic astrocytoma,0.44,LGG_PA_GGST,0.33,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH18-2910,"Histology: Low grade glioma, with possible BRAF V600E mutation  see comment
Methylation profile: In favour of midline pilocytic astrocytoma 
     
BRAF (V600E): Possible mutation (insufficient material for confirmation)
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #072\NH18-2910,0.089,0.02,0.056,-0.049,0.011,-0.037,-0.019,0.074,0.071,0.007,0.097,0.034,-0.179,0.059,-0.04,-0.008,-0.123,0.02,0.061,0.068,0.137,-0.079,-0.034,0.078,-0.075,-0.162,0.063,-0.004,0.01,unmethylated
NH18-2929,202047860035_R08C01,#072,28/12/2018,,1/18/2019,21,ZJ,Diagnostic,072,2,NDP,Nottingham University Hospital,"Pilocytic astrocytoma with high Ki67, cerebellar","(2) unusual histology, location, demographics",A1,10/8/2003,15.2,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.99,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2929,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Pilocytic astrocytoma, posterior fossa

MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #072\NH18-2929,0.162,-0.023,0.029,0.086,0.023,0.012,0.202,0.104,0.178,0.163,0.217,0.009,-0.096,0.06,-0.051,-0.05,-0.057,0.032,0.093,0.063,-0.008,0.096,-0.107,-0.007,-0.012,-0.056,0.085,-0.01,0.032,unmethylated
NH18-2918,202066270083_R01C01,#073,1/1/2019,,1/25/2019,24,SB,Diagnostic,073,9,NDP,NHNN,"Infitrating glioma, type?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/12/1965,53.9,ganglioglioma,0.92,LGG_GG,0.57,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2918,"Infiltrating glioma - see comment
","Molecular profile supportive of an infiltration of glioblastoma, IDH-wildtype (WHO grade IV)  see comment

IDH1 (R132H IHC); IDH1/2Seq: No mutation          
TERT promoter: Mutation     
MGMT Promoter (Illumina array): Unmethylated 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #073\NH18-2918,0.047,0,0.026,0.01,-0.071,0.019,-0.017,0.085,0.073,0.078,0.071,-0.018,0.011,0.025,0.013,0.017,-0.246,-0.124,0.004,0.05,0.091,0.01,-0.005,0.078,0.053,0.045,0.025,-0.121,-0.068,unmethylated
NH19-2,202066270083_R03C01,#073,7/1/2019,,1/25/2019,18,ZJ,Diagnostic,073,3,NDP,Southampton General Hospital,Pineal region glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,4/8/1954,64.7,high-grade astrocytoma with piloid features,0.42,ANAPA,0.53,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2,"Methylation profile: Suggestive of anaplastic pilocytic astrocytoma  see comment
MGMT Promoter (Illumina array): Methylated 

",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #073\NH19-2,0.23,-0.057,0.003,-0.006,-0.012,0.016,-0.005,-0.046,-0.027,-0.01,-0.028,0,0.025,0.044,-1.683,0.347,0.007,0.038,0.066,0.005,0.131,0.198,-0.441,0.012,0.011,0.002,-0.05,0.033,0.04,methylated
NH18-2936,202066270083_R04C01,#073,8/1/2019,,1/25/2019,17,ZJ,Diagnostic,073,1,NDP,NHNN,"Spinal ependymoma, WHO grade II","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,10/30/1949,69.2,myxopapillary ependymoma,1,EPN_MPE,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2936,"Ependymal tumour-see comment
","Methylation profile: Ependymoma, myxopapillary  see supplementary comment 
MGMT Promoter (Illumina array): Unmethylated
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #073\NH18-2936,0.006,-0.034,0.043,0.01,-0.012,-0.003,0.002,0.002,0.01,-0.018,-0.009,0.02,0.004,0.015,-0.033,0.021,0.001,-0.006,0.004,0.026,-0.02,-0.001,-0.02,0.017,0.054,-0.036,-0.006,0.012,0.021,unmethylated
NH18-2850,202066270083_R05C01,#073,11/1/2019,,1/25/2019,14,ZJ,Diagnostic,073,1,NDP,Nottingham University Hospital,Glioblastoma (born in 1994),"(2) unusual histology, location, demographics",D1,5/12/1994,24.6,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.94,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2850,"Histology: Epithelioid glioblastoma (WHO grade IV)
Methylation profile: Anaplastic pleomorphic xanthoastrocytoma  see comment  
MGMT Promoter (Illumina array): Methylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #073\NH18-2850,-0.013,0.027,0.004,-0.04,-0.003,-0.009,0.037,-0.065,-0.071,-0.075,-0.037,-0.008,0.034,0.016,-0.33,0.012,-0.001,0.054,0.049,0.031,0.012,0.012,-0.064,-0.005,0.019,-0.03,0.011,-0.029,0.03,methylated
NH19-36,202066270083_R06C01,#073,11/1/2019,,1/25/2019,14,ZJ,Diagnostic,073,2,NDP,St George's Hospital London,Glioma,"(4) IHC, sequencing, or copy number assay ambiguous",A1,11/9/1968,50.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.94,AIDH_HG,0.56,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-36,"Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma 
IDH1/2Seq: IDH1 mutation (see referring pathology report)     
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B: No deletion
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #073\NH19-36,0.048,-0.093,0.031,0.01,0,0.089,-0.006,-0.012,0.006,0.073,0.014,-0.012,-0.007,0.064,-0.171,-0.011,0.001,0.061,0.175,-0.009,0.06,-0.045,-0.052,0.056,0.05,-0.01,-0.032,-0.007,0.038,unmethylated
NH19-29,202066270083_R08C01,#073,15/01/2019,,1/25/2019,10,SB,Diagnostic,073,2,NDP,Royal London Hospital,"Pilocytic astrocytoma, See NH18-2284 ","(2) unusual histology, location, demographics",DEF1A,12/22/1981,37.1,infratentorial pilocytic astrocytoma,0.92,LGG_PAPF,0.91,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-29,"
Low grade glioma, in favour of pilocytic astrocytoma (WHO grade I), see comment.
","Histology and methylation profile: Low grade glioma, in favour of pilocytic astrocytoma (WHO grade I)  

MGMT Promoter (Illumina array): Unmethylated 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #073\NH19-29,-0.159,0.072,0.042,0.02,0.01,0.076,0.23,-0.037,-0.094,-0.072,0.156,-0.005,0.043,0.053,-0.034,0.016,-0.028,0.067,0.249,-0.041,-0.049,-0.006,-0.07,-0.043,-0.069,-0.052,0.052,-0.041,-0.008,unmethylated
NH19-91,202081130229_R05C01,#074,16/01/2019,,2/1/2019,16,ZJ,Diagnostic,074,1,NDP,Bristol,?Anaplastic astrocytoma,"(2) unusual histology, location, demographics",B2,7/15/1993,25.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-91,"Molecular and methylation profile: Astrocytoma, IDH-mutant  for grading, see comment 

IDH1 (R132H): Mutation (as per referring pathology report)
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q (Illumina array): Retained          
CDKN2A/B: No deletion
MGMT Promoter (Illumina array): Methylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #074\NH19-91,-0.034,-0.03,0.038,-0.012,-0.055,0.052,0.002,-0.002,0.002,-0.255,-0.236,0.063,0.056,0.086,-0.019,0.011,-0.025,-0.036,0.125,-0.042,-0.013,0.003,-0.344,-0.014,0.01,-0.012,-0.097,-0.066,0.048,methylated
NH19-144,203145740106_R01C01,#075,22/01/2019,,2/8/2019,17,ZJ,Diagnostic,075,1,NDP,Manchester,3rd ventricle/hypothalamus LGG,"(2) unusual histology, location, demographics",18,8/13/2005,13.1,papillary glioneuronal tumour,0.35,LGG_PAPF,0.21,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-144,"Low grade glioma, probably corresponding to WHO grade I
Methylation class: No matching methylation class.
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #075\NH19-144,-0.021,-0.02,0.049,0.032,-0.054,0.264,0.257,-0.012,-0.003,-0.052,0.001,-0.022,0.016,0.043,-0.016,-0.004,-0.018,0.022,0.032,0.01,0.03,-0.007,-0.041,-0.03,-0.014,-0.008,-0.001,-0.017,0.006,unmethylated
NH19-146,203145740106_R02C01,#075,22/01/2019,,2/8/2019,17,ZJ,Diagnostic,075,1,NDP,Oxford John Radcliffe Hospital,Atypical central neurocytoma,"(2) unusual histology, location, demographics",1,6/20/1992,26.2,diffuse leptomeningeal glioneuronal tumour,0.95,DLGNT,0.93,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-146,"Histology: Glioneuronal tumour
Methylation class: diffuse leptomeningeal glioneuronal tumour
1p/19 q codeleted
BRAF duplication
 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #075\NH19-146,0.035,0.03,0.037,-0.009,0.043,0.01,0.025,-0.054,-0.001,0.286,0.219,0.029,0.036,0.039,0.048,-0.016,0.012,-0.022,0.088,0.042,0.066,-0.028,-0.021,0.084,-0.062,-0.005,-0.667,-0.02,0.047,methylated
NH19-192,203145740106_R05C01,#075,28/01/2019,,2/8/2019,11,ZJ,Diagnostic,075,1,NDP,Latvia,"Dural-based glial, glioneuronal tumour","(2) unusual histology, location, demographics",B6043-2018,5/18/2002,16.7,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.95,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-192,"Histology: Low grade glioneuronal tumour (WHO grade I)
Methylation profile: Low grade glioma, pilocytic astrocytoma / ganglioglioma spectrum  see comment
 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #075\NH19-192,-0.04,0.013,0.007,0.005,-0.09,0.039,0.017,-0.275,-0.045,0.201,0.174,-0.004,0.059,0.004,-0.018,0.015,-0.01,0.008,0.045,-0.029,0,-0.027,-0.033,-0.031,-0.003,-0.024,-0.044,-0.001,0.021,unmethylated
NH19-197,203145740106_R06C01,#075,28/01/2019,,2/8/2019,11,ZJ,Diagnostic,075,4,NDP,Latvia,"Cerebellar tumour, 2nd surgery","(2) unusual histology, location, demographics",5479-82/18,5/28/2005,13.1,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-197,"Histology and methylation profile: Pilocytic astrocytoma (WHO grade I)
 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #075\NH19-197,-0.052,-0.009,0.005,0.008,-0.036,0.017,0.032,0.001,0.005,-0.033,0.163,0.013,-0.042,-0.005,-0.036,-0.003,0.004,0.017,0.018,-0.02,-0.024,0.014,0.021,-0.008,-0.005,-0.016,-0.047,0.017,0.003,unmethylated
NH19-189,203145740106_R07C01,#075,28/01/2019,,2/8/2019,11,ZJ,Diagnostic,075,3,NDP,"Birmingham, Queen Elizabeth Hospital",Temporal LGG with large swellings (?cellular; ?axonal),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,12/19/1988,30.1,supratentorial pilocytic astrocytoma,0.67,LGG_DNT,0.44,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-189,"Histology: Low grade glioma
Methylation class: No match (see comment)
BRAF: No mutation
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #075\NH19-189,0.047,-0.006,-0.006,0.06,-0.006,-0.033,-0.043,-0.028,-0.006,-0.014,0,-0.016,-0.028,0.062,-0.066,-0.035,0.033,0.034,0.091,0.057,0.043,0.019,-0.029,0.03,0.078,-0.02,-0.002,-0.042,0.048,unmethylated
NH19-195,203145740106_R08C01,#075,28/01/2019,,2/8/2019,11,ZJ,Diagnostic,075,4,NDP,Latvia,"Cerebellar tumour, dissemination to spine","(2) unusual histology, location, demographics",6328-2018,9/9/2007,11.4,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-195,"Histology and methylation profile: Pilocytic astrocytoma (WHO grade I)
 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #075\NH19-195,0.001,-0.012,0.029,-0.017,-0.013,0.002,0.001,0.084,-0.04,-0.017,0.173,0.004,0,0.043,-0.032,-0.019,-0.026,0.039,0.033,-0.008,0.021,-0.046,-0.047,0.032,-0.036,-0.054,0.001,0.025,0.066,unmethylated
NH19-210,202081130208_R01C01,#076,30/01/2019,,2/21/2019,22,ZJ,Diagnostic,076,4,NDP,St George's Hospital London,"Diffuse astrocytoma, ATRX retained","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/24/1959,59.1,ganglioglioma,0.54,GBM_MES,0.58,1,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-210,"Astrocytoma, IDH-wildtype (grading see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained
EGFR: No amplification

","Histology: Low-grade glioma, IDH-wildtype
Methylation class: Glioblastoma, IDH-wildtype (see comment)

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #076\NH19-210,0.074,-0.136,-0.007,0.062,-0.06,0.029,-0.056,0.349,0.384,0.439,0.345,-0.027,0.083,0.008,0.02,-0.016,-0.335,-0.245,-0.042,-0.032,-0.052,0.101,-0.187,0.039,-0.009,0.08,0.011,-0.048,-0.001,unmethylated
NH19-207,202081130208_R05C01,#076,1/2/2019,,2/21/2019,20,ZJ,Diagnostic,076,4,NDP,"Birmingham, Queen Elizabeth Hospital",Cerebellar LGG; ?PA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,6/21/1973,45.6,infratentorial pilocytic astrocytoma,0.67,LGG_PAPF,0.59,0.97,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-207,"Histology: Low grade glioma
Methylation class: Suggestive of pilocytic astrocytoma (see comment)
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #076\NH19-207,0.035,0.061,0.043,-0.06,-0.002,-0.046,-0.023,-0.008,-0.061,-0.041,0.181,0.01,-0.006,0.061,-0.052,-0.011,-0.038,0.075,0.041,-0.033,0.06,0.014,-0.016,0.01,-0.027,-0.008,0.089,0.02,0.065,unmethylated
NH19-310,202081130208_R08C01,#076,7/2/2019,,2/21/2019,14,ZJ,Diagnostic,076,1,NDP,RFH / Marsden,Metasttic MPE to pleura,"(2) unusual histology, location, demographics",A1,6/27/1971,47.6,myxopapillary ependymoma,0.74,EPN_MPE,0.57,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-310,"Histology: Myxopapillary ependymoma (WHO grade I)
Methylation class: Ependymoma, myxopapillary


  
",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #076\NH19-310,-0.157,-0.208,-0.264,-0.137,-0.011,0.364,-0.328,0.135,0.184,0.177,0.127,-0.264,-0.125,-0.167,-0.284,0.119,-0.191,-0.261,-0.026,-0.025,0.017,-0.187,-0.012,-0.022,0.022,0.097,0.283,-0.328,-0.24,unmethylated
NH19-239,202066270113_R02C01,#077,11/2/2019,,2/28/2019,17,ZJ,Diagnostic,077,5,NDP,"Belfast, Royal Victoria Hospital",Spinal glioma (reported GBM),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2,6/5/1990,28.7,diffuse leptomeningeal glioneuronal tumour,1,DLGNT,0.99,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-239,"Histology: Compatible with diffuse leptomeningeal glioneuronal tumour (DLGNT)
Methylation class: Diffuse leptomeningeal glioneuronal tumour (low calibrated score)

1p: deleted
BRAF: Duplication
MGMT Promoter: Unmethylated
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #077\NH19-239,0.26,0.185,0.186,0.086,0.094,0.069,-0.091,0.166,0.548,0.643,0.801,0.201,0.088,0.44,-0.039,0.004,-0.033,-0.016,0.054,-0.015,-0.074,-0.102,-0.103,0.082,-0.09,-0.138,0.026,0.048,0.012,unmethylated
NH19-354,202066270113_R04C01,#077,13/02/2019,,2/28/2019,15,SB,Diagnostic,077,1,NDP,"Birmingham, Queen Elizabeth Hospital",Ependymoma A or B?,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,1/22/1963,56.1,posterior fossa subependymoma,1,SUBEPN_PF,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-354,"Histology: Ependymoma/subependymoma
Methylation class: Subependymoma, posterior fossa
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #077\NH19-354,0.071,-0.046,0.011,0.046,0.011,-0.027,-0.494,-0.025,-0.016,0.015,0.006,-0.015,0.002,-0.001,0.009,-0.024,-0.017,-0.017,0.013,-0.032,0.022,0.068,-0.019,0.018,0.057,-0.006,0.022,-0.023,0.053,unmethylated
NH19-395,202066270120_R01C01,#078,20/02/2019,,3/7/2019,15,SB,Diagnostic,078,1,NDP,NHNN,Spinal LGG/gliosis?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,5/30/1969,49.7,"glioblastoma, IDH-wildtype, mesenchymal type",0.32,CONTR_REACT,0.11,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-395,"
Abnormal glial tissue, see comment 
","No supportive molecular features of neoplasm  see supplementary comment
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #078\NH19-395,-0.086,-0.093,-0.005,0.096,-0.118,0.113,-0.041,-0.064,0.036,-0.075,-0.011,0.014,0.097,-0.058,-0.081,-0.022,-0.063,-0.005,0.072,-0.044,-0.044,0.087,0.034,-0.135,-0.004,0.054,0.021,-0.045,0.096,unmethylated
NH19-410,202066270120_R03C01,#078,20/02/2019,,3/7/2019,15,SB,Diagnostic,078,3,NDP,"Leeds, St James's University Hospital",Temporal anaplastic Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",35103-A1,3/4/1959,59.6,"glioblastoma, IDH-wildtype, RTK2 type",0.95,GBM_MES,0.77,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-410,"Methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV) 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #078\NH19-410,0.002,-0.084,0.024,0.312,-0.055,0.113,-0.583,0.283,0.313,0.295,0.273,-0.486,0.12,0.103,-1.779,0.046,-0.596,-0.498,0.044,-0.052,0.053,0.098,-0.06,-0.018,-0.057,0.066,0.024,-0.551,-0.317,unmethylated
NH18-2810,202066270120_R04C01,#078,20/02/2019,,3/7/2019,15,SB,Diagnostic,078,4,NDP,"Cardiff, University Hospital","anaplastic oligo, no IDH mut??","(2) unusual histology, location, demographics",A3,1/22/1965,53.9,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.95,GBM_MID,0.98,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2810,"High grade glioma  see comment 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Possibly codeleted, but see comment
EGFR: No amplification          
Histone H3F3A: No mutation     
  
","Methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV) 
MGMT Promoter: Methylated 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #078\NH18-2810,0.311,0.03,0.044,-0.061,0.031,0.08,-0.048,0.054,-0.019,-0.113,-0.005,0.031,0.16,0.088,-0.042,0.15,-0.062,-0.068,-0.003,-0.05,0.111,-0.067,-0.09,0.193,0.068,0.014,-0.066,-0.114,0.121,methylated
NH19-471,202066270120_R06C01,#078,27/02/2019,,3/7/2019,8,SB,Diagnostic,078,1,NDP,St George's Hospital London,GBM?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/23/1961,57.5,"glioblastoma, IDH-wildtype, RTK2 type",0.62,GBM_RTKII,0.74,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-471,"Methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV) 
EGFR (Illumina array): Amplification 
MGMT Promoter (Illumina array): Methylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #078\NH19-471,-0.021,-0.136,-0.021,0.134,-0.021,0.143,-0.124,1.815,0.323,0.33,0.27,-0.011,0.235,0.051,-0.565,-0.08,-0.523,-0.627,0.072,-0.05,0.024,0.103,-0.02,-0.007,0.171,0.086,0.187,0.009,0.043,methylated
NH19-117,202081130209_R01C01,#079,27/02/2019,,3/15/2019,16,SB,Diagnostic,079,1,NDP,"Cardiff, University Hospital",RGNT?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,9/11/1988,30.3,infratentorial pilocytic astrocytoma,0.92,LGG_PAPF,0.9,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-117,"Low grade glioma  see comment 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: No amplification          
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
  
","Methylation profile: Pilocytic astrocytoma (WHO grade I) 
MGMT Promoter (Illumina array): Unmethylated
 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #079\NH19-117,0.002,-0.015,0.044,0.011,-0.036,-0.015,0.018,0.136,0.163,0.161,0.148,0.002,0.072,0.024,0.011,0.012,0.013,0.02,0.06,0.001,0.007,0.076,-0.006,0.046,0.008,-0.048,-0.056,0.065,0.074,unmethylated
NH19-450,202081130209_R02C01,#079,27/02/2019,,3/15/2019,16,SB,Diagnostic,079,4,NDP,Nottingham University Hospital,GBM (?),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,11/13/1974,44.3,"glioblastoma, IDH-wildtype, RTK2 type",0.99,GBM_RTKII,0.93,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-450,"Molecular and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)
 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
TERT promoter: Mutation
EGFR (Illumina array): Amplification
MGMT Promoter (Illumina array): Unmethylated
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #079\NH19-450,0.175,-0.052,0.036,-0.115,-0.079,-0.018,0.029,1.134,0.203,0.232,0.165,-0.018,-0.018,0.043,-1.601,-0.023,-0.322,-0.267,-0.021,-0.014,-0.029,0.092,-0.017,0.035,-0.047,-0.023,0.19,0.047,0.058,unmethylated
NH19-401,202081130209_R03C01,#079,27/02/2019,,3/15/2019,16,SB,Diagnostic,079,4,NDP,NHNN,"LGG, DNT, etc?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1C,#N/A,#N/A,"control tissue, hemispheric cortex",0.39,CONTR_HEMI,0.58,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-401,"Multinodular and vacuolating neuronal tumour (WHO grade I)  see comment
","Histology: Multinodular and vacuolating neuronal tumour (WHO grade I)
Methylation profile: Non-contributory findings
 
MGMT Promoter (Illumina array): Unmethylated 
  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #079\NH19-401,-0.017,-0.051,0.005,0.031,-0.032,0.065,-0.035,-0.039,-0.02,0.017,-0.003,-0.006,-0.009,0.036,-0.1,-0.039,0.021,0.025,0.005,-0.076,0.009,0.001,0.014,-0.027,0.046,-0.013,0.027,0.002,0.015,unmethylated
NH19-505,202081130209_R05C01,#079,28/02/2019,,3/15/2019,15,SB,Diagnostic,079,1,NDP,Bristol,"Oligo, IDH mut 1p19q codel, on specific request fro bristol","(4) IHC, sequencing, or copy number assay ambiguous",A1,8/26/1965,53.4,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.95,OIDH,0.88,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-505,"Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted  see comment
 
IDH1 (R132H IHC); IDH1/2Seq: Mutation (as per referring pathology report)     
ATRX (IHC): Retained (as per referring pathology report)     
1p/19q (Illumina array): Codeleted
MGMT Promoter (Illumina array): Methylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #079\NH19-505,0.038,-0.233,-0.065,-0.154,-0.287,0.023,-0.054,-0.03,0.002,-0.014,0.034,0.049,-0.018,0.037,-0.459,-0.1,0.024,0.048,0.04,-0.004,-0.011,-0.042,-0.014,-0.087,-0.18,0.14,-0.247,-0.019,-0.046,methylated
NH19-509,202081130209_R07C01,#079,28/02/2019,,3/15/2019,15,SB,Diagnostic,079,4,NDP,Lund (SE),H3 G34 (?) mutant tumour,"(4) IHC, sequencing, or copy number assay ambiguous",01 & 03,3/10/1992,27,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type B]",1,GBM_MID,0.62,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-509,"Histology: Anaplastic astrocytoma (WHO grade III)
Methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)  see comment
 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
EGFR (Illumina array): No amplification          
CDKN2A/B (Illumina array): Deletion
TERT promoter: No mutation     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #079\NH19-509,-0.003,0.001,0.039,0.024,0.045,0.042,0.027,-0.013,-0.015,-0.025,-0.011,-0.021,0.08,0.04,-0.579,0.015,-0.044,-0.019,-0.083,-0.048,-0.011,0.062,-0.052,-0.008,-0.544,0.024,-0.025,-0.009,0.03,unmethylated
NH19-525,202081130209_R08C01,#079,28/02/2019,,3/15/2019,15,SB,Diagnostic,079,14,NDP,Royal London Hospital,Referred from RLH as lymphoma. Midline HGG?,"(2) unusual histology, location, demographics",,6/7/1980,38.8,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.15,DMG_K27,0.34,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-525,"H3 K27M-mutant diffuse midline glioma, WHO grade IV.
","Diffuse midline glioma, H3 K27M-mutant (WHO grade IV)
 
ATRX (IHC): Loss of expression (indicates mutation) in large proportion of tumour cells     
Histone H3F3A K27M IHC): Mutation
MGMT Promoter (Illumina array): Unmethylated 
",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #079\NH19-525,0.307,-0.29,0.255,0.212,-0.015,-0.163,-0.706,-0.085,0.149,0.433,0.287,1.008,0.411,-0.362,-0.486,0.263,-0.218,-0.239,-0.107,-0.314,0.862,0.37,-0.404,-0.318,0.233,0.043,0.265,0.261,0.47,unmethylated
NH19-489,203145740128_R01C01,#080,28/02/2019,,3/21/2019,21,SB,Diagnostic,080,4,NDP,Southampton General Hospital,"RGNT, H3 K27me3","(2) unusual histology, location, demographics",A,2/11/1977,41.8,rosette-forming glioneuronal tumour,0.99,LGG_RGNT,0.87,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-489,"Rosette forming glioneuronal tumour (WHO grade I)
Histone H3K27me3 loss of expression (see comment)
","Histology and methylation profile: Rosette forming glioneuronal tumour (WHO grade I) 
MGMT Promoter (Illumina array): Unmethylated 
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #080\NH19-489,0.056,-0.053,0.017,0.047,0.032,0.01,-0.029,-0.037,0.018,-0.078,0.01,0.018,0.039,0.031,-0.121,-0.028,0.019,0.029,0.143,0.065,0.053,0.045,-0.027,0.081,0.137,-0.065,-0.012,-0.013,0.121,unmethylated
NH19-476,203145740128_R04C01,#080,6/3/2019,,3/21/2019,15,SB,Diagnostic,080,1,NDP,NHNN,Midline lesion; PA/LGG?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,12/1/1981,37.3,supratentorial midline pilocytic astrocytoma,0.94,LGG_PAMID,0.62,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-476,"Pilocytic astrocytoma, WHO grade I.
","Histology and methylation profile: Pilocytic astrocytoma (WHO grade I)

MGMT Promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #080\NH19-476,0.009,-0.082,0.027,0.04,-0.096,0.098,-0.023,-0.073,-0.053,-0.007,-0.01,-0.003,0.041,0.047,-0.043,-0.001,0.045,0.039,-0.014,-0.066,-0.018,0.097,0.05,0.025,-0.038,0.008,-0.021,-0.024,0.09,unmethylated
NH19-553,203145740128_R05C01,#080,7/3/2019,,3/21/2019,14,SB,Diagnostic,080,4,NDP,Nottingham University Hospital,LGG? Looks like PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,3/23/1954,65,ganglioglioma,0.49,PXA,0.22,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-553,"Glial / glioneuronal tumour, BRAF V600E-mutant  see comment
 
BRAF (V600E): Mutation
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #080\NH19-553,0.202,-0.039,-0.039,0.079,-0.054,0.355,-0.201,0.363,0.402,0.478,0.418,0.218,0.268,0.331,-0.2,-0.005,-0.019,0.043,0.176,0.101,0.285,0.272,0.165,0.028,0.012,-0.139,0.426,0.053,0.16,unmethylated
NH19-396,203145740128_R06C01,#080,13/03/2019,,3/21/2019,8,ZJ,Diagnostic,080,1,NDP,"Birmingham, Queen Elizabeth Hospital",LGG with no KIAA-BRAF or BRAF V600E mutation,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C1,10/6/1999,19.4,infratentorial pilocytic astrocytoma,0.5,LGG_PAPF,0.25,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-396,"Low grade glioma. 
BRAF: No fusion, no mutation
","Histology: Low grade glioma
Methylation profile: No matching methylation class  see supplementary comment 

BRAF (Seq and V600E IHC): No mutation
KIAA1549-BRAF fusions: No fusions between 16_9, 16_11, 15_9 exons 
MGMT Promoter (Illumina array): Unmethylated 
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #080\NH19-396,-0.415,-0.379,0.159,-0.28,-0.007,-0.154,-0.195,-0.145,-0.07,-0.059,-0.039,0.064,-0.283,-0.007,0.24,-0.144,0.011,0.031,0.111,-0.362,0.101,0.229,-0.056,0.159,-0.218,-0.265,0.27,-0.141,0.23,unmethylated
NH19-596,203145740128_R07C01,#080,13/03/2019,,3/21/2019,8,ZJ,Diagnostic,080,4,NDP,St George's Hospital London,"Glioma, NOS","(4) IHC, sequencing, or copy number assay ambiguous",A1,7/3/1957,61.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.88,AIDH,0.55,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-596,"Histology: Anaplastic astrocytoma (WHO grade III)
Methylation profile: IDH glioma, subclass astrocytoma  see comment
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B (Illumina array): No deletion
Copy number variation (Illumina array): Increased          
MGMT Promoter (Illumina array): Methylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #080\NH19-596,-0.088,-0.275,0.001,-0.069,0.338,-0.012,-0.514,0.051,-0.08,0.01,-0.024,-0.038,0.045,0.431,-0.341,-0.185,-0.523,-0.366,-0.087,-0.096,-0.221,0.033,-0.151,0.072,-0.043,-0.087,-0.329,0.09,0.068,methylated
NH19-606,203145740128_R08C01,#080,13/03/2019,,3/21/2019,8,ZJ,Diagnostic,080,1,NDP,Nottingham University Hospital,"Glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B3,9/11/2009,9.5,"supratentorial ependymoma, ZFTA fusion-positive",0.86,MB_SHHINF,0.12,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-606,"Histology: Malignant tumour
Methylation profile: No matching methylation class  see comment
 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #080\NH19-606,0.077,-0.075,0.077,-0.153,-0.328,0.049,-0.007,0.115,0.198,0.247,0.176,0.198,0.199,0.277,-0.428,-0.332,0.204,0.219,0.074,0.177,0.156,0.297,0.16,-0.009,0.056,-0.025,-0.054,-0.08,0.044,unmethylated
NH19-623,203068650141_R01C01,#081,14/03/2019,,4/5/2019,22,ZJ,Diagnostic,081,1,NDP,St George's Hospital London,Spinal ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,9/15/1991,27.5,spinal ependymoma,0.86,EPN_SPINE,0.71,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-623,"Histology: Ependymoma
Methylation class: Ependymoma, spinal
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #081\NH19-623,0.006,-0.005,0.124,0.009,-0.077,-0.076,-0.003,-0.027,0.052,-0.179,-0.045,0.053,0.053,0.018,0.051,0.029,0.04,-0.043,0.057,0.068,0.011,0.065,0.051,0.065,0.104,0.001,-0.132,-0.341,-0.282,unmethylated
NH15-1432,203068650141_R03C01,#081,18/03/2019,,4/5/2019,18,SB,Diagnostic,081,1,NDP,Royal London Hospital,"Midline Glioma, no K27, 4 y survivial? Type?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,5/2/1971,44.2,high-grade astrocytoma with piloid features,0.55,DLGNT,0.26,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH15-1432,"Glial tumour  see comment. 
","Histology: Low grade glioma
Methylation class: Inconclusive (but see comment).
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #081\NH15-1432,-0.07,-0.024,-0.02,-0.037,0.106,-0.028,-0.068,0.025,0.019,0.032,-0.065,0.035,0.013,0.056,0.04,-0.004,-0.046,-0.082,-0.006,0.123,0.124,-0.061,-0.076,-0.014,-0.259,-0.13,-0.076,-0.13,-0.106,unmethylated
NH19-624,203068650141_R04C01,#081,18/03/2019,,4/5/2019,18,ZJ,Diagnostic,081,1,NDP,St George's Hospital London,"Glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/31/1946,72.5,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.78,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-624,"Histology: High-grade glioma, most in keeping with glioblastoma (WHO grade IV) (see referring pathologist's report)
Methylation class: Glioblastoma, IDH-wildtype, subclass mesenchymal
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #081\NH19-624,-0.016,0.085,0.015,-0.065,-0.028,0.026,0.026,0.118,0.701,-0.027,-0.049,-0.033,0.059,-0.192,-0.622,-0.04,-0.198,-0.148,-0.007,-0.008,0.009,0.045,-0.167,-0.016,0.055,0.011,-0.049,0.012,0.032,methylated
NH19-648,203068650141_R06C01,#081,20/03/2019,,4/5/2019,16,ZJ,Diagnostic,081,3,NDP,"Cardiff, University Hospital","Left CPA, LGG, favour ependymoma","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,5/19/1943,75.8,high-grade astrocytoma with piloid features,0.3,GBM_MID,0.37,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-648,"Histology: High-grade astrocytoma (see comment)
Methylation class: Inconclusive, but see comment
",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #081\NH19-648,0.06,-0.006,-0.013,-0.023,0.002,-0.009,-0.028,-0.043,0.034,-0.01,0.06,-0.012,0.008,0.062,-2.064,-0.026,0.002,-0.016,0.047,-0.015,0.556,0.036,-0.092,-0.335,0.037,-0.026,-0.536,-0.028,0.041,methylated
NH19-673,203145740121_R01C01,#082,25/03/2019,,4/11/2019,17,ZJ,Diagnostic,082,5,NDP,NHNN,"Glioma, NOS (spinal)","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,1/10/2001,18.2,infratentorial pilocytic astrocytoma,0.95,LGG_PAPF,0.82,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-673,"Spinal astrocytoma  see comment. 
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Pilocytic astrocytoma (WHO grade I)
Methylation class: Posterior fossa pilocytic astrocytoma
BRAF: KIAA1549-BRAF 15_9 fusion
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #082\NH19-673,0.08,-0.252,-0.158,0.043,0.011,0.218,0.208,-0.006,-0.009,-0.018,0.161,0.133,0.223,0.23,-0.305,-0.201,0.01,0.042,0.058,0.044,0.018,-0.06,-0.271,0.054,0.059,0.001,0.013,-0.03,0.031,unmethylated
NH19-687,203145740121_R06C01,#082,27/03/2019,,4/11/2019,15,ZJ,Diagnostic,082,1,NDP,"Cardiff, University Hospital",LGG (temporal),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,7/15/2000,18.7,dysembryoplastic neuroepithelial tumour,0.97,LGG_DNT,0.91,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-687,"Histology: Low grade glial/glioneuronal tumour
Methylation class: Low grade glioma, dysembryoplastic neuroepithelial tumour, but with low calibrated score (see comment)
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #082\NH19-687,0.004,-0.051,0.02,-0.019,-0.026,0.05,-0.022,-0.063,-0.05,-0.071,-0.041,0.003,0.125,0.018,-0.031,-0.113,0.022,0.051,0.09,-0.02,0.03,-0.031,-0.042,0.002,-0.039,-0.035,-0.031,-0.046,0.015,unmethylated
NH19-759,203145740121_R07C01,#082,28/03/2019,,4/11/2019,14,ZJ,Diagnostic,082,1,NDP,Oxford John Radcliffe Hospital,Unusual glial tumour (reported in 2010 as AO in 10 year old patient),"(2) unusual histology, location, demographics",4C,9/9/2000,9.5,"supratentorial ependymoma, ZFTA:RELA fusion-positive",0.99,EPN_RELA,0.96,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-759,"Histology: Clear cell glial tumour, compatible with ependymoma
Methylation class: Ependymoma, RELA fusion.
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #082\NH19-759,0.361,-0.114,0.015,0.035,-0.057,-0.047,0.081,-0.007,-0.184,0.149,0.001,-0.085,0.078,0.012,-0.009,0.009,-0.064,-0.05,0.119,0.112,0.058,0.146,-0.272,0.24,-0.084,-0.096,-0.143,0.092,0.02,unmethylated
NH19-682,203068650095_R01C01,#083,29/03/2019,,5/16/2019,48,ZJ,Diagnostic,083,2,NDP,"Leeds, St James's University Hospital",Astroblastoma (probably just IDHwt GBM),"(2) unusual histology, location, demographics",A11,5/24/1963,55.8,pleomorphic xanthoastrocytoma(-like),1,PXA,0.99,0.54,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-682,"Histology: Features in keeping with pleomorphic xanthoastrocytoma 
Methylation class: Anaplastic pleomorphic xanthoastrocytoma
CDKN2A/B: Deletion


",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #083\NH19-682,-0.019,-0.064,0.118,-0.049,-0.18,0.068,-0.007,0.028,0.067,-0.047,0.008,-0.023,0.073,-0.034,-0.747,-0.023,-0.147,-0.136,-0.071,-0.036,-0.027,-0.04,-0.164,-0.003,0.055,-0.009,0.064,0.041,0.13,unmethylated
NH19-717,203068650095_R03C01,#083,29/03/2019,,5/16/2019,48,ZJ,Diagnostic,083,1,NDP,Oxford John Radcliffe Hospital,"Anaplstic ependymoma, right frontal","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,2/7/1944,72.9,polymorphous low-grade neuroepithelial tumour of the young,0.2,GBM_MES,0.17,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-717,"Histology: Ependymoma (see referring pathologist's report)
Methylation class: No conclusive result (see comment)
",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #083\NH19-717,0.231,-0.419,0.099,-0.025,-0.225,-0.122,-0.196,0.122,0.133,-0.019,0.118,0.243,0.366,0.435,0.007,0.043,0.032,-0.023,0.018,0.205,0.167,0.205,-0.437,-0.254,-0.673,-0.56,0.09,-0.026,0.085,unmethylated
NH19-664,203068650095_R04C01,#083,4/4/2019,,5/16/2019,42,SB,Diagnostic,083,4,NDP,"Belfast, Royal Victoria Hospital","Anaplastic astro, IDH wt, No TERT, EGFR","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,4/3/1971,48,"Diffuse midline glioma, H3 K27-altered, subtype EGFR-altered",0.25,GBM_RTKII,0.85,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-664,"Anaplastic astrocytoma, IDH-wildtype (WHO grade III), see comment
 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification     
MGMT Promoter: Unmethylated (0%)
  
","Histology: Anaplastic astrocytoma
Methylation class: Glioblastoma, IDH-wildtype
EGFR: Amplification
CDKN2A/B: Deletion
MGMT Promoter: Unmethylated (0%)
  
",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #083\NH19-664,0.209,0.043,0.064,0.176,-0.069,-0.096,-0.549,0.358,-0.056,-0.159,0.053,-0.021,0.024,0.014,-1.327,-0.044,-0.325,-0.408,-0.122,0.059,0.073,0.072,-0.386,0.015,0.031,0.028,-0.069,-0.244,-0.233,unmethylated
NH19-818,203068650095_R08C01,#083,10/4/2019,,5/16/2019,36,SB,Diagnostic,083,1,NDP,"Leeds, St James's University Hospital",anplastic ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,3/26/1967,52.1,"glioblastoma, IDH-wildtype, RTK2 type",0.97,GBM_RTKII,0.77,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-818,"Histology: High-grade glioma
Methylation class: Glioblastoma, IDH-wildtype

",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #083\NH19-818,0.071,-0.241,0.145,0.04,0.041,0.294,-0.21,1.796,0.377,0.412,0.617,0.081,0.142,0.044,-0.198,-0.046,-0.744,-0.829,-0.209,-0.155,0.169,0.098,-0.901,-0.779,0.001,0.081,0.045,-0.561,-0.479,methylated
NH19-829,203145740002_R02C01,#084,10/4/2019,,5/10/2019,30,SB,Diagnostic,084,3,NDP,NHNN,Astrocytoma vs ependymoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,11/25/1994,24.4,supratentorial subependymoma,0.95,SUBEPN_ST,0.92,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-829,"Glioma, please see comment

IDH1 (R132H IHC): No mutation (further tests pending) 
ATRX (IHC): Retained
Further molecular tests: Pending  
","Histology: Low grade glioma
Methylation class: Subependymoma, supratentorial
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #084\NH19-829,-0.01,-0.056,0.058,0.155,0.228,0.153,0.045,-0.033,-0.019,0.024,0.009,-0.362,-0.336,-0.33,-0.011,-0.017,0.029,0.05,-0.035,0.151,0.123,0.192,-0.044,0.181,0.213,0.175,0.201,-0.011,0,methylated
NH19-828,203145740002_R03C01,#084,10/4/2019,,5/10/2019,30,SB,Diagnostic,084,3,NDP,Bristol,GBM? other HGG?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,1/13/1993,24.4,rosette-forming glioneuronal tumour,0.72,LGG_RGNT,0.56,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-828,"Histology: Glial / glioneuronal tumour
Methylation profile: Inconclusive  see comment
MGMT Promoter (Illumina array): Unmethylated (0%)
 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #084\NH19-828,0.377,-0.383,-0.062,-0.013,0.098,-0.093,-0.282,-0.076,-0.127,-0.14,0.09,0.099,-0.052,0.055,-0.005,-0.018,-0.082,-0.158,0.103,0.224,0.165,0.049,-0.034,0.127,-0.011,0.006,-0.011,0.042,0.132,unmethylated
NH19-890,203145740002_R06C01,#084,16/04/2019,,5/11/2019,25,SB,Diagnostic,084,4,NDP,Southampton General Hospital,Midline Pineal HGG,"(2) unusual histology, location, demographics",A1,8/2/1978,40.7,high-grade astrocytoma with piloid features,0.83,ANAPA,0.95,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-890,"Histology: High-grade glioma with features of glioblastoma
Methylation class: Anaplastic pilocytic astrocytoma (see comment)

",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #084\NH19-890,-0.13,-0.021,0.009,0.018,-0.01,0.056,0.073,-0.003,-0.441,-0.463,-0.359,0.002,0.021,0.067,-2.049,0.32,-0.135,-0.278,-0.077,0.316,0,-0.069,0.009,0.014,0.026,0.543,-0.458,-0.059,-0.078,methylated
NH19-881,203068760217_R02C01,#085,17/04/2019,,5/10/2019,23,SB,Diagnostic,085,10,NDP,NHNN,"Temporal large Glioma ?Ependymoma, PXA?","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2A,5/26/1956,62.9,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.67,GBM_RTKII,0.68,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-881,"Ependymoma (WHO grade II)
","Histology: glioma with features raising the possibility of an ependymoma (see comment)
Methylation class: Glioblastoma, IDH-wildtype

",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #085\NH19-881,0.114,0.009,0.006,-0.044,0.02,0.04,-0.3,0.094,0.165,0.176,0.139,-0.009,0.011,-0.013,0.063,0.003,-0.286,-0.235,-0.313,0.142,-0.02,0.008,-0.294,-0.026,0.008,0.021,0.283,-0.291,-0.283,methylated
NH19-918,203068760217_R03C01,#085,18/04/2019,,5/10/2019,22,SB,Diagnostic,085,1,NDP,"Birmingham, Queen Elizabeth Hospital","Enhancing temporal tumour, high grade glioma?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,2/7/1959,60.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.85,GBM_MES,0.3,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-918,"Histology: Glioblastoma (WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype, subclass mesenchyma
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #085\NH19-918,-0.005,0.032,0.01,0,0.007,0.003,-0.093,0.15,0.202,0.182,0.165,-0.005,0.034,0.046,-0.006,0.058,-0.232,-0.212,-0.133,0.003,0.777,1.563,-0.273,0.055,0.05,0.023,-0.058,-0.044,0.046,unmethylated
NH19-913,203068760217_R08C01,#085,24/04/2019,,5/10/2019,16,ZJ,Diagnostic,085,1,NDP,Royal London Hospital,"Ependymoma, right frontal","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,9/19/1976,42.6,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,1,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-913,"Recurrent ependymoma (WHO grade III)
","Histology: Anaplastic ependymoma (WHO grade III)
Methylation class: Ependymoma, RELA fusion

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #085\NH19-913,0.12,0.007,0.056,0.028,-0.043,0.01,0.045,-0.015,-0.025,-0.037,-0.016,0.019,0.058,0.028,-2.911,-0.093,0.026,0.038,-0.006,0.036,-0.012,0.029,-0.026,-0.018,0.049,0.025,-0.051,-0.053,-0.002,unmethylated
NH19-961,203068760218_R02C01,#086,24/04/2019,,5/10/2019,16,ZJ,Diagnostic,086,4,NDP,Latvia,HGG near thalamus,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",555,9/10/2016,2.6,"Diffuse hemispheric glioma, H3 G34-mutant",0.22,GBM_RTKII,0.08,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-961,"Histology and methylation profile: 
Embryonal tumour (PNET), NOS (WHO grade IV)  see comment
MGMT Promoter (Illumina array): Methylated 

",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #086\NH19-961,-0.051,-0.005,0.05,-0.039,-0.042,0.074,0.085,-0.012,0.022,-0.106,-0.006,-0.024,0.108,-0.039,-0.018,-0.028,-0.019,0.021,-0.055,-0.014,-0.051,0.019,0.039,-0.057,0.03,-0.001,0.879,-0.014,0.015,methylated
NH19-968,203068760218_R03C01,#086,25/04/2019,,5/10/2019,15,SB,Diagnostic,086,7,NDP,"Middlesbrough, James Cook Hospital","NF1 and MEN1 syndromes, sarcoma-like lesion in brain","(2) unusual histology, location, demographics",B6,12/29/1971,47.3,"glioblastoma, IDH-wildtype, mesenchymal type",0.24,PXA,0.18,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-968,"Spindle cell tumour  see comment
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #086\NH19-968,0.027,0.141,0.091,0.054,0.144,0.06,0.078,0.197,0.264,0.24,0.266,0.169,0.136,0.304,0.021,-0.042,-0.078,-0.053,-0.049,-0.101,-0.029,-0.036,-0.222,-0.076,-0.079,-0.042,0.168,-0.017,-0.009,unmethylated
NH19-1024,203068760218_R04C01,#086,29/04/2019,,5/10/2019,11,ZJ,Diagnostic,086,1,NDP,"Birmingham, Queen Elizabeth Hospital",LGG in cerebellum,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B,5/2/1993,26,infratentorial pilocytic astrocytoma,0.77,LGG_PAPF,0.51,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-1024,"Histology: Low grade glioma
Methylation class: Posterior fossa pilocytic astrocytoma
","Histology and methylation profile: 
Pilocytic astrocytoma, with KIAA1549-BRAF fusion mutation (WHO grade I)

MGMT Promoter (Illumina array): Unmethylated 

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #086\NH19-1024,-0.058,-0.017,0.022,0.014,-0.004,0.097,-0.087,-0.016,-0.043,-0.089,0.166,-0.032,0.057,0.003,0.018,0.019,-0.006,0.033,0.025,-0.041,0.002,0.069,-0.009,-0.108,-0.075,-0.015,0.029,0.044,0.038,unmethylated
NH19-965,203068760218_R05C01,#086,29/04/2019,,5/10/2019,11,ZJ,Diagnostic,086,4,NDP,Latvia,"Intramedullary cervical spine glioma, (H3K27Mneg)","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",769,3/1/2001,18.1,infratentorial pilocytic astrocytoma,0.75,LGG_PAPF,0.77,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-965,"Histology and methylation profile: Pilocytic astrocytoma (WHO grade I) 
MGMT Promoter (Illumina array): Unmethylated
 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #086\NH19-965,-0.107,-0.073,-0.02,-0.131,-0.259,0.102,0.158,0.059,0.104,0.109,0.272,0.074,0.122,0.089,-0.068,-0.066,-0.051,-0.048,0.102,0.068,0.044,0.128,-0.334,-0.058,-0.068,-0.07,-0.082,-0.218,-0.266,unmethylated
NH19-1047,203068760218_R06C01,#086,30/04/2019,,5/10/2019,10,ZJ,Diagnostic,086,1,NDP,Nottingham University Hospital,Diffuse astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/29/1991,24.2,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type B]",1,DLGNT,0.32,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1047,"Histology and methylation profile: Glioma, not otherwise specified  see comment 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #086\NH19-1047,0.088,-0.004,-0.016,0.074,0.078,0.011,-0.042,-0.058,0.015,-0.077,-0.014,-0.004,0.054,-0.009,0.071,0.046,0.019,-0.007,0.015,0.059,0.088,0.038,-0.012,0.085,0.044,0.032,-0.043,-0.007,0.024,unmethylated
NH19-925,203068760136_R02C01,#087,1/5/2019,,5/16/2019,15,ZJ,Diagnostic,087,3,NDP,NHNN,Oligo vs Astro,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP2A,8/21/1986,32.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.86,AIDH,0.68,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-925,"Anaplastic glioma (WHO grade III) -see comment
","Anaplastic astrocytoma, IDH-mutant (WHO Grade III) see comment 
IDH1 (R132H IHC); IDH1/2Seq: Mutation
ATRX (IHC): Retained
CDKN2A/B: Deletion (Copy number assay from methylation array 
TERT promoter: Mutation
MGMT Promoter: Methylated (>25%)

  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #087\NH19-925,0.032,-0.012,0.032,0.004,0.022,0.06,-0.055,-0.107,-0.149,-0.067,0.024,0.002,0.012,0,-1.972,-0.088,-0.033,-0.391,-0.075,-0.04,-0.044,-0.031,-0.068,-0.038,-0.072,-0.047,-0.541,0.008,0.024,methylated
NH19-1083,203068760136_R06C01,#087,7/5/2019,,5/16/2019,9,ZJ,Diagnostic,087,1,NDP,NHNN,"Spinal cervical ependyoma, WHO II","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,7/6/1961,57.9,spinal ependymoma,1,EPN_SPINE,1,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1083,"Ependymoma (WHO grade II)
","Histology: Ependymoma (WHO grade II) 
Methylation class: Ependymoma, spinal 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #087\NH19-1083,-0.082,-0.067,0.075,0.016,-0.022,-0.028,-0.064,0.174,0.169,0.069,0.178,0.239,0.266,0.263,-0.023,-0.004,0.02,0.066,-0.003,0.242,0.203,0.213,-0.044,-0.022,-0.041,-0.034,-0.105,-0.451,-0.364,unmethylated
NH19-1063,203068760136_R07C01,#087,7/5/2019,,5/16/2019,9,ZJ,Diagnostic,087,4,NDP,Romford,Cerebellar HGG; ?ANAPA; ?Other glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,7/7/1989,29.8,high-grade astrocytoma with piloid features,1,ANAPA,1,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-1063,"Cerebellar glial tumour with high grade features  see comment

IDH1 (R132H IHC): No mutation       
ATRX (IHC): see text
Further molecular tests: Pending  
","Histology: High grade cerebellar glioma
Methylation profile: Anaplastic pilocytic astrocytoma
 
CDKN2A/B (Illumina array): Deletion
BRAF (Illumina array): Duplication
MGMT Promoter: Methylated 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #087\NH19-1063,-0.03,0.008,0.066,-0.044,0.055,0.036,-0.235,-0.085,-0.024,-0.054,0.296,-0.08,0.086,0.089,-1.388,0.026,-0.095,-0.057,-0.155,0.12,0.147,0.132,-0.057,0,0.057,0.009,-0.144,0.399,-0.179,methylated
NH19-1137,203068650124_R01C01,#088,8/5/2019,,5/23/2019,15,ZJ,Diagnostic,088,1,NDP,Nottingham University Hospital,Location not specified; glial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/25/1987,32.2,ganglioglioma,0.99,LGG_GG,0.77,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1137,"Histology: Low grade glioma
Methylation class: low grade glioma, ganglioglioma 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #088\NH19-1137,0.072,-0.113,-0.057,0.051,-0.124,0.038,-0.259,0.019,0.095,0.035,0.095,0.063,0.113,0.135,0.039,0.093,-0.04,-0.05,0.023,0.154,0.193,0.072,0.04,0.06,-0.069,-0.088,0.088,-0.12,0.003,unmethylated
NH19-1130,203068650124_R03C01,#088,8/5/2019,,5/23/2019,15,ZJ,Diagnostic,088,1,NDP,"Charing Cross Hospital, London",Midline glioma vs PA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,8/18/1989,29.7,dysembryoplastic neuroepithelial tumour,0.88,LGG_DNT,0.62,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1130,"Histology: Low grade glial neuronal tumour
Methylation class: low grade glioma, dysembryoplastic neuroepithelial tumor
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #088\NH19-1130,0.138,-0.028,-0.013,0.197,0.038,-0.011,-0.06,-0.017,0.011,-0.069,0.018,-0.026,-0.026,0.001,-0.094,-0.003,0.003,0.002,0.122,0.084,0.083,-0.055,-0.061,0.031,0.031,-0.016,-0.041,0.016,0.044,unmethylated
NH19-900,203068650124_R04C01,#088,8/5/2019,,5/23/2019,15,ZJ,Diagnostic,088,11,NDP,Romford,"GBM, metastatic to scalp","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A7,7/18/1991,27.7,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.97,GBM_MID,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-900,"Scalp lesion: High grade glioma, likely metastatic (WHO grade IV) -see comment

IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Glioblastoma (WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype, subclass midline (see comments)

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
CDKN2A/B: Deletion
TERT promoter: No mutation
MGMT Promoter: Unmethylated (0%)



",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #088\NH19-900,-0.051,-0.039,0.024,0.009,-0.009,0.053,0.028,-0.032,-0.051,-0.101,-0.024,0.34,0.47,0.336,-1.93,0.378,0.052,0.068,-0.002,0.229,0.228,0.263,-0.017,0.022,-0.014,0.21,-0.168,0.03,0.036,unmethylated
NH19-894,203068650124_R05C01,#088,8/5/2019,,5/23/2019,15,ZJ,Diagnostic,088,3,NDP,Newcastle,"Glioma, IDH-mutant, ATRX retained; LOH19q","(4) IHC, sequencing, or copy number assay ambiguous",2A,11/22/1962,56.4,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.72,AIDH_HG,0.85,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-894,"Gemistocytic astrocytoma, IDH-mutant (WHO grade II)
 
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained     
1p/19q: Retained          
CDKN2A/B: No deletion          
TERT promoter: No mutation     
MGMT Promoter: Methylated (>10-25%) 
","Histology: Gemistocytic astrocytoma, IDH mutant
Methylation class: IDH glioma, subclass high grade astrocytoma

IDH1 (R132H IHC); IDH1/2Seq: Mutation
ATRX (IHC): Retained
CDKN2A/B: No deletion
MGMT Promoter: Methylated (>10-25%) 



",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #088\NH19-894,-0.02,-0.084,0.04,-0.014,0.066,0.03,0.052,-0.001,-0.137,0.237,-0.024,0.017,0.087,0.04,-0.107,0.032,-0.036,-0.27,0.041,0.049,-0.004,-0.069,0.03,0.021,-0.001,0.029,-0.083,0.03,0.05,methylated
NH19-1166,203068650124_R08C01,#088,10/5/2019,,5/23/2019,13,ZJ,Diagnostic,088,1,NDP,St George's Hospital London,"T10 Ependymoma, G II","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,9/16/2001,17.6,infratentorial pilocytic astrocytoma,0.42,LGG_PAPF,0.54,0.99,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-1166,"Histology: Low-grade glioma, compatible with pilocytic astrocytoma (WHO grade I)
Methylation class: Pilocytic astrocytoma, subclass posterior fossa pilocytic astrocytoma
",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #088\NH19-1166,0.063,0.009,0.025,0.004,-0.021,-0.017,0.018,-0.069,-0.007,-0.086,-0.027,0.011,0.084,0.053,0.049,0.029,0.028,-0.012,0.083,0.054,0.02,0.023,0.011,0.021,0.016,-0.021,-0.117,0.058,0.038,unmethylated
NH19-958,203068650085_R08C01,#089,20/05/2019,,6/7/2019,18,ZJ,Diagnostic,089,2,NDP,Latvia,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1419-1420/2019,8/11/2015,3.7,dysembryoplastic neuroepithelial tumour,0.94,LGG_DNT,0.85,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-958,"Histology and methylation profile: 
Low grade glial / glioneuronal tumour, compatible with dysembryoplastic neuroepithelial tumour (DNT, DNET) (WHO grade I) - see comment

MGMT Promoter (Illumina array): Unmethylated
 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #089\NH19-958,0.044,-0.14,0.08,-0.034,-0.021,-0.039,-0.045,-0.201,-0.211,-0.465,-0.061,0.02,0.189,-0.009,-0.229,-0.091,0.057,0.031,0.017,0.027,0.039,0.064,0.012,0.027,-0.03,-0.014,-0.004,0.019,0.097,unmethylated
NH19-1282,203068650087_R01C01,#090,21/05/2019,,6/7/2019,17,SB,Diagnostic,090,1,NDP,Oxford John Radcliffe Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",555,10/22/1979,39.6,spinal ependymoma,1,EPN_SPINE,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1282,"Methylation profile: Ependymoma, spinal
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #090\NH19-1282,-0.187,0.041,0.193,-0.054,-0.159,0.112,-0.204,-0.04,-0.137,-0.47,0.005,0.167,0.241,0.142,0.004,0.138,0.006,-0.097,-0.117,0.242,0.242,0.341,-0.142,0.103,0.201,0.073,-0.312,-0.085,-0.03,unmethylated
NH19-1280,203068650087_R02C01,#090,21/05/2019,,6/7/2019,17,SB,Diagnostic,090,1,NDP,Birmingham Children Hospital,"DGLNT, 1p loss ","(2) unusual histology, location, demographics",F,8/27/2010,8.7,infratentorial pilocytic astrocytoma,0.08,DLGNT,0.21,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1280,"Histology: Glial / glioneuronal tumour
Methylation profile: No matching methylation class  see comment 
MGMT Promoter (Illumina array): Unmethylated
 
","Histology: Glial / glioneuronal tumour
Methylation profile: No matching methylation class  see supplementary comment
MGMT Promoter (Illumina array): Unmethylated
BRAF V600E (Seq): No mutation 
KIAA1549-BRAF fusions: Test unsuccessful repeatedly

",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #090\NH19-1280,0.148,-0.04,0.068,0.08,-0.18,-0.028,-0.073,-0.286,-0.14,-0.384,0.039,0.072,0.084,-0.057,-0.006,-0.101,0.069,-0.004,0.119,-0.129,0.087,0.231,-0.014,-0.096,0.076,0.057,-0.289,-0.049,-0.003,unmethylated
NH19-828,203068650087_R05C01,#090,21/05/2019,,6/7/2019,17,ZJ,Diagnostic,090,3,NDP,Bristol,GBM? other HGG?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,1/13/1993,24.4,rosette-forming glioneuronal tumour,0.84,LGG_RGNT,0.58,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-828,"Histology: Glial / glioneuronal tumour
Methylation profile: Inconclusive  see comment
MGMT Promoter (Illumina array): Unmethylated (0%)
 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #090\NH19-828,0.261,-0.267,-0.095,-0.023,-0.015,-0.191,-0.234,-0.154,-0.017,-0.021,0.12,0.123,-0.047,-0.169,-0.06,-0.176,-0.06,-0.314,0.147,0.064,0.215,0.206,-0.184,-0.105,-0.001,-0.186,-0.185,-0.035,0.114,unmethylated
NH19-1324,203068650087_R07C01,#090,24/05/2019,,6/7/2019,14,SB,Diagnostic,090,2,NDP,"Birmingham, Queen Elizabeth Hospital","midline/brainstem tumour, ATRX lost","(4) IHC, sequencing, or copy number assay ambiguous",F,10/6/1987,31.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.91,AIDH,0.99,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-1324,"Histology and methylation profile: Astrocytoma, IDH-mutant (WHO grade II)

ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B (Illumina array): No deletion          
MGMT Promoter: Methylated 
","Astrocytoma, IDH mutant (WHO grade II)
IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion

  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #090\NH19-1324,0.191,0.03,0.079,0.035,0.067,-0.032,-0.169,-0.118,-0.126,-0.209,0.083,0.011,0.078,0.099,-0.127,-0.014,-0.009,-0.06,0.048,0.03,0.07,0.065,-0.135,0.008,0.034,0.028,-0.354,-0.069,-0.028,methylated
NH19-1308,203068650087_R08C01,#090,24/05/2019,,6/7/2019,14,SB,Diagnostic,090,2,NDP,St George's Hospital London,"conus medullaris glioma,? Pilocytic","(2) unusual histology, location, demographics",A1,5/25/1951,68,high-grade astrocytoma with piloid features,1,ANAPA,1,0.59,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-1308,"Methylation profile: Anaplastic pilocytic astrocytoma  see comment
 
CDKN2A/B (Illumina array): Deletion
MGMT Promoter (Illumina array): Methylated 
","Methylation profile: Anaplastic pilocytic astrocytoma
MGMT Promoter: Methylated
BRAF (V600E and three fusions): No mutation  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #090\NH19-1308,0.194,-0.02,-0.025,-0.065,0.044,-0.061,-0.209,-0.235,0.037,-0.071,0.146,-0.04,0.04,0.123,-0.897,-0.056,0.033,-0.252,0,0.013,-0.004,0.503,-0.067,-0.082,0.086,0.158,-0.189,0.083,0.066,methylated
NH19-1323,203068650139_R02C01,#091,29/05/2019,,6/7/2019,9,SB,Diagnostic,091,3,NDP,"Cardiff, University Hospital",Ependymoma?,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,12/20/1996,22.4,spinal subependymoma [subtype B],0.53,GBM_RTKII,0.14,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1323,"Histology: High grade glioma
Methylation profile: No matching methylation class  see comment 
MGMT Promoter (Illumina array): Methylated 

","Histology: High grade glioma  see supplementary comment
Methylation profile: No matching methylation class 
IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR (Illumina array): No amplification          
CDKN2A/B (Illumina array): No deletion          
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter (Illumina array): Methylated 

",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #091\NH19-1323,0.332,0.111,0.143,0.186,-0.068,-0.037,-0.81,0.029,-0.183,-0.531,-0.064,0.082,0.179,-0.001,-0.1,-0.087,0.085,0.067,0.279,-0.027,0.14,-0.048,-0.069,0.032,-0.05,-0.002,-0.094,0.011,-0.225,methylated
NH19-1163,203068650139_R03C01,#091,10/5/2019,,6/7/2019,28,ZJ,Diagnostic,091,1,NDP,St George's Hospital London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/1/1963,55,"glioblastoma, IDH-wildtype, RTK2 type",0.77,GBM_RTKII,0.87,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1163,"Glioblastoma (WHO grade IV)
EGFR: Amplification

","Glioblastoma, IDH-wildtype (WHO grade IV) 
EGR: Amplification
MGMT Promoter (Illumina array): Unmethylated 
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #091\NH19-1163,0.307,-0.106,0.038,-0.125,-0.152,-0.046,-0.162,1.459,-0.23,-0.266,-0.215,0.072,-0.015,0.012,-0.185,0.009,-0.377,-0.5,0.01,-0.074,0.001,0.087,-0.427,-0.056,-0.011,0.056,-0.114,-0.057,0.231,unmethylated
NH19-1383,203153910053_R02C01,#092,4/6/2019,,6/20/2019,16,SB,Diagnostic,092,3,NDP,Brighton and Sussex Hospital,Pilocytic or pilomyxoid Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/21/2001,17.8,supratentorial midline pilocytic astrocytoma,0.3,PXA,0.43,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1383,"Low grade glioma, BRAF V600E-mutant with features favouring pilocytic/pilomyxoid astrocytoma - see comment
","Histology: Pilocytic/pilomyxoid astrocytoma
Methylation class: (Anaplastic) pleomorphic xanthoastrocytoma, (however, low calibrated score, see comment)
BRAF: V600E mutation
CDKN2A/B: Homozygous deletion
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #092\NH19-1383,0.038,0.012,0.025,-0.028,0,0.015,0.055,-0.036,0.012,-0.003,0.002,-0.014,0.025,0.051,-1.228,0.013,-0.001,-0.025,0.046,0.032,-0.027,-0.02,-0.06,0.002,0.023,-0.008,0.049,0.027,0.025,unmethylated
NH19-1450,203153910053_R05C01,#092,5/6/2019,,6/20/2019,15,SB,Diagnostic,092,4,NDP,"Belfast, Royal Victoria Hospital","RGNT, high proliferation","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,9/1/1993,25.7,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.47,LGG_DNT,0.5,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1450,"Glioneuronal/neurocytic tumour, with features most in keeping with:  
Rosette forming glioneuronal tumour (WHO grade)
","Histology: Glioneuronal tumour with features most in keeping with rosette forming glial neuronal tumour (WHO grade I)
Methylation class: Rosette forming glioneuronal tumour (low calibrated score, see comment)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #092\NH19-1450,-0.017,-0.015,-0.031,0.035,0.003,0.056,0.003,-0.068,-0.008,-0.101,-0.02,0.026,0.064,0.014,0.024,-0.013,0.044,-0.025,0.161,0.087,0.071,0.057,0.085,0.086,0.071,0.01,-0.054,0.051,0.037,methylated
NH19-1445,203153910053_R06C01,#092,6/6/2019,,6/20/2019,14,SB,Diagnostic,092,2,NDP,Oxford John Radcliffe Hospital,Occipital ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,6/29/2016,1.5,posterior fossa ependymoma group A1,1,EPN_PFA,1,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1445,"Histology: Ependymoma
Methylation class ependymoma, posterior fossa group A
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #092\NH19-1445,0.121,0.015,0.049,0.03,0.013,-0.006,-0.043,-0.013,0.015,-0.005,-0.024,0.012,-0.039,0.124,0.012,0.06,-0.003,0.013,0.115,0.069,-0.007,-0.016,-0.072,0.066,-0.007,-0.043,-0.137,-0.053,-0.003,unmethylated
NH19-1444,203153910053_R07C01,#092,6/6/2019,,6/20/2019,14,SB,Diagnostic,092,1,NDP,Oxford John Radcliffe Hospital,4th ventricle pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2,9/3/2004,3.7,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.98,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-1444,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation class: posterior fossa pilocytic astrocytoma
BRAF: Duplication/fusion (see copy number profile).
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #092\NH19-1444,0.102,-0.031,0.02,0.007,0.003,0.04,-0.095,-0.103,-0.064,0.036,0.224,-0.055,-0.004,0.025,-0.072,0.003,-0.039,0.015,0.041,-0.021,0.107,-0.012,-0.038,0.081,0.065,-0.16,0.035,-0.055,0.144,unmethylated
NH19-1283,203153910095_R01C01,#093,7/6/2019,,6/20/2019,13,SB,Diagnostic,093,8,NDP,"Cambridge, Addenbrooke's Hospital","HGG, pineal region","(2) unusual histology, location, demographics",B1,3/1/1963,56.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.32,ANAPA,0.34,0.57,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1283,"High-grade glioma, IDH-wildtype (most likely corresponding to WHO grade IV)-see comment
IDH1 (R132H IHC); IDH1Seq: No mutation (see comment)
ATRX (IHC): Retained
EGFR: No amplification
MGMT Promoter: Unmethylated (0%)

",#REF!,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #093\NH19-1283,-0.035,-0.009,0.001,0.026,0.352,0.004,0.026,0.203,0.268,0.262,0.223,-0.003,0.033,0.046,0.165,0.219,-0.025,-0.059,-0.017,0.011,0.087,0.136,-0.067,-0.59,-0.204,0.023,-0.019,-0.026,0.03,unmethylated
NH19-1281,203153910095_R02C01,#093,7/6/2019,,6/20/2019,13,SB,Diagnostic,093,4,NDP,"Birmingham, Queen Elizabeth Hospital",HGG/HGNET,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,10/11/2007,11.5,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.89,GBM_MES,0.29,0.57,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1281,"Glioblastoma, (WHO grade IV) (see comment)
IDH1 (R132H IHC); IDH2Seq: No mutation (see comment)
ATRX (IHC): Loss of expression (indicates mutation)
Histone H3F3A: No mutation
BRAF (V600E): No mutation


","Histology: Glioblastoma (WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype (see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)
Histone H3F3A: No mutation
MYCN: Amplification (see copy number plot)
MGMT Promoter: Unmethylated


",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #093\NH19-1281,0.462,1.308,0.053,0.214,-0.048,0.017,0.035,0.295,0.375,0.424,0.314,-0.042,0.038,0.039,0.073,0.15,-0.044,-0.022,0.03,-0.008,0.055,0.044,-0.053,0.008,0.068,0.003,0.276,-0.047,0.037,unmethylated
NH19-1530,203153910095_R04C01,#093,10/6/2019,,6/20/2019,10,ZJ,Diagnostic,093,1,NDP,"Birmingham, Queen Elizabeth Hospital",Right parietooccipital ?LGG/DNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",E,4/6/1961,58.1,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1530,"Histology: Low grade glioma, compatible with pilocytic astrocytoma (WHO grade I)
Methylation class: Pilocytic astrocytoma, subclass hemispheric pilocytic astrocytoma and ganglioglioma
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #093\NH19-1530,0.002,0.005,-0.031,0.014,-0.074,0.06,0.11,0,0.027,0.024,0.027,0.022,0.085,0.087,0.031,0,0.051,-0.013,0.063,0.024,0.007,-0.006,0.001,0.002,0.03,0.01,-0.035,-0.015,0.006,unmethylated
NH19-1512,203153910095_R05C01,#093,10/6/2019,,6/20/2019,10,ZJ,Diagnostic,093,2,NDP,Oxford John Radcliffe Hospital,Right parietooccipital ?papillary ependymoma; ?astroblastoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3C,5/18/2000,19,pleomorphic xanthoastrocytoma(-like),0.88,PXA,0.76,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1512,"Histology: Pleomorphic xanthoastrocytoma (WHO grade II)
Methylation class: (Anaplastic) pleomorphic xanthoastrocytoma (please see comment regarding reliability of low calibrated scores)
",#N/A,(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #093\NH19-1512,0.077,0.013,0.014,-0.035,0.013,0.01,0.05,0.264,0.336,0.41,0.306,0.014,0.026,0.086,-0.011,-0.318,0.005,-0.001,0.034,0.005,-0.012,0.09,-0.052,-0.311,-0.564,-0.012,0.02,-0.29,-0.328,unmethylated
NH19-1517,203153910095_R07C01,#093,12/6/2019,,6/20/2019,8,ZJ,Diagnostic,093,1,NDP,"Leeds, St James's University Hospital",Right temporal diffuse astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/17/1971,47.4,ganglioglioma,0.76,LGG_PA_GGST,0.46,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1517,"Histology: Low grade glial/glioneuronal tumour (corresponding to WHO grade I)
Methylation class: Low grade glioma, ganglioglioma (see comment)
BRAF: V600E mutation (result from referring hospital)
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #093\NH19-1517,-0.064,0.049,0.001,0.029,-0.02,0.111,0.071,-0.008,0.036,0.03,0.008,-0.023,0.04,0.088,-0.111,0.029,0.027,0.017,0.024,0.026,-0.002,0.026,-0.013,0.055,0.054,0.052,0.008,-0.06,-0.008,unmethylated
NH19-1449,203175830112_R04C01,#094,18/06/2019,,6/28/2019,10,SB,Diagnostic,094,3,NDP,NHNN,"Ependymoma, spinal, unusual histology","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1 a,2/29/1980,39.3,myxopapillary ependymoma,1,EPN_MPE,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1449,"Ependymoma (see comment)
","Methylation profile: Myxopapillary ependymoma
MGMT Promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #094\NH19-1449,0.206,0.08,0.055,0.174,0.118,0.277,-0.032,0.349,0.461,0.426,0.434,-0.03,-0.04,0.124,-0.127,0.034,0.03,-0.022,0.114,0.113,0.018,0.017,-0.044,-0.019,0.015,-0.1,-0.018,0.015,0.086,unmethylated
NH19-1638,203068650122_R01C01,#095,24/06/2019,,7/12/2019,18,SB,Diagnostic,095,1,NDP,St George's Hospital London,Atypical /Anaplasticmeningioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,1/17/1960,59.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.96,PXA,0.07,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1638,#N/A,"Histology: Poorly differentiated tumour, possibly of meningothelial origin
Methylation profile: No matching methylation class
",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #095\NH19-1638,-0.121,-0.142,-0.006,-0.093,-0.207,0.049,-0.046,0.136,0.088,0.269,0.05,0.096,0.404,0.222,-0.826,0.256,-0.005,-0.218,0.147,-0.209,0.066,0.203,-0.095,-0.242,0.078,-0.003,-0.766,-0.097,0.044,methylated
NH19-1591,203068650122_R02C01,#095,24/06/2019,,7/12/2019,18,SB,Diagnostic,095,1,NDP,St George's Hospital London,"Malignant tumour, unusual features, HGG?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,9/30/1942,76.7,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.51,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1591,"Histology and methylation profile: 
Suggestive of glioblastoma, IDH-wildtype (WHO grade IV) 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #095\NH19-1591,0.049,-0.086,-0.01,-0.054,-0.082,-0.006,0.032,-0.061,0.064,0.068,0.128,0.05,-0.047,0.042,-0.022,-0.044,-0.109,-0.225,-0.151,-0.274,-0.161,-0.083,-0.123,-0.056,0.028,0.039,0.139,0.017,-0.002,unmethylated
NH19-1703,203068650122_R04C01,#095,26/06/2019,,7/12/2019,16,SB,Diagnostic,095,1,NDP,Winipeg (CA),"Primitive tumour, (Ependymoma?)","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,1/16/1966,53.5,high-grade astrocytoma with piloid features,0.3,ANAPA,0.2,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-1703,#N/A,"Histology: High-grade glioma
Methylation class: No match 
",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #095\NH19-1703,0.004,-0.013,0.016,-0.013,-0.009,-0.033,-0.169,-0.125,0.121,0.073,0.075,0.141,0.116,0.007,-0.88,0.005,0.032,-0.151,0.101,0.131,0.158,0.348,0.116,0.095,0.061,0.199,-0.236,0.225,-0.182,unmethylated
NH19-1696,203068650122_R05C01,#095,26/06/2019,,7/12/2019,16,SB,Diagnostic,095,3,NDP,"Charing Cross Hospital, London",Anaplastic pilocytic?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/23/1973,46.4,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.42,CONTR_CEBM,0.09,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1696,#N/A,"Histology: High-grade glioma and cerebellar parenchyma
Methylation array: No matching methylation class (see comment).
Copy number profile: EGFR amplification, CDK4 amplification
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #095\NH19-1696,-0.028,-0.325,0.152,0.194,0.196,-0.034,-0.448,2.196,-0.122,-0.276,-0.091,0.128,0.045,0.025,-0.105,0.399,0.016,-0.224,0.155,-0.026,0.991,-0.199,-0.287,-0.089,0.15,0.157,-0.344,-0.002,0.102,unmethylated
NH19-1741,203175830083_R05C01,#096,2/7/2019,,7/19/2019,17,ZJ,Diagnostic,096,1,NDP,"Cardiff, University Hospital",?PA; ?DMG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/17/2015,3.8,supratentorial midline pilocytic astrocytoma,1,LGG_PAMID,0.99,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1741,"Methylation profile: In favour of pilocytic astrocytoma (WHO grade I)
 
H3F3A (K27M IHC): No mutation
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #096\NH19-1741,0.068,0.004,-0.013,-0.019,0.015,0.017,0.037,-0.095,-0.012,-0.046,-0.016,0.193,0.164,0.233,0.135,0.007,0.044,0.018,0.199,0.279,0.249,0.212,0.095,0.13,-0.026,-0.072,-0.014,0.035,0.003,unmethylated
NH19-1827,203175830083_R08C01,#096,10/7/2019,,7/19/2019,9,ZJ,Diagnostic,096,1,NDP,St George's Hospital London,"Diffuse astrocytoma, IDH-mutant","(4) IHC, sequencing, or copy number assay ambiguous",A1,8/26/1964,54,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.94,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1827,"Diffuse astrocytoma, IDH-mutant (WHO grade II)
 
MGMT Promoter (Illumina array): Methylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #096\NH19-1827,0.265,0.093,0.129,0.06,-0.08,-0.18,-0.205,0.159,0.013,-0.079,0.035,-0.036,0.021,0.383,0.074,0.058,-0.071,-0.199,0.092,0.187,0.116,0.052,0.062,0.259,0.045,0.077,-0.051,0.091,-0.005,methylated
NH19-1732,203179340039_R01C01,#097,10/7/2019,,7/27/2019,17,ZJ,Diagnostic,097,1,NDP,"Charing Cross Hospital, London",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",D2,3/13/1980,39.3,"glioblastoma, IDH-wildtype, RTK2 type",0.26,GBM_MES,0.72,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1732,"Infiltration of glioma  see comment
 
Histone H3F3A (K27M IHC): No mutation      
","Histology: Infiltration of glioma
Methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV) - see comment
 
EGFR (Illumina array): Amplification
Histone H3F3A (K27M IHC): No mutation     
MGMT Promoter (Illumina array): Unmethylated

  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #097\NH19-1732,0.056,-0.041,0.068,0.016,-0.053,0.454,-0.027,1.032,-0.116,-0.278,-0.048,0.015,0.029,0.081,0.044,-0.023,0.064,0.021,0.024,0.072,0.054,-0.063,0.006,-0.268,0.005,-0.037,-0.02,0.072,0.15,unmethylated
NH19-1843,203179340039_R02C01,#097,10/7/2019,,7/27/2019,17,ZJ,Diagnostic,097,1,NDP,St George's Hospital London,Meningioma with vascular proliferation,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A4,10/25/1952,66.7,"glioblastoma, IDH-wildtype, mesenchymal type",0.34,GBM_RTKII,0.62,0.56,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1843,#N/A,"Histology: Meningioma (WHO grade I)
Methylation class: Meningioma, benign, subtype 3
",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #097\NH19-1843,0.132,0.046,0.043,0.007,0.215,0.101,-0.184,0.179,0.199,0.15,0.219,0,-0.015,0.148,-1.569,0.206,-0.288,-0.334,-0.239,-0.029,-0.018,0.078,-0.208,-0.451,0.054,0.028,0.015,-0.028,0.007,methylated
NH19-1881,203179340039_R03C01,#097,12/7/2019,,7/27/2019,15,ZJ,Diagnostic,097,3,NDP,Newcastle,High grade 4th ventricle choroid plexus tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2B,3/26/1948,71.3,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.1,MNG,0.12,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1881,"Histology: Referred diagnosis: Differential diagnosis between primary high grade choroid plexus tumour and metastatic carcinoma
Methylation profile: Inconclusive  see comment
 
MGMT Promoter (Illumina array): Unmethylated  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #097\NH19-1881,0.096,-0.266,-0.246,-0.045,-0.018,-0.006,-0.008,0.102,0.154,0.129,0.196,0.174,0.249,0.199,-0.075,-0.009,-0.296,-0.276,-0.089,-0.074,-0.015,0.066,-0.411,-0.364,0.027,0.031,-0.108,-0.018,0.03,unmethylated
NH19-1879,203179340039_R04C01,#097,12/7/2019,,7/27/2019,15,ZJ,Diagnostic,097,2,NDP,"Birmingham, Queen Elizabeth Hospital",Spinal nodules and pontine tumour. ?HGG,"(2) unusual histology, location, demographics",B,8/4/1994,24.9,"spinal ependymoma, MYCN-amplified",1,EPN_PFA,0.77,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1879,"Histology: High grade glioma
Methylation profile: Inconclusive  see comment

Histone H3F3A (K27M IHC): No mutation
H3K27me3 IHC: Retained expression       
MGMT Promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #097\NH19-1879,0.074,0.985,0.056,-0.064,-0.022,-0.059,0.048,-0.078,-0.171,-0.315,-0.04,-0.027,0.102,0.092,-0.029,-0.083,0.086,0.062,0.083,0.037,-0.017,0.096,0.039,0.026,-0.02,-0.01,-0.134,0.051,0.083,unmethylated
NH19-1873,203175830026_R03C01,#098,17/07/2019,,8/1/2019,15,ZJ,Diagnostic,098,5,NDP,Royal London Hospital,?RGNT; ?PA: with florid microvascular proliferation,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,9/15/1994,24.8,rosette-forming glioneuronal tumour,1,LGG_RGNT,0.97,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-1873,"Low grade glial / glioneuronal tumour: See comment.
","Histology and methylation profile: Rosette forming glioneuronal tumour (WHO grade I) 
MGMT Promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #098\NH19-1873,0.038,-0.018,-0.001,-0.019,-0.034,-0.027,0.041,-0.045,-0.056,-0.095,-0.028,0.011,-0.035,0.011,-0.023,0.022,-0.002,-0.015,0.053,0.085,0.03,0.099,0.017,-0.03,0.014,-0.018,0.026,0.028,0.013,unmethylated
NH19-1906,203175830026_R04C01,#098,17/07/2019,,8/1/2019,15,ZJ,Diagnostic,098,1,NDP,Oxford John Radcliffe Hospital,Recurrent / residual PXA WHO grade II,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",E,8/15/1996,22.9,ganglioglioma,1,LGG_GG,0.99,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1906,"Referred diagnosis: Recurrent / residual pleomorphic xanthoastrocytoma, BRAF V600E-mutant (WHO grade II) 

Methylation profile: Ganglioglioma  see comment

MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #098\NH19-1906,0.015,-0.041,0.009,-0.043,-0.039,0.029,0.068,0.123,0.123,0.083,0.115,-0.01,0.008,-0.006,-0.026,0.025,-0.018,-0.024,0.028,-0.011,0.013,-0.008,-0.014,0.008,0,-0.013,0.113,-0.018,0.022,unmethylated
NH19-1937,203175830026_R07C01,#098,19/07/2019,,8/1/2019,13,ZJ,Diagnostic,098,1,NDP,NHNN,L2-L4 spinal ependymoma; conventional vs myxopapillary,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,7/21/1985,34,myxopapillary ependymoma,1,EPN_MPE,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1937,"Ependymal tumour - see comment
","Histology and methylation profile: Myxopapillary ependymoma (WHO grade I) 
MGMT Promoter (Illumina array): Methylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #098\NH19-1937,0.018,-0.067,0.032,0.001,-0.06,-0.006,0.059,-0.035,-0.067,-0.042,-0.02,-0.003,0.03,-0.042,0.206,0.23,-0.238,-0.163,0.004,0.031,0.008,0.021,0.031,0.176,0.222,0.174,-0.028,-0.157,-0.262,methylated
NH19-1961,203145740008_R03C01,#099,22/07/2019,,8/9/2019,18,ZJ,Diagnostic,099,3,NDP,"Cambridge, Addenbrooke's Hospital","Brainstem glioma, IDH-mutant","(4) IHC, sequencing, or copy number assay ambiguous",A1,3/15/1995,24.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.94,AIDH_HG,0.86,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1961,"Histology: Anaplastic astrocytoma, IDH-mutant (WHO grade III)
Methylation class: Glioma, IDH mutant, subclass high grade astrocytoma
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
CDKN2A/B: No deletion (see copy number plot)
MGMT Promoter: Unmethylated (0%)

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #099\NH19-1961,0.12,0.013,0.044,0.024,0.118,-0.06,-0.023,0.087,0.035,-0.071,0.007,-0.024,-0.037,0.063,-0.08,0.023,0.026,0.004,0.032,0.228,0.05,-0.039,-0.063,0.086,0.007,0.175,-0.168,0.012,0.039,unmethylated
NH19-1965,203145740008_R06C01,#099,24/07/2019,,8/9/2019,16,ZJ,Diagnostic,099,5,NDP,London Bridge Hospital,PA vs DMG; looks like PA but has H3 K27me3 loss,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,7/31/1981,38,infratentorial pilocytic astrocytoma,0.94,LGG_PAPF,0.64,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1965,"Provisional diagnosis:
Cerebellar glioma  see comment

IDH1 (R132H IHC): No mutation
H3 (K27M IHC): No mutation, further tests pending 
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Histology: Cerebellar glioma with features of pilocytic astrocytoma
Methylation class: Pilocytic astrocytoma, subclass posterior fossa pilocytic astrocytoma
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #099\NH19-1965,-0.037,0.035,-0.002,0.012,-0.077,0.037,0.113,0.025,0.027,0.012,0.029,-0.045,-0.016,0.013,-0.095,-0.051,0.032,0.023,-0.025,0.048,0.031,0.108,-0.103,-0.079,-0.095,-0.109,-0.108,0.057,0.115,unmethylated
NH19-2003,203145740119_R01C01,#100,25/07/2019,,8/9/2019,15,ZJ,Diagnostic,100,2,NDP,"Leeds, St James's University Hospital",Temporal lobe glioma; GBM vs PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B9,7/26/1981,38,high-grade astrocytoma with piloid features,0.44,PXA,0.58,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2003,"Histology: Pleomorphic high-grade glioma
Methylation class: No match (see comment) 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #100\NH19-2003,0.058,-0.076,0.037,0.187,0.283,0.293,0.051,0.213,0.24,0.238,0.235,0.091,0.105,0.122,0,0.26,0.028,0.004,0.005,0.251,0.298,0.253,-0.065,-0.057,-0.044,0.242,-0.105,0.284,0.277,unmethylated
NH19-1696,203145740119_R04C01,#100,27/07/2019,,8/9/2019,13,ZJ,Diagnostic,100,3,NDP,"Charing Cross Hospital, London",Anaplastic pilocytic?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/23/1973,46.4,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,0.56,GBM_RTKII,0.08,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1696,#N/A,"Histology: High-grade glioma and cerebellar parenchyma
Methylation array: No matching methylation class (see comment).
Copy number profile: EGFR amplification, CDK4 amplification
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #100\NH19-1696,0.158,-0.252,0.041,0.176,0.201,-0.033,-0.302,1.204,-0.087,-0.229,-0.061,0.04,0.067,0.096,-0.07,0.222,0.072,-0.239,0.175,0.062,0.861,-0.142,-0.184,-0.039,0.182,0.164,-0.193,0.053,0.079,unmethylated
NH19-1638,203145740119_R06C01,#100,27/07/2019,,8/9/2019,13,ZJ,Diagnostic,100,1,NDP,St George's Hospital London,Atypical /Anaplasticmeningioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,1/17/1960,59.4,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.13,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1638,#N/A,"Histology: Poorly differentiated tumour, possibly of meningothelial origin
Methylation profile: No matching methylation class
",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #100\NH19-1638,-0.001,-0.041,-0.013,0.024,-0.011,0.124,0.068,0.089,0.179,0.121,0.138,0.026,0.349,0.4,-0.76,0.113,0.05,-0.056,0.188,0.096,0.128,0.204,0,-0.003,0.041,0.017,-0.133,-0.018,0.053,methylated
NH19-1703,203145740119_R07C01,#100,27/07/2019,,8/9/2019,13,ZJ,Diagnostic,100,1,NDP,Winipeg (CA),"Primitive tumour, (Ependymoma?)","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,1/16/1966,53.5,high-grade astrocytoma with piloid features,0.65,ANAPA,0.3,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-1703,#N/A,"Histology: High-grade glioma
Methylation class: No match 
",(4) misleading profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #100\NH19-1703,0.166,0.049,0.014,-0.025,-0.04,-0.074,-0.059,-0.019,0.137,-0.077,0.03,0.049,-0.06,0.054,-0.98,0.019,-0.038,-0.135,0.17,0.315,0.178,0.25,0.017,0.127,0.103,0.033,-0.43,0.198,-0.256,unmethylated
NH19-2099,203068650103_R02C01,#101,5/8/2019,,8/15/2019,10,ZJ,Diagnostic,101,1,NDP,Newcastle,Recurrent optic pilocytic glioma with anaplastic features,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1B,4/26/1979,22.8,diffuse leptomeningeal glioneuronal tumour,0.76,DLGNT,0.95,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-2099,"Histology: Glioneuronal tumour
Methylation class: Diffuse leptomeningeal glioneuronal tumour
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #101\NH19-2099,0.332,0.134,0.004,-0.018,0.074,-0.018,0.023,0.327,0.468,0.442,0.518,-0.1,-0.061,-0.056,0.142,0.142,-0.082,-0.096,0.119,0.031,0.032,0.053,-0.003,-0.043,0.038,0.012,-0.131,0.02,0.103,unmethylated
NH19-2043,203068650103_R04C01,#101,1/8/2019,,8/15/2019,14,ZJ,Diagnostic,101,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG; Ana PXA vs GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A5,7/5/1970,49,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.9,0.97,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2043,"Histology: Glioblastoma, WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype, subclass mesenchymal
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #101\NH19-2043,0.152,-0.104,-0.02,-0.067,-0.035,-0.038,0.025,0.13,0.17,0.2,0.141,-0.007,-0.022,0.13,0.037,0.012,-0.16,-0.16,0.001,0.023,0.057,-0.017,-0.101,-0.162,-0.183,-0.216,-0.018,-0.104,-0.136,unmethylated
NH19-2019,203068650103_R05C01,#101,1/8/2019,,8/15/2019,14,ZJ,Diagnostic,101,1,NDP,Oxford John Radcliffe Hospital,Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",3B,3/3/1964,54.7,spinal subependymoma [subtype A],0.73,SUBEPN_SPINE,0.23,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2019,"Histology: Subependymoma (WHO grade I)
Methylation class: Sub-ependymoma, spinal with low calibrated score (see comment)
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #101\NH19-2019,-0.02,-0.288,-0.133,0.075,-0.005,-0.013,0.064,0.011,0.013,-0.019,0.005,-0.002,0.015,-0.008,-0.011,-0.013,-0.032,0.015,-0.028,-0.048,-0.041,0.023,-0.028,-0.011,-0.017,-0.003,-0.065,-0.008,0.01,unmethylated
NH19-2077,203068650103_R06C01,#101,3/8/2019,,8/15/2019,12,ZJ,Diagnostic,101,1,NDP,Oxford John Radcliffe Hospital,GBM with 4year survival (and still alive),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,11/2/1959,55.6,"glioblastoma, IDH-wildtype, RTK1 type",0.99,GBM_RTKI,0.98,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2077,"Histology: Glioblastoma (WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype, subclass RTK I
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #101\NH19-2077,0.256,-0.165,0.055,-0.06,0.079,-0.087,0.204,0.211,0.278,0.207,0.227,-0.005,0.102,0.357,0.277,0.165,-0.116,-0.559,-0.002,0.16,0.15,0.213,-0.282,0.121,0.122,0.077,-0.271,-0.023,-0.001,methylated
NH19-2088,203068650103_R08C01,#101,3/8/2019,,8/15/2019,12,ZJ,Diagnostic,101,6,NDP,"Belfast, Royal Victoria Hospital",Intraventricular tumour; ?Subependymma; ?Neuronal hamartomatous,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,2/27/1961,58.4,"control tissue, hemispheric cortex",0.16,CONTR_HEMI,0.39,0.56,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-2088,"Histology: Neuropil-rich hamartomatous lesion or low grade glioneuronal tumour 
Methylation array: No matching methylation class 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #101\NH19-2088,0.082,-0.004,-0.007,-0.008,0.005,-0.059,-0.07,-0.071,0.028,-0.044,0.008,0.017,-0.029,0.044,-0.002,0.001,0.034,-0.003,0.026,0.051,0.024,-0.014,-0.012,0.045,0.041,0.038,-0.074,0.016,0.014,unmethylated
NH19-2014,203057570130_R01C01,#102,5/8/2019,,8/23/2019,18,ZJ,Diagnostic,102,7,NDP,NHNN,Spinal pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,6/9/1996,23.1,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.97,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2014,"Pilocytic astrocytoma (WHO grade I)
",#REF!,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #102\NH19-2014,0.022,0.008,0.007,0.029,-0.005,0.008,-0.01,1.021,0.389,0.476,0.379,0.006,0.023,0.046,-0.061,-0.013,-0.391,-0.375,-0.069,0.015,1.042,1.978,-0.121,0.026,0.022,-0.006,0.171,-0.052,0.055,unmethylated
NH19-2035,203057570130_R02C01,#102,31/07/2019,,8/23/2019,23,ZJ,Diagnostic,102,8,NDP,London Clinic,Supratentorial anaplastic ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",6,8/22/1982,36.9,pleomorphic xanthoastrocytoma(-like),0.99,PXA,0.96,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2035,"Anaplastic ependymoma (WHO grade III)  see comment
","Anaplastic pleomorphic xanthoastrocytoma
BRAF (IHC and sequencing): Mutation (V600E), 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #102\NH19-2035,-0.042,-0.018,0.046,0.048,-0.063,-0.027,-0.542,-0.095,0.173,-0.048,-0.06,0.016,0.069,0.121,-2.444,0.122,0.117,-0.575,0.1,0.126,0.121,0.139,0.038,0.058,0.036,0.281,-0.72,-0.028,0.001,unmethylated
NH19-2097,203057570130_R03C01,#102,6/8/2019,,8/23/2019,17,ZJ,Diagnostic,102,1,NDP,Southampton General Hospital,Chordoid glioma of 3rd ventricle,"(2) unusual histology, location, demographics",1A,7/30/1974,45,chordoid glioma,0.43,CHGL,0.25,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-2097,"Referred diagnosis: Chordoid glioma of the third ventricle
Methylation class: No match, low calibrated score, but see comment 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #102\NH19-2097,0.153,-0.102,-0.035,0.042,0.056,-0.059,-0.067,0.366,-0.061,0.199,0.085,0.05,0.036,-0.018,-0.027,0.1,0.142,-0.014,0.177,0.1,0.345,0.264,-0.003,0.081,0.07,0.058,-0.082,-0.037,0.119,unmethylated
NH19-2200,203057570130_R05C01,#102,15/08/2019,,8/23/2019,8,SB,Diagnostic,102,1,NDP,Auckland (NZ),Glioblastoma cerebellum,"(2) unusual histology, location, demographics",19/AH15845.2A,4/17/1954,65.3,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,0.85,ANAPA,0.83,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2200,"Histology: High-grade glioma with features of glioblastoma
Methylation class: Anaplastic pilocytic astrocytoma (see comment)
","See previous diagnosis. No change in diagnosis
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #102\NH19-2200,-0.017,-0.001,0.007,0.066,0.113,-0.17,0.044,0.457,0.116,-0.136,0.082,0.054,0.036,0.591,-0.295,0.124,-0.147,-0.288,0.252,-0.036,0.221,0.263,-0.284,-0.405,-0.457,0.093,-0.173,-0.153,-0.038,methylated
NH19-2024,203057570130_R08C01,#102,9/8/2019,,8/23/2019,14,ZJ,Diagnostic,102,3,NDP,Plymouth,"NF1, high grade glioma GBM vs anaplastic PA","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,4/22/1993,26.2,high-grade astrocytoma with piloid features,0.33,PXA,0.32,0.56,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2024,"Provisional diagnosis: High grade glioma  see comment
 
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained     
BRAF (V600E): No mutation          
KIAA1549-BRAF fusions: No fusions between 16_9, 16_11, 15_9 exons
","Histology: High-grade glioma
Methylation class: Pilocytic astrocytoma, subclass hemispheric pilocytic astrocytoma
CDKN2A/B: homozygous deletion 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #102\NH19-2024,0.198,0.003,0.031,0.162,0.282,0.306,-0.033,0.235,0.271,0.216,0.266,0.247,0.293,0.288,-0.747,0.184,0.042,0.008,0.033,0.33,0.304,0.409,0.011,-0.024,0.037,0.292,-0.083,0.218,0.329,unmethylated
NH19-2142,203060700028_R02C01,#103,14/08/2019,,8/23/2019,9,SB,Diagnostic,103,5,NDP,Brighton and Sussex Hospital,"Ependymoma, myxopapillary","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,4/20/2000,19.3,myxopapillary ependymoma,0.86,EPN_MPE,0.97,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2142,"Ependymoma  see comment
","Histology: Ependymoma 
Methylation class: Myxopapillary ependymoma
WHO grade: I
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #103\NH19-2142,-0.011,0.003,0.053,-0.057,0.066,0.018,-0.048,0.147,0.253,0.162,0.195,0.272,0.203,0.229,0.206,0.314,-0.001,0.005,0.061,0.074,0.052,-0.007,-0.347,0.039,-0.026,0.064,0.016,0.001,0.12,unmethylated
NH19-2146,203060700028_R05C01,#103,14/08/2019,,8/23/2019,9,SB,Diagnostic,103,1,NDP,Nottingham University Hospital,,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,6/19/2006,13.1,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.96,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2146,"Histology: Pilocytic astrocytoma
Methylation class: Pilocytic astrocytoma, subclass hemispheric pilocytic astrocytoma and ganglioglioma

",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #103\NH19-2146,-0.081,-0.113,-0.077,0.028,0.005,0.027,0.155,0.18,0.299,0.297,0.284,-0.008,-0.006,0.13,-0.037,0.012,0.014,0.018,0.072,0.158,0.218,0.236,-0.1,-0.032,-0.101,-0.087,0.012,0.015,0.071,methylated
NH19-2157,203060700028_R06C01,#103,14/08/2019,,8/23/2019,9,SB,Diagnostic,103,2,NDP,Oxford John Radcliffe Hospital,"please see NH19-1906, ganglioglioma","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,8/15/1996,22.9,pleomorphic xanthoastrocytoma(-like),0.99,PXA,0.8,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2157,"Histology: Features in keeping with pleomorphic xanthoastrocytoma (see comment)
Methylation class: pleomorphic xanthoastrocytoma (calibrated score 0.75, see comment)
BRAF: Mutation (V600E)
",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #103\NH19-2157,-0.01,-0.246,-0.162,-0.192,-0.247,-0.058,-0.214,0.043,0.274,0.103,0.041,0.133,0.108,0.248,0.115,-0.132,0.189,-0.029,0.036,0.245,0.299,0.337,0.05,-0.039,-0.193,-0.086,-0.06,-0.061,0.037,unmethylated
NH19-2171,203060700028_R07C01,#103,14/08/2019,,8/23/2019,9,SB,Diagnostic,103,2,NDP,"Charing Cross Hospital, London","ependymoma, cervical","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,6/9/1992,27.2,spinal ependymoma,1,EPN_SPINE,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2171,"Histology: Ependymoma
Methylation class: Ependymoma, spinal
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #103\NH19-2171,-0.047,0.113,0.146,0.144,0.099,-0.052,-0.276,0.072,0.076,-0.017,0.111,0.124,0.097,0.191,0.033,0.135,-0.11,-0.114,0.154,0.28,0.297,0.324,0.054,-0.118,-0.18,-0.259,-0.12,-0.624,-0.491,unmethylated
NH19-2050,203060700028_R08C01,#103,14/08/2019,,8/23/2019,9,SB,Diagnostic,103,4,NDP,NHNN,"astrocytoma, ATRX loss, IDH mutation not detected","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP 1A,7/8/1992,27.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.57,GBM_RTKII,0.65,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2050,"Glioblastoma (WHO grade IV)  see comment

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Glioblastoma, IDH-wildtype (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)
EGFR: Amplification     
MGMT Promoter: Unmethylated (0%)


  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #103\NH19-2050,-0.008,0.004,0.038,-0.02,-0.007,0.056,0.08,0.283,0.301,0.391,0.292,-0.019,0.013,0.041,-1.178,-0.013,0.001,0.049,0.028,-0.017,-0.014,-0.119,-0.023,-0.074,-0.027,0.16,-0.054,0.041,0.004,methylated
NH19-2200,203218690185_R02C01,#104,15/08/2019,,8/30/2019,15,SB,Diagnostic,104,1,NDP,Auckland (NZ),Glioblastoma cerebellum,"(2) unusual histology, location, demographics",19/AH15845.2A,4/17/1954,65.3,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,0.24,ANAPA,0.31,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2200,"Histology: High-grade glioma with features of glioblastoma
Methylation class: Anaplastic pilocytic astrocytoma (see comment)
","See previous diagnosis. No change in diagnosis
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #104\NH19-2200,0.198,-0.116,0.126,0.194,0.133,-0.114,-0.005,0.468,0.139,-0.103,0.065,0.015,-0.255,0.445,-0.308,0.185,-0.381,-0.061,0.403,0.06,0.193,0.248,-0.185,-0.549,-0.547,0.078,-0.235,-0.055,0.094,methylated
NH19-2193,203219640005_R01C01,#105,21/08/2019,,9/13/2019,23,SB,Diagnostic,105,7,NDP,Romford,PA vs DGLNT vs other spinal glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/5/1970,49.1,infratentorial pilocytic astrocytoma,0.98,LGG_PAPF,0.96,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2193,"Features favouring a low grade intrinsic tumour - see comment

IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: In favour of low grade glioma
Methylation profile: Inconclusive  see comment

MGMT Promoter (Illumina array): Methylated  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #105\NH19-2193,-0.013,-0.017,0.046,-0.129,0.066,0.128,0.36,-0.001,0.01,0.028,0.276,0.052,0.118,0.154,0.027,-0.052,0.141,0.001,0.043,0.034,-0.118,0.041,-0.009,0.059,0.331,0.04,-0.006,-0.026,0.073,methylated
NH19-2093,203219640005_R05C01,#105,27/08/2019,,9/13/2019,17,SB,Diagnostic,105,17,NDP,Romford,"Glioma, molPath inconclusive, clinical team needs Dg for Chemo decisionmaking","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,4/23/1950,69.3,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.15,GBM_MID,0.39,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2093,"Diffuse Glioma - see comment.

IDH1 (R132H IHC): No mutation, Further tests pending 
ATRX (IHC): Retained
BRAF V600E (IHC): No mutation
Further molecular tests: Pending
","Histology: Diffuse glioma, IDH-wildtype 
Methylation profile: Suggestive of glioblastoma, IDH-wildtype (WHO grade IV)
 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: No amplification          
TERT promoter: No mutation     
MGMT Promoter: Methylated (>5-10%)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #105\NH19-2093,0.094,-0.097,-0.001,-0.047,-0.006,0.034,0.048,-0.05,-0.062,-0.057,-0.035,-0.02,0.025,-0.033,-0.026,-0.008,0.06,0.116,0.026,-0.038,-0.004,0.033,0.067,0.035,0.023,-0.047,-0.039,0.038,0.077,methylated
NH19-2305,203219640005_R06C01,#105,27/08/2019,,9/13/2019,17,SB,Diagnostic,105,1,NDP,Nottingham University Hospital,"LGG, small smaple","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/6/2016,3.3,"diffuse glioma, MYB(L1)-altered, subtype A [angiocentric glioma-type]",1,LGG_MYB,1,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2305,"Histology: Low grade (angiocentric) glioma (WHO grade I)
Methylation profile: Low grade glioma, MYB/MYBL1 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #105\NH19-2305,0.151,-0.066,0.097,0.094,0.017,-0.02,-0.116,-0.006,-0.021,-0.098,0.011,0.039,-0.035,-0.006,-0.075,-0.057,-0.042,0.101,0.076,0.012,0.092,0.023,-0.026,0.138,0.056,-0.005,-0.035,-0.029,0.019,unmethylated
NH19-2297,203219640005_R07C01,#105,27/08/2019,,9/13/2019,17,SB,Diagnostic,105,4,NDP,"Leeds, St James's University Hospital",Giant cell GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,7/22/1965,48.8,"glioblastoma, IDH-wildtype, mesenchymal type",0.74,CONTR_INFLAM,0.26,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2297,"Histology: Giant cell glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Inconclusive  see comment
 
IDH1 (R132H IHC); IDH1/2Seq: No mutation (as per referring report)
ATRX (IHC): Retained
BRAF (V600E IHC): No mutation      
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #105\NH19-2297,0.353,-0.129,0.012,0.004,-0.03,-0.082,0.057,0.192,0.124,0.266,0.165,-0.021,-0.107,-0.048,-0.026,0.085,-0.005,0.035,0.021,0.039,0.011,0.057,0.075,0.049,-0.077,-0.124,-0.034,-0.016,0.103,methylated
NH19-1901,203219640034_R01C01,#106,27/08/2019,,9/13/2019,17,SB,Diagnostic,106,1,NDP,Southampton General Hospital,LGG temporal. ,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,#N/A,ganglioglioma,1,LGG_GG,0.95,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1901,"Low grade glioneuronal tumour (WHO Grade I): see comment
","Histology: Low grade glioneuronal tumour (WHO grade I)
Methylation profile: Ganglioglioma  see comment

MGMT Promoter (Illumina array): Unmethylated

",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #106\NH19-1901,0.088,-0.007,0.032,-0.029,0.02,-0.075,0.062,-0.035,-0.056,-0.137,-0.022,-0.001,0.024,0.056,-0.029,0.007,0.009,0.066,0.066,0.024,0.001,-0.046,0.03,0.059,-0.023,0.011,0.094,0.006,0.019,unmethylated
NH19-2329,203219640034_R05C01,#106,2/9/2019,,9/13/2019,11,SB,Diagnostic,106,1,NDP,Romford,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/7/1962,56.7,spinal subependymoma [subtype A],0.25,LGG_MYB,0.72,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-2329,"Low grade glioma (best corresponding to WHO grade I)  see comment
","Histology: Low grade glioma (WHO grade I)
Methylation profile: Noncontributory  see comment 
MGMT Promoter (Illumina array): Unmethylated 
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #106\NH19-2329,0.09,-0.145,0.064,0.001,-0.012,-0.169,-0.002,0.01,-0.14,-0.102,-0.022,-0.042,-0.126,-0.057,-0.035,-0.005,-0.099,0.106,0.061,0.002,0.052,0.037,-0.039,0.064,-0.047,-0.05,0.078,0.089,0.122,unmethylated
NH19-2379,203219640034_R07C01,#106,4/9/2019,,9/13/2019,9,SB,Diagnostic,106,1,NDP,Nottingham University Hospital,DNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,4/22/2013,6.3,supratentorial pilocytic astrocytoma,0.64,LGG_PA_GGST,0.79,0.59,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2379,"Histology: Low grade glioma (WHO grade I)
Methylation profile: Low grade glioma, pilocytic astrocytoma / ganglioglioma  
MGMT Promoter (Ilumina array): Unmethylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #106\NH19-2379,0.133,0.036,0.019,0.02,0.049,-0.03,0.057,0.26,0.359,-0.061,0.325,0.039,-0.015,0.071,-0.11,-0.086,-0.019,-0.005,0.038,0.089,0.018,-0.017,-0.094,0.018,-0.017,0.033,0.047,-0.042,0.13,unmethylated
NH19-2321,203219640034_R08C01,#106,4/9/2019,,9/13/2019,9,SB,Diagnostic,106,8,NDP,London Clinic,Ependymoma spinal ,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1,4/23/1973,46.4,spinal ependymoma,1,EPN_SPINE,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2321,"Ependymal tumour (see comment). 
","Histology: Ependymoma (WHO grade II)  see supplementary comment
Methylation profile: Ependymoma, spinal
 
MGMT Promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #106\NH19-2321,0.195,-0.01,0.012,0.084,0.005,-0.038,-0.027,0.081,-0.002,-0.058,0.059,0.09,-0.119,0.084,-0.124,0.001,-0.128,-0.039,0.087,0.404,0.285,0.349,-0.238,0.088,-0.019,0.017,0.004,-0.506,-0.414,unmethylated
NH19-2406,203861150106_R01C01,#107,11/9/2019,,10/4/2019,23,SB,Diagnostic,107,8,NDP,NHNN,Embryonal tumour 2019,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/4/1998,21.6,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.51,GBM_MYCN,0.94,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2406,"Features in keeping with recurrent/residual supratentorial primitive neuro-ectodermal tumour (PNET) (WHO grade IV)
","Histology: Primitive neuroectodermal tumour
Methylation profile: Most in keeping with glioblastoma, close to paediatric GBM with MYCN amplification

",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #107\NH19-2406,0.311,0.945,0.009,0.003,0.002,0.072,0.087,0.219,0.159,0.185,0.148,-0.02,0.015,-0.015,-0.029,0.029,0.023,0.022,0.026,-0.027,-0.026,0.009,0.021,-0.041,-0.025,-0.082,-0.048,0.01,0.046,unmethylated
NH19-2365,203861150106_R03C01,#107,11/9/2019,,10/4/2019,23,SB,Diagnostic,107,9,NDP,Royal London Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,1/26/2000,19.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.88,CONTR_INFLAM,0.15,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2365,"Glioblastoma (WHO grade IV)  see comment

IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained
Further molecular tests: Pending
  
","Glioblastoma, IDH-wildtype (WHO grade IV)
(See comment)
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #107\NH19-2365,0.093,0.113,0.103,0.006,0.152,0.039,-0.01,0.202,0.212,0.209,0.2,0.068,0.055,0.049,-0.273,-0.039,-0.068,-0.005,-0.038,-0.069,-0.024,-0.001,-0.029,-0.043,-0.143,-0.082,0.008,0.003,-0.003,unmethylated
NH19-2409,203861150106_R04C01,#107,11/9/2019,,10/4/2019,23,SB,Diagnostic,107,7,NDP,NHNN,PA vs GBM Imaging HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/19/1964,55.1,ganglioglioma,0.45,GBM_MES,0.79,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2409,"Glioma, favouring low-grade (see comment)

IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
  
","Histology: Low-grade glioma (see comment)
Methylation class: Glioblastoma, IDH-wildtype (corresponding to WHO grade IV)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #107\NH19-2409,-0.004,0.027,0.026,0.213,0.067,0.133,0.037,0.168,0.139,0.199,0.151,-0.013,-0.004,-0.037,0.042,0.027,-0.297,-0.168,0.008,-0.034,-0.004,-0.064,-0.295,-0.069,-0.492,-0.028,0.148,-0.013,0.023,unmethylated
NH19-2175,203861150106_R05C01,#107,11/9/2019,,10/4/2019,23,SB,Diagnostic,107,38,NDP,Manchester Children,Cortical dysplasia?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,#N/A,#N/A,ganglioglioma,0.86,LGG_GG,0.8,0.55,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2175,"Mild Hippocampal Sclerosis (ILAE type 3) and glial nodules in white matter  see comment
","Mild hippocampal sclerosis (ILAE type 3)
Glial nodules in white matter
Methylation class: Ganglioglioma (see comment)
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #107\NH19-2175,-0.005,-0.014,0.039,0.05,-0.018,0.007,0.006,0.008,-0.014,-0.018,0.002,-0.009,0.042,-0.001,-0.013,-0.025,0.001,-0.008,0.018,-0.012,-0.031,0.049,0.036,-0.011,-0.056,-0.027,-0.005,0.008,-0.006,unmethylated
NH19-2459,203861150106_R06C01,#107,13/09/2019,,10/4/2019,21,SB,Diagnostic,107,5,NDP,NHNN,Epemdymoma (PF) vs subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,5/2/1963,56.4,posterior fossa ependymoma group B,1,EPN_PFB,0.99,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2459,"Ependymoma (see comment for grading)
","Histology: Ependymoma
Methylation class: Ependymoma, posterior fossa group B
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #107\NH19-2459,0.046,-0.139,-0.035,0.001,0.065,0.06,-0.113,0.049,0.011,0.043,0.062,-0.127,-0.108,-0.094,0.063,0.036,-0.109,-0.079,0.045,0.018,-0.002,0.046,0.081,-0.199,-0.297,-0.205,-0.116,-0.086,-0.087,unmethylated
NH19-2429,203861150106_R07C01,#107,13/09/2019,,10/4/2019,21,SB,Diagnostic,107,1,NDP,"Cardiff, University Hospital",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/18/1945,74,dysembryoplastic neuroepithelial tumour,0.95,LGG_DNT,0.86,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2429,"Histology: Glial or glial neuronal tumour
Methylation class: Low grade glioma, dysembryoplastic neuroepithelial tumour (please see comment regarding calibrated score)
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #107\NH19-2429,0.111,0.603,-0.05,-0.029,0.02,0.114,0.165,0.232,0.421,0.157,0.231,0.209,0.211,0.073,0.277,0.182,-0.116,-0.05,0.254,0.083,0.057,0.085,-0.006,0.06,-0.14,0.043,0.015,-0.045,0.009,methylated
NH19-2462,203861150106_R08C01,#107,13/09/2019,,10/4/2019,21,SB,Diagnostic,107,1,NDP,Southampton General Hospital,"corpus callosum high-grade glioma, K27M negative","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,5/18/1982,37.3,"glioblastoma, IDH-wildtype, RTK2 type",0.93,GBM_RTKII,0.81,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2462,"Histology: Glioblastoma (WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype, subclass RTK I
EGFR: Amplification
CDKN2A/B: Deletion
MGMT Promoter: Unmethylated

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #107\NH19-2462,0.015,0.007,0.03,0.025,-0.015,0.013,-0.034,1.046,0.257,0.195,0.19,0.011,0.069,0.004,-0.855,-0.022,-0.303,-0.33,-0.011,0.013,0.177,0.071,0.015,-0.007,0.014,0.037,-0.021,-0.303,-0.307,unmethylated
NH19-2446,203861150107_R03C01,#108,16/09/2019,,10/4/2019,18,ZJ,Diagnostic,108,1,NDP,Oxford John Radcliffe Hospital,Lumbar ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2A,8/18/1967,49.6,myxopapillary ependymoma,0.95,EPN_MPE,0.99,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2446,"Histology: Ependymoma
Methylation class: Myxopapillary ependymoma
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #108\NH19-2446,-0.047,-0.121,-0.019,0.024,0.183,0.128,-0.17,0.199,0.188,0.249,0.206,0.261,0.201,0.358,0.411,0.364,-0.077,-0.147,0.054,-0.002,0.116,0.033,0.218,-0.018,-0.189,0.07,0.192,-0.017,0.009,unmethylated
NH19-2495,203861150107_R05C01,#108,16/09/2019,,10/4/2019,18,ZJ,Diagnostic,108,2,NDP,"Birmingham, Queen Elizabeth Hospital",?MPNST,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,3/24/1998,21.4,posterior fossa ependymoma group A1,0.11,GBM_MES,0.12,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2495,"Histology: Neuroectodermal tumour with histological features suggestive of intermediate differentiation/malignancy grade (see comment) 
Methylation class: No match (see comment).

",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #108\NH19-2495,0.072,-0.263,0.037,-0.006,-0.053,-0.016,0.061,-0.002,-0.055,-0.081,-0.014,-0.006,0.004,-0.02,0.004,-0.055,-0.012,0.034,0.006,-0.014,-0.023,-0.075,-0.02,-0.006,-0.037,-0.012,0.008,0.004,0.012,unmethylated
NH19-2496,203861150107_R06C01,#108,16/09/2019,,10/4/2019,18,ZJ,Diagnostic,108,7,NDP,"Cambridge, Addenbrooke's Hospital",Temporal intraventricular; ?PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,6/26/1998,21.2,pleomorphic xanthoastrocytoma(-like),0.85,PXA,0.97,0.96,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2496,"Histology: Pleomorphic xanthoastrocytoma (grading see comment)
Methylation class: (Anaplastic) pleomorphic xanthoastrocytoma, see comment
",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #108\NH19-2496,-0.016,-0.05,-0.009,-0.02,-0.025,0.022,0.025,-0.041,-0.013,-0.254,-0.04,0.003,0.015,0.004,-0.382,0.113,-0.017,0.031,-0.054,-0.026,-0.018,0.015,0.001,-0.014,-0.019,0.038,-0.026,0.008,0.042,methylated
NH19-2525,203861150109_R01C01,#109,17/09/2019,,10/4/2019,17,ZJ,Diagnostic,109,4,NDP,Glasgow,Spinal lesion with additional lesions in cerebellum and cauda equina enhancment,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,5/8/1975,44.4,diffuse leptomeningeal glioneuronal tumour,1,DLGNT,0.98,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-2525,"Histology: Low grade glial/glioneuronal tumour
Methylation class: diffuse leptomeningeal glioneuronal tumour
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #109\NH19-2525,0.161,-0.037,0.039,0.117,-0.007,0.106,-0.163,-0.007,-0.029,0.116,0.293,-0.014,-0.014,0.004,0.014,0.078,-0.025,0.034,-0.003,-0.096,-0.123,-0.065,-0.011,-0.168,-0.211,-0.027,0.133,0.006,0.012,unmethylated
NH19-2504,203861150109_R02C01,#109,18/09/2019,,10/4/2019,16,ZJ,Diagnostic,109,1,NDP,"Leeds, St James's University Hospital",BRAF mutant and TERT mutant IDH-wildtype glioblastoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/17/1944,75.2,"glioblastoma, IDH-wildtype, RTK2 type",0.8,GBM_RTKII,0.87,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2504,"Histology: Glioblastoma (WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype, subclass RTK II
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #109\NH19-2504,-0.022,-0.008,0.018,0.014,0.03,0.058,0.039,0.183,0.218,0.169,0.18,-0.011,0.009,0.033,-1.187,-0.002,-0.945,-0.259,-0.25,-0.029,-0.018,-0.005,-0.044,-0.007,-0.072,-0.014,0.017,-0.26,-0.283,unmethylated
NH19-2515,203861150109_R03C01,#109,18/09/2019,,10/4/2019,16,ZJ,Diagnostic,109,1,NDP,Nottingham University Hospital,"Ependymoma, spinal","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,#N/A,#N/A,spinal ependymoma,1,EPN_SPINE,1,0.48,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2515,"Histology: Small fragment of an intrinsic tumour, compatible with the suggested referred to diagnosis of ependymoma
No matching methylation class
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #109\NH19-2515,-0.375,0.059,0.053,-0.027,0.022,0.03,-0.055,0.132,0.119,0.158,0.133,0.177,0.192,0.176,0.06,-0.032,0.023,0.027,-0.004,0.122,0.096,0.186,-0.228,0.04,-0.161,-0.072,0.055,-0.189,-0.176,unmethylated
NH19-2547,203861150109_R04C01,#109,19/09/2019,,10/4/2019,15,ZJ,Diagnostic,109,1,NDP,NHNN,"Ependymoma, spinal","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,1/18/1990,29.7,myxopapillary ependymoma,0.97,EPN_MPE,0.97,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2547,"Ependymal tumour  see comment
","Histology: Ependymoma (classical)
Methylation class: Ependymoma, myxopapillary
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #109\NH19-2547,-0.011,0.003,0.033,-0.019,0.014,0.031,0.091,-0.001,-0.038,-0.063,0.001,-0.014,0.017,-0.019,-0.004,0.028,-0.361,-0.265,-0.004,0.011,0.023,0.001,0.005,-0.016,-0.049,-0.053,-0.012,0.029,0.043,unmethylated
NH19-2553,203861150109_R05C01,#109,20/09/2019,,10/4/2019,14,ZJ,Diagnostic,109,2,NDP,Nottingham University Hospital,"High grade tumour, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,12/8/2000,18.8,"Diffuse hemispheric glioma, H3 G34-mutant",1,GBM_G34,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2553,"Histology, high grade glioma, most in keeping with glioblastoma (WHO grade IV)
Methylation class: Glioblastoma, H3.3 G34 mutant
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #109\NH19-2553,0.008,-0.021,-0.003,-0.012,-0.033,-0.041,0.127,0.049,-0.004,-0.001,-0.01,0.007,0.022,0.007,-0.294,-0.048,-0.366,-0.359,0.04,0.064,-0.05,-0.001,-0.386,0.007,0.033,0.036,-0.465,-0.048,-0.026,methylated
NH19-2546,203861150109_R07C01,#109,20/09/2019,,10/4/2019,14,ZJ,Diagnostic,109,1,NDP,"Leeds, St James's University Hospital","HGG, ?PXA; ?GBM","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/4/1982,36.9,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.62,0.63,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2546,"Histology: Glioblastoma (WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype, subclass mesenchymal
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #109\NH19-2546,0.018,-0.011,0.018,-0.016,-0.017,0.041,-0.072,0.08,0.124,0.111,0.128,0.012,0.029,0.008,-0.02,0.003,-0.424,-0.178,-0.029,-0.084,-0.008,0.002,-0.143,-0.17,-0.238,0.056,-0.036,-0.103,-0.137,unmethylated
NH19-2533,203861150117_R01C01,#110,20/09/2019,,10/11/2019,21,ZJ,Diagnostic,110,1,NDP,St George's Hospital London,Myxopapillary ependymoma (G I),"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,3/2/1992,27.5,myxopapillary ependymoma,1,EPN_MPE,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2533,"Histology: Myxopapillary ependymoma (WHO grade I)
Methylation class: Ependymoma, myxopapillary
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #110\NH19-2533,0.037,-0.04,0.065,0.024,0.03,0.115,0.005,0.149,0.194,0.169,0.135,-0.255,-0.283,-0.219,0.138,0.177,-0.18,-0.241,-0.009,0.024,-0.045,0.026,0.015,0.154,0.271,0.195,0.136,0.004,-0.001,unmethylated
NH19-2570,203861150117_R04C01,#110,23/09/2019,,10/11/2019,18,ZJ,Diagnostic,110,2,NDP,St George's Hospital London,"Ependymoma, G II, 4th Ventricle","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,6/28/1983,36.2,posterior fossa ependymoma group B,1,EPN_PFB,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2570,"Histology: Ependymoma
Methylation class: Ependymoma, posterior fossa group B

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #110\NH19-2570,-0.129,-0.175,-0.104,-0.006,-0.022,-0.01,-0.457,0.017,0.035,-0.044,0.005,0.033,0.061,-0.006,0.049,0.058,-0.119,-0.119,0.039,0.02,0.051,0.034,-0.04,-0.131,-0.186,-0.199,-0.02,-0.1,-0.101,unmethylated
NH19-2317,203861150117_R05C01,#110,24/09/2019,,10/11/2019,17,ZJ,Diagnostic,110,4,NDP,NHNN,"Glioma, IDH-mutant, ATRX retained, H3K27me3 loss, no 1p/19qLOH, no TERT mutation","(4) IHC, sequencing, or copy number assay ambiguous",SP2A,6/6/1978,41.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.97,AIDH,0.99,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2317,"Diffuse astrocytoma, IDH-mutant (WHO grade II)  see comment

IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: As per report NH19-1986 - No CDKN2A/B deletion, No 1p/19q LOH, MGMT promoter methylated.   
","Diffuse astrocytoma, IDH-mutant (WHO grade II)
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B: No deletion          
TERT promoter: No mutation
MGMT Promoter: Methylated
      
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #110\NH19-2317,0.04,-0.061,0.042,0.085,0.023,0.077,0.078,-0.053,-0.059,-0.04,-0.011,-0.009,-0.041,0.439,-0.02,-0.047,-0.033,0.046,0.213,0.062,0.017,-0.043,0.033,-0.038,-0.091,-0.077,-0.005,0.037,-0.035,methylated
NH19-2615,203861150117_R06C01,#110,26/09/2019,,10/11/2019,15,ZJ,Diagnostic,110,1,NDP,Southampton General Hospital,"Anaplastic ependymoma, right motor cortex","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1B,4/10/1988,31.4,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,0.99,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2615,"Histology: Anaplastic ependymoma WHO Grade III).
Methylation class: ependymoma, RELA fusion
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #110\NH19-2615,0.183,0.098,0.089,-0.09,-0.141,0.091,-0.096,0.157,0.194,0.247,0.176,-0.102,-0.141,-0.104,0.114,0.085,-0.113,-0.07,0.091,0.116,0.073,0.096,-0.099,0.053,0.103,0.09,0.175,-0.072,-0.098,methylated
NH19-2619,203861150117_R08C01,#110,26/09/2019,,10/11/2019,15,ZJ,Diagnostic,110,1,NDP,"Cardiff, University Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,6/13/1977,42.3,posterior fossa ependymoma group B,1,EPN_PFB,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2619,"Histology: Ependymoma
Methylation class: Ependymoma, posterior fossa group B
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #110\NH19-2619,0.095,-0.407,-0.277,-0.131,-0.068,-0.096,-0.293,0.058,0.051,0.037,0.051,0.084,0.078,0.115,-0.046,-0.04,-0.357,-0.286,-0.106,0.086,0.079,0.143,0.107,-0.321,-0.396,-0.337,-0.065,-0.208,-0.293,unmethylated
NH19-2643,203866380079_R03C01,#111,1/10/2019,,10/11/2019,10,ZJ,Diagnostic,111,1,NDP,"Leeds, St James's University Hospital",HGG,"(4) IHC, sequencing, or copy number assay ambiguous",C1,8/18/1993,26.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2643,"Histology: Glioblastoma (WHO grade IV)
Methylation class: Glioma, IDH-mutant, subclass high-grade astrocytoma
","Histology: Glioblastoma, IDH-mutant (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B (Illumina array): Deletion
MGMT Promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #111\NH19-2643,-0.082,-0.057,0.006,-0.007,-0.074,0.07,0.075,0.041,-0.015,0.022,-0.023,-0.026,0,-0.069,-0.924,0.018,-0.247,-0.193,-0.065,-0.033,-0.04,0.061,-0.058,-0.035,0.047,0.022,-0.124,-0.04,-0.004,unmethylated
NH19-2647,203866380079_R05C01,#111,1/10/2019,,10/11/2019,10,ZJ,Diagnostic,111,1,NDP,Oxford John Radcliffe Hospital,"?Infiltration of GBM, IDHwt","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2,5/1/1960,59.4,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.67,0.56,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2647,"Histology: Glioblastoma (WHO grade IV) (see comment)
Methylation class: Glioblastoma, IDH-wildtype, subclass mesenchymal
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #111\NH19-2647,0.102,-0.079,-0.026,-0.046,-0.06,-0.01,-0.222,0.08,0.11,0.087,0.083,-0.023,-0.005,0.046,0.041,-0.022,-0.141,-0.12,-0.036,0.017,0.137,0.03,-0.045,0.042,-0.2,0.018,0.115,-0.038,0.002,unmethylated
NH19-2626,203866380079_R07C01,#111,2/10/2019,,10/11/2019,9,ZJ,Diagnostic,111,5,NDP,Romford,Cerebellar ganglioglioma vs PXA,"(2) unusual histology, location, demographics",A3,2/23/1988,31.6,infratentorial pilocytic astrocytoma,0.93,LGG_PAPF,0.76,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2626,"Cerebellar Ganglioglioma (see comment)
","Histology: Ganglioglioma (WHO grade I)
Methylation class: Low grade glioma, class posterior fossa pilocytic astrocytoma (see class description in the comment below):
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #111\NH19-2626,0.075,-0.14,-0.129,-0.034,-0.03,0.062,0.112,0.08,0.094,0.056,0.079,0.013,-0.005,0.06,-0.066,0.002,0.013,-0.058,0.007,0.166,0.137,0.067,0.12,0.02,-0.003,-0.065,-0.009,0.084,0.085,unmethylated
NH19-2663,203866380079_R08C01,#111,4/10/2019,,10/11/2019,7,ZJ,Diagnostic,111,1,NDP,"Leeds, St James's University Hospital",Parietal anaplastic ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,1/8/1992,27.7,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2663,"Histology: High-grade glioma, compatible with pleomorphic xanthoastrocytoma (WHO grade III)
Methylation class: (Anaplastic) pleomorphic xanthoastrocytoma
CDKN2 2A/B: Homozygous deletion
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #111\NH19-2663,0.007,0.024,0.017,-0.011,0.038,0.008,-0.284,0.173,0.19,0.243,0.174,0.13,0.188,0.281,-2.349,-0.289,-0.278,-0.254,-0.23,-0.034,-0.054,0.062,-0.307,0.142,0.234,0.174,0.062,0.12,0.206,unmethylated
NH19-2662,203869580111_R01C01,#112,4/10/2019,,10/24/2019,20,ZJ,Diagnostic,112,1,NDP,"Birmingham, Queen Elizabeth Hospital",Thalamic HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/2/2006,12.8,infratentorial pilocytic astrocytoma,0.5,LGG_PAMID,0.68,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2662,"Histology: Features compatible with pilocytic astrocytoma
Methylation class: Pilocytic astrocytoma (caveat: Low calibrated score)
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #112\NH19-2662,-0.065,-0.03,0.011,0.05,-0.021,0,0.208,0.153,0.208,0.14,0.104,0.001,0.055,-0.068,-0.088,-0.019,0.102,0.06,0.081,0.087,0.02,0.098,0.026,-0.113,-0.01,-0.038,-0.042,-0.031,-0.077,unmethylated
NH19-2685,203869580111_R03C01,#112,8/10/2019,,10/24/2019,16,SB,Diagnostic,112,4,NDP,Southampton General Hospital,LGG progression,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,9/5/1963,56.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.98,GBM_MES,0.87,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2685,"Histology: High grade glioma, with features compatible with glioblastoma (WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype, subclass mesenchymal

EGFR: Amplification
CDKN2A/B: Deletion
MGMT Promoter: Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #112\NH19-2685,-0.023,-0.029,0.018,0.002,0.018,0.128,-0.013,0.976,0.138,0.156,0.123,-0.004,-0.081,0.013,-0.832,0.003,0.005,0.02,-0.014,0.136,0.13,0.154,-0.266,-0.004,-0.043,-0.018,0.201,-0.007,0.001,methylated
NH19-2635,203869580111_R04C01,#112,8/10/2019,,10/24/2019,16,SB,Diagnostic,112,1,NDP,Southampton General Hospital,Thalamic Astrocytomas,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1G,2/16/1986,33.6,infratentorial pilocytic astrocytoma,0.15,LGG_PAPF,0.23,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2635,"CNS tissue and small fragments of an intrinsic, most likely low-grade tumour.
Methylation class: Control tissue, hypothalamus (see comment)
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #112\NH19-2635,0.036,0.031,0.007,0.008,-0.007,-0.007,0.027,0.002,0.043,-0.076,-0.005,0.118,0.068,-0.02,-0.01,-0.008,0.065,-0.001,0.055,0.018,-0.044,0.013,0.045,0.006,-0.046,-0.047,-0.062,0.018,0.015,unmethylated
NH19-2698,203869580111_R06C01,#112,10/10/2019,,10/24/2019,14,SB,Diagnostic,112,1,NDP,"Leeds, St James's University Hospital","GBM, Ependymoma? ","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B2,1/8/1992,18.7,pleomorphic xanthoastrocytoma(-like),0.49,PXA,0.65,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2698,"Histology: Features compatible with anaplastic pleomorphic xanthoastrocytoma or epithelioid glioblastoma (WHO at least grade III)
Methylation class: No match (see comment)
CDKN 2A/B: Homozygous deletion
","Histology: Anaplastic pleomorphic xanthoastrocytoma - epithelioid glioblastoma spectrum, BRAF V600E-mutant - for grading, see comment

Methylation profile: Anaplastic pleomorphic xanthoastrocytoma 

CDKN2A/B: Deletion
BRAF (V600E IHC, Seq): Mutation

",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #112\NH19-2698,-0.041,0.124,0.035,-0.063,0.022,-0.046,-0.191,0.112,0.139,0.149,0.086,0.101,0.097,0.128,-1.253,-0.199,-0.156,-0.189,-0.221,-0.026,-0.046,-0.05,-0.296,0.122,0.16,0.133,-0.074,0.061,0.078,methylated
NH19-2566,203869580111_R07C01,#112,14/10/2019,,10/24/2019,10,SB,Diagnostic,112,1,NDP,St George's Hospital London,PXA? ,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/11/1994,24.8,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.95,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2566,"Referred diagnosis: Low grade glial/glioneuronal tumour - see comment
 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained 
CDKN2A/B: Deletion
BRAF (V600E): No mutation
","Integrated diagnosis: Anaplastic pleomorphic xanthoastrocytoma (WHO grade III)
Methylation class: (anaplastic) pleomorphic xanthoastrocytoma)
CDKN2A/B: Deletion
MGMT Promoter: Unmethylated

",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #112\NH19-2566,-0.009,0.009,0.013,-0.026,0.008,-0.013,0.008,0.021,0.035,-0.045,0.018,0.029,0.011,0.101,-0.752,-0.119,-0.018,-0.034,-0.041,0.088,0.024,-0.005,-0.019,0.033,-0.282,-0.023,-0.01,-0.031,0.001,unmethylated
NH19-2850,203869580134_R02C01,#113,20/10/2019,,11/1/2019,12,SB,Diagnostic,113,2,NDP,"Belfast, Royal Victoria Hospital",GBM or LGG?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,1/18/1941,78.8,"glioblastoma, IDH-wildtype, RTK1 type",0.95,GBM_RTKI,0.92,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2850,"Histology: Glioblastoma (WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype subclass RTK I 
MGMT Promoter: Methylated 
CDKN2A/B: Deletion


",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #113\NH19-2850,0.08,0.264,-0.001,-0.195,0.969,-0.013,-0.02,0.123,0.129,0.211,0.148,0.035,0.025,0.071,-0.513,-0.001,-0.751,-0.269,-0.163,-0.119,-0.083,-0.003,-0.456,-0.023,-0.013,-0.012,0.071,-0.076,-0.017,methylated
NH19-2744,203869580134_R05C01,#113,15/10/2019,,11/1/2019,17,SB,Diagnostic,113,4,NDP,"Cambridge, Addenbrooke's Hospital",Pilocytic astrocytoma? APA?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",D1,6/18/1997,22.2,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,0.99,ANAPA,0.4,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2744,"Histology: Pilocytic astrocytomas with anaplastic features (grading see comment)
Methylation class: Low calibrated score, suggestive of anaplastic pilocytic astrocytoma 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #113\NH19-2744,0.014,-0.047,-0.024,0.024,-0.049,-0.093,0.022,-0.264,-0.039,-0.008,-0.024,-0.018,-0.019,-0.046,-0.681,0.135,-0.045,0.078,-0.037,-0.077,-0.067,-0.044,-0.214,-0.21,0.049,0.036,-0.209,0.016,0.012,methylated
NH19-2879,203869580125_R04C01,#114,28/10/2019,,11/15/2019,18,SB,Diagnostic,114,1,NDP,Oxford John Radcliffe Hospital,"HGG, Type?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,10/1/1943,76.1,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.86,GBM_MID,0.96,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2879,"Methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV) 
MGMT Promoter (Illumina array): Methylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #114\NH19-2879,0.126,-0.11,-0.08,-0.205,0.469,-0.214,-0.086,-0.046,0.001,-0.028,0.051,0.072,0.082,0.197,-0.357,-0.078,-0.111,-0.152,0.197,0.074,0.036,1.912,-0.147,-0.014,0.104,0.096,-0.077,0.04,0.096,methylated
NH19-2886,203869580125_R06C01,#114,28/10/2019,,11/15/2019,18,SB,Diagnostic,114,1,NDP,NHNN,PA or Anaplastic PA?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,11/13/1959,60,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.98,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2886,"Glioma, see comment.

IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
","Histology: Glioma  see supplementary comment
Methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV) 
MGMT Promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #114\NH19-2886,0.016,-0.009,-0.006,-0.029,-0.032,-0.014,-0.233,0.134,0.172,0.175,0.123,0,0.016,-0.004,-0.467,-0.024,-0.184,-0.141,-0.041,-0.026,-0.036,0.026,-0.175,0.017,-0.155,-0.031,-0.071,-0.126,-0.133,unmethylated
NH19-2876,203869580125_R07C01,#114,29/10/2019,,11/15/2019,17,SB,Diagnostic,114,1,NDP,Brighton and Sussex Hospital,Cerebellar IDH mut tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/21/1945,74.7,"control tissue, cerebellar hemisphere",0.71,CONTR_CEBM,0.99,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2876,"IDH-mutant glioma, see comment.

IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Histology: Glioma, IDH-mutant
Methylation class: No matching methylation class (see comment)
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #114\NH19-2876,-0.036,-0.025,-0.031,-0.048,-0.002,-0.05,0.02,-0.031,-0.025,-0.03,-0.028,-0.002,0.039,-0.001,0.062,-0.019,-0.011,-0.015,-0.028,-0.033,-0.054,0.039,0.037,-0.04,-0.017,-0.029,0.022,-0.016,0.017,methylated
NH19-2867,203869580125_R08C01,#114,29/10/2019,,11/15/2019,17,SB,Diagnostic,114,4,NDP,"Birmingham, Queen Elizabeth Hospital","Thalamus glioma, K27 neg","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/2/1950,69.5,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type B]",1,GBM_MID,0.39,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2867,"Glial tumour  see comment
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #114\NH19-2867,0.245,-0.078,0.039,0.003,-0.043,0.03,0.015,0.003,-0.034,-0.569,0.287,0.003,0.014,-0.01,0.043,0,-0.011,-0.193,-0.006,-0.043,-0.012,0.009,0.043,0.07,-0.026,0.137,-0.003,0.044,0.036,unmethylated
NH19-2904,203219640063_R03C01,#115,31/10/2019,,11/21/2019,21,SB,Diagnostic,115,1,NDP,Southampton General Hospital,Chordoid gioma? see NH19-2097,"(2) unusual histology, location, demographics",A1,7/30/1974,45.2,chordoid glioma,0.68,CHGL,0.37,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2904,"Histology: Chordoid glioma (WHO grade II)
Methylation class: Chordoid glioma of the third ventricle (low calibrated score, see comment
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #115\NH19-2904,0.053,-0.004,-0.008,0.016,0.015,-0.015,0.007,-0.054,-0.066,-0.019,0.007,0.017,0.085,0.03,-0.033,0.001,-0.011,-0.038,0.004,-0.046,-0.018,0.054,-0.004,0.031,0.063,0.007,0.006,-0.039,0.049,unmethylated
NH19-2919,203219640063_R04C01,#115,31/10/2019,,11/21/2019,21,SB,Diagnostic,115,1,NDP,Auckland (NZ),Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",5D,1/20/1990,29.7,"supratentorial ependymoma, ZFTA:RELA fusion-positive",0.96,EPN_RELA,0.85,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2919,"Histology: Anaplastic ependymoma (WHO grade III)
Methylation class: Ependymoma, RELA fusion
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #115\NH19-2919,-0.162,-0.078,0.04,-0.008,-0.138,-0.029,-0.078,-0.162,-0.08,-0.284,-0.119,0.083,-0.048,-0.241,-2.505,-0.51,-0.078,-0.096,-0.145,-0.055,-0.122,0.246,-0.48,0.065,0.122,-0.098,-0.142,0.079,0.102,unmethylated
NH19-2975,203219640063_R06C01,#115,6/11/2019,,11/21/2019,15,SB,Diagnostic,115,1,NDP,"Leeds, St James's University Hospital",GBM-APA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,3/29/1950,69.5,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.99,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-2975,"Histology: Glioblastoma (WHO grade IV)
Methylation class: glioblastoma, IDH wildtype, subclass RTK I 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #115\NH19-2975,-0.03,-0.049,0.01,0.02,-0.018,0.078,0.057,0.168,1.257,0.226,0.366,-0.016,0.001,-0.015,-1.738,-0.007,-1.519,-0.364,-0.014,-0.032,-0.05,0.014,-0.012,-0.012,0.018,-0.005,-0.065,-0.003,-0.003,methylated
NH19-2944,203219640063_R08C01,#115,11/11/2019,,11/21/2019,10,SB,Diagnostic,115,1,NDP,NHNN,Small glial tumour fragment,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/17/1988,31.6,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.48,LGG_RGNT,0.41,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-2944,"Glial/glioneuronal tumour, see comment
","Histology: Glial/glioneuronal tumour
Methylation class: Pilocytic astrocytoma low calibrated score (see comment)
BRAF: Possible fusion/duplication 
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #115\NH19-2944,0.033,-0.003,0.065,-0.018,-0.059,0.04,-0.004,-0.013,-0.059,-0.005,0.17,0.001,0.021,0.018,0.005,0.041,-0.016,0.029,0.057,-0.013,0.007,-0.048,-0.008,0.008,-0.012,-0.033,-0.03,-0.02,0.028,unmethylated
NH19-2997,203583860051_R02C01,#116,11/11/2019,,11/28/2019,17,SB,Diagnostic,116,1,NDP,Nottingham University Hospital,,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,11/8/1976,43,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.99,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2997,"Histology: Glioblastoma (WHO grade IV)
Methylation class: Glioblastoma IDH-wildtype (subclass mesenchymal)
MGMT Promoter: Unmethylated


",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #116\NH19-2997,-0.034,-0.005,0.015,0.017,-0.013,0.027,0.019,0.134,0.183,0.185,0.143,0.002,0.038,0.013,-0.682,0.177,-0.218,-0.198,-0.034,-0.049,-0.006,0.024,-0.007,0.012,-0.263,-0.268,-0.029,-0.014,-0.025,unmethylated
NH19-3048,203583860051_R03C01,#116,12/11/2019,,11/28/2019,16,SB,Diagnostic,116,2,NDP,Plymouth,"Intrinsic temporal tu ,?PA? Oligocompoenet histologically","(2) unusual histology, location, demographics",1A,11/27/1982,36.9,dysembryoplastic neuroepithelial tumour,0.44,LGG_PA_GGST,0.52,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3048,"Histology: Glial tumour, with features raising the possibility of pilocytic astrocytoma
Methylation class: Pilocytic astrocytoma/low grade glioma, subclass hemispheric pilocytic astrocytoma and ganglioglioma (see comment)


",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #116\NH19-3048,-0.026,-0.01,0.01,0.021,-0.04,-0.055,-0.236,-0.036,0.159,-0.017,0.009,0.04,-0.03,-0.09,0.319,0.274,0.059,-0.152,0.027,0.015,0.082,0.096,0.255,0.143,-0.061,-0.02,-0.09,0.09,0.095,unmethylated
NH19-2951,203583860051_R04C01,#116,12/11/2019,,11/28/2019,16,SB,Diagnostic,116,1,NDP,Royal London Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,9/26/1968,51.1,"glioblastoma, IDH-wildtype, RTK1 type",0.73,GBM_RTKI,0.25,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2951,"High grade glioma - see comment

IDH1 (R132H IHC): No mutation, further tests pending 
ATRX (IHC): Retained 
Further molecular tests: Pending
","Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype, subclass mesenchymal
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)
TERT promoter: Mutation
MGMT Promoter: Methylated (>10-25%) 

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #116\NH19-2951,-0.138,-0.071,-0.032,-0.125,0.595,0.052,-0.049,0.097,-0.011,1.088,0.038,0.018,0.034,0.025,-0.515,0.035,-0.169,-0.102,-0.013,-0.011,-0.021,0.022,-0.157,-0.255,-0.059,0.007,-0.04,0.008,0.052,methylated
NU19-122,203583860051_R06C01,#116,12/11/2019,,11/28/2019,16,SB,CRUK OPARATIC,116,1,NDP,Glasgow,GBM OPARATIC TRIAL,"(6) Research sample, for stratification or subclassification",Slides,1/0/1900,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.33,PXA,0.37,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NU19-122,"Histology: Glioblastoma (WHO grade IV)
No matching methylation class (see comment) 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #116\NU19-122,0.351,-0.21,-0.109,0.03,0.13,-0.056,-0.258,0.611,0.581,0.696,0.55,0.251,0.159,0.347,0.185,-0.01,-0.244,-0.422,-0.209,-0.152,0.06,0.128,-0.103,-0.049,-0.095,-0.144,-0.237,0.102,0.093,unmethylated
NU19-123,203583860051_R07C01,#116,12/11/2019,,11/28/2019,16,SB,CRUK OPARATIC,116,1,NDP,Glasgow,GBM OPARATIC TRIAL,"(6) Research sample, for stratification or subclassification",Slides,1/0/1900,#N/A,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,PXA,0.13,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NU19-123,"Histology: Glioblastoma/gliosarcoma (WHO grade IV)
No matching methylation class (see comment)
 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #116\NU19-123,-0.205,-0.183,-0.007,-0.004,0.032,-0.029,0.119,-0.021,0.013,-0.002,0.081,0.022,0.229,-0.08,0.004,0.053,-0.02,-0.276,-0.212,-0.15,-0.159,0.111,-0.946,0.159,0.007,0.087,-0.017,0.168,0.239,unmethylated
NH19-3014,203583860051_R08C01,#116,13/11/2019,,11/28/2019,15,SB,Diagnostic,116,6,NDP,NHNN,PXA?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,#N/A,#N/A,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3014,"Pleomorphic xanthoastrocytoma (PXA) (WHO grade II)  see comment
BRAF V600E mutation  based on immunohistochemistry
","Histology: Pleomorphic and astrocytoma (PXA) (WHO grade II)
BRAF: mutation (V600E) 
Methylation class: (anaplastic) pleomorphic xanthoastrocytoma
CDKN 2A/B homozygous deletion on copy number profile
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #116\NH19-3014,-0.031,-0.016,0.022,-0.004,0.015,0.071,0.012,0.012,-0.009,0.002,0.005,-0.009,0.035,0.002,-0.867,-0.001,-0.019,0.01,-0.005,-0.033,0.022,-0.004,0.009,0.009,0.001,0.016,-0.017,-0.008,0.038,unmethylated
NH19-3012,203550290096_R01C01,#117,13/11/2019,,12/6/2019,23,SB,Diagnostic,117,1,NDP,NHNN,"NF2, Pilocytic, anaplasia? ","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/2/1994,25.7,supratentorial pilocytic astrocytoma,0.36,LGG_PA_GGST,0.5,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3012,"Malignant glioma, at least WHO grade III - see comment
","Histology: Anaplastic glioma (corresponding to at least WHO grade III)
Methylation class: Pilocytic astrocytoma, subclass hemispheric pilocytic astrocytoma/ganglioglioma (see comment):
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #117\NH19-3012,-0.083,-0.004,0.047,0.107,0.096,0.195,0.064,0.17,0.177,0.142,0.169,-0.016,0.041,0.015,-0.039,-0.029,-0.003,0.081,-0.022,0.156,0.176,0.173,-0.08,-0.086,-0.076,-0.084,-0.026,0.144,0.205,unmethylated
NH19-2972,203550290096_R05C01,#117,15/11/2019,,12/6/2019,21,SB,Diagnostic,117,9,NDP,Romford,"HGG ATRX loss ?G34R, IDH?","(2) unusual histology, location, demographics",B1,9/23/1984,35.1,"Diffuse hemispheric glioma, H3 G34-mutant",1,GBM_G34,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2972,"Malignant intrinsic tumour - see comment
","Histology: High grade glioma
Methylation class: Glioblastoma, IDH-wildtype, H3.3 G34 mutant
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #117\NH19-2972,0.005,0.63,0.01,0.144,0.263,0.027,0.057,-0.026,0.017,-0.044,-0.018,0.007,0.037,0.041,-2.034,-0.001,-0.399,-0.425,-0.042,0.215,0.109,0.013,-0.499,-0.003,0.053,0.043,-0.052,-0.035,-0.01,methylated
NH19-3074,203550290096_R07C01,#117,20/11/2019,,12/6/2019,16,ZJ,Diagnostic,117,1,NDP,"Birmingham, Queen Elizabeth Hospital",Recurrent PA (previous in 2010 H10.0.301),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/21/2004,15.7,infratentorial pilocytic astrocytoma,0.99,LGG_PAPF,0.95,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-3074,"Histology (H19-3368): Low grade glioma, with features consistent with a pilocytic astrocytoma (WHO grade I).
Methylation class: Pilocytic astrocytoma, subclass posterior fossa pilocytic astrocytoma (see class description)


",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #117\NH19-3074,-0.026,-0.002,0.008,0.026,-0.084,0.072,0.141,-0.039,-0.024,-0.003,0.111,-0.002,0.071,0.026,0.019,-0.002,0.014,0.005,0.082,0.004,-0.032,0.004,0.065,0.014,0.001,-0.002,-0.041,-0.021,0.052,unmethylated
NH19-3159,203550290096_R08C01,#117,22/11/2019,,12/6/2019,14,ZJ,Diagnostic,117,1,NDP,"Cardiff, University Hospital",?PXA or GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A9,8/29/1966,52.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.92,CONTR_INFLAM,0.1,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-3159,"Histology: Malignant extrinsic tumour (see comment)
Methylation class: No conclusive methylation profile (see comment).
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #117\NH19-3159,0.22,-0.16,-0.261,0.129,0.297,0.048,-0.123,0.142,0.255,0.331,0.304,0.03,-0.18,0.095,-0.604,-0.016,-0.059,-0.149,0.082,0.067,0.185,0.318,-0.044,0.062,-0.083,-0.182,0.061,0.276,0.381,unmethylated
NH19-3142,203583860033_R07C01,#118,26/11/2019,,12/13/2019,17,SB,Diagnostic,118,1,NDP,NHNN,"Ependymoma spinal, classic","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1B,10/23/1988,31.1,myxopapillary ependymoma,0.59,EPN_MPE,0.71,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3142,"Ependymoma (WHO grade II)
","Histology: Ependymoma (WHO grade II)
Methylation class: Ependymoma, myxopapillary (calibrated score 0.66), see comment
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #118\NH19-3142,-0.055,0.021,0.051,-0.03,-0.002,-0.05,0.191,0.102,0.125,0.123,0.102,0.186,0.152,0.141,0.334,0.298,-0.049,-0.045,0.095,0.083,0.09,0.215,-0.352,-0.034,-0.069,-0.061,-0.057,-0.26,-0.296,unmethylated
NH19-2876,203583860037_R05C01,#119,26/11/2019,,12/13/2019,17,SB,Diagnostic,119,1,NDP,Brighton and Sussex Hospital,Cerebellar IDH mut tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/21/1945,74.7,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.26,PXA,0.39,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2876,"IDH-mutant glioma, see comment.

IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Histology: Glioma, IDH-mutant
Methylation class: No matching methylation class (see comment)
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #119\NH19-2876,-0.054,0.01,0.004,-0.046,-0.016,0.004,0.028,-0.058,-0.006,-0.029,-0.028,0.015,0.017,-0.018,0.023,0.002,-0.01,-0.019,-0.006,-0.009,-0.034,0.041,0.032,-0.068,-0.011,-0.024,-0.044,-0.024,-0.005,methylated
NH19-3122,203583860037_R06C01,#119,27/11/2019,,12/13/2019,16,SB,Diagnostic,119,3,NDP,Brighton and Sussex Hospital,"Frontal HGG, PXA?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,3/5/1987,32.7,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type C]",0.94,DMG_K27,0.14,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3122,"High grade astrocytic tumour (WHO grade III/IV)  see comment



IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Glioblastoma, IDH-wildtype (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: Amplification 
BRAF (V600E): No mutation     
MGMT Promoter: Unmethylated (0%) 
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #119\NH19-3122,0.012,0.013,0.059,0.336,0.323,0.374,-0.024,0.347,0.379,0.389,0.376,0.401,0.332,0.382,-0.083,0.017,0.034,0.008,0.31,0.299,0.316,0.37,-0.027,0.035,-0.167,-0.077,-0.045,0.048,0.076,unmethylated
NH19-3119,203583860037_R07C01,#119,27/11/2019,,12/13/2019,16,SB,Diagnostic,119,1,NDP,Romford,Spinal classic ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,2/20/1947,72.8,spinal ependymoma,1,EPN_SPINE,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3119,"Ependymoma (WHO Grade II)
","Histology: Ependymoma (WHO grade II)
Methylation class: Ependymoma, spinal
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #119\NH19-3119,0.075,0.001,0.032,0,-0.051,-0.022,-0.024,0.252,0.273,0.248,0.226,0.043,0.106,-0.007,0.044,0.071,0.017,0.015,0.02,0.247,0.287,0.327,0.042,0.088,-0.009,0.015,0.02,-0.5,-0.376,unmethylated
NH19-3189,203583860037_R08C01,#119,27/11/2019,,12/13/2019,16,SB,Diagnostic,119,1,NDP,Edinburgh,AIII IDH wt. ,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3A,6/25/1947,70.5,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",1,LGG_MYB,0.32,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3189,"Histology: CNS tissue with diffuse infiltration of a glioma, on present material no high-grade features
Methylation class: No matching methylation class (see comment)
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #119\NH19-3189,-0.05,-0.029,0.01,0.04,-0.046,-0.017,0.036,-0.04,0.008,-0.04,-0.023,0.013,0.079,-0.02,-0.007,0.076,0.021,-0.026,-0.016,-0.048,0.036,0.127,0.072,0.049,0.014,0.066,-0.061,-0.031,0.022,unmethylated
NH19-3191,204088040141_R02C01,#120,27/11/2019,,12/19/2019,22,SB,Diagnostic,120,2,NDP,"Birmingham, Queen Elizabeth Hospital","cerebellar PA, ? APA?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,11/26/1997,11.6,high-grade astrocytoma with piloid features,0.19,PXA,0.27,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3191,"Histology: High-grade glioma (see comment)
Methylation class: No matching methylation class, but see comment
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #120\NH19-3191,0.146,-0.251,-0.019,-0.202,0.127,-0.262,-0.105,-0.127,0.25,-0.059,0.017,0.181,-0.446,0.415,-0.84,0.194,-0.018,-0.213,0.113,0.518,-0.13,0.109,0.001,0.351,-0.231,-0.156,0.004,-0.097,0.083,unmethylated
NH19-3221,204088040141_R04C01,#120,2/12/2019,,12/19/2019,17,SB,Diagnostic,120,1,NDP,Southampton General Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B,3/30/1965,54.7,"control tissue, white matter (corpus callosum)",0.32,OIDH,0.35,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3221,"Histology: CNS grey and white matter, with possible focal infiltrative process:
Methylation class: No matching methylation class, see comment
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #120\NH19-3221,-0.075,-0.092,0.021,-0.029,-0.092,-0.004,-0.087,-0.061,-0.008,-0.048,-0.05,0.033,0.15,-0.247,-0.05,0.039,-0.041,-0.075,-0.082,-0.12,-0.023,0.125,-0.031,-0.019,-0.165,0.023,-0.077,0.05,-0.024,unmethylated
NH19-3031,204088040141_R05C01,#120,3/12/2019,,12/19/2019,16,SB,Diagnostic,120,1,NDP,Southampton General Hospital,"Small LGG, cingulate, MB01 non-informative","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,1/29/1975,44.8,ganglioglioma,0.99,LGG_GG,0.65,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3031,"Referred diagnosis: Low grade glioma - see comment

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
TERT promoter: No mutation 
CDKN2A/B (copy number plot methylation array): Homozygous deletion
Methylation class: Ganglioglioma
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #120\NH19-3031,0.009,0.02,0.053,-0.013,-0.01,0.028,-0.009,0.022,-0.029,-0.036,-0.022,0.013,0.054,0.017,-0.554,-0.164,-0.033,0.04,0.002,-0.012,-0.02,0.006,-0.012,0.028,-0.012,-0.001,0.002,-0.017,0.051,unmethylated
NH19-3207,204088040141_R06C01,#120,2/12/2019,,12/19/2019,17,SB,Diagnostic,120,1,NDP,Oxford John Radcliffe Hospital,LGG infiltration zone,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,9/22/1989,30.2,"control tissue, white matter (corpus callosum)",0.99,OIDH,0.22,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3207,"Histology: CNS tissue fragments
Methylation class: control tissue, white matter
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #120\NH19-3207,-0.097,0.018,0.053,-0.019,-0.074,0.066,-0.102,-0.094,0.125,0.079,-0.018,0.014,0.198,-0.086,0.07,-0.007,0.069,-0.084,-0.078,-0.044,0.125,0.029,0.093,0.147,0.157,0.094,-0.155,-0.017,0.023,unmethylated
NH19-3344,203980260029_R02C01,#121,12/12/2019,,1/9/2020,28,SB,Diagnostic,121,2,NDP,"Cardiff, University Hospital",Ependymoma post fossa,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",C1,9/20/2018,1.2,posterior fossa ependymoma group A1,1,EPN_PFA,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3344,"Histology: Anaplastic ependymoma (WHO grade III)
Methylation class: ependymoma, posterior fossa group A
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #121\NH19-3344,0.002,-0.022,0.035,0.01,-0.022,0.042,0.003,-0.035,0.014,-0.019,-0.019,0,0.037,0.046,-0.064,0.002,-0.026,0.005,0.023,-0.005,-0.003,-0.01,-0.027,0.025,0.063,-0.005,-0.025,-0.043,0.054,unmethylated
NH19-3235,203980260029_R03C01,#121,4/12/2019,,1/9/2020,36,SB,Diagnostic,121,3,NDP,"Cambridge, Addenbrooke's Hospital","Oligo-like, neuronal? tumour? ","(2) unusual histology, location, demographics",B1,9/5/1995,24.2,extraventricular neurocytoma,1,LGG_DNT,0.47,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3235,"Histology: Low grade glio-neuronal tumour
Methylation class: low grade glioma, dysembryoplastic neuroepithelial tumour

",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #121\NH19-3235,0.018,0.025,-0.015,-0.045,-0.03,0.017,0.002,-0.062,-0.026,-0.027,-0.034,0.164,0.026,0.045,0.065,-0.019,0.016,-0.015,0.059,-0.002,0.01,-0.003,0.01,0.007,-0.006,-0.013,-0.032,0.028,0.031,methylated
NH19-3233,203980260029_R04C01,#121,5/12/2019,,1/9/2020,35,SB,Diagnostic,121,1,NDP,"Birmingham, Queen Elizabeth Hospital","Glial, neuronal tumour; PA?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,11/6/1981,38,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.56,LGG_DNT,0.98,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3233,"Histology: Low grade glioneuronal tumour, corresponding to WHO grade I)
Methylation class: Dysembryoplastic neuroepithelial tumour
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #121\NH19-3233,0.041,-0.009,0.007,0.113,0.017,-0.053,-0.003,0.025,0.015,-0.05,0.002,0.015,-0.051,0.026,-0.048,0.012,-0.015,0.001,0.048,0.051,0.022,-0.026,-0.051,0.056,-0.035,-0.059,-0.043,-0.029,0.028,unmethylated
NH19-3259,203980260029_R06C01,#121,5/12/2019,,1/9/2020,35,SB,Diagnostic,121,1,NDP,Oxford John Radcliffe Hospital,4th ventr ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,9/28/2000,19.1,posterior fossa ependymoma group B,0.93,EPN_PFB,0.84,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3259,"Histology: Ependymoma (WHO grade II)
Methylation class: Ependymoma, subtype B (see comment for calibrated score)
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #121\NH19-3259,0.025,0.018,0.089,-0.013,-0.004,-0.003,-0.294,0.061,-0.01,-0.012,-0.013,-0.251,-0.116,-0.199,-0.023,0.024,-0.007,0.011,0.249,0.025,0.039,0.04,0.155,-0.211,-0.298,-0.235,-0.034,-0.195,-0.168,unmethylated
NH19-3261,203980260029_R08C01,#121,5/12/2019,,1/9/2020,35,SB,Diagnostic,121,1,NDP,"Birmingham, Queen Elizabeth Hospital",Thalamic PA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,2/13/1999,20.8,infratentorial pilocytic astrocytoma,0.96,LGG_PAPF,0.94,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-3261,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation class: Pilocytic astrocytoma, subclass posterior fossa pilocytic astrocytoma
","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1  see comment
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, subclass posterior fossa pilocytic astrocytoma
KIAA1549-BRAF: fusion
  
",(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #121\NH19-3261,0.014,-0.07,-0.01,-0.025,-0.053,-0.007,-0.021,-0.026,0.063,-0.006,0.163,0.044,-0.015,0.042,-0.048,0.016,-0.051,0.013,0.018,0.04,0.006,-0.006,-0.027,0.03,-0.025,-0.046,-0.052,-0.045,0.02,methylated
NH19-3325,203980260091_R01C01,#122,12/12/2019,,1/9/2020,28,SB,Diagnostic,122,2,NDP,"Leeds, St James's University Hospital",EP_PF,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",C4,4/28/1974,45.6,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3325,"Histology: Anaplastic ependymoma (WHO grade III)
Methylation class, ependymoma, RELA fusion
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #122\NH19-3325,0.246,-0.038,0.042,0.048,-0.01,-0.019,0.001,0.007,0.003,-0.025,-0.013,0.009,0.009,0.014,-0.404,0.006,0.004,-0.016,0.017,-0.001,-0.062,0.016,0.179,0.021,0.022,-0.011,-0.036,0.027,0.015,unmethylated
NH19-3238,203980260091_R04C01,#122,16/12/2019,,1/9/2020,24,SB,Diagnostic,122,1,NDP,Oxford John Radcliffe Hospital,"small PA, LGG","(2) unusual histology, location, demographics",,8/17/2000,19.3,supratentorial pilocytic astrocytoma,0.27,LGG_PA_GGST,0.66,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-3238,"Histology: Low grade glioma with features compatible with pilocytic astrocytoma
Methylation class (low calibrated score): Pilocytic astrocytoma, subclass hemispheric pilocytic astrocytoma and ganglioglioma (see comment

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #122\NH19-3238,0.03,-0.064,-0.007,0.062,0.038,0.094,0.195,-0.03,0.039,-0.292,0.007,0.108,0.008,0.093,0.018,0.05,0.062,-0.047,0.218,0.207,0.116,0.045,0.066,0.165,-0.082,-0.09,-0.083,0.017,0.049,methylated
NH19-3363,203980260091_R05C01,#122,16/12/2019,,1/9/2020,24,SB,Diagnostic,122,1,NDP,Auckland (NZ),Tiny LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,9/7/1996,23.2,infratentorial pilocytic astrocytoma,0.92,LGG_PAPF,0.85,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3363,"Histology: Gliotic CNS tissue (see comment)
Methylation class cannot be established
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #122\NH19-3363,-0.16,-0.098,0.034,0.033,-0.036,-0.024,-0.232,0.031,-0.014,-0.157,-0.051,0.061,0.034,-0.121,-0.065,-0.089,0.031,-0.004,-0.099,-0.01,-0.029,-0.042,0.078,0.027,-0.085,-0.111,0.039,0.013,-0.017,unmethylated
NH19-3406,203980260091_R06C01,#122,17/12/2019,,1/9/2020,23,SB,Diagnostic,122,9,NDP,St George's Hospital London,pituicytoma versus chordoid glioma of the third ventricle,"(2) unusual histology, location, demographics",,7/9/1978,41.5,chordoid glioma,0.99,CHGL,0.9,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3406,"Histology: Features in keeping with a chordoid glioma of third ventricle
Methylation class: Chordoid glioma of the third ventricle 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #122\NH19-3406,0.077,-0.114,0.024,0.004,-0.093,0.053,0.008,-0.014,-0.036,-0.004,0.007,0.011,0.01,0.103,0.022,-0.018,0.032,-0.03,-0.021,0.013,0.003,0.023,0.011,0.112,0,0.018,-0.02,-0.05,-0.015,unmethylated
NH19-3286,203980260091_R07C01,#122,17/12/2019,,1/9/2020,23,SB,Diagnostic,122,7,NDP,NHNN,"DNET, ?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,4/19/1967,52.7,dysembryoplastic neuroepithelial tumour,0.99,LGG_DNT,0.99,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3286,"Probable dysembryoplastic neuroepithelial tumour (WHO grade I), see comment.
","Histology: Dysembryoplastic neuroepithelial tumour (WHO grade I)
Methylation class: Low grade glioma, dysembryoplastic neuroepithelial tumour
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #122\NH19-3286,0.023,-0.052,-0.007,-0.026,-0.018,-0.025,0.1,0.038,0.029,0.007,0.027,0.018,-0.031,0.013,-0.022,0.032,-0.039,0.018,0.047,0.011,-0.022,-0.061,-0.011,0.025,-0.037,-0.076,-0.011,0.003,0.043,methylated
NH19-3385,203980260091_R08C01,#122,18/12/2019,,1/9/2020,22,SB,Diagnostic,122,1,NDP,Brighton and Sussex Hospital,"HGG, type?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2E,10/3/1997,22.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.7,GBM_MES,0.75,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3385,"Anaplastic Glioma (at least WHO Grade III)

IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained
Further molecular tests: Pending  
","Histology: Anaplastic glioma
Methylation class: Glioblastoma, IDH-wild type (WHO grade IV)
MGMT Promoter: Unmethylated (0%)
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #122\NH19-3385,0.003,-0.074,0.012,-0.058,-0.114,0.016,-0.281,0.15,0.049,0.094,0.042,-0.104,-0.099,-0.091,-0.924,-0.043,-0.226,-0.215,-0.058,-0.026,-0.014,0.01,-0.213,0.061,0.117,0.047,-0.041,-0.249,-0.171,unmethylated
NH19-3039,203980260002_R01C01,#123,18/12/2019,,1/16/2020,29,SB,Diagnostic,123,1,NDP,Southampton General Hospital,Giant cell GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,9/28/1984,35.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.41,CONTR_REACT,0.62,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3039,"Glioblastoma, IDH-wildtype (WHO grade IV)

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
MGMT Promoter: Methylated (>0-5%)


","Histology: High-grade glioma, most in keeping with glioblastoma
Methylation class: ""Reactive tumour microenvironment"", please see comment
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #123\NH19-3039,-0.011,0.009,0.014,-0.011,-0.009,-0.003,-0.09,0.051,0.063,0.051,0.05,-0.001,-0.015,0.013,-0.145,-0.102,-0.038,-0.028,-0.071,-0.054,-0.034,-0.027,-0.13,-0.13,-0.198,-0.147,-0.112,-0.107,-0.091,unmethylated
NH19-3378,203980260002_R05C01,#123,18/12/2019,,1/16/2020,29,SB,Diagnostic,123,1,NDP,Oxford John Radcliffe Hospital,"HGG, Type?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,11/6/1951,68.1,"glioblastoma, IDH-wildtype, RTK1 type",0.4,GBM_RTKII,0.38,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3378,"Histology: Anaplastic astrocytoma
Methylation class: Glioblastoma, IDH-wildtype, subclass RTK1
MGMT promoter: Methylated
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #123\NH19-3378,-0.015,-0.041,0,-0.009,-0.054,0.059,-0.248,0.127,0.095,0.125,0.095,0.003,0.02,-0.027,-0.517,0.004,-0.175,-0.134,-0.02,-0.04,-0.018,-0.032,-0.194,-0.057,-0.048,-0.017,-0.246,-0.014,0.033,methylated
NH19-3423,203980260002_R06C01,#123,19/12/2019,,1/16/2020,28,SB,Diagnostic,123,1,NDP,"Charing Cross Hospital, London",Pilomyxoid A,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,12/5/1977,42.1,supratentorial midline pilocytic astrocytoma,0.15,PXA,0.19,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3423,"Histology: Pilocytic astrocytoma
Methylation class: No matching methylation class (see comment)
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #123\NH19-3423,0.049,-0.033,0.024,0.264,0.26,0.233,-0.222,0.261,0.419,0.312,0.317,0.42,0.421,0.377,-0.285,0.311,0.067,-0.05,0.095,0.38,0.406,0.395,0.026,0.042,-0.101,-0.059,0,0.385,0.415,unmethylated
NH19-3158,203980260002_R07C01,#123,23/12/2019,,1/16/2020,24,AM,Diagnostic,123,4,NDP,"Cardiff, University Hospital",Oligodendroglioma,"(4) IHC, sequencing, or copy number assay ambiguous",A1,10/6/1963,56,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.85,AIDH,0.59,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3158,"Diffuse glioma, IDH-mutant (equivalent to WHO grade II) - see comment
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained 
1p/19q: Equivocal results - see comment. 
TERT promoter: 124C> promoter variant detected (referring laboratory, S,20692/19)
","Methylation class: Oligodendroglioma, IDH mutant and 1p/19q codeleted (WHO grade II)
Please see comments regarding chromosomal losses.
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #123\NH19-3158,0.011,-0.008,0.009,0.067,0.005,-0.013,-0.051,0.261,0.249,0.244,0.233,0.257,0.191,0.226,0.011,0.03,-0.023,-0.017,-0.001,0.053,0.021,-0.021,-0.023,0.026,-0.032,-0.036,-0.395,0.066,0.032,unmethylated
NH19-3447,204088020021_R01C01,#124,24/12/2019,,1/16/2020,23,ZJ,Diagnostic,124,1,NDP,"Birmingham, Queen Elizabeth Hospital",BRAF V600E mutant LGG or glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,11/9/1978,40.3,pleomorphic xanthoastrocytoma(-like),0.98,PXA,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3447,"Histology: Astrocytoma
Methylation class: (Anaplastic) pleomorphic xanthoastrocytoma

BRAF (V600E): Mutation (detected in the referring laboratory)
CDKN2A/B: Deletion

",#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #124\NH19-3447,0.112,-0.039,-0.029,0.182,0.203,0.181,-0.091,0.02,0.077,-0.044,-0.021,0.044,0.052,0.125,-1.54,0.086,0.028,0.001,0.012,0.265,0.284,0.312,0.059,0.126,-0.069,0.06,-0.076,0.006,0.037,unmethylated
NH19-3466,204088020021_R03C01,#124,27/12/2019,,1/16/2020,20,ZJ,Diagnostic,124,1,NDP,"Leeds, St James's University Hospital",?PA; ?Diffuse glioma,"(2) unusual histology, location, demographics",A1,3/23/1962,57.8,high-grade astrocytoma with piloid features,1,ANAPA,0.87,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3466,"Histology: Pilocytic astrocytoma
Methylation class anaplastic pilocytic astrocytoma

CDKN2A/B: Deletion
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #124\NH19-3466,-0.012,0.002,-0.026,-0.05,-0.029,-0.021,-0.128,-0.057,0.161,0.059,0.114,0.027,-0.076,-0.012,-0.562,0.091,-0.007,0.016,-0.006,0.186,0.146,0.311,-0.017,0.023,-0.545,-0.142,-0.062,0.044,0.027,methylated
NH19-3485,204088020021_R04C01,#124,27/12/2019,,1/16/2020,20,ZJ,Diagnostic,124,1,NDP,Oxford John Radcliffe Hospital,Ependymoma. G II,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,4/13/1991,28.7,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,0.99,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3485,"Referred diagnosis: Ependymoma, WHO grade II
Methylation class: Ependymoma, RELA fusion
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #124\NH19-3485,0.076,0.197,-0.027,-0.008,-0.092,-0.074,0.053,-0.066,-0.101,-0.169,-0.092,0.172,0.134,0.163,-0.114,-0.063,0.055,0.044,0.09,-0.078,-0.057,-0.108,-0.026,-0.082,-0.179,-0.155,0.145,0.047,0.075,unmethylated
NH19-3503,204088020021_R05C01,#124,2/1/2020,,1/16/2020,14,ZJ,Diagnostic,124,1,NDP,Nottingham University Hospital,PA vs GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/19/1953,66.9,infratentorial pilocytic astrocytoma,0.64,LGG_PAPF,0.66,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3503,"Histology: Pilocytic astrocytoma
Methylation class: Pilocytic astrocytoma, subclass posterior fossa pilocytic astrocytoma
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #124\NH19-3503,0.093,-0.033,-0.003,0.16,-0.019,-0.019,-0.02,0.186,0.242,0.23,0.183,0.008,0.019,0.028,-0.008,-0.022,-0.04,0.008,0.045,-0.022,-0.001,0.03,-0.037,0.055,-0.085,-0.012,-0.07,0.019,0.031,unmethylated
NH19-3510,204088020021_R06C01,#124,2/1/2020,,1/16/2020,14,ZJ,Diagnostic,124,1,NDP,Southampton General Hospital,?GBM with inflammation,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,11/26/1963,56.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.53,CONTR_REACT,0.83,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3510,"Histology: Glioblastoma (WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype, subclass mesenchymal
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #124\NH19-3510,0.017,-0.047,0.008,-0.012,0.01,0.028,-0.011,-0.029,0.007,-0.031,-0.016,-0.008,-0.002,-0.036,-0.172,-0.004,-0.075,-0.036,-0.049,-0.032,0.001,-0.025,-0.058,0.01,-0.011,-0.003,-0.065,-0.005,-0.017,unmethylated
NH19-3274,203845510092_R03C01,#125,14/01/2020,,1/30/2020,16,SB,Diagnostic,125,1,NDP,Royal London Hospital,"unclear Soft tissue tumour, stanmore dg unsatisfactory for treatment","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,5/29/1989,30.5,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.24,MELAN,0.27,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3274,"Malignant spindle cell tumour, see comment.
","EXCISION MARGIN
Fragments.
Review, debulking, soft tissue, spinal canal (level not specified): the features are consistent with spindle cell sarcoma grade 2, not otherwise specified with aberrant cytokeratin expression.
Clinical and radiological correlation is recommended.
Resection margins: intralesional excision.
Lymphovascular invasion: not detected.
Tumour maximum dimension: 25mm.
Pathological staging: pT1b Nx Mx G2 (TNM
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #125\NH19-3274,-0.056,0.289,0.083,-0.082,0.171,0.398,0.013,-0.114,-0.301,-0.272,-0.111,0.303,-0.053,-0.095,0.084,0.115,-0.169,0.079,-0.129,0.173,-0.014,-0.043,0.176,-0.229,0.002,-0.002,-0.066,0.042,-0.053,methylated
NH20-77,203845510092_R04C01,#125,14/01/2020,,1/30/2020,16,SB,Diagnostic,125,1,NDP,St George's Hospital London,Small spinal sample - possibly non-diagn,"(2) unusual histology, location, demographics",A,6/12/1965,54.6,posterior fossa ependymoma group A1,0.1,GBM_MES,0.12,0.96,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-77,"Spinal cord and nerve root, small clusters of the ependymal cells
No matching methylation class (but see diagnostic comment)
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #125\NH20-77,0.008,-0.041,0.021,0.005,-0.021,-0.016,-0.059,-0.018,-0.019,-0.076,-0.008,0.034,0.014,-0.023,-0.002,-0.006,-0.03,-0.023,-0.043,-0.009,-0.03,-0.032,0.046,0.028,-0.052,-0.018,-0.035,0.015,0.016,unmethylated
NH20-122,203980260068_R01C01,#126,16/01/2020,,1/30/2020,14,SB,Diagnostic,126,4,NDP,St George's Hospital London,"anaplastic pilocytic? ATRX loss, H3 K27M neg","(4) IHC, sequencing, or copy number assay ambiguous",A,9/23/1995,24.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.95,AIDH,0.98,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-122,"Histology: Diffuse astrocytoma 
Methylation class: Glioma, IDH-mutant, subclass astrocytoma
","Histology, molecular and methylation profile: 
Diffuse astrocytoma, IDH-mutant (WHO grade II) 
IDH1/2Seq: IDH1 mutation 
ATRX (IHC): Loss of expression (indicates mutation)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #126\NH20-122,-0.281,-0.029,0.043,-0.024,0.003,0.072,0.001,-0.003,-0.034,-0.026,-0.012,0.002,-0.014,-0.022,-0.033,0.002,-0.011,0.053,-0.038,0.02,-0.023,-0.024,-0.048,-0.023,-0.028,-0.048,-0.045,-0.005,0.028,methylated
NH20-107,203980260068_R02C01,#126,16/01/2020,,1/30/2020,14,SB,Diagnostic,126,1,NDP,Auckland (NZ),,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,7/7/1993,26.5,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.99,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-107,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation class: Pilocytic astrocytoma
BRAF duplication
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #126\NH20-107,-0.041,0.031,0.014,0.056,0.024,0.04,0.078,-0.005,0.012,-0.029,0.249,0.011,0.038,-0.034,0.011,0.007,-0.021,-0.005,-0.013,-0.002,-0.006,0.022,0.003,-0.042,-0.067,-0.111,0.05,-0.05,-0.001,unmethylated
NH20-147,203980260068_R03C01,#126,20/01/2020,,1/30/2020,10,SB,Diagnostic,126,4,NDP,"Cardiff, University Hospital",,"(4) IHC, sequencing, or copy number assay ambiguous",B2,1/9/1972,48.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-147,"Histology: Anaplastic astrocytoma (WHO Grade III)
Methylation class: IDH glioma, subclass high grade astrocytoma

ATRX (IHC): Loss of expression (indicates mutation)
MGMT Promoter: Methylated   

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #126\NH20-147,-0.079,0.014,-0.038,0.005,-0.002,0.029,-0.013,0.219,0.369,0.472,0.277,-0.205,-0.027,-0.071,-0.105,0.053,-0.018,-0.16,-0.001,0.035,0.012,0.012,-0.244,0.037,0.033,0.034,-0.074,-0.121,-0.118,methylated
NH20-123,203980260068_R04C01,#126,21/01/2020,,1/30/2020,9,SB,Diagnostic,126,1,NDP,"Leeds, St James's University Hospital",PXA?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/1/1953,66.4,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.88,0.46,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-123,"Histology: Glioblastoma (WHO grade IV)
Methylation class: Glioblastoma, IDH-wildtype, subclass mesenchyma
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #126\NH20-123,0.046,0.016,0.027,-0.013,0,0.003,0.035,0.157,0.111,0.169,0.114,-0.075,-0.039,-0.023,-0.451,-0.143,-0.166,-0.122,-0.032,0.013,0.049,0.011,-0.054,-0.024,-0.193,-0.074,-0.008,-0.147,-0.024,unmethylated
NH20-143,203980260068_R06C01,#126,21/01/2020,,1/30/2020,9,SB,Diagnostic,126,1,NDP,Birmingham Children Hospital,Pilocytic?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/3/2005,14.7,supratentorial pilocytic astrocytoma,0.58,LGG_PA_GGST,0.88,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-143,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation class: Pilocytic astrocytoma, subclass hemispheric pilocytic astrocytoma and ganglioglioma (see comment)
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #126\NH20-143,-0.135,-0.174,-0.13,-0.053,-0.082,0.021,0,0.095,0.156,0.147,0.109,-0.008,0.019,-0.005,-0.188,-0.162,-0.049,-0.016,0.026,0.087,0.072,0.113,-0.16,0.019,-0.005,-0.03,-0.051,-0.022,0.018,unmethylated
NH20-161,203980260068_R08C01,#126,22/01/2020,,1/30/2020,8,SB,Diagnostic,126,2,NDP,"Cardiff, University Hospital",Anaplastic ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,5/14/2011,8.7,posterior fossa ependymoma group A2,0.99,EPN_PFA,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-161,"Histology: Anaplastic ependymoma (WHO grade III)
Histone K27me3: Loss of expression
Methylation class: Ependymoma posterior fossa group A
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #126\NH20-161,0.048,0.066,0.05,-0.048,-0.017,-0.004,-0.509,0.016,-0.03,0.008,-0.021,-0.009,0.049,0.058,0.1,-0.002,0.016,0.052,0.118,0.039,-0.011,0.035,-0.004,0.078,-0.032,0,-0.037,-0.452,-0.44,unmethylated
NH20-113,203845510096_R01C01,#127,24/01/2020,14/02/2020,2/14/2020,21,SB,Diagnostic,127,3,NDP,Brighton and Sussex Hospital,"IDH mutant astroc, some small necrosis ","(4) IHC, sequencing, or copy number assay ambiguous",,3/12/1980,39.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-113,"Diffuse astrocytoma, IDH1-mutant (WHO grade II)

IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Histology: Diffuse astrocytoma, IDH-mutant (WHO Grade II)
Methylation class: IDH glioma, subclass astrocytoma   
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #127\NH20-113,0.012,-0.106,0.008,-0.044,-0.033,-0.023,-0.544,0.006,-0.067,-0.08,-0.049,-0.006,0.034,0.161,-0.219,0.012,0.02,0.002,-0.077,-0.012,-0.011,-0.016,-0.191,0.048,0.021,-0.002,-0.434,0.026,-0.007,methylated
NH20-193,203845510096_R02C01,#127,28/01/2020,14/02/2020,2/14/2020,17,SB,Diagnostic,127,3,NDP,NHNN,Large low grade intrinsic tumour,"(4) IHC, sequencing, or copy number assay ambiguous",DEF1A,5/26/1979,40.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.97,AIDH,0.85,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-193,"Infiltrating glioma  see comment 

IDH1 (R132H IHC): No mutation 
ATRX (IHC): See text
Further molecular tests: Pending
","Histology: Infiltrating glioma; with features compatible with diffuse astrocytoma
Methylation class: Astrocytoma, IDH-mutant
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #127\NH20-193,-0.036,-0.316,-0.09,-0.014,-0.048,0.056,0.021,-0.029,-0.049,-0.006,-0.02,0.081,0.099,0.025,0.048,0.058,0.008,0.094,-0.031,-0.149,-0.016,-0.053,-0.017,0.087,0.136,0.127,-0.021,-0.011,0.015,methylated
NH20-232,203845510096_R04C01,#127,29/01/2020,14/02/2020,2/14/2020,16,SB,Diagnostic,127,4,NDP,"Leeds, St James's University Hospital","Meningioma, Other type? ","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,6/23/2010,9.6,Infant-type hemispheric glioma,0.37,IHG,0.29,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-232,"Histology: Glioma with spindle cell features (see comment)
Methylation profile: No matching methylation class
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #127\NH20-232,-0.087,-0.058,0.068,-0.097,-0.228,-0.186,-0.309,-0.218,-0.107,-0.166,-0.041,0.144,-0.005,-0.152,-0.014,0.032,-0.05,-0.146,0.132,-0.166,0.056,0.163,-0.146,0.088,-0.053,0.097,0.149,-0.014,0.021,unmethylated
NH20-269,203845510096_R06C01,#127,3/2/2020,14/02/2020,2/14/2020,11,SB,Diagnostic,127,1,NDP,Nottingham University Hospital,,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/17/1978,41.7,dysembryoplastic neuroepithelial tumour,0.97,LGG_DNT,0.91,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-269,"Histology: glio-neuronal tumour
Methylation class: Low grade glioma, see comment

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #127\NH20-269,0.037,-0.05,0.034,0.269,0.421,-0.033,-0.026,0.245,0.252,0.236,0.25,0.072,0.076,-0.07,0.026,0.009,0.261,0.21,0.06,0.009,0.034,-0.019,0.036,0.107,-0.09,0.017,0.034,0.094,0.071,unmethylated
NH20-250,203845510096_R07C01,#127,31/01/2020,14/02/2020,2/14/2020,14,SB,Diagnostic,127,1,NDP,"Cambridge, Addenbrooke's Hospital",Ganglioglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/21/1958,61.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.44,CONTR_REACT,0.54,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-250,"Histology: High-grade glioma
Methylation class: No matching methylation class:
Copy number profile: Chromosome 7 gain, chromosome 10 loss
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #127\NH20-250,0.384,-0.11,-0.014,-0.027,-0.069,0.021,-0.074,0.087,0.15,0.105,0.156,-0.002,-0.072,0.008,-0.062,-0.08,-0.07,-0.162,0.064,0.053,0.043,0.058,0.01,0.031,-0.023,-0.114,0.006,-0.027,0.094,unmethylated
NH20-270,203845510096_R08C01,#127,31/01/2020,14/02/2020,2/14/2020,14,SB,Diagnostic,127,3,NDP,"Birmingham, Queen Elizabeth Hospital","Pineal tumour, K27 no mut","(2) unusual histology, location, demographics",A1,3/29/2001,18.8,posterior fossa ependymoma group B,1,EPN_PFB,0.9,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-270,"Histology: Anaplastic ependymoma 
Methylation class: Ependymoma, posterior fossa group B (calibrated score 0.88)
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #127\NH20-270,-0.116,-0.194,-0.086,0.139,0.095,0.119,-0.123,0.195,0.167,0.056,0.149,0.352,0.353,0.339,0.215,0.4,-0.102,-0.11,0.143,0.355,0.273,0.344,-0.183,-0.103,-0.162,-0.156,0.139,-0.597,-0.561,unmethylated
NH20-365,203845510085_R02C01,#129,12/2/2020,28/02/2020,2/27/2020,15,SB,Diagnostic,129,1,NDP,"Birmingham, Queen Elizabeth Hospital","Midline gluoma, H3 K27 neg","(4) IHC, sequencing, or copy number assay ambiguous",A1,1/5/1985,35.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.79,AIDH,0.87,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-365,"Methylation profile: Astrocytoma, IDH-mutant  see comment
CDKN2A/B (Illumina array): No deletion
MGMT Promoter (Illumina array): Methylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #129\NH20-365,-0.026,-0.031,0.066,-0.007,-0.013,0.073,0.008,0.002,0.237,0.28,0.196,0.006,0.018,-0.004,0.032,0.039,-0.016,0.066,-0.03,0.021,0.033,-0.055,-0.002,-0.003,-0.049,-0.061,-0.091,-0.026,0.081,methylated
NH20-360,203845510085_R05C01,#129,12/2/2020,28/02/2020,2/27/2020,15,SB,Diagnostic,129,5,NDP,Oxford John Radcliffe Hospital,Myxo-Pap Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2,8/1/1971,48.5,rosette-forming glioneuronal tumour,0.76,LGG_RGNT,0.89,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-360,"Histology: Low grade glioma
Methylation profile: Raising the possibility of pilocytic astrocytoma  see comment
ATRX (IHC): Retained     
Histone H3F3A (K27M IHC): No mutation     
BRAF (V600E IHC): No mutation
MGMT Promoter (Illumina array): Methylated 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #129\NH20-360,-0.012,0.015,0.012,0.003,-0.055,0.036,0.022,-0.006,-0.026,-0.045,-0.016,0.001,0.046,0.001,0.02,0.045,-0.013,0.017,0.019,-0.015,0,-0.029,0.026,-0.017,0.002,0.002,-0.04,-0.031,0.047,methylated
NH20-362,203845510085_R06C01,#129,12/2/2020,28/02/2020,2/27/2020,15,SB,Diagnostic,129,4,NDP,"Belfast, Royal Victoria Hospital",GBM?,"(4) IHC, sequencing, or copy number assay ambiguous",,7/20/1966,53.6,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.79,OIDH,0.81,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-362,"Histology and methylation profile: 
Oligodendroglioma, IDH-mutant and 1p/19q codeleted (WHO grade II)
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained
1p/19q (Illumina array): Codeleted
MGMT Promoter (Illumina array): Methylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #129\NH20-362,0.088,-0.212,0.038,-0.061,0.168,-0.026,-0.375,-0.112,-0.061,-0.041,0.046,0.218,-0.075,0.438,-0.318,0.17,-0.11,-0.151,-0.237,0,0.116,-0.081,-0.14,0.174,-0.149,-0.062,-0.202,0.127,0.16,methylated
NH20-204,203845520051_R01C01,#130,17/02/2020,6/3/2020,3/6/2020,18,SB,Diagnostic,130,4,NDP,Oxford John Radcliffe Hospital,,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,6/14/1969,50.6,"glioblastoma, IDH-wildtype, RTK1 type",0.37,GBM_MID,0.6,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-204,"Diffuse glioma - see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: No amplification          
CDKN2A/B: No deletion          
Histone H3F3A: No mutation     
MGMT Promoter: Unmethylated (0%)
","Methylation profile: Raising the possibility of glioblastoma, IDH-wildtype (WHO grade IV)  see supplementary comment 

MGMT Promoter (HRM assay and Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #130\NH20-204,-0.052,0.158,-0.002,-0.036,0.21,-0.169,0.014,-0.328,0.159,0.231,0.098,0.003,0.008,0.4,0.03,-0.044,0,0.017,0.047,0.014,-0.017,0.048,-0.002,-0.086,-0.12,-0.056,-0.141,-0.346,-0.26,unmethylated
NH20-435,203845520051_R02C01,#130,17/02/2020,6/3/2020,3/6/2020,18,SB,Diagnostic,130,1,NDP,"Leeds, St James's University Hospital",Cerebellar glioma HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C1,3/29/1952,67.9,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-435,"Histology and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV) 
MGMT Promoter (Illumina array): Unmethylated  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #130\NH20-435,0.111,0.111,0.057,-0.026,1.011,0.032,0.027,0.25,0.218,0.232,0.242,0.233,0.218,0.194,-0.576,-0.088,-0.565,-0.397,-0.014,-0.002,1.216,-0.115,-0.159,-0.074,-0.002,-0.076,-0.066,-0.019,0.113,unmethylated
NH20-126,203845520051_R04C01,#130,17/02/2020,6/3/2020,3/6/2020,18,SB,Diagnostic,130,3,NDP,NHNN,Anaplastic PA?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",127057-01,#N/A,#N/A,high-grade astrocytoma with piloid features,1,ANAPA,1,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-126,#N/A,#N/A,(1) confirmation of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #130\NH20-126,0.063,0.039,-0.071,-0.093,0.069,0.01,-0.068,-0.086,0.015,-0.079,0.013,0.128,0.044,0.073,-0.09,0.057,-0.16,-0.232,-0.119,0.014,0.827,1.796,-0.361,0.067,-0.034,-0.038,-0.088,-0.012,0.06,methylated
NH20-403,203845520051_R05C01,#130,18/02/2020,6/3/2020,3/6/2020,17,ZJ,Diagnostic,130,1,NDP,Royal London Hospital,Pilocytic astrocytoma in occipital lobe,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,4/11/1981,38.9,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.94,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-403,"Pilocytic astrocytoma (WHO grade I)  see comment 

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained 
Further molecular tests: Pending 
","Histology and methylation profile: Pilocytic astrocytoma (WHO grade I) 
MGMT Promoter (Illumina array): Unmethylated 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #130\NH20-403,-0.059,-0.018,-0.026,0.056,0.102,-0.006,0.176,0.109,0.112,0.163,0.056,0.129,0.137,0.102,0.023,0.018,0.015,0.017,-0.108,-0.071,-0.061,0.008,-0.022,-0.124,-0.098,-0.025,-0.166,-0.054,-0.015,unmethylated
NH20-451,203845520051_R06C01,#130,19/02/2020,6/3/2020,3/6/2020,16,ZJ,Diagnostic,130,2,NDP,St George's Hospital London,"Thoracic ependymoma, WHO G II","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,2/19/1951,69,spinal ependymoma,1,EPN_SPINE,1,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-451,"Histology: Ependymoma (WHO grade II)  see comment
Methylation profile: Ependymoma, spinal
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #130\NH20-451,0.081,0.222,0.142,0.02,-0.014,-0.016,-0.017,0.142,0.196,0.104,0.184,0.015,0.026,0.014,0.207,0.151,-0.007,-0.024,0.013,0.164,0.141,0.17,-0.001,0.094,-0.051,-0.037,-0.111,-0.269,-0.235,unmethylated
NH20-450,203845520051_R07C01,#130,19/02/2020,6/3/2020,3/6/2020,16,ZJ,Diagnostic,130,2,NDP,St George's Hospital London,"Thoracic ependymoma, WHO G II","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,6/12/1965,54.7,spinal ependymoma,1,EPN_SPINE,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-450,"Histology: Ependymoma (WHO grade II)  see comment
Methylation profile: Ependymoma, spinal 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #130\NH20-450,0.011,0.222,0.202,0.019,-0.009,-0.016,-0.023,0.205,0.25,0.15,0.211,0.251,0.182,0.176,0.263,0.203,-0.01,-0.031,0.015,0.237,0.177,0.222,-0.037,0.092,-0.03,-0.021,-0.129,0.029,0.105,unmethylated
NH20-500,203845520071_R03C01,#131,23/02/2020,13/03/2020,3/12/2020,18,ZJ,Diagnostic,131,1,NDP,Oxford John Radcliffe Hospital,"LGG, intraventricular","(2) unusual histology, location, demographics",2A,3/1/1956,64,supratentorial pilocytic astrocytoma,0.97,LGG_DNT,0.52,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-500,"Histology and methylation profile: Low grade glioma  see comment 
MGMT Promoter (Illumina array): Methylated
","Low grade glioma (see previous report)
BRAF: No mutations
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #131\NH20-500,-0.015,-0.073,0.004,0.027,-0.064,0.111,0.161,0.089,0.115,0.121,0.095,-0.012,0.025,-0.047,-0.006,-0.016,0.077,0.098,-0.044,0.06,0.07,0.104,0.002,-0.075,0.011,-0.013,-0.106,0.032,0.006,methylated
NH20-478,203845520071_R04C01,#131,24/02/2020,13/03/2020,3/12/2020,17,ZJ,Diagnostic,131,1,NDP,St George's Hospital London,"Ependymoma, WHO G II","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,11/2/1987,32.3,spinal ependymoma,1,EPN_SPINE,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-478,"Histology: Ependymoma (WHO grade II)  see comment
Methylation profile: Ependymoma, spinal 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #131\NH20-478,0.004,-0.005,0.011,0.026,-0.015,-0.021,-0.021,0.196,0.248,0.219,0.189,0.212,0.209,0.162,0.195,0.215,0.008,-0.008,-0.016,0.04,0.029,0.034,-0.029,0.053,-0.001,-0.022,-0.06,-0.3,-0.296,unmethylated
NH20-497,203845520071_R05C01,#131,24/02/2020,13/03/2020,3/12/2020,17,ZJ,Diagnostic,131,1,NDP,Oxford John Radcliffe Hospital,"Glioblastoma, See also NH13-451","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,1/14/1967,53.1,pleomorphic xanthoastrocytoma(-like),0.82,GBM_MES,0.74,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-497,"Histology and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV) 
MGMT Promoter (Illumina array): Methylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #131\NH20-497,0.022,-0.053,-0.016,-0.029,-0.012,0.138,-0.05,0.128,0.178,0.202,0.126,-0.22,-0.016,-0.044,-0.644,-0.016,-0.239,-0.143,-0.041,0.096,0.118,0.169,-0.04,-0.005,-0.015,-0.014,-0.06,-0.165,-0.178,methylated
NH20-522,203845520071_R07C01,#131,26/02/2020,20/03/2020,3/12/2020,15,ZJ,Diagnostic,131,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/4/2016,3.5,infratentorial pilocytic astrocytoma,0.48,LGG_PAMID,0.81,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-522,"Histology and methylation profile: Pilocytic astrocytoma (WHO grade I) 
MGMT Promoter (Illumina array): Unmethylated 
","Pilocytic astrocytoma (WHO grade I)
BRAF: No mutations
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #131\NH20-522,0.01,-0.025,0.026,0.004,-0.033,0.004,0.008,-0.012,0.007,0.008,-0.002,0.003,0.034,-0.011,-0.029,0.001,-0.022,0.008,0.044,0.001,-0.001,0.023,-0.009,-0.006,-0.001,-0.009,-0.054,0.007,0.014,unmethylated
NH20-417,203845520070_R04C01,#132,25/02/2020,13/03/2020,3/12/2020,16,SB,Diagnostic,132,3,NDP,"Stanmore, Royal National Orthopedic Hospital",Spinal Ependymoma classic,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A,3/25/1959,60.9,myxopapillary ependymoma,1,EPN_MPE,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-417,"Spinal ependymoma, Histological subtype : Ependymoma (WHO grade II)
","Histology: Ependymoma (WHO grade II)  see supplementary comment
Methylation profile: Ependymoma, myxopapillary 
MGMT Promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #132\NH20-417,0.001,-0.009,0.064,0.045,-0.002,0.01,0.047,0.265,0.335,0.261,0.283,0.315,0.255,0.332,0.268,0.349,-0.015,0.015,0.256,0.037,-0.039,0.072,-0.018,0.054,-0.037,-0.007,0.082,-0.445,-0.329,unmethylated
NH20-528,203845520070_R05C01,#132,26/02/2020,20/03/2020,3/12/2020,15,ZJ,Diagnostic,132,3,NDP,Bristol,Cerebellar pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/5/1971,48.9,infratentorial pilocytic astrocytoma,0.95,LGG_PAPF,0.81,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-528,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Pilocytic astrocytoma, posterior fossa 
MGMT Promoter (Illumina array): Methylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #132\NH20-528,0.057,-0.022,0.008,0.102,0.133,0.001,-0.065,-0.036,-0.036,-0.028,-0.016,0.006,0.091,0.003,0.01,-0.022,-0.014,0.017,0.062,-0.019,0.004,0.04,-0.24,-0.001,-0.002,0.006,0.02,-0.006,0.087,methylated
NH20-544,203845520070_R07C01,#132,27/02/2020,20/03/2020,3/12/2020,14,SB,Diagnostic,132,1,NDP,"Cambridge, Addenbrooke's Hospital",GBM DD anapla GG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,2/21/1958,62.1,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.86,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-544,"Histology and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV) 
MGMT Promoter (Illumina array): Methylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #132\NH20-544,0.282,-0.051,0.002,-0.021,-0.043,0.083,-0.047,0.23,0.262,0.265,0.206,-0.007,0.019,0.002,-0.039,-0.019,-0.146,-0.104,-0.033,-0.001,0.006,0.012,-0.064,-0.005,-0.055,-0.025,-0.049,-0.006,0.044,methylated
NH20-471,203845520070_R08C01,#132,27/02/2020,20/03/2020,3/12/2020,14,ZJ,Diagnostic,132,6,NDP,"Birmingham, Queen Elizabeth Hospital","Glioma, IDH-mutant; ATRX retained","(4) IHC, sequencing, or copy number assay ambiguous",C2,12/20/1979,40.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.33,AIDH,0.38,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-471,"Molecular and methylation profile: Diffuse astrocytoma, IDH-mutant (WHO grade II)
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: No amplification          
CDKN2A/B: No deletion          
MGMT Promoter: Methylated (>10-25%) 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #132\NH20-471,0.01,0.003,0.019,-0.06,0.003,-0.025,0.026,-0.028,-0.052,-0.042,-0.013,0.003,0.039,0.116,-0.045,-0.021,-0.02,0.08,0.039,0.056,-0.002,-0.011,-0.023,0,-0.023,-0.046,-0.003,0.008,0.027,methylated
NH20-336,203845510052_R01C01,#133,2/3/2020,20/03/2020,3/20/2020,18,ZJ,Diagnostic,133,2,NDP,Romford,Reported as high grade neuroepithelial tumour (likely GBM-IDH-wt),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/15/1944,75.7,"glioblastoma, IDH-wildtype, RTK1 type",0.61,GBM_MID,0.92,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-336,"High grade neuroepithelial tumour 6 see comment 

IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: High grade neuroepithelial tumour, compatible with glioblastoma
Methylation class (calibrated score): glioblastoma, IDH wildtype, subclass midline (0.91/0.64)
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #133\NH20-336,0.28,-0.103,0.08,0.1,0.773,0.045,-0.417,-0.017,0.251,0.214,0.169,-0.454,0.115,0.004,-2.264,0.182,0.016,0.016,0.007,-0.036,0.497,1.356,-0.403,-0.422,-0.629,0.227,-0.025,-0.004,0.041,unmethylated
NH20-539,203845510052_R02C01,#133,2/3/2020,20/03/2020,3/20/2020,18,ZJ,Diagnostic,133,4,NDP,"Cardiff, University Hospital","Glioma, IDH-mutant","(4) IHC, sequencing, or copy number assay ambiguous",A1,11/22/1973,46.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.36,OIDH,0.76,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-539,"Integrated diagnosis: Infiltration of an oligodendroglioma, IDH-mutant and 1p/19q-codeleted (WHO grade II)
Methylation class (calibrated score): IDH glioma, subclass 1p/19q-codeleted oligodendroglioma(0.87/0.79)
IDH1 (R132H IHC); Mutation
ATRX (IHC): Retained
1p/19q: Codeleted
Histone H3 K27me3: Loss of expression 
MGMT Promoter: Methylated
 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #133\NH20-539,0.015,-0.027,0.006,-0.007,-0.032,0.019,-0.078,-0.066,-0.004,-0.036,0.008,0.011,-0.011,-0.08,-0.006,0.005,-0.033,-0.031,-0.031,-0.057,-0.001,-0.071,-0.003,0.005,-0.032,-0.029,-0.115,0.028,0.047,methylated
NH20-564,203845510052_R03C01,#133,2/3/2020,20/03/2020,3/20/2020,18,ZJ,Diagnostic,133,1,NDP,Southampton General Hospital,LGG vs glioneuronal tumour,"(2) unusual histology, location, demographics",1A,11/3/1985,34.3,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.59,LGG_RGNT,0.31,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-564,"Histology: Low grade glioneuronal tumour, in keeping with Dysembryoplastic neuroectodermal tumour (WHO grade I)
Methylation class (calibrated score): See comment
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #133\NH20-564,-0.001,-0.032,0.019,-0.018,-0.04,-0.019,-0.073,0.144,-0.001,-0.066,0.182,0.012,0.072,0.005,-0.033,0.006,-0.046,-0.026,-0.017,-0.034,-0.031,-0.051,-0.02,-0.002,-0.036,0.021,0.032,0.026,0.037,unmethylated
NH20-567,203845510052_R04C01,#133,2/3/2020,20/03/2020,3/20/2020,18,ZJ,Diagnostic,133,3,NDP,"Cambridge, Addenbrooke's Hospital",Ganglioglioma vs inflammation,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/7/1998,22.2,ganglioglioma,0.35,CONTR_REACT,0.18,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-567,"Histology: CNS tissue, gliosis and mild inflammation
Methylation class (calibrated score): Control tissue, hemispheric cortex (0.45)
  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #133\NH20-567,0.043,-0.048,0.003,0.034,-0.061,-0.01,-0.085,-0.05,-0.008,-0.094,0.012,0.024,0.051,-0.037,0.002,-0.047,-0.036,-0.02,-0.047,-0.078,-0.05,0.058,0.059,-0.028,-0.002,-0.022,0.009,0.043,0.009,unmethylated
NH20-397,203845510052_R06C01,#133,4/3/2020,20/03/2020,3/20/2020,16,ZJ,Diagnostic,133,5,NDP,"Belfast, Royal Victoria Hospital",BRAF V600E mutant glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,9/15/1950,69.4,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-397,"Glioma, BRAF-V600E mutant  for grading, see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: No amplification          
BRAF (V600E IHC and Seq): Mutation
MGMT promoter: Unmethylated (0%)
","Histology: Glioma, BRAF-mutant
Methylation class (calibrated score): (anaplastic) pleomorphic xanthoastrocytoma(0.99)
CDKN2A/B: homozygous deletion
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #133\NH20-397,-0.073,0.092,0.221,-0.024,-0.018,0.009,-0.009,-0.066,-0.094,-0.12,-0.054,-0.026,0.078,-0.021,-1.154,0.005,-0.293,-0.213,0.019,-0.015,0.006,-0.034,-0.02,-0.001,-0.018,-0.016,0.009,-0.038,0.036,unmethylated
NH20-570,203845510052_R07C01,#133,5/3/2020,20/03/2020,3/20/2020,15,ZJ,Diagnostic,133,1,NDP,NHNN,DNET in 2009; now enhancing lesion which looks like pilocytic astrocytoma,"(2) unusual histology, location, demographics",DEF1D,1/22/1992,28.1,supratentorial pilocytic astrocytoma,0.96,LGG_PA_GGST,0.66,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-570,"Low grade glial or glioneuronal tumour (WHO grade I)  see comment 
","Histology: Low grade glial or glioneuronal tumour (WHO grade I)
Methylation class (calibrated score): Low grade glioma, subclass hemispheric pilocytic astrocytoma and ganglioglioma (0.59/0.55) (see comment).
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #133\NH20-570,-0.058,-0.062,0.022,0.043,0.091,0.15,0.264,0.103,0.082,0.047,0.104,0.135,0.201,0.13,0.05,-0.064,0.025,0.016,0.163,-0.071,-0.019,-0.081,0.021,0.004,0.015,-0.059,-0.015,0.01,0.089,unmethylated
NH09-1467,203845510052_R08C01,#133,6/3/2020,20/03/2020,3/20/2020,14,ZJ,Diagnostic,133,1,NDP,NHNN,"DNET, 2009 resection","(2) unusual histology, location, demographics",DEF1B,1/22/1992,#N/A,dysembryoplastic neuroepithelial tumour,0.8,LGG_DNT,0.83,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH09-1467,"Dysembryoplastic neuroepithelial tumour (WHO Grade I)
","Histology: Dysembryoplastic neuroepithelial tumour (WHO grade I)
Methylation class (calibrated score): low grade glioma, dysembryoplastic neuroepithelial tumor (0.39)
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #133\NH09-1467,-0.015,0.001,0.051,0.032,-0.142,-0.009,0.118,-0.034,-0.025,-0.154,-0.045,0.064,0.121,0.017,0.002,0.068,-0.02,-0.069,0.117,-0.009,0.053,0.046,-0.066,-0.07,-0.036,0.055,-0.123,-0.064,0.114,unmethylated
NH20-601,203845520072_R03C01,#134,6/3/2020,20/03/2020,3/20/2020,14,ZJ,Diagnostic,134,1,NDP,Nottingham University Hospital,?GBM; ?Anaplastic oligo; ?Other,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/23/1959,60.5,pleomorphic xanthoastrocytoma(-like),0.71,PXA,0.41,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-601,"Histology:  glial tumour, NOS
Methylation class (calibrated score): glioblastoma, IDH-wildtype (0.48)
  
","Integrated diagnosis: Glioma, see comment
Histology: Glioma tumour, NOS
Methylation profile: Pleomorphic xanthoastrocytoma (calibrated score 0.7, see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #134\NH20-601,-0.115,-0.114,0.154,-0.069,-0.027,0.105,-0.157,0.273,0.291,0.276,0.222,0.136,0.192,0.145,0.278,0.317,-0.063,-0.051,-0.093,0.082,0.099,0.119,-0.023,-0.071,-0.202,-0.12,0.25,-0.061,0.014,unmethylated
NH20-579,203845520072_R04C01,#134,6/3/2020,20/03/2020,3/20/2020,14,ZJ,Diagnostic,134,1,NDP,NHNN,Recurrent post fossa ependymoma (first resection 10 years ago),"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,9/26/1947,72.5,posterior fossa subependymoma,1,SUBEPN_PF,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-579,"Recurrent/residual ependymoma (WHO grade II)  for grading, see comment  
","Histology: Ependymal tumour
Methylation class (calibrated score): subependymoma, posterior fossa (0.99) 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #134\NH20-579,0.02,-0.054,0.023,-0.029,0.009,-0.011,-0.453,-0.032,-0.033,-0.032,0.002,0.025,-0.013,-0.014,-0.046,-0.023,-0.04,-0.015,-0.079,-0.042,-0.015,0.037,-0.024,-0.034,-0.013,0.031,0.008,-0.001,0.049,methylated
NH20-589,203845520072_R07C01,#134,6/3/2020,20/03/2020,3/20/2020,14,ZJ,Diagnostic,134,2,NDP,"Stanmore, Royal National Orthopedic Hospital",Myxopapillary ependymoma vs classic ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,#N/A,#N/A,myxopapillary ependymoma,1,EPN_MPE,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-589,#N/A,#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #134\NH20-589,0.011,0.009,0.074,0.162,0.203,0.024,-0.074,0.248,0.256,0.176,0.24,0.27,0.319,0.253,0.262,0.313,-0.005,0.046,0.226,0.021,0.084,-0.064,-0.012,-0.014,0.007,0.004,-0.035,0.033,0.074,unmethylated
NH20-620,203845520072_R08C01,#134,10/3/2020,20/03/2020,3/20/2020,10,ZJ,Diagnostic,134,1,NDP,"Cardiff, University Hospital",Subependymoma vs ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,6/23/1977,42.7,posterior fossa subependymoma,1,SUBEPN_PF,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-620,"Histology: Subependymoma (WHO grade I)
Methylation class: subependymoma, posterior fossa
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #134\NH20-620,0.023,-0.011,0.047,0.069,-0.012,-0.026,-0.083,-0.07,-0.054,-0.134,0.029,0.018,0.084,-0.005,-0.056,-0.008,-0.011,0.005,0.012,-0.064,0.035,0.096,0.053,0.036,0.053,0.077,0.021,-0.021,0.051,unmethylated
NH20-627,203845520031_R01C01,#135,10/3/2020,30/03/2020,3/27/2020,17,ZJ,Diagnostic,135,1,NDP,Lund (SE),?subependymoma; ?glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",102,10/25/1943,76.4,"control tissue, cerebellar hemisphere",0.94,CONTR_CEBM,1,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-627,"Histology: Low grade glial/glioneuronal tumour
Methylation class (calibrated score): control tissue, cerebellar hemisphere (0.98)
  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #135\NH20-627,0.13,0.053,0.004,-0.066,0.015,0.015,-0.158,0.094,-0.053,-0.051,0.039,0.018,0.003,-0.005,-0.126,-0.028,-0.066,-0.047,-0.061,-0.145,-0.169,0.027,-0.049,0.001,-0.004,0.001,0.124,-0.016,0.017,unmethylated
NH20-661,203845520031_R04C01,#135,11/3/2020,30/03/2020,3/27/2020,16,ZJ,Diagnostic,135,1,NDP,Bristol,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,2/28/1960,60.1,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.99,GBM_RTKII,0.41,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-661,"Histology: Diffusely infiltrating glioma
Methylation class (calibrated score): No matching methylation class
  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #135\NH20-661,0.026,-0.015,0.04,0.03,-0.006,-0.024,0.008,0.007,0.076,0.01,0.049,-0.019,0.045,0.053,-0.135,-0.141,-0.055,0.004,-0.048,-0.058,-0.035,0.077,-0.041,-0.051,0.047,0.045,0.017,-0.023,0.076,unmethylated
NH20-638,203845520031_R05C01,#135,11/3/2020,30/03/2020,3/27/2020,16,ZJ,Diagnostic,135,2,NDP,Romford,Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,10/7/1993,26.4,posterior fossa subependymoma,0.99,SUBEPN_PF,0.98,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-638,"Subependymoma (WHO grade I)  see comment
","Histology: subependymoma (WHO grade I)
Methylation class (calibrated score): subependymoma, posterior fossa (0.66)
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #135\NH20-638,-0.082,-0.192,0.113,-0.022,0.109,-0.153,-0.24,-0.129,-0.006,-0.396,0.014,0.038,0.173,0.075,-0.16,-0.023,-0.061,-0.029,0.009,-0.084,-0.001,0.179,-0.043,0.072,0.259,0.119,0.07,0.116,0.028,unmethylated
NH20-689,203845510004_R01C01,#136,14/03/2020,3/4/2020,4/2/2020,19,ZJ,Diagnostic,136,3,NDP,Plymouth,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",S2,12/25/1999,20.2,infratentorial pilocytic astrocytoma,0.97,LGG_PAPF,0.93,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-689,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation class (calibrated score): low grade glioma, subclass posterior fossa pilocytic astrocytoma (0.83/0.80)
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #136\NH20-689,0.033,-0.075,-0.014,0.004,-0.02,0.121,0.176,0.242,0.336,0.335,0.284,0.047,0.023,0.015,-0.02,-0.015,-0.038,-0.008,0.06,0.157,0.16,0.2,-0.032,0.064,0.016,0.008,-0.033,0.025,0.056,unmethylated
NH20-677,203845510004_R02C01,#136,14/03/2020,3/4/2020,4/2/2020,19,ZJ,Diagnostic,136,2,NDP,Latvia,PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",625-626,2/12/2006,14.1,dysembryoplastic neuroepithelial tumour,0.74,LGG_DNT,0.62,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-677,"Histology: Low-grade glioma
Methylation class (calibrated score): low grade glioma, dysembryoplastic neuroepithelial tumor (0.57)
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #136\NH20-677,-0.125,-0.142,-0.059,-0.063,-0.025,-0.002,-0.046,-0.019,0.008,0.017,-0.005,0.2,0.026,-0.012,0.062,0.039,-0.035,-0.011,0.005,0.068,0.066,0.067,-0.001,-0.111,-0.156,-0.125,-0.02,0.107,0.101,unmethylated
NH20-667,203845510004_R03C01,#136,14/03/2020,3/4/2020,4/2/2020,19,ZJ,Diagnostic,136,1,NDP,Latvia,"LGG, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",631-632,11/21/2002,17.3,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.49,GBM_MYCN,0.73,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-667,"Histology: Diffuse glioma 
Methylation class (calibrated score): glioblastoma, IDH wildtype, subclass RTK III (0.92/0.56)
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #136\NH20-667,-0.115,0.022,0.073,-0.017,0.046,0.133,-0.08,-0.037,-0.042,-0.298,-0.056,0.007,0.022,0.03,0.073,-0.056,0.15,-0.048,-0.034,0.001,-0.026,0.167,0.045,0.113,0.033,-0.076,-0.035,-0.013,-0.023,unmethylated
NH20-679,203845510004_R05C01,#136,16/03/2020,3/4/2020,4/2/2020,17,SB,Diagnostic,136,1,NDP,London Clinic,Glioblastoma ,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/17/1958,61.4,"glioblastoma, IDH-wildtype, RTK2 type",0.5,GBM_RTKII,0.69,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-679,"High grade glioma  see comment
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","-istology: High grade glioma
Methylation class (calibrated score): glioblastoma, IDH wildtype, subclass mesenchymal
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #136\NH20-679,-0.095,-0.001,-0.005,-0.026,-0.01,0.019,0.002,0.81,0.363,0.367,0.261,-0.295,-0.006,-0.149,-1.134,0.014,-0.312,-0.218,-0.053,-0.028,-0.023,-0.026,-0.079,0.019,0.024,-0.018,-0.095,0.002,0.047,unmethylated
NH20-655,203845510004_R06C01,#136,17/03/2020,3/4/2020,4/2/2020,16,SB,Diagnostic,136,2,NDP,NHNN,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2A,4/8/1956,64,spinal ependymoma,1,EPN_SPINE,1,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-655,"Ependymoma (WHO grade II)  see comment
","Histology: Ependymoma (WHO grade II)
Methylation class (calibrated score): Ependymoma, spinal (0.99)
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #136\NH20-655,0.009,0.157,0.166,0.034,-0.021,0,-0.036,0.137,0.162,0.212,0.166,0.163,0.171,0.19,0.191,0.166,-0.04,0.011,-0.016,0.144,0.141,0.125,0.148,-0.006,-0.085,-0.053,-0.05,-0.196,-0.297,unmethylated
NH20-733,203845510004_R07C01,#136,20/03/2020,3/4/2020,4/2/2020,13,SB,Diagnostic,136,1,NDP,Oxford John Radcliffe Hospital,"Previously NH19-3414, inconclusive result","(4) IHC, sequencing, or copy number assay ambiguous",1C,1/23/1954,66.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.71,AIDH,0.88,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-733,"Histology: Diffuse astrocytoma (WHO grade II)
Methylation class (calibrated score): IDH-glioma, subclass astrocytoma
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #136\NH20-733,-0.068,-0.028,0.024,-0.056,-0.033,0.018,-0.295,-0.027,-0.068,-0.005,-0.012,0.018,0.047,0.037,0.096,-0.015,-0.062,-0.078,-0.004,0.053,-0.054,0.069,0.008,-0.026,-0.039,0.004,-0.008,0.003,0.024,unmethylated
NH20-708,203845510005_R01C01,#137,18/03/2020,3/4/2020,4/2/2020,15,SB,Diagnostic,137,1,NDP,St George's Hospital London,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,2/17/1952,68.1,myxopapillary ependymoma,0.99,EPN_MPE,0.96,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-708,"Histology: ependymal tumour
Methylation class (calibrated score): ependymoma, myxopapillary
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #137\NH20-708,-0.097,-0.001,-0.378,0.15,0.213,0.422,0.026,0.03,-0.022,-0.035,-0.03,0.008,0.077,0.026,0.437,0.485,0.036,0.022,0.046,0.007,0.041,0.02,0.042,0.271,0.274,0.265,0.243,0.011,0.043,unmethylated
NH20-703,203845510005_R02C01,#137,18/03/2020,3/4/2020,4/2/2020,15,SB,Diagnostic,137,1,NDP,St George's Hospital London,LGG?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/7/1944,76.1,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",1,LGG_DNT,0.14,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-703,"Histology: CNS tissue with diffuse infiltration of a glial tumour
Methylation class (calibrated score): Control tissue, white matter (0.55).
  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #137\NH20-703,0.002,-0.017,0.021,0.035,-0.049,0.004,-0.08,-0.016,0.003,-0.016,-0.014,0.001,0.043,-0.027,-0.031,-0.003,-0.021,-0.015,-0.058,-0.025,-0.005,-0.002,-0.036,0.009,-0.005,-0.034,-0.044,-0.02,0.026,unmethylated
NH20-668,203845510005_R04C01,#137,19/03/2020,3/4/2020,4/2/2020,14,SB,Diagnostic,137,1,NDP,NHNN,Tumur vs inflammation,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",Def 1A,5/5/1943,76.9,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.58,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-668,"CNS tissue with clusters of enlarged cellular elements and lymphohistiocytic infiltrates, see comment.
","Histology: CNS tissue with lymphohistiocytic infiltrates and features raising the possibility of infiltration of a glioma.
Methylation class (calibrated score): glioblastoma, IDH-wildtype, subclass mesenchymal (0.83/0.83)
 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #137\NH20-668,-0.122,-0.002,0.063,-0.058,0.073,-0.007,-0.091,0.084,0.095,0.018,0.063,-0.002,0.042,-0.01,-0.368,-0.067,0.001,0.003,-0.029,-0.056,-0.04,-0.081,0.036,-0.029,-0.08,-0.114,0.149,-0.125,-0.123,methylated
NH20-743,203845510005_R06C01,#137,20/03/2020,3/4/2020,4/2/2020,13,SB,Diagnostic,137,1,NDP,"Leeds, St James's University Hospital",GBM/anapl. PXA?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,10/20/1973,46.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,CONTR_REACT,0.26,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-743,"Histology: High grade glioma with features consistent with glioblastoma (WHO grade IV)
Methylation class (calibrated score): glioblastoma, IDH wildtype, subclass mesenchymal (0.38/0.38)
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #137\NH20-743,0.022,-0.019,0.003,-0.009,-0.046,0.017,0.019,0.065,0.131,0.091,0.093,0.001,0.026,0.01,-0.309,-0.036,-0.144,-0.142,-0.051,-0.056,-0.041,0.042,-0.024,-0.005,-0.236,-0.014,-0.035,-0.136,-0.127,unmethylated
NH17-560,203845510005_R07C01,#137,20/03/2020,3/4/2020,4/2/2020,13,SB,Diagnostic,137,1,NDP,"Middlesbrough, James Cook Hospital","HGG, previously analysed here with convent Mol Path","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/16/1961,55.8,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.92,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-560,"Glioblastoma (WHO grade IV) 
IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Retained 
1p/19q: Retained 
EGFR: No amplification (7p gain only)
MGMT Promoter: Low level methylation (<10%)
  
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV), see previous reports for molecular data
Methylation class (calibrated score): Glioblastoma, IDH wildtype, subclass mesenchymal(0.97/0.94)
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #137\NH17-560,0.052,-0.048,-0.017,-0.089,0.002,-0.078,-0.392,0.3,0.605,-0.339,-0.322,0.019,0.015,-0.003,-0.684,0.05,-0.284,-0.289,0.022,-0.018,0.067,0.053,-0.207,0.039,-0.011,0.035,-0.084,-0.053,0.021,methylated
NH20-753,203845510005_R08C01,#137,25/03/2020,3/4/2020,4/2/2020,8,SB,Diagnostic,137,5,NDP,NHNN,Previously PA low calibrated score,"(2) unusual histology, location, demographics",DEF1A,3/17/1988,32,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.54,LGG_RGNT,0.62,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-753,"Glial tumour, see comment.
","Histology: Low-grade glioma
Methylation class (calibrated score): low grade glioma, subclass posterior fossa pilocytic astrocytoma (0.49/0.39)
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #137\NH20-753,0.005,-0.011,0.044,-0.039,-0.058,0.03,0.013,0.001,-0.023,0.003,0.181,-0.003,0.006,0.004,0.021,-0.007,-0.026,0.037,0.037,-0.033,-0.017,-0.031,-0.009,-0.001,-0.053,-0.011,-0.021,-0.044,0.047,unmethylated
NH20-779,204296550026_R02C01,#138,26/03/2020,24/04/2020,4/23/2020,28,SB,Diagnostic,138,1,NDP,Oxford John Radcliffe Hospital,Supratentorial ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1B,4/30/1957,62.9,"glioblastoma, IDH-wildtype, RTK1 type",0.99,GBM_RTKI,0.93,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-779,"Methylation profile: suggestive of glioblastoma, IDH-wildtype (WHO grade IV) 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #138\NH20-779,-0.093,-0.047,0.003,-0.044,-0.056,0.048,0.036,0.156,0.214,0.262,0.165,-0.006,0.058,0.009,-1.611,0.01,-0.328,-0.328,-0.021,-0.011,-0.009,0.021,0.025,-0.016,-0.019,-0.026,-0.078,-0.028,0.033,unmethylated
NH20-773,204296550026_R03C01,#138,26/03/2020,24/04/2020,4/23/2020,28,SB,Diagnostic,138,8,NDP,St George's Hospital London,RGNT or DLGNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/4/1994,25.5,ganglioglioma,0.42,GBM_MES,0.33,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-773,"Histology: Glial or glioneuronal tumour  see comment
Methylation profile: Inconclusive
MGMT Promoter (Illumina array): Undetermined
","Histology: Low grade glial / glioneuronal tumour, compatible with WHO grade I
Methylation profile: Suggestive of ganglioglioma  see comment 
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #138\NH20-773,-0.019,-0.012,0.029,0.057,0.006,0.146,-0.017,0.265,0.319,0.381,0.259,0.169,0.214,0.176,0.18,0.18,-0.026,-0.013,0.021,0.127,0.131,0.133,0.016,-0.024,-0.142,-0.033,0.276,0.035,0.025,unmethylated
NH20-784,204296550026_R04C01,#138,27/03/2020,24/04/2020,4/23/2020,27,SB,Diagnostic,138,4,NDP,Edinburgh,"primitive CNS tumour, wide differential.","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1B,3/21/1992,28,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.52,GBM_RTKII,0.48,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-784,"Histology: High grade glioma, in favour of glioblastoma (WHO grade IV) 
Methylation profile: Suggestive of glioblastoma, IDH-wildtype  see comment
MGMT Promoter (Illumina array): Methylated 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #138\NH20-784,1.183,0.019,0.045,0.064,0.03,0.165,-0.011,0.33,0.337,0.36,0.299,0.01,0.023,0.014,0.019,-0.011,-0.006,-0.05,-0.066,0.141,0.103,0.187,-0.282,-0.012,-0.014,-0.04,-0.054,0.008,0.015,methylated
NH20-756,204296550026_R06C01,#138,2/4/2020,24/04/2020,4/23/2020,21,SB,Diagnostic,138,1,NDP,NHNN,Gemistocyti astrocytoma,"(4) IHC, sequencing, or copy number assay ambiguous",DEF1A,4/7/1997,23,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.83,AIDH_HG,0.78,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-756,"Gemistocytic astrocytoma, IDH-mutant, see comment.

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Astrocytoma, IDH-mutant (WHO grade II)
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion
MGMT Promoter: Methylated (>0-5%)
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #138\NH20-756,0.015,-0.046,0.008,-0.071,0.01,0.077,0.002,-0.002,-0.012,-0.015,-0.02,0.014,-0.032,-0.033,-0.05,-0.069,-0.094,-0.006,-0.075,0.087,-0.121,-0.149,-0.061,-0.029,-0.028,-0.063,-0.17,-0.025,-0.014,methylated
NH20-810,204296550026_R07C01,#138,6/4/2020,24/04/2020,4/23/2020,17,SB,Diagnostic,138,3,NDP,"Belfast, Royal Victoria Hospital",RGNT?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",42001262,3/21/1986,34,rosette-forming glioneuronal tumour,1,LGG_RGNT,0.99,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-810,"Histology and methylation profile: Rosette forming glioneuronal tumour (WHO grade I) 
MGMT Promoter (Illumina array): Unmethylated
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #138\NH20-810,-0.061,-0.037,-0.005,-0.015,-0.048,0.007,0.021,-0.023,-0.015,0.016,-0.03,0.009,0.014,-0.012,-0.004,-0.029,-0.068,0.012,-0.053,-0.042,-0.071,-0.028,0.009,-0.026,-0.041,0.012,0.008,0.002,0.009,unmethylated
NH20-878,204296590098_R03C01,#139,17/04/2020,1/5/2020,4/30/2020,13,SB,Diagnostic,139,6,NDP,NHNN,PA midline,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,12/14/1996,23.4,supratentorial midline pilocytic astrocytoma,0.93,LGG_PAMID,0.91,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-878,"Features most in keeping with pilocytic astrocytoma (WHO grade I) (see comment)
","Histology and methylation profile: Pilocytic astrocytoma (WHO grade I) 
MGMT Promoter (Illumina array): Unmethylated 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #139\NH20-878,0.007,-0.042,-0.009,-0.037,-0.015,-0.027,-0.025,0.008,-0.004,-0.004,0.126,-0.012,0.036,-0.023,-0.023,-0.031,-0.053,-0.002,0.003,-0.012,-0.018,-0.084,-0.04,0.007,-0.029,-0.01,-0.075,0.031,0.026,unmethylated
NH20-865,204296590098_R07C01,#139,15/04/2020,1/5/2020,4/30/2020,15,SB,Diagnostic,139,2,NDP,Newcastle,Low-grade glioma,"(2) unusual histology, location, demographics",A1,11/18/1984,35.3,"supratentorial ependymoma, ZFTA:RELA fusion-positive",0.14,LGG_MYB,0.16,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-865,"Histology: In keeping with infiltration zone of a high grade glioma (WHO grade III)
Methylation profile: Raising the possibility but not diagnostic of ependymoma with RELA fusion  see comment 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #139\NH20-865,0.012,-0.083,0.017,0.046,-0.054,-0.02,0.005,0.001,-0.037,-0.033,-0.017,0.003,0.037,-0.005,0.008,0.01,0.053,0.014,0.014,-0.013,0.006,-0.01,0.004,0.072,-0.008,-0.031,-0.034,0.077,0.045,unmethylated
NH20-804,204296590103_R04C01,#140,20/04/2020,15/05/2020,5/14/2020,24,AM,Diagnostic,140,7,NDP,St George's Hospital London,High grade neuroepithelial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/18/1980,39.9,"Diffuse hemispheric glioma, H3 G34-mutant",1,GBM_G34,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-804,"High grade neuroepithelial tumour - see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained          
EGFR: No amplification          
CDKN2A/B: Deletion
MGMT Promoter: Methylated (>5-10%)
","Histology and methylation profile: Glioblastoma, H3 G34-mutant (WHO grade IV) 
MGMT Promoter (Illumina array): Methylated 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #140\NH20-804,0.182,0.026,0.002,0.036,0.06,-0.087,0.001,-0.022,0.048,0.012,0.007,0.031,0.006,0.065,-1.66,-0.094,-0.339,-0.321,0.026,-0.098,-0.115,-0.094,-0.21,0.05,0.109,0.029,-0.026,-0.055,0,methylated
NH20-803,204296590103_R05C01,#140,21/04/2020,15/05/2020,5/14/2020,23,AM,Diagnostic,140,6,NDP,St George's Hospital London,? Epithelioid GBM ? Anaplastic PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,9/5/1966,53.6,"glioblastoma, IDH-wildtype, mesenchymal type",1,CONTR_REACT,0.35,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-803,"Likely glioblastoma, IDH-wildtype (WHO grade IV) - see comment

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
CDKN2A/B: No deletion          
Histone H3F3A: No mutation     
BRAF (V600E): Mutation
MGMT Promoter: Unmethylated (0%)
 
","Glioblastoma, BRAF V600-mutant (WHO grade IV) 
MGMT Promoter: Unmethylated (0%)
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #140\NH20-803,0.082,-0.046,-0.062,-0.006,-0.04,-0.032,-0.008,0.014,0.118,0.136,0.101,-0.012,0.027,0.039,-0.26,-0.07,-0.087,-0.33,0.012,0.019,0.016,0.072,0.024,0.048,0.041,-0.001,-0.143,-0.013,0.053,unmethylated
NH20-829,204296590103_R06C01,#140,23/04/2020,15/05/2020,5/14/2020,21,AM,Diagnostic,140,7,NDP,Nottingham University Hospital,High grade neuroepithelial tumour ?G34R mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/27/1986,33.7,pleomorphic xanthoastrocytoma(-like),0.99,PXA,0.93,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-829,"High grade neuroepithelial tumour - see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
Histone H3F3A: No mutation (see comment)     
MGMT Promoter: Methylated (>0-5%)
","Histology: High grade neuroepithelial tumour, compatible with anaplastic pleomorphic xanthoastrocytoma (WHO grade III)
Methylation profile: (anaplastic) pleomorphic xanthoastrocytoma  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B (Illumina array): Deletion
BRAF (V600E IHC): No mutation
MGMT Promoter: Methylated (>0-5%)
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #140\NH20-829,0.045,0.031,-0.002,-0.018,0.045,-0.308,-0.083,-0.063,-0.038,-0.002,-0.001,-0.414,-0.258,-0.365,-1.6,0.229,-0.038,-0.028,-0.046,-0.012,-0.01,0.452,-0.461,-0.368,0.046,-0.012,-0.47,-0.417,-0.404,methylated
NH20-832,204296590103_R08C01,#140,29/04/2020,15/05/2020,5/14/2020,15,AM,Diagnostic,140,6,NDP,"Birmingham, Queen Elizabeth Hospital",High grade neuroepithelial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,7/4/1997,22.7,"Diffuse hemispheric glioma, H3 G34-mutant",1,GBM_G34,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-832,"High grade neuroepithelial tumour - see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
Histone H3F3A: No mutation (see comment)
BRAF (V600E): No mutation     
","Methylation profile: Glioblastoma H3 G34-mutant (WHO grade IV)  see comment
MGMT Promoter: Methylated 

",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #140\NH20-832,0.038,0.152,0.016,-0.018,0.029,0.004,0.012,-0.022,0.042,-0.01,0.049,-0.105,0.029,-0.033,0.067,-0.122,-0.308,-0.469,0.003,0.156,0.045,0.002,-0.433,0.015,0.077,0.068,-0.626,-0.044,0.032,methylated
NH20-921,204296550047_R02C01,#141,1/5/2020,5/22/2020,5/21/2020,20,ZJ,Diagnostic,141,1,NDP,Romford,?Gliosarcoma; ?Any other sarcoma (10yrs ago oligodendroglioma surgery,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/2/1966,54,"glioblastoma, IDH-wildtype, mesenchymal type",0.27,MNG,0.28,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-921,"High grade spindle cell tumour  see comment
","Review, open biopsy, bone, skull: a high grade spindle cell tumour.
The morphological features favour a spindle cell sarcoma, grade 3, which in view of the clinical history is likely radiation induced.

",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #141\NH20-921,-0.025,0.147,0.062,0.052,0.043,0.053,-0.316,-0.031,0.131,0.039,0.033,0.034,0.158,0.142,-0.61,0.048,0.019,0.306,0.085,-0.094,0.061,0.21,-0.177,-0.061,0.03,0.021,0.107,0.033,0.171,methylated
NH20-894,204296550047_R04C01,#141,1/5/2020,5/22/2020,5/21/2020,20,ZJ,Diagnostic,141,2,NDP,"Leeds, St James's University Hospital",GBM vs anaplastic PXA,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,5/18/1988,31.9,"glioblastoma, IDH-wildtype, mesenchymal type",1,HMB,0.14,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-894,"Histology: High grade glioma (see comment)
Methylation class (calibrated score): No matching methylation class (score below 0.3), See comment
  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #141\NH20-894,0.02,-0.054,0.008,0.011,-0.041,0.004,0.005,0.145,0.127,0.128,0.108,0.044,0.012,0.004,-0.083,-0.081,-0.191,-0.247,-0.118,-0.043,-0.067,-0.002,-0.274,-0.174,-0.644,0.035,-0.158,0.058,-0.199,unmethylated
NH20-938,204296550047_R05C01,#141,1/5/2020,5/22/2020,5/21/2020,20,ZJ,Diagnostic,141,2,NDP,"Birmingham, Queen Elizabeth Hospital",Ganglioneuroblastoma or GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,11/27/2006,13.4,"Diffuse hemispheric glioma, H3 G34-mutant",1,GBM_G34,1,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-938,"Histology: Glioblastoma
Methylation class (calibrated score): Glioblastoma, H3.3 G34 mutant (0.99)
  
","Glioblastoma, IDH-wildtype, H3.3 G34R-mutant (WHO grade IV)
Histone H3F3A: Mutation  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #141\NH20-938,0.124,-0.002,0.037,-0.019,0.02,-0.01,-0.077,0.054,0.05,0.021,-0.018,0.031,0.057,0.023,-0.245,0.003,-0.048,-0.126,-0.042,0.091,-0.012,0.048,-0.074,0.071,-0.013,0.003,-0.041,-0.022,0.018,methylated
NH20-895,204296550047_R06C01,#141,1/5/2020,5/22/2020,5/21/2020,20,ZJ,Diagnostic,141,10,NDP,"Cambridge, Addenbrooke's Hospital",High grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1-1,2/19/1981,39.1,"glioblastoma, IDH-wildtype, RTK2 type",0.99,GBM_RTKII,0.97,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-895,"Histology: anaplastic astrocytoma
Methylation class (calibrated score): Glioblastoma, IDH-wildtype, subclass RTK II (0.97/0.9)
EGFR amplification
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #141\NH20-895,-0.032,-0.063,0.004,-0.061,0.013,0.096,0.021,1.328,0.235,0.243,0.168,0,0.118,0.039,-1.713,-0.024,-0.355,-0.4,-0.029,-0.002,0.01,0.013,-0.132,-0.001,-0.008,0.028,-0.085,0.018,0.059,unmethylated
NH20-828,204296550047_R07C01,#141,4/5/2020,5/22/2020,5/21/2020,17,ZJ,Diagnostic,141,1,NDP,Nottingham University Hospital,Lumbar ependymal tumour; ?myxopapillary,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,8/29/1969,50.6,spinal ependymoma,1,EPN_SPINE,1,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-828,"Histology: Ependymoma
Methylation class (calibrated score): Ependymoma, spinal (0.99)
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #141\NH20-828,-0.259,-0.012,0.015,-0.042,-0.031,0.001,-0.023,-0.031,-0.018,-0.027,-0.038,0.022,0.147,0.046,0.107,-0.027,0.006,-0.003,-0.11,-0.006,0.042,-0.006,-0.4,-0.01,-0.065,-0.027,-0.024,-0.393,-0.462,unmethylated
NH20-958,204296550047_R08C01,#141,4/5/2020,5/22/2020,5/21/2020,17,ZJ,Diagnostic,141,3,NDP,Edinburgh,GBM with BRAF V600E mutation,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1B,10/9/1981,38.5,pleomorphic xanthoastrocytoma(-like),1,PXA,0.99,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-958,"Histology: Pleomorphic xanthoastrocytoma
Methylation class (calibrated score): (anaplastic) pleomorphic xanthoastrocytoma (0.94)
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #141\NH20-958,-0.155,0.043,0.102,-0.012,0.13,0.069,-0.484,0.079,0.183,0.156,0.114,-0.108,-0.023,-0.081,-1.619,0.192,-0.41,-0.416,-0.158,0.068,-0.006,0.041,-0.424,-0.198,-0.214,-0.209,0.114,0.119,0.208,unmethylated
NH20-583,204308830074_R02C01,#142,4/5/2020,5/22/2020,5/21/2020,17,ZJ,Diagnostic,142,4,NDP,St George's Hospital London,"Glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,12/21/1965,54.2,ganglioglioma,0.33,GBM_MES,0.19,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-583,"Diffuse astrocytoma, NOS
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
MGMT Promoter: Unmethylated (0%)
  
","Histology: Diffuse astrocytoma, NOS
Methylation class (calibrated score): glioblastoma, IDH-wildtype, subclass mesenchymal (0.55 and 0.54), see comment
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #142\NH20-583,0.036,-0.069,-0.008,0.046,-0.091,-0.021,-0.086,0.054,0.03,0.021,0.036,0.002,0.109,-0.03,0.022,-0.027,-0.067,-0.139,-0.058,-0.071,-0.004,0.01,0.028,0.009,-0.033,-0.001,0.017,0.011,0.082,unmethylated
NH20-582,204308830074_R03C01,#142,4/5/2020,5/22/2020,5/21/2020,17,ZJ,Diagnostic,142,2,NDP,St George's Hospital London,"Glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/9/1963,56.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.92,GBM_MES,0.83,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-582,"Histology: Glioma, NOS
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
1p/19q: Retained
EGFR: No amplification
CDKN2A/B: No deletion
TERT promoter: No mutation
Histone H3F3A: No mutation
BRAF (V600E): No mutation
MGMT Promoter: Unmethylated (0%)

  
","Histology: Diffuse glioma, NOS
Methylation class (calibrated score): glioblastoma, IDH-wildtype, subclass mesenchymal (0,5/0.43), See comment.
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #142\NH20-582,0.06,-0.097,0.009,0.318,-0.101,-0.051,-0.126,0.108,0.085,0.053,0.076,-0.002,0.103,0.037,-0.209,0.017,-0.154,-0.243,-0.009,0.297,0.565,0.899,-0.029,0.035,-0.127,-0.128,0.1,-0.018,0.048,unmethylated
NH20-957,204308830074_R06C01,#142,4/5/2020,5/22/2020,5/21/2020,17,ZJ,Diagnostic,142,1,NDP,Oxford John Radcliffe Hospital,"Poorly differential intrinsic tumour, NOS","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,11/17/1995,24.4,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.98,MB_SHHCHLAD,0.2,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-957,"Histology: features raising the possibility of an anaplastic ependymoma
Methylation class (calibrated score): no matching methylation class, see comment 
MYCN amplification 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #142\NH20-957,0.048,1.339,-0.003,0.031,0.005,-0.014,0.023,-0.019,-0.075,-0.039,0.003,-0.017,0.035,-0.035,-0.085,-0.04,-0.287,-0.265,-0.064,-0.01,0.012,-0.002,-0.122,-0.321,0.275,0.189,-0.234,-0.055,0.045,unmethylated
NH20-969,204308830074_R07C01,#142,5/5/2020,5/22/2020,5/21/2020,16,ZJ,Diagnostic,142,9,NDP,"Birmingham, Queen Elizabeth Hospital",Astrocytoma wiht ATRX mutation,"(2) unusual histology, location, demographics",,7/8/1970,49.8,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type B]",0.84,ANAPA,0.73,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-969,"Histology: cerebellar glioma, favouring anaplastic pilocytic astrocytoma
Methylation class (calibrated score): anaplastic pilocytic astrocytoma (0.78)
  
 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #142\NH20-969,0.157,-0.022,0.004,-0.018,0.043,0.044,0.009,-0.097,-0.06,-0.124,-0.049,-0.049,0.07,-0.007,-0.046,-0.018,-0.011,0.03,0.046,-0.027,0.017,0.052,-0.015,-0.019,0.021,-0.038,-0.303,0.005,0.073,unmethylated
NH17-2533,204308830074_R08C01,#142,5/5/2020,5/22/2020,5/21/2020,16,ZJ,Diagnostic,142,1,NDP,"Birmingham, Queen Elizabeth Hospital",NF1 associated low grade astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",4,6/22/1995,22.3,"control tissue, white matter (corpus callosum)",1,CONTR_WM,0.78,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH17-2533,"
Compatible with NF1 associated low grade astrocytoma  for grading and typing, see comment

IDH1 (R132H IHC); IDH1/2 Seq: No mutation  
ATRX (IHC): Possibly retained (see microscopic description)
Histone H3F3A: No mutation
BRAF (V600E): No mutation 

","Histology: Features in keeping with low-grade astrocytoma
Methylation class (calibrated score): Control tissue, white matter (0.99)
  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #142\NH17-2533,0.058,-0.019,0.001,0.019,0.014,0.045,-0.084,-0.058,-0.075,0.015,0.02,-0.01,0.031,0.034,-0.117,-0.039,-0.035,-0.006,-0.014,-0.051,-0.004,-0.047,-0.109,-0.007,-0.021,-0.019,0.011,-0.062,0.029,unmethylated
NH20-727,204308830041_R02C01,#143,13/05/2020,5/29/2020,5/28/2020,15,AM,Diagnostic,143,4,NDP,St George's Hospital London,IDH-mutant astrocytoma with no CDKN2A/B loss ?high grade,"(4) IHC, sequencing, or copy number assay ambiguous",A1,3/10/1986,34,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.97,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-727,"Diffuse astrocytoma, IDH-mutant (see comment for grading)
IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B: No deletion          
MGMT Promoter: Unmethylated (0%)
","Histology: Astrocytoma, IDH-mutant (WHO grade II)
Methylation class (calibrated score): IDH-glioma, subclass astrocytoma (0.99/0.97)
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #143\NH20-727,0.053,-0.145,0.052,-0.021,0.037,-0.059,-0.035,0.05,0.028,-0.005,-0.008,0.029,0.034,0.25,0.035,0.027,-0.075,-0.144,0.027,0.192,-0.061,-0.288,0.029,0.067,-0.008,0.007,-0.051,0.02,0.05,methylated
NH20-916,204308830041_R03C01,#143,14/05/2020,5/29/2020,5/28/2020,14,AM,Diagnostic,143,4,NDP,"Belfast, Royal Victoria Hospital",Calcifying pseudoneoplasm of the neuraxis (CAPNON),"(4) IHC, sequencing, or copy number assay ambiguous",A,12/6/1980,39.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.19,AIDH,0.38,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-916,"Favoured diagnosis: Calcifying pseudoneoplasm of the Neuraxis (CAPNON)
","Histology: Calcifying pseudo-neoplasm of the neuraxis (CAPNON)
Methylation profile: Inconclusive
IDH1/2Seq: No mutation
BRAF (V600E IHC): No mutation
MGMT Promoter (Illumina array): Unmethylated
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #143\NH20-916,0.022,-0.068,0.142,0.169,-0.115,-0.145,-0.195,0.476,0.142,-0.116,0.002,0.184,0.064,0.03,-0.11,0.251,-0.125,-0.484,0.101,-0.073,-0.039,0.041,-0.096,-0.025,0.156,0.27,-0.167,-0.053,-0.19,unmethylated
NH20-1011,204308830041_R04C01,#143,15/05/2020,5/29/2020,5/28/2020,13,ZJ,Diagnostic,143,5,NDP,Brighton and Sussex Hospital,Spinal ependymal tumour,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,10/8/1992,27.6,myxopapillary ependymoma,1,EPN_MPE,1,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1011,"Myxopapillary ependymoma (WHO grade I)
","Histology: Myxopapillary ependymoma (WHO grade I)
Methylation class (calibrated score): ependymoma, myxopapillary (0.99)
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #143\NH20-1011,-0.084,-0.073,0.011,-0.066,-0.075,0.063,0.163,0.063,0.085,0.111,0.057,-0.056,0.014,-0.023,0.092,0.111,-0.108,-0.027,-0.028,-0.065,-0.065,-0.123,-0.312,0.065,0.092,0.044,0.061,-0.094,-0.009,unmethylated
NH20-1017,204308830041_R06C01,#143,15/05/2020,5/29/2020,5/28/2020,13,ZJ,Diagnostic,143,2,NDP,Oxford John Radcliffe Hospital,Malignant spindle cell tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C,7/18/1938,81.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.64,MNG,0.22,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1017,"Histology: Malignant spindle cell tumour
Methylation class (calibrated score): undifferentiated sarcoma (0.99)
  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #143\NH20-1017,-0.043,0.157,0.069,0.035,0.164,0.174,-0.037,-0.08,0.285,1.087,-0.052,-0.048,0.153,0.167,-0.553,-0.006,-0.07,-0.082,-0.077,-0.035,-0.022,-0.048,-0.067,0.142,0.181,0.238,0.038,0.135,0.212,unmethylated
NH20-1077,204308830073_R02C01,#144,26/05/2020,6/12/2020,6/11/2020,16,SB,Diagnostic,144,2,NDP,Oxford John Radcliffe Hospital,Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2B,5/18/1975,44.8,"glioblastoma, IDH-wildtype, mesenchymal type",0.69,CONTR_REACT,0.19,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1077,"Histology: Low grade glioma with features most in keeping with pilocytic astrocytoma
Methylation class (calibrated score): No matching methylation class
  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #144\NH20-1077,-0.003,0.06,0.007,-0.019,-0.032,-0.003,-0.014,0.005,-0.035,-0.01,-0.01,0.016,-0.002,0.037,-0.019,-0.025,-0.034,-0.013,-0.042,-0.013,-0.047,-0.017,0.005,0.026,-0.048,0.01,0.006,-0.077,-0.016,unmethylated
NH20-1081,204308830073_R03C01,#144,26/05/2020,6/12/2020,6/11/2020,16,SB,Diagnostic,144,1,NDP,Newcastle,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1B,8/2/1951,68.8,"glioblastoma, IDH-wildtype, RTK1 type",0.97,GBM_RTKI,0.99,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1081,"Histology: Glioblastoma (WHO grade IV)
Methylation class (calibrated score): Glioblastoma, IDH-wildtype, subclass RTK I (0.99/0.94)
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #144\NH20-1081,-0.037,-0.051,-0.002,-0.052,0.96,0.049,0.064,0.296,0.408,0.515,0.318,-0.012,0.056,-0.008,0.056,-0.012,-0.421,-0.414,-0.02,-0.001,0.692,1.61,-0.42,-0.012,-0.019,-0.011,-0.075,0.2,0.216,methylated
NH20-896,204308830073_R06C01,#144,29/05/2020,6/12/2020,6/11/2020,13,AM,Diagnostic,144,5,NDP,"Birmingham, Queen Elizabeth Hospital",High grade glioma ,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,10/7/1964,55.5,"supratentorial ependymoma, ZFTA:RELA fusion-positive",0.2,EPN_RELA,0.11,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-896,"High grade glioma, IDH-mutant (WHO grade III at least)  see comment
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained
H3 K27me3: Loss of expression     
1p/19q: Retained (see comment)     
","High grade glioma, favouring anaplastic oligodendroglioma, IDH-mutant (WHO III)  see comment 
IDH1 (R132H IHC): Mutation      
ATRX (IHC): Retained     
1p/19q: Retained (19q deletion)          
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #144\NH20-896,0.213,-0.575,0.013,0.036,0.195,0.2,-0.227,0.791,0.708,0.474,0.173,0.401,-0.038,0.057,-0.868,-0.078,-0.021,-0.156,-0.261,-0.149,0.225,0.183,-0.138,-0.521,0.748,-0.038,-0.03,0.314,-0.521,unmethylated
NH20-1023,204308830073_R07C01,#144,1/6/2020,6/12/2020,6/11/2020,10,AM,Diagnostic,144,2,NDP,HCA,Glioma ? HGG ? LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/22/1964,56.1,ganglioglioma,0.18,GBM_MES,0.67,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1023,"Glioma  see comment



IDH1 (R132H IHC): No mutation; further tests pending 
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Histology: Diffuse glioma
Methylation class (calibrated score): glioblastoma, IDH wildtype, subclass mesenchymal (0.95/0.83)
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #144\NH20-1023,0.028,-0.034,0.031,0.049,-0.037,0.001,-0.059,0.187,0.148,0.175,0.146,0.02,-0.029,-0.012,-0.039,-0.228,-0.248,-0.233,-0.027,0.048,0.007,-0.015,-0.019,0.102,-0.074,-0.079,0.118,-0.194,-0.187,unmethylated
NH20-1118,204308830073_R08C01,#144,2/6/2020,6/12/2020,6/11/2020,9,SB,Diagnostic,144,5,NDP,NHNN,Glioma HGG?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,12/10/1951,68.5,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.85,GBM_RTKI,0.29,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1118,"Glioma, see comment
IDH1 (R132H IHC): Technically non satisfactory, further tests pending. 
ATRX (IHC): Retained
Further molecular tests: Pending
","Histology: Diffuse glioma
Methylation class (calibrated score): Glioblastoma, IDH-wildtype, subclass RTK I (0.87/0.59)
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #144\NH20-1118,0.156,-0.079,-0.01,0.001,-0.02,0.049,-0.245,0.154,0.172,0.124,0.118,0.08,0.075,0.078,-0.636,0.007,-0.239,-0.202,-0.018,-0.023,-0.019,0.027,0,0.054,0.035,0.003,-0.238,-0.188,-0.112,unmethylated
NH20-1147,204308830075_R01C01,#145,3/6/2020,6/19/2020,6/18/2020,15,AM,Diagnostic,145,1,NDP,"Birmingham, Queen Elizabeth Hospital",Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/14/1987,32.8,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.99,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1147,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Pilocytic astrocytoma
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #145\NH20-1147,-0.003,-0.011,-0.033,0.02,-0.017,0.055,0.019,-0.068,-0.008,-0.036,-0.02,-0.018,0.056,0.021,0.057,0.014,0.013,-0.031,0.03,-0.022,0.029,-0.005,-0.004,-0.045,-0.01,0.018,-0.006,0.049,0.049,unmethylated
NH20-1163,204308830075_R03C01,#145,4/6/2020,6/19/2020,6/18/2020,14,AM,Diagnostic,145,2,NDP,Unilabs,Glioblastoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,11/1/1943,76.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.53,GBM_MES,0.26,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1163,"Histology: Infiltration of glioma
Molecular profile: Suggestive of Glioblastoma, IDH-wildtype (WHO grade IV) 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #145\NH20-1163,0.011,-0.036,-0.041,0.006,-0.03,0.021,-0.029,0.019,0.089,0.112,0.067,0.036,0.024,0.008,-0.217,0.002,-0.086,-0.069,-0.026,-0.049,-0.02,0.049,0.028,0.001,0.06,-0.041,-0.047,-0.006,0.016,unmethylated
NH20-1059,204308830075_R04C01,#145,8/6/2020,6/19/2020,6/18/2020,10,AM,Diagnostic,145,9,NDP,NHNN,Glioma ?LGG ?HGG ,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,11/28/1962,57.5,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.1,GBM_MID,0.17,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1059,"Parenchymal infiltration by diffuse glioma - see comment
","Glioma (see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
1p/19q: Retained
EGFR: No amplification
Histone H3F3A: No mutation
BRAF (V600E): No mutation     
MGMT Promoter: Methylated (>0-5%)
  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #145\NH20-1059,0.014,0.08,0.022,-0.027,0.006,0.08,0.002,-0.022,-0.043,-0.024,-0.022,-0.022,-0.023,-0.011,-0.105,-0.073,-0.03,0.136,-0.024,0.097,-0.056,-0.119,-0.048,0.038,-0.02,-0.015,-0.075,0.024,0.022,methylated
NH20-1197,204308830075_R05C01,#145,8/6/2020,6/19/2020,6/18/2020,10,SB,Diagnostic,145,1,NDP,Brighton and Sussex Hospital,"L4 ependymona, histo no myxopap","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,4/3/1978,42.2,myxopapillary ependymoma,1,EPN_MPE,1,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1197,"Ependymoma  grading see comment
","Histology: Ependymal tumour, compatible with myxopapillary ependymoma (WHO grade I)
Methylation profile: Myxopapillary ependymoma  see comment 
MGMT Promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #145\NH20-1197,0.039,-0.008,0.028,0.013,-0.004,0.177,-0.009,0.229,0.288,0.286,0.221,-0.001,0.063,0.015,0.287,0.301,0.017,-0.006,0.011,-0.007,-0.008,0.024,0.013,-0.028,-0.021,0.017,0.01,-0.466,-0.467,unmethylated
NH20-1185,204308830075_R06C01,#145,8/6/2020,6/19/2020,6/18/2020,10,SB,Diagnostic,145,4,NDP,Lund (SE),HGG thalamus,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1.2; 1.3,3/11/1989,31.2,high-grade astrocytoma with piloid features,0.98,ANAPA,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1185,"Histology: High grade glioma
Methylation profile: Anaplastic pilocytic astrocytoma  see comment
MGMT Promoter (Illumina array): Unmethylated
 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #145\NH20-1185,0.072,0,-0.006,0.009,-0.029,0.04,-0.038,-0.037,0.011,-0.114,0.008,-0.429,0.007,-0.009,-0.221,-0.016,-0.103,-0.147,0.059,0.047,0.401,0.696,-0.117,0.059,0.032,0.028,-0.261,0.028,0.03,unmethylated
NH20-1204,204308830132_R01C01,#146,10/6/2020,6/26/2020,6/25/2020,15,SB,Diagnostic,146,1,NDP,Birmingham Children Hospital,Pilomyxoid Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C10,11/27/2007,12.5,supratentorial midline pilocytic astrocytoma,1,LGG_PAMID,1,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1204,"Histology: Pilomyxoid astrocytoma
Methylation profile: Pilocytic astrocytoma  see comment
MGMT Promoter (Illumina array): Unmethylated 
","See main report
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #146\NH20-1204,0.023,-0.013,-0.029,-0.022,-0.005,0.007,0.006,0.008,-0.009,-0.056,-0.018,-0.01,0.003,-0.01,-0.012,-0.006,-0.004,-0.001,-0.028,-0.067,0.011,0.046,-0.029,-0.009,-0.007,-0.035,0.004,0.017,0.02,unmethylated
NH20-1209,204308830132_R02C01,#146,11/6/2020,6/26/2020,6/25/2020,14,SB,Diagnostic,146,1,NDP,Nottingham University Hospital,Optic nerve glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,1/10/1984,36.4,posterior fossa ependymoma group A1,0.07,LGG_PAPF,0.07,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1209,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation class: Inconclusive 
MGMT Promoter (Illumina array): Unmethylated - see comment 
","Pilocytic astrocytoma (WHO grade I) 
BRAF (V600E): No mutation
KIAA1549-BRAF fusions: No fusions between 16_9, 16_11, 15_9 exons          
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #146\NH20-1209,0.254,-0.412,0.014,0.19,-0.211,0.026,-0.25,0.137,-0.17,-0.311,-0.066,0.136,0.222,-0.225,-0.438,-0.243,-0.015,-0.185,-0.255,-0.101,-0.061,-0.062,-0.08,-0.189,0.066,-0.322,-0.217,0.19,0.015,unmethylated
NH20-1172,204308830132_R03C01,#146,11/6/2020,6/26/2020,6/25/2020,14,SB,Diagnostic,146,3,NDP,Bristol,"HGG, Stereotax Bx",(1) small biopsy or nonrepresentative sample;,B1,7/24/1967,52.8,ganglioglioma,0.3,GBM_MES,0.36,0.96,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1172,"Histology: Mild increase in cellularity and oedema
Molecular profile: Inconclusive - see comment
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #146\NH20-1172,-0.114,0,0.011,0,-0.012,0.017,-0.22,-0.043,-0.082,-0.081,-0.019,0.032,0.039,-0.039,-0.133,-0.06,-0.08,-0.124,-0.005,-0.029,-0.013,0.06,0.01,0.043,-0.1,-0.049,0.037,-0.055,-0.133,unmethylated
NH20-1107,204308830132_R04C01,#146,11/6/2020,6/26/2020,6/25/2020,14,SB,Diagnostic,146,8,NDP,Royal London Hospital,"IDH mutant, oligo or Astro?","(2) unusual histology, location, demographics",,12/4/1989,30.5,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,0.99,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1107,"High grade glioma, IDH mutant (at least WHO grade III)  see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Anaplastic ependymoma (WHO grade III)
Methylation profile: Ependymoma, RELA  see comment
MGMT Promoter: Unmethylated 
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #146\NH20-1107,0.2,-0.042,0.043,0.062,0.021,0.221,-0.022,0.154,0.139,0.17,0.109,0.292,0.362,0.276,-0.076,-0.068,0.006,-0.001,0.173,-0.005,-0.019,-0.002,0.115,0.034,-0.062,0.004,0.183,0.011,-0.023,unmethylated
NH20-1217,204308830132_R06C01,#146,12/6/2020,6/26/2020,6/25/2020,13,SB,Diagnostic,146,1,NDP,Romford,"Astrocytoma IDH mutant, unexpected looks like pilocytic","(4) IHC, sequencing, or copy number assay ambiguous",A2,4/7/1965,55.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.78,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1217,"Astrocytoma, IDH-mutant (WHO grade II)
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: Raising the possibility of astrocytoma, IDH-mutant, high grade  see comment
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #146\NH20-1217,0.021,-0.047,0.027,-0.014,-0.067,0.07,0.018,0.05,-0.003,0.134,0.098,0.009,0.014,0.096,-0.023,-0.02,-0.128,-0.103,-0.033,-0.034,-0.125,-0.014,-0.182,-0.023,-0.023,-0.012,-0.06,-0.102,-0.074,methylated
NH20-1248,204308830132_R07C01,#146,15/06/2020,6/26/2020,6/25/2020,10,ZJ,Diagnostic,146,1,NDP,Nottingham University Hospital,?GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,7/15/1951,69,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.78,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1248,"Preliminary diagnosis: High grade glioma
MGMT Promoter: Unmethylated (0%)  
","Histology: High grade glioma
Methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV) 
MGMT Promoter: Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #146\NH20-1248,-0.008,-0.009,-0.007,-0.06,-0.025,0.028,-0.116,0.464,0.06,0.047,0.033,-0.011,0.041,-0.037,-0.477,-0.06,-0.149,-0.157,-0.053,0.025,0.035,0.059,-0.012,-0.007,-0.036,-0.035,-0.112,-0.045,-0.027,unmethylated
NH20-1278,204308830146_R02C01,#147,18/06/2020,7/3/2020,7/2/2020,14,ZJ,Diagnostic,147,2,NDP,Oxford John Radcliffe Hospital,Widely calcified neuroepithelial tumour,"(2) unusual histology, location, demographics",1A,12/15/1984,35.5,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.92,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1278,"Low grade glial or glioneuronal tumour (WHO grade I)
Methylation profile: Suggestive of pilocytic astrocytoma, ganglioglioma spectrum tumour 
MGMT Promoter: Unmethylated (0%)
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #147\NH20-1278,0.01,-0.027,-0.031,-0.025,-0.06,0.032,0.055,-0.06,-0.012,-0.039,-0.013,0.341,0.049,0.028,0.198,0.104,0.01,-0.03,0.11,-0.017,0.012,0.033,0.042,0.026,0.008,0.032,0.026,0.019,-0.003,unmethylated
NH20-1265,204308830146_R03C01,#147,18/06/2020,7/3/2020,7/2/2020,14,ZJ,Diagnostic,147,1,NDP,"Belfast, Royal Victoria Hospital",?Pilocytic; ?PXA,"(2) unusual histology, location, demographics",1,6/20/1987,33,spinal ependymoma,1,EPN_SPINE,1,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1265,"Histology: Compatible with ependymoma (WHO grade II)
Methylation profile: Ependymoma, spinal 
MGMT Promoter (Illumina array): Methylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #147\NH20-1265,-0.043,0.001,0.003,-0.02,-0.011,-0.026,0.002,0.013,0.026,-0.001,0.002,0.01,0.045,0.03,0.03,0.011,-0.124,-0.115,0.01,0.003,-0.023,0.013,-0.258,0.023,0.012,-0.033,-0.01,-0.334,-0.388,methylated
NH20-1294,204308830146_R06C01,#147,19/06/2020,7/3/2020,7/2/2020,13,ZJ,Diagnostic,147,1,NDP,Nottingham University Hospital,?SEGA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,9/29/2014,5.7,subependymal giant cell astrocytoma,1,LGG_SEGA,0.92,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1294,"Histology and methylation profile: 
Suggestive of subependymal giant cell astrocytoma (SEGA, WHO grade I) 
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #147\NH20-1294,0.009,-0.004,0.001,0.017,-0.01,0.016,0.033,0.01,-0.018,-0.008,-0.023,0.021,0.046,-0.004,0.022,-0.008,-0.01,-0.023,-0.031,-0.059,-0.062,-0.008,-0.008,-0.013,-0.036,-0.066,-0.012,-0.019,-0.008,unmethylated
NH20-1307,204308830146_R08C01,#147,22/06/2020,7/3/2020,7/2/2020,10,ZJ,Diagnostic,147,3,NDP,"Leeds, St James's University Hospital",Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,6/18/1986,34,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-1307,"Histology and methylation profile: Pilocytic astrocytoma (WHO grade I)
MGMT Promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #147\NH20-1307,-0.021,-0.002,-0.002,0.06,-0.059,0.205,0.201,0.065,0.101,0.103,0.248,0.067,0.114,0.086,0.002,-0.006,-0.06,0.024,0.077,-0.055,-0.054,-0.019,0.023,-0.009,0.003,-0.045,-0.034,0.053,0.067,unmethylated
NH20-1304,204308830112_R02C01,#148,24/06/2020,7/10/2020,7/9/2020,15,ZJ,Diagnostic,148,7,NDP,Royal London Hospital,HGG in cerebellum with ATRX loss; ?anaplastic pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,4/5/1996,24.2,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,0.77,GBM_MID,0.99,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1304,"High grade glioma (see comment)
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Loss of expression indicating mutation 
Further molecular tests: Pending
  
","Histology: High grade glioma
Molecular and methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B: Deletion
MGMT Promoter: Unmethylated (0%)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #148\NH20-1304,-0.023,0.074,-0.017,-0.042,0.85,-0.11,0.019,-0.018,0.001,1.28,-0.163,-0.017,-0.007,-0.03,-1.524,0.283,-0.324,-0.691,-0.027,-0.04,-0.165,0.033,-0.367,-0.005,0.01,-0.022,-0.077,-0.302,-0.298,unmethylated
NH20-1330,204308830112_R03C01,#148,25/06/2020,7/10/2020,7/9/2020,14,ZJ,Diagnostic,148,1,NDP,Lund (SE),"A G II, IDH-wt","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",01 03,3/9/1942,78.3,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.92,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1330,"Histology: Low grade glioma
Methylation profile: Glioblastoma, IDH-wildtype (WHO grade IV)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #148\NH20-1330,0.04,-0.025,-0.008,0.014,-0.039,0.018,-0.031,0.158,0.205,0.071,0.068,-0.009,-0.019,0.019,-0.213,-0.011,-0.09,-0.151,-0.027,-0.037,0.048,0.041,-0.004,0.009,0.02,-0.021,-0.078,-0.033,0.025,unmethylated
NH20-1329,204308830112_R04C01,#148,25/06/2020,7/10/2020,7/9/2020,14,ZJ,Diagnostic,148,2,NDP,Lund (SE),"Ependymoma II, with H3K27me3 loss","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",01 02,10/1/1959,60.8,posterior fossa ependymoma group A2,0.99,EPN_PFA,0.91,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1329,"Histology: Ependymoma (WHO grade II)
Methylation profile: Suggestive of ependymoma, posterior fossa group A 
MGMT Promoter (Illumina array): Unmethylated 

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #148\NH20-1329,-0.019,0.003,-0.002,-0.003,-0.019,0.023,0.009,-0.009,-0.029,-0.06,-0.033,-0.017,0.013,-0.031,0.045,-0.033,-0.013,-0.02,-0.044,-0.041,-0.032,0.014,-0.029,-0.024,0.001,-0.052,-0.001,-0.026,-0.012,unmethylated
NH20-1339,204308830112_R05C01,#148,26/06/2020,7/10/2020,7/9/2020,13,ZJ,Diagnostic,148,1,NDP,St George's Hospital London,"Ependymoma GII, craniocervical","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,12/4/1958,61.6,posterior fossa ependymoma group B,1,EPN_PFB,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1339,"Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, posterior fossa, group B
MGMT promoter (Illumina array): Methylated 
  
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #148\NH20-1339,-0.108,-0.08,-0.048,0.074,0.244,-0.102,-0.481,0.184,0.232,0.235,0.183,0.096,0.119,0.101,0.293,0.178,-0.067,-0.097,0.05,-0.091,-0.043,-0.02,-0.104,0.051,0.038,0.064,0.052,-0.249,-0.287,methylated
NH20-1259,204308830112_R07C01,#148,26/06/2020,7/10/2020,7/9/2020,13,ZJ,Diagnostic,148,7,NDP,Romford,"IDH-mutant astrocytoma, see also NH20-1217","(4) IHC, sequencing, or copy number assay ambiguous",,4/7/1965,55.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.89,AIDH,0.74,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1259,"Astrocytoma, IDH-mutant (WHO grade II)
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: Raising the possibility of astrocytoma, IDH-mutant, high grade  see comment
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #148\NH20-1259,-0.059,-0.089,-0.007,-0.041,-0.036,0.049,0.014,0.019,-0.019,0.114,0.083,0.022,0.01,0.074,-0.011,-0.004,-0.108,-0.095,-0.066,-0.049,-0.072,-0.036,-0.153,-0.017,-0.025,-0.03,-0.027,-0.083,-0.024,methylated
NH20-1364,204308830031_R04C01,#149,30/06/2020,7/17/2020,7/16/2020,16,ZJ,Diagnostic,149,4,NDP,Birmingham Children Hospital,Cerebellar PA with anaplastic features,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,8/26/2015,4.8,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-1364,"Histology and molecular profile: 
Compatible with pilocytic astrocytoma, with KIAA1549-BRAF fusion (WHO grade I)  see comment
Methylation profile: Posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #149\NH20-1364,0.08,0.007,0.053,-0.076,0.065,-0.083,-0.193,-0.077,0.075,0.066,0.22,0.089,0.096,0.043,0.121,0.042,-0.018,-0.115,0.183,0.148,0.179,-0.07,0.004,0.208,-0.045,0.083,-0.076,0.039,0.087,unmethylated
NH20-1378,204308830031_R05C01,#149,1/7/2020,7/17/2020,7/16/2020,15,SB,Diagnostic,149,6,NDP,NHNN,"High-grade glioma anterior thalamus, no histone or IDH mutation","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF 1A,11/12/1987,32.7,"Diffuse paediatric-type high grade glioma, RTK1 subtype",1,GBM_MID,1,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1378,"Anaplastic astrocytoma (WHO grade III)  see comment 
","Histology: Anaplastic astrocytoma (WHO grade III)
Methylation profile: Glioblastoma, IDH-wildtype, subclass midline (WHO grade IV)
MGMT promoter (Illumina array): Unmethylated
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #149\NH20-1378,0.165,-0.019,-0.031,-0.076,-0.225,0.019,-0.297,-0.017,-0.007,-0.088,-0.043,-0.041,0.033,0.229,-3.781,0.132,-0.017,-0.026,-0.005,-0.016,-0.04,-0.051,-0.327,-0.025,-0.047,-0.017,0.112,0.051,0.141,unmethylated
NH20-1391,204308830031_R07C01,#149,1/7/2020,7/17/2020,7/16/2020,15,ZJ,Diagnostic,149,1,NDP,"Belfast, Royal Victoria Hospital",?SEGA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3,12/20/2016,2.7,"glioblastoma, IDH-wildtype, mesenchymal type",0.55,LGG_SEGA,0.61,0.98,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1391,"Referred histology diagnosis: Infantile hemispheric glioma (ETV6-NTRK3 fusion)
Methylation profile: Inconclusive  see comment 
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #149\NH20-1391,-0.004,0.027,0.043,0.019,-0.01,0,0.049,-0.017,0.023,0.004,-0.011,0.049,0.107,0.063,0.023,-0.014,-0.018,-0.006,0.018,0.072,0.006,-0.05,0.01,-0.016,-0.019,-0.02,-0.006,-0.069,-0.032,unmethylated
NH20-1398,204308830031_R08C01,#149,1/7/2020,7/17/2020,7/16/2020,15,ZJ,Diagnostic,149,4,NDP,Newcastle,"HGG, insular","(4) IHC, sequencing, or copy number assay ambiguous",2A,5/8/1989,31.1,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1398,"Histology and methylation profile: 
Anaplastic oligodendroglioma, IDH-mutant and 1p/19q codeleted (WHO grade III)
IDH1 (R132H IHC): Mutation
1p/19q (Illumina array): Codeletion
MGMT promoter (Illumina array): Methylated 

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #149\NH20-1398,0.114,0.051,0.03,-0.213,-0.267,0.003,-0.002,0.108,0.031,-0.014,0.003,0.061,0.038,0.042,-0.516,0.028,-0.024,-0.125,0.06,0.049,0.029,-0.03,-0.059,0.095,0.008,-0.001,-0.518,-0.022,0.049,methylated
NH20-1406,204296550082_R02C01,#150,2/7/2020,7/17/2020,7/16/2020,14,ZJ,Diagnostic,150,2,NDP,Oxford John Radcliffe Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,1/31/1952,68.4,high-grade astrocytoma with piloid features,1,ANAPA,1,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1406,"Histology: Glial tumour
Methylation profile: Anaplastic pilocytic astrocytoma  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #150\NH20-1406,-0.013,-0.038,0.002,-0.041,-0.064,0.024,-0.067,0.006,-0.018,-0.04,-0.028,0.01,0.011,-0.006,-1.086,-0.01,-0.025,-0.004,0.115,-0.043,-0.029,-0.081,-0.004,-0.14,-0.145,-0.069,-0.016,0.016,0.002,unmethylated
NH20-1416,204296550082_R03C01,#150,2/7/2020,7/17/2020,7/16/2020,14,ZJ,Diagnostic,150,1,NDP,Lund (SE),IDH-mutant GBM,"(4) IHC, sequencing, or copy number assay ambiguous",01 01,1/26/1990,30.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1416,"Histology: Glioblastoma, IDH-mutant (WHO grade IV)
Methylation profile: High grade astrocytoma, IDH-mutant  see comment
CDKN2A/B (Illumina array): Deletion
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #150\NH20-1416,0.023,0.02,0.002,-0.038,0.035,-0.034,-0.437,-0.07,0.42,0.445,0.297,-0.001,-0.314,0.001,-1.487,0.013,-0.276,-0.001,-0.03,0.251,-0.002,-0.02,-0.359,0.127,0.113,0.166,-0.134,-0.362,-0.32,methylated
NH20-1415,204296550082_R04C01,#150,2/7/2020,7/17/2020,7/16/2020,14,ZJ,Diagnostic,150,1,NDP,Lund (SE),IDH-wildtype glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",01 02,12/15/1971,48.6,"glioblastoma, IDH-wildtype, RTK2 type",0.77,GBM_RTKII,0.91,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1415,"Histology: Infiltration of glioma  see comment
Methylation profile: Glioblastoma, IDH wildtype, subclass RTK II (WHO grade IV) 
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #150\NH20-1415,0.163,-0.063,-0.014,-0.016,0.001,0.05,-0.071,0.966,0.245,0.24,0.168,0.016,0.02,0.014,-1.115,-0.032,-0.26,-0.295,-0.26,0.088,0.002,-0.045,-0.307,0.046,-0.06,-0.006,-0.066,-0.004,-0.008,methylated
NH20-1247,204296550082_R05C01,#150,3/7/2020,7/17/2020,7/16/2020,13,ZJ,Diagnostic,150,3,NDP,Nottingham University Hospital,"GBM with ATRX loss, no mutations on sequencing","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/3/1950,70.2,"glioblastoma, IDH-wildtype, RTK2 type",0.77,GBM_RTKII,0.79,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1247,"Glioblastoma, IDH-wildtype (WHO grade IV) 
IDH1/2Seq: No mutation
Histone H3F3A: No mutation
BRAF (V600E): No mutation          
MGMT Promoter: Methylated (>0-5%)
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK II
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #150\NH20-1247,-0.017,-0.051,0.063,0.058,0.391,-0.363,-0.07,0.235,0.498,0.475,0.151,0.11,0.134,0.165,-1.483,0.056,-0.249,-0.359,-0.072,0.121,-0.044,-0.116,-0.293,-0.299,0.008,0.034,-0.085,0.003,0.078,methylated
NH20-1401,204296550082_R06C01,#150,3/7/2020,7/17/2020,7/16/2020,13,SB,Diagnostic,150,3,NDP,Royal London Hospital,IDH mutant glioma ,"(4) IHC, sequencing, or copy number assay ambiguous",DEF1A,7/1/1972,48,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.87,OIDH,0.98,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1401,"Diffuse glioma, grading and typing see comment
IDH1 (R132H IHC): Positive staining, but requires verification by additional molecular tests
ATRX (IHC): Retained 
Further molecular tests: Pending
 


","Histology and methylation profile: 
Oligodendroglioma IDH-mutant and 1p/19q codeleted (WHO grade II)

MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #150\NH20-1401,0.015,-0.042,0.011,-0.098,-0.025,0.003,-0.077,0.017,-0.058,-0.021,-0.003,0.013,-0.024,-0.015,-0.013,-0.007,-0.054,0.046,-0.009,0.017,-0.033,-0.1,-0.049,0.027,-0.058,0.035,-0.204,0.025,0.02,methylated
NH20-1414,204296550088_R01C01,#151,6/7/2020,7/24/2020,7/23/2020,17,SB,Diagnostic,151,3,NDP,NHNN,"IDH mutant GBM, ATRX retained","(4) IHC, sequencing, or copy number assay ambiguous",DEF1A,5/21/1960,60.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.99,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1414,"Glioblastoma, IDH-mutant (WHO grade IV) 
IDH1 (R132H IHC): Mutation  
ATRX (IHC): Retained      
Further molecular tests: Pending
","Histology: Glioblastoma, IDH-mutant (WHO grade IV)
Methylation profile: IDH glioma, subclass high grade astrocytoma  see comment
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
CDKN2A/B (Illumina array): Deleted
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #151\NH20-1414,0.418,-0.19,-0.119,-0.271,0.039,-0.262,0.176,-0.096,0.355,0.985,0.168,0.014,0.054,0.966,-2.785,-0.31,-0.302,-0.289,0.177,0.156,-0.02,0.313,-0.444,0.445,0.305,-0.037,0.454,-0.477,-0.079,methylated
NH20-1447,204296550088_R04C01,#151,8/7/2020,7/24/2020,7/23/2020,15,ZJ,Diagnostic,151,1,NDP,"Belfast, Royal Victoria Hospital","T6/T7 ependymoma, G II","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,2/10/1985,35.4,spinal ependymoma,1,EPN_SPINE,0.99,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1447,"Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #151\NH20-1447,-0.116,-0.039,0.167,-0.26,-0.097,0.013,-0.167,0.094,0.343,0.082,0.224,-0.104,-0.136,0.264,-0.09,0.162,-0.092,0.033,0.007,0.433,0.285,0.461,0.001,0.7,0.419,0.155,0.243,-0.972,-0.564,unmethylated
NH20-1358,204296550088_R06C01,#151,10/7/2020,7/24/2020,7/23/2020,13,ZJ,Diagnostic,151,5,NDP,Oxford John Radcliffe Hospital,?Glioma; ?Clear cell carcinoma; ?Chondroid tumour; ?Melanoma; ?Other,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,7/24/1968,52,ganglioglioma,0.37,GBM_MES,0.16,0.63,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1358,"Referred diagnosis: Diffuse glioma with unusual morphology  see comment 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
1p/19q: Retained     
EGFR: No amplification
TERT promoter: Mutation
","Histology: Diffuse glioma with unusual morphology
Methylation profile: Raising the possibility, but not diagnostic, of glioblastoma, IDH-wildtype (WHO grade IV)  see comment
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #151\NH20-1358,-0.247,0.146,0.053,0.208,-0.087,-0.112,0.179,0.189,0.472,0.312,0.178,-0.001,0.155,0.389,-0.048,-0.071,0.14,-0.188,0.192,0.16,0.151,0.466,-0.128,0.336,0.238,0.248,0.552,-0.343,0.093,unmethylated
NH20-1480,204296550088_R08C01,#151,13/07/2020,7/24/2020,7/23/2020,10,ZJ,Diagnostic,151,2,NDP,Royal London Hospital,"Glioma, NOS in corpus callosum","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,5/9/1991,29.2,"control tissue, white matter (corpus callosum)",0.73,LGG_DNT,0.19,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1480,"Glioma  see comment

IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Histology: Glioma, compatible with dysembryoplastic neuroepithelial tumour (WHO grade I)
Methylation profile: Dysembryoplastic neuroepithelial tumour  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
TERT promoter: No mutation
Histone H3F3A: No mutation
BRAF (V600E): No mutation
MGMT promoter (Illumina array): Unmethylated 
       
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #151\NH20-1480,-0.236,-0.231,-0.09,-0.112,-0.015,-0.186,0.093,-0.113,0.097,-0.045,0.019,0.029,-0.084,0.273,-0.28,-0.05,0.054,0.104,0.006,0.158,0,0.277,-0.295,0.382,0.065,0.009,0.416,-0.479,0.002,unmethylated
NH20-1493,204296550055_R01C01,#152,13/07/2020,7/31/2020,7/30/2020,17,ZJ,Diagnostic,152,1,NDP,"Birmingham, Queen Elizabeth Hospital",?GBM; ?Anaplastic PA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/9/2010,9.6,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,0.3,GBM_RTKIII,0.57,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1493,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: Inconclusive  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #152\NH20-1493,0.019,-0.041,0.028,0.045,1.045,0.035,-0.064,1.133,0.288,0.208,0.208,0.013,0.015,0.026,-0.314,0.007,-0.504,-0.715,0.012,0.23,0.739,1.794,-0.034,0.022,-0.173,0.06,-0.11,-0.014,0.053,unmethylated
NH20-1102,204296550055_R03C01,#152,13/07/2020,7/31/2020,7/30/2020,17,ZJ,Diagnostic,152,5,NDP,Oxford John Radcliffe Hospital,"GBM, IDH-mutant (on histology GII astro)","(4) IHC, sequencing, or copy number assay ambiguous",1B,12/12/1962,57.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.63,AIDH,0.84,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1102,"Diffuse glioma, IDH-mutant, corresponding to WHO grade II - see comment
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
1p/19q: Retained
CDKN2A/B: No deletion
TERT promoter: Inconclusive

","Diffuse glioma, IDH-mutant, corresponding to WHO grade II  see comment
MGMT Promoter: Methylated (>5-10%)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #152\NH20-1102,0.035,-0.052,0.001,-0.028,-0.006,0.018,-0.046,-0.01,-0.012,-0.041,0.006,0.022,0.044,-0.003,-0.053,-0.029,-0.01,0.034,-0.077,-0.017,0.015,-0.051,-0.046,0.001,-0.044,-0.031,-0.016,-0.031,0.023,methylated
NH20-1467,204296550055_R04C01,#152,15/07/2020,7/31/2020,7/30/2020,15,ZJ,Diagnostic,152,2,NDP,Edinburgh,"LGG, LG glioneuronal tumour (?MVNT)","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,8/10/1991,28.9,ganglioglioma,0.45,GBM_MES,0.81,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1467,"Histology: Infiltration of glioma  see comment 
Methylation profile: IDH-wildtype glioblastoma (WHO grade IV)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #152\NH20-1467,0.024,-0.088,-0.016,0.193,0.01,0.169,0.04,0.353,0.376,0.354,0.322,0.008,0.035,-0.023,-0.095,-0.023,-0.299,-0.228,-0.016,0.167,0.138,0.176,-0.024,-0.03,-0.091,-0.046,0.14,-0.238,-0.192,unmethylated
NH20-1534,204296550055_R05C01,#152,15/07/2020,7/31/2020,7/30/2020,15,ZJ,Diagnostic,152,1,NDP,Southampton General Hospital,"Anaplastic ependymoma, right frontal","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1B,5/4/1985,35.2,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,1,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1534,"Histology: Anaplastic ependymoma (WHO grade III)
Methylation profile: Ependymoma, RELA fusion
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #152\NH20-1534,-0.05,-0.04,0.067,-0.031,-0.004,0.032,0.036,-0.011,-0.007,0.016,-0.031,0.05,0.102,0.069,-0.392,-0.414,-0.005,0.018,0.012,-0.019,-0.014,-0.035,-0.035,-0.017,-0.033,0.015,-0.038,0.009,-0.01,unmethylated
NH20-1480,204296550055_R07C01,#152,16/07/2020,7/31/2020,7/30/2020,14,ZJ,Diagnostic,152,2,NDP,Royal London Hospital,"Glioma, NOS in corpus callosum","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,5/9/1991,29.2,dysembryoplastic neuroepithelial tumour,0.85,LGG_DNT,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1480,"Glioma  see comment

IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Histology: Glioma, compatible with dysembryoplastic neuroepithelial tumour (WHO grade I)
Methylation profile: Dysembryoplastic neuroepithelial tumour  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
TERT promoter: No mutation
Histone H3F3A: No mutation
BRAF (V600E): No mutation
MGMT promoter (Illumina array): Unmethylated 
       
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #152\NH20-1480,-0.026,-0.088,0.002,-0.013,-0.002,0.034,0.093,0.009,0.017,-0.025,0.036,-0.013,0.063,0.016,-0.028,0.009,-0.015,0.019,0.014,0.013,0.003,-0.044,0.025,-0.027,-0.006,0.003,0.004,-0.032,0.007,unmethylated
NH20-1417,204296550055_R08C01,#152,16/07/2020,7/31/2020,7/30/2020,14,ZJ,Diagnostic ,152,1,NDP,Wellington (NZ),"Oligodendroglioma, but qPCR not confirmatory","(4) IHC, sequencing, or copy number assay ambiguous",A1,8/27/1969,50.9,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1417,"Oligodendroglioma, IDH-mutant (WHO grade II)
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Oligodendroglioma, IDH-mutant and 1p/19q codeleted (WHO grade II)
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained
1p/19q (Illumina array): Codeleted
MGMT Promoter: Methylated

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #152\NH20-1417,-0.1,-0.044,0.027,-0.033,-0.019,0.034,0.057,0.15,0.02,0.005,-0.006,0.003,0.144,-0.023,-0.036,-0.002,0.027,-0.009,0.06,0.007,0.027,-0.013,-0.021,-0.007,0.027,0.048,-0.61,0.222,0.324,methylated
NH20-1538,204308990002_R03C01,#153,17/07/2020,7/31/2020,7/30/2020,13,ZJ,Diagnostic,153,1,NDP,"Cambridge, Addenbrooke's Hospital","?SEGA, but pleomorphic with necrosis","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1-1,8/21/1962,57.9,subependymal giant cell astrocytoma,0.26,CONTR_INFLAM,0.54,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1538,"Histology: Compatible with subependymal giant cell astrocytoma, but with atypical histology  see comment
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  

",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #153\NH20-1538,-0.011,-0.031,0.041,-0.093,-0.033,-0.023,-0.069,0.065,0.092,0.107,0.055,-0.024,0.105,-0.072,-0.111,-0.13,-0.094,-0.035,-0.063,-0.049,0,0.006,-0.061,-0.037,0.007,0.074,0.033,-0.141,-0.03,unmethylated
NH20-1578,204308990010_R03C01,#154,21/07/2020,8/7/2020,8/7/2020,17,ZJ,Diagnostic,154,1,NDP,Southampton General Hospital,RGNT G I,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,11/2/1986,33.7,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.93,LGG_DNT,0.97,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1578,"Histology: Low grade glioneuronal tumour  see comment
Methylation profile: Low grade glioma, dysembryoplastic neuroepithelial tumor
MGMT promoter (Illumina array): Unmethylated  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #154\NH20-1578,0.077,-0.05,-0.02,-0.051,-0.039,-0.026,-0.02,0.002,0.008,-0.029,-0.002,0.039,-0.016,0.036,-0.017,0.011,-0.045,0.001,0.053,0.085,0.013,0.004,0.017,0.084,0.021,-0.005,-0.039,-0.024,0.08,unmethylated
NH20-1450,204308990010_R04C01,#154,22/07/2020,8/7/2020,8/7/2020,16,ZJ,Diagnostic,154,4,NDP,"Belfast, Royal Victoria Hospital","Glioma, IDH-mutant (ATRX retained, no evidence of 1p/19qLOH, TERT failed)","(4) IHC, sequencing, or copy number assay ambiguous",3,9/18/1993,26.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.75,AIDH,0.75,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1450,"Diffuse glioma, IDH-mutant (WHO grade II)  see comment
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
1p/19q: Retained     
EGFR: No amplification
CDKN2A/B: No deletion
MGMT Promoter: Methylated (>5-10%)

  
","Histology: Diffuse glioma, IDH-mutant (WHO grade II)
Methylation profile: Glioma, IDH-mutant, subclass astrocytoma
MGMT promoter (Illumina array): Unmethylated  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #154\NH20-1450,0.003,-0.046,0.049,-0.016,0.016,0.046,-0.007,0.032,-0.01,0.027,-0.011,-0.003,0.018,0.004,0.001,0.023,-0.017,-0.249,0.086,0.011,-0.131,-0.442,-0.037,0.036,-0.015,-0.047,-0.015,-0.018,0.052,unmethylated
NH20-1579,204308990010_R05C01,#154,23/07/2020,8/7/2020,8/7/2020,15,ZJ,Diagnostic,154,3,NDP,NHNN,"Supratentorial ependymoma, G II","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,12/17/2001,18.6,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1579,"Anaplastic ependymoma (WHO grade III)  see comment 
","Histology: Anaplastic ependymoma (WHO grade III)
Methylation profile: Ependymoma, RELA fusion
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #154\NH20-1579,-0.009,-0.185,-0.041,-0.018,0.029,-0.028,-0.179,-0.038,-0.016,0.037,-0.013,0.001,0.012,0.015,-0.156,-0.131,-0.068,0.02,-0.014,-0.005,-0.025,-0.078,-0.038,-0.023,-0.055,-0.036,-0.006,-0.112,-0.098,unmethylated
NH20-1592,204308990010_R06C01,#154,23/07/2020,8/7/2020,8/7/2020,15,ZJ,Diagnostic,154,3,NDP,Romford,"Lumbar ependymoma, mitotically active, looks conventional","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,9/26/2002,17.8,myxopapillary ependymoma,1,EPN_MPE,0.97,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1592,"Ependymal tumour  see comment
","Histology: Ependymoma
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #154\NH20-1592,-0.018,-0.005,0.023,0.122,0.179,-0.025,0.047,0.227,0.257,0.246,0.203,0.016,-0.045,0.084,0.193,0.244,0.001,-0.003,0.155,0.045,0.022,-0.032,-0.026,0.077,-0.088,-0.035,-0.03,-0.387,-0.39,unmethylated
NH20-1590,204308990010_R07C01,#154,23/07/2020,8/7/2020,8/7/2020,15,ZJ,Diagnostic,154,3,NDP,Brighton and Sussex Hospital,"IDH-mutant astrocytoma with some gemistocytic morphology, and very vocal early MVP; ?high grade","(4) IHC, sequencing, or copy number assay ambiguous",DEF2G,6/8/1982,38.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.96,AIDH,0.97,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1590,"Diffuse astrocytoma, IDH-mutant (WHO grade II)  see comment 
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Histology: Astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH-glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #154\NH20-1590,0.028,-0.042,0.001,0.042,-0.024,-0.015,-0.043,-0.006,0.011,0.098,0.084,0.038,0.015,0.103,-0.117,-0.047,-0.101,-0.089,-0.029,-0.03,-0.21,-0.311,-0.167,-0.024,-0.058,-0.039,-0.026,-0.105,-0.021,methylated
NH20-1615,204308990010_R08C01,#154,27/07/2020,8/7/2020,8/7/2020,11,ZJ,Diagnostic,154,1,NDP,Romford,"Spinal ependymal tumour (myxopapillary vs conventional, former favoured)","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,7/21/1983,37,myxopapillary ependymoma,1,EPN_MPE,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1615,"Ependymal tumour  see comment
","Histology: Ependymoma 
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #154\NH20-1615,-0.005,0.007,0.066,-0.004,0.032,0.174,0.017,0.179,0.223,0.284,0.198,-0.009,0.027,0.041,0.175,0.233,-0.032,0.025,0.043,-0.004,0.005,-0.026,-0.037,0.177,0.215,0.213,-0.03,-0.021,0.039,unmethylated
NH20-1621,204308990007_R02C01,#155,28/07/2020,14/08/2020,8/14/2020,17,ZJ,Diagnostic,155,1,NDP,NHNN,LG Glial or glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,6/5/1996,24.2,supratentorial pilocytic astrocytoma,0.53,LGG_PA_GGST,0.71,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-1621,"Low grade glioma  see comment
","Histology: Low grade glioma
Methylation profile: Pilocytic astrocytoma, subclass hemispheric pilocytic astrocytoma and ganglioglioma 
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #155\NH20-1621,0.016,-0.008,0.003,0.002,-0.055,-0.026,0.013,0.155,0.233,0.168,0.283,0.012,-0.004,-0.012,0.002,-0.039,-0.005,-0.034,-0.017,-0.018,-0.051,-0.005,-0.011,-0.001,-0.021,-0.031,-0.042,0.035,0.05,unmethylated
NH20-1513,204308990007_R03C01,#155,28/07/2020,14/08/2020,8/14/2020,17,ZJ,Diagnostic,155,1,NDP,Brighton and Sussex Hospital,"Diffuse glioma, ?Oligo; ?GBM (IDH mutation not found so far)","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,9/26/1947,72.8,ganglioglioma,0.67,GBM_MES,0.36,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1513,"Diffuse glioma (for grading see comment)
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained
Further molecular tests: Pending
  
","Histology: Diffuse glioma
Methylation profile: Inconclusive, see comment
MGMT promoter (Illumina array): Unmethylated 
  
 
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #155\NH20-1513,0.034,-0.026,0.004,0.08,-0.054,-0.07,-0.099,0.241,-0.007,-0.024,0.126,0.019,0.017,-0.01,-0.186,0.024,-0.423,-0.253,-0.255,0.038,0.002,0.042,-0.043,-0.133,-0.089,-0.201,-0.064,-0.124,-0.135,unmethylated
NH20-1550,204308990007_R04C01,#155,30/07/2020,14/08/2020,8/14/2020,15,ZJ,Diagnostic,155,1,NDP,"Cardiff, University Hospital",Possible PA in posterior fossa,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/1/2011,8.9,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.99,0.98,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-1550,"Low grade glioma, compatible with pilocytic astrocytoma (WHO grade I) 
BRAF (V600E): No mutation 
KIAA1549-BRAF fusions: No fusions between 16_9, 16_11, 15_9 exons 
          
","Histology: Low grade glioma
Methylation profile: Pilocytic astrocytoma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #155\NH20-1550,0.023,-0.018,0.007,0.012,-0.003,-0.021,-0.08,0.004,0.035,-0.049,0.179,0.011,0.024,0.03,0.039,-0.004,-0.017,-0.029,0.099,0.066,-0.005,0.022,0.012,0.061,-0.037,-0.076,-0.066,-0.017,0.025,unmethylated
NH19-2365,204308990007_R06C01,#155,30/07/2020,14/08/2020,8/14/2020,15,ZJ,Diagnostic,155,9,NDP,NHNN,GBM (rec with extensive osteid and chondroid),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2B,1/26/2000,19.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.79,CONTR_INFLAM,0.09,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2365,"Glioblastoma (WHO grade IV)  see comment

IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained
Further molecular tests: Pending
  
","Glioblastoma, IDH-wildtype (WHO grade IV)
(See comment)
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #155\NH19-2365,0.134,0.119,0.095,-0.002,0.117,0.044,-0.092,0.285,0.279,0.335,0.241,0.06,0.073,0.05,-0.379,-0.047,-0.066,0.013,-0.068,-0.114,-0.05,-0.029,-0.055,-0.106,-0.197,-0.135,-0.053,-0.037,-0.049,unmethylated
NH20-1636,204308990007_R07C01,#155,30/07/2020,14/08/2020,8/14/2020,15,ZJ,Diagnostic,155,4,NDP,Brighton and Sussex Hospital,"AA, IDH-mutant (mitotic activity low, but hypercellular and prominent pleomorphism)","(4) IHC, sequencing, or copy number assay ambiguous",DEF1N,12/30/1967,52.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.89,AIDH_HG,0.68,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1636,"Anaplastic astrocytoma, IDH-mutant (WHO grade III)  see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Histology: Anaplastic astrocytoma, IDH mutant (WHO grade III)
Methylation profile: IDH glioma, subclass high grade astrocytoma
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: Deletion (See comment)
MGMT promoter (Illumina array): Methylated 
 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #155\NH20-1636,0.235,-0.059,0.003,0.034,-0.024,0.069,-0.047,0.02,0.256,0.287,0.206,-0.011,0.009,-0.034,-0.34,-0.037,-0.013,-0.153,0.121,-0.011,-0.031,-0.001,-0.03,-0.039,-0.079,-0.036,-0.037,-0.007,0.061,methylated
NH20-1570,204308910079_R03C01,#156,31/07/2020,14/08/2020,8/14/2020,14,ZJ,Diagnostic,156,4,NDP,"Leeds, St James's University Hospital","AA, IDH-mutant, no CDKN2A/B deletion (looks high grade)","(4) IHC, sequencing, or copy number assay ambiguous",B1,4/21/1988,32.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.74,AIDH_HG,0.52,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1570,"Anaplastic astrocytoma, IDH-mutant (WHO grade III)  see comment 
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion
MGMT Promoter: Methylated (>5-10%)
  
","Histology: Anaplastic astrocytoma, IDH-mutant (WHO grade III)
Methylation profile: IDH glioma, subclass high grade astrocytoma (see comment below)
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #156\NH20-1570,0.068,-0.184,-0.016,0.006,0.006,0.044,0.05,0.009,0.016,0.022,-0.007,-0.004,0.032,0.107,-0.347,-0.031,-0.142,-0.074,-0.043,0.223,-0.099,-0.101,-0.092,-0.044,0.01,-0.049,-0.043,0.003,0.011,methylated
NH20-1680,204308910079_R05C01,#156,3/8/2020,14/08/2020,8/14/2020,11,SB,Diagnostic,156,1,NDP,"Belfast, Royal Victoria Hospital","Spinal Tumour, Ependymoma vs GBM","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B2,12/21/2001,18.6,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",1,DMG_K27,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-1680,"Histology: Diffuse midline glioma, H3 K27M mutant
Methylation profile: diffuse midline glioma H3 K27M mutant
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #156\NH20-1680,0.22,0.02,-0.01,-0.055,0.629,0.021,0.129,0.081,-0.068,-0.019,0.01,-0.088,-0.012,-0.066,-0.107,0.048,-0.2,-0.138,-0.1,-0.083,-0.066,-0.054,-0.713,-0.048,-0.015,-0.032,-0.044,-0.008,0.006,unmethylated
NH20-1667,204308910079_R07C01,#156,3/8/2020,14/08/2020,8/14/2020,11,SB,Diagnostic,156,1,NDP,St George's Hospital London,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,4/1/1980,40.3,myxopapillary ependymoma,1,EPN_MPE,1,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1667,"Histology: Ependymoma
Methylation profile: ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #156\NH20-1667,-0.015,-0.157,-0.085,-0.013,-0.015,0.019,0.057,0.029,0.022,0.008,0.007,0.007,0.023,0.028,0,-0.007,-0.052,-0.044,-0.034,-0.147,-0.195,-0.092,-0.402,-0.07,0.033,-0.045,-0.012,-0.109,-0.157,unmethylated
NH20-1685,204308910047_R01C01,#157,5/8/2020,8/21/2020,8/20/2020,15,AM,Diagnostic,157,1,NDP,Oxford John Radcliffe Hospital,Multinodular and vacuolating neuronal tumour (MVNT),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2C,10/24/1991,28.8,dysembryoplastic neuroepithelial tumour,0.31,LGG_DNT,0.37,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1685,"Low grade glial/glioneuronal tumour - see comment

IDH1 (R132H IHC): No mutation  
ATRX (IHC): Retained 
Further molecular tests: Pending
","Histology: Low grade glial/glioneuronal tumour
Methylation profile: control tissue, hemispheric cortex
MGMT promoter (Illumina array): Unmethylated 
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #157\NH20-1685,0.053,-0.028,-0.015,0.04,-0.03,-0.008,-0.115,0.045,0.047,0.029,0.013,0.057,0.013,0.084,-0.003,0.01,-0.047,-0.063,0.007,0.095,0.063,0.032,0.006,0.037,-0.085,-0.035,-0.054,-0.109,-0.001,unmethylated
NH20-1691,204308910047_R02C01,#157,5/8/2020,8/21/2020,8/20/2020,15,SB,Diagnostic,157,1,NDP,"Leeds, St James's University Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,12/12/1963,56.6,"glioblastoma, IDH-wildtype, RTK1 type",0.17,GBM_RTKII,0.16,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1691,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: No matching methylation class, but copy number profile consistent with glioblastoma, IDH-wildtype.
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #157\NH20-1691,-0.07,-0.029,0.001,0.011,0.047,0.085,0.023,0.141,0.133,0.219,0.13,-0.004,-0.004,-0.017,-0.591,-0.199,-0.242,-0.211,-0.047,-0.044,-0.058,0.044,-0.11,-0.04,-0.052,-0.033,-0.039,-0.035,-0.01,unmethylated
NH20-1677,204308910047_R03C01,#157,5/8/2020,8/21/2020,8/20/2020,15,SB,Diagnostic,157,1,NDP,"Birmingham, Queen Elizabeth Hospital","PA, Grade 1","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,4/30/1987,33.2,"diffuse glioma, MYB(L1)-altered, subtype A [angiocentric glioma-type]",0.35,LGG_MYB,0.9,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1677,"Histology: Low grade glioma
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #157\NH20-1677,-0.008,-0.02,0.005,0.024,-0.058,0.018,-0.005,-0.004,-0.041,-0.056,-0.01,0.002,0.012,0.001,0.032,-0.005,-0.025,0,-0.011,-0.031,-0.024,0.033,0.003,-0.037,-0.024,-0.029,-0.018,0.02,0.02,unmethylated
NH20-1359,204308910047_R05C01,#157,6/8/2020,8/21/2020,8/20/2020,14,SB,Diagnostic,157,2,NDP,Oxford John Radcliffe Hospital,Sarcoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,10/10/1941,78.8,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.28,GBM_MID,0.4,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1359,"Referred diagnosis: Glioblastoma (WHO grade IV) 
MGMT Promoter: Methylated (>5-10%)
","1)          S8613-2020: Methylation profile: Glioblastoma, IDH-wildtype, subclass midline. 
2)     3312-02: Methylation profile: Undifferentiated sarcoma 

",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #157\NH20-1359,-0.01,-0.027,0.019,0.019,0.735,0.015,0.037,-0.013,-0.014,-0.03,-0.026,-0.021,-0.022,-0.006,-1.051,0.001,-0.306,0.031,0.017,0.127,0.115,0.239,-0.026,-0.287,-0.473,0.326,-0.022,-0.028,-0.011,methylated
NH20-1715,204308910047_R07C01,#157,6/8/2020,8/21/2020,8/20/2020,14,SB,Diagnostic,157,1,NDP,Southampton General Hospital,Temporal glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,6/6/2001,19.2,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.57,LGG_DNT,0.99,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-1715,"Histology: Dysembryoplastic neuroepithelial tumour
Methylation profile: low grade glioma, dysembryoplastic neuroepithelial tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #157\NH20-1715,0.049,-0.04,0.002,0.028,-0.076,0.047,0.035,-0.006,-0.017,-0.001,0.007,0.005,0.066,-0.017,0.001,-0.028,-0.022,-0.024,-0.004,-0.038,-0.013,0.007,0.019,-0.027,-0.01,0.019,-0.038,0.017,0.043,unmethylated
NH20-1631,204308910081_R05C01,#158,7/8/2020,8/21/2020,8/20/2020,13,SB,Diagnostic,158,1,NDP,"Belfast, Royal Victoria Hospital",pleomorphic glioblastoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",a 1,9/30/1952,67.9,"glioblastoma, IDH-wildtype, with primitive neuronal component",0.92,GBM_RTKII,0.64,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1631,"Glioblastoma, IDH-wildtype (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
CDKN2A/B: No deletion
MGMT Promoter: Unmethylated (0%)

","Histology: Glioblastoma, IDH-wildtype (WHO Grade IV)
Methylation profile: glioblastoma, IDH-wildtype, subclass RTK II
MGMT promoter (Illumina array): Unmethylated
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #158\NH20-1631,0.036,0.004,0.002,-0.262,-0.393,0.067,-0.007,0.192,0.26,0.321,0.179,0.016,-0.024,-0.006,-0.055,-0.007,-0.366,-0.364,-0.078,-0.07,-0.064,0,-0.381,-0.1,-0.136,-0.128,-0.544,-0.285,-0.296,unmethylated
NH20-1684,204308910081_R06C01,#158,10/8/2020,8/21/2020,8/20/2020,10,SB,Diagnostic,158,1,NDP,Romford,Highly pleomorphic glioblastoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/18/1993,27.2,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.7,GBM_MES,0.42,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1684,"Left temporal lobe biopsy: Glioblastoma (WHO grade IV)
","Glioblastoma, IDH-wildtype (WHO grade IV) 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification     
MGMT Promoter: Unmethylated (0%)
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #158\NH20-1684,0.015,-0.038,0.037,0.186,0.194,0.216,0.01,0.292,0.3,0.322,0.247,0.013,0.031,0.008,0.204,0.269,-0.049,0,-0.05,-0.027,-0.025,-0.02,-0.031,-0.008,-0.091,-0.059,-0.058,-0.004,0.036,unmethylated
NH20-1672,204308910081_R07C01,#158,11/8/2020,8/21/2020,8/20/2020,9,SB,Diagnostic,158,1,NDP,St George's Hospital London,Highly pleomorphic glioblastoma,"(4) IHC, sequencing, or copy number assay ambiguous",A3,6/14/1977,43.1,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.98,AIDH,0.74,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1672,"Astrocytoma, IDH-mutant (WHO grade II), see comment
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion
MGMT Promoter: Methylated (>0-5%)

","Histology: Astrocytoma, IDH-mutant (WHO Grade II) 
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #158\NH20-1672,0.015,-0.029,-0.04,-0.017,0.013,-0.02,-0.031,-0.04,0.176,0.146,0.169,0.007,-0.02,0.054,-0.037,-0.027,-0.028,-0.04,-0.014,-0.002,-0.008,-0.009,0.022,0.026,-0.055,-0.053,-0.335,-0.035,0.032,methylated
NH20-1666,204308910081_R08C01,#158,31/07/2020,8/21/2020,8/20/2020,20,ZJ,Diagnostic,158,1,NDP,HCA,"Spinal ependymoma, G II in conus","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,4/12/1941,79.3,myxopapillary ependymoma,1,EPN_MPE,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-1666,"Ependymal tumour  see comment
","Histology: Ependymoma
Methylation profile: ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch #158\NH20-1666,0.025,0.001,0.1,0,-0.044,-0.012,-0.008,-0.005,0.066,0.02,0.01,0.081,0.091,0.087,-0.009,0.1,-0.009,0.011,0.043,0.093,0.054,-0.015,0.012,0.048,-0.014,0.026,-0.014,-0.047,0.016,unmethylated
NH20-1751,204308990011_R03C01,159,12/8/2020,8/28/2020,8/27/2020,15,SB,Diagnostic,159,1,NDP,"Leeds, St James's University Hospital",Ependymoma spinal,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,9/30/2013,6.2,myxopapillary ependymoma,1,EPN_MPE,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1751,"Histology: Myxopapillary ependymoma (WHO Grade I)
Methylation profile: ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 159\NH20-1751,-0.242,-0.337,-0.293,-0.026,0.163,-0.141,-0.449,0.051,0.119,0.005,0.025,0.098,0.072,0.091,0.297,0.361,-0.267,-0.323,0.049,0.14,0.135,0.104,-0.226,0.215,0.013,0.052,-0.051,-0.218,-0.241,unmethylated
NH18-2815,204308990011_R06C01,159,13/08/2020,8/28/2020,8/27/2020,14,SB,Diagnostic,159,1,NDP,Nottingham University Hospital,glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/18/1955,63.3,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.18,GBM_MID,0.98,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2815,"Astrocytoma (WHO grade II) 
MGMT Promoter: Methylated (>0-5%)
","Histology: Diffuse astrocytic glioma
Methylation profile: glioblastoma, IDH-wildtype, subclass midline
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 159\NH18-2815,-0.079,0.033,0.007,-0.052,0.054,0.037,-0.094,0.079,-0.019,-0.105,-0.018,0.026,0.028,-0.029,0.065,0.022,0.022,-0.007,0.01,0.013,0.013,-0.09,0.028,0.066,-0.063,-0.034,-0.039,-0.001,-0.051,methylated
NH20-1778,204308990011_R07C01,159,13/08/2020,8/28/2020,8/27/2020,14,SB,Diagnostic,159,1,NDP,Nottingham University Hospital,,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,9/25/1976,43.9,ganglioglioma,0.44,GBM_MES,0.93,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1778,"Histology: Diffuse astrocytoma
Methylation profile: glioblastoma, IDH wildtype, subclass mesenchymal 
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 159\NH20-1778,0.269,-0.034,-0.057,0.498,0.085,0.024,0.007,0.299,0.285,0.236,0.269,0.045,0.08,0.036,-0.442,0.079,-0.15,-0.123,-0.05,0.057,0.109,0.08,0.004,0.056,-0.113,-0.135,0.153,-0.222,-0.234,methylated
NH20-1774,204308990011_R08C01,159,14/08/2020,8/28/2020,8/27/2020,13,SB,Diagnostic,159,6,NDP,Romford,"high-grade pineal umour, Pineoblastomas?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/31/1976,44.4,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.21,CNSNB_FOXR2,0.16,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1774,"High grade neuroectodermal tumour, see comment.
","Histology: High-grade neuroectodermal tumour
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Unmethylated
  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 159\NH20-1774,0.215,0.054,0.119,0,0.765,-0.042,0.161,0.009,0.372,0.353,0.297,-0.148,-0.072,-0.094,-0.114,-0.078,-0.321,0.15,0.036,0.06,0.084,0.086,0.126,0.082,0.076,0.029,-0.392,0.111,0.236,unmethylated
NH20-1721,204308990009_R01C01,160,14/08/2020,9/4/2020,9/4/2020,21,SB,Diagnostic,160,3,NDP,St George's Hospital London,"Astrocytoma, IDH mutant","(4) IHC, sequencing, or copy number assay ambiguous",A1,7/27/1991,29,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.98,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1721,"Anaplastic astrocytoma, IDH-mutant (WHO grade III)
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion
MGMT Promoter: Methylated (>0-5%)
  
","Histology: Anaplastic astrocytoma, IDH-mutant (WHO grade III)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array):  Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 160\NH20-1721,0.03,-0.037,0.003,-0.009,-0.022,-0.006,-0.201,-0.022,0.012,-0.027,-0.011,0.032,0.038,0.014,-0.017,-0.015,-0.085,-0.233,-0.011,0.127,-0.269,-0.391,-0.027,-0.01,-0.018,-0.002,-0.076,-0.025,-0.03,methylated
NH20-1767,204308990009_R03C01,160,14/08/2020,9/4/2020,9/4/2020,21,SB,Diagnostic,160,1,NDP,Brighton and Sussex Hospital,"Astrocytoma, IDH mutant, G3 /4","(4) IHC, sequencing, or copy number assay ambiguous",DEF1B,4/22/1978,42.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1767,"High grade glioma, IDH-mutant (at least WHO grade III)  see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Histology: Anaplastic astrocytoma, IDH mutant (WHO grade III)
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 160\NH20-1767,0.057,-0.063,0.038,-0.02,0.107,0.063,-0.081,0.066,1.253,0.062,-0.032,-0.002,0.028,-0.047,-0.127,-0.225,-0.158,-0.046,-0.027,0.017,-0.347,-0.473,-0.173,-0.033,-0.005,-0.008,-0.271,-0.032,0.029,methylated
NH20-1760,204308990009_R04C01,160,14/08/2020,9/4/2020,9/4/2020,21,SB,Diagnostic,160,4,NDP,NHNN,"Glioblastoma, unusual morphology","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1C,12/12/1956,63.7,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.85,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1760,"Glioblastoma (WHO grade IV) with areas of astroblastic differentiation  see comment  

IDH1 (R132H IHC): Technically unsatisfactory. 
ATRX (IHC): Retained 
Further molecular tests: Pending
","Histology: Glioblastoma (WHO grade IV) 
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK I
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 160\NH20-1760,-0.044,-0.06,0.018,0.017,1.022,0.074,0.021,0.136,0.207,-0.036,-0.028,-0.005,0.021,-0.029,-0.758,-0.123,-0.327,-0.249,-0.145,-0.061,-0.059,0.012,-0.047,-0.037,-0.038,-0.008,-0.022,-0.018,0.015,unmethylated
NH20-1788,204308990009_R05C01,160,17/08/2020,9/4/2020,9/4/2020,18,SB,Diagnostic,160,2,NDP,NHNN,PXA? Ganglioglioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,1/7/2002,18.6,ganglioglioma,1,LGG_GG,0.98,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1788,"BRAF V600E mutant glial tumour  see comment 

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained 
BRAF V600E: Mutation     
Further molecular tests: Pending
","Histology: Glioma, BRAF-mutant
Methylation profile: low grade glioma, ganglioglioma
MGMT promoter (Illumina array): Unmethylated 
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 160\NH20-1788,-0.04,-0.024,0.038,0.073,0.007,0.139,-0.03,0.215,0.305,0.264,0.25,0.009,0.011,-0.024,0.019,-0.009,-0.065,0.019,-0.011,0.077,0.088,0.126,-0.027,-0.015,-0.061,-0.049,0.125,-0.01,0.04,unmethylated
NH20-1795,204308990009_R06C01,160,17/08/2020,9/4/2020,9/4/2020,18,SB,Diagnostic,160,2,NDP,"Leeds, St James's University Hospital",HGG,"(2) unusual histology, location, demographics",B7,9/9/2018,1.9,posterior fossa ependymoma group A2,1,EPN_PFA,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1795,"Histology: Ependymoma (grading see comment)
Histone H3 K27me3: Loss of expression
Methylation profile: ependymoma, posterior fossa group A
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 160\NH20-1795,0.018,-0.026,0.047,0.019,0.02,0.036,0.008,-0.06,-0.043,-0.034,-0.016,-0.003,-0.007,-0.026,0.007,0.001,-0.077,-0.008,-0.075,-0.057,-0.053,-0.025,-0.031,-0.028,-0.019,-0.066,0.006,0.004,0.001,unmethylated
NH20-1804,204308990009_R08C01,160,18/08/2020,9/4/2020,9/4/2020,17,SB,Diagnostic,160,1,NDP,Southampton General Hospital,DNET? Ganglioglima?,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1A,4/28/1964,56.3,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,0.98,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1804,"Histology: Glioma with varied morphological features
Methylation profile: Ependymoma, RELA fusion
MGMT promoter (Illumina array): Unmethylated Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 160\NH20-1804,-0.028,-0.017,0.067,0.071,0.117,-0.022,0.006,0.007,-0.019,0.005,-0.017,0.025,0.033,0.001,-0.514,-0.242,-0.121,-0.075,-0.018,-0.264,-0.241,-0.364,0.001,-0.065,-0.082,-0.083,-0.027,-0.035,0.009,unmethylated
NH20-1659,204308990022_R03C01,161,18/08/2020,9/4/2020,9/4/2020,17,SB,Diagnostic,161,1,NDP,Southampton General Hospital,"GBM, Type?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,11/3/1960,59.7,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.88,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1659,"High grade glioma, most in keeping with glioblastoma IDH-wildtype (WHO grade IV), but see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
TERT promoter: No mutation
BRAF (V600E): No mutation

","Histology: High-grade glioma, most in keeping with glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: glioblastoma, IDH wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 161\NH20-1659,0.01,-0.034,0,0.01,-0.01,-0.009,-0.189,0.255,0.166,0.115,0.108,-0.01,0.017,-0.023,-0.427,-0.025,-0.17,-0.171,-0.007,-0.025,-0.056,-0.015,-0.149,0.038,-0.239,-0.047,-0.035,-0.155,-0.178,unmethylated
NH20-1743,204308990022_R04C01,161,18/08/2020,9/4/2020,9/4/2020,17,SB,Diagnostic,161,3,NDP,NHNN,IDH mutant Astrocytoma,"(4) IHC, sequencing, or copy number assay ambiguous",A5,3/4/1972,48.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.54,AIDH,0.97,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1743,"Diffuse astrocytoma, IDH-mutant  see comment for grading

IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Histology: Astrocytoma, IDH mutant (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 161\NH20-1743,-0.003,-0.027,0.02,-0.021,-0.026,-0.118,-0.022,-0.001,-0.012,-0.02,-0.012,-0.004,0.037,-0.039,-0.049,-0.019,-0.018,0.028,-0.029,-0.008,-0.04,-0.02,-0.021,-0.025,-0.062,-0.042,-0.269,-0.053,-0.045,unmethylated
NH20-1811,204308990022_R05C01,161,18/08/2020,9/4/2020,9/4/2020,17,SB,Diagnostic,161,6,NDP,"Birmingham, Queen Elizabeth Hospital",,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A14,7/23/1950,70.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.44,CONTR_REACT,0.4,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1811,"Histology: CNS tissue fragments with tissue destruction, gliosis and inflammation.
Methylation profile: Control tissue, hypothalamus
MGMT promoter (Illumina array): Unmethylated 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 161\NH20-1811,0.052,-0.031,-0.01,0.031,-0.048,0.039,0.019,-0.023,0.006,-0.054,-0.008,-0.012,0.048,0.005,0,-0.027,-0.005,0.003,0.034,-0.028,-0.049,0.033,0.023,-0.023,-0.014,-0.035,-0.025,-0.058,0,unmethylated
NH20-1818,204308990022_R06C01,161,19/08/2020,9/4/2020,9/4/2020,16,SB,Diagnostic,161,1,NDP,Brighton and Sussex Hospital,ependymoma posterior fossa,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,2/2/1963,57.6,posterior fossa ependymoma group B,1,EPN_PFB,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1818,"Ependymoma  see comment for grading 
","Histology: Ependymoma (see comment in previous report for grading)
Methylation profile: Ependymoma, posterior fossa group B
MGMT promoter (Illumina array): Unmethylated
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 161\NH20-1818,0.207,-0.204,-0.048,-0.146,-0.078,-0.088,-0.409,0.059,0.113,0.071,0.069,0.083,0.158,0.095,-0.011,0.049,-0.186,-0.136,0.093,0.076,0.062,0.071,0.023,-0.138,-0.195,-0.167,0.047,-0.29,-0.243,unmethylated
NH20-1815,204308990022_R07C01,161,19/08/2020,9/4/2020,9/4/2020,16,SB,Diagnostic,161,1,NDP,Oxford John Radcliffe Hospital,myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2A,9/21/1988,31.9,myxopapillary ependymoma,0.58,EPN_MPE,0.7,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1815,"Histology: Myxopapillary ependymoma (WHO grade I)
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Methylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 161\NH20-1815,-0.02,-0.245,-0.191,0.059,0.098,-0.023,-0.211,0.137,0.123,0.14,0.108,-0.036,0.001,-0.029,0.123,-0.023,-0.253,-0.191,-0.043,0.048,0.014,-0.23,-0.053,-0.028,-0.046,-0.042,0.102,-0.242,-0.261,methylated
NH20-1827,204308990023_R02C01,162,21/08/2020,9/11/2020,9/10/2020,20,SB,Diagnostic,162,1,NDP,St George's Hospital London,GlioblastomaOr abscess granulation tissue?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,2/8/1955,65.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.75,GBM_RTKII,0.52,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1827,"Histology: High-grade glioma, acute and subacute haemorrhage
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 162\NH20-1827,-0.002,-0.152,0.006,0.308,-0.167,0.03,0.053,0.209,0.247,0.208,0.193,-0.121,-0.091,-0.042,-0.382,-0.04,-0.332,-0.263,-0.006,-0.08,0.72,1.53,-0.038,-0.063,-0.008,-0.034,0.172,-0.248,-0.291,methylated
NH20-1850,204308990023_R06C01,162,26/08/2020,9/11/2020,9/10/2020,15,SB,Diagnostic,162,1,NDP,Romford,Ependymal tumour? Referred as Central Neurocytoms,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B4,9/6/1984,36,supratentorial subependymoma,1,SUBEPN_ST,1,0.63,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1850,"Glial tumour, raising the possibility of ependymoma, see comment. 
","Histology: Ependymal tumour
Methylation profile: subependymoma, supratentorial
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 162\NH20-1850,0.015,-0.076,0.011,-0.002,-0.012,-0.031,-0.036,0.059,-0.019,-0.044,-0.017,-0.013,0.006,0.014,-0.04,-0.01,-0.021,0.018,-0.02,-0.008,-0.049,0.019,-0.047,0.01,-0.026,-0.007,-0.056,-0.005,0.036,unmethylated
NH20-1862,204308990023_R07C01,162,26/08/2020,9/11/2020,9/10/2020,15,SB,Diagnostic,162,10,NDP,NHNN,GBM? APXA?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/19/1969,51,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.17,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1862,"Glioblastoma (WHO grade IV). 
IDH1 (R132H IHC): No mutation  
ATRX (IHC): Retained 
Further molecular tests: Pending
","Glioblastoma, IDH-wildtype (WHO grade IV) 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification          
TERT promoter: Mutation
MGMT Promoter: Methylated (>10-25%) 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 162\NH20-1862,0.087,-0.049,0.005,-0.058,-0.007,-0.025,-0.058,0.015,0.021,0.02,0.012,0.03,0.065,-0.018,0.062,0.004,-0.111,-0.115,-0.013,-0.112,-0.074,-0.087,-0.068,-0.13,-0.082,0.018,-0.074,-0.071,-0.1,methylated
NH20-1686,204308990023_R08C01,162,11/8/2020,9/11/2020,9/10/2020,30,SB,Diagnostic,162,1,NDP,"Birmingham, Queen Elizabeth Hospital","midline tumour, K27M and IDH negative (APA?)","(2) unusual histology, location, demographics",A1,5/20/1985,35.2,pleomorphic xanthoastrocytoma(-like),1,PXA,0.98,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1686,"High-grade glioma, most in keeping with glioblastoma (WHO grade IV), see comment
Histone H3 K27: No mutation
","Histology: High-grade glioma
Methylation profile: (Anaplastic) pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 162\NH20-1686,-0.065,0.095,-0.032,-0.005,0.182,0.101,-0.002,0.087,-0.002,0.156,0.058,-0.257,-0.202,-0.22,-1.166,-0.201,-0.342,-0.152,-0.203,0.049,0.026,-0.001,-0.362,-0.048,-0.09,0.042,-0.126,-0.231,0.017,methylated
NP20-32,204308830067_R01C01,163,26/08/2020,9/11/2020,9/10/2020,15,SB,Diagnostic,163,11,NDP,Hemel Hempstead,PF- Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A5,#N/A,#N/A,supratentorial midline pilocytic astrocytoma,0.99,LGG_PAMID,0.99,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NP20-32,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Pilocytic astrocytoma, subclass midline 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 163\NP20-32,-0.098,-0.045,-0.019,-0.027,-0.085,0.039,0.12,-0.025,-0.002,0.031,-0.012,0.017,0.065,0.019,0.067,0.017,0.014,0.048,0.008,-0.006,-0.021,0.025,-0.001,-0.039,-0.041,-0.028,0.002,-0.001,-0.008,unmethylated
NH20-1825,204308830067_R03C01,163,26/08/2020,9/11/2020,9/10/2020,15,SB,Diagnostic,163,1,NDP,Romford,infiltration zone of IDH-wildtype glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,2/12/1969,51.5,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.95,LGG_MYB,0.14,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1825,"CNS tissue with increased cellularity  see comment 
Further molecular tests: Pending
","Histology: CNS tissue with increased cellularity
Methylation profile: Control tissue, hemispheric cortex (see diagnostic comment)
MGMT promoter (Illumina array): Unmethylated 
  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 163\NH20-1825,0.008,-0.087,-0.003,-0.007,-0.119,-0.07,-0.067,0.197,0.179,0.105,0.137,-0.008,0.004,-0.107,-0.104,-0.021,-0.032,-0.021,-0.014,0.05,0.068,0.068,-0.04,0.035,-0.035,-0.071,0.05,-0.036,0.018,unmethylated
NH20-1904,204308830067_R05C01,163,27/08/2020,9/11/2020,9/10/2020,14,SB,Diagnostic,163,1,NDP,Plymouth,,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,3/27/2003,17.4,supratentorial midline pilocytic astrocytoma,0.97,LGG_PAMID,0.87,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1904,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: low grade glioma, subclass midline pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
","Pilocytic astrocytoma (WHO grade I) 
BRAF (V600E): Mutation
KIAA1549-BRAF: No fusion
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 163\NH20-1904,0.214,-0.161,-0.096,0.017,-0.114,-0.143,-0.023,0.103,0.247,0.138,0.095,0.077,0.091,0.08,0.109,0.101,0.016,-0.075,0.113,0.177,0.103,0.115,0.036,0.163,-0.019,-0.038,-0.267,-0.054,0.057,unmethylated
NH20-1895,204308830067_R07C01,163,28/08/2020,9/11/2020,9/10/2020,13,SB,Diagnostic,163,2,NDP,"Cardiff, University Hospital",Sub ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,8/8/1963,57.1,posterior fossa subependymoma,1,SUBEPN_PF,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1895,"Histology: subependymoma (WHO grade I)
Methylation profile: subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 163\NH20-1895,0.112,-0.03,0.03,0.034,-0.004,-0.073,-0.035,0.054,-0.038,-0.015,-0.014,-0.013,-0.038,0.036,0,0.002,-0.064,-0.001,-0.03,-0.015,-0.004,0.072,-0.021,0.084,0.011,-0.036,0.006,0.004,0.072,unmethylated
NH20-1910,204308830067_R08C01,163,28/08/2020,9/11/2020,9/10/2020,13,SB,Diagnostic,163,2,NDP,St George's Hospital London,"Ependymoma, myxopapillary","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B2,5/25/1989,31.3,myxopapillary ependymoma,1,EPN_MPE,1,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1910,"Histology: Myxopapillary ependymoma
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Unmethylated Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 163\NH20-1910,0.019,-0.095,-0.012,0.14,0.176,-0.105,0.208,0.136,0.208,0.13,0.164,-0.03,-0.005,-0.043,0.047,0.211,-0.065,-0.094,0.139,0.043,-0.064,0.023,-0.332,0.237,0.327,0.203,-0.062,-0.289,-0.231,methylated
NH20-1883,204308830020_R01C01,164,1/9/2020,9/18/2020,9/17/2020,16,SB,Diagnostic,164,1,NDP,"Birmingham, Queen Elizabeth Hospital",High grade glioma consistent with GBM grade IV,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/17/1993,27.5,high-grade astrocytoma with piloid features,0.22,PXA,0.19,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1883,"High-grade glioma with histological features of glioblastoma (WHO grade IV)
","Histology: High-grade glioma, with features of glioblastoma
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 164\NH20-1883,0.188,0.063,0.034,-0.023,0.426,0.026,-0.138,-0.088,-0.016,-0.066,-0.017,0.01,-0.016,-0.078,-0.522,0.069,-0.176,0.014,-0.11,0.04,-0.019,-0.069,-0.212,-0.03,0.037,0.056,0.033,0.052,0.002,unmethylated
NH20-1831,204308830020_R02C01,164,1/9/2020,9/18/2020,9/17/2020,16,SB,Diagnostic,164,1,NDP,St George's Hospital London,"low-grade glioma, oligodendroglioma previously tested with us and inconclusive copy number result ","(4) IHC, sequencing, or copy number assay ambiguous",A1 ,6/22/1982,38.2,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.86,OIDH,0.99,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1831,"Diffuse glioma, IDH-mutant (WHO grade II) 
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained     
1p/19q: Retained
TERT promoter: Mutation
MGMT Promoter: Methylated (>0-5%)
","Histology: Oligodendroglioma, IDH-mutant and 1p/19 q codeleted (WHO grade II)
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 164\NH20-1831,-0.039,-0.041,0.034,-0.04,-0.043,0.019,0.029,0.013,0.004,-0.05,-0.031,0.004,0.035,-0.046,-0.001,-0.012,-0.049,-0.04,-0.014,0.005,-0.071,-0.025,-0.027,0.006,-0.068,-0.029,-0.441,0.111,0.212,methylated
NH20-1860,204308830020_R03C01,164,1/9/2020,9/18/2020,9/17/2020,16,SB,Diagnostic,164,7,NDP, Romford ,"GBM, poorly differentiated, other high grade lesion differential","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B 2,2/4/1970,50.6,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.08,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1860,"Malignant epithelioid and spindle-cell neoplasm with multinucleated giant cell component  see comment 
","Histology: Malignant spindle cell neoplasm 
Methylation profile: Undifferentiated sarcoma
MGMT promoter (Illumina array): Methylated 
  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 164\NH20-1860,0.156,-0.188,-0.094,0.021,0.117,0.041,-0.084,0.023,0.146,0.163,0.123,0.193,0.021,0.177,0.128,-0.023,-0.17,-0.227,-0.019,-0.149,-0.145,-0.036,-0.052,-0.072,0.035,-0.111,-0.018,0.089,0.052,methylated
NH20-1777,204308830020_R06C01,164,2/9/2020,9/18/2020,9/17/2020,15,SB,Diagnostic,164,1,NDP,"Belfast, Royal Victoria Hospital","IDH-wt glioma, nos","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/23/1990,30.1,dysembryoplastic neuroepithelial tumour,0.93,LGG_DNT,0.99,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1777,"Astrocytoma, IDH-wildtype (grading see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
CDKN2A/B: No deletion
MGMT Promoter: Methylated (>0-5%)
","Histology: Low grade glioma, NOS
Methylation profile: Low grade glioma, dysembryoplastic neuroepithelial tumor
MGMT promoter (Illumina array):  Methylated 
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 164\NH20-1777,0.003,0.013,0.039,-0.012,-0.032,0.027,-0.031,-0.007,-0.071,-0.058,-0.024,0.011,0.067,-0.042,-0.016,-0.008,-0.051,0.046,0.072,-0.018,-0.052,-0.158,0.06,-0.037,-0.129,-0.037,-0.017,-0.001,0.023,methylated
NH20-1970,204308830066_R02C01,165,8/9/2020,9/18/2020,9/17/2020,9,SB,Diagnostic,165,1,NDP,Southampton General Hospital,"Cerebellar tumour, 2001","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,7/21/1979,22.4,rosette-forming glioneuronal tumour,0.39,LGG_RGNT,0.74,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1970,"Histology: Glioneuronal tumour 
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 165\NH20-1970,0.286,0.125,-0.154,-0.135,0.365,-0.397,-0.038,0.131,0.082,-0.182,0.015,0.117,0.056,0.246,0.023,0.109,0.078,-0.291,0.28,0.381,0.219,0.232,0.036,0.193,0.075,-0.043,-0.097,-0.033,0.092,unmethylated
NH20-1991,204308830066_R04C01,165,8/9/2020,9/18/2020,9/17/2020,9,SB,Diagnostic,165,1,NDP,Newcastle,Fronatal LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]","1A, 2A",1/1/1949,71.7,dysembryoplastic neuroepithelial tumour,0.99,LGG_DNT,0.98,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1991,"Histology: Low grade glioma
Methylation profile: low grade glioma, dysembryoplastic neuroepithelial tumor
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 165\NH20-1991,0.022,-0.027,0.011,0.132,0.126,0.155,0.221,0.177,0.192,0.163,0.165,0.372,0.173,0.162,0.3,0.267,-0.042,0.015,0.216,0.015,0.003,0.001,-0.052,0.002,-0.059,-0.012,-0.056,0.017,0.064,methylated
NH20-1936,204308830066_R05C01,165,8/9/2020,9/18/2020,9/17/2020,9,SB,Diagnostic,165,1,NDP,NHNN,Cerebellum,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/12/2002,18.5,infratentorial pilocytic astrocytoma,0.98,LGG_PAPF,0.98,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1936,"Low grade glioma  see comment
","Histology: Low grade glioma 
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma 
KIAA1549-BRAF: No fusion
BRAF (V600E): No mutation           
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 165\NH20-1936,-0.025,-0.055,0,-0.022,-0.046,0.089,0.04,0.099,0.206,0.212,0.155,0,-0.028,-0.015,-0.03,-0.018,-0.092,0.023,0.032,0.011,-0.032,-0.036,-0.08,-0.067,-0.133,-0.019,-0.031,0.027,0.039,unmethylated
NH20-1944,204308830066_R07C01,165,8/9/2020,9/18/2020,9/17/2020,9,SB,Diagnostic,165,4,NDP,Brighton and Sussex Hospital,Cerebellar NET,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/2/1982,38.1,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.23,LGG_MYB,0.23,0.63,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1944,"Residual/recurrent high-grade neuroepithelial tumour  see comment
","Histology: Residual/recurrent high-grade neuroepithelial tumour
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 165\NH20-1944,0.009,-0.034,0.03,0.027,0.025,-0.018,-0.024,0.053,0.001,-0.019,-0.009,0.011,0.021,-0.026,-0.212,0.072,-0.037,-0.023,-0.012,-0.04,-0.033,-0.006,-0.031,0.003,0.01,0.014,0.021,-0.018,0.028,unmethylated
NH19-2371,204308830066_R08C01,165,8/9/2020,9/18/2020,9/17/2020,9,SB,Diagnostic,165,2,NDP,Brighton and Sussex Hospital,Cerebellar NET,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/2/1982,37.1,"Diffuse midline glioma, H3 K27-altered, subtype EGFR-altered",0.34,GBM_RTKI,0.18,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2371,"Residual/recurrent high-grade neuroepithelial tumour (see comment)
","Histology: Recurrent/residual high grade neuroepithelial tumour
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 165\NH19-2371,0.051,-0.081,0.056,-0.042,-0.042,-0.062,0.028,0.046,0.011,-0.052,-0.005,0.017,0.054,0.131,-0.364,0.014,-0.26,-0.291,0.007,0.051,0.002,-0.002,-0.108,0.018,-0.066,-0.029,-0.099,-0.045,0.023,unmethylated
NH20-2020,204308830064_R01C01,166,11/9/2020,9/25/2020,9/24/2020,13,SB,Diagnostic,166,1,NDP,Nottingham University Hospital,ependymoma? ,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,10/30/1963,56.9,spinal ependymoma,1,EPN_SPINE,0.95,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2020,"Histology: Ependymoma (WHO grade II) 
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 166\NH20-2020,0.046,-0.119,0.032,0.001,-0.126,-0.041,0.263,-0.069,-0.022,-0.134,-0.069,0.172,0.048,0.109,0.114,0.211,-0.078,-0.076,0.045,0.201,0.119,0.262,-0.923,-0.001,-0.006,-0.07,0.104,-0.411,-0.291,unmethylated
NH20-2048,204308830064_R03C01,166,14/09/2020,9/25/2020,9/24/2020,10,SB,Diagnostic,165,5,NDP,Oxford John Radcliffe Hospital,"high grade glioma,","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2,10/23/1963,56.9,"glioblastoma, IDH-wildtype, RTK2 type",0.69,GBM_RTKII,0.67,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2048,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Unmethylated 

",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 166\NH20-2048,0.093,-0.002,0.072,0.006,0.055,0.003,-0.533,1.347,0.34,0.247,0.203,0.049,-0.062,0.157,-1.067,0.081,-0.359,-0.34,0.061,0.11,0.013,0.017,-0.352,0.109,-0.111,-0.039,0.068,-0.483,-0.227,unmethylated
NH20-2034,204308830064_R04C01,166,14/09/2020,9/25/2020,9/24/2020,10,SB,Diagnostic,165,1,NDP,Colombia,poorly differentiated BrainTumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C1,5/24/2016,4.1,supratentorial midline pilocytic astrocytoma,0.99,LGG_PAMID,0.99,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2034,"Histology: Low grade glioma
Methylation profile: Low grade glioma, subclass midline pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
","Histological diagnosis: Low grade glioma 
Methylation profiling: Low grade glioma, subclass midline pilocytic astrocytoma 
BRAF (V600E): No mutation          
KIAA1549-BRAF: No fusion
MGMT promoter: Unmethylated  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 166\NH20-2034,0.056,0.024,0.006,-0.02,0.024,-0.015,-0.029,-0.095,0.018,-0.077,-0.015,0.029,-0.013,0.147,-0.031,0.016,-0.028,-0.008,0.123,0.142,-0.033,0.023,-0.034,0.098,-0.002,-0.038,-0.017,-0.14,0.048,unmethylated
NH20-2035,204308830064_R05C01,166,14/09/2020,9/25/2020,9/24/2020,10,SB,Diagnostic,165,4,NDP,Colombia,pilocytic astrocytoma? Midline,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B01,4/12/2018,2.4,"diffuse glioma, MYB(L1)-altered, subtype A [angiocentric glioma-type]",0.6,LGG_MYB,0.99,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2035,"Histology: Low grade astrocytoma suggestive of angiocentric glioma (WHO grade I)  see comment
Methylation profile: Low grade glioma, MYB/MYBL1
MGMT promoter (Illumina array): Unmethylated

",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 166\NH20-2035,-0.138,-0.147,0.238,0.101,-0.092,-0.13,0.17,0.069,0.054,-0.126,-0.006,0.103,0.28,0.018,0.125,0.093,-0.016,-0.017,0.07,-0.113,0.108,0.15,-0.061,0.134,-0.005,0.016,-0.24,-0.014,0.089,unmethylated
NH20-2010,204308830064_R07C01,166,14/09/2020,9/25/2020,9/24/2020,10,SB,Diagnostic,165,5,NDP,Romford,Astrocytoma IDH mutant,"(4) IHC, sequencing, or copy number assay ambiguous",A2,12/19/1944,75.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.92,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2010,"Diffuse astrocytoma, IDH-mutant (WHO grade II)
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Histology: Diffuse astrocytoma, IDH-mutant (WHO Grade II)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 166\NH20-2010,-0.073,-0.091,0.065,-0.027,-0.036,0.053,0.017,0.022,0.028,-0.002,0,0.03,0.044,0.021,0.031,0.035,-0.031,0.044,0.003,0.008,-0.027,-0.047,-0.018,0.015,0.003,0.006,-0.021,-0.002,0.051,methylated
NH20-2055,204296550078_R03C01,167,15/09/2020,9/25/2020,9/24/2020,9,SB,Diagnostic,166,2,NDP,"Cambridge, Addenbrooke's Hospital",IDH mutant astrocytoma,"(4) IHC, sequencing, or copy number assay ambiguous",A1,9/20/1986,33.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.52,AIDH,0.62,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2055,"Histology: Anaplastic astrocytoma, IDH-mutant (WHO grade III)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 167\NH20-2055,0.003,0.018,0.053,-0.016,-0.003,-0.029,-0.01,0.002,-0.025,-0.009,-0.004,0.008,0.037,0.111,0.022,0.02,0.02,0.03,0.051,-0.01,-0.005,-0.003,-0.047,0.027,0.001,0.05,-0.021,-0.003,0.035,methylated
NH20-2000,204296550078_R04C01,167,15/09/2020,9/25/2020,9/24/2020,9,SB,Diagnostic,166,1,NDP,Lund (SE),ependymoma? ,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",,10/27/1987,32.9,"spinal ependymoma, MYCN-amplified",1,EPN_PFA,0.64,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2000,"Histology: Anaplastic ependymoma (WHO grade III)
Methylation profile: No matching methylation class identified (see comment)
MGMT promoter (Illumina array): Methylated 

","Histology: Anaplastic Ependymoma (WHO Grade III)
Methylation profile: Ependymoma, spinal, MYCN amplified (See comment) 
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 167\NH20-2000,0.016,1.71,0.01,-0.038,-0.063,-0.136,-0.041,0.01,-0.053,-0.037,-0.037,0.06,0.089,0.038,-0.014,0.084,0.007,-0.035,0.075,0.127,0.044,0.01,0.025,0.123,-0.071,0.016,-0.167,-0.049,0.051,methylated
NH20-2054,204296550078_R06C01,167,15/09/2020,9/25/2020,9/24/2020,9,SB,Diagnostic,166,1,NDP,Romford,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,3/31/1976,44.5,"glioblastoma, IDH-wildtype, RTK1 type",0.85,GBM_RTKI,0.19,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2054,"Residual high-grade neuroectodermal tumour  see comment
",#REF!,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 167\NH20-2054,-0.005,-0.017,0.017,-0.059,0.534,0.005,0.109,-0.109,0.242,0.233,0.165,-0.067,-0.077,-0.092,-0.033,-0.038,-0.214,0.03,-0.034,-0.042,-0.067,0.002,-0.092,-0.067,-0.03,-0.055,-0.246,0.047,0.077,methylated
NH20-2066,204296550078_R07C01,167,15/09/2020,9/25/2020,9/24/2020,9,SB,Diagnostic,166,2,NDP,Nottingham University Hospital,pilocytic astrocytoma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/9/1999,21.7,infratentorial pilocytic astrocytoma,0.37,LGG_PAMID,0.41,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2066,"Histology: Low grade glioma/glioneuronal tumour  see comment
Methylation profile: Low grade glioma, subclass midline pilocytic astrocytoma (low calibrated score)  see comment 
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 167\NH20-2066,-0.04,-0.01,0.015,0.031,-0.053,0.064,0.114,0.088,0.108,0.124,0.096,-0.008,-0.003,-0.038,0.14,0.083,-0.011,0.035,0.111,-0.029,0.003,-0.016,0.01,-0.036,-0.065,-0.059,-0.02,0.017,0.028,unmethylated
NH20-2069,204296550078_R08C01,167,15/09/2020,9/25/2020,9/24/2020,9,SB,Diagnostic,166,2,NDP,Nottingham University Hospital,pilocytic astrocytoma?,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,4/27/1982,38.4,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.11,MB_WNT,0.23,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2069,"Histology: Neuroepithelial tumour (see comment) 
Methylation profile: Failed to reliably classify (see comment)
MGMT promoter (Illumina array): Unmethylated
","Histological diagnosis: Neuroepithelial tumour 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
1p/19q: Retained     
EGFR: No amplification          
CDKN2A/B: No deletion     
Histone H3F3A: No mutation
BRAF (V600E): No mutation     
MGMT Promoter: Unmethylated (0%)
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 167\NH20-2069,0.081,0.025,0.027,0.044,0.01,0.02,-0.075,-0.066,0.013,-0.028,-0.033,0.023,-0.006,0.026,-0.004,-0.011,-0.043,0.001,-0.004,-0.01,0.006,0.059,-0.007,0.017,0.057,0.006,-0.019,-0.007,0.075,unmethylated
NH20-1929,204339110074_R01C01,168,18/09/2020,10/2/2020,10/1/2020,13,SB,Diagnostic,167,3,NDP,St George's Hospital London,high-grade glioma unusual presentation clinically,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/26/1965,55,"Diffuse paediatric-type high grade glioma, RTK1 subtype",1,GBM_MID,0.96,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1929,"High-grade glioma, IDH-wildtype (see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
TERT promoter: Technically unsatisfactory
MGMT Promoter: Methylated (>0-5%)
  
","Histology: High grade glioma, IDH-wildtype 
Methylation profile: No matching methylation classes (see comment)
MGMT promoter (Illumina array): Methylated 
  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 168\NH20-1929,-0.008,-0.057,0.012,0.088,0.158,-0.003,0.04,-0.005,0.019,-0.067,-0.011,0.012,0.046,-0.142,0.013,-0.002,-0.004,0.007,-0.038,0.106,0.078,0.241,-0.13,0.09,0.25,0.065,0.026,-0.025,0.016,methylated
NH20-1911,204339110074_R03C01,168,18/09/2020,10/2/2020,10/1/2020,13,SB,Diagnostic,167,1,NDP,St George's Hospital London,high grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/12/1953,67.5,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.98,GBM_MID,0.93,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1911,"Histology: Anaplastic astrocytoma 
Molecular profile: Glioblastoma, IDH-wildtype (WHO grade IV) 
IDH1/2Seq: No mutation
EGFR: No amplification     
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)
","Histology: Anaplastic astrocytoma
Molecular profile: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH wildtype, subclass midline (low calibrated score)  see comment

MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 168\NH20-1911,0.033,0.004,-0.01,0.051,-0.015,0.043,0.013,0.014,0.028,-0.052,-0.014,0.001,0.039,-0.009,0.022,0.04,0.011,-0.039,0.007,0.013,-0.039,0.077,-0.012,0.021,0.038,0.022,-0.166,0.005,0.011,unmethylated
NH20-2129,204339110074_R05C01,168,21/09/2020,10/2/2020,10/1/2020,10,AM,Diagnostic,168,1,NDP,Oxford John Radcliffe Hospital,Low grade glial/glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,12/31/1996,23.7,supratentorial midline pilocytic astrocytoma,0.55,LGG_PAMID,0.65,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2129,"Histology: Low grade glioma/glioneuronal tumour
Methylation profile: Low grade glioma, subclass midline pilocytic astrocytoma (low calibrated score) - see comment

MGMT promoter (Illumina array): Unmethylated
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 168\NH20-2129,0.067,-0.058,0.023,0.004,0.02,-0.009,-0.002,-0.043,-0.041,-0.055,-0.029,0.019,0.054,0.006,0.05,-0.012,0.021,-0.048,0.047,0.012,-0.023,0.029,-0.008,0.034,-0.039,0.03,-0.023,-0.104,-0.128,unmethylated
NH20-1983,204339110074_R08C01,168,21/09/2020,10/2/2020,10/1/2020,10,AM,Diagnostic,168,1,NDP,Royal London Hospital,Diffuse high grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/14/1963,57.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.45,GBM_MES,0.62,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1983,"Diffuse glioma (at least WHO grade III)  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained
Further molecular tests: Pending
","Histology: Diffuse glioma, IDH-wildtype
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal 
MGMT promoter (Illumina array): Unmethylated
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 168\NH20-1983,0.019,-0.018,0.014,0.003,-0.033,0.004,-0.295,0.202,0.173,0.182,0.161,-0.254,-0.245,-0.225,-0.576,-0.001,-0.211,-0.206,-0.005,-0.048,-0.05,0.184,-0.278,-0.029,-0.34,0.033,-0.057,-0.158,-0.21,unmethylated
NH20-2080,204339110023_R02C01,169,21/09/2020,10/9/2020,10/8/2020,17,AM,Diagnostic,169,4,NDP,Brighton and Sussex Hospital,Neuroepithelial tumour of intermediate grade,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,4/3/1961,59.5,"diffuse glioneuronal tumour, non defined type",0.9,DLGNT,0.94,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2080,"Neuroepithelial tumour of intermediate grade  see comment
","Histology:  Neuroepithelial tumor of intermediate grade
Methylation profile: Diffuse leptomeningeal glioneuronal tumor
MGMT promoter (Illumina array): Methylated 
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 169\NH20-2080,0.209,-0.054,0.033,0.016,0.103,0.032,-0.05,0.42,0.521,0.588,0.421,0.25,0.249,0.22,0.309,0.196,0.235,0.243,-0.007,0.172,0.155,0.203,0.025,0.215,0.181,0.237,-0.06,0.048,0.047,methylated
NH20-2090,204339110023_R03C01,169,21/09/2020,10/9/2020,10/8/2020,17,AM,Diagnostic,169,1,NDP,NHNN,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,12/30/1968,51.7,myxopapillary ependymoma,1,EPN_MPE,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2090,"Ependymoma  see comment
","Histology: Ependymoma
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 169\NH20-2090,0.047,-0.013,0.028,-0.005,0.01,-0.015,0.232,-0.01,-0.032,-0.043,-0.018,0.219,0.2,0.212,0.26,0.22,-0.019,0.013,-0.063,0.168,0.139,0.237,-0.558,-0.003,-0.036,-0.044,-0.051,-0.357,-0.456,methylated
NH20-2122,204339110023_R05C01,169,22/09/2020,10/9/2020,10/8/2020,16,AM,Diagnostic,169,1,NDP,Southampton General Hospital,Central neurocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,11/9/1952,67.9,dysembryoplastic neuroepithelial tumour,0.45,LGG_RGNT,0.44,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2122,"Histology: Low grade glioma/glioneuronal tumour 
Methylation profile: No matching methylation classes
MGMT promoter (Illumina array): Methylated 
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 169\NH20-2122,0.049,-0.029,0.041,-0.019,0.01,-0.009,-0.09,0.236,0.266,0.153,0.208,0.383,0.313,0.368,-0.059,-0.014,0.015,0.015,0.155,0.223,0.172,0.201,-0.018,0.025,-0.24,0.109,-0.015,-0.319,-0.272,methylated
NH20-2149,204339110023_R06C01,169,22/09/2020,10/9/2020,10/8/2020,16,AM,Diagnostic,169,1,NDP,Nottingham University Hospital,? Schwannoma ? myxopapillary ependymoma,"(2) unusual histology, location, demographics",A1,12/4/1954,65.8,posterior fossa subependymoma,1,SUBEPN_PF,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2149,"Histology: Low grade neuroepithelial tumour with ependymal differentiation
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 169\NH20-2149,0.029,-0.012,0.013,-0.018,-0.013,-0.041,-0.546,0.064,-0.035,-0.009,0,-0.011,0.005,-0.092,0.047,-0.029,-0.046,0.038,-0.045,-0.067,0.05,0.042,0.031,-0.023,-0.055,0.005,-0.019,-0.019,0.032,unmethylated
NH20-2125,204339110023_R08C01,169,24/09/2020,10/9/2020,10/8/2020,14,AM,Diagnostic,169,5,NDP,Romford,Low grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/28/1968,52.4,supratentorial pilocytic astrocytoma,0.48,LGG_PAPF,0.35,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2125,"Low grade glioma  see comment
","Histology: Low grade glioma
Methylation profile: Pilocytic astrocytoma (low calibrated score, see comment)

MGMT promoter (Illumina array): Unmethylated 
  
",(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 169\NH20-2125,0.08,-0.074,-0.018,-0.007,-0.084,-0.01,0.032,-0.068,0.004,-0.034,0.011,0,0.045,-0.017,0.028,-0.022,-0.006,0.006,0.006,-0.027,0.021,0.01,0.013,0.001,0.045,0.045,-0.092,-0.009,0.031,unmethylated
NH20-2021,204339010096_R04C01,170,24/09/2020,10/9/2020,10/8/2020,14,AM,Diagnostic,170,2,NDP,Nottingham University Hospital,High grade neuroepithelial tumour ?H3 G34,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,9/11/1974,46,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.94,GBM_MID,0.99,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2021,"High grade neuroepithelial tumour - see comment

IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)
Histone H3F3A: No mutation (see comment)
BRAF (V600E): No mutation     
MGMT Promoter: Methylated (>0-5%)
","Histology: High grade neuroepithelial tumour 
Methylation profile: Glioblastoma, IDH wildtype, subclass midline
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 170\NH20-2021,-0.027,-0.026,0.016,-0.077,0.054,-0.092,-0.044,-0.103,-0.025,-0.082,-0.029,0.022,0.05,-0.024,0.046,0.07,-0.009,-0.014,0.005,0.078,0.023,0.015,-0.032,0.098,-0.034,-0.006,0.047,0.013,0.058,unmethylated
NH20-2164,204339010096_R05C01,170,25/09/2020,10/9/2020,10/8/2020,13,AM,Diagnostic,170,4,NDP,"Birmingham, Queen Elizabeth Hospital",? Low grade glioma ? CNS tissue only,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/5/1998,22.7,"diffuse glioma, MYB(L1)-altered, subtype C [isomorphic diffuse glioma-type]",0.51,LGG_MYB,0.89,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2164,"Histology: Low grade glioma (see comment)
Methylation profile: Methylation class with low calibrated score, not suitable for confident diagnosis

MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 170\NH20-2164,0.024,-0.012,0.037,0.029,0.024,0.068,-0.076,0.006,-0.101,-0.078,-0.017,-0.01,0.033,-0.019,0.039,-0.013,-0.02,0.004,0.012,-0.045,0.015,-0.001,0.04,0.018,-0.059,0.022,0.014,0.026,0.063,unmethylated
NH20-2238,204339010096_R07C01,170,30/09/2020,10/9/2020,10/8/2020,8,AM,EQA,170,1,NDP,"King's College Hospital, London",EQA,"(6) Research sample, for stratification or subclassification",2B,1/0/1900,120.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.78,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2238,"Histology: Diffuse astrocytoma (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 170\NH20-2238,0.027,-0.061,-0.004,-0.023,0.03,-0.208,-0.044,-0.024,0.227,0.278,0.203,-0.002,0.076,0.012,-0.03,0.162,0.011,-0.003,-0.077,0.235,0.016,-0.024,-0.123,0.073,-0.022,-0.046,-0.062,-0.005,0.03,methylated
NH20-2239,204339010096_R08C01,170,30/09/2020,10/9/2020,10/8/2020,8,AM,EQA,170,2,NDP,"King's College Hospital, London",EQA,"(6) Research sample, for stratification or subclassification",2B,1/0/1900,120.8,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-2239,"Histology: Oligodendroglioma, WHO Grade II
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 170\NH20-2239,0.062,0.003,0.013,-0.07,-0.056,-0.1,-0.172,-0.121,-0.159,-0.132,-0.11,0.009,0.032,0.076,0.028,0.034,-0.001,-0.066,-0.015,0.008,0.074,-0.008,-0.195,0.055,-0.033,0.013,-0.483,-0.052,0.058,methylated
NH20-2144,204339110097_R02C01,171,25/09/2020,10/16/2020,10/16/2020,21,AM,Diagnostic,171,1,NDP,NHNN,High grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,8/29/1985,35.1,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type C]",0.85,DMG_K27,0.19,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2144,"High grade glioma (at least WHO grade III)
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained
Further molecular tests: Pending
",#REF!,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 171\NH20-2144,-0.003,-0.414,0.035,-0.029,-0.083,0.035,0.031,-0.008,-0.022,0.002,-0.011,-0.03,0.038,0.019,-0.017,-0.01,-0.022,0.029,0.055,-0.041,-0.036,-0.039,-0.36,-0.41,-0.071,0.168,-0.44,0.027,-0.263,unmethylated
NH20-2108,204339110097_R03C01,171,28/09/2020,10/16/2020,10/16/2020,18,SB,Diagnostic,171,1,NDP,Romford,"Anaplastic astrocytoma, IDH-mutant ","(4) IHC, sequencing, or copy number assay ambiguous",A1,12/1/1983,36.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2108,"Anaplastic astrocytoma, IDH-mutant (WHO grade III)
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Histology: Anaplastic astrocytoma, IDH-mutant (WHO grade III)
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 171\NH20-2108,-0.03,-0.439,0.025,0.018,-0.029,0.094,0.001,-0.02,-0.03,-0.053,-0.02,-0.011,0.023,-0.033,-0.086,-0.049,-0.138,-0.299,0.639,-0.037,0.653,-0.027,-0.064,-0.034,-0.067,-0.022,-0.429,0.019,0.031,methylated
NH20-2182,204339110097_R04C01,171,28/09/2020,10/16/2020,10/16/2020,18,AM,Diagnostic,171,1,NDP,"Birmingham, Queen Elizabeth Hospital",? Gliosarcoma ? other sarcoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,#N/A,#N/A,"glioblastoma, IDH-wildtype, with primitive neuronal component",0.74,MB_SHHCHLAD,0.53,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2182,"Histology: High grade neoplasm with neuroepithelial differentiation
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 171\NH20-2182,0.073,1.181,0.023,0.037,0.038,0.012,-0.039,-0.006,-0.005,-0.015,-0.032,-0.349,0.078,-0.431,-0.046,-0.055,-0.505,-0.452,0.405,0.669,0.759,1.876,-0.083,-0.02,-0.003,-0.023,-0.096,0.03,0.066,methylated
NH20-2184,204339110097_R05C01,171,28/09/2020,10/16/2020,10/16/2020,18,AM,Diagnostic,171,1,NDP,Bristol,? low grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,#N/A,#N/A,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.74,LGG_DNT,0.78,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2184,"Histology: Low grade glioneuronal tumour 
Methylation profile: Low grade glioma, rosette forming glioneuronal tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 171\NH20-2184,-0.014,-0.057,0.007,0.149,-0.054,-0.006,0.021,-0.014,-0.025,-0.066,-0.013,-0.005,0.051,-0.028,0.033,-0.021,-0.033,0.021,0.03,0.016,0.011,-0.003,0.012,-0.009,-0.03,-0.012,-0.072,0.008,0.075,unmethylated
NH20-2173,204339110097_R07C01,171,28/09/2020,10/16/2020,10/16/2020,18,AM,Diagnostic,171,1,NDP,NHNN,Recurrent myxopapillary ependyomma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,1/12/1976,44.7,myxopapillary ependymoma,0.96,EPN_MPE,0.82,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2173,"Recurrent myxopapillary ependymoma (WHO grade I) with bone invasion  see comment 
","Histology: Recurrent myxopapillary ependymoma (WHO grade I) with bone invasion
Methylation profile: Ependymoma, myxopapillary (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 171\NH20-2173,0.013,-0.066,0.026,-0.011,0.061,0.029,0.013,0.323,0.422,0.385,0.341,0.015,0.046,0.035,0.408,0.46,-0.046,0.011,0.021,-0.008,-0.022,-0.081,-0.001,-0.037,-0.173,0.356,0.404,0.008,-0.008,unmethylated
NH20-2180,204339110097_R08C01,171,29/09/2020,10/16/2020,10/16/2020,17,,Diagnostic,171,1,NDP,Latvia,Glioma in cerebellum,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3850,#N/A,#N/A,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-2180,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 171\NH20-2180,-0.054,-0.035,0.031,0.008,-0.063,0.045,0.011,-0.025,-0.001,-0.056,0.157,-0.008,0.051,0.022,-0.059,-0.041,-0.034,0.052,0.006,-0.048,-0.035,-0.014,-0.05,-0.082,-0.016,-0.033,-0.023,-0.029,0.006,unmethylated
NH20-2221,204339110105_R01C01,172,29/09/2020,10/16/2020,10/16/2020,17,AM,Diagnostic,172,2,NDP,"Belfast, Royal Victoria Hospital",? GBM ? Anaplastic PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2B,#N/A,#N/A,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.82,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2221,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 172\NH20-2221,0.061,-0.044,0.023,-0.028,-0.064,-0.008,0.02,0.123,0.148,0.166,0.102,-0.017,0.064,0.01,-0.445,-0.029,-0.124,-0.07,-0.011,-0.025,-0.037,-0.069,-0.074,-0.109,-0.121,-0.074,-0.03,0.026,0.036,methylated
NH20-2141,204339110105_R02C01,172,29/09/2020,10/16/2020,10/16/2020,17,AM,Diagnostic,172,2,NDP,NHNN,? Reactive tissue ? Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/22/1967,53.5,supratentorial pilocytic astrocytoma,0.28,CONTR_HEMI,0.18,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2141,"Haemorrhagic necrosis and reactive changes  see comment
",#REF!,(5) Non-contributory profile,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 172\NH20-2141,-0.016,-0.016,-0.01,-0.002,-0.009,-0.012,0.001,-0.025,-0.013,-0.031,-0.011,-0.003,0.004,-0.029,-0.01,-0.052,-0.007,0.009,-0.001,-0.017,-0.066,-0.027,0.03,-0.052,-0.037,-0.065,-0.021,-0.049,0.031,methylated
NH20-1927,204339110105_R04C01,172,25/09/2020,10/16/2020,10/16/2020,21,AM,Diagnostic,170,1,NDP,Southampton General Hospital,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,4/28/1982,38.3,rosette-forming glioneuronal tumour,1,LGG_RGNT,0.96,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1927,"Low grade glioma, favour in pilocytic astrocytoma (WHO grade I) 
BRAF: No fusion mutation, no point mutation
","Histology: Low grade glioma (see comment)
Methylation profile: Low grade glioma, rosette forming glioneuronal tumor
MGMT promoter (Illumina array): Unmethylated 
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 172\NH20-1927,-0.046,-0.052,0.008,-0.018,-0.07,0.004,-0.012,-0.014,-0.035,-0.027,-0.016,-0.002,0.03,-0.023,-0.002,-0.051,-0.009,0.011,0.028,-0.028,0.084,-0.048,-0.014,-0.041,-0.061,-0.014,0.001,0.016,0.036,unmethylated
NH20-2215,204339110105_R08C01,172,1/10/2020,10/16/2020,10/16/2020,15,AM,Diagnostic,172,2,NDP,The London Clinic,? Anaplastic Oligodendroglioma (scanty tissue),"(4) IHC, sequencing, or copy number assay ambiguous",SP1A,3/31/1963,57.5,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2215,"Recurrent glioma - see comment

IDH1 (R132H IHC): Mutation (as per previous biopsy report from Imperial, CNP15-256) 
ATRX (IHC): Retained (as per previous biopsy report from Imperial, CNP15-256)
Further molecular tests: Pending
  
","Histology: Recurrent glioma suggestive of anaplastic oligodendroglioma (WHO grade III)
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 172\NH20-2215,-0.003,-0.049,0.096,-0.017,0.083,0.032,0.006,-0.008,0.454,0.457,0.368,-0.016,0.105,0.022,-0.634,-0.024,0.017,0.057,0.008,-0.015,-0.051,-0.068,-0.078,0.014,-0.69,-0.013,-0.474,0.05,0.056,methylated
NH20-1999,204339010040_R01C01,173,1/10/2020,10/23/2020,10/22/2020,21,AM,Diagnostic,173,1,NDP,The London Clinic,2020 bx- radionecrosis only. 2009 bx received from unilabs - ? recurrent oligodendroglioma,,B (09-13314 B),7/3/1968,52.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.99,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1999,"Radionecrosis, no evidence of recurrent tumour  please see comment
","Excision biopsy from 2009 (review): Diffuse astrocytoma, IDH-mutant (see comment) 
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Technically unsatisfactory (see comment)
1p/19q: Equivocal (see comment)
CDKN2A/B: No loss
MGMT Promoter: Methylated (>0-5%)
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 173\NH20-1999,0.04,-0.153,-0.016,0.036,-0.081,0.063,0.088,0.081,-0.166,-0.002,0.017,-0.049,0.035,0.099,-0.08,0.045,-0.009,-0.096,-0.135,-0.084,-0.457,-0.457,-0.148,0.44,-0.122,0.266,0.201,-0.048,0.061,methylated
NH20-2249,204339010040_R03C01,173,2/10/2020,10/23/2020,10/22/2020,20,AM,Diagnostic,173,4,NDP,Lund (SE),High grade glioma,,01 01,#N/A,69,high-grade astrocytoma with piloid features,1,ANAPA,1,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-2249,"Histology: Pilocytic astrocytoma with anaplasia (see comment)
Methylation profile: Anaplastic pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 173\NH20-2249,-0.128,-0.063,0.082,0.012,0.009,0.086,0.006,0.093,0.324,0.246,0.451,-0.038,0.074,0.04,-1.079,0.096,-0.014,-0.124,-0.021,0.145,0.18,0.317,0.033,0.003,-0.103,-0.099,-0.285,-0.007,0.047,unmethylated
NH20-2242,204339010040_R04C01,173,3/10/2020,10/23/2020,10/22/2020,19,AM,Diagnostic,173,1,NDP,NHNN,? anaplastic ependymoma ? glioblastoma ? other HGG,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,8/17/1989,31.6,"glioblastoma, IDH-wildtype, RTK2 type",0.45,GBM_RTKII,0.7,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2242,"High-grade neuroepithelial tumour  see comment
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Histology: High-grade neuroepithelial tumour
Methylation profile: Glioblastoma, IDH wildtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 173\NH20-2242,-0.114,-0.088,0.168,0.071,0.06,-0.002,-0.106,0.86,0.164,0.183,0.264,-0.064,0.031,-0.006,0.319,0.242,0.017,0.012,-0.07,0.271,0.778,0.208,-0.372,-0.073,-0.177,-0.04,0.099,0.122,0.195,unmethylated
NH20-2275,204339010040_R07C01,173,6/10/2020,10/23/2020,10/22/2020,16,AM,Diagnostic,173,4,NDP,"Cardiff, University Hospital",Spinal cord lesion ? glioma ? vascular lesion,,B1,5/5/1998,22.7,infratentorial pilocytic astrocytoma,0.1,LGG_PAPF,0.1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2275,"Histology: Vascular and glial tissue, insufficient for definitive diagnosis (see comment)
Methylation profile: No matching methylation class (see comment) 
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 173\NH20-2275,-0.612,-0.153,0.152,0.03,-0.115,0.08,-0.092,-0.129,0.319,0.134,0.195,-0.071,0.242,0.085,0.01,-0.3,0.398,-0.257,-0.1,-0.083,-0.088,0.508,0.032,-0.08,1.911,0.157,-0.329,0.013,-0.066,methylated
NH20-2168,204339010084_R01C01,174,7/10/2020,10/23/2020,10/22/2020,15,AM,Diagnostic,174,1,NDP,Oxford John Radcliffe Hospital,? Glioblastoma IDH-wildtype,,2B,7/26/1954,67.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.23,GBM_MES,0.43,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2168,"Diffusely infiltrating glioma, IDH-wildtype  see comment 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
MGMT Promoter: Methylated (>0-5%)
","Histology: Diffusely infiltrating glioma, IDH-wildtype
Methylation profile: Glioblastoma, IDH wildtype, mesenchymal
MGMT promoter (Illumina array): Unmethylated (see comment) 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 174\NH20-2168,0.042,-0.045,0.024,0.007,-0.055,-0.008,-0.016,0.138,0.155,0.058,0.116,-0.018,0.092,-0.005,-0.441,-0.046,-0.154,-0.121,-0.012,-0.005,0.012,-0.061,-0.094,0.022,-0.028,0.007,0.068,-0.042,0.054,unmethylated
NH20-2288,204339010084_R03C01,174,7/10/2020,10/23/2020,10/22/2020,15,AM,Diagnostic,174,1,NDP,"Leeds, St James's University Hospital",? Reactive brain tissue ? infiltrating glioma,,A1,8/26/1950,71.1,subependymal giant cell astrocytoma,0.42,CONTR_REACT,0.56,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2288,"Histology and molecular features: Probable glioblastoma, IDH-wildtype (see comment)
Methylation profile: Non-contributory (low calibrated score, see comment)

MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 174\NH20-2288,-0.014,-0.068,0.014,0.018,-0.136,-0.011,-0.064,0.071,0.064,-0.112,0.041,-0.018,0.105,-0.063,-0.103,-0.043,-0.073,-0.049,-0.079,-0.039,0.011,-0.022,-0.001,0.011,-0.165,-0.034,-0.062,-0.009,0.064,unmethylated
NH20-2259,204339010084_R04C01,174,7/10/2020,10/23/2020,10/22/2020,15,AM,Diagnostic,174,1,NDP,Brighton and Sussex Hospital,? Atypical/malignant meningioma ? Gliosarcoma,,DEF1A,4/10/1953,68.5,"glioblastoma, IDH-wildtype, mesenchymal type",1,PXA,0.19,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2259,"High-grade intrinsic tumour  see comment
","Histology: High grade intrinsic tumour with mesenchymal differentiation 
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 174\NH20-2259,-0.025,-0.127,0.029,-0.062,-0.046,-0.04,-0.195,0.063,0.132,0.134,0.074,-0.057,0.062,-0.024,-0.222,-0.011,-0.081,-0.098,-0.084,-0.058,0.15,0.011,-0.026,-0.112,-0.157,0.007,-0.201,0.025,0.099,unmethylated
NH20-2289,204339010084_R05C01,174,7/10/2020,10/23/2020,10/22/2020,15,AM,Diagnostic,174,1,NDP,Romford,"Astrocytoma, IDH-mutant ? grade ",,1A,12/25/1981,39.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.92,AIDH,0.97,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2289,"Recurrent/residual diffuse astrocytoma, IDH-mutant  see comment
Molecular results taken from previous resection (see NH19-1956 and NH19-3009)
IDH1/2Seq: Mutation
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion (2019)
","Histology: Recurrent/residual diffuse astrocytoma, IDH-mutant (see comment)
Methylation profile: IDH glioma, astrocytoma
CDKN2A/B (Illumina array CNV plot): No loss
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 174\NH20-2289,0.04,-0.16,-0.014,-0.047,-0.097,-0.045,-0.393,0.043,0.036,-0.078,0.014,-0.014,0.096,-0.062,-0.032,-0.022,-0.041,-0.064,-0.069,0.046,0.011,-0.009,-0.073,0.077,-0.05,0.025,-0.197,-0.01,0.043,methylated
NH20-2283,204339010084_R07C01,174,7/10/2020,10/23/2020,10/22/2020,15,AM,Diagnostic,174,3,NDP,Nottingham University Hospital,? Ependymoma ? Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,3/24/1950,66.4,posterior fossa subependymoma,0.98,SUBEPN_PF,0.96,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2283,"Histology: Low grade glioma 
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
","Histology: Low grade glioma
Methylation profile: Subependymoma, posterior fossa (very low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 174\NH20-2283,0.028,-0.041,0.156,0.031,-0.311,-0.162,-0.934,0.223,0,-0.114,0,0.122,-0.06,-0.082,-0.198,0.141,0.204,-0.087,-0.139,0.274,0.221,-0.174,-0.033,0.318,-0.085,-0.17,0.117,0.181,0.089,unmethylated
NH20-2243,204339010084_R08C01,174,8/10/2020,10/23/2020,10/22/2020,14,AM,Diagnostic,174,1,NDP,"Birmingham, Queen Elizabeth Hospital",? HGG,,A,2/25/1963,58.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.45,GBM_MES,0.76,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2243,"Histology: Diffuse glioma (see comment)
Methylation profile: Glioblastoma, IDH wildtype, subclass RTK II
MGMT promoter (Illumina array): Methylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 174\NH20-2243,0.086,-0.013,-0.011,0.25,-0.049,-0.066,-0.082,1.161,0.18,0.14,0.199,-0.029,0.062,0.061,-1.023,0.081,-0.253,-0.441,-0.029,0.128,0.114,0.136,-0.044,0.107,0.02,0.052,0.079,0.024,0.084,methylated
NH20-2321,204339110078_R03C01,175,9/10/2020,10/30/2020,10/29/2020,20,AM,Validation,175,1,NDP,Lund (SE),N/A,"(6) Research sample, for stratification or subclassification","01,02",1/0/1900,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.85,OIDH,0.91,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2321,"Histology: Oligodendroglioma (WHO Grade II) 
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Unmethylated Methylated 
CDKN2A/B: No deletion     
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 175\NH20-2321,0.17,-0.034,-0.007,-0.023,0.049,-0.073,-0.138,0.011,0.01,-0.003,0.019,-0.019,0.019,0.051,0.004,0.072,-0.062,-0.118,-0.05,-0.009,0.102,-0.01,-0.14,0.172,-0.103,-0.038,-0.248,-0.029,0.001,methylated
NH20-2317,204339110078_R04C01,175,9/10/2020,10/30/2020,10/29/2020,20,AM,Validation,175,1,NDP,Lund (SE),N/A,"(6) Research sample, for stratification or subclassification","01,03",1/0/1900,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2317,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: glioblastoma, IDH wildtype, subclass RTK I
MGMT promoter (Illumina array): Methylated 
CDKN2A/B: Deletion
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 175\NH20-2317,0.051,0.04,0.015,-0.149,0.104,-0.206,0.033,0.47,0.342,0.157,0.201,0.064,0.146,0.1,-1.963,0.382,-0.352,-0.885,0.092,0.101,0.137,0.047,-0.401,0.207,-0.034,0.115,-0.271,0.045,0.077,methylated
NH20-2318,204339110078_R05C01,175,9/10/2020,10/30/2020,10/29/2020,20,AM,Validation,175,1,NDP,Lund (SE),N/A,"(6) Research sample, for stratification or subclassification","01,02",1/0/1900,,"glioblastoma, IDH-wildtype, mesenchymal type",0.97,GBM_MES,0.18,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2318,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Methylated 
CDKN2A/B: Undetermined/equivocal (see comment)
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 175\NH20-2318,-0.079,-0.084,0.063,0.042,1.021,0.066,-0.128,0.134,0.154,0.096,0.151,0.033,0.061,0.016,-0.497,0.095,-0.277,-0.242,-0.05,-0.015,0.063,0.021,-0.069,-0.09,-0.093,0.024,-0.001,0.002,-0.039,methylated
NH20-2319,204339110078_R06C01,175,9/10/2020,10/30/2020,10/29/2020,20,AM,Validation,175,1,NDP,Lund (SE),N/A,"(6) Research sample, for stratification or subclassification","01,03",1/0/1900,,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.98,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2319,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH wildtype, subclass RTK II
MGMT promoter (Illumina array): Unmethylated
CDKN2A/B: Deletion
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 175\NH20-2319,0.019,0.008,0.017,0.017,0.038,0.036,0.007,1.43,0.284,0.269,0.217,-0.018,0.024,0.062,-2.081,-0.032,-0.372,-0.432,-0.049,0,-0.037,0.025,-0.075,0.036,-0.062,-0.003,0.273,-0.009,0.014,unmethylated
NH20-2320,204339110078_R07C01,175,9/10/2020,10/30/2020,10/29/2020,20,AM,Validation,175,1,NDP,Lund (SE),N/A,"(6) Research sample, for stratification or subclassification","01,02",1/0/1900,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2320,"Histology: Glioblastoma (WHO grade IV) 
Methylation profile: glioblastoma, IDH wildtype, subclass RTK I 
MGMT promoter (Illumina array): Unmethylated 
CDKN2A/B: Deletion
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 175\NH20-2320,0.32,-0.087,0.044,-0.052,1.583,0.035,0.03,0.243,0.256,0.231,0.223,-0.003,0.078,0.052,-2.279,-0.351,-0.355,-0.461,-0.018,0.021,0.821,0.021,-0.409,0.097,-0.046,0.109,-0.092,0.037,0.047,unmethylated
NH20-2202,204339110078_R08C01,175,12/10/2020,10/30/2020,10/29/2020,17,AM,Diagnostic,175,3,NDP,"Belfast, Royal Victoria Hospital",? anaplastic astrocytoma,,BN,3/19/1965,56.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,0.99,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2202,"Diffuse glioma, IDH-mutant - see comment 
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained
1p/19q: Retained     
EGFR: No amplification          
CDKN2A/B: Deletion
MGMT Promoter: Methylated (>10-25%) 
","Histology: Diffuse glioma, IDH-mutant
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma 
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 175\NH20-2202,0.01,-0.058,0.006,-0.103,-0.084,0.025,0.03,-0.01,-0.023,-0.07,-0.014,0.01,0.042,-0.012,-1.06,-0.026,-0.003,0.007,0.044,-0.008,-0.038,-0.063,-0.033,0.049,0.006,0.049,-0.397,0.032,0.01,methylated
NH20-2339,204339110083_R01C01,176,12/10/2020,10/30/2020,10/29/2020,17,AM,Diagnostic,176,3,NDP,Newcastle,? diffuse midline glioma,,1A,6/22/1982,38.9,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.5,DMG_K27,0.94,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2339,"Thalamus lesion biopsy: Diffuse midline glioma, H3 K27M-mutant (WHO grade IV) 
","Histology: Diffuse midline glioma, H3 K27M-mutant (WHO grade IV) (see previous report)
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 176\NH20-2339,0.225,0.221,0.099,-0.273,0.36,-0.362,-0.218,0.089,0.262,0.188,0.162,-0.159,-0.031,0.166,0.175,0.08,0.081,0.089,-0.066,-0.098,-0.107,-0.143,-0.37,-0.294,0.058,0.04,-0.561,0.026,0.062,unmethylated
NH20-2330,204339110083_R02C01,176,13/10/2020,10/30/2020,10/29/2020,16,AM,Diagnostic,176,2,NDP,"Birmingham, Queen Elizabeth Hospital",? normal brain stem biopsy,,A1,7/26/1976,44.8,"control tissue, white matter (corpus callosum)",0.5,CONTR_HYPTHAL,0.49,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2330,"Brain stem biopsy: Grey matter fragments; no definite neoplasia - see comment

Mutant H3 K27M (IHC): Negative
","Histology: Brain stem biopsy, grey matter fragments
Methylation profile: Control tissue, hemispheric cortex
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 176\NH20-2330,0.055,-0.036,-0.013,0.022,-0.033,-0.068,-0.1,-0.009,0.037,-0.044,0.004,0.003,0.072,-0.009,-0.04,0.008,0.011,-0.024,-0.031,-0.016,0.01,0.01,-0.002,0.023,0.058,-0.035,-0.055,0.032,0.005,unmethylated
NH20-2334,204339110083_R04C01,176,14/10/2020,10/30/2020,10/29/2020,15,AM,Diagnostic,176,1,NDP,Southampton General Hospital,Glioma/glioneurnal tumour (left temporal),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,5/21/1957,64.3,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.46,LGG_PAMID,0.19,0.94,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2334,"Histology: Low grade glial or glial neuronal tumour
Methylation profile: low calibrated score, description see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 176\NH20-2334,0.031,0.002,-0.025,-0.022,-0.022,-0.059,-0.013,0.004,0.038,-0.003,0.005,-0.295,0.054,0.018,-0.001,-0.015,-0.017,-0.011,0.01,0.018,0.035,0.007,-0.129,0.004,0.016,0.02,-0.037,0.027,-0.234,methylated
NH20-2345,204339110083_R05C01,176,14/10/2020,10/30/2020,10/29/2020,15,AM,Diagnostic,176,1,NDP,"Belfast, Royal Victoria Hospital",? PXA,,A,6/27/1999,21.6,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.54,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2345,"Histology: Pleomorphic xanthoastrocytoma
Methylation profile: (Anaplastic) pleomorphic xanthoastrocytoma
CDKN2A/B: deletion
MGMT promoter (Illumina array): Methylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 176\NH20-2345,-0.035,0.001,0.041,-0.038,0.009,-0.011,-0.039,-0.032,-0.052,-0.046,-0.037,0,0.025,0.032,-0.654,-0.235,-0.028,0.029,-0.046,-0.07,-0.029,-0.02,-0.005,-0.007,-0.067,-0.009,0.004,-0.003,-0.006,methylated
NH20-2174,204339110083_R07C01,176,15/10/2020,10/30/2020,10/29/2020,14,AM,Diagnostic,176,4,NDP,St George's Hospital London,? Anaplastic oligo,,A1,8/25/1963,57.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.99,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2174,"High grade glioma  see comment
MGMT Promoter: Methylated (>10-25%).
","High grade glioma, IDH-mutant (WHO grade III at least)
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Retained     
1p/19q: Retained (see comment)
TERT promoter: Mutation
MGMT Promoter: Methylated (>10-25%) 

",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 176\NH20-2174,0.214,-0.043,0.019,-0.012,0.945,0.011,0.055,-0.009,0.015,0.016,-0.014,-0.016,0.253,0.245,0.306,0.039,-3.355,-0.695,-0.117,-0.008,-0.013,-0.002,-0.419,-0.007,-0.05,0.038,-0.285,0.001,0.028,methylated
NH20-2127,204339110083_R08C01,176,15/10/2020,10/30/2020,10/29/2020,14,AM,Diagnostic,176,4,NDP,Southampton General Hospital,? GBM ? meningioma ? mesenchymal tumour ,,1A,11/25/1971,49.5,high-grade astrocytoma with piloid features,0.43,ANAPA,0.91,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2127,"Spindle cell tumour  see comment 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained (see comment)
EGFR: No amplification     
TERT promoter: No mutation     
","Histology: Spindle cell tumour
Methylation profile: Schwannoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 176\NH20-2127,0.005,-0.023,0.032,-0.077,0.623,-0.004,0.056,0.016,-0.012,0.041,-0.011,-0.015,0.046,0.019,-1.166,-0.01,-0.007,0.035,-0.014,-0.033,-0.021,-0.064,-0.247,-0.039,-0.516,0.18,-0.36,0.004,-0.059,methylated
NH20-2264,204339010083_R01C01,177,16/10/2020,11/6/2020,11/5/2020,20,AM,Diagnostic,177,1,NDP,St George's Hospital London,High grade glioma,,A3,9/18/1959,61.9,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",1,GBM_MES,0.18,0.94,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2264,"High grade glioma, IDH-wildtype  see comment 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
MGMT Promoter: Methylated (>25%)  
","Histology: High-grade glioma, IDH-wildtype
Methylation profile: No matching methylation class, but copy number profile suggestive of glioblastoma, IDH-wildtype (WHO grade IV)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 177\NH20-2264,-0.008,-0.046,0.006,0.011,-0.078,0.021,0.009,0.149,0.11,0.147,0.095,-0.02,0.005,-0.032,0.025,-0.003,-0.148,-0.148,-0.023,-0.052,-0.032,0.037,-0.009,-0.028,0.03,0.019,-0.04,0.03,0.012,methylated
NH20-2344,204339010083_R02C01,177,16/10/2020,11/6/2020,11/5/2020,20,AM,Diagnostic,177,1,NDP,NHNN,Pilocytic astrocytoma,,DEF1A,11/22/2002,18.2,infratentorial pilocytic astrocytoma,0.99,LGG_PAPF,0.67,0.94,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-2344,"Pilocytic astrocytoma (WHO grade I)
","Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 

",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 177\NH20-2344,-0.06,-0.04,0.014,0.05,-0.037,0.154,0.159,-0.034,-0.024,-0.018,0.127,-0.015,-0.006,0.009,0.008,-0.006,0.003,0.004,0.013,-0.034,-0.018,-0.086,-0.003,-0.037,-0.076,-0.005,-0.004,0.07,0.027,unmethylated
NH20-2355,204339010083_R03C01,177,16/10/2020,11/6/2020,11/5/2020,20,AM,Diagnostic,177,1,NDP,NHNN,? ependymoma ? GBM (recurrent tumour),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/31/1964,57.4,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2355,"Recurrent high grade glial tumour: see comment

IDH1 (R132H IHC): No mutation (tested NH19-1259) 
ATRX (IHC): Retained (tested NH19-1259)
Further molecular tests: Pending
  
","Histology: Recurrent high grade glioma 
Methylation profile: Ependymoma, RELA fusion
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 177\NH20-2355,0.301,-0.067,0.03,0.033,-0.027,0.112,-0.068,0.149,0.15,0.179,0.131,0.181,0.165,0.158,-2.66,-0.4,-0.027,-0.019,0.001,0.007,-0.003,-0.033,-0.052,-0.025,-0.056,-0.055,-0.019,0.078,0.053,unmethylated
NH20-2365,204339010083_R05C01,177,16/10/2020,11/6/2020,11/5/2020,20,AM,Diagnostic,177,1,NDP,Newcastle,? Pilocytic astrocytoma,,1A,6/20/1934,87.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.2,GBM_MES,0.14,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2365,"Histology: Glioma, most in keeping with low grade astrocytoma
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 177\NH20-2365,-0.009,-0.051,-0.003,-0.074,-0.006,-0.036,-0.261,-0.012,-0.006,-0.016,-0.027,-0.198,-0.152,-0.234,0.016,-0.039,-0.219,-0.175,-0.19,-0.06,-0.024,-0.006,-0.349,-0.254,-0.268,-0.242,-0.004,-0.177,-0.158,unmethylated
NH20-2382,204339010083_R06C01,177,16/10/2020,11/6/2020,11/5/2020,20,AM,Diagnostic,177,2,NDP,Newcastle,Glioma (midline),,1A,8/11/1996,24.5,infratentorial pilocytic astrocytoma,0.32,LGG_PAPF,0.79,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2382,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 177\NH20-2382,-0.05,-0.034,-0.017,-0.088,-0.146,0.04,-0.042,-0.046,0.006,-0.008,-0.019,-0.094,-0.074,-0.103,-0.046,-0.117,0.039,0.006,0.004,0.024,0.052,0.043,0.015,0.034,-0.011,-0.024,-0.009,-0.05,-0.043,methylated
NH20-2253,204339010083_R07C01,177,16/10/2020,11/6/2020,11/5/2020,20,AM,Diagnostic,177,4,NDP,NHNN,IDH-wt Glioma ? grade,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,6/22/1966,55.1,"glioblastoma, IDH-wildtype, RTK1 type",0.3,GBM_RTKII,0.76,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2253,"Glioma  see comment
IDH1 (R132H IHC): Negative. Further tests pending 
ATRX (IHC): Retained
Further molecular tests: Pending
","Histology: Diffuse glioma, IDH-wildtype
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 177\NH20-2253,0.023,-0.04,0.119,0.001,-0.054,0.006,-0.042,0.191,0.186,0.217,0.142,-0.025,-0.014,-0.023,-0.321,-0.26,-0.28,-0.228,-0.039,-0.006,-0.042,-0.027,-0.361,-0.008,-0.026,-0.03,-0.316,0.032,-0.005,unmethylated
NH20-2223,204339010083_R08C01,177,19/10/2020,11/6/2020,11/5/2020,17,AM,Diagnostic,177,1,NDP,"Birmingham, Queen Elizabeth Hospital",High grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/30/1983,38,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.97,GBM_MID,0.78,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2223,"High grade glioma - see comment

Mutant H3 K27M (IHC): Negative
","Histology: High grade glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass midline
MGMT promoter (Illumina array): Unmethylated 

",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 177\NH20-2223,-0.303,-0.048,0.016,-0.279,0,-0.021,-0.36,-0.013,0.035,-0.024,-0.025,-0.003,0.075,-0.013,-2.447,0.408,0.004,0.011,0.032,-0.002,-0.035,0.101,-0.347,0.015,0.019,0.033,-0.109,-0.056,0.003,unmethylated
NH20-2390,204339110084_R02C01,178,20/10/2020,11/6/2020,11/5/2020,16,AM,Diagnostic,178,1,NDP,"Belfast, Royal Victoria Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,9/5/1952,69.1,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2390,"Glioblastoma, IDH-wildtype (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
TERT promoter: Mutation
MGMT Promoter: Methylated (>10-25%) 
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK I
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 178\NH20-2390,-0.001,-0.149,0.007,0.03,-0.037,0.017,0.007,0.219,0.257,0.213,0.208,-0.013,-0.064,-0.182,0.024,0.132,-0.055,0.036,-0.049,-0.085,0.822,-0.011,-0.04,-0.449,0.251,0.18,-0.061,0.036,-0.014,methylated
NH20-2387,204339110084_R08C01,178,21/10/2020,11/6/2020,11/5/2020,15,AM,Diagnostic,178,1,NDP,Bristol,Residual/recurrent high grade glioma,,A2,11/26/1965,55.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.77,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2387,"Histology: Anaplastic oligodendroglioma (WHO grade I I I)
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 178\NH20-2387,0.048,0.045,-0.026,-0.011,-0.018,0.016,-0.046,0.052,0.045,0.008,0.027,-0.024,-0.013,-0.018,-0.462,-0.002,-0.018,-0.031,-0.05,-0.033,-0.014,-0.05,-0.075,0.037,0.018,0.014,-0.487,0.022,0.037,unmethylated
NH20-2368,204894630037_R01C01,179,21/10/2020,11/27/2020,11/26/2020,36,AM,Diagnostic,179,3,NDP,Royal London Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,1/12/1989,32.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.91,AIDH,0.86,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2368,"Glioma, see comment. 

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
",#REF!,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 179\NH20-2368,-0.161,0.001,0.046,-0.056,0.062,0.001,-0.156,-0.037,-0.015,-0.042,-0.043,0.03,0.045,-0.006,0.065,-0.163,-0.111,-0.201,0.118,-0.044,-0.326,-0.098,-0.013,0.02,-0.066,0.008,-0.011,-0.099,-0.13,methylated
NH20-2422,204894630037_R02C01,179,22/10/2020,11/27/2020,11/26/2020,35,AM,Diagnostic,179,3,NDP,"Belfast, Royal Victoria Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1B,4/23/1992,28.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.51,AIDH,0.72,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2422,"Histology: Astrocytoma, IDH-mutant (grading see comment)
Methylation profile: Insufficient/inadequate DNA for testing
IDH1/2Seq: Mutation
ATRX (IHC): Loss of expression (indicates mutation)
MGMT Promoter: Methylated (>0-5%)
 
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 179\NH20-2422,0.239,-0.067,0.164,0.102,-0.126,0.097,-0.523,-0.302,0.106,-0.332,-0.076,-0.094,0.129,-0.326,-0.161,-0.101,0.185,-0.219,-0.426,-0.262,-0.311,-0.088,-0.085,-0.278,0.083,0.028,-0.516,-0.041,0.101,methylated
NH20-2267,204894630037_R03C01,179,22/10/2020,11/27/2020,11/26/2020,35,AM,Diagnostic,179,1,NDP,St George's Hospital London,High grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A4,2/22/1981,40.2,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.93,0.54,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2267,"High grade glioma, IDH-wildtype (see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: No amplification          
BRAF (V600E): No mutation          
Histone H3F3A: No mutation
MGMT Promoter: Unmethylated (0%)

","Histology: High-grade glioma
Methylation profile: Glioblastoma, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 179\NH20-2267,0.174,-0.102,-0.018,-0.015,-0.075,-0.006,-0.084,0.005,0.017,0.005,0.021,0,-0.016,-0.028,-0.5,0.025,-0.048,-0.122,-0.088,-0.05,-0.006,0.018,-0.096,0.044,-0.033,-0.045,-0.065,-0.033,-0.089,unmethylated
NH20-2416,204894630037_R08C01,179,24/10/2020,11/27/2020,11/26/2020,33,AM,Diagnostic,179,1,NDP,Nottingham University Hospital,Paediatric glioma,"(2) unusual histology, location, demographics",B1,3/22/2017,3.6,"diffuse glioma, MYB(L1)-altered, subtype D",0.93,LGG_MYB,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2416,"Histology: Low grade glioma
Methylation profile: low grade glioma, MYB/MYBL1
MGMT promoter (Illumina array): Unmethylated Methylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 179\NH20-2416,0.036,-0.022,0.048,-0.04,-0.056,0.066,-0.046,-0.011,-0.063,0.004,0.013,-0.039,0.001,0.03,-0.136,-0.043,0.01,0.058,0.004,-0.022,-0.037,0.02,-0.048,0.005,0.048,-0.012,0.02,0.016,0.015,unmethylated
NH20-2445,204894630072_R01C01,180,24/10/2020,11/27/2020,11/26/2020,33,AM,Diagnostic,180,1,NDP,Bristol,Diffuse astrocytoma with TERT mutation,"(2) unusual histology, location, demographics",A1,10/1/1958,63,"glioblastoma, IDH-wildtype, mesenchymal type",0.3,GBM_MES,0.82,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2445,"Histology: Diffuse glioma, no high-grade features
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal 
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 180\NH20-2445,0.034,-0.045,-0.001,0.305,-0.034,0.021,-0.02,0.204,0.155,0.161,0.147,0.162,0.241,0.146,0.015,0.018,-0.252,-0.239,-0.045,-0.032,0.037,-0.048,-0.022,0.024,-0.064,0.016,0.156,-0.012,0.039,unmethylated
NH20-2461,204894630072_R03C01,180,27/10/2020,11/27/2020,11/26/2020,30,SB,Diagnostic,180,1,NDP,Edinburgh,High grade Intrinsic Tumour - GBM?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1C,2/11/1985,36.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.96,AIDH_HG,0.77,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2461,"Histology: Glioblastoma, IDH-mutant (WHO grade IV)
Methylation profile: High grade astrocytoma, IDH-mutant  see comment
MGMT promoter (Illumina array): Methylated 
  
  
","High-grade glioma, IDH-mutant - see comments
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 180\NH20-2461,0.123,-0.039,0.005,-0.213,-0.298,0.056,-0.108,-0.022,-0.013,0.034,-0.001,0.087,0.127,0.059,-0.045,-0.081,-0.223,-0.296,-0.038,0.096,0.648,0.104,-0.141,0.002,-0.112,-0.069,-0.395,-0.002,0.023,methylated
NH20-2430,204894630072_R05C01,180,27/10/2020,11/27/2020,11/26/2020,30,SB,Diagnostic,180,4,NDP,"Cambridge, Addenbrooke's Hospital","Small sample, nonspecific glial neoplasm?",(1) small biopsy or nonrepresentative sample;,A2,10/18/1957,63.9,"control tissue, white matter (corpus callosum)",0.42,OIDH,0.1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2430,"Histology: Glioma  see comment
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
","Histology: Glioma  see comment
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 180\NH20-2430,-0.547,0.105,0.102,0.05,-0.016,0.082,0.019,-0.219,0.01,-0.157,-0.12,-0.002,0.202,-0.06,0.227,-0.148,0.329,-0.07,-0.241,-0.142,-0.224,0.098,0.118,0.092,1.671,-0.007,-0.293,-0.001,-0.307,unmethylated
NH20-2478,204894630072_R08C01,180,28/10/2020,11/27/2020,11/26/2020,29,SB,Diagnostic,180,2,NDP,Nottingham University Hospital,"Thalamic lesion, intrinsic, and clear histology","(2) unusual histology, location, demographics",A1,8/7/1958,63.1,ganglioglioma,0.52,GBM_MES,0.48,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2478,"Histology: Glial tumour  see comment
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Methylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 180\NH20-2478,-0.04,-0.04,0.021,-0.015,-0.096,0.143,-0.237,0.234,0.248,0.198,0.177,0.107,0.156,0.065,0.114,0.075,0.049,0.035,-0.027,0.015,0.023,0.044,0.006,-0.118,-0.186,-0.254,0.277,-0.004,0.079,methylated
NH20-2474,204339010020_R01C01,181,28/10/2020,11/20/2020,11/22/2020,25,SB,Diagnostic,181,3,NDP,Newcastle,3rd Ventricle PA,(1) small biopsy or nonrepresentative sample;,1A,8/20/1944,77.3,dysembryoplastic neuroepithelial tumour,0.36,LGG_DNT,0.31,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2474,"Histology: Low grade glioma/glioneuronal tumour (see comment)
Methylation profile: No matching methylation class identified
MGMT promoter (Illumina array): Unmethylated

","Low grade glioma / glioneuronal tumour 

KIAA1549-BRAF: No fusion
BRAF V600E: No mutation
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 181\NH20-2474,0.011,-0.136,-0.019,-0.068,0.063,-0.02,-0.253,-0.082,0.016,-0.097,0.033,0.06,0.032,0.055,-0.055,-0.013,0.053,-0.045,0.188,0.023,-0.006,0.053,0.025,0.107,0.143,0.107,0.096,0.045,0.009,unmethylated
NH20-1919,204339010020_R03C01,181,30/10/2020,11/20/2020,11/22/2020,23,SB,Diagnostic,181,1,NDP,Oxford John Radcliffe Hospital,"Glioma, IDH wt","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,11/5/1983,37.3,ganglioglioma,0.79,LGG_GG,0.31,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1919,"Diffusely infiltrating glioma, IDH-wildtype (grading see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
MGMT Promoter: Methylated (>0-5%)
  
","Histology: Diffusely infiltrating glioma, IDH-wildtype (see comment)
Methylation profile: Methylation class not compatible with histology (see comment)
MGMT promoter (Illumina array): Unmethylated (see comment) 
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 181\NH20-1919,0.009,-0.234,-0.001,0.077,0.047,-0.09,-0.252,0.133,0.087,0.029,0.116,0.017,0.079,-0.061,-0.033,-0.066,0.01,-0.119,-0.092,0.18,0.113,0.052,0.064,0.073,-0.096,-0.115,0.083,-0.032,-0.082,unmethylated
NH20-2496,204339010020_R04C01,181,30/10/2020,11/20/2020,11/22/2020,23,SB,Diagnostic,181,1,NDP,"Cardiff, University Hospital",Oligo Ambiguous 1p/19q,"(4) IHC, sequencing, or copy number assay ambiguous",A1,9/12/1972,48.7,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2496,"Histology: Oligodendroglioma - see comment 
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 181\NH20-2496,-0.056,-0.106,-0.024,-0.044,0.016,0.139,0,0.094,0.127,0.082,0.134,-0.026,0.024,0,-0.006,0.1,-0.026,-0.048,0.052,-0.045,-0.019,-0.125,-0.074,-0.023,-0.127,-0.054,-0.296,0,0.015,methylated
NH20-2497,204339010020_R05C01,181,30/10/2020,11/20/2020,11/22/2020,23,SB,Diagnostic,181,7,NDP,"Middlesbrough, James Cook Hospital","Cerebellar GBM, Small sample",(1) small biopsy or nonrepresentative sample;,C1,3/21/1982,39.1,"glioblastoma, IDH-wildtype, with primitive neuronal component",0.23,MB_SHHCHLAD,0.4,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2497,"Histology: High grade poorly differentiated tumour  
Methylation profile: Methylation class calibrated score too low for interpretation (see comment)
MGMT promoter (Illumina array): Methylated 
  
","High grade astrocytoma, IDH-mutant (WHO grade III at least)  see comment
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion
MGMT promoter: Predicted to be methylated (Illumina array)          
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 181\NH20-2497,-0.023,0.352,0.063,0.044,-0.001,0.167,0.027,-0.014,-0.004,-0.02,-0.003,-0.081,0.051,-0.046,-0.048,0.057,-0.118,-0.066,0.059,-0.143,-0.127,-0.191,-1.453,-0.041,0.012,0.048,-0.549,-0.227,-0.155,methylated
NH20-2494,204339010020_R06C01,181,30/10/2020,11/20/2020,11/22/2020,23,SB,Diagnostic,181,1,NDP,"Birmingham, Queen Elizabeth Hospital","LGG, Type?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,1/8/1997,24.1,subependymal giant cell astrocytoma,1,LGG_SEGA,0.99,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2494,"Histology: Low grade glioma/glioneuronal tumour
Methylation profile: Low grade glioma, subependymal giant cell astrocytoma
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 181\NH20-2494,0.039,-0.051,-0.018,-0.04,-0.012,-0.033,-0.072,-0.068,-0.027,-0.031,0.009,0.034,0.049,0.078,-0.042,-0.026,-0.018,-0.004,-0.021,-0.027,-0.026,0.065,0.025,-0.003,0.018,0.015,0.028,-0.055,0.082,unmethylated
NH20-2204,204339010020_R07C01,181,4/11/2020,11/20/2020,11/22/2020,18,SB,Diagnostic,181,1,NDP,Southampton General Hospital,"LGG, Type?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,6/9/1982,38.9,high-grade astrocytoma with piloid features,1,ANAPA,0.98,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2204,"Histology: Anaplastic astrocytoma with piloid features
Methylation profile: Anaplastic pilocytic astrocytoma
MGMT promoter (Illumina array): Methylated 
  
","Histology: Anaplastic astrocytoma with piloid features 
Methylation profile: Anaplastic pilocytic astrocytoma 

BRAF (V600E): No mutation
KIAA1549-BRAF (fusion): No fusion
ATRX (IHC): Loss of expression (indicating mutation)
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 181\NH20-2204,0.034,-0.049,-0.007,0.004,0.226,0.027,-0.429,-0.079,0.014,-0.067,-0.001,-0.004,-0.169,0.025,-1.972,-0.036,0.024,0.036,-0.056,0.121,0.009,-0.042,-0.064,-0.001,0.091,0.262,-0.046,0.148,0.254,methylated
NH20-2514,204339010020_R08C01,181,2/11/2020,11/20/2020,11/22/2020,20,ZJ,Diagnostic,181,1,NDP,St George's Hospital London,Subependymoma in 3rd and lateral ventricle,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,3/27/1963,58.4,supratentorial subependymoma,1,SUBEPN_ST,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2514,"Histology: Subependymoma (WHO grade I)
Methylation profile: Subependymoma, supratentorial
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 181\NH20-2514,0.002,-0.065,0.058,0.057,0.031,0.007,-0.072,-0.035,-0.01,-0.086,0.011,0.035,0.052,0.02,-0.037,-0.009,-0.027,-0.023,-0.026,0.015,-0.041,0.015,-0.01,0.049,-0.032,-0.01,0.016,-0.047,0.037,methylated
NH20-2559,204339010021_R07C01,182,6/11/2020,11/20/2020,11/22/2020,16,SB,Diagnostic,182,1,NDP,"Cardiff, University Hospital","Pilocytic astrocytoma, mitotic active","(2) unusual histology, location, demographics",B1,1/4/2018,2.9,supratentorial midline pilocytic astrocytoma,1,LGG_PAMID,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-2559,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Low grade glioma, subclass midline pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated
","Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Low grade glioma, subclass midline pilocytic astrocytoma 

BRAF (V600E): No mutation
KIAA1549-BRAF (fusion): See comment
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 182\NH20-2559,0.005,-0.063,-0.007,-0.005,-0.036,0.017,0.004,-0.064,-0.027,-0.006,0.207,-0.008,0.084,0.044,-0.03,-0.024,-0.021,-0.002,0.011,-0.031,-0.043,-0.041,0.033,0.018,0.032,-0.016,0.003,-0.027,0.037,unmethylated
NH20-2556,204894630079_R01C01,183,6/11/2020,11/27/2020,11/26/2020,20,ZJ,Diagnostic,183,3,NDP,"Belfast, Royal Victoria Hospital",?Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,7/6/2017,3.4,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.98,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-2556,"Histology: Pilocytic astrocytoma, with KIAA1549-BRAF fusion mutation (WHO grade I) 
Methylation profile: Posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 183\NH20-2556,0.125,-0.096,0.04,0.043,-0.036,0.001,0.013,-0.023,0.047,0.005,0.156,0.007,0.039,0.079,-0.098,0.023,-0.008,0.027,-0.002,0.029,-0.026,0.006,-0.018,0.096,0.091,-0.009,-0.003,-0.078,0.07,unmethylated
NH20-2577,204894630079_R03C01,183,10/11/2020,11/27/2020,11/26/2020,16,ZJ,Diagnostic,183,1,NDP,"Birmingham, Queen Elizabeth Hospital",,,A1,2/28/1962,59.5,supratentorial pilocytic astrocytoma,0.48,LGG_PA_GGST,0.52,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2577,"Histology: Compatible with pilocytic astrocytoma (WHO grade I)
Methylation profile: Suggestive of low grade glioma in the spectrum of hemispheric pilocytic astrocytoma and ganglioglioma

MGMT promoter (Illumina array): Unmethylated
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 183\NH20-2577,0.027,-0.05,0.007,0.031,-0.028,-0.023,-0.001,0.023,0.016,-0.017,0.015,-0.013,-0.015,-0.018,-0.083,-0.275,-0.027,0.02,-0.018,0.001,0.028,-0.029,-0.065,0.033,-0.024,-0.031,-0.013,-0.036,0.047,unmethylated
NH20-2581,204894630079_R04C01,183,10/11/2020,11/27/2020,11/26/2020,16,ZJ,Diagnostic,183,5,NDP,Oxford John Radcliffe Hospital,,,2D,5/16/1953,68.4,"glioblastoma, IDH-wildtype, RTK2 type",0.58,GBM_RTKII,0.55,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2581,"Histology: Compatible with glioblastoma, IDH-wildtype (WHO grade IV)  see comment
Methylation profile: Glioblastoma, IDH-wildtype 
MGMT promoter (Illumina array): Methylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 183\NH20-2581,-0.069,-0.098,0.045,-0.044,0.038,0.17,0.015,0.001,0.005,0.068,0.006,0.021,0.089,0.028,-0.126,-0.005,-0.302,-0.313,-0.035,-0.065,-0.024,-0.01,-0.058,-0.238,-0.023,0.032,-0.018,-0.221,-0.236,methylated
NH20-1908,204894630079_R05C01,183,10/11/2020,11/27/2020,11/26/2020,16,ZJ,Diagnostic,183,4,NDP,Nottingham University Hospital,IDH-mutant astro with focal anaplasia,"(2) unusual histology, location, demographics",A4,3/9/1990,30.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.96,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1908,"Referred diagnosis: Diffuse astrocytoma
MGMT Promoter: Methylated (>0-5%)
","Histology: Astrocytoma, IDH-mutant with focal malignant transformation
Methylation profile: Astrocytoma, IDH-mutant  see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 183\NH20-1908,0.024,-0.062,0.024,-0.008,-0.019,-0.05,0.047,-0.018,0.078,0.106,0.052,-0.007,0.07,0.032,0.023,-0.037,0.059,-0.043,0.027,0.057,-0.325,-0.468,-0.299,0.006,-0.015,0.041,-0.046,0.009,0.014,methylated
NH20-2594,204894630079_R06C01,183,10/11/2020,11/27/2020,11/26/2020,16,ZJ,Diagnostic,183,2,NDP,Newcastle,"ATRX loss, corpus callosum HGG","(4) IHC, sequencing, or copy number assay ambiguous",1A,6/1/1980,41,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.31,LGG_PA_GGST,0.16,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2594,"Histology: High grade glioma  see comment
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 183\NH20-2594,-0.074,-0.048,0.045,-0.037,0.003,-0.186,-0.081,-0.019,0.025,-0.051,-0.015,-0.008,0.009,-0.01,0.027,0.007,-0.031,-0.103,0.013,0.07,-0.005,-0.024,0.014,0.045,-0.021,-0.012,-0.048,-0.021,0.051,unmethylated
NH20-2517,204894630079_R07C01,183,13/11/2020,11/27/2020,11/26/2020,13,ZJ,Diagnostic,183,1,NDP,NHNN,"Diffuse glioma, IDH-wildtype","(2) unusual histology, location, demographics",DEF1A,5/27/1957,64.4,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.75,GBM_RTKII,0.82,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2517,"Diffuse glioma  see comment

IDH1 (R132H IHC): No mutation      
ATRX (IHC): Technically unsatisfactory
Further molecular tests: Pending
","Histology: Compatible with infiltration of glioblastoma, IDH-wildtype (WHO grade IV)  see comment
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (HRM and Illumina array): Methylated   
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 183\NH20-2517,0.012,-0.052,0.008,0.061,-0.039,-0.006,-0.033,0.255,0.233,0.242,0.196,-0.005,0.002,0.009,0.15,0.171,-0.388,-0.35,-0.036,-0.011,-0.001,-0.002,-0.077,0.044,-0.001,-0.024,0.177,-0.037,0.062,methylated
NH20-2605,204894630079_R08C01,183,13/11/2020,11/27/2020,11/26/2020,13,ZJ,Diagnostic,183,6,NDP,Romford,IDH-mutant astro with focal anaplasia,"(2) unusual histology, location, demographics",A3,11/29/1985,35.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.98,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2605,"Diffuse astrocytoma, IDH-mutant (WHO grade III)  see comment. 

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Histology: Anaplastic astrocytoma, IDH-mutant (WHO grade III)  for grading, see comment
Methylation profile: Astrocytoma, IDH-mutant
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 183\NH20-2605,0.033,-0.084,0.023,0.013,-0.006,-0.025,-0.023,-0.032,0.09,0.07,0.085,-0.019,0.085,0.102,-0.025,-0.035,0.04,0.006,-0.075,-0.015,-0.02,-0.027,-0.071,0.003,0.071,0.006,-0.042,-0.017,0.07,methylated
NH20-2598,204894630080_R01C01,184,13/11/2020,11/27/2020,11/26/2020,13,ZJ,Diagnostic,184,4,NDP,NHNN,C2 spinal tumour; ?Pilocytic,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,6/9/1983,38,infratentorial pilocytic astrocytoma,0.93,LGG_PAPF,0.9,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-2598,"Low grade glioma, favouring pilocytic astrocytoma (WHO grade I)  see comment. 
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","See previous reports
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 184\NH20-2598,0.033,-0.043,0,0.017,-0.042,0.188,0.032,0.01,-0.031,0.009,0.14,0.001,0.013,-0.033,-0.011,-0.008,-0.041,-0.034,-0.015,-0.033,-0.026,-0.015,-0.033,-0.015,-0.064,-0.028,0.007,0.021,0.004,unmethylated
NH20-2503,204894630080_R03C01,184,16/11/2020,11/27/2020,11/26/2020,10,ZJ,Diagnostic,184,1,NDP,Wellington Hospital London,"Thalamic GBM, IDH status uncelar, EGFR amplification","(4) IHC, sequencing, or copy number assay ambiguous",A1,1/2/1952,69.8,"glioblastoma, IDH-wildtype, RTK2 type",0.54,GBM_RTKII,0.83,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2503,"Glioblastoma, IDH-mutant (WHO grade IV)  see comment

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Glioblastoma, IDH-wildtype (WHO grade IV)
IDH1/2Seq: No Mutation (see comment)
ATRX (IHC): Retained
1p/19q: Retained
EGFR: Amplification     
CDKN2A/B: Deletion
MGMT Promoter: Methylated (>0-5%)
Methylation profile: Glioblastoma, IDH wildtype, subclass RTK I (low calibrated score, see comment)
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 184\NH20-2503,-0.005,0.008,0.084,-0.22,0.094,-0.024,0.067,1.515,0.267,0.304,0.188,-0.235,-0.026,-0.071,-1.175,-0.042,-0.159,-0.352,-0.103,-0.078,-0.031,0.059,-0.078,-0.165,-0.061,-0.06,0.029,-0.092,-0.071,unmethylated
NH20-2621,204894630080_R04C01,184,16/11/2020,11/27/2020,11/26/2020,10,SB,Diagnostic,184,2,NDP,Brighton and Sussex Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,1/26/1953,68.8,spinal ependymoma,0.58,EPN_SPINE,0.79,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2621,"Ependymoma (WHO grade II)  see comment. 
","Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, spinal (see comment)
MGMT promoter (Illumina array): Unmethylated
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 184\NH20-2621,-0.01,-0.014,-0.001,-0.009,-0.057,0.045,0.009,0.098,0.094,0.094,0.068,-0.011,0.037,-0.045,-0.01,-0.039,-0.033,-0.012,-0.05,-0.05,-0.047,-0.065,-0.149,-0.028,-0.035,-0.073,-0.061,-0.115,-0.051,unmethylated
NH20-2618,204894630080_R07C01,184,16/11/2020,11/27/2020,11/26/2020,10,SB,Diagnostic,184,2,NDP,Royal London Hospital,"Pilocytic astroctyoma, Cerebellum","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/29/1981,40.2,infratentorial pilocytic astrocytoma,0.24,LGG_RGNT,0.38,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2618,"Low grade glioma, favouring pilocytic astrocytoma (WHO Grade I) - see comment. 

IDH1 (R132H IHC): No mutation      
ATRX (IHC): Retained      
Further molecular tests: Pending
","See previous reports and supplementary comment
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 184\NH20-2618,-0.014,-0.037,0.011,-0.022,-0.003,0.032,-0.039,0.097,0.103,0.128,0.043,-0.017,0.013,-0.006,-0.026,-0.017,0.015,-0.001,0.008,-0.049,-0.04,-0.054,-0.004,-0.033,-0.086,-0.015,-0.013,-0.032,0.06,unmethylated
NH20-2651,204894630080_R08C01,184,17/11/2020,11/27/2020,11/26/2020,9,SB,Diagnostic,184,1,NDP,St George's Hospital London,"Ependymoma, other glioma?","(2) unusual histology, location, demographics",A1,4/15/1981,40.1,papillary glioneuronal tumour,0.89,LGG_DNT,0.34,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2651,"Histology: Low grade glioma/glioneuronal tumour (see comment)
Methylation profile: Low grade glioma, subclass hemispheric pilocytic astrocytoma and ganglioglioma (low calibrated score, see comment)

MGMT promoter (Illumina array): Unmethylated 
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 184\NH20-2651,0.005,-0.024,0.001,-0.002,-0.058,0.037,-0.058,-0.07,-0.046,-0.052,-0.034,-0.005,0.074,0.025,-0.011,-0.021,0.015,0.004,0.033,-0.027,-0.022,-0.032,0.004,-0.038,-0.063,0.002,-0.015,0.011,0.069,unmethylated
NH20-2609,204894630012_R01C01,185,18/11/2020,12/4/2020,12/2/2020,14,SB,Diagnostic,185,2,NDP,"Cardiff, University Hospital",Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,12/16/2010,10,infratentorial pilocytic astrocytoma,0.99,LGG_PAPF,0.89,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-2609,"Histology: Low grade astrocytoma favouring a pilocytic astrocytoma (WHO grade I)
Methylation profile: Pilocytic astrocytoma, subclass posterior fossa
Mutant H3 K27M (IHC): Negative
ATRX: Retained
KIAA1549-BRAF: No fusion (see comment)
BRAF V600E: No mutation
MGMT promoter (Illumina array): Unmethylated 
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 185\NH20-2609,0.067,-0.049,0.02,0.014,0.031,-0.058,-0.144,-0.123,-0.018,-0.026,0.226,0.014,0.062,-0.057,-0.03,-0.025,-0.08,0.006,0.05,-0.028,0.13,0.038,0.015,0.026,-0.095,-0.065,0.047,-0.052,0.12,unmethylated
NH20-2283,204894630012_R03C01,185,16/11/2020,12/4/2020,12/2/2020,16,AM,Diagnostic,185,3,NDP,Nottingham University Hospital,? Subependymoma - repeat MA on alt block,"(2) unusual histology, location, demographics",A1,3/24/1950,66.4,posterior fossa subependymoma,1,SUBEPN_PF,0.99,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2283,"Histology: Low grade glioma 
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
","Histology: Low grade glioma
Methylation profile: Subependymoma, posterior fossa (very low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 185\NH20-2283,0.302,-0.043,0.247,0.293,-0.204,-0.212,-0.514,0.084,-0.038,0.113,0.051,0.201,-0.118,0.2,-0.053,0.266,0.227,-0.134,0.121,0.319,0.398,0.012,0.034,0.331,-0.085,-0.17,0.018,-0.009,0.087,unmethylated
NH20-2653,204894630012_R04C01,185,18/11/2020,12/4/2020,12/2/2020,14,AM,Diagnostic,185,7,NDP,"Cambridge, Addenbrooke's Hospital",Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,2/5/1995,25.9,high-grade astrocytoma with piloid features,1,ANAPA,0.99,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2653,"Histology: Pilocytic astrocytoma (see comment)
Methylation profile: Anaplastic pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 185\NH20-2653,-0.178,-0.073,0,-0.011,0.042,0.07,-0.12,0.072,0.035,0.102,0.085,0.052,0.093,0.017,-0.767,0.151,-0.135,-0.035,-0.036,-0.041,0.051,0.008,-0.201,-0.088,-0.048,-0.028,-0.124,0.043,0.164,unmethylated
NH20-2663,204894630012_R06C01,185,20/11/2020,12/4/2020,12/2/2020,12,AM,Diagnostic,185,1,NDP,Southampton General Hospital,Low grade glioneuronal tumour ?DNET,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,3/2/2000,21,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.83,LGG_DNT,0.81,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2663,"Histology: Low grade glioneuronal tumour (equivalent to WHO grade I), see comment
Methylation profile: Low grade glioma, rosette forming glioneuronal tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 185\NH20-2663,-0.01,-0.009,0.02,0.002,-0.019,0.016,-0.005,-0.009,-0.037,-0.059,-0.018,0.006,0.023,-0.025,0.02,-0.002,-0.068,0.012,0.031,-0.027,-0.03,-0.072,-0.02,0.001,-0.052,-0.096,-0.067,0.007,0.027,unmethylated
NH20-2579,204894630012_R07C01,185,20/11/2020,12/4/2020,12/2/2020,12,AM,Diagnostic,185,4,NDP,Oxford John Radcliffe Hospital,Anaplastic astrocytoma (IDH seq failed),"(4) IHC, sequencing, or copy number assay ambiguous",3C,12/3/1971,49.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.86,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2579,"Diffusely infiltrating glioma (see comment)
IDH1 (R132H IHC): No mutation; further tests pending
ATRX (IHC): Loss of expression (indicates mutation)     
MGMT Promoter: Methylated (>0-5%)
  
","Histology: Anaplastic astrocytoma, IDH-mutant (WHO grade III)  see comment
Methylation profile: IDH glioma, subclass astrocytoma
IDH1/2Seq: Mutation
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion
MGMT Promoter: Methylated (>0-5%)
MGMT promoter (Illumina array): Methylated 
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 185\NH20-2579,0.026,-0.115,0.022,-0.026,0.02,0.022,-0.445,0,-0.03,-0.023,-0.006,0.04,0.054,-0.013,0.002,-0.04,-0.014,0.082,0.026,0.01,-0.134,-0.279,-0.031,0.011,-0.039,-0.028,-0.064,-0.105,-0.08,methylated
NH20-2535,204894630012_R08C01,185,20/11/2020,12/4/2020,12/2/2020,12,AM,Diagnostic,185,1,NDP,St George's Hospital London,"GBM, IDH2 seq did not work","(4) IHC, sequencing, or copy number assay ambiguous",A1,6/26/1972,49,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.37,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2535,"Glioblastoma (WHO grade IV)  see comment
IDH1 (R132H IHC); IDH1 Seq: No mutation (see comment)
ATRX (IHC): Retained
MGMT Promoter: Unmethylated (0%)
","Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 185\NH20-2535,0.05,-0.093,-0.03,0.129,0.03,0.035,0.003,-0.054,0.058,0.037,0.084,0.026,-0.019,-0.02,0.019,-0.037,-0.113,-0.13,-0.074,-0.064,0.569,1.481,-0.019,-0.032,0.01,-0.031,0.051,-0.044,-0.048,unmethylated
NH20-2697,204894630077_R05C01,186,23/11/2020,12/11/2020,12/9/2020,16,AM,Diagnostic,186,1,NDP,"Birmingham, Queen Elizabeth Hospital",Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,7/27/2011,9.4,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-2697,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 186\NH20-2697,-0.006,0.078,0.073,-0.031,0.005,0.022,0.007,0.002,0.046,-0.002,0.156,0.008,0.084,0.059,0.01,0.018,0.036,0.019,0.086,0.028,0.038,-0.028,-0.002,0.03,0.021,0.005,0.007,-0.122,0.031,unmethylated
NH20-2753,204894630077_R08C01,186,27/11/2020,12/11/2020,12/9/2020,12,AM,Diagnostic,186,5,NDP,Sweden,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",01 03,1/15/1989,32.3,spinal ependymoma,1,EPN_SPINE,0.95,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2753,"Histology: Ependymoma (WHO grade II)
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 186\NH20-2753,-0.007,0.206,0.005,0.134,-0.072,-0.191,-0.037,0.289,0.214,0.074,0.286,0.053,-0.052,0.103,0.068,0.183,-0.749,-0.447,0.207,0.555,0.318,0.358,-0.178,0.181,-0.236,-0.078,0.104,-1.128,-1.092,unmethylated
NH20-2771,204894630025_R01C01,188,30/11/2020,12/18/2020,12/16/2020,16,AM,Diagnostic,188,1,NDP,"Birmingham, Queen Elizabeth Hospital",Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,1/23/2002,19.1,supratentorial midline pilocytic astrocytoma,0.76,LGG_PAMID,0.81,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2771,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Pilocytic astrocytoma, midline
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 188\NH20-2771,0.048,-0.092,0.006,-0.044,-0.021,0.001,-0.048,-0.059,-0.007,-0.026,-0.001,0.013,-0.027,0.071,-0.039,0.033,-0.002,0.037,-0.015,0.086,-0.021,0.007,-0.081,0.077,-0.029,-0.101,0.049,-0.078,0.024,unmethylated
NH20-2750,204894630025_R02C01,188,30/11/2020,12/18/2020,12/16/2020,16,AM,Diagnostic,188,7,NDP,Royal London Hospital,Astrocytoma Grade II vs III,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1D,7/2/1984,36.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.97,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2750,"Diffuse astrocytoma, IDH-mutant (WHO grade II)  see comment. 
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Histology: Diffuse astrocytoma, IDH-mutant  for grading, see also comment
Methylation profile: Astrocytoma, IDH-mutant
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 188\NH20-2750,-0.043,-0.056,0.034,-0.022,0.063,0.05,-0.012,0.148,0.133,0.198,0.112,0,0.09,0.051,0.004,0.023,-0.054,-0.083,0.009,0.115,-0.052,-0.03,-0.111,-0.034,-0.07,-0.021,-0.374,-0.011,0.045,unmethylated
NH20-2761,204894630025_R04C01,188,30/11/2020,12/18/2020,12/16/2020,16,AM,Diagnostic,188,2,NDP,Romford,? GBM ? Anaplastic ependymoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/31/1967,54,"glioblastoma, IDH-wildtype, RTK2 type",0.82,GBM_RTKII,0.91,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2761,"High grade glioma  see comment. 
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Glioblastoma, IDH-wildtype (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR:     Amplification
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 188\NH20-2761,-0.109,-0.025,0.014,-0.074,0.004,0.038,0.01,0.698,0.164,0.213,0.133,-0.33,0.033,0.034,-1.251,0.008,-0.332,-0.288,-0.039,0.016,-0.025,-0.005,-0.012,-0.01,-0.069,-0.068,0.171,-0.009,0.053,unmethylated
NH20-2789,204894630025_R05C01,188,1/12/2020,12/18/2020,12/16/2020,15,AM,Diagnostic,188,3,NDP,Oxford John Radcliffe Hospital,low grade glial/glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3,12/8/1991,29.4,extraventricular neurocytoma,1,LGG_DNT,0.68,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2789,"Histology: Low grade glial or glioneuronal tumour
Methylation profile: Inconclusive  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 188\NH20-2789,0.01,-0.043,-0.006,-0.071,0.069,0.009,-0.02,-0.026,-0.022,0.02,0.006,0.028,-0.059,0.041,-0.031,0.007,-0.061,0.01,0.001,0.02,0,-0.068,-0.074,0.03,-0.074,-0.065,-0.009,-0.023,0.069,unmethylated
NH20-2801,204894630038_R02C01,189,2/12/2020,12/18/2020,12/16/2020,14,AM,Diagnostic,189,1,NDP,"Birmingham, Queen Elizabeth Hospital",Likely IDH-mutant GBM,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",3,6/2/1982,39,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2801,"Histology: Glioblastoma, IDH-mutant (WHO grade IV)
Methylation profile: High grade astrocytoma, IDH-mutant  see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 189\NH20-2801,-0.074,0.28,0.063,-0.265,0.008,0.046,0.052,-0.075,-0.054,-0.059,-0.052,-0.017,0.083,0.023,-0.373,0.026,-0.254,-0.297,0.611,0.126,0.268,0.021,-0.13,0.038,0.027,-0.035,-0.11,-0.012,0.041,methylated
NH20-2811,204894630038_R04C01,189,2/12/2020,12/18/2020,12/16/2020,14,AM,Diagnostic,189,3,NDP,"Belfast, Royal Victoria Hospital",? Meningioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1C,7/27/1972,49,supratentorial pilocytic astrocytoma,0.86,LGG_PA_GGST,0.62,0.57,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-2811,"Sample FS (P20-38524)
Histology: Glial tissue, raising the possibility of pilocytic astrocytoma (WHO grade I)  see comment
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
  
Sample 1C (P20-38666)
Histology: Meningothelial tumour, compatible with meningioma (WHO grade I)  see comment
Methylation profile: Meningioma, for subclass  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 189\NH20-2811,-0.134,-0.069,0.006,-0.019,-0.08,0.087,-0.131,-0.101,-0.07,-0.146,-0.026,-0.014,0.092,0.094,0.14,-0.055,-0.003,-0.076,0.112,0.065,0.066,0.054,-0.122,-0.119,-0.252,-0.066,0.027,0.015,0.034,unmethylated
NH20-2803,204894630038_R06C01,189,2/12/2020,12/18/2020,12/16/2020,14,AM,Diagnostic,189,12,NDP,St George's Hospital London,Glioma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A3,5/1/1976,34.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.97,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2803,"2010 (PH20333/10; A3) and 2014 (PH4778/14; A1)
Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH Glioma, subclass astrocytoma
IDH1 (R132H): Mutation
ATRX (IHC): Loss
BRAF V600E (IHC): No mutation
MGMT promoter (Illumina array): Methylated
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 189\NH20-2803,0.338,-0.076,0.04,0.048,0.019,-0.172,-0.03,0.593,0.395,0.44,0.361,0.003,0.153,0.506,-0.082,0.106,-0.059,-0.343,0.053,0.195,0.156,0.089,-0.132,0.259,0.02,0.029,-0.04,0.007,0.111,methylated
NH20-2803,204894630038_R07C01,189,2/12/2020,12/18/2020,12/16/2020,14,AM,Diagnostic,189,12,NDP,St George's Hospital London,Glioma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,5/1/1976,34.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.93,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2803,"2010 (PH20333/10; A3) and 2014 (PH4778/14; A1)
Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH Glioma, subclass astrocytoma
IDH1 (R132H): Mutation
ATRX (IHC): Loss
BRAF V600E (IHC): No mutation
MGMT promoter (Illumina array): Methylated
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 189\NH20-2803,0.208,-0.042,0.027,0.003,0.139,-0.134,0.026,0.118,0.065,0.072,0.051,0.036,-0.068,0.25,0.036,0.012,-0.06,-0.307,0.124,0.263,0.165,-0.24,-0.057,0.232,-0.019,-0.108,-0.178,-0.052,0.041,methylated
NH20-2837,204894630042_R02C01,190,4/12/2020,12/18/2020,12/16/2020,12,AM,Diagnostic,190,1,NDP,Nottingham University Hospital,Glioma/glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,8/7/1992,28.7,extraventricular neurocytoma,1,LGG_DNT,0.35,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2837,"Histology: Glial or glioneuronal tumour
Methylation profile: No matching methylation class  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 190\NH20-2837,0.099,0.018,-0.023,-0.035,0.037,-0.003,-0.011,-0.056,-0.012,-0.042,0.001,0.232,0.186,0.19,0.027,-0.021,-0.019,-0.027,0.167,0.016,0.025,-0.019,-0.041,0.056,0.002,-0.049,-0.033,-0.018,0.026,unmethylated
NH20-2430,204894630042_R03C01,190,4/12/2020,12/18/2020,12/16/2020,12,AM,Diagnostic,190,4,NDP,"Cambridge, Addenbrooke's Hospital",? pilocytic astrocytoma,"(4) IHC, sequencing, or copy number assay ambiguous",B1,10/18/1957,63.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.32,LGG_PAPF,0.26,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2430,"Histology: Glioma  see comment
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
","Histology: Glioma  see comment
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 190\NH20-2430,0.01,-0.055,-0.003,0.026,-0.043,0.032,-0.021,-0.032,-0.018,-0.051,-0.022,-0.017,0.022,-0.026,-0.011,-0.011,-0.016,0.01,-0.004,-0.022,-0.01,0.03,0.01,-0.044,-0.016,-0.012,-0.025,-0.02,0.024,unmethylated
NH20-2699,204894630042_R04C01,190,4/12/2020,12/18/2020,12/16/2020,12,AM,Diagnostic,190,3,NDP,Southampton General Hospital,? PXA ? epithelioid GBM ? Ependymoma,"(2) unusual histology, location, demographics",2C,10/20/1948,73.1,"glioblastoma, IDH-wildtype, RTK2 type",0.2,GBM_MES,0.5,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2699,"Glioma, IDH- and BRAF-wildtype (see comment)
","Histology: Most in keeping with glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Suggestive of glioblastoma, IDH-wildtype  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 190\NH20-2699,-0.059,-0.068,-0.008,-0.033,0.054,0.009,-0.351,-0.024,-0.03,0.027,-0.025,-0.023,-0.013,-0.033,-1.89,-0.349,-0.354,-0.273,-0.131,-0.029,-0.027,0.025,-0.803,-0.371,-0.477,-0.437,-0.04,0.01,0.029,unmethylated
NH20-2828,204894630042_R06C01,190,7/12/2020,12/18/2020,12/16/2020,9,AM,Diagnostic,190,3,NDP,NHNN,? GBM ? Ependymoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,1/21/1975,46.5,"glioblastoma, IDH-wildtype, with primitive neuronal component",1,MB_SHHCHLAD,0.15,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2828,"High grade glioma  see comment

IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Suggestive of glioblastoma, IDH-wildtype  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 190\NH20-2828,0.202,0.013,0.104,0.017,0.016,0.011,-0.042,0.214,0.18,0.192,0.159,0.226,0.228,0.214,-0.465,0.255,-0.051,-0.031,-0.086,-0.02,-0.011,-0.062,-0.013,0.006,-0.054,-0.02,0.153,0.003,0.037,unmethylated
NH20-2723,204894630042_R08C01,190,8/12/2020,12/18/2020,12/16/2020,8,AM,Diagnostic,190,5,NDP,St George's Hospital London,? Oligodendroglioma,"(4) IHC, sequencing, or copy number assay ambiguous",A2,9/4/1995,25.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.43,OIDH,0.64,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2723,"Oligodendroglioma, IDH-mutant (WHO grade II)  see comment and report NH20-2513

IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained
1p/19q: See comment
TERT promoter: No mutation
","Histology: Oligodendroglioma, IDH-mutant (WHO grade II)
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted  see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 190\NH20-2723,-0.024,-0.043,0.026,0.01,-0.002,0.048,0.004,-0.023,-0.023,-0.054,-0.014,-0.007,0.037,0.015,0.053,-0.013,-0.015,0.034,-0.005,-0.021,-0.049,-0.023,-0.015,0.014,-0.007,-0.044,-0.329,-0.009,0.027,methylated
NH20-2700,204894630009_R03C01,191,9/12/2020,1/22/2021,1/13/2021,35,AM,Diagnostic,191,1,NDP,Oxford John Radcliffe Hospital,Glioma / glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3C,11/17/2002,18.2,Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters,0.72,OIDH,0.24,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2700,"Low grade glial / glioneuronal tumour  see comment
","Histology: Low grade glioma/glioneuronal tumour
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 191\NH20-2700,0.055,-0.016,-0.012,-0.022,0.056,0.095,0.001,-0.045,-0.037,-0.017,-0.031,-0.025,0.025,0.009,-0.021,-0.033,0.003,0.021,-0.043,0.029,0.028,-0.022,-0.008,0.034,-0.031,-0.037,-0.234,0.002,0.077,unmethylated
NH20-2665,204894630009_R04C01,191,9/12/2020,1/22/2021,1/13/2021,35,AM,Diagnostic,191,1,NDP,Oxford John Radcliffe Hospital,Infiltration zone of a glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,12/19/1981,39.5,"glioblastoma, IDH-wildtype, RTK1 type",0.18,DMG_K27,0.15,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2665,"In keeping with an infiltration zone of diffuse glioma, IDH-wildtype  see comment

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
1p/19q: Retained
EGFR: No amplification
CDKN2A/B: No deletion
Histone H3F3A: No mutation
MGMT Promoter: Methylated (>0-5%)
","Histology: CNS grey matter with single infiltrating tumour cells
Methylation profile: Control tissue, hemispheric cortex
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 191\NH20-2665,0.006,0.026,0.007,-0.042,0.175,0.057,0.131,-0.011,-0.051,-0.058,-0.032,-0.012,0.192,0.169,0.28,0.172,0.016,0.033,-0.004,0.007,0.587,-0.055,-0.056,0.15,0.066,0.06,-0.017,0.091,0.221,methylated
NH20-2881,204894630009_R06C01,191,11/12/2020,1/22/2021,1/13/2021,33,AM,Diagnostic,191,1,NDP,Nottingham University Hospital,? Pilocytic astrocytoma,(1) small biopsy or nonrepresentative sample;,A2,6/28/2007,13.6,infratentorial pilocytic astrocytoma,0.98,LGG_PAPF,0.93,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-2881,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 191\NH20-2881,-0.082,-0.062,0.006,-0.007,-0.031,0.021,-0.106,0.065,0.102,0.076,0.252,0.115,-0.005,0.133,-0.018,0.007,-0.002,-0.033,-0.007,0.048,-0.043,-0.087,-0.16,0.115,-0.02,-0.023,0.094,-0.072,0.012,unmethylated
NH20-2906,204894630009_R07C01,191,11/12/2020,1/22/2021,1/13/2021,33,AM,Diagnostic,191,10,NDP,Preston,? Paeditric type anaplastic oligodendroglioma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,2/25/1986,35.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.27,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2906,"Histology: High grade intrinsic tumour 
Methylation profile: Glioblastoma, subclass mesenchymal,
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 191\NH20-2906,0.036,-0.009,0.008,0.093,0.033,-0.061,-0.216,0.074,0.134,0.076,0.091,0.018,-0.034,0.061,-0.235,0.005,-0.119,-0.102,0.007,0.042,0.029,-0.058,-0.044,0.036,-0.068,-0.083,0.019,-0.095,0.007,unmethylated
NH20-2760,204894630009_R08C01,191,11/12/2020,1/22/2021,1/13/2021,33,AM,Diagnostic,191,1,NDP,"Belfast, Royal Victoria Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",BN,3/20/1947,74.7,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type C]",1,DMG_K27,0.1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2760,"Diffuse glioma, IDH-wildtype (see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Interpreted as retained. 
Histone H3F3A: No mutation
MGMT Promoter: Methylated (>0-5%)
","Histology: CNS tissue with diffuse infiltration of an IDH-wildtype glioma
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 191\NH20-2760,0.013,-0.005,0.063,-0.046,-0.039,-0.012,0.096,-0.026,-0.076,-0.07,-0.036,0.017,0.048,0.012,-0.007,0.043,-0.003,0.071,0.04,0.066,0.025,-0.047,0.032,0.006,-0.043,-0.015,-0.004,-0.022,0.026,unmethylated
NH20-2767,205021750005_R01C01,192,11/12/2020,1/29/2021,1/29/2021,49,AM,Diagnostic,192,6,NDP,St George's Hospital London,High grade tumour with unusual features,"(2) unusual histology, location, demographics",A1,5/2/1960,61.4,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.94,DMG_K27,0.27,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2767,"High grade neuroepithelial tumour, IDH-wildtype (see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)
TERT promoter: Mutation
Histone H3F3A: No mutation
MGMT Promoter: Unmethylated (0%)
",#REF!,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 192\NH20-2767,0.02,0.017,0.025,0.027,0.032,-0.05,0.032,-0.024,0.007,0.031,-0.019,-0.025,-0.061,0.064,-0.008,0.008,-0.007,0.011,0.046,0.084,0.014,-0.036,-0.058,0.037,0.012,-0.088,-0.016,-0.007,0.009,unmethylated
NH20-2903,205021750005_R02C01,192,11/12/2020,1/29/2021,1/29/2021,49,AM,Diagnostic,192,1,NDP,Oxford John Radcliffe Hospital,Malignant neuroectodermal tumour,"(2) unusual histology, location, demographics",2,6/30/1978,43,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.28,GBM_RTKI,0.57,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2903,"Histology: Poorly differentiated intrinsic tumour
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK I
MGMT promoter (Illumina array): Methylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 192\NH20-2903,-0.022,1.233,0.008,0.039,0.023,-0.026,0.047,0.158,0.274,0.31,0.184,-0.132,-0.211,-0.112,-0.224,-0.172,-0.319,-0.39,-0.388,0.026,0.844,1.503,-0.516,-0.097,0.178,0.064,-0.061,-0.033,0.044,methylated
NH20-2913,205021750005_R05C01,192,16/12/2020,1/29/2021,1/29/2021,44,ZJ,Diagnostic,192,3,NDP,Lund (SE),GBM,"(4) IHC, sequencing, or copy number assay ambiguous",01.02_,3/29/1975,46.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.59,GBM_MES,0.85,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2913,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 192\NH20-2913,0.032,-0.288,0.014,-0.035,-0.285,-0.067,-0.396,0.564,0.088,0.012,0.017,-0.009,0.001,0.125,-0.2,0.029,-0.149,-0.281,-0.05,0.106,0.183,0.031,-0.235,0.076,-0.019,-0.033,-0.08,-0.074,-0.205,methylated
NH20-2914,205021750005_R06C01,192,16/12/2020,1/29/2021,1/29/2021,44,ZJ,Diagnostic,192,4,NDP,Lund (SE),?Ependymoma; ?APA; ?GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",01.02_,5/16/1966,55.4,high-grade astrocytoma with piloid features,0.63,DMG_K27,0.85,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2914,"Diffuse midline glioma, H3K27M-mutant (WHO grade IV)

Histone H3F3A (K27M IHC): Mutation
ATRX (IHC): Retained     
","Histology: Diffuse midline glioma, H3 K27M-mutant
Methylation profile: Diffuse midline glioma H3 K27M-mutant
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 192\NH20-2914,0.095,-0.001,-0.081,-0.106,-0.092,1.03,-0.072,0.043,0.05,0.002,0.024,0.006,-0.251,0.045,0.015,0.03,-0.052,-0.538,0.006,-0.039,0.946,1.84,-0.112,-0.09,0.04,-0.021,-0.031,-0.026,0.016,unmethylated
NH20-2915,205021750005_R07C01,192,16/12/2020,1/29/2021,1/29/2021,44,ZJ,Diagnostic,192,1,NDP,Lund (SE),Cervical spinal tumour; ?GG; ?DLGNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",01.01_,4/7/2006,14.9,diffuse leptomeningeal glioneuronal tumour,0.99,DLGNT,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-2915,"Histology: Low grade glioma/glioneuronal tumour
Methylation profile: Diffuse leptomeningeal glioneuronal tumour
MGMT promoter (Illumina array): Methylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 192\NH20-2915,-0.011,-0.013,-0.014,0.002,0.027,0.006,-0.002,-0.045,0.02,-0.023,0.139,0.038,0.041,0.046,0.063,-0.007,0.009,0.006,0.073,-0.043,0,0.032,0.005,0.022,0.001,-0.026,-0.276,-0.004,0.044,methylated
NH20-2933,204921830024_R02C01,193,16/12/2020,1/22/2021,1/23/2021,38,ZJ,Diagnostic,193,1,NDP,Brighton and Sussex Hospital,"MNG, atypical","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,7/9/1967,54.2,posterior fossa subependymoma,1,SUBEPN_PF,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2933,"Atypical meningioma (WHO grade II)  see comment 
","Histology: Atypical meningioma (WHO grade II)
Methylation profile: Meningioma intermediate A
MGMT promoter (Illumina array): Unmethylated 
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 193\NH20-2933,-0.004,-0.107,0.028,0.068,-0.077,-0.012,-0.002,-0.035,-0.031,0.002,-0.007,-0.001,-0.039,0.032,-0.044,-0.018,-0.006,0.006,0.002,0.005,-0.046,0.02,-0.064,0.073,0.011,-0.021,0.072,-0.029,0.024,methylated
NH20-2945,204921830024_R03C01,193,16/12/2020,1/22/2021,1/23/2021,38,ZJ,Diagnostic,193,1,NDP,Lund (SE),MNG,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",01.03_,7/1/1973,48.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-2945,"Histology: Meningioma, WHO grade I)
Methylation profile: Meningioma intermediate A
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 193\NH20-2945,0.001,-0.052,0.024,-0.012,-0.026,0.046,-0.074,-0.007,-0.044,-0.009,0.017,0.011,-0.038,0.066,-0.108,0.004,-0.023,0.01,-0.035,0.018,-0.025,-0.076,-0.11,0.126,0.016,0.081,0.009,-0.061,0.012,unmethylated
NH20-2954,204921830024_R04C01,193,17/12/2020,1/22/2021,1/23/2021,37,ZJ,Diagnostic,193,2,NDP,Oxford John Radcliffe Hospital,"Ependymoma, 4th v","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2B,3/30/1959,62.6,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.96,0.59,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2954,"Histology: Ependymoma
Methylation profile: Ependymoma, posterior fossa group B
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 193\NH20-2954,0.036,-0.033,-0.002,0.006,-0.025,0.014,-0.05,0.175,0.292,0.247,0.228,-0.009,-0.038,0.068,-0.606,-0.046,-0.193,-0.143,-0.005,0.019,0.02,0.023,-0.237,0.036,-0.604,-0.048,0.028,-0.001,0.074,methylated
NH20-2955,204921830024_R05C01,193,17/12/2020,1/22/2021,1/23/2021,37,ZJ,Diagnostic,193,1,NDP,Oxford John Radcliffe Hospital,HGG,"(2) unusual histology, location, demographics",2A,9/11/1964,57,posterior fossa ependymoma group B,1,EPN_PFB,0.98,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2955,"High grade glioma
MGMT Promoter: Unmethylated (0%)
","Histology: 
Methylation profile:
MGMT promoter (Illumina array): Methylated 
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 193\NH20-2955,-0.117,-0.005,0.104,0.008,-0.033,0.259,0.017,0.463,0.491,0.442,0.456,0.331,0.411,0.366,0.556,0.516,0.07,0.058,0.075,0.266,0.306,0.339,0.283,0.067,-0.082,0.039,0.28,0.014,0.041,unmethylated
NH20-3000,205021750018_R01C01,195,28/12/2020,1/29/2021,1/29/2021,32,ZJ,Diagnostic,195,8,NDP,Brighton and Sussex Hospital,Anapl ganglioglioma,"(2) unusual histology, location, demographics",DEF1A,8/27/1962,59.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.14,GBM_MES,0.5,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-3000,"Anaplastic ganglioglioma (WHO grade III)

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Histology: High-grade glioma (see previous report)
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 195\NH20-3000,0.056,-0.013,0.008,-0.059,-0.004,-0.119,-0.068,0.365,0,0.045,-0.015,-0.019,-0.057,0.032,-1.479,-0.036,-0.36,-0.32,-0.055,0.081,0.024,-0.048,-0.434,0.061,0.064,-0.115,-0.02,-0.071,0.031,methylated
NH20-3000,205021750018_R02C01,195,28/12/2020,1/29/2021,1/29/2021,32,ZJ,Diagnostic,195,8,NDP,Brighton and Sussex Hospital,Anapl ganglioglioma,"(2) unusual histology, location, demographics",DEF1A,8/27/1962,59.2,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.55,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-3000,"Anaplastic ganglioglioma (WHO grade III)

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Histology: High-grade glioma (see previous report)
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 195\NH20-3000,0.011,-0.036,-0.022,-0.038,0.019,-0.015,-0.008,0.669,0.023,0.038,-0.011,-0.015,-0.075,0.008,-0.407,-0.049,-0.137,-0.085,-0.066,-0.004,0.004,-0.077,-0.183,0.001,-0.025,-0.055,-0.036,-0.066,0.026,methylated
NH20-2916,205021750018_R03C01,195,30/12/2020,1/29/2021,1/29/2021,30,ZJ,Diagnostic,195,1,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/11/1952,69.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.22,GBM_MES,0.5,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2916,"Suggestive of glioblastoma, IDH-wildtype (WHO grade IV)  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained               
EGFR: No amplification          
CDKN2A/B: No deletion          
BRAF (V600E): No mutation          
MGMT Promoter: Methylated (>0-5%)
","Histology: High-grade glioma, with features suggestive of glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal, however, low calibrated score
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 195\NH20-2916,0.034,0,-0.015,0.04,0.005,-0.039,0.016,0.014,0.024,0.026,0.009,0.011,-0.004,0.026,-0.025,0.009,-0.205,-0.238,-0.004,0.023,0.001,-0.055,-0.27,-0.198,-0.28,-0.345,-0.083,-0.2,-0.198,unmethylated
NH21-7,205021750018_R06C01,195,5/1/2021,1/29/2021,1/29/2021,24,SB,Diagnostic,195,2,NDP,"Birmingham, Queen Elizabeth Hospital",ganglioglioma/PXA?,"(2) unusual histology, location, demographics",B3,12/31/1984,36.5,pleomorphic xanthoastrocytoma(-like),0.49,PXA,0.75,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-7,"Histology: Low grade glioma with features supportive of pleomorphic xanthoastrocytoma
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Methylated 
  
","Pleomorphic Xanthoastrocytoma (WHO Grade II)
BRAF (V600E): Mutation
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 195\NH21-7,0.037,-0.114,-0.038,0.034,0.182,0.114,-0.104,0.075,0.151,0.148,0.089,0.14,0.104,0.154,-0.071,0.119,-0.253,-0.245,-0.09,0.092,0.117,0.087,-0.115,0.088,0.089,0.073,0.09,-0.046,-0.079,methylated
NH21-20,205021750018_R07C01,195,6/1/2021,1/29/2021,1/29/2021,23,SB,Diagnostic,195,1,NDP,Lund (SE),Glioneuronal tumour,"(2) unusual histology, location, demographics",111,2/28/2005,16.1,supratentorial pilocytic astrocytoma,0.99,LGG_PA_GGST,0.72,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-20,"Histology: Low grade glioma with features of pilocytic/pilomyxoid astrocytoma
Methylation profile: Pilocytic astrocytoma, subclass hemispheric pilocytic astrocytoma (low calibrated score)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 195\NH21-20,-0.061,-0.034,-0.082,-0.044,-0.067,0.031,-0.074,0.158,0.25,0.175,0.154,0.083,-0.041,0.103,0.105,0.054,0.15,0.118,0.135,0.06,-0.006,0.086,0.121,0.008,-0.099,-0.11,-0.097,-0.064,-0.083,unmethylated
NH21-21,205021750018_R08C01,195,6/1/2021,1/29/2021,1/29/2021,23,SB,Diagnostic,195,4,NDP,Lund (SE),"Astrocytoma, IDH mutant","(4) IHC, sequencing, or copy number assay ambiguous",109,12/16/1996,24.4,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-21,"Histology: IDH mutant glioma (WHO grade II)
Methylation profile: Oligodendroglioma, IDH mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 195\NH21-21,0.08,-0.008,0.007,-0.035,0.053,0.005,-0.07,-0.011,-0.01,0.028,0.026,0.001,0.036,0.055,-0.064,0,-0.008,0.011,-0.002,-0.017,-0.007,-0.034,-0.098,0.112,-0.026,-0.004,-0.512,-0.002,0.036,methylated
NH21-34,205022250127_R02C01,196,7/1/2021,1/29/2021,1/29/2021,22,AM,Diagnostic,196,1,NDP,The London Clinic,High grade glioma,(1) small biopsy or nonrepresentative sample;,DEF1A,5/5/1951,70.7,"glioblastoma, IDH-wildtype, RTK2 type",0.78,GBM_RTKII,0.87,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-34,"High grade glioma - see comment
IDH1 (R132H IHC): No mutation  
ATRX (IHC): Retained 
H3 K27M (IHC): Negative
BRAF V600E (IHC): Negative
Further molecular tests: Pending
","Histology: High-grade glioma with features of glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype (subclass mesenchymal)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 196\NH21-34,0.212,-0.049,0.01,-0.027,0.021,0.023,-0.018,0.14,0.218,0.197,-0.016,-0.01,-0.102,0.053,-1.34,0.181,-0.071,-0.027,-0.035,0.075,0.002,-0.054,-0.099,0.081,-0.01,-0.056,-0.35,-0.027,-0.263,unmethylated
NH21-37,205022250127_R04C01,196,7/1/2021,1/29/2021,1/29/2021,22,SB,Diagnostic,196,1,NDP,Bristol,4th ventricle glioma,"(2) unusual histology, location, demographics",B2,1/1/1992,29.3,high-grade astrocytoma with piloid features,1,ANAPA,1,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-37,"Histology: High-grade glioma
Methylation profile: Anaplastic astrocytoma with piloid features
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 196\NH21-37,0.055,-0.018,-0.078,-0.071,0.011,0.095,-0.064,0.003,0.025,0.034,-0.013,0.25,-0.112,0.02,-0.746,0.181,-0.028,0.079,-0.057,0.183,0.185,0.195,-0.115,0.099,-0.052,-0.047,-0.01,-0.004,0.029,unmethylated
NH20-2973,205022250127_R05C01,196,11/1/2021,1/29/2021,1/29/2021,18,SB,Diagnostic,196,1,NDP,NHNN,"Melanoma- GBM,other undiff Tumour?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,9/26/1944,77.3,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2973,"Poorly differentiated S-100 positive metastatic tumour  see comment. 
","Poorly differentiated glial tumour, corresponding to WHO grade IV (see comment) 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
TERT promoter: No mutation
MGMT Promoter: Methylated (>0-5%)

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 196\NH20-2973,0.139,1.006,0.003,0.077,0.225,0.051,-0.136,0.134,0.209,0.186,0.027,-0.148,-0.23,-0.043,-0.149,0.053,-0.385,-0.466,-0.119,0.822,0.501,-0.167,-0.096,0.162,0.076,0.005,-0.265,-0.166,-0.12,unmethylated
NH21-43,205022250127_R06C01,196,11/1/2021,1/29/2021,1/29/2021,18,SB,Diagnostic,196,2,NDP,"Cardiff, University Hospital",Ependymoma PF,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A,2/10/2002,19.1,posterior fossa ependymoma group A1,1,EPN_PFA,0.99,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-43,"Histology: Ependymoma, posterior fossa, group A (see comment)
Methylation profile: Ependymoma, posterior fossa group A
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 196\NH21-43,0.339,-0.028,0.058,0.008,-0.001,0.038,-0.773,0.027,-0.088,-0.025,0,0.06,-0.064,0.04,0.029,0.074,-0.044,-0.486,0.09,-0.034,-0.001,-0.052,-0.162,0.088,-0.104,-0.058,0.063,0.01,0.065,unmethylated
NH21-46,205022250127_R07C01,196,11/1/2021,1/29/2021,1/29/2021,18,SB,Diagnostic,196,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma?,(1) small biopsy or nonrepresentative sample;,A1,3/12/2018,2.9,supratentorial midline pilocytic astrocytoma,1,LGG_PAMID,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-46,"Pilocytic astrocytoma (WHO grade I)
BRAF (V600E): Mutation


","Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Pilocytic astrocytoma, subclass midline pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 196\NH21-46,0.03,-0.044,0.014,0.002,0.038,0.003,-0.034,0.015,0.041,0.035,-0.021,0,-0.042,0.039,-0.029,-0.001,0.006,0.001,0.053,0.056,0.043,-0.004,-0.023,0.057,-0.006,-0.025,-0.085,-0.005,0.033,unmethylated
NH21-47,205022250127_R08C01,196,11/1/2021,1/29/2021,1/29/2021,18,SB,Diagnostic,196,1,NDP,Nottingham University Hospital,Intraventr Ganglioglioma (?),"(2) unusual histology, location, demographics",D2,1/25/1989,32.4,ganglioglioma,0.25,LGG_PA_GGST,0.24,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-47,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Low grade glioma, subclass hemispheric pilocytic astrocytoma and ganglioglioma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 196\NH21-47,-0.14,-0.004,0.051,-0.05,0.02,0.009,0.066,-0.017,-0.06,-0.015,-0.029,0.022,0.022,-0.012,0.032,-0.013,0.001,0.022,-0.007,-0.122,-0.113,-0.041,-0.014,-0.068,-0.14,-0.064,-0.022,-0.066,-0.018,unmethylated
NH21-59,205021750115_R01C01,197,11/1/2021,1/22/2021,1/23/2021,12,SB,Diagnostic,197,1,NDP,Plymouth,GBM?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,5/26/1966,55.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.96,GBM_MES,0.31,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-59,"Histology: High-grade glioma, consistent with glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 197\NH21-59,-0.037,-0.131,-0.042,0.018,-0.013,-0.114,-0.087,0.1,0.15,0.163,0.096,-0.004,0.017,0.049,-0.191,-0.017,-0.44,-0.165,0.015,0.007,0.516,1.138,-0.179,0.056,0.035,-0.015,0.072,-0.022,0.042,unmethylated
NH21-45,205021750115_R02C01,197,11/1/2021,1/22/2021,1/23/2021,12,SB,Diagnostic,197,1,NDP,Nottingham University Hospital,Brain stem glioma,(1) small biopsy or nonrepresentative sample;,A1,5/22/2019,1.6,infratentorial pilocytic astrocytoma,0.99,LGG_PAPF,0.88,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-45,"Histology: Low grade glioma.
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 197\NH21-45,-0.073,0.006,0.05,0.022,0.04,0.018,-0.107,-0.031,-0.047,-0.082,0.103,0.033,0.063,-0.017,0.072,-0.054,0.022,0.022,0.009,-0.027,-0.031,-0.028,0.04,0.015,-0.054,-0.135,-0.007,-0.007,0.043,unmethylated
NH21-26,205021750115_R03C01,197,11/1/2021,1/22/2021,1/23/2021,12,SB,Diagnostic,197,5,NDP,Brighton and Sussex Hospital,"IDH-mutant HGG, A vs O?","(4) IHC, sequencing, or copy number assay ambiguous",DEF1B,11/29/1981,39.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.94,AIDH_HG,0.82,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-26,"High grade glioma, IDH-mutant suggestive of anaplastic oligodendroglioma (WHO grade III)  see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Glioblastoma, IDH-mutant (WHO grade IV)
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 197\NH21-26,-0.006,-0.109,-0.001,-0.197,-0.239,0.023,0.007,0.113,0.085,0.132,0.073,-0.026,0.009,-0.022,-0.31,-0.298,-0.015,0.036,-0.02,0.002,-0.053,-0.035,-0.288,0.007,0.012,-0.026,-0.343,0.008,-0.016,methylated
NH21-48,205021750115_R04C01,197,12/1/2021,1/22/2021,1/23/2021,11,AM,Diagnostic,197,10,NDP,Royal London Hospital,? Glioma ? inflammatory,"(2) unusual histology, location, demographics",DEF1A,11/24/1946,75.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.91,CONTR_REACT,0.19,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-48,"Left parietal brain biopsy: Pathological tissue, without evidence of lymphoma or metastatic carcinoma - see comment
","Histology: CNS tissue, no evidence of lymphoma or metastatic carcinoma
No diagnostic mutations detected.

Methylation profile: Control tissue, hypothalamus
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 197\NH21-48,-0.032,0.003,0.003,-0.001,0.013,-0.05,-0.05,0.011,0.057,0.039,0.031,0.003,0.005,-0.028,-0.085,-0.013,-0.056,-0.019,0.002,-0.036,-0.015,-0.078,-0.015,-0.02,-0.072,-0.023,-0.046,-0.026,0.025,methylated
NH21-53,205021750115_R08C01,197,13/01/2021,1/22/2021,1/23/2021,10,SB,Diagnostic,197,1,NDP,Romford,GBM or aPXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/30/1960,61.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.98,GBM_MES,0.97,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-53,"Glioblastoma (WHO grade IV)  see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained 
BRAF (V600E IHC): No mutation
Further molecular tests: Pending
  
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 197\NH21-53,0.016,-0.056,0.015,0.167,-0.032,-0.049,0.007,0.121,0.118,0.132,0.098,-0.011,0.036,0.044,-0.018,-0.071,-0.248,-0.169,-0.031,0.003,0.907,1.656,-0.034,-0.048,-0.012,-0.099,0.09,-0.014,0.018,unmethylated
NH21-95,205022250165_R01C01,198,15/01/2021,2/5/2021,2/5/2021,21,SB,Diagnostic,198,1,NDP,Nottingham University Hospital,Pilocytic Astrocytoma brain midline,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,3/30/2008,12.9,supratentorial midline pilocytic astrocytoma,1,LGG_PAMID,0.97,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-95,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Low grade glioma, subclass midline pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 198\NH21-95,0.011,-0.041,-0.041,0.079,0.146,-0.007,-0.055,0.163,0.218,0.26,0.204,-0.016,-0.053,0.064,0.06,0.074,0.061,0.069,0.006,0.064,0,-0.039,0.056,-0.093,-0.099,-0.141,-0.031,-0.066,0.016,unmethylated
NH21-102,205022250165_R02C01,198,15/01/2021,2/5/2021,2/5/2021,21,SB,Diagnostic,198,4,NDP,"Cambridge, Addenbrooke's Hospital","IDH-mutant glioma, ATRX retained, no LOH1p/19q","(4) IHC, sequencing, or copy number assay ambiguous",B1,6/27/1985,35.8,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.18,AIDH_HG,0.31,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-102,"Histology: Glioblastoma, IDH-mutant (WHO grade IV) - see comment
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
","Histology: Glioblastoma, IDH-mutant (WHO grade IV)
Methylation profile: IDH glioma, subclass high-grade astrocytoma
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 198\NH21-102,0.052,-0.032,0.041,-0.034,0.075,0.048,-0.027,-0.042,-0.037,-0.034,-0.054,-0.015,-0.018,-0.051,-0.28,0.068,-0.032,0.073,-0.03,0.166,0.032,-0.019,-0.046,0.015,0.028,-0.059,-0.204,0.03,0.037,methylated
NH21-101,205022250165_R03C01,198,15/01/2021,2/5/2021,2/5/2021,21,SB,Diagnostic,198,4,NDP,"Birmingham, Queen Elizabeth Hospital",IDH-mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,1/24/1986,35.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-101,"Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II) - see comment
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 198\NH21-101,0.059,-0.024,0.008,0.009,0.071,-0.083,-0.06,0,0.154,0.266,0.245,-0.03,-0.054,0.063,-0.057,0.006,-0.008,-0.026,0.005,0.117,0.068,-0.119,-0.063,0.088,0.038,-0.026,-0.032,0.025,0.085,methylated
NH21-104,205022250165_R04C01,198,18/01/2021,2/5/2021,2/5/2021,18,SB,Diagnostic,198,2,NDP,Royal London Hospital,Spinal HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/20/1969,52.2,diffuse leptomeningeal glioneuronal tumour,0.51,GBM_MID,0.28,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-104,"High grade glial tumour, see comment 
","Diffuse leptomeningeal glioneuronal tumour (not graded, see comment)
BRAF:KIAA fusion
Chr 1p deletion
Methylation profile: No matching methylation class

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 198\NH21-104,0.06,0.027,0.007,-0.016,0.086,0.024,0.022,-0.031,-0.036,-0.088,0.409,-0.004,-0.184,0.033,-1.583,-0.365,-0.454,-0.405,0.12,0.005,0.003,-0.081,-0.159,0.069,-0.044,-0.039,0.014,-0.363,-0.342,unmethylated
NH20-3024,205022250165_R05C01,198,20/01/2021,2/5/2021,2/5/2021,16,SB,Diagnostic,198,1,NDP,"Belfast, Royal Victoria Hospital","high grade glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C,12/29/1976,44.6,"glioblastoma, IDH-wildtype, with primitive neuronal component",0.94,GBM_RTKI,0.46,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-3024,"High-grade glioma, IDH-wildtype
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Technically unsatisfactory
EGFR: No amplification
TERT promoter: Technically unsatisfactory 
 
","Integrated Diagnosis: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH wildtype, subclass RTK I
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 198\NH20-3024,0.1,1.686,0.021,0.066,0.995,0.006,-0.024,0.215,0.19,0.27,0.222,-0.146,-0.134,-0.169,-0.035,0.035,-0.45,-0.432,0.028,0.024,1.258,0.339,-0.123,-0.071,-0.085,-0.152,-0.091,-0.031,0.049,unmethylated
NH21-120,205022250165_R06C01,198,20/01/2021,2/5/2021,2/5/2021,16,SB,Diagnostic,198,8,NDP,Southampton General Hospital,"High grade glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1B,11/19/1981,39.7,"glioblastoma, IDH-wildtype, mesenchymal type",1,PXA,0.81,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-120,"Histology: High grade/malignant neuroepithelial tumour  see comment
IDH1/2Seq: No mutation
Histone H3F3A: No mutation
BRAF (V600E): Mutation

Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Methylated 
  
","Histology: High grade / malignant neuroepithelial tumour, BRAF V600E mutant
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 198\NH21-120,0.067,0.045,0.14,0.023,0.059,0.15,0.036,0.107,0.26,0.3,0.268,-0.238,0.159,0.172,-1.16,0.243,-0.028,0.058,-0.028,-0.026,0.006,-0.005,-0.082,0.023,0.005,0.192,0.058,0.001,0.004,methylated
NH21-103,205022250165_R08C01,198,20/01/2021,2/5/2021,2/5/2021,16,SB,Diagnostic,198,5,NDP,HCA,"IDH-mutant Astro, ATRX retained,unusual morphology","(4) IHC, sequencing, or copy number assay ambiguous",A1,5/4/1947,74.8,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,OIDH,0.99,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-103,"High-grade glioma, IDH-mutant (WHO grade III)  see comment. 
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Integrated Diagnosis: Anaplastic Oligodendroglioma, IDH-mutant and 1p/19q-codeleted (WHO grade III)
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 198\NH21-103,0.106,-0.061,0.026,-0.471,-0.535,-0.042,-0.007,-0.017,0.007,-0.043,0.013,0.026,0.097,-0.088,-0.109,-0.163,0.01,0.021,0.174,-0.067,-0.054,-0.001,-0.041,0.004,-0.006,-0.028,-0.463,0.011,0.049,methylated
NH21-132,205021750148_R01C01,199,20/01/2021,2/12/2021,2/25/2021,36,SB,Diagnostic,199,14,NDP,"Birmingham, Queen Elizabeth Hospital","EWSR-ATF1 fusion, Myxoid sarcoma, vs HGG","(5) Confirmation of rare, unusual or interesting histo-molecular results",C,6/10/1990,27.6,posterior fossa ependymoma group A1,0.12,GBM_MES,0.17,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-132,"Histology: Tumour with confirmed EWSR1-ATF1 gene fusion
Methylation profile: No matching methylation class  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 199\NH21-132,0.056,-0.027,0.014,-0.053,-0.166,-0.05,0.123,-0.089,-0.021,-0.043,-0.028,0.017,0.045,0.086,0.111,0.036,0.07,-0.057,0.043,0.072,0.056,0.149,-0.135,0.057,0.063,0.032,-0.117,-0.263,-0.179,unmethylated
NH21-146,205021750148_R02C01,199,25/01/2021,2/12/2021,2/25/2021,31,SB,Diagnostic,199,2,NDP,Lund (SE),"ependymoma, L2-L3","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",101,4/24/1991,30.1,myxopapillary ependymoma,1,EPN_MPE,1,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-146,"Histology: Ependymal tumour, compatible with myxopapillary ependymoma (WHO grade I)
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 199\NH21-146,-0.104,-0.033,-0.015,-0.019,0.121,-0.007,-0.26,0.117,0.169,0.093,0.058,-0.28,-0.176,-0.27,0.219,0.181,0.002,-0.105,-0.061,0.095,0.101,0.211,-0.011,0.141,0.227,0.127,0.084,-0.3,-0.269,methylated
NH21-135,205021750148_R04C01,199,23/01/2021,2/12/2021,2/25/2021,33,SB,Diagnostic,199,1,NDP,Nottingham University Hospital,Malignant neuroepithelial tumour ,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/9/1952,69.2,"glioblastoma, IDH-wildtype, RTK2 type",0.74,GBM_RTKII,0.67,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-135,"Histology: High grade glioma, compatible with glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 199\NH21-135,0.162,-0.001,0.017,-0.021,-0.048,0.004,0.083,0.355,0.408,0.427,0.333,-0.002,0.047,0.054,-2.583,0.038,-0.325,-0.553,-0.052,0.036,0.01,0.127,0.026,0.039,0.037,0.022,-0.099,-0.425,-0.356,unmethylated
NH21-151,205022250076_R02C01,200,25/01/2021,2/12/2021,2/11/2021,17,SB,Diagnostic,200,2,NDP,Latvia,ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,11/7/2016,4.3,posterior fossa ependymoma group A1,1,EPN_PFA,1,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-151,"Histology: Ependymal tumour, in keeping with posterior fossa group A
Methylation profile: Ependymoma, posterior fossa group A
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 200\NH21-151,-0.126,0.013,0.043,-0.013,-0.027,0.048,0.057,-0.007,0.003,-0.026,-0.012,-0.027,0.023,0.016,0.163,-0.011,0.02,0.035,0.037,0.008,-0.026,0.063,-0.008,0.004,-0.001,-0.058,0.043,-0.026,0.01,unmethylated
NH21-79,205022250076_R03C01,200,25/01/2021,2/12/2021,2/11/2021,17,SB,Diagnostic,200,4,NDP,St George's Hospital London,LGG-GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/18/1961,60.4,ganglioglioma,0.44,GBM_MES,0.21,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-79,"CNS cortex with glioma infiltration.
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
1p/19q: Retained
EGFR: No amplification
TERT promoter: No mutation
Histone H3F3A: No mutation
BRAF (V600E): No mutation     
MGMT Promoter: Methylated (>5-10%)
  
","Histology: CNS cortex with glioma infiltration
Methylation profile: Control tissue  see comment
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 200\NH21-79,0.058,0.009,0.022,0.014,0.03,0.019,-0.226,0.197,0.185,0.198,0.164,-0.002,0.02,0.027,-0.197,-0.087,-0.158,-0.122,-0.082,0.027,0.43,-0.016,-0.056,0.07,0.068,0.021,-0.156,-0.123,-0.061,methylated
NH21-149,205022250076_R04C01,200,25/01/2021,2/12/2021,2/11/2021,17,SB,Diagnostic,200,1,NDP,"Cardiff, University Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A9,4/26/1964,57.5,spinal subependymoma [subtype A],0.94,CN,0.38,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-149,"Histology: Glial tumour, most in keeping with an ependymal tumour  see comment
Methylation profile: Inconclusive, but suggestive of ependymal tumour (subependymoma)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 200\NH21-149,-0.05,-0.044,0.079,0.004,-0.056,-0.04,0.03,-0.007,-0.017,-0.037,-0.04,-0.006,0.059,-0.031,-0.005,0.047,0.013,0.001,-0.033,-0.014,-0.013,0.046,-0.041,0.027,0.017,-0.007,0.023,-0.027,0.042,unmethylated
NH21-160,205022250076_R05C01,200,25/01/2021,2/12/2021,2/11/2021,17,SB,Diagnostic,200,1,NDP,Nottingham University Hospital,astroblastoma ?,"(2) unusual histology, location, demographics",C1,6/2/1964,57.4,high-grade astrocytoma with piloid features,0.95,ANAPA,0.92,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-160,"Histology: High grade glioma  see comment
Methylation profile: Anaplastic pilocytic astrocytoma 
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 200\NH21-160,0.202,-0.04,0.052,-0.002,0.203,0.104,-0.005,-0.03,-0.039,-0.089,-0.022,-0.016,0.044,0.043,-1.568,0.093,0.031,-0.3,0.101,0.027,0.031,-0.04,-0.085,-0.402,-0.548,1.105,-0.018,0.051,0.085,methylated
NH21-159,205022250076_R06C01,200,25/01/2021,2/12/2021,2/11/2021,17,SB,Diagnostic,200,1,NDP,Nottingham University Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,2/1/2005,16.2,dysembryoplastic neuroepithelial tumour,0.96,LGG_DNT,0.99,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-159,"Histology: Low grade glial or glioneuronal tumour, compatible with WHO grade I
Methylation profile: Low grade glioma, dysembryoplastic neuroepithelial tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 200\NH21-159,0,0.006,-0.001,-0.002,-0.032,0.047,0.102,-0.003,0.029,-0.009,0.037,-0.002,0.054,0.018,0.015,0.01,0.019,0.03,0.088,0.004,0.01,-0.018,-0.023,0.018,0.003,-0.001,-0.004,0.038,0.063,unmethylated
NH21-157,205022250076_R08C01,200,25/01/2021,2/12/2021,2/11/2021,17,SB,Diagnostic,200,1,NDP,Bristol,Astr-IDHmut,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,7/23/1978,43,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-157,"Histology: Glioblastoma, IDH-mutant (WHO grade IV)  for grading, see comment
Methylation profile: Astrocytoma, IDH-mutant 
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 200\NH21-157,0.068,-0.015,-0.031,-0.129,-0.029,-0.37,-0.091,0.005,0.267,0.254,0.294,-0.023,0.016,0.158,-0.019,0.257,-0.003,-0.394,0.023,0.25,-0.006,-0.049,-0.094,0.105,0.102,-0.018,-0.094,-0.126,0.077,methylated
NH21-164,205021750036_R01C01,201,26/01/2021,3/5/2021,3/4/2021,37,SB,Diagnostic,201,1,NDP,Edinburgh,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",4A,6/5/1973,48.2,ganglioglioma,0.16,GBM_MES,0.24,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-164,"Histology: High-grade glioma, with features of anaplastic astrocytoma
Copy number profile: In keeping with glioblastoma, IDH-wildtype
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 201\NH21-164,0.235,-0.054,-0.056,0.017,-0.038,-0.097,-0.518,-0.024,0.206,0.204,0.212,-0.037,-0.018,0.01,-0.263,-0.165,-0.403,-0.44,-0.183,0.253,0.152,0.221,-0.05,0.052,0.245,0.031,0.166,-0.408,-0.175,unmethylated
NH21-166,205021750036_R02C01,201,26/01/2021,3/5/2021,3/4/2021,37,SB,Diagnostic,201,1,NDP,Lund (SE),HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",7,11/21/1966,55,posterior fossa ependymoma group A1,0.1,GBM_MES,0.06,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-166,"Histology: Anaplastic astrocytoma
Copy number profile: Consistent with glioblastoma, IDH-wildtype
Methylation profile:
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 201\NH21-166,0.175,-0.105,0.211,0.118,0.113,0.091,-0.319,0.326,0.216,0.181,0.274,-0.036,0.072,0.169,-0.368,0.074,-0.176,-0.331,-0.206,-0.02,0.012,0.095,-0.176,-0.069,0.019,0.165,-0.28,-0.067,0.197,unmethylated
NH21-180,205021750036_R06C01,201,26/01/2021,3/5/2021,3/4/2021,37,SB,Diagnostic,201,1,NDP,Plymouth,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,5/17/1954,67.7,spinal subependymoma [subtype A],0.2,LGG_MYB,0.16,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-180,"Histology: Diffuse glioma
Methylation profile: Inconclusive result, no matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 201\NH21-180,-0.12,-0.043,0.05,0.318,0.097,0.231,-0.397,0.342,0.069,0.061,0.338,-0.072,0.08,0.163,-0.307,0.157,-0.142,0.159,0.061,0.242,0.211,-0.244,-0.148,0.132,-0.211,-0.076,0.233,-0.178,0.295,unmethylated
NH21-139,205021750036_R07C01,201,28/01/2021,3/5/2021,3/4/2021,35,SB,Diagnostic,201,1,NDP,Brighton and Sussex Hospital,Diffuse IDHwt glioma 7Y history,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,12/23/1952,69.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.57,GBM_MES,0.71,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-139,"Astrocytoma  see comment. 
IDH1 (R132H IHC): Technically unsatisfactory 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Diffuse glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 201\NH21-139,0.197,0.118,0.005,-0.014,-0.026,-0.005,-0.303,1.882,0.118,0.147,0.135,-0.032,0.06,-0.028,-0.936,-0.183,-0.184,-0.213,-0.245,0.045,-0.071,-0.021,-0.289,0.057,0.008,-0.034,0.239,0.108,0.23,unmethylated
NH06-876,205021750100_R04C01,202,25/01/2021,2/19/2021,2/25/2021,31,SB,Diagnostic,202,4,NDP,NHNN,"Spinal glioma, Unusual pattern","(2) unusual histology, location, demographics",B,#N/A,#N/A,"glioblastoma, IDH-wildtype, RTK1 type",0.99,GBM_RTKI,0.98,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH06-876,"Ependymoma  see comment
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 202\NH06-876,-0.024,0.114,0.114,0.031,0.029,0.023,0.032,1.549,0.296,0.378,0.257,0.009,0.054,0.744,-1.948,-0.017,-0.214,-0.418,-0.069,-0.037,-0.043,0.175,-0.096,0.259,0.402,0.264,0.073,-0.101,0.01,unmethylated
NH21-220,205021750109_R01C01,203,3/2/2021,3/5/2021,3/5/2021,30,AM,Diagnostic,203,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,9/11/2019,1.4,supratentorial midline pilocytic astrocytoma,1,LGG_PAMID,1,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-220,"Histology: Pilocytic astrocytoma
BRAF (IHC and sequencing): V600E mutation 
Methylation profile: Low grade glioma, subclass midline pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 203\NH21-220,0.038,-0.012,0.028,0.015,0.121,-0.056,-0.142,-0.076,0.026,-0.005,0.007,-0.003,-0.017,0.052,0.097,-0.018,-0.048,0.01,0.115,0.06,0.121,0.058,0.019,0.021,0.053,-0.032,-0.013,-0.063,0.067,unmethylated
NH21-178,205021750109_R03C01,203,4/2/2021,3/5/2021,3/5/2021,29,AM,Diagnostic,203,4,NDP,NHNN,IDH-mutant astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,6/7/1972,49.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-178,"Recurrent / residual diffuse astrocytoma, IDH-mutant (WHO grade II)  see comment. 
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation) 
Further molecular tests: Pending 
","Integrated diagnosis: Anaplastic astrocytoma, IDH-mutant (WHO grade III)
Histology: Astrocytoma, IDH-mutant (grading see comment) 
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 203\NH21-178,-0.037,-0.026,0.026,-0.02,0.02,-0.111,-0.237,0.002,-0.034,-0.012,-0.017,0.087,0.135,0.031,-0.352,-0.035,-0.017,0.083,0.05,0.087,-0.018,-0.102,-0.206,-0.055,-0.06,-0.063,-0.008,-0.013,0.021,methylated
NH21-251,205021750109_R04C01,203,4/2/2021,3/5/2021,3/5/2021,29,AM,Diagnostic,203,1,NDP,Auckland (NZ),Meningioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,9/22/1968,53.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.16,CONTR_INFLAM,0.18,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-251,"Histology: Soft tissue neoplasm
Methylation profile: Inflammatory myofibroblastic tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 203\NH21-251,-0.035,-0.003,0.031,0.044,0.069,0.004,-0.01,-0.003,-0.011,-0.041,-0.046,0.001,0.063,-0.014,-0.098,-0.132,-0.155,-0.114,-0.001,-0.002,0.01,-0.048,-0.029,-0.032,-0.06,-0.022,-0.037,-0.019,0.044,unmethylated
NH21-257,205021750109_R07C01,203,4/2/2021,3/5/2021,3/5/2021,29,AM,Diagnostic,203,12,NDP,"Riga, Latvia",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",334/21,6/2/2012,8.8,posterior fossa ependymoma group A1,0.51,EPN_PFA,0.84,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-257,"Histology: Ependymal tumour, for grading  see comment
Methylation profile: Ependymoma, posterior fossa, group A  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 203\NH21-257,0.321,0.222,0.266,-0.044,-0.022,0.103,-0.73,0.322,0.306,0.301,0.273,0.177,0.217,0.157,0.215,0.157,-0.113,0.03,-0.009,-0.049,-0.027,-0.215,0.121,-0.088,-0.198,-0.256,0.109,-0.066,-0.044,unmethylated
NH21-209,205021750109_R08C01,203,5/2/2021,3/5/2021,3/5/2021,28,AM,Diagnostic,203,1,NDP,Romford,High grade thalamic glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,11/19/1969,51.9,"glioblastoma, IDH-wildtype, RTK2 type",0.25,GBM_RTKII,0.8,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-209,"Malignant glioma (at least WHO grade III)  see comment. 
IDH1 (R132H IHC): Technically unsatisfactory 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 203\NH21-209,0.034,0.134,0.044,0,-0.052,-0.088,-0.471,0.161,0.209,0.131,0.253,-0.015,0.01,-0.123,-2.265,-0.042,-0.526,-0.513,-0.107,-0.15,-0.125,-0.112,-0.112,0,-0.018,-0.02,0.084,-0.055,0.023,unmethylated
NH21-271,205021750144_R01C01,204,5/2/2021,3/5/2021,3/4/2021,27,AM,Diagnostic,204,1,NDP,Bristol,Anaplastic ganglioglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B3,1/28/1986,35.5,pleomorphic xanthoastrocytoma(-like),0.98,PXA,0.98,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-271,"Histology: High-grade glioma, compatible with pleomorphic xanthoastrocytoma (corresponding to WHO grade III)
Methylation profile: (Anaplastic) pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 204\NH21-271,0.069,-0.115,-0.004,0.032,0.136,0.024,-0.025,0.097,0.048,0.086,0.064,-0.012,-0.006,-0.047,-0.41,0.076,-0.125,-0.041,-0.014,0.09,0.137,0.039,-0.023,-0.104,0.019,-0.072,-0.026,-0.079,-0.06,methylated
NH21-130,205021750144_R02C01,204,5/2/2021,3/5/2021,3/4/2021,27,AM,Diagnostic,204,1,NDP,NHNN,Diffuse glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,5/29/1953,68.6,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.5,GBM_MID,0.97,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-130,"Diffuse glioma  see comment. 
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Diffuse glioma, IDH-wildtype - see comment for grading
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
MGMT Promoter: Unmethylated (0%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 204\NH21-130,0.165,-0.028,-0.013,0.06,0.017,0.029,0.013,-0.12,-0.08,-0.072,-0.052,-0.051,-0.017,-0.064,-0.226,-0.092,-0.023,0.126,-0.028,0.03,-0.215,-0.178,-0.044,-0.052,0.035,-0.045,-0.21,0.076,0.045,unmethylated
NH21-280,205021750144_R04C01,204,5/2/2021,3/5/2021,3/4/2021,27,AM,Diagnostic,204,1,NDP,Newcastle,Low grade glioma/GNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,7/16/1985,36,infratentorial pilocytic astrocytoma,0.31,LGG_PAPF,0.32,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-280,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Pilocytic astrocytoma (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 204\NH21-280,-0.037,-0.014,-0.016,0.023,-0.02,0.01,0.139,0.017,0.028,0.019,0.039,0.032,0.018,-0.017,0.016,-0.028,0.05,0.006,0.077,0.078,0.042,0.05,-0.015,-0.018,-0.007,-0.051,-0.05,0.049,0.015,unmethylated
NH21-76,205021750144_R05C01,204,5/2/2021,3/5/2021,3/4/2021,27,AM,Diagnostic,204,5,NDP,"Birmingham, Queen Elizabeth Hospital",Glioblastoma ? PMMRDIA,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,5/17/1999,22,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.7,AIDH_HG,0.69,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-76,"Glioblastoma, IDH-mutant (WHO grade IV)
IDH1/2Seq: Mutation
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion
  
","Histology: Glioblastoma, IDH mutant (WHO grade IV)
Methylation profile: IDH glioma, subclass high-grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 204\NH21-76,0.225,-0.316,-0.165,-0.083,0.027,-0.06,-0.208,-0.05,-0.049,0.026,-0.031,0,-0.026,-0.081,-0.578,0.036,-0.068,-0.016,-0.008,0.064,0.086,0.045,-0.22,0.026,0.082,-0.094,-0.612,0.066,-0.019,methylated
NH21-277,205021750144_R07C01,204,9/2/2021,3/5/2021,3/4/2021,23,ZJ,Diagnostic,204,1,NDP,St George's Hospital London,Subependymoma,(1) small biopsy or nonrepresentative sample;,A1,5/7/1979,42.4,spinal subependymoma [subtype A],0.98,SUBEPN_SPINE,0.63,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-277,"Histology: Subependymoma (WHO grade I)
Methylation profile: Subependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 204\NH21-277,-0.014,-0.08,0.02,0.083,-0.025,0.006,-0.042,-0.055,-0.044,0.009,-0.009,0.012,-0.033,0.014,0.017,-0.01,-0.005,-0.027,0.079,0.036,-0.052,-0.022,0.006,-0.055,-0.004,-0.043,0.006,0.018,0.018,unmethylated
NH21-279,205021750144_R08C01,204,9/2/2021,3/5/2021,3/4/2021,23,ZJ,Diagnostic,204,1,NDP,Lund (SE),GBM or aPXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",101,3/28/1957,64.8,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.92,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-279,"Histology: Glioblastoma
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 204\NH21-279,-0.041,-0.03,0.022,-0.048,-0.03,-0.033,0.046,0.083,0.067,0.082,0.078,0.009,-0.006,-0.047,-0.022,0.028,-0.193,-0.128,-0.016,-0.012,0.832,1.506,-0.043,0.03,0.104,0.096,-0.065,-0.01,0.019,unmethylated
NH21-288,205021740170_R04C01,205,10/2/2021,3/11/2021,3/10/2021,28,ZJ,Diagnostic,205,1,NDP,Bristol,Likely glioblastoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/15/1966,55.5,"glioblastoma, IDH-wildtype, RTK1 type",0.93,GBM_RTKI,0.39,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-288,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK I
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 205\NH21-288,0,0.02,-0.015,0.043,0.008,0.056,-0.012,0.09,0.141,0.169,0.121,0.108,0.124,0.2,-0.429,-0.003,-0.135,-0.162,-0.03,-0.009,-0.025,0.023,-0.062,0.026,0.002,0.058,0.002,-0.052,0.001,unmethylated
NH21-316,205021740170_R05C01,205,14/02/2021,3/11/2021,3/10/2021,24,ZJ,Diagnostic,205,8,NDP,"Cambridge, Addenbrooke's Hospital",?Oligodendroglioma,"(4) IHC, sequencing, or copy number assay ambiguous",A2,12/9/1965,55.2,"glioblastoma, IDH-wildtype, RTK2 type",0.22,GBM_MES,0.67,0.63,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-316,"Histology: High-grade glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
TERT promoter: Mutation
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 205\NH21-316,0.001,-0.032,0.025,0.189,-0.018,0.113,-0.01,0.189,0.147,0.178,0.146,0.009,0.064,0.01,0.037,0.064,-0.292,-0.331,0.038,0.085,0.067,-0.006,-0.038,0.024,0.043,0.003,0.153,-0.242,-0.262,unmethylated
NH21-314,205021740170_R07C01,205,15/02/2021,3/11/2021,3/10/2021,23,SB,Diagnostic,205,1,NDP,NHNN,"Midline HGG, K27M negative","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,6/20/1961,60.5,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-314,"High grade glioma (at least WHO grade III)  see comment
IDH1 (R132H IHC): No mutation
H3 (K27M IHC): No mutation
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK I
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 205\NH21-314,-0.06,-0.034,0.024,-0.028,0.023,0.012,0.604,0.142,0.194,0.231,0.154,-0.019,0.006,0.034,0.031,0.025,-0.348,-0.323,-0.342,0.012,-0.007,0.014,-0.445,-0.009,-0.007,-0.015,-0.014,0.01,0.036,methylated
NH20-3030,205021740057_R02C01,206,17/02/2021,3/19/2021,3/17/2021,28,ZJ,Diagnostic,206,1,NDP,Oxford John Radcliffe Hospital,HGG,"(4) IHC, sequencing, or copy number assay ambiguous",1D,4/27/1967,54.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.23,GBM_RTKII,0.62,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-3030,"Glioblastoma, IDH-wildtype (WHO grade IV), see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
MGMT Promoter: Unmethylated (0%)
  
","Histology: Glioblastoma, IDH-wildtype (see previous report)
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK I
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 206\NH20-3030,-0.035,0.009,0.022,-0.108,-0.041,0.011,0.034,0.383,0.268,0.227,0.14,-0.39,0.075,0.078,0.155,0.157,-0.307,-0.335,0.048,-0.024,0.683,-0.031,-0.034,-0.05,0.008,0.05,-0.121,0.019,0.091,unmethylated
NH21-329,205021740057_R03C01,206,17/02/2021,3/19/2021,3/17/2021,28,ZJ,Diagnostic,206,6,NDP,"Birmingham, Queen Elizabeth Hospital",?Oligosarcoma,"(2) unusual histology, location, demographics",A3,6/4/1955,66.6,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-329,"Histology: Anaplastic oligodendroglioma (WHO grade III)
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 206\NH21-329,0.043,0.005,-0.008,-0.063,0.006,-0.006,-0.044,0.016,0.014,0.019,-0.002,-0.008,0.025,0.018,-0.006,0,-0.017,-0.027,0.066,0.042,-0.032,-0.045,-0.05,0.062,0.01,0.161,-0.449,-0.013,0.027,methylated
NH21-359,205021740057_R04C01,206,17/02/2021,3/19/2021,3/17/2021,28,ZJ,Diagnostic,206,1,NDP,Nottingham University Hospital,"GBM, family hx of GBMs","(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,8/27/1988,32.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-359,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: IDH glioma, subclass high-grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 206\NH21-359,0.007,0.008,0.031,-0.058,-0.052,-0.058,0.004,0.049,-0.007,0.011,0.015,-0.281,-0.187,0.027,-0.09,-0.028,-0.28,-0.341,-0.058,0.055,-0.001,-0.37,-0.102,0.002,0.049,0.041,-0.132,-0.061,0.057,methylated
NH21-358,205021740057_R05C01,206,17/02/2021,3/19/2021,3/17/2021,28,ZJ,Diagnostic,206,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,(1) small biopsy or nonrepresentative sample;,B1,3/11/2017,4,supratentorial midline pilocytic astrocytoma,0.98,LGG_PAMID,0.99,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-358,"Histology: Low grade glioma with features suggestive of pilocytic astrocytoma
Methylation profile: Low grade glioma, subclass the midline pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 206\NH21-358,-0.012,-0.048,0.016,-0.001,-0.024,0.029,-0.034,-0.032,0.007,-0.023,-0.023,-0.015,0.016,-0.043,0.051,-0.007,0.014,0.021,0.002,-0.032,-0.036,0.009,-0.004,-0.013,-0.018,-0.024,-0.039,-0.007,0.034,unmethylated
NH21-370,205021740057_R07C01,206,17/02/2021,3/19/2021,3/17/2021,28,ZJ,Diagnostic,206,1,NDP,Oxford John Radcliffe Hospital,?Clear cell ependymoma,"(2) unusual histology, location, demographics",2C,5/17/1995,19.9,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-370,"Histology: Anaplastic ependymoma
Methylation profile: Ependymoma,RELA fusion
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 206\NH21-370,0.007,-0.03,0.083,0.115,-0.091,0.104,-0.061,0.001,0.05,0.094,-0.002,0.093,0.117,0.074,-0.055,-0.011,-0.027,0.005,0.214,-0.043,0.07,0.028,0.023,-0.016,-0.058,-0.026,0.184,-0.082,-0.059,unmethylated
NH21-383,205021740057_R08C01,206,19/02/2021,3/19/2021,3/17/2021,26,SB,Diagnostic,206,1,NDP,Romford,High grade glioma,"(2) unusual histology, location, demographics",DEF1A,1/11/1970,51.8,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.97,GBM_MID,0.99,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-383,"Glioblastoma (WHO grade IV)  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH wildtype
MGMT promoter (Illumina array): Methylated
 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
MGMT Promoter: Methylated (>0-5%)
  

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 206\NH21-383,-0.084,-0.005,0.022,0.003,-0.036,0.1,-0.014,0.039,0.329,0.176,-0.314,-0.002,0.079,-0.013,-0.101,0.017,-0.015,0.049,-0.015,0.005,-0.037,-0.006,-0.006,-0.039,0.019,0.224,-0.103,-0.024,0.002,methylated
NH21-386,205021750076_R01C01,207,19/02/2021,3/19/2021,3/17/2021,26,SB,Diagnostic,207,1,NDP,Lund (SE),High grade glioma,"(2) unusual histology, location, demographics",2-Jan,12/7/1957,64.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.33,GBM_MES,0.25,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-386,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 207\NH21-386,0.055,-0.215,-0.005,-0.092,0.251,-0.029,0.07,-0.2,0.015,0.08,-0.009,0.072,-0.016,0.028,-0.049,0.292,-0.116,-0.162,0.003,0.029,-0.018,0.031,-0.065,0.027,0.044,0.028,-0.205,0.01,0.021,methylated
NH21-393,205021750076_R02C01,207,19/02/2021,3/19/2021,3/17/2021,26,SB,Diagnostic,207,1,NDP,Newcastle,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,8/23/1952,69.4,ganglioglioma,0.37,GBM_MES,0.18,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-393,"Histology: Diffuse glioma
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
","Diffuse glioma, IDH-wildtype  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 207\NH21-393,-0.016,-0.054,0.005,0.024,-0.097,-0.065,-0.129,0.259,0.165,0.125,0.079,0.008,0.029,-0.035,0.031,-0.007,-0.126,-0.144,-0.061,0.003,-0.01,0.039,-0.004,-0.008,-0.134,-0.022,-0.069,0.003,-0.018,unmethylated
NH21-424,205021750076_R05C01,207,24/02/2021,3/19/2021,3/17/2021,21,ZJ,Diagnostic,207,1,NDP,"Cambridge, Addenbrooke's Hospital",3rd ventricle HGG or Hglioneuronal,"(2) unusual histology, location, demographics",A1,4/28/1945,76.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,0.98,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-424,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: IDH glioma, subclass high-grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
","Histology: High-grade glioma
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)
Methylation profile: IDH mutant glioma with low calibrated score - see comment regarding discrepancy

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 207\NH21-424,0.129,0.03,0.055,-0.169,-0.091,0.047,-0.076,0.094,0.159,0.15,0.049,0.021,0.031,0.01,-0.212,-0.086,-0.115,-0.438,-0.125,0.038,-0.033,-0.033,-0.388,-0.138,-0.124,0.151,-0.033,0,0.084,methylated
NH21-423,205021750076_R06C01,207,24/02/2021,3/19/2021,3/17/2021,21,ZJ,Diagnostic,207,1,NDP,"Cambridge, Addenbrooke's Hospital",?gemistocytic astrocytoma,"(4) IHC, sequencing, or copy number assay ambiguous",A1,10/3/1961,60.2,"glioblastoma, IDH-wildtype, RTK1 type",0.55,GBM_MES,0.37,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-423,"Histology: High-grade astrocytoma
Methylation profile: Glioblastoma, IDH-wildtype (subclass mesenchymal)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 207\NH21-423,-0.014,-0.053,0.008,-0.005,-0.061,-0.002,-0.003,0.131,0.141,0.158,0.095,-0.008,-0.023,-0.022,-0.007,0.005,-0.448,-0.142,-0.067,-0.045,0.533,0.017,-0.025,-0.038,0,-0.006,-0.091,0.001,0.049,unmethylated
NH21-335,205021750076_R07C01,207,24/02/2021,3/19/2021,3/17/2021,21,ZJ,Diagnostic,207,3,NDP,"Cardiff, University Hospital","LGG or glioneuronal tumour, 2015 resection","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/31/1981,40.1,ganglioglioma,0.76,LGG_GG,0.44,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-335,"Low grade glioneuronal tumour (WHO grade I)
","Histology: Low grade glioneuronal tumour
Methylation profile: Low grade glioma, ganglioglioma
Referred report: BRAF V600E mutation

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 207\NH21-335,-0.142,-0.221,0.067,0.07,-0.052,0.032,-0.095,-0.008,-0.101,0.024,-0.025,0,0.275,-0.222,-0.074,-0.118,0.112,-0.067,-0.008,-0.042,-0.014,0.08,-0.096,0.025,-0.093,-0.02,0.003,-0.156,-0.147,unmethylated
NH21-335,205021750076_R08C01,207,24/02/2021,3/19/2021,3/17/2021,21,ZJ,Diagnostic,207,3,NDP,"Cardiff, University Hospital","LGG or glioneuronal tumour, 2021 resection","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,7/31/1981,40.1,ganglioglioma,0.82,LGG_GG,0.66,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-335,"Low grade glioneuronal tumour (WHO grade I)
","Histology: Low grade glioneuronal tumour
Methylation profile: Low grade glioma, ganglioglioma
Referred report: BRAF V600E mutation

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 207\NH21-335,-0.012,-0.028,0.012,0.006,-0.061,0.024,-0.044,0.002,-0.052,0,-0.024,-0.007,0.078,-0.033,-0.02,-0.04,-0.005,0.002,-0.041,-0.045,-0.041,-0.024,0.016,-0.053,-0.044,0,-0.042,0,-0.004,unmethylated
NH21-420,205021750150_R01C01,208,24/02/2021,3/19/2021,3/19/2021,23,ZJ,Diagnostic,208,1,NDP,"Belfast, Royal Victoria Hospital",Pineocytoma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,2/24/1972,49.7,"supratentorial ependymoma, ZFTA:RELA fusion-positive",0.06,PLEX_PEDB,0.08,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-420,"Histology: Pineocytoma
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 208\NH21-420,0.003,-0.02,-0.006,0.042,0.001,-0.034,0.048,-0.021,-0.032,-0.055,-0.028,0.002,-0.026,-0.01,-0.034,-0.014,0.007,0.012,0.039,0.012,-0.022,-0.074,-0.013,-0.055,0.006,-0.081,-0.023,-0.457,0.007,unmethylated
NH21-306,205021750150_R03C01,208,24/02/2021,3/19/2021,3/19/2021,23,ZJ,Diagnostic,208,1,NDP,"Belfast, Royal Victoria Hospital",Pilocytic astrocytoma,"(2) unusual histology, location, demographics",A1,12/28/1984,36.6,infratentorial pilocytic astrocytoma,0.36,LGG_PAPF,0.66,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-306,"Histology: Low grade glioma, with features of pilocytic astrocytoma
Methylation profile: No matching methylation glass
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 208\NH21-306,0.039,0.093,0.025,0.024,0.064,-0.05,-0.093,0.004,0.037,-0.021,0.128,-0.007,-0.055,0.075,0.003,-0.124,-0.002,0.001,0.038,0.042,0.042,0.009,-0.07,-0.01,-0.03,-0.1,0.019,-0.02,0.015,unmethylated
NH21-430,205021750150_R06C01,208,27/02/2021,3/19/2021,3/19/2021,20,ZJ,Diagnostic,208,4,NDP,Nottingham University Hospital,GBM reccurence after 11years,"(2) unusual histology, location, demographics",B6,1/30/1981,40.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.99,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-430,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: IDH glioma, subclass high-grade astrocytoma
CDKN2A/B: Deletion
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 208\NH21-430,-0.078,-0.18,-0.046,-0.01,0.926,-0.25,-0.265,-0.28,1.053,-0.182,-0.086,0.073,0.107,0.222,-0.785,-0.07,-0.302,-0.714,0.226,0.064,0.002,-0.891,0.04,-0.011,0.139,0.054,-0.418,-0.043,-0.082,methylated
NH21-475,205021750150_R07C01,208,1/3/2021,3/19/2021,3/19/2021,18,SB,Diagnostic,208,1,NDP,St George's Hospital London,Isomorphic glioma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",K5,3/24/1967,37.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-475,"Histology: Diffuse astrocytoma (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
","Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma
CDKN2A/B: No deletion
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 208\NH21-475,-0.267,-0.107,-0.016,0.004,-0.012,0.027,0.072,-0.072,0.107,0.195,0.098,-0.043,-0.07,-0.15,0.015,0.014,-0.035,0.032,-0.048,0.255,-0.084,-0.006,-0.11,-0.13,-0.1,-0.164,-0.053,-0.071,-0.058,methylated
NH21-379,205021740110_R01C01,209,2/3/2021,3/26/2021,3/26/2021,24,ZJ,Diagnostic,209,1,NDP,St George's Hospital London,"GBM, IDH-wt with ATRX loss","(4) IHC, sequencing, or copy number assay ambiguous",A1,8/21/1981,40,"glioblastoma, IDH-wildtype, mesenchymal type",0.87,GBM_MES,0.63,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-379,"Molecular profile suggestive of glioblastoma, IDH-wildtype (WHO grade IV)  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
EGFR: No amplification          
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: Methylated (>5-10%)
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 209\NH21-379,0.012,-0.038,0.017,-0.029,-0.085,-0.191,0.032,0.136,0.162,0.137,0.108,-0.265,-0.186,-0.205,-0.174,0.049,-0.204,-0.284,-0.008,-0.031,0.015,0.03,-0.243,-0.047,0.051,-0.032,-0.411,-0.188,-0.189,methylated
NH21-404,205021740110_R02C01,209,3/3/2021,3/26/2021,3/26/2021,23,SB,Diagnostic,209,4,NDP,NHNN,Astrocytoma IDH-mutant for prognostication,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,5/31/1977,44.4,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.89,AIDH,0.28,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-404,"Diffuse astrocytoma, IDH-mutant (WHO grade II)  see comment. 
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Diffuse astrocytoma, IDH-mutant (WHO grade II)
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion
MGMT Promoter: Unmethylated (0%)
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 209\NH21-404,-0.038,-0.025,0.026,-0.02,0.048,-0.016,0.05,-0.002,0.004,0.043,0.002,0.009,-0.031,-0.006,-0.06,0,-0.109,-0.072,-0.01,-0.023,0.013,-0.12,-0.089,-0.045,-0.109,-0.042,-0.103,0.003,-0.005,unmethylated
NH21-471,205021740110_R03C01,209,8/3/2021,3/26/2021,3/26/2021,18,SB,Diagnostic,209,2,NDP,NHNN,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP3A,5/31/2000,21,"control tissue, hemispheric cortex",0.85,CONTR_HEMI,0.48,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-471,"Anaplastic ependymoma (WHO grade III)  see comment. 
","Histology: Anaplastic ependymoma (WHO grade III)
Methylation profile: Ependymoma, RELA fusion
MGMT promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 209\NH21-471,0.034,0.001,-0.025,-0.022,-0.029,-0.064,0.001,-0.026,-0.014,-0.083,0.011,0.001,0.019,0.005,0.006,-0.024,-0.048,-0.004,0.028,0.006,0.011,-0.028,-0.024,0.008,0.064,-0.012,0.015,0.013,0.041,unmethylated
NH21-481,205021740110_R05C01,209,8/3/2021,3/26/2021,3/26/2021,18,SB,Diagnostic,209,4,NDP,Southampton General Hospital,Anaplastic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,11/14/1963,40.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-481,"Histology: Glioblastoma, IDH_mutant (WHO grade IV) (see comment)
Methylation profile: Glioma IDH-mutantCDKN2 A/B: homozygous deletion
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 209\NH21-481,0.12,-0.428,-0.001,-0.334,0.068,0.042,-0.684,0.064,0.071,0.061,0.097,-0.523,0.01,0.07,-1.799,0.052,0.008,-0.516,0.005,0.14,0.081,0.201,-0.099,0.029,0.014,0.01,-0.367,-0.103,-0.018,methylated
NH21-414,205021740110_R06C01,209,8/3/2021,3/26/2021,3/26/2021,18,SB,Diagnostic,209,4,NDP,NHNN,Astrocytoma IDH-mutant for prognostication,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,2/17/2000,21.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-414,"Diffuse astrocytoma, IDH-mutant (WHO grade II)
IDH1 (R132H IHC): Mutation  
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Histology: Astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 209\NH21-414,-0.05,-0.02,0.044,-0.007,0.051,0.007,-0.032,0.163,0.181,0.228,0.156,0.145,0.16,0.119,0.13,0.171,0.004,0.022,-0.014,0.258,-0.153,-0.368,-0.069,0.132,0.014,-0.056,-0.012,0.007,0.014,unmethylated
NH21-511,204940880063_R01C01,210,8/3/2021,3/26/2021,3/26/2021,18,SB,Diagnostic,210,1,NDP,"Cambridge, Addenbrooke's Hospital",IDH-mutant ATRX retained glioma,"(4) IHC, sequencing, or copy number assay ambiguous",A1,12/1/1963,58,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-511,"Histology: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted (WHO grade II)
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 210\NH21-511,0.043,0.045,0.016,-0.085,-0.008,-0.003,-0.002,-0.004,0.01,0.027,0.022,-0.044,-0.02,-0.055,-0.037,-0.024,0.021,0.016,0.076,0.011,0.011,-0.082,-0.085,0.052,0.05,-0.053,-0.367,0.008,0.046,methylated
NH21-532,204940880063_R02C01,210,8/3/2021,3/26/2021,3/26/2021,18,SB,Diagnostic,210,1,NDP,"Birmingham, Queen Elizabeth Hospital",high grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,7/3/1961,60.2,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.29,GBM_RTKII,0.62,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-532,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: No matter methylation class (see comment)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 210\NH21-532,0.1,0.07,-0.003,0.015,0.008,0.018,-0.021,0.003,0.105,0.028,0.011,-0.013,-0.02,0.1,-0.957,0.067,-0.263,-0.317,-0.03,0.093,0.055,0.043,-0.285,0.125,0.059,-0.012,-0.47,-0.054,0.04,methylated
NH21-470,204940880063_R03C01,210,8/3/2021,3/26/2021,3/26/2021,18,SB,Diagnostic,210,1,NDP,Romford,"HGG, BRAF mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B2,6/21/1970,51.4,pleomorphic xanthoastrocytoma(-like),0.33,PXA,0.35,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-470,"High grade glioma (at least WHO grade III)  see comment
ATRX (IHC): Retained 
BRAF (V600E IHC): Mutation
Further molecular tests: Pending
  
","Histology: High-grade glioma, BRAF V600E-mutant (see comments)
Methylation profile: No matching methylation class (see comments)
MGMT promoter (Illumina array): Unmethylated 
DNA NGS data: BRAF V600E mutation
RNA seq. data: No NTRK fusions 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 210\NH21-470,0.133,0.231,0.196,0.023,0.028,0.183,-0.381,0.382,0.429,0.496,0.366,-0.006,0.07,0.014,0.031,0.018,0.018,0.048,0.031,-0.027,-0.025,0.019,-0.397,-0.036,-0.035,-0.072,0.171,-0.005,0.024,unmethylated
NH21-524,204940880063_R07C01,210,8/3/2021,3/26/2021,3/26/2021,18,AM,Diagnostic,210,1,NDP,Romford,HGNET ?GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,9/22/1950,71.5,"glioblastoma, IDH-wildtype, RTK1 type",0.96,GBM_RTKI,0.81,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-524,"High-grade neuroepithelial tumour  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained)
Further molecular tests: Pending
  
","Histology: High-grade glioma (see previous report)
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK I
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 210\NH21-524,0.641,0.025,-0.012,0.018,0.059,0.007,-0.048,0.228,0.366,0.365,0.279,-0.282,-0.047,0.054,-0.955,-0.008,-0.236,-0.237,-0.062,-0.218,0.03,0.012,-0.076,0.034,0.026,-0.004,0.005,0.016,0,unmethylated
NH21-555,204940880021_R03C01,211,10/3/2021,4/1/2021,3/31/2021,21,SB,Diagnostic,211,1,NDP,Edinburgh,Astroblastoma?,"(5) Confirmation of rare, unusual or interesting histo-molecular results",1B,9/19/1985,18.5,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-555,"Histology: low-grade glioma with features of pilocytic astrocytoma (WHO grade I) (see comment),
Methylation profile: Pilocytic astrocytoma, subclass hemispheric pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 211\NH21-555,0.065,-0.063,-0.003,-0.014,0.005,0.041,0.008,0.079,0.029,0.017,0.052,-0.033,-0.056,0.036,-0.006,0.039,0.027,0.01,-0.043,-0.074,-0.005,0.025,-0.073,0.045,-0.071,-0.051,-0.039,-0.04,0.005,unmethylated
NH21-573,204940880021_R05C01,211,12/3/2021,4/1/2021,3/31/2021,19,AM,Diagnostic,211,1,NDP,Royal London Hospital,HGG ? GBM ?Anaplastic PXA,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2A,6/20/1980,41.3,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type C]",0.82,DMG_K27,0.14,0.99,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-573,"High grade glioma - see comment
IDH1 (R132H IHC): No mutation      
ATRX (IHC): Retained      
BRAF V600E (IHC): No mutation
Further molecular tests: Pending
  
","Histology: high-grade glioma, IDH-wild-type (see comment)
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 211\NH21-573,0.115,0.009,0.027,-0.126,0.141,-0.002,-0.013,0.015,0.002,0.017,-0.012,-0.002,0.005,-0.022,-0.013,-0.005,-0.004,-0.169,-0.045,-0.045,0.578,0.945,-0.061,-0.191,-0.003,0,-0.277,-0.014,-0.015,methylated
NH21-538,204940880021_R06C01,211,12/3/2021,4/1/2021,3/31/2021,19,AM,Diagnostic,211,5,NDP,Romford,HGG ? giant cell GBM,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,11/1/1964,57.2,high-grade astrocytoma with piloid features,0.58,ANAPA,0.93,0.63,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-538,"Glioblastoma (WHO grade IV) - see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
BRAF V600E (IHC): Negative
Further molecular tests: Pending
  
","Histology: High grade glioma
Methylation profile: Anaplastic pilocytic astrocytoma
CDKN2A/B: deletion 
BRAF:KIAA: Fusion suggestive on copy number profile 
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 211\NH21-538,0.059,-0.006,0.007,0,-0.001,0.047,0.042,-0.031,-0.375,0.277,0.204,-0.017,-0.019,-0.016,0.022,-0.007,-0.12,-0.089,-0.012,0.159,0.579,1.132,-0.056,-0.012,-0.017,0.316,-0.298,0.006,0.011,unmethylated
NH21-587,204940880021_R07C01,211,15/03/2021,4/1/2021,3/31/2021,16,SB,Diagnostic,211,1,NDP,Lund (SE),"LGG, small bx",(1) small biopsy or nonrepresentative sample;,01,8/12/1962,59.4,supratentorial pilocytic astrocytoma,0.85,LGG_PAPF,0.34,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-587,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Low calibrated score, suggestive of pilocytic astrocytoma, subclass posterior fossa pilocytic astrocytoma.
BRAF:KIAA: No duplication suggested on copy number plot
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 211\NH21-587,0.051,0.001,-0.005,0.003,0.014,-0.049,-0.001,-0.013,0.027,0.024,-0.005,-0.011,-0.066,0.077,0.006,0.024,-0.024,0.02,0.005,-0.035,0.014,-0.002,-0.032,-0.039,-0.036,0.029,-0.005,-0.013,0.027,unmethylated
NH21-607,204940880096_R01C01,212,15/03/2021,4/9/2021,4/8/2021,24,SB,Diagnostic,212,17,NDP,St George's Hospital London,HGG vs Abscess,"(4) IHC, sequencing, or copy number assay ambiguous",A1,6/3/1963,58.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.98,CONTR_REACT,0.18,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-607,"Histology: Glioblastoma (WHO grade IV) with organisational changes
Methylation profile: No matching methylation class  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 212\NH21-607,0.282,-0.117,-0.055,0.004,-0.045,-0.006,0.065,0.015,0.239,0.185,0.249,-0.042,-0.004,0.27,0.093,0.175,-0.079,-0.198,0.168,0.141,1.427,2.348,-0.062,0.159,0.078,-0.06,0.04,-0.03,0.169,unmethylated
NH21-608,204940880096_R02C01,212,15/03/2021,4/9/2021,4/8/2021,24,SB,Diagnostic,212,11,NDP,Newcastle,CPA tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,9/17/1958,63.4,posterior fossa subependymoma,1,SUBEPN_PF,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-608,"Histology: Ependymoma (WHO grade II) 
Methylation profile: Subependymoma, posterior fossa  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 212\NH21-608,0.062,-0.022,0.047,0.052,-0.013,-0.04,-0.414,0.024,0.005,0.087,-0.002,-0.146,-0.087,-0.093,0.065,-0.018,0.019,-0.01,0.01,0.058,0.027,0.083,0.014,0.02,0.069,-0.016,0.122,0.058,0.114,unmethylated
NH21-610,204940880096_R03C01,212,15/03/2021,4/9/2021,4/8/2021,24,SB,Diagnostic,212,10,NDP,"Cambridge, Addenbrooke's Hospital",Idh-mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,9/29/1996,24.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-610,"Histology: Astrocytoma, IDH-mutant  for grading see comment
Methylation profile: Glioma, IDH-mutant, subclass astrocytoma
IDH1 (R132H IHC): Mutation
ATRX: Loss of expression (indicates mutation)
CDKN2A/B (Illumina array): No deletion
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 212\NH21-610,0.065,0.094,0.017,-0.002,0.088,-0.039,-0.178,0.042,0.15,0.14,0.212,-0.009,0.024,0.127,0.01,-0.017,-0.043,-0.052,-0.018,0.065,0.023,-0.036,-0.059,0.074,0.055,-0.037,-0.007,-0.015,0.021,unmethylated
NH21-574,204940880096_R07C01,212,17/03/2021,4/9/2021,4/8/2021,22,SB,Diagnostic,212,11,NDP,NHNN,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,8/7/1985,36.1,spinal ependymoma,1,EPN_SPINE,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-574,"Ependymoma WHO grade II
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 212\NH21-574,0.015,-0.005,0.031,0.02,0.05,-0.009,-0.026,-0.02,-0.021,-0.026,0.012,-0.006,0.017,0.014,0.005,0.006,-0.017,-0.031,-0.074,-0.033,-0.012,0.005,-0.191,-0.05,-0.01,-0.018,0.042,-0.378,-0.484,unmethylated
NH19-2014,204940880096_R08C01,212,17/03/2021,4/9/2021,4/8/2021,22,SB,Diagnostic,212,7,NDP,NHNN,pilocytic astrocytoma? Malignant clinical progression,"(2) unusual histology, location, demographics",DEF 1A,#N/A,#N/A,supratentorial pilocytic astrocytoma,0.46,LGG_PAPF,0.63,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-2014,"Pilocytic astrocytoma (WHO grade I)
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 212\NH19-2014,0.146,0.025,0.019,-0.011,-0.048,0.034,0.041,0.056,0.005,-0.009,0.153,0.008,0.06,0.016,-0.031,-0.006,-0.031,0.028,-0.008,-0.019,-0.04,0.025,0.023,-0.06,-0.017,-0.057,0.019,-0.055,-0.004,unmethylated
NH21-624,204940880009_R01C01,213,23/03/2021,4/16/2021,4/16/2021,24,SB,Diagnostic,213,1,NDP,HCA,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,12/30/1965,56,myxopapillary ependymoma,1,EPN_MPE,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-624,"Ependymoma (WHO grade II)  please see comment 
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
  
","Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 213\NH21-624,-0.011,-0.039,0.132,-0.04,-0.026,-0.098,-0.093,-0.051,-0.041,-0.112,-0.019,0.058,0.045,-0.028,-0.026,-0.022,-0.661,-0.457,0.031,0.065,0.172,0.003,-0.062,0.025,-0.082,-0.119,0.004,-0.054,-0.016,unmethylated
NH21-492,204940880009_R03C01,213,23/03/2021,4/16/2021,4/16/2021,24,SB,Diagnostic,213,1,NDP,NHNN,Glioblastoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1G,5/23/1964,57.6,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.62,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-492,"Glioblastoma (WHO grade IV)  see comment. 
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 213\NH21-492,0.032,0.011,-0.012,0.036,0.02,-0.032,-0.035,0.075,0.109,0.099,0.108,-0.013,-0.024,0.008,-0.405,-0.165,-0.176,0.012,-0.019,-0.035,-0.039,-0.087,-0.092,-0.014,-0.21,-0.027,0.172,-0.008,0.023,unmethylated
NH21-595,204940880009_R04C01,213,23/03/2021,4/16/2021,4/16/2021,24,SB,Diagnostic,213,1,NDP,"Birmingham, Queen Elizabeth Hospital",Midline Glioma non-H3 K27,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/7/1978,43.1,ganglioglioma,0.14,GBM_MES,0.62,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-595,"Referred diagnosis: Diffuse glioma  see comment 
Histone H3F3A (H3 K27M IHC): No mutation  
","Histology: Diffuse glioma  see comment
Methylation profile: Classified with low calibrated score  see comment
MGMT promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 213\NH21-595,0.026,-0.02,0.07,0.035,-0.052,-0.103,-0.573,0.267,0.158,0.171,0.172,0.012,0.026,-0.015,0.035,-0.014,-0.334,-0.299,-0.044,-0.026,0.046,-0.005,-0.451,0.039,-0.054,-0.05,-0.038,-0.275,-0.267,unmethylated
NH21-544,204940880009_R05C01,213,24/03/2021,4/16/2021,4/16/2021,23,SB,Diagnostic,213,1,NDP,NHNN,GBM-HGG,"(4) IHC, sequencing, or copy number assay ambiguous",DEF1A,8/5/1969,52.3,"glioblastoma, IDH-wildtype, RTK1 type",0.73,GBM_RTKI,0.46,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-544,"Glioblastoma (WHO grade IV)  see comment 
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained
Further molecular tests: Pending
  
","Glioblastoma, IDH-wildtype (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
Histone H3F3A: No mutation
MGMT Promoter: Unmethylated (0%)
Methylation profile: Glioblastoma, IDH wildtype, subclass RTK I (low calibrated score)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 213\NH21-544,-0.015,0.077,0.014,0.075,0.122,0.057,0.056,0.158,0.208,0.183,0.2,0.126,0.099,0.133,-0.985,-0.085,-0.211,-0.175,0.009,-0.029,-0.028,0.028,-0.124,-0.039,0.119,0.057,-0.187,-0.216,-0.146,unmethylated
NH21-689,204940880009_R06C01,213,25/03/2021,4/16/2021,4/16/2021,22,SB,Diagnostic,213,1,NDP,Royal Marsden,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B,5/4/1975,46.5,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.97,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-689,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH wildtype, subclass RTK II
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 213\NH21-689,0.076,-0.004,-0.008,0.014,0.091,-0.004,-0.064,1.3,0.261,0.298,0.243,-0.018,-0.001,0.051,-1.734,-0.046,-0.469,-0.375,-0.065,-0.003,-0.017,-0.083,-0.063,-0.087,-0.026,-0.043,0.339,-0.064,-0.009,methylated
NH21-694,204940880009_R07C01,213,25/03/2021,4/16/2021,4/16/2021,22,SB,Diagnostic,213,1,NDP,Lund (SE),LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",105,2/9/1969,52.9,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.57,GBM_MYCN,0.55,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-694,"Histology: Diffuse glioma  see comment 
Methylation profile: Classified with low calibrated score  see comment
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 213\NH21-694,0.03,0.019,0.047,0.078,0.036,-0.009,-0.063,0.243,0.17,0.207,0.218,0.005,0.048,0.043,-0.001,0.005,-0.02,-0.012,0.04,-0.008,0.008,0.066,-0.035,0.035,0.001,-0.001,-0.056,0.004,0.007,methylated
NH21-703,204940890067_R02C01,214,25/03/2021,4/16/2021,4/16/2021,22,SB,Diagnostic,214,7,NDP,"Cambridge, Addenbrooke's Hospital",Soft tissue tumour )?),"(2) unusual histology, location, demographics",B2,7/21/1949,72.7,"glioblastoma, IDH-wildtype, mesenchymal type",0.98,PXA,0.42,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-703,"Histology: In keeping with gliosarcoma  see comment
Methylation profile: No matching methylation class identified
MGMT promoter (Illumina array): Unmethylated 
","Histology: Gliosarcoma, IDH-wildtype (WHO grade IV)
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 214\NH21-703,0.018,0.004,0.021,0.031,0.203,-0.007,0.035,0.001,-0.012,-0.01,0.007,0.001,-0.048,0.033,-0.477,-0.016,-0.026,0.003,0.16,-0.018,-0.064,-0.012,-0.225,-0.16,-0.129,0.175,0.043,-0.049,-0.054,unmethylated
NH21-674,204940890067_R03C01,214,26/03/2021,4/16/2021,4/16/2021,21,SB,Diagnostic,214,1,NDP,NHNN,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,6/29/1949,72.8,posterior fossa ependymoma group B,1,EPN_PFB,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-674,"Ependymoma (WHO grade II)  for grading see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained
 
  
","Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, posterior fossa group B
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 214\NH21-674,0.09,-0.091,-0.031,0.226,0.227,0.062,-0.095,0.111,0.066,0.088,0.102,-0.103,-0.12,-0.091,-0.137,-0.084,-0.1,-0.036,-0.042,0.134,0.162,0.11,0.116,-0.128,-0.155,-0.194,0.135,-0.094,-0.07,unmethylated
NH21-701,204940890067_R04C01,214,26/03/2021,4/16/2021,4/16/2021,21,SB,Diagnostic,214,1,NDP,Oxford John Radcliffe Hospital,soft tissue tumour,"(2) unusual histology, location, demographics",5,3/18/1954,68,"glioblastoma, IDH-wildtype, mesenchymal type",0.59,MNG,0.21,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-701,"Histology: Malignant tumour with mesenchymal differentiation 
Methylation profile (brain tumour classifier): Inconclusive  see comment 
Methylation profile (sarcoma classifier): Giant cell tumour of bone (low calibrated score)
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 214\NH21-701,0.056,-0.115,0.017,0.012,0.057,0.022,0.008,-0.054,0.065,0.028,0.013,-0.089,0.314,0.391,0.096,-0.079,-0.131,-0.223,-0.036,0.239,-0.016,0.06,-0.233,-0.148,0.12,-0.033,-0.078,-0.033,0.006,unmethylated
NH21-702,204940890067_R05C01,214,26/03/2021,4/16/2021,4/16/2021,21,SB,Diagnostic,214,4,NDP,Newcastle,spinal cord glioma,(1) small biopsy or nonrepresentative sample;,2A,6/8/1969,52.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.65,DMG_K27,0.29,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-702,"Histology: Glioma - see comment
H3 K27M (IHC): Positive
Methylation profile: No matching methylation class identified
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 214\NH21-702,0.13,0.013,-0.004,0.047,0.063,0.09,-0.023,0.078,0.138,0.079,0.095,-0.022,-0.018,-0.013,0.001,-0.009,-0.029,0.006,0.023,-0.019,-0.02,-0.037,-0.078,-0.109,0.144,0.089,0.002,-0.033,0.023,unmethylated
NH21-471,204940890067_R06C01,214,26/03/2021,4/16/2021,4/16/2021,21,SB,Diagnostic,214,2,NDP,NHNN,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,5/31/2000,21,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,0.96,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-471,"Anaplastic ependymoma (WHO grade III)  see comment. 
","Histology: Anaplastic ependymoma (WHO grade III)
Methylation profile: Ependymoma, RELA fusion
MGMT promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 214\NH21-471,0.009,0.03,0.015,0.042,0.035,-0.049,-0.127,-0.008,0.012,-0.02,0.012,-0.005,-0.027,0.044,-0.311,-0.306,-0.014,-0.01,0.007,-0.019,0.028,-0.001,-0.052,-0.021,0.037,-0.037,0.045,-0.13,-0.119,unmethylated
NH21-641,204940890067_R07C01,214,18/03/2021,4/16/2021,4/16/2021,29,SB,Diagnostic,214,1,NDP,Oxford John Radcliffe Hospital,Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2,1/31/1957,65,rosette-forming glioneuronal tumour,0.8,LGG_RGNT,0.58,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-641,"Histology: Glioma / glioneuronal tumour  see comment
Methylation profile: Classified with low calibrated score  see comment
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 214\NH21-641,0.084,-0.044,-0.017,-0.028,-0.009,-0.057,-0.085,-0.013,-0.024,0.005,0.008,0.027,0.04,0.014,-0.308,-0.011,-0.016,-0.024,0.012,0.033,0.164,0.23,-0.215,-0.003,0.025,-0.054,-0.011,-0.062,0.027,methylated
NH21-725,204940890118_R02C01,215,29/03/2021,4/23/2021,4/22/2021,24,SB,Diagnostic,215,1,NDP,"Leeds, St James's University Hospital",GBM/Ependmoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",D3,11/8/1963,58.2,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.96,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-725,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH wildtype, subclass RTK II
MGMT promoter (Illumina array): Methylated
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 215\NH21-725,-0.116,-0.082,-0.001,-0.22,-0.238,0.088,-0.151,1.207,0.113,0.105,0.057,-0.059,0.048,-0.017,-1.994,-0.19,-0.461,-0.453,-0.084,0.068,0.028,0.146,-0.227,-0.053,-0.009,-0.024,0.177,-0.104,-0.006,methylated
NH21-719,204940890118_R03C01,215,29/03/2021,4/23/2021,4/22/2021,24,SB,Diagnostic,215,1,NDP,Bristol,Schwannoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",C1,9/11/1975,46.2,spinal ependymoma,0.21,EPN_SPINE,0.13,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-719,"Histology: Referred diagnosis - Schwannoma (see comment)
Methylation profile (brain tumour and sarcoma classifiers): Inconclusive 
MGMT promoter (Illumina array): Unmethylated
","Histology: Revised diagnosis: glioma
Methylation profile: Pleomorphic Xanthoastrocytoma (New classifier, see comment)
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 215\NH21-719,0.064,-0.028,0.032,-0.067,-0.053,0.034,0.035,0.129,0.132,0.168,0.081,-0.213,-0.122,-0.188,0.011,-0.046,-0.209,-0.162,-0.131,-0.11,-0.033,-0.099,-0.49,-0.175,-0.153,-0.146,0.011,-0.236,-0.153,unmethylated
NH21-779,204940890118_R04C01,215,31/03/2021,4/23/2021,4/22/2021,22,SB,Diagnostic,215,1,NDP,"Cardiff, University Hospital",HGG Spinal,"(2) unusual histology, location, demographics",A1 USS,5/8/1945,77,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,0.66,GBM_MID,0.49,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-779,"Histology: Favouring high-grade glioma
Methylation profile: Glioblastoma, IDH wildtype (Low calibrated score - see comment)
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 215\NH21-779,0.096,0.986,0.072,-0.219,-0.28,0.144,-0.398,-0.673,0.16,1.139,0.104,0.02,-0.017,-0.003,-0.148,-0.113,-0.322,-0.314,-0.004,-0.269,0.668,-0.348,-0.064,-0.288,0.283,0.234,-0.204,-0.18,-0.098,methylated
NH21-767,204940890118_R05C01,215,31/03/2021,4/23/2021,4/22/2021,22,SB,Diagnostic,215,1,NDP,Nottingham University Hospital,DNET,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,9/9/2011,9.7,dysembryoplastic neuroepithelial tumour,1,LGG_DNT,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-767,"Histology: Low-grade glioneuronal tumour, favouring dysembryoplastic neuroepithelial tumour (WHO grade I)

BRAF V600E (IHC): Negative
Methylation profile: Low grade glioma, dysembryoplastic neuroepithelial tumour
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 215\NH21-767,-0.009,-0.056,0.006,0.019,-0.06,0.029,-0.003,-0.024,-0.011,-0.005,-0.01,0.01,0.087,-0.028,0.061,0.003,0.009,-0.007,0.009,-0.009,0.004,0.055,0.022,-0.029,-0.017,-0.026,-0.028,-0.012,-0.001,unmethylated
NH21-766,204940890118_R07C01,215,31/03/2021,4/23/2021,4/22/2021,22,SB,Diagnostic,215,1,NDP,Nottingham University Hospital,Pilocytic,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/14/1996,24.9,infratentorial pilocytic astrocytoma,0.97,LGG_PAPF,0.88,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-766,"Histology: In keeping with a low-grade astrocytoma, favouring a pilocytic astrocytoma (WHO grade I)
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma (low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated
","Histology: Pilocytic astrocytoma, with KIAA1549-BRAF fusion (WHO grade I)
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma 
MGMT promoter (Illumina array): Unmethylated   
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 215\NH21-766,0.005,-0.031,-0.034,0.053,-0.061,0.141,0.238,-0.036,0.007,-0.006,0.165,-0.004,0.003,-0.007,0,-0.026,-0.013,0.012,0.127,-0.006,-0.004,0.059,0.027,-0.017,-0.041,-0.032,-0.1,-0.03,0.027,unmethylated
NH21-742,204940890123_R01C01,216,31/03/2021,4/30/2021,4/28/2021,28,SB,Diagnostic,216,1,NDP,"Leeds, St James's University Hospital",Ependymoma? HGG?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,12/21/1944,77.3,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.64,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-742,"Histology: High grade glioma, in keeping with glioblastoma (WHO grade IV) 
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 216\NH21-742,0.04,0.025,-0.023,0,0.004,-0.012,0.031,0.13,0.204,0.138,0.137,0.004,0.061,0.084,-0.355,0.006,-0.311,-0.135,0.01,0.041,0.01,0.044,0.002,0.079,0.039,0.031,-0.28,-0.024,0.066,unmethylated
NH21-743,204940890123_R02C01,216,31/03/2021,4/30/2021,4/28/2021,28,SB,Diagnostic,216,2,NDP,"Leeds, St James's University Hospital",BRAF Mut HGG,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,9/23/1961,60.3,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.69,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-743,"Histology: High grade glioma, most in keeping with glioblastoma, BRAF V600E-mutant (WHO grade IV) 
Methylation profile: Glioblastoma, IDH-wildtype  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 216\NH21-743,-0.043,0.003,0.01,0.025,-0.002,0.047,0.009,0.195,0.248,0.287,0.209,0.015,0.002,0.027,-1.396,0.009,-0.314,-0.302,-0.118,-0.046,-0.031,0.072,-0.131,0.021,0.041,0.019,-0.114,-0.005,0.005,unmethylated
NH21-746,204940890123_R07C01,216,7/4/2021,4/30/2021,4/28/2021,21,ZJ,Diagnostic,216,10,NDP,NHNN,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,1/12/2003,18.5,"diffuse glioma, MYB(L1)-altered, subtype C [isomorphic diffuse glioma-type]",0.99,LGG_MYB,1,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-746,"Low grade glioma  see comment
IDH1 (R132H IHC): Technically unsatisfactory 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Compatible with MYB/MYBL1-altered low grade glioma  for grading, see comment
Methylation profile: Low grade glioma, MYB/MYBL1
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 216\NH21-746,-0.039,0.007,0.057,0.037,-0.011,0.026,0.018,-0.009,-0.049,0.005,-0.02,-0.018,0.16,-0.018,0.013,-0.015,-0.004,-0.006,0.008,-0.024,-0.044,0.052,0.018,-0.012,-0.011,-0.036,-0.064,-0.015,0.005,unmethylated
NH21-758,204940890123_R08C01,216,7/4/2021,4/30/2021,4/28/2021,21,ZJ,Diagnostic,216,17,NDP,Romford,GBM,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A8,5/8/1949,72.9,"glioblastoma, IDH-wildtype, RTK1 type",0.82,GBM_RTKI,0.93,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-758,"Glioblastoma (WHO grade IV)  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK1
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 216\NH21-758,1.135,-0.048,-0.026,-0.14,-0.126,0.029,-0.22,1.029,0.292,0.362,0.253,0.091,0.075,0.138,-2.593,-0.521,-0.5,-0.39,-0.085,-0.069,-0.034,0.047,-0.092,0.04,0.022,0.016,0.003,-0.043,0.005,unmethylated
NH21-910,205022250094_R03C01,217,19/04/2021,5/7/2021,5/6/2021,17,ZJ,Diagnostic,217,1,NDP,Lund (SE),? Embryonal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",7-Jan,7/23/2007,13.9,"Diffuse paediatric-type high grade glioma, MYCN subtype",1,GBM_MYCN,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-910,"Histology: Compatible with glioblastoma (WHO grade IV)  see comment
Methylation profile: Glioblastoma, IDH-wildtype, subclass MYCN
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 217\NH21-910,0.113,1.105,0.037,-0.299,-0.37,-0.325,-0.38,0.058,0.116,0.128,0.063,-0.388,-0.251,-0.364,0.03,0.062,-0.099,-0.152,-0.465,-0.201,-0.147,-0.134,-0.14,-0.407,-0.47,-0.428,0.05,-0.366,-0.368,unmethylated
NH21-782,205022250094_R04C01,217,10/4/2021,5/7/2021,5/6/2021,26,ZJ,Diagnostic,217,8,NDP,Royal London Hospital,Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF3A,5/25/1973,48.5,posterior fossa subependymoma,1,SUBEPN_PF,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-782,"Subependymoma (WHO grade I)
","Histology: Subependymoma (WHO grade I)
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 217\NH21-782,-0.008,-0.016,0.055,0.038,-0.038,-0.059,0.01,0.007,-0.046,-0.056,-0.016,-0.009,0.04,-0.016,0.039,0.011,0.001,0.033,0.012,-0.033,-0.024,0.006,0.026,-0.013,-0.004,-0.02,-0.035,-0.011,0.039,unmethylated
NH21-807,205022250094_R05C01,217,10/4/2021,5/7/2021,5/6/2021,26,ZJ,Diagnostic,217,6,NDP,Brighton and Sussex Hospital,"AA, IDH-mutant","(4) IHC, sequencing, or copy number assay ambiguous",DEF2A,2/5/1971,50.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-807,"Anaplastic astrocytoma, IDH-mutant (WHO grade III)  see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Histology: Anaplastic astrocytoma, IDH-mutant (WHO grade III)  see comment
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 217\NH21-807,0.004,0.123,0.053,0.008,0.454,-0.017,0.035,0.031,-0.012,0.852,-0.018,0.036,0.196,0.137,0.041,0.07,-0.316,-0.189,0.038,0.091,0.669,-0.14,-0.165,-0.123,-0.082,-0.1,-0.205,0.015,0.077,methylated
NH21-841,205022250094_R06C01,217,13/04/2021,5/7/2021,5/6/2021,23,AM,Diagnostic,217,5,NDP,"Birmingham, Queen Elizabeth Hospital",? GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,4/6/1987,34.5,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-841,"High-grade glioma/glioneuronal tumour  see comment

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification          
CDKN2A/B:      Deletion
TERT promoter: Mutation
BRAF (V600E): Mutation
","Histology: Epithelioid glioblastoma, BRAF V600E-mutant (WHO grade IV)  see comment
Methylation profile: (anaplastic) pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 217\NH21-841,-0.029,0.126,0.095,0.027,0.117,0.039,-0.211,0.115,0.16,0.168,0.135,-0.228,-0.118,-0.205,-1.247,0.074,-0.182,-0.185,-0.218,-0.117,-0.09,-0.075,-0.438,-0.026,-0.091,-0.08,0.067,-0.024,-0.039,unmethylated
NH21-864,205022250067_R02C01,218,13/04/2021,5/7/2021,5/6/2021,23,AM,Diagnostic,218,1,NDP,Bristol,Ganglioglioma,(1) small biopsy or nonrepresentative sample;,A2,6/12/1978,43.3,"control tissue, hemispheric cortex",0.37,CONTR_HEMI,0.64,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-864,"Histology: Referred diagnosis: Ganglioglioma (WHO grade I)  see comment
Methylation profile: Control tissue, hemispheric cortex
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 218\NH21-864,0.016,-0.003,-0.009,0.025,-0.034,-0.008,-0.006,-0.042,-0.01,-0.005,-0.012,0.001,0.014,0.004,-0.005,-0.053,-0.029,0.003,-0.064,-0.007,-0.026,0.013,0.018,-0.008,-0.001,-0.048,-0.055,0.007,0.023,unmethylated
NH21-865,205022250067_R03C01,218,13/04/2021,5/7/2021,5/6/2021,23,AM,Diagnostic,218,2,NDP,"Birmingham, Queen Elizabeth Hospital",? DMG,(1) small biopsy or nonrepresentative sample;,B,4/18/1990,31.4,spinal subependymoma [subtype B],0.49,SUBEPN_SPINE,0.64,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-865,"Glioma favouring an astrocytoma (see comment)

H3 K27M (IHC): Negative
","Histology: Appearances, although not specific, compatible with subependymoma (WHO grade I)
Methylation profile: Suggestive of spinal subependymoma  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 218\NH21-865,-0.036,0.004,0.027,0.02,0.008,-0.061,-0.398,0.017,-0.019,-0.007,-0.041,0.008,0.075,0.001,0.03,0.034,0.03,-0.017,-0.051,-0.061,-0.048,0.067,0.023,-0.012,-0.073,-0.043,-0.054,-0.009,0.054,unmethylated
NH21-887,205022250067_R07C01,218,15/04/2021,5/7/2021,5/6/2021,21,AM,Diagnostic,218,5,NDP,"Birmingham, Queen Elizabeth Hospital",GBM transformed from LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",NA,9/20/1966,55.4,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.84,OIDH,0.89,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-887,"Histology: Diffuse glioma (WHO grade II)  see comment
Methylation profile: IDH-mutant glioma, suggestive of oligodendroglioma, 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 218\NH21-887,0.046,-0.232,-0.098,-0.079,0.027,-0.153,-0.14,0.001,0.108,0.118,0.207,0.167,0.06,0.035,-0.153,0.103,-0.115,-0.189,-0.022,-0.07,-0.082,-0.061,-0.013,0.201,0.146,0.035,-0.277,0.256,0.387,methylated
NH21-888,205022250067_R08C01,218,15/04/2021,5/7/2021,5/6/2021,21,AM,Diagnostic,218,1,NDP,"Birmingham, Queen Elizabeth Hospital",Low grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/12/1972,49.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.98,GBM_MES,0.51,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-888,"Histology: Compatible with glioblastoma (WHO grade IV)  see comment
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 218\NH21-888,-0.055,-0.025,-0.031,0.181,0.007,0,-0.244,0.164,0.193,0.155,0.142,0.166,0.19,0.131,0.088,0.005,-0.106,-0.154,-0.052,-0.013,-0.051,0.083,0.056,-0.035,0.04,0.015,0.075,-0.073,0.068,unmethylated
NH21-799,205291530160_R07C01,220,20/04/2021,5/14/2021,5/14/2021,24,AM,Diagnostic,220,1,NDP,Oxford John Radcliffe Hospital,IDH-WT Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1B,2/5/1951,71.1,ganglioglioma,0.37,GBM_MES,0.9,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-799,"Glioma, IDH-wildtype (see comment) 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation
","Histology: Glioma, IDH-wildtype
Methylation profile (repeat): Glioblastoma, IDH wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 220\NH21-799,0.104,-0.073,-0.025,0.197,0.15,0.171,0.125,0.221,0.216,0.237,0.194,-0.081,-0.078,-0.098,-0.048,-0.035,-0.062,-0.278,-0.005,-0.091,-0.078,-0.054,-0.126,0.076,0.121,0.07,-0.012,-0.029,-0.087,methylated
NH10-827,205022250050_R01C01,221,19/04/2021,5/21/2021,5/20/2021,31,SB,Diagnostic,221,1,NDP,NHNN,"Spinal glioma, unusual pattern","(2) unusual histology, location, demographics",B,#N/A,#N/A,spinal subependymoma [subtype A],0.14,SUBEPN_SPINE,0.16,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH10-827,"Recurrent glial tumour  see comment
","Histology: Recurrent glial tumour with ependymal differentiation
Methylation profile: No matching methylation class 
MGMT promoter (Illumina array): Unmethylated
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 221\NH10-827,0.121,0.091,-0.012,0.06,0.005,-0.015,-0.023,0.681,0.507,0.716,0.604,-0.014,-0.083,0.207,-0.037,0.294,-0.068,-0.049,0.374,0.148,0.053,0.037,-0.109,0.301,-0.091,-0.007,0.039,-0.024,0.025,unmethylated
NH21-972,205022250050_R02C01,221,22/04/2021,5/21/2021,5/20/2021,28,AM,Diagnostic,221,1,NDP,Nottingham University Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/26/1987,34.2,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.46,DMG_K27,0.9,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-972,"Referred diagnosis: High grade glioma  see comment 
MGMT Promoter: Unmethylated (0%)
","Histology: High-grade neuroepithelial tumour
Methylation profile: No matching methylation class (low calibrated score)  see comment
MGMT promoter (Illumina array): Unmethylated
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 221\NH21-972,0.197,0.034,0.045,-0.224,0.311,-0.123,-0.026,-0.036,0.105,1.304,0.133,0.027,0.048,0.165,0.014,0.018,0.017,0.089,0.068,0.01,0.023,0.009,-0.082,-0.152,-0.016,-0.046,-0.323,-0.121,-0.106,unmethylated
NH21-942,205022250050_R08C01,221,28/04/2021,5/21/2021,5/20/2021,22,ZJ,Diagnostic,221,7,NDP,Latvia,Brainstem glioma,"(2) unusual histology, location, demographics",1,9/16/2013,7.7,"Diffuse paediatric-type high grade glioma, RTK2 subtype",1,GBM_RTKIII,0.81,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-942,"Histology: High grade glioma, compatible with infiltration zone of glioblastoma (WHO grade IV) - see comment
Methylation profile: Glioblastoma, IDH wildtype, subclass RTK III
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 221\NH21-942,0.057,-0.003,0.027,-0.012,0.001,0.01,-0.01,0.039,1.627,-0.044,-0.016,-0.045,0.001,-0.015,-0.221,-0.043,-0.396,-0.384,0.004,0.267,-0.051,-0.027,-0.078,0.018,0.003,-0.028,0.032,0.015,-0.024,unmethylated
NH21-983,205291530180_R02C01,222,1/5/2021,5/28/2021,5/26/2021,25,ZJ,Diagnostic,222,3,NDP,Brighton and Sussex Hospital,Recurrent IDH-mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2B,11/28/1992,28.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.83,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-983,"Recurrent Diffuse Astrocytoma (Grade II, IDH mutant)  see comment
","Histology: Recurrent / residual diffuse astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 222\NH21-983,-0.027,0.028,0.014,-0.026,-0.036,0.083,0.016,0.01,-0.012,0.199,0.16,0.013,-0.026,0.062,-0.042,-0.015,-0.028,0.035,0,0.073,-0.063,0.037,-0.352,0.01,0.021,-0.044,-0.016,-0.049,0.029,methylated
NH21-858,205291530180_R03C01,222,1/5/2021,5/28/2021,5/26/2021,25,ZJ,Diagnostic,222,5,NDP,Brighton and Sussex Hospital,"Glioma, IDH wt","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,7/29/1950,71.7,"glioblastoma, IDH-wildtype, mesenchymal type",0.4,GBM_MES,0.51,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-858,"Diffuse glioma  for grading, see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Suggestive of glioblastoma, IDH-wildtype (WHO grade IV)  see comment
Methylation profile: Suggestive of glioblastoma, IDH-wildtype
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
TERT promoter: No mutation
MGMT Promoter (Illumina array and HRM assay): Unmethylated
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 222\NH21-858,0.054,-0.018,-0.024,-0.018,-0.044,0.003,0.065,0.122,0.131,0.088,0.088,-0.016,-0.027,0.058,-0.267,-0.027,-0.134,-0.14,-0.054,0.011,-0.026,0.039,-0.033,0.045,-0.113,-0.033,-0.028,-0.152,-0.094,unmethylated
NH21-1009,205291530180_R07C01,222,4/5/2021,5/28/2021,5/26/2021,22,ZJ,Diagnostic,222,13,NDP,NHNN,High grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1B,5/3/1953,69,"glioblastoma, IDH-wildtype, RTK2 type",0.46,GBM_RTKII,0.86,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1009,"Glioblastoma (WHO grade IV)


IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Glioblastoma, IDH-wildtype (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
TERT promoter: Mutation
MGMT Promoter: Methylated (>0-5%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 222\NH21-1009,0.039,0.022,0.031,-0.046,-0.084,0.076,-0.045,0.313,0.341,0.424,0.294,0.343,0.301,0.386,-2.016,-0.036,-0.03,-0.022,-0.172,0.15,0.188,0.249,-0.259,0.052,0.06,-0.023,0.094,-0.082,-0.102,unmethylated
NH21-995,205291530180_R08C01,222,4/5/2021,5/28/2021,5/26/2021,22,ZJ,Diagnostic,222,6,NDP,NHNN,High grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,#N/A,#N/A,myxopapillary ependymoma,1,EPN_MPE,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-995,#N/A,"Histology: Compatible with myxopapillary ependymoma (WHO grade I)
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 222\NH21-995,0.001,0.051,0.038,0.015,-0.025,-0.03,0.047,0.003,-0.001,-0.003,-0.012,-0.01,-0.031,0.098,-0.009,0.037,0.009,-0.007,-0.029,0.003,-0.033,0.014,-0.06,0.038,0.019,-0.049,0.009,-0.142,-0.154,unmethylated
NH21-881,205291530124_R01C01,223,4/5/2021,5/28/2021,5/26/2021,22,ZJ,Diagnostic,223,9,NDP,NHNN,PA,"(4) IHC, sequencing, or copy number assay ambiguous",SP1A,11/19/1992,28.8,rosette-forming glioneuronal tumour,1,LGG_RGNT,0.88,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-881,"Pilocytic astrocytoma (WHO grade I)  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Compatible with rosette forming glioneuronal tumour (WHO grade I)  see comment
Methylation profile: Low grade glioma, rosette forming glioneuronal tumour
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 223\NH21-881,-0.035,-0.065,-0.002,0.019,-0.04,0.014,0.008,-0.01,-0.005,-0.049,-0.015,0.003,0.013,0.022,0.021,0.015,-0.001,-0.014,0.028,-0.018,0.012,0.049,0.014,-0.026,-0.009,-0.05,-0.021,0.015,0.011,unmethylated
NH21-1053,205291530124_R03C01,223,5/5/2021,5/28/2021,5/26/2021,21,ZJ,Diagnostic,223,1,NDP,"Leeds, St James's University Hospital",Diffuse glioma; ?grade,(1) small biopsy or nonrepresentative sample;,A1,12/14/1993,27.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1053,"Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)  see comment
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 223\NH21-1053,0.054,-0.011,0.023,-0.011,0,0.039,-0.064,0.018,-0.012,0.015,0.007,-0.01,0.022,0.196,-0.046,-0.003,0.002,0,-0.024,0.009,-0.006,0.028,-0.064,0.029,-0.028,-0.043,-0.028,0.02,0.052,methylated
NH21-1125,205291530124_R07C01,223,10/5/2021,5/28/2021,5/26/2021,16,ZJ,Diagnostic,223,14,NDP,"Liverpool, The Walton Centre",IDH-mutant astrocytoma with MVP,"(2) unusual histology, location, demographics",01P,3/27/1989,32.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1125,"Histology: Compatible with diffuse astrocytoma, IDH-mutant (WHO grade II)  see comment
Methylation profile: IDH-glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 223\NH21-1125,-0.005,-0.019,0.021,-0.015,-0.022,0.033,0.016,0.153,0.141,0.174,0.145,0.175,0.187,0.18,0.01,0.011,0.013,-0.29,0.017,-0.002,-0.028,0.008,-0.007,-0.016,-0.018,-0.028,-0.048,0.033,0.039,methylated
NH21-1121,205291530145_R01C01,224,11/5/2021,6/4/2021,6/3/2021,23,AM,Diagnostic,224,1,NDP,"Leeds, St James's University Hospital",High grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/29/1946,75.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.87,GBM_MES,0.69,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1121,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 224\NH21-1121,-0.016,1.009,0.026,0.018,-0.032,0.04,0.047,0.154,0.132,0.168,0.13,0,0.024,0.058,0.007,0.008,-0.205,-0.159,-0.001,-0.048,-0.03,1.789,-0.266,-0.015,-0.011,-0.051,-0.033,-0.015,0.002,unmethylated
NH21-1086,205291530145_R02C01,224,11/5/2021,6/4/2021,6/3/2021,23,AM,Diagnostic,224,4,NDP,NHNN,Ependymoma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF1A,5/13/1969,52.7,spinal ependymoma,1,EPN_SPINE,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1086,"Ependymoma (WHO grade II)  see comment
","Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 224\NH21-1086,-0.003,-0.26,-0.156,-0.016,-0.035,-0.015,0.024,0.116,0.154,0.145,0.121,0.011,0.011,0.03,0.051,0.026,-0.213,-0.196,-0.02,-0.046,-0.048,0.054,-0.679,-0.037,0.028,-0.023,-0.022,-0.202,-0.191,unmethylated
NH21-1139,205291530145_R03C01,224,11/5/2021,6/4/2021,6/3/2021,23,AM,Diagnostic,224,3,NDP,"Belfast, Royal Victoria Hospital",Recurrent IDH-mutant glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2-2,9/8/1973,48.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.71,AIDH_HG,0.91,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1139,"Histology: Astrocytoma, IDH-mutant, grading see comment
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 224\NH21-1139,-0.061,-0.03,0.023,-0.001,0.021,0.035,0.026,0.127,0.128,0.124,0.123,0.166,0.171,0.16,-0.594,0.068,-0.035,-0.056,0.103,0.022,-0.055,0.026,0.109,-0.007,-0.013,-0.005,-0.011,-0.015,0.014,methylated
NH21-1132,205291530145_R04C01,224,12/5/2021,6/4/2021,6/3/2021,22,AM,Diagnostic,224,1,NDP,"Belfast, Royal Victoria Hospital",Spinal ependymoma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A2,9/9/2002,18.9,dysembryoplastic neuroepithelial tumour,0.72,LGG_DNT,0.51,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1132,"Histology: Low grade glioma with features compatible with a pilocytic astrocytoma
Methylation profile: Pilocytic astrocytoma (low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 224\NH21-1132,0,-0.076,-0.013,0.002,-0.045,-0.006,0.035,0.049,0.071,0.046,0.063,0.088,0.148,0.119,0.041,-0.001,0.027,-0.019,0.099,0.138,0.143,0.23,0.022,0.057,0.086,0.057,-0.048,-0.021,0.014,unmethylated
NH21-985,205291530145_R05C01,224,12/5/2021,6/4/2021,6/3/2021,22,AM,Diagnostic,224,2,NDP,St George's Hospital London,"High-grade glioma, BRAF-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,9/13/1971,50.3,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-985,"High-grade glioma, IDH-wildtype - see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression in most tumour cells (indicates mutation)
BRAF (V600E): Mutation
MGMT Promoter: Unmethylated (0%)
","Histology: High-grade glioma, BRAF-mutant
Methylation profile: (Anaplastic) pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 224\NH21-985,0.05,-0.069,0.002,-0.018,0.008,0.01,-0.049,-0.06,-0.016,-0.047,-0.034,-0.005,0.068,0.036,-1.17,0.021,0.007,-0.019,0.018,-0.013,-0.01,0.041,-0.001,-0.342,0.038,-0.016,-0.446,-0.355,-0.295,unmethylated
NH21-1167,205291530145_R06C01,224,13/05/2021,6/4/2021,6/3/2021,21,AM,Diagnostic,224,1,NDP,Nottingham University Hospital,? LGG spinal cord,(1) small biopsy or nonrepresentative sample;,C,9/20/2001,19.9,infratentorial pilocytic astrocytoma,0.29,LGG_PAPF,0.28,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1167,"Histology: CNS tissue, in keeping with spinal cord origin (see comment)
Methylation profile: No matching methylation class, flat copy number profile
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 224\NH21-1167,0.193,-0.154,-0.09,-0.17,0.03,-0.077,-0.012,0.109,-0.099,0.113,0.17,-0.061,0.036,0.341,0.071,-0.009,-0.128,0.02,-0.063,0.002,-0.278,-0.042,-0.114,0.03,0.01,-0.283,0.247,0.003,0.038,unmethylated
NH21-1149,205291530145_R07C01,224,13/05/2021,6/4/2021,6/3/2021,21,AM,Diagnostic,224,1,NDP,Nottingham University Hospital,? Haemorrhage into glioma,(1) small biopsy or nonrepresentative sample;,A1,4/28/1982,39.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1149,"Histology: Diffuse glioma, low grade.
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
","Astrocytoma, IDH-mutant (grading not possible)
IDH1/2Seq: Mutation
ATRX (IHC): Retained 
Methylation profile: IDH glioma, subclass astrocytoma
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 224\NH21-1149,-0.12,-0.039,0.007,-0.014,-0.022,0.043,0.017,-0.006,0.016,0.013,0.005,-0.012,0.049,-0.009,0.042,-0.004,-0.106,-0.078,-0.071,0.021,-0.147,-0.177,-0.127,-0.047,-0.011,-0.005,-0.037,-0.009,0.012,methylated
NH21-1173,205291530145_R08C01,224,13/05/2021,6/4/2021,6/3/2021,21,AM,Diagnostic,224,1,NDP,"Birmingham, Queen Elizabeth Hospital",Glioma ?DMB?PA,"(2) unusual histology, location, demographics",BLOCK,2/22/1987,34.7,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,0.33,ANAPA,0.48,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1173,"Glioma - see comment

Mutant H3 K27M (IHC): Negative
H3 K27me3 (IHC): Retained
ATRX (IHC): Retained
","Histology: Glioma with high grade features. 
Methylation profile: Anaplastic pilocytic astrocytoma (low calibrated score)
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 224\NH21-1173,0.054,-0.001,0.005,0.012,0.039,-0.028,-0.032,-0.052,-0.025,0.015,-0.008,-0.01,0.031,0.045,-0.003,0.029,-0.004,-0.012,0.062,0.004,0.052,0.056,-0.074,-0.287,0.267,0.239,-0.077,-0.012,-0.008,methylated
NH21-1183,205291530119_R01C01,225,13/05/2021,6/11/2021,6/9/2021,27,AM,Diagnostic,225,1,NDP,Southampton General Hospital,LGGNT ?RGNT,"(5) Confirmation of rare, unusual or interesting histo-molecular results",1A,6/15/1971,50.6,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.98,LGG_DNT,0.63,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1183,"Histology: Low grade glioma, favouring dysembryoplastic neuroepithelial tumour (WHO grade I)
Methylation profile: Low grade glioma, dysembryoplastic neuroepithelial tumour
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 225\NH21-1183,-0.07,-0.004,0.056,0.013,-0.052,0,0.042,-0.029,0.035,-0.059,-0.01,0.02,0.06,0.089,0.072,0.006,0.039,0.014,0.067,0.018,0.08,0.096,0.027,0.039,0.012,-0.063,-0.001,-0.032,0.029,methylated
NH21-1031,205291530119_R02C01,225,14/05/2021,6/11/2021,6/9/2021,26,AM,Diagnostic,225,3,NDP,"Cardiff, University Hospital",HGG IDH-mutant,"(4) IHC, sequencing, or copy number assay ambiguous",A1,1/25/1987,34.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1031,"High-grade glioma, IDH-mutant  see comment
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)  see comment
1p/19q: No codeletion  see comment
CDKN2A/B: Indeterminate
TERT promoter: No mutation  
","Histology: Anaplastic astrocytoma, IDH-mutant
Methylation profile: IDH glioma, subclass high-grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 225\NH21-1031,0.039,0.082,0.117,-0.074,0.226,-0.091,-0.002,0.089,0.269,0.961,-0.134,-0.153,0.053,0.315,-0.221,0.428,-0.246,-0.493,0.024,0.359,0.156,0.183,-0.125,0.139,0.132,0.098,0.081,-0.144,-0.072,methylated
NH21-1110,205291530119_R03C01,225,14/05/2021,6/11/2021,6/9/2021,26,AM,Diagnostic,225,4,NDP,NHNN,LGG,"(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF3A,4/10/1966,55.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.27,CONTR_REACT,0.33,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1110,"Low grade glial / glioneuronal tumour  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Low grade glial/glioneuronal tumour
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 225\NH21-1110,-0.041,0,0,0.011,-0.085,0.031,0.062,-0.027,0.006,-0.076,0.018,-0.011,0.082,0.055,0.087,-0.007,0.053,-0.028,0.009,0.045,0.057,0.136,-0.006,0.04,0.082,-0.03,0.027,-0.043,0.03,unmethylated
NH21-1163,205291530119_R06C01,225,17/05/2021,6/11/2021,6/9/2021,23,ZJ,Diagnostic,225,6,NDP,Latvia,"Diffuse midline glioma, vermis","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1837,10/14/2018,2.5,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1163,"Histology: Compatible with pilocytic astrocytoma (WHO grade I)
Methylation profile: Pilocytic astrocytoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 225\NH21-1163,-0.107,-0.027,0.035,0.052,-0.067,0.034,0.055,-0.017,0.003,-0.036,0.144,0.021,0.01,0.035,0.086,0.053,0.053,-0.044,0.04,0.04,0.031,0.104,-0.019,0.006,0.015,-0.075,-0.043,-0.018,0.039,unmethylated
NH21-1190,205291530119_R08C01,225,17/05/2021,6/11/2021,6/9/2021,23,AM,Diagnostic,225,1,NDP,"Belfast, Royal Victoria Hospital",Subependymoma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,11/29/2010,10.6,"diffuse glioneuronal tumour, non defined type",0.95,OIDH,0.2,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1190,"Histology: Glioneuronal tumour.
Methylation profile: No matching this methylation class
MGMT promoter (Illumina array): Unmethylated 
  
","Histology: Glioneuronal tumour
Methylation profile: Glioneuronal tumour-not otherwise specified (see comment)

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 225\NH21-1190,0.079,0.002,-0.006,-0.058,0.011,-0.011,0.031,-0.045,0.016,-0.052,-0.014,-0.005,-0.032,0.129,0.067,0.025,-0.025,0.013,-0.027,0.066,-0.007,-0.023,-0.06,0.14,0.047,-0.011,-0.008,-0.439,-0.407,unmethylated
NH21-1199,205292900028_R01C01,226,17/05/2021,6/11/2021,6/9/2021,23,ZJ,Diagnostic,226,2,NDP,NHNN,"Glioblastoma, 4 year survival","(2) unusual histology, location, demographics",DEF2A,12/12/1946,75.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.95,GBM_MES,0.73,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1199,"Recurrent / residual glioblastoma, IDH-wildtype (WHO grade IV)  see comment
  
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 226\NH21-1199,0.898,-0.017,0.01,-0.017,0.053,-0.007,-0.107,0.162,0.12,0.049,0.044,-0.117,-0.006,0.124,-0.372,0.013,-0.107,-0.065,-0.144,0.087,0.019,0.068,-0.111,0.1,0.053,-0.056,-0.122,-0.144,0.045,methylated
NH21-1211,205292900028_R03C01,226,18/05/2021,6/11/2021,NA,#VALUE!,AM,Diagnostic,226,1,NDP,St George's Hospital London,Spinal Glioma,"(2) unusual histology, location, demographics",B1,5/27/1982,39.5,spinal ependymoma,0.97,EPN_SPINE,0.97,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1211,"Histology: Glial tumour with features supportive of ependymoma 
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 226\NH21-1211,0.006,-0.132,-0.11,0.008,-0.039,-0.049,-0.146,0.088,0.095,0.04,0.033,0.032,0.024,0.17,-0.107,-0.067,-0.112,-0.091,-0.019,0.109,0.105,0.127,-0.374,0.18,0.161,-0.026,0.022,-0.455,-0.192,unmethylated
NH21-1229,205292900028_R06C01,226,18/05/2021,6/11/2021,6/9/2021,22,AM,Diagnostic,226,1,NDP,"Liverpool, The Walton Centre",LGG ? Pilocytic astrocytoma,(1) small biopsy or nonrepresentative sample;,1A,2/24/2002,19.5,supratentorial pilocytic astrocytoma,0.95,LGG_PA_GGST,0.75,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1229,"Histology: Low grade glioma, favouring pilocytic astrocytoma
Methylation profile: Inconclusive (see below)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 226\NH21-1229,-0.043,-0.053,0.002,0.042,-0.061,0.133,0.095,0.196,0.296,0.253,0.221,0.004,0.038,0.073,0.076,-0.044,0.018,-0.02,-0.008,0.154,0.127,0.224,0.027,0.138,0.214,0.103,0.12,-0.022,0.047,methylated
NH21-1253,205292900028_R08C01,226,19/05/2021,6/11/2021,6/9/2021,21,AM,Diagnostic,226,1,NDP,"Stanmore, Royal National Orthopedic Hospital",Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,10/30/1948,73.6,myxopapillary ependymoma,1,EPN_MPE,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1253,"Ependymal tumour favouring a myxopapillary ependymoma - see comment
","Histology: Myxopapillary Ependymoma
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 226\NH21-1253,-0.101,0.05,0.081,0.053,-0.05,0.09,0.096,-0.043,-0.033,-0.041,-0.02,0.015,0.063,0.09,0.042,0.044,-0.012,-0.008,-0.012,0.051,0.007,0.069,-0.065,0.041,-0.054,-0.008,-0.021,-0.064,-0.025,methylated
NH21-1245,205292900118_R01C01,227,21/05/2021,6/18/2021,6/16/2021,26,AM,Diagnostic,227,1,NDP,"Cardiff, University Hospital",Oligodendroglioma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,6/3/1975,46.5,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.98,OIDH,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1245,"Histology: Anaplastic oligodendroglioma (WHO grade III)
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 227\NH21-1245,0.045,0.001,0.007,-0.068,-0.075,0.016,0.008,0.004,-0.004,0.02,0.016,0.002,0.02,0.064,-0.038,0.026,-0.084,-0.095,0.001,0.035,-0.034,-0.037,-0.053,0.006,0.041,0.228,-0.496,-0.017,0.022,methylated
NH21-1248,205292900118_R02C01,227,21/05/2021,6/18/2021,6/16/2021,26,AM,Diagnostic,227,1,NDP,Southampton General Hospital,Astrocytoma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",E,5/22/1980,35.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.95,AIDH,0.95,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1248,"Histology: Diffuse glioma with astrocytic and oligodendroglial features (see comment), IDH-mutant
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 

IDH1 (R132H IHC): Mutation (externally tested)
ATRX (IHC): Retained (externally tested)
1p/19q: Retained (externally tested)

  
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 227\NH21-1248,0.071,0.023,0.018,-0.018,0.031,0.014,0,0.018,0.027,0.014,0.024,-0.012,0.109,0.165,0.009,0.005,0.01,-0.037,0.023,0.161,0.047,0.051,-0.051,0.035,-0.028,-0.016,-0.05,-0.074,-0.001,methylated
NH21-1301,205292900118_R08C01,227,25/05/2021,6/18/2021,6/16/2021,22,ZJ,Diagnostic,227,1,NDP,Newcastle,?PA (diagnosed GBM in 2008),"(4) IHC, sequencing, or copy number assay ambiguous",A2,10/17/1973,35.3,extraventricular neurocytoma,0.88,LGG_PA_GGST,0.26,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1301,"Histology: Low grade glioma
Methylation profile: Pilocytic astrocytoma (note very low calibrated score)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 227\NH21-1301,0.126,0.024,-0.019,-0.007,0.082,0.019,-0.026,-0.031,-0.046,0.027,0.035,-0.03,-0.079,0.161,-0.019,0.054,-0.054,-0.022,0.075,-0.008,0.06,0.12,-0.115,0.1,-0.107,-0.131,-0.002,0.007,0.057,unmethylated
NH21-1278,205292900056_R02C01,228,25/05/2021,6/25/2021,6/25/2021,31,ZJ,Diagnostic,228,3,NDP,Brighton and Sussex Hospital,"AA, IDH-mutant, early reccurence","(4) IHC, sequencing, or copy number assay ambiguous",DEF1A,11/16/1972,49.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1278,"Anaplastic astrocytoma, IDH-mutant (WHO grade III)  see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Weakly retained 
Further molecular tests: Pending

Molecular results from NH18-2117:
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Retained
MGMT Promoter: Methylated (>0-5%) 

  
","Anaplastic astrocytoma, IDH-mutant (WHO grade III)
IDH1 (R132H IHC): Mutation
ATRX (IHC): Predominantly retained, regional loss 
CDKN2A/B: No deletion
MGMT Promoter: Unmethylated (0%)

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 228\NH21-1278,-0.042,-0.057,0.001,-0.004,0.014,0.064,0.103,-0.023,-0.033,0.141,0.068,0.089,0.115,0.166,0.062,-0.001,-0.003,-0.013,-0.009,0.33,-0.046,0.039,-0.263,0,0.009,0.039,-0.076,-0.042,-0.04,methylated
NH18-2117,205292900056_R03C01,228,25/05/2021,6/25/2021,6/25/2021,31,ZJ,Diagnostic,228,1,NDP,Brighton and Sussex Hospital,"A, IDH-mutant","(4) IHC, sequencing, or copy number assay ambiguous",,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-2117,"Diffuse astrocytoma, WHO grade II


IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Test pending
  
","Histology: Astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 228\NH18-2117,0.046,-0.005,0.044,-0.054,0.049,0.016,-0.175,0.041,0.018,0.081,0.104,-0.009,0.105,0.087,0.05,0.048,-0.072,-0.097,-0.003,0.055,0.076,0.025,-0.011,0.034,0.015,0.039,-0.061,0.031,0.092,unmethylated
NH21-1333,205292900056_R06C01,228,28/05/2021,6/25/2021,6/25/2021,28,SB,Diagnostic,228,1,NDP,Royal London Hospital,"Glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2B,6/23/1975,46.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.44,AIDH,0.7,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1333,"Recurrent / residual diffuse astrocytoma, IDH-mutant (WHO grade II)  see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending

Molecular results for NH19-527:
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
EGFR: No amplification
MGMT Promoter: Methylated (>5-10%)  
Methylation Subclass: Inconclusive
  
","Recurrent astrocytoma, IDH-mutant (WHO grade II)
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion
MGMT Promoter (HRM and Illumina array): Methylated (>0-5%)

Methylation profile: IDH glioma, subclass astrocytoma

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 228\NH21-1333,-0.038,-0.067,-0.017,-0.043,-0.028,-0.019,0.002,-0.007,-0.055,-0.029,-0.016,-0.02,0.01,0.005,-0.142,-0.011,0.035,0.077,0.066,-0.035,-0.04,0.035,-0.044,-0.05,0.021,0.039,-0.279,0,0.001,methylated
NH21-1332,205292900056_R07C01,228,28/05/2021,6/25/2021,6/25/2021,28,SB,Diagnostic,228,1,NDP,Lund (SE),LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,4/18/1982,39.7,ganglioglioma,0.94,LGG_GG,0.36,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1332,"Histology: Low-grade glial tumour
Methylation profile: Low-grade glioma, ganglioglioma (See comment)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 228\NH21-1332,0.015,-0.211,0.009,0.035,-0.032,0.014,0.09,-0.001,-0.032,-0.07,-0.017,0.011,0.026,0.017,0.006,0.037,0.021,-0.135,0.008,-0.022,0.008,0.029,-0.008,-0.002,-0.011,0.021,0.036,-0.044,0.005,unmethylated
NH21-1315,205292900056_R08C01,228,28/05/2021,6/25/2021,6/25/2021,28,SB,Diagnostic,228,1,NDP,Romford,Indeterminate Lesion (HGG? Inflamm?),(1) small biopsy or nonrepresentative sample;,A1,5/8/1964,57.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.29,CONTR_REACT,0.29,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1315,"CNS tissue fragments, containing a cellular infiltrate of unknown aetiology  see comment
","Histology: CNS tissue, With cell infiltrate of uncertain aetiology (see previous report) 
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 228\NH21-1315,0.094,0.005,-0.033,0.002,0.026,-0.035,0.016,-0.002,0.073,0.01,0.026,-0.019,-0.003,0.001,0.003,0.058,0.041,0.052,0.004,0.025,-0.058,0.043,-0.005,-0.018,0.001,-0.016,0.085,0.001,0.03,unmethylated
NH21-1335,205291530072_R01C01,229,28/05/2021,6/25/2021,6/25/2021,28,SB,Diagnostic,229,1,NDP,Oxford John Radcliffe Hospital,GBM,(1) small biopsy or nonrepresentative sample;,B,2/28/1953,69.2,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.88,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1335,"Histology: High-grade glioma with features compatible with Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 229\NH21-1335,0.046,-0.021,-0.027,0.072,0.001,-0.014,-0.028,0.147,0.184,0.191,0.116,-0.006,0.02,0.079,-0.407,0.009,-0.098,-0.16,0.02,0.181,0.039,0.066,-0.04,0.038,-0.003,0.018,-0.016,-0.14,-0.197,unmethylated
NH21-1297,205291530072_R03C01,229,28/05/2021,6/25/2021,6/25/2021,28,SB,Diagnostic,229,1,NDP,NHNN,Recurrent GBM previous profile inconclusive,"(2) unusual histology, location, demographics",DEF2A,9/28/1984,37.2,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.56,GBM_MYCN,0.85,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1297,"Recurrent / residual glioblastoma, IDH-wildtype (WHO grade IV)  see comment
Molecular results for NH19-3039:
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
MGMT Promoter: Methylated (>0-5%)
Methylation class: Reactive tumour microenvironment
  
","Histology: Residual/recurrent glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass MYCN
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 229\NH21-1297,0.053,0.001,0.008,-0.012,0.037,-0.059,-0.414,0.039,0.033,-0.002,-0.004,-0.036,0.007,-0.015,-0.318,-0.044,-0.021,-0.01,-0.143,-0.029,-0.066,0.02,-0.43,-0.359,-0.449,-0.408,-0.28,-0.297,-0.305,unmethylated
NH21-1317,205291530072_R05C01,229,28/05/2021,6/25/2021,6/25/2021,28,SB,Diagnostic,229,1,NDP,"Birmingham, Queen Elizabeth Hospital","Glial tumour, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,4/18/1990,31.5,spinal subependymoma [subtype B],0.95,SUBEPN_SPINE,0.62,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1317,"Histology: Low grade glial tumour
Methylation profile:
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 229\NH21-1317,-0.01,-0.084,0.042,0.02,0.018,-0.002,-0.478,0.03,-0.057,-0.08,-0.02,-0.017,0.014,-0.003,0.031,0.003,0.012,0.032,-0.003,-0.039,0.007,0.042,-0.014,-0.014,0.004,-0.032,-0.021,0.008,0.023,unmethylated
NH21-1344,205291530072_R08C01,229,1/6/2021,6/25/2021,6/25/2021,24,SB,Diagnostic,229,1,NDP,London Wellington/HCA,Diffuse astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/26/1969,53,supratentorial pilocytic astrocytoma,0.53,LGG_DNT,0.27,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1344,"Low grade glioma (see comment)
","Histology: low grade glioma
Molecular profile: suggestive of infiltration of IDH-wildtype glioblastoma
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
TERT promoter: Mutation
Methylation profile: Inconclusive (control tissue, hemispheric cortex)

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 229\NH21-1344,-0.055,-0.06,0.007,0.012,-0.033,0.025,-0.008,0.056,-0.047,-0.11,-0.03,0.004,0.068,0.001,0.017,-0.018,0.03,0.003,0.069,-0.028,0.035,0.03,0.003,0.008,0.031,-0.011,0.009,0.001,0.004,methylated
NH21-1192,205291530098_R01C01,230,2/6/2021,7/2/2021,6/30/2021,28,SB,Diagnostic,230,1,NDP,"Belfast, Royal Victoria Hospital","HGG, post fossa","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/15/1982,39.1,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.98,GBM_RTKII,0.26,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1192,"High-grade glioma, IDH-wildtype, at least WHO grade III
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
CDKN2A/B: No deletion
Histone H3F3A: No mutation

","Histology: High-grade glioma, IDH-wildtype, at least WHO grade III
Methylation profile: No matching methylation classes 
MGMT promoter (Illumina array): Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 230\NH21-1192,0.098,0.076,0.048,0.097,0.083,0.042,0.087,0.017,-0.009,-0.008,-0.003,0.083,0.073,0.135,0.004,0.058,-0.001,0.03,-0.072,0.003,0.018,0.01,-0.157,-0.069,-0.166,-0.114,-0.089,0.022,0.037,methylated
NH21-1356,205291530098_R03C01,230,4/6/2021,7/2/2021,6/30/2021,26,SB,Diagnostic,230,1,NDP,"Charing Cross Hospital, London",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,5/12/1969,52.8,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.97,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1356,"High-grade glioma 
MGMT Promoter: Unmethylated (0%)
 
","Histology: High-grade glioma
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 230\NH21-1356,-0.01,0.001,0.026,0.003,-0.004,0.015,0.002,0.198,0.213,0.229,0.205,-0.052,0.003,0.007,-0.906,0.024,-0.351,-0.263,-0.02,-0.054,-0.055,0.044,-0.075,-0.018,-0.185,-0.012,0.219,-0.034,0.05,unmethylated
NH21-1263,205291530098_R05C01,230,7/6/2021,7/2/2021,6/30/2021,23,SB,Diagnostic,230,1,NDP,Royal London Hospital,"Most likely GBM, non-informative tests","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,11/16/1960,61.4,ganglioglioma,0.8,LGG_GG,0.43,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1263,"High grade glioma (at least WHO grade III)  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: High-grade glioma, IDH-wildtype (see comment)
Methylation profile: Low calibrated score  see comment
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 230\NH21-1263,-0.044,-0.087,0.003,0.091,-0.003,0.05,-0.03,0.124,0.077,0.144,0.103,-0.005,0.056,-0.063,0.03,0,-0.115,-0.119,-0.082,-0.113,-0.029,0.093,-0.1,-0.119,-0.027,-0.008,0.063,-0.141,-0.056,methylated
NH21-1411,205291530098_R08C01,230,10/6/2021,7/2/2021,6/30/2021,20,SB,Diagnostic,230,1,NDP,Oxford John Radcliffe Hospital,Posterior fossa LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,1/17/1998,23.7,infratentorial pilocytic astrocytoma,0.41,LGG_PAPF,0.36,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1411,"Histology: Low grade glioma, favouring a pilocytic astrocytoma  see comment 
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma (low calibrated score)  see comment
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 230\NH21-1411,0.054,-0.032,-0.037,-0.008,-0.041,0.041,-0.065,-0.041,-0.033,-0.013,0.017,-0.046,0.065,0.029,0.009,0.05,-0.016,0.026,0.034,-0.004,0.049,0.042,-0.034,-0.041,-0.026,0.024,0.085,-0.001,0.007,unmethylated
NH21-1298,205291530184_R01C01,231,6/11/2021,7/2/2021,6/30/2021,19,SB,Diagnostic,231,3,NDP,St George's Hospital London,Temporal neurocytic tumour,"(2) unusual histology, location, demographics",B1,12/26/1973,48.1,papillary glioneuronal tumour,0.32,DMG_K27,0.11,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1298,"Glial or glioneuronal tumour (see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
1p/19q: Retained
MGMT Promoter: Methylated (>0-5%)
  
","Histology: Glial or Glioneuronal tumour
Methylation profile: No matching methylation class 
MGMT promoter (Illumina array): Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 231\NH21-1298,0.175,-0.018,-0.03,0.042,-0.053,0.005,-0.028,0.069,0.07,0.011,0.049,-0.044,-0.16,-0.102,0.017,0.041,-0.021,-0.039,0.022,0.167,0.237,0.91,-0.122,0.032,0.06,-0.012,-0.124,-0.1,0.035,methylated
NH21-1427,205291530184_R02C01,231,6/11/2021,7/2/2021,6/30/2021,19,SB,Diagnostic,231,1,NDP,NHNN,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A,8/26/1982,39.3,myxopapillary ependymoma,1,EPN_MPE,1,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1427,"Ependymoma  see comment
","Histology: Ependymoma
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Methylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 231\NH21-1427,0.03,-0.072,0.051,0.034,-0.043,-0.02,0.063,0.013,0.034,-0.048,0.003,0.019,0.082,0.011,0.062,0.092,-0.013,0.006,0.011,0.026,0.027,0.073,-0.157,-0.116,-0.123,-0.126,-0.011,-0.411,-0.394,methylated
NH21-1438,205291530184_R03C01,231,6/11/2021,7/2/2021,6/30/2021,19,SB,Diagnostic,231,1,NDP,Romford,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,9/13/1951,70.7,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.69,GBM_RTKII,0.5,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1438,"Glioblastoma (WHO grade IV)  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Family Class- Glioblastoma, IDH wildtype (low calibrated score  see comment)
MGMT promoter (Illumina array): Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 231\NH21-1438,0.171,-0.043,0.069,0.014,-0.036,0.107,0.052,0.405,0.043,0.051,0.07,0.192,0.261,0.252,0.316,0.23,-0.396,-0.386,0.202,0.033,0.068,0.068,-0.026,-0.048,0.276,0.252,-0.026,-0.34,-0.403,methylated
NH21-1460,205291530184_R04C01,231,6/11/2021,7/2/2021,6/30/2021,19,SB,Diagnostic,231,1,NDP,Oxford John Radcliffe Hospital,Glioneurnal tu,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,9/20/1985,36.2,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.55,GBM_MID,0.75,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1460,"Histology: High-grade neuroepithelial tumour 
Methylation profile: Suggestive of Glioblastoma, IDH-wildtype (low calibrated scores  see comment
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 231\NH21-1460,0.239,-0.067,-0.029,-0.04,-0.043,-0.187,-0.313,-0.048,-0.082,-0.062,-0.059,0.129,0.218,0.196,-0.016,0,-0.033,-0.015,-0.009,0.117,0.084,0.199,-0.396,0.157,0.133,0.211,-0.14,-0.382,-0.271,unmethylated
NH21-1465,205291530184_R05C01,231,6/11/2021,7/2/2021,6/30/2021,19,SB,Diagnostic,231,3,NDP,Oxford John Radcliffe Hospital,Glioma NOS,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,12/17/1961,60.3,high-grade astrocytoma with piloid features,1,ANAPA,1,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1465,"Histology: Glioma 
Methylation profile: Anaplastic pilocytic astrocytoma
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 231\NH21-1465,-0.039,-0.059,0.022,-0.016,-0.06,0.104,0.059,-0.005,-0.022,-0.078,-0.026,-0.014,0.009,0.018,-0.809,0.018,-0.017,0.064,0.022,0.091,0.15,0.231,-0.053,-0.018,-0.009,-0.003,-0.004,0.05,-0.004,methylated
NH21-799,205291530184_R06C01,231,6/11/2021,7/2/2021,6/30/2021,19,SB,Diagnostic,231,1,NDP,Oxford John Radcliffe Hospital,GBM,"(2) unusual histology, location, demographics",1B,2/5/1951,71.1,ganglioglioma,0.43,GBM_MES,0.91,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-799,"Glioma, IDH-wildtype (see comment) 
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation
","Histology: Glioma, IDH-wildtype
Methylation profile (repeat): Glioblastoma, IDH wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 231\NH21-799,0.065,-0.082,-0.013,0.208,0.129,0.183,0.127,0.225,0.24,0.235,0.209,-0.085,-0.05,-0.039,-0.034,-0.053,-0.081,-0.261,0.048,-0.049,-0.089,-0.031,-0.113,0.068,0.133,0.082,0.068,-0.056,-0.065,methylated
NH21-1456,205291530184_R08C01,231,15/06/2021,7/2/2021,6/30/2021,15,SB,Diagnostic,231,5,NDP,Oxford John Radcliffe Hospital,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1A,4/25/1984,37.6,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.62,DMG_K27,0.98,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1456,"Histology: Glioma (see comment)
H3 K27M (IHC): Mutation
Methylation profile: Diffuse midline glioma H3 K27M mutant
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 231\NH21-1456,0.037,0.207,0.017,-0.017,0.002,0.109,0.003,0.019,0.011,-0.012,0.004,-0.019,0.033,0.048,0.104,-0.002,0.024,0.034,0.027,0.054,0.12,0.244,-0.047,0.042,-0.553,0.387,-0.114,-0.025,0.05,unmethylated
NH21-1492,205291530174_R01C01,232,15/06/2021,7/9/2021,7/7/2021,22,SB,Diagnostic,232,1,NDP,Southampton General Hospital,Ependymoma,"(2) unusual histology, location, demographics",1A,9/30/1960,61.6,posterior fossa ependymoma group B,0.16,GBM_MES,0.49,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1492,"Histology: High-grade glioma
Methylation profile: Suggestive of Glioblastoma, IDH wildtype (low calibrated score - see comment)
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 232\NH21-1492,0.123,-0.136,0.197,-0.094,-0.365,-0.077,-0.11,0.179,0.134,0.121,0.101,-0.032,-0.067,0.095,-0.005,-0.098,-0.403,-0.342,-0.116,0.023,0.091,-0.135,-0.453,0.083,0.081,-0.568,0.327,-0.159,-0.055,unmethylated
NH21-1429,205291530174_R03C01,232,15/06/2021,7/9/2021,7/7/2021,22,SB,Diagnostic,232,3,NDP,Romford,CNS infiltration,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,5/16/1977,44.7,ganglioglioma,0.37,GBM_MES,0.75,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1429,"CNS tissue with mild increased cellularity and proliferative activity  see comment  
","Histology: Molecular features suggestive of glioblastoma (WHO grade IV)
Methylation profile: Suggestive of Glioblastoma, IDH-wildtype (Low calibrated score see comment)
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 232\NH21-1429,1.235,0.016,0.013,0.013,-0.039,-0.015,-0.209,1.288,0.06,0.046,0.114,0.004,0.075,0.04,0.059,0.041,-0.204,-0.1,0.026,0.035,0.775,0.045,0.02,0.118,-0.006,0.004,0.09,-0.01,0.067,methylated
NH21-1490,205291530174_R04C01,232,15/06/2021,7/9/2021,7/7/2021,22,SB,Diagnostic,232,1,NDP,"Leeds, St James's University Hospital",Melanoma vs Schwannoma,"(2) unusual histology, location, demographics",A1,12/21/1978,43.1,myxopapillary ependymoma,0.95,EPN_MPE,0.92,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1490,"Histology: Neuroepithelial tumour
Methylation profile: Ependymoma, myxopapillary (Low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 232\NH21-1490,0.137,0.056,0.059,0.023,0.016,0.009,0.037,0.294,0.231,0.238,0.214,0.212,0.181,0.304,-0.019,0.014,-0.411,-0.34,0.005,0.024,-0.01,0.036,0.162,0.023,-0.013,-0.049,0.006,-0.396,-0.371,unmethylated
NH21-1489,205291530174_R08C01,232,15/06/2021,7/9/2021,7/7/2021,22,SB,Diagnostic,232,1,NDP,"Birmingham, Queen Elizabeth Hospital",Ependymoma?,"(2) unusual histology, location, demographics",A,5/24/1951,71.1,posterior fossa ependymoma group B,1,EPN_PFB,0.67,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1489,"Histology: Ependymoma
H3 K27M (IHC): Negative
Methylation profile: Ependymoma, posterior fossa group B (low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 232\NH21-1489,-0.034,-0.234,-0.137,0.042,0.122,0.09,-0.519,-0.01,-0.031,-0.051,-0.033,-0.198,-0.116,-0.166,0.029,0.009,-0.186,-0.113,0.015,-0.031,-0.005,0.034,0.001,-0.044,-0.028,-0.008,-0.07,0.07,0.135,unmethylated
NH21-1442,205292900185_R01C01,233,16/06/2021,7/9/2021,7/7/2021,21,SB,Diagnostic,233,1,NDP,NHNN,"IDH mutant A; Histo LG, Imaging enhancing",(1) small biopsy or nonrepresentative sample;,DEF1A,1/9/1988,33.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.6,AIDH_HG,0.57,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1442,"Astrocytoma, IDH-mutant  see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Astrocytoma, IDH-mutant (see comment)

IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion          
MGMT Promoter: Methylated (>0-5%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 233\NH21-1442,0.028,-0.17,0.114,-0.106,0.949,-0.11,-0.069,0.062,0.028,-0.001,-0.008,0.015,0.036,0.163,-0.036,0.068,-0.142,-0.5,-0.06,0.128,0.721,-0.164,-0.218,0.065,0.014,0.03,0.108,-0.101,0,methylated
NH21-1524,205292900185_R02C01,233,17/06/2021,7/9/2021,7/7/2021,20,SB,Diagnostic,233,1,NDP,NHNN,PA Post Foss,"(4) IHC, sequencing, or copy number assay ambiguous",C5,6/12/2005,16.2,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.99,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1524,"Histology: Pilocytic Astrocytoma (WHO grade I)
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
BRAF V600E (Sequencing): No mutation
MGMT promoter (Illumina array): Unmethylated  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 233\NH21-1524,-0.11,0.027,0.045,0.024,-0.043,0.027,0.117,0.021,-0.035,-0.09,0.173,-0.03,0.152,0.038,0.026,0.008,-0.018,-0.026,0.007,-0.035,-0.05,0.034,-0.027,0.031,0.073,0.046,0.051,0.014,0.052,unmethylated
NH21-1589,205292900185_R05C01,233,23/06/2021,7/9/2021,7/7/2021,14,SB,Diagnostic,233,1,NDP,Oxford John Radcliffe Hospital,Spinal Glioma tiny sample,(1) small biopsy or nonrepresentative sample;,1&2,6/6/1961,60.9,high-grade astrocytoma with piloid features,0.99,ANAPA,0.65,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1589,"Histology: Astrocytoma (see comment) 
Methylation profile: Anaplastic pilocytic astrocytoma (low calibrated score, see comment)
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 233\NH21-1589,-0.061,-0.001,0.031,0.036,0.04,0.017,0.083,-0.016,-0.015,-0.024,0.362,-0.012,0.099,0.062,-0.928,-0.003,0.018,0.063,0.044,0.013,0.043,-0.014,-0.285,-0.18,-0.029,-0.032,0.013,-0.01,0.016,methylated
NH21-1562,205292900185_R06C01,233,22/06/2021,7/9/2021,7/7/2021,15,SB,Diagnostic,233,3,NDP,"Cambridge, Addenbrooke's Hospital",Diffuse glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,8/21/1960,61.7,"control tissue, white matter (corpus callosum)",0.63,CONTR_HEMI,0.15,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1562,"Suspicious for a diffusely infiltrating glioma, IDH-wildtype  see comment

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
TERT promoter: Mutation
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
Methylation profile: No matching methylation tumour class (see comment)
MGMT promoter (Illumina array): Unmethylated
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 233\NH21-1562,0.032,-0.036,0.016,0.022,-0.03,-0.016,0.01,0.058,0.102,0.02,0.048,-0.012,-0.015,0.064,-0.051,0.027,-0.041,-0.024,-0.017,0.003,-0.012,0,-0.029,0.056,0.067,0.002,-0.056,-0.024,0.013,unmethylated
NH21-1570,205292900087_R01C01,234,23/06/2021,7/15/2021,7/14/2021,21,SB,Diagnostic,234,1,NDP,Nottingham University Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/13/2003,17.8,supratentorial pilocytic astrocytoma,0.96,LGG_PA_GGST,0.82,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1570,"Histology: Low-grade glioma / glioneuronal tumour 
Methylation profile: Suggestive of pilocytic astrocytoma (low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated 
  
","Low grade glioma/glioneuronal tumour, methylation profile suggestive of pilocytic astrocytoma
KIAA:BRAF: No fusion
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 234\NH21-1570,-0.011,-0.048,-0.041,0.006,-0.07,-0.011,0.052,-0.036,0.061,-0.055,0.062,-0.009,0.082,0.1,0.064,0.007,0.035,-0.01,0.004,0.013,-0.012,0.113,-0.003,0.061,0.06,0.069,0.005,0.042,0.047,unmethylated
NH21-1538,205292900087_R02C01,234,22/06/2021,7/15/2021,7/14/2021,22,AM,Diagnostic,234,1,NDP,Brighton and Sussex Hospital,Low grade glioma/GNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,7/26/1972,49.6,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.56,LGG_DNT,0.55,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1538,"Low-grade glioma  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Low-grade glioma / glioneuronal tumour
Methylation profile: Suggestive of dysembryoplastic neuroepithelial tumour (see comment)
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 234\NH21-1538,-0.036,-0.062,0.016,-0.002,-0.024,0.076,0.083,0.023,0.019,-0.037,0.039,-0.006,-0.007,0.061,0.063,-0.004,0.003,-0.021,-0.014,0.016,0.028,0.136,-0.079,-0.034,-0.051,0.005,0.046,-0.092,-0.108,methylated
NH21-1549,205292900087_R03C01,234,22/06/2021,7/15/2021,7/14/2021,22,AM,Diagnostic,234,1,NDP,NHNN,High grade glioma ? GBM ,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,7/17/1958,63.8,"glioblastoma, IDH-wildtype, RTK1 type",0.87,GBM_RTKI,0.56,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1549,"SP1/DEF1: Left posterior temporal lobe lesion, biopsy: High-grade glioma  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending

SP2/DEF2: Sphenoid wing, extra-axial lesion, excision: Atypical meningioma (WHO grade II)  see comment
","SP1/DEF1: Left posterior temporal lobe: High-grade glioma, IDH-wildtype
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
MGMT Promoter: Unmethylated (0%)

SP2/DEF2: Sphenoid wing lesion: Atypical Meningioma (WHO grade II)
TERT promoter: No mutation
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 234\NH21-1549,-0.011,-0.017,0.013,-0.034,0.447,0.077,-0.127,0.142,0.179,0.182,0.155,-0.011,0.07,0.067,-0.818,0.011,-0.204,-0.25,-0.025,-0.026,-0.035,0.149,0.043,0.024,0.029,0.015,-0.012,0.03,-0.005,unmethylated
NH21-1540,205292900087_R05C01,234,23/06/2021,7/15/2021,7/14/2021,21,AM,Diagnostic,234,1,NDP,Romford,Spinal ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,1/19/1978,44,spinal ependymoma,1,EPN_SPINE,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1540,"Ependymoma  see comment.
","Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 234\NH21-1540,0.045,0.022,-0.005,-0.028,-0.021,0.138,0,0.027,0.048,0.003,-0.009,-0.269,-0.212,-0.154,0.17,0.191,-0.19,-0.253,-0.002,0.033,-0.046,0.005,-0.272,0.029,0.027,-0.003,-0.271,-0.673,-0.716,unmethylated
NH21-1545,205292900087_R06C01,234,23/06/2021,7/15/2021,7/14/2021,21,SB,Diagnostic,234,1,NDP,"Birmingham, Queen Elizabeth Hospital",glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/6/2002,19.3,dysembryoplastic neuroepithelial tumour,0.99,LGG_DNT,0.86,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1545,"Histology: Low grade glioma / glioneuronal tumour (see comment)
Methylation profile: Suggestive of dysembryoplastic neuroepithelial tumour (see comment)
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 234\NH21-1545,-0.085,-0.074,-0.066,-0.016,-0.036,0.043,0.178,0.134,0.178,0.141,0.123,0.015,0.011,0.108,0.057,0.03,0.034,0.055,0.047,0.021,-0.052,0.038,-0.075,-0.023,-0.065,-0.066,-0.083,-0.066,-0.025,unmethylated
NH21-1256,205292900087_R07C01,234,18/06/2021,7/15/2021,7/14/2021,26,SB,Diagnostic,234,1,NDP,NHNN,"PA PF, no BRAF fusion","(4) IHC, sequencing, or copy number assay ambiguous",DEF1A,12/25/1993,27.8,infratentorial pilocytic astrocytoma,0.7,LGG_PAPF,0.39,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1256,"Pilocytic astrocytoma (WHO grade I)  see comment
","Histology: Pilocytic astrocytoma (WHO Grade I)
Methylation profile: Suggestive of pilocytic astrocytoma (see comment)
MGMT promoter (Illumina array): Unmethylated 
Fusion (RNA Seq): MBNL1/RAF1 
KIAA1549-BRAF: No fusion
BRAF V600E (seq): No mutation
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 234\NH21-1256,0.013,0.005,-0.035,-0.008,-0.027,-0.015,0.066,0.005,0.006,0.009,-0.027,-0.006,0.049,0.016,0.026,0.011,0.021,0.005,-0.002,0.008,-0.024,0.002,-0.016,-0.009,0.018,-0.023,-0.045,0.024,0.023,unmethylated
NH21-1543,205292900087_R08C01,234,23/06/2021,7/15/2021,7/14/2021,21,SB,Diagnostic,234,1,NDP,Southampton General Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2B,7/12/1978,43.6,posterior fossa ependymoma group B,1,EPN_PFB,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1543,"Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, posterior fossa group B
MGMT promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 234\NH21-1543,0.013,-0.305,-0.221,0.003,0.009,0.021,-0.265,0.021,-0.016,-0.016,-0.002,0.21,0.217,0.243,0.015,0.042,0.033,0.011,-0.208,0.002,0.013,0.103,-0.03,-0.282,-0.341,-0.296,-0.235,-0.244,-0.278,unmethylated
NH21-1587,205292900085_R02C01,235,24/06/2021,7/15/2021,7/14/2021,20,SB,Diagnostic,235,2,NDP,Newcastle,GBM IDHmut,"(2) unusual histology, location, demographics",1A,12/15/1958,63.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.8,AIDH,0.94,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1587,"PR036103B/19, block 1A: 
Histology: Diffuse astrocytoma (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 

PR018971A/21, block 2A: 
Histology: Glioblastoma (WHO grade IV)
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 235\NH21-1587,0.092,-0.015,0.038,0.044,-0.044,-0.015,-0.076,0.073,0.188,0.231,0.23,-0.033,-0.006,0.044,-0.246,0.065,0.026,-0.067,0.009,0.126,0.002,0.031,-0.023,0.108,0.025,-0.014,-0.196,-0.08,-0.004,methylated
NH21-1587,205292900085_R03C01,235,24/06/2021,7/15/2021,7/14/2021,20,SB,Diagnostic,235,2,NDP,Newcastle,GBM IDHmut,"(2) unusual histology, location, demographics",2A,12/15/1958,63.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.89,AIDH_HG,0.98,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1587,"PR036103B/19, block 1A: 
Histology: Diffuse astrocytoma (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 

PR018971A/21, block 2A: 
Histology: Glioblastoma (WHO grade IV)
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 235\NH21-1587,0.217,-0.025,-0.007,0.001,0.012,0.064,0.026,0.02,0.14,0.351,-0.019,-0.057,0.005,0.208,-0.649,0.016,0.061,0.002,0.03,0.031,-0.002,0.08,-0.188,0.015,0.025,0.153,-0.367,-0.048,-0.01,methylated
NH21-1591,205292900085_R05C01,235,24/06/2021,7/15/2021,7/14/2021,20,AM,Diagnostic,235,3,NDP,NHNN,Spinal ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,4/16/1967,55,spinal ependymoma,0.17,EPN_SPINE,0.24,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1591,"Ependymoma  see comment
","Histology: Ependymoma (WHO grade II)
Methylation profile: Spinal ependymoma (low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 235\NH21-1591,0.088,0.03,0.003,-0.003,0.021,0.023,0.007,0.014,-0.033,0.012,-0.012,0.196,0.261,0.321,0.068,0.037,-0.027,-0.001,0.011,-0.052,-0.067,0.025,-0.039,0.016,-0.018,0.033,0.016,-0.02,0.002,unmethylated
NH21-1588,205292900085_R06C01,235,24/06/2021,7/15/2021,7/14/2021,20,SB,Diagnostic,235,1,NDP,Newcastle,Frontal Astro,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,8/12/1992,29.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.98,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1588,"Anaplastic Astrocytoma, IDH-mutant (WHO grade III at least) - see comment
IDH1/2Seq: Mutation     
ATRX (IHC): Probable loss of expression (indicates probable mutation) - see comment 
TERT promoter: No mutation     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
","Histology: High-grade Astrocytoma, IDH-mutant (WHO grade III at least) - see comments
Methylation profile: IDH-glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 235\NH21-1588,0.007,0.179,0.014,0.009,0.046,-0.017,0.064,-0.004,0.235,0.244,0.248,0.018,0.033,0.686,-0.456,0.033,0.035,0.045,-0.019,0.007,-0.046,0.109,-0.118,-0.01,-0.013,0.053,-0.012,0.015,-0.046,methylated
NH21-1580,205589740077_R01C01,236,25/06/2021,7/16/2021,7/16/2021,21,AM,Diagnostic,236,1,NDP,NHNN,? chordoid meningioma ? metastatic tumour (RCC),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,12/21/1948,73.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.51,MNG,0.28,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1580,"Atypical tumour - see comment
","Histology: Clear cell renal cell carcinoma (see UCLH histopathology report and NHNN supplementary report) 
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 236\NH21-1580,-0.067,0.049,-0.034,-0.041,-0.135,0.02,0.065,0.063,0.059,0.041,0.052,-0.116,-0.089,-0.106,-0.247,-0.031,-0.003,-0.043,-0.057,-0.027,-0.031,0.045,-0.107,-0.031,0.02,-0.037,-0.035,-0.004,-0.013,unmethylated
NH21-1604,205589740077_R02C01,236,25/06/2021,7/16/2021,7/16/2021,21,AM,Diagnostic,236,1,NDP,NHNN,? Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,2/19/2005,16.6,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.96,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1604,"Pilocytic astrocytoma (WHO grade I)  see comment
","Pilocytic astrocytoma (WHO grade I)
KIAA1549-BRAF: Fusion present
BRAF V600E (IHC and seq): No mutation
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 236\NH21-1604,-0.052,-0.039,-0.056,0.005,-0.057,0.072,0.081,0.061,0.117,0.101,0.204,0.019,0,0.089,0.065,0.058,0.041,0.031,0.093,-0.004,-0.078,0.022,0.005,-0.013,-0.021,-0.019,-0.071,-0.024,-0.029,unmethylated
NH21-1632,205589740077_R04C01,236,28/06/2021,7/16/2021,7/16/2021,18,AM,Diagnostic,236,1,NDP,Nottingham University Hospital,? ependymoma ? pilocytic,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,8/24/1968,53.6,posterior fossa subependymoma,1,SUBEPN_PF,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1632,"Histology: Ependymal tumour 
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
","Histology: Pending tumour
Molecular profiling (methylation array): Subependymoma, posterior fossa
Further molecular tests: No BRAF fusion
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 236\NH21-1632,0.031,0.008,-0.009,-0.049,0.048,0.013,-0.367,0.045,-0.012,0.034,-0.008,-0.057,-0.05,0.031,0.028,-0.026,-0.011,-0.006,-0.095,-0.029,-0.078,0.052,-0.044,-0.014,-0.006,0.022,-0.029,-0.018,-0.032,unmethylated
NH21-1613,205589740077_R07C01,236,28/06/2021,7/16/2021,7/16/2021,18,AM,Diagnostic,236,1,NDP,"Belfast, Royal Victoria Hospital",Glioblastoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A4,3/2/1975,47,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1613,"Glioblastoma, IDH-wildtype (WHO grade IV) - see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Not Codeleted
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)

","Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK I
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 236\NH21-1613,0.001,0.033,0.012,0.015,-0.006,0.049,0.011,0.188,0.234,0.27,0.173,-0.039,-0.002,0.05,-0.396,0.008,0.027,0.006,0.027,-0.012,0.02,0.083,-0.038,0.192,0.312,0.219,0.104,-0.056,-0.011,unmethylated
NH21-1420,205589740077_R08C01,236,28/06/2021,7/16/2021,7/16/2021,18,SB,Diagnostic,236,3,NDP,"Belfast, Royal Victoria Hospital",Anaplastic pilocytic astrocytoma,"(2) unusual histology, location, demographics",B1,12/20/1965,56.3,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.4,GBM_RTKI,0.5,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1420,"Histology: Glioblastoma, WHO grade IV
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK II
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 236\NH21-1420,0.02,0.004,-0.009,-0.001,0.015,0.065,0.039,0.931,0.183,0.228,0.159,-0.029,-0.007,-0.003,-0.941,0.007,-0.733,-0.252,-0.04,0,-0.06,0.062,-0.068,-0.003,0.04,0.011,-0.054,-0.266,-0.276,unmethylated
NH21-1585,205589740143_R01C01,237,28/06/2021,7/16/2021,7/16/2021,18,ZJ,Diagnostic,237,1,NDP,Latvia,Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2554,8/14/2004,17.1,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1585,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Pilocytic astrocytoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 237\NH21-1585,-0.026,-0.025,-0.006,0.013,-0.032,0.104,0.136,0.125,0.136,0.171,0.296,0.002,0.014,0.025,0.031,0.046,-0.009,0.016,0.044,0.044,0.004,0.078,-0.033,-0.032,-0.056,0.019,-0.079,-0.018,-0.032,unmethylated
NH21-1668,205589740143_R03C01,237,29/06/2021,7/16/2021,7/16/2021,17,AM,Diagnostic,237,5,NDP,Southampton General Hospital,PF Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1B,11/13/1965,56.4,posterior fossa subependymoma,1,SUBEPN_PF,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1668,"Histology: Ependymoma (WHO grade II)  see comment
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 237\NH21-1668,-0.003,-0.018,0.019,0.041,-0.046,0.022,-0.353,-0.003,-0.01,-0.024,-0.004,-0.014,0.053,0.029,0.077,-0.002,0.027,0.005,0.004,-0.007,-0.013,0.102,0.033,-0.014,0.025,0.017,-0.031,0.006,-0.014,unmethylated
NH21-1546,205589740143_R04C01,237,6/7/2021,7/16/2021,7/16/2021,10,AM,Diagnostic,237,3,NDP,"Cardiff, University Hospital",? LGG ? GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,3/27/1992,29.6,"Diffuse paediatric-type high grade glioma, RTK2 subtype",1,GBM_RTKIII,0.7,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1546,"Low-grade glioma, IDH-wildtype  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Not Codeleted
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
","Histology: Glioma  see comment
Methylation profile: Glioblastoma, IDH-wildtype, RTK III
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 237\NH21-1546,0.068,0.009,0.018,0.042,-0.034,-0.007,-0.029,0.053,0.001,-0.03,-0.003,-0.033,-0.019,0.006,-0.012,0.045,0.02,0.01,0.008,0.043,-0.006,0.084,-0.057,0.039,0.028,0.006,-0.084,-0.007,0.035,unmethylated
NH21-1610,205589740143_R05C01,237,1/7/2021,7/16/2021,7/16/2021,15,AM,Diagnostic,237,1,NDP,"Cardiff, University Hospital",IDH-mutant astrocytoma ? grade,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,4/28/1967,54.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1610,"Histology: Astrocytoma, IDH-mutant (see comment)
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 237\NH21-1610,0.025,-0.049,0.02,0.017,0.007,0.099,0.019,-0.012,0.001,0.034,-0.003,-0.037,0.006,0.194,-0.287,0.002,-0.002,0.015,-0.002,0.196,-0.062,0.045,-0.043,-0.047,0.003,-0.01,-0.067,-0.033,-0.028,methylated
NH21-1635,205589740143_R06C01,237,1/7/2021,7/16/2021,7/16/2021,15,AM,Diagnostic,237,2,NDP,"Birmingham, Queen Elizabeth Hospital",High grade glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,6/11/1965,56.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.84,CONTR_REACT,0.44,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1635,"Histology: High grade glioma, BRAF V600-mutant  for grading, see comment
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 237\NH21-1635,0.03,0.005,-0.004,0.011,0.045,0.082,0.022,0.19,0.253,0.247,0.183,-0.059,-0.021,0.064,-0.084,0.037,-0.052,-0.006,-0.051,-0.042,0.001,0.027,-0.043,0.035,-0.025,-0.038,0.047,-0.122,-0.131,unmethylated
NH21-1661,205589740152_R02C01,238,1/7/2021,7/22/2021,7/21/2021,20,AM,Diagnostic,238,6,NDP,"Birmingham, Queen Elizabeth Hospital",HGG,"(5) Confirmation of rare, unusual or interesting histo-molecular results",B2,1/9/1950,72.5,high-grade astrocytoma with piloid features,0.79,ANAPA,0.69,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1661,"Histology: High grade glioma, compatible with anaplastic astrocytoma with piloid features
Methylation profile: Raising the possibility of anaplastic pilocytic astrocytoma  see comment 
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 238\NH21-1661,0,-0.021,-0.117,-0.02,0.18,0.055,0.006,0.012,0.002,0.042,0.009,-0.025,-0.034,0.055,-1.06,0.029,0.045,0.019,0.019,0.069,0.141,0.28,-0.038,0.009,0.036,0.662,-0.062,-0.046,0.002,methylated
NH21-1676,205589740152_R03C01,238,1/7/2021,7/22/2021,7/21/2021,20,AM,Diagnostic,238,1,NDP,Plymouth,Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1A,6/11/2003,18.3,infratentorial pilocytic astrocytoma,0.51,LGG_RGNT,0.43,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1676,"Histology: Low grade glioma, compatible with pilocytic astrocytoma (WHO grade I)
Methylation profile: Inconclusive  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 238\NH21-1676,-0.032,-0.08,0.024,0.001,-0.05,0,0.024,0.014,0.018,-0.009,-0.012,-0.006,0.002,0.008,0.056,0.018,0.021,0.03,0.047,-0.013,0.031,0.035,-0.039,-0.051,-0.014,-0.043,0.028,-0.014,-0.042,unmethylated
NH21-1638,205589740152_R07C01,238,1/7/2021,7/22/2021,7/21/2021,20,AM,Diagnostic,238,4,NDP,Brighton and Sussex Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,2/3/1957,65.3,spinal ependymoma,1,EPN_SPINE,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1638,"Ependymoma  see comment
","Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 238\NH21-1638,-0.204,0.033,0.122,-0.112,-0.172,0.107,-0.144,0.081,0.08,0.036,0.092,0.113,0.195,0.14,0.166,0.134,-0.138,-0.121,-0.152,0.083,0.098,0.21,-0.185,0.072,0.125,0.13,0.113,-0.702,-0.679,methylated
NH21-1617,205589740152_R08C01,238,1/7/2021,7/22/2021,7/21/2021,20,AM,Diagnostic,238,6,NDP,Romford,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,11/12/1963,58.5,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.31,GBM_MES,0.39,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1617,"Glioma  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: Amplification
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)

Methylation profile: in keeping with glioblastoma, IDH-wildtype,

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 238\NH21-1617,0.254,0.003,0.008,0.043,-0.021,0.05,0.011,0.692,0.382,0.382,0.323,-0.062,0.047,0.045,-0.727,0.023,-0.201,-0.173,0.022,0.011,-0.048,0.025,-0.037,0.04,0.099,0.038,-0.031,-0.058,0.026,unmethylated
NH21-1669,205566000025_R01C01,239,2/7/2021,7/23/2021,7/23/2021,21,AM,Diagnostic,239,1,NDP,Royal London Hospital,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,8/7/1993,28.3,myxopapillary ependymoma,1,EPN_MPE,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1669,"Myxopapillary ependymoma  see comment
","Histology: Myxopapillary ependymoma (WHO grade I)
Methylation profile: Ependymoma, myxopapillary 
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 239\NH21-1669,-0.037,-0.014,0.042,0.153,0.291,0.211,0.022,0.245,0.229,0.287,0.221,0.216,0.26,0.246,0.243,0.274,0.015,0.005,0.005,0.207,0.128,0.294,-0.027,0.219,0.236,0.173,-0.02,0.041,0.014,unmethylated
NH21-1652,205566000025_R04C01,239,2/7/2021,7/23/2021,7/23/2021,21,AM,Diagnostic,239,4,NDP,NHNN,"HGG, IDH-mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,5/12/1981,40.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1652,"High grade glioma, IDH-mutant (WHO grade III at least)  see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Equivocal staining
Further molecular tests: Pending
  
","Histology: Glioblastoma, IDH-mutant (WHO grade IV)
Methylation profile: IDH glioma, subclass high grade astrocytoma
IDH1 (R132H): Mutation
ATRX (IHC): Possible loss of expression
CDKN2A/B: Deletion
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 239\NH21-1652,0.005,-0.061,0.015,-0.335,-0.048,0.099,-0.455,-0.065,-0.05,-0.043,-0.021,-0.013,0.034,-0.013,-0.449,0.009,-0.295,-0.41,-0.053,-0.031,-0.207,-0.119,-0.532,0.082,0.194,0.123,-0.03,-0.385,-0.453,unmethylated
NH21-1637,205566000025_R05C01,239,2/7/2021,7/23/2021,7/23/2021,21,AM,Diagnostic,239,9,NDP,Brighton and Sussex Hospital,? Anaplastic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2H,9/21/1991,30.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.42,AIDH,0.51,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1637,"Anaplastic astrocytoma, IDH-mutant (WHO grade III)  see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Patchy loss of expression (indicating possible mutation)
Further molecular tests: Pending
  
","Histology: Anaplastic astrocytoma, IDH-mutant (WHO grade III)
Methylation profile: IDH glioma, subclass astrocytoma
CDKN2A/B (Illumina array): Deletion
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 239\NH21-1637,-0.006,-0.091,-0.002,0.005,-0.017,0.157,0.002,-0.007,-0.033,-0.067,-0.018,-0.008,0.022,0.015,-0.735,0.178,0.04,-0.044,-0.008,0.124,-0.037,0.06,0.006,0.002,-0.015,0.032,-0.003,0.015,0.004,methylated
NH21-1729,205566000025_R07C01,239,5/7/2021,7/23/2021,7/23/2021,18,AM,Diagnostic,239,1,NDP,"Cambridge, Addenbrooke's Hospital",Glioma,(1) small biopsy or nonrepresentative sample;,B1,1/10/1983,39,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.74,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1729,"Histology: Diffuse astrocytoma, IDH-mutant  for grading, see comment
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 239\NH21-1729,-0.052,-0.096,0.017,-0.013,-0.029,0.108,0.05,-0.031,-0.038,0.175,0.134,-0.007,-0.014,-0.021,0.01,-0.001,0.023,-0.207,-0.043,-0.044,-0.224,-0.261,-0.301,-0.076,-0.023,-0.028,-0.037,-0.013,0.015,unmethylated
NH21-1459,205460730055_R03C01,240,6/7/2021,7/30/2021,7/30/2021,24,AM,Diagnostic,240,2,NDP,Oxford John Radcliffe Hospital,? HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,3/19/1960,62.1,spinal ependymoma,0.11,GBM_MES,0.42,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1459,"High-grade glioma, IDH-wildtype (see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Not codeleted
MGMT Promoter: Unmethylated (0%)
","Histology: High-grade glioma, IDH-wildtype, in keeping with glioblastoma, IDH-wildtype
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 240\NH21-1459,-0.034,-0.039,-0.035,0.04,-0.026,0.087,-0.341,-0.047,-0.044,-0.046,-0.058,-0.072,0.027,0.002,-1.795,0.121,-1.536,-0.24,-0.09,0.04,0.057,0.164,-0.301,0.087,0.457,0.093,0.082,0.034,0.101,unmethylated
NH21-1739,205460730055_R04C01,240,6/7/2021,7/30/2021,7/30/2021,24,AM,Diagnostic,240,2,NDP,"Liverpool, The Walton Centre",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1G,3/26/1959,63.2,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.95,GBM_MES,0.22,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1739,"Low-grade glioma / glioneuronal tumour - see comment
","Histology: Diffusely infiltrating glial tumour
Methylation profile: Inconclusive, but see comment
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 240\NH21-1739,-0.026,0.035,0.018,0.05,-0.057,0.036,0.018,0.164,0.112,0.101,0.095,-0.022,0.083,-0.003,0.017,0.016,-0.017,0.038,0.033,0.053,0.024,0.215,-0.047,-0.049,-0.009,-0.026,0.066,-0.054,0.006,methylated
NH21-1699,205460730055_R05C01,240,7/7/2021,7/30/2021,7/30/2021,23,AM,Diagnostic,240,1,NDP,The London Clinic,? Tumour,(1) small biopsy or nonrepresentative sample;,DEF1A,5/15/1989,32.6,ganglioglioma,0.88,LGG_GG,0.62,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1699,"Grey and white matter with no definite evidence of tumour  see comment
","Histology: Grey and white matter with no definite evidence of tumour
Methylation profile: Control tissue, hemispheric cortex
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 240\NH21-1699,0.068,0.003,-0.045,0.016,-0.019,-0.046,-0.053,-0.034,0.029,-0.034,0.013,-0.025,0.027,0.038,0.038,0.032,0.033,-0.02,-0.026,0.009,0.003,0.057,0.012,0.002,0.053,0.029,-0.029,0.025,0.028,unmethylated
NH21-1705,205460730055_R06C01,240,6/7/2021,7/30/2021,7/30/2021,24,ZJ,Diagnostic,240,2,NDP,HCA (Kuwait),?PA,(1) small biopsy or nonrepresentative sample;,Unstained slides,8/24/2007,14.1,"control tissue, cerebellar hemisphere",0.9,CONTR_CEBM,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1705,"Low grade glioma, suggestive of pilocytic astrocytoma (WHO grade I)  see comment
","Histology: Low grade glioma (see comment)
Methylation profile: Control tissue, cerebellar hemisphere
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 240\NH21-1705,0.017,-0.053,-0.003,0.006,-0.043,0.035,0.06,-0.019,0.012,-0.036,0.062,-0.009,0.083,0.068,0.019,0.019,0.009,0.026,-0.001,-0.084,-0.005,0.07,-0.023,-0.033,-0.02,0.025,0.013,-0.061,0.043,unmethylated
NH21-1702,205460730055_R07C01,240,7/7/2021,7/30/2021,7/30/2021,23,AM,Diagnostic,240,1,NDP,Bristol,? Giant cell GBM,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,12/13/1953,68.5,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.51,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1702,"Histology: High-grade glioma with features of glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 240\NH21-1702,0.111,-0.08,-0.066,-0.085,-0.095,-0.003,-0.113,0.967,0.066,0.016,0.054,-0.086,-0.081,0.005,-0.022,-0.014,-0.102,-0.124,-0.101,-0.006,-0.007,1.519,-0.09,0.044,0.101,0.062,0.047,0,0.076,methylated
NH21-1749,205460730168_R02C01,241,7/7/2021,7/30/2021,7/30/2021,23,AM,Diagnostic,241,1,NDP,"Cambridge, Addenbrooke's Hospital",?Pilocytic with H3K27M IHC+,"(5) Confirmation of rare, unusual or interesting histo-molecular results",B1,4/7/1970,52,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.95,DMG_K27,0.97,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1749,"Histology: Diffuse glioma
Methylation profile: Diffuse midline glioma, H3 K27 M-mutant
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 241\NH21-1749,0.016,-0.012,0.014,-0.03,0.02,-0.046,-0.003,-0.001,0.018,-0.038,-0.008,-0.207,-0.027,0.018,0.143,0.028,-0.051,-0.043,-0.202,0.009,-0.038,-0.074,-0.054,0.003,0.026,-0.117,0,-0.002,0.04,unmethylated
NH21-1741,205460730168_R04C01,241,7/7/2021,7/30/2021,7/30/2021,23,AM,Diagnostic,241,1,NDP,St George's Hospital London,LGG ? Chordoid glioma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A2,11/21/1986,35.1,chordoid glioma,1,CHGL,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1741,"Low-grade glioma - see comment

H3 K27M (IHC): Negative
BRAF V600E (IHC): Negative
","Histology: Low grade glioma
Methylation profile: Chordoid glioma of the third ventricle
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 241\NH21-1741,0.012,0.022,-0.009,0.022,-0.039,-0.01,0.042,0.016,-0.013,-0.018,-0.001,0.005,0.023,0.042,0.053,0.021,0.004,-0.016,0.011,-0.016,-0.043,-0.019,-0.004,-0.032,0.028,-0.044,-0.095,-0.016,0.016,unmethylated
NH21-1717,205460730168_R05C01,241,8/7/2021,7/30/2021,7/30/2021,22,AM,Diagnostic,241,1,NDP,"Cambridge, Addenbrooke's Hospital",Anaplastic PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B3,2/23/1983,38.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.83,CONTR_REACT,0.13,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1717,"Histology: Features compatible with pleomorphic xanthoastrocytoma (WHO grade III)
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 241\NH21-1717,-0.011,-0.038,0.027,0.039,-0.008,0.132,0.036,0.113,0.191,0.294,0.236,-0.036,0.075,-0.003,0.154,0.096,0.006,0.053,-0.029,0.071,0.007,0.057,0.006,-0.042,0.025,-0.004,-0.078,0.105,0.165,methylated
NH21-1727,205460730168_R07C01,241,8/7/2021,7/30/2021,7/30/2021,22,AM,Diagnostic,241,1,NDP,"Belfast, Royal Victoria Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,9/2/1983,38.4,myxopapillary ependymoma,1,EPN_MPE,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1727,"Histology: Ependymal tumour
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 241\NH21-1727,-0.081,0.009,0.075,-0.029,0.01,0.039,0.214,0.165,0.217,0.126,0.162,-0.002,0.086,0.002,0.263,0.225,0.032,0.069,0.186,-0.009,0.01,0.016,-0.323,0.127,0.219,0.126,0.181,-0.242,-0.307,unmethylated
NH21-1537,205460730168_R08C01,241,8/7/2021,7/30/2021,7/30/2021,22,AM,Diagnostic,241,1,NDP,Brighton and Sussex Hospital,? IDH-mutant astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1D,5/25/1995,26.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1537,"Glioma  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Astrocytoma, IDH-mutant (WHO Grade II)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 241\NH21-1537,-0.031,-0.09,0.027,-0.022,-0.006,0.074,0.001,-0.032,-0.055,-0.027,-0.018,-0.017,-0.004,-0.01,0.04,-0.004,0.022,0.049,-0.014,0.212,-0.112,-0.014,-0.024,-0.032,0.013,-0.047,-0.037,0.016,-0.009,methylated
NH21-1533,205605870166_R01C01,242,9/7/2021,8/6/2021,8/4/2021,26,AM,Diagnostic,242,1,NDP,St George's Hospital London,? Glioma ? reactive,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/27/1952,69.5,"control tissue, white matter (corpus callosum)",1,CONTR_WM,0.35,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1533,"CNS tissue with increased cellularity and mild atypia - see comment
","Histology: CNS tissue with increased cellularity and mild atypia
Methylation profile: Control tissue, white matter
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 242\NH21-1533,0.001,-0.019,-0.012,0.059,-0.08,0.008,-0.007,-0.063,0.05,0.001,-0.002,-0.005,0.084,-0.044,0.029,0.027,0.049,-0.062,-0.068,-0.058,0.061,0.138,0.022,0.012,0.076,0.069,-0.065,0.023,0.009,unmethylated
NH21-1768,205605870166_R02C01,242,9/7/2021,8/6/2021,8/4/2021,26,AM,Diagnostic,242,1,NDP,Nottingham University Hospital,Anaplastic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,12/9/1984,37.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.95,AIDH,0.74,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1768,"Histology: Anaplastic astrocytoma (referred diagnosis astrocytoma, IDH-mutant) 
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 242\NH21-1768,0.057,-0.086,0.028,0.042,0.105,-0.006,0.049,0.257,0.262,0.234,0.21,0.216,0.255,0.553,-1.63,0.256,0.054,-0.055,0.027,0.497,0.055,0.018,-0.431,0.263,-0.053,0.037,-0.528,0.011,-0.014,methylated
NH21-1645,205605870166_R03C01,242,13/07/2021,8/6/2021,8/4/2021,22,AM,Diagnostic,242,1,NDP,St George's Hospital London,? GBM ?HGGNT,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,2/21/1962,60.2,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.75,GBM_RTKI,0.65,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1645,"Favouring Glioblastoma, IDH-wildtype (WHO grade IV)  see comment
IDH1 (R132H IHC); IDH1/2Seq: No Mutation     
ATRX (IHC): Retained     
TERT promoter: Mutation
BRAF (V600E): No Mutation
MGMT Promoter: Methylated (>5-10%)
","Histology (including previous tests): Glioblastoma, IDH-wildtype (WHO Grade IV)
Methylation profile: Glioblastoma, IDH wildtype, subclass RTK I
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 242\NH21-1645,-0.03,-0.086,0.044,0.029,0.313,0.035,0.055,0.246,0.266,0.179,0.206,-0.01,0.042,0.038,0.127,0.033,-0.261,-0.411,-0.052,0.049,0.921,0.101,0.012,0.06,-0.001,0.052,-0.115,-0.023,-0.006,methylated
NH21-1474,205605870166_R04C01,242,13/07/2021,8/6/2021,8/4/2021,22,AM,Diagnostic,242,2,NDP,St George's Hospital London,LGG ?PA (repeat MA),"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,4/29/1987,34.6,supratentorial pilocytic astrocytoma,0.99,LGG_PA_GGST,0.87,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1474,"Histology: Low grade glial/glioneuronal tumour.
Methylation profile: low calibrated score (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 242\NH21-1474,0.081,0.001,-0.051,-0.004,-0.056,-0.018,-0.002,0.023,0.022,-0.012,0,0.192,0.006,-0.005,0.09,-0.001,-0.002,-0.085,0.017,0.048,0.003,0.107,0,0.067,0.031,-0.024,-0.115,-0.024,-0.017,unmethylated
NH21-1523,205605870166_R07C01,242,14/07/2021,8/6/2021,8/4/2021,21,AM,Diagnostic,242,4,NDP,"Belfast, Royal Victoria Hospital",?Astrocytoma ? Oligo,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,8/11/1989,32.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.66,AIDH,0.82,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1523,"Diffuse astrocytoma, IDH-mutant (see comment)
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained     
CDKN2A/B: No deletion          
MGMT Promoter: Methylated (>0-5%)
","Histology: Astrocytoma, IDH-mutant (grading see main report)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 242\NH21-1523,-0.008,-0.025,0.004,-0.003,-0.007,0.034,0.03,0.018,0.011,0.051,0.03,-0.005,0.013,0.024,0.016,-0.028,0.013,-0.025,-0.026,0.144,-0.008,-0.004,-0.233,0.029,0.015,-0.029,-0.089,-0.046,0.008,methylated
NH21-1790,205605880001_R01C01,243,16/07/2021,8/6/2021,8/4/2021,19,AM,Diagnostic,243,1,NDP,HCA,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A4,8/24/2007,14.1,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1790,"Low grade glioma, favouring pilocytic astrocytoma (WHO grade I)  see comment 
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Focal loss of expression (equivocal for mutation)
Further molecular tests: Pending
  
","Histology: Low grade glioma, favouring pilocytic astrocytoma (WHO grade I)
Methylation profile: Pilocytic astrocytoma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 243\NH21-1790,-0.126,-0.06,0.022,0.012,-0.09,0.035,0.078,-0.061,-0.006,-0.04,0.188,0.005,0.024,0.04,0.055,-0.034,0.086,0.015,-0.014,-0.004,0.017,0.141,-0.032,0.038,0.04,0.031,-0.022,-0.123,-0.037,unmethylated
NH21-1805,205605880001_R02C01,243,16/07/2021,8/6/2021,8/4/2021,19,AM,Diagnostic,243,1,NDP,Romford,IDH mutant astro ? grade,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/7/1986,35.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1805,"Recurrent / residual diffuse astrocytoma, IDH-mutant  see comment
Molecular pathology results for NH16-1177:
IDH1: G395T mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending (NH21-1805)
  
","Histology: Astrocytoma, IDH-mutant (description and comment see main report)
Methylation profile: IDH glioma, subclass astrocytoma,
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 243\NH21-1805,-0.034,-0.066,0.11,0.032,0.027,-0.321,-0.254,-0.02,0.031,-0.043,-0.026,-0.011,0.163,0.406,0.078,0.033,0.023,-0.079,0.018,0.008,0.168,0.077,-0.12,0.118,-0.014,0.084,-0.016,-0.027,0.082,methylated
NH21-1811,205605880001_R05C01,243,16/07/2021,8/6/2021,8/4/2021,19,AM,Diagnostic,243,3,NDP,Newcastle,DMG,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1B,11/3/2016,4.8,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.98,DMG_K27,0.97,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1811,"Likely, Diffuse Midline Glioma, H3 K27M-mutant (WHO grade IV) - see comment
H3 K27M (IHC): Positive
","Histology: Diffuse midline glioma (H3 K27M-mutant), WHO grade IV)
Methylation profile: Diffuse midline glioma H3 K27M mutant
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 243\NH21-1811,0.236,0.39,0.379,0.2,0.594,0.023,0.048,0.205,0.242,0.227,0.223,-0.035,0.154,0.084,0.187,0.071,0.064,0.036,0.232,0.018,0.107,0.101,-0.028,0.023,0.008,0.072,0.124,0.017,-0.028,unmethylated
NH21-1839,205605880001_R06C01,243,16/07/2021,8/6/2021,8/4/2021,19,AM,Diagnostic,243,1,NDP,"Liverpool, The Walton Centre",Spinal cord glioma,(1) small biopsy or nonrepresentative sample;,1A,11/14/1968,53.4,spinal ependymoma,1,EPN_SPINE,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1839,"Histology: Low grade glioma, DD ependymoma
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 243\NH21-1839,0.104,0.065,0.016,0.023,-0.036,0.156,-0.016,0.294,0.291,0.241,0.253,-0.014,-0.05,-0.223,-0.015,0.019,-0.018,-0.034,0.007,0.25,0.203,0.307,-0.103,0.051,-0.058,-0.127,-0.003,-0.521,-0.385,unmethylated
NH21-1785,205605880001_R08C01,243,16/07/2021,8/6/2021,8/4/2021,19,AM,Diagnostic,243,1,NDP,"Birmingham, Queen Elizabeth Hospital",LGG / LGGNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,9/16/1990,31.3,extraventricular neurocytoma,1,LGG_DNT,0.31,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1785,"Histology: Low grade glioneuronal tumour
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 243\NH21-1785,0.103,-0.047,-0.021,-0.038,-0.024,-0.042,0.036,-0.044,-0.004,0.052,0.002,-0.009,0.006,0.042,-0.059,0.054,0.022,-0.013,0.001,0.092,0.002,0.09,-0.072,0.084,0.07,-0.073,-0.054,-0.061,0.07,unmethylated
NH21-1783,205605880003_R01C01,244,16/07/2021,8/6/2021,8/4/2021,19,AM,Diagnostic,244,1,NDP,"Birmingham, Queen Elizabeth Hospital",LGG/GNT ? DNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/1/2002,19.4,dysembryoplastic neuroepithelial tumour,1,LGG_DNT,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1783,"Histology: Dysembryoplastic neuroepithelial tumour
Methylation profile: low grade glioma, dysembryoplastic neuroepithelial tumor
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 244\NH21-1783,0.108,-0.036,-0.009,-0.035,-0.053,-0.055,-0.016,0.003,0.045,-0.074,0.017,0.254,0.293,0.216,-0.008,0.009,0.041,-0.036,0.048,0.015,0.027,0.011,-0.028,0.028,0.04,-0.033,-0.206,-0.142,-0.114,unmethylated
NH21-1828,205605880003_R08C01,244,21/07/2021,8/6/2021,8/4/2021,14,ZJ,Diagnostic,244,2,NDP,Bristol,Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,2/4/2008,13.6,supratentorial midline pilocytic astrocytoma,0.06,IHG,0.12,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1828,"Histology: Low grade glioneuronal tumour
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 244\NH21-1828,0.139,0.114,0.045,0.049,0.173,-0.034,0.003,0.234,0.227,0.147,0.168,-0.021,0.095,0.476,0.215,0.304,0.015,-0.09,-0.092,0.509,-0.02,0.115,-0.067,0.336,-0.065,-0.087,0.082,0.021,0.174,unmethylated
NH21-1835,205605880035_R02C01,245,21/07/2021,8/6/2021,8/6/2021,16,ZJ,Diagnostic,245,1,NDP,"Charing Cross Hospital, London",Myxopapillary ependymoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/24/1987,34,myxopapillary ependymoma,1,EPN_MPE,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1835,"Histology: Ependymal tumour
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 245\NH21-1835,0.006,-0.016,0.021,0.029,-0.005,0.17,0.056,-0.017,0.009,-0.031,0.004,-0.003,0.055,-0.009,0.285,0.278,0.004,0.019,-0.034,0.005,0.007,0.025,0.018,0.216,0.317,0.213,-0.021,-0.012,0.027,methylated
NH21-1852,205605880035_R05C01,245,21/07/2021,8/6/2021,8/6/2021,16,ZJ,Diagnostic,245,1,NDP,Newcastle,?GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3A,3/3/1951,71.4,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.14,CN,0.1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1852,"Histology: Glial tumour, high-grade
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Methylated 
  
","Histology: Glial tumour, high grade
Methylation profile: no matching methylation class
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 245\NH21-1852,-0.2,-0.02,0.053,0.275,-0.023,0.004,0.021,0.154,0.251,0.174,0.163,-0.122,0.01,-0.226,0.145,-0.062,0.031,-0.173,0.217,0.019,0.193,0.336,-0.008,-0.117,-0.052,0.15,-0.328,-0.536,-0.069,methylated
NH21-1875,205605880035_R06C01,245,22/07/2021,8/6/2021,8/6/2021,15,SB,Diagnostic,245,1,NDP,Royal London Hospital,?GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,10/9/1994,27.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1875,"Glioblastoma, IDH-mutant (WHO grade IV)
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Glioblastoma, IDH-mutant (WHO grade IV)
Methylation profile: IDH glioma, subclass high-grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 245\NH21-1875,-0.065,0.926,0.136,0.075,0.739,0.057,0.151,-0.057,-0.096,-0.039,-0.078,-0.009,0.09,-0.035,0.006,0.077,-0.265,-0.159,0.123,-0.104,0.755,-0.119,-0.034,0.101,-0.006,-0.076,0.045,-0.101,-0.06,methylated
NH21-1885,205605880038_R02C01,246,23/07/2021,8/6/2021,8/6/2021,14,SB,Diagnostic,246,1,NDP,Romford,Unusual Meningioma Recurrence,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A8,11/4/1942,79.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.82,MELAN,0.27,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1885,"Recurrent meningioma, (WHO grade II) - see comment
","Review, excision, occipital brain tumour: a high grade spindle cell tumour with features in keeping with a high grade meningioma. We understand that the original diagnosis of meningioma has been challenged by the result from the methylation profiling, which raised the possibility of an undifferentiated sarcoma.
We do not recommend the use of methylation profiling for classification of sarcoma (see DNA methylation-based profiling of bone and soft tissue tumours: a validation study of the 'DKFZ Sarcoma Classifier'. Lyskjaer I, DeNoon S, Tirabosco R, Rocha AM, Lindsay D, Amary F, Ye H, Schrimpf D, Stichel D, Sill M, Koelsche C, Pillay N,Von Deimling A, Beck S, Flanagan AM. J Pathol Clin Res. 2021 Jul;7(4):350-360. PMID: 33949149
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 246\NH21-1885,-0.075,0.076,-0.01,0.102,0.712,0.275,0.044,-0.077,-0.087,-0.055,-0.041,-0.052,-0.032,0.023,-0.787,-0.069,0.117,0.018,-0.022,-0.143,-0.029,-0.012,-0.062,-0.044,-0.015,0.039,-0.116,0.145,0.076,unmethylated
NH21-1934,205605880038_R04C01,246,27/07/2021,8/6/2021,8/6/2021,10,SB,Diagnostic,246,1,NDP,"Belfast, Royal Victoria Hospital",GBM,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A,11/18/1959,62.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.8,GBM_RTKII,0.51,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1934,"Histology: Glioblastoma (WHO grade IV), see comment
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 246\NH21-1934,-0.009,-0.026,-0.024,-0.064,0.016,0.051,0.077,1.05,0.257,0.3,0.226,-0.023,0.022,0.05,-0.611,0.01,-0.574,-0.182,-0.009,0.004,0.068,0.059,-0.037,-0.033,0.051,0.011,0.072,0.024,0.006,unmethylated
Nh21-1917,205605880038_R06C01,246,27/07/2021,8/6/2021,8/6/2021,10,SB,Diagnostic,246,1,NDP,Nottingham University Hospital,CPP?,"(2) unusual histology, location, demographics",A1,12/4/1994,27,posterior fossa ependymoma group B,1,EPN_PFB,0.55,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",Nh21-1917,"Histology: Papillary intrinsic tumour
Methylation profile: Low calibrated score, see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 246\Nh21-1917,0.002,0.004,-0.104,0.182,0.215,0.368,-0.225,0.29,0.214,0.196,0.213,-0.782,-0.71,-0.668,0.399,0.481,-0.069,-0.098,0.082,0.309,0.212,0.262,0.391,0.358,0.186,0.17,0.244,-0.128,-0.129,methylated
NH21-1913,205605880038_R07C01,246,27/07/2021,8/6/2021,8/6/2021,10,SB,Diagnostic,246,1,NDP,Nottingham University Hospital,Intrinsic tumour,"(2) unusual histology, location, demographics",A1,5/29/1974,47.8,supratentorial pilocytic astrocytoma,0.99,LGG_PA_GGST,0.81,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1913,"Histology: High-grade glioma (see comment)
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
","Glioma, IDH-wildtype (see comments for grading)
IDH1/2Seq: No mutation
ATRX (IHC): Retained     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
Methylation profile: No matching methylation class
MGMT Promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 246\NH21-1913,0.063,-0.058,-0.002,0,-0.044,0.116,0.275,0.074,0.116,0.08,0.094,0.008,0.052,0.034,-0.029,-0.024,0.124,0.062,0.028,0.003,0.008,0.044,-0.01,0.009,0.035,-0.04,-0.031,0.062,0.046,unmethylated
NH21-1944,205605880038_R08C01,246,27/07/2021,8/6/2021,8/6/2021,10,SB,Diagnostic,246,1,NDP,"Riga, Latvia",L2/3 Myxopapillary Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",3038-2021,8/14/2015,6,supratentorial midline pilocytic astrocytoma,1,LGG_PAMID,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1944,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Midline pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 246\NH21-1944,0.041,0.036,0.006,0.049,-0.008,0.017,0.039,0.019,0.038,0.004,0.158,-0.025,0.046,0.028,0.009,0.036,0.029,0.031,0.046,0.007,-0.007,0.037,-0.009,-0.025,0.055,0.004,-0.059,0.002,0.026,unmethylated
NH21-1943,205648300146_R01C01,247,27/07/2021,8/27/2021,8/27/2021,31,SB,Diagnostic,247,1,NDP,"Riga, Latvia",Schwannoma L2/3,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",3041-2021,7/15/2012,9.2,myxopapillary ependymoma,1,EPN_MPE,0.99,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1943,"Histology: Myxopapillary ependymoma (WHO grade I)
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 247\NH21-1943,-0.288,-0.022,-0.044,0.072,0.107,0.066,-0.074,0.151,0.148,0.163,0.127,-0.102,-0.143,0.029,0.186,0.342,-0.089,-0.029,0.095,-0.031,-0.126,-0.146,0.08,0.08,0.171,0.055,0,-0.253,-0.117,unmethylated
NH21-1954,205648300146_R04C01,247,28/07/2021,8/27/2021,8/27/2021,30,SB,Diagnostic,247,9,NDP,Kaunas (LT),"3rd Ventr tumour, Plexus- ca??","(2) unusual histology, location, demographics",,4/28/2012,9.4,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.96,DMG_K27,0.79,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1954,"Histology: High grade glioma  see comment
Methylation profile: Suggestive of diffuse midline glioma, H3 K27-mutant (WHO grade IV)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 247\NH21-1954,0.18,-0.02,0.002,0.13,0.564,-0.033,-0.027,0.022,0.06,0.718,0.164,0.11,0.037,0.146,-0.087,0.045,-0.033,-0.008,0.027,0.014,-0.046,0.054,-0.251,0.121,0.086,-0.027,0.072,-0.131,0.024,unmethylated
NH21-1977,205648300146_R06C01,247,3/8/2021,8/27/2021,8/27/2021,24,SB,Diagnostic,247,1,NDP,Oxford John Radcliffe Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2B,1/31/2005,16.7,"glioblastoma, IDH-wildtype, mesenchymal type",0.42,LGG_SEGA,0.16,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1977,"Low-grade glioma / glioneuronal tumour (WHO grade I)

BRAF V600E: Mutation
","Histology: Low grade glial or glioneuronal tumour
Methylation profile: Inconclusive  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 247\NH21-1977,-0.104,-0.019,0.034,-0.062,-0.125,0.137,0.093,0.105,0.158,0.105,0.087,0.035,0.137,0.129,-0.004,-0.03,-0.028,0.018,-0.074,0.069,0.119,0.147,0.041,0.076,0.057,0.004,0.074,-0.143,0.017,unmethylated
NH21-1947,205648300146_R07C01,247,3/8/2021,8/27/2021,8/27/2021,24,SB,Diagnostic,247,9,NDP,NHNN,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1B,9/24/1990,31.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.97,AIDH,0.83,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1947,"Astrocytoma, IDH-mutant (for grading see comment).
IDH1 (R132H IHC): Mutation      
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH-glioma, subclass astrocytoma  see comment
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 247\NH21-1947,-0.089,-0.06,0.061,-0.047,-0.053,0.059,0.087,-0.005,0.007,-0.048,-0.013,-0.003,0.062,0.059,-0.151,0.022,0.075,0.112,0.039,0.069,0.015,0.077,-0.022,0.035,0.028,-0.032,0.021,-0.101,0.004,methylated
NH14-2217,205605880028_R01C01,248,29/07/2021,8/13/2021,8/11/2021,13,SB,Research,248,5,NDP,NHNN,Oligodendroglioma,"(6) Research sample, for stratification or subclassification",,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-2217,"Anaplastic Oligoastrocytoma (WHO grade III).
IDH1 (R132H IHC): Mutation. 
ATRX (IHC): Loss of expression (indicates mutation). 
1p/19q: Test pending (previous specimen NH13-1919 showed 1p/19q LOH).
  
","Histology: Astrocytoma, IDH-mutant (WHO grade III)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 248\NH14-2217,0.025,0.021,0.054,-0.044,0.015,-0.065,-0.528,0.067,0.072,-0.018,0.024,-0.001,0.053,0.183,-0.334,0.103,0.018,-0.047,0.052,0.125,0.029,0.007,-0.097,0.102,0.047,-0.089,-0.331,-0.242,-0.036,methylated
NH17-540,205605880039_R04C01,249,29/07/2021,8/13/2021,8/11/2021,13,SB,Research,249,1,NDP,NHNN,Oligodendroglioma,"(6) Research sample, for stratification or subclassification",,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.85,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-540,"Recurrent anaplastic oligodendroglioma (WHO Grade III)

IDH1 (R132H IHC): Mutation (tested on the previous resection specimen, NH09-1064)
ATRX (IHC): Retained      
1p/19q: Co-deleted (tested on the previous resection specimen, NH09-1064)
     
 
","Recurrent anaplastic oligodendroglioma (WHO grade III) 
IDH1/2 Seq: IDH1 mutation 
ATRX (IHC): Retained 
1p/19q: Codeleted 
EGFR: No amplification
MGMT Promoter: Intermediate level methylation (>10-25%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 249\NH17-540,-0.032,-0.001,0.069,-0.341,-0.484,-0.002,0.047,-0.008,-0.043,-0.107,-0.068,-0.013,0.079,0.085,-2.591,0.133,0.032,-0.12,0.076,0.104,0.056,0.029,-0.047,0.026,0.026,0.056,-0.685,-0.425,-0.419,methylated
NH21-1964,205648300085_R01C01,250,3/8/2021,8/27/2021,8/27/2021,24,SB,Diagnostic,250,1,NDP,Nottingham University Hospital,Anaplastic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,11/24/1958,63.6,spinal subependymoma [subtype B],0.6,GBM_MYCN,0.16,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1964,"Histology: Glial tumour  see comment
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 250\NH21-1964,0.077,0.421,0.295,0.14,-0.051,-0.121,-0.137,0.672,0.504,0.538,0.467,0.004,0.03,0.17,-0.094,0.024,-0.009,0.05,0.373,0.14,0.098,0.14,-0.024,0.277,0.077,-0.049,0.053,0.123,0.369,unmethylated
NH21-1961,205648300085_R03C01,250,3/8/2021,8/27/2021,8/27/2021,24,SB,Diagnostic,250,3,NDP,Nottingham University Hospital,Diffuse midline glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,9/22/2015,5.9,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",1,DMG_K27,0.98,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1961,"Histology: Diffuse midline glioma, H3 K27M-mutant (WHO grade IV)
Methylation profile: Diffuse midline glioma, H3 K27M-mutant
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 250\NH21-1961,0.254,0.104,0.113,0.016,0.337,-0.487,-0.268,0.11,0.076,0.12,0.021,-0.043,0.052,0.545,0.056,0.311,-0.138,-0.348,0.101,0.145,0.165,0.159,-0.292,-0.181,0.091,0.002,0.13,-0.121,0.121,unmethylated
NH21-1966,205648300085_R04C01,250,3/8/2021,8/27/2021,8/27/2021,24,SB,Diagnostic,250,1,NDP,Bristol,,(1) small biopsy or nonrepresentative sample;,A,12/8/1958,63.5,ganglioglioma,0.53,GBM_MES,0.58,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1966,"Methylation profile: Raising the possibility of glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 250\NH21-1966,-0.092,-0.04,0.026,0.06,-0.076,0.033,-0.043,0.167,0.152,0.204,0.119,-0.003,-0.092,0.054,-0.015,0.024,-0.44,-0.156,-0.013,0.061,-0.016,0.076,-0.006,0.077,-0.288,-0.082,-0.024,-0.211,-0.158,unmethylated
Nh21-1951,205648300085_R05C01,250,3/8/2021,8/27/2021,8/27/2021,24,SB,Diagnostic,250,1,NDP,Southampton General Hospital,Pineal mass; HGG favoured,"(2) unusual histology, location, demographics",1A,10/4/1978,43.4,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.77,GBM_MID,0.84,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",Nh21-1951,"Histology: Compatible with glioblastoma (WHO grade IV)
Methylation profile: Suggestive of glioblastoma, IDH-wildtype, subclass midline
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 250\Nh21-1951,-0.173,0.087,-0.003,0.086,-0.024,0.227,0.053,0.243,0.039,-0.006,-0.032,-0.015,0.046,0.112,-3.195,0.171,-0.129,-0.147,-0.149,0.2,0.011,0.242,-0.485,-0.078,0.066,-0.048,-0.274,-0.095,0.053,unmethylated
NH05-418,205648300085_R06C01,250,5/8/2021,8/27/2021,8/27/2021,22,SB,Diagnostic,250,5,NDP,"Cambridge, Addenbrooke's Hospital",Oligodendroglioma?,"(4) IHC, sequencing, or copy number assay ambiguous",DEF1A,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,0.99,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH05-418,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 250\NH05-418,-0.008,-0.085,0.103,-0.657,-0.67,0.042,-0.002,0.036,-0.032,-0.067,-0.037,0.037,0.175,0.142,0.055,0.196,-0.209,-0.529,0.132,-0.039,0.143,0.174,-0.098,0.076,0.06,0.032,-0.464,0.016,-0.028,unmethylated
NH21-1991,205648300085_R08C01,250,5/8/2021,8/27/2021,8/27/2021,22,SB,Diagnostic,250,1,NDP,Oxford John Radcliffe Hospital,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2C,7/30/2000,21.3,myxopapillary ependymoma,0.83,EPN_MPE,0.55,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1991,"Histology: Myxopapillary ependymoma
Methylation profile: Suggestive of ependymoma, myxopapillary see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 250\NH21-1991,-0.261,-0.386,-0.289,-0.093,-0.062,-0.064,-0.234,0.037,0.044,0.061,-0.005,-0.003,-0.017,0.136,-0.067,0.014,-0.294,-0.258,-0.029,-0.272,-0.292,-0.249,0.138,0.033,0.024,-0.071,0.078,-0.413,-0.274,methylated
NH21-1852,205648300162_R02C01,251,7/8/2021,9/3/2021,9/2/2021,26,SB,Diagnostic,251,1,NDP,Newcastle,? GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3A,3/3/1951,71.4,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.35,GBM_MES,0.37,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1852,"Histology: Glial tumour, high-grade
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Methylated 
  
","Histology: Glial tumour, high grade
Methylation profile: no matching methylation class
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 251\NH21-1852,-0.02,-0.054,0.049,0.174,-0.042,-0.036,0.012,0.203,0.153,0.203,0.15,-0.01,0.024,0.065,0.037,0.033,-0.008,-0.156,-0.018,-0.01,0.066,0.162,0.004,0.021,-0.1,-0.027,-0.033,-0.218,-0.259,methylated
NH21-2015,205648300162_R03C01,251,5/8/2021,9/3/2021,9/2/2021,28,SB,Diagnostic,251,1,NDP,"Belfast, Royal Victoria Hospital",Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/18/2011,10.2,supratentorial pilocytic astrocytoma,0.96,LGG_PA_GGST,0.79,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2015,"Histology: Low grade glioma (please see also previous report NH21-1612)
Methylation profile: Hemispheric pilocytic astrocytoma/ganglioglioma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 251\NH21-2015,-0.029,-0.149,0.02,0.027,-0.045,0.024,0.038,-0.008,0.01,-0.023,-0.015,0.004,0.037,0.033,0.019,-0.016,-0.011,0,0.007,-0.047,-0.049,0.038,-0.013,-0.031,-0.044,-0.021,-0.057,-0.047,-0.022,unmethylated
NH21-2027,205648300162_R04C01,251,5/8/2021,9/3/2021,9/2/2021,28,SB,Diagnostic,251,4,NDP,Nottingham University Hospital,Anaplastic Oligo,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B9,12/15/1997,24,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,OIDH,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2027,"Histology: Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted (WHO grade III)
Methylation profile: Glioma, IDH mutant, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 251\NH21-2027,-0.026,-0.014,0.037,-0.293,-0.367,0.025,0.05,-0.023,-0.024,-0.019,-0.032,0.181,0.186,0.204,0.082,0.059,0.013,0.098,-0.001,0.046,-0.044,0,-0.021,0.002,-0.005,-0.001,-0.463,0.003,0.036,methylated
NH21-2031,205648300162_R06C01,251,5/8/2021,9/3/2021,9/2/2021,28,SB,Diagnostic,251,1,NDP,Nottingham University Hospital,Ependymoma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",B2,7/28/1997,24.4,spinal subependymoma [subtype A],0.69,GBM_MES,0.15,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2031,"Histology: Ependymal tumour (see comment) c
Methylation profile: Possibly inconclusive (see comment)
MGMT promoter (Illumina array): Unmethylated Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 251\NH21-2031,-0.034,-0.02,0.053,0.048,0.008,-0.01,0.261,-0.017,-0.021,-0.028,-0.017,0.007,0.032,0.018,0.025,-0.002,0.005,0.001,-0.031,0,-0.057,0.017,-0.018,-0.01,-0.014,0.01,-0.012,-0.044,-0.005,unmethylated
NH21-2009,205648300162_R08C01,251,5/8/2021,9/3/2021,9/2/2021,28,SB,Diagnostic,251,2,NDP,NHNN,"HGG/GBM, Younng patiner post RT","(2) unusual histology, location, demographics",SP1A,8/27/1987,34.4,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.93,GBM_MID,0.99,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2009,"High grade glioma (at least WHO grade III)  see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: High-grade glioma, IDH-wildtype
Methylation profile: Glioblastoma, IDH-wildtype, subclass midline
MGMT promoter (Illumina array):  Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 251\NH21-2009,-0.141,-0.073,-0.067,-0.265,0.662,-0.166,0.127,-0.112,-0.083,-0.057,-0.087,0.092,0.167,0.079,-0.248,0.192,-0.225,-0.244,-0.078,0.03,0.645,-0.013,-0.568,-0.389,0.069,0.034,-0.086,-0.266,-0.316,methylated
NH21-1996,205648300030_R01C01,252,5/8/2021,9/23/2021,9/22/2021,48,SB,Research,252,1,NDP,"Cape Town, RSA",HGG/GBM,"(6) Research sample, for stratification or subclassification",,12/7/1951,70.7,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.93,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1996,"Histology: Glioblastoma (WHO Grade IV)
Methylation profile: Glioblastoma, IDH wildtype, subclass RTK II
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 252\NH21-1996,-0.212,0.059,0.038,-0.094,0.158,-0.083,0.018,2.617,0.27,0.42,0.44,0.133,-0.015,0.255,-1.857,0.165,-0.621,-0.769,-0.105,-0.185,-0.175,-0.021,-0.13,0.071,0.027,-0.058,0.593,0.167,0.086,methylated
NH21-1997,205648300030_R02C01,252,5/8/2021,9/23/2021,9/22/2021,48,SB,Research,252,1,NDP,"Cape Town, RSA",GBM,"(6) Research sample, for stratification or subclassification",,11/15/1983,38.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.93,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1997,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 252\NH21-1997,-0.032,0.172,-0.068,-0.111,0.198,-0.064,-0.018,-0.148,0.274,0.497,0.07,0.078,0.266,0.401,-1.054,0.266,-0.086,-0.355,-0.041,0.174,0.091,-0.105,-0.015,0.471,-0.026,-0.04,0.146,0.167,0.162,methylated
NH21-1998,205648300030_R03C01,252,5/8/2021,9/23/2021,9/22/2021,48,SB,Research,252,1,NDP,"Cape Town, RSA","Oligodendroglioma IDHmut, 1p/19q del","(6) Research sample, for stratification or subclassification",,2/12/1952,70.5,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-1998,"Histology: Oligodendroglioma, IDH-mutant and 1p/19q codeleted (see comment)
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 252\NH21-1998,0.006,0.071,0.063,-0.235,-0.164,0.055,-0.418,-0.107,-0.067,0.016,0.084,0.09,0.033,0.046,0.008,0.142,-0.287,-0.272,-0.041,-0.086,0.079,0.022,-0.103,-0.131,-0.347,-0.309,-0.502,-0.226,-0.129,methylated
NH21-1999,205648300030_R04C01,252,5/8/2021,9/23/2021,9/22/2021,48,SB,Research,252,1,NDP,"Cape Town, RSA","Oligodendroglioma IDHmut, 1p/19q del","(6) Research sample, for stratification or subclassification",,4/7/1971,51,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1999,"Histology: Oligodendroglioma, IDH mutant and 1p/19q co-deleted (WHO grade II)
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 252\NH21-1999,-0.13,0.011,0.081,-0.004,0.065,-0.021,-0.061,-0.08,-0.143,-0.035,-0.062,0.044,0.112,0.008,-0.449,0.371,-0.023,-0.02,0.005,-0.069,-0.1,-0.074,-0.101,0.043,-0.054,0.261,-0.628,-0.068,-0.047,methylated
NH21-2000,205648300030_R05C01,252,5/8/2021,9/23/2021,9/22/2021,48,SB,Research,252,1,NDP,"Cape Town, RSA",AA IDH wildtype,"(6) Research sample, for stratification or subclassification",,9/7/1987,34.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.91,AIDH_HG,0.97,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2000,"Histology: Anaplastic astrocytoma (grading see comment)
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 252\NH21-2000,-0.175,0.001,0.06,0.078,0.479,-0.146,-0.101,-0.203,-0.229,-0.147,-0.019,0.033,0.037,0.146,-0.38,0.123,-0.432,-0.101,-0.09,-0.06,0.211,-0.077,-0.151,-0.034,0.038,0.115,0.034,0.285,0.133,methylated
NH21-2001,205648300030_R06C01,252,5/8/2021,9/23/2021,9/22/2021,48,SB,Research,252,1,NDP,"Cape Town, RSA",Astro IDHwt WHO II,"(6) Research sample, for stratification or subclassification",,3/23/1958,64.3,"glioblastoma, IDH-wildtype, mesenchymal type",0.29,CONTR_REACT,0.35,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2001,"Histology: CNS tissue with diffuse infiltration of a glioma
Methylation profile: Control tissue, reactive tumour marker environment (See comment) 
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 252\NH21-2001,-0.221,0.055,0.078,0.123,0,0.091,-0.054,-0.115,-0.073,0.032,-0.055,0.063,0.133,0.036,-0.085,0.096,-0.065,-0.005,-0.052,-0.1,0.038,-0.033,-0.167,-0.037,-0.117,-0.082,-0.109,-0.118,0.036,unmethylated
NH21-2002,205648300030_R07C01,252,5/8/2021,9/23/2021,9/22/2021,48,SB,Research,252,1,NDP,"Cape Town, RSA",Astrocytoma IDH-mutant,"(6) Research sample, for stratification or subclassification",,8/29/1975,46.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2002,"Histology: Anaplastic astrocytoma (see comment)
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 252\NH21-2002,-0.292,-0.022,0.22,0.047,0.084,-0.125,-0.017,-0.17,-0.164,-0.038,-0.138,0.034,-0.004,0.002,-0.556,0.033,-0.272,-0.206,-0.085,0.306,-0.211,-0.473,-0.072,-0.165,-0.276,-0.261,0.102,0,0.055,methylated
NH21-2003,205648300030_R08C01,252,5/8/2021,9/23/2021,9/22/2021,48,SB,Research,252,1,NDP,"Cape Town, RSA",GBM,"(6) Research sample, for stratification or subclassification",,10/2/1996,25.2,pleomorphic xanthoastrocytoma(-like),0.35,CONTR_REACT,0.3,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2003,"Histology: Anaplastic astrocytoma (see comment)
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 252\NH21-2003,-0.155,0.066,0.126,0.019,0.011,0.075,-0.073,0.245,0.249,0.234,0.213,0.113,0.142,0.025,-0.247,0.136,-0.013,-0.019,-0.004,0.257,0.127,0.235,-0.118,-0.09,-0.109,-0.103,-0.093,0.046,0.119,methylated
NH21-1970,205648300147_R01C01,253,5/8/2021,8/27/2021,8/27/2021,22,SB,Diagnostic,253,1,NDP,Romford,Glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,2/6/1994,27.9,supratentorial pilocytic astrocytoma,0.97,LGG_PA_GGST,0.77,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1970,"Glial tumour  see comment
","Histology: Glial tumour
Methylation profile: pilocytic astrocytoma subtype, hemispheric (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 253\NH21-1970,-0.173,0.006,0.045,-0.071,-0.087,0.101,0.085,0.052,0.145,0.076,0.067,-0.017,0.117,0.074,0.031,0.001,0.033,-0.009,0.003,0.118,0.11,0.055,-0.029,0.04,0.026,-0.083,0.035,-0.034,0.018,unmethylated
NH21-2053,205648300128_R01C01,254,11/8/2021,9/3/2021,9/2/2021,22,AM,Diagnostic,254,1,NDP,Lund (SE),Low grade glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2-Jan,4/11/1965,57.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2053,"Histology: Astrocytoma (IDH-mutant [see comment]), WHO grade II
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 254\NH21-2053,-0.056,-0.012,0.017,-0.027,0.024,-0.232,-0.013,0.036,0.033,0.012,0.007,-0.003,0.002,0.033,0.039,0.058,0.011,-0.009,-0.001,0.009,-0.022,-0.156,-0.075,0.032,0.034,-0.016,-0.066,-0.036,0.007,methylated
NH21-2052,205648300128_R02C01,254,11/8/2021,9/3/2021,9/2/2021,22,AM,Diagnostic,254,1,NDP,Lund (SE),? DLGNT ?PA,"(5) Confirmation of rare, unusual or interesting histo-molecular results",3-Jan,1/28/2006,15.7,infratentorial pilocytic astrocytoma,0.85,LGG_PAPF,0.62,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2052,"Histology: Low grade glioma
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 254\NH21-2052,-0.005,-0.044,0.026,0.002,-0.051,0.015,0,-0.017,0.002,0.015,-0.02,0.002,0.03,-0.028,0.03,-0.004,-0.001,0,-0.021,-0.043,0.007,0.007,0.004,-0.016,0.005,-0.012,-0.024,-0.032,0.029,unmethylated
NH21-2045,205648300128_R03C01,254,11/8/2021,9/3/2021,9/2/2021,22,AM,Diagnostic,254,1,NDP,Romford,Predominantly necrosis ?GBM,(1) small biopsy or nonrepresentative sample;,A1,8/27/1961,60.8,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.55,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2045,"Necrotic tissue with suspicion for high-grade glioma, but diagnostically challenging  see comment
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 254\NH21-2045,0.023,-0.06,0.014,-0.014,0.003,-0.007,-0.105,0.281,0.315,0.434,0.23,-0.045,-0.041,-0.005,-0.432,-0.059,-0.209,-0.169,-0.003,0.029,-0.051,0.041,-0.076,0.007,-0.429,0.018,-0.036,-0.027,0.079,unmethylated
NH21-2025,205648300128_R04C01,254,12/8/2021,9/3/2021,9/2/2021,21,AM,Diagnostic,254,1,NDP,Royal London Hospital,LGG,(1) small biopsy or nonrepresentative sample;,DEF1A,11/24/1975,46.4,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.26,LGG_DNT,0.19,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2025,"In keeping with Low-grade glioneuronal tumour  see comment

IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
BRAF V600E (IHC): Negative (see comment)
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 254\NH21-2025,-0.006,-0.011,0.002,0.018,-0.017,-0.012,-0.024,0.024,-0.098,-0.106,0.014,0.001,0.02,0.006,0.041,-0.024,-0.007,-0.045,-0.009,0.003,-0.007,0.023,-0.053,0.005,-0.004,0.025,0.017,0.008,0.037,methylated
NH21-2072,205648300128_R06C01,254,13/08/2021,9/3/2021,9/2/2021,20,AM,Diagnostic,254,1,NDP,"Stanmore, Royal National Orthopedic Hospital",? myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,6/30/2003,18.4,myxopapillary ependymoma,1,EPN_MPE,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2072,"Ependymal tumour  see comment
","Histology: Ependymoma (in keeping with a myxopapillary ependymoma)
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 254\NH21-2072,-0.029,0.027,0.024,0.02,-0.045,0.043,0.023,0.221,0.271,0.256,0.202,-0.003,-0.059,0.083,0.405,0.33,-0.033,0.047,-0.009,-0.032,0.03,0.029,-0.01,-0.079,-0.043,-0.013,0.158,-0.066,-0.028,unmethylated
NH21-2064,205648300128_R07C01,254,13/08/2021,9/3/2021,9/2/2021,20,AM,Diagnostic,254,1,NDP,"Birmingham, Queen Elizabeth Hospital",? PXA,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,10/18/1966,55.6,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2064,"Glioblastoma, BRAF V600E-mutant (WHO grade IV)  see comment 
BRAF (V600E IHC and Seq): Mutation
ATRX (IHC): Loss of expression (indicates mutation)               
CDKN2A/B: Deletion
","Histology: Glioblastoma, BRAF V600E-mutant
Methylation profile: (anaplastic) pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 254\NH21-2064,-0.032,-0.059,0.035,-0.052,0.076,0.004,0.088,0.438,0.213,0.27,0.146,-0.06,0.052,0.007,-1.045,0.009,-0.037,0.06,-0.017,-0.043,0.111,0.164,-0.292,-0.034,-0.042,-0.011,-0.335,-0.299,-0.288,methylated
NH21-1752,205648300128_R08C01,254,13/08/2021,9/3/2021,9/2/2021,20,AM,Diagnostic,254,3,NDP,"Belfast, Royal Victoria Hospital",IDH-mutant glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/26/1994,27.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1752,"Astrocytoma, IDH-mutant  for grading, see comment
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B: No deletion     
MGMT Promoter: Methylated (>0-5%)
","Histology: Astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 254\NH21-1752,0.025,-0.032,0.009,0.023,0.02,-0.003,0.011,0.018,-0.01,0.016,0.018,-0.015,0.159,0.157,-0.039,0.048,-0.017,-0.097,0.006,0.015,0.022,-0.046,-0.046,0.018,-0.001,-0.012,-0.052,-0.404,0.029,methylated
NH21-2063,205648300058_R01C01,255,13/08/2021,9/10/2021,9/10/2021,28,AM,Diagnostic,255,1,NDP,"Cambridge, Addenbrooke's Hospital",Mediastinal ependymoma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",1A,8/2/1940,82.1,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.63,EPN_RELA,0.09,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2063,"Histology: Cellular tumour  see comment
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 255\NH21-2063,-0.024,-0.022,0.061,0.157,0.019,-0.021,0.027,-0.012,-0.06,-0.046,-0.028,0.41,0.374,0.448,0,0.03,0.026,0.02,-0.004,0.372,0.37,0.445,-0.052,-0.031,-0.007,-0.03,-0.023,-0.383,-0.439,unmethylated
NH21-2079,205648300058_R02C01,255,13/08/2021,9/10/2021,9/10/2021,28,AM,Diagnostic,255,1,NDP,"Liverpool, The Walton Centre",Limited neuronal ischaemia,"(5) Confirmation of rare, unusual or interesting histo-molecular results",2A,12/15/1974,47.3,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.19,LGG_DNT,0.56,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2079,"Histology: Paucicellular tissue, no evidence of neoplasm
Methylation profile: Control tissue, hemispheric cortex
MGMT promoter (Illumina array): Unmethylated 
  
","Histology: Paucicellular tissue, no evidence of neoplasm
Methylation profile: Control tissue, hemispheric cortex
MGMT promoter (Illumina array): Unmethylated
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 255\NH21-2079,0.051,-0.067,-0.011,-0.019,-0.019,-0.033,-0.048,-0.024,0.009,-0.037,-0.012,-0.005,-0.027,0.003,-0.005,0.01,-0.013,-0.002,-0.028,-0.041,0.035,0.028,-0.033,-0.025,0.011,-0.046,0.016,0.04,-0.005,unmethylated
NH21-2078,205648300058_R03C01,255,13/08/2021,9/10/2021,9/10/2021,28,AM,Diagnostic,255,1,NDP,"Cardiff, University Hospital",Ependymoma II (spinal),"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,6/3/1947,75.3,spinal ependymoma,0.99,EPN_SPINE,0.99,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2078,"Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 255\NH21-2078,0.08,-0.033,-0.02,0.089,0.04,-0.064,-0.02,0.105,0.153,0.085,0.103,0.005,-0.003,0.049,-0.097,-0.079,-0.059,-0.103,-0.047,-0.048,-0.079,-0.081,-0.29,0.152,0.099,0.059,-0.041,-0.315,-0.307,unmethylated
NH21-2074,205648300058_R05C01,255,13/08/2021,9/10/2021,9/10/2021,28,AM,Diagnostic,255,1,NDP,"Cardiff, University Hospital",Ependymoma II (spinal),"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,4/16/1965,57.1,spinal ependymoma,1,EPN_SPINE,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2074,"Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 255\NH21-2074,0.005,-0.015,0.013,0.041,0.007,0.025,0.033,0.166,0.209,0.199,0.198,-0.013,0.036,0.012,0.02,0.023,0.038,-0.009,-0.028,-0.031,-0.014,0.044,-0.05,-0.038,0.002,-0.003,0.012,-0.435,-0.364,unmethylated
NH21-2083,205648300058_R06C01,255,16/08/2021,9/10/2021,9/10/2021,25,AM,Diagnostic,255,10,NDP,Brighton and Sussex Hospital,? Radionecrosis,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,10/8/1957,64.8,"glioblastoma, IDH-wildtype, mesenchymal type",0.37,CONTR_HEMI,0.17,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2083,"Probable radiation induced changes  see comment
","Histology: In keeping with radiation induced changes
Methylation profile: Control tissue, hemispheric cortex
MGMT promoter (Illumina array and HRM MS PCR assay): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 255\NH21-2083,0.096,-0.023,-0.034,-0.01,0.015,-0.033,-0.026,-0.025,0.006,-0.005,0.017,-0.038,-0.012,0.029,-0.001,-0.014,0.005,-0.005,0.005,0.019,-0.001,0.037,-0.033,-0.068,0.048,-0.049,-0.03,0.001,0.037,unmethylated
NH21-2088,205648300059_R01C01,256,18/08/2021,9/15/2021,9/15/2021,28,AM,Diagnostic,256,1,NDP,"Birmingham, Queen Elizabeth Hospital",RGNT,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,1/10/1976,46.2,rosette-forming glioneuronal tumour,1,LGG_RGNT,0.99,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2088,"Histology: Rosette forming glioneuronal tumour (WHO grade I)
Methylation profile: Low grade glioma, rosette forming glioneuronal tumour 
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 256\NH21-2088,0.055,-0.024,-0.004,-0.015,-0.002,-0.023,0.023,0.028,0.03,-0.049,-0.025,0.023,0.065,-0.021,0.055,0,0.081,0.001,0.043,-0.003,0.038,0.096,-0.018,0.056,0.027,-0.028,0.021,0.007,0.014,unmethylated
NH21-2137,205648300059_R05C01,256,24/08/2021,9/15/2021,9/15/2021,22,ZJ,Diagnostic,256,9,NDP,NHNN,LGG or glioneuronal tumour (?RGNT),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,2/23/2004,17.7,dysembryoplastic neuroepithelial tumour,0.78,LGG_DNT,0.99,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2137,"Low grade glioneuronal tumour  see comment
IDH1 (R132H IHC): Technically unsatisfactory 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Histology: Compatible with dysembryoplastic neuroepithelial tumour (WHO grade I)
Methylation profile: Low grade glioma, dysembryoplastic neuroepithelial tumour 
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 256\NH21-2137,0.004,-0.033,0.006,0.157,0.189,-0.026,-0.016,0.082,0.063,0.068,0.06,-0.009,0.033,0.042,0.054,0.032,0.041,0.005,0.052,0.06,-0.006,0.066,-0.061,0.008,0.025,-0.09,-0.033,0.015,-0.037,unmethylated
NH21-2102,205648300059_R06C01,256,24/08/2021,9/15/2021,9/15/2021,22,ZJ,Diagnostic,256,1,NDP,"Birmingham, Queen Elizabeth Hospital",GBM,"(2) unusual histology, location, demographics",A1,3/11/1999,22.7,"Diffuse paediatric-type high grade glioma, MYCN subtype",1,GBM_MYCN,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2102,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass MYCN
MGMT promoter (Illumina array): Unmethylated 
  
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass MYCN  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 256\NH21-2102,0.124,0.249,0.3,-0.066,-0.121,-0.043,0.143,0.272,0.319,0.309,0.256,-0.129,-0.075,-0.099,-0.023,0.005,0.191,-0.083,-0.053,0.327,0.965,-0.097,-0.166,-0.064,-0.049,-0.003,0.097,0.014,0.007,unmethylated
NH21-2147,205648300059_R08C01,256,24/08/2021,9/15/2021,9/15/2021,22,ZJ,Diagnostic,256,1,NDP,"Cardiff, University Hospital",Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,7/26/1965,56.9,myxopapillary ependymoma,1,EPN_MPE,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2147,"Histology: Myxopapillary ependymoma (WHO grade I)
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 256\NH21-2147,-0.039,-0.036,0.039,-0.04,0.027,-0.005,0.007,-0.005,-0.013,-0.047,-0.004,0.021,-0.005,0.028,0.314,0.332,-0.03,0.024,0.043,-0.019,0.026,0.062,-0.049,0.009,0.026,0.015,0.093,0.014,-0.002,methylated
NH21-2151,205648300178_R02C01,257,24/08/2021,9/15/2021,9/15/2021,22,ZJ,Diagnostic,257,2,NDP,Bristol,Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",499,2/4/2008,13.7,pleomorphic xanthoastrocytoma(-like),1,PXA,0.99,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2151,"Histology: Compatible with pleomorphic xanthoastrocytoma (WHO grade II)  see comment
Methylation profile: Pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 257\NH21-2151,0.124,0.034,0.021,-0.017,-0.015,0.002,-0.012,-0.013,0.002,0.032,0.023,-0.037,-0.002,0.112,-0.563,0.078,0.026,-0.022,0.025,0.049,0.059,0.083,-0.11,0.134,-0.023,-0.037,0.038,-0.193,-0.024,unmethylated
NH21-2131,205648300178_R03C01,257,24/08/2021,9/15/2021,9/15/2021,22,ZJ,Diagnostic,257,1,NDP,"Belfast, Royal Victoria Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,11/10/1963,58.6,spinal ependymoma,1,EPN_SPINE,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2131,"Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 257\NH21-2131,-0.021,-0.042,0.05,-0.004,-0.041,0.011,-0.006,0.007,-0.019,0.001,-0.004,-0.114,-0.057,-0.055,0.01,0.005,0.028,0.03,0.055,0.004,0.029,0.021,-0.016,0.023,0.04,-0.009,0.037,-0.422,-0.443,methylated
NH21-2128,205648300178_R04C01,257,24/08/2021,9/15/2021,9/15/2021,22,ZJ,Diagnostic,257,1,NDP,Nottingham University Hospital,Spinal ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,11/1/1980,41.4,myxopapillary ependymoma,0.98,EPN_MPE,0.76,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2128,"Histology: Myxopapillary ependymoma (WHO grade II)
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 257\NH21-2128,-0.13,-0.225,-0.128,0.007,-0.034,-0.031,0.033,0.047,0.041,-0.022,0.012,0.003,0,0.107,0.105,0.182,-0.127,-0.15,0.012,0.06,0.036,0.065,-0.259,-0.126,-0.181,-0.208,0.012,-0.434,-0.456,unmethylated
NH21-2191,205648300178_R08C01,257,27/08/2021,9/15/2021,9/15/2021,19,ZJ,Diagnostic,257,1,NDP,St George's Hospital London,Subependymoma or Ependymoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/10/1969,53.2,posterior fossa ependymoma group B,1,EPN_PFB,0.83,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2191,"Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, posterior fossa group B
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 257\NH21-2191,0.059,-0.028,0.036,0.077,0.004,0.285,-0.01,0.313,0.297,0.309,0.302,0.287,0.318,0.422,0.42,0.52,0.044,0.026,0.032,0.331,0.286,0.389,0.104,0.076,0.004,-0.039,0.321,-0.083,-0.062,unmethylated
NH21-2237,205648300161_R03C01,258,1/9/2021,9/23/2021,9/22/2021,21,SB,Diagnostic,258,7,NDP,Oxford John Radcliffe Hospital,Cerebellar glioma HGG,(1) small biopsy or nonrepresentative sample;,A,1/19/1970,52.4,"control tissue, cerebellar hemisphere",0.87,CONTR_CEBM,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2237,"Histology: Infiltration of glial tumour  see comment
Methylation profile: Control tissue, cerebellar hemisphere
MGMT promoter (Illumina array): Unmethylated 
  
","See main report
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 258\NH21-2237,0.098,-0.048,-0.083,-0.045,0.011,-0.059,-0.051,-0.002,-0.02,-0.026,-0.034,-0.008,-0.028,-0.032,-0.02,0.067,-0.046,-0.095,-0.01,0.018,0.021,-0.039,-0.019,0.046,0.084,-0.018,-0.022,-0.022,0.034,unmethylated
NH21-2215,205648300161_R05C01,258,1/9/2021,9/23/2021,9/22/2021,21,SB,Diagnostic,258,1,NDP,"Cambridge, Addenbrooke's Hospital","Spinal tumour PA, DLGNT ?","(2) unusual histology, location, demographics",A2,4/22/1983,38.9,diffuse leptomeningeal glioneuronal tumour,1,DLGNT,0.97,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2215,"Histology: Compatible with diffuse leptomeningeal glioneuronal tumour
Methylation profile: Diffuse leptomeningeal glioneuronal tumour
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 258\NH21-2215,0.196,0.013,-0.015,-0.019,-0.049,0.028,-0.01,-0.008,0.002,-0.01,0.248,-0.015,0.013,0.009,0.038,0.011,-0.012,0.016,0.004,-0.037,-0.052,0.016,-0.027,-0.006,0.028,-0.009,-0.086,0.017,0.009,methylated
NH21-2213,205648300161_R06C01,258,1/9/2021,9/23/2021,9/22/2021,21,SB,Diagnostic,258,1,NDP,Lund (SE),LGG,(1) small biopsy or nonrepresentative sample;,2-Feb,12/7/1973,48.4,dysembryoplastic neuroepithelial tumour,0.56,LGG_DNT,0.69,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2213,"Histology: Compatible with dysembryoplastic neuroepithelial tumour (WHO grade I)
Methylation profile: Suggestive of low grade glioma, dysembryoplastic neuroepithelial tumour
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 258\NH21-2213,0.033,-0.01,-0.026,-0.026,-0.016,-0.007,-0.015,0.012,-0.011,-0.03,-0.012,-0.025,-0.003,0.033,-0.016,0.013,0.004,-0.004,0.036,0.018,-0.024,0.027,-0.007,0.022,0.015,-0.014,-0.03,-0.093,-0.128,methylated
NH21-2202,205648300161_R07C01,258,1/9/2021,9/23/2021,9/22/2021,21,SB,Diagnostic,258,7,NDP,NHNN,IDH mutb astrocytoma,(1) small biopsy or nonrepresentative sample;,SP1A,12/7/1994,27.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.99,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2202,"Glioblastoma IDH-mutant (WHO grade IV)  see comment     

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Glioblastoma, IDH-mutant (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
MGMT Promoter: Methylated (>0-5%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 258\NH21-2202,-0.033,-0.468,0.027,-0.013,0.015,0.039,0.064,-0.023,-0.036,-0.004,-0.023,-0.017,0.183,0.169,0.037,0.029,-0.139,-0.084,0.01,-0.033,-0.045,-0.014,-0.375,-0.034,0.034,-0.007,-0.108,-0.273,-0.338,methylated
NH21-2251,205676390044_R05C01,259,6/9/2021,10/1/2021,9/29/2021,23,SB,Diagnostic,259,1,NDP,Lund (SE),Mesencephalic glioma,"(2) unusual histology, location, demographics",201,10/15/1964,57.7,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.27,LGG_RGNT,0.34,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2251,"Histology: Glioma / glioneuronal tumour, probable low-grade - see comment
Methylation profile: Classified with low calibrated score - see comment
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 259\NH21-2251,0.002,-0.034,0.009,0.014,-0.059,0.014,0.085,0.009,0.003,0.013,0.006,-0.027,-0.013,0.055,0.031,-0.004,-0.004,0.012,0.034,0.07,0.106,0.159,0.01,-0.001,-0.006,-0.04,-0.052,-0.037,0.001,methylated
NH21-2210,205676390044_R06C01,259,7/9/2021,10/1/2021,9/29/2021,22,AM,Diagnostic,259,1,NDP,Romford,GBM,"(4) IHC, sequencing, or copy number assay ambiguous",A4,10/18/1975,46.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.93,GBM_MES,0.56,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2210,"Glioblastoma (WHO grade IV)  see comment

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Histology and molecular diagnosis: Glioblastoma, IDH-wildtype, WHO grade IV (4) 
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal

MGMT promoter (Illumina array): Unmethylated
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 259\NH21-2210,-0.023,0.043,0.001,-0.001,-0.013,0.046,-0.014,0.152,0.176,0.235,0.165,0.01,-0.002,0.058,-0.694,-0.017,-0.214,-0.257,-0.031,-0.078,0.006,-0.013,-0.071,0.016,-0.024,-0.041,-0.079,-0.235,-0.271,unmethylated
NH21-2270,205676390044_R07C01,259,7/9/2021,10/1/2021,9/29/2021,22,AM,Diagnostic,259,4,NDP,"Liverpool, The Walton Centre",High grade glioma,"(4) IHC, sequencing, or copy number assay ambiguous",1D,11/21/1970,51.5,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.67,GBM_MID,0.98,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2270,"Histology: Glioblastoma, WHO grade IV (4)
Methylation profile: Glioblastoma, IDH wildtype, subclass midline
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 259\NH21-2270,0.015,-0.064,-0.013,-0.033,0.741,0.043,-0.314,0.152,-0.077,-0.05,-0.056,0,0.091,-0.351,-1.831,0.018,-0.385,-0.413,0.039,0.014,0.043,0.069,-0.557,-0.055,-0.074,0.347,-0.53,-0.021,-0.001,methylated
NH21-1972,205676380170_R02C01,260,9/9/2021,10/1/2021,9/29/2021,20,AM,Diagnostic,260,1,NDP,NHNN,LGNT ? PLNTY,"(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF3A,10/7/1985,36.3,ganglioglioma,0.95,LGG_GG,0.7,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1972,"
Low grade glioneuronal tumour (WHO grade I)

Hippocampal Sclerosis (ILAE type 1)
","Histology: Low grade glioneuronal tumour 
Methylation profile: Suggestive of Low grade glioma, ganglioglioma (low calibrated score) 
MGMT promoter: Unmethylated 
DNA NGS data: BRAF variant detected 
RNA seq: No gene fusions detected
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 260\NH21-1972,-0.002,0.006,0.031,-0.01,-0.088,-0.055,0.009,-0.06,0.011,-0.156,-0.016,0.01,0.17,0.036,0.065,0.013,0.063,-0.012,-0.01,-0.076,0.053,0.124,0.053,0.069,0.064,0.099,0.065,-0.039,0.007,unmethylated
NH21-2292,205676380170_R05C01,260,9/9/2021,10/1/2021,9/29/2021,20,AM,Diagnostic,260,1,NDP,Lund (SE),Recc Pilomyxoid astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",0101,1/3/2011,10.8,supratentorial midline pilocytic astrocytoma,0.96,LGG_PAMID,0.98,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2292,"Histology: Low-grade glioma (see comment)
Methylation profile: Low grade glioma, subclass midline pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 260\NH21-2292,0.018,-0.03,-0.016,0.003,-0.012,0.053,0.081,0.02,0.048,0.062,0.013,-0.011,0.057,0.032,0.096,0.098,0.034,-0.014,0.037,0.082,0.064,0.151,-0.017,0.019,0.037,-0.016,0.017,0.001,0.012,unmethylated
NH21-2279,205676380170_R08C01,260,9/9/2021,10/1/2021,9/29/2021,20,SB,Diagnostic,260,2,NDP,NHNN,Astro4 IDH mutant,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,12/7/1994,27.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.33,AIDH_HG,0.48,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2279,"Recurrent/residual glioblastoma, IDH1-mutant (WHO grade IV)  see comment

Tests performed on NH21-2202:
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
MGMT Promoter: Methylated (>0-5%)
","Histology: Recurrent / residual Glioblastoma, WHO grade IV (4)
Methylation profile: Suggestive of IDH-mutant High-Grade Glioma (see comment)
MGMT promoter (Illumina array): Methylated 
NGS data: Pathogenic variants of IDH1, ATRX, TP53, RB1 and PIK3CA
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 260\NH21-2279,0.01,-0.472,0.034,0.019,-0.008,0.256,-0.414,-0.014,-0.035,-0.05,-0.034,-0.019,0.034,-0.42,0.025,0.042,0.017,0.04,-0.005,-0.013,-0.024,0.085,-0.472,-0.038,0.026,-0.02,-0.313,-0.387,-0.442,methylated
NH21-2273,205657600020_R02C01,261,9/9/2021,10/6/2021,10/6/2021,27,AM,Diagnostic,261,1,NDP,Brighton and Sussex Hospital,Ependymal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,11/10/1952,69.8,posterior fossa subependymoma,1,SUBEPN_PF,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2273,"Ependymal tumour  see comment     
","Histology: Ependymal tumour
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Methylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 261\NH21-2273,0.133,0.028,0.033,0.024,0.019,-0.079,-0.065,0.01,-0.007,-0.014,-0.014,0.003,-0.01,0.063,0.011,-0.007,0.019,-0.054,-0.024,-0.01,0.021,0.044,-0.014,0.066,0.017,-0.027,-0.063,0.028,-0.01,methylated
NH21-2272,205657600020_R03C01,261,9/9/2021,10/6/2021,10/6/2021,27,AM,Diagnostic,261,1,NDP,Brighton and Sussex Hospital,Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,12/20/1959,62.6,posterior fossa subependymoma,1,SUBEPN_PF,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2272,"Subependymoma (WHO grade I)  see comment
","Histology: Subependymoma, WHO grade I
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 261\NH21-2272,0.09,0.046,0.041,0.017,-0.011,-0.036,-0.017,0.018,0.014,-0.03,-0.013,-0.01,-0.028,0.046,-0.002,0.01,0.045,-0.027,-0.027,-0.02,0.023,0.066,-0.012,0.065,0.065,-0.007,-0.097,-0.014,0.017,unmethylated
NH21-2308,205657600020_R04C01,261,9/9/2021,10/6/2021,10/6/2021,27,AM,Diagnostic,261,2,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",C1,12/28/1988,33.2,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.99,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2308,"Histology: Pilocytic astrocytoma, WHO grade 1
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated  

BRAF V600E (seq): No mutation
KIAA1549-BRAF fusion: See comment
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 261\NH21-2308,0.024,-0.066,-0.013,0.036,-0.039,0.166,0.14,-0.046,-0.012,-0.083,0.137,-0.002,0.03,0.008,0.037,-0.02,0.026,0.011,0.136,-0.034,0.045,0.083,0.006,-0.025,0.038,0.029,-0.005,0.015,0.032,unmethylated
NH21-2309,205657600020_R05C01,261,9/9/2021,10/6/2021,10/6/2021,27,AM,Diagnostic,261,1,NDP,Lund (SE),Pleomorphic Xanthoastrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",0101,1/8/1991,31.1,high-grade astrocytoma with piloid features,0.7,PXA,0.24,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2309,"Histology: Glioma - see comment
Methylation profile: Classified with low calibrated score  see comment 
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 261\NH21-2309,0.06,-0.008,-0.033,0.085,0.066,0.012,-0.044,0.276,0.436,0.399,0.297,-0.013,0.063,0.022,-0.845,-0.044,0.019,0.043,0.07,0.082,0.142,0.195,-0.027,-0.133,0.265,0.17,-0.144,0.139,0.154,methylated
NH21-2298,205657600020_R06C01,261,10/9/2021,10/6/2021,10/6/2021,26,AM,Diagnostic,261,5,NDP,Romford,IDH-mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,6/8/1972,50,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2298,"Astrocytoma, IDH-mutant  See comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Histology: Astrocytoma, IDH-mutant (see comment)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 261\NH21-2298,0.037,-0.052,0.029,-0.032,-0.014,-0.002,-0.397,0.008,0.004,-0.043,-0.021,-0.005,0.042,-0.026,0.031,-0.004,0.055,-0.14,-0.033,0.018,0.019,0.049,-0.041,-0.014,-0.017,-0.018,-0.064,0.003,0.021,methylated
NH21-2261,205657600020_R07C01,261,13/09/2021,10/6/2021,10/6/2021,23,SB,Diagnostic,261,1,NDP,Newcastle,Brainstem glioma,"(2) unusual histology, location, demographics",1A,3/28/1997,24.8,rosette-forming glioneuronal tumour,0.99,LGG_RGNT,0.9,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2261,"Histology: Glioma / glioneuronal tumour  see comment
Methylation profile: Low grade glioma, rosette forming glioneuronal tumour

MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 261\NH21-2261,0.006,-0.006,0,0.007,-0.01,0.012,-0.06,0.01,0.011,-0.044,0.001,-0.088,0.001,-0.024,0.015,-0.014,0.034,-0.015,0.016,-0.004,0.011,0.057,-0.013,0.009,0.065,0.011,-0.071,0.011,0.006,unmethylated
NH21-2336,205657600005_R02C01,262,15/09/2021,10/6/2021,10/6/2021,21,ZJ,Diagnostic,262,1,NDP,"Birmingham, Queen Elizabeth Hospital",High grade glioma or glioneuronal tumour,"(2) unusual histology, location, demographics",B2,7/1/2005,16.4,supratentorial midline pilocytic astrocytoma,0.18,LGG_PA_GGST,0.22,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2336,"Histology: High-grade or anaplastic glioma / glioneuronal tumour  see comment 
Methylation profile: Low calibrated score (see comment)
MGMT promoter (Illumina array): Unmethylated 

BRAF V600E (Seq.): Mutation
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 262\NH21-2336,-0.057,-0.024,-0.031,-0.02,-0.099,0.057,0.048,-0.05,0.03,0.048,0.075,0.07,0.063,0.121,0.101,0.062,-0.111,-0.111,0.027,-0.041,0.052,0.153,-0.113,0.066,0.07,0.029,-0.032,-0.064,-0.023,unmethylated
NH21-2240,205657600005_R05C01,262,16/09/2021,10/6/2021,10/6/2021,20,ZJ,Diagnostic,262,4,NDP,NHNN,Hhigh grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,1/18/2002,19.9,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.66,GBM_MYCN,0.61,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2240,"High grade glial tumour   See comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 262\NH21-2240,1.273,0.049,0.085,0.046,0.101,-0.051,-0.074,-0.145,-0.005,-0.031,-0.011,-0.001,0.046,1.113,-0.028,0.017,-0.055,-0.008,-0.021,-0.029,-0.009,-0.078,-0.024,-0.013,-0.013,-0.009,0.008,0.004,0.014,unmethylated
NH21-2026,205657600005_R06C01,262,16/09/2021,10/6/2021,10/6/2021,20,ZJ,Diagnostic,262,1,NDP,Oxford John Radcliffe Hospital,Pilomyxoid Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2,2/14/1994,27.9,supratentorial midline pilocytic astrocytoma,0.97,LGG_PAMID,0.91,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2026,"Pilocytic astrocytoma (WHO grade I)
BRAF: No fusion and no point mutation

","Histology: Pilocytic Astrocytoma spectrum - see comment 
Methylation profile: Suggestive of pilocytic astrocytoma  see comment 
MGMT promoter (Illumina array): Unmethylated  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 262\NH21-2026,-0.052,-0.046,0.027,0.02,-0.026,-0.007,-0.067,-0.187,-0.024,-0.056,0.014,0.006,0.073,0.002,0.028,-0.049,-0.033,-0.01,0.006,-0.104,-0.081,0.009,0.03,-0.051,-0.079,0.02,0.095,0.025,-0.045,unmethylated
NH21-2349,205657600005_R07C01,262,16/09/2021,10/6/2021,10/6/2021,20,ZJ,Diagnostic,262,1,NDP,Oxford John Radcliffe Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,5/7/1961,61.2,spinal ependymoma,1,EPN_SPINE,1,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2349,"Histology: Ependymal tumour (see comment)
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 262\NH21-2349,0.033,-0.02,0.077,0.008,-0.018,-0.017,0.002,0.014,-0.013,-0.107,-0.039,0.02,0.055,-0.067,0.049,0.029,-0.014,0.04,0.038,-0.035,-0.06,-0.104,-0.511,-0.003,-0.086,-0.138,-0.055,-0.427,-0.405,unmethylated
NH21-2353,205657600005_R08C01,262,16/09/2021,10/6/2021,10/6/2021,20,ZJ,Diagnostic,262,1,NDP,Oxford John Radcliffe Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,9/15/1956,65.9,myxopapillary ependymoma,0.91,EPN_MPE,0.97,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2353,"Histology: Ependymal tumour 
Methylation profile: Suggestive of myxopapillary ependymoma - see comment
MGMT promoter (Illumina array): Unmethylated  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 262\NH21-2353,-0.005,-0.091,0.083,0.026,0.124,-0.071,-0.508,0.051,0.038,-0.016,0.022,-0.441,-0.233,-0.584,-0.022,0.071,-0.411,-0.402,-0.319,-0.069,-0.095,-0.051,-0.491,-0.366,-0.633,-0.11,-0.07,-0.45,-0.425,unmethylated
NH21-2365,205648300074_R01C01,263,17/09/2021,10/13/2021,10/13/2021,26,ZJ,Diagnostic,263,7,NDP,NHNN,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1B,1/17/1986,36.2,myxopapillary ependymoma,1,EPN_MPE,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2365,"Myxopapillary ependymoma (WHO grade I)  see comment
","Histology: Myxopapillary ependymoma  for grading, see comment
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 263\NH21-2365,-0.057,0.014,0.085,0.148,0.11,0.133,-0.003,0.158,0.182,0.298,0.176,0.007,0.018,0.089,0.328,0.362,0.044,0.048,-0.057,-0.056,-0.032,-0.047,0.002,-0.047,-0.121,-0.056,0.141,-0.031,-0.021,unmethylated
NH21-2367,205648300074_R02C01,263,17/09/2021,10/13/2021,10/13/2021,26,ZJ,Diagnostic,263,6,NDP,NHNN,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,5/14/1958,64.3,spinal subependymoma [subtype B],1,SUBEPN_SPINE,0.23,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2367,"Ependymoma (WHO grade II)  see comment
","Histology: Ependymoma (WHO grade II)
Methylation profile: Spinal subependymoma, subtype B
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 263\NH21-2367,-0.107,0.019,0.041,0.008,0.009,0.041,0.031,-0.033,-0.079,-0.015,-0.014,0.014,0.024,0.043,-0.021,0.03,0.041,0.046,0.009,-0.016,-0.045,0.03,-0.046,-0.003,-0.09,-0.01,-0.177,-0.039,0.014,unmethylated
NH21-2375,205648300074_R03C01,263,17/09/2021,10/13/2021,10/13/2021,26,ZJ,Diagnostic,263,7,NDP,HCA,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A3,2/26/1985,37.1,spinal ependymoma,1,EPN_SPINE,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2375,"Ependymoma (WHO grade II)  see comment
","Histology: Ependymoma (WHO grade II)
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 263\NH21-2375,-0.025,0.226,0.239,0.037,-0.093,0.205,-0.05,0.168,0.203,0.146,0.213,0.279,0.262,0.342,0.225,0.239,0.06,0.057,0.039,0.193,0.219,0.29,-0.04,0.031,-0.091,-0.052,-0.179,-0.052,0.03,unmethylated
NH21-2294,205648300074_R04C01,263,20/09/2021,10/13/2021,10/13/2021,23,SB,Diagnostic,263,1,NDP,Romford,GBM,"(2) unusual histology, location, demographics",A1,12/15/1986,35.2,"glioblastoma, IDH-wildtype, RTK1 type",0.2,GBM_MES,0.17,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2294,"Glioblastoma (WHO grade IV)  see comment
","Glioblastoma, IDH-wildtype (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
MGMT Promoter: Methylated (>0-5%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 263\NH21-2294,-0.063,0.025,0.031,0.076,-0.038,0.067,-0.04,0.248,0.304,0.361,0.304,0.022,0.042,0.13,-0.034,-0.032,-0.323,0.143,-0.008,0.271,0.211,0.363,-0.081,-0.028,0.001,-0.033,-0.16,-0.07,-0.055,methylated
NH21-2394,205648300074_R05C01,263,20/09/2021,10/13/2021,10/13/2021,23,ZJ,Diagnostic,263,7,NDP,"Liverpool, The Walton Centre",Gliosis vs isomorphic glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1R,11/4/1989,32.3,"control tissue, white matter (corpus callosum)",0.46,OIDH,0.21,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2394,"Histology: No evidence of neoplastic process  see comment
Methylation profile: Control tissue
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 263\NH21-2394,-0.14,-0.014,0.079,0.064,-0.04,0.032,-0.149,-0.124,-0.187,-0.129,-0.04,-0.006,0.058,-0.038,-0.084,0.024,-0.013,0.069,0.023,-0.133,0.024,0.042,-0.098,-0.074,-0.128,0.071,-0.136,-0.202,0.097,unmethylated
NH21-2426,205648300074_R06C01,263,28/09/2021,10/13/2021,10/13/2021,15,AM,Diagnostic,263,1,NDP,"Leeds, St James's University Hospital",Anaplastic Oligo ,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2H,3/2/1972,50.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,OIDH,0.99,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2426,"Histology: Referred diagnosis: anaplastic oligodendroglioma (WHO grade III)
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 263\NH21-2426,-0.126,0.073,-0.019,-0.034,-0.117,0.022,0.164,-0.078,-0.052,-0.001,0.002,0.035,0.009,0.045,-0.1,0.012,0.038,-0.044,-0.132,0.041,-0.034,-0.061,-0.098,0.131,0.016,0.138,-0.45,0.099,-0.001,methylated
NH21-2425,205648310002_R02C01,264,24/09/2021,10/13/2021,10/13/2021,19,ZJ,Diagnostic,264,5,NDP,NHNN,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,4/30/1990,31.9,myxopapillary ependymoma,1,EPN_MPE,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2425,"Myxopapillary ependymoma (WHO grade I)  see comment
","Histology: Myxopapillary ependymoma, for grading see comment
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 264\NH21-2425,-0.109,0.032,0.067,0.118,0.136,0.048,0.011,0.15,0.22,0.191,0.216,0.037,0.037,0.086,0.276,0.37,0.018,0.048,-0.015,-0.046,-0.048,-0.045,-0.002,-0.094,-0.114,-0.065,0.133,-0.063,0.013,methylated
NH21-2436,205648310002_R03C01,264,24/09/2021,10/13/2021,10/13/2021,19,ZJ,Diagnostic,264,6,NDP,Royal London Hospital,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,11/4/1999,22.2,myxopapillary ependymoma,1,EPN_MPE,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2436,"Myxopapillary ependymoma (WHO grade I)  see comment
","Histology: Myxopapillary ependymoma, for grading see comment
Methylation profile: Myxopapillary ependymoma
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 264\NH21-2436,-0.073,0.042,0.073,0.057,-0.045,0.144,0.045,0.171,0.196,0.201,0.195,-0.017,0.013,0.095,0.142,0.182,0.032,0.06,-0.036,-0.067,-0.037,-0.036,-0.027,0.165,0.206,0.143,-0.177,-0.09,-0.022,methylated
NH21-2391,205648310002_R04C01,264,24/09/2021,10/13/2021,10/13/2021,19,ZJ,Diagnostic,264,11,NDP,Royal London Hospital,Papillary glioneuronal tumour,"(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF1A,11/29/1991,30.2,papillary glioneuronal tumour,0.61,LGG_DNT,0.3,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2391,"Papillary glioneuronal tumour (WHO grade I)  see comment
","Papillary glioneuronal tumour, with SLC44A1-PRKCA fusion (WHO grade I)

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 264\NH21-2391,-0.071,-0.035,0.007,-0.029,-0.099,0.029,-0.024,-0.069,-0.061,-0.051,-0.008,0.002,0.035,0.096,-0.104,0.027,0,0.057,-0.015,-0.097,-0.028,-0.058,-0.009,-0.041,-0.047,-0.06,-0.114,-0.144,-0.028,methylated
NH21-2371,205648310002_R05C01,264,27/09/2021,10/13/2021,10/13/2021,16,SB,Diagnostic,264,9,NDP,Romford,"Glioma, IDH-mutant","(4) IHC, sequencing, or copy number assay ambiguous",3,4/11/1980,42,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.93,AIDH,0.99,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2371,"Diffuse glioma, IDH1-mutant, for grading - see comment
","Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: Diffuse glioma, IDH-mutant, 1p19q retained, lower grade 
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 264\NH21-2371,-0.141,0.013,-0.032,-0.031,0.007,0.014,-0.016,-0.012,0.084,0.094,0.111,0.079,0.012,0.085,-0.021,0.072,-0.085,-0.049,0.038,-0.015,-0.117,-0.18,-0.174,0.007,-0.022,0.002,-0.152,-0.055,0.053,methylated
NH21-2373,205648310002_R06C01,264,27/09/2021,10/13/2021,10/13/2021,16,SB,Diagnostic,264,1,NDP,Romford,"Glioma, IDH-mutant","(4) IHC, sequencing, or copy number assay ambiguous",6,1/14/1973,49.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2373,"IDH1-mutant glioma, at least WHO grade III  see comment

IDH1 (R132H IHC):     Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Histology: Glioblastoma, IDH-mutant (WHO grade IV)
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 264\NH21-2373,-0.013,0.016,0.037,0.039,0.017,0.116,0.043,-0.032,0.07,-0.017,-0.029,0.026,0.093,0.272,-1.709,-0.152,-0.098,0.034,0.155,0.006,-0.203,-0.171,-0.046,-0.084,-0.248,0.118,-0.153,-0.048,0.02,methylated
NH21-2459,205814850110_R07C01,277,28/09/2021,10/22/2021,10/21/2021,23,AM,Diagnostic,277,1,NDP,"Belfast, Royal Victoria Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",BN,3/20/1980,42.1,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.77,OIDH,0.66,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2459,"Histology: Oligodendroglioma, IDH-mutant and 1p/19q codeleted (WHO grade II)  for grading, see comment
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 277\NH21-2459,-0.037,-0.066,0.031,0.007,0.005,0.044,0.042,-0.04,-0.008,0.013,-0.031,0.015,0.088,-0.012,0.059,-0.026,0.04,-0.017,-0.001,-0.03,0.046,0.065,-0.038,-0.098,-0.032,-0.035,-0.267,-0.046,-0.028,methylated
NH21-2456,205814850110_R08C01,277,28/09/2021,10/22/2021,10/21/2021,23,AM,Diagnostic,277,1,NDP,Lund (SE),Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",0101,5/31/1962,60.2,ganglioglioma,0.68,GBM_MES,0.45,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2456,"Histology: Infiltration of glioma  see comment
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 277\NH21-2456,0.072,-0.031,-0.001,0.009,0.01,-0.045,-0.211,0.115,0.13,0.13,0.128,-0.026,0.033,0.032,-0.018,0.008,-0.136,-0.12,-0.006,-0.033,-0.006,0.026,-0.093,-0.003,-0.135,-0.007,-0.013,-0.147,-0.11,unmethylated
NH21-2471,205809370155_R02C01,278,28/09/2021,10/22/2021,10/21/2021,23,AM,Diagnostic,278,4,NDP,"Cambridge, Addenbrooke's Hospital",Diffuse astro,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/2/1954,68.6,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.58,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2471,"Histology: High grade glioma  see comment
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 278\NH21-2471,0.049,-0.001,-0.012,-0.007,-0.042,0.007,-0.048,0.159,0.237,0.201,0.173,-0.032,0.051,0.048,-0.235,0.004,-0.094,-0.118,-0.018,0.004,-0.004,0.024,-0.03,0.017,0.056,-0.01,-0.072,-0.075,0.054,unmethylated
NH21-55,205809370155_R05C01,278,28/09/2021,10/22/2021,10/21/2021,23,AM,Diagnostic,278,1,NDP,Brighton and Sussex Hospital,"Myxopapillary ependymona, clinically growing ","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1B,6/1/1987,34.1,myxopapillary ependymoma,1,EPN_MPE,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-55,"Myxopapillary ependymoma (WHO grade I)
","Histology: Myxopapillary ependymoma  for grading, see comment
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 278\NH21-55,-0.032,-0.011,0.066,0.026,0.03,0.216,0.001,0.23,0.265,0.285,0.233,0.209,0.279,0.283,0.247,0.277,0.025,0.013,-0.016,0.014,-0.053,-0.029,-0.045,0.236,0.285,0.227,0.208,-0.018,-0.015,unmethylated
NH21-2214,205809370155_R07C01,278,30/09/2021,10/22/2021,10/21/2021,21,AM,Diagnostic,278,5,NDP,Southampton General Hospital,IDH-WT glioma ? GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,11/25/1978,43.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.83,GBM_MES,0.84,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2214,"Glioma, IDH-wildtype - see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
BRAF (V600E): No mutation          
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 278\NH21-2214,-0.008,0.017,0.016,-0.019,-0.045,0.014,-0.277,-0.004,0.051,-0.008,0.002,-0.051,0.001,0.002,-0.657,-0.065,-0.245,-0.218,-0.162,0,-0.045,0.002,-0.306,-0.021,0.032,0.022,-0.025,-0.247,-0.24,methylated
NH21-2491,205809370155_R08C01,278,30/09/2021,10/22/2021,10/21/2021,21,AM,Diagnostic,278,1,NDP,Auckland (NZ),? GBM,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1A,11/13/1984,37.3,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.89,GBM_MID,0.96,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2491,"Histology: High grade glioma  see comment
Methylation profile: Suggestive of glioblastoma, IDH-wildtype, subclass midline 
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 278\NH21-2491,0.034,-0.048,-0.047,-0.212,-0.215,0.101,0.104,-0.077,-0.272,-0.325,-0.255,-0.058,-0.241,0.388,0.02,-0.014,-0.105,-0.109,-0.007,-0.125,0.727,-0.11,-0.465,-0.043,0.076,0.013,0.053,-0.402,-0.399,methylated
NH21-2490,205809380172_R01C01,279,30/09/2021,10/22/2021,10/21/2021,21,AM,Diagnostic,279,2,NDP,Lund (SE),? PA vs PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2-Jan,10/29/2020,0.9,supratentorial midline pilocytic astrocytoma,1,LGG_PAMID,0.98,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2490,"Histology: Compatible with pilocytic astrocytoma (WHO grade I)
Methylation profile: Pilocytic astrocytoma, midline
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 279\NH21-2490,-0.003,-0.035,0.002,0.001,0.024,0.004,-0.051,0.004,0.051,0.025,-0.011,-0.014,0.071,0.055,-0.092,0.017,-0.03,-0.004,0.03,0.034,-0.011,-0.031,-0.071,0.005,0.014,-0.003,0.011,-0.101,-0.013,methylated
NH21-2537,205809380172_R06C01,279,4/10/2021,10/22/2021,10/21/2021,17,AM,Diagnostic,279,7,NDP,St George's Hospital London,GBM recurrent,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/6/1974,48.3,"glioblastoma, IDH-wildtype, mesenchymal type",0.95,PXA,0.27,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2537,"Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, mesenchymal subtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 279\NH21-2537,0.052,-0.095,-0.053,0.028,-0.066,-0.018,0.064,0.153,0.227,0.095,0.159,-0.017,0.024,0.04,-0.518,-0.057,-0.398,-0.264,0.008,-0.168,-0.022,0.102,-0.185,0.019,0.045,-0.041,-0.221,-0.027,0.018,unmethylated
NH21-2546,205809380172_R07C01,279,5/10/2021,10/22/2021,10/21/2021,16,AM,Diagnostic,279,1,NDP,Romford,Meningioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,2/2/1980,42.3,"glioblastoma, IDH-wildtype, mesenchymal type",0.84,GBM_MES,0.84,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2546,"Meningioma  for grading, see comment
","Histology: Meningioma (compatible with WHO grade I)  see comment
Methylation profile: Meningioma, suggestive of benign
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 279\NH21-2546,0.004,-0.024,0.007,-0.009,-0.047,0.01,-0.284,-0.009,0.032,0.028,0.011,-0.068,0.005,-0.006,-0.684,-0.058,-0.24,-0.223,-0.177,0.019,-0.074,0.037,-0.317,-0.018,0.054,-0.013,-0.013,-0.239,-0.232,methylated
NH21-2502,205814850159_R01C01,280,6/10/2021,10/22/2021,10/22/2021,16,SB,Diagnostic,280,13,NDP,NHNN,Astrocytoma IDH-mutant G4,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2C,4/3/1964,58.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,PXA,0.28,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2502,"Glioblastoma, IDH-mutant (WHO grade IV)  see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Histology: High grade glioma, IDH-mutant and 1p/19q codeleted (corresponding to WHO grade IV)  see comment
Methylation profile: Glioma, IDH-mutant, subclass oligosarcoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 280\NH21-2502,0.021,-0.002,-0.023,-0.021,0.026,0.019,0,-0.023,0,0.012,0.005,0.006,-0.02,0.042,-0.586,0.002,-0.052,-0.158,-0.059,-0.19,-0.181,-0.291,-0.047,0.03,-0.064,-0.077,-0.266,-0.156,-0.099,methylated
NH21-1864,205814850159_R03C01,280,6/10/2021,10/22/2021,10/22/2021,16,SB,Diagnostic,280,1,NDP,Southampton General Hospital,Oligodendroglioma G3,"(4) IHC, sequencing, or copy number assay ambiguous",A1,7/12/1977,44.7,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.37,GBM_RTKII,0.62,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1864,"Anaplastic oligodendroglioma, IDH-mutant (WHO grade III)
IDH1/2Seq: Mutation
ATRX (IHC): Retained
TERT promoter: Mutation

","Integrated Diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 280\NH21-1864,-0.015,-0.043,0.06,-0.004,-0.016,-0.02,-0.44,0.247,0.245,0.005,-0.035,-0.001,0.139,0.029,-2.123,0.019,-0.361,-0.395,-0.011,0.006,0.254,0.257,0,0.012,-0.014,-0.017,-0.055,-0.002,0.041,methylated
NH21-2548,205814850159_R06C01,280,6/10/2021,10/22/2021,10/22/2021,16,AM,Diagnostic,280,7,NDP,"Birmingham, Queen Elizabeth Hospital",Low grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A4,1/30/1993,29.1,supratentorial pilocytic astrocytoma,0.77,LGG_PA_GGST,0.64,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2548,"Histology: Glioneuronal tumour, in favour of ganglioglioma (WHO grade I)
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 280\NH21-2548,-0.05,-0.163,-0.145,0.018,0,0.045,0.006,0.052,0.108,0.106,0.091,-0.019,-0.013,0.04,0.024,-0.024,0.002,0.004,0.015,0.004,-0.009,0.05,0.004,0.011,0.029,-0.007,-0.059,-0.022,0.064,unmethylated
NH21-2576,205814850159_R07C01,280,6/10/2021,10/22/2021,10/22/2021,16,AM,Diagnostic,280,7,NDP,Latvia,Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B3515-21,10/8/2015,6.1,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2576,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Pilocytic astrocytoma, subclass posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 280\NH21-2576,0.018,-0.071,-0.009,0.015,-0.058,0.007,-0.041,0.022,0.006,0.008,0.201,-0.024,0.043,-0.017,0.042,-0.009,-0.021,0.025,0.016,-0.01,-0.063,0.025,-0.034,0.006,0.005,-0.007,-0.05,-0.052,0.029,unmethylated
NH21-2577,205605880090_R01C01,281,6/10/2021,10/28/2021,10/27/2021,21,AM,Diagnostic,281,4,NDP,Latvia,? Low grade tumour,"(2) unusual histology, location, demographics",4247-21,6/8/2008,13.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.85,AIDH,0.63,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2577,"Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH-glioma, subclass astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 281\NH21-2577,-0.044,-0.006,0.055,0.004,-0.01,0.006,-0.023,0.002,-0.022,-0.027,-0.03,0.002,0.076,-0.023,-0.01,-0.017,0.009,0.026,-0.033,0.008,0.011,0.045,-0.017,-0.004,-0.037,0.021,-0.172,0.012,0.021,unmethylated
NH21-2636,205605880090_R02C01,281,15/10/2021,10/28/2021,10/27/2021,12,ZJ,Diagnostic,281,3,NDP,St George's Hospital London,"Glioma, nos; ?PA","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/16/1977,44.6,high-grade astrocytoma with piloid features,1,ANAPA,1,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2636,"Histology: Compatible with anaplastic astrocytoma with piloid features
Methylation profile: Anaplastic astrocytoma with piloid features
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 281\NH21-2636,0.016,-0.03,-0.185,0.019,0.011,0.07,-0.017,0.136,0.173,0.145,0.12,-0.218,0.093,-0.021,-1.107,0.01,0.029,-0.009,-0.133,0.177,0.227,0.343,-0.151,-0.09,-0.004,0.22,-0.185,-0.176,-0.13,methylated
NH21-2561,205605880090_R04C01,281,7/10/2021,10/28/2021,10/27/2021,20,AM,Diagnostic,281,1,NDP,"Birmingham, Queen Elizabeth Hospital",? Malignant meningioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,7/9/1968,54,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.23,MNG,0.36,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2561,"Histology: Malignant tumour  see comment
Methylation profile: Inconclusive with brain, meningioma and sarcoma classifiers
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 281\NH21-2561,0.027,-0.106,-0.003,0.002,-0.052,0.082,-0.002,-0.003,0.16,0.158,0.116,0.372,0.438,0.404,-1.493,0.387,0.064,-0.038,0.15,0.23,0.29,0.449,-0.068,-0.014,0.312,0.271,0.304,-0.046,-0.025,unmethylated
NH21-2562,205605880090_R05C01,281,7/10/2021,10/28/2021,10/27/2021,20,AM,Diagnostic,281,1,NDP,St George's Hospital London,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,3/3/1982,40.2,posterior fossa ependymoma group B,1,EPN_PFB,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2562,"Histology: Ependymoma
Methylation profile: Ependymoma, posterior fossa, group B
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 281\NH21-2562,0.324,-0.043,0.156,0.005,-0.011,-0.035,-0.191,0.004,-0.03,-0.011,-0.022,-0.022,0.085,0.004,0.034,0.022,-0.164,-0.129,0.016,0.001,0.02,0.039,-0.213,-0.191,-0.207,-0.18,-0.11,-0.121,-0.138,unmethylated
NH21-2592,205605880090_R06C01,281,7/10/2021,10/28/2021,10/27/2021,20,AM,Diagnostic,281,2,NDP,"Birmingham, Queen Elizabeth Hospital",HGGNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/15/1971,51,pleomorphic xanthoastrocytoma(-like),0.93,PXA,0.88,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2592,"Histology: High grade glioma, for grading and typing - see comment
Methylation profile: Suggestive of (anaplastic) pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 281\NH21-2592,0.223,0.197,0.229,0.142,0.218,0.166,-0.035,0.209,0.22,0.196,0.173,0.218,0.269,0.22,-0.375,-0.085,0.006,0.016,-0.016,-0.016,0.03,0.013,-0.002,-0.018,-0.042,-0.037,0.154,-0.012,0.066,unmethylated
NH21-2588,205605880090_R07C01,281,7/10/2021,10/28/2021,10/27/2021,20,AM,Diagnostic,281,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,6/15/1993,28.7,supratentorial midline pilocytic astrocytoma,1,LGG_PAMID,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2588,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Low grade glioma, subclass midline pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 281\NH21-2588,0.089,-0.035,-0.018,0.012,0.023,-0.07,-0.075,-0.017,0.027,0.003,0.001,0.003,0.046,0.03,0.019,0.02,-0.015,0.004,0.005,0.028,0.039,0.107,-0.042,0.011,0.051,-0.008,-0.062,-0.004,0.073,unmethylated
NH21-2543,205809370163_R01C01,282,8/10/2021,10/28/2021,10/27/2021,19,SB,Diagnostic,282,4,NDP,NHNN,Subependymoma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",SP1A,9/30/1994,27.4,posterior fossa subependymoma,1,SUBEPN_PF,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2543,"1- Choroid plexus papilloma (WHO grade I) 
2- Subependymoma (WHO grade I)
","1.          
Histology: Choroid plexus papilloma (WHO grade I)
Methylation profile: Plexus tumour, subclass adult
MGMT promoter (Illumina array): Unmethylated

2.          
Histology: Subependymoma (WHO grade I)
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated    
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 282\NH21-2543,-0.078,0.004,0.047,0.058,-0.049,-0.006,-0.042,0.05,0.035,0.058,0.003,-0.005,0.085,-0.028,0.082,0.01,0.038,-0.006,0.02,-0.004,0.103,0.019,0.029,0.011,-0.01,0.022,-0.114,-0.066,0.003,unmethylated
NH20-749,205809370163_R03C01,282,8/10/2021,10/28/2021,10/27/2021,19,SB,Diagnostic,282,4,NDP,NHNN,Astrocytoma IDH-mutant (rcurene at King's Diagn as Oligo),"(4) IHC, sequencing, or copy number assay ambiguous",DEF1A,7/27/1989,31.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-749,"Glioma, see comment
IDH1 (R132H IHC):     No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
Histone H3K27me3: Retained
","Astrocytoma, IDH-mutant (WHO grade II)
IDH1 (R132H IHC); IDH1/2Seq: Mutation
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion
MGMT Promoter: Methylated (>0-5%)
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 282\NH20-749,0.027,0.027,0.009,0.001,0.007,0.022,-0.012,0.007,0.318,0.38,0.324,-0.032,0.003,0.044,-0.026,0.036,-0.015,0.009,0.153,0.029,0.026,0.038,-0.064,0.043,-0.047,-0.01,-0.056,-0.019,0.023,methylated
NH21-2379,205809370163_R05C01,282,11/10/2021,10/28/2021,10/27/2021,16,AM,Diagnostic,282,1,NDP,"Belfast, Royal Victoria Hospital",? GBM ?Anaplastic PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/3/1973,48.7,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.42,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2379,"Favouring Glioblastoma, IDH-wildtype (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
CDKN2A/B: No deletion          
BRAF (V600E): No mutation          
MGMT Promoter: Unmethylated (0%)  

","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, mesenchymal subtype 
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 282\NH21-2379,0.001,-0.025,0.013,0.066,-0.064,0.003,-0.02,0.132,0.129,0.159,0.121,-0.015,0.138,0,-0.034,-0.033,-0.045,-0.038,-0.041,-0.072,-0.058,0.031,-0.073,-0.043,-0.032,-0.06,-0.049,-0.03,-0.01,unmethylated
NH21-2601,205809370163_R06C01,282,13/10/2021,10/28/2021,10/27/2021,14,ZJ,Diagnostic,282,1,NDP,"Birmingham, Queen Elizabeth Hospital",GBM vs PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,12/27/1966,55.6,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.92,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2601,"Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 282\NH21-2601,-0.004,-0.037,0.034,-0.035,-0.011,-0.037,-0.266,1.102,0.164,0.176,0.114,-0.042,0.024,-0.041,-0.469,-0.005,-0.173,-0.24,-0.037,-0.005,-0.014,0.025,-0.229,-0.323,0.002,-0.026,-0.099,-0.192,-0.159,unmethylated
NH21-2634,205809370163_R07C01,282,13/10/2021,10/28/2021,10/27/2021,14,ZJ,Diagnostic,282,1,NDP,"Birmingham, Queen Elizabeth Hospital","Glioma, nos","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A8,12/27/1966,55.6,"glioblastoma, IDH-wildtype, mesenchymal type",1,CONTR_REACT,0.22,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2634,"Histology: Diffusely infiltrative glioma  for grading and typing, see comment
Methylation profile: Suggestive of glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 282\NH21-2634,0.052,-0.043,0.023,-0.038,-0.018,0.006,-0.197,0.073,0.079,-0.064,-0.051,0.036,0.128,0.059,-0.349,-0.186,-0.166,-0.098,-0.013,-0.195,-0.043,-0.05,-0.126,-0.047,-0.007,-0.034,-0.161,-0.106,-0.087,unmethylated
NH21-2624,205809370108_R02C01,283,13/10/2021,11/4/2021,11/3/2021,21,ZJ,Diagnostic,283,1,NDP,Lund (SE),Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",01 01,5/4/2011,10.6,supratentorial midline pilocytic astrocytoma,0.93,LGG_PAMID,0.93,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2624,"Histology: Pilocytic astrocytoma (WHO grade I)
Methylation profile: Low grade glioma, subclass midline pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 283\NH21-2624,0.036,-0.09,0.01,-0.029,-0.02,-0.041,-0.086,-0.036,-0.002,-0.04,0.095,-0.012,-0.002,-0.018,-0.027,-0.019,0.007,0.011,-0.018,-0.023,0.018,-0.017,-0.003,0.026,0.005,-0.028,-0.052,0.024,0.005,unmethylated
NH21-2632,205809370108_R03C01,283,13/10/2021,11/4/2021,11/3/2021,21,ZJ,Diagnostic,283,1,NDP,"Cardiff, University Hospital",Anaplastic PA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,12/18/1975,46.5,high-grade astrocytoma with piloid features,1,ANAPA,0.95,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2632,"Histology: Compatible with anaplastic astrocytoma with piloid features  see comment
Methylation profile: Anaplastic astrocytoma with piloid features 
MGMT promoter: Methylated, range [>5-10%]   
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 283\NH21-2632,0.028,-0.019,0.004,0.008,-0.042,0.019,-0.055,-0.038,-0.019,-0.004,-0.009,-0.029,0.044,0.083,-0.459,0.144,0.022,0.026,0.009,-0.067,0.232,0.242,-0.019,0.015,-0.029,-0.042,-0.048,-0.113,-0.011,methylated
NH21-2700,205799790027_R01C01,285,19/10/2021,11/5/2021,11/5/2021,17,ZJ,Diagnostic,285,1,NDP,"Cambridge, Addenbrooke's Hospital","Glial tumour, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/5/1954,68.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.51,AIDH,0.47,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2700,"Histology: Glioma  see comment
Methylation profile: Suggestive of IDH mutant glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 285\NH21-2700,-0.032,0.079,0.034,0.077,-0.067,0.03,-0.05,0.012,-0.025,0.198,0.201,0.034,0.333,0.211,0.019,0.093,-0.069,0.019,0.165,-0.093,-0.023,0.021,-0.049,0.048,-0.086,0.096,0.096,-0.03,0.099,methylated
NH21-2706,205799790027_R02C01,285,19/10/2021,11/5/2021,11/5/2021,17,ZJ,Diagnostic,285,1,NDP,Lund (SE),?DNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",01 01,1/28/2008,13.9,dysembryoplastic neuroepithelial tumour,0.9,LGG_DNT,0.99,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2706,"Histology: Dysembryoplastic neuroepithelial tumour (WHO grade I)
Methylation profile: Low grade glioma, dysembryoplastic neuroepithelial tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 285\NH21-2706,0.008,0.032,-0.014,-0.119,0.042,-0.013,-0.075,-0.016,0.025,-0.012,-0.01,0.049,0.103,0.063,0.031,0.046,0.041,-0.009,0.089,0.105,0.12,0.033,0.019,0.077,0.039,0.03,-0.004,-0.032,0.036,unmethylated
NH17-570,205799790027_R05C01,285,20/10/2021,11/5/2021,11/5/2021,16,SB,Diagnostic,285,2,NDP,NHNN,RGNT,"(2) unusual histology, location, demographics",DEF1A,#N/A,#N/A,rosette-forming glioneuronal tumour,1,LGG_RGNT,0.98,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-570,"Rosette-forming glioneuronal tumour (WHO grade I) 
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 285\NH17-570,0.021,-0.068,0.016,0.001,-0.069,0.028,-0.006,0.022,0.009,-0.05,0.004,-0.016,0.098,0.015,0.077,0.003,0.034,-0.004,0.005,0.056,0.052,-0.001,-0.009,0.052,0.026,0.036,-0.02,-0.003,0.047,unmethylated
NH21-2618,205799790027_R06C01,285,20/10/2021,11/5/2021,11/5/2021,16,ZJ,Diagnostic,285,5,NDP,NHNN,"Fibrotic lesion in brain, nos
","(2) unusual histology, location, demographics",DEF1A,2/20/2005,16.9,supratentorial pilocytic astrocytoma,0.19,LGG_PA_GGST,0.17,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2618,"Vascular malformative lesion  see comment
","Histology: Vascular malformative lesion
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 285\NH21-2618,-0.02,-0.016,0.015,0.012,-0.052,-0.011,-0.068,-0.008,0.014,-0.008,-0.014,-0.031,0.004,0.007,-0.004,-0.005,-0.024,0.033,-0.032,-0.014,-0.032,0.017,-0.039,-0.017,0.039,0.003,0.018,-0.086,0.002,unmethylated
NH20-875,205799790027_R07C01,285,20/10/2021,11/5/2021,11/5/2021,16,SB,Diagnostic,285,5,NDP,Romford,"astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,4/12/1983,37.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-875,"Astrocytoma, IDH mutant (WHO grade II)
IDH1 (R132H IHC): Mutation  
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
 
","Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)  see comment
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 285\NH20-875,0.049,-0.083,0.076,0.023,-0.053,-0.102,-0.128,0.065,0.208,0.163,0.2,-0.035,0.014,0.135,-0.119,0.06,-0.009,-0.043,0.095,0.089,0.067,0.093,-0.333,0.1,0.022,-0.04,-0.12,-0.064,0.044,methylated
NH21-2699,205799790027_R08C01,285,20/10/2021,11/5/2021,11/5/2021,16,SB,Diagnostic,285,3,NDP,Royal London Hospital,"astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,4/12/1983,39.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.82,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2699,"Anaplastic astrocytoma, IDH-mutant (WHO grade III)  see comment
Molecular results for NH20-875:
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion          
MGMT Promoter: In progress (NH21-2699)
","Histology: Recurrent / residual anaplastic astrocytoma, IDH-mutant (WHO grade III)  see comment
Methylation profile: IDH glioma, subclass astrocytoma 
CDKN2A/B (Illumina array): Deletion
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 285\NH21-2699,-0.06,-0.003,0.005,0.131,0.002,0.033,-0.004,0.023,0.224,0.258,0.226,-0.023,0.052,0.02,-0.708,-0.057,-0.044,0.071,0.16,0.004,-0.047,-0.021,-0.39,0.01,0.008,-0.028,0.04,-0.083,-0.018,methylated
NH21-2693,205799790104_R01C01,286,20/10/2021,11/5/2021,11/5/2021,16,SB,Diagnostic,286,1,NDP,NHNN,"astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,3/27/1985,37.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.79,AIDH_HG,0.92,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2693,"Anaplastic astrocytoma, at least WHO grade III  see comment
IDH1 (R132H IHC): No mutation (see comment)       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Histology: Anaplastic astrocytoma, IDH-mutant (WHO grade III)
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 286\NH21-2693,0.025,-0.027,0.098,-0.025,-0.021,0.116,0.024,-0.045,-0.032,0.012,-0.014,0.01,0.031,0.237,0.013,-0.13,-0.069,-0.008,0.03,0.072,-0.036,-0.004,-0.088,-0.043,-0.021,0.006,-0.015,-0.027,0.038,methylated
NH21-2710,205799790104_R02C01,286,21/10/2021,11/5/2021,11/5/2021,15,SB,Diagnostic,286,4,NDP,Brighton and Sussex Hospital,"astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,4/2/1985,37.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.83,AIDH,0.84,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2710,"Diffuse astrocytoma, IDH-mutant (WHO grade II)  grading see comment
IDH1 (R132H IHC): Mutation       
ATRX (IHC):     Loss of expression (indicates mutation)
Further molecular tests: Pending 
","Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 286\NH21-2710,0.04,-0.034,0.015,-0.004,0.036,-0.021,0.011,0.007,-0.006,0.003,0.012,-0.012,0.005,0.033,-0.005,-0.005,0.016,0.031,0.017,0.059,-0.006,0.014,-0.054,0.003,0.065,0.005,-0.021,-0.04,0.031,methylated
NH21-2735,205799790104_R03C01,286,22/10/2021,11/5/2021,11/5/2021,14,ZJ,Diagnostic,286,1,NDP,"Cardiff, University Hospital","Ependymoma, post fossa","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A3,2/28/1940,82.8,posterior fossa subependymoma,1,SUBEPN_PF,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2735,"Histology: Ependymal tumour  see comment
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 286\NH21-2735,-0.034,-0.053,0.042,-0.028,-0.034,0.008,-0.374,-0.025,-0.024,-0.037,-0.014,-0.039,0.076,-0.021,0.046,-0.006,0.009,0.022,-0.034,-0.031,-0.041,0.068,-0.02,-0.027,-0.029,0.003,0.003,0.005,0.029,methylated
NH21-2722,205799790104_R04C01,286,22/10/2021,11/5/2021,11/5/2021,14,ZJ,Diagnostic,286,3,NDP,UniLabs,Glioblastoma,"(2) unusual histology, location, demographics",B,11/25/1976,35.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2722,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: IDH glioma, subclass high grade astrocytoma
CDKN2A/B (Illumina array): Deletion
MGMT promoter (Illumina array): Methylated 
  
","See previous report. 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 286\NH21-2722,0.028,-0.065,0.049,0.017,0,-0.433,-0.033,0.061,0,0.025,0.019,-0.04,-0.041,0.067,-0.58,0.049,0.007,-0.526,0.009,0.3,0.908,-0.433,-0.101,0.055,-0.063,-0.007,-0.247,-0.018,-0.006,methylated
NH21-2400,205799790104_R05C01,286,22/10/2021,11/5/2021,11/5/2021,14,ZJ,Diagnostic,286,1,NDP,Romford,A,"(4) IHC, sequencing, or copy number assay ambiguous",A2,9/15/1994,27.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.82,AIDH,0.93,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2400,"Diffuse astrocytoma, IDH-mutant (WHO grade II)  see comment

IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Histology: Diffuse astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: Suggestive of IDH-glioma, subclass astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 286\NH21-2400,-0.092,-0.111,0.046,-0.02,-0.033,-0.039,-0.759,-0.102,-0.363,-0.044,-0.085,-0.018,-0.03,-0.134,-0.175,-0.266,-0.129,-0.1,-0.184,-0.037,-0.108,-0.219,-0.113,-0.005,-0.212,0.212,0.213,0.235,-0.02,unmethylated
NH21-2709,205799790104_R07C01,286,22/10/2021,11/5/2021,11/5/2021,14,SB,Diagnostic,286,19,NDP,NHNN,"Ganglioglioma, unusual histology","(2) unusual histology, location, demographics",DEF2A,2/27/1997,25,supratentorial pilocytic astrocytoma,0.98,LGG_DNT,0.6,0.97,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2709,"Ganglioglioma (WHO grade I) 
","Histology: Ganglioglioma (WHO grade I)
Methylation profile: Low grade glioma / glioneuronal tumour  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 286\NH21-2709,-0.027,-0.034,0.019,0.038,-0.019,0,0.008,0.033,0.048,0.029,0.08,-0.009,0.001,0.027,-0.002,0.001,-0.038,0.037,0.032,-0.001,-0.025,0.027,-0.041,-0.039,0.044,-0.074,-0.035,-0.027,0.017,unmethylated
NH21-2714,205799790104_R08C01,286,25/10/2021,11/5/2021,11/5/2021,11,SB,Diagnostic,286,1,NDP,Romford,"GBM, relatively young patient","(2) unusual histology, location, demographics",A6,3/20/1975,47.3,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.96,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2714,"Glioblastoma (WHO grade IV)  see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending 
","Histology: Glioblastoma, IDH-wildtype (WHO grade IV)
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK II
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 286\NH21-2714,-0.039,-0.021,0.028,-0.062,0,-0.376,0.111,1.289,0.21,0.273,0.194,-0.028,0.085,0.017,-1.848,0.02,-0.406,-0.358,-0.006,-0.018,-0.055,0.042,-0.04,-0.041,0.024,-0.05,0.258,-0.018,0.019,methylated
NH18-1724,205799790107_R03C01,287,25/10/2021,11/12/2021,11/12/2021,18,SB,Diagnostic,287,2,NDP,NHNN,IDH mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.12,AIDH,0.24,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH18-1724,"Diffuse astrocytoma, WHO grade II.

IDH1 (R132H IHC): No mutation, Further tests pending 
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Test pending
  
","Histology: Astrocytoma, IDH-mutant (WHO grade II)
Methylation profile: IDH glioma, subclass astrocytoma,
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 287\NH18-1724,0.04,-0.062,-0.02,0.015,-0.02,-0.02,-0.05,0.035,0.024,0.103,0.056,-0.036,-0.054,0.184,-0.037,-0.051,-0.056,-0.131,-0.035,0.07,-0.011,0.008,-0.105,-0.029,-0.017,-0.033,-0.037,-0.082,0.002,unmethylated
NH21-2736,205799790107_R04C01,287,25/10/2021,11/12/2021,11/12/2021,18,SB,Diagnostic,287,2,NDP,NHNN,IDH mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,8/2/1970,52,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.17,CONTR_HEMI,0.11,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2736,"Recurrent/ residual diffuse astrocytoma, IDH-mutant (WHO grade II)  see comment
IDH1/2Seq: Mutation (IDH1 C394T) (tested 2014)
ATRX (IHC): Loss of expression (indicates mutation) (tested 2018)
MGMT Promoter: Methylated (>5-10%) (tested 2014 and 2018)
","Histology: Astrocytoma, IDH mutant (WHO grade II)
Methylation profile: Control tissue, hemispheric cortex (see comment)
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 287\NH21-2736,-0.047,-0.004,0.019,0.012,0.03,-0.048,-0.038,-0.019,0.006,-0.004,-0.012,-0.037,-0.042,0.091,0.038,-0.004,-0.019,-0.015,-0.012,0.085,-0.036,-0.044,-0.035,-0.008,-0.026,-0.067,-0.062,0.001,-0.004,methylated
NH21-2758,205799790107_R05C01,287,26/10/2021,11/12/2021,11/12/2021,17,ZJ,Diagnostic,287,2,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,4/28/2017,4.5,infratentorial pilocytic astrocytoma,0.67,CONTR_CEBM,0.36,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2758,"Histology: Low grade glioma, features most in keeping with pilocytic astrocytoma
Methylation profile: Control tissue, cerebellar hemisphere
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 287\NH21-2758,-0.044,-0.05,0.012,-0.025,-0.056,-0.029,0.053,-0.03,0.019,-0.011,0.102,-0.007,0.076,0.041,0.067,0.003,-0.001,0.025,0.051,-0.029,0.014,0.037,0.039,0.005,-0.005,-0.029,-0.005,0.001,0.032,unmethylated
NH21-2766,205799790107_R07C01,287,27/10/2021,11/12/2021,11/12/2021,16,ZJ,Diagnostic,287,1,NDP,St George's Hospital London,High grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,8/9/1966,56,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.33,GBM_RTKII,0.78,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2766,"Histology: Diffuse glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK II
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 287\NH21-2766,1.449,-0.046,0.063,0.056,-0.01,-0.069,-0.083,0.506,0.475,0.51,0.386,-0.016,0.033,-0.01,-1.7,0.064,-1.643,-0.446,-0.065,0.061,-0.013,0.024,-0.066,0.063,-2.157,-0.013,-0.109,-0.016,0.072,unmethylated
NH21-2762,205799790107_R08C01,287,27/10/2021,11/12/2021,11/12/2021,16,ZJ,Diagnostic,287,1,NDP,Lund (SE),GBM vs PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",01-01.,2/10/1974,48.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.98,GBM_MES,0.15,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2762,"Histology: Glioblastoma (WHO grade IV)
Methylation profile: Glioblastoma, mesenchymal subtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 287\NH21-2762,0.101,-0.127,-0.012,-0.036,0.005,-0.007,-0.032,0.173,0.036,-0.017,0.02,-0.034,0.029,0.061,-0.519,0.028,-0.194,-0.083,0.057,-0.022,-0.015,0.054,-0.056,0.051,0.027,0.031,0.071,-0.049,0.107,unmethylated
NH21-2755,205809360046_R01C01,288,27/10/2021,11/19/2021,11/19/2021,23,ZJ,Diagnostic,288,6,NDP,NHNN,Oligodendroglioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2C,3/16/1984,38.2,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.72,OIDH,0.98,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2755,"Oligodendroglioma, IDH-mutant (WHO grade II)  see comment
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Histology: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Methylation profile: IDH glioma, subclass 1p/19q-codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 288\NH21-2755,-0.017,0.051,0.026,-0.025,-0.026,0.009,0.028,0.015,-0.029,0.007,0.029,-0.014,-0.035,0.058,-0.012,0.054,0.001,-0.002,-0.027,-0.028,-0.031,0,-0.076,0.055,0.017,-0.011,-0.344,-0.054,0.05,methylated
NH21-2801,205809360046_R02C01,288,29/10/2021,11/19/2021,11/19/2021,21,ZJ,Diagnostic,288,1,NDP,Romford,Likely astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/1/1964,58.1,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.97,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2801,"Likely astroglial tumour  see comment
","Histology: Astroglial tumour
Methylation profile: Pilocytic astrocytoma, subclass hemispheric pilocytic astrocytoma, and ganglioglioma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 288\NH21-2801,-0.049,0.021,0.017,0.009,-0.048,0.103,0.047,0.223,0.308,0.169,0.236,-0.001,0.009,0.073,0.137,0.111,0.091,0.098,-0.009,0.01,0.013,0.011,-0.044,-0.01,-0.02,0.001,-0.053,-0.009,0.052,methylated
NH21-2780,205809360046_R03C01,288,29/10/2021,11/19/2021,11/19/2021,21,ZJ,Diagnostic,288,1,NDP,Romford,"AA, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,5/1/1965,57.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2780,"Anaplastic astrocytoma, IDH mutant (WHO grade III)  see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: IDH glioma, subclass high-grade astrocytoma
MGMT promoter (Illumina array): Methylated 

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 288\NH21-2780,-0.054,-0.136,0.039,0.021,-0.014,0.058,0.052,0.019,-0.035,-0.071,-0.042,-0.008,0.051,0.039,-0.429,0.019,-0.098,0.017,0.037,0.226,-0.212,-0.273,-0.312,0.013,0.049,0.034,-0.066,-0.002,0.012,methylated
NH21-2730,205809360046_R05C01,288,29/10/2021,11/19/2021,11/19/2021,21,ZJ,Diagnostic,288,1,NDP,Royal London Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,5/25/1989,32.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.96,AIDH_HG,0.98,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2730,"High grade glioma (at least grade III)  see comment
IDH1 (R132H IHC): Negative      
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending  
","See previous report
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 288\NH21-2730,0.032,0.017,0.106,0.073,0.003,0.067,0.064,0.034,-0.005,-0.092,-0.098,0.015,-0.005,0.143,-0.198,-0.042,-0.114,-0.052,-0.046,-0.143,-0.092,-0.026,-0.113,-0.036,0.049,0.005,-0.388,-0.08,-0.043,methylated
NH21-2733,205809360046_R07C01,288,29/10/2021,11/19/2021,11/19/2021,21,ZJ,Diagnostic,288,1,NDP,"Cardiff, University Hospital",DLGNT,"(5) Confirmation of rare, unusual or interesting histo-molecular results",B1,11/24/1990,28.4,dysembryoplastic neuroepithelial tumour,0.36,LGG_DNT,0.26,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2733,"Histology: Low grade glioneuronal tumour
Methylation profile: No matching methylation class, please see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 288\NH21-2733,0.115,-0.257,0.065,-0.085,0.328,-0.244,-0.349,-0.167,-0.072,-0.277,-0.06,0.066,0.061,0.254,0.022,-0.067,-0.01,-0.165,0.215,0.143,0.184,-0.057,-0.037,0.344,-0.21,0.004,0.153,0.038,-0.019,unmethylated
NH21-2802,205809370107_R02C01,289,29/10/2021,11/24/2021,11/24/2021,26,ZJ,Diagnostic,289,1,NDP,NHNN,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,9/1/1955,67.1,spinal ependymoma,0.97,EPN_SPINE,0.85,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2802,"Ependymoma (WHO grade II)  see comment 
","Histology: Spinal Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, Spinal
MGMT promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 289\NH21-2802,-0.056,-0.245,-0.158,-0.128,-0.049,-0.011,0.007,0.059,0.122,0.101,0.072,-0.045,-0.011,-0.012,0.134,0.124,-0.042,-0.034,0.07,-0.058,-0.066,0,-0.272,-0.077,-0.03,-0.075,-0.094,-0.198,-0.244,unmethylated
NH21-2775,205809370107_R03C01,289,29/10/2021,11/24/2021,11/24/2021,26,ZJ,Diagnostic,289,1,NDP,Brighton and Sussex Hospital,"Glioma, nos","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,10/8/1956,66,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.43,GBM_MES,0.1,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2775,"Glioma, for grading see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Glioma (see comment) 
IDH1 (R132H IHC); IDH1/2Seq: No mutation (see comment)
ATRX (IHC): Retained     
Methylation profile: Not suitable for classification due to low tumour content (see comment)
MGMT promoter (Illumina array): Unmethylated  
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 289\NH21-2775,0.002,-0.044,0.004,-0.024,-0.119,0.012,-0.044,0.096,0.126,0.128,0.065,-0.018,0.155,0.026,0.009,-0.031,-0.088,-0.071,-0.062,-0.067,-0.026,0.033,-0.087,-0.027,0.023,-0.085,-0.018,-0.115,-0.052,unmethylated
NH21-1864,205809370107_R04C01,289,1/11/2021,11/24/2021,11/24/2021,23,ZJ,Diagnostic,289,1,NDP,Southampton General Hospital,Anaplastic oligodendroglioma,"(4) IHC, sequencing, or copy number assay ambiguous",1A,7/12/1977,44.7,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.35,GBM_RTKII,0.62,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1864,"Anaplastic oligodendroglioma, IDH-mutant (WHO grade III)
IDH1/2Seq: Mutation
ATRX (IHC): Retained
TERT promoter: Mutation

","Integrated Diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 289\NH21-1864,-0.004,-0.054,0.039,0.018,-0.077,0.012,-0.417,0.236,0.221,-0.041,-0.022,-0.019,0.046,0.014,-2.128,0.012,-0.358,-0.367,-0.045,-0.031,0.229,0.316,-0.008,-0.045,0.017,-0.024,-0.037,0.013,0.044,methylated
NH21-2499,205809370107_R05C01,289,1/11/2021,11/24/2021,11/24/2021,23,ZJ,Diagnostic,289,1,NDP,NHNN,"Glioneuronal tumour, BRAFV600E mutant","(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF2A,11/25/1998,23.2,ganglioglioma,0.88,LGG_GG,0.73,0.95,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2499,"Residual glioneuronal tumour (WHO grade I) -see comment
Hippocampal sclerosis
","Histological Diagnosis: Residual glioneuronal tumour (WHO grade 1)
Methylation profile: Low grade glioma, ganglioglioma (see comment)
MGMT promoter status (array): Unmethylated
BRAF V600E (seq.): Mutation    
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 289\NH21-2499,-0.032,0.064,0.025,0.023,-0.019,0.007,-0.001,0.004,0.008,-0.034,-0.007,-0.009,0.013,0.02,0.002,0.005,-0.039,0.013,-0.034,-0.016,-0.011,0.04,-0.041,-0.026,0.012,-0.033,-0.016,-0.014,0.02,unmethylated
NH21-2689,205809370107_R06C01,289,20/10/2021,11/24/2021,11/24/2021,35,ZJ,Diagnostic,289,1,NDP,"Belfast, Royal Victoria Hospital",GBM,"(2) unusual histology, location, demographics",A4,10/5/1995,26.4,pleomorphic xanthoastrocytoma(-like),0.97,PXA,0.84,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2689,"Histology: Favouring Pleomorphic Xanthoastrocytoma, CNS WHO grade 3 (see comment)
Methylation profile: (Anaplastic) Pleomorphic Xanthoastrocytoma
MGMT promoter (Illumina array): Methylated 
BRAF V600E (IHC): Positive (suggesting mutation)  
","Pleomorphic xanthoastrocytoma, BRAF V600E-mutant, CNS WHO grade 3  see comment
BRAF (V600E): Mutation
MGMT Promoter (Illumina array): Methylated
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 289\NH21-2689,-0.02,0.01,0.051,0.133,0.257,0.193,0.012,0.163,0.174,0.197,0.192,-0.027,0.045,0.027,-1.199,-0.002,-0.04,0.022,-0.039,-0.034,0.01,-0.011,0.096,0.026,-0.067,-0.029,-0.013,-0.26,-0.257,methylated
NH21-2803,205809370107_R07C01,289,1/11/2021,11/24/2021,11/24/2021,23,AM,Diagnostic,289,1,NDP,NHNN,Oligodendroglioma recurrence,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,12/8/1964,57.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.61,AIDH_HG,0.87,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2803,"Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted (WHO grade III)  see comment
Molecular results for NH16-1869:
IDH1/2Seq: Mutation (IDH1, G395A Mutation)
ATRX (IHC): Retained     
1p/19q: Codeletion
","Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained
1p/19q: Codeleted
TERT promoter: Mutation
MGMT Promoter: Methylated (>25%)

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 289\NH21-2803,-0.423,-0.044,0.045,-0.004,-0.02,0.071,0.04,-0.006,-0.029,-0.01,-0.026,0.198,0.013,0.135,-0.197,0.046,-0.337,-0.021,0.135,0.072,-0.012,0.029,-0.018,-0.407,-0.562,-0.056,-0.593,-0.295,-0.382,methylated
NH21-2797,205809370107_R08C01,289,2/11/2021,11/24/2021,11/24/2021,22,AM,Diagnostic,289,3,NDP,NHNN,IDH-mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,10/8/1988,33.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2797,"Astrocytoma, IDH-mutant (WHO grade II)  see comments
IDH1 (R132H IHC): Mutation      
ATRX (IHC): Loss (indicates mutation)      
Further molecular tests: Pending
  
","Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated   
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 289\NH21-2797,-0.047,-0.044,0.022,0.007,-0.013,-0.103,0.054,0.03,-0.031,-0.048,-0.011,0.002,0.075,0.054,-0.014,0.011,0.035,0.005,-0.006,0.219,0.021,0.077,-0.25,-0.017,-0.018,0.022,-0.073,-0.009,0.039,methylated
NH21-2806,205809370165_R01C01,290,2/11/2021,11/24/2021,11/24/2021,22,AM,Diagnostic,290,5,NDP,NHNN,IDH-mutant Oligodendroglioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1D,4/8/1973,49.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2806,"Diffuse glioma favouring an Oligodendroglioma, IDH-mutant (WHO grade II)  see comment
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending 
","Final Diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 290\NH21-2806,-0.036,-0.03,0.039,-0.14,-0.201,-0.004,0.004,-0.004,0.008,-0.007,0.001,-0.009,-0.001,0.011,0.052,0.002,-0.011,0.032,-0.048,-0.003,-0.083,-0.027,-0.117,0.01,-0.018,-0.039,-0.409,-0.011,0.023,methylated
NH21-2827,205809370165_R02C01,290,3/11/2021,11/24/2021,11/24/2021,21,ZJ,Diagnostic,290,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/31/2008,13.9,posterior fossa ependymoma group A1,0.08,LGG_PAPF,0.05,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2827,"Histology: Insufficient material for confident interpretation (see comment)
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 290\NH21-2827,-0.067,-0.459,0.107,0.13,-0.201,-0.121,-0.256,-0.064,0.044,0.014,-0.027,-0.019,0.119,-0.011,-0.48,-0.046,0.007,0.066,-0.124,-0.282,-0.152,-0.291,-0.068,-0.206,0.162,0.01,0.024,-0.133,0.146,unmethylated
NH21-2829,205809370165_R03C01,290,3/11/2021,11/24/2021,11/24/2021,21,ZJ,Diagnostic,290,1,NDP,Nottingham University Hospital,Glioblastoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/11/1947,65.9,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.95,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2829,"Histology: Glioblastoma, CNS WHO grade 4 (see comment)
Methylation profile: Glioblastoma, IDH wildtype
MGMT promoter (Illumina array): Unmethylated   
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 290\NH21-2829,0.025,0.049,0.127,0.13,1.52,-0.025,-0.657,2.016,0.531,0.441,0.436,0.027,0.102,0.216,-1.689,0.154,-1.667,-0.481,0.076,0.124,0.14,0.077,-0.559,0.206,-0.082,-0.004,-0.043,-0.099,-0.022,unmethylated
NH21-2833,205809370165_R04C01,290,3/11/2021,11/24/2021,11/24/2021,21,ZJ,Diagnostic,290,1,NDP,"Cardiff, University Hospital","LGG, ?ependymoma","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/24/1980,42,infratentorial pilocytic astrocytoma,0.61,LGG_PAPF,0.35,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2833,"Histology: Low-grade glioma / glioneuronal tumour (see comment)
Methylation profile: Classified with low confidence (see comment)
MGMT promoter (Illumina array): Unmethylated   
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 290\NH21-2833,0.15,-0.11,0.014,-0.036,-0.046,-0.038,-0.109,0.183,-0.022,-0.021,0.021,-0.074,-0.083,-0.07,-0.082,-0.015,-0.08,0.029,0.056,-0.105,-0.023,-0.001,-0.113,-0.006,-0.161,-0.033,0.05,-0.125,0.019,unmethylated
NH21-2813,205809370165_R05C01,290,3/11/2021,11/24/2021,11/24/2021,21,ZJ,Diagnostic,290,1,NDP,"Cambridge, Addenbrooke's Hospital","Cervicothoracic tumour, nos","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,8/29/1991,25.8,rosette-forming glioneuronal tumour,1,LGG_RGNT,0.97,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2813,"Histology: Low grade glioma / glioneuronal tumour (see comment)
Methylation profile: Low grade glioma, rosette forming glioneuronal tumour
MGMT promoter (Illumina array): Unmethylated  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 290\NH21-2813,0.055,0.006,-0.018,-0.047,-0.058,-0.061,-0.035,0.027,0.031,0.003,-0.005,-0.017,0.027,0.041,0.037,0.011,0,0.007,0.024,0.04,0.035,0.061,-0.027,0.028,0.07,-0.032,-0.014,-0.063,0.074,unmethylated
NH21-2815,205809370165_R06C01,290,3/11/2021,11/24/2021,11/24/2021,21,ZJ,Diagnostic,290,1,NDP,"Cambridge, Addenbrooke's Hospital",Cerebellar ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,5/19/1996,25.8,posterior fossa ependymoma group B,1,EPN_PFB,0.57,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2815,"Histology: Posterior fossa Ependymoma, CNS WHO grade 2 (see comment)
Methylation profile: Ependymoma, posterior fossa group B (low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated   
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 290\NH21-2815,-0.129,0.128,0.118,-0.092,-0.157,-0.109,-0.158,0.112,0.089,0.049,0.098,0.074,0.044,0.157,0.267,0.25,-0.146,-0.099,0.073,0.189,0.2,0.348,0.062,-0.131,-0.172,-0.183,0.071,-0.136,-0.083,unmethylated
NH21-2849,205809370165_R07C01,290,3/11/2021,11/24/2021,11/24/2021,21,ZJ,Diagnostic,290,1,NDP,"Cardiff, University Hospital",Rec astrocytoma with anaplastic features,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/18/1975,46.5,high-grade astrocytoma with piloid features,0.99,ANAPA,0.97,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2849,"Histology: In keeping with recurrent anaplastic astrocytoma with piloid features (see comment)
Methylation profile: Anaplastic pilocytic astrocytoma
MGMT promoter (Illumina array): Methylated   
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 290\NH21-2849,0.12,0.017,0.01,-0.019,-0.053,0.039,-0.228,-0.026,-0.012,-0.029,-0.007,-0.052,0.006,-0.002,-0.423,0.043,-0.021,-0.003,-0.008,0.037,0.069,0.261,-0.116,-0.016,0.063,0.075,-0.054,-0.08,0.036,methylated
NH21-2871,205852210130_R03C01,291,5/11/2021,11/26/2021,11/26/2021,21,ZJ,Diagnostic,291,1,NDP,"Birmingham, Queen Elizabeth Hospital",Cerebellar glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/19/1964,57.9,high-grade astrocytoma with piloid features,0.96,ANAPA,0.99,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2871,"Histology: High-grade astrocytoma with piloid features (see comment)
Methylation profile: Anaplastic Pilocytic Astrocytoma
MGMT promoter (Illumina array): Unmethylated   
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 291\NH21-2871,0.045,-0.048,-0.025,0.035,0.014,-0.003,-0.05,-0.006,0.005,-0.001,0.15,-0.022,-0.016,-0.007,-0.647,0.01,-0.015,0.013,-0.01,-0.022,0.102,0.445,-0.061,0.006,0.175,0.121,0.03,-0.018,0.056,unmethylated
NH21-2571,205852210130_R04C01,291,05/11/20211,11/26/2021,11/26/2021,#VALUE!,ZJ,Diagnostic,291,1,NDP,"Belfast, Royal Victoria Hospital",Cervical pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/15/2009,12.5,diffuse leptomeningeal glioneuronal tumour,1,DLGNT,1,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2571,"Glioma, BRAF V600E-mutant  see comment     
1p/19q: Retained (19qLOH)          
BRAF (V600E, IHC and Seq): Mutation
","Histology: Diffuse Leptomeningeal Glioneuronal Tumour (DLGNT)  see comment
Methylation profile: Diffuse leptomeningeal glioneuronal tumour
BRAF V600E (IHC and seq.): Mutation
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 291\NH21-2571,0.044,0.005,-0.04,-0.004,0.056,-0.045,-0.066,-0.013,0.005,0.271,0.176,-0.028,0.013,0.038,-0.012,0.004,-0.05,0.012,-0.076,0.029,0.039,-0.053,-0.07,-0.003,-0.096,-0.067,-0.084,0,0.041,unmethylated
NH21-2875,205852210163_R01C01,292,5/11/2021,12/3/2021,12/3/2021,28,AM,Diagnostic,292,1,NDP,Romford,Meningioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A3,2/21/1964,58.5,spinal ependymoma,0.61,EPN_SPINE,0.3,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2875,"Meningioma - see comment 
","Histology: Meningioma
Methylation profile: Meningioma, intermediate-A
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 292\NH21-2875,-0.258,0.042,0.207,-0.078,0.06,0.088,-0.152,-0.23,-0.024,-0.19,-0.056,0.259,0.098,0.092,-0.032,0.205,0.041,-0.015,-0.207,0.017,-0.127,-0.148,-0.138,0.018,0.011,-0.04,0.516,-0.367,-0.063,unmethylated
NH21-2840,205852210163_R02C01,292,8/11/2021,12/3/2021,12/3/2021,25,AM,Diagnostic,292,1,NDP,Brighton and Sussex Hospital,Meningioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2A,6/1/1963,59.3,supratentorial subependymoma,0.99,SUBEPN_ST,0.98,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2840,"Meningioma - see comment
","Histology: Meningioma
Methylation profile: Meningioma benign-3
MGMT promoter (Illumina array): Unmethylated 
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 292\NH21-2840,0.027,-0.002,0.108,0.062,-0.035,0.02,0.06,0.018,-0.014,-0.067,-0.032,0.012,0.128,0.068,0.025,0.062,0.064,0.013,0.043,0.046,0.026,0.063,0.044,0.072,0.075,-0.031,-0.068,-0.004,0.048,unmethylated
NH14-1021,205852210163_R05C01,292,25/10/2021,12/3/2021,12/3/2021,39,SB,Diagnostic,292,1,NDP,NHNN,IDH mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",L4210-14,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.95,AIDH_HG,0.8,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-1021,"Gemistocytic astrocytoma (WHO grade II). 
","Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: IDH glioma, subclass high-grade astrocytoma (see comment)
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 292\NH14-1021,0.122,0.05,0.062,-0.095,-0.072,0.081,-0.432,0.001,0.026,-0.001,-0.018,-0.096,0.089,0.076,-0.361,-0.006,-0.034,0.015,0.011,-0.002,-0.033,-0.008,-1.993,0,-0.026,0.112,-0.111,-0.353,-0.292,methylated
NH21-2893,205852210163_R06C01,292,9/11/2021,12/3/2021,12/3/2021,24,ZJ,Diagnostic,292,1,NDP,"Cambridge, Addenbrooke's Hospital",High grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/4/1954,68.1,high-grade astrocytoma with piloid features,1,ANAPA,0.99,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2893,"Histology: Diffuse glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 292\NH21-2893,0.134,-0.012,-0.034,-0.219,-0.287,0.081,-0.022,0.011,-0.004,-0.026,-0.024,-0.002,0.096,0.086,-0.761,-0.014,0.042,-0.181,0.037,-0.202,0.166,0.197,0.021,-0.254,0.052,0.053,-0.072,-0.041,0.022,methylated
NH21-2930,205852210176_R05C01,293,12/11/2021,12/3/2021,12/3/2021,21,ZJ,Diagnostic,293,1,NDP,Romford,"HGG, IDH-mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,12/28/1974,47.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.4,AIDH,0.81,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2930,"High grade Glioma, IDH-mutant (at least WHO grade III)  see comment
IDH1 (R132H IHC): Mutation      
ATRX (IHC): Retained      
Further molecular tests: Pending
  
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 293\NH21-2930,0.122,-0.077,-0.035,-0.058,0.042,-0.233,-0.141,0.079,0.119,-0.088,0.076,0.009,-0.019,0.181,0.052,0.028,0.088,-0.285,0.038,0.136,-0.053,0.054,0.091,0.091,0.158,-0.053,-0.354,0.02,0.057,methylated
NH21-2911,205852210176_R06C01,293,12/11/2021,12/3/2021,12/3/2021,21,ZJ,Diagnostic,293,1,NDP,Brighton and Sussex Hospital,Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/13/1988,34.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.62,GBM_MES,0.9,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2911,"Recurrent glial/glioneuronal tumour  see comment
","Integrated diagnosis: High-grade astrocytoma with piloid features, corresponding to CNS WHO grade 3 (see comment)
Histology: Recurrent glial/glioneuronal tumour
Methylation profile: Anaplastic pilocytic astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 293\NH21-2911,0.113,0.011,0.058,0.039,0.021,-0.012,-0.033,0.147,0.165,0.216,0.181,0.003,-0.013,0.013,0.007,0.027,-0.238,-0.241,-0.043,0.051,0.104,0.168,-0.286,0.024,-0.428,-0.067,-0.009,-0.241,-0.266,methylated
NH21-2926,205852210176_R08C01,293,12/11/2021,12/3/2021,12/3/2021,21,ZJ,Diagnostic,293,1,NDP,"Cardiff, University Hospital",Choroid plexus tumour,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,1/1/1970,52.6,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.5,GBM_RTKIII,0.69,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2926,"Histology: Choroid plexus papilloma, CNS WHO grade 1
Methylation profile: Plexus tumour, subclass adult
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 293\NH21-2926,0.061,-0.083,-0.018,0.031,-0.006,-0.009,-0.177,-0.138,-0.021,-0.015,-0.039,-0.006,0.104,0.008,-0.069,-0.064,0.019,0,-0.028,-0.12,-0.11,0.153,-0.101,-0.049,0.05,0.082,0.144,-0.044,0.11,unmethylated
NH21-2937,205852210024_R02C01,296,12/11/2021,12/8/2021,12/8/2021,26,ZJ,Diagnostic,296,1,NDP,Southampton General Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1B,6/19/1994,27.8,myxopapillary ependymoma,1,EPN_MPE,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2937,"Integrated diagnosis: Myxopapillary ependymoma, WHO CNS grade 2
Histology: Myxopapillary ependymoma
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 296\NH21-2937,-0.103,-0.014,0.067,-0.012,-0.059,-0.006,0.05,-0.004,0.004,0.025,-0.006,-0.045,0.094,0.029,0.021,0.046,-0.008,0.032,-0.014,0,0.02,0.015,-0.005,-0.01,-0.021,-0.037,-0.036,-0.059,0.01,unmethylated
NH21-2938,205852210024_R03C01,296,12/11/2021,12/8/2021,12/8/2021,26,ZJ,Diagnostic,296,1,NDP,Oxford John Radcliffe Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A,8/13/1971,51,spinal ependymoma,1,EPN_SPINE,0.85,0.95,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2938,"Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Ependymoma
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 296\NH21-2938,0.26,0.227,0.298,-0.047,-0.085,0.023,-0.03,0.254,0.269,0.231,0.238,0.258,0.297,0.257,0.424,0.398,0.046,0.064,-0.09,0.38,0.351,0.432,-0.032,0.062,-0.051,-0.034,-0.016,-0.478,-0.399,unmethylated
NH21-2939,205852210024_R04C01,296,12/11/2021,12/8/2021,12/8/2021,26,ZJ,Diagnostic,296,3,NDP,"Cardiff, University Hospital",?Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,5/12/1968,54.3,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.88,DMG_K27,0.61,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2939,"Integrated diagnosis: Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4
Histology: High-grade glioma, NOS
Methylation profile: Diffuse midline glioma H3 K27M mutant
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 296\NH21-2939,-0.027,0.094,-0.213,-0.759,0.796,0.277,-0.246,-0.001,-0.023,-0.087,-0.038,-0.048,0.034,0.017,0.268,0.153,0.012,-0.01,-0.292,-0.216,0.661,-0.304,-0.325,-0.245,0.021,-0.059,-0.448,-0.063,-0.017,unmethylated
NH21-2956,205852210024_R06C01,296,12/11/2021,12/8/2021,12/8/2021,26,ZJ,Diagnostic,296,1,NDP,Oxford John Radcliffe Hospital,Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,12/25/1994,27.3,supratentorial pilocytic astrocytoma,0.95,LGG_PA_GGST,0.74,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2956,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glioma
Methylation profile: Pilocytic astrocytoma, subtype hemispheric
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 296\NH21-2956,0.117,-0.104,-0.058,-0.055,0.032,-0.024,0.039,0.1,0.146,0.187,0.176,-0.024,-0.029,0.12,-0.079,0.039,-0.123,0.054,0.188,0.07,-0.02,0.099,-0.191,0.112,0,-0.05,0.089,-0.03,0.062,unmethylated
NH21-2923,205852210139_R02C01,297,12/11/2021,12/8/2021,12/8/2021,26,ZJ,Diagnostic,297,1,NDP,NHNN,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,8/29/1949,73.3,myxopapillary ependymoma,1,EPN_MPE,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2923,"Ependymoma (WHO grade II)  see comment
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Ependymoma
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 297\NH21-2923,-0.145,0.008,0.097,0.027,0.014,0.221,0.33,0.215,0.226,0.272,0.197,-0.056,0.056,0.077,0.27,0.249,0.005,0.016,0.23,0.016,0.036,-0.021,0.009,0.14,0.227,0.165,-0.048,-0.059,-0.051,unmethylated
NH21-2919,205852210139_R03C01,297,12/11/2021,12/8/2021,12/8/2021,26,ZJ,Diagnostic,297,3,NDP,The Heart Hospital,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3,9/14/2001,20.4,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.99,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-2919,"Pilocytic astrocytoma (WHO grade I)  see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: See comment
  
","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma
Methylation profile: Low-grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 297\NH21-2919,-0.038,-0.092,0.008,-0.015,-0.08,0.033,-0.064,-0.02,-0.029,-0.006,0.172,-0.019,-0.079,0.058,0.014,-0.034,-0.014,0.001,-0.022,-0.011,0.025,0.03,-0.137,0.061,-0.033,-0.035,0.014,-0.058,0.02,unmethylated
NH21-2805,205852210139_R04C01,297,15/11/2021,12/8/2021,12/8/2021,23,ZJ,Diagnostic,297,1,NDP,Southampton General Hospital,?Inf GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,3/31/1977,45.2,ganglioglioma,0.48,GBM_MES,0.52,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2805,"Molecular profile raising the possibility of infiltration of glioblastoma, IDH-wildtype (WHO grade IV)  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: No amplification          
TERT promoter: Mutation
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: CNS infiltration with a high grade glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 297\NH21-2805,-0.013,-0.016,0.016,0.182,-0.06,-0.058,0.011,0.147,0.187,0.179,0.11,0.002,0.061,0.054,-0.013,0.022,-0.177,-0.133,-0.005,0.054,0.133,0.168,0.007,0.025,0.022,-0.021,0.093,-0.241,-0.159,unmethylated
NH21-2946,205852210139_R06C01,297,15/11/2021,12/8/2021,12/8/2021,23,SB,Diagnostic,297,1,NDP,NHNN,"Glioma, probably IDH mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,9/25/1961,61,high-grade astrocytoma with piloid features,1,ANAPA,0.94,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2946,"Diffuse glioma  for grading, see comment
IDH1 (R132H IHC): No mutation      
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Glioma (see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
H3 K27M (IHC) and Histone H3F3A (seq.): No mutation     
BRAF (V600E): No mutation          
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 297\NH21-2946,-0.036,-0.053,0.013,-0.014,-0.066,0.001,-0.002,-0.031,0.018,0.04,-0.01,-0.035,-0.004,0.004,-0.541,-0.046,-0.036,0.107,-0.024,-0.019,-0.026,-0.02,-0.037,-0.014,-0.037,-0.013,-0.22,-0.039,0.061,methylated
NH21-2977,205852210029_R01C01,298,17/11/2021,12/15/2021,12/15/2021,28,SB,Diagnostic,298,1,NDP,"Cambridge, Addenbrooke's Hospital",Glioma infiltration,(1) small biopsy or nonrepresentative sample;,A1,5/22/1941,81.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.32,CONTR_REACT,0.18,0.63,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2977,"Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1/2Seq: No mutation
Methylation profile and MGMT status: Pending
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Methylation profile: Inconclusive  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 298\NH21-2977,-0.102,-0.001,-0.015,0.018,-0.059,0.039,0.097,-0.013,0.014,0.004,-0.013,-0.035,0.014,-0.003,-0.005,-0.062,0.03,-0.047,0.014,-0.011,0.046,0.039,-0.008,-0.017,0.003,-0.062,0.044,-0.021,0.013,unmethylated
NH21-2963,205852210029_R03C01,298,17/11/2021,12/15/2021,12/15/2021,28,SB,Diagnostic,298,7,NDP,NHNN,Oligodendroglioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,2/4/1976,46.4,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2963,"Anaplastic Oligodendroglioma, IDH-mutant (WHO grade III)  see comment
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Anaplastic oligodendroglioma, IDH-mutant and 1p/19q codeleted (WHO grade III)
Histology: Anaplastic oligodendroglioma, IDH-mutant and 1p/19q codeleted (WHO grade III)
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 298\NH21-2963,-0.031,-0.079,0.015,-0.053,-0.138,0.054,0.035,0.023,-0.013,0.018,-0.004,0.008,0.014,0.022,0.026,-0.048,-0.001,-0.013,-0.017,0.068,-0.008,0.047,-0.087,0.026,-0.023,0.007,-0.379,-0.031,-0.013,methylated
NH21-2962,205852210029_R05C01,298,17/11/2021,12/15/2021,12/15/2021,28,SB,Diagnostic,298,1,NDP,Romford,Meningioma Grade 2,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,2/12/1979,43.4,"glioblastoma, IDH-wildtype, RTK1 type",0.6,GBM_RTKI,0.68,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2962,"DEF1A, DEF1B: Chordoid meningioma (WHO grade II)  see comment
DEF1C: Secretory meningioma (WHO grade I)
","DEF1A:
Integrated diagnosis: Meningioma  for grading, see comment
Histology: Chordoid meningioma 
Methylation profile: Suggestive of benign meningioma
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 298\NH21-2962,0.25,-0.074,0.006,0.002,-0.017,-0.033,0.008,0.457,0.459,0.509,0.33,0.022,0.094,0.083,-0.549,-0.367,-1.102,-0.251,-0.032,0.076,-0.044,0.008,-0.182,0.057,0.064,0.013,-0.114,-0.042,0.069,unmethylated
NH21-2968,205852210029_R07C01,298,17/11/2021,12/15/2021,12/15/2021,28,SB,Diagnostic,298,1,NDP,Royal London Hospital,PXA vs GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,10/25/1997,24.4,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.46,PXA,0.34,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2968,"High grade glioma (WHO at least grade III) - see comment 
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Compatible with glioblastoma IDH-wildtype, CNS WHO grade 4  see comment
Histology: High grade glioma
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 298\NH21-2968,-0.044,-0.112,-0.001,-0.004,-0.192,-0.026,-0.067,-0.008,-0.008,0.015,-0.017,0.011,0.032,0.031,-0.198,-0.221,-0.15,-0.165,-0.214,-0.205,-0.147,-0.188,-0.199,-0.21,-0.219,-0.254,0.003,-0.017,-0.007,unmethylated
NH21-2958,205852210029_R08C01,298,17/11/2021,12/15/2021,12/15/2021,28,SB,Diagnostic,298,4,NDP,Brighton and Sussex Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,10/29/1957,65,spinal subependymoma [subtype B],0.57,EPN_PFA,0.54,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2958,"Ependymoma (WHO grade II)  see comment
","Integrated diagnosis: Spinal ependymoma with MYCN amplification  see comment
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Spinal ependymoma with MYCN amplification
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 298\NH21-2958,-0.034,1.269,0.033,-0.072,0.015,0.025,0.064,0.019,-0.008,-0.051,-0.011,-0.021,0.096,0.056,0.034,-0.041,0.061,0.037,0.048,0.015,0.002,0.034,-0.045,0.046,0.065,-0.01,-0.032,0.012,-0.013,unmethylated
NH21-2992,205852210095_R01C01,299,18/11/2021,12/15/2021,12/15/2021,27,SB,Diagnostic,299,1,NDP,Lund (SE),Oligo vs GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",0102,3/3/1948,74.8,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.26,DMG_K27,0.1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2992,"Integrated diagnosis: Compatible with glioblastoma, IDH-wildtype, CNS WHO grade 4  see comment
Histology: Compatible with glioblastoma, IDH-wildtype, CNS WHO grade 4
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 299\NH21-2992,0.536,-0.013,-0.084,0.093,0.063,0.001,-0.135,0.019,-0.165,-0.052,-0.017,-0.003,-0.108,-0.226,-0.143,-0.001,0.004,-0.114,-0.275,-0.103,-0.096,-0.494,-0.147,-0.193,-0.167,-0.102,0.084,0.106,0.183,methylated
NH21-2996,205852210095_R02C01,299,18/11/2021,12/15/2021,12/15/2021,27,SB,Diagnostic,299,1,NDP,Lund (SE),"LGG, vs CNS tissue/reactive","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",0101,8/13/1978,43.9,"control tissue, white matter (corpus callosum)",1,CONTR_WM,0.77,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2996,"Integrated diagnosis: No definite evidence of neoplasm  see comment
Histology: No definite evidence of neoplasm
Methylation profile: Control tissue, white matter
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 299\NH21-2996,0.111,0.006,-0.057,-0.041,-0.065,-0.036,-0.049,0.119,0.128,0.121,0.007,-0.025,-0.071,-0.099,-0.071,0.106,-0.014,0.006,-0.048,-0.037,-0.001,0.114,-0.02,0.074,0.117,0.109,-0.015,-0.012,0.045,unmethylated
NH21-2973,205852210095_R04C01,299,18/11/2021,12/15/2021,12/15/2021,27,SB,Diagnostic,299,1,NDP,NHNN,"Astrocytoma, IDH-mut, Gr 4","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1F,6/29/1984,37.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2973,"Glioblastoma, IDH-mutant (WHO grade IV)  see comment
IDH1 (R132H IHC): Mutation       
ATRX (IHC):  Loss of expression (indicates mutation)
Further molecular tests: Pending  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4  see comment
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4 (aka glioblastoma, IDH-mutant)
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 299\NH21-2973,-0.062,0.911,0.041,-0.013,-0.022,0.096,-0.412,0.003,0.236,0.311,0.192,-0.018,-0.019,0.015,-1.091,-0.061,-0.339,-0.366,-0.02,0.077,-0.015,0.116,-0.128,-0.017,0.008,0.025,-0.454,0.011,-0.055,methylated
NH21-3028,205852210095_R05C01,299,22/11/2021,12/15/2021,12/15/2021,23,SB,Diagnostic,299,1,NDP,"Belfast, Royal Victoria Hospital","RELA Fused Epenymoma, Oligo?","(5) Confirmation of rare, unusual or interesting histo-molecular results",A3,6/29/1992,29.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.69,AIDH_HG,0.83,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3028,"Integrated diagnosis: In favour of astrocytoma, IDH-mutant, CNS WHO grade 4  see comment
Histology: In favour of astrocytoma, IDH-mutant, CNS WHO grade 4  see comment
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 299\NH21-3028,0.053,-0.105,-0.015,-0.007,-0.04,0.043,0.017,0.032,0.052,0.035,-0.007,-0.035,0.021,-0.033,-1.259,0.02,-0.112,-0.132,-0.015,0.21,-0.03,0.016,-0.135,0.046,0.023,0.016,-0.369,-0.032,0,methylated
NH21-3006,205852210095_R07C01,299,23/11/2021,12/15/2021,12/15/2021,22,AM,Diagnostic,299,1,NDP,Wellington Hospital London,Oligodendroglioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,9/22/1984,37.7,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3006,"Diffuse oligodendroglioma (WHO grade II)  see comment
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 299\NH21-3006,0.003,-0.058,0.052,-0.218,-0.294,0.036,0.075,0.021,0.026,-0.011,-0.007,-0.001,0.043,0.048,0.083,-0.002,0.013,0.018,0.01,0.026,0.037,0.042,-0.028,0,0.024,0.012,-0.369,0.007,-0.012,methylated
NH21-3012,205852210141_R01C01,300,23/11/2021,12/15/2021,12/15/2021,22,AM,Diagnostic,300,1,NDP,"Cambridge, Addenbrooke's Hospital",Anaplastic PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,5/30/1986,35.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.29,GBM_MES,0.56,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3012,"Integrated diagnosis: Compatible with glioblastoma, IDH-wildtype, CNS WHO grade 4  see comment
Histology: Compatible with glioblastoma, CNS WHO grade 4
Methylation profile: Suggestive of glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Not determinable 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 300\NH21-3012,0.04,0.013,-0.006,-0.041,-0.046,-0.148,-0.23,0.092,0.113,0.078,0.024,-0.025,0.019,0.008,-0.628,-0.068,-0.187,-0.21,-0.167,0.066,0.134,0.023,-0.244,-0.162,-0.236,0.026,-0.198,-0.012,-0.184,unmethylated
NH21-2993,205852210141_R04C01,300,23/11/2021,12/15/2021,12/15/2021,22,AM,Diagnostic,300,2,NDP,Sweden,? DMG ? Pilocytic with H3K27M+,"(5) Confirmation of rare, unusual or interesting histo-molecular results",0101,3/24/1979,43.3,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.4,DMG_K27,0.47,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2993,"Histology: Glioma, H3 K27M-mutant  see commentMethylation profile: No matching methylation class

MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 300\NH21-2993,0.033,-0.087,-0.024,-0.051,-0.076,0.017,-0.097,1.04,0.05,0.067,0.019,-0.045,0.002,-0.047,-0.052,-0.015,-0.093,-0.033,-0.137,0.002,-0.021,0.038,-0.075,0.04,0.009,0.09,-0.072,-0.018,0.025,unmethylated
NH21-3008,205852210141_R07C01,300,23/11/2021,12/15/2021,12/15/2021,22,AM,Diagnostic,300,1,NDP,Oxford John Radcliffe Hospital,HGG,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,4/30/1988,34,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3008,"Integrated diagnosis: Astrocytoma, IDH-mutant  for grading, see comment
Histology: Referred diagnosis: Anaplastic astrocytoma, IDH-mutant (WHO grade III)
Methylation profile: IDH glioma, subclass astrocytoma 
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 300\NH21-3008,0.017,-0.053,0.011,-0.002,0.005,-0.225,0.04,0.069,0.414,0.441,0.309,-0.021,0.014,0.223,-0.011,-0.002,-0.016,-0.005,-0.038,0.06,0.005,-0.036,-0.082,0.065,0.012,-0.058,-0.062,-0.042,-0.039,methylated
NH21-3036,205852210141_R08C01,300,23/11/2021,12/15/2021,12/15/2021,22,AM,Diagnostic,300,1,NDP,Nottingham University Hospital,? LGG/Glinoneuronal tumour ,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,11/8/1986,35.5,dysembryoplastic neuroepithelial tumour,0.94,LGG_DNT,0.96,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3036,"Integrated diagnosis: Low grade glial / glioneuronal tumour, compatible with dysembryoplastic neuroepithelial tumour, CNS WHO grade 1  see comment
Histology: Low grade glial / glioneuronal tumour
Methylation profile: Suggestive of low grade glioma, dysembryoplastic neuroepithelial tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 300\NH21-3036,0.037,-0.116,-0.031,-0.006,-0.003,-0.118,-0.02,0.175,0.184,0.116,0.126,-0.071,0.021,-0.056,-0.013,-0.03,-0.069,-0.02,-0.005,0.033,0.022,0.002,-0.048,-0.091,-0.017,-0.114,0.023,0.013,0.032,unmethylated
NH21-3029,205852210066_R01C01,301,24/11/2021,12/22/2021,12/22/2021,28,AM,Diagnostic,301,1,NDP,NHNN,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP2C,12/28/1957,64.8,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.21,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3029,"High grade glioma (CNS WHO at least grade 3)  see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending

","Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
TERT promoter: Mutation
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 301\NH21-3029,-0.09,-0.014,0.058,-0.005,-0.032,0.007,-0.018,0.094,0.039,0.04,0.064,-0.016,0.068,-0.019,-0.264,0.071,-0.166,-0.089,0.023,-0.055,-0.004,-0.017,-0.012,-0.023,-0.028,-0.059,-0.024,-0.164,-0.129,methylated
NH21-3062,205852210066_R05C01,301,24/11/2021,12/22/2021,12/22/2021,28,AM,Diagnostic,301,1,NDP,Lund (SE),Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",0106,1/22/1983,39.4,posterior fossa subependymoma,1,SUBEPN_PF,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3062,"Integrated diagnosis: Subependymoma, CNS WHO grade 1
Histology: Ependymal tumour, favoring subependymoma
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated   
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 301\NH21-3062,0.006,0.007,0.071,0.032,0.031,0.006,-0.014,-0.042,-0.069,-0.043,-0.019,0,0.047,0.066,-0.03,0.029,-0.077,0.015,-0.047,-0.111,-0.045,0.044,-0.026,-0.021,-0.018,-0.03,0.01,-0.011,0.066,unmethylated
NH21-3063,205852210066_R06C01,301,24/11/2021,12/22/2021,12/22/2021,28,AM,Diagnostic,301,1,NDP,"Belfast, Royal Victoria Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,9/14/1986,35.7,"spinal ependymoma, MYCN-amplified",1,EPN_PFA,0.36,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3063,"Integrated diagnosis: Suggestive of Spinal ependymoma, MYCN-amplified (see comment)
Histology: High-grade (anaplastic) ependymoma, favouring a CNS WHO grade 3 (see comment)
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Unmethylated   
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 301\NH21-3063,-0.011,1.001,0.071,0.015,-0.016,0.019,0.049,-0.002,-0.1,-0.073,-0.016,0.006,0.08,-0.025,0.007,0.027,-0.022,0.059,0.006,0.021,-0.069,-0.005,0.003,-0.019,-0.01,-0.036,-0.212,-0.035,0.003,unmethylated
NH21-3082,205852210068_R01C01,302,26/11/2021,12/22/2021,12/22/2021,26,AM,Diagnostic,302,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,9/2/1963,59.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.98,GBM_MES,0.77,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3082,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 302\NH21-3082,0.036,0.004,-0.013,0.006,-0.074,0.028,-0.184,0.143,0.177,0.159,0.103,-0.001,-0.02,0.014,-0.37,-0.038,-0.149,-0.124,-0.019,-0.031,-0.044,0.027,-0.202,-0.005,0.033,-0.035,-0.07,-0.031,-0.013,unmethylated
NH21-3055,205852210068_R03C01,302,26/11/2021,12/22/2021,12/22/2021,26,AM,Diagnostic,302,1,NDP,NHNN,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/26/1949,73.8,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.97,0.54,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3055,"Glioma  see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: In favour of glioblastoma, IDH-wildtype, CNS WHO grade 4  see comment
Histology: Glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 302\NH21-3055,-0.037,-0.052,0.01,0.001,-0.017,-0.038,-0.002,0.131,0.142,0.154,0.11,0,0.013,0.014,-0.179,-0.021,-0.203,-0.123,-0.017,-0.021,0.007,-0.067,-0.035,-0.049,-0.355,-0.016,-0.062,-0.17,-0.115,methylated
NH21-3065,205852210068_R04C01,302,26/11/2021,12/22/2021,12/22/2021,26,AM,Diagnostic,302,4,NDP,Brighton and Sussex Hospital,Glioma IDH-mutant,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,4/23/1977,45.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3065,"Glioma, IDH-mutant  see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 302\NH21-3065,-0.148,0.052,0.031,-0.027,0.013,0.01,0.002,0.043,0.205,0.096,0.094,-0.011,0.065,0.023,0.002,-0.015,-0.027,0.06,0.021,0.012,0.023,-0.025,-0.032,0,-0.01,-0.022,-0.401,-0.016,0.073,methylated
NH21-3090,205852210068_R06C01,302,26/11/2021,12/22/2021,12/22/2021,26,AM,Diagnostic,302,1,NDP,Oxford John Radcliffe Hospital,LGG/GNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,5/31/1977,45.1,infratentorial pilocytic astrocytoma,0.47,LGG_PAPF,0.61,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3090,"Integrated diagnosis: Low grade glioma, suggestive of pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glial or glioneuronal tumour, CNS WHO grade 1
Methylation profile: Suggestive of low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 302\NH21-3090,0.024,-0.052,0.018,-0.088,-0.07,-0.005,0.096,0.087,0.105,0.05,0.059,0.084,0.179,0.084,-0.055,-0.138,-0.026,0.023,0.027,0.008,0.012,0.021,-0.215,-0.017,-0.045,0.016,0.067,0.059,0.095,unmethylated
NH21-3071,205852210068_R07C01,302,26/11/2021,12/22/2021,12/22/2021,26,AM,Diagnostic,302,1,NDP,Brighton and Sussex Hospital,BRAF mutant GBM ? Anapl PXA,"(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF2A,9/17/1955,67.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.7,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3071,"Glioblastoma, BRAFV600E-mutant, CNS WHO grade 4  see comment
IDH1 (R132H IHC): No mutation      
ATRX (IHC): Retained 
Further molecular tests: Pending  
","Glioblastoma, BRAF-mutant, CNS WHO grade 4
TERT promoter: Mutation
BRAF (V600E): Mutation
MGMT Promoter: Unmethylated (0%)

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 302\NH21-3071,-0.063,-0.065,0.012,0.028,-0.015,0.026,0.008,0.042,0.017,0.023,-0.002,-0.011,-0.032,0.012,-0.973,-0.017,-0.339,-0.213,-0.044,-0.034,-0.027,0.027,-0.391,0,0.033,-0.04,0.001,-0.011,0.016,methylated
NH16-456,205852210096_R01C01,303,29/11/2021,12/22/2021,12/22/2021,23,AM,Diagnostic,303,1,NDP,NHNN,Oligo 2,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2B,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-456,"Oligodendroglioma, WHO grade II, please see comment.

IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained. 
1p/19q: Test pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, CNS WHO grade 2
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 303\NH16-456,0.064,-0.121,0.017,0.033,0.004,0.02,-0.042,-0.005,0.017,0.017,0.005,-0.028,-0.039,0.02,-0.01,-0.035,-0.038,-0.028,-0.031,-0.006,0.078,0.063,-0.108,0.065,-0.032,-0.027,-0.449,-0.056,0.02,methylated
NH21-3073,205852210096_R02C01,303,29/11/2021,12/22/2021,12/22/2021,23,AM,Diagnostic,303,1,NDP,NHNN,Oligo 2 (recurrence),"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,2/18/1978,44.4,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3073,"Oligodendroglioma, IDH-mutant, 1p/19q co-deleted  see comment
Molecular test results for NH16-456:
IDH1 (R132H IHC); IDH1/2Seq: Mutation (G395A)
ATRX (IHC): Retained     
1p/19q: Co-deleted
EGFR: No amplification 
TERT promoter: Mutation (C228T mutation)
MGMT Promoter: In progress (NH21-3073)
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: In keeping with recurrent /residual Oligodendroglioma, CNS WHO grade 2
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 303\NH21-3073,-0.022,-0.019,0.046,-0.02,0.004,0.024,0.023,-0.018,-0.018,-0.005,-0.008,-0.011,-0.051,0.005,0.047,0.003,-0.014,0.004,-0.058,0.009,-0.005,-0.028,-0.045,0.016,-0.006,-0.004,-0.494,-0.001,-0.015,methylated
NH21-3081,205852210096_R03C01,303,30/11/2021,12/22/2021,12/22/2021,22,AM,Diagnostic,303,1,NDP,Royal London Hospital,Oligo 2,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2B,11/7/1977,44.7,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3081,"Oligodendroglioma, IDH-mutant, CNS WHO grade 2  see comment 
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, CNS WHO grade 2
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated   
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 303\NH21-3081,-0.032,-0.043,0.08,-0.011,-0.01,0.059,0.059,0.005,0.002,-0.017,-0.014,-0.023,0.02,-0.009,0.089,-0.011,-0.02,0.07,0.019,0.054,0.001,-0.033,-0.203,0,-0.002,-0.062,-0.435,0.04,0.027,methylated
NH21-2920,205852210096_R04C01,303,30/11/2021,12/22/2021,12/22/2021,22,AM,Diagnostic,303,1,NDP,Glasgow,? Glioma ? reactive brain,(1) small biopsy or nonrepresentative sample;,B1,4/16/1965,57.4,"control tissue, white matter (corpus callosum)",0.51,CONTR_HEMI,0.16,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2920,"Histology: Brain tissue with patchy mild increased cellularity and reactive changes  see comment
Methylation profile: Low calibrated score  see comment
MGMT promoter (Illumina array): Unmethylated  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 303\NH21-2920,-0.074,-0.121,0.061,0.033,-0.051,0.076,-0.081,0.069,-0.023,0.058,0.033,-0.024,0.074,-0.132,-0.089,-0.018,-0.051,-0.05,-0.067,-0.09,-0.018,0.048,-0.104,-0.023,-0.18,0.017,0.037,-0.089,0.013,unmethylated
NH21-3086,205852210096_R05C01,303,30/11/2021,12/22/2021,12/22/2021,22,AM,Diagnostic,303,1,NDP,Royal London Hospital,IDH mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,3/15/1991,31.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.96,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3086,"Astrocytoma, IDH-mutant  see comment
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending 
","Integrated diagnosis: Astrocytoma, IDH-mutant, likely CNS WHO grade 2 (see comment)
Histology: Astrocytoma, IDH-mutant
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 303\NH21-3086,0.023,-0.035,0.016,-0.023,-0.034,-0.022,-0.06,0.051,-0.025,-0.098,0.007,0.015,-0.05,0.145,-0.095,-0.006,-0.036,-0.012,0.009,-0.024,-0.061,-0.005,-0.081,0.051,-0.05,0.003,-0.01,-0.026,0.039,methylated
NH21-3051,205852210096_R06C01,303,1/12/2021,12/22/2021,12/22/2021,21,AM,Diagnostic,303,1,NDP,NHNN,? Ganglioglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF4A,4/22/1986,36.1,ganglioglioma,0.76,LGG_GG,0.56,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3051,"Ganglioglioma, CNS WHO grade 1

Hippocampal sclerosis (ILAE, Type 1)
","Integrated Diagnosis: Ganglioglioma, CNS WHO grade 1
Methylation Class: Low grade glioma, ganglioglioma (low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated 
BRAF V600E (seq.): No mutation  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 303\NH21-3051,-0.064,-0.027,0.034,0.047,-0.052,-0.002,-0.007,-0.011,0.018,0.032,-0.016,-0.031,-0.017,0.018,0.02,0.013,-0.024,0.028,-0.03,-0.017,-0.026,-0.032,-0.016,-0.028,-0.02,-0.008,-0.095,-0.01,-0.012,unmethylated
NH21-3124,205852210096_R07C01,303,2/12/2021,12/22/2021,12/22/2021,20,AM,Diagnostic,303,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG ?GBM ?APXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,4/23/1969,53.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.77,GBM_RTKII,0.48,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3124,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma
Methylation profile: Glioblastoma, IDH wildtype, subclass RTKII
MGMT promoter (Illumina array): Unmethylated   
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 303\NH21-3124,0.195,0.138,0.144,0.067,0.031,-0.013,-0.031,0.485,0.449,0.47,0.373,-0.02,0.046,0.022,-0.142,0.026,0.015,0,0.008,0.018,0.021,0.019,0.091,0.003,0.011,-0.008,-0.093,-0.216,-0.223,unmethylated
NH21-3128,205852210096_R08C01,303,2/12/2021,12/22/2021,12/22/2021,20,AM,Diagnostic,303,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGNET (paed type),"(2) unusual histology, location, demographics",A3,10/23/2004,17.4,"supratentorial ependymoma, ZFTA:RELA fusion-positive",0.55,EPN_RELA,0.37,0.95,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3128,"Integrated diagnosis: Suggestive of Supratentorial ependymoma, ZFTA fusion-positive (see comment)
Histology: High-grade neuroepithelial tumour with focal ependymal differentiation
CNS WHO grade: 3 (at least)
Methylation profile: Ependymoma, RELA fusion (low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated 

NGS data: Pending
","Supratentorial ependymoma, ZFTA fusion-positive, CNS WHO grade 3

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 303\NH21-3128,-0.021,-0.065,0.085,0.042,-0.002,-0.009,0.022,-0.028,-0.057,-0.005,-0.035,0.015,0.079,0.06,0.051,0.001,-0.004,0.055,-0.006,0.007,0.012,-0.021,-0.029,0.083,0.006,-0.063,-0.093,-0.05,0.034,unmethylated
NH21-3234,205852210008_R02C01,304,15/12/2021,1/7/2021,1/7/2022,23,AM,Diagnostic,304,1,NDP,NHNN,Malignant tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,4/4/1953,69.7,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.37,MB_SHHCHLAD,0.06,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3234,"Poorly differentiated neuroendocrine tumour - see comment  
","Integrated diagnosis: Metastatic small cell carcinoma, possibly lung origin
Histology: Poorly differentiated neuroendocrine carcinoma
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 304\NH21-3234,0.064,-0.097,0.046,-0.012,-0.058,-0.043,0.052,0.029,-0.588,-0.045,0.001,-0.054,-0.018,-0.016,0.029,-0.454,-0.392,0.023,-0.061,-0.018,0.046,0.061,-0.511,-0.036,0.047,-0.015,-0.167,-0.381,-0.46,unmethylated
NH21-2882,205852210008_R04C01,304,2/12/2021,1/7/2021,1/7/2022,36,AM,Diagnostic,304,1,NDP,"Birmingham, Queen Elizabeth Hospital",GBM,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,4/1/1976,46.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.55,GBM_MES,0.71,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2882,"High-grade glioma suggestive of a Glioblastoma, IDH-wildtype (CNS WHO grade 4)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Not Co-deleted
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4,
Histology: High grade glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 304\NH21-2882,-0.008,0.061,0.011,0.257,-0.014,-0.052,0.022,0.088,0.068,0.007,0.052,-0.017,0.013,-0.016,-0.231,0.027,-0.118,-0.121,-0.024,-0.017,0.011,0.025,-0.048,-0.043,0.004,-0.035,0.088,0.003,0.044,unmethylated
NH21-3118,205852210008_R06C01,304,2/12/2021,1/7/2021,1/7/2022,36,AM,Diagnostic,304,1,NDP,Romford,IDH-mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,9/15/1994,27.6,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.29,AIDH,0.79,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3118,"Astrocytoma, IDH-mutant, CNS WHO grade 4  see comment
Immunohistochemistry results for NH21-2400:
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC):     Loss of expression (indicates mutation)     
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Glioma, IDH mutant, subclass astrocytoma (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 304\NH21-3118,-0.103,-0.078,0.02,-0.046,0.152,-0.042,-0.345,0.015,-0.014,0.033,-0.093,0.014,-0.105,0.107,-0.257,0.004,-0.063,-0.092,-0.043,0.055,0.001,0.006,-0.017,-0.02,0.023,-0.057,-0.147,-0.005,-0.007,unmethylated
NH21-2952,205852210008_R07C01,304,3/12/2021,1/7/2021,1/7/2022,35,AM,Diagnostic,304,1,NDP,"Middlesbrough, James Cook Hospital",IDH-mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B6,11/14/1967,54.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.83,AIDH,0.84,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2952,"Astrocytoma, IDH-mutant, CNS WHO grade 4
IDH1/2Seq: Mutation
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Not Codeleted
CDKN2A/B: No deletion          
TERT promoter: Mutation (see comment)
MGMT Promoter: Methylated (>5-10%)
","Astrocytoma, IDH-mutant, CNS WHO grade 4  see comment 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 304\NH21-2952,0.091,0.12,0.019,-0.137,-0.063,0.032,-0.272,0.001,0.013,0.002,0.096,-0.002,-0.017,0.026,-0.017,-0.001,0.031,0.046,-0.002,0.017,-0.031,0.004,-0.079,-0.002,0.034,0.104,-0.326,-0.019,0.01,methylated
NH21-2954,205852210008_R08C01,304,3/12/2021,1/7/2021,1/7/2022,35,AM,Diagnostic,304,1,NDP,Southampton General Hospital,Glioma,(1) small biopsy or nonrepresentative sample;,1A,4/20/1960,62.5,ganglioglioma,0.46,GBM_MES,0.7,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2954,"Glioma, see comment 
IDH1 (R132H IHC); IDH1/2Seq: No mutation (see comment)
ATRX (IHC): Retained     
TERT promoter: Mutation (see comment) 
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Diffuse glioma
Methylation profile: Glioblastoma, IDH-wildtype
Molecular genetic profile: IDH-wildtype; mutations in TERT promoter, NF1, PTEN.
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 304\NH21-2954,0.11,0.05,0.025,0.009,-0.026,-0.02,-0.198,0.278,0.163,0.158,0.138,-0.028,0.021,0.054,-0.007,-0.036,-0.211,-0.189,-0.034,0.023,0.003,-0.091,-0.077,-0.003,-0.014,-0.009,-0.027,-0.227,-0.197,unmethylated
NH21-3142,205852210117_R01C01,305,3/12/2021,12/22/2021,12/22/2021,19,AM,Diagnostic,305,1,NDP,"Birmingham, Queen Elizabeth Hospital",LGG,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,10/4/1993,28.6,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.97,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-3142,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 305\NH21-3142,0.043,-0.097,0.018,0.003,-0.026,0.042,0.142,0.051,-0.054,0.011,0.19,-0.063,0.046,0.018,0.01,-0.046,-0.055,0.02,0.01,-0.053,-0.075,0.089,-0.026,0.008,-0.03,-0.085,-0.021,-0.031,0.066,unmethylated
NH21-3114,205852210117_R02C01,305,3/12/2021,12/22/2021,12/22/2021,19,AM,Diagnostic,305,1,NDP,Royal London Hospital,Myxopapillary Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,9/4/1966,56,myxopapillary ependymoma,1,EPN_MPE,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3114,"Myxopapillary ependymoma, CNS WHO grade 2  see comment
","Integrated diagnosis:  Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 305\NH21-3114,-0.056,-0.04,0.084,0.052,-0.015,0.003,0.07,0.232,0.183,0.246,0.198,-0.056,0.109,0,0.2,0.223,0.006,0.069,-0.008,-0.054,-0.069,-0.024,-0.021,-0.089,-0.084,-0.008,-0.052,-0.033,0.057,methylated
NH21-3144,205852210117_R04C01,305,3/12/2021,12/22/2021,12/22/2021,19,SB,Diagnostic,305,1,NDP,Romford,"Ependymoma, spinal","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,5/9/1981,41.2,spinal ependymoma,1,EPN_SPINE,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3144,"Spinal ependymoma, CNS WHO grade 2
","Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Spinal ependymoma, CNS WHO grade 2
Methylation profile: Spinal ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 305\NH21-3144,-0.018,-0.042,0.095,0.17,0.131,0.176,0.034,0.282,0.249,0.194,0.216,0.245,0.295,0.204,0.049,-0.02,0.048,0.056,0.028,0.228,0.234,0.273,-0.015,0.059,-0.121,0.046,-0.03,-0.415,-0.358,unmethylated
NH21-3027,205852210117_R06C01,305,3/12/2021,12/22/2021,12/22/2021,19,AM,Diagnostic,305,2,NDP,"Belfast, Royal Victoria Hospital",? IDH mutant astro,"(4) IHC, sequencing, or copy number assay ambiguous",A1,10/7/1988,33.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.63,AIDH,0.79,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3027,"Suggestive of Astrocytoma, IDH-mutant, CNS WHO grade 2 (see comment)
IDH1/2Seq: Mutation     
ATRX (IHC): Technically unsatisfactory
MGMT Promoter: Methylated (>0-5%)
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 305\NH21-3027,-0.017,-0.312,0.037,-0.054,0.026,-0.051,-0.026,0.093,-0.052,0.048,0.006,-0.01,-0.008,0.355,-0.013,-0.014,0.091,-0.008,0.19,-0.04,-0.099,-0.078,-0.012,-0.008,-0.059,0.052,0.037,-0.061,0.05,methylated
NH21-3153,205852210117_R08C01,305,8/12/2021,12/22/2021,12/22/2021,14,SB,Diagnostic,305,1,NDP,"Cardiff, University Hospital",Pineal tumour; RGNT,"(5) Confirmation of rare, unusual or interesting histo-molecular results",A1,3/6/1993,29.1,rosette-forming glioneuronal tumour,1,LGG_RGNT,0.96,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3153,"Integrated diagnosis: Rosette forming glioneuronal tumour, CNS WHO grade 1
Histology: Rosette forming glioneuronal tumour, CNS WHO grade 1
Methylation profile: Low grade glioma, rosette forming glioneuronal tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 305\NH21-3153,0.161,-0.022,-0.027,-0.057,0.074,-0.161,-0.095,0.138,0.032,-0.05,0.021,0.002,0.044,-0.107,0.09,0.015,-0.029,-0.006,0.188,0.127,0.084,0.094,-0.025,0.14,0.004,0.062,-0.036,0.012,0.122,unmethylated
NH21-3152,205852210039_R01C01,306,8/12/2021,1/7/2021,1/7/2022,30,SB,Diagnostic,306,1,NDP,"Cardiff, University Hospital",Spinal intramedullary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,8/14/1955,67.3,spinal ependymoma,1,EPN_SPINE,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3152,"Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 306\NH21-3152,-0.053,-0.089,0.053,0.004,-0.018,-0.04,0.036,0.003,0.021,-0.029,-0.014,-0.002,-0.056,-0.023,0.044,0.007,-0.017,0.002,-0.023,0.023,0.074,0.075,-0.477,-0.024,0.033,-0.073,0.015,-0.296,-0.397,unmethylated
NH21-3167,205852210039_R04C01,306,8/12/2021,1/7/2021,1/7/2022,30,SB,Diagnostic,306,1,NDP,Royal London Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2E,3/21/1988,34.2,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.98,OIDH,0.98,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3167,"Oligodendroglioma, IDH-mutant, CNS WHO grade 2  see comment
IDH1 (R132H IHC): Mutation      
ATRX (IHC): Retained      
Further molecular tests: Pending 
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, CNS WHO grade 2
Methylation profile: IDH Glioma, Subclass 1p/19q-codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 306\NH21-3167,-0.08,-0.03,0.044,0.01,-0.004,0.028,0.041,-0.008,-0.033,0.197,0.17,0.003,0.022,-0.006,0.095,0.022,0.007,0.017,-0.011,0.045,-0.008,0.042,-0.044,-0.016,-0.029,-0.007,-0.453,0,0.024,methylated
NH21-3199,205852210039_R07C01,306,8/12/2021,1/7/2021,1/7/2022,30,SB,Diagnostic,306,1,NDP,Oxford John Radcliffe Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3C,8/9/1951,71.3,"glioblastoma, IDH-wildtype, RTK1 type",0.56,GBM_RTKII,0.5,0.59,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3199,"Glioblastoma, CNS WHO grade 4 
MGMT Promoter: Unmethylated (0%)
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma
Methylation profile: Glioblastoma, Subclass RTK1
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 306\NH21-3199,1.064,-0.089,0.027,-0.044,0.43,-0.015,-0.021,0.277,0.285,0.441,0.23,0.002,0.072,0.039,0.041,0.028,-0.227,-0.198,-0.011,-0.015,0.738,0.018,-0.012,-0.118,0.023,0.004,-0.083,0.052,0.021,unmethylated
NH21-3189,205852210041_R02C01,307,9/12/2021,1/7/2021,1/7/2022,29,SB,Diagnostic,307,1,NDP,Newcastle,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,10/28/1967,54.8,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,0.96,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3189,"Integrated diagnosis: Supratentorial ependymoma, ZFTA fusion positive, CNS WHO grade 2
Histology: Ependymal tumour
Methylation profile: Ependymoma, RELA fusion
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 307\NH21-3189,0.05,-0.084,-0.006,0.051,0.055,-0.003,-0.09,0.052,0.022,0.043,0.035,0.036,0.035,0.065,-0.093,-0.116,-0.097,-0.08,0.019,-0.095,-0.033,0.011,-0.126,0.034,0.011,0.006,0.03,-0.048,-0.049,unmethylated
NH21-3188,205852210041_R03C01,307,9/12/2021,1/7/2021,1/7/2022,29,SB,Diagnostic,307,2,NDP,"Leeds, St James's University Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",D1,3/11/1967,55.4,high-grade astrocytoma with piloid features,0.59,ANAPA,0.83,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3188,"Integrated diagnosis: High grade astrocytoma with piloid features
Histology: Diffuse glioma, NOS
Methylation profile: Anaplastic Astrocytoma with piloid features)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 307\NH21-3188,-0.016,-0.104,-0.019,0.068,0.047,0.09,-0.15,-0.018,-0.018,-0.05,-0.043,-0.139,-0.004,-0.044,-0.383,0.022,-0.047,0.006,-0.138,0.025,0.022,0.101,-0.202,-0.296,-0.417,0.005,-0.368,-0.052,-0.008,methylated
NH21-3187,205852210041_R04C01,307,9/12/2021,1/7/2021,1/7/2022,29,SB,Diagnostic,307,1,NDP,"Leeds, St James's University Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A3,4/13/1976,46.3,myxopapillary ependymoma,1,EPN_MPE,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3187,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Ependymal tumour
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 307\NH21-3187,-0.099,-0.006,0.047,-0.013,-0.018,0.002,0.034,0.014,-0.014,-0.004,-0.004,0.012,0.084,0.013,0.078,0.02,0.017,0.027,-0.018,-0.031,-0.01,0.004,-0.053,-0.073,-0.049,-0.003,-0.026,-0.013,-0.014,methylated
NH21-3210,205852210041_R05C01,307,9/12/2021,1/7/2021,1/7/2022,29,SB,Diagnostic,307,1,NDP,St George's Hospital London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/27/1985,37,high-grade astrocytoma with piloid features,1,ANAPA,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3210,"Integrated diagnosis: High grade Astrocytoma with piloid features, CNS WHO grade 3
Histology: Diffuse glioma
Methylation profile: Anaplastic astrocytoma with piloid features
MGMT promoter (Illumina array): Methylated 
  
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 307\NH21-3210,0.018,-0.102,0.047,0.062,0.028,0.059,-0.023,-0.208,0.49,0.511,0.041,0.017,0.154,0.009,-0.941,0.209,0,-0.007,0.117,0.175,0.2,0.319,-0.107,0.059,-0.008,0.086,-0.129,0.144,0.206,methylated
NH21-3175,205852210041_R07C01,307,9/12/2021,1/7/2021,1/7/2022,29,SB,Diagnostic,307,1,NDP,Brighton and Sussex Hospital,Oligodendroglioma?,"(4) IHC, sequencing, or copy number assay ambiguous",DEF2B,6/6/1968,54.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3175,"Glioma, IDH-mutant, CNS WHO grade 2 - see comment
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Glioma, IDH-mutant, CNS WHO grade 2 
IDH1 (R132H IHC); IDH1/2 (seq): Mutation     
ATRX (IHC): Retained     
TERT promoter: Mutation
MGMT Promoter: Methylated (>0-5%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 307\NH21-3175,-0.018,-0.063,0.016,-0.019,-0.091,0.027,0.023,-0.001,-0.058,-0.066,-0.008,-0.001,0.069,0.01,0.008,-0.025,0.051,0.035,-0.021,-0.048,-0.038,0.014,-0.429,-0.003,-0.001,0.02,-0.479,0.132,0.14,methylated
NH21-3213,205852210041_R08C01,307,11/12/2021,1/7/2021,1/7/2022,27,SB,Diagnostic,307,1,NDP,St George's Hospital London,LGG/HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/5/1965,56.7,ganglioglioma,0.49,GBM_MES,0.39,0.63,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3213,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Diffuse glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 

",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 307\NH21-3213,-0.002,-0.037,0.041,-0.009,-0.061,-0.005,-0.152,0.12,0.12,0.095,0.109,-0.026,0.067,0.008,-0.008,-0.013,-0.173,-0.135,-0.028,-0.005,-0.035,0.038,-0.046,0.019,0.04,-0.145,0.084,-0.11,-0.103,unmethylated
NH21-3227,205852210065_R01C01,308,11/12/2021,1/7/2021,1/7/2022,27,SB,Diagnostic,308,1,NDP,Nottingham University Hospital,Pilocytic?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/22/1999,22.7,"diffuse glioneuronal tumour, non defined type",0.79,DLGNT,0.93,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3227,"Integrated diagnosis: Diffuse leptomeningeal glioneuronal tumor, CNS WHO grade 2
Histology: Low grade neuroepithelial tumour
Methylation profile: Diffuse leptomeningeal glioneuronal tumour
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 308\NH21-3227,-0.162,-0.044,0.039,-0.113,0.015,0.046,-0.013,0.08,0.117,0.043,0.136,0.001,0.087,0.033,-0.179,-0.101,0.01,0.033,0.026,0.018,-0.005,0.024,0.041,-0.106,-0.193,-0.16,-0.242,-0.148,-0.057,methylated
NH21-3231,205852210065_R02C01,308,11/12/2021,1/7/2021,1/7/2022,27,SB,Diagnostic,308,1,NDP,Nottingham University Hospital,Pilocytic,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B2,10/5/2016,5.3,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-3231,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  


",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 308\NH21-3231,0.005,-0.066,0.009,0.036,-0.031,-0.028,0.016,0.002,0.004,-0.064,0.165,-0.022,0.031,0.014,0.064,0.007,-0.025,-0.014,0.015,-0.001,-0.046,0.01,-0.051,0.015,0.046,-0.002,-0.015,-0.003,-0.003,unmethylated
NH21-3251,205852210065_R05C01,308,15/12/2021,1/7/2021,1/7/2022,23,ZJ,Diagnostic,308,1,NDP,St George's Hospital London,Glioneruonal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/25/1954,68.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.77,GBM_MES,0.85,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3251,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 308\NH21-3251,0.199,-0.032,0.026,0.029,0.011,0.099,-0.048,0.202,0.165,0.175,0.18,0.009,0.015,0.017,-0.005,0.02,-0.087,-0.044,-0.032,-0.002,0.023,0.001,-0.063,0.002,-0.041,-0.011,-0.092,-0.229,-0.21,methylated
NH21-3238,205852210065_R07C01,308,15/12/2021,1/7/2021,1/7/2022,23,ZJ,Diagnostic,308,1,NDP,"Charing Cross Hospital, London",Astocytoma vs PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C1,2/2/1977,45.5,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.67,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3238,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioma, see comment
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 308\NH21-3238,0.075,-0.011,-0.038,0.017,-0.055,0.053,-0.112,0.201,0.317,0.258,0.201,-0.01,0.054,0.049,-0.11,-0.166,-0.106,-0.136,-0.139,0.106,0.06,0.039,-0.14,-0.14,-0.122,-0.157,0.007,-0.12,-0.1,unmethylated
NH21-3243,205852210065_R08C01,308,18/12/2021,1/7/2021,1/7/2022,20,ZJ,Diagnostic,308,1,NDP,London Independent,"Glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,1/27/1976,46.5,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.3,GBM_RTKII,0.53,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3243,"Glioma, CNS WHO grade 2 at least  see comment 
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 308\NH21-3243,0.036,0.014,0.033,-0.015,-0.073,-0.076,-0.344,0.297,-0.008,-0.044,0.129,-0.03,0.05,-0.036,0.001,0.017,-0.78,-0.283,-0.036,0.008,0.007,0.03,-0.036,0.059,0.071,0.054,-0.049,-0.287,-0.241,unmethylated
NH21-3255,205852210023_R02C01,309,18/12/2021,1/13/2021,1/12/2022,25,ZJ,Diagnostic,309,1,NDP,NHNN,"Astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,2/14/1991,31.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3255,"Astrocytoma, IDH-mutant, CNS WHO grade 2  see comment
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending 
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 309\NH21-3255,-0.042,-0.044,0.029,-0.009,0.007,-0.003,-0.365,-0.029,-0.038,-0.035,-0.028,-0.007,0.002,0.018,0.028,-0.007,0.016,-0.02,-0.016,0.029,0.021,-0.007,-0.01,0.034,-0.014,-0.007,-0.016,0.018,0.027,methylated
NH21-3233,205852210023_R03C01,309,18/12/2021,1/13/2021,1/12/2022,25,ZJ,Diagnostic,309,1,NDP,NHNN,Spinal ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,11/9/1955,67,spinal ependymoma,0.99,EPN_SPINE,0.95,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3233,"Spinal ependymoma, CNS WHO grade 2  see comment
","Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Spinal ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 309\NH21-3233,0.064,0.007,0.047,0.067,0.032,-0.014,0.019,0.251,0.228,0.233,0.223,-0.003,-0.08,0.001,0.422,0.373,0.004,-0.003,0.011,-0.001,0.028,0.014,-0.049,0.054,0.018,-0.012,-0.006,0.029,0.046,unmethylated
NH21-3298,205852210023_R04C01,309,18/12/2021,1/13/2021,1/12/2022,25,ZJ,Diagnostic,309,2,NDP,Newcastle,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,4/28/1949,73.7,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.92,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3298,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 309\NH21-3298,0.042,-0.034,-0.006,0.018,-0.048,0.014,-0.262,0.1,0.148,0.156,0.109,-0.037,0.012,0.018,-0.787,-0.036,-0.218,-0.257,0.018,-0.042,0.022,0.011,-0.245,-0.034,0.022,0.015,-0.004,0.025,0.02,unmethylated
NH21-3284,205852210023_R06C01,309,18/12/2021,1/13/2021,1/12/2022,25,ZJ,Diagnostic,309,1,NDP,Nottingham University Hospital,Rec GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/8/1974,48,"glioblastoma, IDH-wildtype, RTK1 type",0.99,GBM_RTKI,0.58,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3284,"Integrated diagnosis: Glioblastoma, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH wildtype, subclass RTKI
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 309\NH21-3284,0.095,0.053,-0.016,-0.005,0.079,-0.011,-0.002,1.353,0.316,0.283,0.219,0.001,-0.049,0.277,-1.036,0.08,-0.246,-0.366,0.075,0.137,0.077,0.187,-0.037,0.117,-0.012,-0.039,0.066,-0.026,0.006,methylated
NH21-3276,205852210023_R07C01,309,18/12/2021,1/13/2021,1/12/2022,25,ZJ,Diagnostic,309,1,NDP,Sheffield,Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/12/1995,27.1,ganglioglioma,0.96,LGG_GG,0.99,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3276,"Integrated diagnosis: Ganglioglioma, CNS WHO grade 1
Histology: Low grade glioma with extensive calcification
Methylation profile: Ganglioglioma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 309\NH21-3276,-0.066,-0.072,-0.04,0.04,-0.029,0.107,-0.004,0.098,0.131,0.088,0.108,0.115,0.132,0.147,0.076,0.037,-0.092,0.17,0.039,0.064,0.107,0.106,0.042,0.049,-0.018,0.021,0.04,0.014,-0.024,unmethylated
NH21-3262,205852210023_R08C01,309,18/12/2021,1/13/2021,1/12/2022,25,ZJ,Diagnostic,309,1,NDP,"Middlesbrough, James Cook Hospital",Gliosis vs glioma in cerebellum,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/21/2001,21.1,infratentorial pilocytic astrocytoma,0.99,LGG_PAPF,0.98,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3262,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glioma, NOS
Methylation profile: Low grade glioma, pilocytic astrocytoma, subtype infratentorial
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 309\NH21-3262,0.039,-0.006,0,0.037,-0.006,0.027,-0.004,-0.025,-0.025,-0.073,-0.007,-0.009,-0.005,0.052,0.008,-0.017,0.025,-0.007,-0.013,-0.021,-0.072,0.1,-0.016,-0.01,0.037,-0.038,-0.005,0.018,0.018,methylated
NH21-3104,205852220013_R02C01,310,20/12/2021,1/19/2022,1/19/2022,30,ZJ,Diagnostic,310,1,NDP,"Cardiff, University Hospital","Glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/23/1966,56.7,ganglioglioma,0.45,GBM_MES,0.33,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3104,"Glioma  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: No amplification          
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
","Integrated diagnosis: Glioma, NOS
Histology: Glioma, NOS
Methylation profile: Control tissue, hemispheric cortex (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 310\NH21-3104,0.104,0.065,-0.041,0.013,-0.027,-0.081,-0.503,0.381,0.35,0.386,0.364,-0.051,0.001,0.082,0.007,0.002,-0.133,-0.121,0.046,0.14,0.088,0.057,-0.151,0.163,0.101,0.051,-0.014,-0.048,0.086,unmethylated
NH21-3265,205852220013_R03C01,310,20/12/2021,1/19/2022,1/19/2022,30,AM,Diagnostic,310,1,NDP,Romford,"Glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/21/1978,43.8,ganglioglioma,0.39,GBM_MES,0.48,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3265,"Diffuse glioma, provisionally, CNS WHO grade 2  see comment on grading
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Molecular profile raising the possibility of infiltration zone of glioblastoma, IDH-wildtype, CNS WHO grade 4  see comment
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 310\NH21-3265,0.156,0.143,0.025,0.057,0.03,0.282,0.02,0.343,0.316,0.37,0.29,-0.016,-0.11,0.01,-0.065,-0.039,-0.023,0.005,0.002,0.223,0.132,0.12,-0.145,0.045,0.044,-0.091,0.243,-0.039,0.025,unmethylated
NH21-3257,205852220013_R04C01,310,20/12/2021,1/19/2022,1/19/2022,30,AM,Diagnostic,310,1,NDP,Brighton and Sussex Hospital,Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2B,5/15/1987,35.1,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-3257,"Recurrent Pilocytic astrocytoma, CNS WHO grade 1  see comment
","Recurrent pilocytic astrocytoma
BRAF: KIAA1549::BRAF fusion 


  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 310\NH21-3257,0.027,0.012,0.031,0.018,0.014,0.163,0.185,0.11,0.122,0.175,0.307,-0.027,0.001,0.044,-0.013,-0.008,0.05,0.103,0.03,0.131,0.109,0.087,-0.051,-0.015,-0.053,-0.07,0.004,-0.065,0.016,unmethylated
NH21-3267,205852220013_R05C01,310,20/12/2021,1/19/2022,1/19/2022,30,AM,Diagnostic,310,4,NDP,Romford,"Oligodendroglioma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A5,8/17/1977,45,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-3267,"Oligodendroglioma, CNS WHO grade 2  see comment
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2
Methylation profile: IDH glioma, subclass 1p/19q-codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 310\NH21-3267,0.003,0.009,0.016,-0.138,-0.088,-0.018,0.016,-0.035,-0.038,0.021,0.028,-0.02,0.015,0.044,-0.008,0.002,-0.029,0.007,0.003,-0.003,-0.051,-0.067,-0.044,0.052,0.01,0.003,-0.37,-0.054,0.042,methylated
NH21-3287,205852220013_R08C01,310,20/12/2021,1/19/2022,1/19/2022,30,AM,Diagnostic,310,1,NDP,NHNN,"Astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF3A,5/5/1954,68.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3287,"Astrocytoma, IDH-mutant, favouring CNS WHO grade 3 (see comment)
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 310\NH21-3287,-0.017,0.036,-0.009,-0.007,0.067,-0.034,0.026,0.023,0.061,0.21,0.164,-0.083,0.038,0.027,-0.044,-0.056,-0.154,-0.069,0.002,-0.034,-0.088,-0.174,-0.303,-0.006,-0.002,0.004,-0.084,-0.135,0.001,methylated
NH21-3318,205852220004_R02C01,311,22/12/2021,1/13/2021,1/12/2022,21,AM,Diagnostic,311,1,NDP,"Cambridge, Addenbrooke's Hospital","Astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,4/4/1984,35.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.96,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3318,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 311\NH21-3318,-0.02,-0.118,0.02,-0.002,-0.004,0.11,-0.059,0.04,0.001,0.023,0.032,-0.011,-0.006,0.041,-0.046,-0.022,0,-0.045,-0.046,-0.018,0.02,0.005,-0.077,0.016,-0.014,0.01,-0.216,-0.022,0.041,methylated
NH21-3328,205852220004_R04C01,311,22/12/2021,1/13/2021,1/12/2022,21,AM,Diagnostic,311,1,NDP,"Liverpool, The Walton Centre","Glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,7/27/1960,62.2,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,0.37,GBM_MID,0.95,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3328,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: CNS cortex with dense infiltration by a high-grade glioma
Methylation profile: Glioblastoma, IDH wildtype, subclass midline (see comment)

MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 311\NH21-3328,0.087,0.119,0.018,0.042,0.072,-0.038,-0.433,0.019,0.025,-0.042,-0.001,-0.02,0.028,0.056,0.003,0.025,0.03,0.016,0.044,0.045,0.051,0.053,-0.032,0.111,0.064,0.237,-0.099,-0.008,0.037,methylated
NH21-3297,205852220004_R05C01,311,22/12/2021,1/13/2021,1/12/2022,21,AM,Diagnostic,311,1,NDP,"Belfast, Royal Victoria Hospital",? Lhermitte Duclos disease,"(2) unusual histology, location, demographics",A2,10/30/1988,33.6,"control tissue, cerebellar hemisphere",1,CONTR_CEBM,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3297,"Integrated diagnosis: Cerebellar cortex and white matter, small fragments with dysplastic architecture
Histology: Cerebellar cortex with focal possible dysplasia
Methylation profile: Control tissue, cerebellar hemisphere 
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 311\NH21-3297,0.047,0.016,-0.058,-0.011,-0.027,-0.059,-0.017,-0.052,-0.025,-0.056,-0.033,-0.012,-0.021,-0.017,-0.103,0.028,0.028,-0.042,-0.056,-0.052,0.046,0.059,0.012,0.057,0.041,0.03,-0.024,0.009,0.056,unmethylated
NH21-3326,205852220004_R07C01,311,22/12/2021,1/13/2021,1/12/2022,21,AM,Diagnostic,311,1,NDP,Newcastle,? LGG ,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1B,1/20/1993,29.3,infratentorial pilocytic astrocytoma,0.47,LGG_PAPF,0.42,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-3326,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: No matching methylation class
BRAF: KIAA1549-BRAF 15_9 fusion
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 311\NH21-3326,0.06,-0.073,-0.003,0.007,-0.054,-0.043,-0.033,-0.029,-0.014,-0.049,0.154,-0.006,0.02,-0.012,-0.017,-0.037,-0.003,0.024,-0.045,-0.084,-0.025,-0.009,-0.01,-0.016,-0.016,-0.087,0.021,0.033,-0.009,unmethylated
NH21-3321,205852220004_R08C01,311,22/12/2021,1/13/2021,1/12/2022,21,AM,Diagnostic,311,1,NDP,Royal London Hospital,High-grade neuroepithelial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1C,9/21/1968,54,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.95,GBM_MYCN,0.71,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3321,"Right cerebellar tumour excision: High-grade neuroepithelial tumour - see comment
","Integrated diagnosis: High grade neuroepithelial tumour, see discussion
Histology: High grade neuroepithelial tumour
Genetic profile: BCOR mutation, MYB:QKI fusion, PIK3CA Mutation,CDKN2A/B deletion (full report see supplementary table) 
Methylation profile: Glioblastoma, paediatric type, NOS, subtype B
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 311\NH21-3321,0.258,-0.1,0.013,0.021,-0.035,-0.002,0.006,-0.004,-0.041,-0.025,-0.021,-0.016,0.051,0.003,-0.634,-0.001,-0.001,0.002,-0.016,-0.013,0.004,0.029,-0.012,0.03,0.012,-0.039,-0.052,0.002,0.043,unmethylated
NH21-3354,205852210166_R04C01,312,23/12/2021,1/21/2022,1/21/2022,29,AM,Diagnostic,312,1,NDP,"Cardiff, University Hospital",HGG,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,1/9/1970,52.6,"glioblastoma, IDH-wildtype, RTK2 type",0.89,GBM_RTKII,0.78,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3354,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma, corresponding to at least CNS WHO grade 3
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 312\NH21-3354,0.039,0.06,0.063,-0.027,-0.061,0.096,-0.122,0.332,0.324,0.232,0.284,0.019,0.079,-0.009,-1.194,0.101,-0.023,-0.068,0.011,0.206,0.166,0.241,0.012,-0.14,-0.535,0.019,-0.177,0.068,0.109,methylated
NH21-3319,205852210166_R06C01,312,28/12/2021,1/21/2022,1/21/2022,24,AM,Diagnostic,312,2,NDP,Newcastle,? IDH-mutant glioma,(1) small biopsy or nonrepresentative sample;,1A PR46245-21,7/24/1997,24.7,"control tissue, white matter (corpus callosum)",0.55,CONTR_HEMI,0.19,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3319,"Integrated diagnosis: CNS tissue with mild gliosis (see comment)
Histology: CNS tissue with mild gliosis and questionable positive labelling for mutant IDH1, of unclear significance
Methylation profile: Control tissue, hemispheric cortex
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 312\NH21-3319,0.057,-0.018,0.022,0.02,-0.021,-0.012,-0.171,-0.033,-0.009,0,0.01,-0.036,0.057,0,-0.011,0.001,-0.016,0.019,-0.034,-0.075,-0.045,0.012,-0.019,-0.034,-0.028,0.036,0.055,-0.019,0.02,unmethylated
NH21-3357,205852210166_R07C01,312,29/12/2021,1/21/2022,1/21/2022,23,ZJ,Diagnostic,312,17,NDP,Edinburgh,Glioma vs demyelination (vs lymphoma),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2,6/20/1972,50.2,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.67,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3357,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: CNS tissue fragments with a highly pathological infiltrate
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 312\NH21-3357,0.092,-0.092,0.011,-0.026,-0.095,-0.109,-0.021,0.186,0.048,-0.187,-0.045,-0.012,0.068,0.011,-0.011,0.001,-0.054,-0.083,-0.02,-0.07,0.752,1.097,0.06,0.115,0.124,0.107,-0.042,-0.002,0.026,methylated
NH21-3360,205852210166_R08C01,312,29/12/2021,1/21/2022,1/21/2022,23,ZJ,Diagnostic,312,3,NDP,Romford,"Astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A3,8/17/1995,26.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.96,AIDH,0.86,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3360,"Astrocytoma  see comment 
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 312\NH21-3360,-0.438,-0.039,0.036,0.029,0.026,0.071,-0.129,-0.047,-0.045,-0.023,-0.122,0.02,0.061,-0.008,0.031,-0.003,-0.023,-0.4,-0.048,0.103,-0.278,-0.131,-0.231,-0.066,-0.036,-0.012,0.072,-0.018,-0.046,unmethylated
NH21-3351,205852220032_R01C01,313,29/12/2021,1/21/2022,1/21/2022,23,ZJ,Diagnostic,313,6,NDP,Royal London Hospital,Glioneuronal tumour (DNET vs PLGNTY),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,1/24/2000,22.2,dysembryoplastic neuroepithelial tumour,1,LGG_DNT,1,0.99,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3351,"Neuroepithelial neoplasm, in favour of low grade glioneuronal tumour  for grading, see comment 
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 313\NH21-3351,-0.063,-0.001,-0.006,-0.014,-0.013,0.017,-0.029,-0.036,0.005,0.013,0.023,-0.02,0.013,-0.01,0.02,-0.037,-0.004,0.023,-0.025,-0.028,-0.096,-0.044,-0.034,-0.054,-0.009,0.004,0.052,0.008,0.003,unmethylated
NH21-3350,205852220032_R02C01,313,30/12/2021,1/21/2022,1/21/2022,22,ZJ,Diagnostic,313,1,NDP,"Cardiff, University Hospital",Recurrent brainstem glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/9/1981,41,high-grade astrocytoma with piloid features,0.98,ANAPA,0.58,0.94,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-3350,"Integrated diagnosis: High-grade astrocytoma with piloid features, CNS WHO grade 3
Histology: Glioma, compatible with recurrent, progressed pilocytic astrocytoma
Methylation profile: Anaplastic pilocytic astrocytoma (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 313\NH21-3350,0.002,-0.045,0.013,-0.154,-0.076,0.005,0.025,-0.026,0.001,-0.041,0.188,-0.188,-0.002,-0.006,-1.217,0.024,-0.081,-0.028,-0.018,0.013,0.008,0,0.028,-0.001,0.038,-0.018,-0.069,0.024,0.06,unmethylated
NH21-3356,205852220032_R03C01,313,30/12/2021,1/21/2022,1/21/2022,22,ZJ,Diagnostic,313,1,NDP,"Belfast, Royal Victoria Hospital",Pilocytic astrocytoma in cerebellum,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,3/9/2013,6.1,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH21-3356,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 313\NH21-3356,0.028,-0.017,0.013,0.025,0.047,-0.019,-0.095,-0.014,0.003,0.091,0.212,0.038,0.104,0.093,0.089,0.054,0.001,-0.092,0.155,0.162,0.145,0.047,-0.01,0.179,-0.121,-0.077,-0.157,-0.027,-0.037,unmethylated
NH21-3376,205852220032_R07C01,313,30/12/2021,1/21/2022,1/21/2022,22,ZJ,Diagnostic,313,1,NDP,Sweden,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",01-01.,3/1/1948,74.9,posterior fossa ependymoma group B,0.98,EPN_PFB,0.45,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3376,"Integrated diagnosis: Ependymoma, posterior fossa, subtype B, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, posterior fossa group B, subclass 4
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 313\NH21-3376,-0.289,-0.144,-0.029,-0.226,-0.111,0.278,-0.197,0.112,0.065,-0.071,0.051,0.152,0.165,0.097,0.457,0.46,-0.392,-0.306,0.125,0.05,0.146,0.08,-0.151,-0.4,-0.532,-0.44,0.253,-0.284,-0.26,unmethylated
NH21-3404,206053660108_R04C01,314,5/1/2022,1/26/2022,1/26/2022,21,SB,Diagnostic,314,1,NDP,"Liverpool, The Walton Centre",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/10/1975,47.6,ganglioglioma,0.41,LGG_GG,0.39,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3404,"Integrated diagnosis: Infiltration zone of a glioblastoma, IDH-wildtype, CNS WHO grade 4.
Histology: CNS cortex and white matter, with infiltrating tumour cells
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 314\NH21-3404,0.991,0.041,-0.024,0.061,-0.003,-0.054,-0.102,0.045,0.047,0.065,0.095,-0.018,0.035,-0.039,0.013,0.03,-0.1,-0.115,-0.02,-0.077,0.551,0.059,-0.035,-0.045,0.018,0.009,0.129,-0.032,0.109,unmethylated
NH21-3402,206053660108_R05C01,314,5/1/2022,1/26/2022,1/26/2022,21,SB,Diagnostic,314,2,NDP,"Liverpool, The Walton Centre",LGG,(1) small biopsy or nonrepresentative sample;,"3A, 6A",3/13/1953,69.8,ganglioglioma,0.09,GBM_MES,0.41,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3402,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Diffuse glioma, NOS
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 314\NH21-3402,0.126,-0.16,0.086,0.032,-0.087,-0.145,-0.527,0.221,0.252,0.091,0.23,-0.012,0.109,-0.124,-1.323,-0.046,-0.338,-0.504,-0.026,-0.089,-0.056,0.043,-0.249,-0.009,0.062,0.011,0.038,-0.003,0.064,methylated
NH22-18,206053660108_R06C01,314,6/1/2022,1/26/2022,1/26/2022,20,SB,Diagnostic,314,1,NDP,Newcastle,GBM vs ATRT,"(2) unusual histology, location, demographics",A1,1/31/1987,35.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.92,AIDH_HG,0.67,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-18,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, CNS WHO grade 4
Methylation profile: IDH glioma, subclass high-grade astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 314\NH22-18,0.042,-0.186,-0.148,0.063,0.145,-0.186,-0.18,-0.05,-0.113,-0.073,0.035,-0.002,0.037,0.035,-0.05,0.031,-0.051,-0.095,0.079,0.605,-0.327,-0.497,-0.056,0.158,-0.012,0.01,0.104,-0.025,0.017,unmethylated
NH22-17,206053660108_R07C01,314,6/1/2022,1/26/2022,1/26/2022,20,SB,Diagnostic,314,1,NDP,Brighton and Sussex Hospital,posterior fossa ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,4/23/1951,71.7,posterior fossa ependymoma group B,0.99,EPN_PFB,0.98,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-17,"Posterior fossa ependymoma, group PFB, CNS WHO grade 3
","Integrated diagnosis: Posterior fossa ependymoma, group PFB, CNS WHO grade 3
Histology: Posterior fossa ependymoma, group PFB, CNS WHO grade 3
Methylation profile: ependymoma, posterior fossa group b
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 314\NH22-17,-0.151,-0.088,-0.028,0.101,0.136,0.058,-0.187,0.032,0.098,0.092,0.111,0.282,0.267,0.29,0.124,0.151,-0.166,-0.141,0.084,0.17,0.221,0.369,0.077,-0.094,-0.25,-0.176,0.146,0.063,0.116,unmethylated
NH22-20,206053660108_R08C01,314,6/1/2022,1/26/2022,1/26/2022,20,SB,Diagnostic,314,2,NDP,"Liverpool, The Walton Centre",posterior fossa ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,12/14/1978,43.7,posterior fossa ependymoma group B,1,EPN_PFB,1,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-20,"Integrated diagnosis: Ependymoma, posterior fossa group B, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, posterior fossa group B
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 314\NH22-20,0.501,0.015,0.216,0.153,-0.15,-0.087,-0.144,0.371,0.304,0.335,0.282,0.352,0.403,0.243,0.272,0.427,-0.01,0.092,0.456,0.317,0.432,0.303,0.002,0.048,-0.156,-0.021,0.273,0.018,-0.056,unmethylated
NH22-22,205852210006_R01C01,315,6/1/2022,1/26/2022,1/26/2022,20,SB,Diagnostic,315,1,NDP,"Cardiff, University Hospital",IDH-mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,3/1/1981,41.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.99,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-22,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, CNS WHO grade 2
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 315\NH22-22,0.037,-0.029,0.024,-0.061,0.002,-0.002,-0.042,-0.01,-0.03,0.001,0.016,0.011,0.024,0.054,-0.004,-0.034,0.001,-0.03,0.01,-0.013,-0.006,-0.04,-0.025,0.031,0.021,0.082,-0.003,-0.028,0.028,methylated
NH22-45,205852210006_R07C01,315,11/1/2022,1/26/2022,1/26/2022,15,SB,Diagnostic,315,1,NDP,Oxford John Radcliffe Hospital,Pilocytic Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,12/18/2002,12.3,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.92,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-45,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Surgical aspirate of a glial tumour
Methylation profile: Low grade glioma, subclass hemispheric pilocytic astrocytoma and ganglioglioma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 315\NH22-45,-0.048,-0.003,0.015,-0.03,0.075,-0.024,-0.037,-0.02,-0.029,0.036,0.016,-0.027,-0.058,0.039,-0.026,0.016,-0.055,0.016,-0.01,-0.083,-0.027,0.022,-0.07,-0.067,-0.025,-0.037,0.046,-0.094,0.016,unmethylated
NH22-81,206053660070_R01C01,316,13/01/2022,1/28/2022,1/28/2022,15,SB,Diagnostic,316,1,NDP,"Cardiff, University Hospital",Melanoma/melanocytoma,"(2) unusual histology, location, demographics",A,3/20/1942,80.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,0.83,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-81,"Integrated diagnosis: Meningeal melanocytoma  see comment
Histology: Meningeal melanocytoma
Methylation profile: Melanocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 316\NH22-81,-0.025,-0.128,-0.08,-0.016,0.085,-0.079,-0.042,0.067,-0.039,0.036,0.046,-0.028,-0.141,0.087,-0.043,0.097,-0.05,0.018,0.119,0.535,-0.282,-0.479,-0.035,0.181,0.028,0.044,-0.055,-0.095,0.014,unmethylated
NH22-82,206053660070_R02C01,316,13/01/2022,1/28/2022,1/28/2022,15,SB,Diagnostic,316,1,NDP,"Cardiff, University Hospital",Glial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/7/1995,27,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,1,GBM_MID,0.45,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-82,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subtype posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 316\NH22-82,-0.029,-0.068,0.021,-0.053,1.502,-0.009,-0.003,0.015,-0.016,0.03,-0.016,-0.022,0.058,0.002,0.025,0.018,-0.011,-0.223,0.041,-0.068,0.024,-0.061,-0.346,-0.015,-0.044,0.046,-0.046,-0.317,-0.256,unmethylated
NH22-76,206053660070_R03C01,316,13/01/2022,1/28/2022,1/28/2022,15,SB,Diagnostic,316,1,NDP,Nottingham University Hospital,HG Neuroepithelial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/20/1979,43,"glioblastoma, IDH-wildtype, RTK1 type",0.49,GBM_RTKI,0.87,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-76,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 316\NH22-76,-0.049,0.035,0.013,-0.008,-0.014,-0.047,-0.023,1.41,0.001,-0.044,0.009,-0.058,-0.013,0.054,0.023,0.042,-0.441,-0.324,-0.253,-0.001,1.1,0.008,-0.471,0.089,0.027,0.022,-0.068,-0.051,0.049,unmethylated
NH22-90,206053660070_R04C01,316,13/01/2022,1/28/2022,1/28/2022,15,SB,Diagnostic,316,1,NDP,Nottingham University Hospital,Recurrent ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,7/28/1997,24.8,spinal subependymoma [subtype A],0.63,CN,0.14,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-90,"Integrated diagnosis: Ependymal tumour  see comment
Histology: Referred diagnosis: anaplastic ependymoma, CNS WHO grade 3
Methylation profile: See comment
MGMT promoter (Illumina array): Unmethylated 
  
","Integrated diagnosis: Ependymoma with high-grade features (corresponding to CNS WHO grade 3)
Histology: Ependymoma, CNS WHO grade 3 (incorporating results from NH21-2031 and NH22-90)
Methylation profile: Low calibrated score, inconclusive in repeat tests (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 316\NH22-90,-0.06,-0.075,0.038,0.025,0.079,-0.028,0.214,0.034,-0.017,-0.007,0.007,-0.006,0.018,0.002,0.017,-0.044,0.019,0.015,-0.052,-0.03,0.019,0.038,0.037,0.013,-0.061,0.009,-0.01,-0.03,0.01,unmethylated
NH22-73,206053660070_R05C01,316,13/01/2022,1/28/2022,1/28/2022,15,SB,Diagnostic,316,1,NDP,Nottingham University Hospital,HG Neuroepithelial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,12/3/1964,57.9,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.99,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-73,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK1
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 316\NH22-73,-0.057,0.018,0.028,-0.253,1.284,-0.012,-0.063,0.814,0.246,0.206,0.253,-0.004,0.015,0.126,-0.343,0.021,-0.363,-0.265,0.095,0.046,0.984,0.055,-0.015,0.112,0.073,0.031,0.04,-0.029,0.077,unmethylated
NH22-79,206053660070_R06C01,316,13/01/2022,1/28/2022,1/28/2022,15,SB,Diagnostic,316,4,NDP,Nottingham University Hospital,Post Foss GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/12/1963,59.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.97,GBM_MES,0.7,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-79,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 316\NH22-79,-0.032,-0.032,0.025,-0.117,-0.044,0.08,0.002,1.128,0.334,0.355,0.245,-0.015,0.08,0.06,-0.035,-0.005,-0.289,-0.227,-0.042,0.023,0.045,-0.099,-0.032,-0.005,-0.117,-0.04,0.142,-0.01,0.038,unmethylated
NH22-55,206053660070_R07C01,316,14/01/2022,1/28/2022,1/28/2022,14,SB,Diagnostic,316,5,NDP,NHNN,"astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1D,6/27/1993,29,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.35,AIDH,0.63,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-55,"Astrocytoma, IDH mutant, WHO grade 2 - See comment.
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 316\NH22-55,-0.042,-0.061,0.017,-0.002,-0.025,0.031,0.033,-0.029,-0.054,-0.065,-0.014,-0.012,0.004,0.006,-0.133,-0.01,0.041,0.021,-0.003,-0.055,-0.025,-0.014,0.011,-0.032,-0.038,-0.01,-0.229,-0.016,0.001,methylated
NH21-3253,206053660070_R08C01,316,15/01/2022,1/28/2022,1/28/2022,13,MD,Diagnostic,316,1,NDP,"Birmingham, Queen Elizabeth Hospital",Oligodendroglioma,"(4) IHC, sequencing, or copy number assay ambiguous",A1,9/27/1963,59.1,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.97,OIDH,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3253,"Suggestive of oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3  see comment
IDH1/2Seq: IDH2 mutation     
ATRX (IHC): Retained     
1p/19q: Possible codeletion
TERT promoter: Mutation
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
Histology: Suggestive of oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted 
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 316\NH21-3253,-0.007,0.391,0.001,-0.249,-0.094,0,-0.044,-0.004,0.012,0.032,0.028,-0.03,-0.028,0.023,-0.456,0.04,-0.056,-0.142,-0.019,-0.077,-0.014,-0.032,-0.262,0.042,0.026,0.048,-0.491,-0.018,0.033,methylated
NH22-91,206053660072_R03C01,317,17/01/2022,1/28/2022,1/28/2022,11,SB,Diagnostic,317,1,NDP,NHNN,LGG. GNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,4/7/1980,42.4,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.6,LGG_DNT,0.99,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-91,"Low grade glioneuronal tumour, corresponding to CNS WHO grade 1, see comment. 
","Integrated diagnosis: Dysembryoplastic neuroepithelial tumour, CNS WHO grade 1
Histology: Low grade glioma
Methylation profile: Dysembryoplastic neuroepithelial tumour
Next generation sequencing: FGFR1 mutation


",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 317\NH22-91,0.006,-0.036,-0.007,-0.011,-0.056,0.006,0.009,0.037,0.031,0.019,0,0.016,0.004,0.021,0.002,0.012,-0.018,-0.003,-0.004,0.044,-0.021,0.032,-0.059,-0.007,-0.003,0.009,-0.029,-0.05,0.016,unmethylated
NH22-116,206053660072_R06C01,317,19/01/2022,1/28/2022,1/28/2022,9,SB,Diagnostic,317,7,NDP,Brighton and Sussex Hospital,midline pilocytic astrocytoma?,"(2) unusual histology, location, demographics",DEF1A,8/14/1969,53.2,high-grade astrocytoma with piloid features,0.95,ANAPA,0.86,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-116,"Glioma - See comment.
","Integrated diagnosis: Glioma, compatible with high grade astrocytoma with piloid features  see comment
Histology: Glioma
Methylation profile: High grade astrocytoma with piloid features 
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 317\NH22-116,-0.08,-0.006,0.019,-0.022,0.033,0.029,0.05,0.004,-0.007,0.15,-0.002,0.003,-0.003,0.055,-0.026,0.021,-0.039,0.042,0.019,-0.054,-0.091,-0.057,-0.052,-0.091,-0.123,-0.045,0.007,0.099,-0.006,methylated
NH22-106,206053660072_R08C01,317,19/01/2022,1/28/2022,1/28/2022,9,SB,Diagnostic,317,9,NDP,NHNN,"astrocytoma, IDH-mutant, CNS WHO grade 4","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,11/13/1996,25.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-106,"Astrocytoma, IDH-mutant, CNS WHO Grade 4
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, high grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 317\NH22-106,0.194,-0.004,0.029,-0.027,0.117,0.065,0.055,0.016,-0.004,0.1,-0.008,-0.034,-0.007,0.075,-0.032,0.033,-0.075,-0.362,0.013,0.021,-0.001,-0.009,-0.486,0,0.047,-0.058,-0.056,-0.416,-0.412,methylated
NH22-114,206053660071_R01C01,318,19/01/2022,2/3/2022,2/2/2022,14,SB,Diagnostic,318,5,NDP,Brighton and Sussex Hospital,"oligodendroglioma, CNS WHO grade 3","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1D,10/21/1961,61.1,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.75,OIDH,0.86,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-114,"Oligodendroglioma, IDH-mutant, CNS WHO grade 3
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
Histology: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 318\NH22-114,-0.001,-0.052,0.006,-0.081,-0.085,0.02,0.013,0.074,0.188,0.16,0.125,-0.007,-0.072,0.074,-0.078,0.004,-0.044,0.034,0.139,0.036,0.015,-0.025,-0.056,0.083,-0.002,0.095,-0.226,-0.084,0.024,methylated
NH22-107,206053660071_R03C01,318,20/01/2022,2/3/2022,2/2/2022,13,SB,Diagnostic,318,1,NDP,"Leeds, St James's University Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/22/1965,57.3,"glioblastoma, IDH-wildtype, mesenchymal type",0.11,GBM_MES,0.39,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-107,"Integrated diagnosis: Compatible with glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma
Methylation profile: Suggestive of glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 318\NH22-107,0.184,-0.032,0.063,0.018,-0.02,0.035,0.014,0.222,-0.038,0.287,0.204,-0.001,0.03,0.068,0.081,0.127,0.018,0.057,-0.032,-0.004,-0.007,0.063,0.005,0.027,0.005,0.031,-0.03,-0.038,0.03,methylated
NH16-158,206053660071_R05C01,318,20/01/2022,2/3/2022,2/2/2022,13,SB,Diagnostic,318,1,NDP,"Belfast, Royal Victoria Hospital",OD,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2C,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.86,OIDH,0.97,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-158,"Low grade glioma, IDH mutant (corresponding to WHO grade II), see comment... 
IDH1 (R132H IHC); IDH1/2 Seq: IDH2 mutation; 
ATRX (IHC): Retained; 
1p/19q: Retained (retested) 
MGMT Promoter: Low level methylation (<10%); 
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Glioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted 
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 318\NH16-158,-0.069,-0.124,0.037,0.095,0.001,0.095,-0.009,0.022,0.017,0.071,-0.007,-0.038,0,0.052,0.104,0.04,-0.017,-0.065,-0.029,0.019,0.043,-0.025,-0.073,0.043,-0.012,0.077,-0.286,-0.088,-0.049,methylated
NH17-1108,206053660071_R07C01,318,21/01/2022,2/3/2022,2/2/2022,12,SB,Diagnostic,318,2,NDP,Royal London Hospital,Astrocytoma IDHmut Gr2,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-1108,"Diffuse astrocytoma (WHO grade II)

  
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Test pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 318\NH17-1108,0.032,-0.007,0.032,-0.051,0.068,0.027,-0.294,-0.007,0.016,0.138,0.123,-0.01,-0.015,0.228,-0.074,0.061,0,-0.158,0.001,0.158,0.096,-0.012,-0.094,0.083,-0.006,0.006,0.021,-0.111,0.06,methylated
NH22-143,206053660071_R08C01,318,21/01/2022,2/3/2022,2/2/2022,12,SB,Diagnostic,318,4,NDP,Royal London Hospital,Recurrent A-IDH Gr2,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1B,9/2/1986,35.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-143,"Recurrent astrocytoma, IDH-mutant, CNS WHO grade 2
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending 
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 318\NH22-143,-0.025,-0.042,0.02,-0.059,-0.013,-0.168,-0.037,-0.034,0.133,0.149,0.174,0.001,-0.051,0.252,-0.076,0.002,-0.023,-0.078,0.06,0.068,-0.013,-0.031,-0.084,0.031,0.012,0.093,0.086,-0.059,0.037,methylated
NH22-147,206053660044_R04C01,319,21/01/2022,2/11/2022,2/11/2022,21,SB,Diagnostic,319,1,NDP,Newcastle,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,8/4/1958,64.4,ganglioglioma,0.25,GBM_MES,0.14,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-147,"Integrated diagnosis: Infiltration of a glial tumour, with molecular features raising the possibility of a glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: CNS grey matter with diffuse infiltration of a glial tumour
Methylation profile: No matching methylation class (see comment regarding copy number and mutations)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 319\NH22-147,0.142,-0.073,-0.015,-0.061,-0.04,0.009,-0.063,0.451,0.261,0.32,0.269,-0.06,-0.121,0.012,-0.304,-0.002,-0.121,-0.208,0.041,0.009,0.035,0.087,-0.133,0.075,0.045,-0.177,0.063,-0.175,-0.052,unmethylated
NH12-1777,206053660044_R05C01,319,24/01/2022,2/11/2022,2/11/2022,18,SB,Diagnostic,319,1,NDP,NHNN-Cardiff,Anaplastic PA (=NH21-3350),"(2) unusual histology, location, demographics",DEF1A,#N/A,#N/A,infratentorial pilocytic astrocytoma,0.63,LGG_PAPF,0.84,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH12-1777,"Pilocytic astrocytoma (WHO grade I)  see comment
","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 319\NH12-1777,-0.035,0.01,0.037,0.002,-0.024,0.058,0.073,-0.041,0.033,0.084,0.282,-0.021,0.174,0.068,-0.856,0.012,0.034,0.03,0.022,0.008,-0.015,0.13,0.023,0.002,0.011,0.065,-0.059,-0.068,-0.012,unmethylated
NH22-54,206053660044_R06C01,319,25/01/2022,2/11/2022,2/11/2022,17,SB,Diagnostic,319,2,NDP,Brighton and Sussex Hospital,"IDH wt Giant cell GBM, Tert neg, EGFR neg","(2) unusual histology, location, demographics",DEF1A,7/29/1947,75.5,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.29,GBM_RTKII,0.62,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-54,"Giant cell glioblastoma, CNS WHO grade 4  see comment
IDH1 (R132H IHC):  No mutation
ATRX (IHC): Retained     
BRAF V600E: Negative
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK2
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 319\NH22-54,-0.075,-0.028,0.026,-0.036,-0.084,0.044,0.05,0.15,0.14,0.14,0.13,-0.011,0.045,0.002,0.013,0.019,-0.237,-0.227,-0.028,-0.04,-0.064,0.077,0.024,-0.029,0.026,-0.01,-0.062,-0.181,-0.226,methylated
NH22-202,206053660044_R07C01,319,25/01/2022,2/11/2022,2/11/2022,17,SB,Diagnostic,319,1,NDP,"Liverpool, The Walton Centre",poorly differentiated HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1D,11/18/1960,62.1,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.84,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-202,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 319\NH22-202,-0.041,0.01,0.039,0.019,-0.022,0.034,0.051,0.201,0.21,0.199,0.197,-0.008,0.007,0.058,-0.807,0.004,-0.326,-0.247,-0.036,-0.051,-0.043,0.046,-0.069,-0.031,-0.015,-0.047,0.156,-0.164,-0.115,unmethylated
NH22-175,206053660044_R08C01,319,25/01/2022,2/11/2022,2/11/2022,17,SB,Diagnostic,319,4,NDP,"Birmingham, Queen Elizabeth Hospital",,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/30/1989,32.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.63,AIDH,0.91,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-175,"Astrocytoma, IDH-mutant, grading see comment
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2  see comment
Histology: Astrocytoma, IDH-mutant
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 319\NH22-175,0.041,-0.059,0.026,-0.033,-0.044,-0.076,-0.062,-0.022,-0.009,0.011,0.006,-0.001,0.032,0.04,0.005,0.024,0,0.022,-0.025,0.066,-0.073,-0.063,-0.064,-0.013,-0.004,-0.014,0.006,0.004,0.048,methylated
NH22-171,206053660060_R01C01,320,25/01/2022,2/9/2022,2/9/2022,15,SB,Diagnostic,320,1,NDP,"Belfast, Royal Victoria Hospital",SEGA,"(2) unusual histology, location, demographics",A1,4/3/2001,21.1,subependymal giant cell astrocytoma,1,LGG_SEGA,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-171,"Integrated diagnosis: Subependymal giant cell astrocytoma, CNS WHO grade 1
Histology: Subependymal giant cell astrocytoma, CNS WHO grade 1
Methylation profile: Low grade glioma, subependymal giant cell astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 320\NH22-171,-0.045,0.002,0.033,-0.002,0.005,0.038,0.024,-0.024,0.001,-0.049,-0.031,-0.004,0.076,0.028,0.017,0.033,0.008,-0.032,-0.002,0.004,-0.001,0.06,-0.01,0.011,0.002,-0.019,-0.048,-0.019,0.008,unmethylated
NH22-182,206053660060_R04C01,320,25/01/2022,2/9/2022,2/9/2022,15,SB,Diagnostic,320,1,NDP,St George's Hospital London,Ependymom Grade 2,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,3/5/1968,54.7,spinal ependymoma,1,EPN_SPINE,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-182,"Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 320\NH22-182,-0.036,0.061,0.052,-0.018,-0.08,-0.062,0.115,0.132,0.166,0.09,0.137,0.158,0.115,0.166,-0.025,-0.058,-0.067,-0.097,-0.055,0.134,0.078,0.147,-0.485,0.006,-0.099,-0.089,-0.111,-0.369,-0.4,methylated
NH22-188,206053660060_R05C01,320,27/01/2022,2/9/2022,2/9/2022,13,SB,Diagnostic,320,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,4/7/1971,51.5,"glioblastoma, IDH-wildtype, mesenchymal type",1,PXA,0.22,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-188,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Giant cell glioblastoma
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype, subclass B (see class description)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 320\NH22-188,0.011,-0.016,0.039,0.004,-0.029,-0.022,0.044,0.191,0.231,0.268,0.19,-0.004,0.066,0.034,0.056,0.004,-0.008,-0.058,0.001,-0.022,0.021,-0.023,-0.003,-0.014,0.035,0.004,-0.048,-0.016,0.004,unmethylated
NH22-190,206053660060_R06C01,320,27/01/2022,2/9/2022,2/9/2022,13,SB,Diagnostic,320,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,(1) small biopsy or nonrepresentative sample;,B1,4/8/2003,19.1,supratentorial midline pilocytic astrocytoma,1,LGG_PAMID,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-190,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Low grade glioma, subclass midline pilocytic astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 320\NH22-190,-0.034,0.021,0.009,-0.005,-0.034,0.007,0.011,0.106,0.211,0.186,0.255,0.009,0.077,0.026,0.056,0.009,0.023,0.017,0.049,-0.007,0,0.044,0.034,0.042,-0.026,0.014,-0.066,-0.02,0.051,methylated
NH22-168,206053660060_R08C01,320,27/01/2022,2/9/2022,2/9/2022,13,SB,Diagnostic,320,1,NDP,NHNN,BRAF mut PXA,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,1/19/1994,28.4,pleomorphic xanthoastrocytoma(-like),0.58,PXA,0.99,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-168,"Pleomorphic Xanthoastrocytoma, CNS WHO grade 3  see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Pleomorphic xanthoastrocytoma, CNS WHO grade 3
Histology: Pleomorphic xanthoastrocytoma, CNS WHO grade 3
Methylation profile: Pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 320\NH22-168,-0.041,0.071,0.035,-0.019,0.016,0.013,-0.155,-0.02,0.004,-0.019,0.012,-0.021,-0.022,-0.01,-0.287,-0.135,-0.156,-0.164,-0.059,-0.052,-0.026,0.01,-0.071,-0.034,0.021,-0.036,0.028,-0.034,-0.015,unmethylated
NH21-3401,206053660111_R01C01,323,1/2/2022,2/11/2022,2/11/2022,10,SB,Diagnostic,323,1,NDP,,"high-grade glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/27/1954,68.6,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.21,GBM_MES,0.4,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3401,"High grade glioma, IDH-wildtype (grading and typing see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
TERT promoter: Inconclusive 
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma, IDH-wildtype
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK2
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 323\NH21-3401,0.041,0.002,0.039,0.005,-0.039,0.011,-0.019,0.1,0.227,0.189,0.177,0.006,-0.02,0.233,-0.385,-0.026,-0.285,-0.262,-0.051,-0.024,0.103,0.004,-0.056,0.011,-0.408,0.012,-0.028,-0.287,-0.329,unmethylated
NH22-226,206053660111_R04C01,323,1/2/2022,2/11/2022,2/11/2022,10,ZJ,Diagnostic,323,1,NDP,St George's Hospital London,Myxopapillary Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A3,6/5/1993,29.1,myxopapillary ependymoma,1,EPN_MPE,1,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-226,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 323\NH22-226,-0.015,0.023,0.054,0.015,-0.007,0.165,0.034,0.196,0.222,0.239,0.19,0.002,0.04,0.028,0.185,0.221,0.008,0,0.004,-0.006,-0.03,-0.045,-0.027,0.159,0.285,0.226,-0.059,-0.013,0,unmethylated
NH22-225,206053660111_R05C01,323,1/2/2022,2/11/2022,2/11/2022,10,ZJ,Diagnostic,323,4,NDP,"Leeds, St James's University Hospital",Intraventricular HGG,"(2) unusual histology, location, demographics",A1,11/10/1996,25.6,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.98,DMG_K27,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-225,"Integrated diagnosis: Diffuse midline glioma H3K27M mutant, CNS WHO grade 4
Histology: High grade glioma
Methylation profile: Diffuse midline glioma H3K27M-mutant
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 323\NH22-225,-0.013,-0.148,-0.006,-0.054,0.255,-0.018,0.053,-0.017,0.047,0.025,-0.016,0.013,0.086,0.016,0.076,-0.018,0.014,0.017,-0.076,-0.312,-0.027,0.065,-0.295,-0.003,0.023,0.04,-0.181,-0.043,0.051,unmethylated
NH22-211,206053660111_R07C01,323,1/2/2022,2/11/2022,2/11/2022,10,ZJ,Diagnostic,323,1,NDP,Royal London Hospital,"Astrocytoma, G3","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1C,8/1/1972,50.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.86,AIDH_HG,0.78,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-211,"Astrocytoma, IDH-mutant, CNS WHO grade 3
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3 (see comment)
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: IDH glioma, subclass high-grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 323\NH22-211,0.007,1.092,0.045,0.008,0.003,0.085,0.038,-0.006,-0.022,-0.048,-0.018,-0.174,0.055,0.011,-0.071,-0.038,-0.025,0.092,-0.032,0.546,-0.172,-0.175,-0.137,-0.04,-0.013,-0.077,-0.012,0.01,0.048,methylated
NH22-209,206053660111_R08C01,323,1/2/2022,2/11/2022,2/11/2022,10,ZJ,Diagnostic,323,1,NDP,NHNN,"LGG, Glioneuronal tumour","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1B,10/12/2004,17.5,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.99,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-209,"Low grade glial /glioneuronal tumour - See comment.
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 323\NH22-209,-0.076,-0.007,0.032,0.01,-0.077,0.054,0.066,-0.026,-0.012,-0.032,0.169,-0.002,0.118,0.042,0.052,0.029,0.022,0.02,0.026,-0.028,-0.026,0.062,0.057,-0.012,0.01,0.003,-0.032,0.015,-0.005,unmethylated
NH22-235,206053660019_R01C01,324,1/2/2022,2/16/2022,2/16/2022,15,ZJ,Diagnostic,324,2,NDP,NHNN,"Glioblastoma, ATRX loss, IDH IHC neg","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,11/13/1978,43.8,"Diffuse hemispheric glioma, H3 G34-mutant",0.8,GBM_G34,0.84,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-235,"Provisional diagnosis: High grade astrocytoma, CNS WHO grade 4  see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Diffuse hemispheric glioma, H3 G34-mutant, CNS WHO grade 4
Histology: High grade astrocytoma, corresponding to CNS WHO grade 4
Methylation profile: Diffuse hemispheric glioma, H3 G34-mutant
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 324\NH22-235,-0.039,0.004,-0.02,0.123,0.569,0.054,-0.044,-0.082,1.04,0.127,0.105,-0.003,-0.026,0.059,-0.007,-0.062,0.01,-0.156,0.095,0.065,-0.027,-0.002,-0.182,0.042,0.005,0.013,-0.246,0.199,0.189,methylated
NH22-251,206053660019_R04C01,324,5/2/2022,2/16/2022,2/16/2022,11,ZJ,Diagnostic,324,1,NDP,NHNN,"Astrocytoma, IDH-mutant, G3","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,2/8/2000,22.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,0.99,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-251,"Astrocytoma, IDH-mutant, CNS WHO grade 3  see comment
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant; high grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 324\NH22-251,0.053,0.154,-0.017,-0.08,-0.012,-0.11,-0.039,-0.013,0.028,0.018,-0.029,-0.032,0.025,0,-0.025,0,0.012,-0.179,-0.035,0.186,-0.028,-0.031,-0.173,0.016,0.003,-0.037,-0.336,-0.004,-0.039,methylated
NH22-272,206053660019_R05C01,324,5/2/2022,2/16/2022,2/16/2022,11,ZJ,Diagnostic,324,1,NDP,"Birmingham, Queen Elizabeth Hospital",Ependymoma  (?melanotic subtype),"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,9/29/1972,50.1,posterior fossa ependymoma group B,1,EPN_PFB,0.97,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-272,"Integrated diagnosis: Ependymoma, posterior fossa group B, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, posterior fossa group B.
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 324\NH22-272,-0.003,-0.297,-0.145,-0.091,-0.058,-0.051,-0.197,-0.034,0.01,-0.047,-0.025,0.171,0.231,0.159,0.19,0.138,-0.143,-0.203,0.038,0.011,0.039,0.066,-0.201,0.038,0.015,-0.029,-0.021,0.131,0.12,unmethylated
NH22-284,206053660019_R06C01,324,5/2/2022,2/16/2022,2/16/2022,11,ZJ,Diagnostic,324,1,NDP,"Charing Cross Hospital, London",Glioblastoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,5/6/1960,62.6,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.55,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-284,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 324\NH22-284,-0.044,-0.083,-0.016,-0.033,-0.076,-0.132,0.09,0.089,0.119,0.099,0.078,-0.023,0.033,0.044,-0.405,-0.034,-0.131,-0.152,-0.031,-0.027,-0.005,0.04,-0.02,-0.025,-0.256,0.003,0.029,-0.035,-0.032,methylated
NH22-273,206053660019_R08C01,324,5/2/2022,2/16/2022,2/16/2022,11,ZJ,Diagnostic,324,1,NDP,Oxford John Radcliffe Hospital,Spinal astrocytoma,(1) small biopsy or nonrepresentative sample;,A1,7/15/1961,61.4,spinal subependymoma [subtype A],0.99,SUBEPN_SPINE,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-273,"Integrated diagnosis: Subependymoma, spinal, CNS WHO grade 1
Histology: Glioma, NOS
Methylation profile: Subependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 324\NH22-273,-0.019,-0.089,0.059,-0.019,-0.037,0.167,-0.397,-0.077,-0.134,-0.157,-0.005,0.035,-0.082,0.136,-0.091,-0.045,-0.071,-0.027,0.038,0.01,0.011,0.026,-0.138,0.086,-0.169,0.041,0.154,0.035,0.027,unmethylated
NH22-237,206053660110_R01C01,325,5/2/2022,2/16/2022,2/16/2022,11,ZJ,Diagnostic,325,1,NDP,"Cambridge, Addenbrooke's Hospital","Astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,9/11/1989,32.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.59,AIDH_HG,0.75,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-237,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma with predominant gemistocytic phenotype 
Methylation profile: Glioma, IDH-mutant, subclass high-grade astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 325\NH22-237,0.134,-0.037,-0.039,-0.064,-0.02,-0.27,0.014,0.09,0.048,0.067,0.015,-0.174,0.11,0.216,-0.009,0.016,0.014,-0.145,0.089,0.662,-0.128,-0.262,-0.266,0.163,0.115,-0.045,-0.084,-0.046,0.066,unmethylated
NH22-238,206053660110_R02C01,325,5/2/2022,2/16/2022,2/16/2022,11,ZJ,Diagnostic,325,1,NDP,"Cambridge, Addenbrooke's Hospital",Glioblastoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,10/5/1954,68.3,"glioblastoma, IDH-wildtype, mesenchymal type",0.66,GBM_MES,0.8,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-238,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 325\NH22-238,-0.018,0.005,-0.012,-0.062,-0.08,-0.011,-0.004,0.15,0.126,0.139,0.087,-0.036,0.009,0.03,0.02,0.02,-0.134,-0.175,-0.067,-0.106,-0.117,-0.187,-0.397,-0.115,-0.179,-0.161,-0.058,-0.284,-0.352,methylated
NH22-299,206053660110_R05C01,325,7/2/2022,2/16/2022,2/16/2022,9,SB,Diagnostic,325,3,NDP,NHNN,"Astrocytoma, IDH mutant G3","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,9/6/1993,28.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.61,AIDH_HG,0.93,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-299,"Astrocytoma, IDH-mutant, CNS WHO grade 3 (see comment)
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 325\NH22-299,0.042,-0.021,0.017,-0.025,0.017,-0.152,0.025,0.293,0.296,0.321,0.217,-0.037,0.008,0.111,0.002,0.042,0.051,-0.66,0.077,0.064,0.882,-0.174,-0.231,0.044,0.052,0.009,-0.116,-0.133,-0.171,methylated
NH22-176,206053660110_R06C01,325,8/2/2022,2/16/2022,2/16/2022,8,ZJ,Diagnostic,325,4,NDP,"Cardiff, University Hospital","Astrocytoma, IDH-mutant, G2","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A4,8/4/1984,38,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.8,AIDH,0.86,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-176,"Astrocytoma, IDH-mutant, CNS WHO grade 2
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained     
1p/19q: Retained          
CDKN2A/B: No deletion           
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 325\NH22-176,0.077,-0.057,0.02,-0.032,-0.033,-0.084,-0.024,0.008,0.102,0.097,0.132,-0.013,-0.038,0.016,-0.002,-0.024,0.003,0.118,0.008,-0.022,0.124,0.03,0.033,0.067,-0.038,-0.039,0.127,0.062,0.036,methylated
NH22-314,206036370059_R01C01,326,8/2/2022,2/23/2022,2/23/2022,15,SB,Diagnostic,326,4,NDP,NHNN,Oligodendroglioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1B,5/23/1956,66.7,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-314,"Oligodendroglioma, CNS WHO grade 2.
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained 
H3K27me3: Loss of expression
Further molecular tests: Pending
","Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
IDH1/2Seq: Mutation
ATRX (IHC): Retained
1p/19q: Codeleted (see comment)
TERT promoter: Mutation
MGMT Promoter: Methylated (>5-10%)
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 326\NH22-314,0.03,0,0.035,-0.036,0.026,0.02,-0.053,-0.027,-0.023,-0.003,0.031,0.007,-0.082,0.039,0.008,-0.025,-0.085,0.004,0.022,0.045,0.017,-0.025,-0.098,0.01,-0.068,-0.041,-0.27,0.003,0.03,methylated
NH22-319,206036370059_R04C01,326,8/2/2022,2/23/2022,2/23/2022,15,SB,Diagnostic,326,3,NDP,"Cambridge, Addenbrooke's Hospital",Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B3,9/9/1979,43,spinal subependymoma [subtype A],0.62,GBM_MES,0.17,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-319,"Integrated diagnosis: In favour of subependymoma, CNS WHO grade 1
Histology: In favour of subependymoma, CNS WHO grade 1
Methylation profile: Suggestive of subependymoma  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 326\NH22-319,0.043,-0.016,0.045,0.038,0.002,-0.02,-0.005,0.014,0.003,-0.04,0,-0.02,-0.011,0.03,-0.003,0.002,-0.012,0.016,0,-0.012,-0.052,-0.015,-0.045,-0.008,0.02,-0.032,-0.004,-0.045,-0.011,unmethylated
NH22-320,206036370059_R05C01,326,8/2/2022,2/23/2022,2/23/2022,15,SB,Diagnostic,326,1,NDP,"Belfast, Royal Victoria Hospital",Glioma ,(1) small biopsy or nonrepresentative sample;,A1,6/11/1956,66.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.95,GBM_MES,0.71,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-320,"Integrated diagnosis: Suggestive of glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioma, nos
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal. 
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 326\NH22-320,-0.033,-0.092,0.023,-0.178,-0.051,0.007,-0.239,0.049,0.072,0.051,0.082,-0.015,0.008,0.034,-0.481,-0.021,-0.191,-0.122,-0.018,-0.003,0.055,0.038,-0.195,-0.003,-0.011,-0.014,0.001,0.014,0.016,unmethylated
NH22-317,206036370059_R07C01,326,8/2/2022,2/23/2022,2/23/2022,15,SB,Diagnostic,326,4,NDP,"Liverpool, The Walton Centre","astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2A,2/1/1995,27.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-317,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Unmethylated
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 326\NH22-317,-0.026,-0.065,0.091,-0.054,-0.001,-0.035,-0.049,0.262,0.219,0.194,0.206,0.01,0.052,0.423,0.059,-0.086,-0.003,0.036,-0.014,0.2,0.05,0.063,-0.031,0.04,-0.126,-0.038,0.046,0.039,0.02,unmethylated
NH22-318,206036370059_R08C01,326,8/2/2022,2/23/2022,2/23/2022,15,SB,Diagnostic,326,2,NDP,"Cardiff, University Hospital",ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,8/23/2004,17.7,spinal ependymoma,1,EPN_SPINE,1,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-318,"Integrated diagnosis: Ependymoma, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 326\NH22-318,0.064,0.378,0.347,0.058,0.066,0.022,-0.187,0.317,0.262,0.343,0.333,0.531,0.45,0.619,0.254,0.407,0.051,0.019,0.095,0.369,0.355,0.353,-0.048,0.005,-0.075,-0.048,0.054,-0.519,-0.481,unmethylated
NH22-312,206053660109_R05C01,327,9/2/2022,2/18/2022,2/18/2022,9,SB,Diagnostic,327,1,NDP,"Cambridge, Addenbrooke's Hospital",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,6/16/1995,27,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.96,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-312,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, infratentorial
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 327\NH22-312,-0.125,-0.122,-0.061,-0.04,-0.123,0.044,0.089,0.011,0.03,-0.008,0.161,-0.007,0.057,0.038,0.069,0.006,0.03,0.011,0.079,-0.011,0.023,0.083,-0.05,-0.122,-0.121,-0.13,0.001,0.047,-0.01,unmethylated
NH22-187,206053660109_R06C01,327,9/2/2022,2/18/2022,2/18/2022,9,SB,Diagnostic,327,2,NDP,"Birmingham, Queen Elizabeth Hospital",Ependymoma spinal,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B2,10/23/1963,59.1,myxopapillary ependymoma,1,EPN_MPE,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-187,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 327\NH22-187,0.082,0.029,-0.065,0.06,0.218,0.139,-0.316,0.26,0.082,0.083,0.035,-0.017,0.01,0.063,0.011,0.248,-0.222,-0.314,0.011,0.044,-0.031,0.029,-0.309,0.222,0.288,0.207,-0.005,-0.265,-0.253,methylated
NH22-208,206053660109_R07C01,327,9/2/2022,2/18/2022,2/18/2022,9,SB,Diagnostic,327,2,NDP,"Birmingham, Queen Elizabeth Hospital",recurrent molecular glioblastoma,"(2) unusual histology, location, demographics",A2,10/12/1972,50,"control tissue, white matter (corpus callosum)",0.77,CONTR_HEMI,0.22,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-208,"Integrated diagnosis: Appearances compatible with residual glioblastoma, IDH-wildtype with radiotherapy related changes  see comment
Histology: Appearances compatible with residual glioblastoma, IDH-wildtype with radiotherapy related changes  see comment
Methylation profile: See comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 327\NH22-208,0.027,-0.041,0.024,-0.013,0.007,-0.001,-0.022,-0.024,0.034,-0.08,0.014,0.033,0.098,0.056,0.012,-0.029,-0.032,-0.043,0.056,-0.051,0.046,0.124,-0.002,0,-0.004,0.01,0.088,0.01,-0.023,unmethylated
NH22-333,206036370071_R01C01,328,9/2/2022,2/23/2022,2/23/2022,14,SB,Diagnostic,328,1,NDP,NHNN,myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,2/19/1990,32.4,myxopapillary ependymoma,0.99,EPN_MPE,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-333,"Recurrent myxopapillary ependymoma, CNS WHO grade 2.
",#REF!,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 328\NH22-333,-0.08,-0.063,0.038,-0.076,-0.054,0.075,0.057,0.01,0.036,0.03,0.01,-0.023,0.022,-0.005,0.14,0.118,-0.186,-0.163,-0.038,-0.067,-0.052,-0.041,-0.178,0.042,0.051,0.002,0.047,-0.062,-0.054,unmethylated
NH22-347,206036370071_R02C01,328,9/2/2022,2/23/2022,2/23/2022,14,SB,Diagnostic,328,1,NDP,Oxford John Radcliffe Hospital,intramedullary spinal ependymoma ,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",,9/3/1987,34.9,spinal ependymoma,1,EPN_SPINE,1,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-347,"Integrated diagnosis: Ependymoma CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 328\NH22-347,0.012,0.224,0.22,0.174,0.233,-0.005,-0.004,0.231,0.232,0.226,0.219,-0.006,-0.012,0.033,0.255,0.241,0.022,0.026,-0.007,0.233,0.181,0.212,-0.041,0.247,0.255,0.178,0.223,-0.366,-0.435,methylated
NH22-356,206036370071_R03C01,328,11/2/2022,2/23/2022,2/23/2022,12,SB,Diagnostic,328,3,NDP,NHNN,ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,4/27/1973,49.5,posterior fossa subependymoma,1,SUBEPN_PF,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-356,"Ependymal tumour - See comment.
",#REF!,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 328\NH22-356,0.087,-0.01,0.026,0.028,0.021,-0.107,-0.496,0.025,0.025,0.029,-0.011,-0.03,-0.034,0.05,-0.025,-0.007,0.003,-0.006,0.034,0.048,0.024,-0.061,-0.049,0.026,0.025,-0.013,0.003,-0.054,0.002,unmethylated
NH22-359,206036370071_R04C01,328,11/2/2022,2/23/2022,2/23/2022,12,SB,Diagnostic,328,1,NDP,Romford,HGG/GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/2/1970,52.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.82,CONTR_REACT,0.61,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-359,"Glioblastoma, CNS WHO grade 4.
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 328\NH22-359,0.037,-0.085,0.018,-0.057,-0.052,-0.109,0.001,0.363,0.032,-0.001,0.027,-0.023,0.02,0.017,-0.203,-0.13,-0.093,-0.047,-0.087,-0.045,0.027,-0.083,-0.019,0.032,-0.029,-0.07,0.079,0.018,0.017,unmethylated
NH22-321,206036370071_R07C01,328,14/02/2022,2/23/2022,2/23/2022,9,SB,Diagnostic,328,1,NDP,Royal London Hospital,CNS/LGG? Epilepsy,"(2) unusual histology, location, demographics",DEF1A,4/2/1979,43.5,supratentorial pilocytic astrocytoma,0.5,LGG_DNT,0.17,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-321,"CNS grey and white matter, moderately intense widespread gliosis, no neoplasm.
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 328\NH22-321,-0.01,0.026,0.011,0.014,-0.002,-0.039,-0.078,0.006,0.017,-0.003,0.005,-0.023,-0.033,0.015,-0.035,0.027,-0.013,0.007,0.05,-0.018,-0.062,0.042,-0.032,-0.057,0.039,-0.03,-0.019,-0.052,0.034,unmethylated
NH22-392,206036370071_R08C01,328,14/02/2022,2/23/2022,2/23/2022,9,SB,Diagnostic,328,1,NDP,"Tehran, IR",GG Ventricle,"(2) unusual histology, location, demographics",P001948,3/17/2001,21.2,papillary glioneuronal tumour,0.09,LGG_DNT,0.08,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-392,"Histology: Low grade glial/glioneuronal tumour  see comment
Methylation profile: Unsuccessful due to inadequate DNA  see comment 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 328\NH22-392,-0.028,-0.067,-0.059,0.063,-0.078,-0.143,0.035,0.459,-0.072,-0.131,0.075,0.017,0.016,-0.264,0.198,0.175,-0.225,-0.16,-0.184,-0.039,-0.089,-0.009,-0.136,0.057,-0.097,0.263,0.177,0.168,0.033,unmethylated
NH22-372,206036370069_R01C01,331,15/02/2022,3/2/2022,3/2/2022,15,SB,Diagnostic,331,1,NDP,,Ependymoma?,"(2) unusual histology, location, demographics",A1,3/27/1952,61.1,posterior fossa subependymoma,1,SUBEPN_PF,0.98,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-372,"Integrated diagnosis: Posterior fossa ependymoma, NEC  see comment
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated    
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 331\NH22-372,0.118,-0.029,0.082,0.021,0.038,0.004,-0.643,0.145,-0.013,0.041,0.007,0.002,-0.014,0.13,0.031,0.127,0.068,-0.041,0.132,0.082,0.15,0.113,-0.02,0.182,0.036,0.027,-0.016,0.003,0.156,unmethylated
NH21-3217,206036370069_R02C01,331,15/02/2022,3/2/2022,3/2/2022,15,MD,Diagnostic,331,1,NDP,,"Glioma, IDH wildtype","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/12/1998,23.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.99,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-3217,"Glioma, IDH-wildtype (see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Equivocal (see comment) 
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: Methylated (>0-5%)
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 331\NH21-3217,-0.068,-0.005,0.045,0.002,0.009,0.065,0.005,-0.044,-0.036,-0.06,0.005,0.008,-0.026,-0.01,-0.027,-0.026,0.033,0.029,0.052,0.013,-0.021,-0.018,-0.009,-0.002,0,-0.017,0.018,-0.005,0.062,methylated
NH22-396,206036370069_R03C01,331,16/02/2022,3/2/2022,3/2/2022,14,SB,Diagnostic,331,1,NDP,NHNN,"Astrocytoma, IDH mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP2A,12/24/1980,41.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,0.99,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-396,"Astrocytoma, IDH-mutant  grading see comment
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, at least CNS WHO grade 3
Methylation profile: IDH glioma, subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 331\NH22-396,-0.056,-0.036,0.03,-0.146,-0.022,0.03,0.016,0,-0.02,0,-0.026,-0.011,0.03,0.22,-0.304,0.002,0.012,0.093,-0.005,0.37,-0.281,-0.44,-0.014,-0.046,-0.021,-0.022,-0.082,-0.006,0.019,methylated
NH14-176,206036370069_R04C01,331,16/02/2022,3/2/2022,3/2/2022,14,SB,Diagnostic,331,1,NDP,NHNN,"Astrocytoma, IDH mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1B,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-176,"Oligoastrocytoma (WHO Grade II); positive for IDH-1 mutation (R132H)
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 331\NH14-176,-0.096,-0.011,0.055,-0.017,0.009,0.042,-0.06,-0.035,-0.035,-0.018,-0.031,0.092,0.17,0.106,0.001,0.008,0.015,-0.047,0.093,-0.016,-0.032,0.067,-0.069,-0.005,-0.078,-0.002,-0.067,-0.04,0.062,unmethylated
NH22-390,206036370069_R05C01,331,16/02/2022,3/2/2022,3/2/2022,14,SB,Diagnostic,331,1,NDP,"Liverpool, The Walton Centre",LGG,"(2) unusual histology, location, demographics",1A,8/12/1997,24.8,ganglioglioma,1,LGG_GG,0.99,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-390,"Integrated diagnosis: Favouring a Ganglioglioma, CNS WHO grade 1
Histology: Low grade glial/glioneuronal tumour
Methylation profile: Diagnostic classifier  failed to classify; Research classifier - Ganglioglioma
MGMT promoter (Illumina array): Unmethylated  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 331\NH22-390,0.03,-0.002,0.018,-0.024,-0.049,-0.008,-0.095,0.038,-0.016,-0.003,0.017,0.024,0.11,-0.025,0.017,0,0.022,0.049,0.002,-0.027,0.076,0.068,0.032,0.043,0.004,0.048,-0.005,-0.042,0.052,unmethylated
NH22-214,206036370069_R07C01,331,16/02/2022,3/2/2022,3/2/2022,14,SB,Diagnostic,331,1,NDP,Sweden,Repeat Cortical bx (previous mixup),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",01-02.,8/5/1955,67.4,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.16,LGG_DNT,0.12,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-214,"CNS tissue (non-diagnostic)  see comment  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 331\NH22-214,0.01,-0.029,0.057,-0.019,-0.085,-0.046,-0.363,-0.152,-0.056,0.044,-0.025,0.027,0.043,-0.093,-0.164,-0.038,0.049,-0.012,-0.008,-0.043,-0.101,-0.029,0.013,0.013,0.148,0.185,-0.011,-0.056,0.034,unmethylated
NH22-374,206036370021_R03C01,332,16/02/2022,3/2/2022,3/2/2022,14,SB,Diagnostic,332,1,NDP,"Belfast, Royal Victoria Hospital",ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B,3/24/1973,49.6,posterior fossa subependymoma,1,SUBEPN_PF,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-374,"Integrated diagnosis: Posterior fossa ependymoma (see comment)
Histology: Ependymoma, favouring CNS WHO grade 2 (see comment)
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 332\NH22-374,0.004,-0.023,0.032,-0.001,-0.014,-0.024,-0.439,0.043,0.033,-0.022,-0.017,-0.002,0.066,0.062,0.034,-0.016,0.011,-0.008,0.012,0.002,0.039,0.051,-0.006,0.001,0.028,-0.028,-0.087,-0.076,0,unmethylated
NH22-366,206036370021_R04C01,332,16/02/2022,3/2/2022,3/2/2022,14,SB,Diagnostic,332,1,NDP,"Cardiff, University Hospital",Glioneuronal tumour,"(2) unusual histology, location, demographics",A1,6/27/1956,66.5,dysembryoplastic neuroepithelial tumour,0.77,LGG_DNT,0.71,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-366,"Integrated diagnosis: Favouring dysembryoplastic neuroepithelial tumour (DNT)  see comment
Histology: Low grade glial/glioneuronal tumour
Methylation profile: Classified with low calibrated score  see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 332\NH22-366,0.129,-0.004,-0.068,0,-0.017,0.218,0.103,0.34,0.454,0.497,0.434,0.102,0.121,0.143,0.223,0.255,0.256,0.22,0.276,-0.013,0.138,0.123,0.013,0.012,0.026,0.012,0.002,-0.033,0.194,methylated
NH22-395,206036370021_R07C01,332,16/02/2022,3/2/2022,3/2/2022,14,SB,Diagnostic,332,1,NDP,"Cambridge, Addenbrooke's Hospital","Astrocytoma, preumed IDH mutant","(4) IHC, sequencing, or copy number assay ambiguous",6,10/21/1993,28.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.95,AIDH,0.97,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-395,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, with no high grade features
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 332\NH22-395,-0.114,-0.04,0.055,-0.013,-0.047,0.031,-0.046,0.002,-0.034,-0.087,-0.016,0.144,0.147,0.138,0.012,0.018,0.024,0.052,0.06,-0.019,-0.034,-0.051,-0.094,-0.017,0.003,0.006,-0.037,-0.049,0.003,methylated
NH22-413,206053660090_R02C01,333,17/02/2022,3/9/2022,3/9/2022,20,SB,Diagnostic,333,1,NDP,NHNN,inflammation or tumour,"(2) unusual histology, location, demographics",DEF1A,1/15/1955,68.1,"control tissue, optic pathway",0.34,CONTR_HEMI,0.37,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-413,"CNS white matter cores with infiltrates of atypical B cells, raising the possibility of B cell lymphoma (see comment) 
","Histology: Raising the possibility of a B-cell lymphoproliferative disease  see comment and report UR22-462
Methylation profile: See comment
MGMT promoter (Illumina array): Methylated   
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 333\NH22-413,-0.021,-0.03,0.034,0.007,0.05,-0.03,-0.058,-0.031,0,-0.027,-0.005,-0.014,-0.01,0.018,-0.103,-0.04,-0.037,0.002,-0.004,-0.034,-0.014,-0.065,-0.04,-0.028,-0.019,-0.022,0.015,-0.028,-0.036,methylated
NH22-279,206053660090_R03C01,333,18/02/2022,3/9/2022,3/9/2022,19,MD,Diagnostic,333,1,NDP,NHNN,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/22/2003,18.7,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-279,"Pilocytic astrocytoma, CNS WHO grade 1
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Pilocytic astrocytoma, CNS WHO grade 1
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
KIAA1549-BRAF fusion: Present
Methylation profiling: pending 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 333\NH22-279,-0.008,-0.004,0.017,-0.02,-0.061,0.113,-0.037,0.148,0.211,0.198,0.305,0.06,0.074,0.101,0.179,0.17,0.022,0.022,0.017,0.009,0.007,-0.063,-0.048,-0.066,-0.045,-0.062,0.027,0.006,0.026,unmethylated
NH22-434,206053660090_R04C01,333,18/02/2022,3/9/2022,3/9/2022,19,SB,Diagnostic,333,1,NDP,Oxford John Radcliffe Hospital,"DNET, LGG?","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,11/17/1997,24.6,supratentorial pilocytic astrocytoma,0.99,LGG_PA_GGST,0.7,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-434,"Integrated diagnosis: Favouring a Pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glial/glioneuronal tumour
Methylation profile: Pilocytic astrocytoma
MGMT promoter (Illumina array): Methylated 
  
","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glial/glioneuronal tumour
Methylation profile: Pilocytic astrocytoma

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 333\NH22-434,0.006,0.005,-0.008,0.015,-0.015,0.035,0.155,0.032,0.09,0.044,0.076,0.014,0.02,0.04,0.073,0.05,0.037,0.035,0.036,0.016,0.026,0.055,0.042,-0.036,-0.013,-0.013,-0.062,-0.039,0.022,methylated
NH22-448,206053660090_R06C01,333,18/02/2022,3/9/2022,3/9/2022,19,SB,Diagnostic,333,2,NDP,"Belfast, Royal Victoria Hospital","oligo astrocytoma, probably ASTRO-IDH","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,1/5/1982,40.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.45,AIDH,0.49,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-448,"Integrated diagnosis: Astrocytoma, IDH-mutant  see comment
Histology: Astrocytoma, favouring a possible CNS WHO grade 3 (see comment)
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Unmethylated
  
","Astrocytoma, IDH-mutant, in favour of CNS WHO grade 3
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B: Uncertain
MGMT Promoter: Methylated (>0-5%)
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 333\NH22-448,0.005,-0.015,-0.014,-0.125,-0.129,-0.048,-0.079,-0.115,-0.125,0.059,-0.032,-0.034,-0.197,0.289,-0.489,0.098,-0.433,-0.422,-0.025,-0.001,0.079,-0.008,-0.167,0.08,0.035,-0.141,0.077,0.151,-0.017,unmethylated
NH22-417,206053660090_R07C01,333,18/02/2022,3/9/2022,3/9/2022,19,SB,Diagnostic,333,1,NDP,Nottingham University Hospital,astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C1,1/27/1968,54.8,"glioblastoma, IDH-wildtype, RTK2 type",0.96,GBM_RTKII,0.82,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-417,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Consistent with glioblastoma
Methylation profile: Glioblastoma, IDH wildtype
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 333\NH22-417,-0.062,-0.058,0.056,-0.061,-0.031,0.005,0.017,0.194,0.187,-0.081,-0.023,-0.009,0.022,0.003,-1.241,0.053,-0.375,-0.291,-0.026,-0.034,-0.01,0.042,-0.257,-0.015,-0.528,-0.014,0.193,-0.276,-0.307,methylated
NH22-451,206053660090_R08C01,333,22/02/2022,3/9/2022,3/9/2022,15,SB,Diagnostic,333,1,NDP,London Clinic,Spinal ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A,5/11/1964,58.6,spinal ependymoma,1,EPN_SPINE,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-451,"Spinal ependymoma, CNS WHO grade 2, see comment
","Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Spinal ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 333\NH22-451,-0.001,0.333,0.309,-0.005,0.001,0.206,0.048,0.244,0.255,0.215,0.228,0.269,0.294,0.32,0.261,0.313,0.047,0.076,0.087,0.23,0.288,0.254,-0.005,-0.032,-0.01,-0.08,-0.03,-0.002,0.035,unmethylated
NH22-454,206053660074_R01C01,334,22/02/2022,3/9/2022,3/9/2022,15,ZJ,Diagnostic,334,1,NDP,"Liverpool, The Walton Centre",Spinal ependymoma (lumbar),"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1B,3/8/1958,64.9,myxopapillary ependymoma,1,EPN_MPE,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-454,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Ependymoma
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 334\NH22-454,-0.045,0.007,0.069,0.008,0.021,-0.01,0.003,-0.016,-0.014,-0.082,-0.016,0.004,0.023,0.003,0.069,0.006,-0.003,0.006,-0.004,-0.003,0.006,-0.024,-0.023,-0.014,0.017,-0.006,0.01,-0.032,-0.036,methylated
NH22-455,206053660074_R02C01,334,22/02/2022,3/9/2022,3/9/2022,15,ZJ,Diagnostic,334,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/25/1945,77.9,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.38,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-455,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated (see comment)   
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 334\NH22-455,0.029,-0.059,-0.005,-0.022,-0.042,-0.028,-0.023,0.117,0.162,0.14,0.111,-0.009,0.011,0.004,-0.124,-0.037,-0.009,-0.051,-0.003,-0.009,-0.008,-0.02,-0.004,-0.02,0.001,-0.007,0.015,-0.042,-0.007,methylated
NH22-472,206053660074_R03C01,334,26/02/2022,3/9/2022,3/9/2022,11,ZJ,Diagnostic,334,1,NDP,NHNN,Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,7/12/2004,17.9,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.98,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-472,"Pilocytic astrocytoma, CNS WHO grade 1.
","Pilocytic astrocytoma, CNS WHO grade 1
BRAF:KIAA Fusion 
Methylation profile: low-grade glioma, subclass posterior fossa pilocytic astrocytoma 
MGMT Promoter: Unmethylated (0%)(Methylation array)

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 334\NH22-472,-0.033,-0.032,0.022,-0.008,-0.032,0.008,0.018,-0.013,0.019,0.028,0.13,-0.007,0.011,-0.023,0.009,-0.004,-0.018,0.021,0.014,-0.047,0.02,-0.058,0.01,-0.009,-0.008,-0.078,-0.046,0.006,0.022,unmethylated
NH22-443,206053660074_R04C01,334,26/02/2022,3/9/2022,3/9/2022,11,ZJ,Diagnostic,334,1,NDP,Brighton and Sussex Hospital,"Oligodendroglioma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,3/3/1954,69,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-443,"Oligodendroglioma IDH mutant, CNS WHO grade 2 - See comment.

IDH1 (R132H IHC): Mutated       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Oligodendroglioma, IDH-mutant and 1p/19q- codeleted, CNS WHO grade 2
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Retained
1p/19q: Codeleted (see comment)
TERT promoter: Mutation
MGMT Promoter: Methylated (>5-10%)  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 334\NH22-443,-0.004,-0.014,0.024,-0.334,-0.348,-0.14,0.088,0.018,-0.016,-0.017,-0.016,0.002,0.109,0.014,0.027,-0.032,0.018,0.004,0.032,-0.131,-0.159,-0.236,-0.024,0.004,0.02,-0.019,-0.5,-0.018,0.037,methylated
NH22-465,206053660074_R06C01,334,26/02/2022,3/9/2022,3/9/2022,11,ZJ,Diagnostic,334,1,NDP,NHNN,"Astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,4/26/1988,34.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.91,AIDH,0.82,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-465,"Astrocytoma, IDH-mutant, see comment.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2 (see comment)
Histology: Recurrent/residual Astrocytoma, IDH-mutant 
Methylation profile: IDH glioma, subclass astrocytoma
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Retained
CDKN2A/B: No deletion          
MGMT Promoter: Methylated (>0-5%)   
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 334\NH22-465,-0.057,-0.045,0.028,-0.026,0.013,-0.175,0.03,-0.035,0.153,0.202,0.142,-0.009,-0.014,0.245,-0.034,-0.001,0.004,0.077,-0.029,0.01,-0.032,-0.011,0.003,-0.051,-0.058,-0.036,-0.032,0.042,0.021,methylated
NH14-1617,206053660074_R07C01,334,26/02/2022,3/9/2022,3/9/2022,11,ZJ,Diagnostic,334,1,NDP,NHNN,"Astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1B,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-1617,"Diffuse astrocytoma (WHO grade II)  see comment
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2 (2021 classification)
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: IDH glioma, subclass astrocytoma 
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 334\NH14-1617,-0.113,-0.04,0.047,-0.005,-0.018,0.044,0.04,-0.021,0.046,0.068,0.059,-0.013,0.002,0.259,-0.012,0.016,0.017,0.04,-0.044,-0.027,-0.002,0.007,-0.027,-0.069,-0.109,-0.035,-0.048,-0.009,0.037,methylated
NH22-452,206053660069_R02C01,335,26/02/2022,3/11/2022,3/11/2022,13,ZJ,Diagnostic,335,1,NDP,Oxford John Radcliffe Hospital,Infiltration zone of glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,5/16/1969,53.5,"glioblastoma, IDH-wildtype, RTK2 type",0.48,GBM_RTKII,0.7,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-452,"Integrated diagnosis: Suggestive of an infiltration zone of glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioma 
Methylation profile: Glioblastoma, IDH-wildtype (low calibrated score  see comment)
MGMT promoter (Illumina array): Methylated  
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO Grade 4
Histology: High grade glioma
Methylation profile: Glioblastoma, IDH-wildtype
Next generation sequencing: TERT Promoter mutation 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 335\NH22-452,0.132,-0.079,0.008,-0.009,-0.025,0.056,-0.037,1.057,0.154,0.126,0.107,-0.03,0.039,0.027,-0.611,-0.015,-0.553,-0.2,-0.005,-0.024,0,0.047,-0.001,-0.001,0.016,-0.025,-0.042,-0.022,0.026,methylated
NH22-496,206053660069_R04C01,335,28/02/2022,3/11/2022,3/11/2022,11,AM,Diagnostic,335,1,NDP,Sweden,spindle cell tumour ? meningioma ? sarcoma,(1) small biopsy or nonrepresentative sample;,1-Jan,11/18/1976,45.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.9,LGG_SEGA,0.26,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-496,"Histology: Tumour with spindle cell morphology, NOS 
Methylation profile: Inconclusive  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 335\NH22-496,0.024,0.029,-0.004,0,-0.015,0.013,-0.046,0.118,0.095,0.111,0.069,-0.009,-0.023,0.006,-0.135,0.001,-0.073,-0.094,-0.06,-0.069,-0.031,0.008,-0.006,-0.016,-0.053,-0.027,-0.026,-0.091,-0.148,unmethylated
NH22-392,206053660069_R06C01,335,28/02/2022,3/11/2022,3/11/2022,11,ZJ,Diagnostic,335,1,NDP,"Tehran, IR",GG Ventricle,"(2) unusual histology, location, demographics",P001948,3/17/2001,21.2,posterior fossa ependymoma group A1,0.08,DMG_K27,0.04,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-392,"Histology: Low grade glial/glioneuronal tumour  see comment
Methylation profile: Unsuccessful due to inadequate DNA  see comment 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 335\NH22-392,0.135,-0.371,0.238,0.1,0.499,-0.138,-0.017,0.307,0.235,0.039,0.119,-0.015,-0.303,0.012,0.028,-0.046,-0.531,-0.171,0.226,-0.214,-0.082,0.059,-0.206,-0.214,-0.014,0.401,0.115,-0.479,0.078,unmethylated
NH22-208,206053660069_R07C01,335,28/02/2022,3/11/2022,3/11/2022,11,ZJ,Diagnostic,335,2,NDP,"Birmingham, Queen Elizabeth Hospital",Residual GBM with radiotherapy changes,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,10/12/1972,50,"control tissue, white matter (corpus callosum)",0.62,CONTR_HEMI,0.26,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-208,"Integrated diagnosis: Appearances compatible with residual glioblastoma, IDH-wildtype with radiotherapy related changes  see comment
Histology: Appearances compatible with residual glioblastoma, IDH-wildtype with radiotherapy related changes  see comment
Methylation profile: See comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 335\NH22-208,-0.018,-0.038,-0.013,0.01,-0.044,0.034,0.001,0.009,0.028,-0.004,0.017,0.005,0.074,0.024,0.032,-0.008,-0.028,-0.005,0.02,-0.036,-0.038,0.076,0.04,-0.034,0.019,-0.023,0.018,0.035,0.028,unmethylated
NH22-506,206053660069_R08C01,335,28/02/2022,3/11/2022,3/11/2022,11,AM,Diagnostic,335,1,NDP,Hull,Spinal cord astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B ,8/15/1976,46.2,infratentorial pilocytic astrocytoma,0.92,LGG_PAPF,0.78,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-506,"Integrated diagnosis: Favouring pilocytic astrocytoma, CNS WHO grade 1  see comment
Histology: Low grade glial/glioneuronal tumour
Methylation profile: Pilocytic astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 335\NH22-506,-0.029,0.005,0.033,0.027,-0.06,0.073,0.066,-0.013,-0.004,-0.044,-0.024,-0.026,0.071,0.069,0.024,-0.011,0.02,0.066,0.043,-0.028,-0.028,0.056,0.001,-0.019,0.037,-0.029,-0.037,0.016,0.091,methylated
NH22-513,206053660073_R01C01,336,1/3/2022,3/16/2022,3/16/2022,15,AM,Diagnostic,336,1,NDP,"Birmingham, Queen Elizabeth Hospital",High grade glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,12/5/1968,54,"glioblastoma, IDH-wildtype, mesenchymal type",0.32,GBM_RTKII,0.33,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-513,"Integrated diagnosis: Possible Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma with epithelioid change
Methylation profile: See comment
MGMT promoter (Illumina array): Unmethylated  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 336\NH22-513,-0.045,-0.032,-0.018,0.064,-0.022,0.014,-0.217,0.25,0.204,0.135,0.131,-0.024,0.03,-0.022,-0.86,-0.069,-0.164,-0.232,-0.032,-0.064,-0.058,0.082,0.034,-0.344,0.052,-0.002,-0.366,0.027,0.026,unmethylated
NH22-532,206053660073_R03C01,336,1/3/2022,3/16/2022,3/16/2022,15,AM,Diagnostic,336,1,NDP,Sweden,? Gliosis ? glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",22PL01998,2/7/1947,76.2,"control tissue, white matter (corpus callosum)",0.99,CONTR_HEMI,0.26,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-532,"Integrated diagnosis: Favouring infiltration zone of diffuse glioma  see comment
Histology: Brain parenchyma with suspected tumour infiltration  see comment
Methylation profile: Control tissue  see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 336\NH22-532,0.039,0.045,-0.007,-0.038,-0.052,-0.001,-0.119,0.83,0.048,0.049,0.016,-0.051,0.057,-0.001,-0.023,0.013,-0.005,-0.005,-0.059,-0.023,0.061,0.038,-0.019,0.01,0.012,-0.002,-0.03,-0.037,-0.014,methylated
NH22-522,206053660073_R07C01,336,3/3/2022,3/16/2022,3/16/2022,13,AM,Diagnostic,336,1,NDP,NHNN,Recurrent Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1D,2/21/2003,19.3,infratentorial pilocytic astrocytoma,0.96,LGG_PAPF,0.94,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-522,"Favouring a Pilocytic astrocytoma, CNS WHO grade 1 - see comment
","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1, with BRAF fusion
Histology: Favouring pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
KIAA1549-BRAF fusion (RNA seq.): Present
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 336\NH22-522,-0.024,0.001,0.042,0.024,-0.052,0.23,0.2,-0.024,-0.041,-0.054,0.147,0.003,0.028,0.049,0.003,-0.018,0.039,0.053,0.039,-0.041,-0.006,-0.031,-0.025,-0.046,-0.028,-0.081,-0.004,0.075,0.028,unmethylated
NH22-539,206053660073_R08C01,336,3/3/2022,3/16/2022,3/16/2022,13,AM,Diagnostic,336,1,NDP,NHNN,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,7/5/1952,70.7,myxopapillary ependymoma,1,EPN_MPE,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-539,"Myxopapillary ependymoma, CNS WHO grade 2 - see comment
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 336\NH22-539,-0.082,0.002,0.081,0.021,0.01,0.019,0.047,-0.015,-0.029,-0.06,-0.022,-0.001,0.063,0.038,0.235,0.248,0.018,0.069,0.015,-0.05,-0.055,0.032,0.004,-0.017,-0.05,-0.016,-0.026,-0.042,-0.02,methylated
NH22-520,206036370122_R01C01,337,4/3/2022,3/23/2022,3/23/2022,19,MD,Diagnostic,337,1,NDP,Nottingham University Hospital,Glioblastoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,5/22/1989,33.2,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.08,GBM_MES,0.2,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-520,"In keeping with Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
MGMT Promoter: Unmethylated (0%)  

Methylation profile: No matching methylation class
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 337\NH22-520,-0.066,0.001,0.072,-0.029,-0.031,0.388,-0.21,0.31,0.224,0.281,0.22,-0.452,-0.227,-0.452,0.029,0.068,-0.581,-0.396,0.057,-0.407,-0.054,-0.077,-0.433,-0.023,-0.5,0.2,-0.01,-0.515,-0.337,unmethylated
NH22-561,206036370122_R02C01,337,4/3/2022,3/23/2022,3/23/2022,19,AM,Diagnostic,337,1,NDP,Royal London Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/25/1991,31,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-561,"Glioma, IDH-mutant  See comment.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Equivocal (see comment)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Glioma, IDH-mutant
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 337\NH22-561,-0.051,-0.036,0.042,-0.011,0.044,-0.069,-0.056,-0.108,-0.019,-0.039,0.041,-0.018,-0.008,0.04,0.024,-0.019,-0.075,0.013,-0.028,0.001,-0.061,-0.11,-0.078,-0.006,-0.157,-0.02,0.024,0.01,-0.025,methylated
NH22-586,206036370122_R03C01,337,4/3/2022,3/23/2022,3/23/2022,19,AM,Diagnostic,337,1,NDP,Sheffield,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/9/1960,63,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.89,PXA,0.42,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-586,"Integrated diagnosis: Not reached
Histology: Glioma, NOS (see comment)
Methylation profile: Not contributory (see comment)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 337\NH22-586,-0.048,-0.011,0,-0.019,0.023,-0.003,-0.006,-0.137,-0.047,-0.053,0.015,0.025,-0.004,-0.017,0.073,-0.039,-0.034,-0.006,-0.037,0.003,-0.064,0.069,0.006,-0.022,-0.012,-0.011,0.038,-0.028,0.012,methylated
NH22-573,206036370122_R05C01,337,4/3/2022,3/23/2022,3/23/2022,19,AM,Diagnostic,337,1,NDP,Sheffield,"Astrocytoma, hypothalamus",(1) small biopsy or nonrepresentative sample;,B1,2/20/1987,35.5,supratentorial pilocytic astrocytoma,0.95,LGG_PA_GGST,0.56,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-573,"Integrated diagnosis: Favouring pilocytic astrocytoma, CNS WHO grade 1  see comment
Histology: Small biopsies suggestive of low-grade glioma 
Methylation profile: Suggestive of Pilocytic astrocytoma  see comment
MGMT promoter (Illumina array): Unmethylated   
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 337\NH22-573,-0.165,-0.113,0.13,-0.07,-0.005,0.058,-0.204,0.058,0.011,-0.151,0.017,0.093,0.193,0.034,0.086,-0.121,0.006,0.027,0.074,-0.042,-0.016,-0.043,0.02,-0.065,-0.005,-0.157,-0.069,-0.062,-0.076,unmethylated
NH22-572,206036370122_R06C01,337,4/3/2022,3/23/2022,3/23/2022,19,AM,Diagnostic,337,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,1/21/1976,46.7,"glioblastoma, IDH-wildtype, with primitive neuronal component",1,MB_SHHCHLAD,0.16,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-572,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 
Histology: High-grade glioma
Methylation profile: Suggestive of glioblastoma, IDH-wildtype (see comment)
IDH1/2Seq: No mutation          
EGFR: No amplification          
TERT promoter: Mutation
Histone H3F3A: No mutation
MGMT promoter (Illumina array): Unmethylated        
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 337\NH22-572,0.01,0.076,-0.002,0.018,0.047,0,-0.036,0.242,0.238,0.262,0.225,-0.014,-0.054,-0.029,-0.009,0.005,-0.489,-0.423,-0.11,-0.102,-0.024,1.904,-0.545,-0.066,-0.005,0.027,-0.137,-0.08,-0.027,unmethylated
NH22-563,206036370122_R07C01,337,4/3/2022,3/23/2022,3/23/2022,19,AM,Diagnostic,337,1,NDP,"Charing Cross Hospital, London",GBM,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A5,7/18/1970,52.4,"glioblastoma, IDH-wildtype, mesenchymal type",1,CONTR_INFLAM,0.09,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-563,"Integrated diagnosis: Possible Glioblastoma, IDH-wildtype, CNS WHO grade 4  see comment
Histology: Glioblastoma with sarcomatous change  see comment
Methylation profile: See comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 337\NH22-563,0.116,-0.004,0.03,0.08,0.011,0.042,-0.031,-0.03,0.097,0.078,0.086,0.185,0.177,0.185,-0.161,-0.037,-0.311,-0.012,-0.086,-0.141,-0.039,0.041,-0.047,-0.082,-0.07,0.008,-0.004,0.122,0.238,unmethylated
NH22-557,206036370122_R08C01,337,4/3/2022,3/23/2022,3/23/2022,19,AM,Diagnostic,337,1,NDP,"Birmingham, Queen Elizabeth Hospital",? LGG ? HGG (also see NH22-208),"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/12/1972,50,"glioblastoma, IDH-wildtype, mesenchymal type",0.12,GBM_MES,0.21,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-557,"Histology: Appearances compatible with residual/recurrent glioma along with radiotherapy related changes  see comment
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 337\NH22-557,-0.076,0.101,0.032,0.138,-0.065,0.001,-0.239,0.212,0.085,0.068,0.101,0.075,0.251,0.145,0.066,0.042,-0.214,-0.06,-0.049,0.043,-0.023,-0.057,0.011,-0.085,-0.12,-0.073,0.002,-0.105,-0.011,unmethylated
NH22-548,206036370162_R02C01,338,4/3/2022,3/25/2022,3/23/2022,19,AM,Diagnostic,338,10,NDP,NHNN,HGG,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,3/17/1998,24.3,"Diffuse paediatric-type high grade glioma, RTK1 subtype",1,GBM_MID,0.86,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-548,"High grade glioma, CNS WHO grade 4 - see comment.

IDH1 (R132H IHC): No mutation
ATRX (IHC): Equivocal (see comment) 
Further tests: Pending
","Integrated diagnosis: High grade glioma, H3-wildtype and IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma
Methylation profile: High grade glioma  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 338\NH22-548,-0.027,0.002,0.018,-0.007,-0.037,0.012,0.055,-0.001,0,-0.003,-0.024,-0.038,0.052,0.023,0.032,-0.003,0.027,0.091,0.041,0.005,-0.006,-0.032,0.018,-0.025,0.014,-0.017,-0.089,0.007,0.021,unmethylated
NH22-558,206036370162_R05C01,338,4/3/2022,3/25/2022,3/23/2022,19,AM,Diagnostic,338,6,NDP,NHNN,Spinal ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,7/29/1967,55.4,spinal ependymoma,1,EPN_SPINE,1,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-558,"Spinal Ependymoma, favouring CNS WHO grade 2 - See comment
","Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Spinal ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 338\NH22-558,-0.126,0.054,0.083,-0.011,0.022,0.073,-0.082,0.045,0.044,0.045,0.051,0.053,0.055,0.102,0.061,0.048,-0.105,-0.035,-0.068,0.037,0.017,0.062,-0.134,-0.133,-0.131,-0.144,-0.087,-0.095,-0.062,unmethylated
NH22-560,206036370162_R06C01,338,4/3/2022,3/25/2022,3/23/2022,19,MD,Diagnostic,338,4,NDP,"Cambridge, Addenbrooke's Hospital","Astrocytoma, IDH mutant","(5) Confirmation of rare, unusual or interesting histo-molecular results",PN22/136B2,8/9/1979,43.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.55,AIDH_HG,0.74,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-560,"Astrocytoma, IDH-mutant, CNS WHO grade 3
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained          
CDKN2A/B: No deletion          
MGMT Promoter: Methylated (>5-10%) 
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: IDH glioma, suggestive of subclass high grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 338\NH22-560,0.008,-0.202,-0.02,-0.046,0.081,-0.159,0.115,0.041,0.017,0.085,0.026,-0.003,0.098,0.326,0.028,0.03,-0.034,0.049,0.018,0.153,-0.113,-0.112,-0.203,-0.012,-0.029,-0.049,-0.13,-0.099,-0.057,methylated
NH22-625,206036370162_R08C01,338,9/3/2022,3/25/2022,3/23/2022,14,AM,Diagnostic,338,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A6,4/4/1955,67.9,pleomorphic xanthoastrocytoma(-like),1,PXA,0.75,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-625,"Integrated diagnosis: Pleomorphic xanthoastrocytoma, CNS WHO grade 3
Histology: High-grade glioma with features supportive of pleomorphic xanthoastrocytoma
Methylation profile: Pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 338\NH22-625,0.015,-0.023,-0.002,-0.033,-0.021,0.199,-0.537,-0.067,0.011,0.011,0.029,-0.014,0.086,0.007,-1.452,0.018,-0.011,0.011,0.004,-0.089,-0.025,0.088,-0.484,-0.042,0.137,0.037,0.013,-0.044,0.029,unmethylated
NH22-607,206036370160_R02C01,339,9/3/2022,3/25/2022,3/25/2022,16,AM,Diagnostic,339,1,NDP,"Cambridge, Addenbrooke's Hospital",Glioneuronal tumour,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,1/19/1998,24.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.17,CONTR_REACT,0.17,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-607,"Integrated diagnosis: Gliotic tissue  see comment
Histology: Gliotic tissue  see comment
Methylation profile: Inconclusive - see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 339\NH22-607,-0.043,-0.027,-0.011,-0.033,-0.046,0.001,0.006,-0.01,0.018,0.005,-0.008,-0.029,0.012,-0.048,-0.009,-0.026,-0.076,0.01,-0.018,-0.044,-0.02,0.013,-0.023,-0.075,-0.038,-0.041,0.042,-0.029,-0.028,unmethylated
NH22-611,206036370160_R03C01,339,9/3/2022,3/25/2022,3/25/2022,16,AM,Diagnostic,339,1,NDP,"Cardiff, University Hospital",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/13/1984,37.7,"control tissue, white matter (corpus callosum)",0.83,CONTR_HEMI,0.28,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-611,"Histology: Paucicellular CNS tissue  see comment
Methylation profile: Control tissue
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 339\NH22-611,-0.062,-0.027,-0.001,-0.006,-0.001,0.006,-0.107,0.007,0.025,0.006,-0.018,-0.006,0.089,-0.083,0.024,-0.011,0.002,0.019,-0.063,-0.071,0.045,0.065,0.037,0.012,0.008,0.038,0.028,-0.008,-0.022,unmethylated
NH22-609,206036370160_R05C01,339,9/3/2022,3/25/2022,3/25/2022,16,AM,Diagnostic,339,1,NDP,"Cardiff, University Hospital",Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,11/14/1997,24.6,myxopapillary ependymoma,1,EPN_MPE,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-609,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
","Integrated diagnosis: myxopapillary ependymoma, CNS WHO grade 2
MGMT promoter (MS PCR): methylated (range >0%-5%)
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 339\NH22-609,-0.028,0.006,0.067,0.021,-0.026,0.171,0.038,0.201,0.24,0.2,0.173,-0.003,0.056,-0.002,0.182,0.226,0.022,0.042,0.001,0.019,0.028,0.013,0.153,0.177,0.226,0.162,-0.053,-0.002,0.044,unmethylated
NH20-25,206036370160_R07C01,339,11/3/2022,3/25/2022,3/25/2022,14,MD,Diagnostic,339,1,NDP,Southampton General Hospital,"GBM, IDH-mutant ","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1C,2/12/1990,30.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-25,"Glioblastoma, IDH-mutant (WHO grade IV)
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, CNS WHO grade 4
Methylation profile: IDH glioma, subclass high grade astrocytoma
CDKN2A/B: No deletion
MGMT promoter (Illumina array): Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 339\NH20-25,0.038,-0.039,0.007,0.033,-0.013,0.068,0.067,-0.043,0.002,0.004,-0.006,-0.016,0.066,0.117,-0.019,0.015,-0.013,0.049,-0.067,-0.288,-0.05,-0.008,-0.456,-0.068,0.044,-0.001,-0.02,-0.024,0.048,methylated
NH22-469,206036370160_R08C01,339,14/03/2022,3/25/2022,3/25/2022,11,AM,Diagnostic,339,1,NDP,"Belfast, Royal Victoria Hospital",Pilocytic Astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B2,6/8/2012,9.8,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-469,"Low grade glial/glioneuronal tumour  see comment
","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glial/glioneuronal tumour favouring pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 339\NH22-469,-0.024,-0.021,0.028,0.009,-0.029,0.027,0.03,-0.026,0.026,-0.019,0.181,-0.012,0.07,0.055,0.033,0.001,0.007,0.012,0.03,-0.01,0.001,0.053,0.02,-0.012,0.026,0.005,-0.009,-0.035,-0.001,unmethylated
NH22-670,206036370156_R01C01,340,14/03/2022,3/30/2022,3/30/2022,16,AM,Diagnostic,340,4,NDP,Newcastle,? HGG ? Metastatic neuroendocrine tumour,"(2) unusual histology, location, demographics",3B,3/13/1962,60.9,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.12,GBM_RTKII,0.12,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-670,"Histology: In favour of metastatic carcinoma
Methylation profile: No matching methylation class  see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 340\NH22-670,-0.236,0.063,0.107,0.01,-0.02,-0.087,0.096,0.307,0.227,0.331,0.332,0.297,0.224,0.102,-0.151,0.054,-0.616,-0.354,-0.269,-0.044,1.911,2.945,-0.204,-0.071,-0.032,0.022,0.272,0.212,0.149,methylated
NH22-653,206036370156_R03C01,340,14/03/2022,3/30/2022,3/30/2022,16,AM,Diagnostic,340,1,NDP,"Cardiff, University Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B7,11/25/2004,17.5,pleomorphic xanthoastrocytoma(-like),1,PXA,0.99,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-653,"Integrated diagnosis: Pleomorphic xanthoastrocytoma, CNS WHO grade 3
Histology: High grade glial tumour
Methylation profile: Pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 340\NH22-653,-0.113,0.019,0.138,-0.181,-0.066,0.083,-0.529,0.113,0.151,0.069,0.105,0.15,0.222,0.118,-1.538,-0.044,-0.388,-0.332,0.087,0.135,0.102,0.184,0.027,-0.107,-0.158,-0.074,0.101,-0.024,-0.027,unmethylated
NH22-567,206036370156_R05C01,340,14/03/2022,3/30/2022,3/30/2022,16,AM,Diagnostic,340,1,NDP,NHNN,IDH-mutant astrocytoma (recurrent),"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,3/11/1984,38.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-567,"Astrocytoma, IDH-mutant, CNS WHO grade 2 - see comment.

IDH1 (R132H IHC): Negative; C394A mutation detected in NH14-633
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending

","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Recurrent / residual astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 340\NH22-567,-0.027,-0.017,0.034,-0.082,0.014,0.035,-0.035,-0.032,-0.029,-0.034,-0.017,0.015,0.093,0.182,-0.005,0.018,-0.01,0.083,0.012,-0.027,-0.039,-0.064,-0.055,-0.026,-0.053,0.032,0.021,0.003,-0.01,methylated
NH14-633,206036370156_R06C01,340,14/03/2022,3/30/2022,3/30/2022,16,AM,Diagnostic,340,1,NDP,NHNN,IDH-mutant glioma (primary),"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1B,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.8,AIDH,0.94,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-633,"Oligodendroglioma (WHO Grade II); IDH1 (R132H) negative  see comment
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Glioma, CNS WHO grade 2
Methylation profile: IDH glioma, subclass astrocytoma  see comment
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 340\NH14-633,-0.06,-0.048,0.052,-0.001,-0.022,0.057,-0.011,-0.037,-0.095,-0.002,-0.047,-0.028,-0.004,-0.064,-0.046,-0.045,-0.005,0.027,-0.02,-0.104,-0.089,-0.104,-0.055,-0.102,-0.117,-0.047,-0.148,-0.067,-0.014,methylated
NH22-639,206036370156_R08C01,340,16/03/2022,3/30/2022,3/30/2022,14,MD,Diagnostic,340,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,11/23/2018,3.3,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-639,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Low grade glioma, subclass posterior fossa pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 340\NH22-639,0.002,-0.026,0.02,-0.014,-0.062,-0.006,0.002,-0.027,-0.015,-0.061,0.128,-0.003,0.055,0.006,0.032,0.004,0.014,0.026,-0.003,-0.028,-0.027,0.048,0.067,-0.019,0.021,0.025,-0.052,-0.002,0.036,unmethylated
NH22-709,206154250072_R01C01,343,18/03/2022,4/6/2022,4/6/2022,19,AM,Diagnostic,343,1,NDP,Royal London Hospital,HGG,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1B,10/28/1954,68.4,"glioblastoma, IDH-wildtype, RTK2 type",0.97,GBM_RTKII,0.96,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-709,"Favouring a Glioblastoma, CNS WHO grade 4 (see comment)
IDH1 (R132H IHC): No mutation      
ATRX (IHC): Retained      
Further molecular tests: Pending 
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO Grade 4
Histology: Glioblastoma, CNS WHO Grade 4
Methylation profile: Glioblastoma IDH wildtype, subclass RTK I
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 343\NH22-709,-0.025,0.031,0.009,-0.007,-0.003,0.114,-0.024,1.564,0.25,0.254,0.213,-0.024,0.065,0.02,-1.438,-0.009,-0.393,-0.317,-0.059,-0.031,-0.03,0.045,-0.065,0.021,0.015,0.018,0.061,-0.093,-0.008,methylated
NH22-579,206154250072_R04C01,343,22/03/2022,4/6/2022,4/6/2022,15,AM,Diagnostic,343,1,NDP,St George's Hospital London,Glioma ? GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/27/1959,63.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.98,GBM_MES,0.85,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-579,"Glioma, IDH-wildtype  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: No amplification          
TERT promoter: Mutation
MGMT Promoter: Methylated (>10-25%)   
","See previous report. 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 343\NH22-579,0.024,-0.038,0.048,0.014,-0.032,0.024,0.048,0.081,0.076,0.051,0.061,-0.022,0.11,0.026,-0.129,0.004,-0.136,-0.111,-0.005,0.001,0.023,0.004,0.016,-0.008,0.008,0.009,0.077,0.015,0.046,methylated
NH22-727,206154250072_R05C01,343,22/03/2022,4/6/2022,4/6/2022,15,AM,Diagnostic,343,1,NDP,Newcastle,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",4A,9/25/1948,74.5,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.46,LGG_DNT,0.41,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-727,"Integrated diagnosis: Favouring low grade glial/glioneuronal tumour  see comment
Histology: Glioma  see comment
Methylation profile: See comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 343\NH22-727,0.369,-0.016,-0.048,-0.143,0.344,-0.237,-0.239,-0.008,-0.019,-0.163,0.099,0.092,0.034,0.148,-0.04,0.19,-0.123,-0.131,0.367,0.289,0.111,0.135,-0.021,0.306,0.112,0.146,0.032,0.068,0.176,unmethylated
NH22-723,206154250072_R07C01,343,22/03/2022,4/6/2022,4/6/2022,15,AM,Diagnostic,343,1,NDP,NHNN,IDH-mutant glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,3/1/1974,48.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.97,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-723,"Favouring an Astrocytoma, IDH-mutant, CNS WHO grade 2 (see comment)  

IDH1 (R132H IHC): Mutation 
ATRX (IHC): Interpreted as lost (see comment) 
Further molecular tests: Pending 
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO Grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO Grade 2
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 343\NH22-723,-0.006,-0.054,0.037,-0.034,0,-0.058,-0.004,0.009,-0.05,0.011,0.003,0.005,0.094,0.3,-0.01,0.141,0.041,-0.059,0.007,0.062,-0.007,0.03,-0.106,0,-0.073,0.067,-0.048,0.021,0.079,methylated
NH22-720,206154250072_R08C01,343,22/03/2022,4/6/2022,4/6/2022,15,AM,Diagnostic,343,1,NDP,NHNN,"Glioma, nos","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,3/19/1989,33.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.94,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-720,"Glioma  See comment.
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Possible loss of expression (see comment)
Further molecular tests: Pending    
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Diffuse glioma, corresponding to CNS WHO grade 3
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 343\NH22-720,-0.034,0.146,0.044,-0.006,0.025,0.055,-0.03,-0.01,0.019,0.038,0.01,-0.012,0.041,0.027,-0.199,0.004,0.004,0.14,0.098,0.421,-0.004,-0.034,-0.2,0.001,-0.006,-0.01,-0.193,0.006,0.004,unmethylated
NH22-747,206154250074_R01C01,344,22/03/2022,4/6/2022,4/6/2022,15,AM,Diagnostic,344,1,NDP,NHNN,IDH-mutant glioma,"(4) IHC, sequencing, or copy number assay ambiguous",DEF1A,8/21/1998,23.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-747,"Glioma, IDH-mutant - see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Equivocal (see comment)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Diffuse glioma, IDH mutant
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 344\NH22-747,-0.023,0.009,0.039,-0.008,0.019,-0.009,-0.094,0.016,0.093,0.038,0.108,-0.018,0.036,0.145,-0.05,0.039,0.024,-0.049,0.008,0.038,-0.035,0.021,-0.057,0.003,0.03,0.005,-0.093,0.028,0.034,methylated
NH22-785,206154250074_R05C01,344,23/03/2022,4/6/2022,4/6/2022,14,AM,Diagnostic,344,2,NDP,Romford,IDH-mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,4/20/1974,40.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.95,AIDH,0.98,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-785,"Astrocytoma, IDH-mutant (see comment) 
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 344\NH22-785,0.128,-0.016,0.033,-0.03,0.061,0.004,-0.089,0.033,0.2,0.287,0.244,-0.039,-0.014,0.119,0.077,0.034,-0.506,-0.05,0.031,0.004,0.023,-0.009,-0.06,-0.49,-0.122,-0.064,0.018,-0.002,0.07,methylated
NH22-794,206154250074_R08C01,344,24/03/2022,4/6/2022,4/6/2022,13,AM,Diagnostic,344,1,NDP,Nottingham University Hospital,Malignant neuroepithelial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/24/1963,59.1,"glioblastoma, IDH-wildtype, RTK1 type",0.97,GBM_RTKI,0.9,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-794,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK II
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 344\NH22-794,1.702,0.042,0.04,0.019,0.057,-0.03,-0.07,1.624,0.041,-0.142,0.047,-0.021,0.022,0.023,-2.037,0.066,-0.496,-0.45,-0.011,0.032,0.055,0.022,-0.561,-0.023,0.005,-0.016,-0.102,-0.111,-0.432,unmethylated
NH22-792,206154250110_R01C01,345,24/03/2022,4/8/2022,4/8/2022,15,AM,Diagnostic,345,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B2,1/20/2005,17.4,infratentorial pilocytic astrocytoma,0.9,LGG_PAPF,0.87,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-792,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, infratentorial
MGMT promoter (Illumina array): Unmethylated 
  
","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, infratentorial  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 345\NH22-792,0.151,0.134,0.117,0.084,0.226,0.051,-0.117,-0.377,-0.232,-0.231,0.319,0.131,0.176,0.102,-0.147,0.067,-0.26,-0.033,0.059,-0.05,-0.07,0.162,-0.142,0.005,-0.497,-0.166,0.304,0.046,0.002,unmethylated
NH22-804,206154250110_R03C01,345,24/03/2022,4/8/2022,4/8/2022,15,AM,Diagnostic,345,1,NDP,"Cambridge, Addenbrooke's Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/12/1987,35.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-804,"Integrated diagnosis: Astrocytoma, IDH-mutant, favouring CNS WHO grade 2  see comment
Histology: Astrocytoma, favouring CNS WHO grade 2  see comment
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, favouring CNS WHO grade 2
Methylation profile: IDH glioma, subclass astrocytoma 
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 345\NH22-804,-0.122,-0.168,0.107,0.087,-0.015,0.073,-0.216,-0.309,-0.134,-0.274,0.024,0.049,0.201,-0.188,-0.227,-0.071,-0.007,-0.327,-0.14,-0.072,-0.199,-0.136,-0.073,-0.138,-0.407,-0.496,0.334,-0.174,-0.139,unmethylated
NH22-803,206154250110_R04C01,345,24/03/2022,4/8/2022,4/8/2022,15,AM,Diagnostic,345,1,NDP,"Cambridge, Addenbrooke's Hospital",LGGNT,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",D1,8/9/2000,21.9,dysembryoplastic neuroepithelial tumour,0.95,LGG_DNT,0.78,0.94,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-803,"Integrated diagnosis: Favouring dysembryoplastic glioneuronal tumour, CNS WHO grade 1
Histology: Low grade glial/glioneuronal tumour
Methylation profile: Dysembryoplastic neuroepithelial tumour  see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 345\NH22-803,-0.033,0.179,0.184,0.002,-0.097,-0.078,-0.129,0.035,-0.305,-0.375,-0.09,0.054,0.368,-0.403,-0.286,-0.079,0.004,0.146,0.011,-0.074,-0.2,-0.206,0.041,-0.012,-0.123,-0.057,0.02,-0.416,-0.132,unmethylated
NH22-582,206154250110_R05C01,345,24/03/2022,4/8/2022,4/8/2022,15,AM,Diagnostic,345,1,NDP,St George's Hospital London,Glioma ?GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,11/8/1960,62.2,"glioblastoma, IDH-wildtype, RTK2 type",0.45,GBM_MES,0.59,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-582,"Molecular features of a Glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment)

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: Amplification          
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma
Methylation profile: See comment
MGMT promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 345\NH22-582,0.664,0.137,0.061,0.164,0.1,-0.028,-0.397,1.212,0.136,0.08,0.262,0.03,0.268,-0.188,-1.291,-0.073,-0.702,-0.383,-0.057,-0.049,0.006,0.081,-0.023,0.011,-0.082,-0.209,0.339,-0.137,-0.019,unmethylated
NH22-768,206154250110_R06C01,345,24/03/2022,4/8/2022,4/8/2022,15,AM,Diagnostic,345,1,NDP,Wellington Hospital London,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,1/23/1971,51.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.88,AIDH,0.89,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-768,"Glioma  See comment.
IDH1 (R132H IHC): Not satisfactory for interpretation         
ATRX (IHC): Not satisfactory for interpretation       
Further molecular tests: Pending  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Glioma
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 345\NH22-768,-0.118,-0.177,0.148,0.099,-0.052,0.104,-0.123,-0.572,-0.24,-0.363,0.043,0.032,0.139,-0.356,-0.513,-0.149,-0.341,-0.018,-0.16,-0.066,-0.189,-0.173,-0.131,-0.203,-0.107,-0.128,0.493,-0.171,-0.079,methylated
NH22-805,206154250110_R08C01,345,25/03/2022,4/8/2022,4/8/2022,14,AM,Diagnostic,345,2,NDP,"Leeds, St James's University Hospital",Anaplastic ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,11/28/2011,5,posterior fossa ependymoma group A1,0.1,EPN_PFA,0.05,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-805,"Integrated diagnosis: Posterior fossa group A (PFA) ependymoma
Histology: Posterior fossa group A (PFA) ependymoma
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
","Integrated diagnosis: Posterior fossa group A (PFA) ependymoma
Histology: Suggestive of posterior fossa group A ependymoma (see comment)
Methylation profile: Posterior fossa group A ependymoma (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 345\NH22-805,-0.604,0.182,0.131,0.126,-0.194,0.304,-0.176,-0.363,-0.457,-0.24,-0.121,0.069,-0.066,-0.614,0.163,-0.091,-0.362,0.119,-0.302,-0.37,-0.811,0.008,-0.081,-0.317,-0.207,-0.484,0.609,-0.391,-0.009,unmethylated
NH22-823,206154250071_R01C01,347,28/03/2022,4/8/2022,4/8/2022,11,ZJ,Diagnostic,347,1,NDP,Hull,Oligo since 2009 (any other entity?),"(2) unusual histology, location, demographics",A,11/28/1984,24.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.79,AIDH_HG,0.58,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-823,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3 (see comment)
Histology: Astrocytoma
Methylation profile: Astrocytoma, IDH-mutant, high grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 347\NH22-823,-0.043,-0.026,0.027,0,0.034,0.046,-0.106,-0.105,-0.178,-0.122,-0.045,-0.005,-0.049,0.24,-0.233,0.038,-0.122,-0.232,-0.03,0.093,0.032,0.052,-0.191,0.059,-0.081,-0.115,-0.278,-0.129,-0.074,methylated
NH22-828,206154250071_R02C01,347,28/03/2022,4/8/2022,4/8/2022,11,ZJ,Diagnostic,347,1,NDP,Oxford John Radcliffe Hospital,Spinal ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A,10/7/1973,49.1,myxopapillary ependymoma,1,EPN_MPE,1,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-828,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Ependymal tumour
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 347\NH22-828,0.047,-0.021,0.107,-0.012,-0.015,-0.047,-0.034,-0.046,-0.02,-0.08,-0.026,0.016,-0.007,-0.006,-0.031,0.07,-0.016,0.025,-0.018,0.041,0.067,-0.051,-0.037,0.024,-0.044,-0.085,0.007,-0.037,-0.042,unmethylated
NH22-841,206154250071_R06C01,347,30/03/2022,4/8/2022,4/8/2022,9,ZJ,Diagnostic,347,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG or sarcoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,4/17/1974,48.6,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.84,GBM_MYCN,0.36,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-841,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4.
Histology: High-grade glioma, with features of glioblastoma.
Methylation profile: Diffuse Paediatric-type high-grade glioma, MYCN subtype.
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 347\NH22-841,0.447,-0.064,-0.046,0.008,-0.035,0.152,-0.003,1.458,0.4,0.452,0.337,0.16,0.15,0.219,0.022,-0.012,-1.846,-0.236,-0.059,0.008,0.008,0.152,-0.357,0.038,0.068,-0.004,0.021,-0.289,-0.285,unmethylated
NH22-800,206154250035_R01C01,348,31/03/2022,4/22/2022,4/22/2022,22,ZJ,Diagnostic,348,1,NDP,Royal London Hospital,"Glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,5/31/1985,37.3,ganglioglioma,0.96,LGG_GG,0.54,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-800,"Glioma - See comment.
","Glioma with FGFR3:TACC3 fusion - see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained               
TERT promoter: Mutation
FGFR-TACC3: Fusion
MGMT Promoter: Unmethylated (0%)
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 348\NH22-800,-0.061,0.008,0.035,0.108,-0.09,-0.009,0.003,0.144,0.124,0.078,0.068,-0.005,0.089,0.066,-0.007,0.013,-0.106,-0.085,0.035,0.009,0.005,-0.024,0.023,-0.014,-0.015,0.001,0.051,-0.145,-0.036,unmethylated
NH22-847,206154250035_R02C01,348,31/03/2022,4/22/2022,4/22/2022,22,ZJ,Diagnostic,348,1,NDP,HCA,"HGG, recurrent","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,10/23/1967,55.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.48,GBM_MES,0.49,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-847,"High-grade glioma, IDH-wildtype, at least CNS WHO grade 3 (see comment)
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma, IDH-wild-type
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 348\NH22-847,0.017,0.052,0.018,-0.073,-0.075,-0.034,-0.031,0.281,0.289,0.265,0.244,0.018,0.103,0.084,-0.939,0.055,-0.168,-0.166,0.076,0.033,0.078,0.047,0,0.038,-0.106,0.027,-0.027,-0.023,0.11,unmethylated
NH22-858,206154250035_R04C01,348,31/03/2022,4/22/2022,4/22/2022,22,ZJ,Diagnostic,348,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",C2,4/27/1998,24.3,supratentorial midline pilocytic astrocytoma,0.88,LGG_PAMID,0.98,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-858,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Low-grade glioma, subclass midline pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 348\NH22-858,-0.01,-0.012,0.005,-0.008,-0.015,0.087,-0.055,-0.047,0.04,-0.014,0.18,-0.005,-0.038,0.06,-0.018,-0.004,-0.013,-0.003,0.085,0.012,-0.032,0.016,-0.013,-0.019,0.033,-0.011,0.052,-0.026,0.028,unmethylated
NH22-860,206154250035_R05C01,348,31/03/2022,4/22/2022,4/22/2022,22,ZJ,Diagnostic,348,1,NDP,Nottingham University Hospital,"Recurrent neuroepithelial tumour, nos","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/7/1958,64.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.56,PXA,0.73,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-860,"Integrated diagnosis: High-grade glioma, possibly representing pleomorphic xanthoastrocytoma.
Histology: High-grade glioma with extensive inflammation and macrophage infiltration 
Methylation profile: No matching methylation class, see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 348\NH22-860,0.012,0.161,0.138,-0.043,-0.02,0.1,-0.211,0.277,0.283,0.322,0.226,0.019,0.114,0.046,-0.059,-0.081,-0.014,0.057,-0.096,0.038,0.058,0.061,-0.127,-0.107,-0.253,-0.166,0.104,-0.153,-0.051,unmethylated
NH22-861,206154250035_R06C01,348,31/03/2022,4/22/2022,4/22/2022,22,ZJ,Diagnostic,348,1,NDP,Nottingham University Hospital,"ATRX-mutant glioma, nos","(4) IHC, sequencing, or copy number assay ambiguous",A1,7/10/1977,45.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.97,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-861,"Astrocytoma, CNS WHO grade 2 (see comment)

MGMT Promoter: Methylated (>0-5%)


","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 348\NH22-861,0.09,0.014,0.08,-0.023,-0.011,0.108,0.014,0.09,0.186,0.174,0.175,0.017,0.114,0.221,-0.224,0.107,-0.026,-0.021,0.148,0.144,0.026,0.022,-0.115,0.04,0.009,0.012,-0.122,-0.066,-0.032,methylated
NH22-851,206154250035_R07C01,348,1/4/2022,4/22/2022,4/22/2022,21,MD,Diagnostic,348,1,NDP,Romford,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A4,6/30/1967,55.5,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.97,OIDH,0.97,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-851,"Oligodendroglioma, IDH-mutant, CNS WHO grade 2.
IDH1 (R132H IHC):  Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 348\NH22-851,-0.016,0.038,0.037,-0.012,0.034,0.023,-0.025,-0.037,-0.012,-0.038,0.029,0.002,0.026,0.061,-0.147,0.008,-0.06,-0.025,0.018,-0.014,0.001,0.002,-0.124,-0.028,0,-0.035,-0.185,-0.044,0.019,methylated
NH22-877,206154080106_R01C01,349,1/4/2022,4/22/2022,4/22/2022,21,ZJ,Diagnostic,349,1,NDP,Southampton General Hospital,"LGG, nos","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,11/20/1969,53.1,spinal subependymoma [subtype A],0.97,SUBEPN_SPINE,0.73,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-877,"Integrated diagnosis: Subependymoma, spinal, CNS WHO grade 1
Histology: Low grade glioma
Methylation profile: Subependymoma, spinal, subtype A
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 349\NH22-877,-0.002,-0.048,0.035,0.094,-0.011,0.01,-0.035,-0.064,0.018,-0.053,-0.009,-0.065,0.083,0.007,-0.095,0.01,-0.003,0.082,0.077,0,-0.005,0.109,0.047,-0.082,0.053,0.009,0.099,-0.056,0.065,unmethylated
NH22-868,206154080106_R02C01,349,1/4/2022,4/22/2022,4/22/2022,21,ZJ,Diagnostic,349,1,NDP,St George's Hospital London,"Astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B2,8/24/1985,37.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-868,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, no high-grade features
Methylation profile: Astrocytoma, IDH-mutant, low grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 349\NH22-868,-0.417,-0.022,0.036,-0.041,-0.002,0.092,-0.004,0.004,0.02,0.233,0.204,-0.014,0.014,0.039,-1.019,0.029,-0.026,-0.06,0.068,-0.019,-0.018,0.021,-0.039,0.025,0.081,0.043,-0.003,-0.039,-0.007,methylated
NH22-685,206154080106_R05C01,349,5/4/2022,4/22/2022,4/22/2022,17,MD,Diagnostic,349,2,NDP,NHNN,Ganglioglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",FEF7A,9/18/1991,30.9,ganglioglioma,0.78,LGG_GG,0.57,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-685,"
Ganglioglioma, CNS WHO grade 1
Hippocampal sclerosis  probably ILAE subtype 1
","Integrated diagnosis: Ganglioglioma, CNS WHO grade 1
Histology: Ganglioglioma, CNS WHO grade 1
Methylation profile: Low-grade glioma, ganglioglioma
MGMT promoter (Illumina array): Unmethylated 

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 349\NH22-685,-0.019,0.003,0.03,0.026,-0.011,-0.009,0,0,0.037,-0.017,0,-0.02,0.065,0.019,0.015,0.01,-0.006,0.006,-0.022,0.008,-0.037,-0.023,0.005,-0.001,-0.023,-0.036,-0.029,-0.016,0.006,unmethylated
NH22-583,206154080106_R06C01,349,5/4/2022,4/22/2022,4/22/2022,17,MD,Diagnostic,349,1,NDP,St George's Hospital London,LGG,(1) small biopsy or nonrepresentative sample;,B1,9/18/2018,3.5,dysembryoplastic neuroepithelial tumour,0.61,LGG_DNT,0.96,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-583,"Integrated diagnosis: Dysembryoplastic neuroepithelial tumour, CNS WHO grade 1
Histology: Low grade glial/glioneuronal tumour with features supportive of dysembryoplastic neuroepithelial tumour
Methylation profile: Low grade glioma, dysembryoplastic neuroepithelial tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 349\NH22-583,0.071,0.016,0.013,-0.019,-0.033,0.018,-0.072,-0.037,0.005,-0.113,0.004,0.041,0.114,-0.007,0.02,0.036,-0.002,0.027,0.057,0,0.031,0.05,0.028,0.029,0.03,0.041,-0.015,0.019,0.069,unmethylated
NH22-857,206154080106_R08C01,349,11/4/2022,4/22/2022,4/22/2022,11,MD,Diagnostic,349,1,NDP,NHNN,Recurrent GBM,"(5) Confirmation of rare, unusual or interesting histo-molecular results",SP2A,8/4/1992,30.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.58,AIDH,0.86,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-857,"Astrocytoma, IDH-mutant, CNS WHO grade 4 (see comment)
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending

","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4 (but see comment regarding grading)
Histology: Astrocytoma, IDH mutant, CNS WHO grade 4
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 349\NH22-857,-0.029,0.016,0.057,-0.031,0.003,0.041,-0.309,0.006,-0.019,-0.059,-0.028,0.003,0.052,0.005,0.006,-0.017,0.017,0.05,0.022,0.19,-0.046,-0.021,-0.02,0.002,-0.024,-0.023,-0.324,0.071,-0.004,methylated
NH22-908,206154080119_R01C01,350,11/4/2022,4/22/2022,4/22/2022,11,MD,Diagnostic,350,1,NDP,"Liverpool, The Walton Centre",High grade glioma,(1) small biopsy or nonrepresentative sample;,1A,12/21/1968,54.1,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.81,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-908,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma
Methylation profile: Glioblastoma, IDH-wildtype, RTK2
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 350\NH22-908,0.007,0.054,0.062,0.04,0.119,0,-0.001,0.503,0.581,0.508,0.423,-0.031,0.025,-0.012,-0.01,0.066,-0.445,-0.442,0.023,0.085,0.823,2.012,-0.066,-0.003,0.032,-0.03,-0.012,-0.04,0.049,unmethylated
NH22-914,206154080119_R02C01,350,11/4/2022,4/22/2022,4/22/2022,11,MD,Diagnostic,350,1,NDP,Nottingham University Hospital,Pineal cyst?,(1) small biopsy or nonrepresentative sample;,A1,1/12/2004,18.5,posterior fossa ependymoma group A1,0.12,HMB,0.14,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-914,"Integrated diagnosis: Gliotic membrane, in keeping with elements of pineal cyst
Histology: Gliotic , in keeping with elements of pineal cyst
Methylation profile: No matching methylation class

",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 350\NH22-914,-0.051,0.034,0.04,-0.053,-0.009,0.028,-0.069,-0.004,0.005,-0.038,-0.031,0.003,0.172,0.063,0.015,-0.011,0.07,0.044,0.024,-0.055,-0.021,0.024,0.016,0.034,-0.066,-0.062,0.014,-0.025,-0.012,unmethylated
NH22-910,206154080119_R03C01,350,11/4/2022,4/22/2022,4/22/2022,11,MD,Diagnostic,350,2,NDP,"Cardiff, University Hospital","High grade glioma, IDH-mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,2/22/1994,28.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.97,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-910,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant with high-grade features (corresponding to CNS WHO grade 3, see comment)
Methylation profile: IDH glioma, subclass high-grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 350\NH22-910,-0.005,-0.009,0.077,-0.044,0.003,0.046,-0.129,0.053,0.019,0.327,-0.004,0.388,0.211,0.179,-1.345,0.047,-0.116,-0.101,0.08,0.049,0.056,0.018,-0.065,0.056,0.035,0.01,-0.448,0.01,-0.006,methylated
NH22-909,206154080119_R05C01,350,11/4/2022,4/22/2022,4/22/2022,11,MD,Diagnostic,350,1,NDP,Southampton General Hospital,Meningioma? Astroblastoma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3C,10/17/1995,26.8,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.36,PXA,0.2,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-909,"Integrated diagnosis: High-grade glioma, no matching methylation class
Histology: High-grade glioma
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
","Glioblastoma, BRAFV600E-mutant, CNS WHO grade 4 - see comment
CDKN2A/B (Illumina array): Deletion
BRAF (V600E IHC and Seq): Mutation
MGMT Promoter (Illumina array): Unmethylated
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 350\NH22-909,-0.03,0.078,0.326,-0.025,0.04,0.228,-0.031,0.416,0.428,0.449,0.39,-0.008,0.067,0.052,-1.942,0.469,-0.025,0.077,0.047,0.269,0.197,0.251,-0.055,-0.04,-0.123,-0.072,0.459,-0.035,0.042,unmethylated
NH22-905,206154080119_R07C01,350,11/4/2022,4/22/2022,4/22/2022,11,MD,Diagnostic,350,2,NDP,Latvia,Pleomorphic xanthoastrocytoma,(1) small biopsy or nonrepresentative sample;,1150,8/15/2006,15.8,pleomorphic xanthoastrocytoma(-like),0.79,PXA,0.85,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-905,"Integrated diagnosis: Pleomorphic xanthoastrocytoma, BRAF V600E-mutant, CNS WHO grade 2
Histology: Pleomorphic xanthoastrocytoma, CNS WHO grade 2
Methylation profile: Pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 350\NH22-905,-0.082,0,0.013,-0.03,-0.037,0.06,0.014,0.002,0.041,-0.019,0.009,-0.014,0.04,-0.002,-0.301,-0.111,0.013,0.087,-0.034,-0.007,0.002,0.006,-0.03,-0.028,0.003,-0.019,0.035,-0.053,-0.01,unmethylated
NH22-892,206154080118_R02C01,351,11/4/2022,4/27/2022,4/27/2022,16,MD,Diagnostic,351,1,NDP,NHNN,"Oligodendroglioma, IDH-mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1C,4/9/1950,73,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.94,OIDH,0.53,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-892,"Oligodendroglioma, IDH mutant, CNS WHO grade 3  see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
H3K27me3 (IHC): loss in some areas and retained others
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 3
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 351\NH22-892,0.006,-0.015,0,-0.008,0.041,0.029,-0.027,0.009,-0.012,0.012,0.003,-0.01,-0.025,0.001,-0.466,-0.008,-0.008,0.037,-0.049,-0.026,-0.008,-0.028,-0.066,0.021,0.009,0.017,-0.462,0.016,0.016,methylated
NH22-912,206154080118_R04C01,351,11/4/2022,4/27/2022,4/27/2022,16,MD,Diagnostic,351,1,NDP,Nottingham University Hospital,Ganglioglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C1,7/26/2003,19,supratentorial pilocytic astrocytoma,0.53,DLGNT,0.32,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-912,"Integrated diagnosis: Low grade glioma, with features compatible with a pilocytic astrocytoma
Histology: Low grade glioma.
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 351\NH22-912,-0.002,0.038,-0.013,-0.051,-0.087,-0.058,-0.038,0.014,0.096,0.071,0.04,0.004,0.063,0.066,0.079,0.014,0.003,-0.038,0.023,-0.053,-0.06,-0.126,-0.114,-0.168,-0.136,-0.019,-0.123,-0.094,-0.076,unmethylated
NH22-934,206154080118_R05C01,351,11/4/2022,4/27/2022,4/27/2022,16,MD,Diagnostic,351,1,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1B,1/1/1984,38.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-934,"Astrocytoma, CNS WHO grade 2, see comment.
IDH1 (R132H IHC): No mutation (see comment)
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 351\NH22-934,0.019,-0.059,0.033,0.018,0.035,0.017,-0.018,-0.003,-0.036,-0.038,-0.016,0.183,0.209,0.175,-0.127,-0.067,0.049,0.033,0.22,-0.019,0.008,-0.029,-0.149,0.001,-0.009,-0.018,-0.128,0.021,0.003,methylated
NH22-923,206154080118_R06C01,351,13/04/2022,4/27/2022,4/27/2022,14,MD,Diagnostic,351,1,NDP,NHNN,Astrocytic glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/21/1973,49.8,ganglioglioma,0.64,GBM_MES,0.28,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-923,"Astrocytic glioma, grading see comment 
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained
Further molecular tests: Pending  
","Integrated diagnosis: Diffuse glioma, no matching methylation class, see comment
Histology: Diffuse astrocytic glioma
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 351\NH22-923,-0.059,0.009,0.058,-0.025,-0.033,0.046,-0.012,0.135,0.119,0.122,0.117,-0.012,0.057,0.045,0.064,0.012,-0.071,-0.092,-0.005,-0.041,-0.036,0.033,0.016,-0.011,-0.186,0.003,0.012,-0.064,-0.095,unmethylated
NH22-950,206154080118_R07C01,351,13/04/2022,4/27/2022,4/27/2022,14,MD,Diagnostic,351,2,NDP,NHNN,Astrocytoma,(1) small biopsy or nonrepresentative sample;,DEF1A,1/29/1990,32.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.98,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-950,"Astrocytoma IDH mutant, CNS WHO grade 3 (at least)  see comment.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, grading see comment
Methylation profile: Astrocytoma, IDH-mutant, high grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 351\NH22-950,-0.056,-0.488,0.045,0.013,0.807,0.063,-0.214,-0.008,-0.006,0.022,-0.01,-0.036,0.039,0.237,-0.421,0.091,-0.097,-0.337,0.237,-0.03,0.701,0.002,-0.003,-0.049,-0.001,-0.004,-0.056,-0.028,-0.014,methylated
NH22-955,206154080118_R08C01,351,13/04/2022,4/27/2022,4/27/2022,14,MD,Diagnostic,351,1,NDP,Royal National Orthopaedic Hosp.,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",RNOH 2,9/1/1979,43.2,myxopapillary ependymoma,0.96,EPN_MPE,0.99,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-955,"Myxopapillary ependymoma, CNS WHO grade 2.
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 351\NH22-955,0.025,-0.252,-0.089,0.073,0.058,0.109,-0.187,0.161,0.205,0.186,0.149,0.14,0.198,0.188,0.48,0.484,-0.016,-0.081,0.022,0.062,0.157,0.161,0.016,-0.161,-0.197,-0.06,0.264,-0.171,-0.088,unmethylated
NH22-981,206154080043_R01C01,352,13/04/2022,4/27/2022,4/27/2022,14,MD,Diagnostic,352,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,(1) small biopsy or nonrepresentative sample;,A1,6/10/2009,13,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.78,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-981,"Pilocytic astrocytoma, CNS WHO grade 1
KIAA1549-BRAF fusions: No fusions between 16_9, 16_11, 15_9 exons 
BRAF (V600E): No mutation     

","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, hemispheric
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 352\NH22-981,0.015,0.011,-0.005,0.014,-0.03,0.021,0.19,0.24,0.227,0.168,0.149,0.159,0.193,0.217,0.009,-0.017,0.033,0.057,0.208,0.043,-0.027,0.105,0.004,0.068,-0.028,-0.031,-0.027,0.004,0.023,unmethylated
NH22-982,206154080043_R03C01,352,13/04/2022,4/27/2022,4/27/2022,14,MD,Diagnostic,352,1,NDP,Oxford John Radcliffe Hospital,Diffuse glioma,(1) small biopsy or nonrepresentative sample;,1,6/6/1965,57.7,"glioblastoma, IDH-wildtype, mesenchymal type",0.94,GBM_MES,0.79,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-982,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 352\NH22-982,0.051,-0.017,0.005,0.012,-0.053,0.03,-0.02,0.216,0.238,0.259,0.209,-0.025,0.036,0.072,-0.137,-0.227,-0.194,-0.183,-0.061,-0.085,-0.093,-0.055,-0.009,0.043,-0.031,0.016,-0.024,-0.188,-0.154,unmethylated
NH22-974,206154080043_R04C01,352,13/04/2022,4/27/2022,4/27/2022,14,MD,Diagnostic,352,1,NDP,"Belfast, Royal Victoria Hospital",Glioneural tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/20/1975,47.2,supratentorial midline pilocytic astrocytoma,0.74,LGG_PAMID,0.62,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-974,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, midline
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 352\NH22-974,0.006,-0.033,-0.007,-0.003,0.001,0.013,-0.029,-0.072,-0.051,-0.082,-0.018,-0.007,0.059,-0.005,0.081,0.005,0.027,0.043,0.03,-0.051,-0.026,0.072,0.012,-0.014,0.009,0.049,-0.015,-0.042,0.061,methylated
NH22-866,206154080043_R05C01,352,14/04/2022,4/27/2022,4/27/2022,13,MD,Diagnostic,352,1,NDP,St George's Hospital London,High grade glioma,"(4) IHC, sequencing, or copy number assay ambiguous",A1,11/30/1963,59.2,"glioblastoma, IDH-wildtype, mesenchymal type",1,PXA,0.22,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-866,"Favouring high grade glioma  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification     
TERT promoter: No mutation
MGMT Promoter: Unmethylated (0%)

  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, mesenchymal subtype
Histology: High-grade glioma
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype, subclass B
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 352\NH22-866,0.093,-0.006,-0.017,-0.008,0.016,-0.161,0.265,0.319,0.395,0.475,0.473,-0.053,0.073,0.13,-0.167,-0.043,0.044,-0.03,0.055,0.083,0.139,0.154,-0.072,0.017,0.078,0.345,-0.16,-0.024,0.068,unmethylated
NH22-985,206154080043_R06C01,352,14/04/2022,4/27/2022,4/27/2022,13,MD,Diagnostic,352,1,NDP,Southampton General Hospital,HGG,(1) small biopsy or nonrepresentative sample;,2A,9/7/2003,18.8,"control tissue, cerebellar hemisphere",0.66,CONTR_CEBM,0.97,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-985,"Integrated diagnosis: Cerebellar grey and white matter, and high-grade glioma
Histology: Cerebellar grey and white matter, and high-grade glioma
Methylation profile: Control tissue, cerebellum, copy number profile suggestive of CDKN2A/B loss and CDK4 amplification
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 352\NH22-985,0.043,-0.185,-0.013,-0.035,-0.071,-0.186,0.013,-0.182,0.026,-0.195,-0.039,0.015,0.041,0.041,-0.319,0.023,0.042,0.008,-0.073,0.024,0.229,0.697,-0.027,0.033,0.029,0.191,-0.019,0.029,0.057,unmethylated
NH22-959,206154250026_R03C01,353,14/04/2022,5/6/2022,5/6/2022,22,MD,Diagnostic,353,1,NDP,NHNN,Glioma?,(1) small biopsy or nonrepresentative sample;,DEF1A,6/6/1958,64.8,ganglioglioma,0.75,GBM_MES,0.55,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-959,"Likely infiltration margin of glioma  See comment.
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Infiltration of glioma - for grading, see supplementary comment

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR (Illumina array): Amplification          
TERT promoter: Mutation
MGMT Promoter (Illumina array): Unmethylated

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 353\NH22-959,0.046,0.176,-0.006,-0.008,-0.04,-0.023,-0.029,1.055,0.125,0.111,0.212,-0.011,-0.013,0.039,0.009,0.035,-0.141,-0.146,-0.052,0.005,0.426,0.778,-0.05,0.05,0.036,0.003,-0.055,-0.141,-0.111,unmethylated
NH22-931,206154250026_R04C01,353,14/04/2022,5/6/2022,5/6/2022,22,MD,Diagnostic,353,12,NDP,Brighton and Sussex Hospital,"Astrocytoma, IDH mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF3A,10/18/1974,48.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.43,AIDH,0.82,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-931,"Astrocytoma, IDH mutant  see comment for grading.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, favouring CNS WHO grade 2 (see comments)
Histology: Astrocytoma, IDH-mutant
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 353\NH22-931,0.052,-0.074,0.019,-0.035,0.045,0.056,0.033,0.019,0,-0.049,0.001,0.023,0.016,0.025,0.021,0.005,0.1,-0.003,-0.002,0.361,-0.148,-0.146,-0.036,0.019,0.027,-0.006,-0.076,0.012,-0.019,methylated
NH22-993,206154250026_R05C01,353,19/04/2022,5/6/2022,5/6/2022,17,MD,Diagnostic,353,1,NDP,Romford,"White matter with increased cellularity, astroctyoma ?","(2) unusual histology, location, demographics",A2,10/21/1981,41.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.89,AIDH,0.79,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-993,"White matter with mild increase in cellularity  see comment.
","Integrated diagnosis: Glioma / astrocytoma (see comment and also report NH22-1182)
Histology: White matter with mild increase in cellularity
Methylation profile: classified with low calibrated score, but suggestive of an IDH-mutant astrocytoma (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 353\NH22-993,-0.033,-0.237,0.11,0.131,0.005,-0.12,-0.054,-0.032,-0.076,-0.163,-0.042,0.237,0.366,0.217,-0.142,-0.2,0.21,-0.012,0.332,-0.101,0.064,0,-0.061,-0.013,-0.123,-0.016,-0.018,-0.022,0.023,unmethylated
NH22-1013,206154250026_R07C01,353,19/04/2022,5/6/2022,5/6/2022,17,MD,Diagnostic,353,1,NDP,"Cardiff, University Hospital",Non-diagnostic of a lymphoma? other malignancy,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,3/28/1999,23.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.42,LGG_SEGA,0.51,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1013,"Integrated diagnosis: N/A 
Histology: Atypical changes (see comment)
Methylation profile: No matching methylation classes
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 353\NH22-1013,0.008,-0.111,-0.011,-0.038,-0.079,-0.021,0.025,0.017,0.113,0.03,0.055,-0.016,0.055,0.073,-0.226,-0.049,0.052,-0.068,0.054,0.02,0.055,0.079,0.053,0.047,0.095,-0.02,-0.076,0.001,0.033,unmethylated
NH22-1004,206154250026_R08C01,353,19/04/2022,5/6/2022,5/6/2022,17,AM,Diagnostic,353,11,NDP,NHNN,"IDH-mutant astro, grade 4","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,4/24/1978,44.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,0.97,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1004,"Astrocytoma, IDH-mutant, CNS WHO grade 4 - see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: ): IDH glioma, subclass high grade astrocytoma  
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 353\NH22-1004,0.002,-0.056,0.006,-0.01,0.157,0.146,0.037,-0.256,0.002,0.006,0.186,-0.033,0.052,0.025,-0.011,0.243,-0.197,-0.29,0.007,0.038,-0.057,-0.025,-0.336,-0.036,0.067,0.034,-0.043,-0.025,-0.039,unmethylated
NH22-1007,206154250027_R01C01,354,19/04/2022,5/6/2022,5/6/2022,17,AM,Diagnostic,354,1,NDP,Romford,High grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/26/1958,65.1,"control tissue, white matter (corpus callosum)",0.14,CONTR_HEMI,0.2,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1007,"High-grade glioma  see comment.
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Suggestive of infiltration of high-grade glioma, IDH-wildtype (see comments)
Methylation profile: No tumour class identified (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 354\NH22-1007,0.034,-0.024,-0.009,0,0.008,0.013,0.053,0.021,0.021,-0.01,0.004,-0.012,-0.001,0.023,-0.094,-0.051,0,-0.007,0.03,-0.005,-0.022,0.016,-0.007,-0.047,0.011,-0.029,0.003,-0.088,0.011,unmethylated
NH22-1019,206154250027_R03C01,354,20/04/2022,5/6/2022,5/6/2022,16,AM,Diagnostic,354,1,NDP,Romford,Myxopaillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,8/15/1971,51.4,myxopapillary ependymoma,1,EPN_MPE,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1019,"Favouring a myxopapillary ependymoma, CNS WHO grade 2 
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Favouring a myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, myxopapillary  
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 354\NH22-1019,-0.035,0.004,0.053,0.037,0.009,0.187,0.008,0.291,0.412,0.377,0.32,0.008,0.025,0.043,0.285,0.261,0.03,-0.005,0.021,-0.012,-0.048,0.101,-0.034,-0.044,-0.019,0.039,0.198,-0.028,-0.02,unmethylated
NH22-805,206154250027_R04C01,354,21/04/2022,5/6/2022,5/6/2022,15,MD,Diagnostic,354,2,NDP,"Leeds, St James's University Hospital",Anaplastic ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,11/28/2011,5,posterior fossa ependymoma group A1,1,EPN_PFA,0.89,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-805,"Integrated diagnosis: Posterior fossa group A (PFA) ependymoma
Histology: Posterior fossa group A (PFA) ependymoma
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
","Integrated diagnosis: Posterior fossa group A (PFA) ependymoma
Histology: Suggestive of posterior fossa group A ependymoma (see comment)
Methylation profile: Posterior fossa group A ependymoma (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 354\NH22-805,0.176,-0.01,0.035,-0.033,-0.011,0.024,-0.015,0.079,-0.035,-0.048,0.022,-0.021,0.002,-0.022,0.005,0.032,-0.035,-0.014,-0.042,-0.075,-0.033,0.019,-0.043,0.102,-0.103,0.024,0.066,-0.054,-0.025,unmethylated
NH22-894,206154250027_R05C01,354,21/04/2022,5/6/2022,5/6/2022,15,MD,Diagnostic,354,1,NDP,Hull,Mixed ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B,9/28/1955,65.3,posterior fossa subependymoma,1,SUBEPN_PF,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-894,"Integrated diagnosis: Subependymoma, CNS WHO grade 1
Histology: Ependymal tumour favouring a subependymoma, CNS WHO grade 1
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 354\NH22-894,0.025,0.042,0.044,0.066,-0.02,-0.038,0.03,0.068,0.039,-0.02,-0.008,-0.018,0.035,-0.014,0.046,0.011,0.029,-0.007,-0.037,-0.016,0.022,0.146,0.003,-0.023,0.012,-0.007,-0.072,-0.017,-0.058,unmethylated
NH22-1034,206154250027_R06C01,354,21/04/2022,5/6/2022,5/6/2022,15,MD,Diagnostic,354,1,NDP,"Cambridge, Addenbrooke's Hospital",Recurrent astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",D1,8/3/1982,40.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1034,"Astrocytoma, IDH-mutant, CNS WHO grade 2
IDH1/2Seq: Mutation
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion

  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: IDH glioma, subclass astrocytoma (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 354\NH22-1034,0.031,-0.002,0.002,-0.076,0.052,-0.183,-0.053,0.044,-0.03,0.04,0.022,-0.033,-0.053,0.069,-0.014,0.021,0.005,0.016,-0.008,0.019,-0.025,-0.045,-0.178,0.032,-0.047,0.023,0.01,-0.021,0.019,unmethylated
NH22-1008,206154250027_R08C01,354,21/04/2022,5/6/2022,5/6/2022,15,MD,Diagnostic,354,1,NDP,Southampton General Hospital,Myxopapillary ependymoma?,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1B,3/7/1975,47.7,myxopapillary ependymoma,1,EPN_MPE,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1008,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 354\NH22-1008,-0.017,0.063,0.057,0.168,0.255,0.151,0.032,0.239,0.227,0.265,0.22,0.004,0.054,0.046,0.007,-0.005,0.01,0.009,0.005,0.05,-0.035,0.031,-0.467,-0.026,-0.05,-0.034,-0.049,-0.033,-0.004,methylated
NH22-1006,206154250062_R06C01,355,22/04/2022,5/11/2022,5/11/2022,19,MD,Diagnostic,355,1,NDP,Romford,Glioma NOS,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/24/1952,70.9,ganglioglioma,0.48,GBM_MES,0.54,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1006,"Glioma (see comment)

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained
BRAF V600E (IHC): Negative
Further molecular tests: Pending 
","Integrated diagnosis: Favouring Glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment)
Histology: Glioma
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchyma (low calibrated score)
IDH1 (R132H IHC): No mutation (IDH1/2Seq. failed) 
ATRX (IHC): Retained     
1p/19q: No Codeletion
EGFR: Amplification          
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 355\NH22-1006,0.029,0.015,0.004,0.144,0.156,0.189,0.071,0.391,0.436,0.448,0.38,-0.043,0.059,0.044,0.001,0.042,-0.241,-0.2,0.027,-0.02,0.008,-0.074,-0.057,-0.06,-0.095,-0.071,0.006,-0.272,-0.249,unmethylated
NH22-1028,206154250062_R07C01,355,22/04/2022,5/11/2022,5/11/2022,19,MD,Diagnostic,355,1,NDP,Royal London Hospital,Glioma NOS,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,7/21/1977,45.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.94,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1028,"Glioma (see comment) 

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
BRAF V600E (IHC): Negative
Further molecular tests: Pending 
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioma
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: No amplification          
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)
  
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 355\NH22-1028,1.046,-0.054,0.046,-0.038,-0.004,0.051,-0.213,0.152,0.131,0.147,0.121,-0.01,0.036,-0.015,-0.01,-0.033,-0.435,-0.192,-0.062,0.017,0.642,0.042,-0.016,-0.05,-0.9,0.005,-0.006,0.827,0.041,unmethylated
NH22-1076,206154080077_R01C01,357,27/04/2022,5/18/2022,5/18/2022,21,SB,Diagnostic,357,1,NDP,"Leeds, St James's University Hospital",Low grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,9/29/1951,71.6,"control tissue, white matter (corpus callosum)",1,OIDH,0.26,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1076,"Integrated diagnosis: N/A
Histology: Suspicious of an infiltration zone of a glioma (see comment)
Methylation profile: classified as control tissue (see comment)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 357\NH22-1076,-0.038,0.012,0.002,-0.014,0.013,0.02,-0.05,0.043,0.108,0.075,0.03,-0.041,0.024,0.001,0.015,-0.004,-0.039,-0.013,-0.051,0.021,0.051,0.042,-0.014,-0.002,-0.037,-0.003,-0.108,-0.057,0.002,methylated
NH16-793,206154080077_R04C01,357,27/04/2022,5/18/2022,5/18/2022,21,SB,Diagnostic,357,4,NDP,Brighton and Sussex Hospital,Oligodendroglioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.97,OIDH,0.99,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-793,"Oligodendroglioma (WHO grade II) 
IDH1 (R132H IHC): Mutation; 
ATRX (IHC): Retained 
1p/19q: Codeleted; 
  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 357\NH16-793,-0.063,-0.13,0.017,-0.05,0.001,0.018,0.022,0.035,-0.023,-0.046,-0.012,-0.025,0.033,0.045,0.036,0.041,-0.014,-0.044,-0.025,0.012,0.011,-0.022,-0.057,0.053,-0.055,-0.007,-0.335,0.002,-0.035,methylated
NH22-1079,206154080077_R05C01,357,27/04/2022,5/18/2022,5/18/2022,21,SB,Diagnostic,357,2,NDP,Brighton and Sussex Hospital,Oligodendroglioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",,5/13/1974,48.6,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1079,"Recurrent oligodendroglioma, IDH-mutant and 1p/19q co-deleted, CNS WHO grade 2  see comment.
IDH1 (R132H IHC): Mutation (IDH1 R132H see NH16-793)
ATRX (IHC): Retained (see NH16-793)
Further molecular tests: Pending
","Recurrent / residual Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained     
1p/19q: Codeleted
CDKN2A/B: No deletion          
MGMT Promoter: Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 357\NH22-1079,-0.053,-0.067,0.038,-0.047,0.013,0.032,0.037,0.023,-0.006,-0.02,-0.02,-0.001,0.033,0.019,-0.248,-0.041,0.039,0.021,-0.002,0.054,0.024,0.029,-0.031,-0.017,-0.015,-0.006,-0.472,-0.001,0.015,methylated
NH22-1091,206154080077_R07C01,357,28/04/2022,5/18/2022,5/18/2022,20,SB,Diagnostic,357,1,NDP,Nottingham University Hospital,Gliosis or pilocytic astrocytoma or a cyst wall,(1) small biopsy or nonrepresentative sample;,A1,10/5/1991,31,posterior fossa ependymoma group A1,0.07,LGG_PAPF,0.07,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1091,"Integrated diagnosis: N/A
Histology: Atypical CNS tissue, not adequate for definitive diagnosis 
Methylation profile: Unsuccessful due to inadequate DNA
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 357\NH22-1091,-0.116,0.14,-0.031,0.157,-0.092,0.084,-0.311,-0.046,0.001,-0.098,-0.032,-0.078,0.022,-0.049,0.009,0.112,0.34,0.086,-0.135,0.124,-0.293,0.326,-0.071,-0.343,0.121,-0.443,0.191,0.149,-0.041,unmethylated
NH22-795,206154080077_R08C01,357,28/04/2022,5/18/2022,5/18/2022,20,SB,Diagnostic,357,1,NDP,Nottingham University Hospital,IDH-mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A3,7/31/1976,46.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.99,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-795,"Astrocytoma, IDH-mutant, grading see comment
IDH1/2Seq: Mutation
ATRX (IHC): Loss of expression (indicates mutation)
MGMT Promoter: Unmethylated (0%)

  
","Integrated diagnosis: Astrocytoma, IDH-mutant, see comments for grading
Histology: Astrocytoma, IDH-mutant 
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 357\NH22-795,-0.091,-0.029,0.015,-0.018,-0.026,-0.021,-0.042,0.022,0.181,0.175,0.114,-0.015,0.036,0.027,-0.02,0.007,0.003,0.006,0.01,0.033,-0.096,-0.119,-0.051,-0.011,-0.005,-0.019,-0.205,-0.02,-0.012,methylated
NH22-966,206154080121_R01C01,358,28/04/2022,5/25/2022,5/25/2022,27,SB,Diagnostic,358,1,NDP,"Belfast, Royal Victoria Hospital",IDH-mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,10/31/1963,59.3,"glioblastoma, IDH-wildtype, RTK2 type",0.91,GBM_RTKII,0.89,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-966,"Glioblastoma, IDH-wildtype, CNS WHO grade 4  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained               
EGFR: Amplification
TERT promoter: Mutation
MGMT Promoter: Methylated (>10-25%) 

  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, IDH-wildtype, CNS WHO grade 4 
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK II
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 358\NH22-966,1.812,-0.013,0.146,-0.055,0.01,-0.086,-0.01,1.932,0.477,0.311,0.41,0.022,0.181,0.028,-1.397,0.011,-0.389,-0.439,0.004,-0.086,0.046,0.036,0.042,0.009,-0.028,0.082,0.008,-0.009,0.031,methylated
NH22-1109,206154080121_R03C01,358,29/04/2022,5/25/2022,5/25/2022,26,SB,Diagnostic,358,2,NDP,NHNN,Oligodendroglioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",,12/7/1974,48.1,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.98,OIDH,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1109,"Oligodendroglioma, IDH-mutant, see comment.

IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Oligodendroglioma, IDH-mutant and 1p/19q-codeleted (see comments for grading)
IDH1 (R132H IHC); IDH1/2Seq: Mutation     
ATRX (IHC): Retained     
1p/19q: Codeleted
TERT promoter: Mutation
MGMT Promoter: Methylated (>5-10%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 358\NH22-1109,-0.037,0.016,0.032,-0.026,0.013,0.018,-0.028,0.04,0.02,-0.021,0.043,-0.011,0.043,0.012,-0.019,-0.011,-0.012,0.031,-0.035,-0.035,-0.024,-0.018,-0.497,-0.009,-0.088,-0.031,-0.454,0.023,-0.009,methylated
NH22-1122,206154080121_R04C01,358,3/5/2022,5/25/2022,5/25/2022,22,SB,Diagnostic,358,2,NDP,Southampton General Hospital,Diffuse HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,8/25/1977,45.3,pleomorphic xanthoastrocytoma(-like),1,PXA,0.99,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1122,"Integrated diagnosis: Pleomorphic xanthoastrocytoma, BRAF V600E-mutant, CNS WHO grade 2
Histology: Pleomorphic xanthoastrocytoma, CNS WHO grade 2
Methylation profile: Pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 358\NH22-1122,0.086,0.005,0.032,0.005,0.058,-0.019,-0.073,-0.03,-0.011,-0.049,0.026,-0.014,0.045,0.094,-1.488,0.083,-0.076,-0.015,0.128,-0.039,-0.041,0.054,-0.059,0.035,0.013,0.025,0.045,-0.045,0.041,unmethylated
NH22-1153,206154080121_R05C01,358,6/5/2022,5/25/2022,5/25/2022,19,ZJ,Diagnostic,358,1,NDP,Bristol,?pilomyxoid astrocytoma,(1) small biopsy or nonrepresentative sample;,B1,6/13/1991,31.3,rosette-forming glioneuronal tumour,1,LGG_RGNT,0.98,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1153,"Integrated diagnosis: Rosette forming glioneuronal tumour, CNS WHO grade 1
Histology: Low grade glioneuronal tumour, compatible with rosette forming glioneuronal tumour, CNS WHO grade 1
Methylation profile: Rosette forming glioneuronal tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 358\NH22-1153,-0.059,0.001,-0.022,-0.01,-0.037,0.015,0.011,-0.009,-0.046,-0.03,-0.002,-0.097,0.081,-0.023,-0.041,-0.022,-0.016,0.034,0.005,-0.063,-0.089,0.042,0.009,-0.025,-0.026,0.054,-0.002,-0.068,0.058,unmethylated
NH22-925,206154080078_R02C01,359,6/5/2022,5/25/2022,5/25/2022,19,MD,Diagnostic,359,1,NDP,NHNN,"Granular cell astroctyoma, glioblastoma","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,12/24/1979,42.9,supratentorial pilocytic astrocytoma,0.18,LGG_DNT,0.18,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-925,"Granular cell astrocytoma/glioblastoma, grading see comment.
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained 
Further molecular tests: Pending
","Integrated diagnosis: Suggestive of glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Granular cell astrocytoma
Methylation profile: Control tissue, hemispheric cortex
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 359\NH22-925,-0.091,0.004,0.022,0.008,0.043,0.024,0.002,0.068,0.053,0.061,0.047,-0.055,0.066,0.011,-0.05,0.055,-0.048,0.02,-0.038,0.007,-0.021,-0.045,0.004,-0.172,-0.108,-0.05,0.045,-0.064,-0.018,unmethylated
NH22-932,206154080078_R04C01,359,6/5/2022,5/25/2022,5/25/2022,19,MD,Diagnostic,359,1,NDP,Romford,Recurrent astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,11/16/1968,54.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.76,AIDH,0.99,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-932,"Recurrent astrocytoma, IDH-mutant, CNS WHO grade 3  see comment.
IDH1 (R132H IHC): Mutation (IDH-1 C394A mutation, see NH17-2688)
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Recurrent / residual astrocytoma, IDH-mutant, CNS WHO grade 4 - see comment
Histology: Recurrent / residual astrocytoma, IDH-mutant, for grading, see comment
Methylation profile: Astrocytoma, IDH-mutant
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 359\NH22-932,0.017,-0.026,0.036,-0.286,-0.011,0.043,-0.012,0.01,0.265,0.241,0.239,-0.034,0.065,0.186,-0.497,0.006,0.006,0.024,-0.031,-0.001,-0.043,-0.034,-0.163,0.037,0.045,-0.004,-0.005,0.021,0.052,methylated
NH22-1163,206154080078_R07C01,359,7/5/2022,5/25/2022,5/25/2022,18,ZJ,Diagnostic,359,1,NDP,Romford,"Oligodendroglioma, G2","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,2/10/1962,61.1,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1163,"Oligodendroglioma, CNS WHO grade 2.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 359\NH22-1163,0.01,-0.045,-0.042,-0.218,-0.305,0.031,0.054,0.001,-0.033,-0.053,0.023,0.036,0.11,-0.018,-0.165,-0.156,-0.008,-0.005,0.08,-0.005,-0.047,0.027,-0.038,0.045,0.026,0.012,-0.51,-0.001,0.062,methylated
NH22-1169,206154080078_R08C01,359,10/5/2022,5/25/2022,5/25/2022,15,SB,Diagnostic,359,1,NDP,NHNN,GBM,"(2) unusual histology, location, demographics",DEF1A,7/12/1960,62.7,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.88,GBM_RTKI,0.74,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1169,"Glioblastoma, CNS WHO grade 4 - See comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: Amplification           
MGMT Promoter: Methylated (>25%)  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 359\NH22-1169,0.031,-0.012,0.034,0.026,0.646,0.089,-0.021,1.273,0.294,0.33,0.253,-0.018,0.074,-0.014,-0.01,-0.037,-1.372,-0.459,-0.049,-0.052,-0.037,2.336,-0.526,-0.085,-0.052,-0.054,0.003,-0.014,0.025,methylated
NH22-1167,206154080122_R01C01,360,10/5/2022,5/25/2022,5/25/2022,15,SB,Diagnostic,360,1,NDP,NHNN,Recurrent astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,11/9/1984,38,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1167,"Astrocytoma, IDH-mutant, grading see comment.
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3 - for grading, see also comment
Histology: Astrocytoma, IDH-mutant 
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 360\NH22-1167,0.021,-0.05,0.015,0.021,0.014,-0.324,0.011,0.017,-0.006,-0.045,0.006,-0.021,0.083,0.593,-0.029,0.007,0.018,0.045,-0.021,0.269,-0.165,-0.232,-0.036,-0.015,-0.039,0.004,0.047,0.004,0.034,methylated
NH15-1188,206154080122_R02C01,360,10/5/2022,5/25/2022,5/25/2022,15,SB,Diagnostic,360,1,NDP,NHNN,Recurrent astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH15-1188,"Diffuse astrocytoma (WHO Grade II)

IDH1 (R132H IHC): Mutation
H3 (K27): No mutation
ATRX (IHC): Loss of expression (indicates mutation). 
1p/19q: Test pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 360\NH15-1188,0.192,-0.007,0.077,0.048,-0.022,-0.107,-0.07,0.212,0.028,0.048,0.091,-0.016,0.098,0.304,-0.008,0.104,-0.055,-0.101,-0.004,0.164,0.164,-0.068,-0.045,0.097,-0.108,-0.029,-0.036,-0.008,0.058,unmethylated
NH22-1182,206154080122_R03C01,360,10/5/2022,5/25/2022,5/25/2022,15,MD,Diagnostic,360,1,NDP,Romford,"Glioma, IDH mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,10/21/1981,41.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.49,AIDH,0.52,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1182,"Glioma, IDH-mutant - See comment.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Glioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Glioma, IDH-mutant - see comment
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 360\NH22-1182,-0.091,-0.053,0.033,-0.03,-0.039,0.033,0.042,-0.012,-0.059,-0.045,-0.033,0.002,0.073,-0.024,0.011,0.006,0.035,0.035,-0.005,-0.051,-0.042,-0.028,-0.018,-0.026,-0.04,-0.042,-0.256,-0.018,-0.013,methylated
NH22-127,206154080122_R04C01,360,10/5/2022,5/25/2022,5/25/2022,15,MD,Diagnostic,360,1,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,6/20/1978,44.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.99,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-127,"Astrocytoma, IDH-mutant, CNS WHO Grade 4
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, high grade, with CDKN2A/B deletion
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 360\NH22-127,-0.032,-0.068,0.058,-0.071,-0.111,-0.346,0.079,-0.024,0.244,0.295,0.2,-0.376,-0.238,-0.369,-3.184,0.22,-0.434,-0.385,-0.02,-0.063,-0.061,-0.047,-0.525,-0.198,0.007,0.015,-0.073,0.02,0.019,unmethylated
NH22-1139,206154080122_R05C01,360,10/5/2022,5/25/2022,5/25/2022,15,MD,Diagnostic,360,2,NDP,NHNN,Low grade glial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,5/14/1996,26.3,"diffuse glioma, MYB(L1)-altered, subtype D",0.93,LGG_MYB,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1139,"Low grade glial tumour - see comments.
","Integrated diagnosis: Diffuse astrocytoma, MYB/MYBL1-altered, CNS WHO grade 1
Histology: Low grade glial tumour
Methylation profile: Diffuse astrocytoma, MYB/MYBL1-altered
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 360\NH22-1139,0.088,-0.052,0.065,0.065,-0.06,-0.061,-0.068,0.021,-0.064,-0.159,0.015,0.165,0.276,0.183,-0.017,-0.025,-0.016,0.061,0.004,-0.072,-0.002,0.059,-0.03,-0.004,0.029,0.041,0.031,0.008,0.089,unmethylated
NH22-1195,206154080122_R06C01,360,10/5/2022,5/25/2022,5/25/2022,15,MD,Diagnostic,360,1,NDP,Southampton General Hospital,Low grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,11/2/1984,38,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",1,DMG_K27,0.99,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1195,"Integrated diagnosis: Diffuse midline glioma, H3 K27M-alterted, CNS WHO grade 4
Histology: Diffuse midline glioma, H3 K27M-altered, CNS WHO grade 4
Methylation profile: Diffuse midline glioma, H3 K27-altered
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 360\NH22-1195,0.265,-0.001,0.18,-0.047,-0.054,0.074,0.024,0.006,-0.011,-0.035,-0.016,-0.003,0.125,-0.031,0.098,-0.082,0.024,0.064,-0.023,-0.097,0.145,0.32,-0.033,-0.026,-0.012,1.08,-0.722,-0.068,0.021,unmethylated
NH22-1173,206154080122_R08C01,360,10/5/2022,5/25/2022,5/25/2022,15,MD,Diagnostic,360,1,NDP,Brighton and Sussex Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/16/1979,43.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.98,OIDH,0.99,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1173,"Oligodendroglioma, in keeping with recurrence/progression of the previously diagnosed oligodendroglioma, IDH-mutant and 1p/19q codeleted (NH17-192), CNS WHO grade 3 - see the comment.
IDH1/2 Seq: Mutation (NH17-192)
ATRX (IHC): Retained 
1p/19q: Codeleted (NH17-192)
Chromosome 7p: Gain - 3 copies (NH17-192)
Chromosome 10q: LOH (NH17-192)
Further molecular tests: Pending
  
","Integrated diagnosis: Recurrent / residual oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
Histology: Recurrent / residual oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 360\NH22-1173,-0.042,0.06,0.04,0.023,0.029,0.042,-0.035,-0.012,0.303,0.284,0.288,0.019,0.105,0.026,-0.518,0.029,-0.028,-0.007,-0.045,0.364,-0.006,0.018,-0.045,0.029,-0.023,0.05,-0.527,-0.028,0.087,methylated
NH22-1202,206154250108_R02C01,361,11/5/2022,5/27/2022,5/27/2022,16,MD,Diagnostic,361,1,NDP,St George's Hospital London,Ependymoma 2,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,6/3/1970,52.7,posterior fossa ependymoma group B,1,EPN_PFB,1,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1202,"Integrated diagnosis: Ependymoma, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, posterior fossa group B
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 361\NH22-1202,0.033,-0.088,0.019,-0.007,-0.074,0.016,-0.332,-0.021,-0.035,-0.137,-0.058,0.239,0.223,0.198,0.169,0.19,-0.114,-0.201,0.129,0.097,0.08,0.161,-0.077,-0.024,-0.184,-0.057,-0.06,0.03,0.08,unmethylated
NH22-1196,206154250108_R04C01,361,11/5/2022,5/27/2022,5/27/2022,16,MD,Diagnostic,361,1,NDP,"Liverpool, The Walton Centre","Glioma, IDH-1 mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,1/7/1965,58.2,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1196,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2 - for grading, see also comment
Histology: Glioma, IDH-mutant
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 361\NH22-1196,-0.019,0.042,0.023,-0.308,-0.352,0.013,0.028,0.017,0.043,-0.006,0.028,-0.002,0.03,-0.005,-0.01,-0.03,0.017,0.013,0.206,-0.01,-0.053,0.018,-0.043,-0.008,0.019,-0.003,-0.374,0.06,0.002,methylated
NH22-1200,206154250108_R06C01,361,11/5/2022,5/27/2022,5/27/2022,16,MD,Diagnostic,361,1,NDP,St George's Hospital London,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,9/14/1982,40.2,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.96,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1200,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1 - see comment
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, infratentorial
MGMT promoter (Illumina array): Unmethylated 
  
","Integrated diagnosis: Pilocytic astrocytoma, BRAF fusion, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, infratentorial
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 361\NH22-1200,0.068,-0.016,-0.036,0.055,0.044,0.178,0.149,-0.055,0.029,-0.029,0.237,-0.067,0.02,0.049,0.009,0.054,-0.029,-0.012,0.28,0.042,0.025,0.045,-0.025,0.02,-0.057,-0.003,-0.021,-0.043,0.037,unmethylated
NH22-1226,206154250108_R07C01,361,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,361,1,NDP,Nottingham University Hospital,?Low grade glial/glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/5/1981,41.4,ganglioglioma,0.31,LGG_DNT,0.2,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1226,"Integrated diagnosis: Insufficient material for specific diagnosis
Histology: Insufficient material for specific diagnosis
Methylation profile: Control tissue, hemispheric cortex
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 361\NH22-1226,0.04,-0.016,0.007,0.048,-0.032,-0.014,-0.04,0.031,0.038,-0.003,0.003,-0.022,0.054,-0.007,0.018,0.001,-0.026,0.013,0.013,-0.003,-0.015,0.026,0.024,-0.017,0.017,-0.004,0,-0.038,0.03,unmethylated
NH22-1227,206154250108_R08C01,361,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,361,1,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,11/4/1953,69.5,ganglioglioma,0.49,GBM_MES,0.4,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1227,"In keeping with high-grade glioma (see comment) 
MGMT Promoter: Methylated (>0-5%)
","Integrated diagnosis: Indicative of glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma - see comment
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 361\NH22-1227,-0.036,0.001,0.025,0.018,-0.024,0.017,0.019,0.194,0.206,0.186,0.149,0.008,0.066,0.004,0.039,0.015,-0.171,-0.236,-0.01,0.04,-0.008,0.004,0.011,0.042,-0.942,0.006,-0.019,-0.221,-0.166,unmethylated
NH22-1228,206154250056_R01C01,362,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,362,1,NDP,Nottingham University Hospital,Glioblastoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/8/1975,47.9,"glioblastoma, IDH-wildtype, RTK2 type",0.57,GBM_MES,0.9,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1228,"High-grade glioma (see comment)  
MGMT Promoter: Methylated (>5-10%)
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 362\NH22-1228,-0.026,-0.037,0.062,0.186,-0.086,0,0.019,0.389,0.859,0.314,0.29,-0.027,0.106,0.08,-1.212,0.074,-0.322,-0.349,0.023,0.02,0.056,0.083,-0.009,0.064,-0.355,0.024,0.031,-0.428,-0.28,methylated
NH22-1232,206154250056_R02C01,362,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,362,1,NDP,Nottingham University Hospital,Low grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/22/2013,9.2,supratentorial pilocytic astrocytoma,0.99,LGG_PA_GGST,0.87,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1232,"Integrated diagnosis: In favour of pilocytic astrocytoma, CNS WHO grade 1
Histology: In favour of pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, hemispheric
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 362\NH22-1232,0.015,-0.045,0.009,-0.028,-0.055,-0.003,0.02,0.188,0.293,-0.049,0.21,-0.01,0.034,0.032,0.014,-0.035,0.035,-0.025,-0.006,0.039,-0.015,-0.014,0.008,0.007,0.017,0.001,-0.054,-0.032,0.052,unmethylated
NH22-1229,206154250056_R03C01,362,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,362,1,NDP,Nottingham University Hospital,?Malignant glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/10/1976,46.9,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1229,"High-grade glioma (see comment)  
MGMT Promoter: Unmethylated (0%)
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK I
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 362\NH22-1229,0.099,0.118,-0.04,-0.039,-0.083,-0.045,0.021,0.136,0.179,0.143,0.134,-0.001,0.062,0.04,-0.004,0.035,-0.125,-0.175,0.001,0.055,0.647,0.019,-0.087,-1.404,0.113,0.039,0.025,-0.015,0.046,unmethylated
NH22-1231,206154250056_R04C01,362,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,362,1,NDP,Nottingham University Hospital,Glioblastoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/24/1958,65.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.6,CONTR_INFLAM,0.69,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1231,"Referred diagnosis: Glioblastoma (see comment)  
MGMT Promoter: Unmethylated (0%)
","Integrated diagnosis: In favour of glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: In favour of glioblastoma, CNS WHO grade 4
Methylation profile: Suggestive of glioblastoma, IDH-wildtype - see comment
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 362\NH22-1231,0.028,-0.015,-0.006,-0.045,-0.061,0.022,-0.082,0.01,0.042,-0.02,0.001,-0.002,0.001,0.01,-0.144,-0.135,-0.093,-0.086,-0.034,0.001,0.008,0.014,-0.095,0.015,-0.091,-0.015,-0.004,-0.025,-0.034,unmethylated
NH22-1233,206154250056_R05C01,362,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,362,1,NDP,Nottingham University Hospital,Glioblastoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,12/17/1988,33.9,"control tissue, white matter (corpus callosum)",1,OIDH,0.23,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1233,"Histology: Referred diagnosis: Multinodular and vacuolating neuronal tumour, CNS WHO grade 1
Methylation profile: Control tissue, white matter - see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 362\NH22-1233,-0.009,-0.029,0.019,-0.014,-0.064,0.067,-0.013,-0.03,-0.04,-0.101,-0.007,-0.012,0.045,-0.009,0.023,-0.001,0.037,0.036,0.026,-0.026,-0.027,0.066,0.056,-0.025,0.003,-0.018,0.009,-0.033,0.024,methylated
NH22-1187,206154250056_R06C01,362,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,362,4,NDP,Brighton and Sussex Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,3/22/1982,40.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.93,AIDH,0.94,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1187,"Astrocytoma, IDH-mutant, CNS WHO grade 3 
IDH1 (R132H IHC): Mutation      
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 362\NH22-1187,-0.005,-0.023,0.007,-0.034,-0.004,-0.027,-0.008,0.048,-0.058,-0.049,0.026,-0.021,0.042,0.063,0.001,0.129,0.03,-0.001,0.019,0.133,-0.131,-0.126,-0.298,-0.09,-0.124,-0.085,-0.117,-0.026,-0.021,methylated
NH22-1211,206154250056_R08C01,362,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,362,1,NDP,Brighton and Sussex Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,4/13/1984,38.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1211,"Astrocytoma, IDH-mutant, CNS WHO grade 4 
IDH1 (R132H IHC): Mutation, (in biopsy NH15-1018)      
ATRX (IHC): Loss of expression (indicates mutation) (in biopsy NH15-1018)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, high grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 362\NH22-1211,0.103,0.769,0.057,0.175,0.025,-0.325,-0.365,0.036,0.327,0.403,0.288,-0.003,0.1,0.234,-0.262,-0.123,-0.325,-0.369,-0.027,0.669,0.24,-0.474,-0.23,0.089,0.08,0.054,0.005,-0.154,-0.088,methylated
NH22-1127,206154250096_R01C01,363,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,363,1,NDP,"Cardiff, University Hospital",?Low grade glial/glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/21/1989,33.6,papillary glioneuronal tumour,0.26,LGG_PA_GGST,0.27,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1127,"Histology: Low grade glial or glioneuronal tumour, likely corresponding to CNS WHO grade 1
Methylation profile: Low-grade glial / glioneuronal / neuroepithelial tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 363\NH22-1127,0.043,-0.008,0.027,0.031,-0.007,0.098,0.114,0.219,0.24,0.152,0.154,-0.018,0.012,0.084,0.046,0.033,0.156,0.093,0.05,0.083,0.029,0.052,-0.012,0.046,0.013,0.01,-0.079,-0.027,0.009,unmethylated
NH15-1018,206154250096_R03C01,363,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,363,1,NDP,Brighton and Sussex Hospital,Anaplastic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2E,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.97,AIDH,0.98,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH15-1018,"Anaplastic Astrocytoma (WHO Grade III).  

IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation). 
1p/19q: Test pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3 - see comment
Histology: (Anaplastic) astrocytoma, IDH-mutant, CNS WHO grade 3 
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 363\NH15-1018,-0.028,-0.014,0.004,-0.03,-0.019,0.054,0.068,0.016,0.216,0.351,0.284,-0.009,-0.03,0.012,-0.023,0.037,-0.061,0.012,-0.074,-0.004,0.031,-0.029,-0.085,-0.038,-0.076,-0.038,-0.51,-0.044,0,methylated
NH22-1241,206154250096_R04C01,363,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,363,1,NDP,"Charing Cross Hospital, London",?GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/3/1960,63.1,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.95,GBM_MID,0.84,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1241,"
Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma, compatible with glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass midline
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 363\NH22-1241,0.043,-0.007,0.001,-0.299,0.002,-0.001,0.014,-0.483,0.001,0.015,0.026,-0.006,0.021,-0.452,-2.376,0.054,-0.221,-0.235,-0.155,0.023,-0.037,0.123,-0.499,-0.081,-0.069,0.531,-0.501,-0.043,0.001,methylated
NH22-1252,206154250096_R05C01,363,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,363,1,NDP,"Cambridge, Addenbrooke's Hospital",Glioneural tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/6/1987,35.6,dysembryoplastic neuroepithelial tumour,0.99,LGG_DNT,0.99,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1252,"Integrated diagnosis: Dysembryoplastic neuroepithelial tumour, CNS WHO grade 1
Histology: In favour of dysembryoplastic neuroepithelial tumour, CNS WHO grade 1
Methylation profile: Dysembryoplastic neuroepithelial tumour
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 363\NH22-1252,-0.136,-0.094,-0.079,-0.076,-0.137,0.055,0.133,0.063,0.113,0.077,0.087,-0.092,-0.053,-0.022,0.105,0.088,0.097,0.084,0.08,-0.039,-0.092,-0.158,-0.117,-0.116,-0.081,-0.09,-0.14,0.058,0.081,methylated
NH22-1253,206154250096_R06C01,363,12/5/2022,5/27/2022,5/27/2022,15,MD,Diagnostic,363,1,NDP,Southampton General Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",O6NE,11/30/1946,76.5,infratentorial pilocytic astrocytoma,0.2,LGG_PAPF,0.21,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1253,"Histology: In favour of low grade glial or glioneuronal tumour - see comment
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 363\NH22-1253,0.02,0.276,-0.153,-0.141,0.055,-0.273,-0.024,0.262,0.208,0.198,0.176,-0.005,0.109,0.093,-0.124,0.016,0.147,-0.111,0.044,0.267,0.175,0.11,-0.142,0.108,-0.029,-0.247,0.299,-0.029,0.015,unmethylated
NH22-1217,206154250096_R08C01,363,16/05/2022,5/27/2022,5/27/2022,11,MD,Diagnostic,363,1,NDP,NHNN,"Oligodendroglioma, IDH-mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,7/4/1986,36.4,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.64,OIDH,0.97,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1217,"Oligodendroglioma, IDH-mutant, CNS WHO grade 2.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 363\NH22-1217,-0.043,0.004,0.022,-0.036,0.005,-0.014,0.018,0.014,-0.001,-0.009,0.001,0.032,0.018,0.057,0.023,0.005,0.01,0.041,0.014,0.005,-0.033,0.007,-0.114,0.003,0.009,-0.024,-0.351,0.026,0.016,methylated
NH22-1265,206154250099_R01C01,364,16/05/2022,6/1/2022,6/1/2022,16,MD,Diagnostic,364,1,NDP,Bristol,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,11/4/1968,54.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.18,AIDH,0.23,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1265,"Integrated diagnosis: Spinal ependymoma, best corresponding to CNS WHO grade 2
Histology: Low-grade glioma, in keeping with ependymal tumour,
Methylation profile: Spinal ependymoma 
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 364\NH22-1265,-0.031,-0.049,0.039,-0.015,0.036,-0.145,0.045,0.193,0.215,0.059,0.131,0.001,0.069,0.235,0.02,0.043,-0.024,-0.051,-0.031,-0.008,0.461,-0.022,-0.128,-0.006,-0.056,0.023,-0.157,-0.006,0.058,unmethylated
NH22-1246,206154250099_R02C01,364,16/05/2022,6/1/2022,6/1/2022,16,MD,Diagnostic,364,1,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,6/6/1993,29.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.98,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1246,"Astrocytoma, IDH-mutant, CNS WHO grade 3 at least
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, high grade
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 364\NH22-1246,0.005,-0.026,0.016,-0.061,-0.008,-0.078,0.055,0.135,-0.038,-0.099,0.012,-0.023,0.06,0.15,0.006,-0.046,-0.122,-0.031,-0.065,0.003,0.558,-0.175,-0.54,-0.025,-0.016,-0.045,-0.291,-0.128,-0.05,unmethylated
NH22-1284,206154250099_R03C01,364,16/05/2022,6/1/2022,6/1/2022,16,MD,Diagnostic,364,1,NDP,"Cardiff, University Hospital",High grade intrinsic ?embryonal,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A6,11/19/1974,48.2,"supratentorial ependymoma, ZFTA fusion-positive",0.99,EPN_RELA,0.22,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1284,"Integrated diagnosis: Suggestive of ependymoma, ZFTA fusion positive, CNS WHO grade 3 - see comment
Histology: High grade glioma
Methylation profile: Supratentorial ependymoma, ZFTA fusion-positive, subclass D
MGMT promoter (Illumina array): Methylated 
  
","Ependymoma, ZFTA fusion positive, CNS WHO grade 3
",(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 364\NH22-1284,0.275,-0.006,0.082,0.103,0.048,-0.023,-0.055,0.018,-0.025,0.059,-0.032,0.02,0.001,0.026,-0.033,0.056,0.015,-0.018,0.152,-0.2,0.094,-0.002,-0.073,-0.004,-0.06,0.083,0.203,0.047,0.094,methylated
NH22-1317,206154250099_R08C01,364,18/05/2022,6/1/2022,6/1/2022,14,MD,Diagnostic,364,1,NDP,Newcastle,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2C,10/3/1965,57.4,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type C]",1,CNSNB_FOXR2,0.05,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1317,"Integrated diagnosis: Glioblastoma, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: High grade glioma - see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 364\NH22-1317,-0.028,-0.03,0.044,0.068,0.025,-0.084,0.02,-0.072,-0.013,-0.018,0.046,-0.008,-0.297,0.003,-1.25,-0.018,-0.051,-0.003,0.468,-0.104,-0.06,0.056,-0.486,-0.372,-0.301,0.008,-0.496,0.02,0.031,methylated
NH22-1180,206154250070_R01C01,365,18/05/2022,6/1/2022,6/1/2022,14,MD,Diagnostic,365,4,NDP,St George's Hospital London,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/2/1980,42.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.94,AIDH,0.92,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1180,"Astrocytoma, IDH-mutant, favouring CNS WHO grade 3 (see comment)
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B: No deletion          
MGMT Promoter: Methylated (>5-10%)
","Integrated diagnosis: Astrocytoma, IDH-mutant, favouring CNS WHO grade 3 - see comment
Histology: Astrocytoma, IDH-mutant, favouring CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 365\NH22-1180,-0.036,-0.035,0.042,-0.008,0.04,-0.09,0.088,0.185,0.164,0.055,0.153,-0.006,0.025,0.339,0.105,0.013,0.018,-0.079,0.018,-0.002,0.252,0.033,-0.054,0.037,-0.014,0.048,-0.069,0.029,0.01,unmethylated
NH22-1184,206154250070_R02C01,365,18/05/2022,6/1/2022,6/1/2022,14,MD,Diagnostic,365,3,NDP,St George's Hospital London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/29/1983,39.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1184,"Astrocytoma, IDH-mutant, favouring CNS WHO grade 2
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B: No deletion          
MGMT Promoter: Methylated (>0-5%)
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, favouring CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 365\NH22-1184,-0.009,0.034,0.035,-0.008,-0.001,0.036,-0.055,0.036,0.23,0.239,0.222,0.022,0.066,0.042,-0.118,-0.044,0.005,-0.022,0.028,-0.021,0.089,-0.043,-0.081,-0.008,-0.044,-0.039,-0.058,-0.001,0.015,methylated
NH22-1282,206154250070_R04C01,365,18/05/2022,6/1/2022,6/1/2022,14,MD,Diagnostic,365,1,NDP,"Liverpool, The Walton Centre",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1F,6/16/1983,39.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.96,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1282,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, with histological features corresponding to CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, low grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 365\NH22-1282,-0.117,0.015,0.049,-0.041,0.014,0.006,-0.309,0.03,-0.002,-0.021,0.038,0.023,0.019,0.051,-0.523,0.007,0.002,0.013,0.021,0.049,-0.16,-0.124,-0.221,0.07,-0.007,0.017,-0.061,0.034,-0.113,methylated
NH22-1326,206154250070_R07C01,365,19/05/2022,6/1/2022,6/1/2022,13,MD,Diagnostic,365,1,NDP,HCA,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,8/25/1970,52.5,spinal ependymoma,1,EPN_SPINE,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1326,"Ependymoma, corresponding to CNS WHO grade 2 (see comment)
","Integrated diagnosis: Ependymoma, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 365\NH22-1326,0.01,-0.008,0.04,0,-0.002,0.008,-0.025,0.218,0.245,0.243,0.226,-0.398,-0.317,-0.281,0.006,0.034,0,0.009,-0.007,0.184,0.163,0.27,-0.044,0.014,-0.027,-0.015,-0.072,-0.313,-0.271,methylated
NH22-1292,206154250070_R08C01,365,19/05/2022,6/1/2022,6/1/2022,13,MD,Diagnostic,365,4,NDP,Cleveland Clinic London,"Oligodendroglioma, IDH-mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,11/23/1979,43.1,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1292,"Oligodendroglioma, IDH-mutant, CNS WHO Grade 2
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 365\NH22-1292,-0.044,-0.029,0.036,-0.036,0.007,0.032,0.014,-0.027,-0.039,-0.04,0.012,-0.004,-0.007,0.004,0.031,0.006,-0.01,0.024,-0.008,-0.003,-0.046,0.005,-0.023,0.019,-0.028,-0.048,-0.434,0.012,0.025,methylated
NH22-1315,206486300130_R03C01,366,19/05/2022,6/8/2022,6/8/2022,20,MD,Diagnostic,366,1,NDP,Nottingham University Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B2,4/26/2000,22.4,spinal ependymoma,1,EPN_SPINE,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1315,"Integrated diagnosis: Ependymoma, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 366\NH22-1315,-0.084,0.008,-0.005,0.089,0.135,0.161,-0.366,0.197,0.154,0.207,0.163,-0.036,-0.023,0.036,0.136,0.207,-0.08,0.005,0.013,0.129,0.092,0.182,-0.11,0,-0.062,-0.065,0.032,-0.906,-0.851,methylated
NH22-1318,206486300130_R05C01,366,19/05/2022,6/8/2022,6/8/2022,20,MD,Diagnostic,366,2,NDP,Oxford John Radcliffe Hospital,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,7/3/1985,37.4,supratentorial subependymoma,0.48,SUBEPN_ST,0.48,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1318,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: See comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 366\NH22-1318,-0.072,-0.034,0.056,0.17,0.214,0.128,-0.011,0.223,0.211,0.2,0.211,0.011,0.013,0.043,-0.035,0.056,0.007,0.004,0.055,-0.057,-0.069,0.007,-0.09,-0.03,-0.057,0.014,0.03,-0.067,-0.028,unmethylated
NH22-1286,206486300130_R06C01,366,19/05/2022,6/8/2022,6/8/2022,20,MD,Diagnostic,366,1,NDP,NHNN,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,9/23/1947,75.7,supratentorial subependymoma,0.69,SUBEPN_ST,0.77,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1286,"1) Glial tumour, with features raising the possibility of an ependymoma
2) Encapsulated blood and fibrin clot
","Integrated diagnosis: Subependymoma, CNS WHO grade 1
Histology: Ependymal tumour, compatible with subependymoma, CNS WHO grade 1 
Methylation profile: Subependymoma, supratentorial
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 366\NH22-1286,-0.104,0.032,0.068,0.148,0.195,0.139,-0.016,0.179,0.204,0.179,0.161,0.002,0.009,0.022,0.028,0.077,-0.01,0.007,0.044,0.014,0.026,0.002,-0.082,0.001,-0.045,-0.066,-0.063,-0.02,-0.017,methylated
NH22-1310,206486300130_R07C01,366,19/05/2022,6/8/2022,6/8/2022,20,MD,Diagnostic,366,1,NDP,Cleveland Clinic London,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,9/13/1980,42.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1310,"Oligodendroglioma, IDH-mutant, CNS WHO grade 2.
IDH1 (R132H IHC): Mutation  
ATRX (IHC): Retained 
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 366\NH22-1310,-0.026,0.021,0.02,-0.296,-0.3,0.016,0,-0.028,0.013,0.029,0.011,-0.004,0.003,0.007,0.044,0.012,-0.008,0.011,0.025,0.073,0.003,-0.023,-0.042,0.05,-0.012,-0.039,-0.497,-0.019,0.021,methylated
NH22-1293,206486300130_R08C01,366,19/05/2022,6/8/2022,6/8/2022,20,MD,Diagnostic,366,5,NDP,Royal London Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/29/1960,63,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.44,GBM_MID,0.76,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1293,"Oligodendroglioma, CNS WHO Grade 3 - see comment
","High-grade glioma, in keeping with glioblastoma, IDH wildtype, CNS WHO grade 4

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 366\NH22-1293,-0.011,-0.002,0.02,-0.058,0.005,0.073,0.049,-0.043,0,-0.034,-0.018,-0.024,0.078,0.041,0.042,0.006,0.048,0.018,0.023,0.008,-0.008,0.058,-0.011,0.052,-0.002,0.463,-0.058,-0.01,0.026,methylated
NH22-1354,206486300122_R02C01,367,20/05/2022,6/10/2022,6/10/2022,21,MD,Diagnostic,367,1,NDP,"Cambridge, Addenbrooke's Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,12/17/1963,59.3,"glioblastoma, IDH-wildtype, mesenchymal type",0.26,GBM_MES,0.1,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1354,"Integrated diagnosis: High grade glioma/glioneuronal tumour, corresponding to at least CNS WHO grade 3
Histology: High grade glioma/glioneuronal tumour, corresponding to at least CNS WHO grade 3
Methylation profile: No matching methylation class with two classifiers
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 367\NH22-1354,0.036,0.039,0.042,0.018,0.031,0.035,-0.128,0.059,0.092,0.042,0.04,-0.129,-0.101,-0.128,0.01,0.059,-0.056,-0.092,-0.125,-0.066,-0.063,-0.029,-0.144,-0.15,-0.154,-0.136,0.01,-0.173,-0.131,unmethylated
NH22-1341,206486300122_R04C01,367,20/05/2022,6/10/2022,6/10/2022,21,MD,Diagnostic,367,1,NDP,"Leeds, St James's University Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/16/1959,64.3,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,0.36,GBM_MID,0.59,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1341,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade intrinsic neoplasm
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 367\NH22-1341,0.788,0.036,0.062,0.434,1.113,0.042,0.021,0.31,0.332,0.38,0.062,0.255,0.26,0.608,-0.451,0.023,-0.421,-0.462,0.019,0.253,0.94,1.614,-0.077,0.017,-0.082,0.29,-0.005,0.052,0.013,unmethylated
NH22-1339,206486300122_R06C01,367,20/05/2022,6/10/2022,6/10/2022,21,MD,Diagnostic,367,2,NDP,Romford,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/19/1976,46.8,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1339,"Oligodendroglioma IDH mutant, CNS WHO grade 2.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 367\NH22-1339,-0.043,-0.03,0.05,-0.031,0.025,-0.001,0.036,0.138,0.108,0.101,0.113,-0.01,0.075,0.008,0.014,0.02,-0.01,0.049,0.026,-0.012,-0.053,-0.027,-0.027,0.026,-0.069,-0.056,-0.512,0.022,0.027,methylated
NH22-1369,206486300122_R07C01,367,24/05/2022,6/10/2022,6/10/2022,17,MD,Diagnostic,367,1,NDP,"Cambridge, Addenbrooke's Hospital",Recurrent SUbependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,1/24/1974,49,supratentorial subependymoma,0.35,SUBEPN_ST,0.21,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1369,"Integrated diagnosis: Subependymoma, CNS WHO grade 1
Histology: Subependymoma
Methylation profile: Subependymoma, supratentorial
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 367\NH22-1369,-0.085,0.005,0.068,0.071,-0.019,0.181,0.262,0.224,0.252,0.209,0.18,-0.321,-0.184,-0.269,0.021,-0.002,-0.031,0.032,0.013,0.184,0.197,0.137,-0.005,-0.033,-0.052,-0.034,0.153,-0.018,0.005,unmethylated
NH22-1357,206486300119_R03C01,368,24/05/2022,6/10/2022,6/10/2022,17,MD,Diagnostic,368,1,NDP,Bristol,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C1,6/20/1996,26.3,supratentorial pilocytic astrocytoma,0.99,LGG_PA_GGST,0.94,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1357,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, hemispheric
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 368\NH22-1357,0.009,-0.04,0.029,-0.003,-0.014,0.1,0.362,0.135,0.147,0.101,0.135,0.158,0.19,0.162,-0.011,-0.02,-0.034,0.022,0.145,-0.047,0.028,-0.026,-0.047,0.031,-0.035,-0.003,0.033,0.004,0.048,unmethylated
NH22-1358,206486300119_R04C01,368,24/05/2022,6/10/2022,6/10/2022,17,MD,Diagnostic,368,1,NDP,"Cardiff, University Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/21/1972,51.1,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.98,GBM_MID,0.99,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1358,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4.
Histology: High grade astrocytic tumour, corresponding to at least CNS WHO grade 3
Methylation profile: Glioblastoma, IDH-wildtype, subclass midline.
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 368\NH22-1358,0.18,0.182,-0.07,-0.03,0.545,-0.26,0.092,0.147,-0.006,1.329,0.063,-0.008,0.138,0.031,-0.255,0.044,-0.082,-0.308,0.019,-0.07,-0.018,0.041,-0.3,0.053,0.02,0.036,-0.107,-0.034,0.023,methylated
NH22-1372,206486300119_R07C01,368,25/05/2022,6/10/2022,6/10/2022,16,MD,Diagnostic,368,1,NDP,Bristol,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B3,11/15/1952,70.5,"glioblastoma, IDH-wildtype, mesenchymal type",0.15,GBM_RTKII,0.51,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1372,"Integrated diagnosis: CNS infiltration of a glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: CNS tissue with widespread infiltration of a high-grade glioma
Methylation profile: Glioblastoma, IDH-will type, subclass mesenchymal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 368\NH22-1372,0.014,0.016,0.041,-0.027,-0.014,-0.021,-0.242,0.3,0.292,0.223,0.193,-0.011,0.087,0,0.05,0.033,-0.184,-0.167,-0.016,-0.02,-0.024,0.037,-0.001,-0.161,0.006,0.011,-0.248,-0.166,0.079,unmethylated
NH22-1361,206486300046_R01C01,369,29/05/2022,6/22/2022,6/22/2022,24,MD,Diagnostic,369,2,NDP,NHNN,Ganglioglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF8A,3/27/1986,36.7,pleomorphic xanthoastrocytoma(-like),0.5,CONTR_REACT,0.46,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1361,"Ganglioglioma CNS WHO grade 1 ; BRAF V600E mutation (on immunohistochemistry) 
Hippocampal gliosis - see comments
","Integrated diagnosis: Ganglioglioma, BRAF V600E-mutant, CNS WHO grade 1
Histology: Ganglioglioma, CNS WHO grade 1
Methylation profile: No matching methylation class (see comment)
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 369\NH22-1361,0.085,-0.071,0.003,-0.037,-0.02,0.075,-0.012,-0.039,-0.042,-0.043,0.009,-0.01,-0.033,-0.003,-0.067,0.009,-0.025,-0.022,0.023,-0.017,-0.003,0.094,-0.03,-0.009,0.058,0.032,0.05,0.014,0.04,methylated
NH22-1376,206486300046_R02C01,369,30/05/2022,6/22/2022,6/22/2022,23,MD,Diagnostic,369,1,NDP,Romford,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B3,10/19/1957,65.5,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1376,"Oligodendroglioma, IDH-mutant, CNS WHO grade 3.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 369\NH22-1376,-0.012,-0.262,-0.047,-0.218,-0.198,0.063,0.002,-0.024,-0.013,-0.009,0.038,0.023,-0.039,-0.007,-0.002,0.172,-0.007,-0.031,0.007,0.065,0.039,0.027,-0.177,-0.002,-0.015,-0.079,-0.465,0.089,-0.005,methylated
NH22-1408,206486300046_R06C01,369,30/05/2022,6/22/2022,6/22/2022,23,MD,Diagnostic,369,1,NDP,"Cardiff, University Hospital","LGG, LG-Glioneuronal tumour, nos","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,3/28/1999,23.5,pleomorphic xanthoastrocytoma(-like),0.43,LGG_SEGA,0.34,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1408,"Integrated diagnosis: Features supportive of pleomorphic xanthoastrocytoma (grading see comment)
Histology: Pleomorphic xanthoastrocytoma/ganglioglioma spectrum (see comment)
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 369\NH22-1408,-0.098,-0.059,-0.037,-0.042,-0.09,-0.072,0.025,-0.021,0.151,0.02,0.075,-0.01,0.035,-0.115,-0.284,0.062,-0.012,-0.064,0,-0.085,0.012,0.156,0.043,-0.018,0.012,0.048,-0.087,-0.043,0.04,unmethylated
NH22-1194,206486300046_R07C01,369,30/05/2022,6/22/2022,6/22/2022,23,MD,Diagnostic,369,1,NDP,Southampton General Hospital,Astrocytoma,"(4) IHC, sequencing, or copy number assay ambiguous",1A,3/9/1968,54.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.93,AIDH,0.97,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1194,"Astrocytoma, IDH-mutant, CNS WHO grade 2 - for grading, see also comment
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained (19qLOH)          
EGFR: Amplification          
CDKN2A/B: No deletion           
","Integrated diagnosis: Astrocytoma, IDH-mutant, grading see comment
Histology: Astrocytoma, IDH-mutant, histologically CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 369\NH22-1194,0.119,-0.057,0.042,-0.065,0.001,-0.593,-0.083,0.015,0.309,0.34,0.31,0.1,-0.009,0.056,-0.311,0.228,0.009,-0.226,0.009,-0.015,0.113,0.015,-0.036,0.048,0.015,0.002,-0.078,0.066,0.076,methylated
NH22-1427,206486300002_R02C01,371,6/6/2022,6/22/2022,6/22/2022,16,MD,Diagnostic,371,1,NDP,NHNN,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/11/1959,64.2,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.41,GBM_MES,0.4,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1427,"High grade glioma - see comment
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Diffuse high-grade glioma
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 371\NH22-1427,-0.038,-0.017,0.02,0.029,0.04,0.014,-0.24,0.716,0.267,0.241,0.194,-0.036,-0.025,0.02,-0.167,0.012,-0.01,0.017,0.007,-0.002,-0.042,0.008,-0.328,-0.019,-0.013,-0.02,-0.014,-0.035,-0.001,methylated
NH22-1457,206486300002_R03C01,371,7/6/2022,6/22/2022,6/22/2022,15,MD,Diagnostic,371,3,NDP,Nottingham University Hospital,Malignant neuroepithelial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,5/24/1967,55.8,"Diffuse hemispheric glioma, H3 G34-mutant",1,GBM_G34,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1457,"Integrated diagnosis: Diffuse hemispheric glioma, H3 G34-mutant
Histology: High-grade glioma
Methylation profile: Diffuse hemispheric glioma, H3 G34-mutant
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 371\NH22-1457,0.069,0.013,0.051,0.111,0.29,-0.05,-0.502,0.012,0.172,0.018,-0.051,0.012,0.155,0.011,-0.292,0.02,0.12,-0.005,0.069,0.051,-0.339,-0.404,-0.432,0.042,0.134,0.079,-0.097,-0.069,0.001,methylated
NH22-1456,206486300002_R04C01,371,7/6/2022,6/22/2022,6/22/2022,15,MD,Diagnostic,371,1,NDP,Nottingham University Hospital,IDH-mutant glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,6/11/1990,32.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1456,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2 (see comment)
Histology: Astrocytoma, CNS WHO grade 2
Methylation profile: IDH glioma, subclass astrocytoma (lower grade)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 371\NH22-1456,-0.019,-0.102,0.037,0.016,-0.029,0.023,0.063,-0.02,-0.016,-0.015,-0.025,-0.015,0.096,0.046,0.015,0.018,0.04,-0.013,0.154,-0.062,0.05,0.067,-0.07,0.042,-0.009,0.043,-0.041,-0.002,0.083,methylated
NH22-1454,206486300002_R05C01,371,7/6/2022,6/22/2022,6/22/2022,15,MD,Diagnostic,371,1,NDP,"Cardiff, University Hospital",High grade glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A4,2/25/1954,69.3,"glioblastoma, IDH-wildtype, RTK1 type",0.99,GBM_RTKI,0.88,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1454,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 371\NH22-1454,-0.014,-0.017,-0.008,0.013,0.071,0.028,0.097,0.256,0.29,0.319,0.222,-0.044,0.008,-0.039,-1.71,0.032,-0.378,-0.34,-0.034,-0.031,-0.059,0.093,-0.043,-0.045,0.037,-0.04,-0.07,-0.033,0.02,methylated
NH21-2260,206486300002_R06C01,371,7/6/2022,6/22/2022,6/22/2022,15,MD,Diagnostic,371,1,NDP,Southampton General Hospital,"High grade glioma, IDH-wt","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/26/1980,41.7,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.97,GBM_RTKI,0.91,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2260,"Anaplastic astrocytoma, IDH-wildtype (WHO grade III)  see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
Histone H3F3A: No mutation     
BRAF (V600E): No mutation           
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Anaplastic astrocytoma
Methylation profile: Glioblastoma, IDH-wildtype (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 371\NH21-2260,0.17,0.026,0.045,0.099,0.023,-0.072,-0.132,1.636,0.454,0.124,0.286,-0.112,-0.079,0.011,0.028,0.158,-1.419,-0.575,-0.042,0.306,1.068,2.117,-0.144,0.117,0.104,0.091,-0.244,-0.007,0.075,unmethylated
NH22-1459,206486300002_R07C01,371,7/6/2022,6/22/2022,6/22/2022,15,MD,Diagnostic,371,1,NDP,"Liverpool, The Walton Centre","Glioma, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,1/29/1961,62.2,papillary glioneuronal tumour,0.4,ANAPA,0.23,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1459,"Integrated diagnosis: Papillary glioneuronal tumour, CNS WHO grade 1
Histology: Glioneuronal tumour with papillary morphology
Methylation profile: Papillary glioneuronal tumour PRKCA-fused
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 371\NH22-1459,-0.001,0.002,0.008,-0.032,-0.043,0.046,0.042,-0.064,-0.043,-0.029,-0.016,0.012,0.094,-0.016,0.035,0.003,0.024,0.002,0.042,-0.052,-0.029,0.079,-0.004,-0.432,0.05,0.044,-0.018,0.064,0.019,unmethylated
NH22-1192,206486300002_R08C01,371,7/6/2022,6/22/2022,6/22/2022,15,MD,Diagnostic,371,1,NDP,Southampton General Hospital,Suggestive of HGA with piloid features,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1B,9/30/1948,74.6,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.53,GBM_MID,0.49,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1192,"Suggestive of high grade astrocytoma with piloid features - see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)               
CDKN2A/B: Deletion
","Integrated diagnosis: Glioblastoma, IDH-wildtype (see comment)
Histology: High grade glioma
Methylation profile: Glioblastoma, IDH-wildtype (see comment)
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 371\NH22-1192,0.079,-0.077,-0.056,0.114,0.12,0.141,0.176,0.036,0.015,0.018,0.038,0.235,0.072,0.044,-1.401,0.066,-0.162,-0.122,0.183,0.048,0.071,0.249,0.003,0.18,0.289,0.254,-0.229,-0.234,-0.143,methylated
NH22-1475,206486300016_R01C01,372,9/6/2022,6/24/2022,6/24/2022,15,MD,Diagnostic,372,1,NDP,"Cardiff, University Hospital","Astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A4,11/4/1976,46.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.25,AIDH_HG,0.66,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1475,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3 - see comment
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, high grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 372\NH22-1475,-0.012,-0.15,-0.012,-0.016,0.123,0.068,-0.117,0.114,0.047,0.013,0.064,-0.004,0.201,0.681,-0.092,-0.105,0.035,-0.209,0.051,-0.084,-0.107,-0.029,-0.028,-0.039,-0.025,-0.003,-0.028,-0.105,-0.047,methylated
NH22-1473,206486300016_R02C01,372,9/6/2022,6/24/2022,6/24/2022,15,MD,Diagnostic,372,1,NDP,Plymouth,LGG or glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,9/2/1983,39.3,infratentorial pilocytic astrocytoma,0.47,LGG_PAPF,0.66,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1473,"Integrated diagnosis: Low grade glioma - see comment
Histology: Low grade glioma
Methylation profile: Pilocytic astrocytoma, infratentorial - see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 372\NH22-1473,-0.042,0.014,0.002,0.006,-0.098,0.087,0.137,0.073,0.341,0.05,0.183,-0.021,0.036,0.003,0.026,0.014,-0.03,-0.017,0.006,0.001,-0.03,-0.02,0.012,-0.02,-0.018,-0.033,-0.038,-0.02,-0.003,unmethylated
NH22-1474,206486300016_R03C01,372,9/6/2022,6/24/2022,6/24/2022,15,MD,Diagnostic,372,5,NDP,"Middlesbrough, James Cook Hospital","Cerebellar glioma, nos","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,10/31/1987,35.1,infratentorial pilocytic astrocytoma,0.94,LGG_PAPF,0.72,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1474,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glioma, compatible with pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, infratentorial
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 372\NH22-1474,0.005,-0.018,-0.004,-0.013,-0.086,0.03,0.068,-0.019,-0.002,-0.034,-0.017,0.13,0.026,-0.014,0.009,0.002,-0.001,0,0.009,-0.019,-0.041,0.006,0.022,-0.022,0.07,0.024,-0.008,0.006,0.019,methylated
NH22-1444,206486300016_R04C01,372,9/6/2022,6/24/2022,6/24/2022,15,MD,Diagnostic,372,4,NDP,Romford,GBM (born in 1986),"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,5/24/1986,36.5,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.65,AIDH,0.84,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1444,"High grade IDH mutant glioma - see comment
IDH1 (R132H IHC): Mutation       
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: High grade glioma, IDH-mutant
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 372\NH22-1444,-0.109,-0.032,0.092,-0.095,-0.007,0.061,-0.003,-0.006,-0.017,0.481,0.155,-0.114,0.041,0.082,-0.232,-0.01,-0.017,0.002,-0.019,0.028,-0.039,0.117,-0.213,0.017,-0.035,-0.046,-0.103,-0.009,0.023,methylated
NH22-1440,206486300016_R05C01,372,9/6/2022,6/24/2022,6/24/2022,15,MD,Diagnostic,372,5,NDP,NHNN,Astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,5/11/1976,46.7,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,OIDH,1,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1440,"Oligodendroglioma IDH mutant, CNS WHO grade 2
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 372\NH22-1440,-0.033,-0.024,0.038,-0.125,-0.206,0.033,-0.005,-0.038,0.01,-0.002,0.011,0.01,0.027,0.018,0.014,0.001,-0.004,0.004,-0.003,-0.023,-0.015,-0.038,-0.147,0.014,-0.022,-0.027,-0.386,-0.095,-0.059,methylated
NH22-1428,206486300016_R06C01,372,10/6/2022,6/24/2022,6/24/2022,14,MD,Diagnostic,372,4,NDP,NHNN,Oligodendroglioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,2/8/1972,51,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.9,AIDH,0.99,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1428,"Astrocytoma IDH mutant, CNS WHO grade 4.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4 - for grading, see also comment
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 372\NH22-1428,-0.067,-0.054,0.053,-0.056,-0.035,0.072,-0.391,-0.008,-0.025,0.251,0.197,-0.005,0.103,0.053,0.047,0.012,-0.336,-0.327,0.035,-0.006,-0.027,-0.031,-0.008,-0.009,-0.051,-0.007,-0.026,-0.321,-0.361,methylated
NH22-1503,206486300016_R07C01,372,10/6/2022,6/24/2022,6/24/2022,14,MD,Diagnostic,372,1,NDP,Nottingham University Hospital,"Clear cell tumour, nos","(2) unusual histology, location, demographics",C1,11/16/2011,10.7,"diffuse glioneuronal tumour, non defined type",1,DLGNT,0.73,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1503,"Integrated diagnosis: Glial or glioneuronal tumour - see comment
Histology: Glial or glioneuronal tumour
Methylation profile: Diffuse leptomeningeal glioneuronal tumour
MGMT promoter (Illumina array): Unmethylated 
  
","Low grade glioneuronal tumour with FGFR1:TACC1 fusion, see comment
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 372\NH22-1503,0.023,-0.05,0.017,-0.065,-0.012,0.068,0.05,-0.038,-0.013,-0.041,-0.015,0.181,0.137,0.022,0.092,-0.067,0.046,0.018,0.059,0.017,-0.013,0.017,0.037,0.009,-0.007,0.041,-0.034,0.017,0.05,unmethylated
NH22-1498,206486300016_R08C01,372,10/6/2022,6/24/2022,6/24/2022,14,MD,Diagnostic,372,1,NDP,Nottingham University Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/22/1957,65.6,"glioblastoma, IDH-wildtype, RTK1 type",0.23,GBM_RTKII,0.42,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1498,"Integrated diagnosis: Suggestive of glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK I
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 372\NH22-1498,1.644,0.02,0.034,0.057,0.111,0.005,-0.033,1.788,0.236,0.12,0.193,0.005,0.013,-0.086,-0.01,-0.025,-0.283,-0.581,0.046,-0.053,0.968,0.05,0.013,0.194,0.251,0.243,-0.016,-0.061,0.122,unmethylated
NH22-1494,206486300009_R02C01,373,10/6/2022,6/29/2022,6/29/2022,19,MD,Diagnostic,373,1,NDP,Oxford John Radcliffe Hospital,H3 K27M glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1,1/8/1973,50.1,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.56,DMG_K27,0.98,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1494,"Integrated diagnosis: Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4
Histology: Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4
Methylation profile: Diffuse midline glioma, H3 K27-altered
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 373\NH22-1494,-0.057,-0.011,0.031,-0.038,0.248,0.084,0.071,0.011,0.008,-0.041,-0.011,-0.024,0.125,0.017,0.078,0.02,-0.11,-0.254,0.044,-0.029,-0.052,0.062,0.049,-0.005,0.03,0.031,-0.104,-0.052,0.277,unmethylated
NH22-1543,206486300009_R05C01,373,13/06/2022,6/29/2022,6/29/2022,16,MD,Diagnostic,373,1,NDP,Oxford John Radcliffe Hospital,DNET,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2,11/9/1990,32,papillary glioneuronal tumour,0.12,LGG_DNT,0.13,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1543,"Integrated diagnosis: Dysembryoplastic neuroepithelial tumour, CNS WHO grade 1
Histology: Dysembryoplastic neuroepithelial tumour, CNS WHO grade 1
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 373\NH22-1543,0.103,0.128,-0.003,-0.089,-0.076,-0.03,0.218,0.757,0.096,0.083,0.048,0.059,0.161,0.119,-0.033,0.1,-0.046,-0.081,-0.2,0.069,-0.08,-0.024,0.059,0.009,-0.148,-0.021,0.196,0.064,0.3,unmethylated
NH22-1499,206486300009_R07C01,373,13/06/2022,6/29/2022,6/29/2022,16,MD,Diagnostic,373,1,NDP,Nottingham University Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/18/1952,70.8,"glioblastoma, IDH-wildtype, RTK2 type",0.18,GBM_RTKII,0.64,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1499,"Integrated diagnosis: Suggestive of glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK II
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 373\NH22-1499,0.228,-0.186,0.092,0.056,0.209,-0.104,-0.119,0.312,0.195,0.186,0.347,-0.025,-0.154,-0.109,-0.68,0.187,-0.58,-0.421,-0.029,-0.06,0.098,-0.027,-1.276,-0.02,-0.111,-0.047,0.362,0.064,0.186,unmethylated
NH22-1512,206486300009_R08C01,373,13/06/2022,6/29/2022,6/29/2022,16,MD,Diagnostic,373,6,NDP,Sheffield,GBM,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,2/3/1999,23.7,high-grade astrocytoma with piloid features,0.48,ANAPA,0.58,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1512,"Integrated diagnosis: Glioblastoma, CNS WHO grade 4 
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: See comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 373\NH22-1512,0.086,0.368,0.046,0.013,0.938,0.155,-0.311,-0.168,0.088,-0.502,-0.321,0.079,0.13,0.087,-0.345,0.056,-0.246,-0.255,-0.06,0.017,0.212,-0.075,-0.278,-0.39,0.142,0.048,0.038,0.101,0.16,unmethylated
NH22-1560,206486300093_R01C01,374,13/06/2022,6/29/2022,6/29/2022,16,MD,Diagnostic,374,4,NDP,Edinburgh,"Midline glioma, hypothalamic","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",9890,3/22/1964,59.1,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.47,ANAPA,0.65,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1560,"Histology: Glial neoplasm - see comment
Methylation profile: Inconclusive - see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 374\NH22-1560,0.012,-0.402,0.003,-0.027,-0.094,-0.001,0.046,-0.06,0.006,-0.062,0.002,-0.019,0.055,-0.003,-0.262,0.061,-0.034,0.015,0.036,-0.003,-0.04,0.001,-0.005,0.004,0.049,0.258,-0.03,-0.05,0.037,unmethylated
NH22-1317,206486300093_R02C01,374,13/06/2022,6/29/2022,6/29/2022,16,MD,Diagnostic,374,1,NDP,Newcastle,"Glioblastoma, repeat as #364 wrong gender…","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2C,10/3/1965,57.4,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type C]",1,LIPN,0.24,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1317,"Integrated diagnosis: Glioblastoma, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: High grade glioma - see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 374\NH22-1317,-0.157,0.022,0.054,0.013,0.082,-0.147,0.035,-0.073,-0.002,-0.033,-0.005,-0.028,-0.378,-0.015,-2.553,0.036,-0.009,0.082,0.588,-0.107,0.002,0.014,-0.567,-0.604,-0.525,-0.025,-0.642,0.006,0.037,unmethylated
NH22-1516,206486300093_R04C01,374,14/06/2022,6/29/2022,6/29/2022,15,MD,Diagnostic,374,5,NDP,"Charing Cross Hospital, London",Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,2/4/1966,57.2,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,OIDH,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1516,"Oligodendroglioma, IDH-mutant, CNS WHO grade 2.
IDH1 (R132H IHC): Mutation  
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 374\NH22-1516,-0.078,0.002,0.028,-0.013,-0.042,0.059,-0.003,-0.042,0.005,-0.062,0.01,-0.01,0.034,-0.023,-0.004,-0.025,-0.009,0.029,0.002,-0.031,-0.058,-0.021,-0.046,-0.016,0,0.005,-0.395,0.011,0.029,methylated
NH22-1480,206486300093_R05C01,374,14/06/2022,6/29/2022,6/29/2022,15,MD,Diagnostic,374,7,NDP,"Charing Cross Hospital, London",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,4/10/1998,24.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,0.94,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1480,"Astrocytoma, IDH-mutant, CNS WHO Grade 2.

IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, high grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 374\NH22-1480,0.047,-0.048,0.067,0.014,0.132,0.02,0.006,-0.056,-0.052,-0.195,-0.063,-0.116,0.268,0.505,-0.063,0.002,-0.037,0.044,-0.007,-0.577,-0.071,0.007,-0.828,0.01,0.079,0.004,-0.266,-0.054,-0.408,methylated
NH22-1463,206486300093_R06C01,374,14/06/2022,6/29/2022,6/29/2022,15,MD,Diagnostic,374,3,NDP,"Charing Cross Hospital, London",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,11/2/1987,35.1,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.9,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1463,"Glioblastoma, CNS WHO grade 4.
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK II subclass
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 374\NH22-1463,-0.035,0.039,0.047,-0.004,0.019,-0.051,-0.102,1.933,2.049,0.278,0.276,-0.013,0.026,0.115,-0.431,0.112,-0.439,-0.606,-0.064,0.076,0.061,0.14,0.032,0.035,-0.021,0.064,0.236,-0.076,0.04,methylated
NH22-1483,206486300093_R08C01,374,14/06/2022,6/29/2022,6/29/2022,15,MD,Diagnostic,374,5,NDP,"Charing Cross Hospital, London",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,7/1/1976,46.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1483,"Astrocytoma, IDH-mutant, CNS WHO grade 2.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 374\NH22-1483,-0.101,-0.083,0.059,-0.042,0.057,-0.019,-0.124,0.037,-0.008,-0.036,-0.016,0.017,0.082,0.107,0.062,0.052,-0.046,0.004,0.005,0.142,-0.136,-0.155,-0.043,-0.011,-0.01,0.017,-0.164,0,0.067,methylated
NH22-1517,206486300113_R01C01,375,14/06/2022,7/1/2022,7/1/2022,17,MD,Diagnostic,375,1,NDP,"Charing Cross Hospital, London",Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/10/1960,63.2,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.63,OIDH,0.79,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1517,"Oligodendroglioma, IDH-mutant, CNS WHO grade 3.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant, 1p/19q-codeleted, CNS WHO grade 3
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 375\NH22-1517,-0.045,-0.03,0.013,-0.128,-0.057,0.028,0.038,-0.016,0.001,0.023,-0.019,0.01,0.064,0.008,-0.015,-0.015,0.068,0.047,0.013,0.014,-0.056,-0.034,-0.084,-0.014,-0.037,-0.01,-0.223,-0.022,0.001,methylated
NH22-1515,206486300113_R02C01,375,14/06/2022,7/1/2022,7/1/2022,17,MD,Diagnostic,375,1,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,1/30/1980,43,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.99,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1515,"Astrocytoma, IDH-mutant, CNS WHO Grade 2.

IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 375\NH22-1515,-0.145,-0.041,0.032,-0.015,-0.005,0.012,-0.148,0.17,0.226,0.22,0.19,-0.006,0.088,0.01,-0.035,-0.014,0.017,-0.078,0.028,-0.004,-0.095,-0.182,-0.051,-0.025,-0.043,-0.04,-0.01,-0.011,-0.011,methylated
NH22-1265,206486300113_R03C01,375,15/06/2022,7/1/2022,7/1/2022,16,MD,Diagnostic,375,1,NDP,Bristol,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,11/4/1968,54.3,spinal ependymoma,0.99,EPN_SPINE,0.89,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1265,"Integrated diagnosis: Spinal ependymoma, best corresponding to CNS WHO grade 2
Histology: Low-grade glioma, in keeping with ependymal tumour,
Methylation profile: Spinal ependymoma 
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 375\NH22-1265,0.121,-0.085,-0.005,0.139,-0.325,0.068,-0.169,0.064,0.005,0.095,0.195,0.216,0.325,0.216,0.094,0.153,-0.189,-0.046,0.31,0.212,0.306,0.114,-0.728,0.093,-0.24,-0.309,0.181,-0.56,-0.316,unmethylated
NH22-1561,206486300113_R04C01,375,16/06/2022,7/1/2022,7/1/2022,15,MD,Diagnostic,375,1,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1B,11/2/1968,54.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1561,"Astrocytoma, IDH-mutant, CNS WHO grade 4
IDH1 (R132H IHC): Mutation  
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 375\NH22-1561,-0.021,0.037,0.029,-0.003,-0.01,0.046,-0.158,0.019,0.022,-0.006,0.024,-0.019,0.03,-0.004,0.015,0.02,0.013,-0.366,0.022,0.039,-0.154,-0.166,-0.045,-0.06,-0.052,0.013,-0.442,-0.015,0.017,methylated
NH22-1578,206486300113_R05C01,375,16/06/2022,7/1/2022,7/1/2022,15,MD,Diagnostic,375,1,NDP,NHNN,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,7/18/1980,42.5,"glioblastoma, IDH-wildtype, RTK2 type",0.72,GBM_RTKII,0.85,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1578,"Glioblastoma, CNS WHO Grade 4 - see comment. 

IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
","Integrated diagnosis: Glioblastoma, IDH-wild-type, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subtype see comment
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 375\NH22-1578,-0.131,-0.026,0.024,-0.014,-0.007,0.056,0.063,1.013,0.209,0.237,0.141,-0.018,0.065,-0.013,-0.652,-0.011,-0.217,-0.173,-0.018,-0.03,-0.043,-0.021,-0.052,-0.034,0.009,0.056,0.166,0.021,-0.028,unmethylated
NH22-1559,206486300087_R01C01,376,16/06/2022,7/1/2022,7/1/2022,15,MD,Diagnostic,376,1,NDP,Bristol,Diffuse Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,1/15/1983,40,ganglioglioma,0.27,LGG_DNT,0.55,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1559,"Integrated diagnosis: CNS tissue fragments, no molecular profile established
Histology: CNS tissue fragments
Methylation profile: No matching methylation classes.
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 376\NH22-1559,0.06,0.031,-0.003,0.035,0.057,0.002,0.001,0.057,0.114,0.027,0.073,-0.01,0.038,0.033,-0.019,0.03,0.026,-0.019,0.031,0.045,0.109,0.199,-0.026,-0.043,-0.042,0.023,-0.063,-0.031,0.049,unmethylated
NH22-1587,206486300087_R03C01,376,16/06/2022,7/1/2022,7/1/2022,15,MD,Diagnostic,376,1,NDP,Bristol,Anaplastic Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,11/26/1965,57.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.76,AIDH,0.2,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1587,"Integrated diagnosis: Oligodendroglioma, IDH-mutant, 1p/19q-codeleted, CNS WHO grade 3
Histology: High-grade glioma, NOS
Methylation profile: Oligosarcoma, IDH-mutant (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 376\NH22-1587,0.008,-0.017,0.016,-0.066,-0.006,0.069,-0.058,0.06,0.037,-0.025,-0.019,-0.016,0.024,0.032,-0.136,0.016,0.012,0.029,-0.028,-0.13,-0.058,-0.007,-0.095,-0.05,-0.054,0.016,-0.191,-0.022,-0.023,unmethylated
NH22-1607,206486300087_R04C01,376,17/06/2022,7/1/2022,7/1/2022,14,MD,Diagnostic,376,1,NDP,"Cardiff, University Hospital",Glial/Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/15/1966,56.5,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.29,LGG_PAPF,0.27,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1607,"Integrated diagnosis: Low grade glial/glioneuronal tumour (see comment)
Histology: Low grade glioma
Methylation profile: Low grade glial/glioneuronal/neuroepithelial tumours (see comment)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 376\NH22-1607,-0.044,0.014,0.038,0.001,-0.042,0.031,0.206,-0.035,-0.056,-0.127,-0.025,0.134,0.193,0.195,0.053,0.03,0.044,0.031,0.012,0.114,0.073,0.241,-0.037,-0.048,-0.06,-0.02,-0.017,-0.012,0.008,methylated
NH22-1611,206486300087_R05C01,376,17/06/2022,7/1/2022,7/1/2022,14,MD,Diagnostic,376,1,NDP,Nottingham University Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/30/1955,67.7,"glioblastoma, IDH-wildtype, mesenchymal type",0.89,GBM_MES,0.92,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1611,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade astrocytoma
Methylation profile: Glioblastoma, IDH wild type, mesenchymal subtype
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 376\NH22-1611,-0.036,-0.018,0.039,-0.046,-0.013,0.03,0.044,0.187,0.223,-0.084,0.08,-0.146,-0.012,-0.082,-0.329,-0.018,-0.051,-0.105,-0.021,-0.048,-0.038,0.016,0.042,0.023,0.01,0.047,-0.048,-0.008,0.018,methylated
NH22-1500,206486300087_R08C01,376,17/06/2022,7/1/2022,7/1/2022,14,MD,Diagnostic,376,1,NDP,Nottingham University Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,12/30/1950,72.5,"glioblastoma, IDH-wildtype, RTK1 type",0.68,GBM_RTKI,0.39,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1500,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 376\NH22-1500,0.031,0.641,0.037,0.029,0.04,0.058,0.081,0.32,0.416,1.242,0.269,-0.072,0.074,-0.04,0.006,0.025,-0.118,-0.177,-0.081,0.039,0.52,-0.067,-0.05,-0.012,-0.02,0.002,-0.119,-0.001,0.025,unmethylated
NH22-1276,206486300112_R02C01,377,17/06/2022,7/1/2022,7/1/2022,14,MD,Diagnostic,377,1,NDP,St George's Hospital London,"Glioma, IDH wildtype","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/30/1953,69.6,ganglioglioma,0.48,GBM_MES,0.43,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1276,"Glioma, IDH-wildtype, for grading, see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: No amplification          
TERT promoter: Mutation
MGMT Promoter: Methylated (>0-5%)
","Integrated diagnosis: Glioma, IDH-wildtype, possibly high-grade
Histology: Glioma, IDH-wildtype, see previous report
Methylation profile: Control tissue, hemispheric cortex.
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 377\NH22-1276,-0.022,0.049,0.041,-0.052,-0.092,-0.013,-0.297,0.077,-0.077,-0.205,-0.237,0.048,0.144,0.016,-0.122,0.034,-0.123,-0.179,0.009,0.042,0.074,0.129,-0.019,0.027,-0.357,0.012,-0.03,-0.042,0.012,methylated
NH22-1610,206486300112_R03C01,377,17/06/2022,7/1/2022,7/1/2022,14,MD,Diagnostic,377,1,NDP,"Cambridge, Addenbrooke's Hospital",Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,7/1/1974,48.7,infratentorial pilocytic astrocytoma,0.63,LGG_PAPF,0.21,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1610,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glioma, with features in keeping with a pilocytic astrocytoma
Methylation profile: Pilocytic astrocytoma, infratentorial
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 377\NH22-1610,-0.207,-0.122,0.065,0.011,-0.002,-0.035,-0.192,-0.084,0.109,-0.106,-0.03,-0.001,0.099,-0.053,-0.032,-0.064,0.073,-0.018,-0.096,-0.134,-0.208,0.14,0.115,-0.141,0.437,-0.06,-0.144,0.015,-0.039,unmethylated
NH22-1641,206486300112_R05C01,377,17/06/2022,7/1/2022,7/1/2022,14,MD,Diagnostic,377,1,NDP,"Cardiff, University Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,9/9/1961,61.6,myxopapillary ependymoma,1,EPN_MPE,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1641,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 377\NH22-1641,-0.131,0.058,0.049,-0.011,-0.014,-0.009,-0.007,-0.042,-0.042,-0.048,-0.014,-0.007,0.07,-0.056,0.003,0.083,0.003,0.027,0.038,-0.04,-0.041,0.031,0.017,0.004,-0.029,0.037,0.044,-0.105,0,unmethylated
NH22-1630,206486300112_R07C01,377,17/06/2022,7/1/2022,7/1/2022,14,MD,Diagnostic,377,1,NDP,"Cardiff, University Hospital",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/29/1979,43.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1630,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, (IDH-mutant), CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, low grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 377\NH22-1630,0.016,-0.034,0.081,-0.004,-0.005,-0.031,-0.042,0.054,-0.003,-0.065,0.033,-0.059,0.076,0.008,-0.045,0.035,-0.039,-0.044,0.077,-0.032,-0.092,-0.177,-0.019,-0.002,0.014,-0.014,-0.018,-0.024,0.077,methylated
NH22-897,206486300024_R02C01,378,17/06/2022,7/6/2022,7/6/2022,19,MD,Diagnostic,378,1,NDP,Royal London Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF3B,6/30/1962,60.6,"glioblastoma, IDH-wildtype, RTK1 type",0.98,GBM_RTKI,0.58,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-897,"Glioblastoma, CNS WHO grade 4  see comment.
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Glioblastoma, IDH-wildtype, CNS WHO grade 4
ATRX (IHC): Retained
EGFR: No amplification     
TERT promoter: Mutation
MGMT Promoter: Methylated (>25%)

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 378\NH22-897,0.014,-0.034,-0.041,0.011,0.001,0.046,0.15,0.152,0.151,0.092,0.069,0.058,0.11,0.119,0.099,0.087,-0.532,-0.037,-0.046,-0.062,-0.092,-0.067,-0.133,-0.019,-0.085,-0.043,-0.014,0.061,0.021,methylated
NH22-1654,206486300024_R03C01,378,22/06/2022,7/6/2022,7/6/2022,14,MD,Diagnostic,378,1,NDP,"Belfast, Royal Victoria Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/22/1945,78.2,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,0.99,GBM_MID,0.39,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1654,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma, in keeping with glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subtype posterior fossa (novel)
MGMT promoter (Illumina array): Methylated 

",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 378\NH22-1654,0.005,0.118,-0.017,-0.062,0.496,-0.077,0.004,0.132,0.341,-0.007,0.108,0.065,0.097,0.126,-1.523,0.645,0.093,-0.068,0.194,0.253,0.159,0.319,0.026,-0.173,-0.027,0.103,-0.232,-0.098,-0.029,methylated
NH22-1442,206486300024_R04C01,378,22/06/2022,7/6/2022,7/6/2022,14,MD,Diagnostic,378,4,NDP,Oxford John Radcliffe Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,4/25/1956,67.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.91,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1442,"Integrated diagnosis: Astrocytoma, IDH-mutant, grading see comment
Histology: IDH-mutant glioma, morphologically resembling oligodendroglioma.
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 378\NH22-1442,-0.069,-0.054,0.007,-0.066,-0.063,0.007,0.101,-0.027,-0.001,0.292,0.205,-0.016,0.06,0.03,0.039,-0.023,0.054,0.01,-0.027,0.039,0.009,0.102,0.017,-0.166,0.127,0.209,0.013,-0.007,-0.04,methylated
NH22-1534,206486300024_R06C01,378,22/06/2022,7/6/2022,7/6/2022,14,MD,Diagnostic,378,1,NDP,"Charing Cross Hospital, London",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",4,3/16/1993,29.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.98,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1534,"Astrocytoma, IDH-mutant, CNS WHO grade 3 (see comment)
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)

","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 378\NH22-1534,0.051,-0.01,-0.016,-0.037,-0.043,-0.04,0.08,0.097,0.079,0.049,0.015,-0.006,0.092,0.051,0.016,0.012,0.041,-0.022,0.029,0.052,-0.046,-0.083,-0.04,0.078,0.047,0.018,-0.191,-0.018,-0.001,methylated
NH22-1621,206486300007_R01C01,379,22/06/2022,7/8/2022,7/8/2022,16,MD,Diagnostic,379,1,NDP,"Charing Cross Hospital, London",Glioma,(1) small biopsy or nonrepresentative sample;,DEF1A,11/25/1981,41.1,pleomorphic xanthoastrocytoma(-like),0.98,PXA,0.95,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1621,"Small fragment of glial tumour, NOS
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 379\NH22-1621,0.039,0.052,0.016,0.019,0.005,-0.049,-0.03,0.055,0.007,-0.071,0.052,-0.036,-0.001,0.1,-0.636,0.039,-0.023,0.01,0.021,-0.011,0.03,0.07,-0.103,-0.101,-0.163,0.011,0.055,-0.303,-0.225,unmethylated
NH22-1697,206486300031_R01C01,380,24/06/2022,7/8/2022,7/8/2022,14,MD,Diagnostic,380,1,NDP,James Cook,Inf GBM most likely,(1) small biopsy or nonrepresentative sample;,A1,9/24/1948,74.8,"glioblastoma, IDH-wildtype, mesenchymal type",0.52,GBM_MES,0.25,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1697,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: CNS white matter with diffuse infiltration of a glioma
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Methylated 
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: CNS white matter with diffuse infiltration of a glioma
Sequencing/copy number: EGFR amplification, TERT promoter mutation, IDH-wildtype
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Unmethylated Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 380\NH22-1697,0.591,-0.088,0.006,-0.031,0.394,0.043,0.04,0.721,0,-0.042,0.064,-0.024,0.037,-0.044,-0.234,0.011,-0.066,-0.072,0.022,-0.041,-0.024,0.116,0.018,-0.051,-0.033,0.052,-0.045,0.047,0.029,methylated
NH22-1624,206486300031_R02C01,380,24/06/2022,7/8/2022,7/8/2022,14,MD,Diagnostic,380,5,NDP,"Charing Cross Hospital, London",Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/28/1976,46.9,extraventricular neurocytoma,0.98,LGG_PA_GGST,0.22,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1624,"Glioneuronal tumour, CNS WHO grade 1.
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 380\NH22-1624,-0.15,-0.036,0.057,-0.038,-0.114,0.071,0.049,-0.138,0.047,-0.166,-0.021,0.427,0.06,0.045,0.066,-0.043,0.108,-0.092,-0.095,-0.064,-0.137,0.067,0.17,0.008,0.009,-0.02,-0.309,0.014,-0.052,unmethylated
NH22-1664,206486300031_R03C01,380,24/06/2022,7/8/2022,7/8/2022,14,MD,Diagnostic,380,2,NDP,"Charing Cross Hospital, London","Astrocytoma, IDH-mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,7/21/1986,36.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.99,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1664,"Astrocytoma IDH-mutant CNS WHO grade 4 
IDH1 (R132H IHC): Mutation - see comment 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, subclass high-grade astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 380\NH22-1664,-0.054,-0.349,0.059,-0.068,-0.002,-0.237,0.038,-0.018,-0.061,-0.084,0.01,0.022,0.113,0.367,0.003,-0.031,-0.098,-0.391,-0.011,-0.058,0.035,0.072,-0.065,-0.015,-0.133,0.274,-0.448,0.013,0.041,methylated
NH22-1674,206486300031_R04C01,380,24/06/2022,7/8/2022,7/8/2022,14,MD,Diagnostic,380,1,NDP,Brighton and Sussex Hospital,"Astrocytoma, H3K27 mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,9/12/1956,66.7,"control tissue, cerebellar hemisphere",0.85,CONTR_CEBM,0.99,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1674,"High grade astrocytoma, H3K27 mutant - see comment, CNS WHO grade 3 (at least)
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Possible loss of expression
Further molecular tests: Pending
","Integrated diagnosis: High-grade astrocytoma, H3K27M mutant, grading see comment
Histology: Multiple cerebellar fragments and diffuse glioma, H3K27M mutant.
Methylation profile: Control tissue, cerebellar hemisphere
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 380\NH22-1674,0.042,0.002,-0.027,-0.091,0.085,-0.064,-0.099,0.065,-0.015,-0.095,0.004,0.012,0.03,-0.043,-0.208,0.175,0.072,-0.055,-0.038,-0.092,0.022,0.171,0,0.001,-0.031,0.065,-0.183,0.012,0.109,unmethylated
NH22-1613,206486300031_R07C01,380,27/06/2022,7/8/2022,7/8/2022,11,MD,Diagnostic,380,1,NDP,NHNN,Pleomorphic Xanthoastrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,8/15/2000,22.2,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1613,"Pleomorphic xanthoastrocytoma, CNS WHO Grade 2 - see comment.
","Integrated diagnosis: Pleomorphic xanthoastrocytoma, CNS WHO grade 2
Histology: Pleomorphic xanthoastrocytoma, CNS WHO grade 2
Methylation profile: Pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 380\NH22-1613,-0.088,0.018,0.046,-0.025,-0.009,0.079,0.052,0.145,0.183,0.073,0.109,0.017,0.078,-0.017,-0.429,0.016,0.054,-0.018,0.025,0.013,-0.052,0.033,0.043,-0.091,-0.109,0.002,-0.152,0.022,-0.029,unmethylated
NH22-1729,206486300031_R08C01,380,27/06/2022,7/8/2022,7/8/2022,11,MD,Diagnostic,380,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,4/17/1998,24.5,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.98,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1729,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, hemispheric
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 380\NH22-1729,-0.007,0.005,0.01,0,-0.013,0.084,0.034,0.233,0.368,0.353,0.28,-0.004,0.067,0.054,0.033,-0.014,0.057,0.02,0.048,0.149,0.139,0.134,0.027,0.005,-0.006,0.037,-0.074,0.02,0.062,unmethylated
NH22-1725,206486300022_R01C01,381,27/06/2022,7/13/2022,7/13/2022,16,MD,Diagnostic,381,1,NDP,Nottingham University Hospital,"Glioma, nos","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/18/1985,38,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1725,"Integrated diagnosis: Oligodendroglioma, IDH-mutant, 1p/19q-codeleted, CNS WHO grade 2.
Histology: Low grade glioma
Methylation profile: Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 381\NH22-1725,-0.113,-0.051,0.06,-0.093,0.043,0.006,0.002,0.032,0.039,0.007,-0.032,0,0.039,0.037,0.123,-0.009,0.067,0.024,0.169,-0.025,0.14,0.011,0.004,0.269,0.217,0.282,-0.369,-0.094,0.062,methylated
NH22-1586,206486300022_R06C01,381,1/7/2022,7/13/2022,7/13/2022,12,MD,Diagnostic,381,1,NDP,Southampton General Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,12/15/1978,44.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,0.99,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1586,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, high grade
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 381\NH22-1586,0.23,-0.043,0.052,0.007,0.009,-0.406,-0.049,0.05,0,-0.152,0.027,-0.009,0.033,0.045,-0.007,0.058,-0.294,-0.441,0.238,0.046,0.035,-0.015,-0.015,0.057,0.063,0.024,-0.182,-0.039,0.067,unmethylated
NH22-1710,206486300022_R07C01,381,2/7/2022,7/13/2022,7/13/2022,11,MD,Diagnostic,381,2,NDP,Romford,"HGG, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A13,8/17/1995,27.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.78,OIDH,0.58,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1710,"High grade glioma, IDH-Mutant - See comment.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3
Histology: IDH mutant glioma, CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 381\NH22-1710,-0.013,-0.024,0.039,-0.039,-0.073,0.036,0.04,-0.016,0.003,-0.04,0.01,0.204,0.257,0.214,-0.021,0.009,-0.243,-0.301,0.156,-0.05,0.688,-0.058,-0.051,-0.035,-0.002,0.223,-0.449,-0.041,0.024,methylated
NH22-1694,206486300165_R03C01,382,2/7/2022,7/13/2022,7/13/2022,11,MD,Diagnostic,382,1,NDP,"Charing Cross Hospital, London",?glioma vs reactive gliosis,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,3/14/1949,74.3,ganglioglioma,0.75,LGG_GG,0.3,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1694,"
Mildly hypercellular cortical biopsies with no definite tumour confirmed - see comment 
","Integrated diagnosis: CNS tissue fragment with possible infiltration of a glioma (see comment)
Histology: CNS tissue fragment, possible glioma infiltration
Methylation profile: Control tissue, hemispheric cortex
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 382\NH22-1694,-0.055,-0.021,-0.004,-0.013,-0.051,-0.042,-0.192,0.215,0.227,0.165,0.161,-0.027,0.053,-0.012,0.01,-0.037,-0.091,-0.081,-0.046,-0.071,-0.03,-0.059,-0.129,-0.02,-0.027,-0.014,-0.013,0.006,0.022,unmethylated
NH22-1702,206486300165_R05C01,382,2/7/2022,7/13/2022,7/13/2022,11,MD,Diagnostic,382,1,NDP,"Charing Cross Hospital, London","Astrocytoma, IDH-mutant, G 3","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2A,5/31/1979,43.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.94,AIDH_HG,0.76,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1702,"Astrocytoma, IDH-Mutant, CNS WHO grade 3.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Probable loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, high-grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 382\NH22-1702,-0.009,-0.034,0.027,0.002,0.002,0.011,-0.028,0.21,0.05,-0.026,-0.004,-0.021,0.059,0.025,-0.016,-0.012,0.007,-0.08,-0.03,0.148,0.43,-0.273,-0.036,0.015,-0.036,0.04,-0.017,-0.015,0.023,methylated
NH22-1734,206486300165_R06C01,382,2/7/2022,7/13/2022,7/13/2022,11,MD,Diagnostic,382,1,NDP,Cleveland Clinic London,"Glioma, nos","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,6/6/1958,65,ganglioglioma,0.38,GBM_MES,0.64,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1734,"Glioma with focal high grade features- See comment.
IDH1 (R132H IHC): No mutation      
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioma with focal high-grade features
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK2
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 382\NH22-1734,-0.066,0.069,0.038,0.039,-0.038,0.01,0.013,1.202,0.199,0.188,0.326,-0.004,0.017,-0.012,-0.12,0.005,-0.237,-0.217,-0.057,-0.091,0.506,1.162,-0.032,-0.025,-0.052,0.024,-0.025,-0.253,-0.212,unmethylated
NH22-1736,206486300165_R07C01,382,2/7/2022,7/13/2022,7/13/2022,11,MD,Diagnostic,382,1,NDP,"Charing Cross Hospital, London",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,7/7/1972,50.7,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.91,0.56,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1736,"High grade glioma - See comment.
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 382\NH22-1736,-0.045,-0.026,0.028,-0.001,-0.052,0.032,0.047,0.1,0.143,0.153,0.117,0.007,0.066,0.004,-0.358,0.012,-0.088,-0.031,-0.037,-0.052,-0.051,0.003,-0.002,-0.047,-0.059,-0.023,-0.042,-0.013,-0.015,methylated
NH22-1786,206486300163_R01C01,383,2/7/2022,7/20/2022,7/20/2022,18,MD,Diagnostic,383,1,NDP,Nottingham University Hospital,"Glioma, nos","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,11/12/1976,46.3,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.67,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1786,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 383\NH22-1786,-0.082,-0.04,-0.011,-0.128,0.027,0.08,-0.075,0.016,0.051,-0.006,0.018,0.049,0.13,0.04,-0.051,0.005,-0.227,-0.298,-0.137,-0.301,-0.138,-0.214,-0.242,-0.114,-0.152,-0.259,-0.035,-0.075,0.07,methylated
NH22-1742,206486300163_R04C01,383,4/7/2022,7/20/2022,7/20/2022,16,MD,Diagnostic,383,1,NDP,NHNN,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,9/1/1979,43.4,myxopapillary ependymoma,1,EPN_MPE,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1742,"Myxopapillary ependymoma, CNS WHO grade 2.
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 383\NH22-1742,-0.12,-0.069,-0.066,0.055,0.111,0.124,-0.146,0.038,0.106,0.058,0.127,0.12,0.119,0.091,0.372,0.401,-0.144,-0.119,-0.157,0.006,0.036,0.132,0.076,-0.186,-0.241,-0.133,0.393,-0.134,-0.105,unmethylated
NH22-1775,206486300163_R07C01,383,7/7/2022,7/20/2022,7/20/2022,13,MD,Diagnostic,383,7,NDP,Royal London Hospital,HGG H3 G34 mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,11/17/1990,32.1,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.37,GBM_G34,0.72,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1775,"High grade glioma, H3 G34-mutant
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Interpretated as retained ; no mutation
Further molecular tests: Pending
","High grade glioma (glioblastoma), H3 G34-mutant, CNS WHO grade 4
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 383\NH22-1775,-0.199,-0.304,0.164,-0.068,0.012,-0.022,0.044,0.028,0.126,-0.119,0.014,0.041,-0.265,-0.412,-0.519,0.274,0.014,0.085,0.037,0.056,0.08,-0.167,0.014,0.013,0.072,0.036,-0.579,-0.096,0.014,methylated
NH22-1795,206486300168_R01C01,384,7/7/2022,7/20/2022,7/20/2022,13,MD,Diagnostic,384,2,NDP,Romford,Astrocytoma IDH mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/10/1962,61.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.96,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1795,"Astrocytoma, IDH-mutant. See comment.
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss (indicates mutation)      
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, grading see comment
Histology: Astrocytoma, IDH-mutant
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 384\NH22-1795,-0.074,-0.013,0.039,-0.199,0.019,-0.226,-0.052,-0.197,-0.005,-0.102,0.06,0.239,0.022,0.001,-0.088,-0.025,-0.052,0.001,-0.015,-0.115,-0.139,-0.095,-0.007,0.023,-0.108,0.024,-0.103,0.145,0.061,methylated
NH22-1796,206486300168_R04C01,384,7/7/2022,7/20/2022,7/20/2022,13,MD,Diagnostic,384,1,NDP,Romford,Diffuse midline glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/2/2000,22.7,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.98,DMG_K27,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1796,"Diffuse midline glioma, H3K27-altered, CNS WHO grade 4.

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
","Integrated diagnosis: Diffuse midline glioma, H3 K27-altered, CNS WHO Grade 4
Histology: Diffuse midline glioma, H3 K27-altered, CNS WHO Grade 4
Methylation profile: Diffuse midline glioma, H3 K27-altered, subtype H3 K27-mutant or EZHIP expressing
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 384\NH22-1796,-0.224,0.018,0.055,0.007,0.097,0.081,-0.098,-0.077,0.02,-0.132,0.042,0.039,0.065,-0.007,0.029,-0.007,-0.096,-0.425,-0.085,0.473,0.12,0.253,0.062,-0.439,-0.675,0.094,0.075,-0.045,0.02,unmethylated
NH22-1803,206486300168_R05C01,384,7/7/2022,7/20/2022,7/20/2022,13,MD,Diagnostic,384,1,NDP,"Cardiff, University Hospital",Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,4/16/1987,35.7,supratentorial midline pilocytic astrocytoma,0.46,LGG_PAMID,0.46,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1803,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, midline (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 384\NH22-1803,-0.029,0.044,0.078,-0.022,0.023,0.091,-0.086,0.109,0.183,0.133,0.281,0.045,0.077,-0.052,-0.052,-0.032,0.07,0.042,0.046,-0.052,0.002,0.004,0.026,-0.001,-0.039,0.028,-0.039,-0.011,0.029,unmethylated
NH22-1821,206486300168_R06C01,384,7/7/2022,7/20/2022,7/20/2022,13,MD,Diagnostic,384,1,NDP,Hull ,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,1/30/1941,82.6,spinal subependymoma [subtype A],0.46,CN,0.3,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1821,"Integrated diagnosis: Subependymoma, CNS WHO grade 1
Histology: Ependymal tumour, low-grade
Methylation profile: Subependymoma, spinal, subtype a (low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 384\NH22-1821,0.044,0.044,0.101,0.063,0.061,-0.016,-0.09,-0.192,-0.106,-0.167,0.05,-0.521,-0.44,-0.706,-0.115,0.029,-0.055,-0.01,-0.036,-0.16,-0.002,0.065,0.015,-0.113,0.08,0.036,0.177,0.019,0.05,unmethylated
NH22-1822,206486300168_R07C01,384,7/7/2022,7/20/2022,7/20/2022,13,MD,Diagnostic,384,1,NDP,Edinburgh,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B,4/15/1953,70.2,"glioblastoma, IDH-wildtype, RTK2 type",0.98,GBM_RTKII,0.91,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1822,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma, most in keeping with glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK II  
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 384\NH22-1822,0.01,0.029,0.039,0.046,0.392,0.068,-0.031,0.052,0.252,0.143,0.247,0.019,0.015,-0.047,-1.697,0.007,-0.004,-0.005,-0.024,0.326,0.164,0.325,0.026,-0.043,-0.062,0.006,0.082,0.025,-0.029,methylated
NH22-1833,206486300147_R01C01,385,7/7/2022,7/22/2022,7/22/2022,15,MD,Diagnostic,385,1,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/18/1970,53.1,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.97,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1833,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 385\NH22-1833,-0.033,-0.021,0.022,-0.055,-0.042,0.064,0.068,1.119,0.241,0.248,0.184,-0.024,0.042,0.028,-2.434,0.012,-0.357,-0.355,0.002,0,-0.019,0.02,-0.012,-0.015,-0.001,0.032,0.21,0.014,0.018,unmethylated
NH22-1836,206486300147_R03C01,385,7/7/2022,7/22/2022,7/22/2022,15,MD,Diagnostic,385,1,NDP,Nottingham University Hospital,DNET to confirm from 2017,"(5) Confirmation of rare, unusual or interesting histo-molecular results",B1,10/11/2005,17,dysembryoplastic neuroepithelial tumour,1,LGG_DNT,0.99,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1836,"Integrated diagnosis: Dysembryoplastic neuroepithelial tumour, CNS WHO grade 1
Histology: Dysembryoplastic neuroepithelial tumour, CNS WHO grade 1
Methylation profile: Dysembryoplastic neuroepithelial tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 385\NH22-1836,0.03,0.136,0.045,0.037,0.021,-0.008,0.169,0.152,0.043,0.121,0.025,-0.022,-0.011,0.217,-0.098,0.085,-0.024,-0.13,0.029,0.038,0.004,0.063,-0.117,0.165,-0.183,-0.157,0.111,0.016,0.091,unmethylated
NH22-1837,206486300147_R05C01,385,8/7/2022,7/22/2022,7/22/2022,14,MD,Diagnostic,385,1,NDP,Oxford John Radcliffe Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3A,9/16/1988,34.3,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.35,AIDH,0.62,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1837,"Integrated diagnosis: Astrocytoma, IDH-mutant, grading see comment
Histology: Astrocytoma, IDH-mutant
Methylation profile: Glioma, IDH mutant, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 385\NH22-1837,0.112,0.039,0.018,-0.024,-0.05,-0.143,-0.039,-0.019,0.183,0.164,0.15,-0.027,0.067,-0.005,0.005,0.017,0.062,0.031,0.075,0.024,-0.007,0.016,-0.008,-0.047,0.039,0.027,-0.048,-0.027,0,methylated
NH22-1838,206486300147_R06C01,385,8/7/2022,7/22/2022,7/22/2022,14,MD,Diagnostic,385,1,NDP,"Liverpool, The Walton Centre",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1D,10/15/1996,26.1,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.97,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1838,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, hemispheric
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 385\NH22-1838,-0.014,-0.059,-0.054,0.008,-0.02,0.17,0.03,0.086,0.05,-0.008,0.027,-0.016,0.035,0.038,0.046,-0.009,0.048,0.038,0.034,-0.019,-0.008,0.044,0.017,-0.019,0.03,0.008,-0.039,-0.026,0.025,unmethylated
NH22-1865,206486300147_R08C01,385,8/7/2022,7/22/2022,7/22/2022,14,MD,Diagnostic,385,1,NDP,Hull ,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,10/5/1990,32.2,ganglioglioma,0.47,LGG_GG,0.29,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1865,"Integrated diagnosis: CNS tissue with extensive gliosis and haemosiderin deposits, possible low grade glioma 
Histology: CNS tissue with gliosis and possible low grade glioma
Methylation profile: See comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 385\NH22-1865,-0.032,0.036,0.04,0.004,-0.053,-0.004,0.003,-0.008,0.01,-0.027,-0.004,0.015,0.074,0.024,0.049,0.003,0.062,0.062,0.025,-0.047,-0.061,0.085,0.064,0.009,0.003,0.075,0.001,0.002,0.003,unmethylated
NH22-1852,206486300103_R02C01,386,11/7/2022,7/22/2022,7/22/2022,11,MD,Diagnostic,386,1,NDP,Romford,Anaplastic oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/2/1987,35.9,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.89,OIDH,0.99,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1852,"Anaplastic oligodendroglioma, IDH-mutant, CNS WHO Grade 3.

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
 
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 386\NH22-1852,0.035,-0.015,-0.014,-0.225,-0.27,0.002,0.018,0.01,0.039,-0.015,0.02,0.002,0.051,0.03,-0.06,0.02,0.008,0.021,0.1,-0.01,-0.046,0.031,-0.025,-0.008,0.04,0.024,-0.367,-0.01,0,methylated
NH22-1854,206486300103_R04C01,386,12/7/2022,7/22/2022,7/22/2022,10,MD,Diagnostic,386,1,NDP,NHNN,Astrocytoma IDH mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,9/16/1975,47.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1854,"Astrocytoma, IDH-mutant, CNS WHO Grade 2.

IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant; lower grade  
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 386\NH22-1854,-0.05,-0.049,0.037,-0.034,-0.022,0.017,-0.021,-0.007,-0.009,0.018,0.002,-0.006,0.097,0.229,0.04,0.025,0.024,0.012,0.026,0.251,-0.263,-0.333,-0.068,0.007,-0.016,0.002,-0.005,-0.038,-0.022,methylated
NH22-1857,206486300103_R05C01,386,12/7/2022,7/22/2022,7/22/2022,10,MD,Diagnostic,386,1,NDP,"Charing Cross Hospital, London",Astrocytoma IDH mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,9/7/1978,44.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1857,"Astrocytoma, IDH-mutant, CNS WHO Grade 2.


IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 386\NH22-1857,-0.048,0.013,0.031,-0.014,0.006,0.061,0.006,0.001,-0.019,0.307,0.235,0.001,0.052,0.005,0.031,0.006,0.022,0.034,0.038,0.045,-0.012,0.011,-0.037,-0.028,-0.024,0.046,-0.028,0.012,0.014,methylated
NH22-1869,206486300103_R06C01,386,12/7/2022,7/22/2022,7/22/2022,10,MD,Diagnostic,386,1,NDP,Cleveland Clinic London,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,2/21/1989,33.9,myxopapillary ependymoma,1,EPN_MPE,1,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1869,"Myxopapillary ependymoma, CNS WHO Grade 2.
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, myxopapillary 
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 386\NH22-1869,-0.058,-0.033,0.039,0.043,0.081,0.103,0.033,0.095,0.195,0.125,0.11,-0.033,0.127,0.041,0.125,0.249,0.013,-0.017,-0.005,-0.028,-0.035,-0.044,-0.171,0.074,0.159,0.128,-0.071,-0.004,0.026,unmethylated
NH22-1881,206486300103_R08C01,386,12/7/2022,7/22/2022,7/22/2022,10,MD,Diagnostic,386,1,NDP,"Leeds, St James's University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C7,12/8/1968,54.4,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.38,GBM_RTKII,0.38,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1881,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Diffusely infiltrating glioma, NOS
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 386\NH22-1881,1.707,0.01,0.054,0.033,-0.058,0.017,-0.016,0.227,0.232,0.125,0.186,-0.02,0.082,0.034,0.004,0.043,-0.653,0.069,0.059,-0.05,-0.027,0.105,0.006,-0.024,0.053,0.07,-0.074,-0.048,-0.005,unmethylated
NH22-1870,206486300136_R03C01,387,13/07/2022,7/27/2022,7/27/2022,14,MD,Diagnostic,387,8,NDP,NHNN,"Glioma, H3 G34 mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,12/6/1998,23.9,"Diffuse hemispheric glioma, H3 G34-mutant",1,GBM_G34,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1870,"Diffuse hemispheric glioma, H3 G34-mutant, CNS WHO grade 4
H3 G34R (IHC)): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
  
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 387\NH22-1870,0.22,0.029,-0.104,-0.027,0.075,0.081,0.032,-0.013,0.012,0.013,-0.003,-0.042,-0.015,-0.026,0.127,0.002,-0.015,0.087,0.075,-0.01,-0.15,-0.058,-0.344,-0.173,0.021,0.001,-0.037,-0.024,0.032,methylated
NH22-1900,206486300136_R05C01,387,13/07/2022,7/27/2022,7/27/2022,14,MD,Diagnostic,387,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,11/20/1960,62.5,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.95,GBM_MID,0.4,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1900,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma, corresponding to CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass midline
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 387\NH22-1900,-0.008,-0.002,0.057,-0.03,0.704,0.245,0.011,0.033,0.051,-0.122,-0.009,-0.008,0.084,0.016,-1.353,0.012,-0.234,-0.289,0.026,0.019,0.162,0.085,-0.315,0.215,0.071,0.319,-0.336,-0.013,-0.311,methylated
NH22-1902,206486300136_R06C01,387,13/07/2022,7/27/2022,7/27/2022,14,MD,Diagnostic,387,1,NDP,Romford,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B3,5/4/1948,75.3,myxopapillary ependymoma,0.99,EPN_MPE,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1902,"Ependymoma, CNS WHO grade 2
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 387\NH22-1902,-0.029,0.053,0.06,-0.01,-0.021,0.159,0.047,0.005,-0.015,-0.027,-0.015,-0.014,0.059,0.041,0.103,0.112,-0.282,-0.241,0.016,-0.017,-0.013,0.021,-0.118,-0.052,-0.045,-0.013,-0.032,-0.032,0.018,unmethylated
NH22-456,206486300136_R07C01,387,14/07/2022,7/27/2022,7/27/2022,13,MD,Diagnostic,387,1,NDP,Southampton General Hospital,"IDH mutant, Glioma","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1C,5/18/1976,46.4,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.82,OIDH,0.99,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-456,"IDH-mutant glioma, CNS WHO grade 2 (see comment)
IDH1 (R132H IHC); IDH1/2Seq: Mutation
ATRX (IHC): Retained
1p/19q: See comment
TERT promoter: Mutation  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: IDH-mutant glioma, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 387\NH22-456,-0.117,0.025,0.039,-0.021,0.001,0.032,0.038,0.044,0.015,0.053,0.029,0.001,0.019,0.019,0.055,0.006,0.015,0.029,0.011,-0.045,-0.039,-0.015,-0.033,-0.039,-0.036,-0.027,-0.396,-0.034,-0.006,methylated
NH22-1905,206486300136_R08C01,387,14/07/2022,7/27/2022,7/27/2022,13,MD,Diagnostic,387,1,NDP,Cleveland Clinic London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/18/1993,29.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.99,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1905,"Astrocytoma, CNS WHO grade 2 (expected to be IDH-mutant)
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH mutant, CNS WHO grade 2
Histology: Astrocytoma, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 387\NH22-1905,-0.009,-0.004,0.054,-0.038,0.024,0.034,0.045,0.21,0.19,0.215,0.179,0.163,0.063,0.045,0.031,-0.015,0.05,0.071,0.091,0.046,-0.037,0.009,-0.043,-0.009,-0.045,0.158,-0.064,0.003,0.035,methylated
NH22-1943,206601450181_R02C01,388,18/07/2022,7/29/2022,7/29/2022,11,MD,Diagnostic,388,1,NDP,St George's Hospital London,Astroblastoma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/17/1976,46.9,papillary glioneuronal tumour,0.76,LGG_DNT,0.13,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1943,"Integrated diagnosis: Papillary glioneuronal tumour, CNS WHO grade 1
Histology: Compatible with papillary glioneuronal tumour, CNS WHO grade 1
Methylation profile: Papillary glioneuronal tumour, PRKCA-fused
MGMT promoter (Illumina array): Unmethylated 
  
","Integrated diagnosis: Papillary glioneuronal tumour, CNS WHO grade 1
Histology: Compatible with papillary glioneuronal tumour, CNS WHO grade 1
Methylation profile: Papillary glioneuronal tumour, PRKCA-fused
RNA NGS: SLC44A1::PRKCA fusion
MGMT promoter (Illumina array): Unmethylated  
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 388\NH22-1943,-0.058,0.014,-0.09,-0.07,-0.145,0.021,-0.136,1.122,-0.027,0.143,0.069,-0.038,-0.198,0.152,-0.632,-0.125,-0.261,-0.027,-0.064,0.016,-0.06,-0.018,-0.176,0.089,-0.115,0.044,0.159,-0.175,-0.045,unmethylated
NH22-1938,206601450181_R03C01,388,18/07/2022,7/29/2022,7/29/2022,11,MD,Diagnostic,388,1,NDP,"Birmingham, Queen Elizabeth Hospital",Diffuse glioma IDH WT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,8/9/1943,80.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.98,GBM_MES,0.72,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1938,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 388\NH22-1938,-0.027,0.016,0.057,-0.12,-0.038,0.064,-0.052,0.694,-0.019,-0.064,-0.049,-0.017,0.057,0.08,-0.805,-0.014,-0.207,-0.178,0.001,0.024,0.015,0.004,-0.021,0.002,-0.007,-0.006,0.003,-0.303,-0.202,methylated
NH22-1946,206601450181_R06C01,388,19/07/2022,7/29/2022,7/29/2022,10,MD,Diagnostic,388,5,NDP,"Charing Cross Hospital, London",IDH-mutant astrocytoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,4/3/1991,31.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.99,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1946,"Astrocytoma, IDH-mutant, CNS WHO Grade 4

IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, high grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 388\NH22-1946,0.205,-0.024,0.051,0.032,-0.023,-0.297,0.055,-0.005,0.009,0.428,-0.182,-0.022,0.015,0.043,-0.044,0.028,-0.127,-0.109,-0.007,-0.016,-0.077,-0.115,-0.276,0.027,0.07,0.167,-0.06,-0.343,-0.269,methylated
NH22-1920,206601450182_R01C01,389,20/07/2022,8/3/2022,8/3/2022,14,MD,Diagnostic,389,2,NDP,NHNN,Calcifying pesudoneoplasm of the neuraxis,"(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF2A,9/6/1967,55.7,supratentorial pilocytic astrocytoma,0.91,LGG_PA_GGST,0.69,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1920,"Calcifying pseudoneoplasm of the neuraxis
","Integrated diagnosis: Calcifying pseudoneoplasm of the neuraxis
Histology: Calcifying pseudoneoplasm of the neuraxis
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 389\NH22-1920,-0.057,-0.017,0.006,-0.028,-0.055,0.015,0.031,0.002,0.015,0.006,0.005,-0.008,0,0.021,-0.042,0.015,-0.026,0.034,0.025,0.017,-0.01,0.031,-0.043,0.026,0.001,-0.017,0.017,-0.053,-0.01,unmethylated
NH22-1924,206601450182_R02C01,389,20/07/2022,8/3/2022,8/3/2022,14,MD,Diagnostic,389,1,NDP,Cleveland Clinic London,Astrocytoma IDH mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,11/1/1977,45.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.85,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1924,"Astrocytoma, IDH-mutant, CNS WHO grade 3
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, low grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 389\NH22-1924,-0.083,0.027,0.077,-0.032,-0.015,0.045,0.054,0.023,-0.029,-0.024,0.002,-0.013,0.053,0.026,-0.147,0.029,-0.003,0.022,0.186,0.001,-0.013,0.017,-0.491,-0.018,-0.041,0.108,-0.417,0.006,-0.3,methylated
NH22-1925,206601450182_R03C01,389,20/07/2022,8/3/2022,8/3/2022,14,MD,Diagnostic,389,1,NDP,Cleveland Clinic London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/26/1962,61.3,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",1,GBM_RTKII,0.12,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1925,"CNS grey and white matter with dense infiltration by a high-grade glioma
","Integrated diagnosis: Diffuse high-grade glioma, IDH-wildtype, grading see comment
Histology: CNS grey and white matter with infiltration zone of a diffuse glioma
Methylation profile: Adult-type diffuse high-grade glioma, IDH wildtype, subtype F
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 389\NH22-1925,0.012,0.03,0.005,0.024,-0.048,0.044,-0.001,0.212,0.169,0.082,0.118,-0.024,-0.015,-0.018,-0.014,0.006,-0.126,-0.144,-0.033,0.005,0.571,0.024,-0.081,-0.003,0.012,0.059,-0.073,-0.063,0.031,unmethylated
NH22-1936,206601450182_R05C01,389,20/07/2022,8/3/2022,8/3/2022,14,MD,Diagnostic,389,1,NDP,"Charing Cross Hospital, London",Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,10/17/1973,49.5,myxopapillary ependymoma,1,EPN_MPE,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1936,"Myxopapillary ependymoma, CNS WHO grade 2
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, myxopapillary 
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 389\NH22-1936,-0.046,0.026,0.073,-0.022,-0.057,0.189,0.016,0.223,0.267,0.249,0.2,0.009,0.053,0.002,0.255,0.236,0.018,0.046,0.045,-0.018,0.017,0.074,-0.031,-0.01,-0.034,-0.024,-0.061,-0.002,0.06,unmethylated
NH22-1963,206601450182_R07C01,389,20/07/2022,8/3/2022,8/3/2022,14,MD,Diagnostic,389,1,NDP,Brighton and Sussex Hospital,Brainstem glioma,"(2) unusual histology, location, demographics",DEF1A,1/5/1985,38.1,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.23,AIDH,0.37,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1963,"Brainstem biopsy: Favouring a glioma / glioneuronal tumour (see comment)
","Integrated diagnosis: Astrocytoma, IDH-mutant, grading see comment
Histology: CNS tissue cores with infiltration of a glial tumour 
Next generation sequencing: IDH mutation, ATRX mutation, p53 mutation
Methylation profile: Astrocytoma, IDH-mutant
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 389\NH22-1963,-0.024,-0.02,0.017,-0.059,-0.004,0.029,0.032,0.001,-0.004,-0.065,-0.008,-0.008,0.055,-0.001,-0.01,-0.008,-0.004,0.044,-0.022,0.104,-0.121,-0.139,-0.038,-0.004,0.016,-0.006,0.015,-0.016,0.024,methylated
NH22-1960,206601450182_R08C01,389,21/07/2022,8/3/2022,8/3/2022,13,MD,Diagnostic,389,1,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,2/3/1962,61.3,"glioblastoma, IDH-wildtype, RTK1 type",0.78,GBM_MID,0.99,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1960,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH wildtype, subclass midline
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 389\NH22-1960,-0.018,0.009,0.017,0.033,-0.011,0.068,0.02,-0.026,-0.009,-0.051,-0.008,-0.017,0.029,0.002,-0.399,0.007,0.03,0.062,0.03,0.008,-0.05,0.014,-0.019,0.014,0.035,-0.011,0.009,-0.026,-0.001,unmethylated
NH22-1957,206601450196_R01C01,390,21/07/2022,8/3/2022,8/3/2022,13,MD,Diagnostic,390,1,NDP,"Birmingham, Queen Elizabeth Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A4,4/5/1947,76.4,posterior fossa subependymoma,1,SUBEPN_PF,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1957,"Integrated diagnosis: Ependymal tumour, with methylation profile of subependymoma, posterior fossa, grading see comment
Histology: Ependymoma
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
","Integrated diagnosis: Ependymoma, CNS WHO grade 2, with methylation profile of subependymoma, posterior fossa - see comment 

TERT promoter: Mutation 
Chr 6 (Illumina array): Loss
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 390\NH22-1957,-0.065,0.003,0.04,-0.023,0.024,-0.029,-0.326,-0.002,0.017,0.017,0.003,-0.076,-0.042,-0.056,0.002,-0.017,-0.028,0.027,-0.064,-0.088,0.006,0.005,-0.055,-0.051,-0.017,-0.011,0.032,-0.035,0.01,unmethylated
NH22-1955,206601450196_R02C01,390,21/07/2022,8/3/2022,8/3/2022,13,MD,Diagnostic,390,2,NDP,"Birmingham, Queen Elizabeth Hospital",LGG/LGGNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/2/1988,34.7,"control tissue, white matter (corpus callosum)",0.99,CONTR_HEMI,0.26,0.59,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1955,"2019 and 2022 resection: 
Integrated diagnosis: Differential diagnosis between reactive gliosis and low grade glial / glioneuronal tumour - see comment
Histology: Differential diagnosis between reactive gliosis and low grade glial / glioneuronal tumour - see comment
Methylation profile: Control tissue white matter 
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 390\NH22-1955,-0.047,0.026,0.018,-0.107,-0.108,-0.008,-0.101,-0.052,0.013,-0.064,-0.01,-0.006,0.117,-0.041,0.001,0.032,0.037,0.043,-0.021,-0.095,0.004,0.053,0.048,-0.007,0.023,0.062,0.007,-0.02,0.024,unmethylated
NH22-1849,206601450196_R05C01,390,21/07/2022,8/3/2022,8/3/2022,13,MD,Diagnostic,390,1,NDP,St George's Hospital London,LGG IDH mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/4/1978,44.7,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1849,"Low grade glioma, IDH-mutant, CNS WHO grade 2
IDH1 (R132H IHC); IDH1/2Seq: Mutation
ATRX (IHC): Retained
1p/19q: See comment 
TERT promoter: Inconclusive
MGMT Promoter: Methylated (>0-5%)

  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: IDH-mutant glioma, CNS WHO grade 2, inconclusive molecular profile,
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 390\NH22-1849,-0.054,-0.041,0.016,-0.033,-0.008,0.052,0.017,-0.007,-0.027,-0.022,-0.017,0.016,0.027,-0.02,0.105,-0.022,-0.007,0.032,0.008,0.025,-0.037,0.008,-0.051,-0.015,-0.012,-0.014,-0.418,0.014,0.037,methylated
NH22-1970,206601450196_R06C01,390,21/07/2022,8/3/2022,8/3/2022,13,MD,Diagnostic,390,1,NDP,"Liverpool, The Walton Centre",Astrocytoma IDH mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,11/24/1988,34.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.47,AIDH,0.75,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-1970,"Integrated diagnosis: Astrocytoma, IDH-mutant, grading see comment
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, low grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 390\NH22-1970,-0.125,0.015,-0.039,0.018,0.087,0.019,0.008,0.088,0.046,0.016,0.025,0.015,0.1,0.171,0.014,0.091,-0.057,-0.059,0,0.096,-0.013,-0.12,0.061,0.031,-0.11,0.047,0.011,-0.064,0.052,methylated
NH22-1989,206601450138_R02C01,391,22/07/2022,8/5/2022,8/5/2022,14,MD,Diagnostic,391,6,NDP,NHNN,IDH-mutant glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,12/17/1957,65.5,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1989,"Glioma, IDH-mutant, CNS WHO grade 3 (see comment)
IDH1 (R132H IHC): Mutation      
ATRX (IHC): Retained 
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
Histology: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 391\NH22-1989,-0.064,-0.031,0.043,-0.17,-0.141,0.04,-0.004,0.019,0.007,-0.021,-0.021,-0.005,0.016,-0.009,0.069,-0.008,0.02,0.038,0.001,-0.023,-0.019,-0.009,-0.047,0.006,-0.032,-0.007,-0.394,0.007,0.033,methylated
NH22-2025,206601450138_R03C01,391,24/07/2022,8/5/2022,8/5/2022,12,MD,Diagnostic,391,5,NDP,NHNN,IDH-mutant glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1B,4/11/1980,42.9,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2025,"Oligodendroglioma, IDH-mutant, CNS WHO grade 2
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
1p/19q: Codeleted
TERT promoter: Mutation
MGMT Promoter: Methylated (>0-5%)

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 391\NH22-2025,-0.052,-0.009,0.015,-0.026,-0.003,0.005,0.002,-0.007,-0.035,0.029,0.002,0.011,-0.012,-0.026,0.044,0.001,0.012,0.004,-0.031,-0.039,0,0.008,-0.063,0.008,-0.013,0.024,-0.401,0.002,-0.013,methylated
NH22-2029,206601450138_R06C01,391,26/07/2022,8/5/2022,8/5/2022,10,MD,Diagnostic,391,1,NDP,Newcastle ,Infiltrating glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,5/20/1981,41.8,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",1,LGG_MYB,0.3,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2029,"Integrated diagnosis: Glial neoplasm - see comment
Histology: Glial neoplasm
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 391\NH22-2029,-0.067,-0.003,0.041,0.055,-0.067,0.018,-0.009,0.026,-0.016,-0.057,-0.007,-0.029,0.05,-0.006,0.033,0.043,0.018,0.024,0.018,-0.007,0.006,0.081,-0.001,0.007,-0.004,0.032,-0.028,-0.012,-0.01,unmethylated
NH22-2016,206601450138_R07C01,391,26/07/2022,8/5/2022,8/5/2022,10,MD,Diagnostic,391,1,NDP,Oxford John Radcliffe Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2,4/22/1958,65.2,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.26,GBM_MES,0.59,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2016,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 391\NH22-2016,-0.031,-0.016,0.008,0.006,-0.053,-0.041,-0.196,0.191,0.045,0.003,0.003,-0.22,0.031,-0.051,-0.299,0.011,-0.209,-0.17,-0.039,-0.009,-0.028,0.052,-0.05,0.008,0.034,0.048,-0.036,-0.184,-0.133,methylated
NH22-2019,206600570043_R01C01,392,26/07/2022,8/5/2022,8/5/2022,10,MD,Diagnostic,392,2,NDP,Nottingham University Hospital,"GBM, NOS","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/13/1969,54.1,"glioblastoma, IDH-wildtype, mesenchymal type",0.7,GBM_RTKII,0.61,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2019,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 392\NH22-2019,0.003,-0.01,0.021,0.035,0.014,0.018,-0.345,0.219,0.257,0.194,0.166,-0.025,0.16,0.014,-0.845,-0.276,-0.23,-0.189,-0.005,0.042,0.016,0.003,-0.277,-0.006,0.018,-0.026,-0.375,-0.024,0.03,unmethylated
NH22-2030,206600570043_R02C01,392,26/07/2022,8/5/2022,8/5/2022,10,MD,Diagnostic,392,1,NDP,"Cardiff, University Hospital",Glial tumour?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/2/1952,71.5,"glioblastoma, IDH-wildtype, RTK2 type",0.97,GBM_RTKII,0.91,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2030,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma, compatible with glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK II
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 392\NH22-2030,-0.051,-0.032,0.069,-0.045,0.003,0.055,-0.04,0.161,0.21,0.291,0.15,-0.014,0.051,0.02,-2.457,0.043,-1.652,-0.331,-0.035,-0.023,0.017,0.05,-0.033,-0.006,-0.507,0.06,0.011,-0.281,-0.326,methylated
NH22-2055,206600570043_R03C01,392,27/07/2022,8/5/2022,8/5/2022,9,MD,Diagnostic,392,1,NDP,St George's Hospital London,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C1,11/8/2010,11.8,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.7,GBM_RTKIII,0.43,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2055,"CNS tissue, tumour cannot be confirmed morphologically or molecularly
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 392\NH22-2055,0.027,0.079,0.009,0.022,0.02,0.027,-0.001,0.026,0.036,0.022,0.006,-0.022,0.03,0.012,0.027,0.025,-0.018,0.001,0.03,-0.04,-0.006,0.06,-0.026,-0.022,0.076,0.038,-0.053,-0.035,0.05,unmethylated
NH22-2057,206600570043_R04C01,392,27/07/2022,8/5/2022,8/5/2022,9,MD,Diagnostic,392,1,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,11/15/1979,43.3,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.13,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2057,"Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
MGMT Promoter: Unmethylated (0%)


  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 392\NH22-2057,0.09,0.01,-0.005,0.033,0.076,0.072,-0.033,0.113,0.217,0.237,0.125,0.057,0.011,0.148,0.134,0.032,-0.103,-0.129,-0.083,-0.146,-0.131,-0.124,-0.172,-0.132,-0.209,-0.111,-0.119,-0.042,0.034,unmethylated
NH22-2059,206600570043_R05C01,392,27/07/2022,8/5/2022,8/5/2022,9,MD,Diagnostic,392,4,NDP,St George's Hospital London,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,10/28/1963,59.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.2,CONTR_HEMI,0.24,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2059,"Astrocytoma, IDH-mutant, with extensive radiation induced changes
IDH1 (R132H IHC); IDH1/2Seq: Mutation
ATRX (IHC): Loss of expression (indicates mutation)
MGMT Promoter: Methylated (>5-10%)


  
","Integrated diagnosis: Astrocytoma, IDH-mutant with extensive radiation induced changes

MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 392\NH22-2059,-0.026,-0.005,-0.025,-0.001,-0.035,-0.011,-0.002,-0.028,0.024,-0.024,0.009,-0.013,0.012,-0.035,-0.041,-0.013,0.002,0.012,-0.021,0.037,-0.035,-0.003,-0.053,-0.049,-0.012,0.01,-0.032,0.019,0.034,methylated
NH22-2062,206600570043_R06C01,392,27/07/2022,8/5/2022,8/5/2022,9,MD,Diagnostic,392,4,NDP,"Cambridge, Addenbrooke's Hospital",?Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B6,1/3/1986,37,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.33,AIDH,0.65,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2062,"Integrated diagnosis: Astrocytoma, IDH-mutant - for grading, see comment
Histology: Astrocytoma, IDH-mutant
Methylation profile: Astrocytoma, IDH-mutant, suggestive of lower grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 392\NH22-2062,-0.017,-0.037,0.021,-0.01,-0.012,0.092,-0.009,-0.012,0.036,0.176,0.059,-0.006,0.056,0.089,0.021,-0.031,0.004,0.056,-0.042,0.077,-0.037,-0.047,-0.294,-0.042,0.011,0.009,-0.026,-0.013,-0.038,methylated
NH20-2312,206600570043_R07C01,392,28/07/2022,8/5/2022,8/5/2022,8,MD,Diagnostic,392,1,NDP,Romford,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/30/1966,55,"glioblastoma, IDH-wildtype, mesenchymal type",0.61,GBM_RTKII,0.66,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-2312,"Glioblastoma (WHO grade IV)
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 392\NH20-2312,-0.026,0.028,0.01,-0.043,0.088,0.01,0.007,1.134,0.247,0.276,0.195,-0.002,-0.11,0.054,-0.945,0.037,-0.269,-0.297,-0.012,0.017,-0.016,0.067,-0.029,-0.016,0.019,-0.045,0.129,-0.318,-0.312,methylated
NH22-2043,206600570044_R03C01,393,28/07/2022,8/5/2022,8/5/2022,8,MD,Diagnostic,393,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/20/2002,20.4,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.97,GBM_MYCN,0.89,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2043,"Integrated diagnosis: Glioblastoma, IDH-wildtype, MYCN amplified, CNS WHO grade 4 - see comment
Histology: Compatible with glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, MYCN subtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 393\NH22-2043,-0.02,1.074,-0.008,-0.235,0.899,0.143,-0.394,-0.006,0.076,1.548,-0.014,-0.27,-0.062,-0.061,-0.364,0.2,-0.302,-0.337,0.011,0.005,0.622,0.752,-0.243,-0.355,-0.121,-0.129,-0.01,-0.051,0.049,unmethylated
NH22-2042,206600570044_R04C01,393,28/07/2022,8/5/2022,8/5/2022,8,MD,Diagnostic,393,1,NDP,"Birmingham, Queen Elizabeth Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,12/22/1973,49.3,posterior fossa ependymoma group B,1,EPN_PFB,0.94,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2042,"Integrated diagnosis: Ependymoma, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, posterior fossa, group B
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 393\NH22-2042,-0.081,-0.116,-0.109,-0.061,0.013,-0.006,-0.301,-0.006,0.073,0.035,0.018,-0.133,-0.12,-0.103,0.019,0.01,-0.303,-0.241,-0.012,-0.027,0.01,0.079,-0.02,0.022,0.027,0.03,-0.003,-0.038,0.032,unmethylated
NH22-2040,206600570044_R05C01,393,28/07/2022,8/5/2022,8/5/2022,8,MD,Diagnostic,393,1,NDP,"Liverpool, The Walton Centre",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3A,7/10/1985,37.6,high-grade astrocytoma with piloid features,0.76,ANAPA,0.84,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2040,"Integrated diagnosis: High grade astrocytoma with piloid features - see comment
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: High grade astrocytoma with piloid features 
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 393\NH22-2040,0.007,0.023,0.024,0.001,0.042,0.073,-0.434,0.116,-0.049,-0.106,-0.013,-0.04,-0.296,0.004,-1.382,-0.009,0.01,0.03,-0.002,-0.076,0.888,1.771,-0.525,-0.057,-0.095,-0.111,-0.483,-0.029,-0.006,unmethylated
NH22-2038,206600570049_R01C01,394,28/07/2022,8/12/2022,8/12/2022,15,MD,Diagnostic,394,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/30/1967,55.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.97,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2038,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 394\NH22-2038,0.025,-0.15,-0.016,-0.063,0.009,0.044,-0.073,0.04,0.06,0.057,0.044,-0.001,0.08,0.065,0.013,0.11,0.026,-0.29,-0.012,0.044,-0.084,-0.05,-0.108,0.028,0.009,0.045,-0.143,-0.02,-0.038,methylated
NH21-2998,206600570049_R02C01,394,28/07/2022,8/12/2022,8/12/2022,15,MD,Diagnostic,394,1,NDP,St George's Hospital London,GBM,(1) small biopsy or nonrepresentative sample;,A1,1/27/1959,63.7,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type C]",0.36,GBM_RTKI,0.36,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-2998,"Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 394\NH21-2998,-0.059,-0.012,0.112,-0.131,-0.03,-0.103,-0.18,0.363,0.222,0.542,0.196,0.012,0.346,0.186,-0.896,-0.123,-0.343,-0.648,0.228,-0.019,0.228,-0.056,0.027,0.131,-0.024,0.567,0.042,-0.144,0.086,unmethylated
NH22-1879,206600570049_R03C01,394,28/07/2022,8/12/2022,8/12/2022,15,MD,Diagnostic,394,6,NDP,St George's Hospital London,High grade astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/20/1986,36.9,pleomorphic xanthoastrocytoma(-like),1,PXA,0.92,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1879,"Integrated diagnosis: Anaplastic pleomorphic xanthoastrocytoma, BRAF V600E-mutant, CNS WHO grade 3
Histology: Anaplastic pleomorphic xanthoastrocytoma, BRAF V600E-mutant, CNS WHO grade 3 
Methylation profile: (anaplastic) pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 394\NH22-1879,0.152,0.007,-0.021,0.18,0.296,-0.03,0.081,0.201,0.313,0.218,0.198,-0.266,0.005,0.134,-1.327,0.063,0.008,-0.066,0.148,0.138,0.121,0.206,0.015,0.043,0.05,0.127,-0.042,-0.242,-0.181,methylated
NH22-2011,206600570049_R04C01,394,28/07/2022,8/12/2022,8/12/2022,15,MD,Diagnostic,394,2,NDP,Oxford John Radcliffe Hospital,GBM-IDH WT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3A,7/5/1970,52.8,"glioblastoma, IDH-wildtype, RTK1 type",0.98,GBM_RTKI,0.61,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2011,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK 1
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 394\NH22-2011,0.122,-0.049,0.006,0.015,-0.031,-0.007,0.047,0.172,0.233,0.161,0.121,-0.024,0.083,0.053,-0.756,-0.02,-0.139,-0.224,0.009,0.136,0.043,0.089,-0.044,-0.029,-0.003,-0.011,-0.3,-0.04,-0.077,methylated
NH22-2041,206600570049_R05C01,394,28/07/2022,8/12/2022,8/12/2022,15,MD,Diagnostic,394,2,NDP,"Liverpool, The Walton Centre",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,#N/A,#N/A,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.13,GBM_RTKII,0.65,#N/A,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2041,"NB15-1089
Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Suggestive of glioblastoma, IDH-wildtype, CNS WHO grade 4
MGMT promoter (Illumina array): Methylated 

NB14-836
Integrated diagnosis: Glioma, with no high grade features
Histology: Glioma, with no high grade features
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 394\NH22-2041,2.973,0.156,-0.057,-0.041,0.073,-0.06,-0.541,0.439,3.236,0.348,0.267,-0.069,0.136,0.085,0.1,0.022,-0.485,-0.728,-0.017,0.306,0.142,2.52,-0.104,0.114,-0.235,-0.243,0.337,-0.027,0.017,methylated
NH22-2080,206600570049_R07C01,394,29/07/2022,8/12/2022,8/12/2022,14,MD,Diagnostic,394,1,NDP,Nottingham University Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/20/1989,33.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-2080,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 394\NH22-2080,0.065,-0.082,0.015,-0.02,-0.016,0.048,-0.387,0.013,-0.007,-0.077,0.025,-0.008,0.055,0.066,0.035,-0.018,0.069,0.025,0.023,0.017,-0.033,-0.117,0.019,-0.01,0.026,0.042,0.081,-0.031,-0.047,methylated
NH22-2079,206600570049_R08C01,394,29/07/2022,8/12/2022,8/12/2022,14,MD,Diagnostic,394,1,NDP,Nottingham University Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,8/25/1951,72,myxopapillary ependymoma,0.83,EPN_MPE,0.82,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2079,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Ependymal tumour, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 394\NH22-2079,0.142,0.079,0.036,0.056,0.05,0.013,0.132,0.041,-0.04,-0.114,-0.035,0.248,0.347,0.33,0.287,0.308,0.044,0.014,0.157,0.412,0.207,0.346,-0.033,-0.026,-0.048,0.104,0.098,-0.661,-0.48,unmethylated
NH22-2078,206600570058_R01C01,395,29/07/2022,8/12/2022,8/12/2022,14,MD,Diagnostic,395,1,NDP,Nottingham University Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B3,11/26/1995,27.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.82,AIDH,0.75,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2078,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 395\NH22-2078,0.142,-0.049,-0.028,0.055,0.028,0.052,0.147,0.186,0.152,0.153,0.137,0.142,0.239,0.338,0.172,0.175,0.045,-0.239,0.089,0.141,0.026,-0.056,-0.054,-0.026,-0.026,0.047,0.011,-0.077,-0.027,methylated
NH22-2076,206600570058_R02C01,395,29/07/2022,8/12/2022,8/12/2022,14,MD,Diagnostic,395,1,NDP,Nottingham University Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,7/15/2014,8.1,"supratentorial ependymoma, ZFTA:RELA fusion-positive",0.1,EPN_RELA,0.06,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2076,"Integrated diagnosis: High grade glioma - for grading, see comment
Histology: High grade glioma
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 395\NH22-2076,0.143,0.069,0.02,0.028,0.003,0.048,0.145,-0.055,-0.583,-0.639,-0.39,0.026,0.034,0.293,-0.008,0.003,0.051,-0.009,0.023,0.043,0.034,0.065,-0.047,0.082,-0.033,0.067,-0.212,-0.41,-0.326,unmethylated
NH22-2041,206600570058_R05C01,395,29/07/2022,8/12/2022,8/12/2022,14,MD,Diagnostic,395,2,NDP,"Liverpool, The Walton Centre",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,#N/A,#N/A,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",0.6,GBM_RTKI,0.93,#N/A,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2041,"NB15-1089
Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Suggestive of glioblastoma, IDH-wildtype, CNS WHO grade 4
MGMT promoter (Illumina array): Methylated 

NB14-836
Integrated diagnosis: Glioma, with no high grade features
Histology: Glioma, with no high grade features
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 395\NH22-2041,2.212,0.118,0.062,0.057,0.15,0.014,-0.591,0.334,2.429,0.284,0.247,-0.057,0.078,1.555,0.015,0.001,-0.472,-0.619,0.112,0.268,0.028,2.465,-0.164,-0.137,-0.242,0.051,0.047,-0.155,-0.007,methylated
NH22-2108,206600570058_R06C01,395,1/8/2022,8/12/2022,8/12/2022,11,MD,Diagnostic,395,1,NDP,"Liverpool, The Walton Centre",Neuroepithelial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",4A,9/21/1983,39.4,supratentorial pilocytic astrocytoma,0.93,LGG_PA_GGST,0.86,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2108,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glioma, compatible with pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, hemispheric
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 395\NH22-2108,-0.032,0.06,-0.004,0.038,0.055,-0.007,0.093,-0.032,0.033,-0.036,-0.01,-0.088,0.008,0.01,-0.059,-0.031,0.035,0.005,0.091,0.089,0.021,0.009,-0.024,-0.066,0.065,-0.011,0.004,-0.105,-0.111,methylated
NH22-2106,206600570058_R08C01,395,1/8/2022,8/12/2022,8/12/2022,11,MD,Diagnostic,395,1,NDP,"Birmingham, Queen Elizabeth Hospital",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/20/1989,34,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-2106,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, infratentorial
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 395\NH22-2106,0.048,0.039,0.006,-0.023,-0.019,-0.029,0.088,-0.063,0.013,-0.093,0.192,0.03,0.048,0.186,0.063,0.022,0.07,-0.002,0.132,0.079,0.105,0.119,-0.021,0.029,0.054,0.071,0.099,-0.06,-0.04,methylated
NH22-2115,206601450018_R03C01,396,1/8/2022,8/17/2022,8/17/2022,16,MD,Diagnostic,396,1,NDP,"Charing Cross Hospital, London","Astrocytoma, IDH mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,5/3/1971,52,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.97,AIDH,0.94,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2115,"Astrocytoma, CNS WHO grade 2

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, lower grade
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 396\NH22-2115,-0.034,-0.038,0.037,-0.085,0.096,-0.089,-0.056,0.109,0.157,-0.026,0.189,-0.005,-0.031,0.17,-0.02,0.106,0.082,-0.008,0.041,0.107,0.018,-0.013,-0.022,0.028,-0.009,0.051,-0.145,0.053,0.024,unmethylated
NH22-2112,206601450018_R04C01,396,1/8/2022,8/17/2022,8/17/2022,16,MD,Diagnostic,396,1,NDP,Romford,"Astrocytoma, IDH mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/16/1984,39,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2112,"Astrocytoma, IDH-mutant, CNS WHO grade 2

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 396\NH22-2112,-0.018,0.008,0.08,-0.045,0.042,-0.177,-0.112,0.151,0.27,0.114,0.288,0.009,0.106,0.186,-0.006,0.064,0.082,-0.12,0.076,0.159,0.045,0.047,-0.006,0.107,-0.041,0.065,-0.209,0.034,0.058,methylated
NH22-2120,206601450018_R05C01,396,1/8/2022,8/17/2022,8/17/2022,16,MD,Diagnostic,396,4,NDP,HCA,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/16/1983,39.9,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2120,"Astrocytoma, IDH-mutant, CNS WHO grade 2
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending

","Integrated diagnosis: Astrocytoma, IDH-mutant CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 396\NH22-2120,0.033,-0.026,0.026,-0.112,-0.012,0.007,-0.053,0.035,0.187,0.197,0.162,-0.008,0.052,-0.022,-0.023,-0.015,0.017,-0.002,-0.04,0.052,-0.029,-0.008,-0.034,0.004,0.013,0.062,-0.165,0.009,0.024,unmethylated
NH22-1858,206601450018_R08C01,396,3/8/2022,8/17/2022,8/17/2022,14,MD,Diagnostic,396,1,NDP,Romford,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,7/28/1948,75,posterior fossa subependymoma,1,SUBEPN_PF,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1858,"Ependymal tumour, grading see comment 
","Integrated diagnosis: Ependymoma, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Subependymoma, posterior fossa - see comment
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 396\NH22-1858,0.047,0.009,0.029,0.022,-0.038,-0.044,-0.43,0.024,0.016,-0.005,-0.005,-0.039,0.044,0.04,-0.001,-0.018,0.037,0.02,-0.014,0.012,-0.012,0.001,-0.033,0.019,0.033,-0.006,-0.02,0.084,0.142,unmethylated
NH22-2137,206601450005_R07C01,397,4/8/2022,8/19/2022,8/19/2022,15,MD,Diagnostic,397,4,NDP,Newcastle ,IDH mutant astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,8/26/1974,48.6,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.97,AIDH,0.91,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2137,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 397\NH22-2137,-0.009,-0.038,0.032,-0.018,0.007,0.029,0.055,0.085,0.308,0.251,0.235,-0.032,0.075,0.276,0.096,-0.01,0.038,-0.069,0.03,0.014,0.04,0.1,0.013,0.051,-0.038,0.065,-0.458,-0.036,-0.005,methylated
NH22-2142,206601450003_R01C01,398,4/8/2022,8/19/2022,8/19/2022,15,MD,Diagnostic,398,1,NDP,Royal London Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1C,11/8/1958,64.7,"Diffuse paediatric-type high grade glioma, RTK1 subtype",1,GBM_MID,0.99,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2142,"High-grade glioma, most in keeping with glioblastoma, CNS WHO grade 4
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma, most in keeping with glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass midline 
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 398\NH22-2142,0.246,0.027,0.013,-0.046,-0.047,0.082,0.127,0.025,0.006,-0.027,-0.028,0.003,0.132,0.042,0.077,-0.03,0.039,0.092,0,0.03,0.033,0.07,-0.015,0.004,0.011,-0.022,-0.013,-0.023,0.033,methylated
NH22-2146,206601450003_R02C01,398,4/8/2022,8/19/2022,8/19/2022,15,MD,Diagnostic,398,5,NDP,NHNN,Diffuse glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,10/31/1971,51.5,"Diffuse paediatric-type high grade glioma, H3 wildtype and IDH wild type, Subtype A&B (novel)",1,GBM_MYCN,0.77,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2146,"Diffuse glioma, corresponding to at least CNS WHO grade 3
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: High grade glioma
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 398\NH22-2146,-0.079,-0.006,0.043,0.001,-0.081,0.044,-0.312,0.064,0.045,0.013,-0.019,-0.037,0.011,0,-0.024,0.007,-0.01,0.011,0.031,0.019,-0.025,0.032,-0.042,-0.013,0.008,-0.039,-0.073,-0.087,-0.012,unmethylated
NH22-2185,206601450003_R06C01,398,5/8/2022,8/19/2022,8/19/2022,14,MD,Diagnostic,398,4,NDP,St George's Hospital London,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,8/6/1963,59.9,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2185,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 398\NH22-2185,-0.106,-0.015,0.058,-0.018,-0.065,0.042,0.111,-0.001,0.003,-0.083,-0.009,-0.006,0.002,0.008,0.087,-0.012,0.009,0.029,-0.004,0.002,-0.038,0.077,-0.015,0.011,-0.041,0.035,-0.424,-0.005,-0.001,methylated
NH22-2181,206601450003_R07C01,398,5/8/2022,8/19/2022,8/19/2022,14,MD,Diagnostic,398,4,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/16/1968,55,"glioblastoma, IDH-wildtype, mesenchymal type",0.86,GBM_MES,0.52,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2181,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 398\NH22-2181,-0.106,-0.066,0.041,0.033,0.068,0.046,0.078,0.175,0.217,0.207,0.151,-0.021,0.127,0.044,0.072,0.038,-0.217,-0.285,-0.01,0.014,0.689,1.621,0.019,0.033,0.029,0.057,0.113,-0.019,-0.015,methylated
NH22-2179,206601450001_R01C01,399,5/8/2022,8/17/2022,8/17/2022,12,MD,Diagnostic,399,1,NDP,Oxford John Radcliffe Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",3,10/7/2002,20.1,posterior fossa ependymoma group B,1,EPN_PFB,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2179,"Integrated diagnosis: Ependymoma, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, posterior fossa, group B
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 399\NH22-2179,-0.008,0,0.051,0.206,0.336,0.024,-0.44,0.209,0.24,0.229,0.211,0.167,0.21,0.2,0.197,0.25,0.003,0.064,0.066,0.019,0.014,-0.016,0.185,0.008,-0.029,-0.033,0.031,-0.018,0.019,unmethylated
NH22-2182,206601450001_R02C01,399,5/8/2022,8/17/2022,8/17/2022,12,MD,Diagnostic,399,1,NDP,"Leeds, St James's University Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,2/13/1961,62.4,ganglioglioma,0.47,GBM_MES,0.51,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2182,"Integrated diagnosis: Compatible with glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Suggestive of glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 399\NH22-2182,-0.013,0.007,0.029,0.213,-0.068,0.157,0.028,0.17,0.143,0.14,0.126,-0.044,0.019,-0.005,0.097,0.045,-0.007,-0.019,0.013,-0.045,0.019,0.061,-0.017,-0.073,-0.073,-0.071,0.15,-0.043,-0.031,methylated
NH22-2190,206601450001_R03C01,399,5/8/2022,8/17/2022,8/17/2022,12,MD,Diagnostic,399,3,NDP,Romford,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/5/1950,73.5,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.97,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2190,"Glioblastoma, CNS WHO grade 4
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4 
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK II
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 399\NH22-2190,-0.036,-0.035,0.014,-0.054,0.056,0.063,0.058,1.175,0.198,0.211,0.144,-0.041,0.06,0.053,-1.657,-0.014,-0.305,-0.3,-0.029,-0.013,-0.045,0.01,-0.121,-0.016,0.025,-0.006,0.232,-0.035,0.009,methylated
NH22-2183,206601450001_R04C01,399,5/8/2022,8/17/2022,8/17/2022,12,MD,Diagnostic,399,3,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,7/12/1981,41.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,0.99,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2183,"Astrocytoma, IDH-mutant, CNS WHO grade 4
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, high grade with CDKN2A/B deletion
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 399\NH22-2183,0.018,0.024,0.009,0.021,0.006,0.13,0.038,-0.042,0.071,-0.012,0.185,-0.013,0.077,-0.008,-2.022,-0.039,-0.097,-0.739,-0.011,-0.045,-0.019,-0.118,-0.145,-0.047,-0.029,-0.003,-0.027,-0.051,0.025,methylated
NH22-2180,206601450001_R06C01,399,8/8/2022,8/17/2022,8/17/2022,9,MD,Diagnostic,399,1,NDP,"Birmingham, Queen Elizabeth Hospital",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,4/3/1997,25.7,ganglioglioma,0.84,LGG_GG,0.84,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2180,"Integrated diagnosis: Ganglioglioma, CNS WHO grade 1
Histology: Low grade glial or glioneuronal tumour, compatible with CNS WHO grade 1
Methylation profile: Ganglioglioma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 399\NH22-2180,0.01,-0.033,0.052,0.013,-0.03,0.138,0.015,0.293,0.314,0.304,0.271,-0.012,0.078,0.021,0.01,-0.007,0.018,0.016,0.011,0.147,0.189,0.263,-0.011,0.018,-0.013,0.042,0.184,0.034,0.007,unmethylated
NH22-2199,206601450001_R07C01,399,8/8/2022,8/17/2022,8/17/2022,9,MD,Diagnostic,399,3,NDP,Southampton General Hospital,?Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,4/3/2001,21.6,infratentorial pilocytic astrocytoma,0.22,LGG_PAPF,0.17,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2199,"Integrated diagnosis: Differential diagnosis between reactive gliosis and pilocytic astrocytoma - see comment
Histology: Differential diagnosis between reactive gliosis and pilocytic astrocytoma - see comment
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 399\NH22-2199,-0.109,0.032,0.096,0.062,-0.053,0.094,0.11,-0.094,0.023,0.042,-0.053,-0.043,0.414,0.041,0.062,-0.101,0.102,-0.053,-0.108,-0.152,-0.015,0.245,0.152,-0.062,0.332,0.089,0.008,-0.093,0.038,unmethylated
NH22-1955,206600570015_R02C01,400,8/8/2022,8/25/2022,8/24/2022,16,MD,Diagnostic,400,2,NDP,"Birmingham, Queen Elizabeth Hospital",LGG/LGGNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,5/2/1988,34.7,"control tissue, white matter (corpus callosum)",0.99,CONTR_HEMI,0.35,0.59,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1955,"2019 and 2022 resection: 
Integrated diagnosis: Differential diagnosis between reactive gliosis and low grade glial / glioneuronal tumour - see comment
Histology: Differential diagnosis between reactive gliosis and low grade glial / glioneuronal tumour - see comment
Methylation profile: Control tissue white matter 
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 400\NH22-1955,-0.009,0.016,-0.026,-0.041,-0.071,-0.002,-0.036,-0.015,0.051,-0.031,-0.011,-0.003,0.062,-0.021,0.03,0,0.023,0.038,0.002,-0.026,0.002,0.007,0.06,-0.014,0.007,0.013,-0.029,-0.005,0.029,unmethylated
NH22-2231,206600570015_R04C01,400,9/8/2022,8/25/2022,8/24/2022,15,MD,Diagnostic,400,2,NDP,Latvia,?ganglioglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2821,2/9/2020,2.5,ganglioglioma,1,LGG_GG,0.83,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2231,"Integrated diagnosis: Ganglioglioma, CNS WHO grade 1
Histology: Low grade glioneuronal tumour, compatible with ganglioglioma, CNS WHO grade 1
Methylation profile: Ganglioglioma
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 400\NH22-2231,-0.006,0.021,0.022,0.015,-0.017,0.035,0.071,0.02,0.001,-0.073,-0.017,-0.027,0.075,0.006,0.01,0.014,-0.008,0.012,0.008,-0.05,-0.06,0.024,0.046,-0.042,-0.056,0.02,-0.012,-0.036,0.036,unmethylated
NH22-2230,206600570009_R01C01,401,11/8/2022,8/25/2022,8/24/2022,13,MD,Diagnostic,401,1,NDP,"Belfast, Royal Victoria Hospital",Post fossa ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,12/13/1963,59.5,posterior fossa ependymoma group B,0.98,EPN_PFB,0.96,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2230,"Integrated diagnosis: Ependymoma, posterior fossa, group B, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, posterior fossa, group B 
MGMT promoter (Illumina array): Unmethylated 
  
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 401\NH22-2230,0.034,-0.179,-0.068,0.07,0.141,0.121,-0.642,0.267,0.116,-0.218,0.081,-0.154,-0.114,-0.101,-0.524,0.115,-0.12,-0.083,0.246,0.23,0.075,0.181,-0.116,-0.189,-0.178,-0.082,0.262,-0.191,-0.089,unmethylated
NH22-2227,206600570009_R02C01,401,11/8/2022,8/25/2022,8/24/2022,13,MD,Diagnostic,401,1,NDP,Newcastle,?GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,8/23/1952,71,ganglioglioma,0.52,LGG_GG,0.31,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2227,"Integrated diagnosis: Diffuse glioma - see comment
Histology: Diffuse glioma
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 401\NH22-2227,0.065,-0.005,0.009,0.017,-0.075,0.005,-0.186,0.184,0.169,0.11,0.127,-0.031,0.058,-0.005,-0.018,0.026,-0.102,-0.116,-0.004,-0.09,-0.028,0.033,-0.01,-0.087,-0.124,0.029,0.008,-0.022,0.02,unmethylated
NH22-2226,206600570009_R03C01,401,11/8/2022,8/25/2022,8/24/2022,13,MD,Diagnostic,401,1,NDP,Southampton General Hospital,HGG,(1) small biopsy or nonrepresentative sample;,1A,4/13/1957,66.3,"glioblastoma, IDH-wildtype, RTK1 type",0.99,GBM_RTKI,0.84,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2226,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass RTK 1
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 401\NH22-2226,1.021,-0.017,-0.031,0.008,-0.06,0.027,-0.011,0.171,0.26,0.179,0.159,-0.045,0.02,0.003,-0.672,0.061,-0.129,-0.132,-0.025,-0.039,0.011,0.032,-0.079,-0.002,0.06,-0.022,-0.049,-0.03,0.013,unmethylated
NH22-2266,206600570009_R08C01,401,11/8/2022,8/25/2022,8/24/2022,13,MD,Diagnostic,401,1,NDP,Nottingham University Hospital,"Glioma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,7/19/1990,32.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.74,AIDH_HG,0.65,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2266,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, high grade
CDKN2A/B (Illumina array): Deleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 401\NH22-2266,0.058,-0.018,0.029,-0.011,0.001,0.036,-0.458,0.057,0.013,0.01,0.027,-0.017,0.033,0.223,-0.317,0.018,-0.047,-0.052,-0.003,-0.056,-0.009,0.012,-0.456,0.009,0.001,0.011,-0.491,-0.024,0.026,methylated
NH22-2240,206600570011_R03C01,402,15/08/2022,9/1/2022,9/1/2022,17,MD,Diagnostic,402,3,NDP,"Charing Cross Hospital, London","Astrocytoma, IDH mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1C,5/4/1986,36.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.96,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2240,"Astrocytoma, IDH-mutant, CNS WHO Grade 2

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss (indicates mutation)     
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 402\NH22-2240,0.024,-0.008,-0.002,-0.03,-0.012,0.077,0.026,-0.021,0.003,-0.005,0.005,-0.025,0.002,0.026,-0.303,0.08,0.03,0.053,-0.051,0.308,-0.231,-0.379,-0.274,0.02,0.03,-0.007,-0.004,-0.036,-0.319,methylated
NH22-2248,206600570011_R04C01,402,15/08/2022,9/1/2022,9/1/2022,17,MD,Diagnostic,402,4,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,10/4/1980,42.5,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,OIDH,1,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-2248,"Oligodendroglioma, CNS WHO Grade 2

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 402\NH22-2248,-0.054,0.015,0.026,-0.039,-0.025,0.011,0.025,-0.013,-0.01,-0.025,0.016,-0.003,-0.042,0.014,-0.047,0.016,-0.004,0.042,-0.022,0.006,-0.076,-0.01,-0.059,-0.007,-0.058,-0.131,-0.314,-0.045,0.02,methylated
NH22-2251,206600570011_R05C01,402,15/08/2022,9/1/2022,9/1/2022,17,MD,Diagnostic,402,1,NDP,Brighton and Sussex Hospital,Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1B,7/25/1960,62.9,supratentorial subependymoma,1,SUBEPN_ST,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2251,"Subependymoma, CNS WHO grade 1
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Subependymoma, supratentorial, CNS WHO grade 1
Histology: Subependymoma, CNS WHO grade 1
Methylation profile: Subependymoma, supratentorial
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 402\NH22-2251,-0.034,0,0.023,0.02,-0.039,0.024,0.058,-0.005,-0.021,-0.052,-0.013,-0.017,0.047,0.027,0.014,0.021,0.05,0.017,0.036,-0.037,-0.021,0.082,0.032,-0.048,0.022,0.005,0.01,-0.037,0.005,unmethylated
NH22-2247,206600570011_R06C01,402,15/08/2022,9/1/2022,9/1/2022,17,MD,Diagnostic,402,3,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,3/13/1983,40,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.5,OIDH,0.67,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2247,"Recurrent IDH-mutant oligodendroglioma

IDH1 (R132H) (IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, grading see comment
Histology: Oligodendroglioma, IDH-mutant
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 402\NH22-2247,-0.056,-0.043,-0.033,-0.096,-0.119,-0.001,-0.055,-0.015,0.017,-0.014,0.018,-0.003,-0.027,0.009,-0.127,0.025,-0.04,0.018,-0.052,0.052,-0.007,-0.012,-0.024,0.005,0.001,-0.024,-0.213,0.021,-0.04,methylated
NH22-2210,206600570011_R07C01,402,15/08/2022,9/1/2022,9/1/2022,17,MD,Diagnostic,402,3,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,7/12/1981,41.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.94,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2210,"Astrocytoma, IDH-mutant, CNS WHO grade 4
IDH1 (R132H IHC): Mutation  
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, lower grade (see comment)
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 402\NH22-2210,0,0.251,0.043,-0.037,-0.019,0.059,-0.038,0.025,0.138,0.168,0.215,0.003,0.042,0.007,-0.371,0.022,0.004,-0.223,-0.003,-0.031,-0.053,-0.048,-0.069,0.034,0.008,0.012,-0.103,-0.071,-0.003,methylated
NH22-2284,206600570011_R08C01,402,15/08/2022,9/1/2022,9/1/2022,17,MD,Diagnostic,402,5,NDP,St George's Hospital London,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,5/15/1957,66.2,spinal ependymoma,1,EPN_SPINE,1,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2284,"Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Ependymoma
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 402\NH22-2284,-0.021,0.04,0.016,0.008,-0.025,-0.006,0.105,0.013,0.043,-0.017,0.013,-0.408,-0.263,-0.271,0.05,0.013,-0.289,-0.281,-0.01,0.019,-0.012,0.065,-0.356,-0.063,0.089,0,-0.003,-0.363,-0.346,unmethylated
NH22-2233,206600570004_R02C01,403,15/08/2022,9/1/2022,9/1/2022,17,MD,Diagnostic,403,3,NDP,NHNN,Spinal ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,3/2/1978,45.1,myxopapillary ependymoma,1,EPN_MPE,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2233,"Spinal ependymoma, CNS WHO Grade 2
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Spinal ependymoma, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 403\NH22-2233,-0.002,-0.011,0.044,0.01,-0.001,0.019,0.055,0.142,0.201,0.225,0.184,0.005,0.045,0.028,0.053,0.063,0.008,0.024,0.017,0.011,-0.023,0.075,-0.443,0.014,-0.003,-0.025,0.002,-0.35,-0.361,unmethylated
NH22-2126,206600570004_R03C01,403,15/08/2022,9/1/2022,9/1/2022,17,MD,Diagnostic,403,1,NDP,Oxford John Radcliffe Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2B,5/23/1981,41.8,"glioblastoma, IDH-wildtype, RTK1 type",0.31,GBM_MID,0.78,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2126,"Diffuse glioma, IDH wildtype, see comment
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
1p/19q: Retained
EGFR: No amplification
TERT promoter: No mutation
  
","Integrated diagnosis: In favour of glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Diffuse glioma, IDH-wildtype
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 403\NH22-2126,0.187,0.066,0.029,0.01,0.551,0.109,0.188,0.047,0.07,0.034,0.046,-0.051,0.044,-0.014,0.115,0.107,0.045,0.111,-0.017,-0.013,-0.031,0.025,0.079,0.129,0.276,0.156,-0.114,0.001,-0.007,methylated
NH22-2282,206600570004_R04C01,403,15/08/2022,9/1/2022,9/1/2022,17,MD,Diagnostic,403,1,NDP,Oxford John Radcliffe Hospital,"LGG, glioneuronal tumour","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",4,6/21/1998,24.5,ganglioglioma,0.34,LGG_DNT,0.33,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2282,"Integrated diagnosis: Neural tissue with mildly increased cell density, no definite evidence ot tumour - see comment
Histology: Neural tissue with mildly increased cell density
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 403\NH22-2282,-0.033,-0.001,-0.01,0.044,-0.015,0.029,0.035,-0.026,-0.015,-0.037,-0.004,-0.027,0.034,0.017,0.056,-0.01,0.046,0.023,-0.005,-0.026,-0.012,0.101,0.034,-0.018,0.019,0.035,0.004,-0.032,0.027,unmethylated
NH22-2285,206600570004_R06C01,403,15/08/2022,9/1/2022,9/1/2022,17,MD,Diagnostic,403,1,NDP,"Cambridge, Addenbrooke's Hospital","IDH-mutant astrocytoma, G 3","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,9/23/1981,41.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.99,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2285,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3 - see comment
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, lower grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 403\NH22-2285,-0.04,-0.03,0.021,-0.013,0.016,-0.034,-0.002,0.027,0.009,0.035,-0.012,-0.007,0.121,0.295,0.022,0.335,0.034,-0.074,0.029,0.42,-0.185,-0.443,-0.453,0.071,0.004,0.091,-0.051,-0.051,0.016,methylated
NH22-2316,206600570004_R08C01,403,16/08/2022,9/1/2022,9/1/2022,16,MD,Diagnostic,403,1,NDP,"Belfast, Royal Victoria Hospital",Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,11/29/2010,11.9,"diffuse glioneuronal tumour, non defined type",0.97,OIDH,0.22,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2316,"Integrated diagnosis: Glioneuronal tumour - for grading, see comment
Histology: Glioneuronal tumour
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
","Integrated diagnosis: Glioneuronal tumour, with BCR:NTRK2 fusion - see comment
Histology: Glioneuronal tumour
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 403\NH22-2316,-0.06,0.033,0.029,-0.04,0.056,0.078,0.002,-0.017,-0.002,-0.013,0.028,-0.02,0.037,0.044,0.055,0.021,0.018,0.009,0.025,-0.028,0.003,-0.037,-0.024,0.003,0.008,0.025,-0.013,-0.357,-0.274,unmethylated
NH22-2309,206601450077_R02C01,404,16/08/2022,9/1/2022,9/1/2022,16,MD,Diagnostic,404,1,NDP,St George's Hospital London,Glioblastoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,8/22/1952,71,"glioblastoma, IDH-wildtype, RTK2 type",0.98,GBM_RTKII,0.93,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2309,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype
MGMT promoter (Illumina array): Methylated 
  
","Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: No mutation
TERT promoter: Mutation
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 404\NH22-2309,-0.049,0,0.018,-0.012,-0.045,-0.008,0.03,1.178,0.274,0.284,0.189,-0.025,0.063,0.077,-1.43,-0.012,-0.323,-0.35,-0.027,0.039,-0.037,0.06,-0.038,0.015,0.035,-0.05,0.256,-0.073,-0.02,methylated
NH22-2308,206601450077_R03C01,404,18/08/2022,9/1/2022,9/1/2022,14,MD,Diagnostic,404,1,NDP,St George's Hospital London,?glioma vs reactive gliosis,(1) small biopsy or nonrepresentative sample;,A1,12/24/1977,45.3,"glioblastoma, IDH-wildtype, mesenchymal type",0.16,GBM_MES,0.6,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2308,"Integrated diagnosis: Suggestive of infiltration of glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Suggestive of infiltration of glioma
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 404\NH22-2308,0.585,-0.041,0.035,-0.038,-0.119,-0.001,0.03,0.126,0,-0.073,0.1,-0.002,0.082,0.034,0.112,0.05,-0.219,-0.214,-0.023,0.036,0.539,0.083,0.061,0.046,0.047,0.004,0.042,-0.015,0.022,methylated
NH22-2333,206601450077_R06C01,404,19/08/2022,9/1/2022,9/1/2022,13,MD,Diagnostic,404,1,NDP,"Cambridge, Addenbrooke's Hospital",Glial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,1/10/1968,55.4,spinal subependymoma [subtype A],0.99,SUBEPN_SPINE,0.62,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2333,"Integrated diagnosis: Subependymoma, CNS WHO grade 1 - see comment
Histology: Subependymoma, CNS WHO grade 1
Methylation profile: Subependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(3) establishing new diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 404\NH22-2333,-0.021,0.047,0.043,0.034,-0.079,0.007,0.094,-0.008,-0.035,-0.094,-0.024,-0.021,0.105,0.024,0.114,0.034,0.069,-0.028,0.006,0.02,0.017,0.129,0.049,0.065,0.053,0.063,-0.071,0.001,0.06,unmethylated
NH22-2328,206601450077_R07C01,404,19/08/2022,9/1/2022,9/1/2022,13,MD,Diagnostic,404,1,NDP,Nottingham University Hospital,Glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,4/1/1975,48.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2328,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, high grade 
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 404\NH22-2328,-0.026,0.005,0.082,0.054,-0.003,0.137,0.052,-0.024,0.088,0.036,0.051,-0.009,0.081,0.049,0.055,0.029,0.065,0.024,0.083,0.188,-0.027,0.061,-0.009,0.004,-0.002,0.029,-0.102,-0.002,0.032,methylated
NH22-2357,206601450077_R08C01,404,19/08/2022,9/1/2022,9/1/2022,13,MD,Diagnostic,404,1,NDP,St George's Hospital London,Infiltration of glioma,(1) small biopsy or nonrepresentative sample;,A1,3/18/1947,76.5,"control tissue, white matter (corpus callosum)",0.73,LGG_DNT,0.11,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2357,"Integrated diagnosis: Infiltration of glioma - see comment
Histology: Infiltration of glioma
Methylation profile: Control tissue, white matter
MGMT promoter (Illumina array): Unmethylated 
  
","Suggestive of infiltration of glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1/2Seq: No mutation
EGFR: No amplification          
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 404\NH22-2357,0.024,0.044,0.008,0.008,-0.061,-0.04,0.017,0.022,0.134,-0.016,0.07,-0.006,0.058,0.061,-0.04,0.052,-0.01,-0.046,0.009,0,-0.028,0.04,0.031,0.017,0.139,0.088,-0.051,-0.074,-0.035,unmethylated
NH22-2324,206601450080_R02C01,405,19/08/2022,9/7/2022,9/7/2022,19,MD,Diagnostic,405,1,NDP,Oxford John Radcliffe Hospital,Glioma,(1) small biopsy or nonrepresentative sample;,A,1/22/1956,67.5,supratentorial midline pilocytic astrocytoma,0.64,LGG_PAMID,0.4,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2324,"Integrated diagnosis: Compatible with pilocytic astrocytoma, CNS WHO grade 1
Histology: Compatible with pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, midline
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 405\NH22-2324,-0.027,0.046,0.036,-0.124,0.043,-0.037,0.085,-0.141,0.043,0.007,-0.048,0.008,0.148,0.108,0.111,-0.091,0.131,-0.033,0.119,-0.061,-0.05,0.119,0.158,0.013,0.002,0.098,-0.077,0.012,-0.039,methylated
NH22-2353,206601450080_R04C01,405,19/08/2022,9/7/2022,9/7/2022,19,MD,Diagnostic,405,1,NDP,"Cambridge, Addenbrooke's Hospital",Glioma,(1) small biopsy or nonrepresentative sample;,A1,10/14/2003,19.1,infratentorial pilocytic astrocytoma,0.57,LGG_PAPF,0.74,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2353,"Integrated diagnosis: Compatible with pilocytic astrocytoma, CNS WHO grade 1
Histology: Compatible with pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, infratentorial
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 405\NH22-2353,-0.037,0.005,0.037,0.058,-0.041,0.182,0.434,0.466,0.417,0.484,0.365,-0.008,0.055,0.039,-0.021,-0.029,0.032,0.012,0.162,0.146,0.118,0.473,0.044,-0.08,-0.084,0.033,0.031,0.007,0.035,methylated
NH22-2349,206601450080_R07C01,405,19/08/2022,9/7/2022,9/7/2022,19,MD,Diagnostic,405,3,NDP,Southampton General Hospital,Low grade glioneuronal tumour,"(2) unusual histology, location, demographics",1F,3/15/1965,58.3,ganglioglioma,0.3,GBM_MES,0.57,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2349,"Integrated diagnosis: Raising the possibility of infiltration of glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Infiltration of glioma
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Methylated 
  
","Integrated diagnosis: In keeping with infiltration of Glioblastoma, IDH-wildtype, CNS WHO grade 4
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 405\NH22-2349,-0.043,0.009,0.038,0.014,-0.027,0.13,0.045,0.217,0.256,0.189,0.198,-0.007,0.095,0.056,0.074,0.005,0.075,0.015,-0.021,-0.029,-0.018,0.035,0.075,-0.006,-0.001,0.015,0.096,-0.02,0.031,methylated
NH22-2346,206601450080_R08C01,405,19/08/2022,9/7/2022,9/7/2022,19,MD,Diagnostic,405,5,NDP,Southampton General Hospital,Astrocytoma vs oligodendroglioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1F,12/29/1971,51.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.25,OIDH,0.55,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2346,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 405\NH22-2346,0.012,0.04,0.024,-0.003,-0.083,0.055,-0.042,-0.043,0.045,0.006,0.033,0.021,0.053,0.028,-0.003,-0.04,0.046,-0.015,-0.007,-0.087,-0.005,0.055,-0.004,-0.066,0.027,0.055,-0.176,-0.037,0.001,methylated
NH22-2332,206601450107_R01C01,406,19/08/2022,9/7/2022,9/7/2022,19,MD,Diagnostic,406,1,NDP,NHNN,Rec Glioblastoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2A,3/13/1983,40,"glioblastoma, IDH-wildtype, mesenchymal type",0.14,GBM_RTKII,0.11,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2332,"Recurrent Glioblastoma, IDH wild type, WHO grade 4

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Glioblastoma, IDH-wildtype, CNS WHO grade 4
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 406\NH22-2332,0.041,-0.1,-0.06,0.043,-0.062,-0.011,0.092,0.322,0.387,0.434,0.305,0.353,0.295,0.304,0.064,0.006,-1.51,-0.007,-0.129,-0.028,-0.035,0.037,0.023,-0.014,-0.037,0.022,-0.036,-0.052,0.063,unmethylated
NH22-2369,206601450107_R02C01,406,20/08/2022,9/7/2022,9/7/2022,18,MD,Diagnostic,406,1,NDP,NHNN,PNET with recurrences since 2015,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,2/4/1998,24.9,"glioblastoma, IDH-wildtype, with primitive neuronal component",0.78,MB_SHHCHLAD,0.38,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2369,"Recurrent / residual supratentorial primitive neuroectodermal tumour (PNET) / glioblastoma, CNS WHO grade 4 - for classification of the tumour, see comment
","Integrated diagnosis: Recurrent / residual glioblastoma with primitive neuronal component, IDH-wildtype, MYCN-amplified, CNS WHO grade 4
Histology: Recurrent / residual glioblastoma with primitive neuronal component, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, with primitive neuronal component 
MGMT promoter (Illumina array): Unmethylated 
NGS data: TP53, RB1, BCOR pathogenic/likely pathogenic variants; amplification of MYCN; no gene fusions
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 406\NH22-2369,0.302,0.955,0.052,0.002,0.033,0.073,0.028,0.178,0.218,0.201,0.154,-0.004,0.039,-0.048,-0.012,-0.029,-0.121,-0.085,0.052,0.032,-0.016,0.052,-0.4,-0.028,0.011,0.028,-0.131,0.003,-0.028,unmethylated
NH22-2362,206601450107_R04C01,406,24/08/2022,9/7/2022,9/7/2022,14,MD,Diagnostic,406,1,NDP,"Cardiff, University Hospital",IDH mutant glioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,6/12/1983,39.8,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2362,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
Histology: Glioma, IDH-mutant, with focal anaplasia, in favour of CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 406\NH22-2362,-0.033,-0.03,0.013,-0.189,-0.233,0.019,0.023,0.037,0.019,-0.027,0.002,-0.016,-0.002,0.011,0.036,-0.037,-0.017,0.015,-0.011,0.016,-0.047,0.024,-0.312,0.029,-0.003,-0.017,-0.455,-0.034,0.024,methylated
NH22-2361,206601450110_R04C01,407,24/08/2022,9/9/2022,9/9/2022,16,MD,Diagnostic,407,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,2/28/1986,37,high-grade astrocytoma with piloid features,0.33,ANAPA,0.16,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2361,"Integrated diagnosis: Suggestive of high grade glioma with piloid features - see comment
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: High grade astrocytoma with piloid features
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 407\NH22-2361,0.107,0.077,0.124,-0.097,-0.118,-0.023,-0.051,0.04,0.01,0.105,0.051,-0.241,-0.165,-0.105,-0.623,0.014,-0.132,0.121,-0.182,0.026,0.013,0.096,-0.13,-0.15,-0.748,0.099,-0.235,-0.112,-0.036,methylated
NH16-1485,206601450110_R08C01,407,24/08/2022,9/9/2022,9/9/2022,16,MD,Diagnostic,407,1,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,3/13/1983,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH16-1485,"Oligodendroglioma (WHO grade II)-pending molecular analysis
IDH1 (R132H IHC) Mutation
ATRX (IHC): Retained. 
1p/19q: Test pending
  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 407\NH16-1485,-0.014,0.051,0.032,-0.209,-0.176,0.038,0.001,0.007,0.004,0.06,0.036,-0.02,0.014,0.121,-0.006,0.056,-0.003,-0.002,0.022,-0.028,0.04,0.013,-0.077,0.071,-0.049,0.015,-0.542,-0.016,0.101,methylated
NH19-1419,206601450104_R01C01,408,20/08/2022,9/14/2022,9/14/2022,25,MD,Diagnostic,408,1,NDP,Romford,"Astrocytoma, IDH-mutant","(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B3,7/31/1975,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.97,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-1419,"Low grade glioma, IDH-mutant (WHO grade II)

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Technical failure 
Further molecular tests: Pending
  
","Astrocytoma, IDH-mutant (WHO grade II)
IDH1 (R132H IHC); IDH1/2Seq: Mutation
ATRX (IHC): Retained
1p/19q: Retained
MGMT Promoter: Unmethylated (0%)
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 408\NH19-1419,-0.032,-0.077,0.03,0.018,-0.06,0.049,-0.02,-0.083,0.129,0.14,0.328,-0.004,0.086,0.135,-0.191,-0.01,0.025,0.022,0.009,-0.033,0.024,0.036,-0.043,0.078,-0.014,0.026,0.046,-0.079,0.027,methylated
NH22-2380,206601450104_R02C01,408,30/08/2022,9/14/2022,9/14/2022,15,MD,Diagnostic,408,1,NDP,NHNN,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/1/1978,45.2,"glioblastoma, IDH-wildtype, RTK1 type",0.99,GBM_RTKI,0.76,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2380,"High Grade Glioma (please see comment)
IDH1 (R132H IHC): Mutation - Further tests pending 
ATRX (IHC): Retained      
Further molecular tests: Pending
","Glioblastoma, IDH-wildtype, CNS WHO grade 4
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 408\NH22-2380,0.021,-0.044,0.025,0.073,-0.047,0.059,0.009,0.205,0.322,0.269,0.208,-0.004,0,0.064,-1.541,0.01,-0.237,-0.373,0,0.04,0.015,0.11,-0.026,0.076,0.065,0.032,-0.041,-0.072,0.039,unmethylated
NH22-2392,206601450104_R03C01,408,30/08/2022,9/14/2022,9/14/2022,15,PM,Diagnostic,408,1,NDP,Brighton and Sussex Hospital,Anaplastic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,12/29/1981,41.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2392,"Astrocytoma, IDH mutant CNS WHO Grade 4

IDH1 (R132H IHC): Mutation
ATRX (IHC):Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, high grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 408\NH22-2392,0.017,0.073,-0.053,0.079,0.246,-0.025,-0.115,0.121,0.159,0.508,0.072,-0.025,-0.004,-0.017,-0.329,0.058,-0.03,-0.361,-0.015,0.191,0.057,0.247,-0.566,0.121,0.341,0.194,0.009,-0.278,-0.283,methylated
NH22-2439,206601450104_R06C01,408,30/08/2022,9/14/2022,9/14/2022,15,PM,Diagnostic,408,1,NDP,Nottingham University Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,4/30/2003,19.6,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2439,"Integrated diagnosis: Epithelioid glioblastoma, BRAF V600E-mutant, CNS WHO grade 4 - for diagnosis and grading, see comment 
Histology: High grade glioma 
Methylation profile: (anaplastic) pleomorphic xanthoastrocytoma 

MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 408\NH22-2439,-0.186,0.005,0.136,-0.005,-0.091,-0.069,-0.044,0,-0.035,-0.045,-0.004,-0.009,0.048,-0.084,-1.455,-0.333,0.009,-0.106,0.007,-0.053,-0.012,0.1,-0.039,-0.055,-0.102,0.164,-0.01,-0.101,0.064,unmethylated
NH22-2412,206601450104_R07C01,408,30/08/2022,9/14/2022,9/14/2022,15,PM,Diagnostic,408,1,NDP,"Charing Cross Hospital, London",Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,8/15/1996,26.4,myxopapillary ependymoma,1,EPN_MPE,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2412,"Myxopapillary ependymoma, CNS WHO Grade 2
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 408\NH22-2412,-0.058,0.01,0.076,0.016,0.006,0.027,0.295,0.236,0.251,0.23,0.245,-0.01,0.076,0.078,0.365,0.433,0.054,-0.011,0.023,-0.071,-0.055,0.046,-0.011,-0.072,-0.001,0.039,0.04,0.007,0.036,unmethylated
NH22-2417,206601450104_R08C01,408,30/08/2022,9/14/2022,9/14/2022,15,PM,Diagnostic,408,1,NDP,NHNN,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/23/1971,52.3,"glioblastoma, IDH-wildtype, RTK2 type",0.99,GBM_RTKII,0.94,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2417,"Gemistocytic astrocytic tumour - probable high grade (please see comments)
","Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: Amplification
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 408\NH22-2417,0.135,0.284,0.004,-0.014,0.04,-0.004,-0.174,1.191,-0.053,-0.161,-0.066,-0.057,0.044,-0.014,-0.009,-0.282,-0.339,-0.405,-0.055,0.246,0.554,1.721,-0.326,-0.058,-0.032,-0.041,0.062,-0.199,-0.226,unmethylated
NH22-2467,206601450097_R02C01,409,30/08/2022,9/14/2022,9/14/2022,15,PM,Diagnostic,409,1,NDP,Oxford John Radcliffe Hospital,Low grade glial/glioneuronal tumor?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SH894,1/11/1999,23.9,ganglioglioma,0.32,IHG,0.23,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2467,"Integrated diagnosis: Compatible with low grade glial / glioneuronal tumour, CNS WHO grade 1
Histology: Compatible with low grade glial / glioneuronal tumour, CNS WHO grade 1
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 409\NH22-2467,0.183,-0.381,-0.063,0.114,-0.158,-0.038,-0.243,0.065,0.184,-0.046,0.153,-0.145,0.111,-0.125,-0.045,-0.046,0.139,-0.008,0.061,0.139,0.094,0.498,-0.169,-0.315,0.066,0.149,-0.137,-0.17,0.097,unmethylated
NH22-2397,206601450097_R03C01,409,30/08/2022,9/14/2022,9/14/2022,15,PM,Diagnostic,409,1,NDP,Romford,?Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,1/12/1980,43.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.64,GBM_RTKII,0.52,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2397,"Glioblastoma, CNS WHO Grade 4
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 409\NH22-2397,0.025,-0.066,0.06,-0.09,0.33,-0.138,0.061,0.246,0.316,0.242,0.196,-0.022,0.096,0.07,-0.312,0.057,-0.078,-0.315,-0.052,-0.051,-0.013,0.029,-0.266,-0.122,-0.219,-0.005,0.012,0.045,0.102,methylated
NH22-2448,206601450097_R04C01,409,30/08/2022,9/14/2022,9/14/2022,15,PM,Diagnostic,409,1,NDP,Royal London Hospital,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,6/25/2004,18.4,myxopapillary ependymoma,1,EPN_MPE,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2448,"Myxopapillary ependymoma (CNS WHO grade 2)
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 1
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 409\NH22-2448,-0.148,-0.054,0.045,-0.047,-0.11,0.055,-0.052,0.145,0.125,0.161,0.135,-0.274,-0.129,-0.307,0.101,0.093,-0.202,-0.235,-0.048,-0.197,-0.051,0.031,-0.283,-0.015,0.237,0.115,0.184,-0.326,-0.198,unmethylated
NH22-2434,206601450097_R06C01,409,30/08/2022,9/14/2022,9/14/2022,15,PM,Diagnostic,409,7,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,6/11/1988,34.7,"glioblastoma, IDH-wildtype, RTK1 type",0.53,GBM_RTKI,0.66,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2434,"Astrocytoma (CNS WHO grade 4) - please see comment 
IDH1 (R132H IHC): Negative and further tests pending 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
 
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 409\NH22-2434,0.466,-0.026,0.12,-0.2,0.9,0.474,-0.048,-0.07,-0.115,-0.186,-0.077,-0.336,-0.024,0.165,-0.345,0.169,-0.227,-0.308,-0.045,-0.137,-0.27,-0.237,-0.877,-0.091,-0.023,0.023,-0.106,0.096,0.003,methylated
NH22-2468,206601450097_R08C01,409,30/08/2022,9/14/2022,9/14/2022,15,PM,Diagnostic,409,1,NDP,"Belfast, Royal Victoria Hospital",Ependymoma/subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2B,9/4/1952,71,posterior fossa subependymoma,1,SUBEPN_PF,0.99,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2468,"Integrated diagnosis: Ependymoma, CNS WHO grade 2 - see comment
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 409\NH22-2468,-0.122,-0.055,0.044,-0.039,0.01,-0.03,-0.614,-0.044,-0.122,0.039,-0.001,0.01,-0.021,0.013,-0.025,0.037,-0.033,0.007,0.055,-0.129,-0.054,-0.009,-0.015,-0.111,-0.02,0.054,0.134,0.051,0.131,unmethylated
NH22-2395,206601450123_R01C01,410,1/9/2022,9/16/2022,9/16/2022,15,PM,Diagnostic,410,1,NDP,Brighton and Sussex Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,10/13/1980,42.5,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type C]",1,DMG_K27,0.06,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2395,"Glioblastoma, CNS WHO Grade 4
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: No amplification          
MGMT Promoter: Unmethylated (0%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 410\NH22-2395,0.003,0.051,0.037,-0.003,-0.09,0.112,0.058,-0.029,0.415,0.382,0.313,-0.018,0.063,0.057,0.076,0.015,0.067,-0.02,0.044,0.006,-0.015,0.118,0.046,0.042,0.026,0.048,-0.088,0.011,0.023,unmethylated
NH22-2475,206601450123_R02C01,410,5/9/2022,9/16/2022,9/16/2022,11,PM,Diagnostic,410,1,NDP,Southampton General Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1A,9/21/1962,60.8,myxopapillary ependymoma,1,EPN_MPE,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2475,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Ependymoma
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 410\NH22-2475,-0.016,-0.041,0.059,0.039,0.019,0.02,0.058,-0.023,-0.038,-0.012,-0.02,0.003,-0.026,0.035,0.054,0.037,0.016,-0.019,0.013,-0.008,-0.012,0.024,-0.008,0.025,-0.004,-0.001,-0.004,-0.205,-0.223,methylated
NH22-2529,206601450123_R03C01,410,6/9/2022,9/16/2022,9/16/2022,10,PM,Diagnostic,410,5,NDP,"Birmingham, Queen Elizabeth Hospital",Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C1,11/3/1945,78,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",1,GBM_MES,0.2,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2529,"Integrated diagnosis: Favouring infiltration of high-grade glioma / glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment)
Histology: Suspicious for infiltration of a glioma
Methylation profile: Suggestive of high-grade glioma / glioblastoma (see comment)
MGMT promoter (Illumina array): Unmethylated  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 410\NH22-2529,0.05,-0.013,0.026,-0.027,-0.05,-0.024,-0.037,0.166,0.127,0.13,0.087,-0.029,0.053,-0.021,0.026,0.035,-0.065,-0.131,-0.033,0.044,0.007,0.075,-0.02,0.055,0.08,0.026,-0.084,-0.123,-0.093,unmethylated
NH22-2528,206601450123_R04C01,410,7/9/2022,9/16/2022,9/16/2022,9,PM,Diagnostic,410,1,NDP,"Birmingham, Queen Elizabeth Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,5/8/2003,19.6,spinal ependymoma,1,EPN_SPINE,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2528,"Integrated diagnosis: Spinal ependymoma, favouring CNS WHO grade 2 (see comment)
Histology: Ependymal tumour
Methylation profile: Ependymoma, spinal  
MGMT promoter (Illumina array): Unmethylated  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 410\NH22-2528,0.033,0.205,0.222,0.013,0.006,0.024,0.029,0.185,0.214,0.198,0.19,0.221,0.26,0.233,0.261,0.226,0.228,0.196,0.188,0.338,0.302,0.494,-0.028,0.038,-0.025,-0.004,-0.006,-0.3,-0.295,unmethylated
NH22-2523,206601450123_R05C01,410,7/9/2022,9/16/2022,9/16/2022,9,PM,Diagnostic,410,3,NDP,NHNN,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,8/18/1983,39.6,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.98,DMG_K27,0.98,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2523,"High grade glioma - see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained
BRAF (V600E IHC): No mutation      
Further molecular tests: Pending
  
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 410\NH22-2523,0.103,-0.08,-0.061,0.096,0.829,-0.084,-0.409,0.159,0.222,0.218,0.126,0.039,0.059,0.064,-0.107,0.062,-0.008,-0.083,-0.162,-0.086,-0.086,-0.019,-0.384,-0.35,0.349,0.164,-0.145,0.012,0.089,unmethylated
NH22-2509,206601450123_R06C01,410,7/9/2022,9/16/2022,9/16/2022,9,PM,Diagnostic,410,4,NDP,"Liverpool, The Walton Centre",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1R,10/21/1993,28.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.64,AIDH_HG,0.96,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2509,"Integrated diagnosis: Astrocytoma, IDH-mutant, favouring CNS WHO grade 3 (2021 classification 5th ed., see comment)
Histology: Astrocytoma, IDH-mutant (see comment)
Methylation profile: IDH glioma, subclass high grade astrocytoma  
MGMT promoter (Illumina array): Methylated 

IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B: Deletion
 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 410\NH22-2509,0.033,0.01,0.021,-0.023,0.416,-0.248,0.016,0.118,-0.061,-0.13,-0.047,-0.035,-0.009,0.087,-0.221,0.095,-0.18,-0.303,0.006,0.01,0.008,0.049,-0.181,0.109,0.085,0.042,-0.069,-0.39,-0.337,methylated
NH22-2506,206601450123_R07C01,410,7/9/2022,9/16/2022,9/16/2022,9,PM,Diagnostic,410,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,3/20/1974,49.1,"glioblastoma, IDH-wildtype, RTK2 type",0.95,GBM_RTKII,0.96,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2506,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma / glioblastoma, CNS WHO grade 4 
Methylation profile: Glioblastoma, IDH wildtype, subclass RTK II  
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 410\NH22-2506,0.024,0.049,0.063,-0.004,-0.014,0.004,-0.121,1.627,0.251,0.269,0.254,0.038,0.042,0.111,-0.961,0.1,-0.256,-0.232,-0.015,-0.011,-0.035,-0.026,-0.11,0.019,-0.016,0.02,0.164,-0.105,-0.015,unmethylated
NH22-2503,206601450123_R08C01,410,7/9/2022,9/16/2022,9/16/2022,9,PM,Diagnostic,410,5,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,8/12/1973,49.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.88,AIDH,0.89,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-2503,"Recurrent / residual astrocytoma, IDH-mutant, CNS WHO grade 2 - see comment
IDH1: C394A mutation confirmed in 2017 tumour material
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 410\NH22-2503,-0.001,0.072,0.019,-0.028,0.028,0.011,0.025,-0.032,0.04,-0.038,0.034,0.005,0.019,0.127,-0.192,0.062,-0.063,-0.12,0.056,-0.027,-0.131,-0.162,-0.035,-0.046,0.064,-0.016,0.006,-0.057,0.02,methylated
NH22-2495,206601450150_R02C01,411,7/9/2022,9/22/2022,9/22/2022,15,PM,Diagnostic,411,2,NDP,Oxford John Radcliffe Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,11/29/1984,38.3,supratentorial midline pilocytic astrocytoma,0.88,LGG_PAMID,0.76,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2495,"Low-grade astrocytoma, favouring a pilocytic astrocytoma, CNS WHO grade 1 (see comment)
KIAA1549-BRAF: No fusion
BRAF (V600E): Test failed

","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade astrocytoma, favouring pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, midline 
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 411\NH22-2495,-0.041,-0.019,-0.012,-0.03,0.014,0.04,0.005,-0.033,-0.017,-0.072,-0.021,0,0.064,0.03,0.046,0.027,0.014,0.014,0.09,-0.005,0.053,0.091,-0.025,0.008,-0.021,0.022,-0.009,-0.038,-0.017,unmethylated
NH22-2492,206601450150_R03C01,411,7/9/2022,9/22/2022,9/22/2022,15,PM,Diagnostic,411,1,NDP,"Belfast, Royal Victoria Hospital",Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,11/29/2010,10.6,"diffuse glioneuronal tumour, non defined type",0.99,OIDH,0.24,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2492,"Integrated diagnosis: Glioneuronal tumour - for grading, see comment
Histology: Glioneuronal tumour
Methylation profile: Glioneuronal tumour -see comment
MGMT promoter (Illumina array): Unmethylated Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 411\NH22-2492,0.005,0.019,-0.029,-0.074,0.073,0.01,0.025,-0.035,0.092,0.067,0.051,0.012,-0.016,0.022,0.136,0.013,0.045,-0.04,0.068,-0.027,0.033,0.059,-0.023,0.086,0.037,-0.001,-0.071,-0.238,-0.254,unmethylated
NH22-2491,206601450150_R04C01,411,7/9/2022,9/22/2022,9/22/2022,15,PM,Diagnostic,411,8,NDP,NHNN,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,7/25/1998,24.5,supratentorial midline pilocytic astrocytoma,0.98,LGG_PAMID,0.85,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2491,"Glioma - see comment
H3 (K27M IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1 - see comment
Histology: Low grade astrocytoma
Methylation profile: Pilocytic astrocytoma, midline
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 411\NH22-2491,-0.01,-0.022,-0.007,0.012,-0.053,0.037,0.009,-0.048,-0.006,-0.019,-0.02,-0.007,0.026,0.028,0.061,0,0.027,-0.017,0.056,-0.019,0.014,0.106,0.023,0.017,0.042,0.002,-0.039,0.05,0.017,unmethylated
NH19-2671,206601450150_R06C01,411,7/9/2022,9/22/2022,9/22/2022,15,PM,Diagnostic,411,1,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,8/12/1973,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-2671,"Recurrent Diffuse astrocytoma, WHO Grade II, IDH1 mutant


IDH1 (R132H IHC): Mutation - confirmed in previous sample (NH17-2981) 
ATRX (IHC): Loss of expression (indicates mutation) - shown in previous sample (NH17-2981)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 411\NH19-2671,0.025,-0.024,0.037,0,-0.005,0.036,0.003,0.064,0.026,0.033,0.013,-0.019,0.061,0.196,-0.285,0.01,0.022,0.024,-0.014,-0.015,0.031,0.041,-0.028,-0.036,-0.045,0.001,-0.081,-0.051,0.017,methylated
NH22-2599,206601450118_R02C01,412,13/09/2022,9/22/2022,9/22/2022,9,PM,Diagnostic,412,3,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,4/4/1981,42,"glioblastoma, IDH-wildtype, mesenchymal type",0.71,GBM_MES,0.94,0.96,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2599,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4  
Histology: High-grade glioma
IDH11/2Seq: No mutation
TERT promoter: Mutation
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal  
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 412\NH22-2599,0.041,0.003,0.018,0.016,-0.03,-0.057,-0.002,0.269,0.271,0.244,0.21,-0.025,0.025,0.077,0.097,0.073,-0.278,-0.318,0.03,0.056,0.031,0.087,-0.259,-0.283,-1.047,0.005,0.104,0.129,0.045,unmethylated
NH22-2550,206601450118_R03C01,412,13/09/2022,9/22/2022,9/22/2022,9,PM,Diagnostic,412,4,NDP,Romford,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A5,6/3/1947,76.3,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.65,AIDH,0.68,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-2550,"Astrocytoma, IDH-mutant, CNS WHO grade 2 - see comment
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 412\NH22-2550,-0.003,-0.074,0.035,-0.017,0.013,0.026,0.037,-0.069,-0.007,-0.062,-0.009,-0.016,0.015,-0.013,-0.382,0.001,0.018,0.043,-0.007,0.509,-0.006,-0.01,-0.04,-0.023,-0.045,-0.004,-0.272,-0.027,-0.014,methylated
NH22-2547,206601450118_R04C01,412,13/09/2022,9/22/2022,9/22/2022,9,PM,Diagnostic,412,7,NDP,NHNN,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,11/9/1981,41.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.81,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2547,"Recurrent / residual astrocytoma, IDH-mutant, CNS WHO grade 3 - see comment
IDH1 (R132H IHC): No mutation (C394G mutation confirmed in 2015 resection material)
ATRX (IHC): Loss of expression (indicates mutation) (shown in 2015 resection material)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Recurrent / residual astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: IDH glioma, subclass astrocytoma 
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 412\NH22-2547,0.015,-0.035,0.046,0.008,-0.01,0.117,0.025,0.165,0.164,0.352,0.144,0.18,0.17,0.131,0.042,-0.009,0.028,0.032,-0.014,0.12,-0.021,0.016,-0.147,-0.024,-0.04,-0.059,-0.038,0.039,0.012,methylated
NH22-2500,206601450118_R05C01,412,13/09/2022,9/22/2022,9/22/2022,9,PM,Diagnostic,412,1,NDP,Romford,Hemangioblastoma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/5/1997,25.3,"control tissue, cerebellar hemisphere",0.89,CONTR_CEBM,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2500,"Cerebellar parenchyma with focal mild increase in cell density in the white matter - see comment
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 412\NH22-2500,-0.02,0.031,-0.025,-0.017,-0.011,-0.005,0.001,-0.005,-0.004,-0.004,-0.021,0,0.01,-0.025,0.03,0.024,-0.005,-0.001,-0.026,-0.043,-0.034,0.054,0.006,-0.03,-0.01,0.011,-0.018,0,0.007,unmethylated
NH22-2496,206601450118_R06C01,412,13/09/2022,9/22/2022,9/22/2022,9,PM,Diagnostic,412,1,NDP,Brighton and Sussex Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/1/1953,70.5,"glioblastoma, IDH-wildtype, RTK2 type",0.48,GBM_RTKII,0.85,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2496,"Diffuse glioma - for grading, see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Diffuse glioma
Methylation profile: Glioblastoma, IDH wildtype, subclass RTK II  
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 412\NH22-2496,0.929,0.02,0.03,-0.005,0.002,0.614,-0.018,0.393,0.391,0.441,0.318,-0.006,0.033,-0.008,-0.443,-0.006,-0.875,-0.274,-0.062,-0.045,0.008,-0.002,-0.049,-0.065,-0.025,0.028,-0.034,0.084,-0.033,unmethylated
NH15-1334,206601450118_R07C01,412,13/09/2022,9/22/2022,9/22/2022,9,PM,Diagnostic,412,1,NDP,NHNN,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,11/9/1981,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.95,AIDH,0.73,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH15-1334,"Anaplastic astrocytoma (WHO Grade III)

IDH1 (IHC and sequencing): repeat testing in progress
ATRX (IHC): Mutation present
Histone H3K27 (IHC): No mutation
1p/19q: No LOH (previously tested)
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3 [2021 WHO classification]
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: IDH glioma, subclass astrocytoma  
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 412\NH15-1334,-0.055,0.002,0.076,0.045,0.069,0.067,0.023,0.3,0.27,0.587,0.256,0.296,0.302,0.303,0.005,0.047,0.03,0.006,0.015,0.012,-0.005,0.004,-0.077,-0.028,-0.117,-0.056,-0.031,-0.016,-0.016,methylated
NH22-2563,206699910041_R01C01,413,13/09/2022,9/28/2022,9/28/2022,15,PM,Diagnostic,413,1,NDP,"Cambridge, Addenbrooke's Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/16/1961,61.7,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.71,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2563,"Integrated diagnosis: Compatible with glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Cellular tumour
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 413\NH22-2563,-0.05,0.049,0.033,0.003,-0.012,0.016,-0.046,0.214,0.151,0.095,0.111,0.042,0.054,0.1,-0.769,0.117,-0.144,-0.07,-0.105,0.031,0.026,0.157,-0.162,0.159,-0.076,0.096,0.05,-0.249,-0.106,methylated
NH22-2602,206699910041_R02C01,413,13/09/2022,9/28/2022,9/28/2022,15,PM,Diagnostic,413,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,11/25/1963,59.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.79,GBM_MES,0.91,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2602,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subtype mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 413\NH22-2602,0.113,0.1,0.087,-0.015,-0.085,0.135,-0.062,0.246,0.327,0.31,0.254,-0.029,0.015,0.046,-0.373,-0.034,-0.006,-0.02,0.063,0.125,0.077,0.16,-0.016,-0.015,-0.078,-0.066,0.12,-0.149,-0.001,methylated
NH22-2568,206699910041_R03C01,413,14/09/2022,9/28/2022,9/28/2022,14,PM,Diagnostic,413,6,NDP,"Charing Cross Hospital, London",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,11/25/1981,41.4,pleomorphic xanthoastrocytoma(-like),1,PXA,0.98,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2568,"Glioma - for grading, await molecular test results 
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained
H3 (K27M IHC): No mutation      
Further molecular tests: Pending
  
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 413\NH22-2568,-0.082,-0.002,0.053,-0.016,-0.04,-0.006,-0.282,-0.053,-0.017,0.01,-0.004,0.016,-0.016,0.113,-1.139,0.012,-0.275,-0.251,0.032,0.021,-0.016,-0.028,-0.033,-0.269,-0.011,-0.014,-0.333,-0.032,-0.26,unmethylated
NH22-2548,206699910041_R05C01,413,14/09/2022,9/28/2022,9/28/2022,14,PM,Diagnostic,413,1,NDP,St George's Hospital London,HGG?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/4/1981,42,supratentorial pilocytic astrocytoma,0.19,CONTR_HEMI,0.11,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2548,"Integrated diagnosis: Suggestive of glioma infiltration - see comment 
Histology: Suggestive of glioma infiltration
Methylation profile: Inconclusive
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 413\NH22-2548,0.078,-0.022,-0.009,-0.007,-0.06,-0.016,-0.013,-0.034,0.077,-0.009,0.037,0.004,0.012,0.033,0.012,-0.003,-0.019,-0.061,0.007,0.013,-0.01,0.098,0.029,-0.018,0.003,0.048,-0.011,-0.029,0.032,unmethylated
NH22-2597,206699910041_R06C01,413,14/09/2022,9/28/2022,9/28/2022,14,PM,Diagnostic,413,7,NDP,NHNN,Diffuse midline glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/19/1973,50.3,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.91,DMG_K27,0.85,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2597,"Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained
Further molecular tests: Pending
","Integrated diagnosis: Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4
Histology: Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4
Methylation profile: Diffuse midline glioma, H3 K27-altered

MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 413\NH22-2597,-0.019,0.028,0.04,-0.014,-0.063,-0.003,-0.308,-0.025,-0.061,0.472,0.035,0.02,0.006,0.03,0.019,0.038,-0.184,0.138,-0.015,-0.064,0.093,-0.245,-0.247,-0.258,0.054,-0.04,-0.016,-0.042,0.001,unmethylated
NH22-2573,206699910041_R08C01,413,14/09/2022,9/28/2022,9/28/2022,14,PM,Diagnostic,413,3,NDP,NHNN,Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,7/1/2001,21.5,rosette-forming glioneuronal tumour,0.91,LGG_RGNT,0.98,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2573,"Rosette-forming glioneuronal tumour, CNS WHO Grade 1
",#REF!,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 413\NH22-2573,-0.093,0.086,0.033,-0.075,-0.007,0.041,0.158,-0.008,-0.019,-0.074,-0.034,-0.003,0.032,0.042,0.05,-0.015,0.113,0.087,0.067,-0.011,-0.108,0.023,0.055,-0.102,-0.012,0.028,0.055,-0.076,0.017,unmethylated
NH22-2582,206699910161_R01C01,414,14/09/2022,9/28/2022,9/28/2022,14,PM,Diagnostic,414,1,NDP,NHNN,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/1/1978,45.2,high-grade astrocytoma with piloid features,1,ANAPA,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-2582,"Pilocytic Astrocytoma, CNS WHO Grade 1 
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: High-grade astrocytoma with piloid features (see comment)
Histology: Pilocytic astrocytoma
Methylation profile: High-grade astrocytoma with piloid features
KIAA1549-BRAF: Fusion present
BRAF V600E: No mutation
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 414\NH22-2582,-0.189,0,0.055,-0.033,0.003,0.057,0.085,-0.048,-0.031,-0.048,0.275,-0.344,0.091,-0.196,-1.082,0.036,0.036,0.068,0.125,-0.013,-0.037,0.131,-0.053,-0.315,0.05,0.041,-0.138,-0.16,-0.089,unmethylated
NH22-2557,206699910161_R02C01,414,14/09/2022,9/28/2022,9/28/2022,14,PM,Diagnostic,414,1,NDP,Oxford John Radcliffe Hospital,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A,4/12/1986,36.9,myxopapillary ependymoma,1,EPN_MPE,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2557,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2 - see comment
Histology: Myxopapillary ependymoma
Methylation profile: Ependymoma, myxopapillary
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 414\NH22-2557,0.026,0.021,0.077,-0.021,0.039,0.113,0.095,0.129,0.144,0.12,0.129,-0.005,0.031,0.045,0.181,0.199,-0.152,-0.158,0.028,0.014,-0.007,0.049,0.022,-0.016,-0.042,0.011,-0.058,-0.16,-0.183,unmethylated
NH22-2632,206699910161_R04C01,414,15/09/2022,9/28/2022,9/28/2022,13,PM,Diagnostic,414,3,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/15/1946,77.6,"glioblastoma, IDH-wildtype, mesenchymal type",0.26,GBM_RTKII,0.51,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2632,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
1p/19q: Retained          
EGFR: No amplification          
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)
Methylation profile: Suggestive of glioblastoma, IDH-wildtype (see comment) 
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 414\NH22-2632,1.191,0.019,0.019,0.012,-0.017,0.047,0.049,0.186,0.182,0.163,0.13,0.008,0.04,0.023,-0.334,-0.043,-0.144,-0.212,-0.019,-0.066,0.137,0.017,-0.015,-0.001,-0.002,-0.015,-0.05,-0.04,0.009,unmethylated
NH16-2471,206699910161_R08C01,414,16/09/2022,9/28/2022,9/28/2022,12,PM,Diagnostic,414,1,NDP,NHNN,Anaplastic ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,2/17/1982,#N/A,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2471,"Anaplastic ependymoma (WHO grade III)
","Integrated diagnosis: Supratentorial ependymoma, ZFTA fusion-positive, CNS WHO grade 3
Histology: Ependymoma, CNS WHO grade 3 
Methylation profile: Supratentorial ependymoma, ZFTA fusion-positive
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 414\NH16-2471,0.102,-0.024,0.069,0.043,-0.021,0.005,-0.119,0.018,0.107,0.066,0.05,0.033,0.078,0.126,-0.357,-0.491,-0.04,-0.082,-0.028,-0.038,-0.002,0.04,-0.086,0.015,-0.006,0.062,0.016,-0.026,-0.016,methylated
NH22-2637,206699900133_R06C01,415,16/09/2022,10/12/2022,10/12/2022,26,PM,Diagnostic,415,1,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/13/1982,#N/A,"glioblastoma, IDH-wildtype, RTK2 type",0.96,GBM_RTKII,0.91,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2637,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype
  
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: Amplification          
CDKN2A/B: Deletion
TERT promoter: Mutation
MGMT Promoter: Methylated (>0-5%)
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 415\NH22-2637,0.208,-0.008,-0.006,-0.046,-0.003,-0.003,-0.035,1.085,0.198,0.127,0.144,0.016,-0.021,0.008,-0.864,0.013,-0.266,-0.343,-0.004,0.031,0.022,0.026,-0.012,0.033,0.091,-0.01,0.082,0.015,0.033,unmethylated
NH22-2634,206699900133_R07C01,415,21/09/2022,10/12/2022,10/12/2022,21,PM,Diagnostic,415,4,NDP,Romford,Gemistocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/13/1967,56.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.95,AIDH,0.99,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2634,"Gemistocytic astrocytoma, CNS WHO grade 2

IDH1 (R132H IHC): Negative but further tests pending 
ATRX (IHC): Possible loss of expression (may indicate mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Gemistocytic astrocytoma, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 415\NH22-2634,0.052,-0.455,-0.092,-0.338,-0.044,-0.127,-0.054,-0.069,0.118,0.196,0.191,-0.05,0.012,-0.094,-0.071,0.036,-0.088,0.003,-0.055,-0.01,0.048,0.069,-0.038,-0.008,0.045,0.387,-0.033,0.022,0.116,methylated
NH22-2583,206699910042_R01C01,416,21/09/2022,10/7/2022,10/7/2022,16,PM,Diagnostic,416,4,NDP,Romford,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,11/12/1981,41.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH_HG,0.84,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2583,"Astrocytoma, CNS WHO Grade 2 - see comments

IDH1 (R132H IHC): Negative - Further tests pending 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, suggestive of CNS WHO grade 3 - see comment
Histology: Astrocytoma, for grading, see comment
Methylation profile: Astrocytoma, IDH-mutant - see comment
MGMT promoter (Illumina array): Methylated 
      
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 416\NH22-2583,-0.018,0.115,0.132,-0.056,-0.037,-0.034,0.032,0.196,0.249,0.186,0.123,0.024,0.104,0.299,-0.022,-0.039,-0.062,0.028,0.072,0.105,-0.073,-0.12,-0.025,0.046,0.001,0.069,0.074,-0.12,0.084,methylated
NH22-2610,206699910042_R02C01,416,21/09/2022,10/7/2022,10/7/2022,16,PM,Diagnostic,416,6,NDP,"Charing Cross Hospital, London",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,5/2/1962,61.2,"glioblastoma, IDH-wildtype, RTK2 type",0.63,GBM_RTKII,0.72,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2610,"High grade tumour, likely glioblastoma CNS WHO grade 4 - see comments
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Most likely retained within tumour cells
Further molecular tests: Pending
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High grade tumour, likely glioblastoma
Methylation profile: Glioblastoma, IDH-wildtype, RTK 2 subtype  
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification          
TERT promoter: Mutation
MGMT Promoter: Methylated (>0-5%) 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 416\NH22-2610,-0.065,0.236,0.063,-0.056,-0.003,0.025,0.011,0.175,0.205,0.194,0.16,-0.011,0.051,0.062,-1.488,0.066,-0.256,-0.289,0.043,-0.001,0.898,1.676,0.001,0.047,0.064,0.072,0.043,-0.04,0.009,methylated
NH22-2644,206699910042_R03C01,416,22/09/2022,10/7/2022,10/7/2022,15,PM,Diagnostic,416,5,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/18/1976,46.7,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.67,OIDH,0.94,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2644,"Oligodendroglioma, CNS WHO Grade 2
IDH1 (R132H IHC): Mutation      Further tests pending 
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, CNS WHO grade 2
Methylation profile: Oligodendroglioma IDH-mutant and 1p/19q codeleted - see comment
MGMT promoter (Illumina array): Methylated (>0-5%) 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 416\NH22-2644,-0.045,-0.001,0.038,-0.151,-0.256,-0.018,-0.011,-0.05,-0.061,-0.088,-0.035,0.025,0.046,0.031,-0.045,0.015,-0.034,0.035,0.004,-0.009,-0.002,0.041,-0.08,0.084,-0.035,0.108,-0.192,-0.011,0.007,methylated
NH22-2636,206699910042_R04C01,416,22/09/2022,10/7/2022,10/7/2022,15,PM,Diagnostic,416,4,NDP,"Charing Cross Hospital, London",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,7/13/1994,28.6,spinal ependymoma,1,EPN_SPINE,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2636,"Ependymoma, CNS WHO Grade 2
","Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Spinal ependymoma
MGMT promoter (Illumina array): Unmethylated 
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 416\NH22-2636,-0.064,-0.005,0.042,-0.009,0.003,0.008,-0.068,0.091,0.08,0.01,0.048,0.002,0.059,0.045,-0.038,-0.069,-0.04,0.003,-0.039,0.077,0.043,0.05,-0.258,0.036,0.017,-0.005,0.069,-0.568,-0.624,unmethylated
NH22-2679,206699910042_R05C01,416,22/09/2022,10/7/2022,10/7/2022,15,PM,Diagnostic,416,1,NDP,Oxford John Radcliffe Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,12/5/2002,20,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.52,DMG_K27,0.98,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2679,"Integrated diagnosis: Diffuse midline glioma, H3K27M-altered, CNS WHO grade 4
Histology: High-grade glioma
Methylation profile: Diffuse midline glioma, H3 K27-altered 
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 416\NH22-2679,-0.015,0.411,0.032,-0.009,-0.019,-0.035,-0.092,-0.09,-0.003,-0.095,-0.005,0.19,0.057,0.089,-0.459,0.004,-0.008,0.022,0.013,0.004,-0.044,0.035,-0.027,-0.331,-0.057,0.002,-0.363,-0.032,0.01,unmethylated
NH22-2670,206699910042_R06C01,416,22/09/2022,10/7/2022,10/7/2022,15,PM,Diagnostic,416,1,NDP,St George's Hospital London,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,3/14/1959,64.4,myxopapillary ependymoma,1,EPN_MPE,1,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2670,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma 

MGMT promoter (Illumina array): Unmethylated
 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 416\NH22-2670,0.066,-0.027,0.077,0.051,0.06,-0.092,-0.205,0.161,0.338,0.247,0.277,0,0.019,-0.007,0.282,0.36,-0.048,0.017,-0.005,0.001,0.052,0.146,0.02,0.097,0.004,0.037,0.025,-0.014,0.11,unmethylated
NH22-2659,206699910042_R07C01,416,22/09/2022,10/7/2022,10/7/2022,15,PM,Diagnostic,416,3,NDP,"Cambridge, Addenbrooke's Hospital",GBM?PXA?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,4/28/1966,#N/A,pleomorphic xanthoastrocytoma(-like),1,PXA,0.97,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2659,"Integrated diagnosis: Pleomorphic xanthoastrocytoma, BRAF V600E-mutant, CNS WHO grade 2 - see comment
Histology: Glial tumour with features favouring a pleomorphic xanthoastrocytoma
Methylation profile: Pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 416\NH22-2659,-0.017,-0.109,-0.019,-0.035,0.094,0.141,-0.393,-0.087,0.064,-0.006,-0.045,0.026,0.028,0.035,-0.319,-0.011,-0.336,-0.44,0.067,0.022,0.066,-0.028,-0.048,0.071,-0.042,-0.008,-0.023,-0.145,0.09,methylated
NH22-2626,206699900135_R02C01,417,23/09/2022,10/12/2022,10/12/2022,19,PM,Diagnostic,417,7,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,11/24/2000,22.1,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2626,"Oligodendroglioma, CNS WHO Grade 2
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p19q codeleted
MGMT promoter (Illumina array): Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 417\NH22-2626,0.023,0.033,0.019,-0.052,-0.059,0.026,-0.007,-0.007,-0.01,-0.044,0.002,-0.007,0.015,0.012,0.042,0.001,0.048,0.007,-0.003,0,-0.011,-0.005,-0.069,0.044,-0.006,-0.017,-0.416,-0.016,0.004,methylated
NH22-2707,206699900135_R03C01,417,23/09/2022,10/12/2022,10/12/2022,19,PM,Diagnostic,417,1,NDP,"Liverpool, The Walton Centre",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,3/30/2005,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.58,AIDH_HG,0.94,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2707,"Integrated diagnosis: Suggestive of astrocytoma, IDH-mutant, MYCN-amplified, CNS WHO grade 4
Histology: High grade glioma
Methylation profile: Astrocytoma, IDH-mutant - see comment
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 417\NH22-2707,-0.181,0.852,0.072,0.059,0.164,0.014,-0.041,0.136,0.119,0.111,0.091,-0.09,0.027,-0.09,0.058,0.025,-0.21,-0.142,0.195,-0.028,0.662,-0.033,-0.266,0.214,0.357,0.27,0.174,0.033,0.03,unmethylated
NH22-2700,206699900135_R05C01,417,23/09/2022,10/12/2022,10/12/2022,19,PM,Diagnostic,417,1,NDP,Southampton General Hospital,LGG?Ependymoma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,6/28/1977,#N/A,spinal ependymoma,1,EPN_SPINE,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2700,"Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Low grade glial tumour
Methylation profile: Spinal ependymoma 
MGMT promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 417\NH22-2700,-0.06,-0.019,0.003,-0.076,-0.044,-0.028,-0.016,0.016,-0.022,-0.062,-0.034,0.023,0.046,0.026,0.069,-0.018,0.046,0.029,-0.02,-0.156,-0.033,0.107,-0.395,-0.029,-0.007,-0.003,0.017,-0.372,-0.328,unmethylated
NH22-2699,206699900135_R06C01,417,23/09/2022,10/12/2022,10/12/2022,19,PM,Diagnostic,417,6,NDP,Sheffield,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A3,11/11/1942,#N/A,posterior fossa ependymoma group A1,0.1,EPN_MPE,0.59,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2699,"Integrated diagnosis: Glial tumour, compatible with ependymoma, CNS WHO grade 2 - see comment
Histology: Glial tumour
Methylation profile: No matching methylation classes
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 417\NH22-2699,-0.017,0.045,0.038,-0.047,-0.056,0.034,-0.061,-0.005,0.031,-0.002,0.026,-0.098,-0.029,-0.048,-0.009,0.014,-0.092,-0.073,-0.089,-0.065,-0.02,0.022,-0.084,-0.031,0.036,0.038,-0.001,-0.101,-0.089,unmethylated
NH22-2692,206699900135_R08C01,417,23/09/2022,10/12/2022,10/12/2022,19,PM,Diagnostic,417,1,NDP,Auckland (NZ),Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2B,2/3/1947,#N/A,posterior fossa subependymoma,1,SUBEPN_PF,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2692,"Integrated diagnosis: Subependymoma, CNS WHO grade 1
Histology: Subependymoma, CNS WHO grade 1
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 417\NH22-2692,0.094,0.031,0.034,0.013,-0.064,-0.044,-0.036,0.022,-0.01,-0.015,0.006,-0.385,-0.313,-0.258,0,-0.007,0.007,0.02,-0.023,-0.012,0,0.081,0.011,-0.03,0.047,0.06,0.014,-0.004,0.007,unmethylated
NH22-2726,206699900120_R02C01,418,23/09/2022,10/12/2022,10/12/2022,19,PM,Diagnostic,418,4,NDP,"Liverpool, The Walton Centre",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2E,3/9/1989,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.94,AIDH,0.94,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2726,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3 - see comment
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 

IDH1 (R132H): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B: No deletion          
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 418\NH22-2726,0.039,0.008,0.043,-0.06,0.01,0.027,-0.035,0.026,-0.026,0.234,0.224,-0.01,0.171,0.28,-0.212,-0.006,0.002,0.053,0.002,0.049,-0.03,0.009,-0.092,0.048,-0.055,0.019,-0.253,0.016,0.039,methylated
NH22-2558,206699900120_R03C01,418,26/09/2022,10/12/2022,10/12/2022,16,PM,Diagnostic,418,1,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/3/1949,74.4,"glioblastoma, IDH-wildtype, with primitive neuronal component",0.81,GBM_RTKI,0.48,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2558,"Malignant tumour - see comment
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Glioblastoma, CNS WHO grade 4 
Methylation profile: Glioblastoma, IDH-wildtype with primitive neuronal component
MGMT promoter (Illumina array): Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 418\NH22-2558,0.015,1.659,-0.003,0.033,0.095,0.018,-0.031,0.275,0.24,0.29,0.274,-0.235,-0.146,0.573,-0.024,0.032,-0.273,-0.443,0.045,0.021,1.218,0.03,-0.043,-0.471,0.458,0.275,-0.108,-0.003,0.046,methylated
NH22-2643,206699900120_R05C01,418,26/09/2022,10/12/2022,10/12/2022,16,PM,Diagnostic,418,2,NDP,NHNN,Diffuse glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,12/17/1975,47.4,ganglioglioma,0.44,GBM_MES,0.2,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2643,"Suggestive of a diffuse glioma (please see comment)
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Suggestive of an infiltration of glioma, IDH-wildtype - see comment
Histology: Suggestive of diffuse glioma
Methylation profile: Inconclusive - see comment
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 418\NH22-2643,-0.055,-0.029,0.015,0.012,-0.055,-0.021,-0.151,0.128,0.144,0.116,-0.003,-0.01,0.015,-0.012,-0.041,0.006,-0.124,-0.107,-0.027,-0.008,-0.03,-0.003,-0.032,-0.024,-0.016,0.019,-0.049,-0.124,-0.103,methylated
NH22-2689,206699900120_R07C01,418,26/09/2022,10/12/2022,10/12/2022,16,PM,Diagnostic,418,4,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1C,9/9/1991,31.5,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,OIDH,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-2689,"Oligodendroglioma, IDH-mutant, CNS WHO grade 2

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained 
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2 
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2 
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 418\NH22-2689,-0.019,0.002,0.036,-0.039,-0.058,0.019,-0.026,-0.01,-0.034,-0.08,0.004,0.024,0.011,0.054,-0.004,-0.012,0.007,0.047,0.009,-0.023,-0.047,-0.01,-0.098,0.14,0.099,0.055,-0.402,-0.024,0.034,methylated
NH22-2675,206699900120_R08C01,418,26/09/2022,10/12/2022,10/12/2022,16,PM,Diagnostic,418,7,NDP,Brighton and Sussex Hospital,Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/6/2001,21.8,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.97,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2675,"C/W low grade glial/glioneuronal tumour - see comment.

IDH1 (R132H IHC): No mutation
BRAF (V600E IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glial/glioneuronal tumour
Methylation profile: Pilocytic astrocytoma, hemispheric
MGMT promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 418\NH22-2675,-0.133,-0.038,-0.022,-0.024,-0.066,0.062,0.025,0.018,0.124,0.027,0.113,0.107,0.105,0.142,-0.013,-0.011,0.133,0.062,0.121,0.028,-0.012,0.054,0.068,0.033,-0.004,-0.033,-0.059,0.007,0.051,unmethylated
NH22-2730,206699900087_R02C01,419,26/09/2022,10/14/2022,10/14/2022,18,PM,Diagnostic,419,1,NDP,"Charing Cross Hospital, London",Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2A,8/16/1967,55.9,supratentorial subependymoma,0.57,GBM_MES,0.35,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2730,"Supratentorial subependymoma CNS WHO grade 1. 
","Integrated diagnosis: Subependymoma, CNS WHO grade 1 - see comment
Histology: Subependymoma, CNS WHO grade 1
Methylation profile: Subependymoma, supratentorial (v12.5, low calibrated score - see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 419\NH22-2730,0.007,0.005,0.041,0.107,0.169,0.159,0.007,0.182,0.16,0.156,0.157,-0.02,0.059,0.06,0.046,0.002,0.034,0.031,0.017,0.146,0.127,0.177,-0.301,-0.016,-0.059,-0.032,0.187,-0.015,-0.011,unmethylated
NH22-2590,206699900087_R05C01,419,26/09/2022,10/14/2022,10/14/2022,18,PM,Diagnostic,419,4,NDP,Romford,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/27/1962,60.8,"glioblastoma, IDH-wildtype, RTK2 type",0.64,GBM_RTKII,0.82,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2590,"Glioma with some high grade features on histology
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Glioma with some high grade features 
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype
MGMT promoter (Illumina array): Unmethylated (low level MGMT methylation detected with HRM assay)
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 419\NH22-2590,-0.035,-0.049,0.036,-0.011,0.042,0.006,-0.018,0.361,0.151,0.131,0.122,0.009,0.04,0.007,-0.808,-0.007,-0.053,-0.703,0.008,-0.246,0.112,1.349,-0.011,0.031,0.008,-0.015,-0.017,-0.004,0.012,unmethylated
NH22-2666,206699900087_R07C01,419,27/09/2022,10/14/2022,10/14/2022,17,PM,Diagnostic,419,3,NDP,Romford,Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/16/1994,28.7,dysembryoplastic neuroepithelial tumour,0.36,LGG_PAPF,0.54,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2666,"Low grade glioneuronal tumour - see comment. 
","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1 - see comment
Histology: Low grade glial or glioneuronal tumour
Methylation profile: Pilocytic astrocytoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 419\NH22-2666,0.017,-0.005,0.026,-0.042,-0.036,0.054,0.027,-0.016,-0.001,-0.072,-0.02,-0.015,0.041,0.014,0.046,0.007,0.025,0.036,0.063,0.001,-0.003,-0.019,-0.002,0.014,-0.035,-0.091,-0.008,0.024,0.023,unmethylated
NH22-2737,206699900087_R08C01,419,27/09/2022,10/14/2022,10/14/2022,17,PM,Diagnostic,419,4,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/16/1953,70.7,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.91,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2737,"Glioblastoma, IDH-wildtype, CNS WHO grade 4

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: Amplification          
MGMT Promoter: Unmethylated (0%)
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 419\NH22-2737,0.245,0.043,0.023,-0.027,0.005,0.018,0.053,1.097,0.214,0.233,0.194,-0.095,-0.052,-0.017,-0.307,-0.02,-0.224,-0.187,-0.052,-0.06,-0.011,0.038,-0.251,-0.231,-0.057,-0.022,0.039,-0.05,-0.002,unmethylated
NH22-2738,206699900167_R01C01,420,27/09/2022,10/14/2022,10/14/2022,17,PM,Diagnostic,420,1,NDP,"Liverpool, The Walton Centre",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1D,4/17/1963,#N/A,myxopapillary ependymoma,1,EPN_MPE,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2738,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Ependymal tumour, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Methylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 420\NH22-2738,-0.022,0.066,0.057,0.02,0.014,-0.018,0.041,0.199,0.25,0.261,0.227,-0.022,0.031,0.04,0.193,0.26,0.017,0.002,0.033,-0.018,0.004,0.046,-0.039,-0.023,0.017,-0.01,0.008,-0.192,-0.198,methylated
NH22-2736,206699900167_R02C01,420,27/09/2022,10/14/2022,10/14/2022,17,PM,Diagnostic,420,2,NDP,Oxford John Radcliffe Hospital,Diffuse glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,9/19/2001,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.97,AIDH,0.96,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2736,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2 - see comment
Histology: Diffuse glioma
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 420\NH22-2736,-0.066,-0.081,0.018,-0.001,0.003,0.078,0.021,-0.007,-0.018,-0.025,-0.017,-0.017,0.041,0.004,0.031,0.029,0.034,0.038,-0.01,0.012,-0.023,-0.013,-0.014,-0.088,-0.063,-0.052,-0.016,-0.055,-0.053,methylated
NH22-2754,206699900167_R04C01,420,28/09/2022,10/14/2022,10/14/2022,16,PM,Diagnostic,420,4,NDP,St George's Hospital London,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/6/1944,78.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.81,CONTR_REACT,0.65,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2754,"Glioma - see comment

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained      
EGFR: No amplification     
CDKN2A/B (qPCR copy number assay): No deletion     
BRAF (V600E): No mutation          
MGMT Promoter: Unmethylated (0%) 
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Glioma
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 420\NH22-2754,0.027,-0.011,-0.016,-0.025,-0.034,-0.002,-0.046,0.139,0.156,-0.031,0.106,-0.003,-0.005,0.008,-0.075,-0.02,-0.026,-0.064,-0.053,-0.051,-0.001,0.036,0.011,0.016,0.049,0.005,-0.063,-0.016,0.022,unmethylated
NH22-2739,206699900167_R05C01,420,28/09/2022,10/14/2022,10/14/2022,16,PM,Diagnostic,420,1,NDP,"Liverpool, The Walton Centre","Glioma, IDH-1 wildtype","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,11/25/1969,#N/A,"glioblastoma, IDH-wildtype, mesenchymal type",0.42,GBM_MES,0.72,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2739,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Diffuse glioma
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 420\NH22-2739,0.013,0.049,0.089,-0.05,0.032,0.036,-0.226,1.09,0.164,0.113,0.107,0.008,0.04,-0.046,-0.655,-0.103,-0.125,-0.11,-0.178,0.08,0.071,0.102,-0.013,0.048,0.031,0.019,-0.026,-0.083,-0.086,methylated
NH22-2764,206699900167_R06C01,420,29/09/2022,10/14/2022,10/14/2022,15,PM,Diagnostic,420,1,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,6/8/1993,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.93,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2764,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2 - see comment
Histology: Diffuse glioma
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 420\NH22-2764,-0.021,-0.001,0.046,-0.017,-0.032,0.059,0.006,0.015,0.253,0.254,0.206,-0.019,0.05,0.044,0.03,0.005,0.006,-0.317,-0.049,0.12,0.001,-0.009,-0.056,-0.023,-0.042,-0.017,-0.044,-0.028,0.004,unmethylated
NH22-2782,206699900197_R04C01,421,29/09/2022,10/14/2022,10/14/2022,15,PM,Diagnostic,421,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/29/1996,#N/A,supratentorial midline pilocytic astrocytoma,0.78,LGG_PAMID,0.29,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2782,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1 - see comment
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, midline
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 421\NH22-2782,0.017,-0.04,0.007,-0.001,-0.07,0.032,0.023,0.002,0.012,-0.016,-0.02,-0.014,0.064,0,0.058,-0.002,0.015,0.027,-0.01,-0.028,-0.03,0.076,0.023,-0.011,0.032,0.028,-0.032,-0.04,0.045,unmethylated
NH22-2828,206699900158_R01C01,422,3/10/2022,10/19/2022,10/19/2022,16,MD,Diagnostic,422,4,NDP,St George's Hospital London,"Glioma, IDH mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/22/1968,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2828,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Glioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 422\NH22-2828,0.029,-0.008,0.036,-0.11,-0.045,-0.019,0.04,-0.013,-0.032,-0.023,-0.025,-0.044,0.015,-0.061,-0.218,0.007,0.033,0.005,0.011,0.014,-0.024,-0.013,-0.043,0.022,-0.014,0.021,-0.403,-0.018,0.025,methylated
NH22-2829,206699900158_R02C01,422,3/10/2022,10/19/2022,10/19/2022,16,MD,Diagnostic,422,4,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,1/21/1956,#N/A,"glioblastoma, IDH-wildtype, mesenchymal type",0.82,GBM_MES,0.46,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2829,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype, subclass B
MGMT promoter (Illumina array): Unmethylated 

",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 422\NH22-2829,0.019,-0.046,0.015,-0.009,-0.025,-0.007,-0.005,0.262,0.267,0.37,0.218,-0.008,0.074,0.042,0.05,-0.033,0.016,-0.053,-0.018,0.005,-0.012,0.046,0.019,0,0.01,-0.015,-0.061,-0.033,0.038,unmethylated
NH22-2830,206699900158_R03C01,422,3/10/2022,10/19/2022,10/19/2022,16,MD,Diagnostic,422,4,NDP,St George's Hospital London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,3/23/1995,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.62,AIDH_HG,0.87,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2830,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4 - see comment
Histology: Astrocytoma, IDH-mutant - for grading, see comment
Methylation profile: Astrocytoma, IDH-mutant - see comment
MGMT promoter (Illumina array): Unmethylated 
IDH1 (R132H IHC); Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
CDKN2A/B: Deletion
MGMT Promoter (Illumina array): Unmethylated (low level methylation (>0-5%) detected with HRM assay)
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 422\NH22-2830,0.015,-0.019,0.022,0.004,-0.011,0.063,-0.003,-0.034,-0.002,0.02,0.204,-0.016,0.049,-0.009,-1.426,-0.012,-0.111,-0.178,-0.009,0.116,-0.018,0.047,-0.052,-0.01,0.013,0.025,-0.465,-0.02,0.042,unmethylated
NH22-2812,206699900158_R05C01,422,3/10/2022,10/19/2022,10/19/2022,16,MD,Diagnostic,422,1,NDP,"Cardiff, University Hospital",Glial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A8,10/12/1998,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.97,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2812,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3 - see comment
Histology: Glial tumour with high grade features
Methylation profile: Astrocytoma, IDH mutant; lower grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 422\NH22-2812,-0.056,-0.067,0.036,-0.019,0.01,0.076,-0.083,0.008,0.007,0.002,-0.003,-0.004,0.073,-0.006,-0.094,-0.07,-0.278,0.074,0.032,0.021,-0.082,-0.033,-0.01,0.017,0.023,0.032,-0.395,-0.062,-0.013,methylated
NH22-2797,206699900158_R06C01,422,3/10/2022,10/19/2022,10/19/2022,16,MD,Diagnostic,422,7,NDP,Newcastle,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1D,4/2/1964,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.1,LGG_DNT,0.2,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2797,"Integrated diagnosis: Suggestive of low grade glial or glioneuronal tumour- see comment
Histology: Suggestive of low grade glial or glioneuronal tumour. 
Methylation profile: No matching methylation classes
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 422\NH22-2797,-0.152,-0.09,-0.055,0.132,0.111,0.023,-0.069,0.012,-0.18,-0.199,-0.024,-0.038,0.041,-0.352,0,-0.037,-0.059,0.067,-0.03,-0.074,-0.195,-0.004,-0.073,-0.191,-0.155,-0.087,0.149,0.019,0.121,unmethylated
NH22-2783,206699900158_R08C01,422,3/10/2022,10/19/2022,10/19/2022,16,PM,Diagnostic,422,1,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/8/1973,#N/A,"glioblastoma, IDH-wildtype, RTK2 type",0.76,GBM_RTKII,0.56,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2783,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Diffuse glioma
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 422\NH22-2783,0.007,0.012,0.021,0.055,-0.009,-0.041,-0.399,1.081,0.166,0.169,0.152,-0.132,-0.043,-0.108,-1.098,0.034,-0.25,-0.28,-0.111,0.045,0.029,0.072,0.013,0.03,0.06,-0.304,0.169,-0.103,-0.072,methylated
NH22-2766,206699900156_R01C01,423,4/10/2022,10/19/2022,10/19/2022,15,PM,Diagnostic,423,1,NDP,Brighton and Sussex Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/7/1982,41.2,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.94,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2766,"Glioma (please see comment)
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Probable loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Recurrent/residual astrocytoma, IDH-mutant, CNS WHO grade 2 - see comment
Histology: Diffuse glioma
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 
  
IDH1/2Seq: IDH1 mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 423\NH22-2766,-0.091,-0.067,0.024,-0.022,0.03,0.05,0.025,-0.037,-0.037,-0.027,-0.028,-0.012,0.117,0.141,0.019,-0.006,0.037,0.019,0.011,0.046,-0.058,-0.01,-0.051,-0.056,-0.046,0.157,0.012,0.009,-0.009,methylated
NH22-2806,206699900156_R02C01,423,4/10/2022,10/19/2022,10/19/2022,15,MD,Diagnostic,423,1,NDP,"Charing Cross Hospital, London",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/26/1967,55.9,"glioblastoma, IDH-wildtype, mesenchymal type",0.87,CONTR_INFLAM,0.26,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2806,"Glioma with extensive necrosis - see comment


IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Glioma with extensive necrosis
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 423\NH22-2806,0.063,-0.056,-0.061,-0.016,-0.017,0.049,-0.023,0.149,0.144,0.131,0.1,0,0.016,0.032,0.048,-0.025,-0.037,-0.074,-0.07,-0.067,-0.004,1.602,-0.115,-0.021,0.004,0.042,0.031,-0.021,0.031,unmethylated
NH22-2803,206699900156_R04C01,423,4/10/2022,10/19/2022,10/19/2022,15,MD,Diagnostic,423,4,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,10/27/1984,38.5,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2803,"Recurrent diffuse astrocytoma, IDH-mutant, WHO CNS grade 2
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending  
","Integrated diagnosis: Recurrent/residual astrocytoma, IDH-mutant, CNS WHO grade 2 - see comment
Histology: Recurrent/residual astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 423\NH22-2803,-0.037,-0.064,0.032,0.045,0.038,0.072,-0.294,-0.009,0.008,-0.005,-0.02,-0.027,0.051,0.18,-0.02,-0.024,0.029,0.126,0.096,-0.006,-0.016,-0.051,-0.033,-0.046,-0.073,-0.023,-0.054,0.028,0.003,methylated
NH22-2855,206699900156_R05C01,423,4/10/2022,10/19/2022,10/19/2022,15,MD,Diagnostic,423,4,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/3/1961,#N/A,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.99,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2855,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
IDH1/IDH2: No mutation
EGFR: No amplification
CDKN2A/B: Deletion  
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 423\NH22-2855,0.098,-0.023,0.006,-0.005,-0.048,-0.021,-0.021,0.199,0.234,0.29,0.206,-0.026,0.214,0.235,-1.256,0.018,-0.246,-0.336,0.011,-0.026,-0.014,0.063,-0.384,0.04,0.071,0.041,-0.043,-0.036,0.014,unmethylated
NH22-2822,206699900156_R06C01,423,4/10/2022,10/19/2022,10/19/2022,15,MD,Diagnostic,423,9,NDP,Romford,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,11/2/1983,39.5,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.76,AIDH_HG,0.41,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2822,"Astrocytoma, IDH-mutant, CNS WHO Grade 4
","Integrated diagnosis: Astrocytoma, IDH-mutant, with MYCN amplification CNS WHO grade 4 - see comment
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: See comment
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 423\NH22-2822,0.22,1.149,0.036,0.181,0.219,0.068,0.03,0.17,0.239,0.222,0.189,-0.149,-0.061,-0.099,0.038,0.162,-0.02,-0.048,0.002,0.029,0.049,0.105,-0.401,-0.011,-0.016,-0.012,-0.122,0.017,0.044,unmethylated
NH22-2814,206699900156_R07C01,423,4/10/2022,10/19/2022,10/19/2022,15,MD,Diagnostic,423,5,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,10/18/1955,67.9,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2814,"Oligodendroglioma, IDH-mutant, CNS WHO grade 2
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 423\NH22-2814,0.011,0.087,0.038,-0.175,-0.199,-0.037,0.007,-0.021,0.012,0,-0.011,-0.005,0.053,0.017,0.059,-0.028,0,0.133,-0.003,0.011,0.017,0.006,-0.131,0.043,-0.012,0.013,-0.454,0.022,0.004,methylated
NH22-2836,206699910018_R01C01,424,5/10/2022,10/21/2022,10/21/2022,16,MD,Diagnostic,424,3,NDP,Romford,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A5,3/10/1962,61.4,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.92,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2836,"Astrocytoma, IDH-mutant, CNS WHO Grade 3
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO Grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO Grade 3
Methylation profile: Astrocytoma, IDH-mutant; lower grade (see comment)  
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 424\NH22-2836,0.012,0.163,0.049,-0.077,-0.107,-0.159,0.038,-0.001,0.039,0.006,0.026,0.216,-0.026,0.128,-0.12,0.036,-0.017,-0.074,0.007,0.059,-0.247,-0.353,-0.156,0.031,0.128,0.004,0.023,-0.209,-0.175,methylated
NH22-2823,206699910018_R03C01,424,5/10/2022,10/21/2022,10/21/2022,16,MD,Diagnostic,424,1,NDP,NHNN,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,6/2/1970,53.1,ganglioglioma,0.69,GBM_MES,0.58,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2823,"CNS tissue fragments with focal diffuse infiltration by a glioma. 
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: CNS tissue fragments with focal diffuse infiltration by a glioma
Methylation profile: Control tissue, hemispheric cortex - see comment
MGMT promoter (Illumina array): Methylated 
  
IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: Amplification          
MGMT Promoter: Methylated (>5-10%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 424\NH22-2823,0.023,-0.031,0.003,-0.023,-0.081,0.004,0.019,0.918,0.252,0.2,0.199,-0.017,0.064,0.07,0.07,-0.043,-0.055,-0.136,-0.022,0.05,-0.021,0.062,-0.028,0.003,-0.033,0.039,0.006,-0.133,-0.069,methylated
NH22-2856,206699910018_R05C01,424,5/10/2022,10/21/2022,10/21/2022,16,MD,Diagnostic,424,1,NDP,"Leeds, St James's University Hospital",GBM,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",C4,2/10/1983,#N/A,"glioblastoma, IDH-wildtype, mesenchymal type",1,PXA,0.81,0.98,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2856,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype, subclass B
MGMT promoter (Illumina array): Not determinable 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 424\NH22-2856,0.01,0.003,0.108,0.036,0.029,0.162,-0.063,-0.004,0.089,-0.004,0.018,0.022,0.189,0.068,-0.419,-0.071,0.046,0.106,-0.006,-0.075,-0.026,0.068,-0.087,-0.14,0.095,0.187,-0.084,-0.063,-0.067,unmethylated
NH22-2767,206699910018_R06C01,424,5/10/2022,10/21/2022,10/21/2022,16,MD,Diagnostic,424,1,NDP,Brighton and Sussex Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,4/5/1983,40,"glioblastoma, IDH-wildtype, mesenchymal type",0.24,GBM_MES,0.72,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2767,"Glioblastoma, CNS WHO Grade 4
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 424\NH22-2767,-0.049,0.007,0.046,0.053,-0.012,0.018,0.021,0.404,0.379,0.424,0.328,-0.001,0.105,-0.012,0.034,-0.005,0.051,-0.065,0.016,0.166,-0.036,0.088,0.016,-0.046,0.072,-0.007,-0.049,-0.008,0.044,methylated
NH22-2349,206699910018_R08C01,424,5/10/2022,10/21/2022,10/21/2022,16,MD,Diagnostic,424,3,NDP,Southampton General Hospital,,,1D,3/15/1965,58.3,ganglioglioma,0.34,GBM_MES,0.64,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2349,"Integrated diagnosis: Raising the possibility of infiltration of glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Infiltration of glioma
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Methylated 
  
","Integrated diagnosis: In keeping with infiltration of Glioblastoma, IDH-wildtype, CNS WHO grade 4
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 424\NH22-2349,0.039,-0.005,0.06,0.002,0.055,0.153,0.119,0.233,0.268,0.249,0.226,-0.012,0.089,0.055,0.04,-0.001,0.063,0.034,0.058,-0.018,-0.07,0.033,0.023,0.031,-0.062,-0.03,0.175,0.012,0.03,methylated
NH22-2864,206699910081_R01C01,425,6/10/2022,10/26/2022,10/26/2022,20,PM,Diagnostic,425,1,NDP,Nottingham University Hospital,Oligodendroglioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,3/19/1987,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.62,OIDH,0.96,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2864,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 425\NH22-2864,0.019,-0.021,0.008,-0.019,-0.002,-0.01,0.034,-0.001,0.027,-0.036,0.013,-0.031,0,0.007,0.06,-0.008,0.009,-0.008,-0.007,-0.045,0.043,0.043,-0.036,0.04,0.029,-0.005,-0.342,-0.022,0.04,methylated
NH22-2863,206699910081_R02C01,425,6/10/2022,10/26/2022,10/26/2022,20,PM,Diagnostic,425,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A5,4/24/1980,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2863,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2 - see comment
Histology: Astrocytoma, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 425\NH22-2863,0.069,0.044,0.046,-0.025,0.02,-0.03,-0.104,0.058,0.215,0.216,0.236,-0.051,0.023,0.263,-0.049,0.012,-0.077,-0.107,-0.036,0.023,0.037,0.045,-0.053,0.04,0.054,0.006,-0.107,-0.034,0.069,unmethylated
NH22-2887,206699910081_R04C01,425,6/10/2022,10/26/2022,10/26/2022,20,PM,Diagnostic,425,4,NDP,Oxford John Radcliffe Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3C,4/3/1970,#N/A,high-grade astrocytoma with piloid features,1,ANAPA,1,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2887,"High-grade glioma, at least CNS WHO grade 3

IDH1/2Seq: No mutation
ATRX (IHC): Retained     
MGMT Promoter: Methylated (>10-25%) 
 
","Integrated diagnosis: High-grade astrocytoma with piloid features, CNS WHO grade 3 - see comment
Histology: High-grade glioma, at least CNS WHO grade 3
Methylation profile: High-grade astrocytoma with piloid features
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 425\NH22-2887,0.139,-0.12,0.005,0.087,0.135,0.019,0.026,-0.035,0.032,-0.041,-0.025,0.004,0.085,0.011,-0.786,-0.049,-0.001,0.028,0.075,0.181,0.197,0.272,-0.263,-0.026,-0.021,0.273,-0.351,-0.016,0.004,methylated
NH22-2879,206699910081_R08C01,425,10/10/2022,10/26/2022,10/26/2022,16,PM,Diagnostic,425,1,NDP,Royal London Hospital,Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2A,4/4/1976,47.2,posterior fossa subependymoma,1,SUBEPN_PF,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2879,"Subependymoma, CNS WHO grade 1
","Integrated diagnosis: Subependymoma, CNS WHO grade 1
Histology: Subependymoma, CNS WHO grade 1
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 425\NH22-2879,0.021,-0.03,0.038,-0.013,-0.046,0.012,-0.113,-0.012,-0.051,-0.036,-0.029,-0.017,0.021,0.042,0.017,0.003,0.049,0.039,0.016,-0.041,-0.038,0.033,0.011,-0.025,0.069,-0.044,0.04,0.056,0.033,unmethylated
NH22-2898,206699910016_R01C01,426,10/10/2022,10/26/2022,10/26/2022,16,PM,Diagnostic,426,1,NDP,Wellington Hospital London,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,4/4/1996,26.9,spinal ependymoma,1,EPN_SPINE,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2898,"Ependymoma, grading see comment
","Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Ependymoma
Methylation profile: Ependymoma, spinal
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 426\NH22-2898,-0.018,0.03,0.057,0.03,-0.048,0.158,-0.015,0.163,0.186,0.13,0.153,0.162,0.145,0.166,0.187,0.175,0.041,0.028,0.004,0.137,0.106,0.209,-0.032,0.027,-0.055,0.006,0.014,-0.659,-0.77,unmethylated
NH13-1634,206699910016_R03C01,426,10/10/2022,10/26/2022,10/26/2022,16,PM,Diagnostic,426,1,NDP,NHNN,Diffuse astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,10/27/1984,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH13-1634,"Oligoastrocytoma (WHO grade II)
IDH1 mutation (R132H) 
","Diffuse astrocytoma, IDH-mutant (WHO grade II)     

MGMT Promoter: No methylation     
IDH1 (R132H IHC); IDH1/2 Seq: Mutation
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Retained     
EGFR: No amplification          
Chromosome 10q: Retained
Histone H3F3A: No mutation     
BRAF (V600E): No mutation      

",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 426\NH13-1634,-0.002,-0.114,0.063,-0.008,-0.059,-0.025,-0.37,0.05,0.018,-0.028,0.006,0.01,0.14,0.157,0.086,-0.015,-0.007,-0.061,-0.024,-0.037,0.055,0.116,0.023,0.013,-0.13,0.009,-0.044,-0.051,0.015,unmethylated
NH22-2885,206699910016_R04C01,426,10/10/2022,10/26/2022,10/26/2022,16,PM,Diagnostic,426,1,NDP,Royal London Hospital,Glioneural tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,4/5/1999,23.8,ganglioglioma,0.69,GBM_MES,0.29,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2885,"Glioneuronal tumour with features raising the possibility of a ganglioglioma
","Integrated diagnosis: Low grade glioneuronal tumour, with features suggestive of a ganglioglioma, CNS WHO grade 1 - see comment
Histology: Glioneuronal tumour with features raising the possibility of a ganglioglioma
Methylation profile: Ganglioglioma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 426\NH22-2885,-0.02,-0.028,-0.063,-0.083,-0.161,0.153,0.101,0.301,0.266,0.266,0.208,0.047,0.097,0.13,-0.091,-0.07,0.068,0.093,-0.05,0.031,-0.014,0.015,-0.085,-0.104,-0.233,-0.048,0.282,-0.053,-0.108,unmethylated
NH22-1767,206699910016_R05C01,426,10/10/2022,10/26/2022,10/26/2022,16,PM,Diagnostic,426,1,NDP,St George's Hospital London,Oligodendroglioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,3/13/1991,31.7,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.91,AIDH_HG,0.91,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-1767,"Astrocytoma, IDH-mutant, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: Mutation
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion
MGMT Promoter: Methylated (>5-10%)
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4 - see comment
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant; high grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 426\NH22-1767,0.135,0.079,0.106,-0.011,0.074,-0.008,-0.136,0.065,1.487,1.628,0.008,-0.122,-0.032,0,-0.187,-0.072,-0.238,-0.351,0.111,0.124,0.011,-0.001,0.028,0.087,0.168,0.09,-0.311,-0.095,-0.067,methylated
NH22-2871,206699910016_R06C01,426,10/10/2022,10/26/2022,10/26/2022,16,PM,Diagnostic,426,4,NDP,Romford,Diffuse glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,5/9/1965,58.2,"glioblastoma, IDH-wildtype, mesenchymal type",0.5,GBM_MES,0.73,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2871,"Diffuse glioma, grading see comment
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Diffuse glioma
Methylation profile: Glioblastoma, IDH wildtype, subclass mesenchymal
IDH1/2Seq: No mutation
ATRX (IHC): Retained     
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 426\NH22-2871,0.079,0.001,0.015,0.03,-0.046,0.101,0.038,0.155,0.15,0.134,0.111,-0.035,-0.016,0.02,-0.126,0,-0.082,-0.115,0.027,-0.011,0.493,-0.039,-0.001,-0.006,0.049,0.005,-0.038,-0.051,-0.034,unmethylated
NH22-2870,206699910016_R07C01,426,10/10/2022,10/26/2022,10/26/2022,16,PM,Diagnostic,426,4,NDP,Romford,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,8/13/1957,66.1,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.72,AIDH,0.85,0.63,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2870,"Astrocytoma, IDH-mutant, CNS WHO grade 2
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained 

","Integrated diagnosis: Astrocytoma, IDH-mutant - for grading, see comment 
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant; lower grade 
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 426\NH22-2870,-0.022,-0.195,0.013,-0.009,-0.013,-0.132,-0.225,0.196,0.021,0.03,0.02,-0.244,0.124,0.129,-0.115,0.024,0.047,0.028,0.006,-0.013,-0.043,-0.045,-0.131,-0.033,0.047,0.024,-0.013,-0.031,-0.017,methylated
NH17-2901,206699910016_R08C01,426,10/10/2022,10/26/2022,10/26/2022,16,PM,Diagnostic,426,1,NDP,NHNN,Diffuse astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,10/27/1984,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.62,AIDH,0.71,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2901,"Diffuse Astrocytoma, IDH mutant (WHO grade II)
IDH1 (R132H IHC): Mutation       
ATRX (IHC):     Loss of expression (indicates mutation)
","
Diffuse astrocytoma, IDH-mutant (WHO grade II)
 
MGMT Promoter: No methylation

IDH1 (R132H IHC); IDH1/2 Seq: Mutation
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Retained
Chromosome 7p and EGFR: No gain and no amplification
TERT promoter: Test unsuccessful 
Chromosome 10q: Retained

Histone H3F3A: No mutation
BRAF (V600E): No mutation 

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 426\NH17-2901,0.092,-0.08,0.075,-0.035,-0.077,-0.063,-0.265,0.04,0.095,-0.011,0.009,0.046,0.218,0.137,0.033,-0.022,0.011,-0.02,-0.043,-0.068,0.118,0.104,0.036,0.063,-0.022,0.075,-0.05,-0.013,0.019,methylated
NH22-2851,206699910194_R03C01,427,10/10/2022,10/26/2022,10/26/2022,16,PM,Diagnostic,427,6,NDP,Romford,Diffuse midline glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,3/3/1984,39.1,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.91,DMG_K27,0.97,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2851,"Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4

","Integrated diagnosis: Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4
Histology: Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4
Methylation profile: Diffuse midline glioma, H3 K27-altered, subtype H3 K27-mutant or EZHIP expressing
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 427\NH22-2851,-0.04,-0.068,0.023,-0.031,-0.032,0.039,-0.069,0.008,-0.007,-0.018,-0.015,-0.308,-0.134,-0.237,0.23,0.019,-0.086,-0.058,0.041,-0.027,0.032,0.068,0.041,0.033,0.052,0.034,-0.33,-0.036,0.03,methylated
NH22-2880,206699910194_R04C01,427,10/10/2022,10/26/2022,10/26/2022,16,PM,Diagnostic,427,3,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,8/16/1978,44.8,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.99,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2880,"Brain biopsy (right side, site not specified) - Astrocytoma, IDH-mutant, most likely representing CNS WHO Grade 3 - please see comment. 
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3 - see comment
Histology: Astrocytoma, IDH-mutant, most likely representing CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 427\NH22-2880,-0.007,-0.062,0.014,-0.045,0.004,0.003,0.043,0.202,0.18,0.149,0.168,0.172,0.087,0.302,0.1,0.165,0.036,-0.026,-0.037,0.199,-0.026,0.03,-0.059,0.043,-0.008,0.031,-0.032,-0.007,0.015,methylated
NH22-2921,206699910194_R05C01,427,10/10/2022,10/26/2022,10/26/2022,16,PM,Diagnostic,427,1,NDP,"Liverpool, The Walton Centre",Ganglioglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,8/20/1996,#N/A,infratentorial pilocytic astrocytoma,0.96,LGG_PAPF,0.92,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2921,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1 - see comment
Histology: Low grade glial tumour, favouring a pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, infratentorial
MGMT promoter (Illumina array): Unmethylated Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 427\NH22-2921,0.094,-0.025,0.012,0.015,-0.016,0.064,0.104,0.004,0.046,-0.038,0.011,-0.015,0.051,0.017,0.062,0.037,-0.003,0,0.02,0.004,0.022,0.095,0.052,-0.081,-0.064,-0.033,0.002,0.024,0.053,unmethylated
NH22-2937,206699910194_R08C01,427,11/10/2022,10/26/2022,10/26/2022,15,PM,Diagnostic,427,4,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/15/1958,#N/A,"control tissue, white matter (corpus callosum)",0.4,CONTR_HEMI,0.25,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2937,"Integrated diagnosis: Suggestive of glioma infiltration - see comment
Histology: Suggestive of glioma infiltration
Methylation profile: Control tissue
MGMT promoter (Illumina array): Unmethylated 

IDH1 (R132H IHC); No mutation
ATRX (IHC): Retained     
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 427\NH22-2937,0.094,-0.051,-0.014,-0.029,-0.079,0.018,0.009,0.068,0.132,0.014,0.095,0.023,0.12,-0.059,0.028,0.093,0.008,-0.055,0,-0.067,-0.019,0.111,-0.009,0.04,-0.08,0.123,0.007,-0.029,-0.009,unmethylated
NH22-2942,206699900188_R01C01,428,11/10/2022,10/28/2022,10/28/2022,17,PM,Diagnostic,428,1,NDP,"Cardiff, University Hospital",Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A13,11/4/1950,#N/A,posterior fossa subependymoma,0.99,SUBEPN_PF,0.99,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2942,"Integrated diagnosis: Subependymoma, CNS WHO grade 1 
Histology: Subependymoma, CNS WHO grade 1
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 428\NH22-2942,0.046,-0.062,0.043,0.01,-0.003,-0.017,-0.039,0.043,-0.048,-0.001,0.012,-0.026,-0.019,-0.029,-0.004,0.033,-0.014,0.04,0.004,-0.067,0.021,0.062,-0.038,-0.051,-0.053,0.018,0.017,0.039,0.003,unmethylated
NH22-2943,206699900188_R02C01,428,12/10/2022,10/28/2022,10/28/2022,16,PM,Diagnostic,428,1,NDP,HCA,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,9/1/1999,18.9,myxopapillary ependymoma,1,EPN_MPE,1,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2943,"Ependymoma, CNS WHO grade 2
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2 (see comment)
Histology: Ependymoma, CNS WHO grade 2 
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 428\NH22-2943,-0.071,-0.105,-0.077,0.001,0.031,-0.043,-0.219,0.132,0.199,0.121,0.042,0.061,0.049,0.233,0.139,0.187,-0.097,-0.086,0.182,0.212,0.085,0.132,-0.298,0.061,-0.011,0.055,-0.062,0.021,0.04,unmethylated
NH22-2613,206699900188_R03C01,428,12/10/2022,10/28/2022,10/28/2022,16,PM,Diagnostic,428,1,NDP,"Liverpool, The Walton Centre",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,11/1/1987,35.4,"glioblastoma, IDH-wildtype, mesenchymal type",0.93,GBM_MES,0.24,0.95,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2613,"Referred diagnosis: High grade glioma
MGMT Promoter: Methylated (>0-5%)
 
","High-grade glioma - see comment

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: No amplification
TERT promoter: Failed
Histone H3F3A: No mutation     
BRAF (V600E): No mutation          
MGMT Promoter: Methylated (>0-5%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 428\NH22-2613,0.068,-0.049,0.018,-0.042,-0.103,0.089,-0.014,0.149,0.157,0.147,0.083,-0.175,-0.089,-0.11,0.09,-0.007,-0.102,-0.126,-0.046,-0.001,0.038,0.119,-0.08,-0.009,0.063,0.025,-0.069,-0.134,-0.063,methylated
NH22-2948,206699900188_R04C01,428,12/10/2022,10/28/2022,10/28/2022,16,PM,Diagnostic,428,1,NDP,Brighton and Sussex Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2B,2/9/1959,64.6,"glioblastoma, IDH-wildtype, mesenchymal type",1,PXA,0.44,0.61,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2948,"Brain biopsy (left temporal) - Most in keeping with recurrent/residual glioblastoma, IDH-wildtype, CNS WHO grade 4. See comment
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment)
Histology: Recurrent/residual glioblastoma, IDH-wildtype, CNS WHO grade 4
Methylation profile: Suggestive of Glioblastoma, IDH wildtype 
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 428\NH22-2948,0.041,-0.062,-0.016,-0.067,-0.034,0.055,0.082,0.088,0.125,0.082,0.079,-0.027,0.035,0.012,-0.329,0.037,-0.311,-0.006,-0.023,-0.068,-0.011,0.018,-0.136,-0.015,-0.051,0.038,0.045,-0.019,0.002,unmethylated
NH22-2945,206699900188_R05C01,428,12/10/2022,10/28/2022,10/28/2022,16,PM,Diagnostic,428,1,NDP,Cleveland Clinic London,Spinal ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,10/19/1978,#N/A,spinal ependymoma,1,EPN_SPINE,1,0.68,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2945,"Spinal ependymoma, CNS WHO Grade 2
","Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2 
Histology: Spinal ependymoma, CNS WHO grade 2 
Methylation profile: Spinal ependymoma
MGMT promoter (Illumina array): Methylated 
  
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 428\NH22-2945,-0.002,-0.046,0.034,0.004,-0.041,-0.019,0.072,0.161,0.204,0.201,0.161,0.183,0.199,0.175,0.233,0.162,0.064,0.021,-0.011,-0.045,0.016,0.032,-0.291,-0.045,0.014,0.008,-0.022,-0.246,-0.337,methylated
NH22-2962,206699900188_R07C01,428,13/10/2022,10/28/2022,10/28/2022,15,PM,Diagnostic,428,1,NDP,Brighton and Sussex Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/7/1982,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.96,AIDH,0.84,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2962,"Right frontal tumour, 2013 resection (13B007333 / NH13-957)
Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2 (see comment)
Histology: Diffuse glioma
Methylation profile: Astrocytoma, IDH-mutant; lower grade (v12.5, see comment)
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 428\NH22-2962,-0.132,-0.219,0.051,-0.178,0.027,0.064,0.016,0.044,-0.001,0.006,0.003,0.222,0.191,0.115,0.028,-0.019,-0.138,0.02,-0.015,0.02,-0.185,-0.207,-0.153,-0.382,-0.02,0.019,-0.046,-0.02,-0.051,methylated
NH22-2778,206699900188_R08C01,428,13/10/2022,10/28/2022,10/28/2022,15,PM,Diagnostic,428,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/6/1952,70.8,"glioblastoma, IDH-wildtype, RTK2 type",0.53,GBM_MES,0.53,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2778,"High-grade glioma (see comment) 

IDH1 (R132H IHC); IDH1/2Seq: No mutation 
ATRX (IHC): Loss of expression 
TERT promoter: No mutation
MGMT Promoter: Unmethylated (0%)
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment)
Histology: High-grade glioma
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 428\NH22-2778,0.053,-0.028,0.039,0.041,-0.027,-0.061,0.108,0.269,0.285,0.217,0.195,-0.041,0.077,0.037,0.043,0.053,-0.195,-0.247,-0.02,0.107,-0.016,-0.006,-0.315,0.042,0.053,0.014,0.006,-0.049,0.003,unmethylated
NH22-2970,206699900189_R03C01,429,14/10/2022,10/28/2022,10/28/2022,14,PM,Diagnostic,429,1,NDP,Nottingham University Hospital,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,12/14/1973,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.78,OIDH,0.9,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2970,"Integrated diagnosis: Deferred to the referring centre
Histology: Infiltrating glioma
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted (low calibrated score)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 429\NH22-2970,-0.041,-0.028,0.006,-0.037,-0.009,-0.014,-0.12,-0.009,0.197,0.191,0.152,-0.009,-0.007,-0.044,-0.191,0.005,-0.004,0.018,-0.023,0.021,-0.015,-0.016,-0.032,-0.009,-0.02,-0.024,-0.266,-0.017,-0.007,methylated
NH22-2971,206699900189_R04C01,429,14/10/2022,10/28/2022,10/28/2022,14,PM,Diagnostic,429,1,NDP,Nottingham University Hospital,Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,8/24/1961,#N/A,posterior fossa subependymoma,1,SUBEPN_PF,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2971,"Integrated diagnosis: Recurrent / residual subependymoma, CNS WHO grade 1
Histology: Subependymoma, CNS WHO grade 1
Methylation profile: Subependymoma, posterior fossa
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 429\NH22-2971,0.028,0.047,0.013,-0.005,-0.014,-0.022,-0.366,0.028,-0.001,-0.063,-0.011,-0.032,0.01,-0.01,0.021,0.018,0.016,0.007,-0.004,-0.038,-0.024,0.07,0.004,-0.006,0.018,-0.01,-0.056,-0.039,0.047,unmethylated
NH22-2972,206699900189_R05C01,429,14/10/2022,10/28/2022,10/28/2022,14,PM,Diagnostic,429,5,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,1/17/1958,#N/A,"glioblastoma, IDH-wildtype, mesenchymal type",0.86,GBM_MES,0.65,0.63,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2972,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 
Histology: High grade glioma
Methylation profile: Glioblastoma, IDH-wildtype 
MGMT promoter (Illumina array): Unmethylated 

IDH1 (R132H IHC) and IDH1/2 seq.: No mutation
ATRX (IHC): Retained     
Histone H3F3A: No mutation
TERT promoter: Mutation
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 429\NH22-2972,0.419,-0.08,-0.001,-0.015,-0.035,0.028,0.023,1.058,0.108,0.122,0.088,-0.023,-0.018,-0.064,-0.441,-0.032,-0.153,-0.222,-0.022,-0.013,-0.044,0.088,0.023,-0.011,0.065,0.014,0.114,0.003,0.009,unmethylated
NH22-2976,206699900189_R06C01,429,14/10/2022,10/28/2022,10/28/2022,14,PM,Diagnostic,429,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/3/1995,#N/A,infratentorial pilocytic astrocytoma,0.99,LGG_PAPF,0.95,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-2976,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1 
Histology: Pilocytic astrocytoma, CNS WHO grade 1 
Methylation profile: Pilocytic astrocytoma, infratentorial
MGMT promoter (Illumina array): Unmethylated 

BRAF (V600E): No mutation
KIAA1549:BRAF fusion: See comment 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 429\NH22-2976,0.004,0.032,0.001,-0.001,0.009,-0.006,-0.044,0.024,0.03,-0.064,0.2,-0.03,0.002,0.015,0.036,0.036,0.036,-0.001,0.038,-0.014,-0.021,0.041,-0.007,0.03,0.03,-0.01,-0.057,-0.037,0.014,unmethylated
NH22-2834,206699900189_R08C01,429,14/10/2022,10/28/2022,10/28/2022,14,PM,Diagnostic,429,1,NDP,Cleveland Clinic London,Haemangioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,2/9/1973,#N/A,subependymal giant cell astrocytoma,0.25,LGG_SEGA,0.27,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-2834,"Cavernous haemangioma (Cavernoma)
","Histology: Features raising the possibility of a melanocytic tumour (see comments)
Methylation profile: No matching methylation classes
MGMT promoter (Illumina array): Unmethylated 

BRAF (V600E) [IHC and seq.]: No mutation     
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 429\NH22-2834,0.044,0.085,0.063,0.052,0.004,0.101,0.001,0.017,0.018,-0.018,0.026,-0.019,-0.002,-0.032,-0.003,0.025,0.033,0.028,-0.002,-0.034,-0.05,0.085,-0.019,-0.045,0.048,0.034,0.083,-0.101,-0.029,unmethylated
NH22-2984,206699900182_R01C01,430,14/10/2022,11/2/2022,11/2/2022,19,PM,Diagnostic,430,2,NDP,"Cardiff, University Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/11/1972,#N/A,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.74,GBM_MID,0.92,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2984,"Integrated diagnosis: N/A (see comment) 
Histology: High-grade glioma
Methylation profile: Suggestive of high-grade glioma (low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 430\NH22-2984,0.166,-0.067,0.011,0.073,0.229,0.191,0.028,-0.126,0.007,-0.117,-0.024,-0.014,0.138,-0.057,-1.759,-0.039,0.098,0.073,0.129,-0.045,-0.013,0.083,-0.005,-0.459,-0.214,0.625,-0.418,-0.022,0.007,unmethylated
NH22-2995,206699900182_R06C01,430,18/10/2022,11/2/2022,11/2/2022,15,MD,Diagnostic,430,1,NDP,Romford,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/5/1972,#N/A,infratentorial pilocytic astrocytoma,0.33,LGG_PAPF,0.67,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2995,"Possible low-grade glioma - see comment
","Integrated diagnosis: Possible pilocytic astrocytoma (see comment)
Histology: Low grade glioma 
Methylation profile: Suggestive of pilocytic astrocytoma (low calibrated score, see comment)
MGMT promoter (Illumina array): Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 430\NH22-2995,-0.002,-0.016,-0.013,0.031,-0.069,0.09,0.066,-0.01,0.012,-0.04,-0.03,0.001,0.101,0.018,0.042,-0.039,0.063,0.028,0.034,-0.025,-0.022,0.079,0.047,-0.052,0.022,0.012,0.01,0.007,-0.014,methylated
NH22-2987,206699900182_R07C01,430,18/10/2022,11/2/2022,11/2/2022,15,MD,Diagnostic,430,1,NDP,Wellington Hospital London,Ependymal tumour,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,9/1/1999,#N/A,myxopapillary ependymoma,0.99,EPN_MPE,1,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2987,"Ependymal tumour (see comment)  
","Integrated diagnosis: Myxopapillary ependymoma - see comment for grading
Histology: Ependymal tumour
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Methylated   
",(2) refinement of diagnosis,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 430\NH22-2987,-0.12,-0.104,-0.098,-0.023,-0.027,0.01,-0.018,0.025,0.055,0.018,-0.013,0.004,0.123,-0.003,0.021,0.041,-0.016,-0.088,0.029,-0.032,-0.031,0.035,-0.198,-0.012,0.057,0.02,-0.01,-0.273,-0.264,methylated
NH22-2957,206699900134_R01C01,431,18/10/2022,11/2/2022,11/2/2022,15,PM,Diagnostic,431,1,NDP,Brighton and Sussex Hospital,Diffuse glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,12/13/1944,#N/A,ganglioglioma,0.45,GBM_MES,0.44,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2957,"Most suggestive of a diffuse glioma. Please see comment. 
","Integrated diagnosis: Glioma - see comment
Histology: Glioma 
Methylation profile: No tumour class identified
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 431\NH22-2957,0.081,-0.103,0.005,0.061,-0.163,-0.06,-0.026,0.317,0.207,0.127,0.112,0.012,0.08,0.009,-0.07,0.078,0.101,-0.068,0.046,0.092,0.017,0.156,0.053,-0.053,-0.063,0.085,-0.279,-0.174,-0.095,unmethylated
NH22-2947,206699900134_R02C01,431,18/10/2022,11/2/2022,11/2/2022,15,PM,Diagnostic,431,1,NDP,Brighton and Sussex Hospital,Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,9/10/1986,#N/A,dysembryoplastic neuroepithelial tumour,0.98,LGG_DNT,0.89,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2947,"Low grade glial / glioneuronal tumour (please see comment)
","Integrated diagnosis: Low grade glioneuronal tumour - see comment 
Histology: Low grade glioneuronal tumour, favouring a dysembryoplastic neuroepithelial tumour, CNS WHO grade 1
Methylation profile: In keeping with low-grade glioneuronal tumour (see comment)
MGMT promoter (Illumina array): Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 431\NH22-2947,0.151,0.033,-0.075,-0.07,0.048,0.002,0.054,-0.061,0.018,-0.174,0.017,0.097,0.045,0.01,0.11,0,0.091,-0.145,0.13,0.061,0.057,0.094,0.054,0.17,-0.487,0.069,-0.08,-0.023,-0.033,methylated
NH22-2730,206699900134_R04C01,431,19/10/2022,11/2/2022,11/2/2022,14,MD,Diagnostic,431,1,NDP,"Charing Cross Hospital, London",Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2A,8/16/1967,#N/A,supratentorial subependymoma,0.43,GBM_MES,0.32,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2730,"Supratentorial subependymoma CNS WHO grade 1. 
","Integrated diagnosis: Subependymoma, CNS WHO grade 1 - see comment
Histology: Subependymoma, CNS WHO grade 1
Methylation profile: Subependymoma, supratentorial (v12.5, low calibrated score - see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 431\NH22-2730,-0.05,0.004,0.065,0.109,0.15,0.134,0.078,0.165,0.196,0.112,0.161,-0.013,0.083,0.08,0.079,-0.031,0.13,-0.014,0.054,0.118,0.1,0.248,-0.208,0.004,-0.095,0.09,0.233,0.02,-0.012,unmethylated
NH22-2963,206699900134_R05C01,431,20/10/2022,11/2/2022,11/2/2022,13,PM,Diagnostic,431,1,NDP,Latvia,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",39232,#N/A,#N/A,"diffuse glioma, MYB(L1)-altered, subtype C [isomorphic diffuse glioma-type]",1,LGG_MYB,0.99,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2963,"Integrated diagnosis: Diffuse astrocytoma, MYB or MYBL1-altered, CNS WHO grade 1- see comment
Histology: Diffuse glioma
Methylation profile: Diffuse astrocytoma, MYB or MYBL1-altered, subtype C
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 431\NH22-2963,0.041,-0.013,0.061,0.051,-0.126,0.017,0.073,-0.036,-0.109,-0.049,-0.024,-0.022,0.007,0.024,0.048,0.036,0.111,-0.015,0.053,-0.029,-0.082,0.126,0.095,0.087,-0.028,0.079,0.042,-0.01,0.055,unmethylated
NH22-3056,206699900134_R06C01,431,20/10/2022,11/2/2022,11/2/2022,13,PM,Diagnostic,431,1,NDP,St George's Hospital London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/15/1986,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.67,AIDH,0.3,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3056,"Glioblastoma, CNS WHO grade 4 
MGMT Promoter: Methylated (>0-5%)
","Integrated diagnosis: Pending further tests (see comment)
Histology: High-grade glioma
Methylation profile: Glioma, IDH-mutant - see comment
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 431\NH22-3056,0.093,-0.021,-0.015,0.003,-0.057,-0.025,-0.223,0.037,0.429,0.35,0.05,-0.003,0.019,0.138,-0.406,-0.009,-0.023,-0.268,0.03,0.007,-0.059,0.112,0.02,0.025,0.129,0.041,-0.339,0.012,0.022,methylated
NH22-3052,206699900134_R07C01,431,20/10/2022,11/2/2022,11/2/2022,13,PM,Diagnostic,431,1,NDP,St George's Hospital London,Oligo? Astro? Glioneuronal tumour?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,9/6/1972,#N/A,"glioblastoma, IDH-wildtype, mesenchymal type",0.24,GBM_RTKII,0.63,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3052,"Integrated diagnosis: Favouring Glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment)
Histology: High-grade glioma
Methylation profile: Glioblastoma, IDH-wildtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 431\NH22-3052,-0.053,-0.028,0.018,-0.017,-0.081,-0.004,0.14,0.566,0.249,0.244,0.157,-0.035,0.092,0.053,0.13,0.073,-0.128,-0.37,0.062,-0.028,0.616,2.227,0.062,0.029,0.034,0.113,0.172,0.014,0.008,unmethylated
NH22-3019,206699900153_R02C01,432,24/10/2022,11/4/2022,11/7/2022,14,PM,Diagnostic,432,1,NDP,NHNN,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/7/1936,#N/A,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.99,GBM_MID,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3019,"High-grade glioma (please see comment) 
","Integrated diagnosis: 
Histology: 
Methylation profile: 
MGMT promoter (Illumina array): Unmethylated Methylated 
  
IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: No amplification          
Histone H3F3A: No mutation
BRAF (V600E): No mutation          
MGMT Promoter: Unmethylated (0%)
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 432\NH22-3019,0.169,-0.003,0.036,0.039,-0.027,0.103,0.09,0.194,0.211,0.184,0.167,-0.016,0.035,0.013,-1.601,-0.039,0.041,0.104,-0.018,-0.035,-0.1,0.022,-0.006,0.123,0.229,0.245,0.011,-0.024,-0.024,methylated
NH22-3005,206699900153_R03C01,432,24/10/2022,11/4/2022,11/7/2022,14,PM,Diagnostic,432,1,NDP,Romford,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,4/23/1947,#N/A,"glioblastoma, IDH-wildtype, RTK2 type",0.93,GBM_RTKII,0.8,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3005,"Glioma (see comment)

IDH1 (R132H IHC): No mutation      
ATRX (IHC): Retained      
Further molecular tests: Pending  
","Molecular findings favouring a Glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment)  
  
IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: Amplification          
MGMT Promoter: Methylated (>5-10%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 432\NH22-3005,0.019,-0.003,0.097,0.006,-0.039,0.052,0.066,1.446,0.399,0.345,0.261,-0.002,0.111,0.089,-0.122,-0.014,-0.071,-0.335,-0.056,0.048,-0.026,0.135,0.077,0.066,-0.025,0.02,-0.09,-0.024,0.017,methylated
NH22-3033,206699900153_R06C01,432,24/10/2022,11/4/2022,11/7/2022,14,PM,Diagnostic,432,3,NDP,Cleveland Clinic London,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/6/1993,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.39,OIDH,0.38,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3033,"Glioma, favouring Oligodendroglioma, CNS WHO Grade 2 (see comment)

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 432\NH22-3033,0.082,-0.02,0.018,0.001,-0.091,0.021,0.06,-0.052,-0.026,-0.086,-0.01,0.003,0.082,0.12,0.051,-0.021,0.098,-0.007,0.005,0.064,-0.016,0.113,0.047,0.12,-0.032,0.077,-0.26,-0.034,-0.033,methylated
NH22-3039,206699900153_R07C01,432,24/10/2022,11/4/2022,11/7/2022,14,PM,Diagnostic,432,4,NDP,Romford,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,10/5/1990,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3039,"Astrocytoma, IDH-mutant, CNS WHO Grade 2 (see comment)

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 432\NH22-3039,0.015,-0.014,0.074,-0.01,0,0.085,0.05,0.055,-0.036,-0.167,-0.024,0.004,0.09,0.254,0.016,0.019,0.082,-0.368,0.043,0.114,-0.15,-0.057,0.029,0.069,0.012,0.068,-0.026,0.014,0.009,methylated
NH22-3071,206699900180_R03C01,433,24/10/2022,11/4/2022,11/7/2022,14,PM,Diagnostic,433,1,NDP,St George's Hospital London,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,#N/A,supratentorial pilocytic astrocytoma,0.88,LGG_PA_GGST,0.84,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3071,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1 - see comment
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 433\NH22-3071,0.086,-0.163,-0.125,-0.005,-0.074,-0.007,0.042,-0.068,0.131,0.022,0.06,0.014,0.067,0.009,0.054,-0.09,0.087,-0.114,0.025,0.023,-0.083,0.188,0.067,0.021,0.069,0.025,-0.163,-0.027,0.027,unmethylated
NH22-3076,206699900180_R04C01,433,24/10/2022,11/4/2022,11/7/2022,14,PM,Diagnostic,433,1,NDP,St George's Hospital London,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,#N/A,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.99,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3076,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Pilocytic astrocytoma, infratentorial
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 433\NH22-3076,-0.12,-0.048,0.033,-0.039,-0.064,0.004,0.02,-0.009,0.056,-0.047,0.303,-0.017,0.195,0.057,0.055,0.027,0.091,0.058,0.133,0.015,-0.02,0.082,0.091,0.066,0.037,0.067,-0.031,-0.021,-0.028,unmethylated
NH22-3100,206693200059_R01C01,434,25/10/2022,11/9/2022,11/9/2022,15,PM,Diagnostic,434,1,NDP,"Belfast, Royal Victoria Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,#N/A,#N/A,posterior fossa ependymoma group B,0.43,EPN_PFB,0.59,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3100,"Integrated diagnosis: Ependymal tumour, grading see comment
Histology: Ependymal tumour, CNS WHO grade 2
Methylation profile: Subependymoma, posterior fossa (low calibrated score)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 434\NH22-3100,-0.029,-0.009,0.088,-0.017,0.021,-0.019,-0.028,0.213,0.252,0.174,0.165,-0.001,0.101,0.082,0.244,0.203,0.073,0.03,0.043,-0.034,0.027,0.056,0.017,-0.002,-0.019,-0.017,0.217,-0.192,-0.158,methylated
NH22-2779,206693200059_R04C01,434,25/10/2022,11/9/2022,11/9/2022,15,PM,Diagnostic,434,1,NDP,Nottingham University Hospital,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/26/1949,#N/A,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.89,LGG_MYB,0.18,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2779,"Suspicious of infiltrating glioma - see comment

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
TERT promoter: Failed
Histone H3F3A: No mutation     
BRAF (V600E): No mutation       
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 434\NH22-2779,0.22,0.004,0.002,0.094,-0.053,-0.026,-0.037,0.173,0.157,0.075,0.081,-0.019,0.1,-0.001,0.071,0.052,-0.014,-0.089,0.003,0.008,0.082,0.018,-0.011,0.073,0.046,0.07,-0.065,0.015,0.008,unmethylated
NH21-1201,206699900066_R02C01,435,27/10/2022,11/9/2022,11/9/2022,13,PM,Diagnostic,435,1,NDP,St George's Hospital London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/19/1961,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1201,"Oligodendroglioma, IDH-mutant, suggestive of transformation to anaplastic oligodendroglioma (WHO grade III)  see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19- codeleted, CNS WHO grade 3 - see comment
Histology: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 435\NH21-1201,0.047,0.02,0.062,-0.083,0.095,0.014,0.024,0.178,0.129,-0.037,0.043,0.022,0.095,0.06,0.075,0.091,0.047,-0.034,0.083,0.091,0.102,0.063,-0.04,0.147,-0.045,0.069,-0.54,0.063,0.039,methylated
NH22-3081,206699900066_R03C01,435,27/10/2022,11/9/2022,11/9/2022,13,PM,Diagnostic,435,1,NDP,Romford,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,7/23/1950,#N/A,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",1,LGG_MYB,0.19,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3081,"Infiltration zone of a glial tumour (see comment)

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","Integrated diagnosis: Infiltration zone of a glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Infiltration zone of a glial tumour
Methylation profile: Adult-type diffuse high grade glioma, IDH-wildtype, subtype F 
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 435\NH22-3081,0.037,-0.005,0.016,0.026,-0.108,0.018,0.066,0.053,0.012,-0.117,-0.015,-0.011,0.084,-0.001,0.019,0.023,0.088,0.024,0.026,-0.028,-0.024,0.106,0.049,0.071,0.049,0.096,-0.013,0.023,-0.014,unmethylated
NH22-3095,206699900066_R04C01,435,27/10/2022,11/9/2022,11/9/2022,13,PM,Diagnostic,435,1,NDP,NHNN,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,9/8/1976,#N/A,"glioblastoma, IDH-wildtype, mesenchymal type",0.66,GBM_MES,0.55,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3095,"High grade glioma (please see comment)
IDH1 (R132H IHC): Not performed
ATRX (IHC): Not performed
Further molecular tests: Pending
  
","Molecular features suggestive of Glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment)

IDH1/2Seq: No mutation
ATRX (IHC): Not performed (due to limited material)
TERT promoter: Mutation 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 435\NH22-3095,0.009,0.034,-0.002,-0.015,-0.055,0.051,-0.068,1.106,0.213,0.132,0.129,-0.007,0.059,0.022,-0.553,-0.248,-0.148,-0.202,-0.085,0.029,0.008,0.063,-0.219,0.048,0.004,0.027,-0.032,-0.139,-0.18,unmethylated
NH22-3147,206699900066_R06C01,435,27/10/2022,11/9/2022,11/9/2022,13,PM,Diagnostic,435,1,NDP,Southampton General Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,#N/A,#N/A,"Diffuse paediatric-type high grade glioma, RTK1 subtype",1,GBM_MID,0.9,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3147,"Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
IDH1/2Seq: No mutation
ATRX (IHC): No mutation (performed by referring institution)
EGFR: No amplification     
TERT promoter: No mutation     
MGMT Promoter: Methylated (>5-10%)

",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 435\NH22-3147,0.144,0.059,0.035,0.001,0.414,-0.028,0,-0.013,0.009,-0.088,0.008,-0.002,0.075,0.118,-1.764,0.066,0.035,-0.041,0.04,0.416,0.075,0.051,-0.048,0.093,0.07,1.21,-0.085,-0.049,0.251,methylated
NH22-3140,206667650124_R01C01,436,27/10/2022,11/11/2022,11/11/2022,15,PM,Diagnostic,436,1,NDP,Southampton General Hospital,?DNET,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2B,#N/A,#N/A,"Myxoid glioneuronal tumour, PDGFRA-mutant",0.26,LGG_DNT,0.37,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3140,"Integrated diagnosis: Low grade glial / glioneuronal tumour - see comment
Histology: Low grade glial / glioneuronal tumour
Methylation profile: No matching methylation classes
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 436\NH22-3140,0.06,0.099,0.017,-0.023,0.009,-0.043,-0.11,0.003,-0.006,-0.165,-0.012,-0.001,0.062,0.115,0.048,-0.046,0.1,0.107,0.086,0.051,0.032,0.101,0.045,0.086,0.026,0.109,0.028,0.016,0.057,unmethylated
NH22-3122,206667650124_R02C01,436,28/10/2022,11/11/2022,11/11/2022,14,PM,Diagnostic,436,5,NDP,Romford,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,8/12/1993,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3122,"Astrocytoma, IDH-mutant, CNS WHO Grade 4
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4 - see comment
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant; high grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 436\NH22-3122,0.074,0.304,0.134,0,0.12,0.083,0.18,-0.024,-0.004,-0.143,-0.026,-0.155,0.117,0.243,-0.385,0.018,-0.031,-0.076,0.206,0.322,-0.03,0.07,-0.484,0.146,0.058,0.053,-0.104,-0.364,-0.362,methylated
NH22-3164,206667650124_R04C01,436,31/10/2022,11/11/2022,11/11/2022,11,PM,Diagnostic,436,1,NDP,St George's Hospital London,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.86,OIDH,0.95,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3164,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Diffuse glioma, in keeping with oligodendroglioma
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 436\NH22-3164,0.032,-0.042,0.064,-0.065,0.046,0.037,-0.054,0.164,0.144,0.101,0.112,0.02,0.032,0.06,0.029,0.053,0.059,0,0.047,-0.013,0.54,0.002,-0.143,-0.021,-0.031,0.001,-0.343,0.045,0.041,methylated
NH22-3163,206667650124_R05C01,436,31/10/2022,11/11/2022,11/11/2022,11,PM,Diagnostic,436,2,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.46,OIDH,0.67,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3163,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
Histology: High-grade glioma
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma

MGMT promoter (Illumina array): Methylated 
  
",0,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 436\NH22-3163,-0.045,-0.058,0.05,-0.04,0.015,-0.002,0.015,0.114,0.135,0.103,0.094,0.019,0.033,0.061,0.006,0.087,0.048,0.012,0.039,-0.075,0.544,0.007,-0.151,-0.079,-0.035,-0.01,-0.341,0.021,0.086,methylated
NH22-3118,206667650124_R06C01,436,31/10/2022,11/11/2022,11/11/2022,11,PM,Diagnostic,436,1,NDP,Wellington Hospital London,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,11/6/1970,#N/A,spinal subependymoma [subtype B],1,SUBEPN_SPINE,0.47,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3118,"Glial tumour (please see comment)
","Integrated diagnosis: Subependymoma, CNS WHO grade 1
Histology: Glial tumour
Next Generation Sequencing: No fusions detected
Methylation profile: Subependymoma, spinal, subtype B
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 436\NH22-3118,-0.029,0.011,0.074,0.009,0.012,-0.028,0.037,-0.004,-0.019,-0.073,-0.028,-0.006,0.041,0.063,0.051,-0.018,0.076,0.048,0.041,-0.012,-0.023,0.006,-0.013,0.058,-0.024,-0.021,-0.075,-0.005,0.004,unmethylated
NH22-3152,206667650124_R08C01,436,31/10/2022,11/11/2022,11/11/2022,11,PM,Diagnostic,436,1,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.94,AIDH,0.91,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3152,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3 - see comment
Histology: Diffuse glioma
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 436\NH22-3152,0.244,0.065,0.07,-0.014,0.059,-0.213,-0.009,0.115,0.139,-0.02,0.045,-0.058,0.083,0.327,0.072,0.064,0.152,-0.058,0.045,0.528,0.286,-0.162,-0.039,0.202,0.051,0.094,-0.189,0.01,-0.021,methylated
NH22-3153,206667650106_R01C01,437,31/10/2022,11/11/2022,11/11/2022,11,PM,Diagnostic,437,1,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.79,OIDH,0.99,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3153,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2 - see comment
Histology: Diffuse glioma, in keeping with oligodendroglioma
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 437\NH22-3153,0.097,-0.018,0.022,-0.016,0.007,0.003,-0.051,0.188,0.184,0.118,0.164,0.014,-0.057,0.09,-0.012,0.009,0.042,0.005,-0.018,0.045,0.028,0.017,-0.065,0.128,0.03,-0.005,-0.401,0.046,0.047,methylated
NH22-3155,206667650106_R03C01,437,31/10/2022,11/11/2022,11/11/2022,11,PM,Diagnostic,437,1,NDP,Nottingham University Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.11,OIDH,0.11,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3155,"Diffuse glioma, referred as astrocytoma, WHO grade 3. Awaiting methylation array

MGMT Promoter: Methylated (>0-5%)
","Integrated diagnosis: Diffuse glioma, referred as astrocytoma, CNS WHO grade 3 - see comment
Histology: Diffuse glioma
Methylation profile: No matching methylation classes
MGMT promoter (Illumina array): Unmethylated
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 437\NH22-3155,-0.067,-0.084,0.041,-0.003,0.043,-0.106,-0.144,-0.114,-0.191,0.009,0.055,0.003,-0.091,-0.114,-0.145,-0.058,-0.045,-0.003,-0.135,-0.123,-0.078,0.043,-0.37,0.023,-0.006,0.111,0.143,0.074,0.281,unmethylated
NH22-3179,206667650106_R05C01,437,31/10/2022,11/11/2022,11/11/2022,11,PM,Diagnostic,437,1,NDP,St George's Hospital London,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3179,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Diffuse glioma, in keeping with oligodendroglioma
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted 
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 437\NH22-3179,-0.011,0.009,0.042,-0.054,-0.015,-0.012,-0.041,0.076,-0.043,-0.126,-0.014,0.166,0.268,0.248,-0.058,0.078,0.063,0.007,0.055,0.008,0.006,0.041,-0.063,0.093,-0.015,0.03,-0.542,0.021,0.101,methylated
NH22-3129,206667650106_R07C01,437,1/11/2022,11/11/2022,11/11/2022,10,PM,Diagnostic,437,5,NDP,Romford,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,11/30/1978,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3129,"Glioma, IDH-mutant (please see comment)
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Glioma, IDH-mutant
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 437\NH22-3129,0.237,-0.003,0.091,-0.077,0.052,0.029,0.002,0.021,-0.011,-0.115,-0.024,0.027,0.05,0.1,0.03,-0.051,0.037,0.038,0.049,0.018,-0.016,-0.029,-0.024,0.061,-0.035,-0.027,-0.456,0.025,0.063,methylated
NH22-3134,206667650106_R08C01,437,1/11/2022,11/11/2022,11/11/2022,10,PM,Diagnostic,437,6,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,7/27/1988,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.96,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3134,"Astrocytoma, IDH-mutant, CNS WHO grade 3
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Astrocytoma, IDH-mutant, CNS WHO grade 3
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
TERT promoter: No mutation
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 437\NH22-3134,-0.035,-0.084,0.042,-0.082,0.008,-0.011,0.006,-0.06,0.116,0.037,0.098,-0.007,0.076,0.034,-0.25,-0.019,0.071,0.073,-0.008,0.241,-0.054,0.003,0.016,0.056,-0.014,0.013,-0.05,0.006,0.037,methylated
NH22-3157,206667650160_R01C01,438,1/11/2022,11/11/2022,11/11/2022,10,PM,Diagnostic,438,3,NDP,"Charing Cross Hospital, London",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,4/30/1976,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.39,OIDH,0.3,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3157,"Astrocytoma, IDH-mutant, with radiotherapy-related changes, grading see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  


","Integrated diagnosis: Diffuse glioma, with radiotherapy-related changes, with molecular features of an oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
Histology: Astrocytoma, IDH-mutant, with radiotherapy-related changes
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 

IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 438\NH22-3157,0.011,0,0.01,-0.005,-0.03,0.01,-0.041,-0.039,-0.012,-0.065,0.008,0.01,0.011,0.01,0.023,-0.021,0.04,-0.006,0.012,0.042,-0.013,-0.051,-0.008,0.038,0.039,0.021,-0.131,0.025,-0.006,methylated
NH22-3170,206667650160_R04C01,438,2/11/2022,11/11/2022,11/11/2022,9,PM,Diagnostic,438,5,NDP,Cleveland Clinic London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,9/23/1965,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.98,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3170,"Astrocytoma, IDH-mutant, CNS WHO Grade 2
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Astrocytoma, IDH-mutant, CNS WHO grade 2 - see comment
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
TERT promoter: No mutation
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 438\NH22-3170,0.033,0.009,0.029,-0.006,0.003,-0.28,0.004,0.06,0.044,-0.003,0.026,-0.008,0.094,-0.017,-0.011,0.004,0.065,-0.103,-0.018,0.014,-0.069,-0.151,-0.04,0.047,0.033,0.307,-0.066,0.007,0.026,methylated
NH22-3206,206667650160_R07C01,438,2/11/2022,11/11/2022,11/11/2022,9,PM,Diagnostic,438,1,NDP,"Liverpool, The Walton Centre",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,#N/A,#N/A,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.69,GBM_MYCN,0.51,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3206,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma
Methylation profile: Diffuse paediatric-type high grade glioma, RTK2 subtype, subclass B
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 438\NH22-3206,-0.008,-0.024,0.049,0.024,-0.036,-0.104,-0.137,1.176,0.349,0.123,0.197,-0.217,-0.153,-0.191,-1.611,-0.005,-0.302,-0.347,-0.081,0.014,-0.013,0.043,-0.053,-0.364,0.126,0.081,-0.094,-0.315,-0.319,unmethylated
NH22-2994,206667650160_R08C01,438,3/11/2022,11/11/2022,11/11/2022,8,MD,Diagnostic,438,1,NDP,Romford,?Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,9/5/1965,#N/A,"glioblastoma, IDH-wildtype, mesenchymal type",0.33,CONTR_HEMI,0.23,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2994,"Brain biopsy: Reactive changes (see comment)
","Integrated diagnosis: CNS tissue, with reactive changes (no features compatible with neoplastic cells identified)
Histology: CNS tissue with Reactive changes
Next generation sequencing: No mutations detected
Methylation profile: No matching methylation classes
MGMT promoter (Illumina array): Unmethylated 
 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 438\NH22-2994,-0.029,-0.014,0.043,-0.062,-0.045,-0.003,0.012,-0.053,-0.028,-0.099,-0.01,0.011,0.06,0.007,-0.02,-0.064,0.07,0.054,0.015,-0.04,-0.055,0.009,0.006,0.064,-0.05,0.004,0.005,0.013,0.012,unmethylated
NH22-2922,206667650132_R01C01,439,3/11/2022,11/16/2022,11/16/2022,13,PM,Diagnostic,439,1,NDP,Royal National Orthopaedic Hosp.,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",871,5/20/2004,#N/A,myxopapillary ependymoma,1,EPN_MPE,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2922,"Myxopapillary ependymoma, CNS WHO grade 2
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 439\NH22-2922,-0.091,-0.109,-0.037,-0.048,0.063,0.077,-0.126,0.132,0.196,0.137,0.079,-0.092,0.019,0.082,0.354,0.325,0.006,-0.073,0.157,0.15,0.115,0.239,-0.011,0.221,0.206,0.147,0.133,-0.065,-0.014,unmethylated
NH22-3012,206667650132_R02C01,439,3/11/2022,11/16/2022,11/16/2022,13,PM,Diagnostic,439,5,NDP,Southampton General Hospital,Diffuse glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,10/7/1994,#N/A,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type B]",0.99,DMG_K27,0.2,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3012,"Diffuse glioma - for grading, see comment

IDH1/2Seq: No mutation
ATRX (IHC): Retained
1p/19q: Retained          
EGFR: No amplification     
CDKN2A/B: No deletion     
TERT promoter: Mutation
Histone H3F3A: No mutation     
BRAF (V600E): No mutation     
","Integrated diagnosis: Features suggestive of the infiltration zone of a glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Diffuse glioma
Next Generation Sequencing: TERT, BCOR, PPM1D, TP53 mutations
Methylation profile: Adult-type diffuse high grade glioma, IDH-wildtype, subtype B
MGMT promoter (Illumina array): Unmethylated 

IDH1/2Seq: No mutation
ATRX (IHC): Retained
TERT promoter: Mutation
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 439\NH22-3012,0.028,-0.058,0.067,-0.008,-0.04,0.036,0.024,-0.007,-0.01,-0.102,-0.023,-0.013,0.076,-0.017,0.043,0.006,0.082,0.044,0.042,0.005,-0.014,0.099,0.076,0.11,0.063,-0.019,0.003,-0.012,0.023,unmethylated
NH22-3161,206667650132_R03C01,439,3/11/2022,11/16/2022,11/16/2022,13,PM,Diagnostic,439,1,NDP,Wellington Hospital London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,2/13/1960,#N/A,"glioblastoma, IDH-wildtype, RTK1 type",0.98,GBM_RTKI,0.88,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3161,"Glioblastoma (subtype Gliosarcoma), CNS WHO Grade 4 (please see comment)
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending

","Integrated diagnosis: Glioblastoma (subtype gliosarcoma), IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Glioblastoma (subtype gliosarcoma), CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
MGMT promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 439\NH22-3161,-0.033,-0.033,0.048,0.079,0.177,0.063,-0.017,0.228,0.285,0.333,0.187,0.011,0.099,0.089,-1.615,-0.011,-0.193,-0.311,-0.006,0.011,-0.042,0.071,0.028,0.055,0.063,0.037,-0.076,0.038,0.075,unmethylated
NH22-2813,206667650132_R04C01,439,3/11/2022,11/16/2022,11/16/2022,13,PM,Diagnostic,439,5,NDP,"Belfast, Royal Victoria Hospital",Pleomorphic xanthoastrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",22B19780,7/13/2004,#N/A,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.98,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2813,"Glioma, with features favouring a pleomorphic xanthoastrocytoma, BRAF V600E-mutant, CNS WHO grade 2 - see comment

IDH1/2Seq: No mutation
ATRX (IHC): Retained     
TERT promoter: No mutation     
BRAF (V600E): Mutation
","Integrated diagnosis: Glial tumour, favouring a pilocytic astrocytoma, CNS WHO grade 1 - see comment
Histology: Glial tumour, see previous description
Methylation profile: Pilocytic astrocytoma, hemispheric
MGMT promoter (Illumina array): Methylated 

BRAF (V600E): Mutation
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 439\NH22-2813,0.133,-0.048,-0.056,-0.064,-0.083,0.064,0.04,-0.072,0.108,-0.047,0.033,0.058,0.061,0.139,0.139,-0.013,0.078,-0.027,0.034,0.088,0.011,0.157,0.058,0.03,-0.017,-0.058,-0.166,-0.083,-0.035,methylated
NH22-2164,206667650132_R05C01,439,3/11/2022,11/16/2022,11/16/2022,13,PM,Diagnostic,439,1,NDP,"Belfast, Royal Victoria Hospital",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,9/30/2002,#N/A,posterior fossa ependymoma group A1,0.12,GBM_MES,0.11,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2164,"Low grade glioma, NOS
No BRAF point mutation or fusion
","Integrated diagnosis: Low grade glioma - see comment
Histology: Low grade glioma
Methylation profile: No matching methylation classes
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 439\NH22-2164,-0.174,-0.068,0.045,0.039,-0.006,0.024,0.008,-0.019,-0.005,0.018,-0.001,0.019,-0.01,0.039,0.025,-0.02,0.023,0.009,-0.024,-0.059,-0.01,0.112,0.024,-0.062,0.025,0.019,0.023,-0.163,-0.125,unmethylated
NH22-2969,206667650132_R07C01,439,4/11/2022,11/16/2022,11/16/2022,12,MD,Diagnostic,439,1,NDP,Nottingham University Hospital,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/7/1985,#N/A,"control tissue, white matter (corpus callosum)",1,CONTR_WM,0.85,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2969,"Glioma - for grading, see comment

IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained          
EGFR: No amplification     
CDKN2A/B: No deletion     
TERT promoter: No mutation
Histone H3F3A: No mutation     
BRAF (V600E): No mutation     
","Please see main report
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 439\NH22-2969,-0.012,-0.001,0.024,-0.012,0.039,0.041,0.054,-0.031,-0.06,-0.106,-0.004,0.013,0.057,0.029,0.046,-0.012,0.055,0.072,0.022,-0.006,-0.063,0.026,0.065,0.01,-0.07,-0.02,0.03,-0.026,0.029,unmethylated
NH22-3089,206667650132_R08C01,439,4/11/2022,11/16/2022,11/16/2022,12,MD,Diagnostic,439,1,NDP,Nottingham University Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,#N/A,#N/A,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.79,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3089,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype
MGMT promoter (Illumina array): Methylated 
  
IDH1/2Seq: No mutation
TERT promoter: Mutation
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 439\NH22-3089,0.031,-0.054,0.066,-0.066,-0.034,0.032,0.016,1.249,0.198,0.155,0.181,0.005,0.118,0.058,-1.99,0.056,-0.314,-0.313,0.033,0.074,0.024,0.017,0.008,0.076,-0.037,0.027,0.257,-0.382,-0.301,methylated
NH22-3227,206667650134_R03C01,440,4/11/2022,11/16/2022,11/16/2022,12,MD,Diagnostic,440,3,NDP,Oxford John Radcliffe Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1B,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.63,AIDH,0.85,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3227,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: IDH glioma, subclass astrocytoma
MGMT promoter (Illumina array): Methylated 

IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
",0,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 440\NH22-3227,-0.041,-0.007,0.05,-0.027,-0.003,-0.1,0.089,-0.036,0.015,-0.025,0.014,-0.002,0.016,0.12,-0.11,-0.035,-0.072,-0.055,0.011,0.25,0.156,-0.035,-0.072,-0.122,-0.289,-0.141,-0.036,0.001,0,methylated
NH22-3225,206667650134_R04C01,440,4/11/2022,11/16/2022,11/16/2022,12,MD,Diagnostic,440,1,NDP,Oxford John Radcliffe Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3B,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3225,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 
  
IDH1 (R132H IHC), IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 440\NH22-3225,0.011,-0.004,0.058,-0.013,-0.003,0.024,0.021,-0.005,0.084,0.105,0.117,0.015,0.061,0.052,-0.012,-0.035,0.011,0.013,0.006,-0.029,-0.044,0.007,-0.039,-0.053,0.003,-0.034,0.013,-0.034,0.002,methylated
NH22-3207,206667650134_R06C01,440,4/11/2022,11/16/2022,11/16/2022,12,MD,Diagnostic,440,4,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,2/27/1995,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3207,"Astrocytoma, IDH-mutant, CNS WHO grade 3
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3 
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Unmethylated 

IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 440\NH22-3207,-0.351,0.015,0.044,-0.024,-0.017,0.029,0.045,-0.059,-0.042,-0.039,-0.006,0.003,0.056,0.289,0.009,0.009,0.016,0.018,0.01,0.092,-0.09,-0.026,-0.008,-0.003,-0.11,-0.028,-0.065,0.003,-0.001,unmethylated
NH22-3217,206667650134_R08C01,440,4/11/2022,11/16/2022,11/16/2022,12,MD,Diagnostic,440,3,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,5/27/1980,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3217,"Oligodendroglioma, IDH-mutant, grading see comment
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2 - see comment
Histology: Oligodendroglioma, IDH-mutant
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 

IDH1/2Seq: Mutation     
ATRX (IHC): Retained     
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 440\NH22-3217,-0.048,-0.034,0.063,-0.03,-0.001,-0.025,-0.002,-0.042,-0.024,-0.068,0.005,0.001,0.02,-0.004,0.055,-0.028,-0.018,-0.002,-0.056,-0.046,-0.065,0.006,-0.052,0.02,-0.005,0.008,-0.416,-0.009,0.028,methylated
NH22-3223,206667650128_R01C01,441,7/11/2022,11/18/2022,11/18/2022,11,MD,Diagnostic,441,4,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,11/9/1985,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.47,AIDH,0.61,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3223,"Astrocytoma, IDH-mutant, CNS WHO grade 2
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Retained 
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Unmethylated 

IDH1/2Seq: Mutation     
ATRX (IHC): Retained     
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 441\NH22-3223,-0.132,-0.114,0.03,-0.025,0.109,0.042,0.085,-0.082,-0.064,-0.074,-0.005,-0.006,-0.063,0.027,-0.117,0.004,0.016,-0.01,0.117,0.086,-0.124,0.034,-0.05,-0.053,-0.065,0.055,0.042,0.033,0.019,unmethylated
NH22-3276,206667650128_R06C01,441,8/11/2022,11/18/2022,11/18/2022,10,MD,Diagnostic,441,1,NDP,St George's Hospital London,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,#N/A,#N/A,myxopapillary ependymoma,1,EPN_MPE,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3276,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2 - see comment
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
IDH1/2Seq: No mutation
ATRX (IHC): Retained     
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)

",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 441\NH22-3276,0.026,0.019,0.055,0.023,0.052,0.013,0.022,0.147,0.216,0.224,0.217,0.015,0.013,0.039,0.22,0.218,-0.321,-0.336,-0.003,-0.08,0.008,-0.057,0.011,0.022,-0.023,-0.001,-0.011,-0.326,-0.304,unmethylated
NH22-3257,206667650128_R07C01,441,8/11/2022,11/18/2022,11/18/2022,10,MD,Diagnostic,441,4,NDP,NHNN,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3257,"
Oligodendroglioma, IDH-mutant, CNS WHO grade 2


IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
Further molecular tests: Pending
  
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 441\NH22-3257,0.009,-0.003,0.028,-0.002,0.001,0.021,-0.021,-0.067,-0.039,-0.054,0.001,0.025,-0.014,0.011,-0.021,-0.018,-0.021,0.021,-0.009,-0.01,-0.038,-0.027,-0.029,-0.005,-0.044,0.024,-0.412,0.074,-0.042,methylated
NH22-3275,206667650135_R01C01,442,8/11/2022,11/23/2022,11/23/2022,15,PM,Diagnostic,442,1,NDP,St George's Hospital London,Reactive changes vs glial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,#N/A,"supratentorial ependymoma, ZFTA:RELA fusion-positive",0.07,CONTR_HEMI,0.11,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3275,"Tissue fragments with radiation induced changes and suspicion of glioma infiltration

IDH1/2Seq: No mutation
ATRX (IHC): Retained     
MGMT Promoter: Unmethylated (0%)
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 442\NH22-3275,0.305,0.083,0.079,0.099,0.007,0.124,-0.019,-0.416,-0.063,-0.217,0.047,-0.078,0.219,-0.16,-0.119,-0.09,0.001,-0.013,-0.047,-0.206,0.008,0.143,0.127,0.017,-0.154,0.066,0.274,0.025,-0.11,unmethylated
NH22-3316,206667650135_R04C01,442,10/11/2022,11/23/2022,11/23/2022,13,PM,Diagnostic,442,1,NDP,Royal National Orthopaedic Hosp.,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,11/28/1979,#N/A,myxopapillary ependymoma,0.96,EPN_MPE,0.98,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3316,"
Myxopapillary ependymoma CNS WHO grade 2 
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 442\NH22-3316,-0.053,-0.087,-0.018,0.135,0.184,0.136,-0.119,-0.246,-0.062,0.09,0.158,0.155,0.135,0.059,0.151,0.191,-0.143,-0.085,-0.117,-0.055,0.026,0.302,0.143,-0.096,-0.226,-0.127,0.472,-0.07,-0.226,unmethylated
NH22-3258,206667650135_R05C01,442,10/11/2022,11/23/2022,11/23/2022,13,PM,Diagnostic,442,3,NDP,"Charing Cross Hospital, London",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,#N/A,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.94,AIDH,0.98,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3258,"Astrocytoma, IDH-mutant, CNS WHO grade 2
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  

","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 442\NH22-3258,-0.082,-0.061,0.176,-0.029,0.074,-0.075,-0.537,-0.047,0.136,0.051,0.155,0.015,0.236,-0.088,-0.096,-0.03,0.093,0.028,-0.009,-0.034,-0.156,-0.097,0.053,0.003,-0.127,-0.278,0.002,-0.127,-0.139,methylated
NH22-3313,206667650135_R07C01,442,11/11/2022,11/23/2022,11/23/2022,12,PM,Diagnostic,442,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,10/5/1985,#N/A,high-grade astrocytoma with piloid features,0.94,ANAPA,0.54,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3313,"Integrated diagnosis: High-grade astrocytoma with piloid features - grading see comment
Histology: Pilocytic astrocytoma
Methylation profile: High-grade astrocytoma with piloid features
MGMT promoter (Illumina array): Methylated

KIAA1549-BRAF: No fusion
BRAF Seq: No mutation
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 442\NH22-3313,0.142,-0.028,0.157,-0.058,0.036,-0.069,-0.045,-0.072,-0.175,-0.36,-0.091,0.059,0.099,-0.077,-0.864,0.01,0,0.093,-0.012,-0.078,-0.093,0.058,-0.029,0.078,-0.243,-0.212,0.043,-0.211,-0.074,methylated
NH22-3330,206667650135_R08C01,442,11/11/2022,11/23/2022,11/23/2022,12,PM,Diagnostic,442,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,11/8/1985,#N/A,pleomorphic xanthoastrocytoma(-like),0.78,PXA,0.85,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3330,"Integrated diagnosis: Pleomorphic xanthoastrocytoma, CNS WHO grade 3 
Histology: High-grade glioma with features favouring a pleomorphic xanthoastrocytoma, CNS WHO grade 3 
Methylation profile: Pleomorphic xanthoastrocytoma 
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 442\NH22-3330,-0.311,0.013,0.208,-0.031,0.088,0.269,0.072,-0.152,-0.288,-0.529,-0.121,0.06,0.354,-0.296,-2.121,0.052,0.133,0.042,-0.08,-0.089,-0.133,-0.208,0.051,0.042,-0.062,-0.212,-0.474,-0.511,-0.165,unmethylated
NH22-3309,206693200121_R01C01,443,11/11/2022,11/25/2022,11/25/2022,14,PM,Diagnostic,443,5,NDP,Royal London Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/6/1985,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3309,"Astrocytoma, IDH-mutant, CNS WHO grade 3 (at least - see comment)
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant; high grade
MGMT promoter (Illumina array): Methylated 

IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 443\NH22-3309,0.127,-0.087,0.148,0.128,0.092,-0.326,-0.121,-0.6,-0.166,-0.256,0.148,0.09,0.062,0.182,-2.037,-0.173,-0.337,-0.767,0.007,-0.044,-0.101,0.106,-0.058,-0.11,-0.09,-0.004,-0.138,-0.124,-0.216,methylated
NH22-3285,206693200121_R02C01,443,11/11/2022,11/25/2022,11/25/2022,14,PM,Diagnostic,443,1,NDP,Southampton General Hospital,Pleomorphic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3A,#N/A,#N/A,"supratentorial ependymoma, ZFTA:RELA fusion-positive",0.08,PXA,0.2,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3285,"Integrated diagnosis: High grade glioma, IDH-wildtype
Histology: High-grade glioma
Methylation profile: No matching methylation classes
MGMT promoter (Illumina array): Unmethylated
  
IDH1/2Seq: No mutation
Histone H3F3A: No mutation     
BRAF (V600E): No mutation
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 443\NH22-3285,0.304,-0.35,0.085,-0.111,-0.1,-0.229,-0.517,-0.243,-0.141,0.196,0.26,0.462,-0.141,0.395,0.161,0.555,-0.442,-0.392,-0.418,-0.64,-0.55,-0.262,-0.095,-0.117,-0.417,-0.644,0.434,0.653,0.45,unmethylated
NH22-3199,206693200121_R04C01,443,16/11/2022,11/25/2022,11/25/2022,9,MD,Diagnostic,443,1,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,7/25/1947,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.55,AIDH_HG,0.9,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3199,"Astrocytoma, IDH-mutant, CNS WHO grade 3
IDH1 (R132H IHC): Mutation 
ATRX (IHC):     Loss of expression (indicates mutation)
Further molecular tests: Pending
","Astrocytoma, IDH-mutant, CNS WHO grade 3 - see comment

IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
EGFR: No amplification     
MGMT Promoter: Methylated (>25%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 443\NH22-3199,0.043,-0.025,0.09,-0.024,0.025,0.033,0.01,0.197,0.187,-0.124,0.104,-0.005,0.168,-0.019,-0.359,-0.009,-0.014,0.025,0.182,0.028,-0.091,-0.119,0.148,-0.004,-0.081,-0.051,-0.073,-0.067,-0.017,methylated
NH22-3295,206693200121_R06C01,443,16/11/2022,11/25/2022,11/25/2022,9,MD,Diagnostic,443,3,NDP,"Liverpool, The Walton Centre",Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",7A,7/3/1953,#N/A,ganglioglioma,0.07,GBM_MES,0.32,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3295,"Integrated diagnosis: Features suggestive of the infiltration zone of a glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Diffuse glioma
Methylation profile: Glioblastoma, IDH-wildtype, subclass mesenchymal (low calibrated score)
MGMT promoter (Illumina array): Unmethylated  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 443\NH22-3295,0.216,-0.061,0.109,0.137,-0.043,-0.014,-0.196,0.058,0.061,0.121,0.265,-0.037,0.111,-0.092,0.045,-0.007,-0.302,-0.334,-0.075,-0.124,0.706,0.047,0.008,0.025,-0.019,0.047,0.331,0.084,0.015,unmethylated
NH22-3166,206693200121_R07C01,443,16/11/2022,11/25/2022,11/25/2022,9,MD,Diagnostic,443,1,NDP,"Belfast, Royal Victoria Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,#N/A,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.97,DMG_K27,0.12,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3166,"High-grade glioma - see comment

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
EGFR: No amplification     
Histone H3F3A: No mutation     
MGMT Promoter: Unmethylated (0%)
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma
Methylation profile: Diffuse paediatric-type high grade glioma, RTK1 subtype, subclass A 
MGMT promoter (Illumina array): Unmethylated

IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)     
EGFR: No amplification     
Histone H3F3A: No mutation     
MGMT Promoter: Unmethylated (0%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 443\NH22-3166,0.078,0.034,0.124,-0.054,0.062,-0.022,-0.032,-0.085,-0.032,-0.249,-0.02,0.028,0.17,-0.063,0.024,0.05,0.048,0.059,0.1,0.022,-0.026,-0.021,0.089,0.04,-0.073,-0.042,-0.058,-0.115,-0.036,unmethylated
NH22-2269,206693200121_R08C01,443,17/11/2022,11/25/2022,11/25/2022,8,MD,Diagnostic,443,1,NDP,"Belfast, Royal Victoria Hospital",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/25/1947,#N/A,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.96,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-2269,"Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: Amplification
TERT promoter: No mutation
MGMT Promoter: Methylated (>5-10%)


  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype
MGMT promoter (Illumina array): Methylated 

IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: Amplification     
CDKN2A/B: Deletion
MGMT Promoter: Methylated (>5-10%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 443\NH22-2269,0.041,-0.072,0.14,-0.069,0.082,-0.035,-0.046,1.653,0.116,0.026,0.162,0.012,0.185,0.073,-2.792,0.068,-0.44,-0.524,0.014,-0.007,-0.099,-0.025,0.064,0.073,-0.129,-0.026,-0.021,-0.029,0.048,methylated
NH22-3358,206693200123_R01C01,444,18/11/2022,11/30/2022,11/30/2022,12,PM,Diagnostic,444,1,NDP,"Cambridge, Addenbrooke's Hospital",Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,4/19/1959,#N/A,"glioblastoma, IDH-wildtype, mesenchymal type",0.27,CONTR_HEMI,0.14,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3358,"Integrated diagnosis: CNS parenchyma with a diffusely infiltrative glial tumour, copy number profile suggestive of glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment)
Histology: CNS parenchyma with a diffusely infiltrative glial tumour 
Methylation profile: No matching methylation classes (low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 444\NH22-3358,-0.045,-0.037,0.031,0.021,0.027,0.014,-0.002,-0.125,0.018,0.038,0.077,0.04,0.041,-0.095,-0.005,-0.09,-0.125,-0.117,-0.097,-0.2,-0.093,0.053,0.023,-0.051,-0.18,0.035,0.136,-0.056,-0.046,unmethylated
NH22-3380,206693200123_R04C01,444,18/11/2022,11/30/2022,11/30/2022,12,PM,Diagnostic,444,1,NDP,Nottingham University Hospital,GBM NOS,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/2/1971,#N/A,high-grade astrocytoma with piloid features,0.38,ANAPA,0.51,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3380,"Integrated diagnosis: High-grade glioma with features suggestive of a high-grade astrocytoma with piloid features - see comment
Histology: High-grade glioma
Methylation profile: High-grade astrocytoma with piloid features (low calibrated score, see comment)
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 444\NH22-3380,-0.014,0.025,0.059,0.042,-0.001,-0.014,-0.112,-0.228,-0.111,-0.159,0.002,0.032,0.093,-0.029,-0.392,-0.02,-0.024,-0.024,0.032,0.109,0.615,1.072,-0.415,0.014,-0.142,0.024,-0.351,0.009,-0.005,methylated
NH22-3399,206693200123_R06C01,444,18/11/2022,11/30/2022,11/30/2022,12,PM,Diagnostic,444,1,NDP,St George's Hospital London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,12/21/1971,#N/A,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.95,AIDH_HG,0.99,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3399,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant; high grade
MGMT promoter (Illumina array): Methylated 
  
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
MGMT Promoter: Methylated (>25%)
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 444\NH22-3399,0.15,-0.073,0.106,-0.035,0.081,-0.195,-0.096,0.41,-0.188,-0.147,-0.111,0.015,0.137,-0.069,0.009,-0.098,0.125,-0.167,0.013,0.048,-0.185,-0.186,0.08,-0.035,-0.089,0.046,-0.081,-0.036,-0.034,methylated
NH22-3363,206693200123_R07C01,444,22/11/2022,11/30/2022,11/30/2022,8,PM,Diagnostic,444,1,NDP,Cleveland Clinic London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,10/9/1970,#N/A,"glioblastoma, IDH-wildtype, RTK1 type",0.97,GBM_RTKI,0.98,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3363,"Compatible with recurrence of known glioblastoma, IDH-wildtype, CNS WHO Grade 4  see comment 
","Integrated diagnosis: Recurrent glioblastoma, IDH-wildtype, CNS WHO grade 4 
Histology: Recurrent glioblastoma, IDH-wildtype, CNS WHO grade 4 
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype 
MGMT promoter (Illumina array): Methylated 
DNA NGS:  TERT promoter variant 
RNA NGS: No relevant fusions detected
Copy number variants: Deletion of CDKN2A/B, PTEN, RB1. No structural variants
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 444\NH22-3363,-0.174,-0.044,0.118,0.086,0.007,0.13,0.187,0.379,0.299,-0.113,-0.002,0.143,0.225,-0.043,-0.476,0.149,-1.59,0.032,-0.07,0.062,-0.046,0.179,-0.423,0.019,-0.187,-0.105,-0.111,-0.059,0.002,methylated
NH22-3366,206693200095_R05C01,445,22/11/2022,12/7/2022,12/7/2022,15,PM,Diagnostic,445,4,NDP,Romford,Astroglial rich lesion,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,9/5/1965,#N/A,"glioblastoma, IDH-wildtype, mesenchymal type",0.35,CONTR_REACT,0.32,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3366,"Astroglial-rich vacuolated lesion - please see comment. 
","Astroglial-rich vacuolated lesion. See main report for details.
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 445\NH22-3366,0.053,-0.054,-0.004,-0.067,-0.11,0.032,0.002,-0.05,0.013,-0.067,-0.006,-0.021,0.127,0.023,0.025,-0.053,0.054,0.003,0.031,-0.035,0.019,0.076,0.042,0.033,0.03,-0.011,0.006,-0.08,0.029,unmethylated
NH22-3373,206693200125_R02C01,446,22/11/2022,12/7/2022,12/7/2022,15,PM,Diagnostic,446,1,NDP,HCA,Ependymal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,6/5/1984,,myxopapillary ependymoma,1,EPN_MPE,1,0.96,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3373,"Ependymal tumour, CNS WHO grade 2 - see comment
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Ependymal tumour, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 446\NH22-3373,0.093,-0.05,0.079,-0.01,-0.048,-0.014,-0.024,0.174,0.323,0.279,0.236,0.019,0.027,0.069,0.25,0.294,-0.092,-0.165,0.049,0.016,-0.043,0.127,0.022,0.044,0.018,0.04,0.01,0.013,0.044,unmethylated
NH22-3447,206693200125_R03C01,446,22/11/2022,12/7/2022,12/7/2022,15,PM,Diagnostic,446,1,NDP,"Birmingham, Queen Elizabeth Hospital",Neuroepithelial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A7,9/28/1985,,"glioblastoma, IDH-wildtype, with primitive neuronal component",1,GBM_RTKII,0.38,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3447,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: High grade neuroepithelial or glial tumour, grade 4
Methylation profile: Glioblastoma, IDH-wildtype, with primitive neuronal component.
IDH1/2Seq: No mutation
ATRX (IHC): Retained
TERT promoter: Mutation

MGMT promoter (Illumina array): Unmethylated
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 446\NH22-3447,0.287,0.143,0.205,0.062,-0.005,0.256,0.093,0.24,0.237,0.226,0.223,0.012,-0.014,0.072,0.323,0.386,0.01,-2.441,-0.031,-0.03,-0.014,0.063,-0.031,0.225,0.334,0.206,-0.017,-0.459,-0.424,unmethylated
NH22-3386,206693200125_R06C01,446,23/11/2022,12/7/2022,12/7/2022,14,PM,Diagnostic,446,14,NDP,Romford,Astroglial cyctic lesion,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/10/1961,,supratentorial pilocytic astrocytoma,0.18,CONTR_HEMI,0.32,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3386,"Astroglial cystic lesion - see comment 
","Integrated diagnosis: CNS tissue with prominent astroglial reaction, no tumour detected 
Histology: Astroglial cystic lesion, most in keeping with reactive nature
Methylation profile: No matching methylation class
IDH1/2Seq: No mutation
ATRX (IHC): Retained
TERT promoter: No mutation
Histone H3F3A: No mutation
BRAF (V600E): No mutation

MGMT promoter (Illumina array): Unmethylated
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 446\NH22-3386,-0.049,0.052,0.017,-0.039,-0.024,0.027,0.038,-0.001,-0.003,-0.061,-0.013,-0.012,0.041,0.034,0.013,-0.013,0.04,0.02,0.013,-0.006,0.002,-0.004,0.02,-0.024,-0.035,-0.023,0.006,-0.032,0.025,unmethylated
NH22-3341,206693200125_R07C01,446,23/11/2022,12/7/2022,12/7/2022,14,PM,Diagnostic,446,4,NDP,Romford,Diffuse glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,10/20/1986,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.97,AIDH,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3341,"Diffuse glioma. 

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Lost      
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4 - see comment
Histology: Astrocytoma, IDH-mutant, at least CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 446\NH22-3341,-0.032,-0.03,0.055,-0.101,0.003,0.052,-0.034,-0.008,-0.027,-0.091,-0.013,0.006,0.048,0.066,-0.241,0.018,0.025,0.097,0.059,0.137,-0.003,-0.037,-0.097,0.026,-0.037,0.08,-0.021,0.022,0.028,methylated
NH22-3327,206677660087_R01C01,447,23/11/2022,12/7/2022,12/7/2022,14,PM,Diagnostic,447,1,NDP,Royal London Hospital,Glioblastoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,3/1/1952,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.98,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3327,"Most suggestive of a glioblastoma, CNS WHO Grade 4
IDH1 (R132H IHC): Inconclusive - Further tests pending 
ATRX (IHC): Retained 
Further molecular tests: Pending
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
MGMT promoter (Illumina array): Unmethylated
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 447\NH22-3327,-0.081,-0.121,-0.053,-0.049,0.038,0.02,-0.24,0.097,0.134,0.182,0.113,0.033,0.003,0.066,0.002,-0.014,-0.177,-0.225,0.004,-0.003,0.45,0.048,-0.062,0.049,0.067,0.042,0,0.031,0.071,unmethylated
NH22-3379,206677660087_R03C01,447,23/11/2022,12/7/2022,12/7/2022,14,PM,Diagnostic,447,1,NDP,NHNN,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,5/20/2004,,myxopapillary ependymoma,1,EPN_MPE,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3379,"Myxopapillary ependymoma, CNS WHO grade 2
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Unmethylated
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 447\NH22-3379,-0.018,-0.074,0.026,0.028,0.13,0.11,-0.016,0.161,0.166,0.148,0.127,-0.028,0.009,-0.007,0.282,0.293,-0.003,-0.006,0.129,0.135,0.126,0.208,-0.007,0.096,0.215,0.142,0.155,-0.021,0.02,unmethylated
NH22-3469,206677660087_R07C01,447,29/11/2022,12/7/2022,12/7/2022,8,PM,Diagnostic,447,1,NDP,Southampton General Hospital,Glial tumour?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,10/21/1944,,"glioblastoma, IDH-wildtype, mesenchymal type",0.93,GBM_MES,0.93,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3469,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Diffuse glioma, morphologically no high-grade features
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype
MGMT promoter (Illumina array): Unmethylated 
  
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 
Histology: Diffuse glioma, morphologically no high-grade features 
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype 
MGMT promoter (Illumina array): Unmethylated 
DNA Next Generation Sequencing (DNA NGS): Suggested EGFR amplification and RB1 deletion. 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 447\NH22-3469,0.099,-0.007,0.051,0.019,-0.021,0.118,0.003,0.889,0.103,0.065,0.11,-0.041,-0.028,0.003,-0.126,-0.008,-0.142,-0.161,-0.002,0.017,0.001,-0.031,-0.235,0.021,0.001,-0.005,-0.044,-0.136,-0.142,unmethylated
NH22-3468,206677670008_R02C01,448,29/11/2022,12/9/2022,12/9/2022,10,PM,Diagnostic,448,3,NDP,Cleveland Clinic London,Astrocytoma IDH mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,1/13/1993,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.95,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3468,"Astrocytoma, IDH-mutant, CNS WHO grade 4

IDH1 (R132H IHC):      Mutation 
ATRX (IHC):       Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4 
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Unmethylated
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 448\NH22-3468,-0.011,-0.015,0.053,0.004,0.108,-0.048,-0.016,-0.125,-0.032,0.012,0.102,0.032,0.055,0.081,-0.061,0.076,-0.041,-0.046,-0.039,-0.025,-0.094,-0.03,-0.011,0.069,-0.091,0.027,-0.045,-0.016,0.021,unmethylated
NH22-3453,206677670008_R03C01,448,29/11/2022,12/9/2022,12/9/2022,10,PM,Diagnostic,448,1,NDP,Romford,Subependymoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/12/1969,,supratentorial subependymoma,1,SUBEPN_ST,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3453,"Subependymoma, CNS WHO grade 1
","Integrated diagnosis: Subependymoma, CNS WHO grade 1
Histology: Subependymoma, CNS WHO grade 1
Methylation profile: Supratentorial subependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 448\NH22-3453,0.022,0.118,0.165,0.078,-0.079,-0.086,-0.065,0.021,-0.107,-0.227,-0.085,0.029,0.094,-0.061,-0.045,-0.005,0.053,0.065,0.121,0.063,0.029,-0.006,0.091,0.106,-0.01,0.033,-0.031,-0.062,0.057,unmethylated
NH22-3444,206677670008_R04C01,448,29/11/2022,12/9/2022,12/9/2022,10,PM,Diagnostic,448,1,NDP,Cleveland Clinic London,Glioma?,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",SP1A,5/6/1960,,"glioblastoma, IDH-wildtype, mesenchymal type",1,CONTR_REACT,0.59,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3444,"Suspicious (not definitive) for residual / recurrent glioma - see comment 
","Integrated diagnosis: Residual / recurrent glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Features raising the possibility of residual / recurrent glioma 
Methylation profile: glioblastoma, IDH-wildtype, mesenchymal type 
MGMT promoter (Illumina array): Unmethylated 
  
IDH1/2Seq: No mutation
ATRX (IHC): Retained
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 448\NH22-3444,0.01,-0.005,0.103,-0.03,0.008,-0.152,0.09,0.079,0.002,-0.117,0.029,0.018,0.074,-0.057,-0.353,-0.004,-0.136,-0.027,0.002,-0.044,-0.06,-0.248,-0.015,-0.018,-0.275,-0.096,0.009,-0.036,0.007,methylated
NH22-3442,206677670008_R06C01,448,29/11/2022,12/9/2022,12/9/2022,10,PM,Diagnostic,448,1,NDP,Wellington Hospital London,Astrocytoma IDH mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/15/1964,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.88,AIDH_HG,0.44,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3442,"Astrocytoma, IDH-mutant (see comment for grading) 

IDH1 (R132H IHC): Mutation      
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Recurrent / residual astrocytoma, IDH-mutant, at least CNS WHO grade 3 (see comment)
Histology: Astrocytoma, IDH-mutant with radiotherapy related changes and high grade features
Methylation profile: Astrocytoma, IDH-mutant; high grade
MGMT promoter (Illumina array): Methylated 

IDH1 (R132H IHC): Mutation     
ATRX (IHC): Retained     
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 448\NH22-3442,0.004,-0.004,0.125,-0.014,0.055,-0.009,0.045,-0.055,-0.124,-0.236,-0.046,0.057,0.178,-0.186,-0.048,-0.034,0.107,0.004,0.168,0.02,-0.148,-0.122,-0.004,0.065,0.039,0.18,-0.082,-0.069,0.017,methylated
NH22-3484,206677670008_R07C01,448,29/11/2022,12/9/2022,12/9/2022,10,PM,Diagnostic,448,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/9/1970,,"glioblastoma, IDH-wildtype, RTK1 type",0.83,GBM_RTKI,0.77,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3484,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
MGMT promoter (Illumina array): Unmethylated   
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 448\NH22-3484,0.103,-0.078,0.188,0.069,0.137,-0.039,-0.037,0.417,0.373,0.349,0.518,-0.036,0.149,-0.021,0.19,0.277,-0.736,-0.491,1.151,-0.084,1.198,2.699,0.069,-0.002,-0.052,0.132,-0.121,-0.053,0.054,unmethylated
NH22-3486,206677670008_R08C01,448,29/11/2022,12/9/2022,12/9/2022,10,PM,Diagnostic,448,1,NDP,Nottingham University Hospital,Infiltration of tumour cells,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/29/1952,,"control tissue, white matter (corpus callosum)",0.99,CONTR_WM,0.59,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3486,"Integrated diagnosis: White matter with features suggestive of infiltration zone of a glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: White matter with paucicellular glioma infiltrate
Methylation profile: Control tissue, white matter (corpus callosum)
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 448\NH22-3486,0.086,0.098,0.11,-0.035,0.656,0.089,-0.036,-0.188,-0.1,-0.187,-0.101,0.005,0.263,-0.09,-0.19,-0.001,0.084,-0.013,-0.012,-0.089,-0.114,-0.018,0.105,0.09,0.181,-0.043,0.036,-0.129,-0.06,methylated
NH22-3477,206677670005_R02C01,449,29/11/2022,12/9/2022,12/9/2022,10,PM,Diagnostic,449,1,NDP,Royal London Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,8/1/1959,,pleomorphic xanthoastrocytoma(-like),0.9,PXA,0.93,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3477,"Glioblastoma, CNS WHO grade 4 (see comment) 

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: MAPK-Altered (BRAF-mutant) high-grade glioma, see comment 
Histology: High-grade glioma with BRAF V600E mutation
Methylation profile: Pleomorphic xanthoastrocytoma (see methylation class description)
MGMT promoter (Illumina array): Unmethylated 

BRAF (V600E): Mutation
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 449\NH22-3477,-0.026,0.027,0.047,0.03,0.093,0.073,-0.034,-0.285,-0.164,-0.08,0.026,0.034,-0.013,-0.15,-0.672,-0.122,-0.052,-0.049,-0.116,-0.235,-0.092,0.113,0.022,0.015,-0.144,-0.011,0.295,0,-0.046,unmethylated
NH22-3504,206677670005_R03C01,449,29/11/2022,12/9/2022,12/9/2022,10,PM,Diagnostic,449,1,NDP,Nottingham University Hospital,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,2/29/2004,,"spinal ependymoma, MYCN-amplified",1,EPN_PFA,0.49,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3504,"Integrated diagnosis: Spinal ependymoma, MYCN-amplified - see comment
Histology: Glial tumour, with features resembling an ependymoma
Methylation profile: Spinal ependymoma, MYCN-amplified
MGMT promoter (Illumina array): Unmethylated 
","Integrated diagnosis: Spinal ependymoma, MYCN-amplified - see above comment 
Histology: Glial tumour, with features resembling an ependymoma 
Methylation profile: Spinal ependymoma, MYCN-amplified 
MGMT promoter (Illumina array): Unmethylated 
Next Generation Sequencing (NGS): DNA NGS - suggests MYCN amplification; RNA NGS - No relevant gene fusions detected 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 449\NH22-3504,0.077,1.328,0.065,0.091,0.021,0.002,0.035,-0.163,-0.113,-0.179,0.043,0.034,0.059,-0.097,-0.081,-0.028,-0.025,-0.031,-0.067,-0.129,-0.088,0.135,0.057,-0.069,-0.022,-0.123,0.068,0.002,-0.082,unmethylated
NH22-3459,206677670005_R04C01,449,29/11/2022,12/9/2022,12/9/2022,10,MD,Diagnostic,449,1,NDP,Romford,Neuroepithelial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,10/26/1955,,"glioblastoma, IDH-wildtype, with primitive neuronal component",1,MB_SHHCHLAD,0.29,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3459,"Malignant neuroendocrine / neuroepithelial tumour (see comment)
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Malignant neuroendocrine / neuroepithelial tumour
Methylation profile: Glioblastoma, IDH-wildtype, with primitive neuronal component
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 449\NH22-3459,0.34,0.166,0.082,0.064,0.01,0.042,0.033,0.076,0.297,0.124,0.294,-0.472,-0.438,-0.648,-0.035,-0.054,-0.623,-0.554,-0.106,-0.186,-0.137,0.092,-0.508,-0.078,0.088,0.073,0.108,-0.047,0.008,unmethylated
NH22-3493,206677670005_R06C01,449,29/11/2022,12/9/2022,12/9/2022,10,MD,Diagnostic,449,8,NDP,NHNN,Diffuse midline glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,4/27/1978,,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.82,DMG_K27,0.97,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3493,"Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4 
","Integrated diagnosis: Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4 
Histology: Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4 
Methylation profile: Diffuse midline glioma, H3 K27-altered, subtype H3 K27-mutant or EZHIP expressing 
MGMT promoter (Illumina array): Unmethylated
Next Generation Sequencing (NGS): DNA NGS -  H3F3A, ATRX, NF1 and TP53 variants detected; RNA NGS (for gene fusions) - analysis failed due to technical difficulties. 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 449\NH22-3493,0.019,-0.027,0.021,0.013,0.073,0,0.078,-0.278,-0.067,-0.122,0.052,0.048,0.048,-0.11,-0.002,0.001,-0.157,-0.243,-0.042,-0.099,-0.084,0.145,0.074,0.041,-0.023,0.05,0.075,0.074,-0.035,unmethylated
NH22-3479,206677670005_R07C01,449,29/11/2022,12/9/2022,12/9/2022,10,PM,Diagnostic,449,1,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,9/25/1989,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.57,AIDH,0.97,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3479,"Astrocytoma, IDH-mutant, CNS WHO grade 2 (see comment)

IDH1 (R132H IHC): Mutant
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, best corresponding to CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 

IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 449\NH22-3479,-0.064,-0.017,0.133,-0.029,0.128,-0.055,-0.007,0.209,0.121,0.097,0.162,0.029,0.141,0.162,-0.212,-0.086,0.019,0.057,-0.087,0.172,-0.152,-0.264,0.047,0.086,-0.234,-0.001,-0.225,-0.118,-0.137,methylated
NH19-3068,206677670005_R08C01,449,29/11/2022,12/9/2022,12/9/2022,10,PM,Diagnostic,449,1,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF3A,9/25/1989,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.77,AIDH,0.86,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH19-3068,"Low grade diffuse glioma  see comment


IDH1 (R132H IHC): Mutation       
ATRX (IHC): Possible loss of expression  test will be repeated
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, CNS WHO grade 2 - see comment
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 

IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 449\NH19-3068,0.011,0.043,0.174,0.005,-0.018,-0.068,-0.303,0.053,0.015,-0.154,0.085,0.079,0.187,-0.043,-0.371,0.036,-0.068,-0.028,-0.086,-0.112,-0.229,-0.31,0.153,0.067,-0.148,0.015,-0.021,-0.354,-0.062,methylated
NH22-3514,206677660125_R02C01,450,29/11/2022,12/14/2022,12/14/2022,15,PM,Diagnostic,450,1,NDP,St George's Hospital London,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B1,11/29/1958,,spinal subependymoma [subtype A],0.9,SUBEPN_SPINE,0.99,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3514,"Integrated diagnosis: Ependymoma, CNS WHO grade 2 (see comment)
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Spinal subependymoma [subtype A]
MGMT promoter (Illumina array): Unmethylated
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 450\NH22-3514,0.006,-0.039,0.086,0.036,0.016,-0.031,-0.491,-0.029,-0.042,-0.079,-0.001,0.007,0.032,-0.023,-0.007,-0.02,0.014,0.003,0.029,-0.009,-0.02,0.017,-0.014,0.028,0.066,0.012,0.015,0.007,0.004,unmethylated
NH22-3512,206677660125_R04C01,450,29/11/2022,12/14/2022,12/14/2022,15,PM,Diagnostic,450,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,6/10/2003,,dysembryoplastic neuroepithelial tumour,0.66,LGG_RGNT,0.39,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3512,"Integrated diagnosis: Recurrent low-grade glial/glioneuronal tumour - see comment
Histology: Low grade glial/glioneuronal tumour
Methylation profile: Dysembryoplastic neuroepithelial tumour (low-moderate calibrated score)
MGMT promoter (Illumina array): Methylated
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 450\NH22-3512,0.045,-0.033,0.001,-0.096,-0.021,-0.044,-0.001,-0.059,0.004,-0.122,-0.025,-0.002,0.107,-0.006,0.044,0.026,0.033,-0.015,0.141,0.031,0.032,0.031,0.032,0.123,0.061,0.047,-0.006,-0.235,-0.14,methylated
NH22-3528,206677660125_R08C01,450,30/11/2022,12/14/2022,12/14/2022,14,PM,Diagnostic,450,1,NDP,Southampton General Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,1/24/1952,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.94,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3528,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, grading see comment
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Unmethylated
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 450\NH22-3528,-0.11,-0.02,0.08,-0.049,-0.034,0.049,0.054,-0.042,0.194,0.085,0.168,-0.013,0.102,0.207,0.039,0.001,0.068,-0.215,0.026,-0.006,-0.04,0.034,0.036,0.07,0.057,0.06,-0.371,-0.019,0.082,methylated
NH22-3529,206677660124_R01C01,451,30/11/2022,12/14/2022,12/14/2022,14,PM,Diagnostic,451,1,NDP,Southampton General Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1C,5/20/1985,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3529,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3
Histology: Oligodendroglioma, CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 451\NH22-3529,-0.002,-0.027,0.024,-0.295,-0.268,-0.002,0.023,-0.013,-0.009,0.001,0.02,0.047,0,0.091,-0.008,-0.013,-0.025,-0.024,0.113,0.004,-0.022,-0.032,-0.057,0.035,0.004,0.247,-0.377,0.026,-0.02,methylated
NH22-3289,206677660124_R04C01,451,1/12/2022,12/14/2022,12/14/2022,13,PM,Diagnostic,451,1,NDP,Oxford John Radcliffe Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,9/9/1987,,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.62,GBM_RTKII,0.42,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3289,"Glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment.

IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
MGMT Promoter: Unmethylated (0%)
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma, morphologically consistent with glioblastoma
Methylation profile: Diffuse paediatric type high-grade glioma, MYCN subtype
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 451\NH22-3289,-0.069,-0.115,0.058,-0.14,0.344,-0.035,-0.331,0.158,0.194,0.247,0.158,-0.003,0.008,0.039,-0.035,0.008,-0.687,-0.223,-0.077,0.019,0.917,2.064,0.08,0.051,0.028,0.002,-0.004,0.029,0.053,unmethylated
NH22-3525,206677660124_R05C01,451,1/12/2022,12/14/2022,12/14/2022,13,PM,Diagnostic,451,1,NDP,"Belfast, Royal Victoria Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,11/26/1991,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.98,OIDH,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3525,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 

IDH1/2Seq: Mutation
TERT promoter: Mutation
MGMT Promoter: Methylated (>5-10%)
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 451\NH22-3525,-0.011,-0.029,0.039,0.006,0.001,0.017,0.003,0.03,-0.009,-0.114,0.002,0.016,-0.016,0.051,-0.003,-0.013,0.015,-0.054,0.021,0.022,0.006,0.029,-0.088,0.106,0.036,-0.02,-0.483,0.162,0.207,methylated
NH22-3500,206677660124_R07C01,451,1/12/2022,12/14/2022,12/14/2022,13,PM,Diagnostic,451,1,NDP,Latvia,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3869-70/22,5/16/2013,,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.99,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3500,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Intratentorial pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 451\NH22-3500,-0.049,-0.026,0.034,-0.005,-0.073,0.225,0.239,0.065,-0.05,-0.065,0.136,0.003,0.082,-0.058,0.064,-0.003,-0.017,0.024,0.031,-0.029,-0.048,-0.008,0.02,-0.023,-0.025,-0.063,0.031,0.022,0.056,unmethylated
NH22-3502,206677660124_R08C01,451,1/12/2022,12/14/2022,12/14/2022,13,PM,Diagnostic,451,4,NDP,Latvia,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3733-32/22,#N/A,,"control tissue, cerebellar hemisphere",0.96,CONTR_CEBM,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3502,"Integrated diagnosis: Low grade glial/glioneuronal tumour, compatible with rosette-forming glioneuronal tumour, CNS WHO grade 1
Histology: Low grade glial/glioneuronal tumour, CNS WHO grade 1
Methylation profile: Rosette forming glioneuronal tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 451\NH22-3502,-0.207,0.063,0.003,-0.067,-0.025,-0.007,0.02,-0.035,0.003,0.023,-0.02,-0.047,0.113,0.076,0.038,-0.064,0.034,0.023,-0.024,-0.065,-0.092,0.253,0.046,0.003,-0.045,0.127,0.032,-0.079,0.032,unmethylated
NH22-3530,206677660085_R01C01,452,1/12/2022,12/14/2022,12/14/2022,13,PM,Diagnostic,452,1,NDP,"Liverpool, The Walton Centre",Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,7/13/1995,,"glioblastoma, IDH-wildtype, mesenchymal type",0.17,LGG_PAPF,0.36,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3530,"Integrated diagnosis: Spinal cord with glioneuronal tumour
Histology: Spinal cord, glioneuronal tumour with subacute and chronic haemorrhage
Methylation profile: No matching methylation class, see comment and appended report
MGMT promoter (Illumina array): Unmethylated Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 452\NH22-3530,0.066,-0.046,0.018,-0.024,-0.036,-0.018,-0.003,-0.043,0.045,-0.006,0.103,0.018,0.066,0.021,0.032,-0.005,0.024,-0.012,0.033,0.014,-0.033,0.044,0.002,0.029,0.059,0.005,0.013,-0.027,0.012,unmethylated
NH22-3480,206677660085_R02C01,452,1/12/2022,12/14/2022,12/14/2022,13,PM,Diagnostic,452,1,NDP,NHNN,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,1/3/1981,,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.27,HMB,0.11,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3480,"High-grade / malignant tumour (see comment) 
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma
Methylation profile: Diffuse paediatric-type high grade glioma, RTK1 subtype, subclass B (Low calibrated score)

MGMT promoter (Illumina array): Unmethylated

IDH1/2Seq: No mutation
ATRX (IHC): Retained
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 452\NH22-3480,-0.039,-0.046,0.024,-0.01,0.188,0.087,0.071,-0.01,0.003,-0.041,-0.007,-0.019,0.017,0.023,-0.286,-0.026,0.037,0.005,0.024,-0.016,0.022,-0.036,0.011,0.005,0.007,0.093,-0.037,0.022,0.039,unmethylated
NH22-3551,206677660085_R03C01,452,1/12/2022,12/14/2022,12/14/2022,13,PM,Diagnostic,452,1,NDP,Oxford John Radcliffe Hospital,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,1/21/1987,,"control tissue, white matter (corpus callosum)",1,OIDH,0.28,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3551,"CNS white matter, with reactive changes - see comment
MGMT Promoter: Methylated (>5-10%)
","Integrated diagnosis: CNS white matter, no tumour detected with molecular tests
Histology: CNS white matter
Methylation profile: Control tissue, white matter (corpus callosum)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 452\NH22-3551,0.034,-0.025,-0.003,-0.004,-0.049,0.024,0.018,-0.014,0.065,-0.002,-0.004,0.007,0.036,-0.024,0.07,0.035,0.012,-0.014,0.012,0.012,0.011,0.049,0.065,0.011,-0.027,0.012,-0.061,0.008,-0.004,unmethylated
NH22-3544,206677660085_R07C01,452,2/12/2022,12/14/2022,12/14/2022,12,PM,Diagnostic,452,1,NDP,"Charing Cross Hospital, London",Spinal ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,2/9/1958,,spinal ependymoma,1,EPN_SPINE,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3544,"Spinal Ependymoma, CNS WHO grade 2 (see comment)
","Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Spinal ependymoma, CNS WHO grade 2
Methylation profile: Spinal ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 452\NH22-3544,0.011,0.045,0.056,0.062,0.019,-0.026,0.033,0.018,0.063,-0.05,0.026,0.014,0.016,0.055,0.053,0.053,0.034,0.008,0.023,0.064,0.02,0.027,-0.014,0.026,0.076,0.017,-0.018,-0.335,-0.358,unmethylated
NH22-3570,206677660175_R01C01,453,2/12/2022,12/14/2022,12/14/2022,12,PM,Diagnostic,453,1,NDP,Brighton and Sussex Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1C,2/14/1988,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.96,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3570,"Provisional diagnosis: Glioma (see comment)
","Integrated diagnosis: Astrocytoma, IDH-mutant, with molecular high grade features (see comment)
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2 (see previous comment)
Methylation profile: Astrocytoma, IDH-mutant, low grade
MGMT promoter (Illumina array): Unmethylated Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 453\NH22-3570,-0.053,-0.043,0.069,-0.038,-0.021,0.018,-0.293,-0.031,0.15,0.166,0.133,0.011,0.01,0.035,-0.247,-0.003,0.027,0.001,-0.033,0.05,-0.03,-0.01,-0.021,0.024,-0.016,-0.028,-0.03,-0.018,0.005,unmethylated
NH22-3532,206677660175_R02C01,453,2/12/2022,12/14/2022,12/14/2022,12,PM,Diagnostic,453,1,NDP,Royal London Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,6/21/1948,,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.85,GBM_MES,0.24,0.51,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3532,"Suspicious for infiltrating glioma (see comments)
","Integrated diagnosis: CNS infiltration of Glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment) 
Histology: CNS tissue with diffuse infiltration of a glioma 
Methylation profile: Adult-type diffuse high grade glioma, IDH-wildtype, subtype F 
MGMT promoter (Illumina array): Methylated 
DNA Next Generation Sequencing (DNA NGS): Variants in TERT promoter (C228T), EGFR and two likely pathogenic variant in TP53 detected; No IDH1/2 mutations detected; suggested CDK4 amplification.    
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 453\NH22-3532,0.032,-0.03,0.075,-0.078,0.015,0.005,0.038,0.087,-0.018,-0.056,0.03,0.006,-0.05,0.029,0.037,-0.001,-0.081,-0.018,-0.004,-0.017,0.331,0.036,0.007,0.006,-0.011,-0.01,0.06,-0.024,0.007,methylated
NH22-3548,206677660175_R03C01,453,2/12/2022,12/14/2022,12/14/2022,12,PM,Diagnostic,453,1,NDP,Cleveland Clinic London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,4/14/1991,,infratentorial pilocytic astrocytoma,0.23,LGG_PAPF,0.6,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3548,"Astrocytoma (see comment)

IDH1 (R132H IHC): No mutation      
ATRX (IHC): Inconclusive
Further molecular tests: Pending 
","Integrated diagnosis: Low grade glioma, most in keeping with pilocytic astrocytoma, CNS WHO grade 1
Histology: Astrocytoma
Methylation profile: Infratentorial pilocytic astrocytoma (low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 453\NH22-3548,0.008,-0.008,0.02,-0.012,-0.01,0.074,0.006,-0.054,-0.01,-0.071,-0.006,0.022,0.094,0.035,-0.118,-0.039,0.001,-0.008,0.015,-0.016,-0.005,-0.005,-0.019,-0.017,-0.033,0.086,0.048,0.017,0.067,unmethylated
NH22-3577,206677660175_R05C01,453,2/12/2022,12/14/2022,12/14/2022,12,PM,Diagnostic,453,1,NDP,St George's Hospital London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,1/1/1963,,"glioblastoma, IDH-wildtype, RTK2 type",0.99,GBM_RTKII,0.92,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3577,"Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: Amplification
MGMT Promoter: Unmethylated (0%)
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype  
MGMT promoter (Illumina array): Unmethylated
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 453\NH22-3577,0.053,0.018,0.046,-0.001,0.087,0.063,0.026,1.446,0.235,0.243,0.215,0.012,0.044,0.06,-0.732,-0.003,-0.805,-0.421,-0.038,-0.058,0.054,0.074,-0.015,0.021,0.011,0.033,0.265,-0.007,0,unmethylated
NH22-3578,206677660175_R06C01,453,2/12/2022,12/14/2022,12/14/2022,12,PM,Diagnostic,453,1,NDP,St George's Hospital London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/4/1953,,"glioblastoma, IDH-wildtype, RTK2 type",0.99,GBM_RTKII,0.92,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3578,"Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: Amplification
TERT promoter: Mutation
MGMT Promoter: Methylated (>10-25%) 
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype  
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 453\NH22-3578,-0.032,-0.045,0.032,-0.046,0.033,0.01,-0.005,1.088,-0.023,-0.068,-0.031,-0.003,0.069,0.015,-1.087,0.027,-0.254,-0.269,-0.008,-0.035,-0.022,0.008,0.021,-0.01,0.012,0.019,0.192,0.007,0.043,methylated
NH22-3579,206677660175_R07C01,453,2/12/2022,12/14/2022,12/14/2022,12,PM,Diagnostic,453,1,NDP,St George's Hospital London,Glial tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,5/19/1983,,high-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype,0.57,DMG_K27,0.33,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3579,"Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4
IDH1/2Seq: No mutation
ATRX (IHC): Loss of expression (indicates mutation)
H3K27M (IHC): Mutation
Histone H3F3A: K27M Mutation
MGMT Promoter: Methylated (>25%)
","Integrated diagnosis: Diffuse midline glioma, H3 K27M-altered, CNS WHO grade 4
Histology: High-grade glioma
Methylation profile: Diffuse midline glioma H3K27M mutant (see comment)
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 453\NH22-3579,-0.004,-0.01,0.042,0.006,-0.372,0.031,0.031,-0.023,-0.051,-0.033,0.006,-0.464,0.052,-0.012,0.029,-0.007,0.012,-0.003,-0.029,-0.008,-0.047,-0.02,-0.105,0.013,0.337,0.44,-0.491,-0.462,-0.411,methylated
NH22-3580,206677660175_R08C01,453,2/12/2022,12/14/2022,12/14/2022,12,PM,Diagnostic,453,1,NDP,St George's Hospital London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/10/1971,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3580,"Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1/2Seq: No mutation
ATRX (IHC): Retained
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 453\NH22-3580,0.127,0.016,0.1,0.008,0.102,0.025,-0.045,0.462,-0.016,-0.021,0.061,0.047,0.065,0.179,0.03,0.047,-0.392,-0.45,-0.043,0.093,0.656,-0.054,-0.032,0.025,0.057,0.084,-0.042,-0.003,0.042,unmethylated
NH22-3566,206667650182_R01C01,454,5/12/2022,12/16/2022,12/22/2022,17,PM,Diagnostic,454,1,NDP,"Charing Cross Hospital, London",Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,10/6/1988,,infratentorial pilocytic astrocytoma,0.54,LGG_PAPF,0.5,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3566,"Favouring a Pilocytic Astrocytoma, CNS WHO Grade 1 (see comment)
","Integrated diagnosis: Pilocytic astrocytoma, BRAF fusion, CNS WHO grade 1
Histology: Low grade glioma, in keeping with pilocytic astrocytoma
Methylation profile: Infratentorial pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 454\NH22-3566,-0.036,0.009,0.028,0.019,-0.03,0.071,-0.013,-0.071,0.011,-0.034,0.149,-0.007,0.011,-0.016,-0.036,0.008,0.009,0.012,0.037,-0.057,-0.048,-0.047,-0.006,-0.118,-0.05,0.004,0.064,-0.028,-0.009,unmethylated
NH22-3565,206667650182_R03C01,454,5/12/2022,12/16/2022,12/22/2022,17,PM,Diagnostic,454,1,NDP,Romford,Oligodendroglioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,6/23/1989,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.94,OIDH,0.99,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3565,"Oligodendroglioma, IDH-mutant, CNS WHO Grade 2

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q codeleted
MGMT promoter (Illumina array):  Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 454\NH22-3565,-0.059,-0.039,0.003,-0.075,-0.043,-0.008,0.064,-0.044,-0.006,-0.056,-0.037,0.043,0,0.039,0.086,-0.024,0.034,0.073,-0.039,0.001,-0.058,0.001,0.014,0.023,-0.022,-0.007,-0.371,-0.024,-0.03,methylated
NH22-3560,206667650182_R04C01,454,5/12/2022,12/16/2022,12/22/2022,17,PM,Diagnostic,454,1,NDP,NHNN,Ganglioglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,5/2/2005,,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.93,GBM_RTKII,0.22,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3560,"Ganglioglioma, CNS WHO Grade 1  
","Integrated diagnosis: Diffuse high grade glioma, in keeping with glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Hippocampal formation with diffuse infiltration of a glioma
Methylation profile: Adult-type diffuse high grade glioma, IDH-wildtype, subtype F 
MGMT promoter (Illumina array): Unmethylated 
  
BRAF (V600E): No mutation
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 454\NH22-3560,-0.01,0.007,0.015,-0.029,-0.015,-0.013,0.069,0.035,-0.024,-0.024,-0.014,0.009,0.06,0.004,0.09,0.015,0.048,-0.011,-0.007,0.023,-0.038,0.113,-0.345,0.016,0.031,-0.064,-0.014,0.017,0.022,unmethylated
NH22-3490,206667650182_R05C01,454,5/12/2022,12/16/2022,12/22/2022,17,PM,Diagnostic,454,1,NDP,"Charing Cross Hospital, London",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,1/21/1980,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.97,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3490,"Glioblastoma, CNS WHO grade 4 (see comment)

IDH1 (R132H IHC): No mutation  
ATRX (IHC): Retained      
Further molecular tests: Pending
","Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1/2Seq: No mutation
ATRX (IHC): Retained
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 454\NH22-3490,0.01,0.16,0.028,-0.041,-0.004,0.214,0.003,0.252,0.251,0.259,0.215,0.016,0.011,0.02,-1.683,0.023,-0.36,-0.433,0.008,0.053,-0.015,0.062,-0.127,-0.366,0.008,0.002,-0.048,-0.078,-0.047,unmethylated
NH22-3383,206667650182_R06C01,454,5/12/2022,12/16/2022,12/22/2022,17,PM,Diagnostic,454,1,NDP,Southampton General Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,4/10/1984,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3383,"Astrocytoma, IDH-mutant - for grading see comment
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
1p/19q: Retained
CDKN2A/B: No deletion
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3 
Methylation profile: Astrocytoma, IDH-mutant, low grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 454\NH22-3383,0.008,-0.029,0.04,-0.015,-0.01,-0.07,0.014,0.03,0.212,0.236,0.219,0.009,-0.029,-0.015,-0.034,-0.028,0.018,-0.021,-0.019,0.081,0.007,-0.036,-0.082,-0.001,0.003,-0.024,-0.042,-0.01,0.012,methylated
NH22-3586,206667650182_R07C01,454,6/12/2022,12/16/2022,12/22/2022,16,PM,Diagnostic,454,3,NDP,Romford,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,3/27/1956,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.97,AIDH_HG,0.99,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3586,"Astrocytoma, IDH-mutant, CNS WHO grade 4
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma IDH-mutant, high-grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 454\NH22-3586,-0.038,-0.214,-0.168,-0.075,0.091,-0.378,-0.01,-0.008,-0.098,-0.01,-0.079,0.116,0.026,0.096,-0.011,0.076,-0.122,-0.177,0.024,0.26,0.745,-0.261,-0.085,0.069,0.231,0.069,-0.164,-0.088,-0.061,methylated
NH22-3608,207134810006_R04C01,455,8/12/2022,12/16/2022,12/22/2022,14,PM,Diagnostic,455,1,NDP,Brighton and Sussex Hospital,Oligodendroglioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,4/4/1963,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3608,"Oligodendroglioma, CNS WHO grade 3 
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
",0,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 455\NH22-3608,0.034,-0.004,0.004,-0.014,-0.034,-0.203,-0.041,-0.023,-0.035,-0.053,-0.002,0.026,0.018,-0.035,0.01,0.019,0.017,-0.018,-0.049,-0.025,-0.01,-0.021,-0.08,0.022,0.006,-0.055,-0.431,0.046,0.024,methylated
NH22-3430,207134810006_R05C01,455,8/12/2022,12/16/2022,12/22/2022,14,PM,Diagnostic,455,1,NDP,Brighton and Sussex Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1B,7/23/1981,,"glioblastoma, IDH-wildtype, mesenchymal type",0.68,GBM_MES,0.76,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3430,"Glioblastoma, CNS WHO grade 4

IDH1 (R132H IHC): No mutation      
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, [typical mesenchymal type]
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 455\NH22-3430,0.046,-0.004,0.014,-0.042,-0.057,-0.021,0.066,0.276,0.348,0.375,0.241,0.013,0.021,0.106,0.086,0.032,0.045,-0.094,0,0.028,0.007,0.057,0.04,0.011,0.109,0.033,-0.104,-0.019,0.033,methylated
NH22-3630,206667650105_R02C01,456,8/12/2022,12/21/2022,12/21/2022,13,PM,Diagnostic,456,1,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,11/7/1969,,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.39,GBM_RTKII,0.85,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3630,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma with features suggestive of glioblastoma.
Methylation profile: Diffuse paediatric-type high grade glioma, RTK2 subtype, subclass B (novel)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 456\NH22-3630,-0.166,-0.008,0.028,0.037,-0.051,-0.012,-0.093,0.232,0.237,0.245,0.196,-0.013,0.059,-0.068,0.002,-0.008,-0.26,-0.285,-0.056,-0.036,0.72,0.071,-0.293,-0.292,0.04,-0.063,-0.451,-0.023,0.054,methylated
NH22-3629,206667650105_R03C01,456,8/12/2022,12/21/2022,12/21/2022,13,PM,Diagnostic,456,1,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,8/25/1975,,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.51,GBM_RTKII,0.8,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3629,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Diffuse paediatric--type high-grade glioma, RTK2 subtype, subclass B
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 456\NH22-3629,0.239,-0.016,0.032,0.006,-0.006,0.04,-0.272,0.162,0.241,0.233,0.165,0.005,-0.003,0.017,-0.372,-0.018,-0.984,-0.314,0,0.035,0.02,-0.008,-0.016,0.028,0.048,0.003,-0.066,-0.284,-0.274,unmethylated
NH22-3628,206667650105_R04C01,456,8/12/2022,12/21/2022,12/21/2022,13,PM,Diagnostic,456,1,NDP,Nottingham University Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/29/1975,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3628,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, low grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 456\NH22-3628,0.006,-0.034,0.052,-0.003,-0.006,0.013,0.012,0.007,-0.011,-0.008,0.015,0.012,0.026,0.013,0.016,-0.007,0.011,-0.004,-0.015,0.009,-0.008,-0.046,-0.046,0.001,-0.011,0.128,0.026,0.009,-0.008,methylated
NH22-3602,206667650105_R05C01,456,8/12/2022,12/21/2022,12/21/2022,13,PM,Diagnostic,456,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,11/5/1985,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3602,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 456\NH22-3602,-0.01,-0.035,0.005,-0.001,0.036,-0.015,-0.038,-0.016,-0.021,-0.03,0.021,0.05,0.022,0.13,-0.038,0.001,0.033,-0.024,0.029,-0.011,-0.036,-0.066,-0.114,0.028,0.029,0.132,0.019,0.025,0.027,methylated
NH22-3377,206667650105_R06C01,456,8/12/2022,12/21/2022,12/21/2022,13,PM,Diagnostic,456,1,NDP,Southampton General Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,2/24/1987,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3377,"Astrocytoma, IDH-mutant, CNS WHO grade 4
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)     
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 456\NH22-3377,0.061,-0.06,0.021,-0.062,0.032,-0.234,-0.025,0.004,0.03,-0.04,0.097,0.03,0.033,0.13,0.005,0.031,0.018,0.109,0.03,-0.014,-0.04,-0.089,-0.334,0.047,0.024,-0.018,-0.001,0.062,0.057,methylated
NH22-3626,206667650105_R07C01,456,8/12/2022,12/21/2022,12/21/2022,13,PM,Diagnostic,456,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B3,5/16/1974,,"glioblastoma, IDH-wildtype, RTK2 type",0.35,GBM_RTKII,0.79,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3626,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 456\NH22-3626,0.176,-0.11,0.058,-0.051,-0.055,0.043,-0.258,0.814,0.171,0.147,0.126,0.008,0.067,0.086,-0.754,-0.102,-0.328,-0.352,-0.023,0.05,0.032,0.043,-0.063,0.061,0.053,0.001,-0.076,0.033,0.112,unmethylated
NH22-3619,206667650105_R08C01,456,8/12/2022,12/21/2022,12/21/2022,13,PM,Diagnostic,456,1,NDP,Nottingham University Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,2/16/1987,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3619,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3
Histology: High-grade glioma, IDH-mutant, CNS WHO grade 4
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 456\NH22-3619,-0.022,0.007,0.054,-0.059,-0.003,0.001,0.083,0.004,-0.041,-0.078,-0.023,0.016,0.058,0.077,-0.021,0.005,0.027,0.047,0.037,0.047,-0.002,-0.048,-0.036,0.039,-0.007,-0.023,-0.492,0.027,0.044,methylated
NH22-3620,206667650152_R01C01,457,8/12/2022,12/21/2022,12/21/2022,13,PM,Diagnostic,457,1,NDP,Nottingham University Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,7/8/1969,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3620,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted CNS WHO grade 2
Histology: Diffuse glioma, IDH-mutant, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 457\NH22-3620,0.039,-0.014,0.032,-0.012,0.006,-0.007,-0.056,0.012,0.034,-0.037,0.015,0.004,-0.016,0.065,0.083,-0.027,0.011,-0.02,0.024,0.06,0.043,0.049,-0.364,0.125,0.085,-0.036,-0.343,-0.01,0.067,methylated
NH22-3636,206667650152_R04C01,457,9/12/2022,12/21/2022,12/21/2022,12,PM,Diagnostic,457,3,NDP,Romford,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,3/26/1992,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.79,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3636,"Astrocytoma, IDH-mutant, CNS WHO grade 3
IDH1 (R132H IHC): Mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, low grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 457\NH22-3636,0.058,-0.049,0.056,-0.066,-0.007,0.029,0.061,-0.029,-0.064,-0.122,-0.027,0.011,0.026,0.397,0.011,-0.134,-0.279,-0.231,0.018,0.007,-0.002,-0.044,-0.049,0.033,0.015,-0.038,-0.002,0.029,0.02,methylated
NH22-3658,206667650152_R07C01,457,9/12/2022,12/21/2022,12/21/2022,12,PM,Diagnostic,457,2,NDP,"Cardiff, University Hospital",Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,4/22/1983,,myxopapillary ependymoma,0.92,EPN_MPE,0.99,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3658,"Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 457\NH22-3658,0.024,-0.049,0.036,-0.049,-0.047,0.162,0.008,0.089,0.162,0.104,0.078,-0.015,0.06,0.029,0.248,0.227,0.035,-0.015,0.066,-0.036,-0.016,0.048,0.037,0.109,0.158,0.093,0.074,-0.03,-0.012,unmethylated
NH22-3673,207134810057_R01C01,458,12/12/2022,12/23/2022,12/22/2022,10,PM,Diagnostic,458,1,NDP,"Birmingham, Queen Elizabeth Hospital",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/26/1965,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.99,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3673,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 458\NH22-3673,0.03,0.036,0.053,-0.061,0.012,0.064,0.041,0.065,0.107,0.008,0.062,-0.02,0.036,0.105,-1.752,-0.002,-0.229,-0.288,-0.038,-0.073,-0.094,-0.112,-0.053,-1.72,0.089,0.009,-0.516,-0.238,-0.171,methylated
NH22-3657,207134810057_R02C01,458,9/12/2022,12/23/2022,12/22/2022,13,PM,Diagnostic,458,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,7/19/1983,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3657,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, low grade
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 458\NH22-3657,0.006,-0.009,0.085,-0.035,-0.005,-0.037,-0.08,0.093,-0.031,0.108,0.207,-0.018,0.045,-0.033,0.058,0.006,0.072,-0.111,0.069,0.023,0.037,0.025,0.002,0.069,0.008,0.09,-0.056,0.014,0.053,unmethylated
NH22-3651,207134810057_R03C01,458,9/12/2022,12/23/2022,12/22/2022,13,PM,Diagnostic,458,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,5/27/1991,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3651,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, high-grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 458\NH22-3651,0.157,0.362,0.08,0.033,0.122,-0.427,-0.022,0.047,0.07,-0.07,0.003,0.006,0.038,0.171,-0.438,0.439,-0.481,-0.655,0.151,0.475,0.018,0.028,-0.051,0.142,0.068,0.049,0.08,-0.339,-0.236,methylated
NH22-3652,207134810057_R06C01,458,12/12/2022,12/23/2022,12/22/2022,10,PM,Diagnostic,458,3,NDP,Royal London Hospital,Glioma IDH mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,6/25/1981,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.96,OIDH,0.99,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3652,"Glioma, IDH mutant, CNS WHO grade 3 - see comment
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3 
Histology: Glioma, IDH-mutant, CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 458\NH22-3652,-0.013,0.004,0.023,-0.006,-0.035,0.032,-0.017,0.037,-0.02,-0.082,0.003,0.002,0.026,-0.011,0.041,-0.003,-0.017,-0.006,-0.012,-0.007,-0.04,-0.019,-0.091,0.047,-0.019,-0.016,-0.362,0.01,0.003,methylated
NH22-3672,207134810057_R08C01,458,12/12/2022,12/23/2022,12/22/2022,10,PM,Diagnostic,458,1,NDP,Oxford John Radcliffe Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SH1327,8/3/1977,,pleomorphic xanthoastrocytoma(-like),0.98,PXA,0.9,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3672,"Integrated diagnosis: High-grade glioma, BRAF mutant, at least CNS WHO grade 3, see comment
Histology: Poorly differentiated intrinsic tumour, NOS
Methylation profile: Pleomorphic xanthoastrocytoma
MGMT promoter (Illumina array): Unmethylated Methylated 
  
BRAF (V600E): Mutation

",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 458\NH22-3672,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3677,207134810130_R02C01,459,12/12/2022,1/5/2023,1/5/2023,24,PM,Diagnostic,459,1,NDP,"Liverpool, The Walton Centre",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,7/1/1991,,posterior fossa ependymoma group A1,0.07,GBM_MES,0.07,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3677,"Integrated diagnosis: Gliotic tissue - see comment
Histology: Gliotic tissue
Methylation profile: No matching methylation class
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 459\NH22-3677,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NU14-61,207134810130_R03C01,459,13/12/2022,1/5/2023,1/5/2023,23,PM,Diagnostic,459,1,NDP,Romford,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,3/27/1956,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.98,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NU14-61,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 459\NU14-61,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3294,207134810130_R04C01,459,14/12/2022,1/5/2023,1/5/2023,22,PM,Diagnostic,459,1,NDP,"Liverpool, The Walton Centre",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1C,2/27/1987,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3294,"Astrocytoma, IDH-mutant, CNS WHO grade 2 - see comment
IDH1 (R132H IHC): Mutation     
ATRX (IHC): Loss of expression (indicates mutation)
CDKN2A/B: No deletion     
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 459\NH22-3294,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3698,207134810130_R05C01,459,14/12/2022,1/5/2023,1/5/2023,22,PM,Diagnostic,459,1,NDP,"Liverpool, The Walton Centre",Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,11/23/1960,,"glioblastoma, IDH-wildtype, mesenchymal type",0.41,LGG_GG,0.12,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3698,"Integrated diagnosis: Suggestive of glioblastoma, IDH-wildtype, CNS WHO grade 4 - see comment
Histology: Infiltration zone of glioma
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 459\NH22-3698,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3692,207134810107_R01C01,460,15/12/2022,1/5/2023,1/5/2023,21,PM,Diagnostic,460,1,NDP,"Cardiff, University Hospital",IDH mutant glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,11/21/1963,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.96,AIDH,0.98,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3692,"Integrated diagnosis: Astrocytoma, IDH-mutant (see comment)
Histology: Glioma / astrocytoma
Methylation profile: Astrocytoma, IDH-mutant (see comment)
MGMT promoter (Illumina array): Methylated   
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 460\NH22-3692,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3694,207134810107_R02C01,460,15/12/2022,1/5/2023,1/5/2023,21,PM,Diagnostic,460,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,10/14/1986,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.85,AIDH,0.94,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3694,"Integrated diagnosis: Astrocytoma, IDH-mutant, favouring CNS WHO grade 2
Histology: Astrocytoma
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 460\NH22-3694,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3695,207134810107_R03C01,460,15/12/2022,1/5/2023,1/5/2023,21,PM,Diagnostic,460,1,NDP,James Cook,?Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,4/19/1991,,supratentorial pilocytic astrocytoma,0.62,LGG_PA_GGST,0.35,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3695,"Integrated diagnosis: Low-grade glioma / glioneuronal tumour (see comment)
Histology: Low-grade glioma / glioneuronal tumour 
Methylation profile: Classified with low calibrated scores, but supportive of a low-grade glial / glioneuronal / neuroepithelial tumour (see report and comment)
MGMT promoter (Illumina array): Unmethylated  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 460\NH22-3695,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3502,207134810107_R04C01,460,16/12/2022,1/5/2023,1/5/2023,20,PM,Diagnostic,460,4,NDP,Latvia,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3733-32/22,#N/A,,rosette-forming glioneuronal tumour,0.95,LGG_RGNT,0.49,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3502,"Integrated diagnosis: Low grade glial/glioneuronal tumour, compatible with rosette-forming glioneuronal tumour, CNS WHO grade 1
Histology: Low grade glial/glioneuronal tumour, CNS WHO grade 1
Methylation profile: Rosette forming glioneuronal tumour
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 460\NH22-3502,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3713,207134810107_R06C01,460,19/12/2022,1/5/2023,1/5/2023,17,PM,Diagnostic,460,1,NDP,Cleveland Clinic London,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF4A,8/2/1970,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.24,AIDH_HG,0.55,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3713,"Glioma, at least CNS WHO grade 3 - see comment
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Possible loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Pending
Histology: Glioma, at least CNS WHO grade 3 
Methylation profile: Classified with low confidence, but suggests adult-type diffuse glioma
MGMT promoter (Illumina array): Methylated 
Further molecular tests (NGS): Pending 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 460\NH22-3713,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3740,207134810017_R02C01,461,22/12/2022,1/11/2023,1/11/2023,20,PM,Diagnostic,461,3,NDP,Royal London Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,10/2/1987,,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.74,DMG_K27,0.63,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3740,"Glioma - see comment
","Integrated diagnosis: Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4 (see comment)
Histology: High-grade glioma
Methylation profile: Diffuse midline glioma, H3 K27-altered, subtype H3 K27-mutant or EZHIP expressing (low calibrated score)
Next generation sequencing (DNA): Mutations in H3F3A, FGFR1, 
MGMT promoter (Illumina array): Unmethylated  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 461\NH22-3740,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3746,207134810017_R04C01,461,22/12/2022,1/11/2023,1/11/2023,20,PM,Diagnostic,461,5,NDP,Oxford John Radcliffe Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2B,3/7/1986,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.55,AIDH_HG,0.65,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3746,"Integrated diagnosis: 
Histology: Favouring Astrocytoma, IDH-mutant (see comment)
Methylation profile: Astrocytoma, IDH-mutant; high grade (low calibrated score)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 461\NH22-3746,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3163,207134810017_R06C01,461,22/12/2022,1/11/2023,1/11/2023,20,PM,Diagnostic,461,2,NDP,St George's Hospital London,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,,high-grade astrocytoma with piloid features,0.95,ANAPA,0.69,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3163,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
Histology: High-grade glioma
Methylation profile: IDH glioma, subclass 1p/19q codeleted oligodendroglioma

MGMT promoter (Illumina array): Methylated 
  
",0,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 461\NH22-3163,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3774,207134810011_R02C01,462,22/12/2022,1/11/2023,1/11/2023,20,PM,Diagnostic,462,1,NDP,St George's Hospital London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.88,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3774,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained     
EGFR: Amplification          
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype
MGMT promoter (Illumina array and MS PCR): Unmethylated  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 462\NH22-3774,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3775,207134810011_R03C01,462,22/12/2022,1/11/2023,1/11/2023,20,PM,Diagnostic,462,8,NDP,NHNN,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,10/2/1980,,"glioblastoma, IDH-wildtype, mesenchymal type",0.82,PXA,0.5,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3775,"High grade glial tumour, BRAF V600 mutant

IDH1 (R132H IHC): No mutation       
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Favouring Glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment)
Histology: High-grade glioma
BRAF V600E: Mutant
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal type (low calibrated score)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 462\NH22-3775,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3778,207134810011_R04C01,462,22/12/2022,1/11/2023,1/11/2023,20,PM,Diagnostic,462,1,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.31,AIDH,0.16,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3778,"Integrated diagnosis: Deferred to the referring centre
Histology: Glioma (see comment)
Methylation profile: Classified with low calibrated score (see comment)
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 462\NH22-3778,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3782,207134810011_R05C01,462,22/12/2022,1/11/2023,1/11/2023,20,PM,Diagnostic,462,1,NDP,Nottingham University Hospital,IDH mutant glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3782,"Integrated diagnosis: Favouring Astrocytoma, IDH-mutant (see comment)
Histology: Glioma (see comment)
Methylation profile: Astrocytoma, IDH-mutant; lower grade
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 462\NH22-3782,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3784,207134810011_R07C01,462,22/12/2022,1/11/2023,1/11/2023,20,PM,Diagnostic,462,1,NDP,"Liverpool, The Walton Centre",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1A,#N/A,,posterior fossa ependymoma group B,1,EPN_PFB,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3784,"Integrated diagnosis: Posterior fossa group B (PFB) ependymoma
Histology: Ependymal tumour
Methylation profile: Posterior fossa group B (PFB) ependymoma, subclass 3
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 462\NH22-3784,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3777,207134810011_R08C01,462,22/12/2022,1/11/2023,1/11/2023,20,PM,Diagnostic,462,4,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,4/3/1955,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3777,"Oligodendroglioma, CNS WHO grade 2

IDH1 (R132H IHC): Mutation      
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2 (see comment)
Histology: Oligodendroglioma, CNS WHO grade 2 
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted 

MGMT promoter (Illumina array): Methylated  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 462\NH22-3777,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3761,207134810005_R01C01,463,22/12/2022,1/13/2023,1/13/2023,22,PM,Diagnostic,463,3,NDP,Romford,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,10/3/1968,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.98,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3761,"Astrocytoma, IDH mutant, CNS WHO (Grade 3 - see comment)

IDH1 (R132H IHC):Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, high grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 463\NH22-3761,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3795,207134810005_R06C01,463,22/12/2022,1/13/2023,1/13/2023,22,PM,Diagnostic,463,1,NDP,Nottingham University Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,,"Diffuse hemispheric glioma, H3 G34-mutant",0.91,GBM_G34,0.95,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3795,"Integrated diagnosis: Diffuse hemispheric glioma, H3 G34-mutant, CNS WHO grade 4
Histology: High grade, primitive intrinsic tumour
Methylation profile: Diffuse hemispheric glioma, H3 G34-mutant
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 463\NH22-3795,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3803,207134810005_R07C01,463,22/12/2022,1/13/2023,1/13/2023,22,PM,Diagnostic,463,3,NDP,Cleveland Clinic London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2B,10/28/1980,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.79,AIDH,0.74,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3803,"Astrocytoma, IDH1 mutant, CNS WHO grade 4

IDH1 (R132H IHC): Mutation
ATRX (IHC): Probable loss of expression (indicates mutation)
Further molecular tests: Pending
  
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant (see comment0
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 463\NH22-3803,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3763,207134810005_R08C01,463,23/12/2022,1/13/2023,1/13/2023,21,PM,Diagnostic,463,5,NDP,NHNN,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,6/10/1962,,supratentorial pilocytic astrocytoma,0.94,LGG_PA_GGST,0.67,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3763,"Low grade glial/glioneuronal tumour (CNS WHO Grade 1) - see comment
","Integrated diagnosis: Supratentorial pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glial/glioneuronal tumour, CNS WHO grade 1
Methylation profile: Supratentorial pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 463\NH22-3763,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3797,207134810056_R01C01,464,23/12/2022,1/13/2023,1/13/2023,21,PM,Diagnostic,464,1,NDP,"Cambridge, Addenbrooke's Hospital",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,#N/A,,"glioblastoma, IDH-wildtype, mesenchymal type",0.74,GBM_MES,0.54,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3797,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Giant cell glioblastoma
Methylation profile: Glioblastoma, IDH-wildtype, mesenchymal subtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 464\NH22-3797,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3798,207134810056_R02C01,464,23/12/2022,1/13/2023,1/13/2023,21,PM,Diagnostic,464,1,NDP,"Cambridge, Addenbrooke's Hospital",PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,#N/A,,"glioblastoma, IDH-wildtype, mesenchymal type",0.87,PXA,0.87,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3798,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 464\NH22-3798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3800,207134810056_R03C01,464,23/12/2022,1/13/2023,1/13/2023,21,PM,Diagnostic,464,1,NDP,"Belfast, Royal Victoria Hospital",Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.95,OIDH,0.49,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3800,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
Histology: Diffuse high-grade glioma, IDH mutant
Methylation profile: See comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 464\NH22-3800,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3822,207134810056_R08C01,464,23/12/2022,1/13/2023,1/13/2023,21,PM,Diagnostic,464,1,NDP,Oxford John Radcliffe Hospital,Diffuse glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2,11/12/1941,,"glioblastoma, IDH-wildtype, RTK2 type",0.82,GBM_RTKII,0.8,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3822,"In keeping with Glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment)
IDH1/2Seq: No mutation
ATRX (IHC): Retained (Oxford) 
1p/19q: Retained          
EGFR: Amplification          
CDKN2A: Deletion
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%) 
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Diffuse glioma, high grade
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 464\NH22-3822,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3817,207134810072_R02C01,465,23/12/2022,1/18/2023,1/18/2023,26,PM,Diagnostic,465,1,NDP,Colombia,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,#N/A,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.92,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3817,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
MGMT promoter (Illumina array): Unmethylated  
","Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
MGMT Promoter: Unmethylated (0%)

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 465\NH22-3817,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3833,207134810072_R05C01,465,23/12/2022,1/18/2023,1/18/2023,26,PM,Diagnostic,465,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B3,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.77,AIDH_HG,0.83,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3833,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, copy number profile suggestive of CDKN2A/B deletion
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 465\NH22-3833,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3765,207134810072_R06C01,465,23/12/2022,1/18/2023,1/18/2023,26,PM,Diagnostic,465,1,NDP,Cleveland Clinic London,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF3A,1/4/1999,,ganglioglioma,0.95,LGG_GG,0.63,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3765,"Low grade glial/glioneuronal tumour - see comment
","Integrated diagnosis: Ganglioglioma, CNS WHO grade 1
Histology: Low grade glial/glioneuronal tumour, favouring ganglioglioma, CNS WHO grade 1
Methylation profile: Ganglioglioma
Next generation sequencing (DNA): No mutation detected
Next generation sequencing (RNA): No fusions detected
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 465\NH22-3765,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3707,207134810071_R02C01,466,29/12/2022,1/18/2023,1/18/2023,20,MD,Diagnostic,466,2,NDP,Romford,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,4/26/1937,,"glioblastoma, IDH-wildtype, RTK2 type",0.92,GBM_RTKII,0.89,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3707,"Glioblastoma, CNS WHO grade 4
IDH1 (R132H IHC): No mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending
  
","[REVISED] Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment)
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 466\NH22-3707,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3849,207134810071_R05C01,466,29/12/2022,1/18/2023,1/18/2023,20,MD,Diagnostic,466,1,NDP,"Liverpool, The Walton Centre",?Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",7A,#N/A,,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type B]",1,GBM_MID,0.49,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3849,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Diffuse high-grade glioma, NOS
Methylation profile: Adult-type diffuse high-grade glioma, IDH-wildtype, subtype B
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 466\NH22-3849,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3857,207134810071_R06C01,466,29/12/2022,1/18/2023,1/18/2023,20,MD,Diagnostic,466,1,NDP,Auckland (NZ),Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1A,#N/A,,spinal ependymoma,1,EPN_SPINE,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3857,"Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Ependymoma, CNS WHO grade 2
Methylation profile: Spinal ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 466\NH22-3857,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3852,207134810071_R07C01,466,29/12/2022,1/18/2023,1/18/2023,20,MD,Diagnostic,466,1,NDP,"Liverpool, The Walton Centre",Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1H,6/29/1990,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH22-3852,"Astrocytoma, IDH-mutant (see comment)
IDH1/2Seq: Mutation     
ATRX (IHC): Loss of expression (indicates mutation)     
1p/19q: Retained          
CDKN2A/B: No deletion     
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, grading see comment
Methylation profile: Astrocytoma, IDH-mutant
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 466\NH22-3852,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3854,207134810071_R08C01,466,29/12/2022,1/18/2023,1/18/2023,20,MD,Diagnostic,466,1,NDP,Oxford John Radcliffe Hospital,Atypical meningioma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2B,#N/A,,"glioblastoma, IDH-wildtype, mesenchymal type",0.61,MNG,0.26,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3854,"Integrated diagnosis: Anaplastic meningioma, CNS WHO grade 3, CDKN2A/B deletion
Histology: Anaplastic meningioma, CNS WHO grade 3
Methylation profile: Inconclusive (see comments)
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 466\NH22-3854,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3856,207134810135_R01C01,467,29/12/2022,1/20/2023,1/20/2023,22,MD,Diagnostic,467,1,NDP,Auckland (NZ),Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",2A,#N/A,,posterior fossa subependymoma,1,SUBEPN_PF,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3856,"Integrated diagnosis: Posterior fossa subependymoma, with high risk features (see comment) 
Histology: Ependymoma
Methylation profile: posterior fossa subependymoma, see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 467\NH22-3856,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3811,207134810135_R02C01,467,29/12/2022,1/20/2023,1/20/2023,22,MD,Diagnostic,467,1,NDP,Wellington Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,10/25/2000,,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3811,"High grade glial tumour - see comments
","Integrated diagnosis: Supratentorial ependymoma, ZFTA fusion-positive, CNS WHO grade 3
Histology: High-grade glial tumour, with features suggestive of supratentorial ependymoma
Methylation profile: : Supratentorial ependymoma, ZFTA fusion-positive, subtype ZFTA-RELA fused 
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 467\NH22-3811,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3823,207134810135_R03C01,467,29/12/2022,1/20/2023,1/20/2023,22,MD,Diagnostic,467,1,NDP,Romford,Myxopapillary ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,6/22/1951,,myxopapillary ependymoma,1,EPN_MPE,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3823,"Myxopapillary ependymoma, CNS WHO Grade 2
","Integrated diagnosis: Myxopapillary ependymoma, CNS WHO grade 2
Histology: Myxopapillary ependymoma, CNS WHO grade 2
Methylation profile: Myxopapillary ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 467\NH22-3823,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3843,207134810135_R06C01,467,29/12/2022,1/20/2023,1/20/2023,22,MD,Diagnostic,467,1,NDP,Southampton General Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1F,#N/A,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.87,OIDH,0.97,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3843,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, CNS WHO grade 2
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 467\NH22-3843,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3848,207134810135_R07C01,467,29/12/2022,1/20/2023,1/20/2023,22,MD,Diagnostic,467,1,NDP,"Liverpool, The Walton Centre",Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,#N/A,,high-grade astrocytoma with piloid features,1,ANAPA,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3848,"Integrated diagnosis: High-grade astrocytoma with piloid features (grading see comment)
Histology: High grade glioma
Methylation profile: High-grade astrocytoma with piloid features
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 467\NH22-3848,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3710,207134810111_R02C01,468,30/12/2022,1/20/2023,1/20/2023,21,PM,Diagnostic,468,1,NDP,Gencell,Oligodendroglioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2,#N/A,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3710,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2
Histology: Oligodendroglioma, IDH-mutant
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-and codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 468\NH22-3710,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3871,207134810111_R03C01,468,30/12/2022,1/20/2023,1/20/2023,21,PM,Diagnostic,468,1,NDP,"Liverpool, The Walton Centre",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.25,AIDH,0.29,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3871,"Integrated diagnosis: Astrocytoma, IDH-mutant, grading see comment
Histology: Astrocytoma, IDH-mutant (grading see comment)
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 468\NH22-3871,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH22-3888,207134810111_R07C01,468,30/12/2022,1/20/2023,1/20/2023,21,PM,Diagnostic,468,1,NDP,Oxford John Radcliffe Hospital,Pineal tumour?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1428,#N/A,,posterior fossa ependymoma group A1,0.11,HMB,0.09,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3888,"Integrated diagnosis: Gliotic CNS tissue or low-grade glial tumour, biopsy non-diagnostic
Histology: Gliotic CNS tissue or low-grade glial tumour
Methylation profile: Inconclusive methylation and copy number profile
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 468\NH22-3888,0.092,-0.381,0.058,0.063,-0.192,-0.025,-0.079,-0.115,-0.019,-0.051,-0.04,-0.002,-0.029,0.005,-0.152,-0.103,-0.012,-0.044,-0.036,-0.259,-0.016,0.182,-0.114,-0.058,-0.088,0.191,0.065,-0.254,0.099,unmethylated
NH22-3897,207129210008_R01C01,469,4/1/2023,1/25/2023,1/25/2023,21,PM,Diagnostic,469,1,NDP,"Liverpool, The Walton Centre",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,#N/A,,pleomorphic xanthoastrocytoma(-like),0.4,GBM_MES,0.45,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3897,"Integrated diagnosis: Pleomorphic xanthoastrocytoma, CNS WHO grade 3
Histology: Pleomorphic xanthoastrocytoma, CNS WHO grade 3
Methylation profile: Pleomorphic xanthoastrocytoma (low calibrated score)
MGMT promoter (Illumina array): Unmethylated Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 469\NH22-3897,-0.028,0.137,0.108,0.111,0.229,0.329,-0.054,0.226,0.315,0.318,0.287,0.187,0.177,0.198,-0.099,-0.094,-0.101,-0.087,0,0.067,0.149,0.034,-0.463,-0.024,-0.117,-0.119,0.33,-0.078,0.003,unmethylated
NH22-3899,207129210008_R03C01,469,4/1/2023,1/25/2023,1/25/2023,21,PM,Diagnostic,469,1,NDP,"Birmingham, Queen Elizabeth Hospital",Diffuse glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C1,#N/A,,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",1,LGG_MYB,0.24,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3899,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: CNS with diffuse infiltration of a glial tumour
Methylation profile: Adult-type diffuse high grade glioma, IDH-wildtype, subtype F
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 469\NH22-3899,-0.068,0.064,0.075,0.027,-0.003,-0.048,-0.025,-0.003,-0.013,-0.077,-0.026,0.003,0.028,-0.014,0.046,-0.022,-0.014,-0.005,-0.048,-0.037,0.05,0.049,0.046,0.091,0.044,0.067,0.004,0.027,0.004,unmethylated
NH22-3903,207129210008_R04C01,469,4/1/2023,1/25/2023,1/25/2023,21,PM,Diagnostic,469,1,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,#N/A,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3903,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 469\NH22-3903,0.241,0.122,0.102,-0.107,0.128,0.105,-0.064,0.125,0.172,0.151,0.167,0.026,0.023,0.103,-0.203,-0.233,-0.183,-0.238,-0.137,0.045,0.601,-0.321,-0.168,0.051,0.088,0,-0.28,-0.145,-0.179,methylated
NH22-3918,207129210008_R05C01,469,5/1/2023,1/25/2023,1/25/2023,20,PM,Diagnostic,469,1,NDP,"Birmingham, Queen Elizabeth Hospital",Diffuse glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,,ganglioglioma,0.15,GBM_MES,0.47,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3918,"Integrated diagnosis: Cortical infiltration of glioblastoma, IDH-wildtype, CNS WHO Grade 4
Histology: Infiltration of a diffuse glioma
Methylation profile: Glioblastoma, mesenchyma subtype
MGMT promoter (Illumina array): Unmethylated
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 469\NH22-3918,-0.049,0.017,0.057,0.046,0.039,-0.047,-0.324,0.227,0.096,0.102,0.125,-0.001,0.012,0.008,0.041,-0.047,-0.269,-0.316,-0.056,-0.063,-0.062,0.053,-0.008,0.003,-0.057,-0.037,0.038,-0.198,-0.224,unmethylated
NH22-3915,207129210008_R06C01,469,6/1/2023,1/25/2023,1/25/2023,19,PM,Diagnostic,469,1,NDP,"Birmingham, Queen Elizabeth Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",D1,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3915,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 469\NH22-3915,0.006,0.025,0.051,-0.004,0.058,-0.004,-0.043,-0.043,-0.043,0.236,0.15,0.008,-0.004,0.117,0.032,-0.002,0.003,-0.012,-0.001,0.128,-0.047,-0.024,-0.071,0.048,-0.006,-0.02,0.07,0.048,0.034,methylated
NH22-3916,207129210008_R07C01,469,6/1/2023,1/25/2023,1/25/2023,19,PM,Diagnostic,469,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A15,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.98,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3916,"Integrated diagnosis: Astrocytoma, IDH-mutant, grading see comment
Histology: Astrocytoma, grading see comment
Methylation profile: Astrocytoma, IDH-mutant, low grade
MGMT promoter (Illumina array): Unmethylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 469\NH22-3916,-0.004,-0.057,0.066,-0.043,0.017,-0.007,0.029,0,-0.049,-0.106,-0.03,-0.002,0.059,0.017,0.045,0.043,0.012,0.02,0.019,-0.014,-0.008,-0.028,-0.03,0.02,-0.6,-0.051,-0.033,0.008,0.029,unmethylated
NH23-5,207129210014_R01C01,470,6/1/2023,1/25/2023,1/25/2023,19,PM,Diagnostic,470,1,NDP,"Liverpool, The Walton Centre",Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",734,#N/A,,supratentorial pilocytic astrocytoma,0.29,LGG_PA_GGST,0.28,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-5,"Integrated diagnosis: Low grade glioma, suggestive of supratentorial pilocytic astrocytoma
Histology: Low grade glioma/glioneuronal tumour
Methylation profile: Supratentorial pilocytic astrocytoma (low calibrated score, see comment)
MGMT promoter (Illumina array): Unmethylated
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 470\NH23-5,-0.056,-0.143,0.038,-0.073,-0.097,0.079,-0.147,0.028,-0.034,-0.053,0.123,0.081,0.512,-0.01,-0.169,0.019,0.046,0.05,0.143,-0.145,-0.164,0.048,-0.187,-0.103,0.12,0.136,0.302,0.095,0.167,unmethylated
NH23-20,207129210014_R02C01,470,6/1/2023,1/25/2023,1/25/2023,19,PM,Diagnostic,470,1,NDP,"Birmingham, Queen Elizabeth Hospital",Pilocytic astrocytoma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B3,#N/A,,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.88,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-20,"Integrated diagnosis: Supratentorial pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glioma, in keeping with pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Supratentorial pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 470\NH23-20,0.016,0.037,0.044,-0.062,-0.072,0.047,-0.061,-0.018,0.082,0.013,0.071,0.059,0.093,0.121,-0.061,-0.092,0.046,0.014,0.055,-0.071,-0.034,-0.071,-0.056,0.019,-0.017,0.002,0.026,-0.018,-0.007,unmethylated
NH23-22,207129210014_R03C01,470,6/1/2023,1/25/2023,1/25/2023,19,PM,Diagnostic,470,1,NDP,"Liverpool, The Walton Centre",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,#N/A,,supratentorial midline pilocytic astrocytoma,0.72,LGG_PAMID,0.64,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-22,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glioma, with features compatible with pilocytic astrocytoma
Methylation profile: Supratentorial midline pilocytic astrocytoma
MGMT promoter (Illumina array): Methylated 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 470\NH23-22,0.071,0.034,0.048,-0.094,-0.106,-0.062,-0.021,-0.029,-0.02,-0.064,-0.03,0.024,0.063,0.098,-0.003,0.106,0.016,0,0.095,0.011,0.037,0.084,-0.13,0.104,0.038,0.023,-0.025,-0.116,-0.039,methylated
NH22-3875,207129210014_R04C01,470,6/1/2023,1/25/2023,1/25/2023,19,PM,Diagnostic,470,1,NDP,"Charing Cross Hospital, London",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,7/25/1992,,"glioblastoma, IDH-wildtype, RTK1 type",0.99,GBM_RTKI,0.73,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3875,"Glioblastoma, CNS WHO grade 4 
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
MGMT promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 470\NH22-3875,-0.055,-0.118,0.005,-0.049,-0.026,-0.004,0.026,0.114,0.098,0.105,0.073,-0.005,0.02,-0.031,0.172,0.124,-0.2,-0.238,-0.037,-0.043,0.607,1.386,-0.292,-0.017,-0.014,-0.086,0.17,0.022,0.03,unmethylated
NH23-9,207129210120_R04C01,471,9/1/2023,2/1/2023,2/1/2023,23,PM,Diagnostic,471,2,NDP,Romford,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,9/1/1958,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.99,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-9,"High grade glioma, at least CNS WHO grade 3 - see comment.
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma at least CNS WHO grade 3
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 471\NH23-9,-0.001,0.005,0.008,-0.057,0.053,0.049,0.033,1.312,0.478,0.42,0.341,-0.009,0.09,0.056,-1.507,0,-0.301,-0.426,0.045,0.049,0.028,0.076,0.045,0.271,0.336,0.254,-0.1,0.008,0.053,methylated
NH23-30,207129210120_R06C01,471,9/1/2023,2/1/2023,2/1/2023,23,PM,Diagnostic,471,1,NDP,St George's Hospital London,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.99,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-30,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, (IDH-mutant), CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, low grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 471\NH23-30,0.135,-0.037,0.043,0.025,0.026,-0.224,-0.636,0.094,0.024,0.038,0.07,0.002,0.005,0.109,-0.073,0.076,0.051,-0.095,0.314,0.049,0.035,0.031,-0.535,0.158,0.129,0.073,-0.072,-0.409,-0.26,methylated
NH23-32,207129210120_R07C01,471,9/1/2023,2/1/2023,2/1/2023,23,PM,Diagnostic,471,1,NDP,St George's Hospital London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.56,AIDH_HG,0.55,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-32,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4 with CDKN2A/B mutation
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3 (transition to 4, see comment)
Methylation profile: Astrocytoma, IDH-mutant, see comment
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 471\NH23-32,0.026,0.234,0.057,0.009,0.102,-0.497,-0.527,0.129,0.08,0.392,-0.005,-0.059,-0.067,0.351,-1.007,0.147,-0.06,-0.185,0.096,0.267,0.056,-0.008,-0.163,0.148,0.091,0.076,-0.448,-0.008,0.134,methylated
NH23-35,207129210120_R08C01,471,9/1/2023,2/1/2023,2/1/2023,23,PM,Diagnostic,471,1,NDP,"Liverpool, The Walton Centre",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1F,#N/A,,ganglioglioma,0.71,GBM_MES,0.68,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-35,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma, features in keeping with glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, see comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 471\NH23-35,-0.041,-0.162,-0.003,0.345,-0.054,0.1,-0.203,0.319,0.216,0.113,0.2,0.151,0.201,0.203,0.039,0.101,-0.029,-0.009,0.104,0.057,0.067,0.024,0.037,0.014,-0.085,-0.004,0.232,-0.114,-0.022,unmethylated
NH23-45,207129210002_R03C01,472,10/1/2023,2/1/2023,2/1/2023,22,PM,Diagnostic,472,1,NDP,NHNN,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,2/24/1996,,infratentorial pilocytic astrocytoma,0.79,LGG_PAPF,0.73,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-45,"Low grade glioma, most in keeping with pilocytic astrocytoma - see comment.
","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glioma, most in keeping with pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Infratentorial pilocytic astrocytoma (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 472\NH23-45,0.1,-0.104,0.011,-0.077,-0.08,-0.038,-0.052,-0.018,-0.017,-0.085,-0.034,-0.021,0.06,-0.015,-0.01,-0.065,0.035,0.024,-0.016,-0.063,-0.008,-0.021,0.005,0.05,0.035,-0.008,0.034,-0.015,0.02,unmethylated
NH22-3836,207129210002_R05C01,472,10/1/2023,2/1/2023,2/1/2023,22,PM,Diagnostic,472,10,NDP,Brighton and Sussex Hospital,Diffuse midline glioma H3K27M-mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,10/19/1987,,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.99,DMG_K27,0.99,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3836,"Diffuse midline glioma, H3 K27M-mutant, CNS WHO 4
","Integrated diagnosis: Diffuse midline glioma, H3K27-altered, CNS WHO grade 4
Histology: Diffuse midline glioma, H3K27-altered, CNS WHO grade 4
Methylation profile: Diffuse midline glioma, H3 K27-altered, subtype H3 K27-mutant or EZHIP expressing
Next generation sequencing (DNA): Mutations in ATRX, H3F3A, NF1, TP53.
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 472\NH22-3836,0.166,-0.053,0.015,-0.061,0.239,-0.04,-0.184,0.107,0.028,-0.178,-0.041,0.005,0.093,0.027,-0.325,0.104,0.019,-0.062,0.063,0.063,0.097,0.012,-0.298,0.13,0.107,0.021,-0.328,-0.023,-0.004,unmethylated
NH16-1137,207129210002_R06C01,472,12/1/2023,2/1/2023,2/1/2023,20,PM,Diagnostic,472,1,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,7/22/1972,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.91,OIDH,0.98,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-1137,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 472\NH16-1137,-0.113,-0.313,-0.15,-0.144,-0.06,0.084,-0.026,-0.042,-0.279,0.094,0.135,0.216,0.04,-0.091,-0.413,0.242,-0.05,-0.126,-0.017,-0.074,0.096,-0.2,-0.13,0.064,-0.237,-0.176,-0.239,0.265,0.196,methylated
NH22-3791,207129210002_R07C01,472,12/1/2023,2/1/2023,2/1/2023,20,PM,Diagnostic,472,1,NDP,Brighton and Sussex Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1B,5/3/1970,,"glioblastoma, IDH-wildtype, RTK2 type",0.4,GBM_RTKII,0.74,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH22-3791,"Glioblastoma, CNS WHO Grade 4

IDH1 (R132H IHC): No mutation      
ATRX (IHC): Retained      
Further molecular tests: Pending
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 472\NH22-3791,0.039,-0.003,0.013,0.013,0.243,-0.018,-0.007,0.895,0.38,0.335,0.286,0.001,0.091,0.016,0.025,-0.032,-0.67,-0.27,-0.065,-0.031,0.627,0.063,-0.03,0.047,0.104,0.016,0.176,-0.011,0,unmethylated
NH23-54,207129210002_R08C01,472,12/1/2023,2/1/2023,2/1/2023,20,PM,Diagnostic,472,1,NDP,Brighton and Sussex Hospital,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,3/29/1994,,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-54,"Pilocytic astrocytoma, CNS WHO grade 1 - see comment.
","Pilocytic astrocytoma, CNS WHO grade 1
KIAA1549-BRAF 16_9 Fusion
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 472\NH23-54,0.02,0.06,0.005,0.027,-0.028,0.027,0.025,-0.064,-0.015,0.018,0.214,-0.023,0.025,0.027,-0.006,0.008,-0.007,0.007,0.006,-0.083,-0.017,0.008,-0.054,0.006,0.016,0.01,0.052,0.001,0.02,unmethylated
NH23-60,207129210080_R01C01,473,12/1/2023,2/1/2023,2/1/2023,20,PM,Diagnostic,473,4,NDP,Cleveland Clinic London,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,7/22/1972,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-60,"Recurrent oligodendroglioma, IDH-mutant and 1p/19q codeleted, CNS WHO grade 3
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
1p/19q: Codeleted (see NH16-1137)
TERT promoter: Mutation (see NH16-1137) 

","Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3
Histology: Oligodendroglioma, IDH-mutant, CNS WHO grade 3
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 473\NH23-60,0.065,0.006,0.04,-0.298,-0.448,0.06,0.047,-0.019,0.038,-0.026,0.009,0.004,0.013,-0.042,-0.115,0.034,0.017,-0.021,0.184,-0.011,-0.044,0.025,-0.057,0.037,0.04,0.008,-0.425,-0.047,-0.004,methylated
NH23-70,207129210080_R03C01,473,12/1/2023,2/1/2023,2/1/2023,20,PM,Diagnostic,473,1,NDP,NHNN,Diffuse midline glioma H3K27M-mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,1/1/1962,,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.34,DMG_K27,0.73,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-70,"Diffuse midline glioma, H3 K27-altered - see comment.
","Integrated diagnosis: Diffuse midline gliomas, H3 K27M-altered, CNS WHO grade 4
Histology: Diffuse midline gliomas, H3 K27M-altered, CNS WHO grade 4
Methylation profile: Diffuse midline glioma, H3 K27-altered, subtype H3 K27-mutant or EZHIP expressing
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 473\NH23-70,-0.006,-0.015,0.051,0.054,0.359,-0.202,0.062,-0.066,0.004,-0.057,-0.052,0.009,0.073,0.036,0.121,-0.013,0.046,-0.053,0.003,-0.054,-0.049,0.013,-0.363,-0.396,-0.12,0.147,-0.118,0.036,0.073,unmethylated
NH23-81,207129210080_R08C01,473,12/1/2023,2/1/2023,2/1/2023,20,PM,Diagnostic,473,3,NDP,Brighton and Sussex Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,5/30/1968,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-81,"Astrocytoma, IDH-mutant, CNS WHO grade 2 - see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2 (grading see comment)
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 2 
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 473\NH23-81,-0.122,-0.007,0.127,-0.075,0.044,-0.032,-0.008,0.043,-0.058,-0.087,-0.01,0.023,0.055,0.019,-0.003,-0.009,-0.132,-0.117,0.047,0,-0.125,-0.255,-0.007,0.059,0,0.004,-0.024,0.05,0.026,methylated
NH23-63,207129210156_R01C01,474,12/1/2023,2/1/2023,2/1/2023,20,PM,Diagnostic,474,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B3,#N/A,,"glioblastoma, IDH-wildtype, mesenchymal type",0.97,CONTR_REACT,0.35,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-63,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, typical mesenchymal type
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 474\NH23-63,0.058,0.003,0.025,0.044,0.054,0.113,-0.068,0.163,0.229,0.277,0.233,-0.036,-0.014,0.016,-0.049,0.01,-0.038,-0.017,0.035,-0.069,0.085,1.561,-0.066,-0.03,0.006,0.033,0.137,-0.064,-0.034,unmethylated
NH23-84,207129210156_R02C01,474,12/1/2023,2/1/2023,2/1/2023,20,PM,Diagnostic,474,1,NDP,Oxford John Radcliffe Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",1B,#N/A,,"spinal ependymoma, MYCN-amplified",1,EPN_PFA,0.4,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-84,"Integrated diagnosis: Spinal ependymoma, MYCN amplified, CNS WHO grade 3
Histology: Ependymoma, CNS WHO grade 3
Methylation profile: Spinal ependymoma, MYCN amplified
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 474\NH23-84,-0.049,1.11,0.048,0.054,-0.004,0.094,0.09,-0.015,-0.019,0.033,-0.023,0.021,0.034,0.056,0.102,-0.023,-0.29,-0.359,0.102,0.047,0.057,0.078,-0.022,-0.025,-0.06,-0.043,-0.103,-0.04,-0.054,unmethylated
NH23-93,207129210156_R03C01,474,12/1/2023,2/1/2023,2/1/2023,20,PM,Diagnostic,474,1,NDP,Latvia,Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1-2.,#N/A,,ganglioglioma,0.99,LGG_GG,0.97,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-93,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 474\NH23-93,0.053,-0.108,-0.017,0.049,-0.093,0.085,-0.15,0.203,0.35,0.291,0.242,-0.028,0.06,0.104,0.16,0.167,0.046,-0.123,-0.084,0.22,0.185,0.239,0.181,0.055,0.058,0.025,0.036,-0.03,0.06,unmethylated
NH23-94,207129210156_R04C01,474,12/1/2023,2/1/2023,2/1/2023,20,PM,Diagnostic,474,1,NDP,Latvia,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",5285-6,#N/A,,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-94,"Integrated diagnosis: Pilocytic astrocytoma, with KIAA1549_BRAF fusion mutation, CNS WHO grade 1
Histology: Pilocytic astrocytoma, CNS WHO grade 1
Methylation profile: Infratentorial pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 474\NH23-94,0.028,-0.025,0.006,-0.005,0.003,-0.033,0.033,-0.04,-0.019,-0.038,0.108,0.004,-0.001,0.048,0.018,-0.037,0.026,0.015,0.071,-0.008,-0.03,0.068,0.012,0.014,0.003,-0.012,-0.007,-0.054,-0.02,unmethylated
NH23-99,207129210156_R08C01,474,12/1/2023,2/1/2023,2/1/2023,20,PM,Diagnostic,474,1,NDP,"Cambridge, Addenbrooke's Hospital",Ganglioglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,#N/A,,ganglioglioma,1,LGG_GG,0.97,0.58,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-99,"Integrated diagnosis: Multinodular vacuolated neuronal tumour, CNS WHO grade 1
Histology: Multinodular vacuolated neuronal tumour
Methylation profile: Ganglioglioma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 474\NH23-99,0.032,-0.01,0.017,-0.01,0.005,-0.033,0.01,0.018,-0.017,-0.035,-0.014,0.04,0.029,0.029,0.036,-0.007,-0.007,-0.01,0.007,0.025,-0.017,-0.079,-0.027,0.048,-0.006,-0.005,0.015,-0.006,-0.02,unmethylated
NH23-56,207129210070_R03C01,475,13/01/2023,2/1/2023,2/1/2023,19,PM,Diagnostic,475,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,#N/A,,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.91,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-56,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, typical mesenchymal type
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 475\NH23-56,0.034,-0.116,-0.029,-0.014,-0.066,-0.027,-0.302,-0.052,0.021,-0.004,0.024,0.02,0.003,0.027,-0.779,-0.033,-0.234,-0.264,0.03,-0.03,0.039,0.127,-0.221,0.057,-0.174,-0.003,-0.334,-0.333,-0.147,unmethylated
NH23-107,207129210070_R04C01,475,13/01/2023,2/1/2023,2/1/2023,19,PM,Diagnostic,475,1,NDP,"Cardiff, University Hospital",Ganglioglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,#N/A,,ganglioglioma,0.59,GBM_MES,0.31,0.52,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-107,"Integrated diagnosis: CNS with single cell infiltration of a glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: CNS tissue, infiltration with a presumed glial tumour
Methylation profile: See comment
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 475\NH23-107,0.082,-0.008,0.041,0.075,0.011,-0.018,-0.061,0.218,0.144,0.159,0.191,-0.004,0.028,-0.016,-0.107,-0.012,-0.107,-0.148,0.01,-0.024,-0.003,0.054,0.001,0.074,0.049,0.026,-0.009,-0.13,-0.152,unmethylated
NH23-64,207129210070_R05C01,475,13/01/2023,2/1/2023,2/1/2023,19,PM,Diagnostic,475,1,NDP,Nottingham University Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,0.99,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-64,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 4
Methylation profile: Astrocytoma, IDH-mutant, high grade
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 475\NH23-64,0.081,0.581,0.044,-0.054,0.07,0.146,-0.004,-0.003,-0.038,1.642,-0.074,0.059,0.108,0.045,0.274,0.041,-0.295,-0.401,0.002,-0.062,0.933,-0.047,-0.052,-0.067,-0.109,0.136,-0.077,-0.07,0.007,methylated
NH23-100,207129210070_R06C01,475,13/01/2023,2/1/2023,2/1/2023,19,PM,Diagnostic,475,3,NDP,Romford,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,1/16/1997,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.97,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-100,"Astrocytoma, IDH-mutant, CNS WHO grade 3 - see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 3
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3
Methylation profile: Astrocytoma, IDH-mutant, lower grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 475\NH23-100,0.067,-0.066,0.04,-0.021,0.044,0.034,0.052,-0.031,-0.018,-0.035,0.005,-0.002,0.002,-0.01,0.006,-0.021,0.003,-0.004,-0.012,-0.022,-0.026,-0.034,-0.344,0.02,0.004,-0.001,-0.007,-0.099,-0.143,methylated
NH23-106,207129210070_R08C01,475,13/01/2023,2/1/2023,2/1/2023,19,PM,Diagnostic,475,1,NDP,"Cardiff, University Hospital",Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,,infratentorial pilocytic astrocytoma,0.53,LGG_PAPF,0.52,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-106,"Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1
Histology: Low grade glioma, features in keeping with pilocytic astrocytoma
Methylation profile: Infratentorial pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 475\NH23-106,0.033,0.063,0.047,0.022,0.037,0.144,0.242,0.367,0.54,0.528,0.349,0.026,0.101,0.077,0.109,0.088,0.261,0.238,0.126,0.264,0.18,0.302,0.054,0.093,-0.042,0.094,-0.073,0.007,0.131,unmethylated
NH23-122,207129210037_R01C01,476,13/01/2023,2/1/2023,2/1/2023,19,PM,Diagnostic,476,1,NDP,NHNN,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,#N/A,,supratentorial pilocytic astrocytoma,0.98,LGG_PA_GGST,0.74,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-122,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 476\NH23-122,-0.01,-0.038,0.02,-0.012,-0.023,-0.026,-0.01,-0.022,0.008,0.013,0.002,0.016,-0.004,0.023,0.041,-0.039,-0.013,-0.032,0.011,-0.032,0.003,0.013,-0.006,0.008,0.035,-0.03,-0.024,0.046,-0.014,unmethylated
NH23-120,207129210037_R02C01,476,13/01/2023,2/1/2023,2/1/2023,19,PM,Diagnostic,476,4,NDP,Oxford John Radcliffe Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,#N/A,,"glioblastoma, IDH-wildtype, mesenchymal type",0.59,MNG,0.37,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-120,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 476\NH23-120,0.151,0.055,-0.043,0.052,0.064,0.129,-0.068,0.094,0.061,0.072,0.085,0.084,0.04,0.158,-0.713,-0.192,-0.051,-0.123,-0.006,-0.118,0.005,0.1,-0.207,-0.042,-0.002,0.206,-0.21,-0.153,-0.153,unmethylated
NH23-123,207129210037_R03C01,476,13/01/2023,2/1/2023,2/1/2023,19,PM,Diagnostic,476,1,NDP,Nottingham University Hospital,GBM?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,,"glioblastoma, IDH-wildtype, RTK1 type",0.45,GBM_RTKI,0.72,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-123,"Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: Glioblastoma, CNS WHO grade 4
Methylation profile: Glioblastoma, IDH-wildtype, RTK1 subtype
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 476\NH23-123,0.279,0.065,0.07,-0.085,1.319,0.048,0.044,1.656,0.272,0.149,0.217,-0.003,-0.006,-0.004,-0.025,-0.011,-0.339,-0.49,0.008,0.194,0.841,2.245,-0.07,0.017,0.066,0.006,-0.06,-0.054,0.015,unmethylated
NH23-10,207129210037_R04C01,476,16/01/2023,2/1/2023,2/1/2023,16,PM,Diagnostic,476,1,NDP,NHNN,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,7/1/1969,,spinal ependymoma,1,EPN_SPINE,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-10,"Spinal ependymoma, CNS WHO grade 2 - see comment.
","Integrated diagnosis: Spinal ependymoma, CNS WHO grade 2
Histology: Spinal ependymoma, CNS WHO grade 2
Methylation profile: Spinal ependymoma
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 476\NH23-10,-0.006,0.023,0.054,-0.009,0.003,0.001,0.035,-0.019,-0.015,-0.063,-0.007,0.069,0.113,0.066,0.037,0.017,-0.021,-0.024,-0.018,0.063,0.065,0.099,-0.005,-0.041,0.005,-0.03,0.001,-0.281,-0.338,unmethylated
NH23-105,207129210037_R06C01,476,17/01/2023,2/1/2023,2/1/2023,15,PM,Diagnostic,476,1,NDP,Cleveland Clinic London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,#N/A,,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.98,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-105,"High grade glioma, at least CNS WHO grade 3 - see comment.
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Integrated diagnosis: Glioblastoma, IDH-wildtype, CNS WHO grade 4
Histology: High-grade glioma, IDH-wildtype
Methylation profile: Glioblastoma, IDH-wildtype, RTK2 subtype
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 476\NH23-105,-0.034,0.178,0.221,-0.083,-0.036,0.003,0.023,1.188,0.247,0.219,0.155,0.005,0.084,0.018,-1.771,-0.019,-0.329,-0.348,-0.012,0.023,-0.029,-0.003,-0.012,0.024,0.006,-0.023,0.18,-0.009,0.027,methylated
NH23-126,207129210018_R01C01,477,20/01/2023,2/3/2023,2/3/2023,14,PM,Diagnostic,477,1,NDP,Royal London Hospital,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,#N/A,,infratentorial pilocytic astrocytoma,0.98,LGG_PAPF,0.88,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-126,"Glioma with pilocytic features - see comment.
","Integrated diagnosis: Pilocytic astrocytoma, CNS WHO grade 1, KIAA1549-BRAF fusion
Histology: Glioma with pilocytic features
Methylation profile: Infratentorial pilocytic astrocytoma
MGMT promoter (Illumina array): Unmethylated 
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 477\NH23-126,-0.096,0.078,0.136,0.012,-0.024,0.14,0.118,-0.017,-0.098,-0.095,0.088,0.032,0.128,0.008,0.023,0,-0.018,0.057,0.102,-0.085,-0.126,-0.03,-0.08,-0.113,-0.124,-0.023,0.047,-0.11,-0.019,unmethylated
NH23-157,207129210018_R03C01,477,17/01/2023,2/3/2023,2/3/2023,17,PM,Diagnostic,477,1,NDP,"Royal Infirmary,Edinburgh",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,#N/A,,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.42,LGG_DNT,0.13,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-157,"Integrated diagnosis: High-grade glioma, raising the possibility of radiation-induced glioma
Histology: High grade glioma, at least CNS WHO Grade 3
Methylation profile: Diffuse paediatric-type high grade glioma, RTK1 subtype, subclass A (novel) (low calibrated score - see comment
MGMT promoter (Illumina array): Unmethylated
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 477\NH23-157,0.155,-0.467,0.035,-0.12,-0.012,-0.016,-0.038,0.104,-0.08,-0.112,-0.062,0.238,0.252,0.172,-0.019,0.203,-0.392,-0.42,0.003,-0.008,-0.4,-0.587,-0.401,-0.495,0.03,-0.01,-0.118,-0.372,-0.332,unmethylated
NH23-136,207129210018_R04C01,477,20/01/2023,2/3/2023,2/3/2023,14,PM,Diagnostic,477,1,NDP,Romford,DNT,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,#N/A,,dysembryoplastic neuroepithelial tumour,0.71,LGG_DNT,0.56,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-136,"Low grade glial/glioneuronal tumour - see comment.
","Integrated diagnosis: Dysembryoplastic neuroepithelial tumour, CNS WHO grade 1
Histology: Low grade glial/glioneuronal tumour
Methylation profile: Dysembryoplastic neuroepithelial tumour
MGMT promoter (Illumina array): Unmethylated
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 477\NH23-136,-0.065,0.016,0.049,-0.007,0.012,-0.038,-0.025,-0.055,-0.038,-0.16,-0.031,0.007,0.116,-0.047,0.051,-0.015,0.033,0.049,-0.028,-0.071,-0.109,0.04,0.065,-0.016,0.011,0.072,-0.05,-0.059,0.041,unmethylated
NH23-161,207129210018_R06C01,477,20/01/2023,2/3/2023,2/3/2023,14,PM,Diagnostic,477,1,NDP,NHNN,"Glioma, H3K27 mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,#N/A,,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",1,DMG_K27,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-161,"Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4 - see comment.
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
H3K27M (IHC): Positive
H3K27me3 (IHC): Loss
Further molecular tests: Pending
","Integrated diagnosis: Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4
Histology: Diffuse midline glioma, H3 K27-altered, CNS WHO grade 4
Methylation profile: Diffuse midline glioma, H3 K27-altered, subtype H3 K27-mutant or EZHIP expressing
MGMT promoter (Illumina array): Unmethylated
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 477\NH23-161,0.051,-0.001,0.071,0.181,0.212,-0.144,-0.009,0.052,0.001,-0.144,-0.031,-0.425,-0.272,-0.449,0.054,0.034,0.029,0.034,-0.365,-0.002,0.026,-0.102,-0.325,-0.445,-0.669,0.192,-0.187,-0.056,-0.011,unmethylated
NH23-147,207129210018_R07C01,477,20/01/2023,2/3/2023,2/3/2023,14,PM,Diagnostic,477,1,NDP,St.Mary's,GBM?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,#N/A,,"glioblastoma, IDH-wildtype, mesenchymal type",0.49,CONTR_REACT,0.39,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-147,"Probable glial tumour - see comment.
","Integrated diagnosis: Small fragments of glioma, raising the possibility of glioblastoma, IDH-wildtype, CNS WHO grade 4 (see comment)
Histology: Glial tumour, NOS
Methylation profile: Glioblastoma, IDH-wildtype, [typical mesenchymal type], low calibrated score
MGMT promoter (Illumina array): Methylated
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 477\NH23-147,0.16,-0.148,0.04,0.031,0.023,0.042,-0.115,-0.113,0.051,0.019,0.079,0.026,0.072,-0.026,-0.212,-0.073,-0.017,0.011,-0.033,0.08,-0.089,0.109,0.035,-0.07,0.061,0.126,-0.01,-0.018,0.054,methylated
NH23-194,207129210028_R02C01,478,20/01/2023,2/3/2023,2/3/2023,14,PM,Diagnostic,478,1,NDP,"Cardiff, University Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,#N/A,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-194,"Integrated diagnosis: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, final grading see comment
Histology: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, features within CNS WHO grade 2 boundaries
Methylation profile: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
MGMT promoter (Illumina array): Methylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 478\NH23-194,0.031,-0.01,0.067,-0.095,-0.006,-0.124,-0.095,0.04,0.002,-0.108,-0.026,0.067,0.111,-0.249,-0.06,0.055,-0.043,-0.076,-0.01,-0.111,0.082,-0.017,0.003,0.091,-0.057,0.074,-0.596,0.053,0.078,methylated
NH23-215,207129210028_R04C01,478,20/01/2023,2/3/2023,2/3/2023,14,PM,Diagnostic,478,1,NDP,"Liverpool, The Walton Centre",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.32,AIDH,0.41,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-215,"Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 2
Histology: Astrocytoma, (IDH-mutant), CNS WHO grade 2
Methylation profile: Astrocytoma, IDH-mutant, low grade
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 478\NH23-215,-0.105,0.024,0.078,-0.045,-0.01,-0.024,-0.058,-0.001,0.006,-0.066,-0.05,0.005,0.106,-0.054,0.047,-0.04,0.035,0.027,-0.038,-0.105,0.003,0.002,0.078,-0.062,-0.101,0.031,-0.046,-0.104,-0.012,unmethylated
NH23-176,207129210028_R05C01,478,20/01/2023,2/3/2023,2/3/2023,14,PM,Diagnostic,478,1,NDP,Oxford John Radcliffe Hospital,Spinal ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",,#N/A,,"spinal ependymoma, MYCN-amplified",1,EPN_PFA,0.65,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-176,"Integrated diagnosis: Spinal ependymoma, MYCN-amplified, CNS WHO grade 3
Histology: Ependymoma, CNS WHO grade 3
Methylation profile: Spinal ependymoma, MYCN-amplified
MGMT promoter (Illumina array): Unmethylated 
  
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 478\NH23-176,0.017,1.607,0.091,0.03,0.024,0.002,-0.17,-0.183,-0.192,-0.054,-0.01,0.057,0.044,0.024,0.014,-0.013,-0.584,-0.567,-0.002,-0.075,-0.036,0.053,-0.027,-0.028,-0.033,0.057,-0.028,-0.009,0.073,unmethylated
NH23-130,207129210028_R06C01,478,23/01/2023,2/3/2023,2/3/2023,11,MD,Diagnostic,478,1,NDP,"Liverpool, The Walton Centre",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,#N/A,,ganglioglioma,0.91,LGG_GG,0.52,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-130,"Diffuse glioma, IDH-wildtype (see comment)
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
TERT promoter: [Failed]

  
","Integrated diagnosis: Infiltration zone of an IDH-wildtype glioma, NOS
Histology: Diffuse glioma, IDH-wildtype
Methylation profile: Inconclusive (see comment)
MGMT promoter (Illumina array): Unmethylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 478\NH23-130,-0.044,-0.071,0.017,0.009,-0.032,0.01,-0.078,0.01,-0.093,-0.135,-0.008,0.019,0.027,-0.09,0.013,-0.032,-0.216,-0.126,-0.057,-0.111,-0.065,0.04,0.073,0.025,-0.133,0.055,0.087,-0.042,-0.067,unmethylated
NH23-172,207129210028_R08C01,478,23/01/2023,2/3/2023,2/3/2023,11,MD,Diagnostic,478,3,NDP,"Romford, Queen's Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.97,AIDH_HG,0.66,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-172,"Glioma, IDH-mutant, with high grade features, at least CNS WHO grade 3  see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Integrated diagnosis: Astrocytoma, IDH-mutant, CNS WHO grade 4
Histology: Astrocytoma, IDH-mutant, CNS WHO grade 3 (see comment regarding upgrading)
Methylation profile: Astrocytoma, IDH-mutant, high grade
MGMT promoter (Illumina array): Methylated 
  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 478\NH23-172,-0.004,0.002,0.147,-0.061,-0.086,-0.105,-0.237,-0.058,0.025,0.097,0.077,0.106,0.119,0.006,-1.749,-0.153,-0.107,-0.128,-0.232,-0.103,-0.05,0.174,-0.142,0.009,-0.042,0.159,-0.331,-0.035,0.015,methylated
NH23-199,207129210005_R04C01,479,23/01/2023,2/8/2023,2/8/2023,16,MD,Diagnostic,479,1,NDP,Wellington Hospital London,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1B,#N/A,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.76,OIDH,0.89,0.65,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-199,"Recurrent oligodendroglioma, IDH-mutant and 1p/19q co-deleted, CNS WHO grade 2  see comment.
IDH1 (R132H IHC): No mutation (IDH2 A514T mutation - see NH16-1806)
ATRX (IHC): Retained
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 479\NH23-199,0.012,-0.056,0.016,-0.052,0.011,0.027,0.008,0.002,-0.017,-0.029,-0.018,0.025,0.007,0.031,0.074,-0.022,0.034,0.012,-0.003,-0.011,-0.028,0.017,-0.011,0.044,-0.032,0.004,-0.289,-0.023,0.014,methylated
NH23-224,207129210005_R05C01,479,23/01/2023,2/8/2023,2/8/2023,16,MD,Diagnostic,479,1,NDP,St George's Hospital London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.94,AIDH_HG,0.89,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-224,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 479\NH23-224,-0.011,-0.041,0.131,-0.023,-0.052,0.009,0.033,-0.012,0.002,-0.079,-0.009,0.038,0.013,0.008,0.029,-0.1,0.007,-0.022,0.072,0.167,-0.131,-0.087,-0.126,0.034,0.008,-0.055,-0.076,-0.033,0,methylated
NH23-227,207129210005_R07C01,479,23/01/2023,2/8/2023,2/8/2023,16,MD,Diagnostic,479,1,NDP,"Cambridge, Addenbrooke's Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,#N/A,,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.24,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-227,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 479\NH23-227,0.021,-0.034,-0.007,-0.007,-0.048,0.253,-0.028,-0.051,-0.014,0,0.013,0.019,0.005,0.04,-0.445,-0.044,-0.118,-0.12,0.004,-0.122,-0.049,0.07,-0.229,-0.173,0.055,0.067,-0.168,-0.002,0.034,methylated
NH23-197,207129210004_R02C01,480,23/01/2023,2/8/2023,2/8/2023,16,MD,Diagnostic,480,1,NDP,Cleveland Clinic London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.48,AIDH,0.52,0.7,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-197,"Recurrent astrocytoma, IDH-mutant, CNS WHO grade 2 - see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 480\NH23-197,0.052,-0.006,0.023,-0.173,0.013,0.022,0.025,0.13,0.159,0.199,0.133,0.022,0.044,0.084,-0.189,0.012,0.041,0.037,-0.01,0.053,-0.047,-0.045,0.016,0.019,-0.005,-0.029,-0.276,0,0.038,methylated
NH23-226,207129210004_R03C01,480,25/01/2023,2/8/2023,2/8/2023,14,MD,Diagnostic,480,1,NDP,"Charing Cross Hospital, London",Diffuse midline glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF3A,#N/A,,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",1,DMG_K27,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-226,"Favouring a diffuse midline glioma, H3 K27-altered, CNS WHO grade 4 - see comment. 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 480\NH23-226,0.011,-0.05,-0.015,0.057,0,0.001,0.007,-0.031,-0.04,-0.062,-0.004,-0.002,0.066,0.013,0.037,0.009,0.01,-0.009,-0.006,-0.014,-0.032,0.088,0.002,0.055,0.071,0.005,-0.069,-0.009,0.031,unmethylated
NH23-251,207129210004_R05C01,480,25/01/2023,2/8/2023,2/8/2023,14,MD,Diagnostic,480,1,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,#N/A,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.99,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-251,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 480\NH23-251,0.06,0.791,0.005,-0.095,0.797,0.016,0.063,0.004,-0.015,-0.057,-0.023,-0.011,0.06,0.053,0.085,0.062,-0.482,-0.35,0.029,-0.028,-0.014,0.097,-0.221,0.021,0.05,0.041,-0.042,-0.376,-0.188,methylated
NH23-239,207129210004_R06C01,480,25/01/2023,2/8/2023,2/8/2023,14,MD,Diagnostic,480,1,NDP,Southampton General Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1B,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.84,AIDH,0.97,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-239,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 480\NH23-239,-0.011,-0.042,0.072,-0.032,0.012,0.027,0.022,0.216,0.19,0.22,0.176,0.001,0.045,0.218,0.059,-0.012,-0.012,0.093,-0.01,-0.003,-0.022,-0.029,-0.004,0.025,-0.046,-0.004,-0.042,-0.015,0.009,methylated
NH23-200,207129210004_R07C01,480,25/01/2023,2/8/2023,2/8/2023,14,MD,Diagnostic,480,3,NDP,HCA,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,#N/A,,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",1,LGG_MYB,0.49,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-200,"Glioma - see comment.
IDH1 (R132H IHC): No mutation
ATRX (IHC): IHC interpreted as Retained
Further molecular tests: Pending
","Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: No amplification
TERT promoter: Mutation
MGMT Promoter: Unmethylated (0%)
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 480\NH23-200,0.091,0.061,0.069,0.033,-0.002,0.033,-0.001,-0.016,-0.014,-0.053,-0.033,-0.002,0.041,0.015,0.065,-0.266,-0.009,0.003,-0.016,-0.038,-0.043,0.018,-0.022,0.008,-0.01,-0.012,-0.229,-0.007,0,unmethylated
NH23-232,207129210004_R08C01,480,25/01/2023,2/8/2023,2/8/2023,14,MD,Diagnostic,480,1,NDP,"Charing Cross Hospital, London",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF3A,#N/A,,"Diffuse paediatric-type high grade glioma, RTK2 subtype",0.97,GBM_RTKI,0.77,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-232,"High grade glioma, favouring Glioblastoma, CNS WHO grade 4 - see comment.
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
","Glioblastoma, IDH-wildtype, CNS WHO grade 4
IDH1 (R132H IHC); IDH1/2Seq: No mutation
ATRX (IHC): Retained
EGFR: Amplification
MGMT Promoter: Unmethylated (0%)

  
",,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 480\NH23-232,0.004,0.007,0.029,0.054,0.018,0.033,-0.045,1.24,0.256,0.194,0.204,-0.013,0.043,0,-1.332,-0.014,-0.324,-0.347,-0.016,0.002,-0.022,1.752,-0.025,0.018,0.101,0.019,-0.092,-0.018,0.08,unmethylated
NH23-262,207134810112_R01C01,481,25/01/2023,2/8/2023,2/8/2023,14,MD,Diagnostic,481,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,,"glioblastoma, IDH-wildtype, RTK1 type",0.98,GBM_RTKI,0.94,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-262,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 481\NH23-262,0.129,-0.205,-0.108,0.027,0.16,0.039,-0.17,1.364,0.322,0.086,0.106,0.007,-0.031,0.079,-0.093,-0.161,-0.318,-0.389,-0.103,0.068,0.581,1.82,-0.035,0.024,0.099,0.016,-0.111,-0.017,-0.008,unmethylated
NH23-340,207134810112_R05C01,481,25/01/2023,2/8/2023,2/8/2023,14,MD,Diagnostic,481,1,NDP,"Birmingham, Queen Elizabeth Hospital",Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,#N/A,,supratentorial midline pilocytic astrocytoma,0.43,LGG_PAMID,0.25,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-340,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 481\NH23-340,0.088,0.026,0.017,0.002,-0.011,0.137,0.197,0.152,0.191,0.167,0.144,0.171,0.241,0.175,0.091,-0.004,0.177,0.164,0.216,0.268,0.242,0.419,0.003,0.176,0.158,0.146,-0.113,-0.004,0.036,unmethylated
NH23-275,207134810112_R07C01,481,26/01/2023,2/8/2023,2/8/2023,13,MD,Diagnostic,481,1,NDP,"Belfast, Royal Victoria Hospital",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,#N/A,,"glioblastoma, IDH-wildtype, RTK2 type",0.16,GBM_RTKII,0.35,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-275,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 481\NH23-275,2.009,-0.103,0.108,0.123,0.121,-0.151,-0.008,1.998,0.241,0.302,0.232,-0.022,0.114,0.072,-1.825,0.069,-0.725,-0.509,0.157,-0.353,0.225,0.654,0.086,-0.44,0.297,0.25,0.227,-0.262,0.537,methylated
NH23-286,207134810112_R08C01,481,26/01/2023,2/8/2023,2/8/2023,13,MD,Diagnostic,481,1,NDP,St George's Hospital London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,#N/A,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-286,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 481\NH23-286,0.043,0.127,0.041,0.012,-0.022,0.026,-0.132,-0.015,-0.022,0.267,0.225,0.019,0.059,0.384,-0.296,0.002,0.013,-0.001,-0.036,0.264,-0.031,-0.047,-0.022,0.125,0.029,-0.036,-0.041,0.024,0.033,methylated
NH23-273,207134810114_R01C01,482,27/01/2023,2/8/2023,2/8/2023,12,PM,Diagnostic,482,1,NDP,Brighton and Sussex Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1B,,,"glioblastoma, IDH-wildtype, RTK2 type",0.68,GBM_MES,0.52,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-273,"High-grade glioma (see comment)
IDH1 (R132H IHC): No mutation 
ATRX (IHC): Retained      
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 482\NH23-273,0.086,0.009,-0.009,-0.029,-0.042,0.073,-0.325,1.035,0.225,0.262,0.177,-0.062,0.005,-0.008,-0.562,-0.03,-0.262,-0.279,-0.099,-0.079,0.064,-0.027,-0.08,-0.056,0.063,0.033,0,-0.065,0.014,unmethylated
NH23-293,207134810114_R02C01,482,27/01/2023,2/8/2023,2/8/2023,12,MD,Diagnostic,482,1,NDP,"Liverpool, The Walton Centre",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,,,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.54,GBM_RTKII,0.55,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-293,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 482\NH23-293,-0.006,0.029,0.021,-0.02,0.035,0.009,-0.275,0.754,0.181,0.192,0.121,0.006,0.016,0.063,-0.205,0.029,-0.175,-0.188,-0.012,0.052,0.018,0.026,-0.02,-0.199,0.033,-0.032,-0.065,-0.18,-0.159,unmethylated
NH23-294,207134810114_R03C01,482,27/01/2023,2/8/2023,2/8/2023,12,MD,Diagnostic,482,4,NDP,Nottingham University Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-294,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 482\NH23-294,-0.027,-0.037,0.05,-0.246,-0.318,0.025,0.048,0.015,-0.004,-0.055,-0.009,0.001,-0.01,0.005,0.042,-0.014,0.005,0.039,-0.01,0.012,-0.026,-0.017,-0.422,0.033,0.02,-0.053,-0.481,0.015,0.007,methylated
NH23-296,207134810114_R04C01,482,27/01/2023,2/8/2023,2/8/2023,12,MD,Diagnostic,482,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"supratentorial ependymoma, ZFTA:RELA fusion-positive",0.11,CONTR_CEBM,0.11,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-296,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 482\NH23-296,0.103,-0.038,0.003,-0.086,-0.067,0.043,-0.093,1.03,0.009,0.053,0.042,0.021,0.128,0.082,-0.231,-0.044,-0.08,-0.015,-0.021,-0.012,0,0.032,0.06,0.041,0.057,0.155,-0.07,-0.066,-0.014,methylated
NH23-297,207134810114_R05C01,482,27/01/2023,2/8/2023,2/8/2023,12,MD,Diagnostic,482,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.41,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-297,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 482\NH23-297,0.009,-0.04,0.004,-0.072,-0.041,-0.005,-0.01,0.07,0.089,0.136,0.051,-0.033,0.032,-0.051,-0.328,0.001,-0.118,-0.082,0.012,-0.018,-0.013,-0.016,-0.029,-0.005,-0.149,0.063,-0.038,-0.019,0.058,unmethylated
NH23-264,207134810114_R06C01,482,27/01/2023,2/8/2023,2/8/2023,12,MD,Diagnostic,482,1,NDP,"Charing Cross Hospital, London",Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-264,"Favouring Oligodendroglioma, IDH-mutant, CNS WHO grade 2 - see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 482\NH23-264,0.042,-0.044,0.036,-0.068,-0.041,0.004,0.01,0.05,-0.008,-0.079,-0.016,0.028,0.046,0.041,0.056,0.005,-0.021,0.022,0.002,0.029,-0.022,0.007,-0.017,0.079,-0.017,-0.01,-0.427,-0.024,-0.015,methylated
NH23-280,207244230042_R01C01,483,27/01/2023,2/10/2023,2/21/2023,25,PM,Diagnostic,483,4,NDP,"Romford, Queen's Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.81,OIDH,0.84,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-280,"Glioma, IDH-mutant (see comment)

IDH1 (R132H IHC): Mutation       
ATRX (IHC): Retained      
Further molecular tests: Pending 
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 483\NH23-280,-0.083,-0.408,0.038,0.07,-0.041,0.037,-0.191,-0.253,-0.211,-0.178,0.059,0.098,-0.01,-0.157,-0.164,0.237,-0.148,-0.041,-0.098,-0.273,0.089,0.07,-0.212,-0.187,-0.096,0.222,-0.155,0.095,0.284,methylated
NH23-305,207244230042_R04C01,483,27/01/2023,2/10/2023,2/21/2023,25,PM,Diagnostic,483,1,NDP,"Birmingham, Queen Elizabeth Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A2,,,posterior fossa subependymoma,1,SUBEPN_PF,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-305,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 483\NH23-305,0.029,0,0.004,-0.013,-0.045,-0.019,0.011,0.002,-0.036,-0.074,-0.017,-0.011,0.031,-0.031,0.01,0.043,0.019,-0.005,0.024,-0.011,0.01,-0.012,0.063,0.004,0.062,0.031,-0.012,-0.014,0.001,unmethylated
NH23-311,207244230042_R05C01,483,27/01/2023,2/10/2023,2/21/2023,25,PM,Diagnostic,483,1,TRUE,St George's Hospital London,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",C1,,,infratentorial pilocytic astrocytoma,1,LGG_PAPF,0.98,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-311,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 483\NH23-311,0.155,-0.284,-0.076,-0.058,-0.059,-0.025,-0.014,-0.161,-0.053,-0.016,0.188,-0.026,0.092,-0.03,0,0.083,-0.128,-0.062,-0.004,0.031,0.095,0.117,0.033,-0.011,0.124,0.094,-0.054,-0.002,0.094,unmethylated
NH23-269,207244230042_R06C01,483,30/01/2023,2/10/2023,2/21/2023,22,PM,Diagnostic,483,4,NDP,Cleveland Clinic London,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.95,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-269,"Glioma, IDH-mutant -- see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): see comment
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 483\NH23-269,-0.072,-0.034,0.034,-0.009,-0.011,0.007,-0.053,-0.066,-0.049,-0.022,-0.008,0.035,0.008,0.055,-0.048,-0.047,0.014,0.018,-0.01,0.011,-0.006,0.001,-0.096,-0.026,0.036,0.004,0.033,-0.013,0.002,methylated
NH23-323,207244230042_R08C01,483,30/01/2023,2/10/2023,2/21/2023,22,PM,Diagnostic,483,1,NDP,Oxford John Radcliffe Hospital,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",7B,,,posterior fossa ependymoma group A1,0.09,CONTR_INFLAM,0.09,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-323,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 483\NH23-323,0.173,0.325,0.097,-0.209,-0.129,0.027,-0.564,-0.493,0.043,0.054,-0.012,0.193,0.069,0.162,0.034,0.042,-0.698,-0.139,-0.156,-0.873,-0.013,0.511,0.299,-0.554,-0.034,0.023,0.018,-0.159,0.406,unmethylated
NH23-334,207134810148_R02C01,484,30/01/2023,2/15/2023,2/15/2023,16,PM,Diagnostic,484,3,NDP,"Cardiff, University Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-334,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 484\NH23-334,0.03,0.014,0.049,-0.007,0.025,-0.048,-0.087,0.003,0.167,0.166,0.288,-0.017,0.079,0.027,-0.036,0.073,-0.027,-0.124,0.041,-0.033,0.014,0.059,-0.038,0.054,-0.01,0.003,-0.31,-0.013,0.132,methylated
NH23-287,207134810148_R03C01,484,30/01/2023,2/15/2023,2/15/2023,16,PM,Diagnostic,484,3,NDP,NHNN,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1B,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-287,"Glioma, IDH-mutant, favouring CNS WHO grade 2 - see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): see comment
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 484\NH23-287,0.028,0.025,-0.018,-0.044,0.026,0.001,0.021,-0.025,0.015,-0.026,0.031,-0.077,0.024,0.223,0.025,-0.019,0.005,-0.041,-0.011,0.165,-0.117,-0.116,-0.003,0.032,0.011,0.254,-0.041,-0.024,0.04,unmethylated
NH23-289,207134810148_R04C01,484,30/01/2023,2/15/2023,2/15/2023,16,PM,Diagnostic,484,1,NDP,Royal London Hospital,Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,,,posterior fossa subependymoma,1,SUBEPN_PF,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-289,"Subependymoma, CHS WHO grade 1
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 484\NH23-289,0.013,0.039,0.017,0.002,0.008,-0.014,0.019,-0.017,0.02,-0.015,-0.006,-0.014,0.064,0.002,0.009,-0.005,0.028,-0.006,0.011,-0.026,-0.004,0.058,-0.024,0.014,-0.001,0.02,0.059,-0.06,0.016,unmethylated
NH23-291,207134810148_R05C01,484,30/01/2023,2/15/2023,2/15/2023,16,PM,Diagnostic,484,3,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.48,OIDH,0.57,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-291,"Favouring Oligodendroglioma, IDH-mutant, CNS WHO grade 2  see comment. 
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained 
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 484\NH23-291,-0.046,0.034,0.012,-0.019,0.016,0.02,-0.041,-0.063,-0.038,-0.059,0.007,-0.009,0.006,0.033,0.024,0.002,-0.013,0.01,0.015,-0.021,-0.019,0.002,-0.049,0.033,0.015,-0.024,-0.277,-0.007,0.004,methylated
NH23-335,207134810148_R06C01,484,31/01/2023,2/15/2023,2/15/2023,15,PM,Diagnostic,484,2,NDP,"Cardiff, University Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,,,posterior fossa ependymoma group B,1,EPN_PFB,0.5,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-335,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 484\NH23-335,-0.103,-0.323,-0.266,-0.064,-0.087,0.039,-0.056,0.076,0.14,0.082,0.101,0.111,0.171,0.065,0.1,0.116,-0.251,-0.3,0.126,0.074,0.066,0.173,-0.3,-0.076,-0.097,-0.034,0.115,-0.299,-0.287,unmethylated
NH23-336,207134810148_R07C01,484,31/01/2023,2/15/2023,2/15/2023,15,PM,Diagnostic,484,1,NDP,"Birmingham, Queen Elizabeth Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-336,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 484\NH23-336,-0.165,0.025,0.025,-0.024,0.021,-0.034,-0.139,-0.04,-0.01,-0.029,0.033,-0.005,0.088,0.077,-0.017,0.041,-0.029,-0.043,-0.002,-0.029,-0.08,0.075,-0.056,0.023,0.049,0.028,0.082,-0.02,0.035,methylated
NH23-278,207244230113_R01C01,485,31/01/2023,2/17/2023,2/17/2023,17,PM,Diagnostic,485,1,NDP,Romford,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.99,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-278,"Low-grade glioma / glioneuronal tumour (see comment)
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 485\NH23-278,0.102,0.008,0.067,-0.019,-0.027,-0.044,-0.078,0.039,0.143,0.196,0.165,-0.006,0.04,0.607,-0.014,0.04,0.029,-0.086,-0.021,-0.016,0.035,0.05,-0.441,0.107,-0.017,0.023,0.037,-0.008,0.031,unmethylated
NH23-318,207244230113_R02C01,485,2/2/2023,2/17/2023,2/17/2023,15,PM,Diagnostic,485,4,NDP,Royal London Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1I,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.99,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-318,"Astrocytoma, IDH-mutant, CNS WHO grade 3 - see comment.
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 485\NH23-318,-0.12,-0.119,0.031,-0.06,-0.034,-0.08,0.062,-0.023,-0.006,-0.025,-0.044,-0.109,0.015,0.084,-0.842,0,-0.138,-0.291,-0.025,-0.062,-0.147,-0.066,-0.197,0.03,0.072,0.035,-0.365,-0.152,-0.106,methylated
NH23-320,207244230113_R04C01,485,1/2/2023,2/17/2023,2/17/2023,16,PM,Diagnostic,485,1,NDP,Romford,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",0.66,GBM_MES,0.2,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-320,"CNS tissue with mild increased cellularity, no inflammation - see comment.
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 485\NH23-320,0.076,0.033,0.026,0.011,-0.038,-0.001,-0.163,0.668,0.141,0.164,0.103,-0.136,0.042,0.07,-0.096,0.006,-0.077,-0.136,0,-0.077,-0.02,0.205,-0.012,0.071,0.013,0.034,-0.016,-0.047,-0.019,unmethylated
NH23-330,207244230113_R05C01,485,1/2/2023,2/17/2023,2/17/2023,16,PM,Diagnostic,485,3,NDP,"Charing Cross Hospital, London",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,0.99,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-330,"Astrocytoma, IDH-mutant, CNS WHO grade 4 - see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 485\NH23-330,0.219,0.687,0.041,0.011,0.777,0.047,0.013,0.048,0.05,-0.092,0.024,0.02,-0.058,-0.116,0.092,0.015,-0.074,-0.043,-0.105,0.184,-0.066,-0.09,-0.153,0.001,-0.073,-0.101,-0.138,0,0.053,methylated
NH23-313,207244230113_R08C01,485,2/2/2023,2/17/2023,2/17/2023,15,PM,Diagnostic,485,4,NDP,Romford,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-313,"Oligodendroglioma, IDH-mutant, CNS WHO grade 2 - see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 485\NH23-313,-0.067,-0.026,0.048,-0.023,0.055,0.073,0.032,-0.033,0.183,0.226,0.17,-0.001,0.062,0.028,0.008,-0.035,0.059,0.043,-0.013,0.017,-0.074,0.034,-0.074,0.052,-0.066,0.042,-0.491,-0.054,-0.013,methylated
NH23-321,207244230129_R02C01,486,2/2/2023,2/17/2023,2/17/2023,15,PM,Diagnostic,486,2,NDP,Romford,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"glioblastoma, IDH-wildtype, with primitive neuronal component",0.92,MB_SHHCHLAD,0.28,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-321,"High grade neuroectodermal tumour - see comment.
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 486\NH23-321,-0.061,1.219,-0.035,-0.006,-0.016,0.026,0.009,0.144,0.184,0.254,0.164,-0.536,-0.386,-0.623,-0.006,-0.073,-0.471,-0.513,-0.052,-0.157,-0.253,-0.134,-0.465,-0.593,0.076,0.033,0.033,-0.059,-0.503,methylated
NH23-368,207244230129_R06C01,486,2/2/2023,2/17/2023,2/17/2023,15,PM,Diagnostic,486,1,NDP,"Birmingham, Queen Elizabeth Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.98,AIDH_HG,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-368,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 486\NH23-368,0.016,0.791,0.002,-0.029,0.02,0.236,-0.009,-0.004,0.008,0.029,-0.007,-0.029,0.006,-0.024,-0.022,0.005,0.014,-0.241,-0.039,-0.003,0.673,0.867,-0.11,0.022,0.093,-0.005,-0.477,-0.032,-0.039,methylated
NH14-460,207244230129_R07C01,486,2/2/2023,2/17/2023,2/17/2023,15,PM,Diagnostic,486,1,NDP,"Belfast, Royal Victoria Hospital",Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,supratentorial midline pilocytic astrocytoma,0.39,LGG_PAPF,0.64,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH14-460,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 486\NH14-460,-0.099,-0.058,0.034,-0.065,-0.037,-0.056,-0.056,-0.085,-0.124,-0.209,-0.067,0.008,0.031,0.1,-0.028,0.015,0.062,-0.085,0.066,-0.032,-0.056,0.075,-0.063,0.088,-0.205,0.155,0.064,-0.045,0.004,unmethylated
NH23-388,207244230129_R08C01,486,2/2/2023,2/17/2023,2/17/2023,15,PM,Diagnostic,486,1,NDP,"Belfast, Royal Victoria Hospital",PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,pleomorphic xanthoastrocytoma(-like),0.99,PXA,0.99,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-388,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 486\NH23-388,-0.092,-0.053,0.008,-0.035,-0.017,0.02,0.033,-0.032,0.026,-0.088,-0.023,0.013,0.038,-0.008,-0.724,0.01,-0.018,0.006,-0.036,-0.016,0.005,0.014,-0.019,-0.034,0.015,0.003,0.024,0.019,-0.015,unmethylated
NH23-353,207244230096_R03C01,487,3/2/2023,2/21/2023,2/21/2023,18,PM,Diagnostic,487,4,NDP,NHNN,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.43,GBM_RTKII,0.76,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-353,"High grade glioma, CNS WHO grade 4  see comment. 
IDH1 (R132H IHC): No mutation
ATRX (IHC): Retained
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 487\NH23-353,0.029,-0.037,0.122,-0.011,-0.009,0.044,0.03,0.106,0.999,0.195,0.138,-0.03,-0.078,-0.04,-0.332,-0.009,-0.226,-0.12,-0.015,-0.111,0.581,-0.028,-0.361,-0.144,-0.111,-0.132,0.062,0.038,0.05,methylated
NH23-370,207244230096_R06C01,487,3/2/2023,2/21/2023,2/21/2023,18,PM,Diagnostic,487,3,NDP,Royal London Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-370,"Oligodendroglioma, IDH mutant, CNS WHO grade 3  see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 487\NH23-370,0.094,-0.358,-0.049,-0.035,-0.034,-0.026,-0.055,-0.137,-0.131,-0.055,0.01,-0.039,-0.031,-0.044,0.045,0.012,-0.072,-0.016,-0.036,-0.013,0.039,0.03,0.007,0.012,0.06,-0.026,-0.386,0.048,0.06,methylated
NH23-371,207244230096_R07C01,487,3/2/2023,2/21/2023,2/21/2023,18,PM,Diagnostic,487,4,NDP,Royal London Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-371,"Astrocytoma, IDH-mutant, CNS WHO grade 3 - see comment.
IDH1 (R132H IHC): Mutation 
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 487\NH23-371,0.032,-0.057,0.017,-0.045,-0.009,0.02,-0.022,-0.008,-0.048,-0.023,-0.025,0.015,-0.005,-0.029,-0.019,0.022,0.018,0.006,-0.015,0.022,-0.065,-0.107,-0.024,-0.036,0.002,-0.014,-0.085,-0.033,-0.027,methylated
NH23-372,207244230096_R08C01,487,3/2/2023,2/21/2023,2/21/2023,18,PM,Diagnostic,487,4,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.9,OIDH,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-372,"Oligodendroglioma, IDH-mutant, CNS WHO grade 2 - see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Retained
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 487\NH23-372,-0.027,-0.05,0.047,-0.117,0,-0.073,-0.009,-0.07,-0.041,-0.042,0.007,0.006,0.015,-0.008,-0.006,-0.007,-0.021,0.001,-0.056,-0.081,-0.105,-0.064,-0.012,-0.016,-0.034,0.008,-0.279,-0.013,-0.03,methylated
NH23-415,207244230032_R01C01,488,6/2/2023,2/21/2023,2/21/2023,15,PM,Diagnostic,488,1,NDP,"Liverpool, The Walton Centre",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"glioblastoma, IDH-wildtype, RTK1 type",0.34,GBM_RTKII,0.86,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-415,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 488\NH23-415,0.208,-0.158,-0.04,-0.16,-0.135,-0.084,0.03,0.087,0.121,0.22,0.148,-0.006,0.018,-0.045,-1.072,0.046,-0.436,-0.315,-0.119,0.039,-0.06,0.012,0.086,-0.016,0.119,-0.085,0,-0.274,-0.202,methylated
NH23-405,207244230032_R05C01,488,6/2/2023,2/21/2023,2/21/2023,15,PM,Diagnostic,488,1,NDP,Southampton General Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-405,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 488\NH23-405,0.039,-0.088,-0.001,-0.058,-0.026,-0.01,0.07,-0.018,-0.062,-0.001,-0.016,-0.004,-0.038,-0.105,0.045,0.005,-0.045,0.041,-0.053,-0.01,-0.079,-0.073,-0.02,-0.104,0.102,-0.006,-0.338,-0.033,-0.022,methylated
NH23-408,207244230032_R06C01,488,6/2/2023,2/21/2023,2/21/2023,15,PM,Diagnostic,488,1,NDP,"Belfast, Royal Victoria Hospital",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.78,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-408,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 488\NH23-408,0.024,-0.034,0,-0.032,-0.023,0.002,-0.079,0.043,0.039,0.079,0.037,-0.016,0.015,-0.032,-0.059,0.012,-0.128,-0.077,-0.006,-0.021,-0.029,-0.044,-0.008,-0.011,0.043,-0.012,0.061,-0.043,0.004,unmethylated
NH23-396,207244230045_R02C01,489,7/2/2023,2/21/2023,2/21/2023,14,PM,Diagnostic,489,1,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.92,AIDH,0.87,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-396,"Glioma, IDH-mutant, CNS WHO grade 2- see comment.
IDH1 (R132H IHC): Mutation
ATRX (IHC): Pending.
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 489\NH23-396,-0.04,-0.11,0.015,-0.105,-0.042,0.007,-0.006,-0.076,-0.037,-0.004,-0.01,0.028,0.002,0.067,-0.139,-0.082,-0.006,0.043,-0.032,-0.045,-0.112,-0.217,-0.068,-0.009,-0.043,-0.025,-0.091,0.006,-0.01,methylated
NH23-441,207244230045_R03C01,489,7/2/2023,2/21/2023,2/21/2023,14,PM,Diagnostic,489,4,NDP,St George's Hospital London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.71,GBM_RTKII,0.69,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-441,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 489\NH23-441,-0.017,-0.071,-0.014,0.181,-0.041,0,0.028,-0.005,-0.004,0.018,-0.076,-0.217,0.027,-0.012,-1.048,0.008,-0.142,-0.317,0.005,-0.023,-0.041,0.067,0.045,0.113,0.022,-0.009,0.069,-0.097,-0.008,methylated
NH23-431,207244230045_R05C01,489,7/2/2023,2/21/2023,2/21/2023,14,PM,Diagnostic,489,1,NDP,Oxford John Radcliffe Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",,,,myxopapillary ependymoma,1,EPN_MPE,1,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-431,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 489\NH23-431,0.002,0.002,0.058,-0.016,-0.009,0.009,-0.006,-0.041,-0.039,0.013,-0.002,0.006,-0.027,0.017,-0.006,0.022,-0.006,-0.018,-0.012,-0.03,-0.018,-0.037,-0.03,0.004,0.043,0.034,0.018,-0.071,-0.023,methylated
NH23-412,207244230045_R08C01,489,7/2/2023,2/21/2023,2/21/2023,14,PM,Diagnostic,489,1,NDP,Royal London Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-412,"Astrocytoma, CNS WHO grade 2 - see comment

IDH1 (R132H IHC): No mutation  
ATRX (IHC): Loss of expression (indicates mutation)
Further molecular tests: Pending
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 489\NH23-412,0.059,-0.151,0.008,0.001,-0.071,0.002,-0.06,-0.102,0.01,0.068,0.088,0.001,0.207,0.142,-0.035,0.038,-0.054,0.004,-0.056,0.006,0.044,0.018,0.015,0.032,0.085,0.028,-0.016,0.075,0.031,methylated
NH23-345,207134810003_R02C01,490,8/2/2023,3/8/2023,3/8/2023,28,PM,Diagnostic,490,1,NDP,Cleveland Clinic London,DNT?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF4A,,,"control tissue, hemispheric cortex",0.31,CONTR_HEMI,0.34,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-444,"Low grade glial/glioneuronal tumour in keeping with Dysembryoplastic Neuroepithelial tumour (WHO CNS Grade 1)
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 490\NH23-345,0.12,-0.264,0.077,-0.011,-0.091,0.058,-0.258,-0.404,-0.261,-0.13,0.03,0.071,0.202,-0.13,-0.146,0.063,-0.198,-0.111,-0.062,-0.164,-0.111,0.293,-0.069,-0.218,-0.172,0.252,0.411,0.071,0.154,unmethylated
NH23-449,207134810003_R06C01,490,9/2/2023,3/8/2023,3/8/2023,27,MD,Diagnostic,490,1,NDP,Nottingham University Hospital,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,high-grade astrocytoma with piloid features,0.99,ANAPA,0.94,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-449,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 490\NH23-449,-0.125,-0.037,0.109,-0.091,0.064,-0.032,-0.065,-0.091,-0.009,-0.255,-0.083,0.067,0.258,-0.072,-1.045,0.055,0.012,-0.076,0.083,-0.115,-0.058,0.111,0.062,-0.022,0.042,0.099,-0.197,-0.056,0.007,unmethylated
NH23-474,207244230048_R01C01,491,9/2/2023,3/1/2023,3/1/2023,20,MD,Diagnostic,491,1,NDP,"Birmingham, Queen Elizabeth Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",,,,posterior fossa ependymoma group B,1,EPN_PFB,0.99,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-474,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 491\NH23-474,0.029,-0.024,0.106,-0.063,-0.076,0.136,0.001,0.271,0.26,0.18,0.241,0.068,0.091,-0.003,0.453,0.528,0.01,0.053,0.112,0.259,0.365,0.3,0.307,0.068,-0.087,0.023,-0.02,0.02,0.047,unmethylated
NH23-461,207244230048_R02C01,491,9/2/2023,3/1/2023,3/1/2023,20,MD,Diagnostic,491,2,NDP,Oxford John Radcliffe Hospital,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"control tissue, cerebellar hemisphere",1,CONTR_CEBM,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-461,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 491\NH23-461,0.001,0,-0.07,0.023,0.028,0.017,-0.058,-0.113,-0.071,-0.105,-0.02,-0.003,-0.004,0.009,-0.043,0.043,-0.026,-0.034,0.002,-0.059,-0.032,-0.003,-0.014,-0.032,0.007,0.007,0.083,0.039,0.024,unmethylated
NH23-480,207244230048_R03C01,491,9/2/2023,3/1/2023,3/1/2023,20,MD,Diagnostic,491,1,NDP,Oxford John Radcliffe Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",,,,myxopapillary ependymoma,1,EPN_MPE,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-480,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 491\NH23-480,-0.363,-0.332,-0.19,-0.121,-0.035,-0.072,-0.299,-0.286,-0.368,-0.39,-0.325,0.202,0.211,0.201,0.168,0.212,-0.254,-0.226,-0.026,-0.024,-0.03,-0.035,0.008,0,0.006,-0.077,0.003,-0.298,-0.316,unmethylated
NH23-484,207244230048_R06C01,491,9/2/2023,3/1/2023,3/1/2023,20,MD,Diagnostic,491,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"glioblastoma, IDH-wildtype, RTK1 type",0.76,GBM_RTKI,0.49,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-484,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 491\NH23-484,0.306,-0.041,0.259,0.033,0.018,-0.009,-0.428,1.669,0.075,-0.109,0.039,-0.003,0.101,0.045,-1.628,0.251,-0.331,-0.427,0.001,0.109,-0.028,0.065,-0.007,0.026,0.08,0.151,0.313,0.043,0.107,methylated
NH23-485,207244230048_R07C01,491,9/2/2023,3/1/2023,3/1/2023,20,MD,Diagnostic,491,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"glioblastoma, IDH-wildtype, RTK2 type",0.92,GBM_RTKII,0.79,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-485,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 491\NH23-485,0.133,-0.012,0.076,0.062,0.02,-0.025,-0.052,1.658,0.233,0.175,0.203,0.032,0.13,0.082,0.001,-0.064,-0.474,-0.533,-0.208,-0.049,1.206,0.022,-0.075,-0.525,0.06,0.032,0.163,-0.043,0.079,methylated
NH23-490,207244230048_R08C01,491,9/2/2023,3/1/2023,3/1/2023,20,MD,Diagnostic,491,1,NDP,"Romford, Queen's Hospital",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.96,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-490,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 491\NH23-490,2.731,-0.135,0.135,-0.099,2.723,0.045,-0.163,0.33,0.165,0.798,0.352,0.228,-0.092,-0.076,0.043,0.141,-0.569,-0.647,-0.001,-0.121,1.936,0.123,-0.147,0.007,0.022,0.071,0.167,-0.072,0.184,methylated
NH23-496,207109600026_R01C01,492,10/2/2023,3/8/2023,3/8/2023,26,MD,Diagnostic,492,1,NDP,St George's Hospital London,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-496,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 492\NH23-496,-0.162,0.116,0.212,-0.259,-0.026,-0.003,-0.432,0.175,0.227,0.119,0.183,-0.004,0.358,-0.091,-1.635,0.022,-0.147,-0.278,0.019,-0.023,-0.087,0.077,-0.002,-0.284,0.187,0.147,0.134,-0.201,-0.092,unmethylated
NH23-445,207109600026_R04C01,492,10/2/2023,3/8/2023,3/8/2023,26,MD,Diagnostic,492,1,NDP,NHNN,Glioma,,,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-445,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 492\NH23-445,0.008,-0.081,0.029,-0.016,-0.007,0.292,-0.007,-0.712,-0.116,-0.084,0.031,0.011,0.01,0.143,-0.005,-0.034,-0.499,-0.474,-0.043,-0.011,-0.073,0.025,-0.73,-0.105,-0.04,0.007,0.102,-0.012,-0.023,unmethylated
NH23-446,207109600026_R06C01,492,10/2/2023,3/8/2023,3/8/2023,26,MD,Diagnostic,492,2,NDP,Cleveland Clinic London,Ependymoma,,,,,spinal ependymoma,0.59,EPN_SPINE,0.27,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-446,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 492\NH23-446,0.014,0.043,0.09,-0.092,-0.149,-0.013,-0.029,0.006,0.023,-0.023,0.037,-0.001,0.056,-0.085,0.032,0.136,-0.129,-0.073,-0.132,0.052,0.077,0.112,0.047,-0.042,-0.039,-0.008,-0.036,-0.241,-0.103,unmethylated
NH23-443,207109600026_R07C01,492,10/2/2023,3/8/2023,3/8/2023,26,MD,Diagnostic,492,2,NDP,"Romford, Queen's Hospital",Ependymoma,,,,,posterior fossa ependymoma group A1,0.07,PXA,0.07,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-443,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 492\NH23-443,0.204,-0.217,-0.01,-0.129,-0.061,-0.098,-0.373,-0.46,-0.046,-0.108,0.062,0.026,0.11,-0.158,-0.121,0.052,-0.064,-0.059,-0.11,-0.298,-0.048,0.199,0.059,-0.153,0.053,0.157,0.197,0.052,0.2,methylated
NH23-462,207109600026_R08C01,492,10/2/2023,3/8/2023,3/8/2023,26,MD,Diagnostic,492,5,NDP,NHNN,Astrocytoma,,,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.89,AIDH_HG,0.99,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-462,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 492\NH23-462,0.218,-0.142,-0.001,-0.132,-0.073,-0.489,-0.08,0.066,-0.097,0.089,-0.067,0.205,0.351,0.068,-0.347,0.214,-0.154,-0.308,-0.236,0.103,-0.327,-0.47,-0.406,-0.14,-0.018,-0.119,-0.05,-0.382,-0.229,methylated
NH23-457,207244230020_R01C01,493,10/2/2023,3/1/2023,3/1/2023,19,MD,Diagnostic,493,4,NDP,"Charing Cross Hospital, London",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.82,AIDH_HG,0.86,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-457,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 493\NH23-457,0.117,-0.032,0.076,-0.074,-0.01,0.033,-0.015,-0.043,-0.052,-0.067,-0.043,0.027,0.069,0.228,-0.624,-0.025,0.055,0.063,-0.015,0.007,-0.058,-0.002,-0.239,0.053,0.003,0.002,0.017,0,0.039,methylated
NH23-454,207244230020_R02C01,493,10/2/2023,3/1/2023,3/1/2023,19,MD,Diagnostic,493,4,NDP,Cleveland Clinic London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-454,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 493\NH23-454,-0.02,-0.231,0.039,-0.01,0.005,-0.077,-0.044,0.003,-0.006,-0.041,0.007,0.029,0.03,0.057,0.001,-0.004,-0.053,-0.083,-0.015,0.387,0.031,-0.262,-0.068,0.026,0.005,0.049,-0.03,-0.093,-0.095,methylated
NH23-510,207244230020_R05C01,493,14/02/2023,3/1/2023,3/1/2023,15,MD,Diagnostic,493,3,NDP,"Romford, Queen's Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.33,OIDH,0.26,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-510,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 493\NH23-510,-0.04,-0.056,-0.009,-0.063,-0.024,-0.009,-0.048,-0.052,0.007,-0.063,0.012,0.007,0.093,0.042,-0.017,0.009,0.023,-0.017,0.016,0.051,-0.093,-0.04,0.001,0.032,0.037,0.024,-0.048,-0.019,0.018,methylated
NH23-514,207244230020_R07C01,493,14/02/2023,3/1/2023,3/1/2023,15,MD,Diagnostic,493,1,NDP,St George's Hospital London,Reactive gliosis vs infiltration zone,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type D]",1,LGG_MYB,0.17,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-514,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 493\NH23-514,0.204,-0.031,0.047,0.069,-0.101,0.006,-0.029,0.187,0.147,0.071,0.084,-0.006,0.071,0.033,0.061,0.025,-0.013,-0.156,-0.007,-0.016,-0.003,0.086,0.056,0.105,0.123,0.112,-0.08,-0.014,0.017,unmethylated
NH23-513,207244230020_R08C01,493,14/02/2023,3/1/2023,3/1/2023,15,MD,Diagnostic,493,1,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,,,high-grade astrocytoma with piloid features,0.99,ANAPA,0.97,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-513,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 493\NH23-513,0.035,-0.011,0.034,0.008,-0.012,0.066,-0.029,-0.099,-0.044,-0.015,-0.016,0.015,0.003,0.058,-1.198,0.185,0.009,0.012,0.038,-0.063,0.012,0.061,0.016,0.033,-0.007,0.099,0.085,-0.037,-0.021,methylated
NH23-504,207134810153_R01C01,494,14/02/2023,3/1/2023,3/1/2023,15,MD,Diagnostic,494,1,NDP,Nottingham University Hospital,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,,,"Diffuse hemispheric glioma, H3 G34-mutant",1,GBM_G34,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-504,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 494\NH23-504,0.03,0.031,0.02,0.041,0.166,0.015,0.085,-0.082,-0.164,0.037,0.022,0.029,0.155,0.212,0.044,0.032,-0.336,-0.448,-0.087,0.096,-0.124,-0.008,-0.325,-0.159,-0.135,-0.06,0.038,-0.169,-0.098,methylated
NH23-505,207134810153_R02C01,494,14/02/2023,3/1/2023,3/1/2023,15,MD,Diagnostic,494,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,,,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.92,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-505,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 494\NH23-505,0.103,-0.004,0.019,0.036,0.086,-0.007,-0.432,1.491,0.328,0.27,0.258,0.004,0.107,0.082,0.027,-0.011,-1.287,-0.022,0.037,0.077,0.957,0.027,-0.016,-0.437,0.02,0.037,0.247,-0.004,0.063,unmethylated
NH23-507,207134810153_R03C01,494,14/02/2023,3/1/2023,3/1/2023,15,MD,Diagnostic,494,1,NDP,Nottingham University Hospital,Spinal ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,,,spinal ependymoma,0.78,EPN_SPINE,0.46,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-507,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 494\NH23-507,0.029,-0.052,0.061,-0.158,-0.071,0.015,-0.061,0.022,0.044,-0.053,0.014,-0.06,-0.031,-0.106,0.07,-0.011,0.025,0.014,-0.026,-0.037,-0.001,0.085,-0.165,-0.021,0.014,0.001,0.033,-0.463,-0.426,unmethylated
NH16-356,207134810153_R06C01,494,14/02/2023,3/1/2023,3/1/2023,15,MD,Diagnostic,494,1,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.95,AIDH,0.94,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-356,#N/A,#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 494\NH16-356,-0.063,-0.071,0.07,0.057,-0.145,-0.229,-0.754,-0.177,-0.065,-0.137,-0.017,0.084,0.141,-0.365,-0.171,0.21,-0.069,-0.193,-0.036,-0.11,0.142,0.167,-0.106,0.053,-0.069,0.031,-0.469,0.038,0.162,methylated
NH23-435,207134810153_R07C01,494,14/02/2023,3/1/2023,3/1/2023,15,MD,Diagnostic,494,1,NDP,"Romford, Queen's Hospital",White matter?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"control tissue, white matter (corpus callosum)",0.18,CONTR_HEMI,0.3,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-435,"White matter - non diagnostic (see comment)
",#N/A,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 494\NH23-435,-0.034,-0.04,0.046,-0.044,-0.055,0.027,-0.012,-0.054,-0.024,-0.102,-0.026,0,0.107,-0.007,-0.033,-0.047,0.033,0.041,0.021,-0.067,-0.036,-0.008,0.062,-0.005,0.004,-0.013,0.04,-0.055,0.073,unmethylated
NH23-560,207134810036_R02C01,495,16/02/2023,3/10/2023,3/10/2023,22,MD,Diagnostic,495,1,NDP,"LATVIA, Riga, Children's Clinic University Hospital",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B514,,,dysembryoplastic neuroepithelial tumour,0.8,LGG_DNT,0.74,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-560,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 495\NH23-560,0.076,-0.013,0.062,0.034,0.194,-0.145,-0.244,-0.042,0.032,-0.194,-0.059,0.08,0.101,-0.342,-0.097,0.054,-0.128,-0.054,0.091,-0.339,0.104,0.089,-0.094,-0.233,-0.385,0.15,0.086,-0.3,0.073,unmethylated
NH23-571,207134810036_R03C01,495,16/02/2023,3/10/2023,3/10/2023,22,MD,Diagnostic,495,1,NDP,Oxford John Radcliffe Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.94,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-571,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 495\NH23-571,0.012,0.017,0.184,-0.066,0.126,-0.068,-0.315,0.017,-0.047,0.155,0.232,-0.049,0.106,0.28,-0.057,-0.014,0.034,-0.006,-0.012,-0.044,0.047,-0.035,-0.06,0.059,-0.109,0.014,-0.528,-0.077,0.004,unmethylated
NH23-562,207134810036_R06C01,495,16/02/2023,3/10/2023,3/10/2023,22,MD,Diagnostic,495,2,NDP,"LATVIA, Riga, Children's Clinic University Hospital",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",599-600,,,ganglioglioma,0.84,LGG_PA_GGST,0.31,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-562,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 495\NH23-562,0.062,0.038,0.113,0.038,-0.043,-0.026,-0.111,-0.078,-0.089,-0.125,-0.041,0.006,0.072,-0.015,-0.07,0.019,0.087,0.092,0.092,-0.027,-0.048,-0.078,0.077,0.096,0,0.071,0.053,-0.062,-0.04,unmethylated
NH23-509,207134810036_R07C01,495,16/02/2023,3/10/2023,3/10/2023,22,MD,Diagnostic,495,7,NDP,"Romford, Queen's Hospital","HGG, IDH mutant","(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,PXA,0.11,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-509,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 495\NH23-509,-0.037,-0.012,0.064,-0.008,0.098,0.06,-0.034,-0.062,-0.143,-0.203,-0.056,0.038,0.022,-0.008,-0.003,-0.002,0.017,-0.006,-0.101,-0.099,-0.069,-0.086,-0.132,-0.043,-0.016,0.058,-0.108,0.01,0.033,methylated
NH23-525,207134810036_R08C01,495,16/02/2023,3/10/2023,3/10/2023,22,MD,Diagnostic,495,3,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.9,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-525,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 495\NH23-525,0.052,-0.022,0.034,0.036,0.001,0.041,-0.224,-0.251,-0.201,-0.058,0.104,-0.018,-0.047,-0.032,-0.04,-0.136,-0.185,-0.095,-0.099,-0.093,-0.059,-0.023,-0.05,-0.058,-0.079,0.04,-0.264,0.081,-0.017,methylated
NH23-482,207108790102_R01C01,496,16/02/2023,3/8/2023,3/8/2023,20,MD,Diagnostic,496,1,NDP,"Charing Cross Hospital, London",Pleomorphic xanthoastrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.52,GBM_MES,0.22,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-482,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 496\NH23-482,0.265,0.254,0.065,-0.188,-0.191,-0.045,0.004,0.142,0.305,0.223,0.324,-0.026,0.002,-0.109,0.326,0.297,-0.035,-0.065,0.178,-0.093,0.126,0.002,0.068,-0.068,-0.144,-0.033,0.473,0.022,-0.091,unmethylated
NH23-550,207108790102_R02C01,496,16/02/2023,3/8/2023,3/8/2023,20,MD,Diagnostic,496,1,NDP,"Birmingham, Queen Elizabeth Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",B5,,,posterior fossa subependymoma,1,SUBEPN_PF,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-550,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 496\NH23-550,0.009,-0.034,0.08,0.056,0.021,-0.012,-0.239,-0.153,-0.16,-0.095,0.027,0.004,0.019,-0.029,-0.055,-0.036,-0.067,-0.049,-0.056,-0.155,-0.019,0.082,-0.006,0.011,-0.042,-0.038,0.212,0.023,0.029,unmethylated
NH23-589,207108790102_R06C01,496,16/02/2023,3/8/2023,3/8/2023,20,MD,Diagnostic,496,1,NDP,"Romford, Queen's Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A4,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.97,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-589,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 496\NH23-589,-0.038,0.005,0.051,0.009,0.145,0.143,-0.008,-0.148,0.113,0.023,0.155,0.009,0.121,0.256,-0.128,-0.03,0.062,0.056,-0.061,0.134,-0.065,-0.016,-0.02,-0.025,0.019,0.073,-0.107,-0.042,0.065,methylated
NH23-545,207108790102_R07C01,496,16/02/2023,3/8/2023,3/8/2023,20,MD,Diagnostic,496,1,NDP,"Liverpool, The Walton Centre",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-545,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 496\NH23-545,0.063,-0.023,0.082,0.082,0.06,0.052,-0.082,-0.23,-0.122,-0.289,0.048,0.026,0.017,-0.073,-0.267,-0.036,-0.199,-0.088,-0.042,-0.102,-0.111,0.008,-0.034,-0.032,-0.136,0.01,-0.395,0.076,0.089,methylated
NH23-543,207108790102_R08C01,496,16/02/2023,3/8/2023,3/8/2023,20,MD,Diagnostic,496,1,NDP,Southampton General Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,OIDH,0.93,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-543,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 496\NH23-543,0.191,-0.048,0.027,-0.545,-0.504,0.015,-0.029,0.112,0.228,0.16,0.369,0.018,0.018,-0.133,-0.054,-0.006,-0.109,-0.081,0.217,-0.103,-0.006,0.05,-0.028,-0.01,-0.11,0.03,-0.393,0.024,-0.042,methylated
NH23-551,207134810113_R01C01,497,16/02/2023,3/1/2023,3/1/2023,13,MD,Diagnostic,497,1,NDP,Southampton General Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,,,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.87,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-551,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 497\NH23-551,-0.059,-0.042,-0.016,0.046,-0.008,0.053,0.16,0.035,0.159,0.076,0.186,0.013,0.023,-0.006,0.11,0.106,0.106,0.18,0.202,0.08,0.082,0.215,0.003,-0.11,0.007,-0.055,0.05,0.007,0.058,methylated
NH23-542,207134810113_R02C01,497,16/02/2023,3/1/2023,3/1/2023,13,MD,Diagnostic,497,1,NDP,Southampton General Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1D,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-542,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 497\NH23-542,0.022,0.067,0.061,-0.12,0.029,-0.054,-0.021,-0.021,-0.008,-0.117,-0.05,0.028,0.052,0.116,-0.633,0.047,0.017,0.001,0.079,-0.001,0.042,-0.026,-0.133,0.093,-0.043,-0.003,-0.516,-0.033,0.041,methylated
NH20-848,207134810113_R04C01,497,16/02/2023,3/1/2023,3/1/2023,13,MD,Diagnostic,497,23,NDP,,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.82,OIDH,0.5,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH20-848,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 497\NH20-848,0.105,-0.06,-0.02,0.034,0.049,0.051,-0.001,-0.114,-0.048,-0.073,0.022,0.018,-0.003,0.071,-0.011,0.016,0.026,-0.067,0.039,-0.069,0.022,0.06,-0.485,0.033,0.037,-0.033,-0.452,-0.007,0.068,methylated
NH20-1320,207134810113_R05C01,497,16/02/2023,3/1/2023,3/1/2023,13,MD,Diagnostic,497,1,NDP,,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP2A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,1,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1320,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 497\NH20-1320,0.205,-0.116,0.002,0.067,0.01,0.257,-0.375,-0.023,-0.086,-0.019,0.019,0.032,0.086,0.353,0.096,0.276,0.041,-0.612,-0.002,0.036,0.085,0.127,-0.515,0.045,0.089,0.056,-0.373,-0.039,0.085,methylated
NH23-596,207134810113_R06C01,497,16/02/2023,3/1/2023,3/1/2023,13,MD,Diagnostic,497,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.91,GBM_MID,0.97,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-596,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 497\NH23-596,-0.021,-0.054,0.063,-0.084,-0.056,-0.438,0.019,-0.067,-0.036,-0.117,-0.065,-0.02,0.106,-0.001,-2.869,0.497,-0.209,-0.187,0.028,-0.05,-0.048,0.028,-0.448,-0.517,0.376,0.314,-0.329,-0.484,-0.502,unmethylated
NH23-563,207134810113_R07C01,497,16/02/2023,3/1/2023,3/1/2023,13,MD,Diagnostic,497,1,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-563,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 497\NH23-563,-0.004,-0.014,0.02,-0.152,-0.138,-0.011,0.07,-0.041,-0.005,-0.018,-0.005,-0.033,0.115,0.015,0.004,-0.03,-0.04,0.014,-0.002,-0.195,-0.192,-0.248,-0.053,0.03,-0.03,0.014,-0.496,0.062,0.093,methylated
NH23-568,207134810113_R08C01,497,16/02/2023,3/1/2023,3/1/2023,13,MD,Diagnostic,497,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.41,AIDH,0.42,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-568,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 497\NH23-568,0.037,0.095,0.063,-0.004,-0.003,-0.083,-0.086,-0.091,-0.033,0.09,0.113,0.046,0.126,-0.027,0.017,0.038,0.05,-0.07,0.011,0.113,-0.087,-0.146,0.003,0.124,0.077,0.088,-0.07,0.006,0.09,methylated
NH23-567,207134810117_R01C01,498,16/02/2023,3/1/2023,3/1/2023,13,MD,Diagnostic,498,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A4,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.94,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-567,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 498\NH23-567,0.003,0.041,0.103,-0.048,0.017,-0.085,-0.146,0.366,0.205,0.13,0.195,0.021,0.087,0.032,-0.072,0.1,-0.044,-0.079,0.054,0.244,0.08,0.044,-0.117,0,-0.028,0.013,-0.043,-0.022,0.139,unmethylated
NH23-566,207134810117_R02C01,498,16/02/2023,3/1/2023,3/1/2023,13,MD,Diagnostic,498,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.61,AIDH_HG,0.86,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-566,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 498\NH23-566,0.147,0.183,0.07,0.095,1.156,-0.036,0.016,-0.202,0.208,0.115,0.198,0.117,0.147,0.107,-0.179,-0.071,-0.259,-0.381,0.147,0.116,0.029,-0.034,-0.108,0.175,0.032,-0.009,0.063,0.096,0.152,methylated
NH17-2416,207134810117_R03C01,498,20/02/2023,3/1/2023,3/1/2023,9,MD,Diagnostic,498,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,,,high-grade astrocytoma with piloid features,0.95,PXA,0.6,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH17-2416,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 498\NH17-2416,0.043,-0.073,0.037,0.011,-0.011,0.253,-0.103,0.141,0.122,0.143,0.258,0.057,0.168,0.19,-0.899,0.002,-0.016,-0.084,0.024,-0.118,0.015,0.097,-0.204,0.071,-0.165,-0.166,0.126,0.067,0.121,unmethylated
NH23-594,207134810117_R05C01,498,20/02/2023,3/1/2023,3/1/2023,9,MD,Diagnostic,498,1,NDP,Nottingham University Hospital,PA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,,,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-594,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 498\NH23-594,-0.006,-0.044,0.02,0.035,-0.009,0.033,-0.031,-0.029,-0.028,-0.061,0.242,-0.002,0.079,0.03,0.007,0.012,0,-0.012,0.032,-0.036,-0.045,0.011,0,0.001,0.004,-0.007,-0.013,-0.026,0.028,unmethylated
NH23-597,207134810117_R08C01,498,20/02/2023,3/1/2023,3/1/2023,9,MD,Diagnostic,498,1,NDP,Nottingham University Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.74,AIDH,0.97,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-597,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 498\NH23-597,0.024,-0.108,0.034,0.004,0.013,0.025,-0.208,-0.127,-0.071,-0.126,0.013,0.009,0.029,0.083,-0.004,-0.039,-0.027,-0.017,-0.007,0.029,-0.079,-0.051,-0.036,-0.005,-0.006,0.022,0.033,0.099,0.182,methylated
NH23-564,207244230026_R01C01,499,20/02/2023,3/8/2023,3/8/2023,16,MD,Diagnostic,499,1,NDP,NHNN,PA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,supratentorial midline pilocytic astrocytoma,0.58,LGG_PAMID,0.6,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-564,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 499\NH23-564,-0.041,-0.018,0.091,-0.068,-0.036,-0.013,0.191,-0.027,-0.078,-0.182,-0.062,0.021,0.058,-0.098,-0.07,-0.031,-0.067,0.02,0.014,-0.067,-0.051,-0.189,-0.005,0.083,-0.013,0.008,0.027,-0.056,-0.025,unmethylated
NH23-555,207244230026_R02C01,499,20/02/2023,3/8/2023,1/0/1900,-44977,MD,Diagnostic,499,1,NDP,"Romford, Queen's Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.37,GBM_MES,0.65,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-555,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 499\NH23-555,-0.008,-0.035,0.122,0.052,0.005,-0.058,-0.033,0.122,0.094,0.052,0.027,0.029,0.023,0.006,-0.276,-0.081,-0.037,-0.142,-0.035,-0.093,-0.058,0.058,0.054,0.027,-0.032,-0.004,0.104,-0.151,0.1,methylated
NH23-641,207244230026_R06C01,499,22/02/2023,3/8/2023,NA,#VALUE!,MD,Diagnostic,499,1,NDP,Southampton General Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1C,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-641,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 499\NH23-641,-0.098,-0.012,0.101,-0.043,0.035,-0.006,-0.001,-0.035,-0.078,-0.158,-0.052,0.033,0.174,-0.027,-0.028,-0.008,0.078,0.026,0.029,-0.094,-0.096,0.021,0.004,0.047,-0.01,0.031,-0.528,-0.024,-0.015,methylated
NH23-630,207134810004_R06C01,500,22/02/2023,3/10/2023,3/10/2023,16,MD,Diagnostic,500,1,NDP,St George's Hospital London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-630,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 500\NH23-630,-0.003,-0.011,0.091,-0.087,0.066,-0.378,-0.091,0.064,-0.002,-0.181,-0.022,0.065,0.117,0.081,-0.047,0.08,-0.037,-0.144,0.236,0.156,-0.118,-0.212,0.051,0.089,-0.044,-0.03,0.001,-0.057,0.053,methylated
NH23-629,207134810004_R07C01,500,22/02/2023,3/10/2023,3/10/2023,16,MD,Diagnostic,500,1,NDP,St George's Hospital London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,,,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.9,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-629,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 500\NH23-629,-0.013,-0.011,0.079,-0.136,0.03,-0.177,-0.125,1.499,0.164,0.05,0.115,0.013,0.116,-0.04,-0.77,0.012,-0.306,-0.297,0.01,-0.046,0.042,-0.014,0.037,-0.005,0.069,0.088,0.235,-0.075,0.07,unmethylated
NH23-288,207134810004_R08C01,500,27/02/2023,3/10/2023,3/10/2023,11,MD,Diagnostic,500,2,NDP,Royal London Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.29,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-288,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 500\NH23-288,0.034,-0.001,0.024,0.058,0.009,0.01,0.025,-0.14,0.029,-0.062,0.116,0.023,0.05,-0.045,-0.425,-0.049,-0.21,-0.153,-0.064,-0.116,-0.04,0.163,0.056,0.044,-0.015,0.12,0.327,-0.185,-0.087,unmethylated
NH23-707,207321890008_R04C01,501,22/02/2023,3/22/2023,3/22/2023,28,MD,Diagnostic,501,1,NDP,Oxford John Radcliffe Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2B,,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.95,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-707,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 501\NH23-707,-0.013,-0.007,0.058,0.022,0.096,0.024,-0.042,0.021,0.137,0.169,0.217,0.034,0.023,-0.14,-1.693,-0.072,-0.537,-0.421,-0.068,-0.051,-0.078,0.128,0.013,-0.007,-0.124,-0.143,0.148,-0.046,-0.084,unmethylated
NH23-696,207321890008_R05C01,501,22/02/2023,3/22/2023,3/22/2023,28,MD,Diagnostic,501,3,NDP,Southampton General Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,0.97,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-696,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 501\NH23-696,-0.052,-0.113,0.083,-0.055,0.063,-0.061,-0.025,-0.053,-0.096,-0.154,-0.06,0.055,0.156,-0.164,-0.053,-0.002,0.074,-0.007,-0.061,0.003,-0.13,-0.137,-0.033,-0.007,-0.094,0.152,-0.573,-0.112,-0.097,methylated
NH23-695,207321890008_R06C01,501,22/02/2023,3/22/2023,3/22/2023,28,MD,Diagnostic,501,1,NDP,Southampton General Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-695,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 501\NH23-695,0.12,-0.356,-0.065,-0.309,-0.574,0.021,-0.167,-0.312,-0.288,-0.086,-0.033,0.077,0.188,-0.161,-0.06,-0.113,-0.239,-0.078,-0.244,-0.074,-0.062,0.101,0.105,-0.168,-0.189,-0.128,-0.276,-0.005,0.036,methylated
NH23-662,207321890008_R07C01,501,27/02/2023,3/22/2023,3/22/2023,23,MD,Diagnostic,501,1,NDP,Brighton and Sussex Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.82,GBM_MES,0.65,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-662,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 501\NH23-662,-0.098,-0.757,0.003,0.013,-0.089,0.002,-0.221,-0.119,-0.257,0.067,0.187,0.055,0.233,-0.346,-0.693,-0.036,-0.273,-0.05,-0.051,-0.45,-0.25,-0.059,-0.099,-0.594,-0.488,0.098,0.507,-0.277,-0.225,unmethylated
NH22-93,207321890008_R08C01,501,22/02/2023,3/22/2023,3/22/2023,28,MD,Diagnostic,501,5,NDP,"Romford, Queen's Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.57,AIDH_HG,0.72,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-642,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 501\NH22-93,0.103,-0.236,0.154,0.03,0.292,0.158,-0.275,-0.398,-0.257,-0.246,0.004,0.263,0.165,-0.003,-0.098,0.016,-0.218,-0.326,-0.362,-0.324,-0.187,-0.066,-0.411,-0.109,-0.096,-0.071,0.014,0.089,-0.007,methylated
NH23-602,207321890077_R02C01,502,22/02/2023,3/22/2023,3/22/2023,28,MD,Diagnostic,502,4,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-602,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 502\NH23-602,-0.027,-0.082,0.052,-0.231,0.027,0.059,-0.004,-0.212,0.386,0.351,0.377,0.015,-0.011,-0.032,0.016,0.002,-0.02,-0.032,0.008,-0.056,-0.052,-0.031,-0.037,-0.024,-0.089,0.017,-0.396,0.025,-0.01,methylated
NH23-609,207321890077_R03C01,502,22/02/2023,3/22/2023,3/22/2023,28,MD,Diagnostic,502,1,NDP,"Romford, Queen's Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.82,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-609,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 502\NH23-609,-0.012,-0.057,0.043,-0.189,-0.024,0.08,-0.014,0.19,0.316,0.333,0.332,0.032,0.091,-0.013,0.016,-0.039,-0.285,-0.342,-0.037,-0.087,0.953,2.242,-0.272,-0.075,0.005,0.089,0.097,-0.024,0.007,unmethylated
NH23-103,207321890077_R04C01,502,22/02/2023,3/22/2023,3/22/2023,28,MD,Diagnostic,502,1,NDP,"Charing Cross Hospital, London",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.8,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-103,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 502\NH23-103,0.053,-0.217,0.027,-0.324,0.161,-0.193,-0.113,1.887,0.172,0.178,0.195,-0.531,0,1.191,-2.692,0.121,-0.681,-0.792,-0.137,0.18,0.047,0.087,0.058,-0.676,-0.032,0.047,-0.833,0.15,0.225,methylated
NH23-624,207321890077_R05C01,502,22/02/2023,3/22/2023,3/22/2023,28,MD,Diagnostic,502,3,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.83,AIDH_HG,0.86,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-624,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 502\NH23-624,0.015,0.017,0.046,-0.037,-0.02,-0.128,0.012,-0.038,-0.052,-0.153,0.162,0.016,0.11,0.142,-1.371,0.035,-0.055,-0.153,0.195,0.027,0.003,-0.014,-0.245,0.011,0.016,-0.013,-0.14,-0.072,0.013,methylated
NH23-713,207321890077_R08C01,502,22/02/2023,3/22/2023,3/22/2023,28,MD,Diagnostic,502,1,NDP,"Liverpool, The Walton Centre",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.7,,,,,NH23-713,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 502\NH23-713,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NH23-714,207321890010_R01C01,503,22/02/2023,3/22/2023,3/22/2023,28,MD,Diagnostic,503,1,NDP,"Liverpool, The Walton Centre",,,,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.95,AIDH,0.95,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-714,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 503\NH23-714,-0.145,-0.021,0.132,-0.014,0.049,-0.252,0.161,-0.133,0.046,0.031,0.132,0.044,0.039,-0.144,-0.017,0.021,-0.244,-0.317,-0.047,-0.087,-0.113,-0.121,0.016,0.003,-0.024,0.064,-0.056,-0.091,0.036,methylated
NH23-638,207321890010_R03C01,503,22/02/2023,3/22/2023,3/22/2023,28,MD,Diagnostic,503,1,NDP,Royal London Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.61,GBM_MES,0.73,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-638,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 503\NH23-638,-0.039,-0.008,0.06,-0.116,0.035,-0.017,0.106,0.176,-0.001,-0.102,0.068,0.028,0.087,-0.029,0.03,0.038,-0.133,-0.24,0.027,-0.088,-0.112,-0.016,-0.024,0.037,0.03,0.021,0.043,-0.246,-0.204,methylated
NH23-625,207321890010_R04C01,503,22/02/2023,3/22/2023,3/22/2023,28,MD,Diagnostic,503,2,NDP,Cleveland Clinic London,Diffuse midline glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF3A,,,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.51,DMG_K27,0.62,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-625,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 503\NH23-625,0.038,-0.012,0.103,-0.087,-0.052,0.012,-0.208,-0.163,-0.096,0.074,0.141,0.128,0.204,0.031,0.105,0.074,-0.173,-0.084,-0.112,-0.097,-0.085,0.048,-0.021,-0.124,-0.036,0.07,0.12,-0.018,-0.018,unmethylated
NH23-644,207321890010_R05C01,503,22/02/2023,3/22/2023,3/22/2023,28,MD,Diagnostic,503,7,NDP,Cleveland Clinic London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-644,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 503\NH23-644,-0.028,-0.067,0.076,-0.082,-0.005,-0.015,0.098,-0.094,-0.103,-0.157,-0.066,0.072,0.123,-0.052,-0.033,0.001,0.014,-0.011,-0.032,-0.096,-0.089,-0.042,-0.027,0.007,-0.018,0.044,-0.023,-0.075,-0.017,unmethylated
NH23-717,207321890059_R01C01,504,24/02/2023,3/22/2023,3/22/2023,26,MD,Diagnostic,504,1,NDP,"Cardiff, University Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,,,"glioblastoma, IDH-wildtype, RTK2 type",0.82,GBM_RTKII,0.73,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-717,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 504\NH23-717,0.093,-0.392,-0.004,0.313,0.247,-0.188,-0.759,-0.462,-0.117,-0.057,0.141,0.223,-0.335,-0.329,-1.985,0.268,-0.896,-0.835,-0.522,-0.071,0.385,0.771,-0.492,-0.218,-0.41,-0.04,-0.226,0.012,-0.07,methylated
NH23-720,207321890059_R02C01,504,24/02/2023,3/22/2023,3/22/2023,26,MD,Diagnostic,504,1,NDP,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.87,GBM_MES,0.71,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-720,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 504\NH23-720,-0.021,-0.007,0.097,-0.189,-0.14,-0.022,0.119,0.032,0.073,-0.076,0.018,-0.11,0.003,-0.229,0.186,0.119,-0.086,-0.24,0.08,-0.297,-0.05,0.07,-0.432,-0.046,-0.014,0.014,-0.171,-0.207,0.01,unmethylated
NH23-722,207321890059_R04C01,504,24/02/2023,3/22/2023,3/22/2023,26,MD,Diagnostic,504,1,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,,,infratentorial pilocytic astrocytoma,1,LGG_PAPF,1,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-722,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 504\NH23-722,-0.083,0.085,0.02,-0.047,-0.014,-0.143,0.013,-0.107,0.049,-0.105,0.19,0.084,0.074,-0.034,0.075,0.084,-0.021,-0.134,0.001,-0.005,0.016,0.087,0.082,0.007,0.01,0.027,-0.271,-0.154,0.027,unmethylated
NH23-766,207321890059_R05C01,504,24/02/2023,3/22/2023,3/22/2023,26,MD,Diagnostic,504,1,NDP,"Belfast, Royal Victoria Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,high-grade astrocytoma with piloid features,0.97,ANAPA,0.82,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-766,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 504\NH23-766,0.083,-0.019,0.005,-0.303,-0.068,-0.096,0.069,-0.081,-0.08,-0.151,-0.03,0.034,0.057,0.189,-1.424,0.436,0.004,-0.045,-0.062,-0.022,-0.041,0.017,0.045,-0.477,-0.278,0.282,-0.485,-0.062,0.024,methylated
NH21-1298,207321890059_R07C01,504,24/02/2023,3/22/2023,3/22/2023,26,MD,Diagnostic,504,1,NDP,St George's Hospital London,Glioneuronal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,,,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type C]",0.24,DMG_K27,0.07,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-1298,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 504\NH21-1298,0.394,-0.309,-0.039,0.035,-0.044,-0.01,-0.317,-0.278,-0.022,-0.08,0.157,0.021,-0.189,-0.507,-0.092,0.22,-0.147,-0.166,0.115,-0.015,0.261,1.482,-0.127,-0.385,-0.19,0.061,-0.019,0.026,0.073,methylated
NH23-724,207244230038_R02C01,505,24/02/2023,3/17/2023,3/17/2023,21,MD,Diagnostic,505,1,NDP,Brighton and Sussex Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1C,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-724,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 505\NH23-724,0.039,-0.04,0.094,-0.14,0.024,-0.015,0.03,0.01,-0.006,-0.109,-0.038,0.019,0.098,0.007,-0.176,-0.181,0.018,0.039,0.113,-0.006,-0.113,-0.251,-0.008,0.047,-0.066,-0.041,-0.484,-0.04,0.056,methylated
NH23-737,207244230038_R03C01,505,24/02/2023,3/17/2023,3/17/2023,21,MD,Diagnostic,505,3,NDP,Southampton General Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.46,GBM_RTKII,0.61,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-737,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 505\NH23-737,0.001,-0.012,0.082,-0.073,-0.035,-0.04,-0.392,0.434,0.136,0.089,0.136,-0.023,0.083,-0.062,-0.649,-0.005,-0.057,0.046,0.011,-0.043,-0.064,-0.021,-0.266,0.014,-0.051,-0.057,-0.044,-0.308,-0.254,unmethylated
NH23-738,207244230038_R04C01,505,24/02/2023,3/17/2023,3/17/2023,21,MD,Diagnostic,505,4,NDP,Brighton and Sussex Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"glioblastoma, IDH-wildtype, RTK2 type",0.3,GBM_RTKII,0.75,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-738,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 505\NH23-738,0.007,-0.056,0.098,-0.189,-0.214,-0.057,0.017,0.19,0.102,0.099,0.123,0.009,0.076,-0.071,0.012,-0.002,-0.401,-0.318,0.023,-0.231,-0.161,-0.22,-0.573,-0.069,-0.164,-0.123,-0.301,-0.385,-0.374,methylated
NH23-778,207244230038_R07C01,505,24/02/2023,3/17/2023,3/17/2023,21,MD,Diagnostic,505,1,NDP,"Birmingham, Queen Elizabeth Hospital",IDH1 mutant glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B2,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.22,OIDH,0.32,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-778,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 505\NH23-778,-0.01,0.068,0.04,0.033,0.052,-0.001,-0.05,-0.247,-0.133,-0.158,0.026,0.033,0.044,-0.166,-0.02,-0.087,-0.039,-0.032,-0.044,-0.129,-0.082,0.06,-0.008,-0.083,-0.097,-0.035,0.256,0.016,-0.006,unmethylated
NH23-790,207244230038_R08C01,505,24/02/2023,3/17/2023,3/17/2023,21,MD,Diagnostic,505,1,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"glioblastoma, IDH-wildtype, RTK1 type",0.99,GBM_RTKI,0.78,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-790,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 505\NH23-790,0.056,-0.06,0.183,-0.446,-0.414,-0.16,0.013,0.333,0.147,0.132,0.211,0.054,0.206,-0.01,-2.035,0.021,-0.447,-0.336,0.058,-0.016,-0.051,-0.025,-0.183,-0.368,-0.072,-0.136,-0.605,0.012,-0.045,unmethylated
NH23-791,207244230119_R01C01,506,24/02/2023,3/17/2023,3/17/2023,21,MD,Diagnostic,506,1,NDP,Nottingham University Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-791,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 506\NH23-791,0.041,-0.136,0.008,-0.019,-0.05,0.024,0.03,-0.247,-0.135,-0.113,-0.011,0.057,0.133,-0.099,-0.061,-0.109,-0.01,-0.077,-0.072,-0.127,-0.139,0.047,-0.105,-0.03,-0.147,-0.04,-0.253,0.004,-0.044,methylated
NH23-795,207244230119_R02C01,506,24/02/2023,3/17/2023,3/17/2023,21,MD,Diagnostic,506,1,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.99,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-795,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 506\NH23-795,0.008,-0.109,0.034,0.007,0.103,-0.031,-0.055,-0.179,-0.142,-0.196,0.161,-0.03,0.09,-0.085,0.049,-0.052,-0.39,-0.608,-0.069,-0.038,-0.035,0.009,-0.531,-0.044,-0.011,0.041,-0.057,-0.013,-0.092,methylated
NH23-803,207244230119_R03C01,506,24/02/2023,3/17/2023,3/17/2023,21,MD,Diagnostic,506,1,NDP,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-803,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 506\NH23-803,0.05,-0.067,0.122,-0.028,0.029,-0.062,-0.043,0.061,-0.081,-0.12,-0.038,0.012,0.04,-0.119,0.018,0.01,-0.011,0.025,-0.006,-0.02,-0.298,-0.613,-0.009,0.026,-0.102,-0.075,0.014,-0.047,-0.025,unmethylated
NH23-807,207244230119_R06C01,506,24/02/2023,3/17/2023,3/17/2023,21,MD,Diagnostic,506,4,NDP,Oxford John Radcliffe Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,,,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.27,0.67,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-807,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 506\NH23-807,0.013,-0.085,0.027,0.027,0.019,0.027,0.034,-0.073,0.142,0.118,0.176,0.027,0.087,-0.072,-0.558,-0.253,-0.258,-0.254,-0.076,-0.133,-0.104,0.041,-0.149,-0.215,-0.111,0.042,0.183,-0.001,0.023,unmethylated
NH23-639,207244230119_R08C01,506,24/02/2023,3/17/2023,3/17/2023,21,MD,Diagnostic,506,1,NDP,Royal London Hospital,Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",,,,posterior fossa subependymoma,0.99,SUBEPN_PF,0.97,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-639,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 506\NH23-639,-0.019,-0.208,0.121,0.195,-0.026,0.117,-0.091,-0.356,-0.253,-0.215,-0.037,0.091,0.146,-0.058,-0.057,-0.073,-0.115,-0.023,0.035,-0.219,-0.216,0.126,-0.016,-0.054,-0.239,-0.643,0.366,0.107,0.059,unmethylated
NH19-2683,207321900056_R01C01,507,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,507,1,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.39,AIDH,0.49,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH19-2683,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 507\NH19-2683,0.127,-0.307,0.143,0.004,0.108,-0.041,-0.24,1.378,0.035,0.138,0.209,0.081,-0.044,-0.07,-0.525,-0.018,-0.251,-0.39,-0.052,-0.149,0.062,1.275,-0.068,0.037,-0.064,0.058,0.201,-0.128,-0.031,unmethylated
NH23-748,207321900056_R02C01,507,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,507,1,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-748,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 507\NH23-748,-0.071,-0.021,0.078,-0.18,-0.168,-0.011,-0.183,-0.008,-0.048,-0.073,-0.045,0.029,0.103,-0.039,-0.163,-0.175,-0.156,-0.108,0.117,-0.069,-0.118,-0.07,0,0.024,-0.02,-0.016,-0.461,-0.03,-0.005,methylated
NH16-2094,207321900056_R03C01,507,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,507,1,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH16-2094,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 507\NH16-2094,0.064,0.119,0.156,-0.197,0.009,-0.118,-0.226,0.016,0.022,-0.173,-0.032,0.045,0.088,0.07,-0.134,0.138,-0.186,-0.336,0.124,-0.056,0.064,-0.048,-0.019,0.141,-0.031,0.136,-0.675,-0.025,0.114,methylated
NH23-753,207321900056_R05C01,507,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,507,1,NDP,NHNN,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,,,myxopapillary ependymoma,1,EPN_MPE,1,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-753,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 507\NH23-753,-0.228,0.023,0.055,0.037,0.063,-0.009,-0.04,-0.041,0.015,-0.005,0.083,-0.179,-0.111,-0.223,-0.049,-0.027,-0.228,-0.202,-0.067,-0.103,-0.102,0.043,-0.104,-0.14,-0.072,-0.049,0.134,-0.09,-0.148,unmethylated
NH23-785,207321900056_R07C01,507,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,507,1,NDP,NHNN,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.86,AIDH,0.53,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-785,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 507\NH23-785,-0.014,-0.056,0.047,0.018,0.094,0.053,-0.034,-0.141,-0.106,-0.127,0.008,0.004,0.056,-0.133,-0.233,-0.059,-0.118,-0.078,-0.073,-0.154,-0.119,0.02,-0.379,-0.003,-0.029,0.098,-0.288,0.018,-0.035,methylated
NH15-2146,207321900056_R08C01,507,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,507,1,NDP,NHNN,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.49,OIDH,0.67,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH15-2146,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 507\NH15-2146,-0.32,-0.174,0.25,-0.001,-0.18,-0.038,-0.04,0.191,-0.293,-0.356,0.062,0.058,0.52,-0.464,-0.201,0.23,0.055,-0.04,0.079,0.117,-0.524,0.217,0.065,-0.396,-0.402,-0.175,-0.704,-0.082,-0.351,methylated
NH23-813,207321900006_R02C01,508,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,508,1,NDP,"Liverpool, The Walton Centre",IDH mutant glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-813,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 508\NH23-813,0.05,0.053,0.038,0.062,0.122,0.011,-0.042,-0.107,-0.073,-0.148,0.042,0.011,0.076,0.122,-0.014,-0.04,-0.088,-0.041,0.042,-0.011,0.021,-0.119,-0.061,-0.014,-0.038,0.02,-0.371,-0.006,0.032,methylated
NH23-825,207321900006_R03C01,508,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,508,1,NDP,Southampton General Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,,,"control tissue, white matter (corpus callosum)",1,CONTR_WM,0.31,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-825,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 508\NH23-825,-0.01,0.032,0.082,-0.054,-0.027,-0.003,-0.061,-0.075,-0.064,-0.147,-0.042,0.004,0.054,-0.017,-0.024,0.007,0.032,0.046,0.037,-0.027,-0.053,-0.05,0.025,0.028,-0.017,-0.021,-0.016,-0.008,-0.004,methylated
NH23-827,207321900006_R05C01,508,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,508,1,NDP,Southampton General Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.92,AIDH,0.84,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-827,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 508\NH23-827,0.218,0.034,0.024,-0.106,-0.125,-0.078,-0.104,-0.142,-0.085,0.465,0.607,0.005,0.044,0.429,-0.012,-0.021,-0.076,-0.017,-0.041,-0.018,-0.007,-0.004,-0.203,-0.016,0.007,0.01,0.12,-0.034,-0.008,unmethylated
NH23-840,207321900006_R06C01,508,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,508,1,NDP,"Liverpool, The Walton Centre",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",3A,,,"glioblastoma, IDH-wildtype, with primitive neuronal component",0.52,MB_SHHCHLAD,0.21,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-840,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 508\NH23-840,0.276,-0.102,0.052,-0.091,-0.038,-0.127,-0.337,0.106,0.153,0.096,0.126,0.17,0.263,0.143,-0.229,-0.233,-0.286,-0.178,-0.027,-0.063,-0.401,-0.352,0.005,-0.447,-0.114,-0.044,0.041,-0.338,-0.393,methylated
NH23-802,207321900006_R07C01,508,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,508,1,NDP,"Charing Cross Hospital, London",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,,,posterior fossa ependymoma group B,1,EPN_PFB,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-802,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 508\NH23-802,0.012,-0.311,-0.161,0.101,0.29,-0.092,-1.021,0.015,-0.039,-0.125,-0.047,0.226,0.315,0.155,-0.058,0.009,-0.342,-0.185,0.024,-0.006,-0.052,-0.19,0.039,-0.014,-0.047,-0.09,0.024,0,0.012,unmethylated
NH23-699,207321900014_R01C01,509,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,509,1,NDP,Nottingham University Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,,,ganglioglioma,0.15,LGG_MYB,0.11,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-699,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 509\NH23-699,0.001,0.038,0.05,0.011,0.055,0.04,-0.226,0.485,0.059,-0.017,0.139,-0.15,0.129,-0.107,-0.155,-0.037,-0.202,-0.149,-0.079,-0.118,-0.083,0.082,0.006,-0.064,-0.091,0.006,0.254,0.034,0.006,unmethylated
NH15-643,207321900014_R02C01,509,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,509,4,NDP,Brighton and Sussex Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1B,,,myxopapillary ependymoma,0.38,EPN_MPE,0.21,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH15-643,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 509\NH15-643,-0.332,-0.363,-0.6,-0.002,-0.083,-0.154,-0.329,-0.246,-0.077,-0.471,-0.026,0.52,0.463,0.055,0.284,0.708,-0.515,-0.425,0.037,-0.189,0.298,0.314,-0.087,0.247,-0.023,0.437,-0.053,0.134,0.258,methylated
NH23-810,207321900014_R03C01,509,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,509,1,NDP,Cleveland Clinic London,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1B,,,"supratentorial ependymoma, ZFTA:RELA fusion-positive",1,EPN_RELA,0.96,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-810,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 509\NH23-810,0.343,-0.082,0.039,0.006,0.007,0.18,-0.602,-0.222,-0.054,-0.031,-0.003,0.029,0.073,-0.045,-0.481,-0.584,-0.466,-0.486,-0.042,-0.217,-0.058,0.056,-0.507,0.014,0.002,0.043,0.067,0.018,0.001,unmethylated
NH23-866,207321900014_R07C01,509,10/3/2023,3/22/2023,3/22/2023,12,MD,Diagnostic,509,1,NDP,"Liverpool, The Walton Centre",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1R,,,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.92,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-866,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 509\NH23-866,-0.035,-0.057,0.093,-0.283,0.425,0.282,-0.126,1.732,0.211,0.011,0.321,0.02,0.058,-0.145,-1.935,0.049,-0.691,-0.73,-0.02,-0.225,-0.056,0.071,-0.033,-0.068,-0.116,-0.033,0.177,-0.291,-0.379,methylated
NH23-905,207321900046_R03C01,510,13/03/2023,3/22/2023,3/22/2023,9,PM,Diagnostic,510,1,NDP,St George's Hospital London,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A1,,,myxopapillary ependymoma,0.99,EPN_MPE,0.98,0.95,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-905,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 510\NH23-905,0.259,-0.362,-0.077,0.228,0.303,0.105,-0.273,-0.02,0.11,0.075,0.173,-0.132,-0.095,-0.267,0.223,0.148,-0.19,-0.281,-0.13,0.301,0.251,0.417,-0.076,0.13,0.104,0.183,0.235,-0.147,-0.087,methylated
NH23-788,207321900046_R04C01,510,13/03/2023,3/22/2023,3/22/2023,9,PM,Diagnostic,510,1,NDP,Royal London Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1D,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-788,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 510\NH23-788,-0.008,-0.039,0.042,-0.301,-0.49,0.032,0.017,-0.203,-0.054,-0.103,0.009,0.002,0.108,-0.101,-0.385,-0.431,-0.088,-0.075,-0.099,-0.142,-0.032,-0.007,0,-0.06,-0.118,-0.075,-0.46,0.052,0.004,methylated
NH23-842,207321900046_R05C01,510,13/03/2023,3/22/2023,3/22/2023,9,PM,Diagnostic,510,1,NDP,Wellington Hospital London,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.89,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-842,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 510\NH23-842,-0.013,-0.041,0.087,-0.033,0.064,-0.079,0.022,-0.005,-0.103,-0.085,-0.067,0.018,0.118,-0.126,-0.01,-0.019,-0.011,0.061,-0.001,-0.088,-0.154,-0.088,0.006,0.003,-0.114,-0.033,-0.599,0.002,0.033,methylated
NH23-892,207321890035_R02C01,511,13/03/2023,3/24/2023,3/24/2023,11,PM,Diagnostic,511,1,NDP,Oxford John Radcliffe Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-892,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 511\NH23-892,0.038,-0.01,0.03,0.018,0.056,-0.008,-0.022,-0.064,-0.008,-0.057,0.02,0.017,-0.005,0.003,-0.03,-0.016,-0.058,-0.072,0.007,0.027,0.034,-0.026,-0.06,0.035,-0.002,0.056,-0.37,0.057,0.011,methylated
NH23-901,207321890035_R04C01,511,13/03/2023,3/24/2023,3/24/2023,11,PM,Diagnostic,511,1,NDP,"Cardiff, University Hospital",IDH mutant glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.99,AIDH_HG,0.93,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-901,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 511\NH23-901,0.051,1.032,0.051,0.021,0.112,0.006,-0.088,-0.056,-0.086,-0.22,-0.041,0.041,0.068,-0.027,-0.002,0.032,-0.023,-0.066,0.022,-0.05,0.009,0.12,-0.374,-0.001,0.083,0.073,-0.139,0.001,0.101,unmethylated
NH23-876,207321890035_R06C01,511,13/03/2023,3/24/2023,3/24/2023,11,PM,Diagnostic,511,1,NDP,"Liverpool, The Walton Centre",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1C,,,"glioblastoma, IDH-wildtype, RTK2 type",0.55,GBM_RTKII,0.43,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-876,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 511\NH23-876,-0.049,0.041,0.076,-0.08,0.034,-0.041,-0.002,0.881,-0.054,-0.129,-0.047,-0.344,0.059,-0.049,-1.163,-0.005,-0.289,-0.234,0.025,-0.041,-0.075,0.015,-0.327,-0.016,0.06,0.009,0.021,-0.329,-0.288,unmethylated
NH23-875,207321890035_R08C01,511,13/03/2023,3/24/2023,3/24/2023,11,PM,Diagnostic,511,1,NDP,"Royal Infirmary,Edinburgh",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.94,GBM_MES,0.91,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-875,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 511\NH23-875,0.017,0.013,0.038,0.108,0.051,-0.017,-0.064,0.009,0.03,0.024,0.141,-0.008,0.043,-0.021,-0.442,-0.051,-0.205,-0.24,-0.079,-0.09,-0.054,0.04,-0.111,-0.089,-0.02,0.042,0.067,0,-0.207,unmethylated
NH23-872,207321890102_R01C01,512,13/03/2023,3/24/2023,3/24/2023,11,PM,Diagnostic,512,3,NDP,Nottingham University Hospital,Pilocytic astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.32,LGG_PAPF,0.34,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-872,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 512\NH23-872,-0.031,0.048,0.028,0.047,0.005,-0.038,-0.027,-0.061,0.006,-0.041,0.187,0.015,0.047,0.013,0.085,-0.013,-0.003,-0.005,0.001,-0.032,0,-0.051,-0.014,-0.01,-0.007,-0.027,0.075,-0.005,0.003,unmethylated
NH23-869,207321890102_R02C01,512,13/03/2023,3/24/2023,3/24/2023,11,PM,Diagnostic,512,3,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"glioblastoma, IDH-wildtype, RTK1 type",0.26,AIDH_HG,0.35,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-869,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 512\NH23-869,-0.056,-0.378,-0.194,-0.024,-0.038,0.009,0.032,0.036,0.037,-0.491,-0.345,0.02,0.024,-0.143,-1.47,0.07,-0.158,-0.066,0.01,-0.349,-0.017,-0.087,-0.197,-0.032,-0.062,-0.07,-0.385,-0.099,-0.28,unmethylated
NH23-852,207321890102_R07C01,512,13/03/2023,3/24/2023,3/24/2023,11,PM,Diagnostic,512,6,NDP,"Romford, Queen's Hospital",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,,,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.98,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-852,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 512\NH23-852,0.045,0.102,0.043,0.036,0.035,0.007,-0.058,0.198,0.3,0.34,0.307,-0.255,0.039,0.023,-0.848,0.028,-0.288,-0.215,-0.07,-0.101,-0.033,0.025,-0.044,-0.034,-0.037,0.012,0.094,0.049,0.013,methylated
NH23-882,207321890102_R08C01,512,13/03/2023,3/24/2023,3/24/2023,11,PM,Diagnostic,512,3,NDP,Brighton and Sussex Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-882,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 512\NH23-882,0.026,0.022,0.031,0.005,0.038,-0.073,-0.105,-0.125,-0.066,-0.095,0.037,0.005,0.043,0.041,0.025,-0.007,-0.05,-0.039,-0.066,0.035,-0.153,0.045,-0.03,-0.01,-0.035,0.025,0.101,0.018,-0.024,methylated
NH23-858,207321890060_R02C01,513,13/03/2023,3/29/2023,3/29/2023,16,PM,Diagnostic,513,3,NDP,"Charing Cross Hospital, London",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.88,0.63,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-858,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 513\NH23-858,-0.005,-0.053,0.05,-0.034,0.075,0.056,-0.23,1.14,0.134,0.069,0.181,0.041,0.064,-0.046,-0.782,-0.055,-0.242,-0.318,-0.081,-0.147,-0.116,0.109,0.04,-0.037,-0.133,0.008,-0.15,0.066,-0.047,unmethylated
NH21-242,207321890060_R04C01,513,13/03/2023,3/29/2023,3/29/2023,16,PM,Diagnostic,513,1,NDP,NHNN,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP2A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.99,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH21-242,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 513\NH21-242,0.061,-0.062,0.036,-0.019,0.054,-0.149,0.103,0.051,-0.132,-0.216,-0.01,0.06,0.176,-0.041,-2.13,-0.096,-0.38,-0.489,0.086,-0.415,-0.172,-0.162,-0.054,0.067,-0.084,0.015,-0.418,-0.009,-0.408,unmethylated
NH23-906,207321890060_R05C01,513,13/03/2023,3/29/2023,3/29/2023,16,PM,Diagnostic,513,2,NDP,St George's Hospital London,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,ganglioglioma,0.21,CONTR_HEMI,0.12,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-906,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 513\NH23-906,0.027,0.008,0.024,0.041,0.037,-0.005,-0.118,-0.111,0.022,-0.041,0.107,0.051,0.067,-0.101,0.023,0.016,-0.125,-0.148,-0.049,-0.107,-0.072,0.057,-0.003,-0.019,-0.15,-0.282,0.088,-0.007,0.047,methylated
NH23-873,207321580032_R01C01,514,14/03/2023,3/29/2023,3/29/2023,15,PM,Diagnostic,514,1,NDP,Brighton and Sussex Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF3B,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-873,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 514\NH23-873,0.016,0.032,0.047,-0.029,0.056,-0.029,-0.009,-0.111,-0.103,-0.154,0.024,0.019,0.016,-0.061,-0.024,-0.038,-0.053,-0.077,-0.025,0.032,-0.132,0.102,-0.066,-0.011,-0.049,-0.025,-0.288,-0.038,0.054,methylated
NH23-920,207321580032_R03C01,514,14/03/2023,3/29/2023,3/29/2023,15,PM,Diagnostic,514,1,NDP,"Cardiff, University Hospital",Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,OIDH,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-920,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 514\NH23-920,-0.001,-0.023,0.05,-0.003,0.022,-0.01,-0.091,-0.128,-0.051,-0.218,0.036,0.06,0.02,0.004,-0.005,-0.032,-0.083,-0.071,-0.005,-0.051,-0.002,0.118,-0.408,0.079,-0.032,0.089,-0.316,0.041,0.122,methylated
NH23-941,207321580032_R07C01,514,17/03/2023,3/29/2023,3/29/2023,12,PM,Diagnostic,514,2,NDP,"Romford, Queen's Hospital",Pineal parenchymal tumour,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.37,AIDH_HG,0.15,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-941,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 514\NH23-941,-0.014,0.035,0.141,-0.008,-0.006,0.005,0.038,-0.015,-0.067,-0.182,-0.049,-0.241,0.095,-0.116,0.03,0.091,0.032,0.06,0.002,0.059,-0.044,-0.034,0.044,-0.009,-0.007,0.048,-0.066,-0.026,0.095,unmethylated
NH23-903,207321580032_R08C01,514,17/03/2023,3/29/2023,3/29/2023,12,PM,Diagnostic,514,3,NDP,Royal London Hospital,Glioma H3K27M mutant,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",0.96,DMG_K27,0.86,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-903,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 514\NH23-903,-0.024,-0.031,0.126,-0.042,0.092,-0.086,-0.064,-0.714,0.139,0.006,0.145,0.05,0.119,0.014,-0.559,0.097,-0.314,-0.354,0.115,-0.149,-0.205,0.077,-0.45,-0.45,-0.497,0.004,-0.532,-0.472,-0.263,unmethylated
NH23-945,207321580053_R01C01,515,17/03/2023,3/29/2023,3/29/2023,12,PM,Diagnostic,515,5,NDP,Cleveland Clinic London,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-945,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 515\NH23-945,-0.063,-0.018,0.018,-0.224,-0.085,0.004,-0.068,-0.103,-0.03,-0.071,0.026,0.016,0.05,-0.02,0.018,0,-0.069,-0.028,-0.006,-0.058,-0.006,0.007,-0.07,-0.008,-0.035,-0.045,-0.417,0.002,-0.043,methylated
NH23-939,207321580053_R02C01,515,17/03/2023,3/29/2023,3/29/2023,12,PM,Diagnostic,515,3,NDP,Brighton and Sussex Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.98,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-939,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 515\NH23-939,-0.039,-0.06,0.036,-0.002,-0.012,0.014,-0.107,-0.139,0.121,0.066,0.174,0.04,0.01,-0.018,0.004,0,-0.015,0.016,-0.037,-0.076,-0.049,-0.056,-0.027,-0.068,-0.029,0.035,0.131,0.016,-0.02,methylated
NH23-935,207321580053_R03C01,515,17/03/2023,3/29/2023,3/29/2023,12,PM,Diagnostic,515,4,NDP,Wellington Hospital London,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1D,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.84,OIDH,0.93,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-935,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 515\NH23-935,-0.043,-0.039,0.021,-0.003,0.017,0.009,-0.016,-0.182,-0.096,0.138,0.158,0.003,-0.052,0,-0.018,-0.063,-0.028,0.03,-0.046,-0.109,-0.08,-0.022,-0.018,-0.081,-0.033,-0.045,-0.233,0.013,-0.007,methylated
NH23-950,207321580053_R05C01,515,20/03/2023,3/29/2023,3/29/2023,9,PM,Diagnostic,515,1,NDP,"Cardiff, University Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.99,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-950,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 515\NH23-950,0.071,-0.109,-0.058,-0.034,-0.057,0.022,-0.062,-0.018,0.09,0.024,0.133,0.048,0.046,0.045,-0.021,0.023,-0.409,-0.383,0.036,-0.078,0.852,2.405,-0.002,-0.103,-0.074,-0.076,0.093,-0.035,0.09,unmethylated
NH23-937,207321580053_R07C01,515,20/03/2023,3/29/2023,NA,#VALUE!,PM,Diagnostic,515,1,NDP,Oxford John Radcliffe Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",273,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-937,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 515\NH23-937,0,-0.026,0.04,0.01,0.01,-0.027,-0.107,0.066,0.164,0.091,0.212,0.001,0.1,0.105,-0.028,0.151,-0.038,-0.061,-0.074,0.14,-0.033,-0.051,-0.005,-0.034,-0.049,-0.09,-0.281,0.029,0.019,methylated
NH23-924,207321580051_R01C01,516,21/03/2023,3/31/2023,3/31/2023,10,PM,Diagnostic,516,3,NDP,Cleveland Clinic London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.73,GBM_MES,0.59,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-924,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 516\NH23-924,0.001,-0.028,-0.017,0.001,-0.055,0.022,-0.004,0.957,0.221,0.16,0.152,-0.016,0.076,-0.018,-0.67,0.019,-0.163,-0.232,-0.034,0.04,0.039,0.063,-0.178,0.052,0.109,0.004,-0.047,-0.189,-0.17,unmethylated
NH23-957,207321580051_R02C01,516,21/03/2023,3/31/2023,3/31/2023,10,PM,Diagnostic,516,1,NDP,"Birmingham, Queen Elizabeth Hospital",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A2,,,dysembryoplastic neuroepithelial tumour,0.99,LGG_DNT,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-957,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 516\NH23-957,0.04,-0.002,-0.002,-0.055,-0.025,0.098,-0.011,-0.004,-0.024,-0.085,-0.018,0,0.1,0.009,0.078,-0.015,0.082,-0.004,0.039,0.103,0.099,0.152,0.064,0.072,-0.012,0.032,0,-0.009,0.049,unmethylated
NH23-961,207321580051_R03C01,516,21/03/2023,3/31/2023,3/31/2023,10,PM,Diagnostic,516,1,NDP,Nottingham University Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.96,OIDH,0.98,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-961,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 516\NH23-961,0.033,-0.042,0.019,-0.062,0.004,0.013,0.038,0.002,-0.021,-0.056,-0.018,0.008,0.012,0.044,0.09,-0.017,0.045,-0.01,0.011,0.013,-0.005,0.048,-0.005,0.056,0.025,-0.016,-0.276,-0.023,0.02,methylated
NH23-962,207321580051_R04C01,516,21/03/2023,3/31/2023,3/31/2023,10,PM,Diagnostic,516,1,NDP,Nottingham University Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.32,AIDH,0.76,0.6,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-962,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 516\NH23-962,-0.001,-0.066,-0.004,0.009,-0.015,-0.002,0.015,-0.026,-0.029,-0.024,-0.018,0.068,-0.004,-0.009,0.006,-0.023,0.024,0.011,-0.026,0.021,-0.015,-0.009,-0.003,0.009,-0.001,-0.034,-0.026,0.046,0.002,methylated
NH23-964,207321580051_R05C01,516,21/03/2023,3/31/2023,3/31/2023,10,PM,Diagnostic,516,1,NDP,"Birmingham, Queen Elizabeth Hospital",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A4,,,myxopapillary ependymoma,1,EPN_MPE,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-964,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 516\NH23-964,0.046,-0.03,0.086,0.116,0.213,0.157,-0.021,0.204,0.223,0.218,0.19,0.024,0.045,0.04,0.425,0.391,0.044,0.019,0.059,0.029,0.04,0.025,-0.028,0.038,-0.025,-0.03,0.192,-0.327,-0.393,methylated
NH23-971,207321580051_R06C01,516,21/03/2023,3/31/2023,3/31/2023,10,PM,Diagnostic,516,1,NDP,St George's Hospital London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"glioblastoma, IDH-wildtype, RTK1 type",1,GBM_RTKI,0.99,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-971,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 516\NH23-971,0.029,-0.006,0.018,-0.086,0.021,-0.024,-0.01,0.954,0.237,0.117,0.16,0.01,0.274,0.032,-1.347,0.031,-1.202,-0.33,0.031,0.035,0.024,0.128,-0.343,0.028,0.064,0.034,-0.093,0.007,0.033,unmethylated
NH23-970,207321580051_R07C01,516,21/03/2023,3/31/2023,3/31/2023,10,PM,Diagnostic,516,1,NDP,"Belfast, Royal Victoria Hospital",Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",A3,,,posterior fossa subependymoma,1,SUBEPN_PF,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-970,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 516\NH23-970,0.006,-0.008,0.052,-0.001,-0.01,-0.024,0.063,-0.024,-0.051,-0.043,-0.023,-0.002,0.072,0.02,0.045,0.006,0.023,-0.008,0.022,-0.029,-0.009,0.036,0.03,0.006,0.001,0.005,-0.042,-0.005,0.038,unmethylated
NH23-965,207321580051_R08C01,516,21/03/2023,3/31/2023,3/31/2023,10,PM,Diagnostic,516,1,NDP,Nottingham University Hospital,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.86,OIDH,0.92,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-965,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 516\NH23-965,0.106,-0.063,0.016,-0.025,0.059,0.007,-0.07,0.012,0.028,-0.07,0.037,-0.007,0.035,-0.067,-0.035,0.032,0.064,-0.037,0.055,0.06,0.052,0.001,-0.086,0.066,0.121,0.104,-0.325,-0.012,0.099,methylated
NH20-1763,207321580085_R01C01,517,21/03/2023,3/31/2023,3/31/2023,10,MD,Diagnostic,517,1,NDP,Brighton and Sussex Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.97,AIDH_HG,0.93,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH20-1763,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 517\NH20-1763,0.264,-0.656,0.04,0.114,0.198,-0.671,-0.035,0.172,0.033,0.112,-0.027,0.135,0.061,0.324,-3.373,0.131,0.107,-1.229,0.291,0.315,0.064,-0.012,-0.143,-0.268,0.168,0.013,-0.234,-0.115,-0.001,methylated
NH23-966,207321580085_R05C01,517,22/03/2023,3/31/2023,3/31/2023,9,PM,Diagnostic,517,1,NDP,"Birmingham, Queen Elizabeth Hospital",Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,,,supratentorial pilocytic astrocytoma,0.42,LGG_GG,0.24,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-966,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 517\NH23-966,0.026,-0.047,0,-0.034,-0.025,-0.046,-0.057,0.033,0.028,-0.002,-0.007,0.001,0.047,0.018,0.035,-0.023,0.009,0.023,-0.037,-0.026,-0.014,0.042,0.024,-0.002,0.008,-0.005,-0.035,-0.034,0.022,unmethylated
NH23-991,207321890034_R02C01,518,22/03/2023,3/31/2023,3/31/2023,9,MD,Diagnostic,518,1,NDP,"Liverpool, The Walton Centre",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2B,,,"Diffuse paediatric-type high grade glioma, RTK1 subtype",0.99,GBM_MID,0.7,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-991,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 518\NH23-991,0.038,0.008,0.02,-0.007,0.016,0.001,0.015,0.015,0.023,-0.01,-0.013,-0.036,-0.033,-0.039,-0.014,0.018,0.022,0.004,-0.006,-0.013,0.012,0.092,-0.03,0.012,0.068,0.042,-0.156,-0.05,-0.013,unmethylated
NH23-978,207321890034_R04C01,518,22/03/2023,3/31/2023,3/31/2023,9,MD,Diagnostic,518,1,NDP,"Cardiff, University Hospital",Glioma (GBM/PXA)?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A7,,,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.93,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-978,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 518\NH23-978,0.066,-0.033,-0.055,-0.035,-0.042,-0.041,-0.05,1.094,0.22,0.164,0.182,0.152,0.015,0.061,-0.674,0.191,-0.191,-0.25,0.026,-0.003,0.029,0.104,-0.01,0.105,-0.184,0.062,0.162,-0.04,0.015,unmethylated
NH23-979,207321890034_R05C01,518,22/03/2023,3/31/2023,3/31/2023,9,MD,Diagnostic,518,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A3,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.99,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-979,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 518\NH23-979,0.085,0.031,0.041,-0.009,0.013,-0.078,0.007,0.109,0.03,-0.054,0.018,-0.007,-0.016,0.067,-0.057,0.045,0.047,-0.072,0.026,0.258,-0.028,-0.332,-0.022,0.093,0.077,0.051,-0.003,-0.146,-0.162,methylated
NH23-948,207321890034_R06C01,518,22/03/2023,3/31/2023,3/31/2023,9,PM,Diagnostic,518,1,NDP,NHNN,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"glioblastoma, IDH-wildtype, RTK1 type",0.33,GBM_RTKI,0.51,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-948,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 518\NH23-948,0.651,-0.046,-0.012,-0.011,-0.024,0.028,-0.282,0.418,0.342,0.359,0.251,-0.009,0.015,0.012,-0.762,-0.168,-0.209,-0.243,-0.021,0.012,0.005,0.021,-0.279,0.012,0.022,-0.013,-0.141,-0.028,0.003,unmethylated
NH23-740,207321890034_R08C01,518,23/03/2023,3/31/2023,3/31/2023,8,PM,Diagnostic,518,1,NDP,Oxford John Radcliffe Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2B,,,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.39,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-740,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 518\NH23-740,-0.083,-0.05,0.02,-0.016,-0.064,-0.027,0.038,0.082,0.209,0.192,0.091,-0.024,0.071,0.059,-0.45,0.062,-0.081,-0.192,0.044,0.095,0.041,0.084,0.074,0.01,0.062,0.071,0.033,-0.019,-0.033,methylated
NH23-1024,207321890002_R01C01,519,23/03/2023,4/14/2023,4/14/2023,22,PM,Diagnostic,519,1,NDP,St George's Hospital London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"glioblastoma, IDH-wildtype, RTK2 type",0.78,GBM_RTKII,0.69,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1024,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 519\NH23-1024,-0.022,-0.063,0.028,-0.04,0.241,-0.003,-0.031,0.909,0.144,0.131,0.157,0.013,-0.018,-0.033,-1.033,-0.005,-0.315,-0.283,-0.031,-0.04,-0.02,-0.056,-0.045,0.005,0.043,-0.045,0.152,0.027,-0.002,methylated
NH23-1025,207321890002_R02C01,519,23/03/2023,4/14/2023,4/14/2023,22,PM,Diagnostic,519,1,NDP,St George's Hospital London,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"glioblastoma, IDH-wildtype, RTK2 type",1,GBM_RTKII,0.84,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1025,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 519\NH23-1025,0.311,-0.147,-0.023,-0.117,-0.094,-0.268,0.038,1.671,0.257,0.066,0.18,0.037,0.055,0.245,-1.708,0.174,-0.575,-0.689,-0.081,0.179,0.107,0.089,0.172,0.072,0.114,0,-0.276,-0.052,0.096,unmethylated
NH23-972,207321890002_R08C01,519,24/03/2023,4/14/2023,4/14/2023,21,PM,Diagnostic,519,1,NDP,NHNN,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,,,supratentorial pilocytic astrocytoma,1,LGG_PA_GGST,0.97,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-972,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 519\NH23-972,0.006,-0.009,-0.058,-0.048,-0.036,0.076,0.102,0.036,0.074,0.142,0.076,0.067,0.069,-0.013,-0.084,-0.104,-0.059,-0.06,0.001,0.003,0,0.013,-0.037,0.01,0.077,-0.006,-0.065,-0.067,-0.039,unmethylated
NH23-980,207321890017_R01C01,520,24/03/2023,4/14/2023,4/14/2023,21,PM,Diagnostic,520,1,NDP,Cleveland Clinic London,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,,,posterior fossa ependymoma group B,0.99,EPN_PFB,0.68,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-980,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 520\NH23-980,0.118,-0.209,-0.092,0.049,0.021,0.052,-0.111,0.069,0.057,0.106,0.083,0.242,0.242,0.149,0.096,0.125,0.091,0.061,-0.132,0.22,0.166,0.308,-0.093,-0.128,-0.083,-0.122,0.062,-0.127,-0.078,unmethylated
NH23-974,207321890017_R02C01,520,24/03/2023,4/14/2023,4/14/2023,21,PM,Diagnostic,520,1,NDP,NHNN,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"glioblastoma, IDH-wildtype, mesenchymal type",1,CONTR_REACT,0.66,0.72,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-974,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 520\NH23-974,0.013,-0.022,0,-0.054,0.029,0.019,-0.033,0.589,0.044,0.031,0.062,-0.09,0.032,0.011,-0.131,0.01,-0.095,-0.085,0.007,0.009,-0.013,0.032,-0.027,0.01,0.018,0.005,0.115,-0.065,-0.094,unmethylated
NH23-837,207321890017_R03C01,520,24/03/2023,4/14/2023,4/14/2023,21,MD,Diagnostic,520,1,NDP,Brighton and Sussex Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,,,posterior fossa ependymoma group A1,0.13,HMB,0.17,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-837,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 520\NH23-837,-0.13,-0.175,-0.091,-0.078,-0.082,-0.03,0.159,-0.058,0.038,0.019,-0.019,0.097,0.124,0.135,0.106,0.067,-0.001,-0.074,-0.015,-0.068,-0.068,0.083,0.095,-0.018,0.071,0.065,-0.05,0,-0.05,methylated
NH23-1012,207321890017_R04C01,520,27/03/2023,4/14/2023,4/14/2023,18,PM,Diagnostic,520,1,NDP,Royal London Hospital,H3K27M mutant glioma,"(5) Confirmation of rare, unusual or interesting histo-molecular results",DEF1A,,,"diffuse midline glioma, H3 K27-mutant / EZHIP overexpressing",1,DMG_K27,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1012,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 520\NH23-1012,-0.048,0.185,-0.016,-0.029,-0.054,0.031,0.075,-0.026,-0.032,-0.028,-0.036,0.005,0.049,-0.108,0.366,0.242,-0.017,-0.035,-0.124,0.073,0.349,0.658,-0.038,-0.475,0.054,-0.035,-0.577,0.031,-0.044,unmethylated
NH23-995,207321890017_R05C01,520,27/03/2023,4/14/2023,4/14/2023,18,PM,Diagnostic,520,1,NDP,Brighton and Sussex Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1C,,,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.99,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-995,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 520\NH23-995,0.045,-0.067,-0.039,-0.062,-0.073,-0.057,0.03,0.096,0.123,0.124,0.081,0.01,-0.106,-0.19,-0.406,-0.022,-0.186,-0.216,-0.074,0.159,-0.005,0.014,-0.207,-0.039,-0.075,-0.033,-0.023,-0.174,-0.15,methylated
NH23-911,207321890017_R06C01,520,27/03/2023,4/14/2023,4/14/2023,18,PM,Diagnostic,520,2,NDP,Alder Hey Children's,DNET?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,,,posterior fossa ependymoma group A1,0.06,PXA,0.05,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-911 (1A),,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 520\NH23-911,0.579,0.236,0.085,-0.093,0.07,0.012,0.07,0.048,0.09,-0.073,0.009,-0.049,0.349,0.357,0.147,-0.131,0.281,-0.056,0.101,-0.219,0.124,0.355,0.141,0.108,-0.165,0.151,-0.131,-0.189,-0.018,unmethylated
NH23-998,207321890017_R07C01,520,27/03/2023,4/14/2023,4/14/2023,18,PM,Diagnostic,520,1,NDP,"Romford, Queen's Hospital",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.99,GBM_MES,0.92,0.74,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-998,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 520\NH23-998,0.01,0.012,0.026,-0.017,-0.054,0.102,0.061,0.217,0.296,0.276,0.2,-0.004,0.058,-0.012,-0.378,-0.143,-0.128,-0.228,-0.023,0.003,0.399,0.065,0.009,-0.01,0.006,-0.009,-0.045,0.02,0.023,methylated
NH23-1003,207321890017_R08C01,520,27/03/2023,4/14/2023,4/14/2023,18,PM,Diagnostic,520,1,NDP,"Charing Cross Hospital, London",GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",0.64,OIDH,0.98,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1003,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 520\NH23-1003,0.012,-0.151,-0.046,-0.238,0.097,0.015,0.048,0.192,0.287,0.263,0.22,0.012,0.004,-0.016,-0.397,-0.441,0.032,0.039,0.017,-0.011,0.171,-0.019,-0.048,-0.015,0.029,-0.012,-0.521,-0.013,0.009,methylated
NH23-1006,207321890003_R01C01,521,27/03/2023,4/14/2023,4/14/2023,18,PM,Diagnostic,521,5,NDP,Cleveland Clinic London,Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1B,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1006,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 521\NH23-1006,-0.008,-0.007,0.03,-0.077,-0.046,-0.012,0.017,-0.023,-0.015,-0.006,0.007,0.015,-0.006,0.017,-0.014,0.007,0.001,0.001,-0.027,0.065,-0.025,-0.042,-0.066,0.011,-0.036,-0.013,-0.35,-0.004,-0.041,methylated
NH23-1032,207321890003_R03C01,521,27/03/2023,4/14/2023,4/14/2023,18,PM,Diagnostic,521,1,NDP,"Liverpool, The Walton Centre",Ependymoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2A,,,spinal ependymoma,0.97,EPN_SPINE,0.98,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1032,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 521\NH23-1032,-0.02,-0.055,0.036,-0.039,0.002,-0.07,0.024,0.006,-0.032,-0.069,-0.018,0.002,0.053,0.022,0.018,-0.003,0.017,0.03,0.008,-0.02,0.001,-0.021,-0.313,-0.004,0.008,-0.025,0.013,-0.281,-0.242,unmethylated
NH23-911,207321890003_R08C01,521,28/03/2023,4/14/2023,4/14/2023,17,PM,Diagnostic,521,2,NDP,Alder Hey Children's,DNET?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1B,,,dysembryoplastic neuroepithelial tumour,0.64,LGG_DNT,0.61,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-911 (1B),,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 521\NH23-911,-0.091,-0.172,-0.082,-0.168,0.071,-0.168,-0.197,1.377,0.225,-0.106,0.123,0.102,0.27,-0.111,-0.328,0.106,-0.238,-0.4,0.318,-0.047,0.216,0.186,-0.011,0.164,-0.079,-0.052,-0.041,-0.261,-0.237,unmethylated
NH23-1074,207321890053_R01C01,522,28/03/2023,4/14/2023,4/14/2023,17,PM,Diagnostic,522,1,NDP,Nottingham University Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",C1,,,spinal ependymoma,1,EPN_SPINE,1,0.87,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1074,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 522\NH23-1074,-0.005,0.007,0.028,0.036,0.002,-0.079,-0.059,0.17,0.224,0.163,0.176,0.019,0.032,0.039,0.009,-0.003,0.015,-0.036,0.023,0.252,0.175,0.247,-0.409,0.166,0.135,0.099,0.017,-0.313,-0.287,unmethylated
NH23-1068,207321890011_R07C01,523,30/03/2023,4/14/2023,4/14/2023,15,PM,Diagnostic,523,1,NDP,Southampton General Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,,,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.88,0.93,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1068,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 523\NH23-1068,0.058,-0.01,0.018,0.025,-0.052,-0.042,-0.053,0.097,0.169,0.254,0.094,-0.004,0.07,0.05,-0.224,0,-0.082,-0.124,-0.001,0.036,0.053,0.057,0.007,0.028,-0.096,0.005,0.044,-0.136,-0.115,methylated
NH23-1047,207321890011_R08C01,523,31/03/2023,4/14/2023,4/14/2023,14,PM,Diagnostic,523,1,NDP,"Romford, Queen's Hospital",Oligodendroglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.58,OIDH,0.4,0.69,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1047,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 523\NH23-1047,0.055,-0.05,0.005,-0.059,0.019,0.001,-0.02,-0.044,-0.004,-0.016,0.009,0.003,0.013,0.017,-0.062,0.019,0.007,-0.017,0.004,-0.075,-0.071,-0.033,-0.051,-0.013,-0.019,-0.002,-0.222,0.057,0.002,methylated
NH23-1078,207355710048_R02C01,524,31/03/2023,4/19/2023,4/19/2023,19,PM,Diagnostic,524,1,NDP,Brighton and Sussex Hospital,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF2A,,,"glioblastoma, IDH-wildtype, RTK2 type",0.97,GBM_RTKII,0.71,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1078,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 524\NH23-1078,-0.009,0.091,0.015,0.45,0.103,-0.017,0.013,0.067,0.16,0.166,0.198,-0.003,0.002,-0.072,-1.615,-0.044,-0.552,-0.379,-0.028,0.027,0,0.054,0.024,-0.035,-0.255,-0.031,0.124,-0.339,-0.409,unmethylated
NH23-1066,207355710048_R03C01,524,31/03/2023,4/19/2023,4/19/2023,19,PM,Diagnostic,524,2,NDP,NHNN,Pleomorphic xanthoastrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B,,,pleomorphic xanthoastrocytoma(-like),1,PXA,0.98,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1066 (B),,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 524\NH23-1066,-0.011,0.047,0.087,-0.025,0.123,0.021,-0.245,0.088,0.058,0.051,0.072,-0.003,0.039,0.012,-0.665,0.008,-0.068,0.047,-0.032,0.161,0.105,0.341,0.011,-0.034,-0.058,-0.137,-0.129,-0.048,-0.019,methylated
NH23-1098,207355710048_R06C01,524,3/4/2023,4/19/2023,4/19/2023,16,PM,Diagnostic,524,1,NDP,Royal London Hospital,Glioma?,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.17,CONTR_HEMI,0.18,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1098,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 524\NH23-1098,-0.077,0.089,0.001,0.052,0.211,-0.003,0.027,-0.09,-0.014,0.007,0.055,-0.011,-0.099,-0.077,-0.05,-0.075,-0.083,0.02,-0.063,-0.037,-0.015,0.037,-0.025,-0.072,-0.134,0.001,0.225,-0.019,-0.052,unmethylated
NH23-1101,207355710048_R07C01,524,3/4/2023,4/19/2023,4/19/2023,16,PM,Diagnostic,524,1,NDP,NHNN,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,,,"glioblastoma, IDH-wildtype, RTK2 type",0.99,GBM_RTKII,0.93,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1101,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 524\NH23-1101,0.703,-0.016,0.083,-0.103,0.001,-0.068,0.046,0.94,0.103,0.136,0.137,-0.023,0.045,-0.147,-1.337,-0.03,-0.436,-0.259,-0.011,-0.064,-0.076,-0.183,-0.012,-0.071,-0.059,-0.151,0.238,-0.082,-0.038,methylated
NH23-1121,207355710048_R08C01,524,3/4/2023,4/19/2023,4/19/2023,16,PM,Diagnostic,524,1,NDP,Oxford John Radcliffe Hospital,,,,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.75,GBM_MES,0.57,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1121,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 524\NH23-1121,0.189,-0.168,0.003,0.068,0.201,-0.034,-0.253,-0.04,0.15,0.158,0.262,0.312,0.194,0.301,0.173,0.164,-0.264,-0.482,-0.026,-0.223,-0.052,-0.006,-0.114,-0.06,-0.269,-0.056,0.108,0.252,0.305,methylated
NH23-1133,207355710003_R02C01,525,3/4/2023,4/19/2023,4/19/2023,16,PM,Diagnostic,525,1,NDP,St George's Hospital London,,,,,,Infant-type hemispheric glioma,0.18,GBM_MES,0.48,0.88,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1133,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 525\NH23-1133,0.03,0.026,0.093,0.026,-0.023,-0.045,0.009,0.266,0.274,0.219,0.215,0.023,0.031,-0.045,0.055,0.028,-0.008,-0.01,0.019,-0.022,0.004,-0.097,0.027,0.023,0.007,0.019,-0.099,-0.023,0.032,methylated
NH23-1066,207355710003_R03C01,525,30/03/2023,4/19/2023,4/19/2023,20,PM,Diagnostic,525,2,NDP,NHNN,Pleomorphic xanthoastrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A,,,pleomorphic xanthoastrocytoma(-like),1,PXA,1,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1066 (A),,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 525\NH23-1066,0.019,0.018,0.062,-0.001,0.052,0.083,-0.099,0.138,0.105,0.081,0.094,0.003,0.033,-0.006,-0.655,0,-0.011,0.011,0.008,0.108,0.054,0.16,-0.038,-0.021,-0.009,-0.03,-0.012,0.039,-0.063,unmethylated
NH23-1126,207355710003_R04C01,525,3/4/2023,4/19/2023,4/19/2023,16,PM,Diagnostic,525,5,NDP,St George's Hospital London,,,,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",1,OIDH,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1126,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 525\NH23-1126,-0.005,-0.025,0.022,-0.154,-0.184,-0.017,-0.002,-0.106,-0.051,-0.014,0.001,0.018,-0.004,0.03,0.07,-0.023,-0.053,-0.039,-0.025,-0.072,-0.076,-0.015,-0.022,0.019,-0.024,0.051,-0.377,0.015,0.011,methylated
NH23-1108,207355710003_R06C01,525,4/4/2023,4/19/2023,4/19/2023,15,PM,Diagnostic,525,3,NDP,Royal London Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.96,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-1108,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 525\NH23-1108,-0.014,-0.05,0.063,-0.042,0.026,0.025,0.012,0.002,0.527,-0.108,0.003,0.013,-0.02,0.347,-0.154,-0.056,-0.091,0.103,0.025,-0.004,-0.192,-0.253,-0.179,-0.004,-0.144,-0.111,0.036,-0.001,0.096,unmethylated
NH23-1116,207355710003_R07C01,525,4/4/2023,4/19/2023,4/19/2023,15,PM,Diagnostic,525,3,NDP,"Charing Cross Hospital, London",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,OIDH,1,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1116,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 525\NH23-1116,-0.019,-0.009,0.061,-0.056,0.04,-0.03,-0.008,0.061,-0.002,0.034,0.035,0.023,0.022,-0.012,0.045,0.001,0.002,0.024,-0.027,0.068,-0.179,-0.034,-0.064,0.002,-0.082,-0.066,-0.449,0.004,-0.016,methylated
NH23-1142,207355710003_R08C01,525,5/4/2023,4/19/2023,4/19/2023,14,PM,Diagnostic,525,1,NDP,"Birmingham, Queen Elizabeth Hospital",,,,,,ganglioglioma,0.91,LGG_GG,0.45,0.86,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1142,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 525\NH23-1142,-0.026,-0.053,0.011,0.075,0.016,-0.016,-0.036,-0.023,0.078,0.05,0.117,0.012,0.009,-0.057,-0.023,-0.031,-0.193,-0.186,-0.042,-0.076,-0.068,0.042,-0.13,-0.031,-0.221,0.035,0.186,-0.187,-0.122,unmethylated
NH23-1165,207321890038_R02C01,526,5/4/2023,4/19/2023,4/19/2023,14,PM,Diagnostic,526,1,NDP,St George's Hospital London,,,,,,"glioblastoma, IDH-wildtype, RTK1 type",0.75,GBM_RTKI,0.36,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1165,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 526\NH23-1165,-0.017,-0.037,-0.017,0.028,0.03,0.076,0.047,-0.017,0.071,0.154,0.173,0.101,0.087,0.025,0.059,-0.029,-0.092,-0.056,-0.099,-0.145,-0.037,-0.033,-0.241,-0.001,-0.065,0.003,0.129,-0.135,-0.083,unmethylated
NH23-1154,207321890038_R03C01,526,5/4/2023,4/19/2023,4/19/2023,14,PM,Diagnostic,526,1,NDP,Oxford John Radcliffe Hospital,,,,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.96,AIDH,0.88,0.84,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1154,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 526\NH23-1154,0.075,0.031,0.127,-0.03,0.068,-0.063,-0.094,0.03,0.166,0.143,0.169,0.244,0.293,0.108,-0.069,-0.073,-0.061,0.082,0.194,-0.011,0.002,-0.107,-0.04,-0.009,-0.134,-0.102,0.013,0.078,0.016,methylated
NH23-1130,207321890038_R04C01,526,11/4/2023,4/19/2023,4/19/2023,8,MD,Diagnostic,526,1,NDP,NHNN,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,ganglioglioma,0.14,LGG_GG,0.11,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1130,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 526\NH23-1130,0.085,-0.03,0.017,0.026,-0.004,-0.041,-0.18,0.008,0.054,-0.004,0.099,-0.005,-0.024,-0.053,0.075,0.033,-0.148,-0.113,-0.043,-0.034,-0.047,0.013,-0.017,-0.011,-0.167,0.079,0.143,-0.099,-0.093,unmethylated
NH23-1170,207321890038_R06C01,526,11/4/2023,4/19/2023,4/19/2023,8,MD,Diagnostic,526,1,NDP,"Charing Cross Hospital, London",Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF1A,,,myxopapillary ependymoma,1,EPN_MPE,1,0.92,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1170,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 526\NH23-1170,-0.017,0.016,0.122,-0.006,0.009,-0.036,-0.068,0.006,-0.017,-0.125,-0.039,0.014,0.044,-0.172,0.004,0.033,-0.046,0.053,0.027,0.01,-0.029,-0.075,-0.545,0.03,-0.069,-0.105,-0.022,-0.336,-0.439,methylated
NH23-1186,207321890038_R08C01,526,11/4/2023,4/19/2023,4/19/2023,8,MD,Diagnostic,526,1,NDP,Southampton General Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1D,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.99,AIDH,0.92,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1186,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 526\NH23-1186,-0.013,-0.016,0.095,-0.057,0.104,-0.059,-0.186,-0.005,-0.091,-0.098,-0.053,0.004,0.049,-0.069,-0.016,-0.006,0.065,0.033,-0.027,-0.044,-0.123,-0.059,-0.451,0.025,-0.057,-0.026,-0.036,-0.041,0.021,methylated
NH23-1187,207355710088_R01C01,527,11/4/2023,4/21/2023,4/21/2023,10,MD,Diagnostic,527,1,NDP,"Cambridge, Addenbrooke's Hospital",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",E1,,,ganglioglioma,0.69,LGG_GG,0.41,0.82,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1187,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 527\NH23-1187,0.131,-0.016,-0.045,0.068,0.05,-0.076,-0.074,-0.089,0.046,-0.037,0.008,-0.016,0.006,0.011,0.064,0.002,0.048,-0.032,0.022,0.048,0.043,0.028,0.052,-0.013,0.078,-0.017,-0.063,-0.028,0.075,unmethylated
NH23-1188,207355710088_R02C01,527,11/4/2023,4/21/2023,4/21/2023,10,MD,Diagnostic,527,1,NDP,Nottingham University Hospital,Ganglioglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,supratentorial pilocytic astrocytoma,0.83,LGG_PA_GGST,0.57,0.83,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1188,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 527\NH23-1188,0.074,-0.134,-0.002,0.077,-0.033,0.117,-0.056,-0.014,0.027,0.117,0.101,0.108,0.157,0.152,-0.084,-0.034,-0.018,-0.017,0.087,-0.07,-0.004,0.017,-0.099,0.014,-0.067,-0.051,0.05,-0.111,0.057,unmethylated
NH23-1184,207355710088_R03C01,527,11/4/2023,4/21/2023,4/21/2023,10,MD,Diagnostic,527,1,NDP,"Liverpool, The Walton Centre",LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,posterior fossa ependymoma group A1,0.08,LGG_PAPF,0.06,0.8,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1184,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 527\NH23-1184,0.357,0.365,0.1,0.066,0.328,0.216,0.118,0.3,-0.06,-0.188,-0.014,0.07,-0.435,0.064,-0.345,0.149,-0.123,-0.016,-0.4,-0.172,0.307,0.299,-0.295,0.034,-0.144,-0.414,0.042,-0.363,-0.059,unmethylated
NH23-1167,207355710088_R04C01,527,11/4/2023,4/21/2023,4/21/2023,10,MD,Diagnostic,527,1,NDP,"Liverpool, The Walton Centre",Subependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",3A,,,spinal subependymoma [subtype A],1,SUBEPN_SPINE,1,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1167,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 527\NH23-1167,0.061,-0.016,0.044,0.062,0.043,-0.032,-0.533,0.02,0.025,-0.004,-0.005,-0.019,0.027,-0.015,0.011,-0.012,0.017,0.003,0.019,-0.009,0.009,-0.059,-0.06,0,0.034,-0.044,-0.026,0.024,0.03,unmethylated
NH23-1166,207355710088_R06C01,527,11/4/2023,4/21/2023,4/21/2023,10,MD,Diagnostic,527,2,NDP,Cleveland Clinic London,HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",DEF1A,,,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.78,0.64,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1166,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 527\NH23-1166,-0.019,-0.062,-0.003,-0.052,-0.001,0.031,-0.021,0.093,0.1,0.11,0.085,-0.001,0.042,-0.033,-0.622,-0.015,-0.196,-0.214,-0.189,0.009,-0.009,-0.039,-0.249,-0.039,-0.277,-0.054,-0.052,0.042,0.009,unmethylated
NH23-1201,207355710032_R02C01,528,12/4/2023,4/21/2023,4/21/2023,9,PM,Diagnostic,528,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,0.9,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1201,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 528\NH23-1201,0.064,-0.014,0.024,-0.024,0.051,-0.376,-0.082,0.029,-0.002,-0.029,0.041,-0.004,0.005,0.291,-0.258,0.027,0.024,-0.061,0.009,0.329,-0.078,-0.092,-0.125,0.092,0.094,0.037,-0.145,-0.141,-0.012,methylated
NH23-1202,207355710032_R03C01,528,12/4/2023,4/21/2023,4/21/2023,9,PM,Diagnostic,528,1,NDP,"Cardiff, University Hospital",Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.98,AIDH,0.83,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1202,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 528\NH23-1202,0.056,-0.142,-0.103,-0.094,-0.003,0.034,0.022,0.063,-0.011,-0.086,-0.035,-0.01,0.064,0.068,0.2,0.175,0.112,0.056,0.065,0.047,-0.201,0.09,-0.345,0.056,0.046,0.018,-0.026,-0.265,-0.229,methylated
NH23-1234,207355710032_R04C01,528,13/04/2023,4/21/2023,4/21/2023,8,PM,Diagnostic,528,1,NDP,Southampton General Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",,,,"spinal ependymoma, MYCN-amplified",1,EPN_PFA,0.67,0.79,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1234,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 528\NH23-1234,0.017,0.879,0.047,-0.037,-0.011,0.084,-0.004,-0.026,-0.009,-0.047,-0.037,-0.016,0.001,0.027,0.001,-0.039,-0.288,-0.3,-0.01,0.003,-0.028,0.014,-0.065,-0.003,0.017,-0.021,-0.073,0.028,-0.008,unmethylated
NH23-1219,207355710032_R07C01,528,13/04/2023,4/21/2023,4/21/2023,8,PM,Diagnostic,528,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse high-grade neuroepithelial tumour [adult-type, non-defined type C]",0.94,CNSNB_FOXR2,0.32,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1219,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 528\NH23-1219,0.079,0.042,0.017,0.026,-0.019,-0.289,0.056,-0.004,-0.008,-0.016,-0.072,-0.006,0.005,0.065,-0.329,-0.004,-0.311,-0.38,0.187,-0.358,-0.06,0.129,-0.481,-0.325,0.45,0.283,-0.433,-0.34,-0.349,unmethylated
NH23-1231,207355710089_R01C01,529,13/04/2023,4/21/2023,4/21/2023,8,PM,Diagnostic,529,1,NDP,St George's Hospital London,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.15,AIDH_HG,0.18,0.62,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1231,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 529\NH23-1231,-0.14,-0.174,-0.005,0.084,0.105,0.01,-0.109,0.114,-0.154,-0.011,0.021,0.014,-0.044,0.057,0.087,-0.02,-0.134,-0.123,-0.05,-0.027,0.253,0.068,-0.156,-0.092,0.031,0.017,-0.071,0.002,-0.004,methylated
NH23-1196,207355710089_R02C01,529,13/04/2023,4/21/2023,4/21/2023,8,PM,Diagnostic,529,1,NDP,NHNN,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type], high grade",1,AIDH_HG,0.99,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1196,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 529\NH23-1196,0.059,-0.293,0.21,-0.05,0.015,0.06,0.061,0.025,-0.044,-0.107,-0.026,0.02,0.045,0.067,0.032,-0.066,-0.077,-0.248,0.067,0.353,0.405,0.659,-0.106,-0.063,-0.44,-0.106,-0.405,0.06,0.052,methylated
NH23-1236,207355710089_R03C01,529,13/04/2023,4/21/2023,4/21/2023,8,PM,Diagnostic,529,1,NDP,Southampton General Hospital,Astrocytoma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",0.77,AIDH,0.75,0.91,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1236,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 529\NH23-1236,0.013,-0.063,0.038,0.01,-0.011,0.033,-0.037,-0.024,-0.053,-0.167,-0.03,0.012,0.021,0.042,-0.077,0.007,0.012,-0.073,-0.009,0.018,0.062,-0.049,-0.018,0.017,-0.005,-0.016,-0.036,0.048,-0.022,unmethylated
NH23-1249,207355710089_R04C01,529,14/04/2023,4/21/2023,4/21/2023,7,PM,Diagnostic,529,1,NDP,St George's Hospital London,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.81,GBM_MES,0.67,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1249,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 529\NH23-1249,0.045,0.036,0.022,0.001,0.036,-0.032,-0.006,0.857,0.156,0.109,0.115,-0.009,-0.034,0.104,-0.468,-0.006,-0.101,-0.158,-0.038,-0.016,-0.133,1.163,-0.062,0.009,0.05,0.022,0.098,-0.015,0.017,methylated
NH23-1254,207355710089_R05C01,529,14/04/2023,4/21/2023,4/21/2023,7,PM,Diagnostic,529,1,NDP,Nottingham University Hospital,PXA,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,infratentorial pilocytic astrocytoma,0.79,LGG_PAPF,0.31,0.66,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1254,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 529\NH23-1254,0.103,0.08,0,-0.021,-0.004,-0.081,-0.055,-0.031,0.016,-0.056,-0.029,0.034,0.029,0.04,-0.03,-0.03,0.055,0.031,-0.004,-0.1,-0.083,0.106,-0.03,0.107,-0.002,-0.009,-0.138,0.068,0.07,unmethylated
NH23-1220,207355710089_R06C01,529,14/04/2023,4/21/2023,4/21/2023,7,PM,Diagnostic,529,1,NDP,"Birmingham, Queen Elizabeth Hospital",HGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",,,,"Diffuse paediatric-type high grade glioma, MYCN subtype",0.71,GBM_MYCN,0.97,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1220,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 529\NH23-1220,0.89,0.969,0.042,-0.002,0.099,-0.027,0.027,0.961,0.01,-0.036,-0.024,-0.006,0.013,0.023,0.011,-0.029,-0.301,-0.331,-0.018,-0.012,0.016,0.037,-0.428,0.008,0.074,0.022,-0.064,0,0.002,unmethylated
NH23-1235,207355710089_R08C01,529,14/04/2023,4/21/2023,4/21/2023,7,PM,Diagnostic,529,1,NDP,Southampton General Hospital,,,,,,"glioblastoma, IDH-wildtype, mesenchymal type",0.43,GBM_RTKII,0.63,0.73,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1235,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 529\NH23-1235,0.053,0.02,0.027,-0.127,0.232,-0.042,-0.007,0.717,0.204,0.211,0.166,-0.317,-0.244,-0.289,0.074,0.033,-0.269,-0.274,-0.046,-0.24,-0.177,-0.259,-0.4,-0.045,-0.038,-0.067,0.16,-0.101,-0.066,methylated
NH23-1238,207355700085_R01C01,530,14/04/2023,4/26/2023,4/26/2023,12,PM,Diagnostic,530,1,NDP,Southampton General Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1C,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,OIDH,1,0.76,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1238,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 530\NH23-1238,0.124,-0.052,0.021,-0.078,-0.087,0.014,0.012,-0.006,-0.023,0.034,0.046,0.052,0.036,0.092,-0.1,-0.049,0.051,0.071,-0.035,-0.1,-0.048,-0.096,-0.083,-0.059,-0.075,-0.051,-0.437,0.053,0.083,methylated
NH23-1239,207355700085_R02C01,530,14/04/2023,4/26/2023,4/26/2023,12,PM,Diagnostic,530,1,,Southampton General Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1C,,,"diffuse glioma, IDH-mutant and 1p19q co-deleted [oligodendroglial type]",0.99,OIDH,1,0.71,"CNPs at bands 7q33, 7q34 and 7q35 are consistent with a KIAA1549-BRAF fusion event.",NH23-1239,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 530\NH23-1239,0.04,-0.285,0.035,-0.049,0.017,0,-0.035,-0.01,-0.013,-0.05,0.021,0.002,-0.091,-0.066,0.044,-0.023,-0.128,-0.014,-0.071,-0.054,-0.057,-0.001,-0.044,0.025,0.014,-0.008,-0.279,-0.048,-0.068,methylated
NH23-1209,207355700085_R06C01,530,14/04/2023,4/26/2023,4/26/2023,12,PM,Diagnostic,530,1,,NHNN,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",SP1A,,,supratentorial pilocytic astrocytoma,0.79,LGG_PA_GGST,0.83,0.85,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1209,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 530\NH23-1209,0.079,-0.16,-0.162,-0.167,0.103,-0.033,0.051,0.082,0.133,0.071,0.143,0.052,0.054,0.023,0.117,0.098,0.019,0.051,-0.046,0.039,0.025,0.049,0.111,0.041,-0.06,-0.029,-0.02,-0.169,-0.132,unmethylated
NH23-1252,207355700085_R07C01,530,14/04/2023,4/26/2023,4/26/2023,12,PM,Diagnostic,530,1,,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"glioblastoma, IDH-wildtype, RTK1 type",0.87,DMG_K27,0.17,0.75,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1252,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 530\NH23-1252,1.044,0.026,0.067,0.055,-0.008,-0.023,-0.016,0.291,0.121,0.13,0.107,0.179,0.136,0.168,-0.546,-0.055,-0.289,-0.038,0.038,-0.049,-0.057,0.135,-0.028,0.038,-0.026,0.014,-0.021,0,0.004,unmethylated
NH23-1253,207355700085_R08C01,530,14/04/2023,4/26/2023,4/26/2023,12,PM,Diagnostic,530,1,,Nottingham University Hospital,GBM,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"glioblastoma, IDH-wildtype, RTK2 type",0.99,GBM_RTKII,0.96,0.77,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1253,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 530\NH23-1253,-0.02,-0.078,0.042,-0.045,-0.047,-0.031,0.018,1.147,-0.071,-0.07,-0.051,0.001,0.072,-0.02,-1.518,-0.41,-0.337,-0.31,-0.042,-0.019,0.729,-0.01,-0.081,0.029,-0.042,-0.026,0.203,-0.007,0.017,methylated
NH23-1216,207355700067_R01C01,531,14/04/2023,4/26/2023,4/26/2023,12,PM,Diagnostic,531,2,,Southampton General Hospital,Ganglioglioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",1A,,,supratentorial pilocytic astrocytoma,0.82,LGG_PA_GGST,0.53,0.81,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1216,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 531\NH23-1216,-0.06,0.053,0.059,-0.041,-0.001,0.003,0.008,-0.03,-0.119,-0.109,-0.055,-0.005,0.096,0.076,0.001,-0.028,0.001,0.052,0.053,-0.058,-0.075,-0.067,-0.066,-0.065,-0.051,-0.075,0.078,0.025,0.043,methylated
NH23-1210,207355700067_R07C01,531,14/04/2023,4/26/2023,4/26/2023,12,PM,Diagnostic,531,1,,Brighton and Sussex Hospital,Ependymoma,"(7) Establish  methylation class for histologcally defined entities, e.g. Medullo, ependymoma, etc",DEF2A,,,spinal ependymoma,1,EPN_SPINE,1,0.78,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1210,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 531\NH23-1210,-0.032,-0.023,0.025,0.063,0.005,0.047,-0.034,0.025,0.027,-0.017,0.039,-0.01,0.009,0.013,-0.004,-0.037,-0.009,-0.009,-0.033,-0.046,-0.013,0.114,-0.473,-0.023,-0.033,-0.015,-0.012,-0.516,-0.34,unmethylated
NH23-1247,207355700047_R01C01,532,17/04/2023,4/26/2023,4/26/2023,9,PM,Diagnostic,532,1,,"MALTA, Mater Dei Hospital",Diffuse glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",B1,,,"glioblastoma, IDH-wildtype, RTK2 type",0.49,GBM_RTKII,0.78,0.9,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1247,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 532\NH23-1247,1.149,-0.023,0.046,0.05,0.066,-0.033,-0.505,0.259,0.301,0.222,0.265,-0.031,-0.036,0.019,-1.298,0.049,-1.035,-0.403,0.005,0.053,0.043,-0.107,-0.087,-0.001,0.042,-0.014,0.085,-0.364,-0.278,unmethylated
NH23-1263,207355700047_R02C01,532,17/04/2023,4/26/2023,4/26/2023,9,PM,Diagnostic,532,1,,Nottingham University Hospital,LGG,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]",1,AIDH,1,,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1263,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 532\NH23-1263,0.083,0.015,0.006,-0.005,0.074,-0.03,-0.019,-0.036,0.235,0.242,0.221,0.022,0.025,0.042,-0.011,0.013,0.006,-0.021,-0.028,0.067,0.018,0.014,-0.074,0.077,0.04,-0.031,-0.021,0.03,0.039,methylated
NH23-1264,207355700047_R03C01,532,17/04/2023,4/26/2023,4/26/2023,9,PM,Diagnostic,532,1,,Nottingham University Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",A1,,,"glioblastoma, IDH-wildtype, mesenchymal type",1,GBM_MES,0.96,,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1264,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 532\NH23-1264,0.086,-0.07,0.008,-0.063,-0.036,-0.052,-0.286,0.135,0.147,0.138,0.102,0.004,0.061,0.02,-0.241,-0.103,-0.346,-0.19,-0.13,-0.235,-0.18,-0.335,-0.285,-0.235,-0.403,-0.282,-0.02,-0.023,0.045,methylated
NH23-1270,207355700047_R06C01,532,17/04/2023,4/26/2023,4/26/2023,9,PM,Diagnostic,532,1,,Oxford John Radcliffe Hospital,Glioma,"(3) non-specific histology [e.g. high-grade tumour with no distinctive features, low-grade tumour with no distinctive features]",2,,,dysembryoplastic neuroepithelial tumour,0.64,LGG_DNT,0.27,,"CNPs at bands 7q33, 7q34 and 7q35 are NOT consistent with a KIAA1549-BRAF fusion event.",NH23-1270,,,,,S:\IoN_Scanned_Slides_CLIN\Biopsy\Surgical Neuropathology\ILLUMINA\Batch 532\NH23-1270,0.078,-0.051,0.06,-0.098,0.005,-0.048,-0.07,0.01,-0.058,-0.059,-0.025,0.019,0.06,-0.015,-0.009,-0.08,0,0.046,-0.04,-0.013,-0.025,-0.074,-0.062,0.016,-0.005,-0.031,0.009,0.057,0.09,unmethylated
